PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	HUME, RI; DINGLEDINE, R; HEINEMANN, SF				HUME, RI; DINGLEDINE, R; HEINEMANN, SF			IDENTIFICATION OF A SITE IN GLUTAMATE RECEPTOR SUBUNITS THAT CONTROLS CALCIUM PERMEABILITY	SCIENCE			English	Article							EXCITATORY AMINO-ACIDS; CENTRAL NERVOUS-SYSTEM; FUNCTIONAL EXPRESSION; CHLORIDE CURRENT; XENOPUS OOCYTES; CHANNELS; NEURONS; FAMILY; INJECTION; CLONING	The neurotransmitter glutamate mediates excitatory synaptic transmission throughout the brain. A family of genes encoding subunits of the non-N-methyl-D-aspartate (non-NMDA) type of glutamate receptor has been cloned. Some combinations of these subunits assemble into receptors with a substantial permeability to calcium, whereas others do not. To investigate the structural features that control ion permeation through these ligand-gated channels, mutant receptors subunits with single-amino acid changes were constructed. Mutation of a certain amino acid that results in a net charge change (from glutamine to arginine or vice versa) alters both the current-voltage relation and the calcium permeability of non-NMDA receptors. A site has thus been identified that regulates the permeation properties of these glutamate receptors.	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA; UNIV MICHIGAN, DEPT BIOL, ANN ARBOR, MI 48109 USA; UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	Salk Institute; University of Michigan System; University of Michigan; University of North Carolina; University of North Carolina Chapel Hill			, Richard/AAI-5000-2020; dingledine, Ray/F-5173-2011	Hume, Richard/0000-0001-9807-112X; Dingledine, Ray/0000-0001-7128-4520	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025782, R01NS021043, R01NS028709] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28709, NS25782, NS21043] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BOTON R, 1989, J PHYSIOL-LONDON, V408, P511, DOI 10.1113/jphysiol.1989.sp017473; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DASCAL N, 1986, SCIENCE, V231, P1147, DOI 10.1126/science.2418503; DINGLEDINE R, 1990, TRENDS PHARMACOL SCI, V11, P334, DOI 10.1016/0165-6147(90)90238-4; DINGLEDINE R, UNPUB; GILBERTSON TA, 1991, SCIENCE, V251, P1613, DOI 10.1126/science.1849316; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MORRIS RGM, 1990, PHILOS T ROY SOC B, V329, P187, DOI 10.1098/rstb.1990.0164; MURPHY SN, 1987, J NEUROSCI, V7, P4145; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	23	621	634	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 30	1991	253	5023					1028	1031		10.1126/science.1653450	http://dx.doi.org/10.1126/science.1653450			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1653450				2022-12-01	WOS:A1991GC98200045
J	IWAKURA, Y; TOSU, M; YOSHIDA, E; TAKIGUCHI, M; SATO, K; KITAJIMA, I; NISHIOKA, K; YAMAMOTO, K; TAKEDA, T; HATANAKA, M; YAMAMOTO, H; SEKIGUCHI, T				IWAKURA, Y; TOSU, M; YOSHIDA, E; TAKIGUCHI, M; SATO, K; KITAJIMA, I; NISHIOKA, K; YAMAMOTO, K; TAKEDA, T; HATANAKA, M; YAMAMOTO, H; SEKIGUCHI, T			INDUCTION OF INFLAMMATORY ARTHROPATHY RESEMBLING RHEUMATOID-ARTHRITIS IN MICE TRANSGENIC FOR HTLV-I	SCIENCE			English	Article							T-CELL LEUKEMIA; ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS TYPE-I; GENE; PROMOTER; PROTEIN; EXPRESSION; ACTIVATION; DISEASE; INVITRO	Human T cell leukemia virus type-I (HTLV-I) is the etiologic agent of adult T cell leukemia and has also been suggested to be involved in other diseases such as chronic arthritis or myelopathy. To elucidate pathological roles of the virus in disease, transgenic mice were produced that carry the HTLV-I genome. At 2 to 3 months of age, many of the mice developed chronic arthritis resembling rheumatoid arthritis. Synovial and periarticular inflammation with articular erosion caused by invasion of granulation tissues were marked. These observations suggest a possibility that HTLV-I is one of the etiologic agents of chronic arthritis in humans.	TOKYO WOMENS MED COLL, INST RHEUMATOL, SHINJUKU KU, TOKYO 163, JAPAN; UNIV TOKYO, FAC MED, BUNKYO KU, TOKYO 113, JAPAN; KYOTO UNIV, CHEST DIS RES INST, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, INST VIRUS RES, SAKYO KU, KYOTO 606, JAPAN; KOHNO CLIN MED RES INST, SHINAGAWA KU, TOKYO 140, JAPAN	Tokyo Women's Medical University; University of Tokyo; Kyoto University; Kyoto University	IWAKURA, Y (corresponding author), UNIV TOKYO, INST MED SCI, 4-6-1 SHIROKANEDAI, MINATO KU, TOKYO 108, JAPAN.		Takiguchi, Masafumi/E-7468-2013; Iwakura, Yoichiro/E-5457-2011; Yamamoto, Kazuhiko/N-5096-2015	Iwakura, Yoichiro/0000-0002-9934-5775; 				AREND WP, 1990, ARTHRITIS RHEUM-US, V33, P305, DOI 10.1002/art.1780330302; BENTIN J, 1990, ARTHRITIS RHEUM, V33, P268, DOI 10.1002/art.1780330217; CHEEVERS WP, 1988, LAB INVEST, V58, P510; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE BC, 1979, ARTHRITIS RHEUM, V22, P1375, DOI 10.1002/art.1780221209; Decker J L, 1984, Ann Intern Med, V101, P810; ESPINOZA LR, 1988, ARTHRITIS RHEUM-US, V31, P1034, DOI 10.1002/art.1780310815; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HANG L, 1982, J EXP MED, V155, P1690, DOI 10.1084/jem.155.6.1690; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; IWAKURA Y, 1988, EMBO J, V7, P3757, DOI 10.1002/j.1460-2075.1988.tb03259.x; IWAKURA Y, UNPUB; KITAJIMA I, 1989, ARTHRITIS RHEUM, V32, P1342, DOI 10.1002/anr.1780321030; KOGA T, 1985, INFECT IMMUN, V50, P27, DOI 10.1128/IAI.50.1.27-34.1985; KRANE SM, 1985, ARTHRITIS ALLIED CON, P593; KRIEG AM, 1990, J AUTOIMMUN, V3, P137, DOI 10.1016/0896-8411(90)90137-H; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIYASAKA N, IN PRESS J AUTOIMMUN; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NISHIOKA K, 1989, LANCET, V1, P441; SABE H, 1988, INT J CANCER, V41, P880, DOI 10.1002/ijc.2910410619; TAKIGUCHI M, UNPUB; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TOSU M, UNPUB; VANDENBROEK MF, 1989, J EXP MED, V170, P449, DOI 10.1084/jem.170.2.449; VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117; WANO Y, 1987, J CLIN INVEST, V80, P911, DOI 10.1172/JCI113152; WINCHESTER R, 1987, ANN INTERN MED, V106, P19, DOI 10.7326/0003-4819-106-1-19; ZIEGLER B, 1988, Arthritis and Rheumatism, V31, pS35	32	305	315	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 30	1991	253	5023					1026	1028		10.1126/science.1887217	http://dx.doi.org/10.1126/science.1887217			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887217				2022-12-01	WOS:A1991GC98200044
J	LEWIS, C; KRAMER, T; ROBINSON, S; HILVERT, D				LEWIS, C; KRAMER, T; ROBINSON, S; HILVERT, D			MEDIUM EFFECTS IN ANTIBODY-CATALYZED REACTIONS	SCIENCE			English	Article							HISTIDINE-DECARBOXYLASE; 6-NITROBENZISOXAZOLE-3-CARBOXYLATE; BINDING; ESTER	Catalytic antibody technology has been used to explore the contribution of medium effects to the overall rate of an enzyme-catalyzed reaction. An antibody generated against a derivative of 2-acetamido-1,5-napthalenedisulfonate efficiently catalyzes the decarboxylation of 5-nitro-3-carboxybenzisoxazole. This unimolecular reaction is not susceptible to general acid-base catalysis but is highly sensitive to microenvironment; thus, it provides a simple chemical model for biologically important decarboxylations. The 10(4)-fold rate acceleration observed for the antibody reflects the kinetic advantage of the low-dielectric environment of the binding pocket acting to destabilize the substrate by desolvation and to stabilize the charge-delocalized transition state through dispersion interactions. These results are pertinent to an understanding of solvent effects in enzymic reactions in general and suggest approaches for developing antibody catalysts for numerous other reactions that involve large changes in charge distribution as the reaction coordinate is traversed.	Scripps Res Inst, RES INST, DEPT CHEM, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NIGMS NIH HHS [GM38273] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038273, R01GM038273] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELL KWY, 1986, TETRAHEDRON LETT, V27, P1085, DOI 10.1016/S0040-4039(86)80055-7; ALSTON TA, 1987, BIOCHEMISTRY-US, V26, P4082, DOI 10.1021/bi00387a051; Azzi A, 1974, Methods Enzymol, V32, P234; BUNTON CA, 1975, J ORG CHEM, V40, P1321, DOI 10.1021/jo00897a031; BUNTON CA, 1973, J AM CHEM SOC, V95, P3262, DOI 10.1021/ja00791a032; CROSBY J, 1970, J AM CHEM SOC, V92, P2891, DOI 10.1021/ja00712a048; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; GALLAGHER T, 1989, J BIOL CHEM, V264, P12737; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; HILVERT D, 1990, BIOMIMETIC POLYMERS, P95; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P645; KEMP DS, 1978, TETRAHEDRON LETT, V8, P741; KLOTZ IM, 1946, J AM CHEM SOC, V68, P1486, DOI 10.1021/ja01212a030; KUNITAKE T, 1980, J AM CHEM SOC, V102, P7877, DOI 10.1021/ja00547a009; OLEARY MH, 1981, BIOCHEMISTRY-US, V20, P2743, DOI 10.1021/bi00513a007; PARKER AJ, 1969, CHEM REV, V69, P1, DOI 10.1021/cr60257a001; SCHMIDTCHEN FP, 1986, J CHEM SOC PERK T 2, P135, DOI 10.1039/p29860000135; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; SELIGER HH, 1978, METHOD ENZYMOL, V57, P560; SHAH SC, 1978, J AM CHEM SOC, V100, P1426, DOI 10.1021/ja00473a017; SMID J, 1975, J AM CHEM SOC, V97, P5932, DOI 10.1021/ja00853a058; STRYER L, 1968, SCIENCE, V162, P526, DOI 10.1126/science.162.3853.526; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; SUH J, 1976, J AM CHEM SOC, V98, P7060, DOI 10.1021/ja00438a054; TURNER DC, 1968, BIOCHEMISTRY-US, V7, P3381, DOI 10.1021/bi00850a011; Williams J W, 1979, Methods Enzymol, V63, P437	27	75	76	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1991	253	5023					1019	1022		10.1126/science.1887215	http://dx.doi.org/10.1126/science.1887215			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887215				2022-12-01	WOS:A1991GC98200042
J	REAL, LA				REAL, LA			ANIMAL CHOICE BEHAVIOR AND THE EVOLUTION OF COGNITIVE ARCHITECTURE	SCIENCE			English	Article							FORAGING PREFERENCES; BUMBLE BEES; RISK-AVERSE; GREAT TIT; MEMORY; UNCERTAINTY; REPRESENTATION; FORAGERS; FALLACY; MODEL	Animals process sensory information according to specific computational rules and, subsequently, form representations of their environments that form the basis for decisions and choices. The specific computational rules used by organisms will often be evolutionarily adaptive by generating higher probabilities of survival, reproduction, and resource acquisition. Experiments with enclosed colonies of bumblebees constrained to foraging on artificial flowers suggest that the bumblebee's cognitive architecture is designed to efficiently exploit floral resources from spatially structured environments given limits on memory and the neuronal processing of information. A non-linear relationship between the biomechanics of nectar extraction and rates of net energetic gain by individual bees may account for sensitivities to both the arithmetic mean and variance in reward distributions in flowers. Heuristic rules that lead to efficient resource exploitation may also lead to subjective misperception of likelihoods. Subjective probability formation may then be viewed as a problem in pattern recognition subject to specific sampling schemes and memory constraints.			REAL, LA (corresponding author), UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA.							ANDERSON JR, 1987, BEHAV BRAIN SCI, V10, P467, DOI 10.1017/S0140525X00023554; ANGERMEIER WF, 1984, EVOLUTION OPERANT LE; BALDA RP, 1989, ANIM BEHAV, V38, P486, DOI 10.1016/S0003-3472(89)80041-7; BARNARD CJ, 1985, BEHAV ECOL SOCIOBIOL, V16, P161, DOI 10.1007/BF00295150; BATTALIO RC, 1990, J RISK UNCERTAINTY, V3, P25; BATTALIO RC, 1985, AM ECON REV, V75, P597; CARACO T, 1983, BEHAV ECOL SOCIOBIOL, V12, P63, DOI 10.1007/BF00296934; CARACO T, 1981, BEHAV ECOL SOCIOBIOL, V8, P213, DOI 10.1007/BF00299833; CARACO T, 1980, ANIM BEHAV, V28, P820, DOI 10.1016/S0003-3472(80)80142-4; CARACO T, 1986, QUANT ANAL BEHAV, V6, P1; CARTAR RV, 1990, BEHAV ECOL SOCIOBIOL, V26, P121, DOI 10.1007/BF00171581; CHENEY D, 1986, SCIENCE, V234, P1361, DOI 10.1126/science.3538419; CHENEY DL, 1990, COGNITION, V37, P167, DOI 10.1016/0010-0277(90)90022-C; CUTHILL IC, 1990, ANIM BEHAV, V40, P625, DOI 10.1016/S0003-3472(05)80692-X; DAVISON MC, 1969, J EXP ANAL BEHAV, V12, P247, DOI 10.1901/jeab.1969.12-247; DUKAS R, UNPUB; DUKAS R, IN PRESS ANIM BEHAV; FEINSINGER P, 1978, ECOL MONOGR, V48, P269, DOI 10.2307/2937231; French Simon, 1986, DECISION THEORY; Gallistel C.R., 1990, ORG LEARNING; GETTY T, 1985, AM NAT, V125, P239, DOI 10.1086/284339; GETTY T, 1985, AM NAT, V125, P39, DOI 10.1086/284327; GILLIAM JF, 1982, AM NAT, V119, P875, DOI 10.1086/283962; HARDER LD, 1987, ECOLOGY, V68, P1104, DOI 10.2307/1938384; HARVEY PH, 1990, SCIENCE, V249, P140, DOI 10.1126/science.2196673; Heinrich B., 1984, Life Sciences Research Report, P135; Henderson JMJM., 1980, MICROECONOMIC THEORY; HERRNSTEIN RJ, 1964, J EXP ANAL BEHAV, V7, P179, DOI 10.1901/jeab.1964.7-179; Holifield Robert J., 1987, DARWIN EMERGENCE EVO, P418; KAGEL JH, 1990, AM ECON REV, V80, P912; KAHNEMAN D, 1979, ECONOMETRICA, V47, P263, DOI 10.2307/1914185; Kahneman D, 1982, JUDGEMENT UNCERTAINT; KARMARKAR US, 1979, ORGAN BEHAV HUM PERF, V24, P67, DOI 10.1016/0030-5073(79)90016-3; Keeney, 1976, DECISIONS MULTIPLE O; KREBS JR, 1990, ANIM BEHAV, V39, P1127, DOI 10.1016/S0003-3472(05)80785-7; KREBS JR, 1991, BEHAVIOURAL ECOLOGY; Loria DE, 1990, BEHAV ECOL, V1, P24, DOI 10.1093/beheco/1.1.24; MACHINA MJ, 1982, ECONOMETRICA, V50, P277, DOI 10.2307/1912631; MACPHAIL EM, 1987, BEHAV BRAIN SCI, V10, P645, DOI 10.1017/S0140525X00054984; Markowitz H. M., 1959, PORTFOLIO SELECTION; MENZEL R, 1979, NATURE, V281, P368, DOI 10.1038/281368a0; Menzel R, 1985, EXPT BEHAV ECOLOGY, P55; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/0033-295X.101.2.343; MOORE FR, 1986, EXPERIENTIA, V42, P1054, DOI 10.1007/BF01940730; Newell A., 1989, FDN COGNITIVE SCI, P93; PEARCE JM, 1987, INTRO ANIMAL COGNITI; PEARCE JM, 1989, ANNU REV PSYCHOL, V40, P155; PLEASANTS JM, 1979, OECOLOGIA, V41, P283, DOI 10.1007/BF00377432; POSSINGHAM HP, 1990, ECOLOGY, V71, P1622, DOI 10.2307/1938298; Pyke G.H., 1983, P7; REAL L, 1987, AM NAT, V130, P399, DOI 10.1086/284717; REAL L, 1990, ECOLOGY, V71, P1625, DOI 10.2307/1938299; REAL L, 1982, ECOLOGY, V63, P1617, DOI 10.2307/1940101; REAL L, 1986, ANNU REV ECOL SYST, V17, P371, DOI 10.1146/annurev.es.17.110186.002103; REAL LA, 1981, ECOLOGY, V62, P20, DOI 10.2307/1936663; REAL LA, UNPUB; REAL LA, 1989, BEHAVIORAL MECHANISM, P1; Roitblat H. L., 1987, INTRO COMP COGNITION; ROITBLAT HL, 1982, BEHAV BRAIN SCI, V5, P353, DOI 10.1017/S0140525X00012486; ROSETT RN, 1971, REV ECON STUD, V38, P481, DOI 10.2307/2296691; RUMMELHART DE, 1989, F COGNITIVE SCI, P133; RUMMELHART DE, 1986, PARALLEL DISTRIBUTED; SHERRY DF, 1987, PSYCHOL REV, V94, P439, DOI 10.1037/0033-295X.94.4.439; SHETTLEWORTH SJ, 1983, ADV ANAL BEHAV, P1; Sommer L, 1955, ECONOMETRICA, V23, P235, DOI 10.2307/1907897; STADDON JER, 1983, ADAPTIVE BEHAVIOR LE; Stephens D.W., 1986, pi; TOBIN J, 1957, REV ECON STUD, V25, P65; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; TURELLI M, 1982, AM NAT, V119, P879, DOI 10.1086/283963; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; VanLehn K., 1989, FDN COGNITIVE SCI, P1; WADDINGTON KD, 1981, ANIM BEHAV, V29, P779, DOI 10.1016/S0003-3472(81)80011-5; WASER NM, 1986, AM NAT, V127, P593, DOI 10.1086/284507; WILSON B, 1985, Q J EXP PSYCHOL-B, V37, P313, DOI 10.1080/14640748508401173; Wuketits F. M., 1990, EVOLUTIONARY EPISTEM; WUNDERLE JM, 1985, BEHAV ECOL SOCIOBIOL, V17, P371, DOI 10.1007/BF00293215; YAARI ME, 1965, Q J ECON, V79, P278, DOI 10.2307/1880632	78	254	261	4	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 30	1991	253	5023					980	986		10.1126/science.1887231	http://dx.doi.org/10.1126/science.1887231			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887231				2022-12-01	WOS:A1991GC98200034
J	ROBERTS, SB; SEGIL, N; HEINTZ, N				ROBERTS, SB; SEGIL, N; HEINTZ, N			DIFFERENTIAL PHOSPHORYLATION OF THE TRANSCRIPTION FACTOR OCT1 DURING THE CELL-CYCLE	SCIENCE			English	Article							SV40 DNA-REPLICATION; HISTONE H2B GENE; CONSENSUS ELEMENT; MAMMALIAN-CELLS; PROTEIN-KINASE; FISSION YEAST; H-1 GENE; S-PHASE; MITOSIS; ACTIVATION	Orderly progression through the somatic cell division cycle is accompanied by phase-specific transcription of a variety of different genes. During S phase, transcription of mammalian histone H2B genes requires a specific promoter element and its cognate transcription factor Oct1 (OTF1). A possible mechanism for regulating histone H2B transcription during the cell cycle is direct modulation of Oct1 activity by phase-specific posttranslational modifications. Analysis of Oct1 during progression through the cell cycle revealed a complex temporal program of phosphorylation. A p34cdc2-related protein kinase that is active during mitosis may be responsible for one mitotic phosphorylation of Oct1. However, the temporally controlled appearance of Oct1 phosphopeptides suggests the involvement of multiple kinases and phosphatases. These results support the idea that cell cycle-regulated transcription factors may be direct substrates for phase-specific regulatory enzymes.			ROBERTS, SB (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOLEC BIOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM 32544, GM 13752] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032544, F32GM013752] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTISHEVSKY A, 1987, NATURE, V328, P823, DOI 10.1038/328823a0; ARTISHEVSKY A, 1984, MOL CELL BIOL, V4, P2364, DOI 10.1128/MCB.4.11.2364; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; DALTON S, 1988, EMBO J, V7, P49, DOI 10.1002/j.1460-2075.1988.tb02782.x; DALTON S, 1988, MOL CELL BIOL, V8, P4576, DOI 10.1128/MCB.8.10.4576; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1990, TRENDS BIOL SCI, V15, P178; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GALLINARI P, 1989, MOL CELL BIOL, V9, P1566, DOI 10.1128/MCB.9.4.1566; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARVEY RP, 1982, NUCLEIC ACIDS RES, V10, P7851, DOI 10.1093/nar/10.23.7851; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEINTZ N, 1984, P NATL ACAD SCI-BIOL, V81, P2713, DOI 10.1073/pnas.81.9.2713; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; HEREFORD L, 1982, CELL, V30, P305, DOI 10.1016/0092-8674(82)90036-8; JOHNSON DG, 1990, MOL CELL BIOL, V10, P982, DOI 10.1128/MCB.10.3.982; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LABELLA F, 1989, GENE DEV, V3, P982; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NUSSE M, 1984, CELL TISSUE KINET, V17, P13, DOI 10.1111/j.1365-2184.1984.tb00564.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PEDRALINOY G, 1980, NUCLEIC ACIDS RES, V8, P377, DOI 10.1093/nar/8.2.377; PERRY M, 1985, J MOL BIOL, V185, P479, DOI 10.1016/0022-2836(85)90065-8; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; ROBERTS SA, UNPUB; SEGIL N, UNPUB; SITTMAN DB, 1983, P NATL ACAD SCI-BIOL, V80, P1849, DOI 10.1073/pnas.80.7.1849; SIVE HL, 1986, P NATL ACAD SCI USA, V83, P6382, DOI 10.1073/pnas.83.17.6382; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7; [No title captured]	48	129	130	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1991	253	5023					1022	1026		10.1126/science.1887216	http://dx.doi.org/10.1126/science.1887216			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887216				2022-12-01	WOS:A1991GC98200043
J	SCHULTZ, SC; SHIELDS, GC; STEITZ, TA				SCHULTZ, SC; SHIELDS, GC; STEITZ, TA			CRYSTAL-STRUCTURE OF A CAP-DNA COMPLEX - THE DNA IS BENT BY 90-DEGREES	SCIENCE			English	Article							GENE ACTIVATOR PROTEIN; AMP RECEPTOR PROTEIN; NUCLEIC-ACID INTERACTION; REPRESSOR OPERATOR COMPLEX; INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; CYCLIC-AMP; RNA-POLYMERASE; B-DNA; BINDING DOMAIN	The 3 angstrom resolution crystal structure of the Escherichia coli catabolite gene activator protein (CAP) complexed with a 30-base pair DNA sequence shows that the DNA is bent by 90-degrees. This bend results almost entirely from two 40-degrees kinks that occur between TG/CA base pairs at positions 5 and 6 on each side of the dyad axis of the complex. DNA sequence discrimination by CAP derives both from sequence-dependent distortion of the DNA helix and from direct hydrogen-bonding interactions between three protein side chains and the exposed edges of three base pairs in the major groove of the DNA. The structure of this transcription factor-DNA complex provides insights into possible mechanisms of transcription activation.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511	Yale University; Howard Hughes Medical Institute; Yale University	SCHULTZ, SC (corresponding author), YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511, USA.		Steitz, Thomas A./C-6559-2009; Shields, George C/C-6454-2012	Shields, George C/0000-0003-1287-8585	NIGMS NIH HHS [GM-22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON J, 1984, P NATL ACAD SCI-BIOL, V81, P1307, DOI 10.1073/pnas.81.5.1307; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BANTZ DA, 1974, ACTA CRYSTALLOGR A, VA 30, P257, DOI 10.1107/S0567739474000520; BECKWITH J, 1972, J MOL BIOL, V69, P155, DOI 10.1016/0022-2836(72)90031-9; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BETTER M, 1982, P NATL ACAD SCI-BIOL, V79, P5837, DOI 10.1073/pnas.79.19.5837; BIENKOWSKA J, 1989, PROGRAM LOLIPLOT; BLAZY B, 1980, MOL BIOL REP, V6, P39, DOI 10.1007/BF00775753; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNGER AT, 1989, PROGRAM XPLOR; BRUNGER AT, COMMUNICATION; BUSBY S, 1987, MICROBIOL SCI, V4, P371; CRICK FHC, 1975, NATURE, V255, P530, DOI 10.1038/255530a0; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; DICKERSON RE, 1987, J BIOMOL STRUCT DYN, V5, P557, DOI 10.1080/07391102.1987.10506413; DICKERSON RE, COMMUNICATION; DICKSON RC, 1977, J MOL BIOL, V111, P65, DOI 10.1016/S0022-2836(77)80132-0; DIGABRIELE AD, 1989, P NATL ACAD SCI USA, V86, P1816, DOI 10.1073/pnas.86.6.1816; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; DRIPPS D, 1987, J BIOMOL STRUCT DYN, V5, P1; EBRIGHT RH, 1990, NUCLEIC ACIDS RES, V18, P1457, DOI 10.1093/nar/18.6.1457; EBRIGHT RH, 1984, NATURE, V311, P232, DOI 10.1038/311232a0; EBRIGHT RH, 1987, P NATL ACAD SCI USA, V84, P6083, DOI 10.1073/pnas.84.17.6083; ESCHENLAUER AC, IN PRESS J BACTERIOL; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRATINI AV, 1982, J BIOL CHEM, V257, P4686; FREDERICK CA, 1984, NATURE, V309, P327, DOI 10.1038/309327a0; FURNISH G, 1989, PROGRAM PLOT; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GENT ME, 1987, BIOCHEM J, V242, P645, DOI 10.1042/bj2420645; GILADI H, 1990, J MOL BIOL, V213, P109, DOI 10.1016/S0022-2836(05)80124-X; GOTOH O, 1981, BIOPOLYMERS, V20, P1033, DOI 10.1002/bip.1981.360200513; IRWIN N, 1987, P NATL ACAD SCI USA, V84, P8315, DOI 10.1073/pnas.84.23.8315; JANSEN C, 1987, BIOCHEM J, V246, P227, DOI 10.1042/bj2460227; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; JORDAN SR, 1985, SCIENCE, V230, P1383; KATTI S, COMMUNICATION; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOLB A, 1983, NUCLEIC ACIDS RES, V11, P7833, DOI 10.1093/nar/11.22.7833; KOSTURKO LD, 1989, NUCLEIC ACIDS RES, V17, P317, DOI 10.1093/nar/17.1.317; KOTLARZ D, 1986, EMBO J, V5, P799, DOI 10.1002/j.1460-2075.1986.tb04284.x; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LESK AM, 1982, SCIENCE, V216, P539, DOI 10.1126/science.7071602; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; Lu P, 1985, Adv Biophys, V20, P153, DOI 10.1016/0065-227X(85)90035-8; MAJORS J, 1977, THESIS HARVARD U CAM; MALAN TP, 1984, J MOL BIOL, V180, P881, DOI 10.1016/0022-2836(84)90262-6; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; ORNSTEIN RL, 1978, BIOPOLYMERS, V17, P2341, DOI 10.1002/bip.1978.360171005; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; PASSNER J, UNPUB; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERLO A, PROGRAM SZAZAM VERSI; PINKNEY M, 1988, BIOCHEM J, V250, P897, DOI 10.1042/bj2500897; PORSCHKE D, 1984, EMBO J, V3, P2873, DOI 10.1002/j.1460-2075.1984.tb02223.x; RAVISHANKER G, 1989, J BIOMOL STRUCT DYN, V6, P669, DOI 10.1080/07391102.1989.10507729; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROULD MR, 1990, PROGRAM MAXIMAGE; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SAYRE D, 1982, COMPUTATIONAL CRYSTA, P303; SCHULTZ SC, 1990, J MOL BIOL, V213, P159, DOI 10.1016/S0022-2836(05)80128-7; SHIELDS GC, UNPUB; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SOBELL HM, 1976, P NATL ACAD SCI USA, V73, P3068, DOI 10.1073/pnas.73.9.3068; SPASSKY A, 1984, EMBO J, V3, P43, DOI 10.1002/j.1460-2075.1984.tb01759.x; STEITZ TA, 1983, J BIOMOL STRUCT DYN, V1, P1023, DOI 10.1080/07391102.1983.10507500; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STRANEY DC, 1989, J MOL BIOL, V206, P41, DOI 10.1016/0022-2836(89)90522-6; SUSSMAN JL, 1978, P NATL ACAD SCI USA, V75, P103, DOI 10.1073/pnas.75.1.103; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; ULLMANN A, 1983, ADV CYCL NUCL RES<D>, V15, P1; WARWICKER J, 1987, PROTEINS, V2, P283, DOI 10.1002/prot.340020404; WEBER IT, 1984, P NATL ACAD SCI-BIOL, V81, P3973, DOI 10.1073/pnas.81.13.3973; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YOON C, 1988, P NATL ACAD SCI USA, V85, P6332, DOI 10.1073/pnas.85.17.6332; ZHANG XP, 1990, P NATL ACAD SCI USA, V87, P4717, DOI 10.1073/pnas.87.12.4717; ZHURKIN VB, 1979, NUCLEIC ACIDS RES, V6, P1081, DOI 10.1093/nar/6.3.1081; ZINKEL SS, 1990, BIOPOLYMERS, V29, P29, DOI 10.1002/bip.360290106	91	1038	1050	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1991	253	5023					1001	1007		10.1126/science.1653449	http://dx.doi.org/10.1126/science.1653449			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1653449	Green Submitted			2022-12-01	WOS:A1991GC98200037
J	WADE, MJ; GOODNIGHT, CJ				WADE, MJ; GOODNIGHT, CJ			WRIGHT SHIFTING BALANCE THEORY - AN EXPERIMENTAL-STUDY	SCIENCE			English	Article							GROUP SELECTION; SMALL POPULATIONS; FINITE POPULATIONS; GENETIC VARIANCE; FOUNDER EVENTS; SEX-RATIO; DIFFERENTIATION; MIGRATION; TRIBOLIUM	Experimental confirmation of Wright's shifting balance theory of evolution, one of the most comprehensive theories of adaptive evolution, is presented. The theory is regarded by many as a cornerstone of modern evolutionary thought, but there has been little direct empirical evidence supporting it. Some of its underlying assumptions are viewed as contradictory, and the existence and efficacy of the theory's fundamental adaptive process, interdemic selection, is the focus of controversy. Interdemic selection was imposed on large arrays of laboratory populations of the flour beetle Tribolium castaneum in the manner described by Wright: the differential dispersion of individuals from demes of high fitness into demes of low fitness. A significant increase in average fitness was observed in the experimental arrays when compared to control populations with equivalent but random migration rates. The response was not proportional to the selection differential: The largest response occurred with interdemic selection every two generations rather than every generation or every three generations. The results indicate that the interdemic phase of Wright's shifting balance theory can increase average fitness and suggest that gene interactions are involved in the observed response.	UNIV VERMONT,DEPT ZOOL,BURLINGTON,VT 05405	University of Vermont	WADE, MJ (corresponding author), UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637, USA.		Goodnight, Charles/K-3208-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022523] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22523] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COCKERHAM CC, 1988, P NATL ACAD SCI USA, V85, P1563, DOI 10.1073/pnas.85.5.1563; COLLIAS NE, 1991, ANIM BEHAV, V41, P613, DOI 10.1016/S0003-3472(05)80900-5; CRAIG DM, 1982, EVOLUTION, V36, P271, DOI 10.1111/j.1558-5646.1982.tb05041.x; CROW JF, 1990, EVOLUTION, V44, P233, DOI [10.2307/2409403, 10.1111/j.1558-5646.1990.tb05194.x]; DOBZHANSKY T, 1977, EVOLUTION, P164; Falconer D. S, 1981, INTRO QUANTITATIVE G; Futuyma DJ, 1986, EVOL BIOL; GOODNIGHT CJ, 1985, EVOLUTION, V39, P545, DOI 10.1111/j.1558-5646.1985.tb00394.x; GOODNIGHT CJ, 1987, EVOLUTION, V41, P80, DOI 10.1111/j.1558-5646.1987.tb05772.x; GOODNIGHT CJ, 1988, EVOLUTION, V42, P441, DOI 10.1111/j.1558-5646.1988.tb04151.x; HARTL DL, 1989, PRINCIPLES POPULATIO, P324; HARTL DL, 1980, PRINCIPLES POPULATIO, P343; HILL WG, 1972, BIOMETRICS, V28, P767, DOI 10.2307/2528761; LOVELESS MD, 1984, ANNU REV ECOL SYST, V15, P65, DOI 10.1146/annurev.es.15.110184.000433; Mettler L.E., 1988, POPULATION GENETICS; NEI M, 1987, MOL EVOLUTIONARY GEN, P422; Provine W. B., 1986, SEWALL WRIGHT EVOLUT; TACHIDA H, 1989, GENET RES, V53, P63, DOI 10.1017/S0016672300027877; Templeton A.R., 1982, P15; WADE MJ, 1984, GENET RES, V43, P249, DOI 10.1017/S0016672300026045; WADE MJ, 1982, EVOLUTION, V36, P949, DOI 10.1111/j.1558-5646.1982.tb05465.x; WADE MJ, 1984, EVOLUTION, V38, P1047, DOI 10.1111/j.1558-5646.1984.tb00375.x; WADE MJ, 1978, Q REV BIOL, V53, P101, DOI 10.1086/410450; WADE MJ, 1976, P NATL ACAD SCI USA, V73, P4604, DOI 10.1073/pnas.73.12.4604; WADE MJ, 1980, EVOLUTION, V34, P799, DOI [10.2307/2408034, 10.1111/j.1558-5646.1980.tb04019.x]; WADE MJ, 1977, EVOLUTION, V31, P134, DOI 10.1111/j.1558-5646.1977.tb00991.x; WADE MJ, 1980, GENET RES, V36, P10; WADE MJ, 1991, EVOLUTION, V44, P2004; WILSON DS, 1981, EVOLUTION, V35, P882, DOI [10.2307/2407858, 10.1111/j.1558-5646.1981.tb04952.x]; Wright S, 1931, GENETICS, V16, P0097; WRIGHT S, 1982, EVOLUTION, V36, P427, DOI 10.1111/j.1558-5646.1982.tb05065.x; Wright S., 1984, THEORY GENE FREQUENC; Wright S., 1978, EVOLUTION GENETICS P, V4; WRIGHT S, 1977, EVOLUTION GENETICS P, V3, P454; [No title captured]	35	113	114	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1991	253	5023					1015	1018		10.1126/science.1887214	http://dx.doi.org/10.1126/science.1887214			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887214				2022-12-01	WOS:A1991GC98200041
J	ACSADI, G; DICKSON, G; LOVE, DR; JANI, A; WALSH, FS; GURUSINGHE, A; WOLFF, JA; DAVIES, KE				ACSADI, G; DICKSON, G; LOVE, DR; JANI, A; WALSH, FS; GURUSINGHE, A; WOLFF, JA; DAVIES, KE			HUMAN DYSTROPHIN EXPRESSION IN MDX MICE AFTER INTRAMUSCULAR INJECTION OF DNA CONSTRUCTS	NATURE			English	Article							MUSCLE; MOUSE; INVIVO; TRANSFECTION; MYOPATHY; PROTEIN; REPEAT	DUCHENNE'S muscular dystrophy (DMD), which affects one in 3,500 males, causes progressive myopathy of skeletal and cardiac muscles and premature death 1. One approach to treatment would be to introduce the normal dystrophin gene into diseased muscle cells. When pure plasmid DNA is injected into rodent skeletal 2 or cardiac muscle 3-5, the cells express reporter genes. We now show that a 12-kilobase full-length human dystrophin complementary DNA gene and a 6.3-kilobase Becker-like gene 6 can be expressed in cultured cells and in vivo. When the human dystrophin expression plasmids are injected intramuscularly into dystrophin-deficient mdx mice, the human dystrophin proteins are present in the cytoplasm and sarcolemma of approximately 1% of the myofibres. Myofibres expressing human dystrophin contain an increased proportion of peripheral nuclei. The results indicate that transfer of the dystrophin gene into the myofibres of DMD patients could be beneficial, but a larger number of genetically modified myofibres will be necessary for clinical efficacy.	UNIV WISCONSIN,WAISMAN CTR MENTAL RETARDAT & HUMAN DEV,DEPT PEDIAT,MADISON,WI 53706; UNIV WISCONSIN,WAISMAN CTR MENTAL RETARDAT & HUMAN DEV,DEPT MED GENET,MADISON,WI 53706; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT EXPTL PATHOL,LONDON SE1 9RT,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC GENET GRP,OXFORD OX3 9DU,ENGLAND	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Oxford				Love, Donald/0000-0003-4669-8769				ACSADI G, 1991, NEW BIOL, V3, P71; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; DICKSON G, IN PRESS HUMAN GENET; ELLIS JM, 1990, LANCET, V336, P881, DOI 10.1016/0140-6736(90)92392-U; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FORREST S M, 1988, Genomics, V2, P109, DOI 10.1016/0888-7543(88)90091-2; FRITZ JD, 1989, ANAL BIOCHEM, V180, P205, DOI 10.1016/0003-2697(89)90116-4; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1990, J NEUROL SCI, V99, P9, DOI 10.1016/0022-510X(90)90195-S; KARPATI G, 1989, AM J PATHOL, V135, P27; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; KOENIG M, 1990, J BIOL CHEM, V265, P4560; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEE CC, 1991, NATURE, V349, P334, DOI 10.1038/349334a0; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; MORGAN JE, 1990, J CELL BIOL, V111, P2437, DOI 10.1083/jcb.111.6.2437; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; TANABE Y, 1986, ACTA NEUROPATHOL, V69, P91, DOI 10.1007/BF00687043; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; WANG AM, 1990, PCR PROTOCOLS GUIDE, P70; WESSEL HB, 1990, PEDIATR NEUROL, V6, P3, DOI 10.1016/0887-8994(90)90071-8; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WOLFF JA, IN PRESS BIOTECHNIQU	30	390	497	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					815	818		10.1038/352815a0	http://dx.doi.org/10.1038/352815a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1881437				2022-12-01	WOS:A1991GC96400064
J	COHEN, S; TYRRELL, DAJ; SMITH, AP				COHEN, S; TYRRELL, DAJ; SMITH, AP			PSYCHOLOGICAL STRESS AND SUSCEPTIBILITY TO THE COMMON COLD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VOLUNTEERS; INFECTION	Background. It is not known whether psychological stress suppresses host resistance to infection. To investigate this issue, we prospectively studied the relation between psychological stress and the frequency of documented clinical colds among subjects intentionally exposed to respiratory viruses. Methods. After completing questionnaires assessing degrees of psychological stress, 394 healthy subjects were given nasal drops containing one of five respiratory viruses (rhinovirus type 2, 9, or 14, respiratory syncytial virus, or coronavirus type 229E), and an additional 26 were given saline nasal drops. The subjects were then quarantined and monitored for the development of evidence of infection and symptoms. Clinical colds were defined as clinical symptoms in the presence of an infection verified by the isolation of virus or by an increase in the virus-specific antibody titer. Results. The rates of both respiratory infection (P < 0.005) and clinical colds (P < 0.02) increased in a dose-response manner with increases in the degree of psychological stress. Infection rates ranged from approximately 74 percent to approximately 90 percent, according to levels of psychological stress, and the incidence of clinical colds ranged from approximately 27 percent to 47 percent. These effects were not altered when we controlled for age, sex, education, allergic status, weight, the season, the number of subjects housed together, the infectious status of subjects sharing the same housing, and virus-specific antibody status at base line (before challenge). Moreover, the associations observed were similar for all five challenge viruses. Several potential stress-illness mediators, including smoking, alcohol consumption, exercise, diet, quality of sleep, white-cell counts, and total immunoglobulin levels, did not explain the association between stress and illness. Similarly, controls for personality variables (self-esteem, personal control, and introversion-extraversion) failed to alter our findings. Conclusions. Psychological stress was associated in a dose-response manner with an increased risk of acute infectious respiratory illness, and this risk was attributable to increased rates of infection rather than to an increased frequency of symptoms after infection.	UNIV WALES COLL CARDIFF,HLTH PSYCHOL RES UNIT,CARDIFF CF1 1XL,S GLAM,WALES; MRC,COMMON COLD UNIT,SALISBURY,ENGLAND	Cardiff University	COHEN, S (corresponding author), CARNEGIE MELLON UNIV,DEPT PSYCHOL,PITTSBURGH,PA 15213, USA.		Winwood, Peter/A-6363-2008; Smith, Andrew P/B-2192-2010	Cohen, Sheldon/0000-0003-2248-4600; Smith, Andrew/0000-0001-8805-8028	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023072] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23072] Funding Source: Medline; NIMH NIH HHS [MH00721] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ader R., 1981, PSYCHONEUROIMMUNOLOG, V1st ed.; Afifi A.A., 1984, COMPUTER AIDED MULTI; ALEXANDER R W, 1956, Stud Med, V4, P61; BARCLAY WS, 1987, J VIROL METHODS, V15, P53, DOI 10.1016/0166-0934(87)90048-6; BEARE AS, 1977, CHEMOPROPHYLAXIS VIR, V2, P27; BOYCE WT, 1977, PEDIATRICS, V60, P609; BROADBENT DE, 1984, J PSYCHOSOM RES, V28, P511, DOI 10.1016/0022-3999(84)90085-0; CALABRESE JR, 1987, AM J PSYCHIAT, V144, P1123; CALLOW KA, 1985, J HYG-CAMBRIDGE, V95, P173, DOI 10.1017/S0022172400062410; CLUFF LE, 1966, ARCH INTERN MED, V117, P159, DOI 10.1001/archinte.117.2.159; COHEN S, 1991, PSYCHOL BULL, V109, P5, DOI 10.1037/0033-2909.109.1.5; COHEN S, 1988, SOCIAL PSYCHOL HLTH, P31; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Eysenck HJ, 1964, MANUAL EYSENCK PERSO, DOI DOI 10.1007/SPRINGERREFERENCE_184643; FELTEN DL, 1985, J IMMUNOL, V135, pS755; FELTEN SY, 1987, J NEUROSCI RES, V18, P37, DOI 10.1002/jnr.490180108; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; FLEMING JS, 1980, J PERS SOC PSYCHOL, V39, P921, DOI 10.1037/0022-3514.39.5.921; GRAHAM NMH, 1986, AM J EPIDEMIOL, V124, P389, DOI 10.1093/oxfordjournals.aje.a114409; Henderson, 1981, NEUROSIS SOCIAL ENV; Hosmer D, 2013, APPL LOGISTIC REGRES; JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435; KIECOLT-GLASER J K, 1988, Brain Behavior and Immunity, V2, P67, DOI 10.1016/0889-1591(88)90007-4; Kiecolt-Glaser JK, 1991, PSYCHONEUROIMMUNOLOG, P849; Laudenslager ML, 1987, VIRUSES IMMUNITY MEN, P391; Lazarus R.S., 1984, STRESS APPRAISAL; MEYER RJ, 1962, PEDIATRICS, V29, P539; MORAHAN PS, 1989, NAT IMMUN, P557; PAULHUS D, 1983, J PERS SOC PSYCHOL, V44, P1253, DOI 10.1037/0022-3514.44.6.1253; RABIN BS, 1989, CRIT REV IMMUNOL, V9, P279; SHAVIT Y, 1984, SCIENCE, V223, P188, DOI 10.1126/science.6691146; TOTMAN R, 1980, J PSYCHOSOM RES, V24, P155, DOI 10.1016/0022-3999(80)90037-9; Tyrrell DAJ, 1988, LAB DIAGNOSIS INFECT, V2, P723; ZEVON MA, 1982, J PERS SOC PSYCHOL, V43, P111, DOI 10.1037/0022-3514.43.1.111	34	1149	1163	2	183	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1991	325	9					606	612		10.1056/NEJM199108293250903	http://dx.doi.org/10.1056/NEJM199108293250903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GC328	1713648				2022-12-01	WOS:A1991GC32800003
J	DATTA, B; WEINER, AM				DATTA, B; WEINER, AM			GENETIC-EVIDENCE FOR BASE-PAIRING BETWEEN U2 AND U6 SNRNA IN MAMMALIAN MESSENGER-RNA SPLICING	NATURE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; 2'-OME RNA; YEAST; U1; OLIGONUCLEOTIDES; PARTICLES; SELECTION; INVITRO; U4	REMOVAL of introns from eukaryotic nuclear messenger RNA precursors is catalysed by a large ribonucleoprotein complex called the spliceosome, which consists of four small nuclear ribonucleoprotein particles (U1, U2, U5, and U4/U6 snRNPs) and auxiliary protein factors 1,2. We have begun a genetic analysis of mammalian U2 snRNA by making second-site mutations in a suppressor U2 snRNA 3. Here we find that several mutations in the 5' end of U2 (nucleotides 3-8) are deleterious and that one of these can be rescued by compensatory base changes in the 3' end of U6 (nucleotides 92-95). The results demonstrate genetically that the base-pairing interaction between U2 (nucleotides 3-11) and U6 snRNA (nucleotides 87-95), originally proposed on the basis of psoralen photocrosslinking experiments 4, can influence the efficiency of mRNA splicing in mammals. The U2/U6 interaction in yeast, however, is fairly tolerant to mutation 5 (D. J. Field and J. D. Friesen, personal communication), emphasizing the potential for facultative RNA interactions within the spliceosome.			DATTA, B (corresponding author), YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510, USA.							BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FRENDEWEY D, 1987, COLD SPRING HARB SYM, V52, P287, DOI 10.1101/SQB.1987.052.01.034; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HAMM J, 1989, CELL, V59, P159, DOI 10.1016/0092-8674(89)90878-7; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LUCIA JS, IN PRESS BIOCHEMISTR; LUHRMANN R, 1988, STRUCTURE FUNCTION M, P71; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; PAN ZQ, 1989, GENE DEV, V3, P1887, DOI 10.1101/gad.3.12a.1887; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SHUSTER EO, 1990, NATURE, V345, P270, DOI 10.1038/345270a0; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; SUSSMAN JL, 1978, J MOL BIOL, V123, P607, DOI 10.1016/0022-2836(78)90209-7; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; YUO CY, 1989, GENE DEV, V3, P697, DOI 10.1101/gad.3.5.697; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	29	158	160	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					821	824		10.1038/352821a0	http://dx.doi.org/10.1038/352821a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1831879				2022-12-01	WOS:A1991GC96400066
J	DOLCI, S; WILLIAMS, DE; ERNST, MK; RESNICK, JL; BRANNAN, CI; LOCK, LF; LYMAN, SD; BOSWELL, HS; DONOVAN, PJ				DOLCI, S; WILLIAMS, DE; ERNST, MK; RESNICK, JL; BRANNAN, CI; LOCK, LF; LYMAN, SD; BOSWELL, HS; DONOVAN, PJ			REQUIREMENT FOR MAST-CELL GROWTH-FACTOR FOR PRIMORDIAL GERM-CELL SURVIVAL IN CULTURE	NATURE			English	Article							RECEPTOR TYROSINE KINASES; C-KIT; SI-LOCUS; LIGAND; MOUSE; IDENTIFICATION; PROGENITORS; EXPRESSION; CLONING; RAT	MAST-CELL growth factor (MGF) is encoded by the murine steel (Sl) locus and is a ligand for the tyrosine kinase receptor protein encoded by the proto-oncogene c-kit at the murine dominant white spotting (W) locus. Mutations at both these loci affect mast cells, primordial germ cells (PGCs), haemopoietic stem cells and melanocytes. In many Sl and W mutants, the rapid proliferation of PGC that normally occurs between day 7 and 13.5 of embryonic development fails to occur. As c-kit is expressed in PGCs 1,2 while MGF is expressed in the surrounding mesenchyme 2,3, MGF might promote the proliferation of PGCs. Here we report that MGF is essential for PGC survival in culture, but does not stimulate PGC proliferation. Moreover, whereas both the transmembrane and soluble proteolytic cleavage forms of MGF stimulate mast-cell proliferation, soluble MGF has a relatively limited ability to support survival of PGCs in culture, thus explaining the sterility in mice carrying the steel-dickie (Sl(d)) mutation, which encodes only a soluble form of MGF, and providing a functional role for a transmembrane growth factor.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MOLEC MECHANISMS CARCINOGENESIS LAB,FREDERICK,MD 21702; IMMUNEX CORP,DEPT EXPTL HEMATOL,SEATTLE,WA 98101; IMMUNEX CORP,DEPT MOLEC BIOL,SEATTLE,WA 98101; INDIANA UNIV,SCH MED,INDIANAPOLIS,IN 46202; UNIV ROME TOR VERGATA 2,DIPARTIMENTO SANITA PUBBL & BIOL CELLULARE,I-00173 ROME,ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Immunex Corporation; Immunex Corporation; Indiana University System; Indiana University-Purdue University Indianapolis; University of Rome Tor Vergata			dolci, susanna/B-8363-2013	dolci, susanna/0000-0002-6864-3673				ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BOSWELL HS, 1987, EXP HEMATOL, V15, P46; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CAIRNS L, 1987, THESIS U LOND; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DONOVAN PJ, 1986, CELL, V44, P831, DOI 10.1016/0092-8674(86)90005-X; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GODIN I, 1990, DEVELOPMENT, V108, P357; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KESHET E, IN PRESS EMBO J; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MCCOSHEN JA, 1975, EXPERIENTIA, V31, P589, DOI 10.1007/BF01932475; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; ORR UA, 1990, DEVELOPMENT, V109, P911; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	26	437	448	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					809	811		10.1038/352809a0	http://dx.doi.org/10.1038/352809a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1715518				2022-12-01	WOS:A1991GC96400062
J	DOORBAR, J; ELY, S; STERLING, J; MCLEAN, C; CRAWFORD, L				DOORBAR, J; ELY, S; STERLING, J; MCLEAN, C; CRAWFORD, L			SPECIFIC INTERACTION BETWEEN HPV-16 E1-E4 AND CYTOKERATINS RESULTS IN COLLAPSE OF THE EPITHELIAL-CELL INTERMEDIATE FILAMENT NETWORK	NATURE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; OPEN READING FRAMES; HUMAN KERATINOCYTES; VACCINIA VIRUS; PROTEINS; E4; IDENTIFICATION; TRANSFORMATION; L1; CYTOSKELETON	THE human papillomaviruses (HPV) are associated specifically with epithelial lesions, ranging from benign warts to invasive carcinoma (for review, see refs 1, 2). The virus encodes three late proteins, which are produced only in terminally differentiating keratinocytes, two of which are structural components of the virion 3. The third, E1-E4, is derived primarily from the E4 open reading frame, which represents a region of maximal divergence between different HPV types 4,5. E1-E4 does not seem to be a component of the virus particle or to be needed for transformation in vitro 6,7, but accumulates in the cytoplasm 5,8-10, where in certain benign lesions it can comprise 20-30% of total cell protein 4,10. We show here that expression of the HPV-16 E1-E4 protein in human keratinocytes (the natural host cell for HPV infection) results in the total collapse of the cytokeratin matrix. Tubulin and actin networks are unaffected by E1-E4, as are the nuclear lamins.			DOORBAR, J (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,IMPERIAL CANC RES FUND,TUMOUR VIRUS GRP,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.							ADAMS JC, 1988, J CELL BIOL, V107, P1927, DOI 10.1083/jcb.107.5.1927; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BREITBURD F, 1987, CANCER CELL, V5, P115; Broker T.R., 1986, CANCER CELL, V4, P17; BROWN DR, 1988, VIROLOGY, V165, P262, DOI 10.1016/0042-6822(88)90680-0; BROWNE HM, 1988, J GEN VIROL, V69, P1263, DOI 10.1099/0022-1317-69-6-1263; CRUM CP, 1990, VIROLOGY, V178, P238, DOI 10.1016/0042-6822(90)90399-C; DOORBAR J, 1988, EMBO J, V7, P825, DOI 10.1002/j.1460-2075.1988.tb02881.x; DOORBAR J, 1987, J VIROL, V61, P2793, DOI 10.1128/JVI.61.9.2793-2799.1987; DOORBAR J, 1989, VIROLOGY, V172, P51, DOI 10.1016/0042-6822(89)90106-2; DOORBAR J, 1990, VIROLOGY, V178, P254, DOI 10.1016/0042-6822(90)90401-C; Eckert B S, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 1, P403; Foisner R, 1991, CURR OPIN CELL BIOL, V3, P75, DOI 10.1016/0955-0674(91)90168-X; HARLOW E, 1988, ANTIBODIES LABORATOR; HILLER G, 1979, VIROLOGY, V98, P142, DOI 10.1016/0042-6822(79)90533-6; Lane E B, 1990, Semin Cancer Biol, V1, P165; LIEBOWITZ D, 1987, MOL CELL BIOL, V7, P2299, DOI 10.1128/MCB.7.7.2299; MACKETT M, 1985, DNA CLONING PRACTICA, V2; MCLEAN CS, 1990, J CLIN PATHOL, V43, P488, DOI 10.1136/jcp.43.6.488; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; SEEDORF K, 1987, EMBO J, V6, P139, DOI 10.1002/j.1460-2075.1987.tb04731.x; SHYY TT, 1989, J CELL BIOL, V108, P997, DOI 10.1083/jcb.108.3.997; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; ZURHAUSEN H, 1990, PAPOVAVIRIDAE	27	226	236	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					824	827		10.1038/352824a0	http://dx.doi.org/10.1038/352824a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1715519				2022-12-01	WOS:A1991GC96400067
J	FALLON, AM				FALLON, AM			DNA-MEDIATED GENE-TRANSFER - APPLICATIONS TO MOSQUITOS	NATURE			English	Article							AEDES-ALBOPICTUS CELLS; ANOPHELES-GAMBIAE; TRANSIENT EXPRESSION; INTEGRATION; DROSOPHILA; VECTOR				FALLON, AM (corresponding author), UNIV MINNESOTA,ENTOMOL,1980 FOLWELL AVE,ST PAUL,MN 55108, USA.							BESANSKY NJ, 1990, MOL CELL BIOL, V10, P863, DOI 10.1128/MCB.10.3.863; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DOBENS L, 1991, MOL CELL BIOL, V11, P1846, DOI 10.1128/MCB.11.4.1846; DURBIN JE, 1985, GENE, V36, P173, DOI 10.1016/0378-1119(85)90082-4; DURBIN JE, 1988, BIOCHIM BIOPHYS ACTA, V950, P182, DOI 10.1016/0167-4781(88)90010-3; Fallon A. M., 1987, Advances in Cell Culture, V5, P97; GERENDAY A, 1989, INSECT BIOCHEM, V19, P679, DOI 10.1016/0020-1790(89)90104-2; HENDRICKS MB, 1989, BIO-TECHNOL, V7, P1271; JAMES AA, 1954, GENE, V75, P7389; KJER KM, 1991, ARCH INSECT BIOCHEM, V16, P189, DOI 10.1002/arch.940160305; MCGRANE V, 1988, AM J TROP MED HYG, V39, P502, DOI 10.4269/ajtmh.1988.39.502; MENTO SJ, 1978, SOMAT CELL GENET, V4, P179, DOI 10.1007/BF01538983; MILLER LH, 1987, SCIENCE, V237, P779, DOI 10.1126/science.3039658; MORRIS AC, 1989, MED VET ENTOMOL, V3, P1, DOI 10.1111/j.1365-2915.1989.tb00467.x; QIAN S, 1988, P NATL ACAD SCI USA, V85, P9601, DOI 10.1073/pnas.85.24.9601; ROMANS P, 1991, J MED ENTOMOL, V28, P147, DOI 10.1093/jmedent/28.1.147; SHOTKOSKI FA, IN PRESS EUR J BIOCH; SINGH KRP, 1967, CURR SCI INDIA, V36, P506; TATEM J, 1986, VIRUS RES, V5, P121, DOI 10.1016/0168-1702(86)90012-2; WHEELER DA, 1991, SCIENCE, V251, P1082, DOI 10.1126/science.1900131	21	17	18	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					828	829		10.1038/352828a0	http://dx.doi.org/10.1038/352828a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1679196				2022-12-01	WOS:A1991GC96400068
J	FLANAGAN, WM; CORTHESY, B; BRAM, RJ; CRABTREE, GR				FLANAGAN, WM; CORTHESY, B; BRAM, RJ; CRABTREE, GR			NUCLEAR-ASSOCIATION OF A T-CELL TRANSCRIPTION FACTOR BLOCKED BY FK-506 AND CYCLOSPORINE-A	NATURE			English	Article							CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CIS-TRANS ISOMERASE; IMMUNOSUPPRESSANT FK506; FK506-BINDING PROTEIN; GEL-ELECTROPHORESIS; NEUROSPORA-CRASSA; MACROLIDES FK-506; CYCLOPHILIN; ACTIVATION	CYCLOSPORIN A and FK506 inhibit T- and B-cell activation and other processes essential to an effective immune response 1-3. In T lymphocytes these drugs disrupt an unknown step in the transmission of signals from the T-cell antigen receptor to cytokine genes that coordinate the immune response 4-6. The putative intracellular receptors for FK506 and cyclosporin are cis-trans prolyl isomerases 7-11. Binding of the drug inhibits isomerase activity 8,10,11, but studies with other prolyl isomerase inhibitors 12 and analysis of cyclosporin-resistant mutants in yeast suggest that the effects of the drug result from the formation of an inhibitory complex between the drug and isomerase 13,14, and not from inhibition of isomerase activity. A transcription factor, NF-AT, which is essential for early T-cell gene activation, seems to be a specific target of cyclosporin A and FK506 action because transcription directed by this protein is blocked in T cells treated with these drugs, with little or no effect on other transcription factors such as AP-1 and NF-kappa-B (refs 15-17). Here we demonstrate that NF-AT is formed when a signal from the antigen receptor induces a pre-existing cytoplasmic subunit to translocate to the nucleus and combine with a newly synthesized nuclear subunit of NF-AT. FK506 and cyclosporin A block translocation of the cytoplasmic component without affecting synthesis of the nuclear subunit.			FLANAGAN, WM (corresponding author), STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,BECKMAN CTR MOLEC & GENET MED,STANFORD,CA 94305, USA.							BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; CIRILLO R, 1990, J IMMUNOL, V144, P3891; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FISCHER G, 1985, BIOCHIM BIOPHYS ACTA, V828, P39, DOI 10.1016/0167-4838(85)90006-8; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GAO EK, 1988, NATURE, V336, P176, DOI 10.1038/336176a0; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GUNTER KC, 1989, J IMMUNOL, V142, P3286; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HOHMAN R J, 1990, New Biologist, V2, P663; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; KAY JE, 1989, CELL IMMUNOL, V124, P175, DOI 10.1016/0008-8749(89)90121-4; KINCAID RL, 1987, NATURE, V330, P176, DOI 10.1038/330176a0; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; LANG K, 1988, NATURE, V331, P453, DOI 10.1038/331453a0; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; SUNG SSJ, 1988, J EXP MED, V168, P1539, DOI 10.1084/jem.168.5.1539; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; WISKOCIL R, 1985, J IMMUNOL, V134, P1599	34	1030	1063	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					803	807		10.1038/352803a0	http://dx.doi.org/10.1038/352803a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1715516				2022-12-01	WOS:A1991GC96400060
J	GODIN, I; DEED, R; COOKE, J; ZSEBO, K; DEXTER, M; WYLIE, CC				GODIN, I; DEED, R; COOKE, J; ZSEBO, K; DEXTER, M; WYLIE, CC			EFFECTS OF THE STEEL GENE-PRODUCT ON MOUSE PRIMORDIAL GERM-CELLS IN CULTURE	NATURE			English	Article							TYROSINE KINASE RECEPTOR; C-KIT; GROWTH-FACTOR; W-LOCUS; PROTO-ONCOGENE; SI-LOCUS; EXPRESSION; LIGAND; RAT	MUTATIONS at the steel (sl) and dominant white spotting (W) loci in the mouse affect primordial germ cells (PGC), melanoblasts and haemopoietic stem cells 1. The W gene encodes a cell-surface receptor of the tyrosine kinase family 2,3, the proto-oncogene c-kit. In situ analysis has shown c-kit messenger RNA expression in PGC in the early genital ridges 4. The Sl gene encodes the ligand for this receptor, a peptide growth factor, called here stem cell factor (SCF) 5-7. SCF mRNA is expressed in many regions of the early mouse embryo, including the areas of migration of these cell types 8. It is important now to identify the role of the Sl-W interaction in the development of these migratory embryonic stem cell populations. Using an in vitro assay system 9, we show that SCF increases both the overall numbers and colony sizes of migratory PGC isolated from wild-type mouse embryos, and cultured on irradiated feeder layers of STO cells (a mouse embryonic fibroblast line). In the absence of feeder cells, SCF causes a large increase in the initial survival and apparent motility of PGC in culture. But labelling with bromodeoxyuridine shows that SCF is not, by itself, a mitogen for PGC. SCF does not exert a chemotropic effect on PGC in in vitro assays. These results suggest that SCF in vivo is an essential requirement for PGC survival. This demonstrates the control of the early germ-line population by a specific trophic factor.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,DEPT EXPTL HAEMATOL,MANCHESTER M20 9BX,LANCS,ENGLAND; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	University of Cambridge; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Amgen	GODIN, I (corresponding author), UNIV CAMBRIDGE,WELLCOME CANC RES CAMPAIGN INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		GODIN, Isabelle/K-5769-2013	GODIN, Isabelle/0000-0001-8577-8388	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; DEXTER TM, 1990, PHILOS T ROY SOC B, V327, P85, DOI 10.1098/rstb.1990.0045; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DONOVAN PJ, 1986, CELL, V44, P831, DOI 10.1016/0092-8674(86)90005-X; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GODIN I, 1990, DEVELOPMENT, V108, P357; MANIATIS T, 1987, MOL CLONING; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; Silver W. K., 1979, COAT COLORS MICE MOD, P243; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	15	372	382	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					807	809		10.1038/352807a0	http://dx.doi.org/10.1038/352807a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1715517				2022-12-01	WOS:A1991GC96400061
J	HANCOCK, SL; COX, RS; MCDOUGALL, IR				HANCOCK, SL; COX, RS; MCDOUGALL, IR			THYROID-DISEASES AFTER TREATMENT OF HODGKINS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NECK IRRADIATION; GRAVES-DISEASE; RADIATION-THERAPY; MANTLE IRRADIATION; FOLLICULAR CARCINOMA; RADIOTHERAPY; DYSFUNCTION; HYPOTHYROIDISM; HYPERTHYROIDISM; OPHTHALMOPATHY	Background and Methods. Thyroid disease, especially hypothyroidism, is common in patients with Hodgkin's disease who have been treated with irradiation. We reviewed the records of 1787 patients (740 women and 1047 men) with Hodgkin's disease who were treated with radiation therapy alone (810 patients), radiation and chemotherapy (920 patients), or chemotherapy alone (57 patients) at Stanford University between 1961 and 1989. Among these patients, 1533 were alive at the last follow-up, and 254 had died of causes other than Hodgkin's disease. Four other patients were excluded from the analysis because they had undergone thyroidectomy before treatment for Hodgkin's disease. The thyroid was irradiated in 1677 patients. Follow-up averaged 9.9 years. Results. A total of 573 patients had clinical or biochemical evidence of thyroid disease. Among the 1677 patients whose thyroid was irradiated, the actuarial risk of thyroid disease 20 years after treatment was 52 percent, and it was 67 percent at 26 years. Hypothyroidism was found in 513 patients. A total of 486 patients received thyroxine therapy for elevated serum thyrotropin concentrations and either low free thyroxine (208 patients) or normal free thyroxine values (278 patients); 27 had transient elevations of the serum thyrotropin level that were not treated. Graves' hyperthyroidism developed in 30 patients (2 of whom had not undergone thyroid irradiation), and ophthalmopathy developed in 17 of these patients. Ophthalmopathy developed in four other patients with Graves' disease during a period of hypothyroidism (n = 3) or euthyroidism (n = 1). The risk of Graves disease was 7.2 to 20.4 times that for normal subjects. Silent thyroiditis with thyrotoxicosis developed in six patients. Forty-four patients were found to have single or multiple thyroid nodules, 26 of whom underwent thyroidectomy. Six of the 44 had papillary or follicular cancers. Among the patients who did not undergo operation, 12 had small functioning nodules, 4 had cysts, and 2 had multinodular goiters. The actuarial risk of thyroid cancer was 1.7 percent. The risk of thyroid cancer was 15.6 times the expected risk. Conclusions. High risks of thyroid disease persist more than 25 years after patients have received radiation therapy for Hodgkin's disease, reinforcing the need for continued clinical and biochemical evaluation. Prolonged follow-up confirms an elevated risk of thyroid cancer and Graves' disease as well as hypothyroidism in these patients.	STANFORD UNIV, MED CTR, SCH MED, DEPT DIAGNOST RADIOL & NUCL MED, STANFORD, CA 94305 USA	Stanford University	HANCOCK, SL (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT RADIAT ONCOL, A089, STANFORD, CA 94305 USA.				NATIONAL CANCER INSTITUTE [P01CA034233] Funding Source: NIH RePORTER; NCI NIH HHS [CA-34233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIN R, 1983, BRIT J RADIOL, V56, P768, DOI 10.1259/0007-1285-56-670-768; AREM R, 1990, ARCH INTERN MED, V150, P2097, DOI 10.1001/archinte.150.10.2097; BAKRI K, 1983, CANCER, V52, P465, DOI 10.1002/1097-0142(19830801)52:3<465::AID-CNCR2820520315>3.0.CO;2-6; BANTLE JP, 1985, INT J RADIAT ONCOL, V11, P1999, DOI 10.1016/0360-3016(85)90283-4; BERGLUND J, 1990, J INTERN MED, V227, P137, DOI 10.1111/j.1365-2796.1990.tb00132.x; BLITZER JB, 1985, ARCH INTERN MED, V145, P1734, DOI 10.1001/archinte.145.9.1734; CONSTINE LS, 1984, CANCER-AM CANCER SOC, V53, P878, DOI 10.1002/1097-0142(19840215)53:4<878::AID-CNCR2820530411>3.0.CO;2-J; CONSTINE LS, 1982, CLIN NUCL MED, V7, P69, DOI 10.1097/00003072-198202000-00006; COX DR, 1972, J R STAT SOC B, V34, P187; DEAN JW, 1985, BRIT MED J, V290, P1555, DOI 10.1136/bmj.290.6481.1555; EINHORN J, 1967, RADIOLOGY, V88, P326, DOI 10.1148/88.2.326; FURSZYFER J, 1970, MAYO CLIN PROC, V45, P636; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.1093/biomet/52.1-2.203; GHANDOUR C, 1985, ACTA HAEMATOL-BASEL, V74, P137, DOI 10.1159/000206189; Greene M H, 1985, Natl Cancer Inst Monogr, V68, P191; Groover TA, 1929, J AMER MED ASSOC, V92, P1730, DOI 10.1001/jama.1929.02700470006003; JACKSON R, 1979, CANCER TREAT REP, V63, P1393; JACOBSON DR, 1984, AM J MED SCI, V288, P217, DOI 10.1097/00000441-198412000-00005; KALDOR JM, 1987, INT J CANCER, V39, P571, DOI 10.1002/ijc.2910390506; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN MM, 1983, AM J MED, V74, P272, DOI 10.1016/0002-9343(83)90626-5; KINSELLA TJ, 1982, CANCER TREAT REP, V66, P991; LOEFFLER JS, 1988, INT J RADIAT ONCOL, V14, P175, DOI 10.1016/0360-3016(88)90065-X; MARCIALVEGA VA, 1990, INT J RADIAT ONCOL, V18, P613, DOI 10.1016/0360-3016(90)90068-U; MARKSON JL, 1965, BRIT MED J, V1, P1228, DOI 10.1136/bmj.1.5444.1228; MAUCH PM, 1983, CANCER-AM CANCER SOC, V51, P925, DOI 10.1002/1097-0142(19830301)51:5<925::AID-CNCR2820510527>3.0.CO;2-O; MCDOUGALL IR, 1980, CANCER-AM CANCER SOC, V45, P2056, DOI 10.1002/1097-0142(19800415)45:8<2056::AID-CNCR2820450812>3.0.CO;2-M; MCHARDYY.S, 1965, BRIT MED J, V2, P230, DOI 10.1136/bmj.2.5455.230-a; MEYER O O, 1971, Wisconsin Medical Journal, V70, P129; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; MOROFF SV, 1986, MED PEDIATR ONCOL, V14, P216, DOI 10.1002/mpo.2950140406; MORTIMER RH, 1986, AUST NZ J MED, V16, P347, DOI 10.1111/j.1445-5994.1986.tb01184.x; NELSON DF, 1978, CANCER-AM CANCER SOC, V42, P2553, DOI 10.1002/1097-0142(197812)42:6<2553::AID-CNCR2820420608>3.0.CO;2-H; NICOL F, 1982, POSTGRAD MED J, V58, P180, DOI 10.1136/pgmj.58.677.180; PETERSEN M, 1989, J NUCL MED, V30, P255; PILEPICH MV, 1978, JAMA-J AM MED ASSOC, V240, P1381, DOI 10.1001/jama.240.13.1381; PORTER AT, 1988, J ROY SOC MED, V81, P45, DOI 10.1177/014107688808100119; SCHIMPFF SC, 1980, ANN INTERN MED, V92, P91, DOI 10.7326/0003-4819-92-1-91; SERIES JJ, 1988, CLIN CHIM ACTA, V172, P217, DOI 10.1016/0009-8981(88)90326-9; SHALET SM, 1977, CLIN RADIOL, V28, P511, DOI 10.1016/S0009-9260(77)80066-4; SLATSTEI.E, 1971, J CLIN ENDOCR METAB, V32, P833, DOI 10.1210/jcem-32-6-833; SMITH RE, 1981, JAMA-J AM MED ASSOC, V245, P46, DOI 10.1001/jama.245.1.46; Storm H H, 1985, Natl Cancer Inst Monogr, V68, P389; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; WASNICH RD, 1973, J CLIN ENDOCR METAB, V37, P703, DOI 10.1210/jcem-37-5-703; WESHLER Z, 1978, ACTA RADIOL ONCOL, V17, P383, DOI 10.3109/02841867809128248; YOUNG RC, 1990, J NCI MONOGR, V10, P55; 1986, NATL CANCER I MONOGR, V70, P84	48	367	375	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1991	325	9					599	605		10.1056/NEJM199108293250902	http://dx.doi.org/10.1056/NEJM199108293250902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC328	1861693				2022-12-01	WOS:A1991GC32800002
J	MANGO, SE; MAINE, EM; KIMBLE, J				MANGO, SE; MAINE, EM; KIMBLE, J			CARBOXY-TERMINAL TRUNCATION ACTIVATES GLP-1 PROTEIN TO SPECIFY VULVAR FATES IN CAENORHABDITIS-ELEGANS	NATURE			English	Article							C-ELEGANS; CELL-INTERACTIONS; GROWTH-FACTOR; LIN-12 GENE; MUTATIONS; NEMATODE; DROSOPHILA; INDUCTION; STABILITY; DECISION	THE glp-1 and lin-12 genes encode homologous transmembrane proteins 1,2 that may act as receptors for cell interactions during development 3,4. The glp-1 product is required for induction of germ-line proliferation and for embryogenesis 3,5. By contrast, lin-12 mediates somatic cell interactions, including those between the precursor cells that form the vulval hypodermis (VPCs) 6. Here we analyse an unusual allele of glp-1, glp-1(q35), which displays a semidominant multivulva phenotype (Muv), as well as the typical recessive, loss-of-function Glp phenotypes (sterility and embryonic lethality) 3. We find that the effects of glp-1(q35) on VPC development mimic those of dominant lin-12 mutations, even in the absence of lin-12 activity. The glp-1(q35) gene bears a nonsense mutation predicted to eliminate the 122 C-terminal amino acids, including a ProGluSerThr (PEST) sequence thought to destabilize proteins. We suggest that the carboxy terminus bears a negative regulatory domain which normally inactivates glp-1 in the VPCs. We propose that inappropriate glp-1(q35) activity can substitute for lin-12 to determine vulval fate, perhaps by driving the VPCs to proliferate.	UNIV WISCONSIN,MOLEC BIOL LAB,1525 LINDEN DR,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; SYRACUSE UNIV,DEPT BIOL,SYRACUSE,NY 13214	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Syracuse University				Mango, Susan/0000-0002-2146-3237				AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BRENNER S, 1974, GENETICS, V77, P71; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HODGKIN J, 1989, GENETICS, V123, P301; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; KELLERMAN KA, 1990, GENE DEV, V4, P1936, DOI 10.1101/gad.4.11.1936; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; PRIESS JR, 1987, CELL, V51, P610; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SEYDOUX G, 1990, CELL, V61, P939, DOI 10.1016/0092-8674(90)90060-R; SEYDOUX G, 1991, THESIS U PRINCETON; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	27	60	78	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					811	815		10.1038/352811a0	http://dx.doi.org/10.1038/352811a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1881436	Green Submitted			2022-12-01	WOS:A1991GC96400063
J	REITNER, A; SHARPE, LT; ZRENNER, E				REITNER, A; SHARPE, LT; ZRENNER, E			IS COLOR-VISION POSSIBLE WITH ONLY RODS AND BLUE-SENSITIVE CONES	NATURE			English	Article							SPECTRAL SENSITIVITY; ACHROMATOPSIA; MONOCHROMACY	AT night all cats are grey, but with the approach of dawn they take on colour. By starlight, a single class of photoreceptors, the rods, function, whereas by daylight, three classes, the blue-, green- and red-sensitive cones, are active and provide colour vision. Only by comparing the rates of quantal absorption in more than one photoreceptor class is colour vision possible. Although the comparisons generally take place between the cones, they can involve the rods as well 1-4. Here we investigate the wavelength discrimination of an extremely rare group of individuals, blue-cone monochromats, who have only rods and one class of cones 5-8. We find that these individuals can distinguish wavelengths (440 to 500 nm) in the twilight region where the rods and blue-sensitive cones are simultaneously active.	UNIV FREIBURG,NEUROL KLIN,W-7800 FREIBURG,GERMANY; UNIV TUBINGEN,HOSP EYE,DEPT PATHOPHYSIOL VIS & NEUROOPHTHALMOL,W-7400 TUBINGEN 1,GERMANY	University of Freiburg; Eberhard Karls University of Tubingen	REITNER, A (corresponding author), ZWEITE UNIV VIENNA,AUGENKLIN,ALSERSTR 4,A-1090 VIENNA,AUSTRIA.							ALPERN M, 1965, ARCH OPHTHALMOL-CHIC, V74, P334; ALPERN M, 1971, J PHYSIOL-LONDON, V212, P211, DOI 10.1113/jphysiol.1971.sp009318; BLACKWELL HR, 1961, VISION RES, V1, P62, DOI 10.1016/0042-6989(61)90022-0; Boynton R. M., 1979, HUMAN COLOR VISION; Clarke F. J. J., 1960, OPT ACTA, V7, P355; DZMURA M, 1986, VISION RES, V26, P1273, DOI 10.1016/0042-6989(86)90108-2; GOURAS P, 1966, J PHYSIOL-LONDON, V184, P499, DOI 10.1113/jphysiol.1966.sp007928; GOURAS P, 1965, SCIENCE, V147, P1593, DOI 10.1126/science.147.3665.1593; HANSEN E, 1978, NATURE, V276, P390, DOI 10.1038/276390a0; HESS RF, 1989, J PHYSIOL-LONDON, V417, P123, DOI 10.1113/jphysiol.1989.sp017794; INGLING CR, 1977, VISION RES, V17, P1083, DOI 10.1016/0042-6989(77)90014-1; MCCANN JJ, 1972, SCIENCE, V176, P1255, DOI 10.1126/science.176.4040.1255; MOLLON JD, 1977, PHILOS T ROY SOC B, V278, P207, DOI 10.1098/rstb.1977.0038; NATHANS J, 1989, SCIENCE, V245, P831, DOI 10.1126/science.2788922; PALMER DA, 1978, J OPT SOC AM, V68, P1501, DOI 10.1364/JOSA.68.001501; REITNER A, IN  PRESS VISION RES; SHARPE LT, 1989, SCIENCE, V244, P354, DOI 10.1126/science.2711186; SMITH VC, 1983, INVEST OPHTH VIS SCI, V24, P451; SMITH VC, 1972, VISION RES, V12, P2059, DOI 10.1016/0042-6989(72)90058-2; SMITH VC, 1977, J OPT SOC AM, V67, P213, DOI 10.1364/JOSA.67.000213; STABELL B, 1974, VISION RES, V14, P1389, DOI 10.1016/0042-6989(74)90013-3; TREZONA PW, 1970, VISION RES, V10, P317, DOI 10.1016/0042-6989(70)90103-3; TREZONA PW, 1973, VISION RES, V13, P9, DOI 10.1016/0042-6989(73)90161-2; van den Berg T J, 1978, Mod Probl Ophthalmol, V19, P341; WILLMER EN, 1960, J THEOR BIOL, V2, P141; Wright WD, 1937, P PHYS SOC, V49, P329, DOI 10.1088/0959-5309/49/4/301; Wyszecki Gunter, 1982, COLOR SCI, V8; YOUNG RSL, 1985, INVEST OPHTH VIS SCI, V26, P1543; ZRENNER E, 1988, KLIN MONATSBL AUGENH, V193, P510, DOI 10.1055/s-2008-1050292	29	75	75	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					798	800		10.1038/352798a0	http://dx.doi.org/10.1038/352798a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1881435				2022-12-01	WOS:A1991GC96400058
J	TANABE, T; ADAMS, BA; NUMA, S; BEAM, KG				TANABE, T; ADAMS, BA; NUMA, S; BEAM, KG			REPEAT-I OF THE DIHYDROPYRIDINE RECEPTOR IS CRITICAL IN DETERMINING CALCIUM-CHANNEL ACTIVATION KINETICS	NATURE			English	Article							SODIUM-CHANNEL; SKELETAL-MUSCLE; POTASSIUM CHANNELS; EXPRESSION; MEMBRANE; CDNA	MEMBRANE depolarization causes many kinds of ion channels to open, a process termed activation 1. For both Na+ channels 2-4 and Ca2+ channels 5,6, kinetic analysis of current has suggested that during activation the channel undergoes several conformational changes before reaching the open state. Structurally, these channels share a common motif 7: the central element is a large polypeptide with four repeating units of homology (repeats I-IV), each containing a voltage-sensing region, the S4 segment 8-11. This suggests that the distinct conformational transitions inferred from kinetic analysis may be equated with conformational changes of the individual structural repeats 8. To investigate the molecular basis of channel activation, we constructed complementary DNAs encoding chimaeric Ca2+ channels in which one or more of the four repeats of the skeletal muscle dihydropyridine receptor are replaced by the corresponding repeats derived from the cardiac dihydropyridine receptor. We report here that repeat I determines whether the chimaeric Ca2+ channel shows slow (skeletal muscle-like) 12 or rapid (cardiac-like) 13 activation.	KYOTO UNIV, FAC MED, DEPT MED CHEM, KYOTO 606, JAPAN; KYOTO UNIV, FAC MED, DEPT MOLEC GENET, KYOTO 606, JAPAN; COLORADO STATE UNIV, COLL VET MED & BIOMED SCI, DEPT PHYSIOL, FT COLLINS, CO 80523 USA	Kyoto University; Kyoto University; Colorado State University			Tuluc, Petronel/C-2527-2011					ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; ARMSTRONG CM, 1981, PHYSIOL REV, V61, P644, DOI 10.1152/physrev.1981.61.3.644; GLUECKSOHNWAELS.S, 1963, SCIENCE, V142, P1269, DOI 10.1126/science.142.3597.1269; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; Hille B, 1984, IONIC CHANNELS EXCIT; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; KEYNES RD, 1990, PROC R SOC SER B-BIO, V240, P411, DOI 10.1098/rspb.1990.0045; KOSTYUK PG, 1981, J PHYSIOL-LONDON, V310, P403, DOI 10.1113/jphysiol.1981.sp013557; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; NUMA S, 1989, HARVEY LECT, V83, P121; SANCHEZ JA, 1983, J PHYSIOL-LONDON, V337, P1; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29	27	121	123	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 29	1991	352	6338					800	803		10.1038/352800a0	http://dx.doi.org/10.1038/352800a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1652692				2022-12-01	WOS:A1991GC96400059
J	VANDEPERRE, P; SIMONON, A; MSELLATI, P; HITIMANA, DG; VAIRA, D; BAZUBAGIRA, A; VANGOETHEM, C; STEVENS, AM; KARITA, E; SONDAGTHULL, D; DABIS, F; LEPAGE, P				VANDEPERRE, P; SIMONON, A; MSELLATI, P; HITIMANA, DG; VAIRA, D; BAZUBAGIRA, A; VANGOETHEM, C; STEVENS, AM; KARITA, E; SONDAGTHULL, D; DABIS, F; LEPAGE, P			POSTNATAL TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 FROM MOTHER TO INFANT - A PROSPECTIVE COHORT STUDY IN KIGALI, RWANDA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-MILK; HIV-INFECTION; AIDS; SHEEP; CELL	Background. Although transmission of human immunodeficiency virus type 1 (HIV-1) from mother to infant has been well documented during pregnancy and delivery, little is known about the possible transmission of HIV-1 during the postnatal period. Methods. We conducted a prospective cohort study in Kigali, Rwanda, of 212 mother-infant pairs who were seronegative for HIV-1 at delivery. All the infants were breast-fed. The subjects were followed at three-month intervals, with Western blot assays for antibodies to HIV-1 and testing of mononuclear cells by a double polymerase chain reaction (PCR) using three sets of primers. To evaluate potential risk factors, each mother who seroconverted was matched with three seronegative control women. Results. After a mean follow-up of 16.6 months, 16 of the 212 mothers became seropositive for HIV-1. Of their 16 infants, 9 became seropositive. One infant was excluded from the analysis because of a positive test by PCR on the blood sample obtained at birth. Postnatal seroconversion to HIV-1 occurred in four of the five infants born to the mothers who seroconverted during the first 3 months post partum, and in four infants of the 10 mothers who seroconverted between month 4 and month 21. In all cases, the infant seroconverted during the same three-month period as the mother. The main risk factor for maternal seroconversion was being single. Conclusions. HIV-1 infection can be transmitted from mothers to infants during the postnatal period. Colostrum and breast milk may be efficient routes for the transmission of HIV-1 from recently infected mothers to their infants.	CTR HOSP,DEPT PEDIAT,KIGALI,RWANDA; UNIV BORDEAUX 2,INSERM,U330,F-33076 BORDEAUX,FRANCE; STATE UNIV LIEGE,CTR TRANSFUS,B-4000 LIEGE,BELGIUM	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; University of Liege	VANDEPERRE, P (corresponding author), NATL AIDS CONTROL PROGRAM,AIDS REFERENCE LAB,BP 780,KIGALI,RWANDA.		DABIS, FRANCOIS/S-9298-2019; Van de Perre, Philippe/B-9692-2008	DABIS, FRANCOIS/0000-0002-1614-8857; Van de Perre, Philippe/0000-0002-3912-0427				ALLEN S, 1990, 6TH INT C AIDS SAN F, V3, P104; BUCENS M, 1988, 4TH P INT C AIDS STO, V1; COMMEAU A, 1990, GENETIC SCREENING NE, P159; FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P271; GOLDMAN AS, 1982, J PEDIATR-US, V100, P563, DOI 10.1016/S0022-3476(82)80753-1; GOUDSMIT J, 1986, LANCET, V2, P177; HINO S, 1989, Acta Paediatrica Japonica, V31, P428; HIRA SK, 1990, J PEDIATR-US, V117, P421, DOI 10.1016/S0022-3476(05)81084-4; LAWTON JWM, 1977, LANCET, V1, P253; LEPAGE P, 1991, AIDS, V5, P295, DOI 10.1097/00002030-199103000-00008; LEPAGE P, 1981, LANCET, V2, P409; LEVY JA, 1988, JAMA-J AM MED ASSOC, V259, P3037, DOI 10.1001/jama.259.20.3037; NARAYAN O, 1985, REV INFECT DIS, V7, P89; NATHANSON N, 1985, REV INFECT DIS, V7, P75; OXTOBY MJ, 1988, PEDIATR INFECT DIS J, V7, P825, DOI 10.1097/00006454-198807120-00001; OXTOBY MJ, 1990, PEDIATR INFECT DIS J, V9, P609; POKROVSKY VV, 1990, 6TH INT C AIDS SAN F, V1, P145; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; THIRY L, 1985, LANCET, V2, P891; TUDORWILLIAMS G, 1991, AIDS, V5, P103, DOI 10.1097/00002030-199101000-00017; VOGT MW, 1986, LANCET, V1, P525; WELSH JK, 1979, J PEDIATR-US, V94, P1, DOI 10.1016/S0022-3476(79)80340-6; WILLIAMS P, 1990, AIDS, V4, P393, DOI 10.1097/00002030-199005000-00003; 1986, MMWR, V35, P76; 1985, OCT WORKSH AIDS CENT; 1989, MMWR, V38, P1	26	288	292	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1991	325	9					593	598		10.1056/NEJM199108293250901	http://dx.doi.org/10.1056/NEJM199108293250901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC328	1812850	Bronze			2022-12-01	WOS:A1991GC32800001
J	WU, J; MANLEY, JL				WU, J; MANLEY, JL			BASE-PAIRING BETWEEN U2 AND U6 SNRNAS IS NECESSARY FOR SPLICING OF A MAMMALIAN PRE-MESSENGER-RNA	NATURE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; BRANCH SITE SELECTION; GENES EVEN THOUGH; U1 SNRNA; EFFICIENT TRANSCRIPTION; DIFFERENT POLYMERASE; 2'-OME RNA; YEAST; PARTICLES; ELEMENTS	SPLICING of pre-messenger RNA in eukaryotic cells occurs in a multicomponent complex termed the spliceosome, which contains small nuclear ribonucleoprotein particles (snRNPs), protein factors and substrate pre-mRNA 1-3. Assembly of the spliceosome involves the stepwise binding of snRNPs and protein factors to the pre-mRNA through a poorly understood mechanism which probably involves specific RNA-RNA, RNA-protein and protein-protein interactions. Of particular interest are the interactions between snRNPs, which are likely to be important not only for assembly of the spliceosome but also for catalysis. U1 snRNP interacts with the 5' splice site and U2 snRNP with the branch site of the pre-mRNA; both of these interactions involve Watson-Crick base pairing 4-9. But very little is known about how other factors such as the U4/U6 and U5 snRNPs reach the spliceosome and function in splicing. Here we report evidence that U6 snRNA interacts directly with U2 snRNA by a mechanism involving base-pairing, and that this interaction can be necessary for splicing of a mammalian pre-mRNA in vivo.			WU, J (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Manley, James/0000-0002-8341-1459				BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLACK DL, 1986, CELL, V46, P697, DOI 10.1016/0092-8674(86)90345-4; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FRENDEWEY D, 1987, COLD SPRING HARB SYM, V52, P287, DOI 10.1101/SQB.1987.052.01.034; FU XY, 1987, MOL CELL BIOL, V7, P738, DOI 10.1128/MCB.7.2.738; FU XY, 1988, MOL CELL BIOL, V8, P3582, DOI 10.1128/MCB.8.9.3582; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LIAO XL, 1990, GENE DEV, V4, P1766, DOI 10.1101/gad.4.10.1766; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; NOBLE JCS, 1988, GENE DEV, V2, P1460, DOI 10.1101/gad.2.11.1460; NOBLE JCS, 1987, CELL, V50, P227, DOI 10.1016/0092-8674(87)90218-2; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5462; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SHANNON KW, 1991, GENE DEV, V5, P773, DOI 10.1101/gad.5.5.773; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	32	160	161	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					818	821		10.1038/352818a0	http://dx.doi.org/10.1038/352818a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1831878				2022-12-01	WOS:A1991GC96400065
J	GOODWIN, FK				GOODWIN, FK			ALCOHOL, CAFFEINE, AND FETAL CELLS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							HENDERSON GI, 1991, ALCOHOL CLIN EXP RES, V15, P175, DOI 10.1111/j.1530-0277.1991.tb01850.x	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1056	1056						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1650851				2022-12-01	WOS:A1991GB97500008
J	GOODWIN, FK				GOODWIN, FK			COCAINE WITHDRAWAL AND THE BRAIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							1991, AM J PSYCHIAT, V148, P621	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1056	1056						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB975	1650851				2022-12-01	WOS:A1991GB97500007
J	GOODWIN, FK				GOODWIN, FK			DIAZEPAM AND MEMORY LOSS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							1991, AM J DRUG ALCOHOL AB, V17, P129	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1056	1056						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB975	1650851				2022-12-01	WOS:A1991GB97500006
J	KATZ, SJ; MIZGALA, HF; WELCH, HG				KATZ, SJ; MIZGALA, HF; WELCH, HG			BRITISH-COLUMBIA SENDS PATIENTS TO SEATTLE FOR CORONARY-ARTERY SURGERY - BYPASSING THE QUEUE IN CANADA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURVIVAL	Concern about waiting lists for elective procedures has become a highly visible challenge to the universal health insurance program in Canada. In response to lengthening queues for patients waiting for cardiac surgery, British Columbia made contracts with four Seattle hospitals to send a total of 200 patients for coronary artery bypass surgery This article examines the cause of the queue for cardiac surgery in British Columbia and the events that led to outside contracting. Global hospital budgets and restrictions on capital expansion have limited hospital capacity for cardiac surgery This constrained supply, combined with periodic shortages in critical care nurses and cardiac perfusion technologists, has resulted in a rapid increase in the waiting list. Reducing wide variations in the lengths of queues for individual surgeons may afford an opportunity to reduce long waits. While the patient queue for cardiac surgery has sparked a public debate about budget limits and health care needs, its clinical impact remains uncertain.	UNIV BRITISH COLUMBIA,DIV CARDIOL,VANCOUVER V6T 1W5,BC,CANADA; VANCOUVER GEN HOSP,VANCOUVER V5Z 1M9,BC,CANADA; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED,HANOVER,NH 03756; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT COMMUNITY & FAMILY MED,HANOVER,NH 03756; DEPT VET AFFAIRS MED CTR,WHITE RIVER JCT,VT; UNIV WASHINGTON,SEATTLE,WA 98195	University of British Columbia; University of British Columbia; Dartmouth College; Dartmouth College; University of Washington; University of Washington Seattle	KATZ, SJ (corresponding author), UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,DIV GEN MED,3116 TAUBMAN,BOX 0376,ANN ARBOR,MI 48109, USA.		KATZ, STEVEN/ABH-8886-2020					ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; EVANS RG, 1982, RESOURCES HLTH TECHN; LEBOURDAIS E, 1990, CAN MED ASSOC J, V143, P306; NAYLOR CD, 1990, AM J PUBLIC HEALTH, V80, P1246, DOI 10.2105/AJPH.80.10.1246; PASSAMANI E, 1985, NEW ENGL J MED, V312, P1665, DOI 10.1056/NEJM198506273122603; WHALEN RE, 1982, CIRCULATION, V65, P49, DOI 10.1161/01.CIR.65.7.49; 1988, REPORT MINISTRY HLTH; 1984, NEW ENGL J MED, V311, P1333	8	52	52	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1108	1111		10.1001/jama.266.8.1108	http://dx.doi.org/10.1001/jama.266.8.1108			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1865544				2022-12-01	WOS:A1991GB97500034
J	ORENTLICHER, D				ORENTLICHER, D			HIV-INFECTED SURGEONS - BEHRINGER V MEDICAL-CENTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											ORENTLICHER, D (corresponding author), AMER MED ASSOC,ETH & HLTH POLICY COUSEL,CHICAGO,IL 60610, USA.							BARAFF LJ, 1989, ANN EMERG MED, V18, P654, DOI 10.1016/S0196-0644(89)80522-0; Barnes M, 1990, Law Med Health Care, V18, P311; BRENNAN TA, 1991, NEW ENGL J MED, V324, P1504, DOI 10.1056/NEJM199105233242112; DICKEY NW, 1991, JAMA-J AM MED ASSOC, V265, P2338, DOI 10.1001/jama.1991.03460180043023; FRIEDLAND GH, 1990, NEW ENGL J MED, V322, P1000, DOI 10.1056/NEJM199004053221409; GERBERDING JL, 1986, NEW ENGL J MED, V315, P1562, DOI 10.1056/NEJM198612113152434; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GOSTIN L, 1991, ARCH INTERN MED, V151, P663, DOI 10.1001/archinte.151.4.663; JONSEN AR, 1991, ARCH INTERN MED, V151, P660, DOI 10.1001/archinte.151.4.660; KLEIN RS, 1991, AM J MED, V90, P141, DOI 10.1016/0002-9343(91)80152-C; RHAME FS, 1990, JAMA-J AM MED ASSOC, V264, P507, DOI 10.1001/jama.264.4.507; WONG ES, 1991, JAMA-J AM MED ASSOC, V265, P1123, DOI 10.1001/jama.265.9.1123; 1988, JAMA-J AM MED ASSOC, V259, P1360; 1991, MMWR, V40, P1; 1991, AM ACAD ORTHOP SU S2, V39, P1; 1990, OBSTET GYNECOL, V75, P1043; 1985, MMWR, V34, P681; 1987, MMWR S2S, V36, pS3; 1991, JAMA-J AM MED ASSOC, V265, P1872; 1991, PHYSICIAN CHARACTERI, P90; 1991, MMWR, V40, P377; 1989, CURRENT OPINIONS, P32	22	16	18	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1134	1137		10.1001/jama.266.8.1134	http://dx.doi.org/10.1001/jama.266.8.1134			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1865550				2022-12-01	WOS:A1991GB97500041
J	RILEY, WA; SCHNECKENBURGER, WA				RILEY, WA; SCHNECKENBURGER, WA			THE MARYLAND EXPERIENCE AND A PRACTICAL PROPOSAL TO EXPAND EXISTING MODELS IN AMBULATORY PRIMARY CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Two unique models for caring for the uninsured and underinsured are operating in Maryland. The first is a group practice, primary care model with a unique ambulatory Medicare waiver that has had a positive impact on patients and physicians. The second is a financial model - an all-payer prospective rate-setting system for all critical care inpatient hospitals that, during a 13-year period from 1977 through 1989, has saved the citizens of the state approximately $5.361 billion, has allowed hospitals to provide $1.657 billion of charity care and bad debts, and has earned $517 million in net profits. The reasons for the success of each of the models are discussed and form the basis for a practical and politically feasible proposal: merge the best aspects of each model into an ambulatory primary care - based model financed through an all-payer prospective charge system.			RILEY, WA (corresponding author), GREATER BALTIMORE MED CTR,DEPT MED,6701 N CHARLES ST,BALTIMORE,MD 21204, USA.							1986, 5 CITY PROGRAM IMPRO, V1, P13; 1989, HOSPITAL STATISTICS	2	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1118	1122		10.1001/jama.266.8.1118	http://dx.doi.org/10.1001/jama.266.8.1118			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1865546				2022-12-01	WOS:A1991GB97500037
J	SCHWARTZ, B; SCHUCHAT, A; OXTOBY, MJ; COCHI, SL; HIGHTOWER, A; BROOME, CV				SCHWARTZ, B; SCHUCHAT, A; OXTOBY, MJ; COCHI, SL; HIGHTOWER, A; BROOME, CV			INVASIVE GROUP-B STREPTOCOCCAL DISEASE IN ADULTS - A POPULATION-BASED STUDY IN METROPOLITAN ATLANTA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BACTEREMIA; POLYSACCHARIDE; INFECTIONS; COMMUNITY; VACCINE; COUNTY; WOMEN	Objective.-To define the incidence and clinical spectrum of group B streptococcus infection in adults. To characterize groups at increased risk for infection. Design.-Retrospective population-based surveillance of group B streptococcus infections occurring in adults. Patients were identified by review of microbiology records at all surveillance area hospital laboratories. Demographic and clinical data were abstracted from patient medical records. Setting.-Metropolitan Atlanta, Ga, 1982 through 1983. Patients.-We identified 70 adult patients with invasive group B streptococcus infections; 14 infections occurred in pregnant women and 56 in nonpregnant adults. Results.-The annual incidence of group B streptococcus infection in men and nonpregnant women was 2.4 cases per 100 000 population. Incidence increased with age and was higher in blacks than in whites. The case-fatality rate was 32%. Group B streptococcus was most often isolated from blood (71%) and soft tissue (16%). Common clinical presentations included skin and soft-tissue infection (36%), bacteremia without focus (34%), pneumonia (11%), arthritis (9%), and endocarditis (9%). Compared with the general population's risk of infection, the risk of infection in persons with diabetes mellitus was increased 10.5-fold (95% confidence interval [Cl], 7.8 to 14.4); in persons with cancer, it was increased 16.4-fold (95% Cl, 11.5 to 23.3). Conclusions.-Group B streptococcus infections cause serious disease in adults as well as in neonates, providing an additional rationale for vaccine development. Determining the incidence of adult disease and groups at greatest risk will help in focusing prevention efforts.	CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,MENINGITIS & SPECIAL PATHOGENS BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,STAT SERV ACTIV,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								ANTHONY BF, 1975, J INFECT DIS, V132, P561, DOI 10.1093/infdis/132.5.561; BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802; BAKER CJ, 1985, REV INFECT DIS, V7, P458; BAKER CJ, 1990, NEW ENGL J MED, V322, P1857, DOI 10.1056/NEJM199006283222606; BAKER CJ, 1990, INFECT DIS, P742; BAYER AS, 1976, AM J MED, V61, P498, DOI 10.1016/0002-9343(76)90329-6; DWORZACK DL, 1979, AM J MED SCI, V277, P67, DOI 10.1097/00000441-197901000-00008; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; FILICE GA, 1980, AM J EPIDEMIOL, V112, P828, DOI 10.1093/oxfordjournals.aje.a113055; FRASER DW, 1974, AM J EPIDEMIOL, V100, P29, DOI 10.1093/oxfordjournals.aje.a112005; GALLAGHER PG, 1985, AM J MED, V78, P795, DOI 10.1016/0002-9343(85)90285-2; GIBBS RS, 1981, AM J OBSTET GYNECOL, V140, P405, DOI 10.1016/0002-9378(81)90034-X; HARRIS M, 1985, NIH851468 PUBL, V8, P3; LAGERGARD T, 1990, INFECT IMMUN, V58, P687, DOI 10.1128/IAI.58.3.687-694.1990; LEDGER WJ, 1975, AM J OBSTET GYNECOL, V121, P205, DOI 10.1016/0002-9378(75)90641-9; LERNER PI, 1977, MEDICINE, V56, P457, DOI 10.1097/00005792-197711000-00001; MUFSON MA, 1982, JAMA-J AM MED ASSOC, V248, P1486, DOI 10.1001/jama.248.12.1486; PAOLETTI LC, 1990, J BIOL CHEM, V265, P18278; SCHUCHAT A, 1990, J INFECT DIS, V162, P672, DOI 10.1093/infdis/162.3.672; VERGHESE A, 1986, REV INFECT DIS, V8, P912; 1981, J INFECTION, V3, P385; 1985, DISEASES IMPORTANCE, V1, P423	22	177	181	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1112	1114		10.1001/jama.266.8.1112	http://dx.doi.org/10.1001/jama.266.8.1112			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1865545				2022-12-01	WOS:A1991GB97500035
J	GULLIFORD, MC; PETRUCKEVITCH, A; BURNEY, PGJ				GULLIFORD, MC; PETRUCKEVITCH, A; BURNEY, PGJ			SURVIVAL WITH BLADDER-CANCER, EVALUATION OF DELAY IN TREATMENT, TYPE OF SURGEON, AND MODALITY OF TREATMENT	BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL DEATH RATES; GEOGRAPHICAL VARIATION; MORTALITY; QUALITY; RADIOTHERAPY; CYSTECTOMY; CARCINOMA; SEVERITY; ILLNESS; CARE	Objective-To determine whether length of delay before treatment; specialty and grade of the surgeon; and use made of surgery, radiotherapy, and chemotherapy influenced the survival of patients with cancer of the bladder, after adjusting for case severity. Design-Retrospective cohort study. Setting-South East and South West Thames health regions. Patients-609 men aged under 75 resident in the South Thames regions who had been registered as new cases of bladder cancer in 1982, 35 of whom were excluded, leaving 574 eligible patients. Analysis was based on 75% retrieval rate for case notes. Main outcome measures-Duration of survival from date of diagnosis of the bladder tumour. Results-10 prognostic variables were used to adjust for case severity. The median delay from referral to first treatment was 48 (interquartile range 27-84) days. Treatment after a short delay was associated with shorter survival because of the early treatment of more severe cases. Consultants treated 68% of patients, trainee surgeons treated less severe cases. Initial treatment was by a urologist in 67% of cases, but the specialty of the surgeon was not associated with prognosis. The associations of radiotherapy, cystectomy, and systemic chemotherapy with survival were interpreted in terms of selection bias as well as therapeutic effect. Conclusions-Case severity was the most important influence on survival and influenced length of delay before treatment, grade and specialty of the surgeon, and main treatment allocation. After adjusting for case severity variations in these processes of care were not strongly associated with variations in survival.			GULLIFORD, MC (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT PUBL HLTH MED,ST THOMAS CAMPUS,LONDON SE1 7EH,ENGLAND.		Gulliford, Martin C/I-8606-2018	Gulliford, Martin C/0000-0003-1898-9075; Burney, Peter/0000-0001-8635-5678	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABEL PD, 1988, BRIT J UROL, V62, P103, DOI 10.1111/j.1464-410X.1988.tb04286.x; ASO Y, 1986, PROG CLIN BIOL RES, V162, P257; BISHOP MC, 1990, BRIT J UROL, V65, P433, DOI 10.1111/j.1464-410X.1990.tb14781.x; Buck N, 1987, REPORT CONFIDENTIAL; CHARLTON JRH, 1983, LANCET, V1, P691; DELAMOTHE T, 1990, BRIT MED J, V301, P1011; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2, P759; DUBOIS RW, 1987, AM J PUBLIC HEALTH, V77, P1162, DOI 10.2105/AJPH.77.9.1162; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; GULLIFORD MC, 1991, BRIT MED J, V302, P1128, DOI 10.1136/bmj.302.6785.1128; HOLLAND WW, 1988, EUROPEAN COMMUNITY A; HOPESTONE HF, 1984, UROLOGY, V24, P315, DOI 10.1016/0090-4295(84)90199-7; Hopkins A., 1990, MEASURING QUALITY ME; KARJALAINEN S, 1990, J EPIDEMIOL COMMUN H, V44, P210, DOI 10.1136/jech.44.3.210; MAMEGHAN H, 1989, BRIT J UROL, V63, P251, DOI 10.1111/j.1464-410X.1989.tb05185.x; MOMMSEN S, 1983, SCAND J UROL NEPHROL, V17, P163, DOI 10.3109/00365598309180162; MOULD RF, 1986, LANCET, V1, P1385; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; RAGHAVAN D, 1990, NEW ENGL J MED, V322, P1129, DOI 10.1056/NEJM199004193221607; RICHARDS B, 1986, PROG CLIN BIOL RES, V162, P271; SHEARER RJ, 1988, BRIT J UROL, V62, P558, DOI 10.1111/j.1464-410X.1988.tb04426.x; Silman A J, 1981, Community Med, V3, P291, DOI 10.1007/BF02549184; SOLOWAY MS, 1987, CANCER, V60, P502, DOI 10.1002/1097-0142(19870801)60:3+<502::AID-CNCR2820601512>3.0.CO;2-W; SPIESSL B, 1989, UICC TNM ATLAS, P245; TONKIN K, 1988, MANAGEMENT BLADDER C, P228; TRUNKEY D, 1989, BRIT MED J, V299, P31, DOI 10.1136/bmj.299.6690.31; WALLACE DM, 1965, LANCET, V2, P332; 1990, REV NATIONAL CANCER, P9; 1980, BMJ, V280, P590; 1982, CANCER STATISTIC MB1	31	54	54	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					437	440		10.1136/bmj.303.6800.437	http://dx.doi.org/10.1136/bmj.303.6800.437			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912834	Green Published, Bronze			2022-12-01	WOS:A1991GC46500014
J	HALL, MH				HALL, MH			HEALTH OF PREGNANT-WOMEN	BRITISH MEDICAL JOURNAL			English	Article											HALL, MH (corresponding author), ABERDEEN ROYAL INFIRM,ABERDEEN AB9 2ZB,SCOTLAND.							BANTA D, 1989, EFFECTIVE CARE PREGN, P1449; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BERAL V, 1979, BRIT MED J, V2, P632, DOI 10.1136/bmj.2.6191.632; BRYCE R, 1989, EFFECTIVE CARE PREGN, P1313; Carstairs V., 1991, DEPRIVATION HLTH SCO; Chalmers I, 1989, EFFECTIVE CARE PREGN; FORREST CG, 1982, BRIT MED J, V285, P1475; FRANCOME C, 1986, ABORTION PRACTICE BR; FRANKEL S, 1991, LANCET, V337, P1588, DOI 10.1016/0140-6736(91)93276-F; HOLLAND WW, 1988, EUROPEAN COMMUNITY A; KLINE J, 1990, EARLY PREGNANCY FAIL, P240; MACFARLANE A, 1984, BIRTH COUNTS STATIST; Oakley Ann, 1990, MISCARRIAGE; TEMMERMAN M, 1991, EUR J OBSTET GYN R B, V39, P13; TOWNSEND P, 1988, INEQUALITIES HLTH BL; 1991, REPORT UK 1985 7	16	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					460	462		10.1136/bmj.303.6800.460	http://dx.doi.org/10.1136/bmj.303.6800.460			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912841	Green Published, Bronze			2022-12-01	WOS:A1991GC46500021
J	HOWARD, AJ; DUNKIN, KT; MUSSER, JM; PALMER, SR				HOWARD, AJ; DUNKIN, KT; MUSSER, JM; PALMER, SR			EPIDEMIOLOGY OF HAEMOPHILUS-INFLUENZAE TYPE-B INVASIVE DISEASE IN WALES	BRITISH MEDICAL JOURNAL			English	Article							MEMBRANE PROTEIN SUBTYPES; 10 YEARS EXPERIENCE; HEMOPHILUS-INFLUENZAE; BACTERIAL-MENINGITIS; CONJUGATE VACCINES; CHILDREN; POPULATION; AMPICILLIN; PREVENTION; RESISTANCE	Objective-To investigate the epidemiology of invasive disease due to Haemophilus influenzae type b, the clones responsible, and the antibiotic resistance of the isolates. Design-Prospective population based analysis of clinical and epidemiological data collected for Gwynedd during 1980-90 and in the whole of Wales during 1988-90. Setting-19 hospitals in Wales; all medical microbiology laboratories in Wales participated. Patients-82 patients with confirmed invasive infections caused by H influenzae type b in Gwynedd during 1980-90 and 207 in Wales during 1988-90. Main outcome measures-Clinical and epidemiological measures; analysis of the clonal types of the isolates based on the electrophoretic mobilities of 17 metabolic enzymes; and antibiotic resistance. Results-The annual incidence of H influenzae type b infections in Gwynedd was 3.2 cases/100 000 and in Wales was 2.5 cases/100 000. Most cases occurred in children aged under 5 years, the highest annual incidence being in those aged under 1 (84.6/100 000 and 56.9/100 000 in Wales). The cumulative risk of acquiring H influenzae type b disease by the fifth birthday was one in 456 in Gwynedd and one in 578 in Wales. Fifteen per cent of cases in Gwynedd and 7% of those in Wales occurred in adults. Predominant clinical conditions were meningitis in children and pneumonia in adults. In Gwynedd 2/70 (3%) children and 5/12 (42%) adults died. Long term neurological sequelae occurred in 8% (4/48) of children who survived haemophilus meningitis. Children presenting with infection were usually the youngest members of their family. No secondary household cases were identified. 100 of 128 (78%) strains were of a single clone, electrophoretic type 12.5, and 4/207 (1.9%) isolates from Wales were resistant to both ampicillin and chloramphenicol. Conclusions-The annual rate of infection in children aged under 5 in four Welsh counties was 12-44% higher than that previously published for the United Kingdom. The study emphasises the potential value of a vaccine effective in early infancy and provides baseline data to assess its efficacy after its introduction. Alternatives to ampicillin and chloramphenicol should be used as first line, empirical treatment for severe infections that might be caused by H influenzae type b in Wales.	PENN STATE UNIV,INST MOLEC EVOLUT GENET,UNIVERSITY PK,PA 16802; COMMUNICABLE DIS SURVEILLANCE CTR,WELSH UNIT,CARDIFF CF4 3QX,WALES	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	HOWARD, AJ (corresponding author), GWYNEDD HOSP,DEPT MED MICROBIOL,BANGOR LL57 2PW,WALES.				PHS HHS [A1 24332] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARENKAMP SJ, 1983, J INFECT DIS, V148, P1127, DOI 10.1093/infdis/148.6.1127; BROOME CV, 1987, PEDIATR INFECT DIS J, V6, P779, DOI 10.1097/00006454-198708000-00036; CAMPBELL H, 1990, PEDIATRICS, V86, P102; Cartwright K A, 1991, CDR (Lond Engl Rev), V1, pR2; DAVEY PG, 1982, J HYG-CAMBRIDGE, V88, P383, DOI 10.1017/S002217240007025X; DELRIO MDA, 1983, LANCET, V1, P1241; DYAS A, 1986, J INFECTION, V13, P179, DOI 10.1016/S0163-4453(86)93093-8; FEIGIN RD, 1976, J PEDIATR-US, V88, P542, DOI 10.1016/S0022-3476(76)80002-9; GOLDACRE MJ, 1976, LANCET, V1, P28; GRANOFF DM, 1986, J INFECT DIS, V153, P448, DOI 10.1093/infdis/153.3.448; GUNN BA, 1974, LANCET, V2, P845; HAMPTON CM, 1983, J CLIN MICROBIOL, V18, P596, DOI 10.1128/JCM.18.3.596-600.1983; HOWARD AJ, 1988, J ANTIMICROB CHEMOTH, V21, P251, DOI 10.1093/jac/21.2.251; MACHKA K, 1988, EUR J CLIN MICROBIOL, V7, P14, DOI 10.1007/BF01962165; MAKELA PH, 1990, PEDIATRICS, V85, P651; MUSSER JM, 1985, P NATL ACAD SCI USA, V82, P5078, DOI 10.1073/pnas.82.15.5078; MUSSER JM, 1990, REV INFECT DIS, V12, P75; SELL SHW, 1972, PEDIATRICS, V49, P206; SPROLES ET, 1969, J PEDIATR-US, V75, P782, DOI 10.1016/S0022-3476(69)80300-8; TAKALA AK, 1989, PEDIATR INFECT DIS J, V8, P297; TAKALA AK, 1990, ARCH INTERN MED, V150, P2573, DOI 10.1001/archinte.150.12.2573; TAKALA AK, 1990, 30TH INT C ANT AG CH, P187; TAYLOR HG, 1990, NEW ENGL J MED, V323, P1657, DOI 10.1056/NEJM199012133232403; TEJANI A, 1982, DEV MED CHILD NEUROL, V24, P338; THOMAS WJ, 1974, LANCET, V1, P313; TROLLFORS B, 1984, EUR J CLIN MICROBIOL, V3, P180, DOI 10.1007/BF02014874; WARD JI, 1979, NEW ENGL J MED, V301, P122, DOI 10.1056/NEJM197907193010302; WEINBERG GA, 1988, J PEDIATR-US, V113, P621, DOI 10.1016/S0022-3476(88)80369-X; WILLIAMS GT, 1989, ARCH DIS CHILD, V64, P517; 1985, DIGEST WELSH STATIST; 1989, DIGEST WELSH STATIST; 1984, PEDIATRICS, V74, P301	32	45	46	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					441	445		10.1136/bmj.303.6800.441	http://dx.doi.org/10.1136/bmj.303.6800.441			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912835	Green Published, Bronze			2022-12-01	WOS:A1991GC46500015
J	HUNTER, JO				HUNTER, JO			FOOD ALLERGY - OR ENTEROMETABOLIC DISORDER	LANCET			English	Note							IRRITABLE BOWEL SYNDROME; CONTROLLED TRIAL; DIET; INTOLERANCE; MIGRAINE; DISEASE				HUNTER, JO (corresponding author), ADDENBROOKES HOSP,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND.							ATHERTON DJ, 1978, LANCET, V1, P401; Bayliss C E, 1986, Ann Ist Super Sanita, V22, P959; BENTLEY SJ, 1983, LANCET, V2, P295; BOND JH, 1980, GASTROENTEROLOGY, V78, P444; BURKE DA, 1988, BMJ-BRIT MED J, V297, P102, DOI 10.1136/bmj.297.6641.102; DARLINGTON LG, 1986, LANCET, V1, P236; EBRINGER RW, 1979, ANN RHEUM DIS, V37, P145; EGGER J, 1985, LANCET, V1, P540; EGGER J, 1983, LANCET, V2, P865; Hanington E., 1983, Clinical reactions to food, P155; HYAMS JS, 1983, GASTROENTEROLOGY, V84, P30; JEWETT DL, 1990, NEW ENGL J MED, V323, P429, DOI 10.1056/NEJM199008163230701; Jones V. A., 1985, Food and the gut, P208; JONES VA, 1982, LANCET, V2, P1115; JONES VA, 1985, LANCET, V2, P177; LESSOF MH, 1980, Q J MED, V195, P259; LITTLEWOOD J, 1982, LANCET, V1, P983; RAVICH WJ, 1983, GASTROENTEROLOGY, V84, P26; SANDLER M, 1970, BACKGROUND MIGRAINE; SHEPPACH W, 1988, GASTROENTEROLOGY, V95, P1549; VANDERWAAIJ D, 1983, ANTIBIOTIC CHOICE IM; 1984, J R COLL PHYSICIANS, V18	23	33	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1991	338	8765					495	496		10.1016/0140-6736(91)90557-6	http://dx.doi.org/10.1016/0140-6736(91)90557-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC153	1678455				2022-12-01	WOS:A1991GC15300017
J	HUSSEY, RM; CLARKE, CA				HUSSEY, RM; CLARKE, CA			DEATHS FROM RH HEMOLYTIC-DISEASE IN ENGLAND AND WALES IN 1988 AND 1989	BRITISH MEDICAL JOURNAL			English	Article									UNIV LIVERPOOL,DEPT GENET & MICROBIOL,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool	HUSSEY, RM (corresponding author), UNIV LIVERPOOL,DEPT PUBL HLTH,POB 147,LIVERPOOL L69 3BX,ENGLAND.							CLARKE CA, 1989, J ROY COLL PHYS LOND, V23, P181; THOMSON A, 1990, LANCET, V336, P1147, DOI 10.1016/0140-6736(90)92767-C; 1956, VITAL STATISTICS U A, V2	3	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					445	446		10.1136/bmj.303.6800.445	http://dx.doi.org/10.1136/bmj.303.6800.445			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912836	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1991GC46500016
J	REID, GS; ROBERTSON, AJ; BISSETT, C; SMITH, J; WAUGH, N; HALKERSTON, R				REID, GS; ROBERTSON, AJ; BISSETT, C; SMITH, J; WAUGH, N; HALKERSTON, R			CERVICAL SCREENING IN PERTH AND KINROSS SINCE INTRODUCTION OF THE NEW CONTRACT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine changes in the cervical screening service since the introduction of the new general practitioner contract on 1 April 1990. Design-Analysis of computerised records of cervical screening both before and after introduction of the new contract. Setting-General practices in Perth and Kinross Unit, Tayside. Patients-A total of 30 071 women aged 21-60 on 26 general practitioner partnership lists. Main outcome measures-Percentage average of target population for cervical screening in each practice for first three quarters on introduction of the contract. Results-Perth and Kinross Unit completed a computerised cervical screening call programme in July 1989, which produced an increase from 71% to 78% in the mean percentage of women aged 20-60 who had had cervical smear tests within 5.5 years. Six months after the introduction of the new general practitioner contract the mean population coverage was increased to 85% in women aged 21-60 and only four practices had not attained the 80% upper target compared with 10 on 1 April 1990. Detailed examination of randomly selected practices immediately before the new contract was introduced showed an average artificial list inflation of 4.3% in health board records when compared with practice records, a hysterectomy rate of 6.2%, and an additional 3% of women who were considered to be ineligible for smear testing due to putative virginity or illness or infirmity, or both. There was a considerable shift away from use of well woman clinics (2.7% of smears in 1990 compared with 5.6% in 1988) for taking cervical smears, potentially threatening the long term viability of the clinics. Conclusion-The introduction of the new contract for general practitioners has brought about a further sustained increase in population coverage for cervical screening in a small Scottish unit with a stable population, well motivated general practitioners, and a fully integrated computerised call and recall system based on the community health index. To optimise the screening service revision of the targets levels is necessary.	PERTH ROYAL INFIRM,DEPT PATHOL,PERTH PH1 1NX,SCOTLAND; TAYSIDE HLTH BOARD,DEPT PUBL HLTH MED,DUNDEE,SCOTLAND; MARYFIELD HOSP,E COAST SCOTLAND COMP CONSORTIUM,DUNDEE,SCOTLAND									CHAMBERLAIN J, 1984, BRIT MED J, V289, P853, DOI 10.1136/bmj.289.6449.853; CHOMET J, 1990, BRIT MED J, V300, P1504, DOI 10.1136/bmj.300.6738.1504; GEMMELL J, 1990, BRIT J OBSTET GYNAEC, V97, P58, DOI 10.1111/j.1471-0528.1990.tb01717.x; Robertson A J, 1990, Cytopathology, V1, P3, DOI 10.1111/j.1365-2303.1990.tb00320.x; SEFTON C, 1990, PULSE            DEC, P41; SHROFF KJ, 1988, BRIT MED J, V297, P1317, DOI 10.1136/bmj.297.6659.1317; WAUGH NR, 1990, BRIT MED J, V301, P238, DOI 10.1136/bmj.301.6745.238; 1986, STATEMENT FEES ALLOW; 1985, CERVICAL CANCER SCRE; 1985, LANCET, V2, P363; 1988, CERVICAL CANCER SCRE; 1988, HLTH B EDINB, V46, P146; 1990, STATEMENT FEES ALLOW, P57	13	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					447	450		10.1136/bmj.303.6800.447	http://dx.doi.org/10.1136/bmj.303.6800.447			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912838	Green Published, Bronze			2022-12-01	WOS:A1991GC46500018
J	BADING, H; GREENBERG, ME				BADING, H; GREENBERG, ME			STIMULATION OF PROTEIN TYROSINE PHOSPHORYLATION BY NMDA RECEPTOR ACTIVATION	SCIENCE			English	Article							LONG-TERM POTENTIATION; SERINE-THREONINE KINASE; NERVOUS-SYSTEM; GENE-PRODUCT; MAP KINASE; INSULIN; ANTAGONIST; EXPRESSION; BLOCKADE; CORTEX	The N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptors, plays a key role in synaptic plasticity in the nervous system. After NMDA receptor activation, calcium entry into the postsynaptic neuron is a critical initial event. However, the subsequent mechanisms by which the NMDA receptor signal is processed are incompletely understood. Stimulation of cultured rat hippocampal cells with glutamate resulted in the rapid and transient tyrosine phosphorylation of a 39-kilodalton protein (p39). Tyrosine phosphorylation of p39 was triggered by the NMDA receptor and required an influx of Ca2+ from the extracellular medium. Because p39 was found to be highly related or identical to the microtubule-associated protein 2 kinase, the NMDA receptor signal may be processed by a sequential activation of protein kinases.			BADING, H (corresponding author), HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115, USA.				NCI NIH HHS [CA 43855] Funding Source: Medline; NINDS NIH HHS [NS 28829] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028829, R37NS028829] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKERS RF, 1986, SCIENCE, V231, P587, DOI 10.1126/science.3003904; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; ASCHER P, 1987, TRENDS NEUROSCI, V10, P284, DOI 10.1016/0166-2236(87)90174-3; BADING H, UNPUB; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Chung J.-H., UNPUB; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FURSHPAN EJ, 1989, NEURON, V3, P199, DOI 10.1016/0896-6273(89)90033-0; GREENGARD P, 1989, NATURE, V340, P554; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSAMONDO AJ, IN PRESS J BIOL CHEM; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; STRATTON KR, 1989, P NATL ACAD SCI USA, V86, P2498, DOI 10.1073/pnas.86.7.2498; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; Weber M., UNPUB	36	448	455	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1991	253	5022					912	914		10.1126/science.1715095	http://dx.doi.org/10.1126/science.1715095			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1715095				2022-12-01	WOS:A1991GC15200048
J	BAUSKIN, AR; ALKALAY, I; BEN-NERIAH, Y				BAUSKIN, AR; ALKALAY, I; BEN-NERIAH, Y			REDOX REGULATION OF A PROTEIN TYROSINE KINASE IN THE ENDOPLASMIC-RETICULUM	CELL			English	Article							REDUCTION SENSITIVE INTERACTION; BETA-N-ACETYLGLUCOSAMINIDASE; CELLULAR 50-KDA PROTEIN; 5' NONCODING REGION; OXIDATION-REDUCTION; DISULFIDE ISOMERASE; INSULIN-RECEPTOR; TRANSMEMBRANE PROTEINS; SECRETORY PROTEINS; DNA FRAGMENTATION	The subcellular localization of the mouse Ltk transmembrane protein tyrosine kinase was studied in transfected COS cells, a mature B lymphocyte line, and a low expressing transfected lymphocyte clone. Indirect immunofluorescence and immunogold staining of COS transfectants and endoglycosidase analysis of both COS transfectants and lymphocytes indicate the unusual localization of Ltk to the endoplasmic reticulum (ER). Ltk resembles a receptor tyrosine kinase; it has a short, glycosylated, and cysteine-rich N-terminal domain. Yet, it appears to function in a ligand-independent mechanism: its in vivo catalytic activity is markedly enhanced by alkylating and thiol-oxidizing agents, and the active fraction of the protein occurs as disulfide-linked multimers. The catalytic activity of Ltk in the ER may be regulated via changes in the cellular redox potential, a novel mechanism for regulating protein tyrosine kinases. The ability to respond to redox changes in the cell may, however, be shared with certain receptor kinases during their passage through the ER.			BAUSKIN, AR (corresponding author), HEBREW UNIV JERUSALEM, HADASSAH MED SCH, LAUTENBERG CTR GEN & TUMOR IMMUNOL, IL-91010 JERUSALEM, ISRAEL.		Ben-Neriah, Yinon/L-6285-2019					ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BUMP EA, 1990, PHARMACOL THERAPEUT, V47, P117, DOI 10.1016/0163-7258(90)90048-7; CLANCEY CJ, 1987, J BIOL CHEM, V262, P13545; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ERNST V, 1978, P NATL ACAD SCI USA, V75, P4110, DOI 10.1073/pnas.75.9.4110; FARKASH Y, 1986, ENDOCRINOLOGY, V118, P1353, DOI 10.1210/endo-118-4-1353; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GERONIMO J, 1983, P NATL ACAD SCI USA, V80, P6848; GIUGNI TD, 1985, J BIOL CHEM, V260, P5081; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LAB MANUA, P363; HEDO JA, 1983, J BIOL CHEM, V258, P20; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; INOUYE S, 1988, SYNTHESIS APPLICATIO; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KAMPS MP, 1988, ONCOGENE, V2, P305; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.bi.54.070185.003215; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MARU Y, 1990, ONCOGENE RES, V5, P199; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; NAJITA L, 1990, P NATL ACAD SCI USA, V87, P5846, DOI 10.1073/pnas.87.15.5846; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OLSON TS, 1987, J BIOL CHEM, V262, P6816; OLSON TS, 1988, J BIOL CHEM, V263, P7342; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER S, 1986, ONCOGENES GROWTH CON, P70; PORUCHYNSKY MS, 1985, J CELL BIOL, V101, P2199, DOI 10.1083/jcb.101.6.2199; RICE GC, 1986, CANCER RES, V46, P6105; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; ROWE GT, 1984, J MOL CELL CARDIOL, V16, P1075, DOI 10.1016/S0022-2828(84)80020-6; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SISK WP, 1986, GENE, V48, P183, DOI 10.1016/0378-1119(86)90076-4; SITIA R, 1987, EMBO J, V6, P3939; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TAKAHASHI S, 1989, EUR J IMMUNOL, V19, P1911, DOI 10.1002/eji.1830191023; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WORD CJ, 1981, MOL IMMUNOL, V18, P311, DOI 10.1016/0161-5890(81)90055-9; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	77	249	251	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 23	1991	66	4					685	696		10.1016/0092-8674(91)90114-E	http://dx.doi.org/10.1016/0092-8674(91)90114-E			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652370				2022-12-01	WOS:A1991GC74500009
J	DETHE, H; LAVAU, C; MARCHIO, A; CHOMIENNE, C; DEGOS, L; DEJEAN, A				DETHE, H; LAVAU, C; MARCHIO, A; CHOMIENNE, C; DEGOS, L; DEJEAN, A			THE PML-RAR-ALPHA FUSION MESSENGER-RNA GENERATED BY THE T(15-17) TRANSLOCATION IN ACUTE PROMYELOCYTIC LEUKEMIA ENCODES A FUNCTIONALLY ALTERED RAR	CELL			English	Article							RETINOIC ACID RECEPTOR; DNA-BINDING DOMAIN; V-ERBA; SACCHAROMYCES-CEREVISIAE; DIFFERENTIAL EXPRESSION; RESPONSIVE ELEMENT; ESTROGEN-RECEPTOR; GENE-EXPRESSION; VIRUS TYPE-1; ZINC FINGER	We have previously shown that the t(15; 17) translocation specifically associated with acute promyelocytic leukemia (APL) fuses the retinoic acid receptor-alpha (RAR-alpha) locus to an as yet unknown gene, initially called myl and now renamed PML. We report here that this gene product contains a novel zinc finger motif common to several DNA-binding proteins. The PML-RAR-alpha mRNA encodes a predicted 106 kd chimeric protein containing most of the PML sequences fused to a large part of RAR-alpha, including its DNA- and hormone-binding domains. In transient expression assays, the hybrid protein exhibits altered transactivating properties if compared with the wild-type RAR-alpha progenitor. Identical PML-RAR-alpha fusion points are found in several patients. These observations suggest that in APL, the t(15;17) translocation generates an RAR mutant that could contribute to leukemogenesis through interference with promyelocytic differentiation.	UNIV PARIS 07,BIOL CELLULAIRE HEMATOPOET LAB,F-75221 PARIS 05,FRANCE; HOP ST LOUIS,SERV CLIN MALAD SANG,F-75010 PARIS,FRANCE; HOP ST LOUIS,SERV MED NUCL,F-75010 PARIS,FRANCE; HOP ST LOUIS,INSERM,U93,F-75010 PARIS,FRANCE	UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	DETHE, H (corresponding author), INST PASTEUR,INSERM,U163,UNITE RECOMBINAISON & EXPRESS GENET,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Dejean, Anne/L-5145-2018; Lavau, Catherine/Q-2928-2019	Lavau, Catherine/0000-0003-4800-1320; CHOMIENNE, Christine/0000-0001-5513-5752				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERG JM, 1990, J BIOL CHEM, V265, P6513; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1981, BLOOD, V57, P1000; BROCKES J, 1990, NATURE, V345, P766, DOI 10.1038/345766a0; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHANET R, 1988, GENE, V74, P543, DOI 10.1016/0378-1119(88)90187-4; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; KAKIZUKA A, 1991, CELL, V66; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOEFFLER HP, 1985, CHRONIC ACUTE LEUKEM, P27; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANOTTE M, 1991, BLOOD, V77, P1080; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PERRY LJ, 1986, J GEN VIROL, V67, P2365, DOI 10.1099/0022-1317-67-11-2365; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROBERTS AB, 1984, RETINOIDS, V2, P209; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; THIEM SM, 1989, J VIROL, V63, P4489, DOI 10.1128/JVI.63.11.4489-4497.1989; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	62	1244	1263	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					675	684		10.1016/0092-8674(91)90113-D	http://dx.doi.org/10.1016/0092-8674(91)90113-D			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652369				2022-12-01	WOS:A1991GC74500008
J	DIMICHELE, L; PAYNTER, KT; POWERS, DA				DIMICHELE, L; PAYNTER, KT; POWERS, DA			EVIDENCE OF LACTATE DEHYDROGENASE-B ALLOZYME EFFECTS IN THE TELEOST, FUNDULUS-HETEROCLITUS	SCIENCE			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; GENETIC-VARIATION; LDH-B; GENOTYPES; POLYMORPHISM; LOCI; ADAPTATION; FISH; CELL	The evolutionary significance of protein polymorphisms has long been debated. Exponents of the balanced theory advocate that selection operates to maintain polymorphisms, whereas the neoclassical school argues that most genetic variation is neutral. Some studies have suggested that protein polymorphisms are not neutral, but their significance has been questioned because one cannot eliminate the possibility that linked loci were responsible for the observed differences. Evidence is presented that an enzymatic phenotype can affect carbon flow through a metabolic pathway. Glucose flux differences between lactate dehydrogenase-B phenotypes of Fundulus heteroclitus were reversed by substituting the Ldh-B gene product of one homozygous genotype with that of another.	JOHNS HOPKINS UNIV,CHESAPEAKE BAY INST,SHADY SIDE,MD 20764; STANFORD UNIV,HOPKINS MARINE STN,PACIFIC GROVE,CA 93950	Johns Hopkins University; Stanford University	DIMICHELE, L (corresponding author), TEXAS A&M UNIV SYST,DEPT WILDLIFE & FISHERIES SCI,COLLEGE STN,TX 77843, USA.		Paynter, Kennedy/F-9717-2013					BURTON RS, 1983, BIOCHEM GENET, V21, P239, DOI 10.1007/BF00499136; CAVENER DR, 1981, P NATL ACAD SCI-BIOL, V78, P4444, DOI 10.1073/pnas.78.7.4444; DIMICHELE L, 1986, AM ZOOL, V26, P201; DIMICHELE L, 1982, NATURE, V296, P563, DOI 10.1038/296563a0; DIMICHELE L, 1984, PHYSIOL ZOOL, V57, P52, DOI 10.1086/physzool.57.1.30155967; GONZALEZVILLASENOR LI, 1990, EVOLUTION, V44, P27, DOI 10.1111/j.1558-5646.1990.tb04277.x; HARRIS H, 1976, FED PROC, V35, P2079; HILBISH TJ, 1982, NATURE, V298, P688, DOI 10.1038/298688a0; KACSER H, 1981, GENETICS, V97, P639; KLYACHKO OS, 1982, J EXP ZOOL, V222, P137, DOI 10.1002/jez.1402220205; KOEHN RK, 1980, P NATL ACAD SCI-BIOL, V77, P5385, DOI 10.1073/pnas.77.9.5385; KOEHN RK, 1986, AM SCI, V74, P659; LANGRIDGE R, 1985, BIOCHEMISTRY-US, V24, P629; Lewontin RC, 1974, GENETIC BASIS EVOLUT; Nei M, 1983, EVOLUTION GENES PROT; Newsholme EA, 1973, REGULATION METABOLIS; PLACE AR, 1978, BIOCHEM GENET, V16, P577, DOI 10.1007/BF00484221; PLACE AR, 1979, P NATL ACAD SCI USA, V76, P2354, DOI 10.1073/pnas.76.5.2354; PLACE AR, 1984, J BIOL CHEM, V76, P1304; PLACE AR, 1978, BIOCH GENET, V16, P593; PLACE AR, 1984, J BIOL CHEM, V76, P1299; POWERS DA, 1983, ISOZYMES-CURR T BIOL, V10, P147; POWERS DA, 1986, AM ZOOL, V26, P131; SRIVASTAVA DK, 1987, ANNU REV BIOPHYS BIO, V16, P175; SRIVASTAVA DK, 1989, P NATL ACAD SCI USA, V86, P6464, DOI 10.1073/pnas.86.17.6464; SRIVASTAVA DK, 1985, BIOCHEMISTRY-US, V24, P623, DOI 10.1021/bi00324a013; SRIVASTAVA DK, 1984, BIOCHEMISTRY-US, V23, P4538, DOI 10.1021/bi00315a006; WATT WB, 1983, GENETICS, V103, P725; WATT WB, 1985, GENETICS, V109, P157; WATT WB, 1983, ISOZYMES, V15, P27; ZAMMER WE, 1989, P NATL ACAD SCI USA, V86, P2737; ZOUROS E, 1983, ISOZYMES, V13, P1; 1988, SAS STAT USERS GUIDE, P549	33	48	48	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1991	253	5022					898	900		10.1126/science.1876847	http://dx.doi.org/10.1126/science.1876847			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1876847				2022-12-01	WOS:A1991GC15200043
J	ELLISEN, LW; BIRD, J; WEST, DC; SORENG, AL; REYNOLDS, TC; SMITH, SD; SKLAR, J				ELLISEN, LW; BIRD, J; WEST, DC; SORENG, AL; REYNOLDS, TC; SMITH, SD; SKLAR, J			TAN-1, THE HUMAN HOMOLOG OF THE DROSOPHILA NOTCH GENE, IS BROKEN BY CHROMOSOMAL TRANSLOCATIONS IN T-LYMPHOBLASTIC NEOPLASMS	CELL			English	Article							HAMSTER OVARY CELLS; CDNA CLONES; PROTEIN; RECEPTOR; LOCUS; NEUROGENESIS; SIMILARITY; SEQUENCES; LEUKEMIA; GROWTH	Previously we described joining of DNA in the beta-T cell receptor gene to DNA of an uncharacterized locus in a t(7;9)(q34;q34.3) chromosomal translocation from a case of human T lymphoblastic leukemia (T-ALL). We now show that the locus on chromosome 9 contains a gene highly homologous to the Drosophila gene Notch. Transcripts of the human gene, for which we propose the name TAN-1, and its murine counterpart are present in many normal human fetal and adult mouse tissues, but are most abundant in lymphoid tissues. In t(7;9)(q34;q34.3) translocations from three cases of T-ALL, the breakpoints occur within 100 bp of an intron in TAN-1, resulting in truncation of TAN-1 transcripts. These observations suggest that TAN-1 may be important for normal lymphocyte function and that alteration of TAN-1 may play a role in the pathogenesis of some T cell neoplasms.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV DIAGNOST MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Ellisen, Leif W/AAA-6572-2022; West, Daniel/AAW-3111-2020	Ellisen, Leif W/0000-0003-0444-7910; West, Daniel/0000-0002-0909-4213	NATIONAL CANCER INSTITUTE [R01CA038621] Funding Source: NIH RePORTER; NCI NIH HHS [CA38621] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; ARTAVANISTSAKONAS S, 1983, P NATL ACAD SCI-BIOL, V80, P1977, DOI 10.1073/pnas.80.7.1977; Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; Battey, 1986, BASIC METHODS MOL BI; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOI S, 1987, BLOOD, V70, P1619; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GILLARD S, 1986, P NATL ACAD SCI USA, V83, P5573, DOI 10.1073/pnas.83.15.5573; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; GOETZL DJ, 1990, ADV IMMUNOL, V48, P161; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Maniatis T., 1982, MOL CLONING; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RAIMONDI SC, 1987, BLOOD, V69, P131; REYNOLDS TC, 1987, CELL, V50, P107, DOI 10.1016/0092-8674(87)90667-2; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWENK HU, 1975, BLUT, V31, P229; SMITH SD, 1988, BLOOD, V71, P395; SMITH SD, 1989, BLOOD, V73, P2182; SMITH TF, 1985, NUCLEIC ACIDS RES, V13, P645, DOI 10.1093/nar/13.2.645; SPEHNER D, 1988, J VIROL, V62, P1297, DOI 10.1128/JVI.62.4.1297-1304.1988; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; TYCKO B, 1989, J EXP MED, V169, P3369; TYCKO B, 1991, IN PRESS J EXP MED; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	50	1453	1575	1	42	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					649	661		10.1016/0092-8674(91)90111-B	http://dx.doi.org/10.1016/0092-8674(91)90111-B			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1831692				2022-12-01	WOS:A1991GC74500006
J	FANG, F; NEWPORT, JW				FANG, F; NEWPORT, JW			EVIDENCE THAT THE G1-S AND G2-M TRANSITIONS ARE CONTROLLED BY DIFFERENT CDC2 PROTEINS IN HIGHER EUKARYOTES	CELL			English	Article							CELL-CYCLE CONTROL; MATURATION-PROMOTING FACTOR; YEAST SCHIZOSACCHAROMYCES-POMBE; HISTONE H-1 KINASE; CONTROL GENE CDC2+; FISSION YEAST; DNA-REPLICATION; M-PHASE; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE	Xenopus eggs contain two distinct cdc2 homologs of 34 and 32 kd. We show that the 32 kd cdc2 protein, like the 34 kd protein, is a kinase. However, unlike the 34 kd homolog, the 32 kd cdc2 kinase activity does not decrease dramatically at the end of mitosis. The 32 kd protein does not associate with mitotic cyclins B1 and B2 but does associate with cyclin A and a novel doublet of proteins of 54 kd that may regulate its activity. We also show that depletion of the 32 kd cdc2 homolog from a Xenopus extract blocks DNA replication, but does not inhibit entry into mitosis. By contrast, depletion of the 34 kd cdc2 homolog or absence of mitotic cyclins from an extract does not inhibit replication, but does block entry into mitosis. Our results indicate that in higher eukaryotes, DNA replication (G1-S) and mitosis (G2-M) may be controlled by distinctly different cdc2 proteins.			FANG, F (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL 0322, LA JOLLA, CA 92093 USA.				NIGMS NIH HHS [GM33523-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033523, R37GM033523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRILL SJS, 1990, GENE DEV, V4, P968; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEE M, 1988, TRENDS GENET, V4, P287, DOI 10.1016/0168-9525(88)90171-0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MIAKELYE R, 1985, CELL, V41, P165, DOI 10.1016/0092-8674(85)90071-6; MIAKELYE R, 1983, J CELL BIOL, V97, P81, DOI 10.1083/jcb.97.1.81; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1989, J CELL SCI, P149; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	52	501	518	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 23	1991	66	4					731	742		10.1016/0092-8674(91)90117-H	http://dx.doi.org/10.1016/0092-8674(91)90117-H			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652371				2022-12-01	WOS:A1991GC74500012
J	FERNANDEZMORENO, MA; CABALLERO, JL; HOPWOOD, DA; MALPARTIDA, F				FERNANDEZMORENO, MA; CABALLERO, JL; HOPWOOD, DA; MALPARTIDA, F			THE ACT CLUSTER CONTAINS REGULATORY AND ANTIBIOTIC EXPORT GENES, DIRECT TARGETS FOR TRANSLATIONAL CONTROL BY THE BLDA TRANSFER-RNA GENE OF STREPTOMYCES	CELL			English	Article							TETRACYCLINE-RESISTANCE GENE; NUCLEOTIDE-SEQUENCE ANALYSIS; ANION-EXCHANGE PROTEIN; COELICOLOR A3(2); ESCHERICHIA-COLI; TRANSCRIPTIONAL REGULATION; HETEROLOGOUS HOST; CLONING; BIOSYNTHESIS; EXPRESSION	The actII region, flanked by biosynthetic genes in the 25 kb act cluster of S. coelicolor, consists of four open reading frames, including a transcriptional activator for the biosynthetic genes, and genes controlling antibiotic export. A TTA codon (extremely rare in Streptomyces) is present both in actII-ORF2 (encoding a putative transmembrane export protein) and actII-ORF4 (the transcriptional activator gene). Change of the TTA in ORF4 to TTG reverses the normal interruption of actinorhodin synthesis caused by mutation in the pleiotropic regulatory gene bldA (which encodes the cell's tRNA(UUA)Leu). We conclude that initiation of actinorhodin synthesis via the actII-ORF4 product, and the final step in production, antibiotic export, are twin targets via which bldA exerts developmental control of actinorhodin production.	JOHN INNES INST,JOHN INNES INST,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	FERNANDEZMORENO, MA (corresponding author), CTR NACL BIOTECNOL,SERRANO 115,E-28006 MADRID,SPAIN.		Malpartida, Francisco/D-2563-2009; Caballero, José L./L-2067-2014; Fernandez-Moreno, Miguel Angel/K-4425-2017	Caballero, José L./0000-0002-2678-4849; Fernandez-Moreno, Miguel Angel/0000-0002-3461-0726				ADAMIDIS T, 1990, J BACTERIOL, V172, P2962, DOI 10.1128/jb.172.6.2962-2969.1990; ANZAI H, 1987, J BACTERIOL, V169, P3482, DOI 10.1128/jb.169.8.3482-3488.1987; BERNARDI A, 1984, NUCLEIC ACIDS RES, V12, P9415, DOI 10.1093/nar/12.24.9415; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CABALLERO JL, 1991, IN PRESS MOL GEN GEN; CHAMPNESS WC, 1988, J BACTERIOL, V170, P1168, DOI 10.1128/jb.170.3.1168-1174.1988; CHATER KF, 1983, GENE, V26, P67, DOI 10.1016/0378-1119(83)90037-9; CHATER KF, 1989, TRENDS GENET, V5, P372, DOI 10.1016/0168-9525(89)90172-8; COVARRUBIAS L, 1982, GENE, V17, P79, DOI 10.1016/0378-1119(82)90103-2; CUNDLIFFE E, 1989, ANNU REV MICROBIOL, V43, P207, DOI 10.1146/annurev.micro.43.1.207; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEITELSON JS, 1983, MOL GEN GENET, V190, P394, DOI 10.1007/BF00331065; GUTHRIE EP, 1990, J BACTERIOL, V172, P6189, DOI 10.1128/jb.172.11.6189-6193.1990; HALLAM SE, 1988, GENE, V74, P305, DOI 10.1016/0378-1119(88)90165-5; HARA O, 1983, J GEN MICROBIOL, V129, P2939; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.biochem.59.1.933; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; Hopwood D. A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1988, PROC R SOC SER B-BIO, V235, P121, DOI 10.1098/rspb.1988.0067; HOPWOOD DA, 1986, REGULATION SECONDARY, P23; HORINOUCHI S, 1990, GENE, V95, P49, DOI 10.1016/0378-1119(90)90412-K; HOSHINO T, 1985, GENE, V37, P131; KANAZAWA S, 1988, MOL CELL BIOL, V8, P664, DOI 10.1128/MCB.8.2.664; KLOCK G, 1985, J BACTERIOL, V161, P326, DOI 10.1128/JB.161.1.326-332.1985; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWLOR EJ, 1987, GENE DEV, V1, P1305, DOI 10.1101/gad.1.10.1305; LESKIW BK, 1991, P NATL ACAD SCI USA, V88, P2461, DOI 10.1073/pnas.88.6.2461; LIRAS P, 1990, TRENDS BIOTECHNOL, V8, P184, DOI 10.1016/0167-7799(90)90170-3; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MALPARTIDA F, 1986, MOL GEN GENET, V205, P66, DOI 10.1007/BF02428033; MALPARTIDA F, 1990, GENE, V93, P91, DOI 10.1016/0378-1119(90)90141-D; MALPARTIDA F, 1984, NATURE, V309, P462, DOI 10.1038/309462a0; Maniatis T., 1982, MOL CLONING; MARTIN JF, 1989, ANNU REV MICROBIOL, V43, P173, DOI 10.1146/annurev.micro.43.1.173; MARTIN JF, 1980, MICROBIOL REV, V44, P230, DOI 10.1128/MMBR.44.2.230-251.1980; MERRICK MJ, 1976, J GEN MICROBIOL, V96, P299, DOI 10.1099/00221287-96-2-299; NARVA KE, 1990, J BACTERIOL, V172, P326, DOI 10.1128/JB.172.1.326-333.1990; NORMARK S, 1983, ANNU REV GENET, V17, P499, DOI 10.1146/annurev.ge.17.120183.002435; NORRANDER J, 1983, GENE, V26, P102; OCHI K, 1987, J BACTERIOL, V169, P3608, DOI 10.1128/jb.169.8.3608-3616.1987; OHNUKI T, 1985, J BACTERIOL, V164, P85, DOI 10.1128/JB.164.1.85-94.1985; PABO LO, 1984, ANN REV BIOCH, V34, P293; PASSANTINO R, 1991, IN PRESS J GEN MICRO; PEDEN KWC, 1983, GENE, V22, P277, DOI 10.1016/0378-1119(83)90112-9; PIEPERSBERG W, 1988, BIOL ACTINOMYCETES, P92; POSTLE K, 1984, NUCLEIC ACIDS RES, V12, P4849, DOI 10.1093/nar/12.12.4849; REYNES JP, 1988, J GEN MICROBIOL, V134, P585; RODICIO MR, 1985, GENE, V34, P283, DOI 10.1016/0378-1119(85)90137-4; RUDD BAM, 1979, J GEN MICROBIOL, V114, P35, DOI 10.1099/00221287-114-1-35; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SENO ET, 1989, REG SEC MET ACT, P1; STEIN D, 1989, J BACTERIOL, V171, P2258, DOI 10.1128/jb.171.4.2258-2261.1989; WATERS SH, 1983, NUCLEIC ACIDS RES, V11, P6089, DOI 10.1093/nar/11.17.6089; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YAZYU H, 1984, J BIOL CHEM, V259, P4320	60	310	335	4	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					769	780		10.1016/0092-8674(91)90120-N	http://dx.doi.org/10.1016/0092-8674(91)90120-N			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878971				2022-12-01	WOS:A1991GC74500015
J	HEITMAN, J; MOVVA, NR; HALL, MN				HEITMAN, J; MOVVA, NR; HALL, MN			TARGETS FOR CELL-CYCLE ARREST BY THE IMMUNOSUPPRESSANT RAPAMYCIN IN YEAST	SCIENCE			English	Article							CIS-TRANS ISOMERASE; CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; FK506-BINDING PROTEIN; CYCLOSPORIN-A; SACCHAROMYCES-CEREVISIAE; MACROLIDES FK-506; FK506; CYCLOPHILIN; ACTIVATION	FK506 and rapamycin are related immunosuppressive compounds that block helper T cell activation by interfering with signal transduction. In vitro, both drugs bind and inhibit the FK506-binding protein (FKBP) proline rotamase. Saccharomyces cerevisiae cells treated with rapamycin irreversibly arrested in the G1 phase of the cell cycle. An FKBP-rapamycin complex is concluded to be the toxic agent because (i) strains that lack FKBP proline rotamase, encoded by FPR1, were viable and fully resistant to rapamycin and (ii) FK506 antagonized rapamycin toxicity in vivo. Mutations that conferred rapamycin resistance altered conserved residues in FKBP that are critical for drug binding. Two genes other than FPR1, named TOR1 and TOR2, that participate in rapamycin toxicity were identified. Nonallelic noncomplementation between FPR1, TORI, and TOR2 alleles suggests that the products of these genes may interact as subunits of a protein complex. Such a complex may mediate nuclear entry of signals required for progression through the cell cycle.	UNIV BASEL,BIOCTR,DEPT BIOCHEM,CH-4056 BASEL,SWITZERLAND; SANDOZ PHARMA LTD,PRECLIN RES,CH-4002 BASEL,SWITZERLAND	University of Basel; Novartis; Sandoz			Heitman, Joseph/ABC-6006-2021	Hall, Michael N/0000-0002-2998-0757				ATKINSON KD, 1985, GENETICS, V111, P1; ATKINSON KD, 1988, PLANT MEMBRANES STRU, P65; BAKER H, 1978, J ANTIBIOT, V31, P539, DOI 10.7164/antibiotics.31.539; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BIERER BE, 1990, SCIENCE, V250, P1948; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; CIANCIOTTO NP, 1989, INFECT IMMUN, V57, P1255, DOI 10.1128/IAI.57.4.1255-1262.1989; COLLIER J, 1990, CURR OPIN IMMUNOL, V2, P854; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; ENGLEBERG NC, 1989, INFECT IMMUN, V57, P1263, DOI 10.1128/IAI.57.4.1263-1270.1989; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FOXWELL BMJ, 1988, TRANSPLANTATION, V46, pS35; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; GRANELLIPIPERNO A, 1990, J EXP MED, V172, P1869, DOI 10.1084/jem.172.6.1869; GRANELLIPIPERNO A, 1984, J EXP MED, V160, P1792, DOI 10.1084/jem.160.6.1792; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HAYS TS, 1989, MOL CELL BIOL, V9, P875, DOI 10.1128/MCB.9.3.875; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, UNPUB; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOMYK T, 1988, GENETICS, V119, P105; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; KUSCH M, 1986, GENETICS, V113, P621; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; PERRY ACF, 1988, J BACTERIOL, V170, P1691, DOI 10.1128/jb.170.4.1691-1697.1988; ROSE MD, 1988, LABORATORY COURSE MA; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEARNS T, 1988, GENETICS, V119, P249; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; STEINMANN B, 1991, J BIOL CHEM, V266, P3630; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THOMSON AW, 1990, IMMUNOL TODAY, V11, P35; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; VANDUYNE SGD, 1991, NATURE, V351, P248; WICKER LS, 1990, EUR J IMMUNOL, V20, P2277, DOI 10.1002/eji.1830201017; WIEDERRECHT G, 1991, P NATL ACAD SCI USA, V88, P1029, DOI 10.1073/pnas.88.3.1029	47	1446	1512	8	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1991	253	5022					905	909		10.1126/science.1715094	http://dx.doi.org/10.1126/science.1715094			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1715094				2022-12-01	WOS:A1991GC15200046
J	KAKIZUKA, A; MILLER, WH; UMESONO, K; WARRELL, RP; FRANKEL, SR; MURTY, VVVS; DMITROVSKY, E; EVANS, RM				KAKIZUKA, A; MILLER, WH; UMESONO, K; WARRELL, RP; FRANKEL, SR; MURTY, VVVS; DMITROVSKY, E; EVANS, RM			CHROMOSOMAL TRANSLOCATION T(15-17) IN HUMAN ACUTE PROMYELOCYTIC LEUKEMIA FUSES RAR-ALPHA WITH A NOVEL PUTATIVE TRANSCRIPTION FACTOR, PML	CELL			English	Article							RETINOIC ACID RECEPTOR; DNA-BINDING DOMAIN; ZINC FINGER; GLUCOCORTICOID RECEPTOR; INSITU HYBRIDIZATION; RESPONSIVE ELEMENT; GENE-EXPRESSION; VIRUS TYPE-1; BETA-GENE; PROTEIN	A unique mRNA produced in leukemic cells from a t(15; 17) acute promyelocytic leukemia (APL) patient encodes a fusion protein between the retinoic acid receptor-alpha (RAR-alpha) and a myeloid gene product called PML. PML contains a cysteine-rich region present in a new family of apparent DNA-binding proteins that includes a regulator of the interleukin-2 receptor gene (Rpt-1) and the recombination-activating gene product (RAG-1). Accordingly, PML may represent a novel transcription factor or recombinase. The aberrant PML-RAR fusion product, while typically retinoic acid responsive, displays both cell type- and promoter-specific differences from the wild-type RAR-alpha. Because patients with APL can be induced into remission with high dose RA therapy, we propose that the nonliganded PML-RAR protein is a new class of dominant negative oncogene product. Treatment with RA would not only relieve this inhibition, but the activated PML-RAR protein may actually promote myelocyte differentiation.	HOWARD HUGHES MED INST,LA JOLLA,CA 92037; MEM SLOAN KETTERING CANC CTR,LEUKEMIA & DEV CHEMOTHERAPY SERV,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,MOLEC MED LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CANC GENET LAB,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	KAKIZUKA, A (corresponding author), SALK INST BIOL STUDIES,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	NCI NIH HHS [CA-09207-14] Funding Source: Medline; FDA HHS [FD-R-000674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FDA HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BERG JM, 1990, J BIOL CHEM, V265, P6513; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1991, CELL, V66; DOOLITTLE RF, 1987, URFS ORFS PRIMER HOW; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JHANWAR SC, 1983, P NATL ACAD SCI-BIOL, V80, P4794, DOI 10.1073/pnas.80.15.4794; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; KAKIZUKA A, 1990, J BIOL CHEM, V265, P10102; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T., 1982, MOL CLONING; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MILLER WH, 1990, J NATL CANCER I, V82, P1932, DOI 10.1093/jnci/82.24.1932; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MITELMAN F, 1988, CATALOG CHROMOSOME A; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEEL BG, 1982, P NATL ACAD SCI-BIOL, V79, P7842, DOI 10.1073/pnas.79.24.7842; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PERRY LJ, 1986, J GEN VIROL, V67, P2365, DOI 10.1099/0022-1317-67-11-2365; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; ROWLEY JD, 1977, LANCET, V1, P549; ROWLEY JD, 1977, INT J CANCER, V20, P860; SALVATO MS, 1989, VIROLOGY, V173, P1, DOI 10.1016/0042-6822(89)90216-X; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; THIEM SM, 1989, J VIROL, V63, P4489, DOI 10.1128/JVI.63.11.4489-4497.1989; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; UMEX RM, 1991, SCIENCE, V251, P288; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	65	1353	1378	1	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					663	674		10.1016/0092-8674(91)90112-C	http://dx.doi.org/10.1016/0092-8674(91)90112-C			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652368	Green Published			2022-12-01	WOS:A1991GC74500007
J	LEE, JY; GOLDFARB, A				LEE, JY; GOLDFARB, A			LAC REPRESSOR ACTS BY MODIFYING THE INITIAL TRANSCRIBING COMPLEX SO THAT IT CANNOT LEAVE THE PROMOTER	CELL			English	Article							COLI RNA-POLYMERASE; LAC UV5 PROMOTER; RIBONUCLEIC-ACID POLYMERASE; TRANSCRIPTION INITIATION; TERNARY COMPLEXES; CHAIN ELONGATION; LACTOSE OPERON; SIGMA-SUBUNIT; INVITRO; PROTEIN	RNA polymerase engaged in the joint complex with the lac repressor at the lac UV5 promoter cannot escape into elongation but generates abortive RNA oligomers. The joint complex actively transcribes a few initial base pairs in a reaction unusually sensitive to a decrease in the substrate concentration. The joint complex, however, fails to traverse a point in the initial transcribed sequence that normally requires a high concentration of the elongating substrate. Thus, the repressor acts by augmenting a natural high "k(NTP)" site (pause site) embedded in the promoter. A lethal RNA polymerase mutation that mimics the effect of the repressor leads to an analogous block of promoter clearance and shortened abortive product pattern on several promoters, reflecting the widespread occurrence of high k(NTP) sites in promoters.			LEE, JY (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30717] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAHMBERLIN MJ, 1974, ANN REV BIOCH, V43, P721; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAN PT, 1989, J BIOL CHEM, V264, P21277; CHEN B, 1971, NATURE-NEW BIOL, V233, P67, DOI 10.1038/newbio233067a0; De Crombrugghe B, 1971, Nat New Biol, V231, P139; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; GRALLA JD, 1980, BIOCHEMISTRY-US, V19, P5864, DOI 10.1021/bi00566a031; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; GUIDIRONTANI C, 1985, J MOL BIOL, V186, P527, DOI 10.1016/0022-2836(85)90127-5; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; IWABE N, 1991, J MOL EVOL, V32, P70, DOI 10.1007/BF02099931; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; JOHNSTON DE, 1976, RNA POLYM, P101; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; KASSAVETIS GA, 1981, J BIOL CHEM, V256, P2777; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; MAJORS J, 1975, P NATL ACAD SCI USA, V72, P4394, DOI 10.1073/pnas.72.11.4394; MALAN TP, 1984, CELL, V39, P173, DOI 10.1016/0092-8674(84)90203-4; MALIK S, 1984, J BIOL CHEM, V4259, P13292; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.biochem.54.1.171; MENENDEZ M, 1987, EMBO J, V6, P4227, DOI 10.1002/j.1460-2075.1987.tb02771.x; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; Miller J. H., 1980, OPERON; PACE HC, 1990, P NATL ACAD SCI USA, V87, P1870, DOI 10.1073/pnas.87.5.1870; RHODES G, 1974, J BIOL CHEM, V249, P6675; ROZOVSKAYA TA, 1982, FEBS LETT, V137, P100, DOI 10.1016/0014-5793(82)80323-2; SCHMIDT MC, 1984, BIOCHEMISTRY-US, V23, P197, DOI 10.1021/bi00297a004; SCHMITZ A, 1979, NUCLEIC ACIDS RES, V6, P111, DOI 10.1093/nar/6.1.111; SPASSKY A, 1984, EMBO J, V3, P43, DOI 10.1002/j.1460-2075.1984.tb01759.x; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; STRANEY SB, 1987, BIOCHEMISTRY-US, V26, P5063, DOI 10.1021/bi00390a027; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1242; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	37	67	68	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					793	798		10.1016/0092-8674(91)90122-F	http://dx.doi.org/10.1016/0092-8674(91)90122-F			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878972				2022-12-01	WOS:A1991GC74500017
J	LIU, J; FARMER, JD; LANE, WS; FRIEDMAN, J; WEISSMAN, I; SCHREIBER, SL				LIU, J; FARMER, JD; LANE, WS; FRIEDMAN, J; WEISSMAN, I; SCHREIBER, SL			CALCINEURIN IS A COMMON TARGET OF CYCLOPHILIN-CYCLOSPORINE-A AND FKBP-FK506 COMPLEXES	CELL			English	Article							T-CELL ACTIVATION; DEPENDENT PROTEIN PHOSPHATASE; CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CIS-TRANS ISOMERASE; IMMUNOSUPPRESSANT FK506; LIMITED PROTEOLYSIS; MACROLIDES FK-506; CALCIUM-BINDING; CALMODULIN	Although the immediate receptors (immunophilins) of the immunosuppressants cyclosporin A (CsA) and FK506 are distinct, their similar mechanisms of inhibition of cell signaling suggest that their associated immunophilin complexes interact with a common target. We report here that the complexes cyclophilin-CsA and FKBP-FK506 (but not cyclophilin, FKBP, FKBP-rapamycin, or FKBP-506BD) competitively bind to and inhibit the Ca2+- and calmodulin-dependent phosphatase calcineurin, although the binding and inhibition of calcineurin do not require calmodulin. These results suggest that calcineurin is involved in a common step associated with T cell receptor and IgE receptor signaling pathways and that cyclophilin and FKBP mediate the actions of CsA and FK506, respectively, by forming drug-dependent complexes with and altering the activity of calcineurin-calmodulin.	STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,DEPT PATHOL,STANFORD,CA 94305; HARVARD UNIV,MICROCHEM FACIL,CAMBRIDGE,MA 02138; STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,DEPT DEV BIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Harvard University; Howard Hughes Medical Institute; Stanford University	LIU, J (corresponding author), HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138, USA.				NCI NIH HHS [5T32 CA 09302] Funding Source: Medline; NIGMS NIH HHS [GM-38627, GM-40660] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038627, R01GM038627, P01GM040660] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1984, EUR J BIOCHEM, V139, P663, DOI 10.1111/j.1432-1033.1984.tb08055.x; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; FRIEDMAN J, 1991, CELL, V66; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1991, IN PRESS SCIENCE; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; JOHANSSON A, 1990, TRANSPLANTATION, V50, P1001, DOI 10.1097/00007890-199012000-00021; KINCAID RL, 1987, NATURE, V330, P176, DOI 10.1038/330176a0; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KLEE CB, 1978, BIOCHEMISTRY-US, V17, P120, DOI 10.1021/bi00594a017; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; LIN CS, 1991, CELL IMMUNOL, V133, P269, DOI 10.1016/0008-8749(91)90103-I; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302	43	3627	3848	13	237	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					807	815		10.1016/0092-8674(91)90124-H	http://dx.doi.org/10.1016/0092-8674(91)90124-H			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1715244				2022-12-01	WOS:A1991GC74500019
J	MOLL, T; TEBB, G; SURANA, U; ROBITSCH, H; NASMYTH, K				MOLL, T; TEBB, G; SURANA, U; ROBITSCH, H; NASMYTH, K			THE ROLE OF PHOSPHORYLATION AND THE CDC28 PROTEIN-KINASE IN CELL-CYCLE REGULATED NUCLEAR IMPORT OF THE SACCHAROMYCES-CEREVISIAE TRANSCRIPTION FACTOR-SWI5	CELL			English	Article							HO GENE; C-MYB; B-MYB; YEAST; DNA; SACCHAROMYCES; BINDING; IDENTIFICATION; NUCLEOPLASMIN; TRANSLOCATION	The intracellular localization of the S. cerevisiae transcription factor SWI5 is cell cycle dependent. The protein is nuclear in G1 cells but cytoplasmic in S, G2, and M phase cells. We have identified SWI5's nuclear localization signal (NLS) and show that it can confer cell cycle-dependent nuclear entry to a heterologous protein. Located within or close to the NLS are three serine residues, mutation of which results in constitutive nuclear entry. These residues are phosphorylated in a cell cycle-dependent manner in vivo, being phosphorylated when SWI5 is in the cytoplasm and dephosphorylated when it is in the nucleus. As all three serines are phosphorylated by purified CDC28-dependent H1 kinase activity in vitro, we propose a model in which the CDC28 kinase acts directly to control nuclear entry of SWI5.			MOLL, T (corresponding author), INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.		Surana, Uttam/H-1142-2011	Nasmyth, Kim/0000-0001-7030-4403; Tebb, Graham/0000-0002-1294-2025; Surana, Uttam/0000-0002-4785-6514				BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BUCKINGTHROM E, 1973, EXP CELL RES, V76, P99, DOI 10.1016/0014-4827(73)90424-2; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DANG CV, 1989, J BIOL CHEM, V264, P18019; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HICKS JB, 1976, GENETICS, V83, P245; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NASMYTH K, 1987, SCIENCE, V237, P1162, DOI 10.1126/science.3306917; NASMYTH K, 1985, CELL, V42, P213, DOI 10.1016/S0092-8674(85)80117-3; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1980, GENETICS, V95, P561; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Rubin G M, 1975, Methods Cell Biol, V12, P45; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; SUISSA M, 1983, ANAL BIOCHEM, V133, P511, DOI 10.1016/0003-2697(83)90117-3; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V	47	459	463	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					743	758		10.1016/0092-8674(91)90118-I	http://dx.doi.org/10.1016/0092-8674(91)90118-I			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652372				2022-12-01	WOS:A1991GC74500013
J	MONTESANO, R; SCHALLER, G; ORCI, L				MONTESANO, R; SCHALLER, G; ORCI, L			INDUCTION OF EPITHELIAL TUBULAR MORPHOGENESIS INVITRO BY FIBROBLAST-DERIVED SOLUBLE FACTORS	CELL			English	Article							TUMOR-CELL INVASION; MESENCHYMAL INTERACTIONS; POLARIZED EPITHELIUM; SCATTER FACTOR; GROWTH-FACTOR; MDCK CYSTS; LINE MDCK; MEMBRANE; DIFFERENTIATION; EXPRESSION	We have designed an in vitro system in which Madin-Darby canine kidney (MDCK) epithelial cells are cocultured in collagen gels with fibroblasts under conditions precluding heterocellular contact. Using this experimental approach, we have obtained evidence that fibroblast-derived soluble factors play a crucial role in the control of epithelial morphogenesis. First, MDCK cells suspended alone in collagen gels form spherical cysts, whereas in the presence of fibroblasts they form branching tubules. Second, MDCK cells grown as a monolayer on fibroblast-containing collagen gels invade the underlying matrix, within which they form a network of tubules. Third, fibroblast-conditioned medium mimics the effects of coculture by eliciting tubulogenesis by MDCK cells. These results demonstrate the involvement of diffusible paracrine factors in morphogenetic epithelial-mesenchymal interactions and provide a strategy for their molecular characterization.			MONTESANO, R (corresponding author), UNIV GENEVA, MED CTR, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND.							BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BENNETT DC, 1980, NATURE, V285, P657, DOI 10.1038/285657a0; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; Bernfield M., 1984, ROLE EXTRACELLULAR M, P545; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; CHAMBARD M, 1981, J CELL BIOL, V91, P157, DOI 10.1083/jcb.91.1.157; CUNHA GR, 1985, CELL DIFFER DEV, V17, P137, DOI 10.1016/0045-6039(85)90481-6; EDELMAN GM, 1990, MORPHOREGULATORY MOL; Ekblom P, 1984, ROLE EXTRACELLULAR M, P173; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GOSPODAROWICZ D, 1984, J CELL BIOL, V99, P947, DOI 10.1083/jcb.99.3.947; GRANTHAM JJ, 1989, KIDNEY INT, V35, P1379, DOI 10.1038/ki.1989.137; GROBSTEIN C, 1956, ADV CANCER RES, V4, P187, DOI 10.1016/S0065-230X(08)60725-3; GURDON JB, 1987, DEVELOPMENT, V99, P285; HADLEY MA, 1985, J CELL BIOL, V101, P1511, DOI 10.1083/jcb.101.4.1511; HALL HG, 1982, P NATL ACAD SCI-BIOL, V79, P4672, DOI 10.1073/pnas.79.15.4672; HODGES GM, 1982, BR SOC CELL BIOL S, V5, P333; LEIGHTON J, 1970, CANCER-AM CANCER SOC, V26, P1022, DOI 10.1002/1097-0142(197011)26:5<1022::AID-CNCR2820260509>3.0.CO;2-M; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOUVARD D, 1980, P NATL ACAD SCI-BIOL, V77, P4132, DOI 10.1073/pnas.77.7.4132; MANGOOKARIM R, 1989, P NATL ACAD SCI USA, V86, P6007, DOI 10.1073/pnas.86.15.6007; MCATEER JA, 1987, ANAT REC, V217, P229, DOI 10.1002/ar.1092170303; McRoberts J. A., 1981, FUNCTIONALLY DIFFERE, P117; MERCOLA M, 1988, DEVELOPMENT, V102, P451; MISFELDT DS, 1976, P NATL ACAD SCI USA, V73, P1212, DOI 10.1073/pnas.73.4.1212; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MONTESANO R, 1983, J CELL BIOL, V97, P935, DOI 10.1083/jcb.97.3.935; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NAKANISHI Y, 1989, BIOESSAYS, V11, P163, DOI 10.1002/bies.950110602; OJAKIAN GK, 1987, AM J PHYSIOL, V253, pC433, DOI 10.1152/ajpcell.1987.253.3.C433; PICTET RL, 1977, CELL INTERACTIONS DI, P339; RICHARDSON JCW, 1981, BIOCHIM BIOPHYS ACTA, V673, P26, DOI 10.1016/0304-4165(81)90307-X; RICHMAN PI, 1988, J PATHOL, V156, P197, DOI 10.1002/path.1711560305; RINDLER MJ, 1979, J CELL BIOL, V81, P635, DOI 10.1083/jcb.81.3.635; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SAWYER RH, 1983, EPITHELIAL MESENCHYM; Saxen L., 1976, CELL SURFACE ANIMAL, P331; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHOR SL, 1987, BIOESSAYS, V7, P200, DOI 10.1002/bies.950070503; SCHOR SL, 1987, EXP CELL BIOL, V55, P11; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SLACK JMW, 1989, LANCET, V1, P1312; SPOONER BS, 1986, REGULATION MATRIX AC, P339; SPORN MB, 1990, PEPTIDE GROWTH FACTO, V1; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKAHASHI Y, 1991, DEVELOPMENT, V111, P327; TAUB M, 1990, P NATL ACAD SCI USA, V87, P4002, DOI 10.1073/pnas.87.10.4002; UENO N, 1990, Progress in Growth Factor Research, V2, P113, DOI 10.1016/0955-2235(90)90027-H; VANDENHOOFF A, 1988, ADV CANCER RES, V50, P159, DOI 10.1016/S0065-230X(08)60437-6; WANG AZ, 1990, J CELL SCI, V95, P137; WANG AZ, 1990, J CELL SCI, V95, P153; WARREN SL, 1987, MOL CELL BIOL, V7, P1326, DOI 10.1128/MCB.7.4.1326; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WELLER A, 1991, DEV BIOL, V144, P248, DOI 10.1016/0012-1606(91)90419-4; YANG J, 1979, P NATL ACAD SCI USA, V76, P3401, DOI 10.1073/pnas.76.7.3401	60	460	477	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 23	1991	66	4					697	711		10.1016/0092-8674(91)90115-F	http://dx.doi.org/10.1016/0092-8674(91)90115-F			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878968				2022-12-01	WOS:A1991GC74500010
J	PAGE, DL; DUPONT, WD				PAGE, DL; DUPONT, WD			PROLIFERATIVE BREAST DISEASE - DIAGNOSIS AND IMPLICATIONS	SCIENCE			English	Article							TERM FOLLOW-UP; CANCER; LESIONS; WOMEN		VANDERBILT UNIV,MED CTR,SCH MED,DEPT PREVENT MED,DIV BIOSTAT,NASHVILLE,TN 37232	Vanderbilt University	PAGE, DL (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT PATHOL,NASHVILLE,TN 37232, USA.		Dupont, William D./I-4430-2012	Bishop, Tim/0000-0002-8752-8785; albright, lisa/0000-0003-2602-3668				BIBBO M, 1988, ACTA CYTOL, V32, P193; CARTER CL, 1988, AM J EPIDEMIOL, V128, P467, DOI 10.1093/oxfordjournals.aje.a114995; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; DUPONT WD, 1987, AM J EPIDEMIOL, V125, P769, DOI 10.1093/oxfordjournals.aje.a114594; PAGE DL, 1985, CANCER, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A; SKOLNICK MH, 1990, SCIENCE, V250, P1715, DOI 10.1126/science.2270486; TAVASSOLI FA, 1990, CANCER, V65, P518, DOI 10.1002/1097-0142(19900201)65:3<518::AID-CNCR2820650324>3.0.CO;2-O	7	19	19	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1991	253	5022					915	915		10.1126/science.1876848	http://dx.doi.org/10.1126/science.1876848			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1876848				2022-12-01	WOS:A1991GC15200049
J	PARKER, CN; HALFORD, SE				PARKER, CN; HALFORD, SE			DYNAMICS OF LONG-RANGE INTERACTIONS ON DNA - THE SPEED OF SYNAPSIS DURING SITE-SPECIFIC RECOMBINATION BY RESOLVASE	CELL			English	Article							LAMBDA INTEGRATIVE RECOMBINATION; TN3 RESOLVASE; TN21 RESOLVASE; RECOGNITION FUNCTIONS; BACTERIOPHAGE-LAMBDA; LAC REPRESSOR; BINDING-SITES; RES SITES; PROTEIN; PRODUCTS	A noninvasive method for monitoring communications on DNA was developed from the specificity of resolvase for the arrangement of its recombinational sites. Constraints in DNA structure, caused by interactions between distant sites, can be detected by resolvase as they arise. The method was used to follow the formation and decay of synaptic intermediates during site-specific recombination by resolvase. Synaptic complexes were formed very rapidly, at a rate limited by the initial association of the protein with DNA rather than the physical motion of DNA segments. The recombinational sites seem to encounter each other by an ordered motion, perhaps dictated by DNA super-coiling instead of random collisions, so that the first encounter produces the active complex.	UNIV BRISTOL,CTR MOLEC RECOGNIT,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABREMSKI K, 1988, J MOL BIOL, V202, P59, DOI 10.1016/0022-2836(88)90518-9; ABREMSKI K, 1985, J MOL BIOL, V184, P211, DOI 10.1016/0022-2836(85)90374-2; ACKROYD AJ, 1990, J MOL BIOL, V216, P633, DOI 10.1016/0022-2836(90)90388-3; AVILA P, 1990, J MOL BIOL, V216, P645, DOI 10.1016/0022-2836(90)90389-4; BEDNARZ AL, 1990, GENE DEV, V4, P2366, DOI 10.1101/gad.4.12b.2366; BELLOMY GR, 1990, PROG NUCL ACIDS RES, V30, P81; BENJAMIN HA, 1989, J BIOL CHEM, V265, P6441; BENJAMIN HW, 1988, EMBO J, V7, P1897, DOI 10.1002/j.1460-2075.1988.tb03023.x; BENJAMIN HW, 1986, P RA WELCH F C CHEM, V29, P107; Berg O, 1981, BIOCHEMISTRY-US, V20, P6926; BERG OG, 1984, BIOPOLYMERS, V23, P1869, DOI 10.1002/bip.360231005; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.bb.14.060185.001023; BETTER M, 1982, P NATL ACAD SCI-BIOL, V79, P5837, DOI 10.1073/pnas.79.19.5837; BOOCOCK MR, 1986, BIOCHEM SOC T, V14, P214; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; CASTELL SE, 1989, NUCLEIC ACIDS RES, V17, P7045, DOI 10.1093/nar/17.17.7045; CASTELL SE, 1986, NUCLEIC ACIDS RES, V14, P7213, DOI 10.1093/nar/14.18.7213; CASTELL SE, 1988, THESIS U BRISTOL BRI; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; DIVER WP, 1983, MOL GEN GENET, V191, P189, DOI 10.1007/BF00334812; GELLERT M, 1987, NATURE, V325, P401, DOI 10.1038/325401a0; HAGERMAN P, 1908, ANNU REV BIOPHYS BIO, V17, P165; HALFORD SE, 1985, MOL GEN GENET, V200, P169, DOI 10.1007/BF00383331; HALFORD SE, 1983, BIOCHEM J, V211, P405, DOI 10.1042/bj2110405; HATFULL GF, 1988, GENETIC RECOMBINATIO, P3257; KLEIN J, 1990, SCIENCE, V250, P640, DOI 10.1126/science.250.4981.640; KRAMER H, 1988, EMBO J, V7, P547, DOI 10.1002/j.1460-2075.1988.tb02844.x; KRASNOW MA, 1983, CELL, V32, P1313, DOI 10.1016/0092-8674(83)90312-4; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; Luke P A, 1987, Gene Amplif Anal, V5, P185; Maniatis T., 1982, MOL CLONING; MIZUUCHI K, 1980, J MOL BIOL, V141, P485, DOI 10.1016/0022-2836(80)90256-9; MUKHERJEE S, 1988, P NATL ACAD SCI USA, V85, P6287, DOI 10.1073/pnas.85.17.6287; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; ROGOWSKY P, 1985, EMBO J, V4, P2135, DOI 10.1002/j.1460-2075.1985.tb03904.x; SALDANHA R, 1987, J MOL BIOL, V196, P505, DOI 10.1016/0022-2836(87)90028-3; SALVO JJ, 1988, STRUCTURE EXPRESSION, V3, P105; SHERRATT D, 1989, MOBILE DNA, P163; SPENGLER SJ, 1985, CELL, V42, P325, DOI 10.1016/S0092-8674(85)80128-8; STARK WM, 1989, TRENDS GENET, V5, P304, DOI 10.1016/0168-9525(89)90113-3; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WASSERMAN SA, 1985, P NATL ACAD SCI USA, V82, P1079, DOI 10.1073/pnas.82.4.1079	47	58	58	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					781	791		10.1016/0092-8674(91)90121-E	http://dx.doi.org/10.1016/0092-8674(91)90121-E			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652373				2022-12-01	WOS:A1991GC74500016
J	PIERETTI, M; ZHANG, FP; FU, YH; WARREN, ST; OOSTRA, BA; CASKEY, CT; NELSON, DL				PIERETTI, M; ZHANG, FP; FU, YH; WARREN, ST; OOSTRA, BA; CASKEY, CT; NELSON, DL			ABSENCE OF EXPRESSION OF THE FMR-1 GENE IN FRAGILE-X SYNDROME	CELL			English	Article								We previously reported the isolation of a gene (FMR-1) expressed in brain at the fragile X locus. One exon of this gene lies within an EcoRI fragment that exhibits length variation in fragile X patients. This exon also contains the CGG repeat within the CpG island hypermethylated in fragile X patients. To study the involvement of the FMR-1 gene in the fragile X syndrome, its expression was studied in lymphoblastoid cell lines and leukocytes derived from patients and normal controls. FMR-1 mRNA was absent in the majority of male fragile X patients, suggesting a close involvement of this gene in development of the syndrome. Normal individuals and carriers all show expression. The methylation status of the BssHII site at the CpG island was also studied by Southern blot analysis of DNA from patients, carriers, and controls. The minority of fragile X affected males that show expression of FMR-1 demonstrated an associated incomplete methylation of the BssHII site.	ERASMUS UNIV,DEPT CELL BIOL,3000 DR ROTTERDAM,NETHERLANDS; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322	Erasmus University Rotterdam; Emory University; Emory University	PIERETTI, M (corresponding author), BAYLOR COLL MED,HOWARD HUGHES MED INST,HUMAN GENOME CTR,INST MOLEC GENET,HOUSTON,TX 77030, USA.		Warren, Stephen T/A-2498-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020521, R37HD020521] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20521] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; DIETRICH A, 1991, NUCLEIC ACIDS RES, V19, P2567, DOI 10.1093/nar/19.10.2567; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; HIRST MC, 1991, GENOMICS, V10, P243, DOI 10.1016/0888-7543(91)90506-A; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; McKusick VA, 1990, MENDELIAN INHERITANC; NELSON DL, 1991, P NATL ACAD SCI USA, V88, P6157, DOI 10.1073/pnas.88.14.6157; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; OOSTRA BA, 1990, GENOMICS, V6, P129, DOI 10.1016/0888-7543(90)90457-6; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	15	1206	1225	1	58	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					817	822		10.1016/0092-8674(91)90125-I	http://dx.doi.org/10.1016/0092-8674(91)90125-I			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878973				2022-12-01	WOS:A1991GC74500020
J	RENFRANZ, PJ; CUNNINGHAM, MG; MCKAY, RDG				RENFRANZ, PJ; CUNNINGHAM, MG; MCKAY, RDG			REGION-SPECIFIC DIFFERENTIATION OF THE HIPPOCAMPAL STEM-CELL LINE HIB5 UPON IMPLANTATION INTO THE DEVELOPING MAMMALIAN BRAIN	CELL			English	Article							FLUORESCENT LATEX MICROSPHERES; INTERMEDIATE FILAMENT PROTEIN; MEDIATED GENE-TRANSFER; CHICKEN OPTIC TECTUM; RAT FASCIA DENTATA; PRECURSOR CELLS; VISUAL-CORTEX; RECOMBINANT RETROVIRUS; COMMON PROGENITOR; MOLECULAR LAYER	Proliferating precursors to the distinct cell types constituting the mammalian brain can be identified by the presence of the nestin intermediate filament. We report the establishment of a nestin-positive cell line, HiB5, from embryonic precursor cells to the rat hippocampus. Since it was immortalized using the temperature-sensitive allele tsA58 of SV40 large T antigen, these cells grow continuously at 33-degrees-C, but not at 39-degrees-C, the body temperature of rodents. To test their developmental capacity, HiB5 cells were implanted into both the neonatal hippocampus and cerebellum. The cells integrated into the host tissue and acquired morphologies characteristic of the neurons and glial cells found at the implant site. HiB5 cells might thus be useful in characterizing the signals regulating cell type determination in the mammalian brain.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,BOSTON,MA 02115; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)								ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; ALTMAN J, 1963, ANAT REC, V145, P573, DOI 10.1002/ar.1091450409; ALTMAN J, 1972, J COMP NEUROL, V145, P353, DOI 10.1002/cne.901450305; ALTMAN J, 1972, J COMP NEUROL, V145, P465, DOI 10.1002/cne.901450403; ALTMAN J, 1990, J COMP NEUROL, V301, P365, DOI 10.1002/cne.903010304; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; ANGEVINE JB, 1965, EXP NEUROL        S2, V13, P1; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BARTLETT PF, 1988, P NATL ACAD SCI USA, V85, P3255, DOI 10.1073/pnas.85.9.3255; BAYER SA, 1980, J COMP NEUROL, V190, P87, DOI 10.1002/cne.901900107; BJORKLUND A, 1976, NATURE, V262, P787, DOI 10.1038/262787a0; Brodal A, 1981, NEUROLOGICAL ANATOMY; Cajal S.R., 1894, NEW IDEAS STRUCTURE; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CEPKO C, 1988, TRENDS NEUROSCI, V11, P6, DOI 10.1016/0166-2236(88)90039-2; CEPKO CL, 1989, ANNU REV NEUROSCI, V12, P47, DOI 10.1146/annurev.ne.12.030189.000403; CLAIBORNE BJ, 1990, J COMP NEUROL, V302, P206, DOI 10.1002/cne.903020203; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; FROTSCHER M, 1983, J COMP NEUROL, V215, P299, DOI 10.1002/cne.902150306; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GODEMENT P, 1987, DEVELOPMENT, V101, P697; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; KAPLAN MP, 1990, J NEUROSCI, V10, P2735; KATZ LC, 1990, NEUROSCIENCE, V34, P511, DOI 10.1016/0306-4522(90)90159-2; KATZ LC, 1987, J NEUROSCI, V7, P1223; KATZ LC, 1984, NATURE, V310, P498, DOI 10.1038/310498a0; LANDER AD, 1987, MOL NEUROBIOL, V1, P213, DOI 10.1007/BF02936609; LEE HJ, 1990, J NEUROSCI, V10, P1779; LENDAHL U, 1990, TRENDS NEUROSCI, V13, P132, DOI 10.1016/0166-2236(90)90004-T; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LOGIN GR, 1985, AM J PATHOL, V120, P230; LUBBERS K, 1987, ANAT EMBRYOL, V177, P1, DOI 10.1007/BF00325285; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; Palay S.L., 1974, CEREBELLAR CORTEX CY; PRICE J, 1988, DEVELOPMENT, V104, P473; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; ROGERS A, 1967, TECHNIQUES QAUTORADI; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; SANDELL JH, 1988, J HISTOCHEM CYTOCHEM, V36, P555, DOI 10.1177/36.5.3356898; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHLESSINGER AR, 1978, ANAT EMBRYOL, V154, P153, DOI 10.1007/BF00304660; SCHLESSINGER AR, 1975, J COMP NEUROL, V159, P149, DOI 10.1002/cne.901590202; SCHLESSINGER J, 1977, SCIENCE, V195, P307, DOI 10.1126/science.556653; SCHMUED LC, 1986, BRAIN RES, V377, P147, DOI 10.1016/0006-8993(86)91199-6; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; THANOS S, 1987, J COMP NEUROL, V261, P155, DOI 10.1002/cne.902610114; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; Witter MP, 1989, HIPPOCAMPUS NEW VIST, P53; YEN SE, 1982, J CELL BIOL, V88, P115	62	440	469	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					713	729		10.1016/0092-8674(91)90116-G	http://dx.doi.org/10.1016/0092-8674(91)90116-G			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878969				2022-12-01	WOS:A1991GC74500011
J	WAHLE, E				WAHLE, E			A NOVEL POLY(A)-BINDING PROTEIN ACTS AS A SPECIFICITY FACTOR IN THE 2ND PHASE OF MESSENGER-RNA POLYADENYLATION	CELL			English	Article							BINDING-PROTEIN; POLY(A) POLYMERASE; AAUAAA SEQUENCE; CLEAVAGE; NUCLEAR; SITE; RECOGNITION; INVITRO; DOMAIN; TAIL	Polyadenylation of mRNA precursors by poly(A) polymerase depends on a specificity factor, CPF, recognizing the polyadenylation signal AAUAAA. This paper describes an apparently novel poly(A)-binding protein that acts as a second specificity factor, mediating the recognition of the growing poly(A) tail. A transition from a slow initiation phase of polyadenylation to rapid elongation occurs when the growing tail is long enough to serve as a binding site for the poly(A)-binding protein. Elongation of an RNA carrying a tail of 10 or more adenylate residues can occur independently of CPF. A sharp decrease in the poly(A) chain growth rate after the addition of approximately 200 adenylate residues invites speculations about a role of the poly(A)-binding protein in poly(A) tail length control.			WAHLE, E (corresponding author), UNIV BASEL,BIOCTR,DEPT CELL BIOL,KINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.			Wahle, Elmar/0000-0003-2504-0677				ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; BARDWELL VJ, 1990, MOL CELL BIOL, V10, P295, DOI 10.1128/MCB.10.1.295; BARDWELL VJ, 1991, CELL, V65, P125, DOI 10.1016/0092-8674(91)90414-T; BIENROTH S, 1991, IN PRESS J BIOL CHEM, V266; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BLOBEL G, 1973, P NATL ACAD SCI USA, V70, P924, DOI 10.1073/pnas.70.3.924; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; CHRISTOFORI G, 1988, CELL, V54, P75; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; KELLY RC, 1976, J BIOL CHEM, V251, P7240; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; MEANS GE, 1968, BIOCHEMISTRY-US, V7, P2192, DOI 10.1021/bi00846a023; MOORE CL, 1984, CELL, V36, P581, DOI 10.1016/0092-8674(84)90337-4; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; SACHS AB, 1985, MOL CELL BIOL, V5, P1993, DOI 10.1128/MCB.5.8.1993; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J., 1989, MOL CLONING LAB MANU; SETYONO B, 1981, CELL, V24, P775, DOI 10.1016/0092-8674(81)90103-3; SHEETS MD, 1989, GENE DEV, V3, P1401, DOI 10.1101/gad.3.9.1401; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHUMAN S, 1988, J BIOL CHEM, V263, P8405; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TSIAPALIS CM, 1975, J BIOL CHEM, V250, P4486; WAHLE LE, 1991, J BIOL CHEM, V266, P3131; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; ZARKOWER D, 1986, MOL CELL BIOL, V6, P2317, DOI 10.1128/MCB.6.7.2317; ZELUS BD, 1989, MOL CELL BIOL, V9, P2756, DOI 10.1128/MCB.9.6.2756	42	244	245	3	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					759	768		10.1016/0092-8674(91)90119-J	http://dx.doi.org/10.1016/0092-8674(91)90119-J			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878970				2022-12-01	WOS:A1991GC74500014
J	WANG, C; LEHMANN, R				WANG, C; LEHMANN, R			NANOS IS THE LOCALIZED POSTERIOR DETERMINANT IN DROSOPHILA	CELL			English	Article							SEGMENTATION GENE HUNCHBACK; EGF-LIKE REPEATS; BICOID PROTEIN; MATERNAL GENE; ABDOMINAL SEGMENTATION; PATTERN-FORMATION; ANTERIOR PATTERN; NEUROGENIC GENE; EMBRYO; MELANOGASTER	Segmental pattern in the Drosophila embryo is established by two maternal factors localized to the anterior and posterior poles of the egg cell. Here we provide molecular evidence that the localized posterior factor is the RNA of the nanos (nos) gene. nos RNA is localized to the posterior pole of early embryos, and nos protein acts at a distance to direct abdomen formation. Synthetic nos RNA has biological activity identical to that of the posterior pole plasm. Injection of nos RNA rescues the segmentation defect of embryos derived from females mutant for all nine known posterior group genes. Injection of nos RNA into the anterior is able to direct formation of ectopic posterior structures. Our results demonstrate that a localized source of nos RNA is sufficient to specify abdominal segmentation and imply that other posterior group genes are required for localization, stabilization, or distribution of the nos gene product.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	WANG, C (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.							ALTON AK, 1988, GENETICS, V118, P235; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELDON ED, 1991, DEVELOPMENT, V111, P367; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; FYRBERG EA, 1983, CELL, V33, P115, DOI 10.1016/0092-8674(83)90340-9; GAUL U, 1987, CELL, V51, P549, DOI 10.1016/0092-8674(87)90124-3; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LEHMANN R, 1989, DEVELOPMENT, V107, P21; LEHMANN R, 1988, DEVELOPMENT, V104, P17; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1977, ROUX ARCH DEV BIOL, V183, P249, DOI 10.1007/BF00867325; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; Sambrook J., 1989, MOL CLONING LAB MANU; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VASSIN H, 1987, GENETICS, V116, P433; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; Wieschaus E., 1986, P199	47	423	436	1	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					637	647		10.1016/0092-8674(91)90110-K	http://dx.doi.org/10.1016/0092-8674(91)90110-K			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1908748				2022-12-01	WOS:A1991GC74500005
J	WELLS, FB; GAHM, SJ; HEDRICK, SM; BLUESTONE, JA; DENT, A; MATIS, LA				WELLS, FB; GAHM, SJ; HEDRICK, SM; BLUESTONE, JA; DENT, A; MATIS, LA			REQUIREMENT FOR POSITIVE SELECTION OF GAMMA-DELTA-RECEPTOR-BEARING T-CELLS	SCIENCE			English	Article							LYMPHOCYTES-T; CYCLOSPORINE-A; STEM-CELLS; ANTIGEN; THYMUS; MICE; EXPRESSION; CD8; SPECIFICITY; RECOGNITION	The alpha-beta and gamma-delta-T cell receptors for antigen (TCR) delineate distinct T cell populations. TCR-alpha-beta-bearing thymocytes must be positively selected by binding of the TCR to major histocompatibility complex (MHC) molecules on thymic epithelium. To examine the requirement for positive selection of TCR gamma-delta-T cells, mice bearing a class I MHC-specific gamma-delta-transgene (Tg) were crossed to mice with disrupted beta-2 microglobulin (beta-2M) genes. The Tg+beta-2M- (class I MHC-) offspring had Tg+ thymocytes that did not proliferate to antigen or Tg-specific monoclonal antibody and few peripheral Tg+ cells. This is evidence for positive selection within the gamma-delta-T cell subset.	NCI, FREDERICK CANC RES & DEV CTR, MOLEC IMMUNOREGULAT LAB, BIOL RESPONSE MODIFIERS PROGRAM, FREDERICK, MD 21702 USA; NCI, HOWARD HUGHES MED INST, RES SCHOLARS PROGRAM, BETHESDA, MD 20892 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, FREDERICK, MD 21701 USA; UNIV CHICAGO, BEN MAY INST, DEPT PATHOL, COMM IMMUNOL, CHICAGO, IL 60637 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Chicago			Hedrick, Stephen M/E-9171-2010	Hedrick, Stephen/0000-0002-6345-8751	NIAID NIH HHS [AI 26847-03, AI00602] Funding Source: Medline; PHS HHS [N01-C0-74102] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026847] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BONNEVILLE M, 1990, NATURE, V344, P163, DOI 10.1038/344163a0; BORN W, 1990, IMMUNOL TODAY, V11, P40; BRUCE J, 1981, J IMMUNOL, V127, P2496; Bucy R P, 1991, Semin Immunol, V3, P109; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CRON RQ, 1989, J IMMUNOL, V142, P3754; DENT AL, 1990, NATURE, V343, P714, DOI 10.1038/343714a0; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; ITOHARA S, 1990, P NATL ACAD SCI USA, V87, P7935, DOI 10.1073/pnas.87.20.7935; JANEWAY CA, 1984, J IMMUNOL, V132, P662; JENKINS MK, 1988, SCIENCE, V241, P1655, DOI 10.1126/science.3262237; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KOLLER B, UNPUB; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KOSUGI A, 1989, J IMMUNOL, V142, P3026; LEFRANCOIS L, 1990, CELL, V63, P333, DOI 10.1016/0092-8674(90)90166-C; MATIS LA, 1987, NATURE, V330, P262, DOI 10.1038/330262a0; PARDOLL DM, 1988, J IMMUNOL, V140, P4091; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SIM GK, 1990, CELL, V61, P397, DOI 10.1016/0092-8674(90)90522-G; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; WELLS FB, UNPUB; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	32	74	74	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 23	1991	253	5022					903	905		10.1126/science.1831565	http://dx.doi.org/10.1126/science.1831565			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1831565				2022-12-01	WOS:A1991GC15200045
J	ALDRICH, CJ; HAMMER, RE; JONESYOUNGBLOOD, S; KOSZINOWSKI, U; HOOD, L; STROYNOWSKI, I; FORMAN, J				ALDRICH, CJ; HAMMER, RE; JONESYOUNGBLOOD, S; KOSZINOWSKI, U; HOOD, L; STROYNOWSKI, I; FORMAN, J			NEGATIVE AND POSITIVE SELECTION OF ANTIGEN-SPECIFIC CYTOTOXIC LYMPHOCYTES-T AFFECTED BY THE ALPHA-3 DOMAIN OF MHC-I MOLECULES	NATURE			English	Article							HISTOCOMPATIBILITY COMPLEX ANTIGENS; CELLS; CD8; EXPRESSION; HLA-A2	THE alpha-1 and alpha-2 domains of major histocompatibility complex (MHC) class I molecules function in the binding and presentation of foreign peptides to the T-cell antigen receptor and control both negative and positive selection of the T-cell repertoire 1-3. Although the alpha-3 domain of class I is not involved in peptide binding, it does interact with the T-cell accessory molecule, CD8 (refs 4, 5). CD8 is important in the selection of T cells as anti-CD8 antibody injected into perinatal mice interferes with this process 6. We previously used a hybrid class I molecule with the alpha-1/alpha-2 domains from L(d) and the alpha-3 domain from Q7b and showed that this molecule binds an L(d)-restricted peptide but does not interact with CD8-dependent cytotoxic T lymphocytes 7. Expression of this molecule in transgenic mice fails to negatively select a subpopulation of anti-L(d) cytotoxic T lymphocytes. In addition, positive selection of virus-specific L(d)-restricted cytotoxic T lymphocytes does not occur. We conclude that besides the alpha-1/alpha-2 domains of class I, the alpha-3 domain plays an important part in both positive and negative selection of antigen-specific cells.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV ULM,VIROL ABT,W-7900 ULM,GERMANY; CALTECH,DEPT BIOL,PASADENA,CA 91125	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; Ulm University; California Institute of Technology	ALDRICH, CJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235, USA.							ALDRICH CJ, 1991, J IMMUNOL, V146, P3082; ALDRICH CJ, 1986, J IMMUNOL, V136, P383; ALEXANDER MA, 1991, J EXP MED, V173, P849, DOI 10.1084/jem.173.4.849; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BUDD RC, 1987, J IMMUNOL, V138, P1009; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; KOSZINOWSKI UH, 1987, J EXP MED, V166, P289, DOI 10.1084/jem.166.1.289; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LIE WR, 1991, J EXP MED, V173, P449, DOI 10.1084/jem.173.2.449; MACDONALD HR, 1982, IMMUNOL REV, V68, P89, DOI 10.1111/j.1600-065X.1982.tb01061.x; MARUSICGALESIC S, 1988, NATURE, V333, P180, DOI 10.1038/333180a0; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SPRENT J, 1990, IMMUNOL REV, V117, P213, DOI 10.1111/j.1600-065X.1990.tb00574.x; STROYNOWSKI I, 1990, ANNU REV IMMUNOL, V8, P501, DOI 10.1146/annurev.iy.08.040190.002441; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	24	84	84	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1991	352	6337					718	721		10.1038/352718a0	http://dx.doi.org/10.1038/352718a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1652099	Green Submitted			2022-12-01	WOS:A1991GC06400059
J	HILGEMANN, DW; NICOLL, DA; PHILIPSON, KD				HILGEMANN, DW; NICOLL, DA; PHILIPSON, KD			CHARGE MOVEMENT DURING NA+ TRANSLOCATION BY NATIVE AND CLONED CARDIAC NA+/CA2+ EXCHANGER	NATURE			English	Article							SODIUM-CALCIUM EXCHANGE; SARCOLEMMAL MEMBRANE PATCHES; CURRENT-VOLTAGE RELATIONSHIP; PIG VENTRICULAR MYOCYTES; CA EXCHANGE; GUINEA-PIG; NA/K PUMP; DEPENDENCE; STOICHIOMETRY; TRANSIENTS	Na+/Ca2+ EXCHANGE is electrogenic and moves one net positive charge per cycle 1,2. Although the cardiac exchanger has a three-to-one Na+/Ca2+ stoichiometry 3, details of the reaction cycle are not well defined 2,4-8. Here we associate Na+ translocation by the cardiac exchanger with positive charge movement in giant membrane patches from cardiac myocytes 9,10 and oocytes expressing the cloned cardiac Na+/Ca2+ exchanger 11. The charge movements are initiated by step increments of the cytoplasmic Na+ concentration in the absence of Ca2+. Giant patches from control oocytes lack both steady-state Na/Ca2+ exchange current (I(NaCa)) and Na+-induced charge movements. Charge movements indicate about 400 exchangers per mu-m2 in guinea-pig sarcolemma. Fully activated I(NaCa) densities (20-30-mu-A cm-2) indicate maximum turnover rates of 5,000 s-1. As has been predicted for consecutive exchange models 4-7, the apparent ion affinities of steady state I(NaCa) increase as the counterion concentrations are decreased. Consistent with an electroneutral Ca2+ translocation, we find that voltage dependence of I(NaCa) in both directions is lost as Ca2+ concentration is decreased. The principal electrogenic step seems to be at the extracellular end of the Na+ translocation pathway.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,CARDIOVASC RES LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	HILGEMANN, DW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235, USA.							ALLEN TJA, 1986, J PHYSIOL-LONDON, V378, P77, DOI 10.1113/jphysiol.1986.sp016208; ALLEN TJA, 1989, SODIUM CALCIUM EXCHA; BORLINGHAUS R, 1987, J MEMBRANE BIOL, V97, P161, DOI 10.1007/BF01869220; CRESPO LM, 1990, NATURE, V345, P618, DOI 10.1038/345618a0; FENDLER K, 1987, FEBS LETT, V224, P83, DOI 10.1016/0014-5793(87)80427-1; FORBUSH B, 1984, P NATL ACAD SCI-BIOL, V81, P5310, DOI 10.1073/pnas.81.17.5310; GADSBY DC, 1989, J GEN PHYSIOL, V94, P511, DOI 10.1085/jgp.94.3.511; GLYNN IM, 1975, ANNU REV PHYSIOL, V37, P13, DOI 10.1146/annurev.ph.37.030175.000305; GOLDSHLEGGER R, 1987, J PHYSIOL-LONDON, V387, P331, DOI 10.1113/jphysiol.1987.sp016576; HILGEMANN DW, 1988, PROG BIOPHYS MOL BIO, V51, P1, DOI 10.1016/0079-6107(88)90009-0; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1989, PFLUG ARCH EUR J PHY, V415, P247, DOI 10.1007/BF00370601; KHANANSHVILI D, 1990, BIOCHEMISTRY-US, V29, P2437, DOI 10.1021/bi00462a001; LAGNADO L, 1988, P NATL ACAD SCI USA, V85, P4548, DOI 10.1073/pnas.85.12.4548; LAGNADO L, 1990, J MEMBRANE BIOL, V113, P177, DOI 10.1007/BF01870070; LAUGER P, 1987, J MEMBRANE BIOL, V99, P1, DOI 10.1007/BF01870617; LI JM, 1990, J GEN PHYSIOL, V96, P777, DOI 10.1085/jgp.96.4.777; LI ZP, 1991, J BIOL CHEM, V266, P1014; NAKAO M, 1989, J GEN PHYSIOL, V94, P539, DOI 10.1085/jgp.94.3.539; NAKAO M, 1986, NATURE, V323, P628, DOI 10.1038/323628a0; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NIGGLI E, 1991, NATURE, V349, P621, DOI 10.1038/349621a0; RAKOWSKI RF, 1989, J GEN PHYSIOL, V93, P903, DOI 10.1085/jgp.93.5.903; STURMER W, 1989, J MEMBRANE BIOL, V110, P67, DOI 10.1007/BF01870994	24	191	194	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1991	352	6337					715	718		10.1038/352715a0	http://dx.doi.org/10.1038/352715a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1876186				2022-12-01	WOS:A1991GC06400058
J	INGOLD, AL; LANDEL, C; KNALL, C; EVANS, GA; POTTER, TA				INGOLD, AL; LANDEL, C; KNALL, C; EVANS, GA; POTTER, TA			CO-ENGAGEMENT OF CD8 WITH THE T-CELL RECEPTOR IS REQUIRED FOR NEGATIVE SELECTION	NATURE			English	Article							PROTEIN KINASE P56LCK; I ALPHA-3 DOMAIN; TRANSGENIC MICE; LYMPHOCYTES-T; RECOGNITION; DELETION; MOLECULE; ANTIGEN; SELF; SUBSTITUTION	ALTHOUGH it is established that the CD8 and CD4 co-receptors are involved in T-lymphocyte recognition and activation in the periphery, it is less clear whether these molecules participate in thymic selection events. Analysis of thymic selection in mice transgenic for T cell-receptor genes 1-4 or for major histocompatibility complex (MHC) genes 5, or mice injected with antibodies against CD8, CD4 or MHC molecules 6-8, is consistent with the participation of CD8 and CD4 in thymic selection. But antibody-mediated crosslinking of surface receptors in thymic organ cultures 9 has indicated that CD8 is not involved in thymic deletion. We show here that mice transgenic for a mutant MHC class I molecule that cannot interact with CD8 do not delete CD8-dependent T cells reactive with the wild-type molecule. This finding unequivocally establishes that for negative selection in the thymus, CD8 must interact with the same MHC class I molecule as the T cell receptor.	UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,CTR CANC,DENVER,CO 80206; SALK INST BIOL STUDIES,MOLEC GENET LAB,SAN DIEGO,CA 92138	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Salk Institute	INGOLD, AL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC IMMUNOL,DENVER,CO 80206, USA.							BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BIEBERICH C, 1986, MOL CELL BIOL, V6, P1339, DOI 10.1128/MCB.6.4.1339; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; FOWLKES BJ, 1988, NATURE, V334, P620, DOI 10.1038/334620a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; JANEWAY CA, 1989, IMMUNOL REV, V109, P77, DOI 10.1111/j.1600-065X.1989.tb00020.x; KALINKE U, 1990, NATURE, V348, P642, DOI 10.1038/348642a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LOH DY, 1989, COLD SH Q B, V54, P147, DOI 10.1101/SQB.1989.054.01.018; MACDONALD HR, 1988, NATURE, V335, P174, DOI 10.1038/335174a0; MCDONALD HR, 1982, IMMUNOL REV, V68, P89; POTTER TA, 1987, J EXP MED, V166, P956, DOI 10.1084/jem.166.4.956; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YACHELINI P, 1990, J IMMUNOL, V145, P1382; YOSHIOKA T, 1987, J IMMUNOL, V139, P3861; ZUNIGAPFLUCKER JC, 1989, COLD SPRING HARB SYM, V54, P153	23	85	85	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1991	352	6337					721	723		10.1038/352721a0	http://dx.doi.org/10.1038/352721a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1908563				2022-12-01	WOS:A1991GC06400060
J	JULIAN, BA; LASKOW, DA; DUBOVSKY, J; DUBOVSKY, EV; CURTIS, JJ; QUARLES, LD				JULIAN, BA; LASKOW, DA; DUBOVSKY, J; DUBOVSKY, EV; CURTIS, JJ; QUARLES, LD			RAPID LOSS OF VERTEBRAL MINERAL DENSITY AFTER RENAL-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE HISTOMORPHOMETRIC DATA; INDUCED OSTEOPOROSIS; ILIAC BONE; OSTEOMALACIA; RESORPTION; OSTEOPENIA; ALUMINUM	Background. Osteopenia is a major complication of renal transplantation. Immunosuppressive regimens including cyclosporine, which permit the use of lower doses of glucocorticoids, may reduce glucocorticoid-induced osteopenia. Methods. We prospectively studied the magnitude, distribution, and mechanism of bone loss in 20 adults who received renal allografts from living related donors, who had good renal function, and who were treated with azathioprine, cyclosporine, and low doses of prednisone. We measured serum biochemical markers of bone metabolism, determined the bone mineral density of the second, third, and fourth lumbar vertebrae and the shaft of the radius, and analyzed the histomorphometric features of iliac bone at the time of transplantation and six months later. Measurements of vertebral mineral density were repeated 18 months after transplantation in 17 of the patients. Results. After transplantation, the mean serum concentrations of Parathyroid hormone, phosphorus, and alkaline phosphatase decreased and the serum calcitriol concentration increased. The mean (+/- SD) bone mineral density of the vertebrae had decreased 6.8 +/- 5.6 percent 6 months after transplantation (P < 0.05) and 8.8 +/- 7.0 percent 18 months after transplantation. In contrast, the bone mineral density of the radius had increased six months after transplantation (P < 0.05). The histomorphometric studies showed that the rate of bone formation decreased from 50.5 +/- 44.8 to 23.1 +/- 13.8-mu-m3 per square micrometer per year (P < 0.05), and the formation period lengthened from 70 +/- 42 to 146 +/- 144 days (P < 0.05). Consequently, the amount of bone replaced during a remodeling cycle diminished. Conclusions. Osteopenia associated with renal transplantation remains a problem in the cyclosporine era. The loss of vertebral bone in our subjects was due to an imbalance in bone remodeling consistent with a toxic effect of glucocorticoids.	UNIV ALABAMA, DEPT SURG, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT RADIOL, BIRMINGHAM, AL 35294 USA; DUKE UNIV, DEPT MED, DURHAM, NC 27706 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Duke University	JULIAN, BA (corresponding author), UNIV ALABAMA, DEPT MED, DIV NEPHROL, THT 643, UAB STN, BIRMINGHAM, AL 35294 USA.			Quarles, L. Darryl/0000-0002-5082-7896	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037308] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00032] Funding Source: Medline; NIAMS NIH HHS [2 ROI AR 37308] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BONOMINI V, 1975, J UROL NEPHROL, V81, P941; BRINER V, 1987, KIDNEY INT, V32, P431; DEMPSTER DW, 1983, CALCIFIED TISSUE INT, V35, P410, DOI 10.1007/BF02405069; DUBOVSKY J, 1987, OSTEOPOROSIS 1987, V1, P60; EASTELL R, 1990, J BONE MINER RES, V5, P1237; EISMAN JA, 1976, ARCH BIOCHEM BIOPHYS, V176, P235, DOI 10.1016/0003-9861(76)90161-2; HADDAD JG, 1971, J CLIN ENDOCR METAB, V33, P992, DOI 10.1210/jcem-33-6-992; KANIS JA, 1990, J BONE MINER RES, V5, P209, DOI 10.1002/jbmr.5650050302; KIMMEL DB, 1990, BONE MINER, V11, P217, DOI 10.1016/0169-6009(90)90061-J; KLEEREKOPER M, 1983, INT C SERIES, V617, P200; LOERTSCHER R, 1983, TRANSPLANTATION, V36, P115; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; LYLES KW, 1982, CALCIFIED TISSUE INT, V34, P125, DOI 10.1007/BF02411222; MALLUCHE HH, 1982, CALCIFIED TISSUE INT, V34, P449, DOI 10.1007/BF02411283; MALONEY NA, 1982, J LAB CLIN MED, V99, P206; MCCARRON DA, 1982, KIDNEY INT, V22, P662, DOI 10.1038/ki.1982.227; MOORHEAD JF, 1974, LANCET, V1, P694; MOVSOWITZ C, 1988, ENDOCRINOLOGY, V123, P2571, DOI 10.1210/endo-123-5-2571; NETER J, 1974, APPLIED LINEAR STATI; NUSSBAUM SR, 1987, CLIN CHEM, V33, P1364; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PARFITT AM, 1986, CPC SERIES CASES MET, P1; PECK WA, 1967, P NATL ACAD SCI USA, V57, P1599, DOI 10.1073/pnas.57.6.1599; POCOCK NA, 1987, ANN INTERN MED, V107, P319, DOI 10.7326/0003-4819-107-2-319; QUARLES LD, 1989, J BONE MINER RES, V4, P671; QUARLES LD, 1988, J CLIN INVEST, V81, P1056, DOI 10.1172/JCI113417; RECKER RR, 1988, J BONE MINER RES, V3, P133; SCHWARTZ MP, 1981, CALCIFIED TISSUE INT, V33, P561, DOI 10.1007/BF02409492; SKJODT H, 1984, Calcified Tissue International, V36, pS50; SLATOPOLSKY E, 1984, ADV EXP MED BIOL, V171, P353; STEIN B, 1991, ENDOCRINOLOGY, V128, P1369, DOI 10.1210/endo-128-3-1369; STEWART PJ, 1986, J BONE MINER RES, V1, P285; STEWART PJ, 1989, CALCIFIED TISSUE INT, V45, P222, DOI 10.1007/BF02556041; VILLANUEVA AR, 1974, STAIN TECHNOL, V49, P1, DOI 10.3109/10520297409116928	34	555	567	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					544	550		10.1056/NEJM199108223250804	http://dx.doi.org/10.1056/NEJM199108223250804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1857390	Bronze			2022-12-01	WOS:A1991GB44700004
J	KIM, JW; CLOSS, EI; ALBRITTON, LM; CUNNINGHAM, JM				KIM, JW; CLOSS, EI; ALBRITTON, LM; CUNNINGHAM, JM			TRANSPORT OF CATIONIC AMINO-ACIDS BY THE MOUSE ECOTROPIC RETROVIRUS RECEPTOR	NATURE			English	Article							CULTURED ANIMAL-CELLS; GLUCOSE TRANSPORTER; MAMMALIAN-CELLS; RAT-LIVER; GENE; MEMBRANE; PROTEIN; SYSTEM; HISTIDINE; PROMOTER	SUSCEPTIBILITY of rodent cells to infection by ecotropic murine leukaemia viruses (MuLV) is determined by binding of the virus envelope to a membrane receptor that has multiple membrane-spanning domains 1. Cells infected by ecotropic MuLV synthesize envelope protein, gp70, which binds to this receptor, thereby preventing additional infections. The consequences of envelope-MuLV receptor binding for the infected host cell have not been directly determined, partly because the cellular function of the MuLV receptor protein is unknown. Here we report a coincidence in the positions of the first eight putative membrane-spanning domains found in the virus receptor 1 and in two related proteins 2, the arginine 2-4 and histidine 2,3,5 permeases of Saccharomyces cerevisiae (Fig. 1), but not in any other proteins identified by computer-based sequence comparison of the GenBank data base 1. Xenopus oocytes injected with receptor-encoding messenger RNA show increased uptake of L-arginine, L-lysine and L-ornithine. The transport properties and the expression pattern of the virus receptor behave in ways previously attributed to y+ (refs 6, 7), the principal transporter of cationic L-amino acids in mammalian cells.	BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,75 FRANCIS ST,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Closs, Ellen/ABD-5217-2020	Closs, Ellen/0000-0002-9505-2289				ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; ARONSON DL, 1981, BIOCHEMISTRY-US, V20, P7064, DOI 10.1021/bi00528a002; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; CHRISTENSEN HN, 1967, J BIOL CHEM, V238, P3686; Cooper T., 1982, MOL BIOL YEAST SACCH, P399; DESJEUX JF, 1987, PEDIATR RES, V21, P477, DOI 10.1203/00006450-198705000-00011; HATZOGLOU M, 1990, J BIOL CHEM, V265, P17285; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; JAENISCH R, 1980, CELL, V19, P181, DOI 10.1016/0092-8674(80)90399-2; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OXENDER DL, 1963, J BIOL CHEM, V238, P3686; PARDRIDGE WM, 1975, AM J PHYSIOL, V228, P1155; ROSENBERG LE, 1962, J BIOL CHEM, V237, P2265; SAMARZIJA I, 1982, PFLUG ARCH EUR J PHY, V393, P199, DOI 10.1007/BF00584070; SEGAL S, 1977, SCIENCE, V197, P169, DOI 10.1126/science.877548; SHOTWELL MA, 1983, BIOCHIM BIOPHYS ACTA, V737, P267, DOI 10.1016/0304-4157(83)90003-5; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; TANAKA J, 1985, GENE, V38, P205, DOI 10.1016/0378-1119(85)90219-7; VADGAMA JV, 1987, J BIOL CHEM, V262, P13273; VANWINKLE LJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P173, DOI 10.1016/0304-4157(88)90024-X; WEBER E, 1988, J MOL EVOL, V27, P342; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WHITE MF, 1982, J BIOL CHEM, V257, P4443; WHITE MF, 1983, J BIOL CHEM, V258, P8028	29	492	507	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1991	352	6337					725	728		10.1038/352725a0	http://dx.doi.org/10.1038/352725a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1652100				2022-12-01	WOS:A1991GC06400062
J	KNOWLES, MR; CLARKE, LL; BOUCHER, RC				KNOWLES, MR; CLARKE, LL; BOUCHER, RC			ACTIVATION BY EXTRACELLULAR NUCLEOTIDES OF CHLORIDE SECRETION IN THE AIRWAY EPITHELIA OF PATIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROTEIN-KINASE-C; RESPIRATORY EPITHELIA; LUNG-DISEASE; CHANNELS; PERMEABILITY; TRANSPORT; AMILORIDE	Background. Cystic fibrosis is characterized by abnormal electrolyte transport across the epithelia of the airways. In particular, there is excessive sodium absorption and deficient chloride secretion. Drugs that block excessive sodium absorption may provide clinical benefit in cystic fibrosis, but there are no available therapeutic agents to improve chloride secretion. In vitro studies in cultured human-airway epithelia indicate that triphosphate nucleotides (ATP and UTP) induce chloride secretion through apical-membrane purinergic receptors. Methods. We tested the ability of nucleotides to induce chloride secretion in vivo in 9 normal subjects and 12 patients with cystic fibrosis by measuring responses of nasal transepithelial potential difference (PD) to superfusion of nucleotides. Changes in transepithelial bioelectric properties and the permeability of the apical membrane to chloride in response to extracellular (apical) UTP were determined with ion-selective microelectrodes in cultured nasal epithelia. Results. ATP and UTP induced chloride secretion in vivo in both groups. At their maximal effective concentrations of 10(-4) M, ATP and UTP were more effective chloride secretagogues in the patients with cystic fibrosis (mean [+/- SE] change in PD, -19.8 +/- 1.4 mV and -15.0 +/- 1.7 mV, respectively) than in the normal subjects (-6.9 +/- 0.6 mV and -8.1 +/- 0.9 mV, respectively). Microelectrode studies established that extracellular UTP stimulated a larger increase in PD and chloride secretory current in epithelial cells from patients with cystic fibrosis than in cells from normal subjects, by actions localized to the apical membrane. Conclusions. Extracellular nucleotides are effective in vivo chloride secretagogues in the nasal epithelia of patients with cystic fibrosis. The equipotency of ATP and UTP suggests that the effect is mediated by P2 nucleotide receptors. Selected nucleotides, such as UTP or nucleotide analogues, should be investigated as therapeutic agents for lung disease in cystic fibrosis.			KNOWLES, MR (corresponding author), UNIV N CAROLINA,DEPT MED,DIV PULM DIS,CB 7020,724 BURNETT WOMACK BLDG,CHAPEL HILL,NC 27599, USA.		Clarke, Lane L/AAK-2866-2020	Clarke, Lane L/0000-0002-4938-6261	NCRR NIH HHS [RR-000046] Funding Source: Medline; NHLBI NIH HHS [HL-19171, HL-34322] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322, P50HL019171] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; APP EM, 1990, AM REV RESPIR DIS, V141, P605, DOI 10.1164/ajrccm/141.3.605; Bean B P, 1990, Ion Channels, V2, P169; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; BOYER JL, 1989, TRENDS PHARMACOL SCI, V10, P360, DOI 10.1016/0165-6147(89)90008-4; BURNS RF, 1990, ANN NY ACAD SCI, V603, P211; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CHINET T, 1991, FASEB J, V5, pA1763; CLARKE L, 1991, FASEB J, V5, pA1018; CLARKE LL, 1990, PEDIATR PULM S, V5, P216; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; DUBYAK GR, 1990, ANN NY ACAD SCI, V603, P227; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; PARADISO AM, 1991, AM J PHYSIOL, V261, pL63, DOI 10.1152/ajplung.1991.261.2.L63; RIORDAN JR, 1989, SCIENCE, V245, P1066; WALTNER WE, 1987, TRENDS PHARMACOL SCI, V8, P316, DOI 10.1016/0165-6147(87)90127-1; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1045, DOI 10.1152/ajpcell.1989.256.5.C1045; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1033, DOI 10.1152/ajpcell.1989.256.5.C1033; Willumsen NJ, 1989, AM J PHYSIOL, V256, pC1054, DOI 10.1152/ajpcell.1989.256.5.C1054; Winer BJ., 1971, STAT PRINCIPLES EXPT; YANKASKAS JR, 1985, AM REV RESPIR DIS, V132, P181; 1990, ANN NY ACAD SCI, V603, P1	34	475	498	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					533	538		10.1056/NEJM199108223250802	http://dx.doi.org/10.1056/NEJM199108223250802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1857389	Bronze, Green Submitted			2022-12-01	WOS:A1991GB44700002
J	RIVIERE, GR; WAGONER, MA; BAKERZANDER, SA; WEISZ, KS; ADAMS, DF; SIMONSON, L; LUKEHART, SA				RIVIERE, GR; WAGONER, MA; BAKERZANDER, SA; WEISZ, KS; ADAMS, DF; SIMONSON, L; LUKEHART, SA			IDENTIFICATION OF SPIROCHETES RELATED TO TREPONEMA-PALLIDUM IN NECROTIZING ULCERATIVE GINGIVITIS AND CHRONIC PERIODONTITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHAGEDENIS BIOTYPE REITER; MONOCLONAL-ANTIBODY; NICHOLS; SERUM; POLYPEPTIDES; DIAGNOSIS; PERTENUE; PROTEINS; DISEASE	Background. Spirochetes are commonly associated with periodontal disease, but it is not known whether these treponemes are pathogenic or merely opportunistic. We sought to determine whether spirochetes present in periodontal disease share antigens thought to be unique to spirochetes that are known pathogens. Methods. We examined dental plaque from 24 healthy subjects, from ulcerative sites in 17 patients with ulcerative gingivitis, and from areas of involvement in 19 patients with chronic periodontitis, using an immunocytochemical technique with monoclonal antibodies against pathogen-specific determinants on 47-kd and 37-kd molecules from Treponema pallidum subspecies pallidum. Serum was tested against T pallidum by immunoblotting and by serologic assays for syphilis. Results. Spirochetes with a pathogen-specific epitope on a 47-kd molecule were not found in plaque samples from any of the 24 healthy subjects, but they were identified in plaque samples from 11 of 17 patients with ulcerative gingivitis (P < 0.001) and from 10 of 19 patients with periodontitis (P < 0.01). Monoclonal antibodies directed against a 37-kd molecule reacted with spirochetes in plaque samples from 1 of 14 controls, from all 11 patients with gingivitis from whom samples could be obtained (P < 0.001), and from 14 of 19 patients with periodontitis (P < 0.001). Five of 18 normal subjects had IgG against 47-kd and 37-kd molecules, but none had IgG against 14-kd or 12-kd molecules from T. pallidum subspecies pallidum. Among 19 patients with ulcerative gingivitis, IgG was identified against 47-kd molecules in 15, against 37-kd molecules in 12, against 14-kd molecules in 4, and against 12-kd molecules in 15. Conclusions. The spirochetes found in dental plaque from patients with ulcerative gingivitis or chronic periodontitis have antigens that are thought to be unique to pathogenic treponemes. This close antigenic relation suggests that T. pallidum or a closely related organism may be involved in the pathogenesis of periodontal disease.	USN,DENT RES INST,GREAT LAKES,IL 60088; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; OREGON HLTH SCI UNIV,SCH DENT,DEPT PERIODONTOL,PORTLAND,OR 97201	United States Department of Defense; United States Navy; University of Washington; University of Washington Seattle; Oregon Health & Science University	RIVIERE, GR (corresponding author), OREGON HLTH SCI UNIV,SCH DENT,DEPT PEDIAT DENT,611 SW CAMPUS DR,PORTLAND,OR 97201, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018988] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18988] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKERZANDER SA, 1983, INFECT IMMUN, V42, P634, DOI 10.1128/IAI.42.2.634-638.1983; BAKERZANDER SA, 1985, J INFECT DIS, V15, P264; BARRON SL, 1991, ORAL MICROBIOL IMMUN, V6, P97, DOI 10.1111/j.1399-302X.1991.tb00458.x; BLANCO DR, 1986, J IMMUNOL, V137, P2031; COURTOIS GJ, 1983, J PERIODONTOL, V54, P671, DOI 10.1902/jop.1983.54.11.671; HANFF PA, 1982, J IMMUNOL, V129, P1287; HOOK EW, 1985, J CLIN MICROBIOL, V22, P241, DOI 10.1128/JCM.22.2.241-244.1985; ISAACS RD, 1989, INFECT IMMUN, V57, P3403, DOI 10.1128/IAI.57.11.3403-3411.1989; JACOBS PA, 1982, J MOL CATAL, V17, P145, DOI 10.1016/0304-5102(82)85026-8; JOHNSON BD, 1986, J PERIODONTOL, V57, P141, DOI 10.1902/jop.1986.57.3.141; JONES SA, 1984, J EXP MED, V160, P1404, DOI 10.1084/jem.160.5.1404; KORNMAN KS, 1987, J PERIODONTAL RES, V22, P192, DOI 10.1111/j.1600-0765.1987.tb01566.x; LAI CH, 1986, J CLIN PERIODONTOL, V13, P752, DOI 10.1111/j.1600-051X.1986.tb00878.x; LINDHE J, 1980, J PERIODONTOL, V51, P264, DOI 10.1902/jop.1980.51.5.264; LISTGARTEN M. A., 1965, ARCH ORAL BIOL, V10, P127, DOI 10.1016/0003-9969(65)90064-6; LISTGARTEN MA, 1965, J PERIODONTOL, V36, P328, DOI 10.1902/jop.1965.36.4.328; LISTGARTEN MA, 1976, J PERIODONTOL, V47, P1, DOI 10.1902/jop.1976.47.1.1; LISTGARTEN MA, 1967, J PERIODONTOL, V38, P379, DOI 10.1902/jop.1967.38.5.379; Loesche W J, 1988, Adv Dent Res, V2, P275; LOESCHE WJ, 1981, HOST PARASITE INTERA, P62; LUKEHART SA, 1985, J IMMUNOL, V134, P585; RADOLF JD, 1988, INFECT IMMUN, V56, P1825, DOI 10.1128/IAI.56.7.1825-1828.1988; RADOLF JD, 1986, INFECT IMMUN, V54, P626, DOI 10.1128/IAI.54.3.626-634.1986; TEW JG, 1985, J PERIODONTAL RES, V20, P580, DOI 10.1111/j.1600-0765.1985.tb00842.x; THORNBURG RW, 1983, INFECT IMMUN, V42, P623, DOI 10.1128/IAI.42.2.623-627.1983; Umemoto T, 1988, Adv Dent Res, V2, P292; 1969, MANUAL TESTS SYPHILI, P15	27	65	67	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					539	543		10.1056/NEJM199108223250803	http://dx.doi.org/10.1056/NEJM199108223250803			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1713299	Bronze			2022-12-01	WOS:A1991GB44700003
J	ROBINSON, DR; GULL, K				ROBINSON, DR; GULL, K			BASAL BODY MOVEMENTS AS A MECHANISM FOR MITOCHONDRIAL GENOME SEGREGATION IN THE TRYPANOSOME CELL-CYCLE	NATURE			English	Article							BRUCEI-BRUCEI; MICROTUBULES; INVITRO	THE mitochondrial genome of Trypanosoma brucei is organized in the form of a complex catenated network of circular DNA molecules. This mass of DNA, known as the kinetoplast, is present at a unique site in the single mitochondrion, and is replicated in a discrete, periodic S phase of the cell cycle. The single-copy nature of the kinetoplast suggests that there is a mechanism ensuring segregation fidelity of replicated copies to each daughter cell. Historically, speculation regarding the nature of this mechanism has often attributed significance to the close association between the kinetoplast and the flagellum basal body. We provide here direct evidence that this mitochondrial DNA complex is indeed linked to the basal body, and segregation of the kinetoplast DNA is dependent on a microtubule-mediated separation of the new and old flagellar basal bodies during the cell cycle. This unique system may represent the remnants of an evolutionarily archaic mechanism for genome segregation.	UNIV MANCHESTER, SCH MED, DEPT BIOCHEM & MOLEC BIOL, OXFORD RD, MANCHESTER M13 9PT, LANCS, ENGLAND	University of Manchester								BRUN R, 1979, ACTA TROP, V36, P289; CHOW KC, 1988, MOL PHARMACOL, V34, P467; HIRUKI T, 1987, ZBL BAKT-INT J MED M, V264, P392; LEWIS DH, 1975, J PROTOZOOL, V22, P344, DOI 10.1111/j.1550-7408.1975.tb05184.x; MOLYNEUX DH, 1969, PARASITOLOGY, V59, P55, DOI 10.1017/S0031182000069821; OOTSU K, 1980, CANCER RES, V40, P1707; PATEL S, 1990, ANTI-CANCER DRUG DES, V5, P149; Robertson M, 1913, PHILOS T R SOC LON B, V203, P161, DOI 10.1098/rstb.1913.0005; SHAPIRO TA, 1990, P NATL ACAD SCI USA, V87, P950, DOI 10.1073/pnas.87.3.950; SHERWIN T, 1987, J CELL BIOL, V104, P439, DOI 10.1083/jcb.104.3.439; SHERWIN T, 1989, PHILOS T R SOC B, V323, P573, DOI 10.1098/rstb.1989.0037; SIMPSON L, 1968, J PROTOZOOL, V15, P132, DOI 10.1111/j.1550-7408.1968.tb02097.x; SOUTOPADRON T, 1984, J CELL SCI, V69, P167; Steinert M., 1976, P193; VICKERMAN K., 1962, TRANS ROY SOC TROP MED AND HYG, V56, P487, DOI 10.1016/0035-9203(62)90072-X; WOODS A, 1989, J CELL SCI, V93, P491	16	262	263	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 22	1991	352	6337					731	733		10.1038/352731a0	http://dx.doi.org/10.1038/352731a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1876188	Green Submitted			2022-12-01	WOS:A1991GC06400064
J	RUPPERSBERG, JP; STOCKER, M; PONGS, O; HEINEMANN, SH; FRANK, R; KOENEN, M				RUPPERSBERG, JP; STOCKER, M; PONGS, O; HEINEMANN, SH; FRANK, R; KOENEN, M			REGULATION OF FAST INACTIVATION OF CLONED MAMMALIAN IK(A) CHANNELS BY CYSTEINE OXIDATION	NATURE			English	Article							DELAYED RECTIFIER PROPERTIES; BRAIN POTASSIUM-CHANNEL; RAT-BRAIN; EXPRESSION; CLONING; FAMILY; APLYSIA; MEMBER; CDNA	MODULATION of neuronal excitability by regulation of K+ channels potentially plays a part in short-term memory 1 but has not yet been studied at the molecular level. Regulation of K+ channels by protein phosphorylation 2-5 and oxygen 6 has been described for various tissues and cell types; regulation of fast-inactivating K+ channels mediating I(K)(A) currents has not yet been described. Functional expression of cloned mammalian K+ channels 7-13 has provided a tool for studying their regulation at the molecular level. We report here that fast-inactivating K+ currents mediated by cloned K+ channel subunits derived from mammalian brain expressed in Xenopus oocytes are regulated by the reducing agent glutathione. This type of regulation may have a role in vivo to link metabolism to excitability and to regulate excitability in specific membrane areas of mammalian neurons.	MAX PLANCK INST BIOPHYS CHEM, MEMBRANBIOPHYS ABT, W-3400 GOTTINGEN, GERMANY; ZENTRUM MOLEK BIOL, W-6900 HEIDELBERG, GERMANY; RUHR UNIV BOCHUM, LEHRSTUHL BIOCHEM, W-4600 BOCHUM, GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg; Ruhr University Bochum	RUPPERSBERG, JP (corresponding author), MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, JAHNSTR 29, W-6900 HEIDELBERG 1, GERMANY.		Stocker, Martin/C-1844-2008	Heinemann, Stefan H./0000-0002-4144-0251				ABRAMS TW, 1988, TRENDS NEUROSCI, V11, P128, DOI 10.1016/0166-2236(88)90137-3; ALKON DL, 1982, SCIENCE, V215, P693, DOI 10.1126/science.7058334; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; CASTRO B, 1977, J CHEM RES, V182, P2118; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; FRANK R, 1988, MODERN METHODS PROTE, V3; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; KACZMAREK LK, 1988, ADV SEC MESS PHOSPH, V22, P113; KRAMER RH, 1990, NEURON, V4, P335, DOI 10.1016/0896-6273(90)90046-I; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; MCCORMACK T, 1990, P NATL ACAD SCI USA, V87, P5227, DOI 10.1073/pnas.87.13.5227; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; STOCKER M, 1990, P NATL ACAD SCI USA, V87, P8903, DOI 10.1073/pnas.87.22.8903; STOCKER M, IN PRESS P R SOC L B; STRONG JA, 1986, J NEUROSCI, V6, P814; STUHMER W, 1988, FEBS LETT, V242, P199, DOI 10.1016/0014-5793(88)81015-9; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	25	442	448	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 22	1991	352	6337					711	714		10.1038/352711a0	http://dx.doi.org/10.1038/352711a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1908562				2022-12-01	WOS:A1991GC06400057
J	RUTALA, WA; WEBER, DJ				RUTALA, WA; WEBER, DJ			INFECTIOUS WASTE - MISMATCH BETWEEN SCIENCE AND POLICY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; MICROBIAL-CONTAMINATION; HOSPITAL INCINERATOR; HOUSEHOLD REFUSE; UNITED-STATES; MANAGEMENT; EMISSION; BACTERIA; HIV-1				RUTALA, WA (corresponding author), UNIV N CAROLINA,CHAPEL HILL,NC 27599, USA.							ALLEN RJ, 1989, JAPCA J AIR WASTE MA, V39, P164, DOI 10.1080/08940630.1989.10466516; ALTHAUS H, 1983, ZBL BAKT MIK HYG B, V178, P1; BARBA PD, 1987, NOV MID AIR POLL CON; BECK M, 1989, NEWSWEEK        1127, P75; Beck Melinda, 1989, NEWSWEEK, P66; BLENKHARN JI, 1989, J HOSP INFECT, V14, P73, DOI 10.1016/0195-6701(89)90137-0; COOPER RC, 1975, WATER RES, V9, P733, DOI 10.1016/0043-1354(75)90065-2; DONNELLY JA, 1984, EPA600824119 MUN ENV; DRIVER JH, 1989, 1989 P INT C U CAL I; ENGELBRECHT RS, 1974, VIRUS SURVIVAL WATER, P201; GARNER JS, 1985, INFECTIVE WASTE GUID; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; JAGER E, 1989, ZBL HYG UMWELTMED, V188, P343; KALNOWSKI G, 1983, ZBL BAKT MIK HYG B, V178, P364; KARPIAK J, 1991, AM J INFECT CONTROL, V19, P8, DOI 10.1016/0196-6553(91)90155-6; LEE HH, 1990, J INFECT DIS, V162, P347, DOI 10.1093/infdis/162.2.347; MARCHESE JT, 1990, 3RD INT C NOS INF AT; MOSE JR, 1985, ZBL BAKT MIK HYG B, V181, P98; OHARA K, 1989, TRASH AM BEACHES NAT; PAHREN HR, 1987, CRC CRIT R ENVIRON, V7, P187; RESNICK L, 1986, JAMA-J AM MED ASSOC, V255, P1887, DOI 10.1001/jama.255.14.1887; RICHARDSON JH, 1988, HHS NIH888395 DEP HL; RUTALA WA, 1989, JAMA-J AM MED ASSOC, V262, P1635, DOI 10.1001/jama.262.12.1635; RUTALA WA, 1983, INFECT CONT HOSP EP, V4, P198, DOI 10.1017/S0195941700058227; RUTALA WA, 1987, ASEPSIS, V9, P2; RUTALA WA, 1987, CLIN CRITICAL CARE M, V12, P131; SLADE JS, 1989, WATER SCI TECHNOL, V21, P55, DOI 10.2166/wst.1989.0078; SLAVIK N, 1988, HLTH FACILITIES  SEP, P22; SOBSEY MD, 1978, AM J PUBLIC HEALTH, V68, P858, DOI 10.2105/AJPH.68.9.858; SOBSEY MD, 1975, APPL MICROBIOL, V30, P565, DOI 10.1128/AEM.30.4.565-574.1975; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; 1990, PUBLIC HLTH IMPLICAT; 1988, STATE INFECTIOUS WAS; 1990, OTA0459 OFF TECHN AS; 1989, INVENTORY MED WASTE; 1986, EPA530SW86014 REP; 1989, FED REGISTER, V54, P12326; 1990, EPA530SW90087A INT R; 1990, EPA530SW90051A INT R; 1987, MMWR S2S, V36, P3; 1988, INVESTIGATION SOURCE; 1989, SUMMARY POTENTIAL RI	42	24	24	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					578	582		10.1056/NEJM199108223250811	http://dx.doi.org/10.1056/NEJM199108223250811			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1649972	Green Submitted			2022-12-01	WOS:A1991GB44700011
J	TUNIS, SR; BASS, EB; STEINBERG, EP				TUNIS, SR; BASS, EB; STEINBERG, EP			THE USE OF ANGIOPLASTY, BYPASS-SURGERY, AND AMPUTATION IN THE MANAGEMENT OF PERIPHERAL VASCULAR-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANS-LUMINAL ANGIOPLASTY; LIMB-THREATENING ISCHEMIA; CORONARY HEART-DISEASE; INTERMITTENT CLAUDICATION; BALLOON DILATATION; SURGICAL PRACTICE; FRAMINGHAM; MORTALITY; IMPACT	Background. Percutaneous transluminal angioplasty has been adopted widely as a treatment for patients with peripheral vascular disease of the lower extremities. However, the effect of this procedure on the overall management of peripheral vascular disease and on the outcomes of patients has not been clearly delineated. In particular, it is not known whether angioplasty has replaced other treatments for peripheral vascular disease. Methods. To assess the extent to which angioplasty is used and the associated changes in the surgical management of peripheral vascular disease of the lower extremities, we used data on hospital discharges in Maryland to identify all angioplasty procedures, peripheral bypass operations, and lower-extremity amputations performed for peripheral vascular disease in Maryland hospitals between 1979 and 1989. Results. We estimate that from 1979 to 1989 the annual rate of percutaneous transluminal angioplasty for peripheral vascular disease of the lower extremities, adjusted for age and sex, rose from 1 to 24 per 100,000 Maryland residents (P < 0.0001 by linear regression). Despite this increase in the use of angioplasty, the adjusted annual rate of peripheral bypass surgery also rose substantially, from 32 to 65 per 100,000 (P < 0.001), whereas the adjusted annual rate of lower-extremity amputation remained stable at about 30 per 100,000. Total charges for hospitalizations during which a peripheral revascularization procedure was performed increased from $14.7 million in 1979 (in 1989 dollars) to $30.5 million in 1989. Conclusions. In Maryland, the adoption of percutaneous transluminal angioplasty for peripheral vascular disease of the lower extremities has been associated with an increase in the use of peripheral bypass surgery and with no decline in lower-extremity amputations. These results could be due to increased diagnosis of peripheral vascular disease, expanded indications for procedural interventions; or an increased number of repeat procedures performed in patients with peripheral vascular disease of the lower extremities.	JOHNS HOPKINS PROGRAM MED TECHNOL & PRACTICE ASSES, 1830 E MONUMENT ST, RM 8068, BALTIMORE, MD 21205 USA	Johns Hopkins University				Bass, Eric/0000-0001-9106-527X	NHLBI NIH HHS [2 T32 HL07180] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007180] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAR R, 1989, J VASC SURG, V10, P57, DOI 10.1067/mva.1989.vs0100057; ANDERSON GM, 1988, AM J PUBLIC HEALTH, V78, P251, DOI 10.2105/AJPH.78.3.251; ANDERSON JB, 1986, BRIT J SURG, V73, P17, DOI 10.1002/bjs.1800730108; ASCER E, 1990, J VASC SURG, V11, P576, DOI 10.1067/mva.1990.18640; BECKER GJ, 1989, RADIOLOGY, V170, P921, DOI 10.1148/radiology.170.3.2521745; BILD DE, 1989, DIABETES CARE, V12, P24, DOI 10.2337/diacare.12.1.24; BLAIR JM, 1989, J VASC SURG, V9, P698, DOI 10.1067/mva.1989.vs0090698; CASARELLA WJ, 1986, CURR PROB CARDIOLOGY, V11, P138; CINTORA I, 1988, ANN SURG, V208, P625, DOI 10.1097/00000658-198811000-00014; CODD JE, 1979, AM J SURG, V138, P770, DOI 10.1016/0002-9610(79)90294-0; CUMBERLAND DC, 1988, CLIN RADIOL, V39, P573, DOI 10.1016/S0009-9260(88)80043-6; DAGOSTINO RB, 1989, INT J EPIDEMIOL, V18, pS67; DALEN JE, 1990, AM HEART J, V119, P502, DOI 10.1016/S0002-8703(05)80271-6; DAVIS PK, 1989, ANN THORAC SURG, V47, P493, DOI 10.1016/0003-4975(89)90422-0; DOUBILET P, 1984, NEW ENGL J MED, V310, P95, DOI 10.1056/NEJM198401123100206; EICKHOFF JH, 1980, ACTA CHIR SCAND, P181; ERNST CB, 1987, J VASC SURG, V6, P611, DOI 10.1067/mva.1987.avs0060611; FEINLEIB M, 1989, CIRCULATION, V79, P13; FRY SM, 1990, INVEST RADIOL, V25, P93, DOI 10.1097/00004424-199001000-00023; GALLINO A, 1984, CIRCULATION, V70, P619, DOI 10.1161/01.CIR.70.4.619; HOLLIER LH, 1989, J VASC SURG, V9, P627, DOI 10.1067/mva.1989.vs0090627; HOLLMAN J, 1988, INT J CARDIOL, V20, P193, DOI 10.1016/0167-5273(88)90263-X; JEANS WD, 1986, BRIT J RADIOL, V59, P453, DOI 10.1259/0007-1285-59-701-453; JEANS WD, 1990, RADIOLOGY, V177, P559, DOI 10.1148/radiology.177.2.2145608; JEANS WD, 1986, BRIT J RADIOL, V59, P457, DOI 10.1259/0007-1285-59-701-457; JOHNSTON KW, 1987, ANN SURG, V206, P403, DOI 10.1097/00000658-198710000-00002; KANNEL WB, 1985, J AM GERIATR SOC, V33, P13, DOI 10.1111/j.1532-5415.1985.tb02853.x; KANNEL WB, 1970, CIRCULATION, V41, P875, DOI 10.1161/01.CIR.41.5.875; MAINI BS, 1978, ARCH SURG-CHICAGO, V113, P1297; SAMSON RH, 1984, ANN SURG, V199, P234, DOI 10.1097/00000658-198402000-00017; SHEINER NM, 1985, CAN J SURG, V28, P193; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; TAYLOR LM, 1990, J VASC SURG, V11, P193, DOI 10.1067/mva.1990.17235; Veith F J, 1990, Ann Vasc Surg, V4, P85, DOI 10.1007/BF02042697; VEITH FJ, 1990, ANN SURG, V212, P402, DOI 10.1097/00000658-199010000-00003; VEITH FJ, 1990, ACTA CHIR SCAND, P139; WEINTRAUB WS, 1990, AM J CARDIOL, V65, P183, DOI 10.1016/0002-9149(90)90082-C; WIDLUS DM, 1989, JAMA-J AM MED ASSOC, V261, P3148, DOI 10.1001/jama.261.21.3148; Wilson S E, 1990, Ann Vasc Surg, V4, P351, DOI 10.1007/BF02000498; ZARINS CK, 1989, JAMA-J AM MED ASSOC, V261, P416, DOI 10.1001/jama.261.3.416; 1985, SAS USERS GUIDE STAT; 1988, HOSPITAL REPORT CLIN; 1990, CODING CLIN ICD9CM, P16; 1990, STATISTICAL ABSTRACT, P99	44	221	226	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					556	562		10.1056/NEJM199108223250806	http://dx.doi.org/10.1056/NEJM199108223250806			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1857391				2022-12-01	WOS:A1991GB44700006
J	WANG, H; KAVANAUGH, MP; NORTH, RA; KABAT, D				WANG, H; KAVANAUGH, MP; NORTH, RA; KABAT, D			CELL-SURFACE RECEPTOR FOR ECOTROPIC MURINE RETROVIRUSES IS A BASIC-AMINO-ACID TRANSPORTER	NATURE			English	Article							ENVELOPE GLYCOPROTEIN; LEUKEMIA VIRUSES; SACCHAROMYCES-CEREVISIAE; GENE; INTERFERENCE; MEMBRANE; ERYTHROLEUKEMIA; EXPRESSION; INFECTION; PROTEINS	THE complementary DNA sequence encoding the cell-surface receptor for ecotropic host-range murine retroviruses (ecoR) shows that it contains 622 amino acids and 14 hydrophobic potentially membrane-spanning sequences 1. Because this receptor occurs on many or all murine cells 2 and is probably essential for viability of cultured fibroblasts 3, its normal function might be to transport an essential metabolite. We expressed ecoR in Xenopus laevis oocytes by injecting RNA transcribed from the cloned cDNA. These oocytes specifically bound the gp70 envelope glycoprotein from an ecotropic murine leukaemia virus. An inward current was recorded electrophysiologically when a mixture of amino-acids was applied: this resulted from a stereoselective, saturable uptake of lysine, arginine and ornithine; it was independent of sodium and not substantially altered by gp70. Cysteine and homoserine were also taken up, but sodium was necessary for their transport. These properties of ecoR correspond to those of the y+ amino-acid transporter 4-6. Our results demonstrate the subversion of a ubiquitous cell membrane protein, in this case a basic amino acid transporter, for use as a retroviral receptor.	OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA	Oregon Health & Science University	WANG, H (corresponding author), OREGON HLTH SCI UNIV, DEPT BIOCHEM, PORTLAND, OR 97201 USA.		North, Richard/GQA-6156-2022					ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; CHRISTENSEN HN, 1966, J BIOL CHEM, V241, P5542; CHRISTENSEN HN, 1969, P NATL ACAD SCI USA, V63, P948, DOI 10.1073/pnas.63.3.948; CHRISTENSEN HN, 1989, METHOD ENZYMOL, V173, P576; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; CIANCIOLO GJ, 1985, SCIENCE, V230, P453, DOI 10.1126/science.2996136; DELARCO J, 1976, CELL, V8, P365, DOI 10.1016/0092-8674(76)90148-3; DELWART EL, 1989, J VIROL, V63, P273, DOI 10.1128/JVI.63.1.273-280.1989; HANDELIN BL, 1985, VIROLOGY, V140, P183, DOI 10.1016/0042-6822(85)90458-1; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; IHLE JN, 1984, ADV VIRAL ONCOL, V4, P95; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KABAT D, 1989, VIROLOGY, V171, P467, DOI 10.1016/0042-6822(89)90616-8; KLEINERMAN ES, 1987, J IMMUNOL, V139, P2329; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; McGrath M S, 1980, Contemp Top Immunobiol, V11, P157; MITANI M, 1987, P NATL ACAD SCI USA, V84, P237, DOI 10.1073/pnas.84.1.237; MOORE JP, 1991, J VIROL, V65, P1133, DOI 10.1128/JVI.65.3.1133-1140.1991; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; OHARA B, 1990, CELL GROWTH DIFFER, V1, P119; REIN A, 1982, VIROLOGY, V120, P251, DOI 10.1016/0042-6822(82)90024-1; SEGAL S, 1989, METABOLIC BASIS INHE, P2479; SITBON M, 1986, CELL, V47, P851, DOI 10.1016/0092-8674(86)90800-7; SOMMERFELT MA, 1990, VIROLOGY, V176, P58, DOI 10.1016/0042-6822(90)90230-O; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; SZUREK PF, 1988, J VIROL, V62, P357, DOI 10.1128/JVI.62.1.357-360.1988; TANAKA J, 1985, GENE, V38, P205, DOI 10.1016/0378-1119(85)90219-7; WEISS R, 1984, RNA TUMOR VIRUSES, P209; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WHITE MF, 1982, J BIOL CHEM, V257, P4443	31	395	402	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 22	1991	352	6337					729	731		10.1038/352729a0	http://dx.doi.org/10.1038/352729a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1908564				2022-12-01	WOS:A1991GC06400063
J	WANK, R; THOMSSEN, C				WANK, R; THOMSSEN, C			HIGH-RISK OF SQUAMOUS-CELL CARCINOMA OF THE CERVIX FOR WOMEN WITH HLA-DQW3	NATURE			English	Article							HERPES-SIMPLEX VIRUS; CLASS-II MOLECULES; HLA-DR ANTIGEN; ANKYLOSING-SPONDYLITIS; ASSOCIATION; SPECIFICITIES; H-2-COMPLEX; COMPLEX; LOCUS	MANY immune responses are controlled by genes of the major histocompatibility complex (MHC) 1. In man these include the loci encoding the HLA-A, -B, -C, -DR, -DQ and -DP antigens, and many diseases have been linked with these 2-5. But attempts to identify HLA genes in man that might explain why an immune response against malignant tumours should be ineffective have so far been disappointing, apart from the association reported between the HLA-DRI antigen and a susceptibility to a rare carcinoma of the thyroid gland 6. Here we describe another strong connection between a common malignant tumour and an HLA antigen, namely between HLA-DQw3 and squamous cell carcinoma of the cervix: from the 1988 United States tumour registry, 1 in every 63 newborn girls will develop this invasive cancer 7. We found that 88% of 66 patients had the leukocyte antigen HLA-DQw3 when it would normally be expected in only 50% of individuals. In animals the immune system and the MHC act in defence against virally induced tumours, but until now there has been no evidence that they do so in humans 8: as squamous cell carcinoma is probably virally induced, our discovery of its association with an HLA antigen will be important to the understanding of the immunogenetic basis of a susceptibility to this tumour.	TECH UNIV MUNICH, DEPT OBSTET & GYNAECOL, W-8000 MUNICH 80, GERMANY	Technical University of Munich	WANK, R (corresponding author), UNIV MUNICH, DEPT IMMUNOL, GOETHESTR 31, W-8000 MUNICH 2, GERMANY.		Thomssen, Christoph/ABC-3102-2021					BARBER HRK, 1989, MANUAL GYNAECOLOGIC, P212; BAUR MP, 1984, HISTOCOMPATIBILITY T, P333; BODMER JG, 1990, TISSUE ANTIGENS, V35, P1, DOI 10.1111/j.1399-0039.1990.tb01749.x; Bodmer W. F., 1989, IMMUNOBIOLOGY HLA, V1, P72; BOYUM A, 1968, SCAND J CLIN LAB I S, V97, P21; BREWERTON DA, 1973, LANCET, V1, P904; CHESEBRO B, 1974, J EXP MED, V140, P1457, DOI 10.1084/jem.140.6.1457; DUNN OJ, 1961, J AM STAT ASSOC, V56, P52, DOI 10.2307/2282330; FESTENSTEIN H, 1986, NATURE, V322, P64, DOI 10.1038/322064a0; GISSMANN L, 1986, ORIGINS FEMALE GENIT, P217; HALDANE JBS, 1956, ANN HUM GENET, V20, P309; JOHNSON JP, 1987, TISSUE ANTIGENS, V29, P26; JOHNSON JP, 1984, J EXP MED, V160, P1350, DOI 10.1084/jem.160.5.1350; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KAMPGEN E, 1988, ARCH DERMATOL, V124, P1372, DOI 10.1001/archderm.124.9.1372; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; KJAER SK, 1988, INT J CANCER, V41, P518, DOI 10.1002/ijc.2910410408; KLEIN J, 1981, NATURE, V291, P455, DOI 10.1038/291455a0; KNOWLES RW, 1989, IMMUNOBIOLOGY HLA, V1, P365; KOENIG UD, 1976, LANCET, V2, P857; LACHMAN PJ, 1982, CLIN ASPECTS IMMUNOL, P1263; Lilly F., 1973, Advances in Cancer Research, V17, P231, DOI 10.1016/S0065-230X(08)60532-1; LONAI P, 1980, IMMUNOGENETICS, V11, P21, DOI 10.1007/BF01567766; MAEDA H, 1984, TISSUE ANTIGENS, V23, P163; MILFORD EL, 1989, IMMUNOBIOLOGY HLA HI, V1, P93; PANZA N, 1982, TISSUE ANTIGENS, V20, P155; PARK MS, 1978, TRANSPLANT P, V10, P823; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; TAIT BD, 1989, IMMUNOBIOLOGY HLA, V1, P269; TERMIJTELEN A, 1980, TISSUE ANTIGENS, V16, P140; TIWARI JL, 1985, HLA DISEASE ASS; VEGA MA, 1986, J IMMUNOL, V137, P3557; Zur Hausen H, 1982, LANCET, V2, P1370, DOI DOI 10.1016/S0140-6736(82)91273-9	33	240	248	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 22	1991	352	6337					723	725		10.1038/352723a0	http://dx.doi.org/10.1038/352723a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1876187				2022-12-01	WOS:A1991GC06400061
J	BAGGIO, B; GAMBARO, G; MARCHINI, F; MARZARO, G; WILLIAMS, HE; BORSATTI, A				BAGGIO, B; GAMBARO, G; MARCHINI, F; MARZARO, G; WILLIAMS, HE; BORSATTI, A			CORRECTION OF ERYTHROCYTE ABNORMALITIES IN IDIOPATHIC CALCIUM-OXALATE NEPHROLITHIASIS AND REDUCTION OF URINARY OXALATE BY ORAL GLYCOSAMINOGLYCANS	LANCET			English	Article							PROTEIN-PHOSPHORYLATION; INHIBITION; TRANSPORT; EXCHANGE; CLONING; KINASE; FLUX; CDNA	Calcium-oxalate nephrolithiasis is associated with a defect in erythrocyte oxalate self-exchange and an abnormal rate of erythrocyte membrane protein phosphorylation. There is evidence that glycosaminoglycans (GAGs) have a regulatory effect on both of these processes. This study tested the hypothesis that modifications of erythrocyte oxalate self-exchange induced by oral GAGs are paralleled by similar changes in overall oxalate metabolism. 40 patients with idiopathic calcium-oxalate nephrolithiasis were treated for 15 days with 60 mg/day of a mixture of GAGs. By day 15 of treatment there were significant reductions from baseline in erythrocyte oxalate self-exchange (mean [SD] 1.67 [1.18] vs 2.59 [1.63] x 10(2) per min; p < 0.005) and erythrocyte membrane protein phosphorylation (55.8 [7.3] vs 72.9 [6.8] x 10(-3) cpm/mg protein; p < 0.005), but also in urinary oxalate excretion (0.24 [0.09] vs 0.31 [0.15) mmol/24 h; p < 0.005). This finding suggests similar changes in both erythrocytes and other cells more important in oxalate handling. The changes had reversed by 15 days after withdrawal of treatment. Acute intravenous administration of GAGs (60 mg) induced a fall in carbon-14-labelled oxalate renal clearance (143 [13] vs 169 [28] ml/min; p < 0.005), which strongly suggests the participation of the kidney. However, reduced oxalate absorption from the intestine, and even decreased synthesis of oxalate, cannot be ruled out.	UNIV PADUA,INST INTERNAL MED,DIV NEPHROL,I-35100 PADUA,ITALY; UNIV CALIF DAVIS,SCH MED,DAVIS,CA 95616	University of Padua; University of California System; University of California Davis				Gambaro, Giovanni/0000-0001-5733-2370				ALPER SL, 1987, KIDNEY INT       S23, V32, P117; BAGGIO B, 1984, LANCET, V2, P12, DOI 10.1016/S0140-6736(84)91998-6; BAGGIO B, 1986, IRCS MED SCI-BIOCHEM, V14, P368; BAGGIO B, 1984, LANCET, V2, P223; BAGGIO B, 1990, CLIN SCI, V79, P113, DOI 10.1042/cs0790113; BAGGIO B, 1986, NEW ENGL J MED, V314, P599, DOI 10.1056/NEJM198603063141002; BAGGIO B, 1988, INHIBITORS CRYSTALLI, P211; BIOVIN P, 1985, FEBS LETT, V186, P89; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; CHOI HR, 1988, MOL CELL BIOL, V8, P4416; DEMUTH DR, 1986, EMBO J, V5, P1205, DOI 10.1002/j.1460-2075.1986.tb04348.x; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; SUGIMOTO T, 1989, UROLITHIASIS, P431; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WILLIAMS HE, 1989, J UROLOGY, V141, P742, DOI 10.1016/S0022-5347(17)40999-2; WILLIAMS HE, 1971, CLIN SCI, V41, P213, DOI 10.1042/cs0410213; WISE BC, 1982, J BIOL CHEM, V257, P8489; WORCESTER EM, 1986, J CLIN INVEST, V77, P1888, DOI 10.1172/JCI112516	20	26	27	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					403	405		10.1016/0140-6736(91)91030-X	http://dx.doi.org/10.1016/0140-6736(91)91030-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678082				2022-12-01	WOS:A1991GB44600003
J	DAGOSTINO, RB; BELANGER, AJ; KANNEL, WB; CRUICKSHANK, JM				DAGOSTINO, RB; BELANGER, AJ; KANNEL, WB; CRUICKSHANK, JM			RELATION OF LOW DIASTOLIC BLOOD-PRESSURE TO CORONARY HEART-DISEASE DEATH IN PRESENCE OF MYOCARDIAL-INFARCTION - THE FRAMINGHAM-STUDY	BRITISH MEDICAL JOURNAL			English	Article							REGRESSION DILUTION BIAS; PROLONGED DIFFERENCES; RISK-FACTORS; FOLLOW-UP; J-CURVE; HYPERTENSION; REDUCTION; STROKE	Objective - To examine the hypothesis that a J curve relation between blood pressure and death from coronary heart disease is confined to high risk subjects with myocardial infarction. Design - Cohort longitudinal epidemiological study with biennial examinations since 1950. Setting - Framingham, Massachusetts, USA. Subjects - 5209 subjects in the Framingham study cohort followed up by a person examination approach. Main outcome measures - Coronary heart disease deaths and non-cardiovascular disease deaths in men and women with or without myocardial infarction relative to blood pressure. Results - Among subjects without myocardial infarction non-cardiovascular disease deaths were twice to three times as common as coronary heart disease deaths. Furthermore, there was no significant relation between non-cardiovascular disease death and diastolic or systolic blood pressure. Also coronary heart disease deaths were linearly related to diastolic and systolic blood pressures. Among high risk patients (that is, people with myocardial infarction but free of congestive heart failure) death from coronary heart disease was more common than non-cardiovascular disease death. There. was a significant U shaped relation between coronary heart disease death and diastolic blood pressure. Although there was an apparent U shaped relation between coronary heart disease death and systolic blood pressure, it did not attain statistical significance when controlling for age and change in systolic blood pressure from the pre-myocardial infarction level. None of the above conclusions changed when adjustments were made for risk factors such as serum cholesterol concentration, antihypertensive treatment, and left ventricular function. The U shaped relation between diastolic blood pressure and high risk subjects existed for both those given antihypertensive treatment and those not. Conclusions - These data suggest that an age and sex independent U curve relation exists for diastolic blood pressure and coronary heart disease deaths in patients with myocardial infarction but not for low risk subjects without myocardial infarction. The relation seems to be independent of left ventricular function and antihypertensive treatment.	BOSTON UNIV,STAT UNIT,BOSTON,MA 02215; BOSTON UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02118; WYTHENSHAWE HOSP,DEPT CARDIAC,MANCHESTER M23 9LT,LANCS,ENGLAND	Boston University; Boston University; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	DAGOSTINO, RB (corresponding author), BOSTON UNIV,COLL LIBERAL ARTS,DEPT MATH,BOSTON,MA 02215, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL040423, R01HL040423] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-40423] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ANDERSON TW, 1978, LANCET, V2, P1139; COOPE J, 1990, J HUM HYPERTENS, V4, P1; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CRUICKSHANK JM, 1987, LANCET, V1, P581; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; Cupples LA, 1987, FRAMINGHAM HEART STU; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; FLETCHER AE, 1988, J HUM HYPERTENS, V2, P11; LEW EA, 1973, AM J MED, V55, P281, DOI 10.1016/0002-9343(73)90130-7; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; SAMUELSSON OG, 1990, J HYPERTENS, V8, P547, DOI 10.1097/00004872-199006000-00008; STAESSEN J, 1989, BMJ-BRIT MED J, V298, P1552, DOI 10.1136/bmj.298.6687.1552; STEWART IMG, 1979, LANCET, V1, P861; STOKES J, 1987, CIRCULATION, V75, P65; WALLER PC, 1988, J HUM HYPERTENS, V2, P7	17	191	194	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1991	303	6799					385	389		10.1136/bmj.303.6799.385	http://dx.doi.org/10.1136/bmj.303.6799.385			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB599	1912805	Green Published, Bronze			2022-12-01	WOS:A1991GB59900014
J	DEPREZ, PH; GHOSH, P; GOODLAD, RA; LACEY, SL; MILLERSHIP, S; PLAYFORD, RJ; LEE, CY; CALAM, J				DEPREZ, PH; GHOSH, P; GOODLAD, RA; LACEY, SL; MILLERSHIP, S; PLAYFORD, RJ; LEE, CY; CALAM, J			HYPERGASTRINEMIA - A NEW MECHANISM	LANCET			English	Note							ACID	The mechanism by which lack of gastric acid causes hypergastrinaemia was investigated in seven patients with pernicious anaemia. Perfusion of gastric juice from the fasting patients (adjusted to pH 7.0) into the stomachs of conscious rats caused a significant rise in plasma gastrin (median 14 [range 2-20] pmol/l to 27 [12-65] pmol/l; p < 0.01), whereas perfusion of bicarbonate buffer (18 [13-23] pmol/l to 20 [9-25] pmol/l) or gastric juice from a duodenal ulcer patient (also pH 7.0; 13 [3-30] pmol/l to 17 [9-27] pmol/l) had no significant effect. During gastric lavage at pH 7.0 the median plasma gastrin concentration of the pernicious anaemia patients fell from 320 (63-1760) pmol/l to 125 (46-760) pmol/l (p < 0.03).	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,DU CANE RD,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT BACTERIOL,LONDON W12 0NN,ENGLAND; IMPERIAL CANC RES FUND,DEPT HISTOPATHOL,LONDON WC2A 3PX,ENGLAND	Imperial College London; Imperial College London; Cancer Research UK			Deprez, Pierre/AAC-5546-2019	Deprez, Pierre/0000-0001-8926-8967; Playford, Raymond/0000-0003-1235-8504; Goodlad, Robert/0000-0002-7660-4287				BORDI C, 1991, CANCER-AM CANCER SOC, V67, P663, DOI 10.1002/1097-0142(19910201)67:3<663::AID-CNCR2820670323>3.0.CO;2-L; BURLINSON B, 1990, LANCET, V335, P419, DOI 10.1016/0140-6736(90)90260-C; CALAM J, 1991, CLIN SCI, V80, P281, DOI 10.1042/cs0800281; FUKUOKA SI, 1990, PANCREAS, V5, P1, DOI 10.1097/00006676-199001000-00001; GOODLAD RA, 1987, GUT, V28, P177; HEATHCOTE JG, 1965, NATURE, V207, P941, DOI 10.1038/207941a0; YALOW RS, 1970, GASTROENTEROLOGY, V58, P1	7	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					410	411		10.1016/0140-6736(91)91034-R	http://dx.doi.org/10.1016/0140-6736(91)91034-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678084				2022-12-01	WOS:A1991GB44600005
J	EVANS, JG				EVANS, JG			THE HEALTH OF THE NATION - RESPONSES - CHALLENGE OF AGING	BRITISH MEDICAL JOURNAL			English	Article							LIFE				EVANS, JG (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DIV GERIATR MED,OXFORD OX2 6HE,ENGLAND.							ACLAND H, 1854, MEMOIR CHOLERA OXFOR; BEAGLEHOLE R, 1991, BRIT MED J, V303, P69, DOI 10.1136/bmj.303.6794.69; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P1126, DOI 10.2105/AJPH.74.10.1126; DOLL R, 1971, J R STAT SOC SER A-G, V134, P133, DOI 10.2307/2343871; EVANS JG, 1982, NEUROLOGICAL DISORDE, P1; EVANS JG, 1986, STROKE EPIDEMIOLOGIC, P33; FAIRWEATHER DS, 1991, METABOLIC MOL BASIS, V1, P213; FITZGERALD JF, 1988, NEW ENGL J MED, V319, P1392, DOI 10.1056/NEJM198811243192106; HARRIS J, 1987, J MED ETHICS, V13, P117, DOI 10.1136/jme.13.3.117; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; KHAW KT, 1990, AGE AGEING, V19, P277, DOI 10.1093/ageing/19.5.277; Rees J L, 1982, Community Med, V4, P100, DOI 10.1007/BF02548823; 1988, SURVEY DISABILITY GR; 1991, CM1523	14	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1991	303	6799					408	409		10.1136/bmj.303.6799.408	http://dx.doi.org/10.1136/bmj.303.6799.408			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB599	1912811	Bronze, Green Published			2022-12-01	WOS:A1991GB59900023
J	KILPI, T; ANTTILA, M; KALLIO, MJT; PELTOLA, H				KILPI, T; ANTTILA, M; KALLIO, MJT; PELTOLA, H			SEVERITY OF CHILDHOOD BACTERIAL-MENINGITIS AND DURATION OF ILLNESS BEFORE DIAGNOSIS	LANCET			English	Article							INFLUENZAE TYPE-B; C-REACTIVE PROTEIN; CEREBROSPINAL-FLUID; PNEUMOCOCCAL MENINGITIS; CHILDREN; INFECTIONS; SEQUELAE; ASSOCIATION; BLOOD	Rapid diagnosis of childhood bacterial meningitis (BM) is generally believed to be essential to avoid poor outcome. To see whether duration of illness before admission to hospital was related to the severity of illness, data from children with BM diagnosed in 18 paediatric hospitals in Finland from 1984 to 1989 were collected prospectively. We divided 286 cases with culture-positive cerebrospinal fluid (CSF) into three groups: BM with a history of up to 24 h (short-history group, n = 141), of more than 24 h and up to 48 h (intermediate-history group, n = 75), and of more than 48 h (long-history group, n = 70). The longer the history, the better the clinical condition of the child. If symptoms or signs of BM lasted 48 h or less, the child did significantly worse, as judged by seven variables, than if the history was longer than 48 h (level of consciousness, p < 0.001; seizures, p < 0.01; CSF protein concentration, p < 0.001; positive CSF gram-stain, p < 0.01; positive blood culture, p < 0.05 in Haemophilus influenzae meningitis, serum C-reactive reactive protein, p < 0.01 between intermediate-history and long-history groups, and urine sodium concentration, p < 0.001 ). The differences were not affected by causative organism, sex, age, or preadmission oral antimicrobial agents. The findings show that if BM follows an insidious pattern of disease, diagnostic delay may be unavoidable, which may have medicolegal implications.	UNIV HELSINKI, CHILDRENS HOSP, STENBACKINKATU 11, SF-00290 HELSINKI 29, FINLAND	University of Helsinki								BAIRD DR, 1976, LANCET, V2, P1344; DODGE PR, 1965, NEW ENGL J MED, V272, P954, DOI 10.1056/NEJM196505062721806; DODGE PR, 1965, NEW ENGL J MED, V272, P1003, DOI 10.1056/NEJM196505132721906; EDWARDS MS, 1981, J PEDIATR-US, V99, P540, DOI 10.1016/S0022-3476(81)80250-8; FEIGIN RD, 1976, J PEDIATR-US, V88, P542, DOI 10.1016/S0022-3476(76)80002-9; FELDMAN WE, 1982, J PEDIATR-US, V100, P209, DOI 10.1016/S0022-3476(82)80636-7; GARY N, 1989, AM J DIS CHILD, V143, P307, DOI 10.1001/archpedi.1989.02150150061018; JARVIS CW, 1972, CLIN PEDIATR, V11, P201, DOI 10.1177/000992287201100406; KAPLAN SL, 1986, PEDIATR INFECT DIS J, V5, P626, DOI 10.1097/00006454-198611000-00005; KAPLAN SL, 1978, J PEDIATR-US, V92, P758, DOI 10.1016/S0022-3476(78)80144-9; KAPLAN SL, 1985, BACTERIAL MENINGITIS, P83; KLEIN JO, 1986, PEDIATRICS, V75, P959; KRASINSKI K, 1987, AM J EPIDEMIOL, V125, P499, DOI 10.1093/oxfordjournals.aje.a114556; LASCOLEA LJ, 1984, J CLIN MICROBIOL, V19, P187, DOI 10.1128/JCM.19.2.187-190.1984; LAXER RM, 1977, AM J DIS CHILD, V131, P850, DOI 10.1001/archpedi.1977.02120210028004; NIEMOLLER UM, 1989, EUR J CLIN MICROBIOL, V8, P109, DOI 10.1007/BF01963892; OLCEN P, 1979, SCAND J INFECT DIS, V11, P111, DOI 10.3109/inf.1979.11.issue-2.03; PELTOLA H, 1988, J PEDIATR-US, V113, P641, DOI 10.1016/S0022-3476(88)80372-X; PELTOLA HO, 1982, LANCET, V1, P980; QUAGLIARELLO VJ, 1986, J CLIN INVEST, V77, P1084, DOI 10.1172/JCI112407; ROMER FK, 1977, LANCET, V2, P345; SMALES ORC, 1979, BMJ-BRIT MED J, V1, P588, DOI 10.1136/bmj.1.6163.588; SWARTZ MN, 1965, NEW ENGL J MED, V272, P779, DOI [10.1056/NEJM196504152721506, 10.1056/NEJM196504222721607]; SWARTZ MN, 1965, NEW ENGL J MED, V272, P725, DOI 10.1056/NEJM196504082721406; SYROGIANNOPOULOS GA, 1988, J INFECT DIS, V157, P237, DOI 10.1093/infdis/157.2.237; VALMARI P, 1987, EUR J PEDIATR, V146, P515, DOI 10.1007/BF00441607; VALMARI P, 1987, INFECT MED, V4, P308	27	70	72	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 17	1991	338	8764					406	409		10.1016/0140-6736(91)91032-P	http://dx.doi.org/10.1016/0140-6736(91)91032-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678083				2022-12-01	WOS:A1991GB44600004
J	ODARCEDERLOF, I; THEODORSSON, E; ERICSSON, F; KJELLSTRAND, CM				ODARCEDERLOF, I; THEODORSSON, E; ERICSSON, F; KJELLSTRAND, CM			PLASMA-CONCENTRATIONS OF CALCITONIN GENE-RELATED PEPTIDE IN FLUID OVERLOAD	LANCET			English	Note							ATRIAL-NATRIURETIC-PEPTIDE	To investigate the hypothesis that calcitonin gene-related peptide (CGRP), a potent vasodilator, is an important physiological defence against fluid overload, plasma CGRP concentrations were measured in various degrees of fluid overload in 26 haemodialysis patients, for whom diuresis, mediated by atrial natriuretic peptide (ANP), is not a possible defence mechanism. Plasma CGRP concentrations were positively correlated with the degree of fluid excess (r = 0.815, p = 0.0001) and were significantly higher in 5 patients with severe fluid overload than in those less severely affected (143 [SE 14] vs 52 [11] pmol/l; p < 0.001). CGRP may be an effective defence against complications of fluid overload since if can increase capitance by vasodilatation.	KAROLINSKA HOSP,DEPT CLIN CHEM,S-10401 STOCKHOLM 60,SWEDEN; UNIV ALBERTA HOSP,DEPT MED,DIV NEPHROL,EDMONTON T6G 2B7,ALBERTA,CANADA	Karolinska Institutet; Karolinska University Hospital; University of Alberta	ODARCEDERLOF, I (corresponding author), KAROLINSKA HOSP,DEPT INTERNAL MED,DIV NEPHROL,BOX 60500,S-10401 STOCKHOLM 60,SWEDEN.		Theodorsson, Elvar/H-2096-2011	Theodorsson, Elvar/0000-0003-0756-7723				BERGLUND H, 1990, BRIT HEART J, V64, P9; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; CURRIE MG, 1983, SCIENCE, V221, P71, DOI 10.1126/science.6857267; ERICSSON F, 1983, NEPHRON, V33, P173, DOI 10.1159/000182937; GENNARI C, 1990, CARDIOVASC RES, V3, P239; GREENBERG B, 1987, BRIT J PHARMACOL, V92, P789, DOI 10.1111/j.1476-5381.1987.tb11382.x; LANG RE, 1985, NATURE, V314, P264, DOI 10.1038/314264a0; ODARCEDERLOF I, 1989, J INTERN MED, V226, P177, DOI 10.1111/j.1365-2796.1989.tb01376.x; TALARTSCHIK J, 1988, Z KARDIOL, V77, P72; YAMAMOTO A, 1988, BIOCHEM BIOPH RES CO, V155, P1452, DOI 10.1016/S0006-291X(88)81304-4	10	31	31	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					411	412		10.1016/0140-6736(91)91035-S	http://dx.doi.org/10.1016/0140-6736(91)91035-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678085				2022-12-01	WOS:A1991GB44600006
J	PIETERS, R; HUISMANS, DR; LOONEN, AH; HAHLEN, K; VANDERDOESVANDENBERG, A; VANWERING, ER; VEERMAN, AJP				PIETERS, R; HUISMANS, DR; LOONEN, AH; HAHLEN, K; VANDERDOESVANDENBERG, A; VANWERING, ER; VEERMAN, AJP			RELATION OF CELLULAR-DRUG RESISTANCE TO LONG-TERM CLINICAL OUTCOME IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Article							DYE EXCLUSION ASSAY; MTT-ASSAY; LEUKEMIA-CELLS; CANCER-CHEMOTHERAPY; CHEMOSENSITIVITY; INVITRO; CHILDREN; INVIVO; SENSITIVITY	The clinical relevance of cellular drug resistance in children with acute lymphoblastic leukaemia (ALL) is unknown. The relation between in-vitro sensitivity to chemotherapeutic drugs at initial diagnosis and long-term clinical outcome was investigated in 44 children with ALL. The short-term MTT assay was used to assess sensitivity to prednisolone, vincristine, colaspase (asparaginase), daunorubicin, and thioguanine (instead of mercaptopurine which is unstable in vitro). For vincristine and colaspase there was no difference in outcome (probability of continuous complete remission) between sensitive and resistant patients. However, the probability of continuous complete remission was significantly lower in patients with resistant cells than in those with sensitive cells for thioguanine (p < 0.01), daunorubicin (p < 0.02), and prednisolone (p < 0.05). For prednisolone there was a significant worsening of the prognosis (p < 0.05) from the extremely sensitive patients through an intermediate group to the most resistant group. The prognostic significance of cellular drug resistance was independent of white-blood-cell count, age, sex, and hepatosplenomegaly. Leukaemic cells from boys were more resistant to thioguanine than those from girls. Thus, the short-term highly efficient MTT assay can help to predict long-term response to chemotherapy in childhood ALL.	ERASMUS UNIV,SOPHIA CHILDRENS HOSP,SUBDIV HAEMATO ONCOL,3000 DR ROTTERDAM,NETHERLANDS; DUTCH CHILDHOOD LEUKEMIA STUDY GRP,THE HAGUE,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital	PIETERS, R (corresponding author), FREE UNIV AMSTERDAM HOSP,DEPT PEDIAT,DE BOELELAAN 1117,1081 HV AMSTERDAM,NETHERLANDS.		Veerman, Anjo/AAT-2443-2020	Veerman, Anjo JP/0000-0002-9309-301X				ASSELIN BL, 1989, CANCER RES, V49, P4363; BIRD MC, 1985, HEMATOL ONCOL, V3, P1, DOI 10.1002/hon.2900030102; CAMPLING BG, 1988, LEUKEMIA RES, V12, P823, DOI 10.1016/0145-2126(88)90036-7; EVANS WE, 1989, PEDIATR CLIN N AM, V36, P1199; HONGO T, 1990, CANCER-AM CANCER SOC, V65, P1263, DOI 10.1002/1097-0142(19900315)65:6<1263::AID-CNCR2820650602>3.0.CO;2-S; HONGO T, 1987, JPN J CANC CHEMOTHER, V14, P472; KERN DH, 1990, J NATL CANCER I, V82, P582, DOI 10.1093/jnci/82.7.582; KIRKPATRICK DL, 1990, LEUKEMIA RES, V14, P459, DOI 10.1016/0145-2126(90)90033-6; LENNARD L, 1987, CLIN PHARMACOL THER, V41, P18, DOI 10.1038/clpt.1987.4; LENNARD L, 1989, J CLIN ONCOL, V7, P1816, DOI 10.1200/JCO.1989.7.12.1816; LILLEYMAN JS, 1984, BRIT J CANCER, V49, P703, DOI 10.1038/bjc.1984.111; MATTERN J, 1982, CANCER TREAT REV, V9, P267, DOI 10.1016/S0305-7372(82)80041-8; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PIETERS R, 1988, CANCER LETT, V41, P323, DOI 10.1016/0304-3835(88)90294-7; PIETERS R, 1989, BRIT J CANCER, V59, P217, DOI 10.1038/bjc.1989.44; PIETERS R, 1990, BLOOD, V76, P2327; PIETERS R, 1991, THESIS FREE U AMSTER; RIEHM H, 1987, ACUTE LEUKEMIAS PROG, P139; ROTHENBERG ML, 1989, BLOOD, V74, P1388; SANTINI V, 1989, HEMATOL ONCOL, V7, P287, DOI 10.1002/hon.2900070405; SARGENT JM, 1989, BRIT J CANCER, V60, P206, DOI 10.1038/bjc.1989.252; TAWA A, 1990, JPN J PEDIATR HEMATO, V4, P38; Thompson E B, 1986, Adv Exp Med Biol, V196, P111; TIDEFELT U, 1989, EUR J HAEMATOL, V43, P374; TWENTYMAN PR, 1989, BRIT J HAEMATOL, V71, P19, DOI 10.1111/j.1365-2141.1989.tb06268.x; TWENTYMAN PR, 1985, BRIT J CANCER, V51, P295, DOI 10.1038/bjc.1985.42; VANDENDOEL LJ, 1988, EUR J HAEMATOL, V41, P170; VEERMAN AJP, 1990, BRIT J HAEMATOL, V74, P381, DOI 10.1111/j.1365-2141.1990.tb06323.x; WEISENTHAL LM, 1986, CANCER TREAT REP, V70, P1283; WEISENTHAL LM, 1985, CANCER TREAT REP, V69, P615	30	217	220	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					399	403		10.1016/0140-6736(91)91029-T	http://dx.doi.org/10.1016/0140-6736(91)91029-T			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678081				2022-12-01	WOS:A1991GB44600002
J	SANJOSE, S; ROMAN, E; BERAL, V				SANJOSE, S; ROMAN, E; BERAL, V			LOW-BIRTH-WEIGHT AND PRETERM DELIVERY, SCOTLAND, 1981-84 - EFFECT OF PARENTS OCCUPATION	LANCET			English	Article							GESTATIONAL-AGE; PREGNANCY; REPRODUCTION; PREMATURITY; WORK	The relation between prematurity and parenteral occupation was examined in a national study of 252 147 liveborn babies delivered in Scotland between 1981 and 1984. Information about mothers' and fathers' work was routinely collected at the first antenatal visit, and birthweight and gestational age were recorded at delivery. Preterm delivery (< 37 weeks' gestation) and low birthweight (< 2500 g) were more frequent in the children of mothers and of fathers employed in manual rather than in non-manual jobs. The risk of preterm delivery and/or low birthweight was more than 50% higher in the children of women who worked with electrical, metal, or leather goods than in the children of other female manual workers. These findings were not explained by maternal age, gravidity, marital status, previous perinatal death, baby's sex, or father's social class. For male manual workers, only the children of ceramic workers had an increased risk of prematurity. The risk of a baby being small-for-gestational age (less-than-or-equal-to 5th gestation-specific birthweight percentile) varied little with mother's or father's occupation. Overall, the results suggest that parental occupational exposures do not have a pronounced effect on the risk of prematurity, and when there are adverse effects they are associated with maternal rather than paternal exposures.	RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND; INT AGCY RES CANC,F-69372 LYONS,FRANCE	Radcliffe Infirmary; University of Oxford; World Health Organization; International Agency for Research on Cancer (IARC)				Roman, Eve/0000-0001-7603-3704				[Anonymous], 1980, CLASSIFICATION OCCUP; ARMSTRONG BG, 1989, BRIT J IND MED, V46, P196; AXELSON O, 1989, BRIT J IND MED, V46, P505; CLARKE M, 1985, BRIT MED J, V290, P1235, DOI 10.1136/bmj.290.6477.1235; COLE SK, 1980, PERINATAL AUDIT SURV, P39; FLETCHER AC, 1985, REPRODUCTIVE HAZARDS; LIPSCOMB JA, 1991, J OCCUP ENVIRON MED, V33, P597; MAMELLE N, 1984, AM J EPIDEMIOL, V119, P309, DOI 10.1093/oxfordjournals.aje.a113750; MCDONALD AD, 1988, BRIT J IND MED, V45, P56; McDowall M. E., 1985, STUDIES MED POPULATI; ROSENBERG MJ, 1987, J OCCUP ENVIRON MED, V29, P584; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; SANJOSE S, 1989, THESIS LONDON U; SAVITZ DA, 1989, AM J EPIDEMIOL, V129, P1201, DOI 10.1093/oxfordjournals.aje.a115241; 1987, BIRTHWEIGHT STATISTI; 1990, LANCET, V336, P1289	16	57	57	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					428	431		10.1016/0140-6736(91)91045-V	http://dx.doi.org/10.1016/0140-6736(91)91045-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB446	1678094				2022-12-01	WOS:A1991GB44600015
J	WENGER, JD; PIERCE, R; DEAVER, KA; PLIKAYTIS, BD; FACKLAM, RR; BROOME, CV				WENGER, JD; PIERCE, R; DEAVER, KA; PLIKAYTIS, BD; FACKLAM, RR; BROOME, CV			EFFICACY OF HAEMOPHILUS-INFLUENZAE TYPE-B POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE VACCINE IN UNITED-STATES CHILDREN AGED 18-59 MONTHS	LANCET			English	Article							RISK-FACTORS; BACTERIAL-MENINGITIS; PROTECTIVE EFFICACY; IMMUNOGENICITY; DISEASE; INFANTS; SAFETY; COUNTY	Vaccines prepared from the polyribosylribitol phosphate (PRP) capsule of Haemophilus influenzae b (Hib) have not consistently shown good efficacy in protecting children aged over 18 months from invasive Hib disease. To evaluate the efficacy of conjugate-PRP vaccines in this age-group, and to compare their effect with that of PRP vaccines, a post-marketing case-control study was conducted among 10 400 000 persons. Between Oct 1, 1988, and Feb 28, 1990, 75 patients with Hib disease and 161 control children between 18 and 60 months of age were enrolled. To minimise potentially confounding socioeconomic variables, controls were selected either from among patients' classmates at their day-care centre or from among family acquaintances. 9 of the 75 patients had received the diphtheria toxoid conjugate Hib vaccine more than 2 weeks before onset of illness. After adjusting for age and household crowding, the efficacy of PRP Hib vaccine was 64% (95% Cl = -20, 89) and efficacy of the diphtheria toxoid conjugate Hib vaccine was 74% (95% Cl = 30, 90). The study shows that the protective efficacy of this conjugate vaccine is less than ideal and highlights the need for additional post-licensing studies to confirm and expand understanding of the efficacy of these new products.	CTR DIS CONTROL, RESP DIS BRANCH, ATLANTA, GA 30333 USA; CTR DIS CONTROL, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, ATLANTA, GA 30333 USA; CTR DIS CONTROL, NATL CTR INFECT DIS, MENINGITIS & SPECIAL PATHOGENS BRANCH, ATLANTA, GA 30333 USA; CTR DIS CONTROL, NATL CTR INFECT DIS, BIOSTAT & INFORMAT MANAGEMENT BRANCH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								[Anonymous], 1991, MMWR Recomm Rep, V40, P1; BERKOWITZ CD, 1987, J PEDIATR-US, V110, P509, DOI 10.1016/S0022-3476(87)80540-1; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; BLACK SB, 1988, PEDIATR INFECT DIS J, V7, P149, DOI 10.1097/00006454-198803000-00003; COCHI SL, 1986, J PEDIATR-US, V108, P887, DOI 10.1016/S0022-3476(86)80922-2; FRASER DW, 1973, J INFECT DIS, V127, P271, DOI 10.1093/infdis/127.3.271; GREENBERG DP, 1991, JAMA-J AM MED ASSOC, V265, P987, DOI 10.1001/jama.265.8.987; HARRISON LH, 1988, JAMA-J AM MED ASSOC, V260, P1413, DOI 10.1001/jama.260.10.1413; ISTRE GR, 1985, J PEDIATR-US, V106, P190, DOI 10.1016/S0022-3476(85)80285-7; MADORE DV, 1990, PEDIATRICS, V86, P527; MURPHY TV, 1990, CLIN RES, V38, pA183; NOAH ND, 1987, BACTERIAL MENINGITIS, P93; OSTERHOLM MT, 1988, JAMA-J AM MED ASSOC, V260, P1423, DOI 10.1001/jama.260.10.1423; OSTERHOLM MT, 1989, 29TH INT C ANT AG CH; PELTOLA H, 1984, NEW ENGL J MED, V310, P1561, DOI 10.1056/NEJM198406143102404; REDMOND SR, 1984, JAMA-J AM MED ASSOC, V252, P2581, DOI 10.1001/jama.252.18.2581; SHAPIRO ED, 1989, J INFECT DIS, V160, P1064, DOI 10.1093/infdis/160.6.1064; SHAPIRO ED, 1988, JAMA-J AM MED ASSOC, V260, P1419, DOI 10.1001/jama.260.10.1419; SHAPIRO ED, 1990, 30TH INT C ANT AG CH; WARD JI, 1988, PEDIATRICS, V81, P887; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316	21	40	41	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 17	1991	338	8764					395	398						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678080				2022-12-01	WOS:A1991GB44600001
J	BALZER, I; HARDELAND, R				BALZER, I; HARDELAND, R			PHOTOPERIODISM AND EFFECTS OF INDOLEAMINES IN A UNICELLULAR ALGA, GONYAULAX-POLYEDRA	SCIENCE			English	Article							MELATONIN; PINEAL; DINOFLAGELLATE; ANOLIS; CLOCK	Mediation of photoperiodic effects by indoleamines, especially melatonin, is known in higher vertebrates. A similar mechanism may occur in a unicellular alga, the dinoflagellate Gonyaulax polyedra. This organism entered the dormant stage of a cyst upon short-day treatment at lowered temperatures. Interruption of darkness by 2 hours of light prevented cyst formation, even when the overall duration of light was the same as in cyst-inducing short days. When given in a noninducing photoperiod, melatonin and an analog, 5-methoxytryptamine, substances that had previously been shown to occur in Gonyaulax, provoked cyst formation. Methoxylated indoleamines may play a role as mediators of darkness in this unicellular, in a similar way as in vertebrates, suggesting a common biochemical basis of photoperiodism.			BALZER, I (corresponding author), UNIV GOTTINGEN, INST ZOOL, BERLINER STR 28, W-3400 GOTTINGEN, GERMANY.							ANDERSON DM, 1987, NATURE, V325, P616, DOI 10.1038/325616a0; ANDERSON DM, 1989, RED TIDES BIOL ENV S, P461; ARENDT J, 1986, OXFORD REV REPROD B, V8, P266; BALZER I, 1991, COMP BIOCHEM PHYS C, V98, P395, DOI 10.1016/0742-8413(91)90223-G; Balzer I., 1990, EUR J CELL BIOL S30, V51, P52; FINOCCHIARO L, 1988, J NEUROCHEM, V50, P382, DOI 10.1111/j.1471-4159.1988.tb02923.x; HARDELAND R, 1991, Journal of Interdisciplinary Cycle Research, V22, P122; HOFFMANN K, 1973, J COMP PHYSIOL, V85, P267, DOI 10.1007/BF00694233; MENAKER M, 1983, P NATL ACAD SCI-BIOL, V80, P6119, DOI 10.1073/pnas.80.19.6119; Menaker M., 1982, P1; MORITA M, 1984, J EXP ZOOL, V231, P273, DOI 10.1002/jez.1402310212; POGGELER B, 1989, ACTA ENDOCR-COP   S1, V120, P97; POGGELER B, IN PRESS NATURWISSEN; Reiter R J, 1980, Endocr Rev, V1, P109; REITER RJ, 1984, PINEAL GLAND; REITER RJ, 1985, HDB PHARM METHODOLOG, P331; Taylor F.J.R., 1987, BIOL DINOFLAGELLATES; UEMURA T, 1984, PROGR TRYPTOPHAN SER, P673; UNDERWOOD H, 1985, J COMP PHYSIOL A, V157, P57, DOI 10.1007/BF00611095; VIVIENROELS B, 1984, NEUROSCI LETT, V49, P153, DOI 10.1016/0304-3940(84)90152-6; VOLKNANDT W, 1984, COMP BIOCHEM PHYS B, V77, P493, DOI 10.1016/0305-0491(84)90264-5; WETTERBERG L, 1987, CHRONOBIOLOGIA, V14, P377	22	132	140	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 16	1991	253	5021					795	797		10.1126/science.1876838	http://dx.doi.org/10.1126/science.1876838			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1876838				2022-12-01	WOS:A1991GB29500040
J	KAPILOFF, MS; FARKASH, Y; WEGNER, M; ROSENFELD, MG				KAPILOFF, MS; FARKASH, Y; WEGNER, M; ROSENFELD, MG			VARIABLE EFFECTS OF PHOSPHORYLATION OF PIT-1 DICTATED BY THE DNA RESPONSE ELEMENTS	SCIENCE			English	Article							POU-SPECIFIC DOMAIN; GROWTH-HORMONE; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; BINDING; ACTIVATION; PROTEIN; OCT-1; PROMOTERS; SEQUENCE	Pit-1, a tissue-specific POU domain transcription factor, is required for the activation of the prolactin, growth hormone, and Pit-1 promoters that confer regulation by epidermal growth factor, adenosine 3',5'-monophosphate (cAMP), and phorbol esters. Pit-1 is phosphorylated in pituitary cells at two distinct sites in response to phorbol esters and cAMP. Phosphorylation of Pit-1 modifies its conformation on DNA recognition elements and results in increased binding at certain sites and decreased binding at other sites, dependent on DNA sequences adjacent to the core Pit-1 binding motif. One residue (Thr220), located in the POU homeodomain within a sequence conserved throughout the POU-domain family, confers these responses.	UNIV CALIF SAN DIEGO, SCH MED, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego	KAPILOFF, MS (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, EUKARYOT REGULATORY BIOL PROGRAM, LA JOLLA, CA 92093 USA.			Wegner, Michael/0000-0002-4586-3294; Kapiloff, Michael/0000-0002-7005-6953	NIDDK NIH HHS [DK 18477] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018477] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BULLOUGH DA, 1986, J BIOL CHEM, V261, P5722; CAPPS GG, 1989, J CELL BIOL, V108, P1317, DOI 10.1083/jcb.108.4.1317; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; COPP RP, 1989, MOL ENDOCRINOL, V3, P790, DOI 10.1210/mend-3-5-790; DANA S, 1989, MOL ENDOCRINOL, V3, P815, DOI 10.1210/mend-3-5-815; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KAPILOFF MS, UNPUB; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MOHR IJ, 1989, P NATL ACAD SCI USA, V86, P6479, DOI 10.1073/pnas.86.17.6479; MURDOCH GH, 1985, J BIOL CHEM, V260, P1852; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; VOSS J, IN PRESS GNEES DEV; VOSS J, IN PRESS J BIOL CHEM	33	196	199	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 16	1991	253	5021					786	789		10.1126/science.1652153	http://dx.doi.org/10.1126/science.1652153			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1652153				2022-12-01	WOS:A1991GB29500037
J	KENYON, K; CONTENTE, S; TRACKMAN, PC; TANG, J; KAGAN, HM; FRIEDMAN, RM				KENYON, K; CONTENTE, S; TRACKMAN, PC; TANG, J; KAGAN, HM; FRIEDMAN, RM			LYSYL OXIDASE AND RRG MESSENGER-RNA	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; SEQUENCE; CELLS		BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University	KENYON, K (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814, USA.		Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X; Contente, Sara/0000-0002-8099-2817	NATIONAL CANCER INSTITUTE [R01CA037351] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018880] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA37351-04A1] Funding Source: Medline; NHLBI NIH HHS [P01 HL13262] Funding Source: Medline; NIAMS NIH HHS [R37 AR18880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P4863; BENSON D, 1990, GENOMICS, V6, P389, DOI 10.1016/0888-7543(90)90583-G; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; INDIK Z, 1990, ARCH BIOCHEM BIOPHYS, V280, P80, DOI 10.1016/0003-9861(90)90521-Y; KAGAN HM, 1984, J BIOL CHEM, V259, P1203; KAGAN HM, 1983, BIOCHEM BIOPH RES CO, V115, P186, DOI 10.1016/0006-291X(83)90987-7; KESHMIRIAN J, 1989, J NEUROCYTOL, V18, P491, DOI 10.1007/BF01474545; KUIVANIEMI H, 1986, FEBS LETT, V195, P261, DOI 10.1016/0014-5793(86)80172-7; KUIVANIEMI H, 1986, BIOCHIM BIOPHYS ACTA, V883, P326, DOI 10.1016/0304-4165(86)90325-9; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; SCHUPPAN D, 1990, SEMIN LIVER DIS, V10, P1, DOI 10.1055/s-2008-1040452; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TRACKMAN PC, IN PRESS BIOCHEMISTR	14	201	213	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1991	253	5021					802	802		10.1126/science.1678898	http://dx.doi.org/10.1126/science.1678898			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1678898				2022-12-01	WOS:A1991GB29500045
J	MUSIERFORSYTH, K; USMAN, N; SCARINGE, S; DOUDNA, J; GREEN, R; SCHIMMEL, P				MUSIERFORSYTH, K; USMAN, N; SCARINGE, S; DOUDNA, J; GREEN, R; SCHIMMEL, P			SPECIFICITY FOR AMINOACYLATION OF AN RNA HELIX - AN UNPAIRED, EXOCYCLIC AMINO GROUP IN THE MINOR GROOVE	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; CHEMICAL SYNTHESIS; RECOGNITION; OLIGORIBONUCLEOTIDES; RESOLUTION; IDENTITY; BINDING; ALANINE	An acceptor stem G3.U70 base pair is a major determinant of the identity of an alanine transfer RNA. Hairpin helices and RNA duplexes consisting of complementary single strands are aminoacylated with alanine if they contain G3.U70. Chemical synthesis of RNA duplexes enabled the introduction of base analogs that tested the role of specific functional groups in the major and minor grooves of the RNA helix. The results of these experiments indicate that an unpaired guanine 2-amino group at a specific position in the minor groove of an RNA helix marks a molecule for aminoacylation with alanine.	MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA; UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA	Harvard University; Massachusetts General Hospital; University of Colorado System; University of Colorado Boulder					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015539, P01GM037641, R37GM015539] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37641, GM15539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1967, J MOL BIOL, V27, P525, DOI 10.1016/0022-2836(67)90056-3; DOUDNA JA, 1990, J ORG CHEM, V55, P5547, DOI 10.1021/jo00308a003; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; FRANCKLYN C, UNPUB; FRANCKLYN CS, 1990, CHEM REV, V90, P1327, DOI 10.1021/cr00105a013; GREEN R, NUCLEIC ACIDS RES; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; MCCLAIN WH, 1988, SCIENCE, V242, P1681, DOI 10.1126/science.2462282; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; OLLIS DL, 1987, CHEM REV, V87, P981, DOI 10.1021/cr00081a006; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PARK SJ, 1989, BIOCHEMISTRY-US, V28, P2740, DOI 10.1021/bi00432a056; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHI JP, 1990, BIOCHEMISTRY-US, V29, P3621, DOI 10.1021/bi00467a005; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552	20	150	150	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 16	1991	253	5021					784	786		10.1126/science.1876835	http://dx.doi.org/10.1126/science.1876835			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1876835				2022-12-01	WOS:A1991GB29500036
J	SARAGOVI, HU; FITZPATRICK, D; RAKTABUTR, A; NAKANISHI, H; KAHN, M; GREENE, MI				SARAGOVI, HU; FITZPATRICK, D; RAKTABUTR, A; NAKANISHI, H; KAHN, M; GREENE, MI			DESIGN AND SYNTHESIS OF A MIMETIC FROM AN ANTIBODY COMPLEMENTARITY-DETERMINING REGION	SCIENCE			English	Article							SEQUENCE; ANTIGEN	A technique for producing non-peptide compounds (mimetics) of designed specificities was developed that permitted the synthesis of a conformationally restricted molecule that mimicked the binding and functional properties of monoclonal antibody (MAb) 87.92.6, which recognizes the reovirus type 3 cellular receptor. Binding of either MAb 87.92.6, peptide analogs, or 87.1-mimetic to the cellular receptor inhibited cellular proliferation. The mimetic was a synthetic beta-loop structure that mimics the second complementarity-determining region of the MAb. These studies may lead to strategies for the synthetic design of antibody complementarity regions, ligands, and other pharmacologically active agents that are water soluble, resistant to proteolysis, and nonimmunogenic.	UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; UNIV ILLINOIS, DEPT CHEM, CHICAGO, IL 60680 USA	University of Pennsylvania; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; CHEN SH, UNPUB; DELAPAZ P, 1986, EMBO J, V5, P415, DOI 10.1002/j.1460-2075.1986.tb04227.x; FULLER WD, 1990, J AM CHEM SOC, V112, P7414, DOI 10.1021/ja00176a063; HOFFMAN RV, 1990, TETRAHEDRON LETT, V31, P2953, DOI 10.1016/S0040-4039(00)88996-0; KAHN M, UNPUB; KANG CY, 1988, SCIENCE, V240, P1034, DOI 10.1126/science.3368787; Kieber-Emmons T, 1987, Int Rev Immunol, V2, P339, DOI 10.3109/08830188709044761; NEPOM J T, 1982, Survey of Immunologic Research, V1, P255; NOVOTNY J, 1986, J MOL BIOL, V189, P715, DOI 10.1016/0022-2836(86)90502-4; POLJAK RJ, 1974, P NATL ACAD SCI USA, V71, P3440, DOI 10.1073/pnas.71.9.3440; SARAGOVI HU, UNPUB; SEGAL DM, 1974, P NATL ACAD SCI USA, V71, P4298, DOI 10.1073/pnas.71.11.4298; TAUB R, 1989, J BIOL CHEM, V264, P259; WILLIAMS WV, 1991, J BIOL CHEM, V266, P5182; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537	16	153	204	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 16	1991	253	5021					792	795		10.1126/science.1876837	http://dx.doi.org/10.1126/science.1876837			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1876837				2022-12-01	WOS:A1991GB29500039
J	SONG, WC; BRASH, AR				SONG, WC; BRASH, AR			PURIFICATION OF AN ALLENE OXIDE SYNTHASE AND IDENTIFICATION OF THE ENZYME AS A CYTOCHROME-P-450	SCIENCE			English	Article							MICROSOMAL CYTOCHROME-P-450; HYDROPEROXIDE ISOMERASE; MARINE PROSTANOIDS; PLEXAURA-HOMOMALLA; LINOLENIC ACID; BIOSYNTHESIS; CYCLASE; CORAL; LIPOXYGENASE; METABOLISM	Fatty acid hydroperoxides (lipoxygenase products) are metabolized to allene oxides by a type of dehydrase that has been detected in plants, corals, and starfish oocytes. The allene oxides are unstable epoxide precursors of more complex products such as jasmonic acid, the plant growth hormone. Characterization of the dehydrase enzyme of flaxseed revealed that it is a 55-kilodalton hemoprotein. The spectral characteristics of this dehydrase revealed it to be a cytochrome P-450. It operates with the remarkable activity of greater-than-or-equal-to 1000 turnovers per second. The results establish a new catalytic activity for a cytochrome P-450 and illustrate the cooperation of different oxygenases in pathways of fatty acid metabolism.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035275] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35275] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAERTSCHI SW, 1988, BIOCHEMISTRY-US, V27, P18, DOI 10.1021/bi00401a004; BLACK SD, 1986, CYTOCHROME P 450 STR, pCH6; BRASH AR, 1989, J AM CHEM SOC, V111, P1891, DOI 10.1021/ja00187a060; BRASH AR, 1987, J BIOL CHEM, V262, P15829; BRASH AR, UNPUB; CAMP RL, 1968, J AM CHEM SOC, V90, P7349, DOI 10.1021/ja01028a032; CHAN TH, 1978, J ORG CHEM, V43, P2994, DOI 10.1021/jo00409a013; CHAN TH, 1980, TETRAHEDRON, V36, P2269, DOI 10.1016/0040-4020(80)80123-2; COREY EJ, 1987, J AM CHEM SOC, V109, P289, DOI 10.1021/ja00235a053; COREY EJ, 1988, TETRAHEDRON LETT, V29, P2555, DOI 10.1016/S0040-4039(00)86110-9; CRANDALL JK, 1968, J HETEROCYCLIC CHEM, V6, P777; CROMBIE L, 1988, J CHEM SOC CHEM COMM, P558, DOI 10.1039/c39880000558; GROSSMAN S, 1983, BIOCHIM BIOPHYS ACTA, V572, P65; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; HAMBERG M, 1988, BIOCHEM BIOPH RES CO, V156, P543, DOI 10.1016/S0006-291X(88)80876-3; HAMBERG M, 1990, ARCH BIOCHEM BIOPHYS, V276, P518, DOI 10.1016/0003-9861(90)90753-L; HAMBERG M, 1987, BIOCHIM BIOPHYS ACTA, V920, P76, DOI 10.1016/0005-2760(87)90313-4; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; HIGASHI K, 1985, AGR BIOL CHEM TOKYO, V49, P2399, DOI 10.1080/00021369.1985.10867084; IWASAKI M, 1991, J BIOL CHEM, V266, P3380; JEFCOATE CR, 1969, BIOCHEMISTRY-US, V8, P3464, DOI 10.1021/bi00836a050; PETERSON JA, 1971, ARCH BIOCHEM BIOPHYS, V144, P678, DOI 10.1016/0003-9861(71)90375-4; VICK BA, 1981, PLANT PHYSIOL, V67, P92, DOI 10.1104/pp.67.1.92; VICK BA, 1987, PLANT PHYSIOL, V85, P1073, DOI 10.1104/pp.85.4.1073; VICK BA, 1983, BIOCHEM BIOPH RES CO, V111, P470, DOI 10.1016/0006-291X(83)90330-3; VICK BA, 1970, PLANT PHYSIOL, V46, P445; ZIMMERMAN DC, 1978, LIPIDS, V13, P313, DOI 10.1007/BF02533720; ZIMMERMAN DC, 1966, BIOCHEM BIOPH RES CO, V23, P398, DOI 10.1016/0006-291X(66)90740-6	28	232	241	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1991	253	5021					781	784		10.1126/science.1876834	http://dx.doi.org/10.1126/science.1876834			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1876834				2022-12-01	WOS:A1991GB29500035
J	THOMPSON, CC; BROWN, TA; MCKNIGHT, SL				THOMPSON, CC; BROWN, TA; MCKNIGHT, SL			CONVERGENCE OF ETS-RELATED AND NOTCH-RELATED STRUCTURAL MOTIFS IN A HETEROMERIC DNA-BINDING COMPLEX	SCIENCE			English	Article							CELL-CYCLE CONTROL; IMMUNOGLOBULIN ENHANCER-BINDING; NF-KAPPA-B; TRANSCRIPTION FACTOR; CONTROL PROTEINS; RNA-POLYMERASE; REL ONCOGENE; GENE; DROSOPHILA; SEQUENCE	Analysis of the heteromeric DNA binding protein GABP has revealed the interaction of two distinct peptide sequence motifs normally associated with proteins located in different cellular compartments. The alpha-subunit of GABP contains an 85-amino acid segment related to the Ets family of DNA binding proteins. The ETS domain of GABP-alpha facilitates weak binding to DNA and, together with an adjacent segment of 37 amino acids, mediates stable interaction with GABP-beta. The beta-subunit of GABP contains four imperfect repeats of a sequence present in several transmembrane proteins including the product of the Notch gene of Drosophila melanogaster. These amino-terminal repeats of GABP-beta mediate stable interaction with GABP-alpha and, when complexed with GABP-alpha, directly contact DNA. These observations provide evidence for a distinct biochemical role for the 33-amino acid repeats, and suggest that they may serve as a module for the generation of specific dimerization interfaces.			THOMPSON, CC (corresponding author), CARNEGIE INST WASHINGTON,DEPT EMBRYOL,HOWARD HUGHES RES LABS,BALTIMORE,MD 21210, USA.							ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BAUERLE PA, 1988, CELL, V53, P211; BAUERLE PA, 1988, SCIENCE, V242, P540; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BROWN TB, UNPUB; CHODOSH L, 1988, CURRENT PROTOCOLS MO, V2; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HASKILL S, 1991, CELL, V65; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMPSON C, UNPUB; TRIEZENBERG SL, 1989, GENE DEV, V3, P1372; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	37	435	440	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1991	253	5021					762	768		10.1126/science.1876833	http://dx.doi.org/10.1126/science.1876833			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1876833				2022-12-01	WOS:A1991GB29500029
J	TURKA, LA; SCHATZ, DG; OETTINGER, MA; CHUN, JJM; GORKA, C; LEE, K; MCCORMACK, WT; THOMPSON, CB				TURKA, LA; SCHATZ, DG; OETTINGER, MA; CHUN, JJM; GORKA, C; LEE, K; MCCORMACK, WT; THOMPSON, CB			THYMOCYTE EXPRESSION OF RAG-1 AND RAG-2 - TERMINATION BY T-CELL RECEPTOR CROSS-LINKING	SCIENCE			English	Article							RECOMBINATION ACTIVATING GENE; V(D)J RECOMBINATION; DEVELOPMENTAL BIOLOGY; ANTIGEN RECEPTOR; MATURE THYMOCYTES; CHAIN TRANSCRIPTS; SURFACE-ANTIGEN; ADJACENT GENES; LYMPHOCYTES-T; THYMUS	The expression of the V(D)J [variable (diversity) joining elements] recombination activating genes, RAG-1 and RAG-2, has been examined during T cell development in the thymus. In situ hybridization to intact thymus and RNA blot analysis of isolated thymic subpopulations separated on the basis of T cell receptor (TCR) expression demonstrated that both TCR- and TCR+ cortical thymocytes express RAG-1 and RAG-2 messenger RNA's. Within the TCR+ population, RAG expression was observed in immature CD4+CD8+ (double positive) cells, but not in the more mature CD4+CD8- or CD4-CD8+ (single positive) subpopulations. Thus, although cortical thymocytes that bear TCR on their surface continue to express RAG-1 and RAG-2, it appears that the expression of both genes is normally terminated during subsequent thymic maturation. Since thymocyte maturation in vivo is thought to be regulated through the interaction of the TCR complex with self major histocompatibility complex (MHC) antigens, these data suggest that signals transduced by the TCR complex might result in the termination of RAG expression. Consistent with this hypothesis, thymocyte TCR cross-linking in vitro led to rapid termination of RAG-1 and RAG-2 expression, whereas cross-linking of other T cell surface antigens such as CD4, CD8, or HLA class I had no effect.	UNIV MICHIGAN,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	TURKA, LA (corresponding author), UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109, USA.		Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176; McCormack, Wayne/0000-0002-2117-8727	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001899] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-01899] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON JP, 1987, ANNU REV IMMUNOL, V5, P503, DOI 10.1146/annurev.iy.05.040187.002443; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; FINKEL TH, 1989, CELL, V58, P1047, DOI 10.1016/0092-8674(89)90503-5; FINKEL TH, 1989, J IMMUNOL, V142, P3006; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; MARCHE PN, 1986, P NATL ACAD SCI USA, V83, P2190, DOI 10.1073/pnas.83.7.2190; MARRACK P, 1987, SCIENCE, V238, P1047; MATHIESON BJ, 1984, IMMUNOL REV, V82, P141, DOI 10.1111/j.1600-065X.1984.tb01121.x; MATIS LA, 1988, J EXP MED, V168, P2379, DOI 10.1084/jem.168.6.2379; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCGHEE D, 1979, THYMUS, V1, P151; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P9324, DOI 10.1073/pnas.87.23.9324; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; NIETO MA, 1990, J IMMUNOL, V145, P1364; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; SAMUELSON LE, 1991, CELL, V64, P875; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCOLLAY R, 1983, THYMUS, V5, P245; SCOLLAY RG, 1980, EUR J IMMUNOL, V10, P210, DOI 10.1002/eji.1830100310; SHORTMAN K, 1987, J IMMUNOL, V138, P342; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616; SPRENT J, 1989, FUNDAMENTAL IMMUNOLO, P69; STROMINGER JL, 1989, SCIENCE, V244, P943, DOI 10.1126/science.2658058; TOYONAGA B, 1987, ANNU REV IMMUNOL, V5, P585, DOI 10.1146/annurev.iy.05.040187.003101; TRIEBEL F, 1988, J IMMUNOL, V140, P300; TURKA LA, 1990, J IMMUNOL, V144, P1646; TURKA LA, 1991, J IMMUNOL, V146, P1428; TURKA LA, UNPUB; VANEWIJK W, 1981, J IMMUNOL, V127, P2594; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEISSMAN IL, 1973, J EXP MED, V137, P504, DOI 10.1084/jem.137.2.504; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0	42	234	243	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1991	253	5021					778	781		10.1126/science.1831564	http://dx.doi.org/10.1126/science.1831564			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1831564				2022-12-01	WOS:A1991GB29500034
J	WALTERS, ET; ALIZADEH, H; CASTRO, GA				WALTERS, ET; ALIZADEH, H; CASTRO, GA			SIMILAR NEURONAL ALTERATIONS INDUCED BY AXONAL INJURY AND LEARNING IN APLYSIA	SCIENCE			English	Article							SENSORY NEURONS; TRANSMITTER RELEASE; PRESYNAPTIC FACILITATION; BEHAVIORAL SENSITIZATION; SYNAPTIC CONNECTIONS; CELLULAR MECHANISM; INNERVATING TAIL; GILL-WITHDRAWAL; MODULATION; SUGGESTS	Learning in the marine mollusk Aplysia has been associated with enhanced sensory function, expressed in mechanosensory neurons as (i) decreases in action potential threshold, accommodation, and afterhyperpolarization, and (ii) increases in action potential duration, afterdischarge, and synaptic transmission. These alterations also occur, with a delay, after sensory axons are injured under conditions in which synaptic transmission is severely reduced. The latency and specificity of injury-induced alterations indicate that induction signals are generated at the site of injury and conveyed centrally by axonal transport. Similarities in neuronal modifications support the hypothesis that some memory mechanisms evolved from mechanisms of injury-induced sensory compensation and repair.			WALTERS, ET (corresponding author), UNIV TEXAS,SCH MED,DEPT PHYSIOL & CELL BIOL,HOUSTON,TX 77225, USA.			Walters, Edgar/0000-0003-0718-102X	NIAID NIH HHS [AI11361] Funding Source: Medline; NIMH NIH HHS [MH38726] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011361] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038726] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABRAMS TW, 1988, TRENDS NEUROSCI, V11, P128, DOI 10.1016/0166-2236(88)90137-3; ALIZADEH H, 1990, Society for Neuroscience Abstracts, V16, P597; BILLY AJ, 1989, J NEUROSCI, V9, P1254; BRONS JF, 1980, J NEUROPHYSIOL, V44, P605, DOI 10.1152/jn.1980.44.3.605; CROW TJ, 1980, SCIENCE, V209, P412, DOI 10.1126/science.209.4454.412; DISTERHOFT JF, 1986, P NATL ACAD SCI USA, V83, P2733, DOI 10.1073/pnas.83.8.2733; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GLANZMAN DL, 1989, J NEUROSCI, V9, P4200; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8410, DOI 10.1073/pnas.83.21.8410; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KLEIN M, 1978, P NATL ACAD SCI USA, V75, P3512, DOI 10.1073/pnas.75.7.3512; KLEIN M, 1986, P NATL ACAD SCI USA, V83, P7994, DOI 10.1073/pnas.83.20.7994; MACKEY SL, 1989, J NEUROSCI, V9, P4227; SCHOLZ KP, 1987, SCIENCE, V235, P685, DOI 10.1126/science.2433766; TITMUS MJ, 1990, PROG NEUROBIOL, V35, P1, DOI 10.1016/0301-0082(90)90039-J; WALTERS E, UNPUB; WALTERS ET, 1987, J NEUROSCI, V7, P408; WALTERS ET, 1991, BIOL BULL, V180, P241, DOI 10.2307/1542394; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1522, DOI 10.1152/jn.1983.50.6.1522; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1543, DOI 10.1152/jn.1983.50.6.1543; WALTERS ET, 1983, SCIENCE, V219, P405, DOI 10.1126/science.6294834	22	89	92	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1991	253	5021					797	799		10.1126/science.1652154	http://dx.doi.org/10.1126/science.1652154			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GB295	1652154				2022-12-01	WOS:A1991GB29500041
J	ANDERSON, RM; MAY, RM; BOILY, MC; GARNETT, GP; ROWLEY, JT				ANDERSON, RM; MAY, RM; BOILY, MC; GARNETT, GP; ROWLEY, JT			THE SPREAD OF HIV-1 IN AFRICA - SEXUAL CONTACT PATTERNS AND THE PREDICTED DEMOGRAPHIC-IMPACT OF AIDS	NATURE			English	Review							HUMAN IMMUNODEFICIENCY VIRUS; PREFERRED NUCLEOTIDE SUBSTITUTIONS; INTRAVENOUS DRUG-USERS; NEW-YORK-CITY; HETEROSEXUAL TRANSMISSION; TRANSMITTED DISEASES; HOUSEHOLD CONTACTS; VIRAL MIXTURES; INFECTION; CHILDREN	The spread of HIV-1 in Africa is examined here in the light of recent information on the main epidemiological and behavioural determinants of transmission. Mathematical models incorporating demographic, epidemiological and behavioural processes are used to assess the potential demographic impact of the disease AIDS. These analyses highlight the significance of patterns of sexual behaviour, and in particular networks of sexual contact, on the predicted spread of infection. Current data reveal substantial variations in the degree of spread between and in countries, but new analyses support earlier predictions that in the worst-afflicted areas AIDS is likely to change population growth rates from positive to negative values in a few decades.	UNIV OXFORD, DEPT ZOOL, OXFORD OX1 3PS, ENGLAND	University of Oxford	ANDERSON, RM (corresponding author), UNIV LONDON IMPERIAL COLL SCI & TECHNOL, DEPT BIOL, PARASITE EPIDEMIOL RES GRP, LONDON SW7 2BB, ENGLAND.		Garnett, Geoffrey P/A-9312-2008	Boily, Marie-Claude/0000-0003-3919-006X; Anderson, Roy/0000-0002-9528-3175				ANDERSON RM, 1988, J ROY STAT SOC A STA, V151, P66, DOI 10.2307/2982185; ANDERSON RM, 1989, ANN NY ACAD SCI, V569, P240, DOI 10.1111/j.1749-6632.1989.tb27374.x; ANDERSON RM, 1988, NATURE, V333, P514, DOI 10.1038/333514a0; ANDERSON RM, 1988, NATURE, V332, P191; ANDIHAN WA, 1990, AIDS, V4, P758; ANDREASSON PA, 1989, 5 INT C AIDS MONTR; ANZALA A, 1989, 5 INT C AIDS MONTR; AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; BALDWIN JD, 1988, J SEX RES, V25, P181, DOI 10.1080/00224498809551454; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BERKELY SF, 1989, 4 INT C AIDS ASS CAN; BERKLEY S, 1990, AIDS, V4, P1237, DOI 10.1097/00002030-199012000-00009; BIBERFELD G, 1986, SCAND J INFECT DIS, V18, P497, DOI 10.3109/00365548609021653; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BLOWER SM, 1990, J ACQ IMMUN DEF SYND, V3, P763; BOILY MC, IN PRESS IMA J MATH; BONGAARTS J, 1989, STAT MED, V8, P103, DOI 10.1002/sim.4780080111; BROWN RC, 1990, AIDS, V4, P1267, DOI 10.1097/00002030-199012000-00014; CARAEL M, IN PRES SADIS; DECOCK KM, 1984, SCIENC, V224, P497; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DEVINCENZI I, 1989, BRIT MED J, V298, P411; FISCHL MA, 1987, JAMA-J AM MED ASSOC, V257, P640, DOI 10.1001/jama.257.5.640; FRANCE AJ, 1988, BRIT MED J, V296, P526, DOI 10.1136/bmj.296.6621.526; GANORE E, 1990, 6 INT C AIDS MONTR; GIESECKE J, 1988, BRIT MED J, V297, P99, DOI 10.1136/bmj.297.6641.99; GLASER JB, 1989, ARCH INTERN MED, V149, P645, DOI 10.1001/archinte.149.3.645; GOEDERT JJ, 1989, LANCET, V2, P1351; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; GUAY L, 1990, 6 INT C AIDS SAN FRA; GUPTA S, 1989, AIDS, V3, P807, DOI 10.1097/00002030-198912000-00005; HEWLETT IK, 1990, J ACQ IMMUN DEF SYND, V3, P714; HGSBORG M, IN PRESS ANTHR STUDI; HIRA SK, 1989, BRIT MED J, V299, P1250, DOI 10.1136/bmj.299.6710.1250; HUDSON CP, 1988, AIDS, V2, P255, DOI 10.1097/00002030-198808000-00003; HYMAN JM, 1989, MATH BIOSCI, V8, P103; JACQUEZ JA, 1988, MATH BIOSCI, V92, P119, DOI 10.1016/0025-5564(88)90031-4; JOHN JT, 1989, LANCET, V1, P160; JOHNSON AM, 1989, AIDS, V3, P367, DOI 10.1097/00002030-198906000-00005; KILLEWO J, 1990, AIDS, V4, P1081, DOI 10.1097/00002030-199011000-00005; KONINGS E, 1989, AIDS, V3, P245; KREISS J, 1988, GENITOURIN MED, V64, P1; LIFOON AR, 1990, 6 INT C AIDS SAN FRA; LIOMBA NG, 1989, 5 INT C AIDS MONTR; LISSE IM, 1990, AIDS, V4, P1263, DOI 10.1097/00002030-199012000-00013; LPAGE P, 1989, 4 INT C AIDS ASS CAN; MAIGA MK, 1989, 5 INT C AIDS MONTR; MATI J, 1989, 6 INT C AIDS MONTR; MAY RM, 1988, MATH BIOSCI, V90, P475, DOI 10.1016/0025-5564(88)90079-X; MAY RM, 1990, PARASITOLOGY, V100, pS89, DOI 10.1017/S0031182000073042; May RM, 1989, LECT NOTES BIOMATHEM, V81, P220; MAY RM, 1989, CURRENT TOPICS AIDS, V2, P33; MELBYE M, 1986, LANCET, V2, P1113; MURLIE A, 1989, 5 INT C AIDS MONTR; NGALY B, 1988, J ACQ IMMUN DEF SYND, V1, P551; NOWAK MA, 1990, AIDS, V4, P1095, DOI 10.1097/00002030-199011000-00007; NTOZI JPM, IN PRESS ANTHR STUDI; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PECKHAM CS, 1991, LANCET, V337, P253; PECKHAM CS, 1988, LANCET, V2, P1039; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PIOT P, 1989, BRIT MED J, V298, P623, DOI 10.1136/bmj.298.6674.623; PIOT P, 1987, J INFECT DIS, V155, P1108, DOI 10.1093/infdis/155.6.1108; POTTS M, IN PRESS LANCET; REEVES GK, 1989, PHIL T R SOC B, V325, P109; REZZA G, 1989, AIDS, V3, P87, DOI 10.1097/00002030-198902000-00006; ROGERS MF, 1987, PEDIATRICS, V79, P1008; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; ROWLEY JT, 1990, AIDS, V4, P47, DOI 10.1097/00002030-199001000-00007; RYDER RW, 1990, AIDS, V4, P725, DOI 10.1097/00002030-199008000-00002; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SHARP PM, 1988, NATURE, V336, P315, DOI 10.1038/336315a0; TAYLOR JMG, 1991, J ACQ IMMUN DEF SYND, V4, P69; THANGCHARVEN P, 1989, HIV INFECTION THAILA; TOVO PA, 1988, LANCET, V2, P1043; VANDEPERRE P, 1985, LANCET, V2, P524; VANICHSENI S, 1989, 5 INT C AIDS MONTR; WARD J, 1990, 6 INT C AIDS SAN FRA; WELLINGS K, 1990, NATURE, V348, P276, DOI 10.1038/348276a0; YOKOYAMA S, 1988, MOL BIOL EVOL, V5, P237; 1990, NATIONAL HIV SEROPRE; 1990, HIV AIDS SURVEILLANC; 1989, HIV SEROPREVALENCE B; 1987, MORBIDITY MORTALITY, V36, P593	87	261	262	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					581	589		10.1038/352581a0	http://dx.doi.org/10.1038/352581a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1865922				2022-12-01	WOS:A1991GB21100044
J	BASILE, AS; HUGHES, RD; HARRISON, PM; MURATA, Y; PANNELL, L; JONES, EA; WILLIAMS, R; SKOLNICK, P				BASILE, AS; HUGHES, RD; HARRISON, PM; MURATA, Y; PANNELL, L; JONES, EA; WILLIAMS, R; SKOLNICK, P			ELEVATED BRAIN CONCENTRATIONS OF 1,4-BENZODIAZEPINES IN FULMINANT HEPATIC-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BENZODIAZEPINE RECEPTOR LIGANDS; GAMMA-AMINOBUTYRIC-ACID; ANIMAL-MODEL; RABBIT MODEL; ANTAGONIST FLUMAZENIL; ENCEPHALOPATHY; COMPLEX; REVERSAL; DIAZEPAM; POTATO	Background. Increased gamma-aminobutyric acid (GABA) neurotransmission has been implicated in the pathogenesis of hepatic encephalopathy. The mechanism by which GABA-ergic activity is increased in hepatic failure is unclear, but recent studies in animals with encephalopathy due to fulminant hepatic failure suggest that GABA-ergic neurotransmission may be increased by the presence of elevated concentrations of benzodiazepine agonists such as diazepam and N-desmethyldiazepam. Methods and Results. Samples of frontal cortex were obtained at autopsy from 11 patients with hepatic encephalopathy who died of acetaminophen-induced fulminant hepatic failure and 8 patients who died of cardiovascular disease or trauma. None of the 19 patients had received benzodiazepines while hospitalized. Chromatographic analyses of extracts of these samples revealed 4 to 19 peaks representing substances that inhibited the binding of a radiolabeled imidazobenzodiazepine ([H-3]flumazenil) to its receptors. Several of these peaks had retention times corresponding to those of known 1,4-benzodiazepines. Ultraviolet- and mass-spectroscopic analysis confirmed that two of these peaks represented diazepam and N-desmethyldiazepam. The patients who died of fulminant hepatic failure could be divided into two groups: six who had had significantly elevated brain concentrations (2-fold to 10-fold higher than normal) of substances inhibiting the binding of [H-3]flumazenil and five who had normal concentrations. Conclusions. Brain concentrations of substances inhibiting the binding of [H-3]flumazenil to its receptors are increased in some patients with hepatic encephalopathy due to fulminant hepatic failure. The origin of these substances is unknown, but these findings provide a rational basis for trials of benzodiazepine-receptor antagonists in the management of this disorder.	NIDDKD,DIGEST DIS BRANCH,BIOORGAN CHEM LAB,BETHESDA,MD 20892; NIDDKD,DIGEST DIS BRANCH,LIVER DIS SECT,BETHESDA,MD 20892; UNIV LONDON KINGS COLL,SCH MED & DENT,LIVER UNIT,LONDON WC2R 2LS,ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of London; King's College London	BASILE, AS (corresponding author), NIDDKD,DIGEST DIS BRANCH,NEUROSCI LAB,BLDG 8,RM 111,BETHESDA,MD 20892, USA.		Harrison, Phillip M/D-5374-2009	opoku, anita/0000-0001-7243-8157				BANSKY G, 1989, GASTROENTEROLOGY, V97, P744, DOI 10.1016/0016-5085(89)90647-1; BASILE AS, 1989, J NEUROCHEM, V53, P1057, DOI 10.1111/j.1471-4159.1989.tb07395.x; BASILE AS, 1990, NEUROPSYCHOPHARMACOL, V3, P61; BASILE AS, 1991, SYNAPSE, V7, P141, DOI 10.1002/syn.890070208; BASILE AS, 1988, J NEUROSCI, V8, P2414; BASILE AS, 1990, P NATL ACAD SCI USA, V87, P5263, DOI 10.1073/pnas.87.14.5263; BASILE AS, 1991, PHARMACOL REV, V43, P28; BASSETT ML, 1987, GASTROENTEROLOGY, V93, P1069, DOI 10.1016/0016-5085(87)90571-3; BASSETT ML, 1990, GASTROENTEROLOGY, V98, P747, DOI 10.1016/0016-5085(90)90298-F; Conn HO, 1978, HEPATIC COMA SYNDROM; FERENCI P, 1989, GASTROENTEROLOGY, V96, P240, DOI 10.1016/0016-5085(89)90787-7; FOERSTER EH, 1978, J ANAL TOXICOL, V2, P50, DOI 10.1093/jat/2.2.50; GAMMAL SH, 1990, HEPATOLOGY, V11, P371, DOI 10.1002/hep.1840110307; Greenblatt DJ, 1987, PSYCHOPHARMACOLOGY 3, P1377; GRIMM G, 1988, LANCET, V2, P1392; JONES EA, 1988, LIVER BIOL PATHOBIOL, P985; Luckner M., 1984, SECONDARY METABOLISM, V2nd, P12, DOI DOI 10.1007/978-3-662-09838-7; MEDINA JH, 1988, BIOCHEM BIOPH RES CO, V152, P534, DOI 10.1016/S0006-291X(88)80070-6; MENNINI T, 1983, BENZODIAZEPINE RECOG, P189; MULLEN KD, 1989, METAB BRAIN DIS, V4, P253, DOI 10.1007/BF00999771; MULLEN KD, 1990, LANCET, V336, P81, DOI 10.1016/0140-6736(90)91594-Z; OLASMAA M, 1990, J NEUROCHEM, V55, P2015, DOI 10.1111/j.1471-4159.1990.tb05790.x; OLASMAA M, 1989, LANCET, V1, P491; OSSELTON MD, 1977, J FORENSIC SCI SOC, V17, P189, DOI 10.1016/S0015-7368(77)71147-8; SANGAMESWARAN L, 1986, P NATL ACAD SCI USA, V83, P9236, DOI 10.1073/pnas.83.23.9236; SCHAFER DF, 1982, LANCET, V1, P18, DOI 10.1016/S0140-6736(82)92559-4; SCHENKER S, 1988, HEPATIC ENCEPHALOPAT, P15; SCOLLOLAVIZZARI G, 1985, LANCET, V1, P1324; SKOLNICK P, 1988, ISI ATLAS-PHARMACOL, V2, P19; STEINDL P, 1990, Gastroenterology, V98, pA636; UNSELD E, 1990, BIOCHEM PHARMACOL, V39, P210, DOI 10.1016/0006-2952(90)90668-B; WILDMANN J, 1987, J NEURAL TRANSM, V70, P383, DOI 10.1007/BF01253613; WILDMANN J, 1988, BIOCHEM PHARMACOL, V37, P3549, DOI 10.1016/0006-2952(88)90384-X; WILDMANN J, 1988, BIOCHEM BIOPH RES CO, V157, P1436, DOI 10.1016/S0006-291X(88)81036-2; 1985, DISEASES LIVER BILIA, P91	35	144	145	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					473	478		10.1056/NEJM199108153250705	http://dx.doi.org/10.1056/NEJM199108153250705			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1649403	Bronze			2022-12-01	WOS:A1991GA76300005
J	BOZZETTE, SA; LARSEN, RA; CHIU, J; LEAL, MAE; TILLES, JG; RICHMAN, DD; LEEDOM, JM; MCCUTCHAN, JA				BOZZETTE, SA; LARSEN, RA; CHIU, J; LEAL, MAE; TILLES, JG; RICHMAN, DD; LEEDOM, JM; MCCUTCHAN, JA			FLUCONAZOLE TREATMENT OF PERSISTENT CRYPTOCOCCUS-NEOFORMANS PROSTATIC INFECTION IN AIDS	ANNALS OF INTERNAL MEDICINE			English	Note							ACQUIRED IMMUNODEFICIENCY SYNDROME; MENINGITIS		UNIV CALIF IRVINE, IRVINE, CA 92717 USA	University of California System; University of California Irvine	BOZZETTE, SA (corresponding author), UNIV CALIF SAN DIEGO, MED CTR, DIV INFECT DIS, H-208, 225 DICKINSON, SAN DIEGO, CA 92103 USA.							BOZZETTE SA, 1991, NEW ENGL J MED, V324, P580, DOI 10.1056/NEJM199102283240902; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; DIAMOND RD, 1974, ANN INTERN MED, V80, P176, DOI 10.7326/0003-4819-80-2-176; KOVACS JA, 1985, ANN INTERN MED, V103, P533, DOI 10.7326/0003-4819-103-4-533; LARSEN RA, 1990, ANN INTERN MED, V113, P183, DOI 10.7326/0003-4819-113-3-183; LARSEN RA, 1989, ANN INTERN MED, V111, P125, DOI 10.7326/0003-4819-111-2-125; SAAG MS, 1988, ANTIMICROB AGENTS CH, V32, P1, DOI 10.1128/AAC.32.1.1; STERN JJ, 1988, AM J MED, V85, P477, DOI 10.1016/S0002-9343(88)80081-0; ZUGER A, 1988, ANN INTERN MED, V109, P592, DOI 10.7326/0003-4819-109-7-592; ZUGER A, 1986, ANN INTERN MED, V104, P234, DOI 10.7326/0003-4819-104-2-234	10	23	23	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					285	286		10.7326/0003-4819-115-4-285	http://dx.doi.org/10.7326/0003-4819-115-4-285			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1854112				2022-12-01	WOS:A1991GA76400008
J	CLACKSON, T; HOOGENBOOM, HR; GRIFFITHS, AD; WINTER, G				CLACKSON, T; HOOGENBOOM, HR; GRIFFITHS, AD; WINTER, G			MAKING ANTIBODY FRAGMENTS USING PHAGE DISPLAY LIBRARIES	NATURE			English	Article							IMMUNOGLOBULIN VARIABLE DOMAINS; POLYMERASE CHAIN-REACTION; ESCHERICHIA-COLI; IMMUNE-RESPONSE; EXPRESSION; PROTEIN; LAMBDA; DNA; ANTI-2-PHENYLOXAZOLONE; REPERTOIRE	To by-pass hybridoma technology and animal immunization, we are trying to build antibodies in bacteria by mimicking features of immune selection1. Recently we used fd phage2 to display antibody fragments fused to a minor coat protein3,4, allowing enrichment of phage with antigen3. Using a random combinatorial library of the rearranged heavy (VH) and kappa (V-kappa) light chains5-8 from mice immune to the hapten 2-phenyloxazol-5-one (phOx), we have now displayed diverse libraries of antibody fragments on the surface of fd phage. After a single pass over a hapten affinity column, fd phage with a range of phOx binding activities were detected, at least one with high affinity (dissociation constant, K(d) = 10(-8) M). A second pass enriched for the strong binders at the expense of the weak. The binders were encoded by V genes similar to those found in anti-phOx hybridomas but in promiscuous combinations (where the same V gene is found with several different partners). By combining a promiscuous VH or V-kappa gene with diverse repertoires of partners to create hierarchical libraries, we elicited many more pairings with strong binding activities. Phage display offers new ways of making antibodies from V-gene libraries, altering V-domain pairings and selecting for antibodies with good affinities.	CTR PROT ENGN, CAMBRIDGE CB2 2QH, ENGLAND	University of Cambridge	CLACKSON, T (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.		Baird, Cheryl L/F-6569-2011; Griffiths, Andrew D/A-1370-2010	Griffiths, Andrew D/0000-0002-0808-3539				ALZARI PM, 1990, EMBO J, V9, P3807, DOI 10.1002/j.1460-2075.1990.tb07598.x; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BEREK C, 1985, NATURE, V316, P412, DOI 10.1038/316412a0; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; CATON AJ, 1990, P NATL ACAD SCI USA, V87, P6450, DOI 10.1073/pnas.87.16.6450; CATON AJ, 1991, P NATL ACAD SCI USA, V88, P1590; CLACKSON T, IN PRESS PCR PRACTIC; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEBELLIS D, 1990, NUCLEIC ACIDS RES, V18, P1311; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DILDROP R, 1984, IMMUNOL TODAY, V5, P85, DOI 10.1016/0167-5699(84)90034-3; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; EISEN H N, 1964, Methods Med Res, V10, P115; FOOTE J, IN PRESS NATURE; GHERARDI E, 1990, J IMMUNOL METHODS, V126, P61, DOI 10.1016/0022-1759(90)90012-K; Gibson T.J., 1984, THESIS U CAMBRIDGE; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; GOTTESMAN ME, 1980, J MOL BIOL, V140, P57, DOI 10.1016/0022-2836(80)90356-3; GUSSOW D, 1989, NUCLEIC ACIDS RES, V17, P4000; HARLOW E, 1988, ANTIBODIES LABORATOR; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUDSON NW, 1987, J IMMUNOL, V139, P2715; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; MAKELA O, 1978, J EXP MED, V148, P1644, DOI 10.1084/jem.148.6.1644; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MCMANUS S, 1991, BIOCHEMISTRY-US, V30, P5851, DOI 10.1021/bi00238a007; MULLINAX RL, 1990, P NATL ACAD SCI USA, V87, P8095, DOI 10.1073/pnas.87.20.8095; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; PERELSON AS, 1989, IMMUNOL REV, V110, P5, DOI 10.1111/j.1600-065X.1989.tb00025.x; PERSSON MAA, 1991, P NATL ACAD SCI USA, V88, P2432, DOI 10.1073/pnas.88.6.2432; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SEGAL I, 1975, ENZYME KINETICS, P73; SHIMATAKE H, 1981, NATURE, V292, P128, DOI 10.1038/292128a0; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	45	928	2461	3	150	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					624	628		10.1038/352624a0	http://dx.doi.org/10.1038/352624a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1907718				2022-12-01	WOS:A1991GB21100057
J	GIBBONS, IR; GIBBONS, BH; MOCZ, G; ASAI, DJ				GIBBONS, IR; GIBBONS, BH; MOCZ, G; ASAI, DJ			MULTIPLE NUCLEOTIDE-BINDING SITES IN THE SEQUENCE OF DYNEIN BETA-HEAVY CHAIN	NATURE			English	Article							SEA-URCHIN SPERM; OUTER ARM DYNEIN; PHOTOSENSITIZED CLEAVAGE; MOLECULAR-CLONING; FLAGELLA; MYOSIN; ALPHA; PROTEINS; KINESIN; ATP	AXONEMAL dyneins have two or three globular heads joined by flexible tails to a common base, with each head/tail unit consisting of a single heavy-chain polypeptide of relative molecular mass > 400,000. The sizes of the components have been deduced by electron microscopy 1-3 . The isolated-beta heavy chain of sea urchin sperm flagella, which is immunologically identical to that of the embryo cilia (data not shown; ref. 4), is of particular interest as it retains the capability for microtubule translocation in vitro 5,6. Limited proteolysis of the beta-heavy chain divides it into two fragments, A and B, which sediment separately at 12S and 6S, and possibly correspond to the head and tail domains of the molecule 7. Dynein ATPase is the energy-transducing enzyme that generates the sliding movement between tubules that underlies the beating of cilia and flagella of eukaryotes, and possibly also other large intracellular movements 8,9. Here we report that the deduced amino-acid sequence of the beta-heavy chain of axonemal dynein from embryos of the sea urchin Tripneustes gratilla has 4,466 residues and contains the consensus motifs for five nucleotide-binding sites. The probable hydrolytic ATP-binding site can be identified by its location close to or at the V1 site of vanadate-mediated photocleavage 10. The general features of the map of photocleavage and proteolytic peptides reported earlier have been confirmed, except that the map's polarity is reversed. The predicted secondary structure of the beta-heavy chain consists of an alpha/beta-type pattern along its whole length. The two longest regions of potential alpha helix, with unbroken heptad hydrophobic repeats 120 and 50 amino acids long, may be of functional importance. But dynein does not seem to contain an extended coiled-coil tail domain.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus	GIBBONS, IR (corresponding author), UNIV HAWAII,PACIFIC BIOMED RES CTR,HONOLULU,HI 96822, USA.		Mocz, Gabor/A-7308-2009; Gibbons, Ian/B-5842-2013	Mocz, Gabor/0000-0001-9855-2206				CREMO CR, 1990, BIOCHEMISTRY-US, V29, P7982, DOI 10.1021/bi00486a029; CREMO CR, 1991, BIOPHYS J, V59, P513; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; FOLTZ KR, 1990, CELL MOTIL CYTOSKEL, V16, P33, DOI 10.1002/cm.970160106; GARBER AT, 1989, EMBO J, V8, P1727, DOI 10.1002/j.1460-2075.1989.tb03565.x; GASCUEL O, 1988, COMPUT APPL BIOSCI, V4, P357; GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; GIBBONS IR, 1988, J BIOL CHEM, V263, P15837; GIBBONS IR, IN PRESS P NATN ACAD; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; HAYASHI M, 1972, BIOCHEMISTRY-US, V11, P2977, DOI 10.1021/bi00766a008; KING SM, 1989, J BIOL CHEM, V264, P10210; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MOCZ G, 1990, J BIOL CHEM, V265, P2917; MOCZ G, 1988, J CELL BIOL, V106, P1607, DOI 10.1083/jcb.106.5.1607; MOCZ G, 1990, BIOCHEMISTRY-US, V29, P48; MOCZ G, IN PRESS BIOCHEMISTR; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OGAWA K, 1990, CELL MOTIL CYTOSKEL, V16, P58, DOI 10.1002/cm.970160108; OGAWA K, 1991, P JPN ACAD B-PHYS, V67, P27, DOI 10.2183/pjab.67.27; OGAWA K, IN PRESS P INT ECHIN; OW RA, 1987, J BIOL CHEM, V262, P3409; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SALE WS, 1988, J CELL BIOL, V107, P1793, DOI 10.1083/jcb.107.5.1793; SALE WS, 1985, J CELL BIOL, V101, P1400, DOI 10.1083/jcb.101.4.1400; SMITH EF, 1991, CELL MOTIL CYTOSKEL, V18, P258, DOI 10.1002/cm.970180403; TANG WJY, 1987, J BIOL CHEM, V262, P17728; VALE RD, 1987, ANNU REV CELL BIOL, V3, P347, DOI 10.1146/annurev.cb.03.110187.002023; VALE RD, 1989, CELL, V59, P915, DOI 10.1016/0092-8674(89)90614-4; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cellbio.3.1.379; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	34	222	225	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					640	643		10.1038/352640a0	http://dx.doi.org/10.1038/352640a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1830927				2022-12-01	WOS:A1991GB21100062
J	GITTER, MJ; GOLDSMITH, SR; DUNBAR, DN; SHARKEY, SW				GITTER, MJ; GOLDSMITH, SR; DUNBAR, DN; SHARKEY, SW			COCAINE AND CHEST PAIN - CLINICAL-FEATURES AND OUTCOME OF PATIENTS HOSPITALIZED TO RULE OUT MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article							ABUSE; ISCHEMIA	Objective: To investigate the clinical features, electrocardiographic findings, and hospital course in patients admitted with acute chest pain temporally related to cocaine use. Design: Retrospective data analysis. Setting: A 485-bed county hospital. Patients: One hundred and one consecutive patients with cocaine-related chest pain admitted to the hospital to rule out myocardial infarction. Measurements and Main Results: The quality of the chest pain frequently suggested myocardial ischemia. Dyspnea was common (56%). The onset of chest pain occurred during cocaine use in 21% of patients, within 1 hour of use in 37%, and after 1 hour of use in 42%. Admission electrocardiographic findings were interpreted as normal in 32% of patients; as acute myocardial injury in 8%; as early repolarization variant in 32%; as left ventricular hypertrophy in 16%; and as "other" in 12%. Forty-three percent of patients had ST-segment elevation meeting the electrocardiographic criteria for use of thrombolytic therapy, but such elevation was usually due to the early repolarization variant. The initial total creatine kinase was elevated more than 3.3-mu-kat/L (200 U/L) in 43% of patients, and an elevated total creatine kinase was recorded at some time during the hospital course in 47% of patients. The creatine kinase MB fraction was less than 0.02 in all patients. Myocardial infarction was ruled out in all patients. No patient experienced in-hospital cardiovascular complications. Conclusion: The quality of acute chest pain related to cocaine use is indistinguishable from that experienced in acute myocardial ischemia. Abnormal or normal variant electrocardiographic findings are common in patients with chest pain related to cocaine use, but nevertheless the incidence of acute myocardial infarction is low. The ST-segment and T-wave changes can mimic acute myocardial injury and are most likely normal findings in young black men that can be readily recognized in the emergency department. Most of these patients do not require admission to an intensive	HENNEPIN CTY MED CTR, DIV CARDIOL, 701 PK AVE, MINNEAPOLIS, MN 55415 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities								AMIN M, 1990, AM J CARDIOL, V66, P1434, DOI 10.1016/0002-9149(90)90529-A; BLACKMAN NS, 1964, AM HEART J, V67, P304, DOI 10.1016/0002-8703(64)90004-3; BRODY SL, 1990, AM J MED, V88, P325, DOI 10.1016/0002-9343(90)90484-U; CHELTON LG, 1955, AM J MED SCI, V230, P54, DOI 10.1097/00000441-195507000-00008; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; CREGLER LL, 1985, AM J CARDIOL, V56, P794, DOI 10.1016/0002-9149(85)91140-3; GOLDBERGER AL, 1980, MOD CONC CARDIOV DIS, V49, P13; GOLDBERGER AL, 1984, MYOCARDIAL INFARCTIO, P167; GOLDMAN MJ, 1953, AM HEART J, V46, P817, DOI 10.1016/0002-8703(53)90080-5; HERZLICH BC, 1988, ANN INTERN MED, V109, P335, DOI 10.7326/0003-4819-109-4-335; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; LANGE RA, 1989, NEW ENGL J MED, V321, P1557, DOI 10.1056/NEJM198912073212301; LANGE RA, 1990, CARDIOLOGY, V8, P74; LEE TH, 1986, ANN INTERN MED, V105, P221, DOI 10.7326/0003-4819-105-2-221; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; LEE TH, 1987, ANN INTERN MED, V106, P181, DOI 10.7326/0003-4819-106-2-181; LITTMANN D, 1946, AM HEART J, V32, P370, DOI 10.1016/0002-8703(46)90797-1; MATHIAS DW, 1986, AM J MED, V81, P675, DOI 10.1016/0002-9343(86)90556-5; OSHER HL, 1953, AM J MED SCI, V226, P541, DOI 10.1097/00000441-195322650-00011; PASCUALLEONE A, 1990, NEUROLOGY, V40, P404, DOI 10.1212/WNL.40.3_Part_1.404; PASTERNACK PF, 1985, AM J CARDIOL, V55, P847, DOI 10.1016/0002-9149(85)90172-9; ROTH D, 1988, NEW ENGL J MED, V319, P673, DOI 10.1056/NEJM198809153191103; RUBIN RB, 1989, AM J MED, V86, P551, DOI 10.1016/0002-9343(89)90383-5; SMITH HWB, 1987, ANN INTERN MED, V107, P13, DOI 10.7326/0003-4819-107-1-13; THOMAS J, 1960, AM J CARDIOL, V5, P468, DOI 10.1016/0002-9149(60)90102-8; Thompson WP, 1943, AM HEART J, V25, P372, DOI 10.1016/S0002-8703(43)90831-2; TOKARSKI GF, 1990, ANN EMERG MED, V19, P1088, DOI 10.1016/S0196-0644(05)81509-4; WIENER L, 1964, AM HEART J, V67, P684, DOI 10.1016/0002-8703(64)90340-0; ZIMMERMAN FH, 1987, J AM COLL CARDIOL, V9, P964, DOI 10.1016/S0735-1097(87)80256-5	29	96	99	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					277	282		10.7326/0003-4819-115-4-277	http://dx.doi.org/10.7326/0003-4819-115-4-277			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1854111				2022-12-01	WOS:A1991GA76400006
J	HILL, AVS; ALLSOPP, CEM; KWIATKOWSKI, D; ANSTEY, NM; TWUMASI, P; ROWE, PA; BENNETT, S; BREWSTER, D; MCMICHAEL, AJ; GREENWOOD, BM				HILL, AVS; ALLSOPP, CEM; KWIATKOWSKI, D; ANSTEY, NM; TWUMASI, P; ROWE, PA; BENNETT, S; BREWSTER, D; MCMICHAEL, AJ; GREENWOOD, BM			COMMON WEST AFRICAN HLA ANTIGENS ARE ASSOCIATED WITH PROTECTION FROM SEVERE MALARIA	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; FRAGMENT-LENGTH-POLYMORPHISM; CD8+ T-CELLS; MHC POLYMORPHISM; MIXED ANCESTRY; DQ ANTIGENS; SELECTION; SUBSTITUTION; HAPLOTYPES; ALLELES	A large case-control study of malaria in West African children shows that a human leucocyte class I antigen (HLA-Bw53) and an HLA class II haplotype (DRB1*1302-DQB1*0501), common in West Africans but rare in other racial groups, are independently associated with protection from severe malaria. In this population they account for as great a reduction in disease incidence as the sickle-cell haemoglobin variant. These data support the hypothesis that the extraordinary polymorphism of major histocompatibility complex genes has evolved primarily through natural selection by infectious pathogens.	MRC LABS, FAJARA, SENEGAMBIA; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND; ROYAL VICTORIA HOSP, BANJUL, SENEGAMBIA	University of London; London School of Hygiene & Tropical Medicine	HILL, AVS (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, MOLEC IMMUNOL GRP, OXFORD OX3 9DU, ENGLAND.		HILL, Adrian V>S>/C-1306-2008	Kwiatkowski, Dominic/0000-0002-5023-0176	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIZAWA M, 1986, HLA ASIA OCEANIA; ALLISON AC, 1964, COLD SPRING HARB SYM, V29, P137, DOI 10.1101/SQB.1964.029.01.018; ALLSOPP CEM, 1991, HUM IMMUNOL, V30, P105, DOI 10.1016/0198-8859(91)90078-N; BAUR MP, 1984, HISTOCOMPATIBILITY T, P333; BENGTSSON BO, 1981, TISSUE ANTIGENS, V18, P356, DOI 10.1111/j.1399-0039.1981.tb01404.x; BIDWELL J, 1988, IMMUNOL TODAY, V9, P18, DOI 10.1016/0167-5699(88)91351-5; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER JG, 1991, TISSUE ANTIGENS, V37, P97, DOI 10.1111/j.1399-0039.1991.tb01853.x; BOUHAROUNTAYOUN H, 1990, J EXP MED, V172, P1633, DOI 10.1084/jem.172.6.1633; BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; BRILES WE, 1977, SCIENCE, V195, P193, DOI 10.1126/science.831269; BROWN PJ, 1981, HUM BIOL, V53, P367; Bruce-Chwatt L. J., 1988, Malaria: principles and practice of malariology. Volume 1., P1; CARLSSON B, 1987, HUM IMMUNOL, V20, P95, DOI 10.1016/0198-8859(87)90025-5; CLARKE B, 1966, NATURE, V211, P999, DOI 10.1038/211999a0; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; COLOMBO B, 1985, J MED GENET, V22, P291, DOI 10.1136/jmg.22.4.291; DOHERTY PC, 1975, LANCET, V1, P1406, DOI 10.1016/S0140-6736(75)92610-0; Dupont B, 1989, IMMUNOBIOLOGY HLA, V1st; DUTOIT ED, 1990, TISSUE ANTIGENS, V36, P122, DOI 10.1111/j.1399-0039.1990.tb01812.x; DUTOIT ED, 1988, TISSUE ANTIGENS, V31, P109; FAREWELL VT, 1984, BIOMETRICS, V40, P547, DOI 10.2307/2531409; FERNANDEZVINA M, 1990, HUM IMMUNOL, V28, P51, DOI 10.1016/0198-8859(90)90102-U; FESTENSTEIN H, 1972, HISTOCOMPATIBILITY T, P175; FIGUEROA F, 1988, NATURE, V335, P265, DOI 10.1038/335265a0; GILLESPIE JH, 1985, THEOR POPUL BIOL, V27, P222, DOI 10.1016/0040-5809(85)90011-5; GORSKI J, 1989, J EXP MED, V170, P1027, DOI 10.1084/jem.170.3.1027; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2; GREENWOOD BM, 1990, PARASITOL TODAY, V6, P188, DOI 10.1016/0169-4758(90)90351-4; GREENWOOD BM, IN PRESS PARASITOL T; GYLLENSTEN UB, 1990, P NATL ACAD SCI USA, V87, P1835, DOI 10.1073/pnas.87.5.1835; Haldane J. B. S., 1963, Journal of Genetics, V58, P237, DOI 10.1007/BF02986143; HAYASHI H, 1990, IMMUNOGENETICS, V32, P195, DOI 10.1007/BF02114973; HEDRICK PW, 1983, GENETICS, V104, P449; HEDRICK PW, 1988, GENETICS, V119, P205; HILL AVS, 1991, LANCET, V337, P640, DOI 10.1016/0140-6736(91)92452-8; HILL AVS, IN PRESS MOL EVOLUTI; HOFFMAN SL, 1989, SCIENCE, V244, P1078, DOI 10.1126/science.2524877; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; KLEIN J, 1987, HUM IMMUNOL, V19, P155, DOI 10.1016/0198-8859(87)90066-8; KLITZ W, 1986, AM J HUM GENET, V39, P340; KWIATKOWSKI D, 1991, P NATL ACAD SCI USA, V88, P5111, DOI 10.1073/pnas.88.12.5111; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; LAWLOR DA, 1988, NATURE, V335, P268, DOI 10.1038/335268a0; LEE KW, 1990, HUM IMMUNOL, V29, P202; LEE KW, 1990, J IMMUNOL, V145, P3119; LEE TD, 1990, TISSUE ANTIGENS, V35, P64, DOI 10.1111/j.1399-0039.1990.tb01758.x; MARTELL RW, 1989, HUM IMMUNOL, V26, P237, DOI 10.1016/0198-8859(89)90002-5; MARTELL RW, 1990, HUM IMMUNOL, V28, P32, DOI 10.1016/0198-8859(90)90100-4; MCPHERSON GG, 1988, AM J PATHOL, V119, P385; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MOLYNEUX ME, 1989, Q J MED, V71, P441; OKOYE RC, 1985, TISSUE ANTIGENS, V25, P142; PARHAM P, 1988, P NATL ACAD SCI USA, V85, P4005, DOI 10.1073/pnas.85.11.4005; PIAZZA A, 1985, ANN HUM GENET, V49, P47, DOI 10.1111/j.1469-1809.1985.tb01675.x; PLAYFAIR JHL, 1982, BRIT MED BULL, V38, P153, DOI 10.1093/oxfordjournals.bmb.a071752; RESTREPO M, 1988, REV I MED TROP, V30, P323, DOI 10.1590/S0036-46651988000500001; RILEY EM, 1991, PARASITOL TODAY, V7, P5, DOI 10.1016/0169-4758(91)90076-Z; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; RONNINGEN KS, 1990, HUM IMMUNOL, V29, P275, DOI 10.1016/0198-8859(90)90041-M; SCHARF SJ, 1989, P NATL ACAD SCI USA, V86, P6215, DOI 10.1073/pnas.86.16.6215; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; SCHREUDER GMT, 1989, IMMUNOBIOLOGY HLA, V1, P252; SERJEANTSON SW, 1989, TRANSPL P, V21, P598; SERJEANTSON SW, 1989, COLONIZATION PACIFIC, P120; SNELL GD, 1968, FOLIA BIOL-PRAGUE, V14, P335; Sy N E, 1984, Southeast Asian J Trop Med Public Health, V15, P1; TAKAHATA N, 1990, GENETICS, V124, P967; TAKAHATA N, 1981, GENETICS, V98, P427; TIWARI JL, 1985, HLA DISEASE ASS; VRIES RRPD, 1979, J IMMUNOGENET, V6, P271; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; WORDSWORTH BP, 1990, IMMUNOGENETICS, V32, P413; YAMAZAKI K, 1976, J EXP MED, V144, P1324, DOI 10.1084/jem.144.5.1324; [No title captured]	75	1238	1263	1	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					595	600		10.1038/352595a0	http://dx.doi.org/10.1038/352595a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1865923	Bronze			2022-12-01	WOS:A1991GB21100046
J	HOSTETTER, MK; IVERSON, S; THOMAS, W; MCKENZIE, D; DOLE, K; JOHNSON, DE				HOSTETTER, MK; IVERSON, S; THOMAS, W; MCKENZIE, D; DOLE, K; JOHNSON, DE			MEDICAL EVALUATION OF INTERNATIONALLY ADOPTED-CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYTOMEGALO-VIRUS INFECTION; HEPATITIS-B VIRUS; DAY-CARE; TRANSMISSION; TUBERCULOSIS; EPIDEMIOLOGY; PHYSICIANS; PREVALENCE; COUNTRIES; RISKS	Background. Despite many reports of medical illness in children adopted from abroad, there are currently no accepted guidelines for medical evaluation of this population. Methods. Two hundred ninety-three children adopted from 15 countries (mean age, 14.0 months; 55 percent girls) were evaluated by history taking, physical examination, and screening tests for hepatitis B virus (HBV), human immunodeficiency virus type 1, tuberculin reactivity, intestinal parasites, syphilis, excretion of cytomegalovirus, renal disease, and anemia. All but four were seen within one month of their arrival in the United States. Results. Fifty-seven percent of the children (168 of 293) were found to have at least one important medical condition. Eighty-one percent of the diagnoses were established by screening test, rather than by history taking or physical examination. Infectious diseases made up the majority of the medical conditions (73 percent). Serologic testing for hepatitis B surface antigen was positive in 5 percent of the children. Characteristics associated with the acquisition of HBV infection included arrival within the first three years of the study (P = 0.017), Asian origin (P = 0.011), and receipt of a blood transfusion abroad (P = 0.008). Ten children (3 percent) had positive Mantoux skin tests, and four of these had active pulmonary tuberculosis. Tuberculin reactivity was significantly associated with older age (P < 0.001) and lower weight (P = 0.037). Intestinal parasites were isolated from 14 percent of the international adoptees. Non-Korean adoptees were 16 times more likely to be harboring at least one intestinal parasite than were Korean adoptees (P = 0.005). Conclusions. Directed screening tests should be a routine component of the medical evaluation of all children adopted from abroad, regardless of age, sex, or country of origin.	UNIV MINNESOTA, SCH PUBL HLTH, DIV BIOSTAT, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	HOSTETTER, MK (corresponding author), UNIV MINNESOTA, DEPT PEDIAT, INT ADOPT CLIN, UMHC BOX 296, 420 DELAWARE ST SE, MINNEAPOLIS, MN 55455 USA.							AACH RD, 1987, TXB PEDIATRIC INFECT, V1, P718; ADLER SP, 1988, J PEDIATR-US, V112, P366, DOI 10.1016/S0022-3476(88)80314-7; BASS JL, IN PRESS PEDIATRICS; BLACK RE, 1977, PEDIATRICS, V60, P486; BLACKMAN JA, 1987, PEDIATR INFECT DIS J, V6, P1011, DOI 10.1097/00006454-198706110-00001; CHRISTENSON B, 1986, SCAND J INFECT DIS, V18, P105, DOI 10.3109/00365548609032315; FRIEDE A, 1988, AM J PUBLIC HEALTH, V78, P26, DOI 10.2105/AJPH.78.1.26; GREENBLATT M, 1985, NEW ENGL J MED, V312, P1639; HERSHOW RC, 1987, PEDIATR INFECT DIS J, V6, P431, DOI 10.1097/00006454-198705000-00002; HOSTETTER M, 1989, AM J DIS CHILD, V143, P325, DOI 10.1001/archpedi.1989.02150150079022; HOSTETTER MK, 1989, PEDIATRICS, V83, P559; HOSTETTER MK, 1989, PEDIATRICS, V84, P936; JACKSON JB, 1990, J CLIN MICROBIOL, V28, P16, DOI 10.1128/JCM.28.1.16-19.1990; JENISTA JA, 1987, AM J DIS CHILD, V141, P298, DOI 10.1001/archpedi.1987.04460030076029; KAUNITZ AM, 1987, JAMA-J AM MED ASSOC, V258, P3537, DOI 10.1001/jama.258.24.3537; LANGE WR, 1989, PEDIATR INFECT DIS J, V8, P625, DOI 10.1097/00006454-198909000-00012; LANGE WR, 1987, PEDIATR INFECT DIS J, V6, P447, DOI 10.1097/00006454-198705000-00006; MURPH JR, 1988, AM J DIS CHILD, V142, P843, DOI 10.1001/archpedi.1988.02150080049020; NORDENFELT E, 1978, SCAND J INFECT DIS, V10, P161, DOI 10.3109/inf.1978.10.issue-3.01; PASS RF, 1987, NEW ENGL J MED, V316, P1366, DOI 10.1056/NEJM198705283162203; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; SCHULZER M, 1987, INT J EPIDEMIOL, V16, P584, DOI 10.1093/ije/16.4.584; Smith-Garcia T, 1989, J Community Health, V14, P227, DOI 10.1007/BF01338874; SOBESLAVSKY O, 1980, B WORLD HEALTH ORGAN, V58, P621; VERNON TM, 1976, JAMA-J AM MED ASSOC, V235, P2829, DOI 10.1001/jama.235.26.2829; WALPOLE RE, 1982, INTRO STATISTICS, P40; WESSEL MA, 1960, NEW ENGL J MED, V262, P446, DOI 10.1056/NEJM196003032620906; WHITE NH, 1989, J INFECT DIS, V159, P1013, DOI 10.1093/infdis/159.6.1013; 1985, MMWR, V34, P313; 1985, ADOPTION FACTBOOK, P126; 1990, STATISTICAL ABSTRACT, P835; 1985, MMWR, V34, P329; 1988, PEDIATRICS, V82, P941; 1983, MEASURING CHANGE NUT, P75; 1990, MMWR, V39, P1	35	119	120	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					479	485		10.1056/NEJM199108153250706	http://dx.doi.org/10.1056/NEJM199108153250706			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1649404				2022-12-01	WOS:A1991GA76300006
J	LANG, DM; ALPERN, MB; VISINTAINER, PF; SMITH, ST				LANG, DM; ALPERN, MB; VISINTAINER, PF; SMITH, ST			INCREASED RISK FOR ANAPHYLACTOID REACTION FROM CONTRAST-MEDIA IN PATIENTS ON BETA-ADRENERGIC BLOCKERS OR WITH ASTHMA	ANNALS OF INTERNAL MEDICINE			English	Article							ADVERSE REACTIONS; BLOCKADE; IMMUNOTHERAPY; ANTAGONISTS; HISTAMINE; HYPERSENSITIVITY; EPINEPHRINE; EXERCISE; RELEASE; AGENTS	Objective: To determine whether greater risk for anaphylactoid reaction from intravenous urographic contrast media exists in patients receiving beta-adrenergic blockers or in asthmatic patients. Design: Case-control study. Setting: Tertiary care, referral-based medical center. Patients: Of 28 978 intravenous urographic contrast media procedures done from July 1987 to June 1988, 49 patients experienced moderate to severe anaphylactoid reaction. Medical records from these 49 reactors were compared with those from a control group matched for gender, age, and date and type of contrast study who received intravenous urographic contrast media without adverse reaction. Main Results: Patients exposed to beta-adrenergic blockers or with asthma comprised 39% (19 of 49) of reactors, compared to 16% (13 of 83) of matched controls (odds ratio, 3.43; 95% Cl, 1.45 to 8.15; P = 0.005). Exposure to beta-blockers was 27% among reactors and 12% in matched controls (odds ratio, 2.67; Cl, 1.01 to 7.05; P = 0.036). Asthma was found in 12% of reactors and 4% of controls; after correction for beta-blocker use, asthma was also associated with increased risk for anaphylactoid reaction (odds ratio, 4.54; Cl, 1.03 to 20.05; P = 0.046). Compared with nonasthmatic patients not taking beta-blockers, asthmatic patients were at greater risk for anaphylactoid reaction with bronchospasm (P = 0.02). Five of 13 reactors receiving beta-blockers became hypotensive, and three needed hospitalization. Compared with nonasthmatic patients not taking beta-blockers, patients exposed to beta-blocking drugs were almost nine times (odds ratio, 8.7; Cl, 0.81 to 93.5; P = 0.075) more likely to be hospitalized after an anaphylactoid reaction. Conclusion: Increased risk for moderate to severe anaphylactoid reaction from intravenous urographic contrast media exists in patients receiving beta-adrenergic blockers or with asthma. These patients are appropriate target populations for efforts to reduce risk before intravenous urographic contrast media are administered.	HENRY FORD HOSP, DETROIT, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital				Visintainer, Paul/0000-0002-2491-1242				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; ANSELL G, 1980, INVEST RADIOL, V15, pS32, DOI 10.1097/00004424-198011001-00010; AWAI LE, 1984, ANN ALLERGY, V53, P48; BARRETTBEE K, 1978, BIOCHEM BIOPH RES CO, V84, P998, DOI 10.1016/0006-291X(78)91682-0; BENITAH E, 1986, THERAPIE, V41, P139; BERKELMAN RL, 1986, ANN INTERN MED, V104, P134, DOI 10.7326/0003-4819-104-1-134_1; BUTCHERS PR, 1980, BRIT J PHARMACOL, V71, P663, DOI 10.1111/j.1476-5381.1980.tb10987.x; CAPELLIER G, 1989, PRESSE MED, V18, P181; CORNAILLE G, 1985, PRESSE MED, V14, P790; DAVIS PB, 1986, J ALLERGY CLIN IMMUN, V77, P667, DOI 10.1016/0091-6749(86)90406-9; ENRIGHT T, 1989, ANN ALLERGY, V62, P302; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; FRISHMAN WH, 1988, MED CLIN N AM, V72, P37, DOI 10.1016/S0025-7125(16)30786-6; GREENBERGER PA, 1985, ARCH INTERN MED, V145, P2197, DOI 10.1001/archinte.145.12.2197; GREENBERGER PA, 1987, J ALLERGY CLIN IMMUN, V80, P698, DOI 10.1016/0091-6749(87)90290-9; HAAS F, 1988, AM REV RESPIR DIS, V137, P833, DOI 10.1164/ajrccm/137.4.833; HAMILTON G, 1985, CAN MED ASSOC J, V133, P122; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; HIATT WR, 1985, CLIN PHARMACOL THER, V37, P2, DOI 10.1038/clpt.1985.2; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; JACOBSON PD, 1988, JAMA-J AM MED ASSOC, V260, P1586, DOI 10.1001/jama.260.11.1586; KALIMO K, 1980, ANN ALLERGY, V45, P253; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; KALINER M, 1984, INVEST RADIOL, V19, P116, DOI 10.1097/00004424-198403000-00007; KAPLAN AP, 1989, J ALLERGY CLIN IMMUN, V84, P129, DOI 10.1016/0091-6749(89)90186-3; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; KING BF, 1989, MAYO CLIN PROC, V64, P976, DOI 10.1016/S0025-6196(12)61226-9; KLEINBAUM DG, 1982, LIFETIME LEARNING PU, V53, P379; LARSSON K, 1985, EUR J RESPIR DIS, V66, P1; LASSER EC, 1977, RADIOLOGY, V125, P1; LAXENAIRE M C, 1984, Annales Francaises d'Anesthesie et de Reanimation, V3, P453, DOI 10.1016/S0750-7658(84)80146-X; LIEBERMAN P, 1986, CLIN REV ALLERG, V4, P229; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; MADOWITZ JS, 1979, JAMA-J AM MED ASSOC, V241, P2813, DOI 10.1001/jama.241.26.2813; MATSUMURA Y, 1976, J ALLERGY CLIN IMMUN, V58, P387, DOI 10.1016/0091-6749(76)90119-6; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; MOTULSKY HJ, 1982, NEW ENGL J MED, V307, P18, DOI 10.1056/NEJM198207013070104; NEWMAN BR, 1981, ANN ALLERGY, V47, P35; NISAM MR, 1978, J APPL PHYSIOL, V44, P455, DOI 10.1152/jappl.1978.44.3.455; PSATY BM, 1990, JAMA-J AM MED ASSOC, V263, P1653, DOI 10.1001/jama.263.12.1653; ROSENFIELD AT, 1977, INVEST RADIOL, V12, P295, DOI 10.1097/00004424-197705000-00016; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; SHEREFF RH, 1973, J ALLERGY CLIN IMMUN, V52, P328, DOI 10.1016/0091-6749(73)90091-2; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; SULLIVAN TJ, 1988, CURRENT THERAPY ALLE, V3, P91; SVENTIVANYI A, 1968, J ALLERGY, V42, P203; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; TOOGOOD JH, 1987, CAN MED ASSOC J, V136, P929; TUNG R, 1982, J IMMUNOL, V128, P2067; WILLIAMS ME, 1985, NEW ENGL J MED, V312, P823, DOI 10.1056/NEJM198503283121304; ZALOGA GP, 1986, ANN INTERN MED, V105, P65, DOI 10.7326/0003-4819-105-1-65; 1988, FDA DRUG B       NOV, P30	53	129	134	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					270	276		10.7326/0003-4819-115-4-270	http://dx.doi.org/10.7326/0003-4819-115-4-270			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1677239				2022-12-01	WOS:A1991GA76400005
J	LANGE, C; JUGEL, A; WALTER, J; NOYERWEIDNER, M; TRAUTNER, TA				LANGE, C; JUGEL, A; WALTER, J; NOYERWEIDNER, M; TRAUTNER, TA			PSEUDO DOMAINS IN PHAGE-ENCODED DNA METHYLTRANSFERASES	NATURE			English	Article							TARGET-RECOGNIZING DOMAINS; BACILLUS-SUBTILIS PHAGES; SEQUENCE; ORGANIZATION; RESTRICTION; MOTIFS; SPR	5-Cytosine-DNA-methyltransferases, which are found in many organisms ranging from bacteriophages to mammals, transfer a methyl group from S-adenosylmethionine to the carbon-5 of a cytosine residue in specific DNA target sequences 1. Some phage-encoded methyltransferases methylate more than one sequence: these enzymes contain several independent target-recognizing domains each responsible for recognizing a different site. The amino-acid sequences of these multispecific methyltransferases reveal that some enzymes in addition carry domains that do not contribute to the enzymes' methylation potential, but strongly resemble previously identified target-recognizing domains. Here we show that introducing defined amino-acid alterations into these inactive domains endows these enzymes with additional methylation specificities. Gel retardation analysis demonstrates that these novel methylation specificities correlate with the acquisition of additional DNA-binding potential of the proteins.			LANGE, C (corresponding author), MAX PLANCK INST MOLEC GENET,IHNESTR 73,W-1000 BERLIN 33,GERMANY.							BALGANESH TS, 1987, EMBO J, V6, P3543, DOI 10.1002/j.1460-2075.1987.tb02681.x; BEHRENS B, 1987, EMBO J, V6, P1137, DOI 10.1002/j.1460-2075.1987.tb04869.x; BUHK HJ, 1984, GENE, V29, P51; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANGE C, 1991, GENE, V100, P213, DOI 10.1016/0378-1119(91)90369-M; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; RATCLIFF SW, 1979, MOL GEN GENET, V168, P165, DOI 10.1007/BF00431442; RAZIN A, 1984, DNA METHYLATION BIOC; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TRANBETCKE A, 1986, GENE, V42, P89, DOI 10.1016/0378-1119(86)90153-8; TRAUTNER TA, 1988, NUCLEIC ACIDS RES, V16, P6649, DOI 10.1093/nar/16.14.6649; WILKE K, 1988, EMBO J, V7, P2601, DOI 10.1002/j.1460-2075.1988.tb03110.x	16	27	27	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					645	648		10.1038/352645a0	http://dx.doi.org/10.1038/352645a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1865925				2022-12-01	WOS:A1991GB21100064
J	LLOYD, A; YANCHEVA, N; WASYLYK, B				LLOYD, A; YANCHEVA, N; WASYLYK, B			TRANSFORMATION SUPPRESSOR ACTIVITY OF A JUN TRANSCRIPTION FACTOR LACKING ITS ACTIVATION DOMAIN	NATURE			English	Article							C-JUN; GENE; EXPRESSION; CELLS	THE oncoprotein c-Jun is thought to be a mediator of ras transformation as both its synthesis and activity as a transcription factor are stimulated by ras expression 1,2. But c-Jun co-operates with ras in transformation assays 3, suggesting that they act along different pathways (reviewed in ref. 4). Here we show by means of a dominant-negative mutated transcription factor that c-Jun potentially in conjunction with other factors that interact with it is necessary for transformation by ras. The mutant Jun lacks an activation domain and blocks stimulation of transcription by several oncoproteins, including Ras, v-Src, polyoma middle T, c-Jun and c-Fos, as well as by the tumour promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). The inhibition is specific for motifs that bind Jun: activation of an NF-kappa B/Rel motif is not affected. This Jun mutant acts as an anti-oncogene in ras-transformed cells, generating non-transformed revertants that have acquired anchorage and density-dependent growth, as well as reduced tumorigenicity in vivo. Mutants of other transcription factors designed to inhibit transformation will enable us to study their role in signal transduction.	FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; Kane S E, 1990, Semin Cancer Biol, V1, P127; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; MERCOLA D, 1988, GENE, V72, P253, DOI 10.1016/0378-1119(88)90151-5; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SCHNEIKERT J, 1991, NUCLEIC ACIDS RES, V19, P783, DOI 10.1093/nar/19.4.783; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x	17	181	184	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					632	638		10.1038/352635a0	http://dx.doi.org/10.1038/352635a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1907719				2022-12-01	WOS:A1991GB21100060
J	NATSOULIS, G; BOEKE, JD				NATSOULIS, G; BOEKE, JD			NEW ANTIVIRAL STRATEGY USING CAPSID NUCLEASE FUSION PROTEINS	NATURE			English	Article							VIRUS-LIKE PARTICLES; SACCHAROMYCES-CEREVISIAE; STAPHYLOCOCCAL NUCLEASE; ELEMENT TRANSPOSITION; REVERSE-TRANSCRIPTASE; TY1 TRANSPOSITION; YEAST; GENE; RIBONUCLEASE; EXPRESSION	OVEREXPRESSION of dominant-negative mutants of various viral proteins can result in 'intracellular immunization' (refs 1, 2). Here we describe a new approach to interfering with viral replication in which a nuclease is fused to a capsid component so that the nuclease is encapsidated inside the virion where it can inactivate viral nucleic acid. We used Ty1, a yeast retrotransposon whose transposition closely parallels retroviral replication mechanisms and serves as an easily manipulated model for the retroviral infection process 3. We constructed fusion genes consisting of the region encoding the N-terminal portion of the TYA/TYB open reading frames of retrotransposon Ty1 and either of two different nuclease genes. Ty1-nuclease fusion proteins are targeted to Ty1 virus-like particles, and are active in degrading nucleic acids. A Ty1-barnase fusion protein causes 98-99% reduction in the efficiency of Ty1 transposition in vivo, presumably by degrading encapsidated Ty1 RNA. This strategy, referred to as capsid-targeted viral inactivation, may be useful for interfering with the replication of retroviruses and other viruses.			NATSOULIS, G (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,725 N WOLFE ST,BALTIMORE,MD 21205, USA.							ADAMS SE, 1987, CELL, V49, P111, DOI 10.1016/0092-8674(87)90761-6; ADAMS SE, 1987, NATURE, V329, P68, DOI 10.1038/329068a0; ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; BOEKE JD, 1988, SCIENCE, V239, P280, DOI 10.1126/science.2827308; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BOEKE JD, 1988, MOL CELL BIOL, V8, P1432, DOI 10.1128/MCB.8.4.1432; BOEKE JD, 1989, MOBILE DNA, P335; BRIERLEY C, 1990, NUCLEIC ACIDS RES, V18, P2947, DOI 10.1093/nar/18.10.2947; CUATRECA.P, 1967, J BIOL CHEM, V242, P1541; EICHINGER DJ, 1988, CELL, V54, P955, DOI 10.1016/0092-8674(88)90110-9; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; GARFINKEL DJ, 1985, CELL, V42, P507, DOI 10.1016/0092-8674(85)90108-4; HARTLEY RW, 1989, TRENDS BIOCHEM SCI, V14, P450, DOI 10.1016/0968-0004(89)90104-7; HARTLEY RW, 1988, J MOL BIOL, V202, P913, DOI 10.1016/0022-2836(88)90568-2; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JONES TA, 1990, J VIROL, V64, P2265, DOI 10.1128/JVI.64.5.2265-2279.1990; MARIANI C, 1990, NATURE, V347, P737, DOI 10.1038/347737a0; MELLOR J, 1985, NATURE, V318, P583, DOI 10.1038/318583a0; MOSSAKOWSKA DE, 1989, BIOCHEMISTRY-US, V28, P3843, DOI 10.1021/bi00435a033; MULLER F, 1987, MOL GEN GENET, V207, P421, DOI 10.1007/BF00331610; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; SIKORSKI RS, 1989, GENETICS, V122, P19; TUCKER PW, 1978, MOL CELL BIOCHEM, V22, P67, DOI 10.1007/BF00496235; WEBER DJ, 1990, BIOCHEMISTRY-US, V29, P8632, DOI 10.1021/bi00489a020; WELDON RA, 1990, J VIROL, V64, P4169, DOI 10.1128/JVI.64.9.4169-4179.1990; YOSHINAKA Y, 1985, P NATL ACAD SCI USA, V82, P1618, DOI 10.1073/pnas.82.6.1618; YOSHIOKA K, 1990, EMBO J, V9, P535, DOI 10.1002/j.1460-2075.1990.tb08140.x; YOUNGREN SD, 1988, J MOL CELL BIOL, V8, P1421	29	62	87	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					632	635		10.1038/352632a0	http://dx.doi.org/10.1038/352632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1650915				2022-12-01	WOS:A1991GB21100059
J	NUNNARI, JM; ZIMMERMAN, DL; OGG, SC; WALTER, P				NUNNARI, JM; ZIMMERMAN, DL; OGG, SC; WALTER, P			CHARACTERIZATION OF THE ROUGH ENDOPLASMIC-RETICULUM RIBOSOME-BINDING ACTIVITY	NATURE			English	Article							MICROSOMAL-MEMBRANES; IDENTIFICATION; TRANSLOCATION; PROTEINS	THE rough endoplasmic reticulum membranes of mammalian cells contain specific ribosome-binding sites 1. A purification to apparent homogeneity of a negatively charged protein (ERpl80) of relative molecular mass 180,000 (180 K) was reported which was proposed to function as a rough endoplasmic reticulum ribosome receptor 2 We report here that ribosome-binding site activity quantitatively solubilized from rough endoplasmic reticulum membranes does not cofractionate with ERpl80. By contrast, ribosome-binding site activity fractionates as a much smaller, positively charged protein.			NUNNARI, JM (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Ogg, Stephen/0000-0003-4157-1654				BORGESE N, 1974, J MOL BIOL, V88, P559, DOI 10.1016/0022-2836(74)90408-2; COLLINS PG, IN PRESS J CELL BIOL; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; TAZAWA S, 1991, J BIOCHEM-TOKYO, V109, P89; WALTER P, 1983, METHOD ENZYMOL, V96, P682; YOSHIDA H, 1987, BIOCHEM J, V245, P811, DOI 10.1042/bj2450811	8	31	31	2	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					638	640		10.1038/352638a0	http://dx.doi.org/10.1038/352638a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1650916				2022-12-01	WOS:A1991GB21100061
J	OGAWA, K				OGAWA, K			4 ATP-BINDING SITES IN THE MIDREGION OF THE BETA-HEAVY CHAIN OF DYNEIN	NATURE			English	Article							URCHIN SPERM FLAGELLA; PHOTOSENSITIZED CLEAVAGE; TAU-PROTEIN; FRAGMENT-A; OUTER ARM; SEQUENCE; IRRADIATION; SUBUNITS; ENZYMES; MOTOR	THE 'motor' proteins of eukaryotic cells contain specialized domains that hydrolyse ATP to produce force and movement along a cytoskeletal polymer (actin in the case of the myosin family; microtubules in the case of the kinesin family and dyneins). There are motor-protein superfamilies in which each member has a conserved force-generating domain joined to a different 'tail' which conveys specific attachment properties (see ref. 1 for a review). The minus-end-directed microtubule motors, the dyneins 2, may also constitute a superfamily of force-generating proteins with distinct attachment domains 3. Axonemal outer-arm dynein from sea urchin spermatozoa is a multimeric protein consisting of two heavy chains (alpha and beta) with ATPase activity. three intermediate chains and several light chains 4. Here I report the sequence of cloned complementary DNA encoding the beta-heavy chain of a dynein motor molecule. The predicted amino-acid sequence reveals four ATP-binding consensus sequences in the central domain. The dynein beta-heavy chain is thought to associate transiently with a microtubule during ATP hydrolysis 5, but the ATP-dependent microtubule-binding sequence common to the kinesin superfamily is not found in the dynein beta-heavy chain. These unique features distinguish the dynein beta-heavy chain from other motor protein superfamilies and may be characteristic of the dynein superfamily.			OGAWA, K (corresponding author), NATL INST BASIC BIOL, DEPT CELL BIOL, OKAZAKI, AICHI 444, JAPAN.							GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; GIBBONS IR, 1981, J CELL BIOL, V91, pS107, DOI 10.1083/jcb.91.3.107s; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NISHIKAWA K, 1986, J BIOCHEM-TOKYO, V100, P1043, DOI 10.1093/oxfordjournals.jbchem.a121783; NISHIKAWA K, 1991, METHOD ENZYMOL, V202, P31; OGAWA K, 1975, J BIOL CHEM, V250, P6476; OGAWA K, 1987, EUR J CELL BIOL, V43, P3; OGAWA K, 1990, CELL MOTIL CYTOSKEL, V16, P58, DOI 10.1002/cm.970160108; OGAWA K, 1991, P JPN ACAD B-PHYS, V67, P27, DOI 10.2183/pjab.67.27; OW RA, 1987, J BIOL CHEM, V262, P3409; PFISTER KK, 1984, J BIOL CHEM, V259, P8499; SALE WS, 1988, J CELL BIOL, V107, P1793, DOI 10.1083/jcb.107.5.1793; SALE WS, 1985, J CELL BIOL, V101, P1400, DOI 10.1083/jcb.101.4.1400; TANG WJY, 1982, J BIOL CHEM, V257, P508; TANG WJY, 1987, J BIOL CHEM, V262, P17728; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	21	173	176	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					643	645		10.1038/352643a0	http://dx.doi.org/10.1038/352643a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1830928				2022-12-01	WOS:A1991GB21100063
J	PEREIRA, BJG; MILFORD, EL; KIRKMAN, RL; LEVEY, AS				PEREIRA, BJG; MILFORD, EL; KIRKMAN, RL; LEVEY, AS			TRANSMISSION OF HEPATITIS-C VIRUS BY ORGAN-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; LIVER-DISEASE; RENAL-TRANSPLANTATION; HEPATOCELLULAR-CARCINOMA; HEMODIALYSIS-PATIENTS; CYTOMEGALO-VIRUS; VIRAL-HEPATITIS; ANTIBODIES; RECIPIENTS	Background. Liver disease is a frequent and major complication after organ transplantation. We sought to determine whether hepatitis C virus (HCV) is transmitted by organ transplantation and whether it causes post-transplantation liver disease. Methods. Serum samples from all cadaver organ donors to the New England Organ Bank between 1986 and 1990 were screened retrospectively for antibodies to HCV (anti-HCV) by enzyme-linked immunosorbent assay (ELISA). We reviewed the hospital records of all recipients of organs from anti-HCV-positive donors for evidence of liver disease. Serum samples from recipients obtained before transplantation and during follow-up were analyzed for anti-HCV. Results. Of 716 organ donors, 13 (1.8 percent) were positive for anti-HCV. Their organs (19 kidneys, 6 hearts, and 4 livers) went to 29 recipients. Non-A, non-B hepatitis developed after transplantation in 14 of the 29 (48 percent), for a prevalence 7.4 times the 6.5 percent prevalence after transplantation from untested donors that was previously reported by two institutions in the organ bank (P < 0.0001). The liver disease began a mean of 3.8 months after transplantation and became chronic in 12 patients; the other 2 had subfulminant hepatic failure. Liver disease was more frequent in the patients who had received antilymphocyte preparations (P = 0.04). HCV was the cause of the post-transplantation liver disease in 12 of the 13 recipients (92 percent) for whom serum samples were available. Anti-HCV was detected by ELISA in eight and enzyme immunoassay in one; in three others, HCV RNA was detected by polymerase chain reaction in serum samples obtained after transplantation. Conclusions. Organ transplantation can transmit hepatitis C. This raises serious questions about the continued acceptance of organs from donors positive for anti-HCV.	NEW ENGLAND ORGAN BANK INC,138 HARVARD ST,BROOKLINE,MA 02146									ALTER MJ, 1987, AM J EPIDEMIOL, V125, P133, DOI 10.1093/oxfordjournals.aje.a114496; ANDRES A, 1990, J AM SOC NEPHROL, V1, P754; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; BOYCE NW, 1988, AM J KIDNEY DIS, V11, P307, DOI 10.1016/S0272-6386(88)80135-5; BRAUN WE, 1990, KIDNEY INT, V37, P1363, DOI 10.1038/ki.1990.123; BRUIX J, 1989, LANCET, V2, P1004; CHEESEMAN SH, 1979, NEW ENGL J MED, V300, P1345, DOI 10.1056/NEJM197906143002401; CHEESEMAN SH, 1980, ANN INTERN MED, V93, P39, DOI 10.7326/0003-4819-93-1-39; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1989, LANCET, V2, P1006; Debure A, 1988, Adv Nephrol Necker Hosp, V17, P375; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P743; ESTABAN JI, 1989, LANCET, V2, P294; FERNANDEZ JA, 1990, J AM SOC NEPHROL, V1, P757; GILLI P, 1990, LANCET, V336, P243, DOI 10.1016/0140-6736(90)91766-4; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; HARNETT JD, 1987, TRANSPLANTATION, V44, P369, DOI 10.1097/00007890-198709000-00009; HESS G, 1989, LANCET, V2, P987; JEFFERS LJ, 1990, KIDNEY INT, V38, P320, DOI 10.1038/ki.1990.203; KIDD S, 1990, 8TH INT C VIR BERL; KUBO Y, 1989, NUCLEIC ACIDS RES, V17, P10367, DOI 10.1093/nar/17.24.10367; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAQUAGLIA MP, 1981, TRANSPLANTATION, V32, P504, DOI 10.1097/00007890-198112000-00011; MAHONY JF, 1989, TRANSPLANT P, V21, P1433; MASIH AS, 1988, AM J SURG PATHOL, V12, P362, DOI 10.1097/00000478-198805000-00004; MONDELLI MU, 1990, LANCET, V336, P244; MORTIMER PP, 1989, LANCET, V2, P798; PAR A, 1990, LANCET, V336, P123, DOI 10.1016/0140-6736(90)91644-P; PARFREY PS, 1985, TRANSPLANTATION, V39, P610, DOI 10.1097/00007890-198506000-00007; PARKER RL, 1946, JAMA-J AM MED ASSOC, V131, P95, DOI 10.1001/jama.1946.02870190019005; PEREZROMERO M, 1990, ANN INTERN MED, V113, P411, DOI 10.7326/0003-4819-113-5-411; RIESTRA S, 1990, ANN INTERN MED, V113, P411; ROGGENDORF M, 1989, LANCET, V2, P324; RUBIN RH, 1989, TRANSPL P, V21, P1440; SCHLIPKOTER U, 1990, LANCET, V335, P1409, DOI 10.1016/0140-6736(90)91296-M; SHERLOCK S, 1989, DISEASES LIVER BILIA, V32, P339; SOPKO J, 1978, AM J MED, V64, P139, DOI 10.1016/0002-9343(78)90190-0; TREPO C, 1990, 8TH INT C VIR BERL; WARE AJ, 1979, ANN INTERN MED, V91, P364, DOI 10.7326/0003-4819-91-3-364; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; WEIR MR, 1985, KIDNEY INT, V28, P839, DOI 10.1038/ki.1985.206; WILLIAMS AE, 1990, ANN CLIN LAB SCI, V20, P192; YAMAGUCHI K, 1990, LANCET, V335, P1409; ZELDIS JB, 1990, ANN INTERN MED, V112, P958, DOI 10.7326/0003-4819-112-12-958	45	354	354	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					454	460		10.1056/NEJM199108153250702	http://dx.doi.org/10.1056/NEJM199108153250702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1649402				2022-12-01	WOS:A1991GA76300002
J	POTTS, WK; MANNING, CJ; WAKELAND, EK				POTTS, WK; MANNING, CJ; WAKELAND, EK			MATING PATTERNS IN SEMINATURAL POPULATIONS OF MICE INFLUENCED BY MHC GENOTYPE	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MUS-MUSCULUS; HOUSE MOUSE; POLYMORPHISM; LOCI; OVERDOMINANT; PREFERENCES; RECOGNITION; SELECTION; HUMANS	BECAUSE of the central role of major histocompatibility complex (MHC) genes in immune recognition 1-3, it is often assumed that parasite-driven selection maintains the unprecedented genetic diversity of these genes 4-7. But associations between MHC genotype and specific infectious diseases have been difficult to identify 8,9 with a few exceptions such as Marek's disease 10 and malaria 11. Alternatively, MHC-related reproductive mechanisms such as selective abortion 12-15 and mating preferences 16,17 could be responsible for the diversity. To determine both the nature and strength of selection operating on MHC genes by we have studied components of selection in seminatural populations of mice (Mus musculus domesticus). Here we assess MHC-related patterns of reproduction and early (preweaning) mortality by analysing 1,139 progeny born in nine populations, and 662 progeny from laboratory matings. Reproductive mechanisms, primarily mating preferences, result in 27% fewer MHC-homozygous offspring than expected from random mating. MHC genotype had no detectable influence on neonatal (preweaning) mortality. These mating preferences are strong enough to account for most of the MHC genetic diversity found in natural populations of Mus.	UNIV WASHINGTON,DEPT PSYCHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	POTTS, WK (corresponding author), UNIV FLORIDA,DEPT PATHOL & LAB MED,MOLEC GENET LAB,GAINESVILLE,FL 32610, USA.			Potts, Wayne/0000-0003-4137-0326				BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BRONSON FH, 1979, Q REV BIOL, V54, P265, DOI 10.1086/411295; BROWN JL, 1983, ETHICAL QUESTIONS BR, P111; CLARKE B, 1966, NATURE, V211, P999, DOI 10.1038/211999a0; DOHERTY PC, 1975, NATURE, V256, P50, DOI 10.1038/256050a0; EGID K, 1989, ANIM BEHAV, V38, P548, DOI 10.1016/S0003-3472(89)80051-X; GILBERT AN, 1986, J COMP PSYCHOL, V100, P262, DOI 10.1037/0735-7036.100.3.262; HAMILTON M, 1978, J REPROD IMMUNOL, V19, P267; HILL AVS, 1991, NATURE, V352; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KARLIN S, 1968, GENETICS, V59, P117; Klein J., 1986, NATURAL HIST MAJOR H; MCCONNELL TJ, 1988, NATURE, V332, P651, DOI 10.1038/332651a0; MELVOLD RW, 1990, TRANSGENIC MICE MUTA; NADEAU JH, 1981, GENET RES, V37, P17, DOI 10.1017/S0016672300019984; NEI M, 1991, EVOLUTION AT THE MOLECULAR LEVEL, P222; PALM J, 1974, CANCER RES, V34, P2061; PARTRIDGE L, 1988, PHILOS T R SOC B, V319, P525, DOI 10.1098/rstb.1988.0063; PAZDERKA F, 1975, IMMUNOGENETICS, V2, P93, DOI 10.1007/BF01572279; POTTS WK, 1990, TRENDS ECOL EVOL, V5, P181, DOI 10.1016/0169-5347(90)90207-T; ROY S, 1989, SCIENCE, V244, P572, DOI 10.1126/science.2470147; SINGH PB, 1987, NATURE, V327, P161, DOI 10.1038/327161a0; TAKAHATA N, 1990, GENETICS, V124, P967; THOMAS ML, 1985, AM J OBSTET GYNECOL, V151, P1053, DOI 10.1016/0002-9378(85)90379-5; TIWARI JL, 1985, HLA DISEASE ASS; Uyenoyama M. K., 1988, EVOLUTION SEX EXAMIN, P212; WEIR BS, 1973, GENET RES, V21, P247, DOI 10.1017/S0016672300013446; WILKINSON GS, 1988, ETHOLOGY, V77, P103; YAMAZAKI K, 1976, J EXP MED, V144, P1324, DOI 10.1084/jem.144.5.1324; YAMAZAKI K, 1979, J EXP MED, V150, P755, DOI 10.1084/jem.150.4.755; YOKOYAMA S, 1979, GENETICS, V91, P609	32	487	499	0	76	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					619	621		10.1038/352619a0	http://dx.doi.org/10.1038/352619a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1865924				2022-12-01	WOS:A1991GB21100055
J	SCHORLE, H; HOLTSCHKE, T; HUNIG, T; SCHIMPL, A; HORAK, I				SCHORLE, H; HOLTSCHKE, T; HUNIG, T; SCHIMPL, A; HORAK, I			DEVELOPMENT AND FUNCTION OF T-CELLS IN MICE RENDERED INTERLEUKIN-2 DEFICIENT BY GENE TARGETING	NATURE			English	Article							EMBRYONIC STEM-CELLS; SEVERE COMBINED IMMUNODEFICIENCY; GERM-LINE TRANSMISSION; MOUSE INTERLEUKIN-2; HPRT GENE; RECEPTOR; ANTIBODY; DIFFERENTIATION; CULTURE	INTERLEUKIN-2 (IL-2) is a lymphocytotropic hormone which is thought to have a key role in the immune response of mammalian cells. It is produced by a subpopulation of activated T-lymphocytes and acts in vitro as the principal auto- and paracrine T-cell growth factor (for reviews see refs 1-3). IL-2 is, however, not the sole T-cell growth factor 4,5, nor does it act exclusively on T cells, also promoting growth of NK cells 6 and differentiation of B cells 7. A role for IL-2 in T-cell development has been postulated but remains controversial 8-12. Here we test the requirement for IL using IL-2-deficient mice generated by targeted recombination. We find that mice homozygous for the IL-2 gene mutation are normal with regard to thymocyte and peripheral T-cell subset composition, but that a dysregulation of the immune system is manifested by reduced polyclonal in vitro T-cell responses and by dramatic changes in the isotype levels of serum immunoglobulins.	UNIV WURZBURG, INST VIROL & IMMUNOBIOL, VERSBACHERSTR 7, W-8700 WURZBURG, GERMANY	University of Wurzburg			Schorle, Hubert/S-1713-2019; Schorle, Hubert/M-5001-2016	Schorle, Hubert/0000-0001-8272-0076				CHAZEN GD, 1989, P NATL ACAD SCI USA, V86, P5923, DOI 10.1073/pnas.86.15.5923; CHENBETTECKEN U, 1985, P NATL ACAD SCI USA, V82, P7384, DOI 10.1073/pnas.82.21.7384; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FUSE A, 1984, NUCLEIC ACIDS RES, V12, P9323, DOI 10.1093/nar/12.24.9323; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JENKINSON EJ, 1987, NATURE, V329, P160, DOI 10.1038/329160a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; MACDONALD HR, 1988, IMMUNOL REV, V104, P157, DOI 10.1111/j.1600-065X.1988.tb00762.x; MOLINARO GA, 1975, EUR J IMMUNOL, V5, P771, DOI 10.1002/eji.1830051108; MOSMANN TR, 1989, PROG IMMUNOL, V7, P611; PAHWA R, 1989, P NATL ACAD SCI USA, V86, P5069, DOI 10.1073/pnas.86.13.5069; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PLUM J, 1988, EUR J IMMUNOL, V18, P795, DOI 10.1002/eji.1830180521; Shortman K, 1990, Semin Immunol, V2, P3; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; TAKACS L, 1984, EUR J IMMUNOL, V14, P1152, DOI 10.1002/eji.1830141217; TENTORI L, 1988, J EXP MED, V168, P1741, DOI 10.1084/jem.168.5.1741; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; TRINCHIERI G, 1984, J EXP MED, V160, P1147, DOI 10.1084/jem.160.4.1147; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZURAWSKI SM, 1988, EMBO J, V7, P1061, DOI 10.1002/j.1460-2075.1988.tb02914.x	29	779	787	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					621	624		10.1038/352621a0	http://dx.doi.org/10.1038/352621a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1830926				2022-12-01	WOS:A1991GB21100056
J	SHARIEF, MK; HENTGES, R				SHARIEF, MK; HENTGES, R			ASSOCIATION BETWEEN TUMOR-NECROSIS-FACTOR-ALPHA AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE-SCLEROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-BRAIN-BARRIER; STATUS SCALE EDSS; CEREBROSPINAL-FLUID; LESIONS; CYCLOPHOSPHAMIDE; PLASMAPHERESIS; ASTROCYTES; EXCHANGE; SERUM; GAMMA	Background. Cachectin, or tumor necrosis factor-alpha (TNF-alpha), is a principal mediator of the inflammatory response and may be important in the pathogenesis and progression of multiple sclerosis, an inflammatory disease of the central nervous system. Methods. In a 24-month prospective study, we used a sensitive enzyme-linked immunosorbent assay to determine levels of TNF-alpha in cerebrospinal fluid and serum in 32 patients with chronic progressive multiple sclerosis and in 20 with stable multiple sclerosis and 85 with other neurologic diseases. An attempt was made to relate TNF-alpha levels with the degree of disability of the patients with multiple sclerosis and with their neurologic deterioration during the 24 months of observation. Results. High levels of TNF-alpha were found in the cerebrospinal fluid of 53 percent of the patients with chronic progressive multiple sclerosis and in none of those with stable multiple sclerosis (P < 0.001). TNF-alpha was detected in the cerebrospinal fluid of 7 percent of the controls (P < 0.01) with other neurologic disease. In patients with chronic progressive multiple sclerosis, mean TNF-alpha levels were significantly higher in the cerebrospinal fluid than in corresponding serum samples (52.41 vs. 11.88 U per milliliter; range, 2 to 178 vs. 2 to 39; P < 0.001). In these patients, cerebrospinal fluid levels of TNF-alpha correlated with the degree of disability (r = 0.834, P < 0.001) and the rate of neurologic deterioration (r = 0.741, P < 0.001) before the start of the study. Cerebrospinal fluid levels also correlated with the increase in neurologic disability after 24 months of observation (r = 0.873, P < 0.001). Conclusions. These data provide evidence of intrathecal synthesis of TNF-alpha in multiple sclerosis and suggest that the level of TNF-alpha in cerebrospinal fluid correlates with the severity and progression of the disease. Our results suggest that TNF-alpha may reflect histologic disease activity in multiple sclerosis and could be used to monitor outcomes or responses to therapy.	FREE UNIV BRUSSELS, DEPT NEUROPSYCHIAT, B-1050 BRUSSELS, BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel	SHARIEF, MK (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, INST NEUROL, DEPT CLIN NEUROCHEM, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							ADAMS CWM, 1989, J NEUROL SCI, V92, P291, DOI 10.1016/0022-510X(89)90144-5; BECK J, 1988, ACTA NEUROL SCAND, V78, P318, DOI 10.1111/j.1600-0404.1988.tb03663.x; BJORVATN B, 1984, BRIT MED J, V288, P439, DOI 10.1136/bmj.288.6415.439; BROSNAN CF, 1988, J NEUROIMMUNOL, V18, P87, DOI 10.1016/0165-5728(88)90137-3; CAMPBELL MJ, 1988, BRIT MED J, V296, P1454, DOI 10.1136/bmj.296.6634.1454; CHUNG IY, 1990, J IMMUNOL, V144, P2999; EBERS GC, 1986, DIS NERV SYST, P1268; FRANCIOTTA DM, 1989, ANN NEUROL, V26, P787, DOI 10.1002/ana.410260618; GALLO P, 1991, J NEUROL SCI, V101, P227, DOI 10.1016/0022-510X(91)90050-H; GAY D, 1991, BRAIN, V114, P557, DOI 10.1093/brain/114.1.557; GOODKIN DE, 1987, ARCH NEUROL-CHICAGO, V44, P823, DOI 10.1001/archneur.1987.00520200027013; HAUSER SL, 1983, NEW ENGL J MED, V308, P173, DOI 10.1056/NEJM198301273080401; HAUSER SL, 1986, ANN NEUROL, V19, P578, DOI 10.1002/ana.410190610; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; JAMES PB, 1989, LANCET, V1, P46; JERSILD C, 1973, LANCET, V2, P1221; KERMODE AG, 1990, BRAIN, V113, P1477, DOI 10.1093/brain/113.5.1477; KHATRI BO, 1985, NEUROLOGY, V35, P312, DOI 10.1212/WNL.35.3.312; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LUXTON RW, 1989, CLIN CHEM, V35, P1731; MAIMONE D, 1991, J NEUROIMMUNOL, V32, P67, DOI 10.1016/0165-5728(91)90073-G; MCCULLAGH P, 1983, GENERALIZED LINEAR M, P99; MCLAUGHLIN PJ, 1990, IMMUNOL CELL BIOL, V68, P51, DOI 10.1038/icb.1990.7; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MINTZ M, 1989, AM J DIS CHILD, V143, P771, DOI 10.1001/archpedi.1989.02150190021012; MUSTAFA M M, 1989, Pediatric Infectious Disease Journal, V8, P907, DOI 10.1097/00006454-198912000-00037; MUSTAFA MM, 1989, J PEDIATR-US, V115, P208, DOI 10.1016/S0022-3476(89)80067-8; NOSEWORTHY JH, 1990, NEUROLOGY, V40, P971, DOI 10.1212/WNL.40.6.971; NOSEWORTHY JH, 1991, LANCET, V337, P441; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; POSER S, 1982, ACTA NEUROL SCAND, V66, P355; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; ROBERTSON B, 1988, J IMMUNOL, V140, P4300; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SLUNGAARD A, 1990, J EXP MED, V171, P2025, DOI 10.1084/jem.171.6.2025; TOURTELLOTTE WW, 1978, NEUROLOGY, V28, P76, DOI 10.1212/WNL.28.9_Part_2.76; TOURTELLOTTE WW, 1988, J NEUROIMMUNOL, V20, P217, DOI 10.1016/0165-5728(88)90163-4; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; TROTTER JL, 1989, ANN NEUROL, V25, P172, DOI 10.1002/ana.410250211; WAKSMAN BH, 1984, P SOC EXP BIOL MED, V175, P282; WALKER RWH, 1983, J NEUROIMMUNOL, V4, P141, DOI 10.1016/0165-5728(83)90018-8; WOLINSKY JS, 1990, ANN NEUROL, V27, P591	43	710	731	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					467	472		10.1056/NEJM199108153250704	http://dx.doi.org/10.1056/NEJM199108153250704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1852181	Bronze			2022-12-01	WOS:A1991GA76300004
J	TABCHARANI, JA; CHANG, XB; RIORDAN, JR; HANRAHAN, JW				TABCHARANI, JA; CHANG, XB; RIORDAN, JR; HANRAHAN, JW			PHOSPHORYLATION-REGULATED CL- CHANNEL IN CHO CELLS STABLY EXPRESSING THE CYSTIC-FIBROSIS GENE	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CHLORIDE CHANNEL; CAMP; TOXIN	A CYCLIC AMP-stimulated chloride conductance appears when the cystic fibrosis gene is expressed in non-epithelial cells by infection with recombinant viruses 1,2. Cyclic AMP-stimulated conductance in this system is mediated by the same ohmic, low-conductance Cl- channel as in human secretory epithelia 2-4, but control of this channel by phosphorylation has not been directly demonstrated. Here we report the appearance of the low-conductance Cl- channel in Chinese hamster ovary cells after stable transfection with the cystic fibrosis gene. The channel is regulated on-cell by membrane-permeant analogues of cAMP and off-cell by protein kinases A and C and by alkaline phosphatase. These results are further evidence that the cystic fibrosis transmembrane regulator is a Cl- channel which can be activated by specific phosphorylation events and inactivated by dephosphorylation; they reveal an unsuspected synergism between converging kinase regulatory pathways.	MCGILL UNIV, DEPT PHYSIOL, 3655 DRUMMOND ST, MONTREAL H3G 1Y6, QUEBEC, CANADA; UNIV TORONTO, TORONTO M5S 1A1, ONTARIO, CANADA; HOSP SICK CHILDREN, RES INST, TORONTO M5G 1X8, ONTARIO, CANADA	McGill University; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Hanrahan, John/AGG-1926-2022	Hanrahan, John/0000-0001-9080-2039				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRUM G, 1983, PFLUG ARCH EUR J PHY, V398, P147, DOI 10.1007/BF00581064; CHANG EB, 1985, AM J PHYSIOL, V249, pC356, DOI 10.1152/ajpcell.1985.249.3.C356; COHEN P, 1989, REV BIOCH, V58, P453; FONDACARO JD, 1985, AM J PHYSIOL, V249, pG422, DOI 10.1152/ajpgi.1985.249.3.G422; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HARDIE G, 1988, NATURE, V335, P592, DOI 10.1038/335592a0; HERSCHELER J, 1987, EUR J BIOCHEM, V165, P261; JAHR H, 1988, EUR J BIOCHEM, V178, P535; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LACERDA AE, 1988, NATURE, V335, P245; LEVITAN IB, 1990, ADV SEC MESS PHOSPH, V24, P36; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHENOLIKAR S, 1991, ADV 2ND MESSENGER PH, V23, P1; SHUSTER MJ, 1985, NATURE, V313, P392, DOI 10.1038/313392a0; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O	20	527	539	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					628	631		10.1038/352628a0	http://dx.doi.org/10.1038/352628a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1714039				2022-12-01	WOS:A1991GB21100058
J	CASTELLANO, AR; NETTLEMAN, MD				CASTELLANO, AR; NETTLEMAN, MD			COST AND BENEFIT OF SECONDARY PROPHYLAXIS FOR PNEUMOCYSTIS-CARINII PNEUMONIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; TRIMETHOPRIM-SULFAMETHOXAZOLE; AIDS; PENTAMIDINE; PREVENTION	Objective.-To determine the relative cost and benefit of aerosolized pentamidine and the combination product of sulfamethoxazole and trimethoprim sulfate as secondary prophylaxis for Pneumocystis carinii pneumonia. Design.-A Markov-based cost-benefit analysis was performed. Drug efficacies, toxicities, and mortality rates were drawn from the current literature. Setting.-Hypothetical. Patient Population.-Patients infected with the human immunodeficiency virus who had had at least one episode of P carinii pneumonia. Interventions.-Regimen 1 required the use of aerosolized pentamidine as the sole first-line prophylactic agent in all patients. Regimen 2 required the use of sulfamethoxazole-trimethoprim in all patients who had no history of a toxic reaction to the drug; only patients with a history of toxic effects and those who developed toxic effects while receiving the drug would receive aerosolized pentamidine. Regimen 3 required that no secondary prophylaxis be given. Main Outcome Measures.-Net cost, median patient survival, and 5-year survival for each regimen and for regimens 1 and 2 compared with regimen 3. Main Results.-Regimen 2 was dominant, with a net cost of $6332 per patient and a median survival of 2.050 years. Compared with no prophylaxis, regimen 2 resulted in a savings of $16 503 per patient and a 0.696-year increase in median survival. Compared with regimen 1, regimen 2 resulted in a savings of $2904 and a 0.067-year increase in median survival. Conclusions.-Secondary prophylaxis for P carinii saves money and extends survival. Current data suggest that sulfamethoxazole-trimethoprim should be given whenever it can be tolerated. Use of aerosolized pentamidine as a first-line agent would result in a modest increase in cost and a decrease in life expectancy.	UNIV IOWA,COLL MED,IOWA CITY,IA 52242	University of Iowa								BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BERNARD E, 1988, 4TH INT C AIDS STOCK, P420; BERNARD EM, 1987, CLIN RES, V35, pA468; BIRGITTE NJ, 1989, 5TH INT C AIDS MONTR, P296; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; CLOTET B, 1990, 6TH INT C AIDS SAN F, P225; CONTE JE, 1988, 4TH INT C AIDS STOCK, P419; CORCKERY KJ, 1988, RESPIR CARE, V33, P676; CREIGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; Friedberg G, 1988, J Palliat Care, V4, P38; GABIN SJ, 1988, 4TH INT C AIDS STOCK, P419; GOLDEN JA, 1989, LANCET, V1, P654; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; KAPLAN LD, 1985, CLIN RES, V33, pA406; KELLY J, 1990, 6TH INT C AIDS SAN F, P225; KEYES C, 1989, 5TH INT C AIDS MONTR, P295; KOVACS JA, 1988, J INFECT DIS, V158, P254, DOI 10.1093/infdis/158.1.254; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; LANG OS, 1989, 5TH INT C AIDS MONTR, P196; LEOUNG GS, 1988, 4TH INT C AIDS STOCK, P419; LEOUNG GS, 1989, 5TH INT C AIDS MONTR, P299; MASUR H, 1989, PRINCIPLES PRACTICE, P3; MEDINA I, 1987, 27TH INT C ANT AG CH, P261; METROKA CE, 1989, 5TH INT C AIDS MONTR, P196; MOON MW, 1989, 5TH INT C AIDS MONTR, P298; NETTLEMAN MD, 1988, INFECT CONT HOSP EP, V9, P88, DOI 10.2307/30144149; NIELSEN TL, 1990, 6TH INT C AIDS SAN F, P225; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; RUSKIN J, 1991, LANCET, V337, P468, DOI 10.1016/0140-6736(91)93402-U; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; SHAFER RW, 1989, J ACQ IMMUN DEF SYND, V2, P389; SMITH DE, 1988, 4TH INT C AIDS STOCK, P418; STASZEWSKI S, 1989, 5TH INT C AIDS MONTR, P299; TORRES R, 1990, 6TH INT AIDS C SAN F, P223; TORRES RA, 1989, 5TH INT C AIDS MONTR, P299; VANGUNDY KP, 1988, 4TH INT C AIDS STOCK, P420; WEINKE T, 1988, 4TH INT C AIDS STOCK, P421; Weinstein MC, 1980, CLIN DECISION ANAL; WEISMAN J, 1989, 5TH INT C AIDS MONTR, P219; WHARTON JM, 1986, ANN INTERN MED, V105, P37, DOI 10.7326/0003-4819-105-1-37; WOFSY CB, 1987, REV INFECT DIS, V9, pS184; 1989, MMWR SS5, V38, P1	44	44	44	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					820	824		10.1001/jama.266.6.820	http://dx.doi.org/10.1001/jama.266.6.820			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1907671				2022-12-01	WOS:A1991GA07300034
J	CHUTE, CG; CHUANG, TY; BERGSTRALH, EJ; SU, WPD				CHUTE, CG; CHUANG, TY; BERGSTRALH, EJ; SU, WPD			THE SUBSEQUENT RISK OF INTERNAL CANCER WITH BOWENS DISEASE - A POPULATION-BASED STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CELL CARCINOMA; MALIGNANCY; DERMATOMYOSITIS; ROCHESTER; MINNESOTA	Objective.-To address the subsequent risk of internal cancer in a population-based cohort of patients with Bowen's disease. Design.-Incident cases of skin cancers other than malignant melanoma occurring in a defined population were classified as basal cell carcinoma, squamous cell carcinoma, or Bowen's disease. Through medical records, all patients were followed up for the development of subsequent internal cancer until they died, moved from Rochester, Minn, or January 1, 1986, whichever came first. Incidence rates of skin cancer and subsequent cancer were computed; the subsequent rate of internal cancer was compared with that prevailing in the community Patients.-Enrolled were all permanent residents in the population base of Rochester, Minn, who developed basal cell carcinoma (n = 657), squamous cell carcinoma (n = 169), or Bowen's disease (n = 71) on the basis of pathologic examination and clinical presentation from 1976 through 1984. Main Outcome Measure.-The relative risk of subsequent internal cancer among patients with Bowen's disease compared with that of the population base from which they arose was 1.1 (95% confidence limits, 0.5, 1.6). Results.-Annual incidence rates, adjusted to the 1980 US white population, were 14.9 per 100 000 for Bowen's disease, 38.8 for squamous cell carcinoma, and 146 for basal cell carcinoma. The estimated relative risk for subsequent cancer was 0.9 (95% confidence limits, 0.5, 1.6) among patients with squamous cell carcinoma and 1.0 (95% confidence limits, 0.7, 1.3) for patients with basal cell carcinoma. These risks were not significantly different for various durations of follow-up or for sun-exposed vs sun-protected sites. Conclusions.-We find no evidence in these population-based cohort data of an increased risk of subsequent internal cancer associated with Bowen's disease or other forms of nonmelanomatous skin cancer.	WRIGHT STATE UNIV,DEPT DERMATOL,4100 W 3RD ST,BLDG 307,ROOM 128,DAYTON,OH 45428; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT DERMATOL,ROCHESTER,MN 55905	Wright State University Dayton; Mayo Clinic; Mayo Clinic					NIAMS NIH HHS [AR30582] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSEN SL, 1973, ARCH DERMATOL, V108, P367, DOI 10.1001/archderm.108.3.367; ARBESMAN H, 1987, JAMA-J AM MED ASSOC, V257, P516, DOI 10.1001/jama.257.4.516; BARNES BE, 1976, ANN INTERN MED, V84, P68, DOI 10.7326/0003-4819-84-1-68; BERKSON J, 1946, BIOMETRICS BULL, V2, P47, DOI 10.2307/3002000; CALLEN JP, 1980, ARCH DERMATOL, V116, P422, DOI 10.1001/archderm.116.4.422; CALLEN JP, 1988, ARCH DERMATOL, V124, P675, DOI 10.1001/archderm.124.5.675; CHUANG TY, 1988, J AM ACAD DERMATOL, V19, P47, DOI 10.1016/S0190-9622(88)70150-4; CHUANG TY, 1990, J AM ACAD DERMATOL, V22, P413, DOI 10.1016/0190-9622(90)70056-N; CHUANG TY, 1990, ARCH DERMATOL, V126, P185, DOI 10.1001/archderm.126.2.185; CHUANG TY, 1990, AM J PREV MED, V6, P238, DOI 10.1016/S0749-3797(18)31010-9; EEDY DJ, 1987, BRIT J DERMATOL, V117, P715, DOI 10.1111/j.1365-2133.1987.tb07351.x; EPSTEIN E, 1960, ARCH DERMATOL, V80, P349; GRAHAM JH, 1959, ARCH DERMATOL, V80, P133, DOI 10.1001/archderm.1959.01560200001001; GRAHAM JH, 1961, ARCH DERMATOL, V83, P738, DOI 10.1001/archderm.1961.01580110026004; HAYNES HA, 1983, HARRISONS PRINCIPLES, P829; HUGO NE, 1967, PLAST RECONSTR SURG, V39, P190, DOI 10.1097/00006534-196702000-00011; ISSELBACHER KJ, 1980, HARRISONS PRINCIPLES, V1, P802; JOHNSON ML, 1982, CECIL TXB MED, P1029; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; KURLAND LT, 1973, USES EPIDEMIOLOGY PL, P164; LAKHANPAL S, 1986, MAYO CLIN PROC, V61, P645, DOI 10.1016/S0025-6196(12)62030-8; MARFING TE, 1987, DIS COLON RECTUM, V30, P782, DOI 10.1007/BF02554627; MIKI Y, 1982, J AM ACAD DERMATOL, V6, P26, DOI 10.1016/S0190-9622(82)70003-9; MYERS M, 1980, NIH802044 PUBL, P53; PETERKA ES, 1961, ARCH DERMATOL, V84, P623, DOI 10.1001/archderm.1961.01580160087015; RAGOZZINO MW, 1982, NEW ENGL J MED, V307, P393, DOI 10.1056/NEJM198208123070701; RAGOZZINO MW, 1984, MAYO CLIN P, V59, P720; REES JL, 1988, BRIT J DERMATOL, V119, P113; REYMANN F, 1988, ARCH DERMATOL, V124, P677, DOI 10.1001/archderm.124.5.677; SCHROEDER DJ, 1982, MAYO CLIN TECH REP S; Stone J L, 1986, Hawaii Med J, V45, P281; THESTRUPPEDERSEN K, 1988, ACTA DERM-VENEREOL, V68, P236	32	55	55	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					816	819		10.1001/jama.266.6.816	http://dx.doi.org/10.1001/jama.266.6.816			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865520				2022-12-01	WOS:A1991GA07300033
J	HOOFNAGLE, JH				HOOFNAGLE, JH			THROMBOCYTOPENIA DURING INTERFERON ALFA THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CHRONIC HEPATITIS; ALPHA-INTERFERON				HOOFNAGLE, JH (corresponding author), NIH,BETHESDA,MD 20892, USA.							ALEXANDER GJM, 1987, LANCET, V2, P66; HOOFNAGLE JH, 1988, GASTROENTEROLOGY, V95, P1318, DOI 10.1016/0016-5085(88)90367-8; MAYET WJ, 1989, HEPATOLOGY, V10, P24, DOI 10.1002/hep.1840100106; PERRILLO RP, 1990, NEW ENGL J MED, V323, P337	4	35	35	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					849	849		10.1001/jama.266.6.849	http://dx.doi.org/10.1001/jama.266.6.849			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865526				2022-12-01	WOS:A1991GA07300042
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND FOR DIDEOXYCYTIDINE (DDC)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					769	769						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865513				2022-12-01	WOS:A1991GA07300009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND FOR PURGING USE IN AUTOLOGOUS BONE-MARROW TRANSPLANTS FOR ACUTE MYELOGENOUS LEUKEMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					769	769						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865513				2022-12-01	WOS:A1991GA07300008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PUBLIC MEETING ON DIETARY-SUPPLEMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							1991, FED REG         0716, V56, P32436	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					769	769						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865513				2022-12-01	WOS:A1991GA07300006
J	NIGHTINGALE, SL				NIGHTINGALE, SL			INGREDIENT LABELING PROPOSAL PUBLISHED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							FED REGISTER, V56, P28592	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					769	769						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865513				2022-12-01	WOS:A1991GA07300007
J	NOVELLO, AC; CLINTON, JJ; WISE, PH; MITCHELL, WI				NOVELLO, AC; CLINTON, JJ; WISE, PH; MITCHELL, WI			CARING FOR CHILDREN WITH HIV-INFECTION - THE NEED FOR A COMMON EMBRACE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									OFF SURGEON GEN,HUBERT H HUMPHREY BLDG,ROOM 718-E,WASHINGTON,DC 20201									NOVELLO AC, GUIDE FAMILY CTR COM	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					770	770						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865514				2022-12-01	WOS:A1991GA07300010
J	AYLETT, M; KETCHIN, S				AYLETT, M; KETCHIN, S			STOPPING TREATMENT IN PATIENTS WITH HYPERTENSION	BRITISH MEDICAL JOURNAL			English	Article											AYLETT, M (corresponding author), GLENDALE SURG,WOOLER NE71 6DN,NORTHD,ENGLAND.							BERGLUND G, 1976, BRIT MED J, V2, P554, DOI 10.1136/bmj.2.6035.554; HART JT, 1987, HYPERTENSION, P132; SAUNDERS JB, 1987, BRIT MED J, V294, P1045, DOI 10.1136/bmj.294.6579.1045; WETHERALL DJ, 1987, OXFORD TXB MED, V13, P360; 1989, BMJ, V298, P694	5	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					345	345		10.1136/bmj.303.6798.345	http://dx.doi.org/10.1136/bmj.303.6798.345			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1912776	Bronze, Green Published			2022-12-01	WOS:A1991GA60600022
J	BINGHAM, S				BINGHAM, S			DIETARY ASPECTS OF A HEALTH STRATEGY FOR ENGLAND	BRITISH MEDICAL JOURNAL			English	Article											BINGHAM, S (corresponding author), MRC,DUNN CLIN NUTR CTR,CAMBRIDGE CB2 1QL,ENGLAND.							BINGHAM S, 1990, DIET CANCER BRIEFING; BRETT A, 1986, HUM NUTR-APPL NUTR, V40A, P217; BUSS DH, 1988, P NUTR SOC, V47, P295, DOI 10.1079/PNS19880047; Doll R., 1981, J NATL CANCER I, V66, P1192; Gregory F., 1990, DIETARY NUTR SURVEY; KNIGHT I, 1984, HEIGHTS WEIGHTS ADUL; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; LEAN MEJ, 1988, INT J OBESITY, V12, P15; SHAPER AG, 1988, CORONARY HEART DISEA; Willett W, 1990, NUTRITIONAL EPIDEMIO; 1991, DIETARY REFERENCE VA; 1988, DHHS8850210 DEP HLTH; 1990, WHO TECH REP SER, V797; 1991, HLTH NATION; 1988, MONOGRAPH EVALUATION, V44	15	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					353	355		10.1136/bmj.303.6798.353	http://dx.doi.org/10.1136/bmj.303.6798.353			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1823133	Green Published, Bronze			2022-12-01	WOS:A1991GA60600027
J	BIRD, AG; GORE, SM; LEIGHBROWN, AJ; CARTER, DC				BIRD, AG; GORE, SM; LEIGHBROWN, AJ; CARTER, DC			ESCAPE FROM COLLECTIVE DENIAL - HIV TRANSMISSION DURING SURGERY	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD; AIDS		MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2BW,ENGLAND; UNIV EDINBURGH,DIV BIOL SCI B,EDINBURGH EH9 3JN,MIDLOTHIAN,SCOTLAND; ROYAL INFIRM,DEPT ENVIRONM,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	MRC Biostatistics Unit; University of Edinburgh; Royal Infirmary of Edinburgh	BIRD, AG (corresponding author), ROYAL INFIRM,HIV IMMUNOL UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							ARMSTRONG FP, 1987, MIL MED, V152, P414; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BERGLUND O, 1988, AIDS, V2, P51, DOI 10.1097/00002030-198802000-00009; BERKELMAN R, 1990, HIV HLTH CARE WORKER; DECLERCQ A, 1991, BRIT MED J, V302, P51, DOI 10.1136/bmj.302.6767.51; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GERBERT B, 1991, JAMA-J AM MED ASSOC, V265, P1845, DOI 10.1001/jama.265.14.1845; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407; LANGE JMA, 1990, NEW ENGL J MED, V322, P1375, DOI 10.1056/NEJM199005103221907; LOT F, 1990, BEH, V49, P207; MANNING S, 1991, J MED DEF UNION, V2, P43; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; SACKS JJ, 1985, NEW ENGL J MED, V313, P1017, DOI 10.1056/NEJM198510173131610; SIMMONDS P, 1990, AIDS S1, V4, P577; WELCH J, 1989, LANCET, V1, P205; 1988, AIDS HIV INFECTED HE; 1991, JAMA-J AM MED ASSOC, V265, P1872; 1989, MMWR S56, V1, P3; 1991, MMWR, V40, P377; 1991, MMWR, V40, P21	22	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					351	352		10.1136/bmj.303.6798.351	http://dx.doi.org/10.1136/bmj.303.6798.351			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1912780	Green Published, Bronze			2022-12-01	WOS:A1991GA60600026
J	BRISSONNOEL, A; AZNAR, C; CHUREAU, C; NGUYEN, S; PIERRE, C; BARTOLI, M; BONETE, R; PIALOUX, G; GICQUEL, B; GARRIGUE, G				BRISSONNOEL, A; AZNAR, C; CHUREAU, C; NGUYEN, S; PIERRE, C; BARTOLI, M; BONETE, R; PIALOUX, G; GICQUEL, B; GARRIGUE, G			DIAGNOSIS OF TUBERCULOSIS BY DNA AMPLIFICATION IN CLINICAL-PRACTICE EVALUATION	LANCET			English	Article							POLYMERASE CHAIN-REACTION; MYCOBACTERIUM-TUBERCULOSIS; IDENTIFICATION; SEQUENCE; COMPLEX; IS6110	Various polymerase chain reaction (PCR) assays have been devised for the rapid identification of mycobacteria in clinical specimens. To assess the value of such assays in routine laboratory work the results obtained by PCR were compared with those obtained by standard microbiological methods for 514 specimens collected for investigation of mycobacterial infection. Specimens were tested for the presence of Mycobacterium tuberculosis complex and atypical mycobacteria in two assays, one based on amplification of the 65 kDa gene and the other on the IS6110 insertion sequence. For the 489 samples that did not contain inhibitors of the amplification reaction PCR findings correlated well with bacteriological and/or clinical data in 476 (97.4%). 6 PCR results turned out to be false negatives, 3 to be false positives and 4 to be mis-identification of strains. Pre-treatment of samples with guanidium thiocyanate reduced the proportion of false-negative results and of samples that contained inhibitors. This study confirms the potential of DNA amplification for early diagnosis of mycobacterial infections.	HOP DESGENETTES,LYONS,FRANCE; HOP LOUIS PASTEUR,PARIS,FRANCE; INST PASTEUR,UNITE GENIE MICROBIOL,CNRS,URA 1300,F-75724 PARIS 15,FRANCE; CTR MED EDOUARD RIST,PARIS,FRANCE; INST PASTEUR,DEV BIOL MED LAB,F-75724 PARIS 15,FRANCE; HOP ST ANNE,TOULON,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	BRISSONNOEL, A (corresponding author), DIAGNOST PASTEUR,3 BLVD RAYMOND POINCARE,F-92430 MARNES COQUETTE,FRANCE.							BODDINGHAUS B, 1990, J CLIN MICROBIOL, V28, P1751; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BRISSONNOEL A, 1989, LANCET, V2, P1069; DEWIT D, 1990, J CLIN MICROBIOL, V28, P2437, DOI 10.1128/JCM.28.11.2437-2441.1990; EISENACH KD, 1990, J INFECT DIS, V161, P977, DOI 10.1093/infdis/161.5.977; HANCE AJ, 1989, MOL MICROBIOL, V3, P843, DOI 10.1111/j.1365-2958.1989.tb00233.x; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P1204, DOI 10.1128/JCM.28.6.1204-1213.1990; Maniatis T., 1984, MOL CLONING; MANJUNATH N, 1991, TUBERCLE, V72, P21, DOI 10.1016/0041-3879(91)90020-S; MULLIS KB, 1987, METHOD ENZYMOL, V155, P355; PAO CC, 1990, J CLIN MICROBIOL, V28, P1877, DOI 10.1128/JCM.28.9.1877-1880.1990; SHANKAR P, 1990, LANCET, V335, P423, DOI 10.1016/0140-6736(90)90268-A; SJOBRING U, 1990, J CLIN MICROBIOL, V28, P2200; THIERRY D, 1990, J CLIN MICROBIOL, V28, P2668, DOI 10.1128/JCM.28.12.2668-2673.1990; THIERRY D, 1990, NUCLEIC ACIDS RES, V18, P188, DOI 10.1093/nar/18.1.188	15	273	282	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					364	366		10.1016/0140-6736(91)90492-8	http://dx.doi.org/10.1016/0140-6736(91)90492-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677709				2022-12-01	WOS:A1991GA60700016
J	BROWNER, WS; SEELEY, DG; VOGT, TM; CUMMINGS, SR				BROWNER, WS; SEELEY, DG; VOGT, TM; CUMMINGS, SR			NONTRAUMA MORTALITY IN ELDERLY WOMEN WITH LOW BONE-MINERAL DENSITY	LANCET			English	Article							ESTROGEN REPLACEMENT THERAPY; STROKE-ASSOCIATED MORTALITY; HIP FRACTURE; LONG-TERM; RISK; THIAZIDE; HYPERTENSION; OSTEOPOROSIS; POPULATION; MENOPAUSE	9704 ambulatory women aged 65 years or older were prospectively studied to determine whether low bone mineral density (osteopenia) was associated with mortality. Bone mineral density was measured at entry to the study by single-photon absorptiometry. 299 women died during a mean of 2.8 years' follow-up. Osteopenia was associated with increased non-trauma mortality, probably because it is a marker for several other adverse factors. Each standard deviation decrease in proximal radius bone mineral density (0.104 g/cm2) was associated with a 1.19-fold increase in mortality (95% confidence interval 1.04-1.36), adjusted for age and duration of follow-up. Diminished bone mineral density at the proximal radius was strongly associated with deaths from stroke (relative risk = 1.74; 95% Cl 1.12-2.70), an association that was not confounded by history of previous stroke, hypertension, postmenopausal use of oestrogen, thiazide diuretic treatment, diabetes mellitus, and smoking. Most deaths in women with low bone mineral density are unrelated to the occurrence of fractures-an observation that should be taken into account when estimating the need for and cost-effectiveness of bone-density screening and fracture prevention programmes.	VET AFFAIRS MED CTR,DEPT MED,GEN INTERNAL MED SECT,SAN FRANCISCO,CA; KAISER PERMANENTE CTR HLTH RES,PORTLAND,OR; UNIV CALIF SAN FRANCISCO,DEPT MED,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143	US Department of Veterans Affairs; Veterans Health Administration (VHA); Kaiser Permanente; University of California System; University of California San Francisco	BROWNER, WS (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,PREVENT SCI GRP,74 NEW MONTGOMERY,SUITE 600,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35582] Funding Source: Medline; NIA NIH HHS [AG05407, AG05394] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AITKEN JM, 1987, OSTEOPOROSIS 1987, P45; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BOHANNON RW, 1986, ARCH PHYS MED REHAB, V67, P390; BRICKMAN AS, 1990, HYPERTENSION, V16, P515, DOI 10.1161/01.HYP.16.5.515; BUKOSKI RD, 1990, HYPERTENSION, V16, P523, DOI 10.1161/01.HYP.16.5.523; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; Callaway C., 1988, ANTHROPOMETRIC STAND, P39; CAULEY JA, 1990, AM J EPIDEMIOL, V132, P884, DOI 10.1093/oxfordjournals.aje.a115731; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; COX DR, 1972, J R STAT SOC B, V34, P187; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; DYKEN ML, 1985, 71022A AM HEART ASS; ETTINGER B, 1988, MATURITAS, V10, P271, DOI 10.1016/0378-5122(88)90063-1; FELSON DT, 1991, JAMA-J AM MED ASSOC, V265, P370, DOI 10.1001/jama.265.3.370; FRANKS AL, 1987, AM J OBSTET GYNECOL, V156, P20, DOI 10.1016/0002-9378(87)90196-7; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HENDERSON BE, 1988, FERTIL STERIL, V49, pS9; JACOBSEN SJ, 1990, AM J EPIDEMIOL, V132, P755; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; KHAW KT, 1984, STROKE, V15, P244, DOI 10.1161/01.STR.15.2.244; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LINDSAY R, 1976, LANCET, V1, P1038; MACMAHON SW, 1986, PROG CARDIOVASC DIS, V29, P99, DOI 10.1016/0033-0620(86)90038-1; MELTON LJ, 1988, J CLIN EPIDEMIOL, V41, P985; SCRAGG R, 1990, INT J EPIDEMIOL, V19, P559, DOI 10.1093/ije/19.3.559; SLEMENDA C, 1987, J CLIN INVEST, V80, P1261, DOI 10.1172/JCI113201; TOSTESON ANA, 1990, ANN INTERN MED, V113, P594, DOI 10.7326/0003-4819-113-8-594; WASNICH R, 1990, BRIT MED J, V301, P1303, DOI 10.1136/bmj.301.6764.1303; WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605; 1980, INT CLASSIFICATION D, V1	31	337	348	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					355	358		10.1016/0140-6736(91)90489-C	http://dx.doi.org/10.1016/0140-6736(91)90489-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677708				2022-12-01	WOS:A1991GA60700014
J	CRABTREE, JE; TAYLOR, JD; WYATT, JI; HEATLEY, RV; SHALLCROSS, TM; TOMPKINS, DS; RATHBONE, BJ				CRABTREE, JE; TAYLOR, JD; WYATT, JI; HEATLEY, RV; SHALLCROSS, TM; TOMPKINS, DS; RATHBONE, BJ			MUCOSAL IGA RECOGNITION OF HELICOBACTER-PYLORI 120-KDA PROTEIN, PEPTIC-ULCERATION, AND GASTRIC PATHOLOGY	LANCET			English	Article							CAMPYLOBACTER-PYLORIDIS; C-PYLORIDIS; ULCERS; DISEASE	The gastric IgA response to Helicobacter pylori was examined in 100 dyspeptic patients by means of immunoblotting of supernatants from antral biopsy and gastric mononuclear cell cultures. 76 of 78 patients with chronic gastritis, 2 of 8 with reactive gastritis, and 1 of 14 subjects with normal mucosa showed positive responses. Of patients with chronic gastritis, 75%, 83%, 97%, and 76%, respectively, showed responses to the 120 kDa, 90 kDa, 61 kDa, and 31 kDa proteins. None of the 19 patients with chronic gastritis who did not recognise the 120 kDa protein had peptic ulcers, whereas 25 of 57 with positive recognition had peptic ulcers (p < 0.001). Mucosal recognition of the H pylori 120 kDa protein was also positively associated with the activity of gastritis (polymorph infiltration) (p < 0.002) and with the extent of surface degeneration (p < 0.01). These findings suggest that 120-kDa-positive strains of H pylori have pathogenic features associated with active gastritis and peptic ulceration. infection with 120-kDa-negative strains may explain why peptic ulceration develops in only a proportion of subjects infected with H pylori.	BRADFORD ROYAL INFIRM,DEPT MICROBIOL,BRADFORD,ENGLAND; ST JAMES UNIV HOSP,DEPT PATHOL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND	Bradford Royal Infirmary; Saint James's University Hospital	CRABTREE, JE (corresponding author), ST JAMES UNIV HOSP,DEPT MED,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.		Crabtree, Jean E/A-3549-2010					APEL I, 1988, ZBL BAKT-INT J MED M, V268, P271; ARMITAGE P, 1987, STATISTICAL METHODS; COGHLAN JG, 1987, LANCET, V2, P1109; COVER TL, 1990, INFECT IMMUN, V58, P603, DOI 10.1128/IAI.58.3.603-610.1990; CRABTREE JE, 1989, GUT, V30, P347, DOI 10.1136/gut.30.3.347; CRABTREE JE, 1991, J CLIN PATHOL, V44, P768, DOI 10.1136/jcp.44.9.768; CRABTREE JE, 1991, DIGEST DIS SCI, V44, P768; CRABTREE JE, 1991, GUT, V44, P768; EIDT S, 1990, HELICOBACTER PYLORI, P228; EMERY AEH, 1976, METHODOLOGY MED GENE, P98; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; FIGURA N, 1990, REV ESP ENF DIGES S1, V78, P7; GOODWIN CS, 1987, J INFECT DIS, V155, P488, DOI 10.1093/infdis/155.3.488; HESSEY SJ, 1990, GUT, V31, P134, DOI 10.1136/gut.31.2.134; KALOGEROPOULOS NK, 1988, J CLIN PATHOL, V41, P1093, DOI 10.1136/jcp.41.10.1093; Keenan D.R, 1990, WATSONS BAY LINE SYD; MARSHALL BJ, 1984, LANCET, V1, P1311; MORGAN DR, 1989, CAMPYLOBACTER PYLORI, P115; NEWELL DG, 1987, J GEN MICROBIOL, V133, P163; OMAHONY S, 1991, GUT, V32, P29, DOI 10.1136/gut.32.1.29; RASKOV H, 1987, SCAND J GASTROENTERO, V22, P568, DOI 10.3109/00365528708991899; RAUWS EA, 1988, GASTROENTEROLOGY, V94, P33, DOI 10.1016/0016-5085(88)90606-3; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SHALLCROSS TM, 1989, CAMPYLOBACTER PYLORI, P155; SOBALA GM, 1991, LANCET, P94; VONWULFFEN H, 1988, J CLIN PATHOL, V41, P653, DOI 10.1136/jcp.41.6.653; WYATT JI, 1987, J CLIN PATHOL, V40, P841, DOI 10.1136/jcp.40.8.841	27	593	613	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					332	335		10.1016/0140-6736(91)90477-7	http://dx.doi.org/10.1016/0140-6736(91)90477-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677696				2022-12-01	WOS:A1991GA60700002
J	ECK, HP; STAHLHENNIG, C; HUNSMANN, G; DROGE, W				ECK, HP; STAHLHENNIG, C; HUNSMANN, G; DROGE, W			METABOLIC DISORDER AS EARLY CONSEQUENCE OF SIMIAN IMMUNODEFICIENCY VIRUS-INFECTION IN RHESUS MACAQUES	LANCET			English	Note							GLUTAMATE CONCENTRATION; MACROPHAGES; CYSTEINE; PLASMA	To establish whether the high plasma glutamate and low acid-soluble thiol (mainly cysteine) concentrations previously found in patients with HIV-1 infection are a consequence of the infection or a risk factor for its development, a closely related animal model, rhesus and fascicularis macaques infected with simian immunodeficiency virus (SIV(mac251)), was studied. The 23 infected macaques had significantly lower mean plasma thiol and higher glutamate concentrations than 18 uninfected controls (p < 0.001). The changes were apparent by 1 week after infection. Thus, abnormal plasma glutamate and thiol concentrations are, at least in this model, a direct and early consequence of the retroviral infection.	GERMAN PRIMATE CTR,DEPT VIROL & IMMUNOL,GOTTINGEN,GERMANY	Deutsches Primatenzentrum (DPZ)	ECK, HP (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,INST IMMUNOL & GENET,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY.							BUHL R, 1989, LANCET, V2, P1294; CRANAGE MP, 1990, ANIMAL MODELS AIDS, P103; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DROGE W, 1988, BIOL CHEM H-S, V369, P143, DOI 10.1515/bchm3.1988.369.1.143; DROGE W, 1988, J CANCER RES CLIN, V114, P124, DOI 10.1007/BF00417824; ECK HP, 1989, BIOL CHEM H-S, V370, P109, DOI 10.1515/bchm3.1989.370.1.109; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; FENDRICH C, 1989, AIDS, V3, P305, DOI 10.1097/00002030-198905000-00010; STAHLHENNIG C, 1990, AIDS, V4, P611, DOI 10.1097/00002030-199007000-00001; WATANABE H, 1987, J EXP MED, V165, P628, DOI 10.1084/jem.165.3.628	10	59	60	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					346	347		10.1016/0140-6736(91)90482-5	http://dx.doi.org/10.1016/0140-6736(91)90482-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677701				2022-12-01	WOS:A1991GA60700007
J	FALANGA, V; KIRSNER, RS; EAGLSTEIN, WH; KATZ, MH; KERDEL, FA				FALANGA, V; KIRSNER, RS; EAGLSTEIN, WH; KATZ, MH; KERDEL, FA			STANOZOLOL IN TREATMENT OF LEG ULCERS DUE TO CRYOFIBRINOGENEMIA	LANCET			English	Note								Five consecutive patients with cryofibrinogenaemia in association with painful leg ulcers and intravascular dermal thrombi were treated with stanozolol, an androgenic steroid with fibrinolytic properties. In all patients treatment was followed by rapid and striking pain relief and healing of the ulcers. Cryofibrinogenaemia was not detected on subsequent laboratory evaluation, and dermal intravascular thrombi had resolved on repeat histological examination.			FALANGA, V (corresponding author), UNIV MIAMI,SCH MED,DEPT DERMATOL & CUTANEOUS SURG,POB 016250,MIAMI,FL 33136, USA.			Falanga, Vincent/0000-0003-2292-2017				AYRES ML, 1981, BRIT J SURG, V68, P51, DOI 10.1002/bjs.1800680117; COPEMAN PWM, 1979, BRIT J DERMATOL, V101, P57; JARRETT PEM, 1975, BRIT J SURG, V62, P654; KLEIN AD, 1991, ARCH DERMATOL, V127, P133; KLUFT C, 1984, THROMB HAEMOSTASIS, V51, P157; KORST DR, 1955, BLOOD, V10, P945, DOI 10.1182/blood.V10.9.945.945; MIALE JB, 1977, LABORATORY MED HEMAT, P1047; RACHMILEWITZ EA, 1970, ISRAEL J MED SCI, V6, P32; SMITH SB, 1972, AM J CLIN PATHOL, V58, P524; STATHAKIS NE, 1978, BLOOD, V51, P1211; ZLOTNICK A, 1969, ACTA HAEMATOL-BASEL, V42, P8, DOI 10.1159/000208756	11	50	50	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					347	348		10.1016/0140-6736(91)90483-6	http://dx.doi.org/10.1016/0140-6736(91)90483-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677702				2022-12-01	WOS:A1991GA60700008
J	JEANNEL, D; TUPPIN, P; BRUCKER, G; DANIS, M; GENTILINI, M				JEANNEL, D; TUPPIN, P; BRUCKER, G; DANIS, M; GENTILINI, M			IMPORTED AND AUTOCHTHONOUS KALA-AZAR IN FRANCE	BRITISH MEDICAL JOURNAL			English	Article							VISCERAL LEISHMANIASIS; DISEASE	Objective - To study the epidemiological, clinical, and biological features of imported and autochthonous kala-azar in France. Design-Prospective survey of all patients in France with kala-azar diagnosed over the two years 1986-7. Information was obtained from parasitology laboratories in regional hospitals and all hospital laboratories and haematology departments capable of diagnosing leishmaniasis in the south of France. Setting-107 public hospitals in France. Patients-89 patients with kala-azar. Interventions-All patients were treated with drugs. In the first instance meglumine antimonate was given to all but two patients. Main outcome measures-Prevalence of the various clinical and biological features of kala-azar; proportion of patients with HIV infection. Results-Half (44) of the patients were children under 8 years old. Seventy patients acquired the disease in France. Imported kala-azar was acquired mainly in Mediterranean countries (9/18 cases). Only 46 (52%) of the patients had all three of the classic associated clinical features of fever, splenomegaly, and hepatomegaly. Anaemia was the commonest biological sign, and the association of the four usual biological signs-anaemia, leucopenia, thrombocytopenia, and hypergammaglobulinaemia -was present in only 14 (33%) of the children under 8 and 26 (60%) adults. Fourteen of the patients over 8 years old were infected with HIV. Conclusion-Doctors must be aware of kala-azar in Mediterranean areas, especially as patients often present without the characteristic features and the disease affects young children preferentially.	INST HLTH & DEV,NATL CTR IMPORTED DIS,F-75270 PARIS,FRANCE; HOP LA PITIE SALPETRIERE,DEPT TROP DIS & PARASITOL,F-75651 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite								BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104; BRYCESON ADM, 1985, T ROY SOC TROP MED H, V79, P705, DOI 10.1016/0035-9203(85)90199-3; HEILMANN K, 1971, DEUT MED WOCHENSCHR, V96, P36, DOI 10.1055/s-0028-1108196; HILL FGH, 1975, BRIT MED J, V3, P334; JEANNEL D, 1989, LANCET, V2, P804, DOI 10.1016/S0140-6736(89)90868-4; KILLICKKENDRICK R, 1984, ANN PARASIT HUM COMP, V59, P555, DOI 10.1051/parasite/1984596555; KINMOND S, 1989, LANCET, V2, P325, DOI 10.1016/S0140-6736(89)90502-3; MONTALBAN C, 1987, J INFECTION, V15, P247, DOI 10.1016/S0163-4453(87)92728-9; NEVA FA, 1990, NEW ENGL J MED, V322, P55, DOI 10.1056/NEJM199001043220111; OGUNKOLADE BW, 1988, VET PARASITOL, V28, P33, DOI 10.1016/0304-4017(88)90016-7; PUGIN P, 1968, SCHWEIZ MED WOCHENSC, V93, P1320; QUILICI M, 1987, ANN PEDIATR-PARIS, V34, P369; ROCHA H, 1979, PRINCIPLES PRACTICE, P2210; WHEATLEY T, 1983, J INFECTION, V7, P166, DOI 10.1016/S0163-4453(83)90716-8; 1984, WHO TECH REP SER, V701; 1987, B EPIDEMIOLOGIQUE HE, V7, P3	16	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					336	338		10.1136/bmj.303.6798.336	http://dx.doi.org/10.1136/bmj.303.6798.336			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1912774	Green Published, Bronze			2022-12-01	WOS:A1991GA60600019
J	LOCKYER, MJ				LOCKYER, MJ			PREVALENCE OF MULTIPLE-SCLEROSIS IN 5 RURAL SUFFOLK PRACTICES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine a point prevalence of multiple sclerosis in part of Suffolk. Design-Multiple source search for patients with multiple sclerosis in five general practices. Patients were reviewed and categorised by using general practice notes. Setting-Five rural general practices in Suffolk, 12 May 1988. Subjects-31 379 patients registered with five practices. Main outcome measures-Multiple sclerosis diagnosed by a specialist. Results-The search produced a provisional list of 62 eligible patients with multiple sclerosis. Review of case notes showed that 48 had probable disease, 10 early disease, and four possible disease. The probable cases gave a crude prevalence of 153/100 000 population (95% confidence interval 109/100 000 to 196/100 000). Conclusions-Although the results should be interpreted cautiously because of the small sample size, they suggest that the prevalence of multiple sclerosis in Suffolk is higher than has been estimated from hospital data.			LOCKYER, MJ (corresponding author), IXWORTH SURG,BURY ST EDMUNDS IP31 2HD,SUFFOLK,ENGLAND.							Allison RS, 1954, ULSTER MED J      S2, V23, P5; FOG M, 1966, ACTA NEUROL SCAND, VS 42, P9; OBRIEN B, 1987, MULTIPLE SCLEROSIS; POSKANZER DC, 1963, J NEUROL NEUROSUR PS, V26, P368, DOI 10.1136/jnnp.26.4.368; POSKANZER DC, 1980, J EPIDEMIOL COMMUN H, V34, P229, DOI 10.1136/jech.34.4.229; SHEPHERD DI, 1980, J NEUROL NEUROSUR PS, V43, P310, DOI 10.1136/jnnp.43.4.310	6	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					347	348		10.1136/bmj.303.6798.347	http://dx.doi.org/10.1136/bmj.303.6798.347			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GA606	1912778	Bronze, Green Published			2022-12-01	WOS:A1991GA60600024
J	MCLELLAN, DL				MCLELLAN, DL			REHABILITATION	BRITISH MEDICAL JOURNAL			English	Article											MCLELLAN, DL (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,REHABIL RES UNIT,LEVEL C,W WING,SOUTHAMPTON S09 4XY,ENGLAND.							Alexander J. L., 1979, Evaluation of Efficacy of Medical Action, P287; BEARDSHAW V, 1988, LAST LIST COMMUNITY; CANTRELL E, 1985, PRISONERS HANDICAP; CARPENTER GI, 1990, BMJ-BRIT MED J, V300, P1253, DOI 10.1136/bmj.300.6734.1253; Cornes P, 1991, Int Disabil Stud, V13, P5; EDWARDS FC, 1990, HLTH SERVICES ADULTS; GODFREY HPD, 1988, ARCH PHYS MED REHAB, V69, P458; MCLELLAN DL, 1987, J SOC OCCUP MED, V37, P94; ROBINE JM, 1991, BMJ-BRIT MED J, V302, P457, DOI 10.1136/bmj.302.6774.457; THOMAS AP, 1989, CLIN DEV MED, V106; WILSON BA, 1988, NEUROPSYCHOL REHABIL, P69; 1989, SURVEY DISABILITY GR, V1; 1991, CM1523	13	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					355	357		10.1136/bmj.303.6798.355	http://dx.doi.org/10.1136/bmj.303.6798.355			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1833005	Green Published, Bronze			2022-12-01	WOS:A1991GA60600028
J	NELSON, SR; HAWKINS, PN; RICHARDSON, S; LAVENDER, JP; SETHI, D; GOWER, PE; PUGH, CW; WINEARLS, CG; OLIVER, DO; PEPYS, MB				NELSON, SR; HAWKINS, PN; RICHARDSON, S; LAVENDER, JP; SETHI, D; GOWER, PE; PUGH, CW; WINEARLS, CG; OLIVER, DO; PEPYS, MB			IMAGING OF HEMODIALYSIS-ASSOCIATED AMYLOIDOSIS WITH I-123 SERUM AMYLOID-P COMPONENT	LANCET			English	Article							LONG-TERM HEMODIALYSIS; SYSTEMIC AMYLOIDOSIS; BETA-2-MICROGLOBULIN AMYLOIDOSIS; RENAL-TRANSPLANTATION; DEPOSITS; PROTEIN	Long-term haemodialysis is frequently complicated by amyloid deposition in which the fibrils consist of beta-2-microglobulin. Dialysis-related amyloid disease causes extensive morbidity and has been associated with deaths in some cases. All amyloid deposits contain amyloid P component that is derived from the normal circulating protein, serum amyloid P component (SAP). We have used scintigraphic imaging after injection of I-123-labelled SAP to assess the distribution of amyloidosis in 38 patients receiving long-term haemodialysis for end-stage renal failure. There was focal localisation of tracer at all sites where histological examination confirmed amyloid deposition. Splenic uptake was seen in 12 patients, indicating splenic amyloidosis, but there was no evidence of other visceral involvement. 6 control subjects who had been dialysed for under 1.5 years showed no localisation of tracer, nor was there any uptake of I-123-labelled human serum albumin in 3 long-term dialysis patients with histologically confirmed amyloidosis and positive I-123-SAP images. Negative scans were also obtained in 5 patients who had been transplanted 0.8-2.4 years previously, despite past evidence of dialysis arthropathy (5) and histologically proven amyloidosis (4). I-123-SAP scintigraphy may be helpful as a non-invasive method for both the diagnosis and monitoring of dialysis-associated amyloidosis.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,IMMUNOL MED UNIT,DU CANE RD,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT RADIOL,LONDON W12 0NN,ENGLAND; CHARING CROSS HOSP,DEPT MED,RENAL UNIT,LONDON W6 8RP,ENGLAND; CHURCHILL HOSP,RENAL UNIT,OXFORD OX3 7LJ,ENGLAND	Imperial College London; Imperial College London; Imperial College London; University of Oxford			Hawkins, Philip N/C-5573-2008	Pugh, Chris/0000-0002-5170-1662				BALTZ ML, 1986, CLIN EXP IMMUNOL, V66, P691; CHOI HSH, 1989, GASTROENTEROLOGY, V96, P230, DOI 10.1016/0016-5085(89)90785-3; DESTRIHOU CV, 1990, INT YB NEPHROLOGY, P217; FLOEGE J, 1989, NEPHRON, V51, P444, DOI 10.1159/000185351; FLOEGE J, 1990, KIDNEY INT, V38, P1169, DOI 10.1038/ki.1990.329; FUCHS A, 1987, AM J CLIN PATHOL, V88, P302, DOI 10.1093/ajcp/88.3.302; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GOREVIC PD, 1985, J CLIN INVEST, V76, P2425, DOI 10.1172/JCI112257; HAWKINS PN, 1988, J EXP MED, V167, P903, DOI 10.1084/jem.167.3.903; HAWKINS PN, 1988, LANCET, V1, P1413; HAWKINS PN, 1990, J CLIN INVEST, V86, P1862, DOI 10.1172/JCI114917; HAWKINS PN, 1990, NEW ENGL J MED, V323, P508, DOI 10.1056/NEJM199008233230803; JADOUL M, 1989, CLIN NEPHROL, V32, P194; MAHER ER, 1988, BRIT MED J, V297, P265, DOI 10.1136/bmj.297.6643.265; MANTZOURANIS EC, 1985, J BIOL CHEM, V280, P7752; OHNISHI S, 1986, J BIOCHEM-TOKYO, V100, P849, DOI 10.1093/oxfordjournals.jbchem.a121797; ORFILA C, 1987, NEPHROL DIAL TRANSPL, V2, P448; Pepys M. B, 1988, IMMUNOLOGICAL DISEAS, V1, P631; PEPYS MB, CLIN EXP; PRELLI F, 1985, J BIOL CHEM, V260, P12865; SETHI D, 1989, AM J NEPHROL, V9, P173, DOI 10.1159/000167959; SHINODA T, 1989, CLIN NEPHROL, V32, P284; STONE WJ, 1989, AM J NEPHROL, V9, P177, DOI 10.1159/000167962; THEAKER JM, 1987, J CLIN PATHOL, V40, P1247, DOI 10.1136/jcp.40.10.1247	24	98	99	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					335	339		10.1016/0140-6736(91)90478-8	http://dx.doi.org/10.1016/0140-6736(91)90478-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677697				2022-12-01	WOS:A1991GA60700003
J	PEDERSENBJERGAARD, J; DAUGAARD, G; HANSEN, SW; PHILIP, P; LARSEN, SO; RORTH, M				PEDERSENBJERGAARD, J; DAUGAARD, G; HANSEN, SW; PHILIP, P; LARSEN, SO; RORTH, M			INCREASED RISK OF MYELODYSPLASIA AND LEUKEMIA AFTER ETOPOSIDE, CISPLATIN, AND BLEOMYCIN FOR GERM-CELL TUMORS	LANCET			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; THERAPY-RELATED LEUKEMIA; ACUTE MYELOID-LEUKEMIA; DISSEMINATED TESTICULAR CANCER; NON-HODGKINS LYMPHOMA; ALKYLATING-AGENTS; COMBINATION CHEMOTHERAPY; OVARIAN-CARCINOMA; CYTO-TOXICITY; SOLID TUMORS	Among the cytostatic drugs only the alkylating agents have been firmly established as being leukaemogenic. This report describes 4 cases of acute myeloid leukaemia and 1 of myelodysplasia occurring in a cohort of 212 patients with germ-cell tumours treated with etoposide, cisplatin, and bleomycin. The mean cumulative risk of leukaemic complications was 4.7% (SE 2.3) 5.7 years after start of etoposide-containing chemotherapy, and, compared with the risk in the general population, the relative risk of overt leukaemia was 336 (95% Cl 92-861). No leukaemias were detected in a previous cohort of 127 patients with germ-cell tumours treated with cisplatin, bleomycin, and vinblastine. The increased risk of leukaemia was most probably due to etoposide alone or in combination with cisplatin or bleomycin, since other published work has also not revealed an excess of leukaemias among patients with germ-cell tumours treated with only cisplatin, bleomycin, and vinblastine. The risk of leukaemia was dose related since all 5 patients with leukaemic complications were among the 82 who had received a cumulative dose of more than 2000 mg/m2 etoposide, whereas no leukaemias were observed among 130 patients who had received up to 2000 mg/m2 (p = 0.004). 3 of the leukaemic patients had balanced chromosome translocations affecting bands 11q23 and 21q22. These translocations, and perhaps also other balanced aberrations, seem to be characteristic of myelodysplasia and acute leukaemia occurring after therapy with cytostatic agents acting on DNA-topoisomerase II.	STATE SERUM INST,DEPT BIOSTAT,COPENHAGEN,DENMARK; RIGSHOSP,DEPT ONCOL ONK,DK-2100 COPENHAGEN,DENMARK; RIGSHOSP,FINSEN LAB,DK-2100 COPENHAGEN,DENMARK	Statens Serum Institut; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	PEDERSENBJERGAARD, J (corresponding author), RIGSHOSP,DEPT HAEMATOL L4132,9 BLEGDAMSVEJ,DK-2100 COPENHAGEN,DENMARK.		Daugaard, Gedske/AAD-4009-2019	Daugaard, Gedske/0000-0002-9618-9180				ANDERSSON M, 1990, CANCER, V65, P2460, DOI 10.1002/1097-0142(19900601)65:11<2460::AID-CNCR2820651110>3.0.CO;2-S; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BASSETT WB, 1986, J CLIN ONCOL, V4, P614; BLAYNEY DW, 1987, NEW ENGL J MED, V316, P710, DOI 10.1056/NEJM198703193161203; CHAGANTI RSK, 1989, GENE CHROMOSOME CANC, V1, P83, DOI 10.1002/gcc.2870010113; CHAK LY, 1984, J CLIN ONCOL, V2, P385, DOI 10.1200/JCO.1984.2.5.385; CHAMBERS SK, 1989, CANCER, V64, P2459, DOI 10.1002/1097-0142(19891215)64:12<2459::AID-CNCR2820641210>3.0.CO;2-T; CUZICK J, 1987, BRIT J CANCER, V55, P523, DOI 10.1038/bjc.1987.107; EDER JP, 1987, J CLIN INVEST, V79, P1524, DOI 10.1172/JCI112983; EINHORN LH, 1977, ANN INTERN MED, V87, P293, DOI 10.7326/0003-4819-87-3-293; GREENE MH, 1982, NEW ENGL J MED, V307, P1416, DOI 10.1056/NEJM198212023072302; GREENE MH, 1983, CANCER RES, V43, P1891; INGRAM L, 1987, BRIT J CANCER, V55, P463, DOI 10.1038/bjc.1987.91; KANTARJIAN HM, 1986, CANCER, V58, P924, DOI 10.1002/1097-0142(19860815)58:4<924::AID-CNCR2820580420>3.0.CO;2-Y; KANTARJIAN HM, 1986, J CLIN ONCOL, V4, P1748, DOI 10.1200/JCO.1986.4.12.1748; KAUFMANN SH, 1991, CANCER RES, V51, P1129; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; NICHOLS CR, 1990, NEW ENGL J MED, V322, P1425, DOI 10.1056/NEJM199005173222004; OZOLS RF, 1988, J CLIN ONCOL, V6, P1031, DOI 10.1200/JCO.1988.6.6.1031; PECKHAM MJ, 1983, BRIT J CANCER, V47, P613, DOI 10.1038/bjc.1983.99; PEDERSENBJERGAARD J, 1991, BLOOD, V78, P1147; PEDERSENBJERGAARD J, 1985, BLOOD, V66, P1393; PEDERSENBJERGAARD J, 1987, LANCET, V2, P83, DOI 10.1016/S0140-6736(87)92744-9; PEDERSENBJERGAARD J, 1985, ANN INTERN MED, V103, P195, DOI 10.7326/0003-4819-103-2-195; PEDERSENBJERGAARD J, 1980, CANCER-AM CANCER SOC, V45, P19, DOI 10.1002/1097-0142(19800101)45:1<19::AID-CNCR2820450106>3.0.CO;2-L; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; POMMIER Y, 1988, CANCER RES, V48, P512; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1990, LANCET, V336, P417, DOI 10.1016/0140-6736(90)91956-B; RATAIN MJ, 1987, BLOOD, V70, P1412; RUBIN CM, 1990, BLOOD, V76, P2594; TAN KB, 1987, P NATL ACAD SCI USA, V84, P7668, DOI 10.1073/pnas.84.21.7668; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VANIMHOFF GW, 1986, CANCER, V57, P984, DOI 10.1002/1097-0142(19860301)57:5<984::AID-CNCR2820570518>3.0.CO;2-H; WILLIAMS SD, 1987, NEW ENGL J MED, V316, P1435, DOI 10.1056/NEJM198706043162302	36	316	318	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					359	363		10.1016/0140-6736(91)90490-G	http://dx.doi.org/10.1016/0140-6736(91)90490-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1713639				2022-12-01	WOS:A1991GA60700015
J	SAMUEL, BU; CHERIAN, T; SRIDHARAN, G; MUKUNDAN, P; JOHN, TJ				SAMUEL, BU; CHERIAN, T; SRIDHARAN, G; MUKUNDAN, P; JOHN, TJ			IMMUNE-RESPONSE TO INTRADERMALLY INJECTED INACTIVATED POLIOVIRUS VACCINE	LANCET			English	Note							POLIOMYELITIS; IMMUNIZATION	Immune response to intradermal inoculation of a fractional dose of inactivated poliovirus vaccine (IPV) was measured in 8 adults and 10 children who were previously immune. A striking 4-fold to 1024-fold antibody booster response to all 3 poliovirus serotypes was found in 15 subjects and a similar response to 2 poliovirus serotypes occurred in the other 3 children. Induration and erythema of 3 mm diameter or above, indicative of a cell-mediated immune response, was seen in 12 subjects. Intradermal inoculation of IPV may be a useful technique for secondary immunisation programmes against polio and its use for primary immunisation merits investigation.	CHRISTIAN MED COLL & HOSP,INDIAN COUNCIL MED RES,CTR VIROL,VELLORE 632004,TAMIL NADU,INDIA	Christian Medical College & Hospital (CMCH) Vellore; Indian Council of Medical Research (ICMR)								BEALE AJ, 1990, LANCET, V335, P839, DOI 10.1016/0140-6736(90)90945-2; MCBEAN AM, 1987, PEDIATR INFECT DIS J, V6, P881, DOI 10.1097/00006454-198710000-00001; SULEKHA C, 1990, INT J EPIDEMIOL, V19, P177, DOI 10.1093/ije/19.1.177; TURK JL, 1980, RES MONOGRAPHS IMMUN, V1, P45	4	38	40	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					343	344		10.1016/0140-6736(91)90480-D	http://dx.doi.org/10.1016/0140-6736(91)90480-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677699				2022-12-01	WOS:A1991GA60700005
J	SEURI, M				SEURI, M			RISK OF APPENDECTOMY IN OCCUPATIONS ENTAILING CONTACT WITH PIGS	BRITISH MEDICAL JOURNAL			English	Article							YERSINIA; INFECTION				SEURI, M (corresponding author), UNIV KUOPIO,DEPT COMMUNITY HLTH & GEN PRACTICE,POB 1627,SF-70211 KUOPIO,FINLAND.							ASPLUND K, 1990, ACTA VET SCAND, V31, P39; ATTWOOD SEA, 1987, LANCET, V1, P529; ATTWOOD SEA, 1989, BRIT J SURG, V76, P499, DOI 10.1002/bjs.1800760523; MERILAHTIPALO R, 1991, SCAND J INFECT DIS, V23, P55, DOI 10.3109/00365549109023375; TERTTI R, 1984, J INFECT DIS, V149, P245, DOI 10.1093/infdis/149.2.245	5	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					345	346		10.1136/bmj.303.6798.345-a	http://dx.doi.org/10.1136/bmj.303.6798.345-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GA606	1912777	Green Published, Bronze			2022-12-01	WOS:A1991GA60600023
J	SIGURGEIRSSON, B; LINDELOF, B; EKLUND, G				SIGURGEIRSSON, B; LINDELOF, B; EKLUND, G			CONDYLOMATA ACUMINATA AND RISK OF CANCER - AN EPIDEMIOLOGIC-STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENITAL WARTS; PAPILLOMAVIRUSES; ROCHESTER; MINN	Objective-To determine whether patients with condylomata acuminata have an increased risk o developing cancer. Design-Prospective cohort study on patients diagnosed as having condylomata acuminata. The number of malignant tumours in the cohort was compared with national incidences obtained from the Swedish Cancer Registry. Setting-Dermatology department of the Karolinska Hospital, Stockholm, Sweden. Subjects-3260 patients (2549 males and 711 females, median (range) age 23 (1-80) years) seen during 1969-84, with a mean follow up of 7.8 years. Main outcome measures-Number of malignant tumours observed in the cohort during the study period and expected number from national incidence. Results-There were 27 malignancies in the study group. There was no significant increase genital cancer in females compared with the national incidence. Only one patient had invasive cervical cancer (relative risk = 1.8; 95% confidence interval 0 to 10.1). Seventeen women had cervical carcinoma in situ (1.5; 0.9 to 2.5) compared with an expected number of 11.5; this increase was not significant. For males 22 cancers were observed at all sites (1.6; 1.0 to 2.5). The number of genitourinary cancers observed in males was almost three times higher than expected (2.6; 1.2 to 5.0). Conclusion-The results indicate that the risk of developing cervical carcinoma in situ or invasive cervical cancer after a genital human papillomavirus infection is less than previously thought. The implications of increase in the genitourinary malignancies in males are uncertain.	KAROLINSKA HOSP, DEPT CANC EPIDEMIOL, S-10401 STOCKHOLM 60, SWEDEN	Karolinska Institutet; Karolinska University Hospital	SIGURGEIRSSON, B (corresponding author), KAROLINSKA HOSP, DEPT DERMATOL, S-10401 STOCKHOLM 60, SWEDEN.		Sigurgeirsson, Bárður/B-6130-2011; Sigurgeirsson, Bardur/AAP-7755-2020	Sigurgeirsson, Bardur/0000-0002-9733-9742				ADAMI HO, 1989, ACTA ONCOL, V28, P463, DOI 10.3109/02841868909092251; ARMSTRONG B, 1988, LANCET, V1, P756; BAFVERSTEDT B, 1967, ACTA DERM-VENEREOL, V47, P376; BARRETT TJ, 1954, JAMA-J AM MED ASSOC, V154, P333, DOI 10.1001/jama.1954.02940380043010c; BERKSON J, 1946, BIOMETRICS BULL, V2, P47, DOI 10.2307/3002000; BREHART M, 1984, EMBO J, V3, P1151; BUNNEY MH, 1985, VIRAL WARTS THEIR BI, P22; CHUANG TY, 1984, ARCH DERMATOL, V120, P469, DOI 10.1001/archderm.120.4.469; CHUANG TY, 1984, ARCH DERMATOL, V120, P476, DOI 10.1001/archderm.120.4.476; CHUANG TY, 1987, J AM ACAD DERMATOL, V16, P376, DOI 10.1016/S0190-9622(87)70053-X; DUNN AEG, 1968, J ULTRA MOL STRUCT R, V22, P282, DOI 10.1016/S0022-5320(68)90021-X; GISSMANN L, 1982, INT J CANCER, V29, P143, DOI 10.1002/ijc.2910290205; GISSMANN L, 1986, BANBURY REPORT, V21, P217; Grisson, 1915, DERMATOL WOCHENSCHR, V60, P89; HAUSEN HZ, 1985, PROG MED VIROL, V32, P15; HAUSEN HZ, 1977, CURR TOP MICROBIOL, P1; KAPAUR TR, 1982, INDIAN J DERMATOL, V48, P23; KOVI J, 1974, AM J CLIN PATHOL, V61, P702; LYNCH PJ, 1985, CLIN OBSTET GYNECOL, V28, P142, DOI 10.1097/00003081-198528010-00017; MATTSSON B, 1984, THESIS KAROLINSKA I, P1; MCCANCE DJ, 1988, NATURE, V335, P765, DOI 10.1038/335765a0; MCNICOL PJ, 1990, J CLIN MICROBIOL, V28, P409, DOI 10.1128/JCM.28.3.409-412.1990; ORIEL JD, 1977, SEX TRANSM DIS, V4, P153, DOI 10.1097/00007435-197710000-00009; ORTH G, 1978, B CANCER, V65, P151; RAGOZZINO MW, 1984, MAYO CLIN PROC, V59, P719, DOI 10.1016/S0025-6196(12)62062-X; SHAFEEK MA, 1979, OBSTET GYNECOL, V54, P120, DOI 10.1097/00006250-197907000-00027; SIEGEL A, 1962, AM J SURG, V103, P613, DOI 10.1016/0002-9610(62)90531-7; SIGURGEIRSSON B, IN PRESS COMPUT METH; SYRJANEN KJ, 1983, OBSTET GYNECOL, V62, P617; VONKROGH G, 1982, ACTA DERM-VENEREOL, V62, P1; WALKER PG, 1983, BRIT J VENER DIS, V59, P120; 1961, CANCER INCIDENCE SWE	32	25	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 10	1991	303	6798					341	344		10.1136/bmj.303.6798.341	http://dx.doi.org/10.1136/bmj.303.6798.341			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1781836	Green Published, Bronze			2022-12-01	WOS:A1991GA60600021
J	SMITH, I; COOK, B; BEASLEY, M				SMITH, I; COOK, B; BEASLEY, M			REVIEW OF NEONATAL SCREENING-PROGRAM FOR PHENYLKETONURIA	BRITISH MEDICAL JOURNAL			English	Article							DEFICIENCY; QUALITY	Objective-To review the neonatal screening programme during 1984-8. Design-Analysis of data from screening laboratories and paediatricians. Subjects-All live births in United Kingdom. Main outcome measures-Structure of programme; number of infants tested and number with phenylketonuria; number of infants missed; ages at testing and treatment. Results-The proportion of infants tested approached 100%. The incidence of phenylketonuria was 11.7/100 000 births (445 subjects): 273 had classic phenylketonuria and three had defects of cofactor metabolism. One child with phenylketonuria was known to have been missed compared with three in 1979-83 and six in 1974-8. Seven subjects had been missed over the 15 years due to negative test results. All seven had been tested with the bacterial inhibition assay, although only 53% of infants had been so tested; the difference between the expected and observed proportion was significant (Fisher's exact test, p = 0.017). Eleven infants with classic phenylketonuria were not tested by 14 days of age and 23 (8%) did not start treatment until after 20 days, an improvement compared with 36 (15%) in 1979-83. There were, however, wide regional variations (0% to 27% treated after 20 days). Conclusion-The screening programme achieves high coverage and effectiveness, although some children are still missed. A national practice for screening may help reduce regional variations.			SMITH, I (corresponding author), INST CHILD HLTH,DEPT CHILD HLTH,MRC,DEPT HLTH PHENYLKETONURIA REGISTER,LONDON WC1N 1EH,ENGLAND.							GRANT DB, 1988, BRIT MED J, V296, P1355, DOI 10.1136/bmj.296.6633.1355; GREEVES LG, 1990, EUR J PEDIATR, V149, P713, DOI 10.1007/BF01959529; HUNTER R, 1988, HEAL HEAL SCREENING; LEEMING RJ, 1984, ARCH DIS CHILD, V59, P58, DOI 10.1136/adc.59.1.58; MCCABE ERB, 1983, PEDIATRICS, V72, P390; OKANO Y, 1991, NEW ENGL J MED, V324, P1232, DOI 10.1056/NEJM199105023241802; SMITH I, 1986, ARCH DIS CHILD, V61, P130, DOI 10.1136/adc.61.2.130; SMITH I, 1990, ARCH DIS CHILD, V65, P472, DOI 10.1136/adc.65.5.472; SMITH I, 1990, INBORN METABOLIC DIS, P183; SMITH I, 1985, BUTTERWORTHS INT MED, V5, P166; WESTWOOD AS, 1982, EUR J PEDIATR, V71, P859; WHITEHEAD TP, 1981, J CLIN PATHOL, V34, P947, DOI 10.1136/jcp.34.9.947; 1981, SCREENING EARLY DETE; 1981, BMJ, V282, P1680	14	57	60	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					333	335		10.1136/bmj.303.6798.333	http://dx.doi.org/10.1136/bmj.303.6798.333			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1912773	Bronze, Green Published			2022-12-01	WOS:A1991GA60600018
J	DYNLACHT, BD; HOEY, T; TJIAN, R				DYNLACHT, BD; HOEY, T; TJIAN, R			ISOLATION OF COACTIVATORS ASSOCIATED WITH THE TATA-BINDING PROTEIN THAT MEDIATE TRANSCRIPTIONAL ACTIVATION	CELL			English	Article							RNA POLYMERASE-II; ANTENNAPEDIA GENE-COMPLEX; FUNCTIONAL-ANALYSIS; PREINITIATION COMPLEX; PROMOTER INTERACTIONS; DROSOPHILA; BOX; YEAST; INITIATION; DOMAINS	A key step in the regulation of transcription involves interactions between promoter-selective factors and various components of the transcriptional apparatus. Here we report the requirements for transcriptional activation directed by NTF-1, a developmentally regulated transcription factor in Drosophila. Reconstituted transcription with fractionated Drosophila basal factors reveals that activation by NTF-1 requires factors present in the endogenous TFIID fraction that are distinct from the purified TATA-binding protein (TBP). Glycerol gradient sedimentation and immunoprecipitation analyses indicate that TFIID is a multiprotein complex containing TBP and at least six tightly bound TBP-associated factors (TAFs). Preparations of TBP lacking TAFs after fractionation with denaturants no longer support activation by NTF-1 but retain basal level activity. Addition of immunopurified and renatured TAFs to free TBP restores the ability of NTF-1 to activate transcription without influencing basal transcription. These results suggest that one or more of the TAF polypeptides confer coactivator function.			DYNLACHT, BD (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DREIVER W, 1989, NATURE, V342, P149; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; RUSHLOW C, 1987, GENE DEV, V1, P1268, DOI 10.1101/gad.1.10.1268; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223	40	606	622	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					563	576		10.1016/0092-8674(81)90019-2	http://dx.doi.org/10.1016/0092-8674(81)90019-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1907890				2022-12-01	WOS:A1991GA94100017
J	GRODEN, J; THLIVERIS, A; SAMOWITZ, W; CARLSON, M; GELBERT, L; ALBERTSEN, H; JOSLYN, G; STEVENS, J; SPIRIO, L; ROBERTSON, M; SARGEANT, L; KRAPCHO, K; WOLFF, E; BURT, R; HUGHES, JP; WARRINGTON, J; MCPHERSON, J; WASMUTH, J; LEPASLIER, D; ABDERRAHIM, H; COHEN, D; LEPPERT, M; WHITE, R				GRODEN, J; THLIVERIS, A; SAMOWITZ, W; CARLSON, M; GELBERT, L; ALBERTSEN, H; JOSLYN, G; STEVENS, J; SPIRIO, L; ROBERTSON, M; SARGEANT, L; KRAPCHO, K; WOLFF, E; BURT, R; HUGHES, JP; WARRINGTON, J; MCPHERSON, J; WASMUTH, J; LEPASLIER, D; ABDERRAHIM, H; COHEN, D; LEPPERT, M; WHITE, R			IDENTIFICATION AND CHARACTERIZATION OF THE FAMILIAL ADENOMATOUS POLYPOSIS-COLI GENE	CELL			English	Article							COLORECTAL CANCERS; POINT MUTATIONS; HUMAN DNA; POLYMORPHISMS; CHROMOSOME-5; INHERITANCE; DELETION	DNA from 61 unrelated patients with adenomatous polyposis coli (APC) was examined for mutations in three genes (DP1, SRP19, and DP2.5) located within a 100 kb region deleted in two of the patients. The intron-exon boundary sequences were defined for each of these genes, and single-strand conformation polymorphism analysis of exons from DP2.5 identified four mutations specific to APC patients. Each of two aberrant alleles contained a base substitution changing an amino acid to a stop codon in the predicted peptide; the other mutations were small deletions leading to frameshifts. Analysis of DNA from parents of one of these patients showed that his 2 bp deletion is a new mutation; furthermore, the mutation was transmitted to two of his children. These data have established that DP2.5 is the APC gene.	UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84132; UNIV UTAH,HLTH SCI CTR,DEPT PATHOL,SALT LAKE CITY,UT 84132; UNIV UTAH,HLTH SCI CTR,DEPT MED,DIV GASTROENTEROL,SALT LAKE CITY,UT 84132; ST MARKS HOSP,SALT LAKE CITY,UT 84117; UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of California System; University of California Irvine	GRODEN, J (corresponding author), UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132, USA.		McPherson, John D/D-2633-2017; Pillay, Nischalan/F-9536-2012	McPherson, John D/0000-0001-8049-9347; Le Paslier, Denis/0000-0003-4335-9956	NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040886] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09602] Funding Source: Medline; NHGRI NIH HHS [HG-00320] Funding Source: Medline; NIGMS NIH HHS [R01-GM40886-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOURNE HR, 1991, NATURE, V351, P188, DOI 10.1038/351188a0; BURT RW, 1985, NEW ENGL J MED, V312, P1540, DOI 10.1056/NEJM198506133122403; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; Maniatis T., 1982, MOL CLONING; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RIVERA H, 1990, J MED GENET, V27, P267, DOI 10.1136/jmg.27.4.267; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X	28	2345	2415	2	62	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					589	600		10.1016/0092-8674(81)90021-0	http://dx.doi.org/10.1016/0092-8674(81)90021-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651174				2022-12-01	WOS:A1991GA94100019
J	GRONENBORN, AM; FILPULA, DR; ESSIG, NZ; ACHARI, A; WHITLOW, M; WINGFIELD, PT; CLORE, GM				GRONENBORN, AM; FILPULA, DR; ESSIG, NZ; ACHARI, A; WHITLOW, M; WINGFIELD, PT; CLORE, GM			A NOVEL, HIGHLY STABLE FOLD OF THE IMMUNOGLOBULIN BINDING DOMAIN OF STREPTOCOCCAL PROTEIN-G	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; DISTANCE GEOMETRY; 3-DIMENSIONAL STRUCTURES; STAPHYLOCOCCUS-AUREUS; MOLECULAR-DYNAMICS; SPECTROSCOPY; CRYSTALLOGRAPHY; RESOLUTION; PROGRAM; CRAMBIN	The high-resolution three-dimensional structure of a single immunoglobulin binding domain (BI, which comprises 56 residues including the NH2-terminal Met) of protein G from group G Streptococcus has been determined in solution by nuclear magnetic resonance spectroscopy on the basis of 1058 experimental restraints. The average atomic root-mean-square distribution about the mean coordinate positions is 0.27 angstrom (angstrom) for the backbone atoms, 0.65 angstrom for all atoms, and 0.39 angstrom for atoms excluding disordered surface side chains. The structure has no disulfide bridges and is composed of a four-stranded 13 sheet, on top of which lies a long helix. The central two strands (beta-1 and beta-4), comprising the NH2- and COOH-termini, are parallel, and the outer two strands (beta-2 and beta-3) are connected by the helix in a +3x crossover. This novel topology (-1, +3x, -1), coupled with an extensive hydrogen-bonding network and a tightly packed and buried hydrophobic core, is probably responsible for the extreme thermal stability of this small domain (reversible melting at 87-degrees-C).	GENEX CORP, GAITHERSBURG, MD 20877 USA; NIH, PROT EXPRESS LAB, OFF DIRECTOR, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA	GRONENBORN, AM (corresponding author), NIDDKD, CHEM PHYS LAB, BLDG 2, BETHESDA, MD 20892 USA.		Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Wingfield, Paul/0000-0002-9515-4752; Gronenborn, Angela M/0000-0001-9072-3525				AKERSTROM B, 1986, J BIOL CHEM, V261, P240; BAX A, 1989, METHOD ENZYMOL, V176, P151; BJORCK L, 1984, J IMMUNOL, V133, P969; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1988, XPLOR MANUAL; CHOTHIA C, 1990, ANNU REV BIOCHEM, V59, P1007, DOI 10.1146/annurev.bi.59.070190.005043; CLICHE L, 1990, P NATL ACAD SCI USA, V87, P3240; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; CLORE GM, 1987, PROTEIN ENG, V1, P275, DOI 10.1093/protein/1.4.275; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1991, ANNU REV BIOPHYS BIO, V20, P29, DOI 10.1146/annurev.biophys.20.1.29; CREIGHTON TE, 1986, METHOD ENZYMOL, V131, P157; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FAHNESTOCK S, COMMUNICATION; FAHNESTOCK SR, 1987, TRENDS BIOTECHNOL, V5, P79, DOI 10.1016/S0167-7799(87)80016-1; FAHNESTOCK SR, 1986, J BACTERIOL, V167, P870, DOI 10.1128/jb.167.3.870-880.1986; FAHNESTOCK SR, 1990, BACTERIAL IMMUNOGLOB, V1, P133; FORMANKAY JD, 1991, BIOCHEMISTRY-US, V30, P2685, DOI 10.1021/bi00224a017; GUSS B, 1986, EMBO J, V5, P1567, DOI 10.1002/j.1460-2075.1986.tb04398.x; HAVEL T, 1984, B MATH BIOL, V46, P673, DOI 10.1007/BF02459510; HAVEL TF, 1986, QUANTUM CHEM PROGRAM, V507; HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0; JAMES MNG, 1980, J MOL BIOL, V144, P43, DOI 10.1016/0022-2836(80)90214-4; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; LANGONE JJ, 1982, ADV IMMUNOL, V32, P157; MARION D, 1988, J MAGN RESON, V80, P528, DOI 10.1016/0022-2364(88)90250-8; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; Pfeil W., 1986, THERMODYNAMIC DATA B, P349; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Schulz G.E., 1979, PRINCIPLES PROTEIN S; SJOBRING U, 1991, J BIOL CHEM, V266, P399; SJOBRING U, 1989, J IMMUNOL, V143, P2948; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.physchem.38.1.463; WALTER J, 1982, ACTA CRYSTALLOGR B, V38, P1462, DOI 10.1107/S0567740882006153; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; WUTHRICH K, 1989, ACCOUNTS CHEM RES, V22, P36, DOI 10.1021/ar00157a006; Wuthrich K., 1986, NMR PROTEINS NUCL AC	47	705	726	3	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1991	253	5020					657	661		10.1126/science.1871600	http://dx.doi.org/10.1126/science.1871600			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA304	1871600				2022-12-01	WOS:A1991GA30400037
J	HOYT, MA; TOTIS, L; ROBERTS, BT				HOYT, MA; TOTIS, L; ROBERTS, BT			SACCHAROMYCES-CEREVISIAE GENES REQUIRED FOR CELL-CYCLE ARREST IN RESPONSE TO LOSS OF MICROTUBULE FUNCTION	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; DIVISION CYCLE; YEAST; KINASE; DNA; MUTATIONS; MUTANTS	We have identified mutant strains of S. cerevisiae that fail to properly arrest their cell cycles at mitosis in response to the loss of microtubule function. New bud emergence and DNA replication (but not cytokinesis) occur with high efficiency in the mutants under conditions that inhibit these events in wild-type cells. The inability to halt cell cycle progression is specific for impaired microtubule function; the mutants respond normally to other cell cycle-blocking treatments. Under microtubule-disrupting conditions, the mutants neither achieve nor maintain the high level of histone H-1 kinase activity characteristic of wild-type cells. Our studies have defined three genes required for normal cell cycle arrest. These findings are consistent with the existence of a surveillance system that halts the cell cycle in response to microtubule perturbation.			HOYT, MA (corresponding author), JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA.				NCRR NIH HHS [S07RR07041] Funding Source: Medline; NIGMS NIH HHS [GM40714] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040714] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; Dustin P., 1984, MICROTUBULES; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; HUFFAKER TC, 1988, J CELL BIOL, V106, P1997, DOI 10.1083/jcb.106.6.1997; HUTTER KJ, 1978, A VAN LEEUW J MICROB, V44, P269, DOI 10.1007/BF00394305; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LANGE P, 1980, MOL GEN GENET, V180, P605, DOI 10.1007/BF00268067; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RIEDER CL, 1989, MECHANISMS CHROMOSOM, P185; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sherman F., 1983, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SLATER ML, 1973, J BACTERIOL, V113, P263, DOI 10.1128/JB.113.1.263-270.1973; STEARNS T, 1988, GENETICS, V119, P249; STEARNS T, 1990, GENETICS, V124, P251; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3	36	951	978	2	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1991	66	3					507	517		10.1016/0092-8674(81)90014-3	http://dx.doi.org/10.1016/0092-8674(81)90014-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651171				2022-12-01	WOS:A1991GA94100012
J	HUESMANN, M; SCOTT, B; KISIELOW, P; VONBOEHMER, H				HUESMANN, M; SCOTT, B; KISIELOW, P; VONBOEHMER, H			KINETICS AND EFFICACY OF POSITIVE SELECTION IN THE THYMUS OF NORMAL AND T-CELL RECEPTOR TRANSGENIC MICE	CELL			English	Article							RESTRICTED ANTIGEN RECEPTOR; IMMATURE THYMOCYTES; DIFFERENTIATION; EXPRESSION; PROLIFERATION	DNA-labeling studies in alpha-beta T cell receptor (TCR) transgenic mice show that the lifespan of immature CD4+8+ thymocytes is 3.5 days irrespective of whether they are selected for maturation or not. While nonselected cells die, the binding of the TCR to thymic major histocompatibility complex molecules rescues CD4+8+ cells from programmed cell death and induces first upregulation of the TCR level and then differentiation into CD4+8- or CD4-8+ cells in the absence of any cell division. When most CD4+8+ thymocytes express a selectable transgenic TCR the formation of mature cells with high TCR levels is 10-20 times as efficient as observed in normal mice, yet still only 20% of the CD4+8+ cells become mature. This is due to the limited availability of selecting 'niches': most CD4+8+ thymocytes with a selectable transgenic TCR will undergo maturation when they represent only 5% or less of all CD4+8+ cells.			HUESMANN, M (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.							BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; CEREDIG R, 1990, INT IMMUNOL, V2, P859, DOI 10.1093/intimm/2.9.859; CRISTANTI A, 1986, EMBO J, V5, P2837, DOI 10.1002/j.1460-2075.1986.tb04577.x; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; GONCHOROFF NJ, 1985, CYTOMETRY, V6, P506, DOI 10.1002/cyto.990060604; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1984, J IMMUNOL, V133, P1117; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; MATSUYAMA M, 1966, J EXP MED, V123, P559, DOI 10.1084/jem.123.3.559; NIKOLICZUGIC J, 1989, EUR J IMMUNOL, V19, P1957, DOI 10.1002/eji.1830191030; NIKOLICZUGIC J, 1988, P NATL ACAD SCI USA, V85, P8663; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PENIT C, 1990, INT IMMUNOL, V2, P629, DOI 10.1093/intimm/2.7.629; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; ROEHM N, 1984, CELL, V38, P577, DOI 10.1016/0092-8674(84)90512-9; SCOLLAY R, 1978, NATURE, V276, P79, DOI 10.1038/276079a0; SCOTT B, 1989, NATURE, V338, P595; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHORTMAN K, 1974, CELL IMMUNOL, V12, P230, DOI 10.1016/0008-8749(74)90075-6; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VANEWIJK W, 1990, EUR J IMMUNOL, V20, P129, DOI 10.1002/eji.1830200119; VONBOEHMER H, 1986, IMMUNOL TODAY, V7, P333; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; ZIJSTRA M, 1990, NATURE, V344, P742	34	352	354	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					533	540		10.1016/0092-8674(81)90016-7	http://dx.doi.org/10.1016/0092-8674(81)90016-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1868548				2022-12-01	WOS:A1991GA94100014
J	JOSLYN, G; CARLSON, M; THLIVERIS, A; ALBERTSEN, H; GELBERT, L; SAMOWITZ, W; GRODEN, J; STEVENS, J; SPIRIO, L; ROBERTSON, M; SARGEANT, L; KRAPCHO, K; WOLFF, E; BURT, R; HUGHES, JP; WARRINGTON, J; MCPHERSON, J; WASMUTH, J; LEPASLIER, D; ABDERRAHIM, H; COHEN, D; LEPPERT, M; WHITE, R				JOSLYN, G; CARLSON, M; THLIVERIS, A; ALBERTSEN, H; GELBERT, L; SAMOWITZ, W; GRODEN, J; STEVENS, J; SPIRIO, L; ROBERTSON, M; SARGEANT, L; KRAPCHO, K; WOLFF, E; BURT, R; HUGHES, JP; WARRINGTON, J; MCPHERSON, J; WASMUTH, J; LEPASLIER, D; ABDERRAHIM, H; COHEN, D; LEPPERT, M; WHITE, R			IDENTIFICATION OF DELETION MUTATIONS AND 3 NEW GENES AT THE FAMILIAL POLYPOSIS LOCUS	CELL			English	Article							ADENOMATOUS POLYPOSIS; COLORECTAL CANCERS; SHORT ARM; CHROMOSOME-5; LOCALIZATION; FRAGMENTS; RNA	Small (100-260 kb), nested deletions were characterized in DNA from two unrelated patients with familial adenomatous polyposis coli (APC). Three candidate genes located within the deleted region were ascertained and a previous candidate gene, MCC, was shown to be located outside the deleted region. One of the new genes contained sequence identical to SRP19, the gene coding for the 19 kd component of the ribosomal signal recognition particle. The second, provisionally designated DP1 (deleted in polyposis 1), was found to be transcribed in the same orientation as MCC. Two other cDNAs, DP2 and DP3, were found to overlap, forming a single gene, DP2.5, that is transcribed in the same orientation as SRP19.	UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84132; UNIV UTAH,HLTH SCI CTR,DEPT PATHOL,SALT LAKE CITY,UT 84132; UNIV UTAH,HLTH SCI CTR,DEPT MED,DIV GASTROENTEROL,SALT LAKE CITY,UT 84132; ST MARKS HOSP,SALT LAKE CITY,UT 84117; UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of California System; University of California Irvine	JOSLYN, G (corresponding author), UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132, USA.		McPherson, John D/D-2633-2017	McPherson, John D/0000-0001-8049-9347; Le Paslier, Denis/0000-0003-4335-9956	NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040886] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09602] Funding Source: Medline; NHGRI NIH HHS [HG-00320] Funding Source: Medline; NIGMS NIH HHS [R01-GM40886-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BURT RW, 1988, GASTROENTEROL CLIN N, V17, P657; CIRULLO RE, 1983, MOL CELL BIOL, V3, P892, DOI 10.1128/MCB.3.5.892; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GARDINER K, 1986, SOMAT CELL MOLEC GEN, V12, P185, DOI 10.1007/BF01560665; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KINZLER K, 1991, IN PRESS SCIENCE; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LINGELBACH K, 1988, NUCLEIC ACIDS RES, V16, P9431, DOI 10.1093/nar/16.20.9431; MANIATIS T, 1982, MOL CLONING LABORATO, P150; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; OVERHAUSER J, 1986, AM J HUM GENET, V39, P562; OVERHAUSER J, 1987, NUCLEIC ACIDS RES, V15, P4617, DOI 10.1093/nar/15.11.4617; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	24	685	706	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					601	613		10.1016/0092-8674(81)90022-2	http://dx.doi.org/10.1016/0092-8674(81)90022-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1678319				2022-12-01	WOS:A1991GA94100020
J	KINGSBURY, J; KOSHLAND, D				KINGSBURY, J; KOSHLAND, D			CENTROMERE-DEPENDENT BINDING OF YEAST MINICHROMOSOMES TO MICROTUBULES INVITRO	CELL			English	Article							MITOTIC CHROMOSOME TRANSMISSION; BASE-PAIR MUTATIONS; SACCHAROMYCES-CEREVISIAE; KINETOCHORE INVITRO; S-CEREVISIAE; DNA; PROTEIN; REPLICATION; CHROMATIN; MUTANTS	We present an in vitro assay for yeast centromere function; isolated yeast minichromosomes require a functional centromere to bind to bovine microtubules and sediment with them. Centromere-bovine microtubule complexes form at physiological microtubule concentrations. Two of the three centromere DNA elements, which are necessary for centromere function in vivo, are also necessary for centromeres to bind microtubules in vitro. However, purified centromere DNA alone does not bind to microtubules. These results suggest that microtubule binding must be mediated by the two centromere DNA elements and factors that associate with one or both of them. The percent of centromeres with microtubule-binding activity is 7- to 10-fold higher in lysates made from nocodazole-arrested G2-M cells than from alpha-factor G1 cells, suggesting that this centromere activity is regulated during the cell cycle. The potential of this assay for dissecting centromere assembly, function, and regulation is discussed.			KINGSBURY, J (corresponding author), CARNEGIE INST WASHINGTON, DEPT EMBRYOL, BALTIMORE, MD 21210 USA.							BAKER RE, 1989, J BIOL CHEM, V264, P10843; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; BRAM RJ, 1987, MOL CELL BIOL, V7, P403, DOI 10.1128/MCB.7.1.403; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CAI MJ, 1989, MOL CELL BIOL, V9, P2544, DOI 10.1128/MCB.9.6.2544; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; CLARKE L, 1980, P NATL ACAD SCI-BIOL, V77, P2173, DOI 10.1073/pnas.77.4.2173; DEAN A, 1989, METHOD ENZYMOL, V170, P26; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; FITZGERALDHAYES M, 1987, YEAST, V3, P187, DOI 10.1002/yea.320030306; GAUDET A, 1987, MOL CELL BIOL, V7, P68, DOI 10.1128/MCB.7.1.68; HARTWELL LH, 1985, GENETICS, V110, P381; HEGEMANN JH, 1988, MOL CELL BIOL, V8, P2523, DOI 10.1128/MCB.8.6.2523; HIETER P, 1985, CELL, V42, P913, DOI 10.1016/0092-8674(85)90287-9; HUITOREL P, 1988, J CELL BIOL, V106, P151, DOI 10.1083/jcb.106.1.151; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KOSHLAND D, 1987, CELL, V48, P801, DOI 10.1016/0092-8674(87)90077-8; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; MAINE GT, 1984, GENETICS, V106, P365; MCGREW J, 1986, MOL CELL BIOL, V6, P530, DOI 10.1128/MCB.6.2.530; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MITCHISON TJ, 1985, J CELL BIOL, V101, P755, DOI 10.1083/jcb.101.3.755; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; NEFF NF, 1983, CELL, V33, P211, DOI 10.1016/0092-8674(83)90350-1; PEDERSON DS, 1986, P NATL ACAD SCI USA, V83, P7206, DOI 10.1073/pnas.83.19.7206; PETERSON JB, 1976, J CELL SCI, V22, P219; PLARR CM, 1990, NATURE, V345, P263; RATTNER JB, 1990, CELL MOTIL CYTOSKEL, V17, P227, DOI 10.1002/cm.970170309; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; SAUNDERS M, 1988, P NATL ACAD SCI USA, V85, P175, DOI 10.1073/pnas.85.1.175; SHERO J, 1991, IN PRESS GENES DEV; SPENCER F, 1990, GENETICS, V124, P237; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; Strehler B L, 1968, Methods Biochem Anal, V16, P99, DOI 10.1002/9780470110348.ch2	36	46	46	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1991	66	3					483	495		10.1016/0092-8674(81)90012-X	http://dx.doi.org/10.1016/0092-8674(81)90012-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1868546				2022-12-01	WOS:A1991GA94100010
J	LI, R; MURRAY, AW				LI, R; MURRAY, AW			FEEDBACK-CONTROL OF MITOSIS IN BUDDING YEAST	CELL			English	Article							MITOTIC CHROMOSOME TRANSMISSION; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; DNA-REPLICATION; CHROMATIN CONDENSATION; MAMMALIAN-CELLS; TUBULIN GENES; PROTEIN; MUTANTS; CALCIUM	We have investigated the feedback control that prevents cells with incompletely assembled spindles from leaving mitosis. We isolated budding yeast mutants sensitive to the anti-microtubule drug benomyl. Mitotic arrest-deficient (mad) mutants are the subclass of benomyl-sensitive mutants in which the completion of mitosis is not delayed in the presence of benomyl and that die as a consequence of their premature exit from mitosis. A number of properties of the mad mutants indicate that they are defective in the feedback control over the exit from mitosis: their killing by benomyl requires passage through mitosis; their benomyl sensitivity can be suppressed by an independent method for delaying the exit from mitosis; they have normal microtubules; and they have increased frequencies of chromosome loss. We cloned MAD2, which encodes a putative calcium-binding protein whose disruption is lethal. We discuss the role of feedback controls in coordinating events in the cell cycle.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	LI, R (corresponding author), UNIV CALIF SAN FRANCISCO,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143, USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; ENGLE DB, 1990, J BIOL CHEM, V265, P16132; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GORDENIN DA, 1990, YEAST, V7, P37; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1985, GENETICS, V110, P381; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; JOHNSTON GC, 1983, EXP CELL RES, V149, P1, DOI 10.1016/0014-4827(83)90375-0; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LIRAS P, 1978, GENETICS, V88, P651; MCCUSKER JH, 1981, GENETICS, V99, P383; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1983, CELL, V34, P961, DOI 10.1016/0092-8674(83)90553-6; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1986, CELL, V45, P529, DOI 10.1016/0092-8674(86)90284-9; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PALMER RE, 1990, GENETICS, V125, P763; PICARD A, 1988, DEV BIOL, V128, P121, DOI 10.1016/0012-1606(88)90273-4; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3711, DOI 10.1128/MCB.6.11.3711; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SCHLEGEL R, 1987, J CELL PHYSIOL, V131, P85, DOI 10.1002/jcp.1041310113; Sherman R., 1974, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPENCER F, 1990, GENETICS, V124, P237; STEARNS T, 1988, GENETICS, V119, P249; STEARNS T, 1990, GENETICS, V124, P251; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; STUART DI, 1986, NATURE, V324, P84, DOI 10.1038/324084a0; TOMBES RM, 1989, J CELL BIOL, V109, P627, DOI 10.1083/jcb.109.2.627; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; VYAS NK, 1987, NATURE, V327, P635, DOI 10.1038/327635a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120	50	987	1012	0	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					519	531		10.1016/0092-8674(81)90015-5	http://dx.doi.org/10.1016/0092-8674(81)90015-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651172				2022-12-01	WOS:A1991GA94100013
J	MANGELSDORF, DJ; UMESONO, K; KLIEWER, SA; BORGMEYER, U; ONG, ES; EVANS, RM				MANGELSDORF, DJ; UMESONO, K; KLIEWER, SA; BORGMEYER, U; ONG, ES; EVANS, RM			A DIRECT REPEAT IN THE CELLULAR RETINOL-BINDING PROTEIN TYPE-II GENE CONFERS DIFFERENTIAL REGULATION BY RXR AND RAR	CELL			English	Article							ACID-RESPONSIVE ELEMENT; THYROID-HORMONE; NUCLEAR RECEPTORS; SMALL-INTESTINE; BETA-GENE; EXPRESSION; IDENTIFICATION; CLONING	The vitamin A derivative retinoic acid exerts its effects on transcription through two distinct classes of nuclear receptors, the retinoic acid receptor (RAR) and the retinoid X receptor (RXR). We provide evidence that expression of the gene for cellular retinol-binding protein type II (CRBPII), a key protein in the intestinal absorption of vitamin A, is dramatically up-regulated by retinoic acid in the presence of RXR but not RAR. This regulation is conferred through a specific cis element in the CRBPII promoter that contains five nearly perfect tandem repeats of the sequence AGGTCA spaced by a single nucleotide. The discovery of this new RX response element provides a means for distinguishing between the two retinoid receptor systems and suggests that an RXR-mediated pathway exists for modulating vitamin A metabolism.	SALK INST BIOL STUDIES,LA JOLLA,CA 92186	Salk Institute	MANGELSDORF, DJ (corresponding author), HOWARD HUGHES MED INST,LA JOLLA,CA 92186, USA.		Evans, Ronald/AAF-4001-2019; Borgmeyer, Uwe/D-4662-2012	Evans, Ronald/0000-0002-9986-5965; Borgmeyer, Uwe/0000-0003-3727-4083; Mangelsdorf, David/0000-0002-4355-0796				BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACDONALD PN, 1988, J BIOL CHEM, V263, P12478; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANGELSDORF DJ, 1991, TRANSCRIPTIONAL REGU; ONG DE, 1987, ARCH DERMATOL, V123, P1693, DOI 10.1001/archderm.123.12.1693; ONG DE, 1987, J BIOL CHEM, V262, P2729; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; Sporn M.B., 1984, RETINOIDS, V1-2; SPORN MB, 1984, RETINOIDS, V2; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WEI LN, 1989, MOL ENDOCRINOL, V3, P454, DOI 10.1210/mend-3-3-454; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559	29	622	659	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					555	561		10.1016/0092-8674(81)90018-0	http://dx.doi.org/10.1016/0092-8674(81)90018-0			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651173				2022-12-01	WOS:A1991GA94100016
J	MCCLURKIN, JW; OPTICAN, LM; RICHMOND, BJ; GAWNE, TJ				MCCLURKIN, JW; OPTICAN, LM; RICHMOND, BJ; GAWNE, TJ			CONCURRENT PROCESSING AND COMPLEXITY OF TEMPORALLY ENCODED NEURONAL MESSAGES IN VISUAL-PERCEPTION	SCIENCE			English	Article							TWO-DIMENSIONAL PATTERNS; SINGLE UNITS; CORTEX; STREAMS	The intrinsic neuronal code that carries visual information and the perceptual mechanism for decoding that information are not known. However, multivariate statistics and information theory show that neurons in four visual areas simultaneously carry multiple, stimulus-related messages by utilizing multiplexed temporal codes. The complexity of these temporal messages increases progressively across the visual system, yet the temporal codes overlap in time. Thus, visual perception may depend on the concurrent processing of multiplexed temporal messages from all visual areas.	NIMH, NEUROPSYCHOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	MCCLURKIN, JW (corresponding author), NEI, SENSORIMOTOR RES LAB, BETHESDA, MD 20892 USA.							Ahmed N., 1975, ORTHOGONAL TRANSFORM, P86; Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; COBURN KL, 1990, BEHAV NEUROSCI, V104, P62, DOI 10.1037/0735-7044.104.1.62; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; MCCLURKIN JW, IN PRESS J NEUROPHYS; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; OPTICAN LM, 1987, J NEUROPHYSIOL, V57, P162, DOI 10.1152/jn.1987.57.1.162; RICHMOND BJ, 1990, J NEUROPHYSIOL, V64, P370, DOI 10.1152/jn.1990.64.2.370; RICHMOND BJ, 1987, J NEUROPHYSIOL, V57, P147, DOI 10.1152/jn.1987.57.1.147; RICHMOND BJ, 1988, SOC NEUR ABSTR, V14, P308; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Uttal W.R., 1973, PSYCHOBIOLOGY SENSOR; VANESSEN DC, 1983, TRENDS NEUROSCI, V6, P370, DOI 10.1016/0166-2236(83)90167-4; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	14	100	100	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1991	253	5020					675	677		10.1126/science.1908118	http://dx.doi.org/10.1126/science.1908118			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA304	1908118				2022-12-01	WOS:A1991GA30400042
J	NISHISHO, I; NAKAMURA, Y; MIYOSHI, Y; MIKI, Y; ANDO, H; HORII, A; KOYAMA, K; UTSUNOMIYA, J; BABA, S; HEDGE, P; MARKHAM, A; KRUSH, AJ; PETERSEN, G; HAMILTON, SR; NILBERT, MC; LEVY, DB; BRYAN, TM; PREISINGER, AC; SMITH, KJ; SU, LK; KINZLER, KW; VOGELSTEIN, B				NISHISHO, I; NAKAMURA, Y; MIYOSHI, Y; MIKI, Y; ANDO, H; HORII, A; KOYAMA, K; UTSUNOMIYA, J; BABA, S; HEDGE, P; MARKHAM, A; KRUSH, AJ; PETERSEN, G; HAMILTON, SR; NILBERT, MC; LEVY, DB; BRYAN, TM; PREISINGER, AC; SMITH, KJ; SU, LK; KINZLER, KW; VOGELSTEIN, B			MUTATIONS OF CHROMOSOME-5Q21 GENES IN FAP AND COLORECTAL-CANCER PATIENTS	SCIENCE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; P53 GENE; CELL-LINES; CARCINOMAS; RATES; COLI; TUMORIGENESIS; ANTIONCOGENES; LOCALIZATION; ONCOGENES	Previous studies suggested that one or more genes on chromosome 5q2l are responsible for the inheritance of familial adenomatous polyposis (FAP) and Gardner's syndrome (GS), and contribute to tumor development in patients with noninherited forms of colorectal cancer. Two genes on 5q2l that are tightly linked to FAP (MCC and APC) were found to be somatically altered in tumors from sporadic colorectal cancer patients. One of the genes (APC) was also found to be altered by point mutation in the germ line of FAP and GS patients. These data suggest that more than one gene on chromosome 5q2l may contribute to colorectal neoplasia, and that mutations of the APC gene can cause both FAP and GS. The identification of these genes should aid in understanding the pathogenesis of colorectal neoplasia and in the diagnosis and counseling of patients with inherited predispositions to colorectal cancer.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOKYO 170,JAPAN; HYOGO MED UNIV,DEPT SURG 2,NISHINOMIYA,HYOGO 663,JAPAN; HAMAMATSU MED COLL,DEPT SURG 2,SHIZUOKA 43131,JAPAN; ICI PLC,PHARMACEUT,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND; JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,DEPT MED,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,MOLEC GENET LAB,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH HYG,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH PUBL HLTH,BALTIMORE,MD 21218	Japanese Foundation for Cancer Research; Hyogo College of Medicine; University of Hyogo; Hamamatsu University School of Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Bryan, Tracy M/B-8468-2014; Horii, Akira/AAW-2839-2021	Horii, Akira/0000-0002-3967-3291; Nilbert, Mef/0000-0003-2717-1937; Bryan, Tracy/0000-0002-7990-5501	NATIONAL CANCER INSTITUTE [P30CA006973, R37CA035494, R01CA035494, R01CA044688] Funding Source: NIH RePORTER; NCI NIH HHS [CA35494, CA44688, CA06973] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; ASHTONRICKARDT PG, IN PRESS ONCOGENE; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BELDJORD C, 1988, NUCLEIC ACIDS RES, V16, P4927, DOI 10.1093/nar/16.11.4927; BISHOPJM, 1990, CELL, V64, P235; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BONADIO J, 1990, J BIOL CHEM, V265, P2262; CHIBA I, 1990, ONCOGENE, V5, P1603; DELATTRE O, 1989, LANCET, V2, P353; DUNLOP MG, 1989, GENOMICS, V5, P350, DOI 10.1016/0888-7543(89)90068-2; ELMORE E, 1983, CANCER RES, V43, P1650; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GROSS ME, 1991, CANCER RES, V51, P1452; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HARWOOD J, 1991, MOL CELL BIOL, V11, P3163, DOI 10.1128/MCB.11.6.3163; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; JOSLYN G, IN PRESS CELL; KADEN D, 1989, CANCER RES, V49, P3374; KENDAL WS, 1986, CANCER RES, V46, P6131; KHAN PM, 1988, HUM GENET, V79, P183, DOI 10.1007/BF00280563; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1985, CANCER RES, V45, P1437; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LOEB LA, 1991, CANCER RES, V51, P3075; MIKI Y, IN PRESS JPN J CANCE; MORRIS C, 1990, CYTOGENET CELL GENET, V53, P4; MYERS RM, 1986, COLD SPRING HARB SYM, V51, P275, DOI 10.1101/SQB.1986.051.01.033; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, UNPUB; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; SASAKI M, 1989, CANCER RES, V49, P4402; SESHADRI R, 1987, CANCER RES, V47, P407; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; Suqarbaker J, 1985, CANCER PRINCIPLES PR, P800; UTSUNOMIYA J, 1990, HEREDITARY COLORECTA; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; WADDELL WR, 1989, AM J SURG, V157, P174; WEINBERG RA, 1989, CANCER RES, V49, P3713	50	1599	1707	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1991	253	5020					665	669		10.1126/science.1651563	http://dx.doi.org/10.1126/science.1651563			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA304	1651563				2022-12-01	WOS:A1991GA30400039
J	NUGENT, JM; PALMER, JD				NUGENT, JM; PALMER, JD			RNA-MEDIATED TRANSFER OF THE GENE COXII FROM THE MITOCHONDRION TO THE NUCLEUS DURING FLOWERING PLANT EVOLUTION	CELL			English	Article							OXIDASE SUBUNIT-II; CHLOROPLAST DNA; STRUCTURAL ORGANIZATION; OENOTHERA MITOCHONDRIA; RIBOSOMAL-PROTEIN; COMPLETE SEQUENCE; MESSENGER-RNAS; NO INTRON; EXPRESSION; GENOME	The gene coxII, normally present in the mitochondrion, was functionally transferred to the nucleus during flowering plant evolution. coxII transfer is estimated to have occurred between 60 and 200 million years ago, whereas loss of coxII from the mitochondrion occurred much more recently, being restricted to a single genus of legumes. Most legumes have coxII in both the nucleus and the mitochondrion; however, no evidence is found for simultaneous coxII expression in both compartments. The nuclear coxII sequence more closely resembles edited mitochondrial coxII transcripts than the genes encoding these RNAs. Hence, gene transfer appears to have involved reverse transcription of an edited RNA intermediate. The nuclear gene contains an intron at the junction of the transit peptide sequence and the mature protein-coding sequence; exon shuffling may have played a role in assembling a functional coxII gene in the nucleus.	INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA	Indiana University System; Indiana University Bloomington	NUGENT, JM (corresponding author), UNIV MICHIGAN, DEPT BIOL, ANN ARBOR, MI 48104 USA.		Palmer, Jeffrey/P-6747-2014	Palmer, Jeffrey/0000-0002-4626-2220	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1988, PLANT MOL BIOL REPOR, DOI DOI 10.1007/BF02669591; BALDAUF SL, 1990, NATURE, V344, P262, DOI 10.1038/344262a0; BARTNIK E, 1986, NUCLEIC ACIDS RES, V14, P2407, DOI 10.1093/nar/14.5.2407; BENNETT MD, 1976, PHILOS T R SOC B, V274, P227, DOI 10.1098/rstb.1976.0044; BINDER S, 1990, CURR GENET, V17, P353, DOI 10.1007/BF00314884; BLAND MM, 1986, MOL GEN GENET, V204, P8, DOI 10.1007/BF00330180; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; BONEN L, 1984, EMBO J, V3, P2531, DOI 10.1002/j.1460-2075.1984.tb02168.x; BONEN L, 1987, NUCLEIC ACIDS RES, V15, P10393, DOI 10.1093/nar/15.24.10393; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CAPALDI RA, 1983, BIOCHIM BIOPHYS ACTA, V726, P135, DOI 10.1016/0304-4173(83)90003-4; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; COVELLO PS, 1990, NUCLEIC ACIDS RES, V18, P5189, DOI 10.1093/nar/18.17.5189; CREPET WL, 1985, SCIENCE, V228, P1087, DOI 10.1126/science.228.4703.1087; Cronquist A., 1988, EVOLUTION CLASSIFICA, V2; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; DONOGHUE MJ, 1989, INT CONGR SER, V824, P181; Doyle JJ., 1987, FOCUS, V19, P11, DOI DOI 10.2307/2419362; DROUIN G, 1987, NATURE, V328, P557, DOI 10.1038/328557a0; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FOX TD, 1981, CELL, V26, P315, DOI 10.1016/0092-8674(81)90200-2; FROMAN BE, 1989, MOL GEN GENET, V217, P126, DOI 10.1007/BF00330951; GANTT JS, IN PRESS EMBO J; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GRABAU EA, 1987, CURR GENET, V11, P287, DOI 10.1007/BF00355402; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; GUALBERTO JM, 1990, NUCLEIC ACIDS RES, V18, P3771, DOI 10.1093/nar/18.13.3771; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HIESEL R, 1983, EMBO J, V2, P2173, DOI 10.1002/j.1460-2075.1983.tb01719.x; HIESEL R, 1990, CURR GENET, V18, P371, DOI 10.1007/BF00318219; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; IZUCHI S, 1990, CURR GENET, V18, P239, DOI 10.1007/BF00318387; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; KAO TH, 1984, NUCLEIC ACIDS RES, V12, P7305, DOI 10.1093/nar/12.19.7305; KIM YH, 1990, J BIOL CHEM, V265, P848; KOLODNER R, 1972, P NATL ACAD SCI USA, V69, P1830, DOI 10.1073/pnas.69.7.1830; Maniatis T, 1982, MOL CLONING; MARECHALDROUARD L, 1990, NUCLEIC ACIDS RES, V18, P3689, DOI 10.1093/nar/18.13.3689; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; MOON E, 1985, NUCLEIC ACIDS RES, V13, P3195, DOI 10.1093/nar/13.9.3195; NEWTON KJ, 1988, ANNU REV PLANT PHYS, V39, P503, DOI 10.1146/annurev.arplant.39.1.503; NUGENT JM, 1988, CURR GENET, V14, P501, DOI 10.1007/BF00521276; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; OLSEN GJ, 1988, METHOD ENZYMOL, V164, P793; OLSEN GJ, 1987, COLD SPRING HARB SYM, V52, P825, DOI 10.1101/SQB.1987.052.01.090; Polhill R.M., 1981, ADV LEGUME SYSTEMATI, P191; PRUITT KD, 1989, CURR GENET, V16, P281, DOI 10.1007/BF00422115; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUSTER W, 1990, EMBO J, V9, P263, DOI 10.1002/j.1460-2075.1990.tb08104.x; SCHUSTER W, 1990, MOL CELL BIOL, V10, P2428, DOI 10.1128/MCB.10.5.2428; SCHUSTER W, 1987, EMBO J, V6, P2857, DOI 10.1002/j.1460-2075.1987.tb02587.x; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SHIH MC, 1986, CELL, V47, P73, DOI 10.1016/0092-8674(86)90367-3; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; Stern D. B., 1988, METHODS PLANT MOL BI, P309; STERN DB, 1982, NATURE, V299, P698, DOI 10.1038/299698a0; TAKESHIMA H, 1988, J MOL BIOL, V200, P1, DOI 10.1016/0022-2836(88)90328-2; TSUZUKI T, 1987, J MOL BIOL, V198, P21, DOI 10.1016/0022-2836(87)90454-2; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAHLEITHNER JA, 1990, P NATL ACAD SCI USA, V87, P548, DOI 10.1073/pnas.87.2.548; WAHLEITHNER JA, 1988, NUCLEIC ACIDS RES, V16, P6897, DOI 10.1093/nar/16.14.6897; WATSON JC, 1986, METHOD ENZYMOL, V118, P57; WOLFE KH, 1989, J MOL EVOL, V29, P208, DOI 10.1007/BF02100204; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201	66	283	290	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1991	66	3					473	481		10.1016/0092-8674(81)90011-8	http://dx.doi.org/10.1016/0092-8674(81)90011-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1714355	Green Published			2022-12-01	WOS:A1991GA94100009
J	RAJU, U; KOUMENIS, C; NUNEZREGUEIRO, M; ESKIN, A				RAJU, U; KOUMENIS, C; NUNEZREGUEIRO, M; ESKIN, A			ALTERATION OF THE PHASE AND PERIOD OF A CIRCADIAN OSCILLATOR BY A REVERSIBLE TRANSCRIPTION INHIBITOR	SCIENCE			English	Article							PROTEIN-SYNTHESIS; SUPRACHIASMATIC NUCLEUS; GENE-EXPRESSION; APLYSIA EYE; RHYTHM; PACEMAKER; INVOLVEMENT; SEROTONIN; SHIFTS; CAMP	A function for transcription in the mechanism of a circadian oscillator was investigated with the reversible transcription inhibitor 5,6-dichloro-1-beta-D-ribobenzimidazole (DRB). Two-hour treatments with DR-B shifted the phase of the circadian rhythm of the isolated eye of Aplysia, and continuous treatments of DRB lengthened the free running period of this rhythm. Camptothecin, an inhibitor of transcription that is structurally unrelated to DRB, had similar effects on the circadian rhythm. These results suggest that transcription may be part of the circadian oscillating mechanism.	UNIV HOUSTON, DEPT BIOCHEM & BIOPHYS SCI, HOUSTON, TX 77204 USA	University of Houston System; University of Houston			Koumenis, Constantinos/B-2002-2008	Koumenis, Costas/0000-0001-5945-4726	NIMH NIH HHS [MH41979] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH041979, R37MH041979] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; DUNLAP JC, 1990, TRENDS GENET, V6, P159, DOI 10.1016/0168-9525(90)90151-U; EARNEST DJ, 1990, EXP NEUROL, V109, P353, DOI 10.1016/S0014-4886(05)80027-5; ESKIN A, 1977, J COMP PHYSIOL, V117, P1, DOI 10.1007/BF00605521; ESKIN A, 1983, SCIENCE, V220, P82, DOI 10.1126/science.6298939; ESKIN A, 1984, P NATL ACAD SCI-BIOL, V81, P7637, DOI 10.1073/pnas.81.23.7637; ESKIN A, 1982, P NATL ACAD SCI-BIOL, V79, P660, DOI 10.1073/pnas.79.2.660; FELDMAN JF, 1967, P NATL ACAD SCI USA, V57, P1080, DOI 10.1073/pnas.57.4.1080; GRANICK D, 1975, J CELL BIOL, V65, P398, DOI 10.1083/jcb.65.2.398; HALL JC, 1990, ANNU REV GENET, V24, P659; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARTWIG R, 1985, P NATL ACAD SCI USA, V82, P6899, DOI 10.1073/pnas.82.20.6899; HORWITZ SB, 1971, MOL PHARMACOL, V7, P632; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JACKLET JW, 1977, SCIENCE, V198, P69, DOI 10.1126/science.897685; JACKLET JW, 1984, INT REV CYTOL, V89, P251, DOI 10.1016/S0074-7696(08)61305-4; JACKLET JW, 1979, J EXP BIOL, V63, P222; KARAKASHIAN MW, 1962, P NATL ACAD SCI USA, V48, P2130, DOI 10.1073/pnas.48.12.2130; KHALSA SBS, 1988, J COMP PHYSIOL A, V164, P195, DOI 10.1007/BF00603950; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; KOUMENIS C, IN PRESS SOC NEUR AB; MILOS P, 1990, NATURWISSENSCHAFTEN, V77, P87, DOI 10.1007/BF01131782; NAKASHIMA J, 1986, J BIOL RHYTHM, V1, P163; PROSSER RA, 1989, P NATL ACAD SCI USA, V86, P6812, DOI 10.1073/pnas.86.17.6812; RAJU U, 1990, AM J PHYSIOL, V258, pR256, DOI 10.1152/ajpregu.1990.258.1.R256; ROBERTS MH, 1989, BRAIN RES, V504, P211, DOI 10.1016/0006-8993(89)91359-0; ROBERTSON LM, 1988, J NEUROSCI, V8, P12; ROTHMAN BS, 1976, J GEN PHYSIOL, V68, P359, DOI 10.1085/jgp.68.4.359; ROTHMAN BS, 1977, FED PROC, V36, P2050; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; STRUMWASSER F, 1988, J PHYSIOLOGY PARIS, V83, P246; TAMM I, 1976, J CELL BIOL, V69, P229, DOI 10.1083/jcb.69.2.229; TAMM I, 1978, ADV VIRUS RES, V22, P188; TECHEL D, 1990, J COMP PHYSIOL B, V159, P695, DOI 10.1007/BF00691715; WOOLUM JC, 1983, J COMP PHYSIOL, V151, P253, DOI 10.1007/BF00623902; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; YEUNG SJ, 1987, P NATL ACAD SCI USA, V84, P279, DOI 10.1073/pnas.84.1.279; YEUNG SJ, 1988, J BIOL RHYTHM, V3, P225, DOI 10.1177/074873048800300301; ZWARTJES RE, 1990, J NEUROBIOL, V21, P376, DOI 10.1002/neu.480210210	39	72	72	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1991	253	5020					673	675		10.1126/science.1871602	http://dx.doi.org/10.1126/science.1871602			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA304	1871602				2022-12-01	WOS:A1991GA30400041
J	RESNICK, NM; MALOY, WL; GUY, HR; ZASLOFF, M				RESNICK, NM; MALOY, WL; GUY, HR; ZASLOFF, M			A NOVEL ENDOPEPTIDASE FROM XENOPUS THAT RECOGNIZES ALPHA-HELICAL SECONDARY STRUCTURE	CELL			English	Article							EUKARYOTIC SIGNAL PEPTIDASE; CLEAVAGE SITE; SECRETORY GRANULES; HORMONE PRECURSORS; SINGLE ARGININE; LIPID BILAYERS; LAEVIS SKIN; SUBSTRATE; SEQUENCE; FORMS	The magainin peptides of Xenopus laevis are broad-spectrum antimicrobial agents. Upon discharge from the skin glands, these basic, amphipathic peptides are each further processed at a single Xaa-Lys bond into half-peptides by a cosecreted protease. We describe the characterization and purification to homogeneity of this endopeptidase from Xenopus skin. The enzyme is a metalloprotease 110 kd in size. Analyses of substrate specificity revealed that the endopeptidase recognizes peptides that share the ability to adopt an amphipathic, alpha-helical motif composed of at least 12 residues, with one face strongly hydrophobic. Cleavage occurs on the amino side of a specific lysine that must be precisely positioned relative to the hydrophobic face of the alpha-helix. This enzyme, which we propose to call "magaininase," represents a novel class of endopeptidases that hydrolyzes peptides on the basis of specific secondary structure rather than primary amino acid sequence.	UNIV PENN,MOLEC BIOL GRAD GRP,PHILADELPHIA,PA 19104; MAGAININ SCI INC,PLYMOUTH MEETING,PA 19462; NCI,MATH BIOL LAB,BETHESDA,MD 20892	University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	RESNICK, NM (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV HUMAN GENET,PHILADELPHIA,PA 19104, USA.							BECHINGER B, 1991, IN PRESS J BIOMOL NM; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; BEINFELD MC, 1989, J BIOL CHEM, V264, P4460; BEK E, 1990, BIOCHEMISTRY-US, V29, P178, DOI 10.1021/bi00453a024; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOMAN HG, 1989, J BIOL CHEM, V264, P5852; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; BRAKCH N, 1989, J BIOL CHEM, V264, P15912; CAULFIELD MP, 1989, J BIOL CHEM, V264, P15813; DARBY NJ, 1990, BIOSCIENCE REP, V10, P1, DOI 10.1007/BF01116845; DARBY NJ, 1991, EUR J BIOCHEM, V195, P65, DOI 10.1111/j.1432-1033.1991.tb15676.x; DOCHERTY K, 1989, J BIOL CHEM, V264, P18335; DOCKRAY GJ, 1975, J CELL BIOL, V64, P724, DOI 10.1083/jcb.64.3.724; DUCLOHIER H, 1989, BIOPHYS J, V56, P1017, DOI 10.1016/S0006-3495(89)82746-8; DUFFAUD G, 1988, J BIOL CHEM, V263, P10224; FOLZ RJ, 1988, J BIOL CHEM, V263, P2070; Gabriel, 1971, METHOD ENZYMOL, V22, P565, DOI 10.1016/0076-6879(71)22041-3; GIBSON BW, 1986, J BIOL CHEM, V261, P5341; GIOVANNINI MG, 1987, BIOCHEM J, V243, P113, DOI 10.1042/bj2430113; GLUSCHANKOF P, 1988, FEBS LETT, V234, P149, DOI 10.1016/0014-5793(88)81322-X; GLUSCHANKOF P, 1987, NEUROCHEM RES, V12, P951, DOI 10.1007/BF00966318; GOMEZ S, 1989, EMBO J, V8, P2911, DOI 10.1002/j.1460-2075.1989.tb08440.x; HURT EC, 1987, J BIOL CHEM, V262, P1420; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; KAISER ET, 1987, ANN REV BIOPHYS CHEM, V16, P562; KUKS PFM, 1989, J BIOL CHEM, V264, P14609; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOH YP, 1988, MOL MECHANISMS SECRE, P525; MARION D, 1988, FEBS LETT, V227, P21, DOI 10.1016/0014-5793(88)81405-4; MATSUZAKI K, 1989, BIOCHIM BIOPHYS ACTA, V981, P130, DOI 10.1016/0005-2736(89)90090-4; MAULET Y, 1983, BIOCHEMISTRY-US, V22, P5680, DOI 10.1021/bi00293a035; MCDOWELL L, 1985, BIOCHEMISTRY-US, V24, P2979, DOI 10.1021/bi00333a026; MIZUNO K, 1986, BIOCHEM BIOPH RES CO, V137, P984, DOI 10.1016/0006-291X(86)90322-0; MOLLAY C, 1986, EUR J BIOCHEM, V160, P31, DOI 10.1111/j.1432-1033.1986.tb09935.x; OCHS D, 1983, ANAL BIOCHEM, V135, P470, DOI 10.1016/0003-2697(83)90714-5; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PATEL YC, 1981, ENDOCRINOLOGY, V109, P1943, DOI 10.1210/endo-109-6-1943; PLEVRAKIS I, 1989, BIOCHEMISTRY-US, V28, P2705, DOI 10.1021/bi00432a051; POULTER L, 1988, J BIOL CHEM, V263, P3279; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; RICHTER K, 1986, J BIOL CHEM, V261, P3676; SCHWARTZ TW, 1986, FEBS LETT, V200, P1, DOI 10.1016/0014-5793(86)80500-2; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SURES I, 1984, P NATL ACAD SCI-BIOL, V81, P380, DOI 10.1073/pnas.81.2.380; TATEMOTO K, 1978, P NATL ACAD SCI USA, V75, P4115, DOI 10.1073/pnas.75.9.4115; THORNE BA, 1990, J BIOL CHEM, V265, P8436; TOSTESON MT, 1981, BIOPHYS J, V36, P109, DOI 10.1016/S0006-3495(81)84719-4; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WILLIAMS RW, 1990, BIOCHEMISTRY-US, V29, P4490, DOI 10.1021/bi00470a031; ZAKARIAN S, 1982, BIOCHEM J, V202, P561, DOI 10.1042/bj2020561; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910	52	76	78	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					541	554		10.1016/0092-8674(81)90017-9	http://dx.doi.org/10.1016/0092-8674(81)90017-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1868549				2022-12-01	WOS:A1991GA94100015
J	RISE, ML; FRANKEL, WN; COFFIN, JM; SEYFRIED, TN				RISE, ML; FRANKEL, WN; COFFIN, JM; SEYFRIED, TN			GENES FOR EPILEPSY MAPPED IN THE MOUSE	SCIENCE			English	Article							EL MOUSE; QUANTITATIVE TRAITS; MENDELIAN FACTORS; LINKAGE MAP; MICE; PROVIRUSES; ANTICONVULSANTS; SUSCEPTIBILITY; SEIZURES; PROBES	The neurological mutant mouse strain El is a model for complex partial seizures in humans. The inheritance of epileptic seizures with seven conventional chromosomal markers and over 60 endogenous proviral markers was studied by means of backcrosses of El with two seizure-resistant strains, DBA/2J and ABP/LeJ. The major gene responsible for this epileptic phenotype (El-1) was localized to a region distal with respect to the centromere on chromosome 9. At least one other gene, El-2, linked to proviral markers on chromosome 2, also influences the seizure phenotype. In addition, a potential modifier of seizures was detected in the DBA/2J background. The location of El-1 on distal chromosome 9 may allow identification of an epilepsy candidate gene in humans on the basis of conserved synteny with human chromosome 3.	BOSTON COLL,DEPT BIOL,CHESTNUT HILL,MA 02167; TUFTS UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,BOSTON,MA 02111	Boston College; Tufts University				Seyfried, Thomas/0000-0003-1491-3989	NATIONAL CANCER INSTITUTE [R35CA044385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023355] Funding Source: NIH RePORTER; NCI NIH HHS [R35CA44385] Funding Source: Medline; NINDS NIH HHS [NS 23355] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON VE, 1986, ADV NEUROL, P59; BARANOV VS, 1987, CHROMOSOMA, V96, P60, DOI 10.1007/BF00285885; BAUMANN RJ, 1982, GENETIC BASIS EPILEP, P11; BRIGANDE J V, 1989, Epilepsia, V30, P652; DELGADOESCUETA AV, 1983, NEW ENGL J MED, V308, P1508, DOI 10.1056/NEJM198306233082506; EYFRIED TN, 1986, ADV NEUROL, P115; FELTON J, 1974, J BIOL CHEM, V249, P3267; FRANKEL WN, 1989, J VIROL, V63, P3810, DOI 10.1128/JVI.63.9.3810-3821.1989; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; FRANKEL WN, 1990, GENETICS, V124, P221; FRANKEL WN, 1989, J VIROL, V63, P1762; FRANKEL WN, 1991, MOUSE GENOME, V89, P266; FUETA Y, 1986, Journal of UOEH, V8, P417; FUKAHORI M, 1990, BRAIN RES, V529, P16, DOI 10.1016/0006-8993(90)90806-M; GLASER GH, 1977, PRACT MED, V10, P1; HAUSER WA, 1982, GENETIC BASIS EPILEP, P3; HONDA T, 1984, BRAIN DEV-JPN, V6, P22, DOI 10.1016/S0387-7604(84)80005-4; Imaizumi K., 1959, B EXP ANIM TOKYO, V8, P6; Kurokawa M, 1966, Prog Brain Res, V21, P112; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANDER ES, 1989, GENETICS, V121, P185; NADEAU JH, 1984, P NATL ACAD SCI-BIOL, V81, P814, DOI 10.1073/pnas.81.3.814; NADEAU JH, 1989, TRENDS GENET, V5, P82, DOI 10.1016/0168-9525(89)90031-0; NEUMANN PE, 1990, BEHAV GENET, V20, P307, DOI 10.1007/BF01067798; NEUMANN PE, IN PRESS P NATL ACAD; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; RISE ML, UNPUB; SEARLE A G, 1987, Genomics, V1, P3, DOI 10.1016/0888-7543(87)90099-1; SEYFRIED TN, 1985, EPILEPSIA, V26, P143, DOI 10.1111/j.1528-1157.1985.tb05398.x; SEYFRIED TN, 1982, MOUSE BIOMEDICAL RES, P97; STOYE JP, 1988, J VIROL, V62, P168, DOI 10.1128/JVI.62.1.168-175.1988; SUGAYA E, 1986, EPILEPSIA, V27, P354, DOI 10.1111/j.1528-1157.1986.tb03553.x; SUZUKI J, 1976, EXPERIENTIA, V32, P336, DOI 10.1007/BF01940824; SUZUKI J, 1983, BRAIN RES, V266, P359, DOI 10.1016/0006-8993(83)90670-4	34	184	187	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1991	253	5020					669	673		10.1126/science.1871601	http://dx.doi.org/10.1126/science.1871601			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA304	1871601				2022-12-01	WOS:A1991GA30400040
J	RUOHOLA, H; BREMER, KA; BAKER, D; SWEDLOW, JR; JAN, LY; JAN, YN				RUOHOLA, H; BREMER, KA; BAKER, D; SWEDLOW, JR; JAN, LY; JAN, YN			ROLE OF NEUROGENIC GENES IN ESTABLISHMENT OF FOLLICLE CELL FATE AND OOCYTE POLARITY DURING OOGENESIS IN DROSOPHILA	CELL			English	Article							EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; NOTCH LOCUS; C-ELEGANS; ANTEROPOSTERIOR POLARITY; CAENORHABDITIS-ELEGANS; TRANSMEMBRANE PROTEIN; BICOID RNA; MELANOGASTER; PATTERN	Oogenesis in Drosophila involves specification of both germ cells and the surrounding somatic follicle cells, as well as the determination of oocyte polarity. We found that two neurogenic genes, Notch and Delta, are required in oogenesis. These genes encode membrane proteins with epidermal growth factor repeats and are essential in the decision of an embryonic ectodermal cell to take on the fate of neuroblast or epidermoblast. In oogenesis, mutation in either gene leads to an excess of posterior follicle cells, a cell fate change reminiscent of the hyperplasia of neuroblasts seen in neurogenic mutant embryos. Furthermore, the Notch mutation in somatic cells causes mislocalization of bicoid in the oocyte. These results suggest that the neurogenic genes Notch and Delta are involved in both follicle cell development and the establishment of anterior-posterior polarity in the oocyte.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GRAD GRP BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	RUOHOLA, H (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.		Baker, David/K-8941-2012	Baker, David/0000-0001-7896-6217; Jan, Yuh Nung/0000-0003-1367-6299; Swedlow, Jason/0000-0002-2198-1958; Jan, Lily/0000-0003-3938-8498				ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BROWER DL, 1981, J EMBRYOL EXP MORPH, V63, P233; BUSSON D, 1983, GENETICS, V105, P309; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPOSORTEGA JA, 1988, TRENDS NEUROSCI, V11, P400, DOI 10.1016/0166-2236(88)90077-X; CAMPOSORTEGA JA, 1991, IN PRESS ANN REV NEU; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; DELACONCHA A, 1988, GENETICS, V118, P499; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; DRIEVER W, 1990, DEVELOPMENT, V109, P811; EPHRUSSI A, 1991, IN PRESS CELL, V66; FASANO L, 1988, DEVELOPMENT, V104, P245; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; HAENLIN M, 1990, DEVELOPMENT, V110, P905; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JIMENEZ F, 1982, ROUX ARCH DEV BIOL, V191, P191, DOI 10.1007/BF00848335; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1983, CELL, V34, P421, DOI 10.1016/0092-8674(83)90376-8; King RC., 1970, OVARIAN DEV DROSOPHI; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KOCH EA, 1969, Z ZELLFORSCH MIK ANA, V102, P129, DOI 10.1007/BF00336421; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; MAHOWALD AP, 1983, DEV BIOL, V98, P437, DOI 10.1016/0012-1606(83)90373-1; MAHOWALD AP, 1978, GENET BIOL DROSOPHIL, P141; MANSEAU LJ, 1989, TRENDS GENET, V5, P400, DOI 10.1016/0168-9525(89)90198-4; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SEYDOUX G, 1990, CELL, V61, P939, DOI 10.1016/0092-8674(90)90060-R; SHELLENBARGER DL, 1975, GENETICS, V81, P143; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VASSIN H, 1985, J NEUROGENET, V2, P291, DOI 10.3109/01677068509102325; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WIESCHAUS E, 1980, DEV NEUROBIOLOGY DRO, P85; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	60	329	330	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					433	449		10.1016/0092-8674(81)90008-8	http://dx.doi.org/10.1016/0092-8674(81)90008-8			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1907889				2022-12-01	WOS:A1991GA94100006
J	VOJTEK, A; HAARER, B; FIELD, J; GERST, J; POLLARD, TD; BROWN, S; WIGLER, M				VOJTEK, A; HAARER, B; FIELD, J; GERST, J; POLLARD, TD; BROWN, S; WIGLER, M			EVIDENCE FOR A FUNCTIONAL LINK BETWEEN PROFILIN AND CAP IN THE YEAST SACCHAROMYCES-CEREVISIAE	CELL			English	Article							ACTIN-BINDING PROTEINS; PHOSPHOLIPASE C-II; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; ACANTHAMOEBA PROFILIN; ADENYLATE-CYCLASE; A-431 CELLS; GENE	CAP is a component of the S. cerevisiae adenylyl cyclase complex. The N-terminal domain is required for cellular RAS responsiveness. Loss of the C-terminal domain is associated with morphological and nutritional defects. Here we report that cap- cells bud randomly and are defective in actin distribution. The morphological and nutritional defects associated with loss of the CAP C-terminal domain are suppressed by overexpression of PFY, the gene encoding profilin, an actin- and polyphosphoinositide-binding protein. The phenotype of cells lacking PFY resembles that of cells lacking the CAP C-terminal domain. Study of mutated yeast profilins and profilins from Acanthamoeba suggests that the ability of profilin to suppress cap- cells is dependent upon a property other than, or in addition to, its ability to bind actin. This property may be its ability to bind polyphosphoinositides. We propose that CAP and profilin provide a link between growth signals and remodeling of the cellular cytoskeleton.	UNIV MICHIGAN, SCH MED, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48109 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, BALTIMORE, MD 21205 USA	University of Michigan System; University of Michigan; Johns Hopkins University	VOJTEK, A (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.			Wigler, Michael/0000-0003-4396-1971				ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; AMATRUDA JF, 1990, NATURE, V344, P352, DOI 10.1038/344352a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KAISER DA, 1986, J CELL BIOL, V102, P221, DOI 10.1083/jcb.102.1.221; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LASSING I, 1988, J CELL BIOCHEM, V37, P255, DOI 10.1002/jcb.240370302; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; Maniatis T., 1982, MOL CLONING; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1991, IN PRESS CELL MOTIL; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; ROSE MD, 1990, METHODS YEAST GENETI; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WAHL M, 1988, J BIOL CHEM, V263, P7581; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254	35	179	180	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1991	66	3					497	505		10.1016/0092-8674(81)90013-1	http://dx.doi.org/10.1016/0092-8674(81)90013-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1868547	Green Published			2022-12-01	WOS:A1991GA94100011
J	WEEKS, KM; CROTHERS, DM				WEEKS, KM; CROTHERS, DM			RNA RECOGNITION BY TAT-DERIVED PEPTIDES - INTERACTION IN THE MAJOR GROOVE	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SEQUENCE-SPECIFIC RECOGNITION; HIV-1 TAT; TRANS-ACTIVATION; MESSENGER-RNA; RESPONSIVE SEQUENCE; GENE-EXPRESSION; LOOP SEQUENCE; NUCLEIC-ACIDS; NASCENT RNA	Replication of human immunodeficiency virus requires binding of the viral Tat protein to its RNA target sequence TAR; peptides derived from Tat bind to a TAR "contact site" spanning 5 bp and a trinucleotide pyrimidine bulge. We find that high affinity binding requires a U residue in the bulge loop and 2 specific adjacent base pairs. Other bulged RNAs bind in a lower affinity nonspecific manner; sequence-specific binding requires a bulge loop of more than 1 nucleotide. Reaction with diethyl pyrocarbonate indicates that one effect of the bulge is to make the otherwise deep and narrow RNA major groove accessible. A model consistent with these data involves local distortion of A-form geometry at the bulge, which bends the helix and permits protein binding and interactive access in the RNA major groove.			WEEKS, KM (corresponding author), YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039546, R37GM021966, R01GM021966] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 39546, GM 21966] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V48, P1392, DOI 10.1016/0006-291X(72)90867-4; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; Endo S, 1989, Virus Genes, V3, P99; FAUS I, 1990, J MOL BIOL, V212, P53, DOI 10.1016/0022-2836(90)90304-5; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364; HOLBROOK SR, 1983, BIOPOLYMERS, V22, P1145, DOI 10.1002/bip.360220410; JAEGER JA, 1990, METHODS ENZYMOL, V183, P281; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; JEYAPAUL J, 1990, P NATL ACAD SCI USA, V87, P7030, DOI 10.1073/pnas.87.18.7030; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; MOUGEL M, 1987, J MOL BIOL, V198, P91, DOI 10.1016/0022-2836(87)90460-8; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; MYERS G, 1990, HUMAN RETROVIRUSES A; PEATTIE DA, 1980, P NATL ACAD SCI-BIOL, V77, P4679, DOI 10.1073/pnas.77.8.4679; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; SUBRAMANIAN T, 1990, VIROLOGY, V176, P178, DOI 10.1016/0042-6822(90)90242-J; SUSSMAN JL, 1976, SCIENCE, V192, P853, DOI 10.1126/science.775636; TANG RS, 1990, BIOCHEMISTRY-US, V29, P5232, DOI 10.1021/bi00474a003; VANSTOLK BJ, 1984, J MOL BIOL, V180, P151, DOI 10.1016/0022-2836(84)90435-2; VARANI G, 1989, BIOCHEMISTRY-US, V28, P7760, DOI 10.1021/bi00445a036; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011	48	337	345	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					577	588		10.1016/0092-8674(81)90020-9	http://dx.doi.org/10.1016/0092-8674(81)90020-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1907891				2022-12-01	WOS:A1991GA94100018
J	WOODS, DF; BRYANT, PJ				WOODS, DF; BRYANT, PJ			THE DISKS-LARGE TUMOR SUPPRESSOR GENE OF DROSOPHILA ENCODES A GUANYLATE KINASE HOMOLOG LOCALIZED AT SEPTATE JUNCTIONS	CELL			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; AFFECTING IMAGINAL DISKS; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; PHOSPHOLIPASE-C; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; RECESSIVE ONCOGENE; MEMBRANE-PROTEINS; EPITHELIAL-CELLS	Mutations of the lethal(1)discs large-1 (dlg) tumor suppressor gene of Drosophila cause neoplastic overgrowth of the imaginal discs. Sequencing of a near full-length cDNA predicts a protein containing a domain homologous to yeast guanylate kinase and a region homologous to SH3, a putative regulatory motif in nonreceptor protein tyrosine kinases and other signal transduction proteins. Immunofluorescence analysis using antibodies directed against fusion peptides shows that the dlg gene product is localized in an apical belt of the lateral cell membrane, at the position of the septate junction. The results suggest that a signal transduction process involving guanine nucleotides occurs at the septate junction and is necessary for cell proliferation control in Drosophila epithelia.			WOODS, DF (corresponding author), UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717, USA.							ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BERGER A, 1989, EUR J BIOCHEM, V184, P433, DOI 10.1111/j.1432-1033.1989.tb15035.x; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BOS JL, 1989, CANCER RES, V49, P4682; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BRYANT PJ, 1988, DEV BIOL, V129, P541, DOI 10.1016/0012-1606(88)90399-5; BRYANT PJ, 1971, DEV BIOL, V24, P233, DOI 10.1016/0012-1606(71)90097-2; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEQUIN R, 1984, DEV BIOL, V104, P37, DOI 10.1016/0012-1606(84)90034-4; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DOMENIGHINI M, 1990, MOL MICROBIOL, V4, P787, DOI 10.1111/j.1365-2958.1990.tb00649.x; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; EICHENBERGERGLINZ S, 1979, ROUX ARCH DEV BIOL, V186, P333, DOI 10.1007/BF00848457; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GATEFF E, 1989, Critical Reviews in Oncogenesis, V1, P221; GATEFF E, 1974, ROUXS ARCH, V176, P23; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Goebel S.J., 1990, VIROLOGY, V179, P517; HALL SW, 1986, EUR J BIOCHEM, V161, P551, DOI 10.1111/j.1432-1033.1986.tb10477.x; HANRATTY WP, 1984, ROUX ARCH DEV BIOL, V193, P98, DOI 10.1007/BF00848637; HERZLINGER DA, 1984, J CELL BIOL, V98, P1777, DOI 10.1083/jcb.98.5.1777; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; JURSNICH VA, 1990, DEV BIOL, V140, P413, DOI 10.1016/0012-1606(90)90090-6; KLAMBT C, 1989, DEV BIOL, V133, P425, DOI 10.1016/0012-1606(89)90046-8; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LIOTTA LA, 1990, J NATL CANCER I, V82, P1170, DOI 10.1093/jnci/82.14.1170; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN P, 1977, DEV BIOL, V55, P213, DOI 10.1016/0012-1606(77)90168-3; MARTIN PF, 1982, J EXP ZOOL, V222, P97, DOI 10.1002/jez.1402220113; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; MERZ R, 1990, ENVIRON HEALTH PERSP, V88, P163, DOI 10.2307/3431068; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURPHY C, 1974, DEV BIOL, V39, P23, DOI 10.1016/S0012-1606(74)80005-9; Noirot-Timothee C., 1980, International Review of Cytology, V63, P97, DOI 10.1016/S0074-7696(08)61758-1; PAWSON T, 1988, ONCOGENE, V3, P491; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERRIMON N, 1988, DEV BIOL, V127, P392, DOI 10.1016/0012-1606(88)90326-0; PERRIMON N, 1983, DEV BIOL, V100, P365, DOI 10.1016/0012-1606(83)90231-2; PISAM M, 1976, J CELL BIOL, V71, P907, DOI 10.1083/jcb.71.3.907; PONDER BAJ, 1990, TRENDS GENET, V6, P213, DOI 10.1016/0168-9525(90)90181-5; POODRY CA, 1970, ROUX ARCH DEV BIOL, V166, P1, DOI 10.1007/BF00576805; POODRY CA, 1990, ROUX ARCH DEV BIOL, V199, P219, DOI 10.1007/BF01682081; Potts W M, 1988, Oncogene Res, V3, P343; RAMIREZ F, 1990, ANN NY ACAD SCI, V580, P74, DOI 10.1111/j.1749-6632.1990.tb17919.x; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEHLE T, 1990, J MOL BIOL, V211, P249, DOI 10.1016/0022-2836(90)90024-G; STEWART M, 1972, DEV BIOL, V27, P71, DOI 10.1016/0012-1606(72)90113-3; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WEINER J, 1990, J CELL BIOL, V22, P587; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; ZIOMEK CA, 1980, J CELL BIOL, V86, P849, DOI 10.1083/jcb.86.3.849	75	779	791	0	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					451	464		10.1016/0092-8674(81)90009-X	http://dx.doi.org/10.1016/0092-8674(81)90009-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651169				2022-12-01	WOS:A1991GA94100007
J	BARRETT, SCH; CHARLESWORTH, D				BARRETT, SCH; CHARLESWORTH, D			EFFECTS OF A CHANGE IN THE LEVEL OF INBREEDING ON THE GENETIC LOAD	NATURE			English	Article							PLANT-POPULATIONS; DELETERIOUS MUTATIONS; DEPRESSION; EVOLUTION; RATES; LOCUS	"THE effects of inbreeding may not be as noticeable in the first generation as the invigoration immediately apparent after crossing" 1. This statement, published in 1919, has received little attention, and has apparently never been tested empirically, although the reduction of the genetic load of populations by inbreeding is well known in theoretical terms 2-5. Because inbreeding increases homozygosity, and hence the effectiveness of selection against recessive or partially recessive detrimental alleles, changes in levels of inbreeding can lead to a reduction in the frequencies of such mutant alleles. This results in equilibration at higher population mean fitness 6 and is referred to as 'purging' populations of their genetic load. Severe inbreeding can also reduce genetic load due to overdominant alleles, provided selection coefficients are not symmetrical at all loci, because alleles giving lower fitness will be reduced in frequency at equilibrium 7-8. With either fitness model, however, reduction in genetic load takes time, and the initial effect of an increase in inbreeding is reduced fitness due to homozygosity. There are few data relating to the extent to which fitness is reduced during inbreeding in a set of lines and to how long the reduction lasts before increasing again to the initial level, or higher. Inbreeding experiments involving sib mating in mice and Drosophila subobscura 10, and successive bottlenecks in house flies 11 have yielded some evidence consistent with the purging hypothesis. Here, we report results of an experiment demonstrating a prolonged time-course of recovery of mean fitness under self-fertilization of a naturally outcrossing plant, and also compare our results with expectations derived by computer calculations. Our results show that the genetic load present in an outcrossing population can be explained only with a high mutation rate to partially recessive deleterious alleles, and that inbreeding purges the population of mutant alleles.	UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637	University of Chicago	BARRETT, SCH (corresponding author), UNIV TORONTO,DEPT BOT,25 WILLCOCKS ST,TORONTO M5S 3B2,ONTARIO,CANADA.		Charlesworth, Deborah/F-3071-2011; Barrett, Spencer CH/M-3751-2013; Barrett, Spencer C.H./S-5782-2019	Barrett, Spencer C.H./0000-0002-7762-3455				BARRETT S C H, 1990, Plant Species Biology, V5, P41, DOI 10.1111/j.1442-1984.1990.tb00191.x; BROWN AHD, 1979, THEOR POPUL BIOL, V15, P1, DOI 10.1016/0040-5809(79)90025-X; BRYANT EH, 1990, AM NAT, V136, P542, DOI 10.1086/285112; CHARLESWORTH B, 1990, NATURE, V347, P380, DOI 10.1038/347380a0; CHARLESWORTH D, 1987, ANNU REV ECOL SYST, V18, P237, DOI 10.1146/annurev.ecolsys.18.1.237; CHARLESWORTH D, 1990, EVOLUTION, V44, P870, DOI 10.1111/j.1558-5646.1990.tb03811.x; CHARLESWORTH D, 1990, EVOLUTION, V44, P1469, DOI [10.1111/j.1558-5646.1990.tb03839.x, 10.2307/2409330]; CROW J. F., 1970, Biomathematics. Volume 1. Mathematical topics in population genetics., P128; CROW JF, 1948, GENETICS, V33, P477; EAST EM, 1919, INBREEDING OUTBREEDI, P147; FALCONER DS, 1972, GENET RES CAMB, V17, P215; GLOVER DE, 1987, HEREDITY, V59, P7, DOI 10.1038/hdy.1987.91; GRIFFIN AR, 1985, THEOR APPL GENET, V71, P334, DOI 10.1007/BF00252077; HOLLINGSWORTH M. J., 1955, JOUR GENETICS, V53, P295, DOI 10.1007/BF02993984; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1985, GENETICS, V111, P635; LANDE R, 1985, EVOLUTION, V39, P24, DOI [10.2307/2408514, 10.1111/j.1558-5646.1985.tb04077.x]; OHTA T, 1974, GENET RES, V23, P191, DOI 10.1017/S0016672300014816; SHULL GH, 1950, HETEROSIS, P14; SING CF, 1973, GENETICS, V75, P381; TEMPLETON AR, 1984, ZOO BIOL, V3, P177, DOI 10.1002/zoo.1430030302; WILTON AN, 1989, GENET RES, V54, P129; Wright S., 1977, EVOLUTION GENETICS P, V3; ZIEHE M, 1989, GENETICS, V121, P861	24	342	347	0	86	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					522	524		10.1038/352522a0	http://dx.doi.org/10.1038/352522a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865906				2022-12-01	WOS:A1991GA22600060
J	BEATTIE, KL; FOWLER, RF				BEATTIE, KL; FOWLER, RF			SOLID-PHASE GENE ASSEMBLY	NATURE			English	Editorial Material							CHEMICAL SYNTHESIS; OLIGONUCLEOTIDES; DNA		HOUSTON ADV RES CTR,THE WOODLANDS,TX 77381		BEATTIE, KL (corresponding author), BAYLOR UNIV,CTR BIOTECHNOL,4000 RES FOREST DR,THE WOODLANDS,TX 77381, USA.							BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BEATTIE KL, 1988, BIOTECHNOL APPL BIOC, V10, P510; CONNER BJ, 1983, P NATL ACAD SCI-BIOL, V80, P278, DOI 10.1073/pnas.80.1.278; FRANK R, 1983, NUCLEIC ACIDS RES, V11, P4365, DOI 10.1093/nar/11.13.4365; HOSTOMSKY Z, 1987, NUCLEIC ACIDS RES, V15, P4849, DOI 10.1093/nar/15.12.4849; JAYARAMAN K, 1991, P NATL ACAD SCI USA, V88, P4084, DOI 10.1073/pnas.88.10.4084; KHORANA HG, 1979, SCIENCE, V203, P614, DOI 10.1126/science.366749; MATTHES HWD, 1984, EMBO J, V3, P801, DOI 10.1002/j.1460-2075.1984.tb01888.x; MCBRIDE LJ, 1983, TETRAHEDRON LETT, V24, P245, DOI 10.1016/S0040-4039(00)81376-3; MULLIS KB, 1987, METHOD ENZYMOL, V155, P355; RIORDAN ML, 1991, NATURE, V350, P442, DOI 10.1038/350442a0; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	15	23	31	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					548	549		10.1038/352548a0	http://dx.doi.org/10.1038/352548a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865911				2022-12-01	WOS:A1991GA22600071
J	FERNANDEZDELCASTILLO, C; HARRINGER, W; WARSHAW, AL; VLAHAKES, GJ; KOSKI, G; ZASLAVSKY, AM; RATTNER, DW				FERNANDEZDELCASTILLO, C; HARRINGER, W; WARSHAW, AL; VLAHAKES, GJ; KOSKI, G; ZASLAVSKY, AM; RATTNER, DW			RISK-FACTORS FOR PANCREATIC CELLULAR INJURY AFTER CARDIOPULMONARY BYPASS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL REVASCULARIZATION; DISCRIMINANT-ANALYSIS; LABORATORY TESTS; CARDIAC-SURGERY; BLOOD-FLOW; HYPERAMYLASEMIA; HYPERCALCEMIA; AMYLASE; SERUM; MORTALITY	Background. Pancreatitis is a known complication of cardiac surgery with cardiopulmonary bypass. Although ischemia is believed to be a factor, the cause of pancreatitis after cardiopulmonary bypass remains unknown. Methods. We prospectively studied 300 consecutive patients undergoing cardiac surgery with cardiopulmonary bypass. Serum amylase, pancreatic isoamylase, and serum lipase were measured on postoperative days 1, 2, 3, 7, and 10. Pancreatic cellular injury was defined as the presence of hyperamylasemia (> 123 U per liter) with an increase in either the serum level of lipase (> 24 U per liter) or the peak level of pancreatic isoamylase. Trypsinogen-activation peptides, which indicate intrapancreatic enzyme activation, were measured in the urine of the last 101 patients studied. Results. Evidence of pancreatic cellular injury was detected in 80 patients (27 percent), of whom 23 had associated abdominal signs or symptoms and 3 had severe pancreatitis (2 with pancreatic abscess and 1 with necrotizing hemorrhagic pancreatitis). Two of 19 postoperative deaths were secondary to pancreatitis. In multivariate analyses, the development of pancreatic cellular injury was significantly associated with preoperative renal insufficiency, valve surgery, postoperative hypotension, and perioperative administration of calcium chloride. The administration of more than 800 mg of calcium chloride per square meter of body-surface area was an independent predictor of pancreatic cellular injury, and the increase in risk was dose-related. No differences were found in the level of trypsinogen-activation peptides between patients who had pancreatic cellular injury and those who did not. Conclusions. Pancreatic cellular injury, as indicated by hyperamylasemia of pancreatic origin, is common after cardiac surgery. The administration of large doses of calcium chloride is an independent predictor of pancreatic cellular injury and may be a cause of it.	MASSACHUSETTS GEN HOSP, DEPT SURG, ACC337, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT ANESTHESIA, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, DEPT STAT, CAMBRIDGE, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University			Castillo, Carlos Fenandez-del/AAO-2602-2020					AVRAM RM, 1982, NEPHRON, V32, P60, DOI 10.1159/000182804; AZIZ S, 1985, SURGERY, V97, P653; CATES MC, 1988, SURGERY, V104, P137; CLAVIEN PA, 1989, BRIT J SURG, V76, P1234, DOI 10.1002/bjs.1800761205; COSGROVE DM, 1984, J THORAC CARDIOV SUR, V88, P673; DEWAELE B, 1989, PANCREAS, V4, P378, DOI 10.1097/00006676-198906000-00017; DROP LJ, 1985, ANESTH ANALG, V64, P432; ECKFELDT JH, 1989, CLIN LAB MED, V9, P731, DOI 10.1016/S0272-2712(18)30601-2; FRICK TW, 1987, AM J SURG, V154, P487, DOI 10.1016/0002-9610(87)90260-1; FRICK TW, 1990, GASTROENTEROLOGY, V98, P1675, DOI 10.1016/0016-5085(90)91106-G; GAFTER U, 1976, JAMA-J AM MED ASSOC, V235, P2004, DOI 10.1001/jama.235.18.2004; GUDGEON AM, 1990, LANCET, V335, P4, DOI 10.1016/0140-6736(90)90135-R; HAAS GS, 1985, AM J SURG, V149, P508, DOI 10.1016/S0002-9610(85)80048-9; HURLEY PR, 1988, J IMMUNOL METHODS, V111, P195, DOI 10.1016/0022-1759(88)90127-5; IZSAK EM, 1980, GASTROENTEROLOGY, V79, P555; KAZMIERCZAK SC, 1988, CLIN CHEM, V34, P916; KOLARS JC, 1984, DIGEST DIS SCI, V29, P289, DOI 10.1007/BF01318510; Koski G, 1988, J Cardiothorac Anesth, V2, P570, DOI 10.1016/0888-6296(88)90239-6; LEFER AM, 1974, ANN SURG, V179, P868, DOI 10.1097/00000658-197406000-00009; Leijala M, 1988, Eur J Cardiothorac Surg, V2, P324; MCCORMICK PA, 1985, BRIT MED J, V290, P1472, DOI 10.1136/bmj.290.6480.1472-a; MCGRATH LB, 1990, ANN THORAC SURG, V49, P410, DOI 10.1016/0003-4975(90)90245-2; MELTZER LE, 1962, ANN INTERN MED, V57, P1008, DOI 10.7326/0003-4819-57-6-1008; MILLER DC, 1983, J THORAC CARDIOV SUR, V85, P197; MISSAVAGE AE, 1984, AM SURGEON, V50, P297; MIXTER CG, 1962, NEW ENGL J MED, V266, P265, DOI 10.1056/NEJM196202082660601; MORI A, 1988, JPN CIRC J, V52, P219, DOI 10.1253/jcj.52.219; NAUNHEIM KS, 1988, ANN THORAC SURG, V46, P666, DOI 10.1016/S0003-4975(10)64731-5; Panebianco A C, 1970, Ann Thorac Surg, V9, P562; PANTEGHINI M, 1989, CLIN CHEM, V35, P417; RATTNER DW, 1989, ANN SURG, V209, P279, DOI 10.1097/00000658-198903000-00005; ROBERT JH, 1988, INT J PANCREATOL, V3, P283; ROSE DM, 1984, ANN SURG, V199, P168, DOI 10.1097/00000658-198402000-00006; SANFEY H, 1985, AM J SURG, V150, P297, DOI 10.1016/0002-9610(85)90064-9; SCOTT WC, 1985, J THORAC CARDIOV SUR, V89, P400; SVENSSON LG, 1985, ANN THORAC SURG, V39, P409, DOI 10.1016/S0003-4975(10)61945-5; TIETZ NW, 1986, CLIN CHEM, V32, P301; TRAVERSO LW, 1977, AM J SURG, V133, P298, DOI 10.1016/0002-9610(77)90532-3; WALLWORK J, 1980, BRIT J SURG, V67, P410, DOI 10.1002/bjs.1800670609; WARSHAW AL, 1978, ANN SURG, V188, P197, DOI 10.1097/00000658-197808000-00012; WARSHAW AL, 1977, J SURG RES, V22, P362, DOI 10.1016/0022-4804(77)90158-5; 1990, 1990 HEART STROKE FA	42	148	149	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 8	1991	325	6					382	387						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ804	1712076				2022-12-01	WOS:A1991FZ80400002
J	FOOTE, J; MILSTEIN, C				FOOTE, J; MILSTEIN, C			KINETIC MATURATION OF AN IMMUNE-RESPONSE	NATURE			English	Article							SOMATIC MUTATION; ANTIBODY; ANTI-2-PHENYLOXAZOLONE; 2-PHENYLOXAZOLONE; SEQUENCES; OXAZOLONE; MOUSE	IS the affinity maturation of antibodies under thermodynamic or kinetic control, or both? We compared the physical constants of hapten binding by antibodies from 2-phenyl-5-oxazolone-specific hybridomas from primary, secondary and tertiary responses. In addition to an increase in equilibrium constant, there was a shift in the antibody repertoire after the primary response towards an immunoglobulin family with an extremely high on-rate constant. This shift occurred in spite of the average or below-average affinity of this group of antibodies. This is consistent with B-lymphocyte proliferation being subject to a kinetic selection, with a premium on binding target antigens rapidly, in parallel with a thermodynamic selection based on binding tightly.			FOOTE, J (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							ALZARI PM, 1990, EMBO J, V9, P3807, DOI 10.1002/j.1460-2075.1990.tb07598.x; Benson S. W., 1960, FOUNDATIONS CHEMICAL, P81; BEREK C, 1987, EUR J IMMUNOL, V17, P1121, DOI 10.1002/eji.1830170808; BEREK C, 1985, NATURE, V316, P412, DOI 10.1038/316412a0; DAY LA, 1963, ANN NY ACAD SCI, V103, P611, DOI 10.1111/j.1749-6632.1963.tb53721.x; DENIZOT FC, 1979, MOL IMMUNOL, V16, P509, DOI 10.1016/0161-5890(79)90078-6; DILDROP R, 1984, IMMUNOL TODAY, V5, P85, DOI 10.1016/0167-5699(84)90034-3; EISEN H N, 1964, Methods Med Res, V10, P115; EVEN J, 1985, EMBO J, V4, P3439, DOI 10.1002/j.1460-2075.1985.tb04102.x; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; KAARTINEN M, 1983, NATURE, V304, P320, DOI 10.1038/304320a0; MAKELA O, 1978, J EXP MED, V148, P1644, DOI 10.1084/jem.148.6.1644; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MASON DW, 1986, HDB EXPT IMMUNOLOGY, V1; SCHLESINGER DH, 1975, NATURE, V255, P423, DOI 10.1038/255423a0; SEGAL I, 1975, ENZYME KINETICS, P73; SEHON AH, 1963, ANN NY ACAD SCI, V103, P626, DOI 10.1111/j.1749-6632.1963.tb53722.x; SMITH TW, 1975, BIOCHEMISTRY-US, V14, P1496, DOI 10.1021/bi00678a023; TITMAN JJ, 1991, J CHEM SOC CHEM COMM, P419, DOI 10.1039/c39910000419; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	20	262	286	0	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 8	1991	352	6335					530	532		10.1038/352530a0	http://dx.doi.org/10.1038/352530a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1907716				2022-12-01	WOS:A1991GA22600063
J	GOODNOW, CC; BRINK, R; ADAMS, E				GOODNOW, CC; BRINK, R; ADAMS, E			BREAKDOWN OF SELF-TOLERANCE IN ANERGIC LYMPHOCYTES-B	NATURE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; T-CELL TOLERANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; TRANSGENIC MICE; CLONAL ANERGY; RECEPTOR; INACTIVATION; EXPRESSION; INDUCTION; DELETION	PRODUCTION of autoantibodies, which characterizes most autoimmune diseases, is normally avoided by active elimination 1-7 or functional inactivation (anergy) 8-15 of B and T lymphocytes bearing receptors for self antigens. The mechanisms leading to the escape of self-reactive clones from these normal tolerance mechanisms in autoimmune diseases nevertheless remain obscure. Here, we demonstrate that clonal anergy in B lymphocytes is a reversible process, and that silenced self-reactive B cells can be reactivated under particular conditions to give rise to vigorous antibody responses. Reactivation of anergic lymphocytes may explain many examples of transient autoimmune reactions in normal individuals, and may under pathological conditions be important in the development of chronic autoimmune disease.	STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	GOODNOW, CC (corresponding author), UNIV SYDNEY, CENTENARY INST CANC MED & CELL BIOL, SYDNEY, NSW 2006, AUSTRALIA.		Brink, Robert/B-7910-2010; Goodnow, Christopher C/V-8108-2018	Brink, Robert/0000-0002-9586-3655; Goodnow, Christopher C/0000-0001-5296-6155				ADAMS E, 1990, P NATL ACAD SCI USA, V87, P5687, DOI 10.1073/pnas.87.15.5687; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BONNEVILLE M, 1990, NATURE, V344, P163, DOI 10.1038/344163a0; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; Burnet FM, 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; GLEICHMANN E, 1982, EUR J IMMUNOL, V12, P152, DOI 10.1002/eji.1830120210; GLEICHMANN E, 1976, EUR J IMMUNOL, V6, P899, DOI 10.1002/eji.1830061212; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HANG L, 1983, J EXP MED, V157, P874, DOI 10.1084/jem.157.3.874; IZUI S, 1977, J EXP MED, V145, P1115, DOI 10.1084/jem.145.5.1115; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; NAPARSTEK Y, 1986, J EXP MED, V164, P614, DOI 10.1084/jem.164.2.614; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; PRIMI D, 1977, J EXP MED, V145, P21, DOI 10.1084/jem.145.1.21; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; Weigle W O, 1980, Adv Immunol, V30, P159	24	223	223	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 8	1991	352	6335					532	536		10.1038/352532a0	http://dx.doi.org/10.1038/352532a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1830923				2022-12-01	WOS:A1991GA22600064
J	KNIGHT, MR; CAMPBELL, AK; SMITH, SM; TREWAVAS, AJ				KNIGHT, MR; CAMPBELL, AK; SMITH, SM; TREWAVAS, AJ			TRANSGENIC PLANT AEQUORIN REPORTS THE EFFECTS OF TOUCH AND COLD-SHOCK AND ELICITORS ON CYTOPLASMIC CALCIUM	NATURE			English	Article							SUSPENDED CALLUS-CULTURES; ELICITATION; EXPRESSION	METHODS for measuring plant cytoplasmic calcium using microelectrodes or microinjected fluorescent dyes are associated with extensive technical problems, so measurements have been limited to single or small groups of cells in tissue strips or protoplasts 1,2. Aequorin is a calcium-sensitive luminescent protein 3 from the coelenterate Aequorea victoria (A. forskalea) which is formed from apoaequorin, a polypeptide of relative molecular mass approximately 22,000, and coelenterazine, a hydrophobic luminophore 4. Microinjected aequorin has been widely used for intracellular calcium measurement in animal cells 4, but its use in plants has been limited to exceptionally large cells 5. We show here that aequorin can be reconstituted in transformed plants and that it reports calcium changes induced by touch, cold-shock and fungal elicitors. Reconstituted aequorin is cytoplasmic and nonperturbing; measurements can be made on whole plants and a calcium indicator can be constituted in every viable cell. Now that apoaequorin can be targeted to specific organelles, cells and tissues, with the range of coelenterazines with differing calcium sensitivities and properties available 6, this new method could be valuable for determining the role of calcium in intracellular signalling processes in plants.	UNIV WALES COLL MED, DEPT MED BIOCHEM, CARDIFF CF4 4XN, S GLAM, WALES	Cardiff University	KNIGHT, MR (corresponding author), UNIV EDINBURGH, INST CELL & MOLEC BIOL, EDINBURGH EH9 3JH, MIDLOTHIAN, SCOTLAND.		Smith, Steven/HDM-9496-2022; Campbell, Anthony K/N-5855-2014; Smith, Steven M/G-7183-2015	Campbell, Anthony K/0000-0002-2506-5500; Smith, Steven M/0000-0001-5661-9994; Knight, Marc/0000-0002-4830-8608				BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Blinks J.R., 1978, Methods in Enzymology, V57, P292; BRAAM J, 1990, CELL, V60, P357, DOI 10.1016/0092-8674(90)90587-5; BROOKS CJW, 1986, PHYTOCHEMISTRY, V25, P1089, DOI 10.1016/S0031-9422(00)81559-9; Campbell A.K, 1983, INTRACELLULAR CALCIU; CAMPBELL AK, 1988, BIOCHEM J, V252, P143, DOI 10.1042/bj2520143; DIXON RA, 1986, BIOL REV, V61, P239, DOI 10.1111/j.1469-185X.1986.tb00719.x; Draper J., 1988, PLANT GENETIC TRANSF; EBEL J, 1988, TRENDS BIOCHEM SCI, V13, P23, DOI 10.1016/0968-0004(88)90014-X; FRANCK A, 1980, CELL, V21, P285, DOI 10.1016/0092-8674(80)90136-1; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; GILROY S, 1986, FEBS LETT, V199, P217, DOI 10.1016/0014-5793(86)80483-5; HAHN MG, 1978, PLANT PHYSIOL, V62, P107, DOI 10.1104/pp.62.1.107; HARLOW E, 1988, ANTIBODIES LABORATOR; MAUCH F, 1989, PLANT CELL, V1, P447, DOI 10.2307/3869105; MINORSKY PV, 1985, PLANT CELL ENVIRON, V8, P75, DOI 10.1111/j.1365-3040.1985.tb01226.x; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; PRASHER D, 1985, BIOCHEM BIOPH RES CO, V126, P1259, DOI 10.1016/0006-291X(85)90321-3; PRASHER DC, 1986, BIOLUMINESCENCE CHEM; Sambrook J., 1989, MOL CLONING LAB MANU; SHIMOMURA O, 1962, J CELL COMPAR PHYSL, V59, P223, DOI 10.1002/jcp.1030590302; SHIMOMURA O, 1989, BIOCHEM J, V261, P913, DOI 10.1042/bj2610913; WATSON DG, 1985, PHYTOCHEMISTRY, V24, P2195, DOI 10.1016/S0031-9422(00)83009-5; WILLIAMSON RE, 1982, NATURE, V296, P647, DOI 10.1038/296647a0	25	919	987	2	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 8	1991	352	6335					524	526		10.1038/352524a0	http://dx.doi.org/10.1038/352524a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865907				2022-12-01	WOS:A1991GA22600061
J	LACERDA, AE; KIM, HS; RUTH, P; PEREZREYES, E; FLOCKERZI, V; HOFMANN, F; BIRNBAUMER, L; BROWN, AM				LACERDA, AE; KIM, HS; RUTH, P; PEREZREYES, E; FLOCKERZI, V; HOFMANN, F; BIRNBAUMER, L; BROWN, AM			NORMALIZATION OF CURRENT KINETICS BY INTERACTION BETWEEN THE ALPHA-1-SUBUNIT AND BETA-SUBUNIT OF THE SKELETAL-MUSCLE DIHYDROPYRIDINE-SENSITIVE CA2+ CHANNEL	NATURE			English	Article							CALCIUM-CHANNEL; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; GAMMA-SUBUNIT; CA-2+ CHANNEL; RECEPTOR; SEQUENCE; PROTEIN; CELLS; CDNA	PURIFICATION of skeletal muscle dihydropyridine binding sites has enabled protein complexes to be isolated from which Ca2+ currents have been reconstituted. Complementary DNAs encoding the five subunits of the dihydropyridine receptor, alpha-1, beta, gamma, alpha-2 and delta (ref. 1), have been cloned 2-6 and it is now recognized that alpha-2 and delta are derived from a common precursor 7,8. The alpha-1 subunit can itself produce Ca2+ currents, as was demonstrated using mouse L cells lacking alpha-2-delta (refs 9, 10), beta (ref. 10) and gamma (our unpublished results). In L cells, stable expression of skeletal muscle-alpha-1 alone was sufficient to generate voltage-sensitive, high-threshold L-type Ca2+ channel currents which were dihydropyridine-sensitive and blocked by Cd2+, but the activation kinetics were about 100 times slower than expected for skeletal muscle Ca2+ channel currents. This could have been due to the cell type in which alpha-1 was being expressed or to the lack of a regulatory component particularly one of the subunits that copurifies with alpha-1. We show here that coexpression of skeletal muscle-beta with skeletal muscle-alpha-1 generates cell lines expressing Ca2+ channel currents with normal activation kinetics as evidence for the participation of the dihydropyridine-receptor beta-subunits in the generation of skeletal muscle Ca2+ channel currents.	BAYLOR UNIV,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR UNIV,DIV NEUROSCI,HOUSTON,TX 77030; UNIV SAARLAND,FAC MED,INST PHYSIOL CHEM,W-6650 HOMBURG,GERMANY	Baylor University; Baylor University; Saarland University	LACERDA, AE (corresponding author), BAYLOR UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030, USA.							BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; BROWN AM, 1983, J PHYSIOL-LONDON, V344, P549, DOI 10.1113/jphysiol.1983.sp014956; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; COGNARD C, 1986, PFLUG ARCH EUR J PHY, V407, P677, DOI 10.1007/BF00582651; COGNARD C, 1986, P NATL ACAD SCI USA, V83, P1518, DOI 10.1073/pnas.83.5.1518; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; JAY SD, 1991, J BIOL CHEM, V266, P3287; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KIM HS, 1990, J BIOL CHEM, V265, P11858; LACERDA AE, 1989, J GEN PHYSIOL, V93, P1243, DOI 10.1085/jgp.93.6.1243; LIAO CF, 1989, J BIOL CHEM, V264, P7328; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; NUKADA T, 1987, FEBS LETT, V211, P5, DOI 10.1016/0014-5793(87)81263-2; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SCHWARTZ LM, 1985, NATURE, V314, P747, DOI 10.1038/314747a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	21	268	273	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					527	530		10.1038/352527a0	http://dx.doi.org/10.1038/352527a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1650913				2022-12-01	WOS:A1991GA22600062
J	LUISI, BF; XU, WX; OTWINOWSKI, Z; FREEDMAN, LP; YAMAMOTO, KR; SIGLER, PB				LUISI, BF; XU, WX; OTWINOWSKI, Z; FREEDMAN, LP; YAMAMOTO, KR; SIGLER, PB			CRYSTALLOGRAPHIC ANALYSIS OF THE INTERACTION OF THE GLUCOCORTICOID RECEPTOR WITH DNA	NATURE			English	Article							TRANSCRIPTION FACTOR-IIIA; STEROID-HORMONE RECEPTOR; TARGET GENE SPECIFICITY; ZINC-BINDING DOMAINS; MAMMARY-TUMOR VIRUS; CRYSTAL-STRUCTURE; ESTROGEN-RECEPTOR; RESPONSE ELEMENT; AMINO-ACIDS; RESOLUTION	Two crystal structures of the glucocorticoid receptor DNA-binding domain complexed with DNA are reported. The domain has a globular fold which contains two Zn-nucleated substructures of distinct conformation and function. When it binds DNA, the domain dimerizes, placing the subunits in adjacent major grooves. In one complex, the DNA has the symmetrical consensus target sequence; in the second, the central spacing between the target's half-sites is larger by one base pair. This results in one subunit interacting specifically with the consensus target half-site and the other nonspecifically with a noncognate element. The DNA-induced dimer fixes the separation of the subunits' recognition surfaces so that the spacing between the half-sites becomes a critical feature of the target sequence's identity.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	Yale University; Howard Hughes Medical Institute; Yale University; University of California System; University of California San Francisco			Otwinowski, Zbyszek/F-3665-2011	Otwinowski, Zbyszek/0000-0003-3640-8545				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BROWN RS, 1985, FEBS LETT, V186, P274; BRUNGER AT, 1988, CRYSTALLOGRAPHIC COM, V4; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FREEDMAN LP, 1988, CELL, V54, P444, DOI 10.1016/0092-8674(88)90063-3; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GREEN S, 1988, EMBO J, V7, P3037, DOI 10.1002/j.1460-2075.1988.tb03168.x; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HARD T, 1990, BIOCHEMISTRY-US, V29, P5358; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PONTA H, 1985, P NATL ACAD SCI USA, V82, P1020, DOI 10.1073/pnas.82.4.1020; PRESLEY JP, 1988, J APPL CRYSTALLOGR, V21, P572; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SAENGER W, 1984, PRINCIPLES NUCLEIC A, V120; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHEIDEREIT C, 1986, DNA-J MOLEC CELL BIO, V5, P383, DOI 10.1089/dna.1986.5.383; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHEVITZ RW, 1981, ACTA CRYSTALLOGR A, V37, P669, DOI 10.1107/S0567739481001526; SCHULTZ S, IN PRESS SCIENCE; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SOMERS WA, 1991, THESIS U LEEDS; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0	55	1274	1292	0	50	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					497	505		10.1038/352497a0	http://dx.doi.org/10.1038/352497a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865905				2022-12-01	WOS:A1991GA22600052
J	RUSTGI, AK; DYSON, N; BERNARDS, R				RUSTGI, AK; DYSON, N; BERNARDS, R			AMINO-TERMINAL DOMAINS OF C-MYC AND N-MYC PROTEINS MEDIATE BINDING TO THE RETINOBLASTOMA GENE-PRODUCT	NATURE			English	Article							ADENOVIRUS E1A PROTEINS; DNA-BINDING; SUSCEPTIBILITY GENE; TRANSFORMATION; ONCOPROTEINS; MUTATIONS; ONCOGENES; REGIONS	THE proteins encoded by the myc gene family are involved in the control of cell proliferation and differentiation, and aberrant expression of myc proteins has been implicated in the genesis of a variety of neoplasms 1. In the carboxyl terminus, myc proteins have two domains that encode a basic domain/helix-loop-helix and a leucine zipper motif, respectively. These motifs are involved both in DNA binding and in protein dimerization 2-5. In addition, myc protein family members share several regions of highly conserved amino acids in their amino termini that are essential for transformation 6,7. We report here that an N-terminal domain present in both the c-myc and N-myc proteins mediates binding to the retinoblastoma gene product, pRb. We show that the human papilloma virus E7 protein competes with c-myc for binding to pRb, indicating that these proteins share overlapping binding sites on pRb. Furthermore, a mutant Rb protein from a human tumour cell line that carried a 35-amino-acid deletion in its C terminus failed to bind to c-myc. Our results suggest that c-myc and pRb cooperate through direct binding to control cell proliferation.	MASSACHUSETTS GEN HOSP,CTR CANC,DIV MOLEC ONCOL,BOSTON,MA 02150; MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02150; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	RUSTGI, AK (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,DIV MOLEC GENET,149 13TH ST,BOSTON,MA 02150, USA.			Bernards, Rene/0000-0001-8677-3423				BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; JONES RE, 1990, J BIOL CHEM, V265, P12782; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MOORE JP, 1987, ONCOGENE RES, V2, P65; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PENDERGAST GC, 1991, SCIENCE, V251, P186; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUSTGI AK, 1990, P NATL ACAD SCI USA, V87, P8707, DOI 10.1073/pnas.87.22.8707; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	27	327	333	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					541	544		10.1038/352541a0	http://dx.doi.org/10.1038/352541a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865909	Green Submitted			2022-12-01	WOS:A1991GA22600067
J	STAMPFER, MJ; SACKS, FM; SALVINI, S; WILLETT, WC; HENNEKENS, CH				STAMPFER, MJ; SACKS, FM; SALVINI, S; WILLETT, WC; HENNEKENS, CH			A PROSPECTIVE-STUDY OF CHOLESTEROL, APOLIPOPROTEINS, AND THE RISK OF MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; HIGH-DENSITY LIPOPROTEIN; ISCHEMIC HEART-DISEASE; A-I; CARDIOVASCULAR-DISEASE; DISCRIMINATIVE VALUES; MALE SURVIVORS; TROMSO HEART; SERUM-LIPIDS; SUBFRACTIONS	Background. The independent contributions of subfractions of high-density lipoprotein (HDL) cholesterol (HDL2 and HDL3) and apolipoproteins in predicting the risk of myocardial infarction are unclear. Prospective data are sparse, but HDL2 is widely believed to be a more important predictor than HDL3. Methods. Blood samples were collected at base line from 14,916 men (ages, 40 to 84 years) who were participants in the Physicians' Health Study. After five years of follow-up, plasma samples from 246 men with new myocardial infarction (case subjects) were analyzed together with specimens from 246 men matched to them for age and smoking status who had not had a myocardial infarction. Results. The levels of total cholesterol and apolipoprotein B-100 were significantly associated with an increased risk of myocardial infarction (data on levels of low-density lipoprotein cholesterol were unavailable). Both HDL cholesterol and HDL2 levels were associated with a substantially decreased risk of myocardial infarction, but the HDL3 level was the strongest predictor; the relative risk was 0.3 (95 percent confidence interval, 0.2 to 0.6) for those in the fifth of the group with the highest HDL3 levels, as compared with the fifth with the lowest levels. The benefit of a higher HDL cholesterol level was most pronounced among those with lower total cholesterol levels. Levels of apolipoprotein A-I and apolipoprotein A-II were also associated with decreased risk. However, the levels of HDL subfractions and apolipoproteins did not add significantly to the value of a multivariate model that included the ratio of total to HDL cholesterol in predicting myocardial infarction, whereas that ratio remained a significant independent predictor of risk. After adjustment for other risk factors, a change of one unit in the ratio of total to HDL cholesterol was associated with a 53 percent change in risk (95 percent confidence interval, 26 percent to 85 percent). Conclusions. This study underscores the importance of HDL cholesterol in predicting the risk of myocardial infarction and demonstrates protective effects of both the HDL3 and HDL2 subfractions of HDL cholesterol. We found little or no predictive value for the levels of apolipoproteins A-1, A-11, and B or HDL subfractions after conventional risk factors and the ratio of total to HDL cholesterol were considered.	BRIGHAM & WOMENS HOSP,DEPT PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	STAMPFER, MJ (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,180 LONGWOOD AVE,BOSTON,MA 02115, USA.				NCI NIH HHS [CA 42182] Funding Source: Medline; NHLBI NIH HHS [HL 26490, HL 34595] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042182] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1978, METABOLISM, V27, P479, DOI 10.1016/0026-0495(78)90102-6; ALBERS JJ, 1976, METABOLISM, V25, P633, DOI 10.1016/0026-0495(76)90060-3; [Anonymous], 1989, NEW ENGL J MED, V321, P129; AVOGARO P, 1979, LANCET, V1, P901; AVOGARO P, 1980, ATHEROSCLEROSIS, V37, P69, DOI 10.1016/0021-9150(80)90094-5; AVOGARO P, 1982, LIPOPROTEINS CORONAR, P123; Bachorik P S, 1986, Methods Enzymol, V129, P78; BALLANTYNE FC, 1982, METABOLISM, V31, P433, DOI 10.1016/0026-0495(82)90230-X; BENNETT WI, 1988, NY TIMES MAGAZI 0110, P55; BERG K, 1976, LANCET, V1, P499; BERG K, 1976, LANCET, V2, P40; BITTOLO BG, 1984, ATHEROSCLEROSIS, V53, P69; BROOK JG, 1982, CIRCULATION, V66, P923, DOI 10.1161/01.CIR.66.5.923; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CREMER P, 1988, KLIN WOCHENSCHR, V66, P42; DEBACKER G, 1982, ATHEROSCLEROSIS, V42, P197, DOI 10.1016/0021-9150(82)90150-2; DESAGER JP, 1984, LATENT DYSLIPOPROTEI, P165; ENGER SC, 1979, ARTERY, V5, P170; FAGER G, 1981, ARTERIOSCLEROSIS, V1, P273, DOI 10.1161/01.ATV.1.4.273; FAGER G, 1980, ATHEROSCLEROSIS, V36, P67, DOI 10.1016/0021-9150(80)90199-9; FRANZEN J, 1986, ATHEROSCLEROSIS, V59, P37, DOI 10.1016/0021-9150(86)90030-4; GIDEZ LI, 1982, J LIPID RES, V23, P1206; GOFMAN JW, 1966, CIRCULATION, V34, P679, DOI 10.1161/01.CIR.34.4.679; GOLDBOURT U, 1979, AM J EPIDEMIOL, V109, P296, DOI 10.1093/oxfordjournals.aje.a112683; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GORDON T, 1981, ARCH INTERN MED, V141, P1128, DOI 10.1001/archinte.141.9.1128; GRUNDY SM, 1987, INTERNAL MED, P2035; HAMSTEN A, 1986, ATHEROSCLEROSIS, V59, P223, DOI 10.1016/0021-9150(86)90051-1; HENNEKENS CH, 1987, CIRCULATION, V76, P501; ISHIKAWA T, 1978, EUR J CLIN INVEST, V8, P179, DOI 10.1111/j.1365-2362.1978.tb00832.x; JAMES RW, 1986, ATHEROSCLEROSIS, V60, P49, DOI 10.1016/0021-9150(86)90086-9; JOHANSSON S, 1988, ARTERIOSCLEROSIS, V8, P742, DOI 10.1161/01.ATV.8.6.742; JONES PH, 1990, HEART ARTERIES VEINS, P378; KAUPPINENMAKELIN R, 1988, ATHEROSCLEROSIS, V74, P65, DOI 10.1016/0021-9150(88)90192-X; KEMPEN HJ, 1987, J LAB CLIN MED, V109, P19; KLADETZKY RG, 1980, ARTERY, V7, P191; KUKITA H, 1984, ATHEROSCLEROSIS, V51, P261, DOI 10.1016/0021-9150(84)90173-4; LAAKSO M, 1985, ARTERIOSCLEROSIS, V5, P653, DOI 10.1161/01.ATV.5.6.653; LEHTONEN A, 1986, ATHEROSCLEROSIS, V59, P215, DOI 10.1016/0021-9150(86)90050-X; LEITERSDORF E, 1986, ATHEROSCLEROSIS, V59, P75, DOI 10.1016/0021-9150(86)90035-3; LEVY RI, 1984, CIRCULATION, V69, P325, DOI 10.1161/01.CIR.69.2.325; MACIEJKO JJ, 1983, NEW ENGL J MED, V309, P385, DOI 10.1056/NEJM198308183090701; MILLER NE, 1981, BRIT MED J, V282, P1741, DOI 10.1136/bmj.282.6278.1741; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; MOGADAM M, 1990, ARCH INTERN MED, V150, P1645, DOI 10.1001/archinte.150.8.1645; MUSLINER TA, 1988, CLIN CHEM, V34, pB78; NOMA A, 1983, ATHEROSCLEROSIS, V49, P1, DOI 10.1016/0021-9150(83)90002-3; OHTA T, 1989, ARTERIOSCLEROSIS, V9, P90, DOI 10.1161/01.ATV.9.1.90; PARRA H, 1984, LATENT DYSLIPOPROTEI, P187; REARDON MF, 1985, CIRCULATION, V71, P881, DOI 10.1161/01.CIR.71.5.881; REINHART RA, 1990, ARCH INTERN MED, V150, P1629, DOI 10.1001/archinte.150.8.1629; RIESEN WF, 1980, ATHEROSCLEROSIS, V37, P157, DOI 10.1016/0021-9150(80)90104-5; SALONEN JT, 1985, AM J CARDIOL, V56, P226, DOI 10.1016/0002-9149(85)90839-2; SATTERFIELD S, 1990, AM J PREV MED, V6, P290, DOI 10.1016/S0749-3797(18)30997-8; SCHMIDT SB, 1985, AM J CARDIOL, V55, P1459, DOI 10.1016/0002-9149(85)90953-1; STAMPFER MJ, 1985, STAT MED, V4, P111, DOI 10.1002/sim.4780040202; STORER BE, 1983, APPL STAT-J ROY ST C, V32, P172; THOMAS DJB, 1987, BRIT J CLIN PRACT, V41, P741; WALLENTIN L, 1986, ATHEROSCLEROSIS, V59, P131, DOI 10.1016/0021-9150(86)90041-9; WIKLUND O, 1980, ATHEROSCLEROSIS, V37, P631, DOI 10.1016/0021-9150(80)90070-2; 1985, SAS USERS GUIDE STAT; 1988, ARCH INTERN MED, V148, P36; 1982, SAS USERS GUIDE BASI; [No title captured]	65	972	1011	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 8	1991	325	6					373	381		10.1056/NEJM199108083250601	http://dx.doi.org/10.1056/NEJM199108083250601			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ804	2062328				2022-12-01	WOS:A1991FZ80400001
J	STEDMAN, HH; SWEENEY, HL; SHRAGER, JB; MAGUIRE, HC; PANETTIERI, RA; PETROF, B; NARUSAWA, M; LEFEROVICH, JM; SLADKY, JT; KELLY, AM				STEDMAN, HH; SWEENEY, HL; SHRAGER, JB; MAGUIRE, HC; PANETTIERI, RA; PETROF, B; NARUSAWA, M; LEFEROVICH, JM; SLADKY, JT; KELLY, AM			THE MDX MOUSE DIAPHRAGM REPRODUCES THE DEGENERATIVE CHANGES OF DUCHENNE MUSCULAR-DYSTROPHY	NATURE			English	Article							SKELETAL-MUSCLE MYOPATHY; SATELLITE CELLS; RAT; PRODUCT; GROWTH; INVIVO; GENE	ALTHOUGH murine X-linked muscular dystrophy (mdx) and Duchenne muscular dystrophy (DMD) are genetically homologous and both characterized by a complete absence of dystrophin 1,2, the limb muscles of adult mdx mice suffer neither the detectable weakness nor the progressive degeneration that are features of DMD 3-8. Here we show that the mdx mouse diaphragm exhibits a pattern of degeneration, fibrosis and severe functional deficit comparable to that of DMD limb muscle, although adult mice show no overt respiratory impairment. Progressive functional changes include reductions in strength (to 13.5% of control by two years of age), elasticity, twitch speed and fibre length. The collagen density rises to at least seven times that of control diaphragm and ten times that of mdx hind-limb muscle. By 1.5 years of age, similar but less severe histological changes emerge in the accessory muscles of respiration. On the basis of these findings, we propose that dystrophin deficiency alters the threshold for work-induced injury. Our data provide a quantitative framework for studying the pathogenesis of dystrophy and extend the application of the mdx mouse as an animal model.	UNIV PENN,SCH VET MED,PHILADELPHIA,PA 19104	University of Pennsylvania	STEDMAN, HH (corresponding author), UNIV PENN,SCH MED,3800 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Sweeney, H Lee/F-1862-2010; panettieri, reynold/AAG-9485-2019					ANDERSON JE, 1988, J MUSCLE RES CELL M, V9, P499, DOI 10.1007/BF01738755; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P299, DOI 10.1111/j.1365-2990.1988.tb00890.x; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; DANGAIN J, 1984, MUSCLE NERVE, V7, P700, DOI 10.1002/mus.880070903; DIMARIO J, 1989, SCIENCE, V244, P688, DOI 10.1126/science.2717945; DUSTERHOFT S, 1990, DIFFERENTIATION, V45, P185, DOI 10.1111/j.1432-0436.1990.tb00472.x; GRIFFITHS RI, 1987, J NEUROSCI METH, V21, P159, DOI 10.1016/0165-0270(87)90113-0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; KASPER CE, 1990, J APPL PHYSIOL, V68, P533, DOI 10.1152/jappl.1990.68.2.533; KELLY AM, 1978, DEV BIOL, V65, P1, DOI 10.1016/0012-1606(78)90174-4; LEE CC, 1991, NATURE, V349, P334, DOI 10.1038/349334a0; MANDEL JL, 1989, NATURE, V339, P584, DOI 10.1038/339584a0; MCCULLY KK, 1987, RESPIRATORY MUSCLES, P317; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; NARUSAWA M, 1987, J CELL BIOL, V104, P447, DOI 10.1083/jcb.104.3.447; NEWMAN S, 1984, J APPL PHYSIOL, V56, P753, DOI 10.1152/jappl.1984.56.3.753; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; SCHMALBRUCH H, 1977, ANAT REC, V189, P169, DOI 10.1002/ar.1091890204; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; SMITH PEM, 1987, NEW ENGL J MED, V316, P1197, DOI 10.1056/NEJM198705073161906; STAHL WR, 1967, J APPL PHYSIOL, V22, P453, DOI 10.1152/jappl.1967.22.3.453; SWITZER BR, 1971, ANAL BIOCHEM, V39, P487, DOI 10.1016/0003-2697(71)90438-6; SYME DA, 1990, J PHYSIOL-LONDON, V424, P301, DOI 10.1113/jphysiol.1990.sp018068; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	25	744	754	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					536	539		10.1038/352536a0	http://dx.doi.org/10.1038/352536a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865908				2022-12-01	WOS:A1991GA22600065
J	TRINH, TQ; SINDEN, RR				TRINH, TQ; SINDEN, RR			PREFERENTIAL DNA SECONDARY STRUCTURE MUTAGENESIS IN THE LAGGING STRAND OF REPLICATION IN ESCHERICHIA-COLI	NATURE			English	Article							ESCHERICHIA-COLI; MUTATION; SEQUENCES; JUNCTION; REPAIR; GENE	WHEN present in single-stranded DNA, palindromic or quasipalindromic sequences have the potential to form complex secondary structures, including hairpins, which may facilitate interstrand misalignment of direct repeats and be responsible for diverse types of replication-based mutations, including deletions, additions, frameshifts and duplications 1-5. In regions of palindromic symmetry, specific deletion events may involve the formation of a hairpin or other DNA secondary structures which can stabilize the misalignment of direct repeats 1,2. One model suggests that these deletions occur during DNA replication by slippage of the template strand and misalignment with the progeny strand 6,7. The concurrent DNA replication model, involving an asymmetric dimeric DNA polymerase III complex which replicates the leading and lagging strands 8, has significant implications for mutagenesis. The intermittent looping of the lagging strand template, and the fact that the lagging strand template may contain a region of single-stranded DNA the length of an Okazaki fragment, provides an opportunity for DNA secondary-structure formation and misalignment. Here we report our design of a palindromic fragment to create an 'asymmetric palindromic insert' in the chloramphenicol acetyltransferase gene of plasmid pBR325. The frequency with which the insert was deleted in Escherichia coli depends on the orientation of the gene in the plasmid. Our results suggest that replication-dependent deletion between direct repeats may occur preferentially in the lagging strand.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,231 BETHESDA AVE,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati			Sinden, Richard/AAE-3086-2019					ALBERTINI AM, 1982, CELL, V29, P319, DOI 10.1016/0092-8674(82)90148-9; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; DRAKE JW, 1983, AM SCI, V71, P621; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUCKETT DR, 1990, EMBO J, V9, P1659, DOI 10.1002/j.1460-2075.1990.tb08286.x; GLICKMAN BW, 1984, P NATL ACAD SCI USA, V81, P4046; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; RIPLEY LS, 1982, P NATL ACAD SCI-BIOL, V79, P4128, DOI 10.1073/pnas.79.13.4128; RIPLEY LS, 1983, UCLA S MOL CELLULAR, V10, P521; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; SCHAAPER RM, 1986, J MOL BIOL, V189, P273, DOI 10.1016/0022-2836(86)90509-7; SCOTT JR, 1984, MICROBIOL REV, V48, P1; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WEAVER DT, 1984, J MOL BIOL, V180, P961, DOI 10.1016/0022-2836(84)90266-3	17	210	214	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					544	547		10.1038/352544a0	http://dx.doi.org/10.1038/352544a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865910				2022-12-01	WOS:A1991GA22600068
J	VORTKAMP, A; GESSLER, M; GRZESCHIK, KH				VORTKAMP, A; GESSLER, M; GRZESCHIK, KH			GLI3 ZINC-FINGER GENE INTERRUPTED BY TRANSLOCATIONS IN GREIG SYNDROME FAMILIES	NATURE			English	Article							CEPHALOPOLYSYNDACTYLY SYNDROME; LOCALIZATION; CHROMOSOME-7	THE Greig cephalopolysyndactyly syndrome (GCPS) is an autosomal dominant disorder affecting limb and craniofacial development in humans 1,2. GCPS-affected individuals are characterized by postaxial polysyndactyly of hands, preaxial polysyndactyly of feet, macroephaly, a broad base of the nose with mild hypertelorism and a prominent forehead. The genetic locus has been pinpointed to chromosome 7p13 by three balanced translocations associated with GCPS in different families 3,4,19. This assignment is corroborated by the detection of two sporadic GCPS cases carrying overlapping deletions in 7p13 (ref. 7), as well as by tight linkage of GCPS to the epidermal growth factor receptor gene in 7p12-13 (ref. 8). Of the genes that map to this region, those encoding T cell receptor-gamma, interferon-beta-2, epidermal growth factor receptor, and Hox1.4, a potential candidate gene for GCPS, have been excluded from the region in which the deletions overlap 7,9. Here we show that two of the three translocations interrupt the GLI3 gene, a zinc-finger gene of the GLI-Kruppel family already localized to 7p13 (refs 5, 6). The breakpoints are within the first third of the coding sequence. In the third translocation, chromosome 7 is broken at about 10 kilobases downstream of the 3' end of GLI3. Our results indicate that mutations disturbing normal GLI3 expression may have a causative role in GCPS.			VORTKAMP, A (corresponding author), UNIV MARBURG,INST HUMANGENET,BAHNHOFSTR 7A,W-3550 MARBURG,GERMANY.			Gessler, Manfred/0000-0002-7915-6045				BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; BRUETON L, 1988, AM J MED GENET, V31, P799, DOI 10.1002/ajmg.1320310412; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DRABKIN H, 1989, GENOMICS, V4, P518, DOI 10.1016/0888-7543(89)90275-9; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOLLOP TR, 1985, AM J MED GENET, V22, P59, DOI 10.1002/ajmg.1320220106; GREIG DAVID M., 1926, EDINBURGH MED JOUR, V33, P189; JOBS A, 1990, HUM GENET, V84, P147; KRUGER G, 1989, AM J MED GENET, V32, P411, DOI 10.1002/ajmg.1320320329; Maniatis T., 1982, MOL CLONING; POHL TM, 1990, DEVELOPMENT, V110, P1153; ROMMENS JM, 1988, AM J HUM GENET, V43, P645; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; TOMMERUP N, 1983, AM J MED GENET, V16, P313, DOI 10.1002/ajmg.1320160304; VORTKAMP A, IN PRESS GENOMICS; WAGNER K, 1990, GENOMICS, V8, P487, DOI 10.1016/0888-7543(90)90035-S; WINTER RM, 1988, AM J MED GENET, V31, P793, DOI 10.1002/ajmg.1320310411	19	472	486	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					539	540		10.1038/352539a0	http://dx.doi.org/10.1038/352539a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1650914	Green Submitted			2022-12-01	WOS:A1991GA22600066
J	BLANC, PD; GALBO, M; HIATT, P; OLSON, KR				BLANC, PD; GALBO, M; HIATT, P; OLSON, KR			MORBIDITY FOLLOWING ACUTE IRRITANT INHALATION IN A POPULATION-BASED STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OCCUPATIONAL EXPOSURES; DYSFUNCTION SYNDROME; CHLORINE GAS; ASTHMA; BRONCHIECTASIS; ILLNESS; DIOXIDE	Study Objective.-To estimate the incidence of and risk factors for morbidity due to inhalation of respiratory irritants. Design.-Six-month case series of inhalational exposures reported to a poison control center with follow-up, structured interviews of subjects. Setting.-A regional poison control center providing 24-hour telephone consultation to health professionals and the public. Patients.-Consecutive sample of 683 inhalation cases, with interviews of 323 subjects. Measurements and Main Results.-Moderate to severe irritants accounted for 160 (50%) of the inhalational exposures in interviewed subjects. Persistent symptoms lasting 14 days or longer were reported by only 20 (6%) of the subjects. Irritant exposure was a statistically significant risk factor for acute respiratory symptoms (relative risk [RR] = 1.7; 95% confidence interval [Cl], 1.4 to 2.1) but was unrelated to persistent symptoms. Preexisting lung conditions RR = 2.4; 95% Cl, 1.4 to 4.2) and cigarette smoking (RR = 1.7; 95% Cl, 1.3 to 2.2) were both statistically significant risk factors for persistent symptoms. Conclusions.-Symptomatic inhalational exposures due to irritants are frequent in reports from poison control centers. Residual morbidity was uncommon and did not appear to be statistically related to the degree of irritant exposure. Host-related factors may be better predictors of ongoing morbidity after inhalational exposure.	UNIV CALIF SAN FRANCISCO,SCH PHARM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143; SAN FRANCISCO BAY AREA REG POISON CONTROL CTR,SAN FRANCISCO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	BLANC, PD (corresponding author), UNIV CALIF SAN FRANCISCO,DIV OCCUPAT & ENVIRONM MED,BOX 0924,SAN FRANCISCO,CA 94143, USA.				PHS HHS [R49CCR903697-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALFORD P T, 1988, Chest, V94, p87S; BECKLAKE MR, 1989, AM REV RESPIR DIS, V140, pS85, DOI 10.1164/ajrccm/140.3_Pt_2.S85; BLANC PD, 1989, ANN INTERN MED, V111, P238, DOI 10.7326/0003-4819-111-3-238; BOULET LP, 1988, CHEST, V94, P476, DOI 10.1378/chest.94.3.476; BROOKS SM, 1987, AM REV RESPIR DIS, V135, P268; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; DEVINENI R, 1989, CHEST, V96, pS169; DOUGLAS WW, 1989, MAYO CLIN PROC, V64, P291, DOI 10.1016/S0025-6196(12)65249-5; FLETA J, 1986, HUM TOXICOL, V5, P99, DOI 10.1177/096032718600500205; HARKONEN H, 1983, AM REV RESPIR DIS, V128, P890; HEDBERG K, 1989, JAMA-J AM MED ASSOC, V262, P3014; KASS I, 1972, CHEST, V62, P282, DOI 10.1378/chest.62.3.282; KORN RJ, 1987, AM REV RESPIR DIS, V136, P298, DOI 10.1164/ajrccm/136.2.298; KRAUT A, 1988, CHEST, V94, P208, DOI 10.1378/chest.94.1.208; LERMAN S, 1988, AM FAM PHYSICIAN, V38, P135; LITOVITZ TL, 1990, AM J EMERG MED, V8, P394, DOI 10.1016/0735-6757(90)90234-Q; MITCHELL JT, 1989, CHEST, V96, pS169; MORABIA A, 1988, INT J EPIDEMIOL, V17, P148, DOI 10.1093/ije/17.1.148; RABONOWITZ S, 1989, AM REV RESPIR DIS, V139, P556; SCHWARTZ DA, 1987, OCCUP MED, V2, P297; SCHWARTZ DA, 1990, CHEST, V97, P820, DOI 10.1378/chest.97.4.820; SEGEV JS, 1983, CHEST, V83, P169; SLUTZKER AD, 1989, CHEST, V95, P1349, DOI 10.1378/chest.95.6.1349; SUMMER W, 1981, CLIN CHEST MED, V2, P273; TARLO SM, 1989, CHEST, V96, P297, DOI 10.1378/chest.96.2.297; WALD PH, 1987, INTENS CARE MED, V2, P260; 1983, MMWR, V32, P541	27	29	29	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1991	266	5					664	669		10.1001/jama.266.5.664	http://dx.doi.org/10.1001/jama.266.5.664			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ140	2072476				2022-12-01	WOS:A1991FZ14000024
J	COBB, N; ETZEL, RA				COBB, N; ETZEL, RA			UNINTENTIONAL CARBON-MONOXIDE RELATED DEATHS IN THE UNITED-STATES, 1979 THROUGH 1988	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; ISCHEMIC-HEART-DISEASE; MORTALITY; ARRHYTHMIAS; EXPOSURE; ANGINA	Objective.-To describe the epidemiology of recent unintentional carbon monoxide poisoning deaths in the United States. Design.-Descriptive analysis of carbon monoxide-related deaths in the United States from 1979 through 1988, based on death certificate reports compiled by the National Center for Health Statistics. Population Studied.-All US deaths, 1979 through 1988. Results.-We reviewed data from 56 133 death certificates that contained codes implicating carbon monoxide as a contributing cause of death. Of these, 25 889 were suicides, 21 0 were homicides, 15 523 were associated with severe burns or house fires, and 11 547 were classified as unintentional. The number of unintentional deaths decreased steadily by about 63 deaths per year, from 1513 in 1979 to 878 in 1988. The highest death rates occurred in winter and among males, blacks, the elderly, and residents of northern states. Motor vehicle exhaust gas caused 6552 (57%) of the unintentional deaths; 5432 (83%) of these were associated with stationary automobiles. Conclusions.-The rate of unintentional death from carbon monoxide poisoning is decreasing. This may be attributable to improvements in automobile pollution control systems and improved safety of cooking and heating appliances. Prevention programs should target young drivers, males, and the elderly.			COBB, N (corresponding author), CTR DIS CONTROL, CTR ENVIRONM HLTH & INJURY CONTROL, ATLANTA, GA 30333 USA.		Etzel, Ruth A./N-5700-2019	Etzel, Ruth A./0000-0002-5236-3976				ALLRED EN, 1989, NEW ENGL J MED, V321, P1426, DOI 10.1056/NEJM198911233212102; ANDERSON EW, 1973, ANN INTERN MED, V79, P46, DOI 10.7326/0003-4819-79-1-46; DAVIES DM, 1980, ENVIRON RES, V21, P197, DOI 10.1016/0013-9351(80)90022-5; GITTELSOHN A, 1979, AM J PUBLIC HEALTH, V69, P680, DOI 10.2105/AJPH.69.7.680; GLASSER JH, 1981, AM J PUBLIC HEALTH, V71, P231, DOI 10.2105/AJPH.71.3.231; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GOODMAN RA, 1982, JAMA-J AM MED ASSOC, V247, P793, DOI 10.1001/jama.247.6.793; QUARLES J, 1990, NEW CLEAN AIR ACT GU; SCHAPLOWSKY AF, 1974, J ENV HLTH, V36, P569; SHEPS DS, 1990, ANN INTERN MED, V113, P343, DOI 10.7326/0003-4819-113-5-343; STERN FB, 1988, AM J EPIDEMIOL, V128, P1276, DOI 10.1093/oxfordjournals.aje.a115081; THOM SR, 1989, J TOXICOL-CLIN TOXIC, V27, P141; WALDEN SM, 1990, ANN INTERN MED, V113, P337, DOI 10.7326/0003-4819-113-5-337; 1980, PHS801260 US DEP HLT; 1989, ASHRAE621989 AM SOC; 1979, UNDERLYING CAUSE DEA; 1991, MMWR, V40, P154; 1991, EPA450491004 PUBL	18	218	222	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1991	266	5					659	663		10.1001/jama.266.5.659	http://dx.doi.org/10.1001/jama.266.5.659			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ140	1712865				2022-12-01	WOS:A1991FZ14000023
J	KEELER, JR; HURST, CG; DUNN, MA				KEELER, JR; HURST, CG; DUNN, MA			PYRIDOSTIGMINE USED AS A NERVE AGENT PRETREATMENT UNDER WARTIME CONDITIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To determine the adverse effects of pretreatment with pyridostigmine bromide for nerve agent exposure during wartime. Design. -A retrospective study Setting. - Southwest Asia. Participants. -Personnel who provided medical support to the XVIII Airborne Corps. These medical officers supplied information pertaining to symptoms and disposition of 41 650 soldiers who received pyridostigmine at the onset of hostilities of Operation Desert Storm. Intervention.-Pyridostigmine bromide, 30 mg orally, was self-administered every 8 hours while under the threat of nerve agent attack (for 1 to 7 days). Main Outcome Measure.-Physiologic changes attributable to pyridostigmine that resulted in need for medical attention, discontinuation of the drug, hospitalization, and/or evacuation f rom Southwest Asia. Results.- About half of the population noted physiologic changes that were not incapacitating, such as increased flatus, abdominal cramps, soft stools, and urinary urgency Approximately 1% of the soldiers believed they had effects that warranted medical attention, but fewer than 0.1% had effects sufficient to discontinue the drug. Nonincapacitating symptoms often occurred; however, military mission performance was not impaired. Conclusion.-While under the threat of nerve agent attack, pyridostigmine can be administered to virtually all soldiers.			KEELER, JR (corresponding author), USA,MED RES INST CHEM DEF,SGRD UV YY LTC KEELER,ABERDEEN PROVING GROUND,MD 21010, USA.							DUNN MA, 1989, JAMA-J AM MED ASSOC, V262, P649, DOI 10.1001/jama.262.5.649; GALL E, 1981, FUNDAM APPL TOXICOL, V1, P214; GAWRON VJ, 1988, ADA198828; KLUWE WM, 1987, 6TH P MED CHEM DEF B, P227; KOLKA MA, 1991, ADA232726; KORNHAUSER D, 1986, BIOAVAILABILITY ORAL; KORNHAUSER D, 1990, SAFETY TOLERANCE PHA; 1990, FED REG         1221, V55, P5281; 1990, FM8285 HEADQ DEP ARM	9	154	154	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1991	266	5					693	695		10.1001/jama.266.5.693	http://dx.doi.org/10.1001/jama.266.5.693			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ140	2072481				2022-12-01	WOS:A1991FZ14000029
J	BRAHAMS, D				BRAHAMS, D			PERTUSSIS-VACCINE AND ENCEPHALOPATHY, AN IRISH CASE	LANCET			English	Editorial Material																			0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1991	338	8762					305	305		10.1016/0140-6736(91)90437-T	http://dx.doi.org/10.1016/0140-6736(91)90437-T			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ565	1677124				2022-12-01	WOS:A1991FZ56500018
J	CHEN, ZM; PETO, R; COLLINS, R; MACMAHON, S; LU, JR; LI, WX				CHEN, ZM; PETO, R; COLLINS, R; MACMAHON, S; LU, JR; LI, WX			SERUM-CHOLESTEROL CONCENTRATION AND CORONARY HEART-DISEASE IN POPULATION WITH LOW CHOLESTEROL CONCENTRATIONS	BRITISH MEDICAL JOURNAL			English	Article							FACTOR INTERVENTION TRIAL; PLASMA-CHOLESTEROL; CANCER MORTALITY; FOLLOW-UP; RISK; DEATH; MEN; REGRESSION; STROKE; LIPOPROTEIN	Objective-To examine the relation between serum cholesterol concentration and mortality (from coronary heart disease and from other causes) below the range of cholesterol values generally seen in Western populations. Design-Prospective observational study based on 8-13 years of follow up of subjects in a population with low cholesterol concentrations. Setting-Urban Shanghai, China. Subjects-9021 Chinese men and women aged 35-64 at baseline. Main outcome measure-Death from coronary heart disease and other causes. Results-The average serum cholesterol concentration was 4.2 mmol/l at baseline examination, and only 43 (7%) of the deaths that occurred during 8-13 years of follow up were attributed to coronary heart disease. There was a strongly positive, and apparently independent, relation between serum cholesterol concentration and death from coronary heart disease (z = 3.47, p < 0.001), and within the range of usual serum cholesterol concentration studied (3.8-4.7 mmol/l) there was no evidence of any threshold. After appropriate adjustment for the regression dilution bias, a 4 (SD 1)% difference in usual cholesterol concentration was associated with a 21 (SD 6)% (95% confidence interval 9% to 35%) difference in mortality from coronary heart disease. There was no significant relation between serum cholesterol concentration and death from stroke or all types of cancer. The 79 deaths due to liver cancer or other chronic liver disease were inversely related to cholesterol concentration at baseline. Conclusion-Blood cholesterol concentration was directly related to mortality from coronary heart disease even in those with what was, by Western standards, a "low" cholesterol concentration. There was no good evidence of an adverse effect of cholesterol on other causes of death.	SHANGHAI CHEST HOSP,SHANGHAI,PEOPLES R CHINA; SHANGHAI MED UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,SHANGHAI,PEOPLES R CHINA	Shanghai Jiao Tong University; Fudan University	CHEN, ZM (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,NUFFIELD DEPT CLIN MED,MRC,IMPERIAL CANC RES FUND,OXFORD OX2 6HE,ENGLAND.							USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; BEAGLEHOLE R, 1980, BMJ-BRIT MED J, V280, P285, DOI 10.1136/bmj.280.6210.285; BEASLEY RP, 1981, LANCET, V2, P1129; BERKSON J, 1950, J AM STAT ASSOC, V45, P164, DOI 10.2307/2280676; CHEN DY, 1987, CHIN MED J, V7, P382; CHEN ZM, 1989, NEW ENGL J MED, V321, P1339; COX DR, 1972, J R STAT SOC B, V34, P187; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; EDERER F, 1972, J CHRON DIS, V25, P277, DOI 10.1016/0021-9681(72)90164-6; FEINLEIB M, 1981, AM J EPIDEMIOL, V114, P5, DOI 10.1093/oxfordjournals.aje.a113173; GOLDBOURT U, 1985, BMJ-BRIT MED J, V290, P1239, DOI 10.1136/bmj.290.6477.1239; HAN QQ, 1984, ACTA ACAD MED PRIMAE, V11, P181; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; JIANG YT, 1982, VIRAL HEPATITIS, P121; KEIL U, 1989, INT J EPIDEMIOL, V18, pS46; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; LI SC, 1985, NEUROLOGY, V35, P1708, DOI 10.1212/WNL.35.12.1708; LI WX, 1979, ACTA ACAD MED PRIMAE, V6, P65; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OLIVER MF, 1981, LANCET, V2, P1090; PEARSON S, 1953, ANAL CHEM, V25, P813, DOI 10.1021/ac60077a041; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1985, CIRCULATION, V72, P451; RAGLAND DR, 1988, AM J EPIDEMIOL, V127, P462, DOI 10.1093/oxfordjournals.aje.a114823; ROBERTSON TL, 1977, AM J CARDIOL, V39, P239, DOI 10.1016/S0002-9149(77)80197-5; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; ROSE G, 1980, LANCET, V1, P523; SCHATZKIN A, 1987, LANCET, V2, P298; SHERWIN RW, 1987, JAMA-J AM MED ASSOC, V257, P943; SIMONS LA, 1986, AM J CARDIOL SG, V57, P5; SOLONEN JT, 1982, AM J EPIDEMIOL, V116, P622; Speizer, 1976, NATURAL HIST CHRONIC, P218; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; TORNBERG SA, 1986, NEW ENGL J MED, V315, P1629, DOI 10.1056/NEJM198612253152601; WILLIAMS RR, 1981, JAMA-J AM MED ASSOC, V245, P247, DOI 10.1001/jama.245.3.247; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; ZAK B, 1954, AM J CLIN PATHOL, V24, P1307, DOI 10.1093/ajcp/24.11_ts.1307; [No title captured]; 1982, JAMA-J AM MED ASSOC, V248, P2853	44	469	488	1	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					276	282		10.1136/bmj.303.6797.276	http://dx.doi.org/10.1136/bmj.303.6797.276			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888927	Green Published, Bronze			2022-12-01	WOS:A1991FZ72100018
J	FERGUSON, CJ; WILLIAMS, JD; SILVER, A; WOODHEAD, JS; SALAMAN, JR				FERGUSON, CJ; WILLIAMS, JD; SILVER, A; WOODHEAD, JS; SALAMAN, JR			EFFECTS OF PARATHYROID-HORMONE ON DELAYED RENAL-ALLOGRAFT FUNCTION	BRITISH MEDICAL JOURNAL			English	Article									UNIV WALES COLL MED,DEPT MED BIOCHEM,CARDIFF CF4 4XN,S GLAM,WALES; CARDIFF ROYAL INFIRM,INST NEPHROL,CARDIFF CF2 1SZ,S GLAM,WALES	Cardiff University; Cardiff Royal Infirmary	FERGUSON, CJ (corresponding author), CARDIFF ROYAL INFIRM,DEPT SURG,CARDIFF CF2 1SZ,S GLAM,WALES.							BROWN RC, 1987, J CLIN ENDOCR METAB, V65, P407, DOI 10.1210/jcem-65-3-407; CHARBON GA, 1974, ENDOCRINOLOGY, V95, P621, DOI 10.1210/endo-95-2-621; ELLISON DH, 1984, AM J PHYSIOL, V246, pF551, DOI 10.1152/ajprenal.1984.246.5.F551; PANG PKT, 1983, ENDOCRINOLOGY, V112, P284, DOI 10.1210/endo-112-1-284; VARGHESE Z, 1988, BRIT MED J, V296, P393, DOI 10.1136/bmj.296.6619.393	5	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					287	288		10.1136/bmj.303.6797.287	http://dx.doi.org/10.1136/bmj.303.6797.287			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888930	Bronze, Green Published			2022-12-01	WOS:A1991FZ72100022
J	FISHER, BM; HEATLEY, C; SMALL, M				FISHER, BM; HEATLEY, C; SMALL, M			REUSE OF DISPOSABLE PLASTIC INSULIN SYRINGES	BRITISH MEDICAL JOURNAL			English	Article									GARTNAVEL ROYAL HOSP,DIABET CLIN,GLASGOW G12 0YN,SCOTLAND	Gartnavel Royal Hospital								ALEXANDER WD, 1988, BRIT MED J, V296, P877, DOI 10.1136/bmj.296.6626.877; BLOOM A, 1985, BRIT MED J, V290, P727, DOI 10.1136/bmj.290.6470.727; HEATLEY C, 1990, PRACTICAL DIABETES, V7, P33; LESTER E, 1984, BRIT MED J, V289, P1498, DOI 10.1136/bmj.289.6457.1498-a; 1983, BMJ, V286, P369	5	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					286	287		10.1136/bmj.303.6797.286	http://dx.doi.org/10.1136/bmj.303.6797.286			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888929	Green Published, Bronze			2022-12-01	WOS:A1991FZ72100021
J	GILL, GV; ALBERTI, KGMM				GILL, GV; ALBERTI, KGMM			OUTCOME OF BRITTLE DIABETES	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK	GILL, GV (corresponding author), WALTON HOSP,CTR DIABET,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND.							DORMAN JS, 1984, DIABETES, V33, P271, DOI 10.2337/diabetes.33.3.271; GILL GV, 1981, DIABETOLOGIA, V21, P507; Pirart J., 1978, DIABETES CARE, V1, P168, DOI DOI 10.2337/DIACARE.1.3.168; TATTERSALL R, 1991, BRIT MED J, V302, P1240, DOI 10.1136/bmj.302.6787.1240; WILLIAMS G, 1988, DIABETES RES CLIN EX, V7, P13	5	10	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					285	286		10.1136/bmj.303.6797.285	http://dx.doi.org/10.1136/bmj.303.6797.285			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888928	Green Published, Bronze			2022-12-01	WOS:A1991FZ72100020
J	KING, MB; PATTISON, P				KING, MB; PATTISON, P			HOMOSEXUALITY AND PARENTHOOD	BRITISH MEDICAL JOURNAL			English	Article							HETEROSEXUAL MOTHERS; LESBIAN MOTHERS; CHILDREN; FATHERS; GAY		BURTON PATTISON SOLICITORS,LONDON W1X 7AA,ENGLAND		KING, MB (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON NW3 2QG,ENGLAND.		King, Michael B/D-7477-2011	King, Michael B/0000-0003-4715-7171				Abel G G, 1988, Bull Am Acad Psychiatry Law, V16, P153; BANCROFT J, 1989, HUMAN SEXUALITY ITS; BELL AP, 1987, SEXUAL PREFERENCE IT; BIGNER JJ, 1989, J HOMOSEXUAL, V18, P173, DOI 10.1300/J082v18n01_09; BOZETT FW, 1989, J HOMOSEXUAL, V18, P137, DOI 10.1300/J082v18n01_07; Bradley D., 1987, INT J LAW FAMILY, V1, P155; BREWAEYS A, 1989, HUM REPROD, V4, P850, DOI 10.1093/oxfordjournals.humrep.a137000; CONTE JR, 1991, CLIN APPROACHES SEX, P11; GOLOMBOK S, 1983, J CHILD PSYCHOL PSYC, V24, P551, DOI 10.1111/j.1469-7610.1983.tb00132.x; GREEN R, 1986, ARCH SEX BEHAV, V15, P167, DOI 10.1007/BF01542224; GREEN R, 1978, PSYCHIATRY, V135, P692; HARRIS MB, 1985, J HOMOSEXUAL, V12, P101; HUGGINS SL, 1989, J HOMOSEXUAL, V18, P123, DOI 10.1300/J082v18n01_06; HUI TY, 1990, INDEPENDENT     1003, P25; Langevin R., 1983, SEXUAL STRANDS UNDER; LESTER D, 1975, UNUSUAL SEXUAL BEHAV; LEWIS KG, 1980, SOC WORK, V25, P198, DOI 10.1093/sw/25.3.198; MILLER B, 1979, FAMILY COORDINAT OCT, P544; MONEY J, 1988, GAY STRAIGHT BETWEEN; Money J., 1972, MAN WOMAN BOY GIRL; RIDDLE DI, 1978, J SOC ISSUES, V34, P38, DOI 10.1111/j.1540-4560.1978.tb02613.x; Socarides C., 1979, SEXUAL DEVIATION, P243; WAKELING A, 1979, SEXUAL DEVIATION, P1; 1980, FAMILY LAW REV, V1, P143; 1987, JAMA-J AM MED ASSOC, V258, P222; 1986, LESBIAN MOTHERS LEGA	26	4	4	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					295	297		10.1136/bmj.303.6797.295	http://dx.doi.org/10.1136/bmj.303.6797.295			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FZ721	1888934	Bronze, Green Published			2022-12-01	WOS:A1991FZ72100026
J	RAMAIYA, KL; SWAI, ABM; MCLARTY, DG; BHOPAL, RS; ALBERTI, KGMM				RAMAIYA, KL; SWAI, ABM; MCLARTY, DG; BHOPAL, RS; ALBERTI, KGMM			PREVALENCES OF DIABETES AND CARDIOVASCULAR-DISEASE RISK-FACTORS IN HINDU INDIAN SUBCOMMUNITIES IN TANZANIA	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; CORONARY HEART-DISEASE; ASIAN COMMUNITY; EAST LONDON; MORTALITY; CHINESE; SINGAPORE; MORBIDITY; MELLITUS; PATTERNS	Objectives-To seek differences in the prevalence of diabetes mellitus and other coronary heart disease risk factors, and to identify factors associated with these differences within a Hindu Indian community. Design-Population based cross sectional survey. Setting-Dar-es-Salaam, Tanzania. Subjects-Of 20 Hindu subcommunities categorised by caste in Dar-es-Salaam, seven were randomly selected. 1147 (76.7%) of 1495 subjects aged 15 or over participated. Main outcome measures-Blood glucose concentrations (fasting and two hours after oral glucose loading), serum total cholesterol and serum triglyceride concentrations, blood pressure, and height and weight. Results-The subcommunities differed substantially in socioeconomic characteristics and lifestyle. Overall, 9.8% of subjects (109/1113) had diabetes, 17.0% (189/1113) impaired glucose tolerance, 14.5% (166/1143) hypertension, and 13.3% (151/1138) were obese. The mean fasting blood glucose concentration was 4.9 mmol/l, the blood glucose concentration two hours after oral loading (75 g) 6.0 mmol/l, the total cholesterol concentration 4.9 mmol/l, the serum triglyceride concentration 1.4 mmol/l, and body mass index (weight/height2; kg/m2) 24.3. Systolic and diastolic blood pressures were 121 and 77 mm Hg respectively. There were important intercommunity differences even after standardisation for age, sex, and body mass index - for example, in mean fasting blood glucose concentration (range 4.5 (Jains) to 5.9 mmol/l (Patels)), serum total cholesterol concentration (range 4.5 (Jains) to 6.2 mmol/l (Suthars)), systolic blood pressure (range 110 (Limbachias) to 127 mm Hg (Bhatias)), and prevalences of diabetes (range 3.4% (3/87 Limbachias) to 18% (20/111 Navnats)) and hypertension (range 5.7% (5/87 Limbachias) to 19.4% (43/222 Bhatias). Variables which showed significant linear correlation with subcommunity variations were entered into a multiple regression model. Intercommunity variations persisted. The Limbachia and Jain communities had the lowest prevalence of and mean values for coronary heart disease risk factors and the Bhatia and Patel communities had the highest. Conclusions-In this series intercommunity variations in disease and risk factors might have been related to genetic, dietary, socioeconomic, and lifestyle differences but could not be explained by the characteristics studied. Studies of Indian subcommunities are warranted to confirm and extend these descriptive findings and explore the genetic basis of diabetes. Communities of Indian origin should not be perceived as homogeneous.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,NEWCASTLE TYNE NE2 4HH,ENGLAND; HINDU MANDAL HOSP,DAR ES SALAAM,TANZANIA; UNIV NEWCASTLE UPON TYNE,SCH MED,DIV EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND; UNIV DAR ES SALAAM,MUHIMBILI MED CTR,DEPT MED,DAR ES SALAAM,TANZANIA	Newcastle University - UK; Newcastle University - UK; University of Dar es Salaam								ADELSTEIN AM, 1963, BRIT J PREV SOC MED, V17, P29; ARMITAGE P, 1987, STATISTICAL METHODS, P194; ARMITAGE P, 1987, STATISTICAL METHODS, P204; BALARAJAN R, 1984, BRIT MED J, V289, P1185, DOI 10.1136/bmj.289.6453.1185; BECKLES GLA, 1986, LANCET, V1, P1298; BHOPAL RS, 1986, COMMUNITY MED, V8, P315; Chen A J, 1980, Ann Acad Med Singap, V9, P411; DEEG R, 1982, CLIN CHEM, V28, P1574; DONALDSON LJ, 1983, BRIT MED J, V286, P949, DOI 10.1136/bmj.286.6369.949; DOWSE GK, 1990, DIABETES, V39, P390, DOI 10.2337/diabetes.39.3.390; Gupta O P, 1978, Adv Metab Disord, V9, P147; HENLEY A, 1979, ASIAN PATIENTS HOSPI; HUGHES K, 1990, J EPIDEMIOL COMMUN H, V44, P24, DOI 10.1136/jech.44.1.24; HUGHES K, 1990, J EPIDEMIOL COMMUN H, V44, P29, DOI 10.1136/jech.44.1.29; MALHOTRA SL, 1967, BRIT HEART J, V29, P895; MALHOTRA SL, 1988, BMJ, V207, P977; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1988, BRIT HEART J, V60, P390; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MCKEIGUE PM, 1985, LANCET, V2, P1086; MCKEIGUE PM, 1989, DIABETIC MED S1, V6, pA41; MEGRAM ER, 1982, CLIN CHEM, V25, P273; MELIA RJW, 1988, BRIT MED J, V296, P1438, DOI 10.1136/bmj.296.6634.1438; NORUSIS MJ, 1986, SPSS IBM PC XT AT; OMAR MAK, 1985, S AFR MED J, V67, P924; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; SHAPER AG, 1959, LANCET, V2, P534; SHAUNAK S, 1986, BRIT MED J, V293, P1169, DOI 10.1136/bmj.293.6555.1169; SILMAN A, 1985, J EPIDEMIOL COMMUN H, V39, P301, DOI 10.1136/jech.39.4.301; SIMMONS D, 1989, BRIT MED J, V298, P18, DOI 10.1136/bmj.298.6665.18; SWAI ABM, 1990, DIABETES RES CLIN PR, V8, P227, DOI 10.1016/0168-8227(90)90121-9; THAI A C, 1987, Journal of the Medical Association of Thailand, V70, P63; TUOMILEHTO J, 1984, B WORLD HEALTH ORGAN, V62, P133; WYNDHAM CH, 1982, S AFR MED J, V61, P987; ZIMMET P, 1983, AM J EPIDEMIOL, V118, P673, DOI 10.1093/oxfordjournals.aje.a113678; 1978, WHO TECH REP SER, V628; 1985, WHO TECH REP SER, V727	37	32	32	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					271	276		10.1136/bmj.303.6797.271	http://dx.doi.org/10.1136/bmj.303.6797.271			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888926	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1991FZ72100017
J	BENITO, M; PORRAS, A; NEBREDA, AR; SANTOS, E				BENITO, M; PORRAS, A; NEBREDA, AR; SANTOS, E			DIFFERENTIATION OF 3T3-L1 FIBROBLASTS TO ADIPOCYTES INDUCED BY TRANSFECTION OF RAS ONCOGENES	SCIENCE			English	Article							GROWTH FACTOR-I; FATTY-ACID SYNTHASE; ADIPOSE CELL LINE; H-RAS; MOLECULAR-CLONING; MESSENGER-RNAS; NEURONAL DIFFERENTIATION; RESPONSIVENESS INVITRO; SIGNAL TRANSDUCTION; POTENTIAL MEDIATOR	Mammalian 3T3-L1 cells differentiate into adipocytes after continuous exposure to pharmacological doses of insulin or physiological doses of insulin-like growth factor I (IGF-1). Expression of transfected ras oncogenes led to differentiation of these cells into adipocytes in the absence of externally added insulin or IGF-I. Cells transfected with normal ras genes or the tyrosine kinase trk oncogene did not differentiate. Transfection with a dominant inhibitory ras mutant resulted in inhibition of differentiation. Exposure of untransfected 3T3-L1 cells to insulin stimulated formation of the active Ras.GTP complex. These observations indicate that Ras proteins participate in signal transduction pathways initiated by insulin and IGF-I in these cells.	NIAID, MOLEC MICROBIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Porras, Almudena/N-2121-2015; Nebreda, Angel Rodriguez/R-9594-2019; Benito, Manuel/J-5637-2014	Porras, Almudena/0000-0002-6495-3308; Benito, Manuel/0000-0002-7218-406X				AILHAUD G, 1982, MOL CELL BIOCHEM, V49, P17; ALLENDE CC, 1988, FEBS LETT, V234, P426, DOI 10.1016/0014-5793(88)80130-3; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHAPMAN AB, 1984, J BIOL CHEM, V259, P5548; COOK JS, 1988, P NATL ACAD SCI USA, V85, P2949, DOI 10.1073/pnas.85.9.2949; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAUNER H, 1990, ENDOCRINOLOGY, V127, P865, DOI 10.1210/endo-127-2-865; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KOZAK LP, 1983, P NATL ACAD SCI-BIOL, V80, P3020, DOI 10.1073/pnas.80.10.3020; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCCORMICK F, 1990, ONCOGENE, V5, P1281; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; OGISO Y, 1990, CELL GROWTH DIFFER, V1, P217; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PEARSE AGE, 1968, HISTOCHEMISTRY, P697; PINTZAS A, 1989, GENE ANAL TECH, V6, P125, DOI 10.1016/0735-0651(89)90003-4; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; ROSEN OM, 1978, J BIOL CHEM, V253, P7579; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHMIDT W, 1990, J BIOL CHEM, V265, P15489; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TOSCANI A, 1990, J BIOL CHEM, V265, P5722	45	167	169	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 2	1991	253	5019					565	568		10.1126/science.1857988	http://dx.doi.org/10.1126/science.1857988			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1857988				2022-12-01	WOS:A1991FZ34700040
J	BOTHE, K; AGUZZI, A; LASSMANN, H; RETHWILM, A; HORAK, I				BOTHE, K; AGUZZI, A; LASSMANN, H; RETHWILM, A; HORAK, I			PROGRESSIVE ENCEPHALOPATHY AND MYOPATHY IN TRANSGENIC MICE EXPRESSING HUMAN FOAMY VIRUS GENES	SCIENCE			English	Article							HUMAN SPUMARETROVIRUS; TAT GENE; DEGENERATION; NEURONS; CELLS; AIDS	Transgenic mice carrying the bel region of human foamy retrovirus (HFV) under transcriptional control of its own long terminal repeat expressed the transgene in their central nervous systems and in smooth and striated muscle tissues. The animals developed a progressive degenerative disease of the central nervous system and of the striated muscle. Because expression of the transgene was closely correlated with the appearance of structural damage and inflammatory reactions were scanty, the disease is likely to be caused directly by the HFV proteins. These unexpected findings call for a reevaluation of the pathogenic potential of HFV in humans.	UNIV WURZBURG,INST VIROL & IMMUNOBIOL,VERSBACHERSTR 7,W-8700 WURZBURG,GERMANY; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; INST NEUROL,A-1090 VIENNA,AUSTRIA	University of Wurzburg; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Aguzzi, Adriano/A-3351-2008; Lassmann, Hans/Z-2269-2019	Lassmann, Hans/0000-0001-8617-5052; Aguzzi, Adriano/0000-0002-0344-6708				ACHONG G, 1971, J NATL CANCER I, V42, P299; AGUZZI A, 1991, ONCOGENE, V6, P113; AGUZZI A, 1990, New Biologist, V2, P533; AGUZZI A, UNPUB; BOTHE K, UNPUB; CAMERONKR, 1978, LANCET, V2, P796; FLUGEL RM, 1987, EMBO J, V6, P2077, DOI 10.1002/j.1460-2075.1987.tb02473.x; GIANGASPERO F, 1989, ACTA NEUROPATHOL, V78, P662, DOI 10.1007/BF00691293; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; Hogan B., 1986, MANIPULATING MOUSE E; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228; KLEIHUES P, 1985, ACTA NEUROPATHOL, V68, P333, DOI 10.1007/BF00690837; MULLER RH, 1980, J GEN VIROL, V47, P399; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; PETITO CK, 1985, NEW ENGL J MED, V312, P874, DOI 10.1056/NEJM198504043121402; PICCARDO P, 1988, ANN NEUROL S, V23, P156; RETHWILM A, 1990, VIROLOGY, V175, P568, DOI 10.1016/0042-6822(90)90442-T; RETHWILM A, 1991, P NATL ACAD SCI USA, V88, P941, DOI 10.1073/pnas.88.3.941; RETHWILM A, 1990, NUCLEIC ACIDS RES, V18, P733, DOI 10.1093/nar/18.4.733; SHARPE AH, 1990, NATURE, V346, P181, DOI 10.1038/346181a0; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WEISS RA, 1988, NATURE, V333, P497, DOI 10.1038/333497a0; YOUNG D, 1973, ARCH GES VIRUSFORSCH, V42, P228, DOI 10.1007/BF01265647; [No title captured]	27	98	102	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1991	253	5019					555	557		10.1126/science.1650034	http://dx.doi.org/10.1126/science.1650034			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1650034	Green Submitted			2022-12-01	WOS:A1991FZ34700036
J	CHUNG, SK; REINHART, PH; MARTIN, BL; BRAUTIGAN, D; LEVITAN, IB				CHUNG, SK; REINHART, PH; MARTIN, BL; BRAUTIGAN, D; LEVITAN, IB			PROTEIN-KINASE ACTIVITY CLOSELY ASSOCIATED WITH A RECONSTITUTED CALCIUM-ACTIVATED POTASSIUM CHANNEL	SCIENCE			English	Article							K+ CHANNELS; PHOSPHORYLATION; MODULATION; NEURONS; CONDUCTANCE; CELLS; BRAIN; FAMILY	Modulation of the activity of potassium and other ion channels is an essential feature of nervous system function. The open probability of a large conductance Ca2+-activated K+ channel from rat brain, incorporated into planar lipid bilayers, is increased by the addition of adenosine triphosphate (ATP) to the cytoplasmic side of the channel. This modulation takes place without the addition of protein kinase, requires Mg2+, and is mimicked by an ATP analog that serves as a substrate for protein kinases but not by a nonhydrolyzable ATP analog. Addition of protein phosphatase 1 reverses the modulation by MgATP. Thus, there may be an endogenous protein kinase activity firmly associated with this K+ channel. Some ion channels may exist in a complex that contains regulatory protein kinases and phosphatases.	BRANDEIS UNIV, DEPT BIOCHEM, WALTHAM, MA 02254 USA; BRANDEIS UNIV, CTR COMPLEX SYST, WALTHAM, MA 02254 USA; BROWN UNIV, DIV BIOL & MED, BIOCHEM SECT, PROVIDENCE, RI 02912 USA	Brandeis University; Brandeis University; Brown University					NIDDK NIH HHS [DK31374] Funding Source: Medline; NINDS NIH HHS [NS17910] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017910] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; BARABAN JM, 1985, P NATL ACAD SCI USA, V82, P2538, DOI 10.1073/pnas.82.8.2538; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; BRAUTIGAN DL, 1985, J BIOL CHEM, V260, P4295; DEPEYER JE, 1982, P NATL ACAD SCI-BIOL, V79, P4207; DOERNER D, 1988, J NEUROSCI, V8, P4069; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; FERNANDEZ A, 1990, J CELL BIOL, V111, P103, DOI 10.1083/jcb.111.1.103; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; GRAY MA, 1990, J MEMBRANE BIOL, V115, P203, DOI 10.1007/BF01868636; HAUNG K, 1988, J BIOL CHEM, V263, P14839; HSIAO KJ, 1978, J BIOL CHEM, V253, P6901; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; KACZMAREK LK, 1988, ADV SEC MESS PHOSPH, V22, P113; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LECHLEITER JD, 1988, NEURON, V1, P227, DOI 10.1016/0896-6273(88)90143-2; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; MEISLER MH, 1969, J BIOL CHEM, V244, P4961; POO MM, 1974, NATURE, V247, P438, DOI 10.1038/247438a0; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; REINHART PH, 1991, J NEUROSCI, V11, P1627; REINHART PH, 1989, NEURON, V2, P1031, DOI 10.1016/0896-6273(89)90227-4; SADOSHIMA JI, 1988, AM J PHYSIOL, V255, pH754, DOI 10.1152/ajpheart.1988.255.4.H754; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SIKDAR SK, 1989, BRAIN RES, V496, P113, DOI 10.1016/0006-8993(89)91057-3; TANK DW, 1982, J CELL BIOL, V92, P207, DOI 10.1083/jcb.92.1.207; WHITTAKER VP, 1964, BIOCHEM J, V90, P293, DOI 10.1042/bj0900293	28	181	186	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 2	1991	253	5019					560	562		10.1126/science.1857986	http://dx.doi.org/10.1126/science.1857986			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1857986				2022-12-01	WOS:A1991FZ34700038
J	CUNNINGHAM, BC; MULKERRIN, MG; WELLS, JA				CUNNINGHAM, BC; MULKERRIN, MG; WELLS, JA			DIMERIZATION OF HUMAN GROWTH-HORMONE BY ZINC	SCIENCE			English	Article							PITUITARY; PROLACTIN; RECEPTOR; PROTEIN	Size-exclusion chromatography and sedimentation equilibrium studies demonstrated that zinc ion (Zn 2+) induced the dimerization of human growth hormone (hGH). Scatchard analysis of Zn-65(2+) binding to hGH showed that two Zn+ ions associate per dimer of hGH in a cooperative fashion. Cobalt (II) can substitute for Zn2+ in the hormone dimer and gives a visible spectrum characteristic of cobalt coordinated in a tetrahedral fashion by oxygen- and nitrogen-containing ligands. Replacement of potential Zn2+ ligands (His 18, His 21, and Glu 174) in hGH with alanine weakened both Zn2+ binding and hGH dimer formation. The Zn+-hGH dimer was more stable than monomeric hGH to denaturation in guanidine-HCl. Formation of a Zn2+-hGH dimeric complex may be important for storage of hGH in secretory granules.	GENENTECH INC,DEPT PROT ENGN,SAN FRANCISCO,CA 94080	Roche Holding; Genentech								ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ACKERS GK, 1965, P NATL ACAD SCI USA, V53, P342, DOI 10.1073/pnas.53.2.342; Bertini I, 1984, Adv Inorg Biochem, V6, P71; CUNNINGHAM BA, UNPUB; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAUGHADAY WF, 1985, TXB ENDOCRINOLOGY, P577; HANDEL T, 1990, J AM CHEM SOC, V112, P6710, DOI 10.1021/ja00174a039; HO KY, 1987, J CLIN ENDOCR METAB, V64, P51, DOI 10.1210/jcem-64-1-51; LABELLA F, 1973, BIOCHEM BIOPH RES CO, V52, P786, DOI 10.1016/0006-291X(73)91006-1; LEWIS UJ, 1984, ANNU REV PHYSIOL, V46, P33; LORENSON MY, 1983, J BIOL CHEM, V258, P8618; LOWMAN HB, 1991, J BIOL CHEM, V266, P10982; LOWMAN HB, UNPUB; MARTIN MT, 1989, INORG CHEM, V36, P27; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; REGAN L, 1990, BIOCHEMISTRY-US, V29, P10878, DOI 10.1021/bi00501a003; ROOT AW, 1979, J NUTR, V109, P958, DOI 10.1093/jn/109.6.958; SHIRE SJ, IN PRESS BIOCHEMISTR; TAYLOR AL, 1969, J CLIN INVEST, V48, P2349, DOI 10.1172/JCI106201; THOMPSON RG, 1972, J CLIN INVEST, V51, P3193, DOI 10.1172/JCI107146; THORLACIUSUSSING O, 1987, NEUROENDOCRINOLOGY, V45, P233, DOI 10.1159/000124731; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	25	205	222	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1991	253	5019					545	548		10.1126/science.1907025	http://dx.doi.org/10.1126/science.1907025			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1907025				2022-12-01	WOS:A1991FZ34700033
J	KRAUZLIS, RJ; LISBERGER, SG				KRAUZLIS, RJ; LISBERGER, SG			VISUAL-MOTION COMMANDS FOR PURSUIT EYE-MOVEMENTS IN THE CEREBELLUM	SCIENCE			English	Article							HORSERADISH-PEROXIDASE; RHESUS-MONKEY; VESTIBULOOCULAR REFLEX; PRIMATE FLOCCULUS; PURKINJE-CELLS; PROJECTIONS; MACAQUE; TRANSPORT; RESPONSES; NUCLEI	Eye movements that follow a target (pursuit eye movements) facilitate high acuity visual perception of moving targets by transforming visual motion inputs into motor commands that match eye motion to target motion. The performance of pursuit eye movements requires the cerebellar flocculus, which processes both visual motion and oculomotor signals. Electrophysiological recordings from floccular Purkinje cells have allowed the identification of their firing patterns during generation of the image velocity and image acceleration signals used for pursuit. Analysis with a method based on a behavioral model converted the time-varying spike trains of floccular Purkinje cells into a description of the firing rate contributed by three visual motion signals and one oculomotor input. The flocculus encodes all the signals needed to guide pursuit.	UNIV CALIF SAN FRANCISCO,GRAD PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	KRAUZLIS, RJ (corresponding author), UNIV CALIF SAN FRANCISCO,WM KECK FDN CTR INTEGRAT NEUROSCI,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Richard, Krauzlis/0000-0002-1826-0447				BALABAN CD, 1981, NEUROSCI LETT, V27, P101, DOI 10.1016/0304-3940(81)90251-2; BRODAL P, 1982, J COMP NEUROL, V204, P44, DOI 10.1002/cne.902040106; BRODAL P, 1978, BRAIN, V101, P251, DOI 10.1093/brain/101.2.251; BRODAL P, 1979, NEUROSCIENCE, V4, P193, DOI 10.1016/0306-4522(79)90082-4; Gerrits NM, 1987, EXP BRAIN RES SUPPL, V17, P26; GLICKSTEIN M, 1980, J COMP NEUROL, V190, P209, DOI 10.1002/cne.901900202; GOLDREICH D, 1987, Society for Neuroscience Abstracts, V13, P170; GOLDREICH D, IN PRESS J NEUROPHYS; Krauzlis RJ, 1989, NEURAL COMPUT, V1, P116, DOI 10.1162/neco.1989.1.1.116; KRAUZLIS R J, 1987, Society for Neuroscience Abstracts, V13, P170; KRAUZLIS R J, 1988, Society for Neuroscience Abstracts, V14, P798; LANGER T, 1985, J COMP NEUROL, V235, P1, DOI 10.1002/cne.902350102; LANGER T, 1985, J COMP NEUROL, V235, P26, DOI 10.1002/cne.902350103; LISBERGER SG, 1987, ANNU REV NEUROSCI, V10, P97, DOI 10.1146/annurev.ne.10.030187.000525; LISBERGER SG, 1988, SCIENCE, V242, P771, DOI 10.1126/science.3142040; LISBERGER SG, 1978, J NEUROPHYSIOL, V41, P733, DOI 10.1152/jn.1978.41.3.733; MILES FA, 1975, SCIENCE, V189, P1000, DOI 10.1126/science.1083068; MILES FA, 1980, J NEUROPHYSIOL, V43, P1437, DOI 10.1152/jn.1980.43.5.1437; MORRIS E J, 1985, Society for Neuroscience Abstracts, V11, P79; NODA H, 1909, J PHYSIOL-LONDON, V294, P349; Pearlmutter BA, 1989, NEURAL COMPUT, V1, P263, DOI 10.1162/neco.1989.1.2.263; RASHBASS C, 1961, J PHYSIOL-LONDON, V159, P326, DOI 10.1113/jphysiol.1961.sp006811; STONE LS, 1990, J NEUROPHYSIOL, V63, P1241, DOI 10.1152/jn.1990.63.5.1241; STONE LS, 1990, J NEUROPHYSIOL, V63, P1262, DOI 10.1152/jn.1990.63.5.1262; STONE LS, 1989, EXP BRAIN RES S, V17, P299; ZEE DS, 1981, J NEUROPHYSIOL, V46, P878, DOI 10.1152/jn.1981.46.4.878	26	34	34	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1991	253	5019					568	571		10.1126/science.1907026	http://dx.doi.org/10.1126/science.1907026			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1907026				2022-12-01	WOS:A1991FZ34700041
J	PINKER, S				PINKER, S			RULES OF LANGUAGE	SCIENCE			English	Article							IMPAIRMENT; WORDS	Language and cognition have been explained as the products of a homogeneous associative memory structure or alternatively, of a set of genetically determined computational modules in which rules manipulate symbolic representations. Intensive study of one phenomenon of English grammar and how it is processed and acquired suggests that both theories are partly right. Regular verbs (walk-walked) are computed by a suffixation rule in a neural system for grammatical processing; irregular verbs (run-ran) are retrieved from an associative memory.			PINKER, S (corresponding author), MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA.		Pinker, Steven/GPX-7942-2022		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018381] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson S. R., 1988, LINGUISTICS CAMBRIDG, VI, P146; Ariew Roger, 1989, PHILOS ESSAYS; ARONOFF M, 1983, ANNU REV ANTHROPOL, V12, P355, DOI 10.1146/annurev.an.12.100183.002035; BELLUGI U, 1990, AM J MED GENET, P115; BERKO J, 1958, WORD, V14, P150, DOI 10.1080/00437956.1958.11659661; BROWN R, 1973, 1ST LANGUAGE; BYBEE JL, 1983, LANGUAGE, V59, P251, DOI 10.2307/413574; BYBEE JL, 1982, LANGUAGE, V58, P265, DOI 10.2307/414099; Bybee JoanL., 1985, MORPHOLOGY; Chomsky N., 1980, RULES REPRESENTATION; CHOMSKY N, 1990, SOUND PATTERN ENGLIS; CURTISS S, 1988, EXCEPTIONAL BRAIN; EGEDI D, UNPUB; Fodor JA., 1983, MODULARITY MIND; Francis W, 1982, FREQUENCY ANAL ENGLI; GOPNIK M, 1990, NATURE, V344, P715, DOI 10.1038/344715a0; GOPNIK M, IN PRESS COGNITION; GOPNIK M, 1990, LANG ACQUIS, V1, P139; GORDON P, 1985, COGNITION, V21, P73, DOI 10.1016/0010-0277(85)90046-0; HEBB DO, 1949, ORG BEHAVIOR; HICKOK G, UNPUB; Hume D., 1955, INQUIRY HUMAN UNDERS; Jespersen Otto., 1961, MODERN ENGLISH GRAMM; KEMPLEY ST, 1982, BRIT J PSYCHOL, V73, P441, DOI 10.1111/j.2044-8295.1982.tb01826.x; KIM J, IN PRESS PAP REP CHI; KIM JJ, 1991, COGNITIVE SCI, V15, P173, DOI 10.1207/s15516709cog1502_1; Kiparsky Paul, 1982, STRUCTURE PHONOLOGIC, P93; KLIMA E, UNPUB; KUCZAJ SA, 1977, J VERB LEARN VERB BE, V16, P589, DOI 10.1016/S0022-5371(77)80021-2; LACHTER J, 1988, COGNITION, V28, P195, DOI 10.1016/0010-0277(88)90033-9; LENNEBERG EH, 1967, BIOL F LANGUAGE; MARCUS G, 1990, MIT41 CTR COG SCI OC; MARIN OSM, 1976, ANN NY ACAD SCI, V280, P868, DOI 10.1111/j.1749-6632.1976.tb25550.x; MENCKEN HL, 1936, AM LANGUAGE; NEWELL A, 1961, SCIENCE, V134, P2011, DOI 10.1126/science.134.3495.2011; PINKER S, 1988, COGNITION, V28, P73, DOI 10.1016/0010-0277(88)90032-7; PRASADA S, 1990, 31ST ANN M PSYCH SOC; PRASADA S, UNPUB; Rumelhart D.E., 1986, PARALLEL DISTRIBUTED, V1, P318, DOI [DOI 10.7551/MITPRESS/5236.001.0001, 10.1016/b978-1-4832-1446-7.50035-2]; Rumelhart D.E., 1986, PARALLEL DISTRIBUTED, V2, P216, DOI DOI 10.7551/MITPRESS/5237.001.0001; STANNERS RF, 1979, J VERB LEARN VERB BE, V18, P399, DOI 10.1016/S0022-5371(79)90219-6; TALLAL P, 1989, J SPEECH HEAR DISORD, V54, P167, DOI 10.1044/jshd.5402.167; TOMBLIN J, UNPUB; TOMBLIN JB, 1989, J SPEECH HEAR DISORD, V54, P287, DOI 10.1044/jshd.5402.287; ULLMAN M, 1991, MAR SPRING S AAAI ST	45	564	572	0	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 2	1991	253	5019					530	535		10.1126/science.1857983	http://dx.doi.org/10.1126/science.1857983			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	FZ347	1857983				2022-12-01	WOS:A1991FZ34700029
J	SZCZYLIK, C; SKORSKI, T; NICOLAIDES, NC; MANZELLA, L; MALAGUARNERA, L; VENTURELLI, D; GEWIRTZ, AM; CALABRETTA, B				SZCZYLIK, C; SKORSKI, T; NICOLAIDES, NC; MANZELLA, L; MALAGUARNERA, L; VENTURELLI, D; GEWIRTZ, AM; CALABRETTA, B			SELECTIVE-INHIBITION OF LEUKEMIA-CELL PROLIFERATION BY BCR-ABL ANTISENSE OLIGODEOXYNUCLEOTIDES	SCIENCE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOCYTIC-LEUKEMIA; NORMAL HUMAN HEMATOPOIESIS; PHILADELPHIA-CHROMOSOME; SYNTHETIC OLIGONUCLEOTIDES; KINASE-ACTIVITY; PROTEIN; MICE; RNA; TRANSFORMATION	To determine the role of the BCR-ABL gene in the proliferation of blast cells of patients with chronic myelogenous leukemia, leukemia blast cells were exposed to synthetic 18-mer oligodeoxynucleotides complementary to two identified BCR-ABL junctions. Leukemia colony formation was suppressed, whereas granulocyte-macrophage colony formation from normal marrow progenitors was unaffected. When equal proportions of normal marrow progenitors and blast cells were mixed, exposed to the oligodeoxynucleotides, and assayed for residual colony formation, the majority of residual cells were normal. These findings demonstrate the requirement for a functional BCR-ABL gene in maintaining the leukemic phenotype and the feasibility of gene-targeted selective killing of neoplastic cells.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; UNIV PENN,DEPT PATHOL & MED,PHILADELPHIA,PA 19103; INST REGINA ELENA STUDIO & CURA TUMORI,I-00165 ROME,ITALY; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Malaguarnera, Lucia/K-5530-2018	Malaguarnera, Lucia/0000-0002-4516-7571; MANZELLA, Livia/0000-0002-9908-6443	NATIONAL CANCER INSTITUTE [R23CA036896, T32CA009644, R01CA036896, R01CA046782] Funding Source: NIH RePORTER; NCI NIH HHS [CA36896, CA46782, CA09644] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; CARACCIOLO D, 1989, SCIENCE, V245, P1107, DOI 10.1126/science.2672339; CARACCIOLO D, 1990, J CLIN INVEST, V85, P55, DOI 10.1172/JCI114433; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KOEFFLER HP, 1981, NEW ENGL J MED, V304, P1201, DOI 10.1056/NEJM198105143042004; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P316; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; NOWELL PC, 1960, SCIENCE, V132, P1497; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; ROSENTHAL S, 1977, AM J MED, V63, P542, DOI 10.1016/0002-9343(77)90199-1; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; ROWLEY JD, 1980, ANNU REV GENET, V14, P17, DOI 10.1146/annurev.ge.14.120180.000313; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; SZCZYLIK C, UNPUB; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; ZAMECNIK PC, 1986, P NATL ACAD SCI USA, V83, P4143, DOI 10.1073/pnas.83.12.4143	34	322	353	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1991	253	5019					562	565		10.1126/science.1857987	http://dx.doi.org/10.1126/science.1857987			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1857987				2022-12-01	WOS:A1991FZ34700039
J	DAVIDSON, DR; CRAWLEY, A; HILL, RE; TICKLE, C				DAVIDSON, DR; CRAWLEY, A; HILL, RE; TICKLE, C			POSITION-DEPENDENT EXPRESSION OF 2 RELATED HOMEOBOX GENES IN DEVELOPING VERTEBRATE LIMBS	NATURE			English	Article							CHICK WING BUD; PATTERN-FORMATION; POLARIZING REGION; RETINOIC ACID; MOUSE; DROSOPHILA	MANY genes that control pattern formation in insects contain a conserved homeobox region which encodes a domain involved in DNA binding 1. One approach to understanding pattern formation in vertebrates is to examine the role of homeobox-containing genes in the developing limb 2. Two such genes, Hox-7.1 and Hox-8.1, are expressed in distal mesoderm, but not in the proximal core, of mouse forelimb (refs 3,4, and D.R.D., manuscript in preparation). The proximodistal cartilage pattern in the chick wing is progressively determined in the distal mesoderm, which is maintained as a 'progress zone' by the overlying apical ectodermal ridge 5. Indeed, proximal cells are reprogrammed to form distal structures when placed in the progress zone 6 and we therefore expect that genes involved in controlling limb pattern should be activated in such grafts. We tested this requirement for Hox-7.1 and Hox-8.1 in mouse limb mesoderm placed in chick wing buds. Our results reported here indicate that both genes are rapidly activated by a signal from the apical ectoderm. These properties, taken with the DNA-binding properties of the homeodomain, strongly suggest that Hox-7.1 and Hox-8.1 have fundamental roles in limb-pattern formation.	UNIV COLL & MIDDLESEX SCH MED,DEPT ANAT & DEV BIOL,LONDON W1P 6DB,ENGLAND	University of London; University College London	DAVIDSON, DR (corresponding author), WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,DEV GENET GRP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							CAIRNS JM, 1965, DEV BIOL, V12, P36, DOI 10.1016/0012-1606(65)90019-9; COTTRILL CP, 1990, CELL DIFFER DEV, V29, P67, DOI 10.1016/0922-3371(90)90025-R; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DOLE P, 1990, DEVELOPMENT, V110, P1133; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HAMBURGER V, 1979, J MORPHOL, V50, P217; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JORQUERA B, 1971, CR ACAD SCI D NAT, V272, P1522; LYONS KM, 1990, DEVELOPMENT, V109, P833; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; SAUNDERS JW, 1959, DEV BIOL, V1, P281, DOI 10.1016/0012-1606(59)90030-2; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TICKLE C, 1976, NATURE, V259, P396, DOI 10.1038/259396a0; Wolpert L, 1975, Ciba Found Symp, V0, P95	20	188	191	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					429	431		10.1038/352429a0	http://dx.doi.org/10.1038/352429a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1677742				2022-12-01	WOS:A1991FZ34600064
J	HAGELBERG, E; GRAY, IC; JEFFREYS, AJ				HAGELBERG, E; GRAY, IC; JEFFREYS, AJ			IDENTIFICATION OF THE SKELETAL REMAINS OF A MURDER VICTIM BY DNA ANALYSIS	NATURE			English	Article							POLYMERASE CHAIN-REACTION; DINUCLEOTIDE REPEAT; MINISATELLITES; POLYMORPHISMS; AMPLIFICATION	THERE is considerable anthropological and forensic interest in the possibility of DNA typing skeletal remains. Trace amounts of DNA can be recovered even from 5,500-year-old bones and multicopy human mitochondrial DNA sequences can frequently be amplified from such DNA using the polymerase chain reaction (PCR) 1,2. But given the sensitivity of PCR, it is very difficult to exclude contaminating material. We now report the successful identification of the 8-year-old skeletal remains of a murder victim, by comparative typing of nuclear microsatellite markers 3-5 in the remains and in the presumptive parents of the victim. This analysis establishes the authenticity of the bone DNA and the feasibility of bone DNA typing in forensic investigations.	UNIV LEICESTER, DEPT GENET, LEICESTER LE1 7RH, ENGLAND	University of Leicester	HAGELBERG, E (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, MRC, MOLEC HAEMATOL UNIT, OXFORD OX3 9DU, ENGLAND.		Schneider, Peter M./A-6661-2011		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHAKRABORTY R, IN PRESS DNA FINGERP; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; HAGELBERG E, 1989, NATURE, V342, P485, DOI 10.1038/342485a0; HAGELBERG E, 1991, P ROY SOC B-BIOL SCI, V244, P45, DOI 10.1098/rspb.1991.0049; HOUCK CM, 1979, J MOL BIOL, V132, P289, DOI 10.1016/0022-2836(79)90261-4; JEFFREYS AJ, 1988, NUCLEIC ACIDS RES, V16, P10953, DOI 10.1093/nar/16.23.10953; JEFFREYS AJ, 1990, CELL, V60, P473, DOI 10.1016/0092-8674(90)90598-9; LITT M, 1989, AM J HUM GENET, V44, P397; WEBER JL, 1990, GENOMICS, V7, P524, DOI 10.1016/0888-7543(90)90195-Z; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P2199; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x	13	220	227	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 1	1991	352	6334					427	429		10.1038/352427a0	http://dx.doi.org/10.1038/352427a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861721				2022-12-01	WOS:A1991FZ34600063
J	HEEMSKERK, J; DINARDO, S; KOSTRIKEN, R; OFARRELL, PH				HEEMSKERK, J; DINARDO, S; KOSTRIKEN, R; OFARRELL, PH			MULTIPLE-MODES OF ENGRAILED REGULATION IN THE PROGRESSION TOWARDS CELL FATE DETERMINATION	NATURE			English	Article							SEGMENT-POLARITY GENE; DROSOPHILA EMBRYOS; DEVELOPMENTAL COMPARTMENTALIZATION; AUTO-REGULATION; WINGLESS GENE; EXPRESSION; LOCALIZATION; TRANSCRIPTS; PROTEIN; LOCUS	The engrailed gene product of Drosophila specifies the fate of a subset of cells in each segment. Our studies of engrailed regulation suggest that fate determination is an elaborate, multistep process. At the time in embryogenesis when the engrailed-dependent cell fate is probably determined, four modes of control act in an overlapping progression to govern engrailed expression. After activation by pair-rule genes, both an extracellular signal, wingless, and autoregulation are required for engrailed expression. Autoregulation graduates to wingless independence, but is transient, and is superseded by an engrailed- independent mode of maintenance.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	Rockefeller University; University of California System; University of California Berkeley	HEEMSKERK, J (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.			DiNardo, Stephen/0000-0003-4131-5511; O'Farrell, Patrick/0000-0003-0011-2734	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037193] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM037193, R01 GM037193-10] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEVELOPMENT, V103, P289; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BUSTURIA A, 1988, DEVELOPMENT, V104, P713; CLINE TW, 1984, GENETICS, V107, P231; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DURA JM, 1988, DEVELOPMENT, V103, P733; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1976, DEV BIOL, V48, P132, DOI 10.1016/0012-1606(76)90052-X; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KASSIS JA, 1990, GENE DEV, V4, P433, DOI 10.1101/gad.4.3.433; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; POOLE SJ, 1988, DEVELOPMENT, V104, P85; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Slack J, 1983, EGG EMBRYO; SMOUSE D, 1988, GENE DEV, V2, P830, DOI 10.1101/gad.2.7.830; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STRUHL G, 1985, EMBO J, V4, P3259, DOI 10.1002/j.1460-2075.1985.tb04075.x; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WEDEEN C, 1986, CELL, V44, P739, DOI 10.1016/0092-8674(86)90840-8	33	240	242	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 1	1991	352	6334					404	410		10.1038/352404a0	http://dx.doi.org/10.1038/352404a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861720	Green Accepted			2022-12-01	WOS:A1991FZ34600055
J	HSU, VW; YUAN, LC; NUCHTERN, JG; LIPPINCOTTSCHWARTZ, J; HAMMERLING, GJ; KLAUSNER, RD				HSU, VW; YUAN, LC; NUCHTERN, JG; LIPPINCOTTSCHWARTZ, J; HAMMERLING, GJ; KLAUSNER, RD			A RECYCLING PATHWAY BETWEEN THE ENDOPLASMIC-RETICULUM AND THE GOLGI-APPARATUS FOR RETENTION OF UNASSEMBLED MHC CLASS-I MOLECULES	NATURE			English	Article							HEAVY-CHAINS; BREFELDIN-A; PROTEINS; ER; ANTIBODIES; RECEPTOR; COMPLEX	ASSEMBLY of Class I major histocompatibility complex (MHC) molecules involves the interaction of two distinct polypeptides (the heavy and light chains) with peptide antigen. Cell lines synthesizing both chains but expressing low levels of MHC class I molecules on their surface as a result of a failure in assembly and transport have been identified 1. We now report that although the apparent steady-state distribution in these cells of class I molecules is in the endoplasmic reticulum (ER), the molecules in fact are recycled between the ER and Golgi, rather than retained in the ER. This explains the failure of class I molecules to negotiate the secretory pathway. Class I molecules do not seem to be modified by Golgi enzymes, suggesting that the proteins do not reach the Golgi apparatus during recycling. But morphological and subcellular fractionation evidence indicates that they pass through the cis Golgi or a Golgi-associated organelle, which we postulate to be the recycling organelle. This compartment, which we call the 'cis-Golgi network', would thereby be a sorting organelle that selects proteins for return to the ER.	GERMAN CANC RES CTR,INST IMMUNOL & GENET,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)	HSU, VW (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.							BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; JAMIESON JD, 1968, J CELL BIOL, V39, P589, DOI 10.1083/jcb.39.3.589; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.bi.54.070185.003215; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189	14	161	161	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					441	444		10.1038/352441a0	http://dx.doi.org/10.1038/352441a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861723				2022-12-01	WOS:A1991FZ34600069
J	KEMP, DS; BOYD, JG; MUENDEL, CC				KEMP, DS; BOYD, JG; MUENDEL, CC			THE HELICAL S-CONSTANT FOR ALANINE IN WATER DERIVED FROM TEMPLATE-NUCLEATED HELICES	NATURE			English	Article							IMMUNOGENIC PEPTIDE-FRAGMENTS; ROTATING-FRAME; ALPHA-HELIX; PROTEINS; H-1-NMR; SPECTROSCOPY	FORMATION of alpha-helices from disordered polypeptides depends on the degree to which amino acids favour the helical state. The folding of helical oligopeptides can be modelled by two parameters: sigma which reflects helix initiation and s which reflects propagation of a pre-existing helix and measures helical bias 1,2. Scheraga has reported s values for oligopeptides of about 1.1, implying a weak helical bias for amino-acid residues 3. By contrast, certain helical peptides studied by Baldwin seem to require much larger s values for alanine 4. Resolution of this inconsistency requires experiments that disentangle the ease of propagation from that of initiation. In this study varying lengths of polyalanine are linked to a 'template' that initiates helical structure and permits study solely of propagation. We report here that the s value for alanine in water is close to 1, supporting the earlier results of Scheraga but not the more recent results of Baldwin.			KEMP, DS (corresponding author), MIT,DEPT CHEM,ROOM 18-584,CAMBRIDGE,MA 02139, USA.							BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BIERZYNSKI A, 1982, P NATL ACAD SCI-BIOL, V79, P2470, DOI 10.1073/pnas.79.8.2470; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; ESPOSITO G, 1987, BIOCHEMISTRY-US, V26, P1043, DOI 10.1021/bi00378a010; KARLE IL, 1987, P NATL ACAD SCI USA, V84, P5087, DOI 10.1073/pnas.84.15.5087; KEMP DS, 1988, TETRAHEDRON LETT, V29, P4931, DOI 10.1016/S0040-4039(00)80644-9; KEMP DS, IN PRESS J ORG CHEM; KEMP DS, 1990, PEPT P AM PEPT S, V11, P677; KESSLER H, 1987, J AM CHEM SOC, V109, P607, DOI 10.1021/ja00236a063; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; POLARD D, 1970, THEORY HELIX COLI TR; SCHERAGA HA, 1978, PURE APPL CHEM, V50, P315, DOI 10.1351/pac197850040315; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; WAGNER G, 1983, J AM CHEM SOC, V105, P5948, DOI 10.1021/ja00356a056; WUETHRICH K, 1984, J MOL BIOL, V180, P715; ZIMM BH, 1959, J CHEM PHYS, V31, P526, DOI 10.1063/1.1730390	21	132	133	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					451	454		10.1038/352451a0	http://dx.doi.org/10.1038/352451a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861726				2022-12-01	WOS:A1991FZ34600072
J	LEE, C; LEVITT, M				LEE, C; LEVITT, M			ACCURATE PREDICTION OF THE STABILITY AND ACTIVITY EFFECTS OF SITE-DIRECTED MUTAGENESIS ON A PROTEIN CORE	NATURE			English	Article							FREE-ENERGY CALCULATIONS; T4 LYSOZYME; STAPHYLOCOCCAL NUCLEASE; HYDROPHOBIC CORE; PACKING; THERMOSTABILITY; REPRESSOR	THEORETICAL prediction of the structure, stability and activity of proteins, an important unsolved problem in molecular biology, would be of use for guiding site-directed mutagenesis and other protein-engineering techniques. X-ray diffraction studies have provided extensive structural information for many proteins, challenging theorists to develop reliable techniques able to use such knowledge as a base for prediction of mutants' characteristics. Here we report theoretical calculation of stabilization energies for 78 triple-site sequence variants of lambda-repressor characterized experimentally by Lim and Sauer 1. The calculated energies correlate with the mutants' measured activities; active and inactive mutations are discriminated with 92% reliability. They correlate even more directly with the mutants' thermostabilities, correctly identifying two of the mutants to be more stable than the wild type.			LEE, C (corresponding author), STANFORD UNIV,MED CTR,DEPT CELL BIOL,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305, USA.		Levitt, Michael/E-4582-2012	Levitt, Michael/0000-0002-8414-7397				BASH PA, 1987, SCIENCE, V236, P564, DOI 10.1126/science.3576184; DAGGETT V, IN PRESS PROTEIN ENG; DANG LX, 1989, J AM CHEM SOC, V111, P8505, DOI 10.1021/ja00204a027; DAOPIN S, 1990, PROTEINS, V7, P198, DOI 10.1002/prot.340070208; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KARPUSAS M, 1989, P NATL ACAD SCI USA, V86, P8237, DOI 10.1073/pnas.86.21.8237; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; LEE C, 1991, J MOL BIOL, V217, P373, DOI 10.1016/0022-2836(91)90550-P; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; MALCOLM BA, 1990, NATURE, V345, P86, DOI 10.1038/345086a0; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; McCammon JA, 1991, CURR OPIN STRUC BIOL, V1, P196; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SHORTLE D, 1989, ARCH BIOCHEM BIOPHYS, V272, P103, DOI 10.1016/0003-9861(89)90200-2; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SHORTLE D, 1986, Proteins Structure Function and Genetics, V1, P81, DOI 10.1002/prot.340010113; TIDOR B, 1991, BIOCHEMISTRY-US, V30, P3217, DOI 10.1021/bi00227a009	19	161	172	1	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					448	451		10.1038/352448a0	http://dx.doi.org/10.1038/352448a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861725				2022-12-01	WOS:A1991FZ34600071
J	MISHU, B; GRIFFIN, PM; TAUXE, RV; CAMERON, DN; HUTCHESON, RH; SCHAFFNER, W				MISHU, B; GRIFFIN, PM; TAUXE, RV; CAMERON, DN; HUTCHESON, RH; SCHAFFNER, W			SALMONELLA-ENTERITIDIS GASTROENTERITIS TRANSMITTED BY INTACT CHICKEN EGGS	ANNALS OF INTERNAL MEDICINE			English	Article							GRADE-A EGGS; INFECTIONS	Objective: To determine the source and to describe the clinical importance of a large outbreak of Salmonella enteritidis gastroenteritis in Tennessee, which is outside the geographic focus of the S. enteritidis pandemic. Design: A case-control study and tracing of the source eggs. Setting: A Tennessee community and a large layer farm in Indiana. Patients: Case patients ate at the implicated restaurant and subsequently developed S. enteritidis gastroenteritis; controls ate with the case patients, but did not develop gastroenteritis. Measurements: Eighty-one case patients were identified; 73 (90%) had eaten egg-containing sauces at a local restaurant on a given evening. The eggs were traced to their farm of origin in Indiana. The farm was inspected 5 weeks after the outbreak. Main Results: Of 24 patients with culture-proved cases, 11 were hospitalized. Hollandaise and bernaise sauces prepared with intact, extra-large, grade-A eggs were strongly associated with illness (P < 0.001). Salmonella enteritidis was isolated from specimens collected from chickens and the farm. Antimicrobial susceptibility patterns, phage typing, and plasmid profiles of isolates from the farm and from patients were indistinguishable. Conclusions: Salmonella enteritidis infection is a large and growing public health problem that is spreading beyond the northeastern United States. This study shows a direct link between infected poultry flocks and an outbreak of human illness.	VANDERBILT UNIV, NASHVILLE, TN 37240 USA; TENNESSEE DEPT HLTH & ENVIRONM, NASHVILLE, TN USA	Vanderbilt University; Tennessee Department Health	MISHU, B (corresponding author), CTR DIS CONTROL, ENTER DIS BRANCH, MSC09, ATLANTA, GA 30333 USA.							BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROWNELL JR, 1969, AVIAN DIS, V13, P804, DOI 10.2307/1588588; HOPPER SA, 1988, VET REC, V123, P351, DOI 10.1136/vr.123.13.351; HUMPHREY TJ, 1989, EPIDEMIOL INFECT, V103, P415, DOI 10.1017/S0950268800030818; HUMPHREY TJ, 1989, EPIDEMIOL INFECT, V103, P35, DOI 10.1017/S0950268800030338; LISTER SA, 1988, VET REC, V123, P350, DOI 10.1136/vr.123.13.350; PAVIA AT, 1990, J INFECT DIS, V161, P255, DOI 10.1093/infdis/161.2.255; POTTER M, 1987, POULTRY EGG RELATED, P44; RODRIGUE D, 1989, 29TH INT C ANT AG CH; RODRIGUE DC, 1990, EPIDEMIOL INFECT, V105, P21, DOI 10.1017/S0950268800047609; ROMBAUER IS, 1975, JOY COOKING, P357; STLOUIS ME, 1988, JAMA-J AM MED ASSOC, V259, P2103, DOI 10.1001/jama.259.14.2103; TAYLOR DN, 1982, J INFECT DIS, V146, P322, DOI 10.1093/infdis/146.3.322; TELZAK EE, 1990, NEW ENGL J MED, V323, P394, DOI 10.1056/NEJM199008093230607; THOMAS RD, 1989, JAMA-J AM MED ASSOC, V261, P2064, DOI 10.1001/jama.261.14.2064; WAITES WM, 1990, LANCET, V336, P722, DOI 10.1016/0140-6736(90)92213-2; WARD LR, 1987, EPIDEMIOL INFECT, V99, P291, DOI 10.1017/S0950268800067765; WILLIAMS LP, 1970, AM J PUBLIC HEALTH N, V60, P926, DOI 10.2105/AJPH.60.5.926; 1988, USDA FDA FOOD SERVIC, P1; 1989, J AM VET MED ASSOC, V194, P626; 1988, LANCET, V2, P720; 1990, RETAIL FOOD PROTECTI, P1; 1990, MMWR, V38, P877; 1990, FED REG         0216, V55, P5576; 1990, FED REG         0401; 1990, MMWR, V39, P909	27	65	67	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1991	115	3					190	194		10.7326/0003-4819-115-3-190	http://dx.doi.org/10.7326/0003-4819-115-3-190			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY152	2058873				2022-12-01	WOS:A1991FY15200005
J	NOEBELS, JL; MARCOM, PK; JALILIANTEHRANI, MH				NOEBELS, JL; MARCOM, PK; JALILIANTEHRANI, MH			SODIUM-CHANNEL DENSITY IN HYPOMYELINATED BRAIN INCREASED BY MYELIN BASIC-PROTEIN GENE DELETION	NATURE			English	Article							ACTION-POTENTIAL CONDUCTION; DYSMYELINATING MUTANT MICE; CENTRAL NERVOUS-SYSTEM; SHIVERER MOUSE; OPTIC-NERVE; RAT; EXPRESSION; DIFFERENTIATION; GLYCOPROTEIN; DEFICIENT	TROPHIC control over the expression and membrane distribution of voltage-dependent ion channels is one of the principal organizing events underlying the maturation of excitable cells. The myelin sheath is a major structural determinant of regional ion channel topography in central axons 1,2, but the exact molecular signals that mediate local interactions between the oligodendrocyte and axolemma are not known. We have found that large caliber fibre pathways in the brain of the mutant mouse shiverer (shi, gene on chromosome 18), whose developmental fate of myelination is averted by deletion of five exons in the myelin basic protein gene 3-5, have a striking excess of sodium channels. As cytoplasmic membranes of shiverer oligodendroglia still adhere to axons 6-8, the evidence indicates that myelin basic protein or a myelin basic protein-dependent glial transmembrane signal associated with compact myelin formation, rather than a simple glial-axon contact inhibition or an intrinsic genetic program of neuronal differentiation, could be critical in downregulating sodium channel density in axons. Here we use the shiverer mutant to show that mature central nervous system projection neurons with large caliber unmyelinated fibres sustain functional excitability by increasing sodium channel density. This axon plasticity, triggered by the absence of a single glial protein, contributes to the unexpectedly mild degree of neurological impairment in the mutant brain without myelin, and may be a potentially inducible mechanism determining the recovery of function from dysmyelinating disease.	BAYLOR UNIV,DEPT BIOCHEM,HOUSTON,TX 77030	Baylor University	NOEBELS, JL (corresponding author), BAYLOR UNIV,INST MOLEC GENET,DEPT NEUROL,DIV NEUROSCI,NEUROPHYSIOL SECT,DEV NEUROGENET LAB,HOUSTON,TX 77030, USA.		Marcom, Paul/M-4516-2019; Marcom, Paul/AAE-4761-2020	Marcom, Paul/0000-0001-5302-6368; Noebels, Jeffrey/0000-0002-2887-0839				BARRES BA, 1989, NEURON, V2, P1375, DOI 10.1016/0896-6273(89)90076-7; BIRD TD, 1978, J NEUROCHEM, V31, P387, DOI 10.1111/j.1471-4159.1978.tb12479.x; CAMPAGNONI AT, 1988, J NEUROCHEM, V51, P1, DOI 10.1111/j.1471-4159.1988.tb04827.x; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; CHIU SY, 1987, J PHYSIOL-LONDON, V391, P631, DOI 10.1113/jphysiol.1987.sp016760; FRAIL DE, 1985, J NEUROCHEM, V45, P1071, DOI 10.1111/j.1471-4159.1985.tb05525.x; HODGKIN A, 1975, PHILOS T ROY SOC B, V270, P297, DOI 10.1098/rstb.1975.0010; INOUE Y, 1981, BRAIN RES, V219, P85, DOI 10.1016/0006-8993(81)90269-9; LEMKE G, 1988, NEURON, V1, P535, DOI 10.1016/0896-6273(88)90103-1; LIDOW MS, 1988, BRAIN RES, V459, P105, DOI 10.1016/0006-8993(88)90290-9; MOLINEAUX SM, 1986, P NATL ACAD SCI USA, V83, P7542, DOI 10.1073/pnas.83.19.7542; MOURRE C, 1988, BRAIN RES, V448, P128, DOI 10.1016/0006-8993(88)91109-2; OFFARD J, 1989, NEURON, V2, P1447; PRIVAT AC, 1979, NEUROSCI LETT, V142, P107; ROACH A, 1985, CELL, V42, P149, DOI 10.1016/S0092-8674(85)80110-0; ROSENBLUTH J, 1980, J COMP NEUROL, V194, P639, DOI 10.1002/cne.901940310; ROSENBLUTH J, 1988, INT J DEV NEUROSCI, V6, P3, DOI 10.1016/0736-5748(88)90025-1; ROSENBLUTH J, 1981, BRAIN RES, V208, P283, DOI 10.1016/0006-8993(81)90558-8; SCHEINMAN RI, 1989, J BIOL CHEM, V264, P1060; SCHMIDT J, 1985, P NATL ACAD SCI USA, V82, P4847, DOI 10.1073/pnas.82.14.4847; SHARKEY RG, 1984, BIOCHEMISTRY-US, V23, P6078, DOI 10.1021/bi00320a027; SHEEDLO HJ, 1987, BRAIN RES, V415, P105, DOI 10.1016/0006-8993(87)90273-3; SMITH KJ, 1980, NATURE, V286, P154, DOI 10.1038/286154a0; SONTHEIMER H, 1989, NEURON, V2, P1135, DOI 10.1016/0896-6273(89)90180-3; SORG BA, 1987, J NEUROCHEM, V49, P1146, DOI 10.1111/j.1471-4159.1987.tb10005.x; STUMER W, 1987, EUR BIOPHYS J, V14, P131; WAXMAN SG, 1990, J NEUROCYTOL, V19, P11, DOI 10.1007/BF01188436; WAXMAN SG, 1989, P NATL ACAD SCI USA, V86, P1406, DOI 10.1073/pnas.86.4.1406; Waxman SG, 1987, PROG BRAIN RES <D>, V71, P121; WISNIEWSKI HM, 1976, J NEUROPATH EXP NEUR, V35, P327, DOI 10.1097/00005072-197605000-00063	30	55	55	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					431	434		10.1038/352431a0	http://dx.doi.org/10.1038/352431a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1713650				2022-12-01	WOS:A1991FZ34600065
J	PUTKONEN, P; THORSTENSSON, R; GHAVAMZADEH, L; ALBERT, J; HILD, K; BIBERFELD, G; NORRBY, E				PUTKONEN, P; THORSTENSSON, R; GHAVAMZADEH, L; ALBERT, J; HILD, K; BIBERFELD, G; NORRBY, E			PREVENTION OF HIV-2 AND SIVSM INFECTION BY PASSIVE-IMMUNIZATION IN CYNOMOLGUS MONKEYS	NATURE			English	Article							MACACA-FASCICULARIS; IMMUNODEFICIENCY; VIRUS; GLYCOPROTEIN; PROTECTION; CHIMPANZEES; MACAQUES; LEUKEMIA; GP71	INFECTION of macaques with simian immunodeficiency virus (SIV) 1,2 and human immunodeficiency virus type 2 (HIV-2) 3,4 are useful models for studies of immunotherapy and vaccination against HIV as well as for testing of antiviral drugs. Vaccine research showing protective immunity in immunized monkeys 4-10 has indicated that it will be possible to develop a vaccine for prevention of human HIV infection, although many hurdles remain. The design of an HIV vaccine would be helped if the basis of the protective immunity could be elucidated. Passive immune prophylaxis offers a means to determine the relative role of antibodies in protection against infection. We have studied whether a transfer of antibodies can prevent HIV-2 and SIV(sm) (SIV of sooty mangabey origin) infection in cynomolgus monkeys. Sera with high antibody titres were collected, heat-treated and injected into naive animals 6 h before challenge with 10-100 monkey-infectious doses of live homologous virus. All control animals treated with normal monkey serum (n = 6) or no serum (n = 39) became infected by the challenge virus, whereas five out of seven animals pretreated with antibody-containing serum at a dose of 9 ml kg-1 resisted infection. Thus passively transferred antibodies can protect against a low-dose lentivirus challenge in a nonhuman primate.	NATL BACTERIOL LAB,DEPT VIROL,S-10521 STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT VIROL,S-10521 STOCKHOLM,SWEDEN	Karolinska Institutet	PUTKONEN, P (corresponding author), NATL BACTERIOL LAB,DEPT IMMUNOL,S-10521 STOCKHOLM,SWEDEN.							ALBERT J, 1990, J CLIN MICROBIOL, V28, P1560, DOI 10.1128/JCM.28.7.1560-1564.1990; ALBERT J, 1990, AIDS, V4, P291, DOI 10.1097/00002030-199004000-00002; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BIBERFELD G, 1988, AIDS, V2, P195; BJORLING E, IN PRESS P NATN ACAD; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; DENORONHA F, 1978, VIROLOGY, V85, P617, DOI 10.1016/0042-6822(78)90467-1; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; DESROSIERS RC, 1989, INTERVIROLOGY, V30, P301, DOI 10.1159/000150108; HUNSMANN G, 1975, VIROLOGY, V66, P327, DOI 10.1016/0042-6822(75)90203-2; KATAOKA R, 1990, BLOOD, V76, P1657; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; NORRBY E, 1991, AIDS RES HUM RETROV, V7, P279, DOI 10.1089/aid.1991.7.279; PRINCE AM, 1988, P NATL ACAD SCI USA, V85, P6944, DOI 10.1073/pnas.85.18.6944; PUTKONEN P, 1989, J ACQ IMMUN DEF SYND, V2, P366; PUTKONEN P, 1991, AIDS RES HUM RETROV, V7, P271, DOI 10.1089/aid.1991.7.271; PUTKONEN P, 1989, J ACQ IMMUN DEF SYND, V2, P359; PUTKONEN P, 1990, AIDS, V4, P783, DOI 10.1097/00002030-199008000-00010; STOTT EJ, 1990, LANCET, V336, P1538, DOI 10.1016/0140-6736(90)93310-L; THORSTENSSON R, 1991, J ACQ IMMUN DEF SYND, V4, P374	20	203	210	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					436	438		10.1038/352436a0	http://dx.doi.org/10.1038/352436a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1677743				2022-12-01	WOS:A1991FZ34600067
J	RONNBLOM, LE; ALM, GV; OBERG, KE				RONNBLOM, LE; ALM, GV; OBERG, KE			AUTOIMMUNITY AFTER ALPHA-INTERFERON THERAPY FOR MALIGNANT CARCINOID-TUMORS	ANNALS OF INTERNAL MEDICINE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; LEUKOCYTE-DERIVED INTERFERON; LONG-TERM THERAPY; THYROID-DISEASE; ANTIBODIES; AUTOANTIBODIES; LYMPHOCYTES; ENHANCEMENT; ASSOCIATION; CIRCULATION	Objective: To determine the incidence of autoantibodies and autoimmune disease and their influence on therapeutic results during alpha-interferon treatment in patients with malignant midgut carcinoid tumors. Design: Consecutive sample of patients. Setting: University hospital. Patients: One hundred thirty-five patients (70 women, 65 men; median age, 59 years) with biopsy-proven tumors, liver metastases, and no autoimmune disease. Interventions: Leukocyte alpha-interferon (n = 88) or alpha-interferon 2b (n = 47) three times a week. Main Outcome Measures: Signs and symptoms of autoimmune disease or development of autoantibodies to thyroid antigens, nuclear antigens, or gastric parietal cells. Tumor responses were determined by reduced liver metastases or reduced urinary 5-hydroxyindole acetic acid excretion, or both. Results: Twenty-five patients (19%) developed the following autoimmune disorders after a median of 9 months of therapy: thyroid disease (n = 18), systemic lupus erythematosus (n = 1), pernicious anemia (n = 4), and vasculitis (n = 2). Antibodies to microsomal thyroid antigen or thyroglobulin were detected in 16 patients before therapy and in another 11 patients during therapy. Antinuclear antibodies were detected in 16 patients before and in another 19 patients during therapy. Clinical thyroid disease developed in more than 60% of patients who had or developed thyroid antibodies but in only 7% of initially autoantibody-negative patients. Autoimmunity did not correlate with objective tumor response. Conclusion: Patients with malignant carcinoid tumors may develop autoimmune disease during alpha-interferon therapy, especially when autoantibodies are present. They should therefore be monitored for autoimmunity, which does not appear, however, to influence tumor responses.	UNIV HOSP UPPSALA, LUDWIG INST CANC RES, S-75185 UPPSALA, SWEDEN; CENT HOSP BODEN, BODEN, SWEDEN	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University Hospital			Oberg, Kjell/AAG-7118-2019					ABDI EA, 1986, SCAND J HAEMATOL, V36, P515; BANKHURST AD, 1987, J RHEUMATOL, V14, P63; BJORO T, 1984, ACTA ENDOCRINOL-COP, V105, P324; BURMAN P, 1986, J CLIN ENDOCR METAB, V63, P1086, DOI 10.1210/jcem-63-5-1086; BURMAN P, 1985, LANCET, V2, P100; CANTELL K, 1978, J GEN VIROL, V39, P541, DOI 10.1099/0022-1317-39-3-541; CIAMPOLILLO A, 1989, LANCET, V1, P1096; CONLON KC, 1990, CANCER, V65, P2237, DOI 10.1002/1097-0142(19900515)65:10<2237::AID-CNCR2820651013>3.0.CO;2-5; DEVRIES RRP, 1985, PROG ALLERGY, V36, P1; DONIACH D, 1982, CLIN ASPECTS IMMUNOL, V2, P903; FAIRLEY GH, 1972, BR J HAEMATOL S, V23, P231; FENTIMAN IS, 1988, EUR J CANCER CLIN ON, V24, P1299, DOI 10.1016/0277-5379(88)90219-2; FESSEL WJ, 1974, ARCH INTERN MED, V134, P1027, DOI 10.1001/archinte.134.6.1027; GIDLUND M, 1978, NATURE, V273, P759, DOI 10.1038/273759a0; GRANDER D, 1990, LANCET, V336, P337, DOI 10.1016/0140-6736(90)91879-F; HARFAST B, 1981, J IMMUNOL, V127, P2146; HAWKINS BR, 1979, J CLIN LAB IMMUNOL, V2, P217; HAWKINS BR, 1980, LANCET, V2, P1057; HOOKS JJ, 1979, NEW ENGL J MED, V301, P5, DOI 10.1056/NEJM197907053010102; HOOKS JJ, 1982, ARTHRITIS RHEUM, V25, P396, DOI 10.1002/art.1780250406; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; KARLSSONPARRA A, 1990, CLIN EXP IMMUNOL, V81, P72; KIM T, 1987, CLIN EXP IMMUNOL, V70, P562; LAZARUS JH, 1984, ACTA ENDOCRINOL-COP, V106, P199, DOI 10.1530/acta.0.1060199; LINDAHL P, 1972, P NATL ACAD SCI USA, V69, P721, DOI 10.1073/pnas.69.3.721; NELSON DS, 1977, PATHOLOGY, V9, P155, DOI 10.3109/00313027709085253; OBERG K, 1987, ACTA ONCOL, V26, P429; OBERG K, 1983, NEW ENGL J MED, V309, P129, DOI 10.1056/NEJM198307213090301; OBERG K, 1986, CANCER TREAT REP, V70, P1297; OBERG K, 1989, J NATL CANCER I, V81, P531, DOI 10.1093/jnci/81.7.531; PAK CY, 1988, LANCET, V2, P1; PANGALIS GA, 1988, CANCER, V61, P869, DOI 10.1002/1097-0142(19880301)61:5<869::AID-CNCR2820610503>3.0.CO;2-I; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; RONNBLOM LE, 1990, J INTERN MED, V227, P207; SCHATTNER A, 1986, CLIN IMMUNOL IMMUNOP, V38, P327, DOI 10.1016/0090-1229(86)90242-4; SCHULTZ RM, 1977, SCIENCE, V197, P674, DOI 10.1126/science.877584; STRANDER H, 1986, ADV CANCER RES, V46; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TUNBRIDGE WMG, 1981, BRIT MED J, V282, P258, DOI 10.1136/bmj.282.6260.258; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; VENTO S, 1987, CLIN EXP IMMUNOL, V68, P225	41	419	423	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1991	115	3					178	183		10.7326/0003-4819-115-3-178	http://dx.doi.org/10.7326/0003-4819-115-3-178			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY152	2058872				2022-12-01	WOS:A1991FY15200003
J	SANDLER, DP; BURR, FR; WEINBERG, CR				SANDLER, DP; BURR, FR; WEINBERG, CR			NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND THE RISK FOR CHRONIC RENAL-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article							PLASMA-RENIN ACTIVITY; PROSTAGLANDIN SYNTHESIS; ANTIINFLAMMATORY DRUGS; ANALGESIC NEPHROPATHY; FAILURE; INDOMETHACIN; IBUPROFEN; ASPIRIN; INFORMATION; MECHANISM	Objective: To evaluate the risk for chronic renal disease associated with regular use of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs). Design: Multicenter case-control study. Patients: Patients were 554 North Carolina residents (age range, 30 to 79 years) hospitalized between 1980 and 1982 with a discharge diagnosis indicating newly diagnosed chronic renal dysfunction and a serum creatinine level consistently at or above 130-mu-mol/L (1.5 mg/dL). Controls were 516 persons chosen randomly by telephone screening (if younger than 65 years of age) and from listings of Medicare recipients (if 65 years of age or older), frequency-matched to patients by age, race, sex, and proximity to study hospitals. Measurements: Data on use of prescription NSAIDs and other analgesics before 1980, other risk factors, and potential confounders were obtained by telephone interviews. Patients were classified by frequency and duration of use; daily users were those who took an NSAID for at least 360 consecutive days. Main Results: A twofold risk for chronic renal disease was associated with previous daily use of NSAIDs (adjusted odds ratio, 2.1; 95% Cl, 1.1 to 4.1). Increased risk was predominantly limited to men older than 65 years, for whom the odds ratio for daily use was 10.0 (Cl, 1.2 to 82.7) after adjusting for use of other analgesics. In other age-sex groups, the risk associated with NSAID use tended to be increased among those with heart disease or other factors that might indicate compromised renal circulation. These findings did not result from confounding by known renal disease risk factors and were not readily explained by potential biases. Conclusions: Regular use of NSAIDs may increase the risk for chronic kidney disease in some high-risk groups. With the recent over-the-counter availability and increasing popularity of NSAIDs, the possibility of an increased risk for chronic renal disease associated with their use may warrant further scrutiny.			SANDLER, DP (corresponding author), NIEHS, EPIDEMIOL BRANCH, MD A305, POB 12233, RES TRIANGLE PK, NC 27709 USA.			Sandler, Dale/0000-0002-6776-0018; Weinberg, Clarice/0000-0002-7713-8556				ADAMS DH, 1986, LANCET, V1, P57; BADR KF, 1988, NEW ENGL J MED, V319, P623; BENDER WL, 1984, AM J MED, V76, P1006, DOI 10.1016/0002-9343(84)90849-0; BLACKSHEAR JL, 1983, ARCH INTERN MED, V143, P1130, DOI 10.1001/archinte.143.6.1130; BOKELMAN DL, 1971, TOXICOL APPL PHARM, V19, P111, DOI 10.1016/0041-008X(71)90195-5; BOYER TD, 1979, GASTROENTEROLOGY, V77, P215; BRANDSTETTER RD, 1978, BRIT MED J, V2, P1194, DOI 10.1136/bmj.2.6146.1194-a; CIABATTONI G, 1984, NEW ENGL J MED, V310, P279, DOI 10.1056/NEJM198402023100502; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; DECRESPIGNY PJC, 1988, KIDNEY INT, V33, P135; DONKER AJM, 1976, NEPHRON, V17, P288, DOI 10.1159/000180733; DUNN MJ, 1980, KIDNEY INT, V18, P609, DOI 10.1038/ki.1980.179; FERREIRA SH, 1971, NATURE-NEW BIOL, V231, P237, DOI 10.1038/newbio231237a0; FINDLING JW, 1980, JAMA-J AM MED ASSOC, V244, P1127, DOI 10.1001/jama.244.10.1127; FOX DA, 1984, JAMA-J AM MED ASSOC, V251, P1299, DOI 10.1001/jama.251.10.1299; GARELLA S, 1984, MEDICINE, V63, P165, DOI 10.1097/00005792-198405000-00003; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; HENRICH WL, 1983, AM J KIDNEY DIS, V2, P478, DOI 10.1016/S0272-6386(83)80083-3; HERRMANN N, 1985, AM J EPIDEMIOL, V121, P937, DOI 10.1093/oxfordjournals.aje.a114064; KIMBERLY RP, 1978, AM J MED, V64, P804, DOI 10.1016/0002-9343(78)90520-X; KIMBERLY RP, 1979, ARTHRITIS RHEUM, V22, P281, DOI 10.1002/art.1780220311; Kincaid-Smith P, 1986, Med Toxicol, V1 Suppl 1, P14; KLEINKNECHT D, 1986, CLIN NEPHROL, V25, P275; MORLANS M, 1990, BRIT J CLIN PHARMACO, V30, P717, DOI 10.1111/j.1365-2125.1990.tb03841.x; MURRAY MD, 1990, ANN INTERN MED, V112, P559, DOI 10.7326/0003-4819-112-8-559; NANRA RS, 1978, KIDNEY INT, V13, P79, DOI 10.1038/ki.1978.11; NANRA RS, 1973, PROBLEMS PHENACETIN, P67; ORME MLE, 1986, BRIT MED J, V292, P1621, DOI 10.1136/bmj.292.6536.1621; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; ROBERTSON CE, 1980, LANCET, V2, P232; ROTH SH, 1988, ANN INTERN MED, V109, P353, DOI 10.7326/0003-4819-109-5-353; SANDLER DP, 1989, NEW ENGL J MED, V320, P1238, DOI 10.1056/NEJM198905113201903; SCHNEIDER PD, 1986, ANN INTERN MED, V105, P303, DOI 10.7326/0003-4819-105-2-303_3; SEDOR JR, 1986, AM J MED, V81, P58, DOI 10.1016/0002-9343(86)90908-3; SHELLEY JH, 1978, KIDNEY INT, V13, P15, DOI 10.1038/ki.1978.3; SIMON LS, 1980, NEW ENGL J MED, V302, P1179; SIMON LS, 1980, NEW ENGL J MED, V302, P1237; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WALSHE JJ, 1979, ANN INTERN MED, V91, P47, DOI 10.7326/0003-4819-91-1-47; WHELTON A, 1990, ANN INTERN MED, V112, P568, DOI 10.7326/0003-4819-112-8-568; WISEMAN EH, 1975, AGENTS ACTIONS, V5, P322, DOI 10.1007/BF02205239; 1984, JAMA-J AM MED ASSOC, V251, P3123	43	162	167	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1991	115	3					165	172		10.7326/0003-4819-115-3-165	http://dx.doi.org/10.7326/0003-4819-115-3-165			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY152	2058870				2022-12-01	WOS:A1991FY15200001
J	SCHAFER, DA; GELLES, J; SHEETZ, MP; LANDICK, R				SCHAFER, DA; GELLES, J; SHEETZ, MP; LANDICK, R			TRANSCRIPTION BY SINGLE MOLECULES OF RNA-POLYMERASE OBSERVED BY LIGHT-MICROSCOPY	NATURE			English	Article							TERNARY COMPLEXES; MOVEMENTS; TRACKING	THE kinetics of transcription by Escherichia coli RNA polymerase relate directly to the regulation of transcription and to the properties of processive enzymes in general 1, but analysis of RNA polymerase movement along the DNA template has so far been limited to the study of populations of enzyme molecules. The ability to view nanometre-sized particles with the light microscope 2,3 suggested a method of monitoring transcription by individual RNA polymerase molecules. We describe here the behaviour of 40-nm-diameter particles of colloidal gold attached to the ends of DNA molecules being transcribed by RNA polymerase immobilized on a glass surface. The tethered gold particles are released from the surface at times after addition of nucleoside triphosphates that are consistent with the kinetics of transcription by RNA polymerase in solution. Analysis of the brownian motion of the gold particles enabled us to measure the movement along the template DNA of individual polymerase molecules.	WASHINGTON UNIV,DEPT CELL BIOL,ST LOUIS,MO 63130; WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254; BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254	Washington University (WUSTL); Washington University (WUSTL); Duke University; Brandeis University; Brandeis University				Gelles, Jeff/0000-0001-7910-3421				ALLEN RD, 1983, J MICROSC-OXFORD, V129, P3, DOI 10.1111/j.1365-2818.1983.tb04157.x; GEERTS H, 1987, BIOPHYS J, V52, P775, DOI 10.1016/S0006-3495(87)83271-X; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LANDICK R, 1987, J MOL BIOL, V196, P363, DOI 10.1016/0022-2836(87)90697-8; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; Press WH., 1988, NUMERICAL RECIPES C; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; YAGER TD, 1989, CELLULAR MOL BIOL, P1241	13	238	245	0	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					444	448		10.1038/352444a0	http://dx.doi.org/10.1038/352444a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861724				2022-12-01	WOS:A1991FZ34600070
J	WARD, RHR; CAPON, DJ; JETT, CM; MURTHY, KK; MORDENTI, J; LUCAS, C; FRIE, SW; PRINCE, AM; GREEN, JD; EICHBERG, JW				WARD, RHR; CAPON, DJ; JETT, CM; MURTHY, KK; MORDENTI, J; LUCAS, C; FRIE, SW; PRINCE, AM; GREEN, JD; EICHBERG, JW			PREVENTION OF HIV-1 IIIB INFECTION IN CHIMPANZEES BY CD4 IMMUNOADHESIN	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RECOMBINANT SOLUBLE CD4; TYPE-1; IMMUNIZATION	THE first step in infection by the human immunodeficiency virus (HIV) is the specific binding of gp120, the envelope glycoprotein of HIV, to its cellular receptor, CD4 (see ref. 1 for review). To inhibit this interaction, soluble CD4 analogues that compete for gp120 binding and block HIV infection in vitro have been developed 2-8. To determine whether these analogues can protect an uninfected individual from challenge with HIV, we used the chimpanzee model system of cell-free HIV infection. Chimpanzees are readily infected with the IIIB strain of HIV-1, becoming viraemic within about 4-6 weeks of challenge, although they do not develop the profound CD4+ T-cell depletion and immunodeficiency characteristic of HIV infection in humans 9. CD4 immunoadhesin (CD4-IgG), a chimaeric molecule consisting of the N-terminal two immunoglobulin-like regions of CD4 joined to the Fc region of human IgG1 (refs 8, 10), was selected as the CD4 analogue for testing because it has a longer half-life than CD4, contributed by the IgG Fc portion of the molecule. In humans, this difference results in a 25-fold increased concentration of CD4-IgG in the blood compared with recombinant CD4 (ref. 11). Here we report that pretreatment with CD4-IgG can prevent the infection of chimpanzees with HIV-1. The need for a preventative agent is particularly acute in perinatal HIV transmission. As recombinant CD4-IgG, like the parent IgG molecule, efficiently crosses the primate placenta 10, it may be possible to set up an immune state in a fetus before HIV transfer occurs, thus preventing infection.	CELL GENESYS INC,FOSTER CITY,CA 94404; SW FDN BIOMED RES,SAN ANTONIO,TX 78284; NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,NEW YORK,NY 10021	Cell Genesys Inc; Texas Biomedical Research Institute; New York Blood Center	WARD, RHR (corresponding author), GENENTECH INC,460 PT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							ANDERSON KP, 1989, J INFECT DIS, V160, P960, DOI 10.1093/infdis/160.6.960; BERGER EA, 1988, P NATL ACAD SCI USA, V85, P2357, DOI 10.1073/pnas.85.7.2357; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BERNARD N, 1990, NEW ENGL J MED, V323, P916; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0; CAPON D, 1991, REV IMMUNOL, V9, P649; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; EICHBERG JW, 1990, ANIMAL MODELS AIDS, P47; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; HU SL, 1987, NATURE, V328, P721, DOI 10.1038/328721a0; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; LANGE JMA, 1990, NEW ENGL J MED, V322, P1375, DOI 10.1056/NEJM199005103221907; MARRIN LN, 1990, 8TH A S NONH PRIM MO; MCCUNE JM, 1990, SCIENCE, V247, P564, DOI 10.1126/science.2300816; MORDENTI J, IN PRESS PHARM RES; SAIKI RK, 1985, SCIENCE, V230, P487; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; THOMAS RM, 1989, B LOND MATH SOC, V21, P463, DOI 10.1112/blms/21.5.463; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0	23	59	68	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					434	436		10.1038/352434a0	http://dx.doi.org/10.1038/352434a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1907354	Bronze			2022-12-01	WOS:A1991FZ34600066
J	WILLIAMS, DA; RIOS, M; STEPHENS, C; PATEL, VP				WILLIAMS, DA; RIOS, M; STEPHENS, C; PATEL, VP			FIBRONECTIN AND VLA-4 IN HEMATOPOIETIC STEM-CELL MICROENVIRONMENT INTERACTIONS	NATURE			English	Article							HUMAN-PLASMA FIBRONECTIN; BONE-MARROW; GROWTH-FACTOR; PRECURSOR CELLS; ADHERENT CELLS; ADHESION; PROLIFERATION; IDENTIFICATION; HEMATOPOIESIS; RECEPTOR	THE self-renewal and differentiation of haematopoietic stem cells occurs in vivo and in vitro in direct contact with cells making up the haematopoietic microenvironment 1-4. In this study we used adhesive ligands and blocking antibodies to identify stromal cell-derived extracellular matrix proteins involved in promoting attachment of murine haematopoietic stem cells. Here we report that day-12 colony-forming-unit spleen (CFU-S12) 5 cells and reconstituting haematopoietic stem cells attach to the C-terminal, heparin-binding fragment of fibronectin by recognizing the CS-1 peptide of the alternatively spliced non-type III connecting segment (IIICS) of human plasma fibronectin. Furthermore, CFU-S12 stem cells express the alpha-4 subunit of the VLA-4 integrin receptor, which is known to be a receptor for the CS-1 sequence, and monoclonal antibodies against the integrin alpha-4 subunit of VLA-4 block adhesion of CFU-S12 stem cells to plates coated with the C-terminal fibronectin fragment. Finally, polyclonal antibodies against the integrin beta-1 subunit of VLA-4 inhibit the formation of CFU-S12-derived spleen colonies and medullary haematopoiesis in vivo following intravenous infusion of antibody-treated bone marrow cells.	HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School								AIZAWA S, 1988, P NATL ACAD SCI USA, V85, P3180, DOI 10.1073/pnas.85.9.3180; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BERNARDI P, 1987, J CELL BIOL, V105, P489, DOI 10.1083/jcb.105.1.489; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; EAVES AC, 1986, P NATL ACAD SCI USA, V83, P5306, DOI 10.1073/pnas.83.14.5306; GORDON MY, 1989, BONE MARROW TRANSPL, V4, P335; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HO MK, 1982, J IMMUNOL, V128, P2281; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; KENNETT RH, 1980, MONOCLONAL ANTIBODIE; LAMAR EE, 1984, CELL, V37, P171, DOI 10.1016/0092-8674(84)90312-X; LAMBERTSEN RH, 1984, BLOOD, V63, P287; LORD BI, 1975, BLOOD, V46, P65; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; MCCARTHY JB, 1986, J CELL BIOL, V102, P179, DOI 10.1083/jcb.102.1.179; PATEL VP, 1986, J CELL BIOL, V102, P449, DOI 10.1083/jcb.102.2.449; RIOS M, 1990, J CELL PHYSIOL, V145, P434, DOI 10.1002/jcp.1041450307; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TRENTIN JJ, 1967, PROLIFERATION SPREAD, V713; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WILLIAMS DA, 1988, MOL CELL BIOL, V8, P3864, DOI 10.1128/MCB.8.9.3864; ZIPORI D, 1988, HEMATOPOIESIS LONG T, P27; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U; ZUCKERMAN KS, 1983, BLOOD, V61, P540	34	451	471	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 1	1991	352	6334					438	441		10.1038/352438a0	http://dx.doi.org/10.1038/352438a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861722				2022-12-01	WOS:A1991FZ34600068
J	BOROK, Z; BUHL, R; GRIMES, GJ; BOKSER, AD; HUBBARD, RC; HOLROYD, KJ; ROUM, JH; CZERSKI, DB; CANTIN, AM; CRYSTAL, RG				BOROK, Z; BUHL, R; GRIMES, GJ; BOKSER, AD; HUBBARD, RC; HOLROYD, KJ; ROUM, JH; CZERSKI, DB; CANTIN, AM; CRYSTAL, RG			EFFECT OF GLUTATHIONE AEROSOL ON OXIDANT-ANTIOXIDANT IMBALANCE IN IDIOPATHIC PULMONARY FIBROSIS	LANCET			English	Note							LOWER RESPIRATORY-TRACT; INTERSTITIAL LUNG-DISEASES; CHRONIC INFLAMMATION; UNKNOWN CAUSE; DEFICIENCY; FLUID	Idiopathic pulmonary fibrosis (IPF) is characterised by alveolar inflammation, exaggerated release of oxidants, and subnormal concentrations of the antioxidant glutathione in respiratory epithelial lining fluid (ELF). Glutathione (600 mg twice daily for 3 days) was given by aerosol to 10 patients with IPF. Total ELF glutathione rose transiently, ELF oxidised glutathione concentrations increased, and there was a decrease in spontaneous superoxide anion release by alveolar macrophages. Thus, glutathione by aerosol could be a means of reversing the oxidant-antioxidant imbalance in IPF.	NHLBI,PULM BRANCH,BLDG 10 ROOM 6D03,BETHESDA,MD 20892; NIH,CTR CLIN,DEPT PHARM,BETHESDA,MD 20892; CHU SHERBROOKE,SERV PNEUMOL,SHERBROOKE J1H 5N4,QUEBEC,CANADA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); University of Sherbrooke				Holroyd, Kenneth/0000-0001-6050-3935; Borok, Zea/0000-0001-8673-8177				BUHL R, 1990, P NATL ACAD SCI USA, V87, P4063, DOI 10.1073/pnas.87.11.4063; BUHL R, 1989, LANCET, V2, P1294; CANTIN AM, 1989, AM REV RESPIR DIS, V139, P370, DOI 10.1164/ajrccm/139.2.370; CANTIN AM, 1987, J CLIN INVEST, V79, P1665, DOI 10.1172/JCI113005; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P235, DOI 10.1056/NEJM198401263100406; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P154, DOI 10.1056/NEJM198401193100304; FORMAN HJ, 1990, AM J PHYSIOL, V259, pL102, DOI 10.1152/ajplung.1990.259.2.L102; MEISTER A, 1988, J BIOL CHEM, V263, P17205; SIES H, 1984, METHOD ENZYMOL, V105, P445; TURNERWARWICK M, 1980, THORAX, V35, P171, DOI 10.1136/thx.35.3.171	10	169	176	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					215	216		10.1016/0140-6736(91)90350-X	http://dx.doi.org/10.1016/0140-6736(91)90350-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676780				2022-12-01	WOS:A1991FY50400005
J	DALE, C; GALLUS, A; WYCHERLEY, A; LANGLOIS, S; HOWIE, D				DALE, C; GALLUS, A; WYCHERLEY, A; LANGLOIS, S; HOWIE, D			PREVENTION OF VENOUS THROMBOSIS WITH MINIDOSE WARFARIN AFTER JOINT REPLACEMENT	BRITISH MEDICAL JOURNAL			English	Article							INTERMITTENT CALF; COMPRESSION		FLINDERS UNIV,MED CTR,DEPT HAEMATOL,HAEMOSTASIS & THROMBOSIS LAB,BEDFORD PK,SA 5042,AUSTRALIA; UNIV ADELAIDE,ADELAIDE,SA 5001,AUSTRALIA; ROYAL ADELAIDE HOSP,RADIOL,ADELAIDE,SA 5000,AUSTRALIA; ROYAL ADELAIDE HOSP,ORTHOPAEDIC SURG & TRAUMA,ADELAIDE,SA 5000,AUSTRALIA; FLINDERS UNIV,MED CTR,NUCL MED,BEDFORD PK,SA 5042,AUSTRALIA	Flinders University South Australia; University of Adelaide; Royal Adelaide Hospital; Royal Adelaide Hospital; Flinders University South Australia				Gallus, Alexander/0000-0001-7347-9989; Howie, Donald/0000-0003-1702-3279				BERN MM, 1990, ANN INTERN MED, V112, P423, DOI 10.7326/0003-4819-76-3-112-6-423; GALLUS A, 1983, BRIT J SURG, V70, P17, DOI 10.1002/bjs.1800700106; Gallus A S, 1990, Baillieres Clin Haematol, V3, P651, DOI 10.1016/S0950-3536(05)80023-X; MCKENNA R, 1980, BRIT MED J, V280, P514, DOI 10.1136/bmj.280.6213.514; POLLER L, 1987, BRIT MED J, V295, P1309, DOI 10.1136/bmj.295.6609.1309	5	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					224	224		10.1136/bmj.303.6796.224	http://dx.doi.org/10.1136/bmj.303.6796.224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ563	1884060	Bronze, Green Published			2022-12-01	WOS:A1991FZ56300024
J	EHRNST, A; LINDGREN, S; DICTOR, M; JOHANSSON, B; SONNERBORG, A; CZAJKOWSKI, J; SUNDIN, G; BOHLIN, AB				EHRNST, A; LINDGREN, S; DICTOR, M; JOHANSSON, B; SONNERBORG, A; CZAJKOWSKI, J; SUNDIN, G; BOHLIN, AB			HIV IN PREGNANT-WOMEN AND THEIR OFFSPRING - EVIDENCE FOR LATE TRANSMISSION	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VERTICAL TRANSMISSION; MATERNAL ANTIBODIES; CHILDREN BORN; INFECTION; TYPE-1; BLOOD; PLACENTA; INFANTS; MOTHERS	To assess the role of maternal viraemia in vertical transmission of HIV and the extent to which viraemia occurs during the various stages of pregnancy, we have attempted to detect human immunodeficiency virus (HIV) in 44 pregnant HIV-1 infected women during 47 pregnancies (30 continued, 17 aborted) and in 30 children and 12 fetuses. Infectious HIV was detected at some time during pregnancy in 59% of women from plasma and in 83% from either peripheral blood mononuclear cells or plasma. HIV was not isolated from any of the newborn babies (0/27) at birth. The mothers had a significantly higher frequency of viraemia during pregnancy than their children had by 6 months of age (p = 0.002); by this time HIV was recovered from 5 (26%) of 19 infants. HIV was not detected by virus isolation, in-situ hybridisation, or polymerase chain reaction (PCR) in 10 fetuses; the other 2 fetuses were positive either by in-situ hybridisation or by PCR but neither result could be confirmed in a second organ or by the other methods of detection. The findings show that there is no consistent spread of HIV across the placenta during maternal viraemia, and indicate that in most cases transmission occurs close to or at delivery.	HUDDINGE UNIV HOSP,DEPT OBSTET & GYNAECOL,S-14186 HUDDINGE,SWEDEN; HUDDINGE UNIV HOSP,DEPT PEDIAT,S-14186 HUDDINGE,SWEDEN; UNIV LUND HOSP,DEPT PATHOL,S-22185 LUND,SWEDEN	Karolinska Institutet; Karolinska Institutet; Lund University; Skane University Hospital	EHRNST, A (corresponding author), STOCKHOLM CTY COUNCIL,CENT MICROBIOL LAB,DEPT VIROL,BOX 70470,S-10726 STOCKHOLM,SWEDEN.		Sönnerborg, Anders/W-2011-2019	Sönnerborg, Anders/0000-0001-8928-3374				BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BROLIDEN PA, 1989, AIDS, V3, P577, DOI 10.1097/00002030-198909000-00004; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; EHRNST A, 1988, J MED VIROL, V26, P23, DOI 10.1002/jmv.1890260105; GENDELMAN HE, 1986, IN SITU HYBRIDIZATIO, P203; GOEDERT JJ, 1989, LANCET, V2, P1351; GREENSPOON JS, 1989, AM J OBSTET GYNECOL, V161, P501, DOI 10.1016/0002-9378(89)90556-5; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOUSSET C, 1990, HUM PATHOL, V21, P404, DOI 10.1016/0046-8177(90)90202-G; JOVAISAS E, 1985, LANCET, V2, P1129; LYNMAN WD, 1990, AIDS, V4, P917; MARION RW, 1987, AM J DIS CHILD, V141, P429, DOI 10.1001/archpedi.1987.04460040087022; MARION RW, 1986, AM J DIS CHILD, V140, P429; MYERS G, 1990, HUMAN RETROVIRUSES A; PEUCHMAUR M, 1989, AM J OBSTET GYNECOL, V160, P765, DOI 10.1016/S0002-9378(89)80083-3; PIZZO PA, 1990, J INFECT DIS, V161, P316, DOI 10.1093/infdis/161.2.316; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; RUBINSTEIN A, 1986, CLIN IMMUNOL IMMUNOP, V40, P115, DOI 10.1016/0090-1229(86)90074-7; Rubinstein A, 1986, Curr Probl Pediatr, V16, P361; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; Siegel S., 2009, NONPARAMETRIC STAT B, V2nd; SONNERBORG A, IN PRESS AIDS RES HU; SONNERBORG A, IN PRESS IMMUNOL INF; SPRECHER S, 1986, LANCET, V2, P288; 1991, LANCET, P253; [No title captured]	29	192	193	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					203	207		10.1016/0140-6736(91)90347-R	http://dx.doi.org/10.1016/0140-6736(91)90347-R			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676777				2022-12-01	WOS:A1991FY50400002
J	JACKSON, R; SCRAGG, R; BEAGLEHOLE, R				JACKSON, R; SCRAGG, R; BEAGLEHOLE, R			ALCOHOL-CONSUMPTION AND RISK OF CORONARY HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							U-SHAPED CURVE; MORTALITY; MEN	Objective - To investigate the hypothesis that the apparent protective effect of habitual alcohol consumption on coronary heart disease is due to drinkers at high risk of coronary heart disease becoming non-drinkers. Design - Case-control population based study. Data were obtained from interviews with patients with non-fatal myocardial infarction and their controls and with the next of kin of those who had died of coronary heart disease and their controls. Setting - Auckland, New Zealand. Subjects - Two groups of cases were studied. The first comprised 227 men and 72 women with non-fatal myocardial infarction identified from a population based surveillance programme for coronary heart disease; controls were 525 men and 341 women randomly selected from the same population group and matched for age and sex. The second group comprised 128 men and 30 women who had died of coronary heart disease and had been identified from the surveillance programme; controls were a sample of the previous control group and comprised 330 men and 214 women matched for age and sex. All participants were aged 25-64 years and without diagnosed coronary heart disease. Main outcome measures - Regular alcohol consumption; high density lipoprotein cholesterol and low density lipoprotein concentrations. Results - Men with myocardial infarction and men who had died of coronary heart disease were more likely to have been never drinkers (had never drunk more than once a month) than controls (18% v 12% and 23% v 13% respectively). After possible confounding factors had been controlled for, people in all categories of drinking (up to more than 56 drinks per week) had at least a 40% reduction in risk of fatal and non-fatal coronary heart disease compared with never drinkers. Former drinkers also had a lower risk of non-fatal myocardial infarction than never drinkers (relative risks 0.41 and 0.10 in men and women respectively) but a similar risk of death from coronary heart disease. The reduction in risk was consistently greater in women than in men in all drinking categories but there was no clear dose-response effect in either sex. Conclusions - The results support the hypothesis that light and moderate alcohol consumption reduces the risk of coronary heart disease. This protective effect in this population was not due to the misclassification of former drinkers with a high risk of coronary heart disease as non-drinkers.			JACKSON, R (corresponding author), UNIV AUCKLAND,SCH MED,DEPT COMMUNITY HLTH,AUCKLAND 1,NEW ZEALAND.			Jackson, Rod/0000-0001-5914-6934; Scragg, Robert/0000-0003-0013-2620				ALANKO T, 1984, RES ADV ALCOHOL DRUG, V8, P299; BONITA R, 1983, COMMUNITY HEALTH ST, V7, P111; CRIQUI MH, 1990, BRIT J ADDICT, V85, P854; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; FRASER G, 1986, PREVENTIVE CARDIOLOG; HARREL F, 1983, LOGIST PROCEDURE; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; JACKSON R, 1988, NEW ZEAL MED J, V101, P658; JACKSON R, 1987, BRIT MED J, V294, P1588, DOI 10.1136/bmj.294.6587.1588; KITTNER SJ, 1983, AM J EPIDEMIOL, V117, P538, DOI 10.1093/oxfordjournals.aje.a113576; KLATSKY AL, 1986, AM J CARDIOL, V58, P710, DOI 10.1016/0002-9149(86)90342-5; KOZAREVIC DJ, 1981, LANCET, V1, P613; MACLURE M, 1987, AM J EPIDEMIOL, V126, P161, DOI 10.1093/aje/126.2.161; MACMAHON S, 1987, HYPERTENSION, V9, P111, DOI 10.1161/01.HYP.9.2.111; MARMOT MG, 1984, INT J EPIDEMIOL, V13, P160, DOI 10.1093/ije/13.2.160; MARMOT MG, 1981, LANCET, V1, P580; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MIKHAILIDIS DP, 1983, BRIT MED J, V287, P1495, DOI 10.1136/bmj.287.6404.1495; PEARCE NE, 1983, NEW ZEAL MED J, V96, P281; Rose G.A., 1982, CARDIOVASCULAR SURVE; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, LANCET, V2, P1267; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; 1988, J CLIN EPIDEMIOL, V41, P105	25	202	203	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					211	216		10.1136/bmj.303.6796.211	http://dx.doi.org/10.1136/bmj.303.6796.211			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ563	1884056	Green Published, Bronze			2022-12-01	WOS:A1991FZ56300019
J	LALLOZ, MRA; MCVEY, JH; PATTINSON, JK; TUDDENHAM, EGD				LALLOZ, MRA; MCVEY, JH; PATTINSON, JK; TUDDENHAM, EGD			HEMOPHILIA-A DIAGNOSIS BY ANALYSIS OF A HYPERVARIABLE DINUCLEOTIDE REPEAT WITHIN THE FACTOR-VIII GENE	LANCET			English	Article							HEMOPHILIA-A; INVITRO AMPLIFICATION; PRENATAL-DIAGNOSIS; DNA ANALYSIS; POLYMORPHISM; MICROSATELLITE; POLYMERASE; SEQUENCES; PROBE	The diagnosis of haemophilia A and the identification of carriers has greatly improved with knowledge of the structure of the gene for factor VIII. This has permitted the defect to be tracked in families by the study of restriction fragment length polymorphisms (RFLPs), irrespective of the nature of the molecular defect. However, this approach is time-consuming and the information yielded falls away as more polymorphisms are added. Within the factor VIII gene lies another source of polymorphism, a dinucleotide repeat sequence of varying length known as (CA)n. Conventional mapping localised this (CA)n repeat to intron 13. The polymerase chain reaction, used to examine (CA)n variability in genomic DNA from 25 males and 67 females, revealed eight allelic bands between n = 16 and n = 24. 91% of females were heterozygous for this repeat, and family studies showed X-linked mendelian inheritance with allelic frequencies ranging from 1% to 45%. The intron 13 (CA)n repeat is tightly linked with established RFLPs and tracks with haemophilia A in family studies. The analysis requires DNA from other family members, and relatives of sporadic cases of haemophilia A are only amenable to exclusion. Nonetheless, this intron 13 (CA)n repeat provides the most highly informative marker so far available for factor VIII gene tracking studies in haemophilia A kindreds and a result can be available within a day.			LALLOZ, MRA (corresponding author), CLIN RES CTR,HAEMOSTASIS RES GRP,HARROW HA1 3UJ,MIDDX,ENGLAND.		Tuddenham, Edward/AAS-6196-2020	Tuddenham, Edward/0000-0001-8955-2909; McVey, John/0000-0002-7416-533X				AHRENS P, 1987, HUM GENET, V76, P127, DOI 10.1007/BF00284907; ANTONARAKIS SE, 1985, NEW ENGL J MED, V313, P842, DOI 10.1056/NEJM198510033131402; GITSCHIER J, 1985, NATURE, V314, P738, DOI 10.1038/314738a0; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GRAHAM JB, 1990, BRIT J HAEMATOL, V76, P75, DOI 10.1111/j.1365-2141.1990.tb07839.x; HARPER K, 1984, LANCET, V2, P6; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LITT M, 1989, AM J HUM GENET, V44, P397; Maniatis T., 1982, MOL CLONING; MILLAR DS, 1990, HUM GENET, V86, P219; OBERLE I, 1985, NEW ENGL J MED, V312, P682, DOI 10.1056/NEJM198503143121103; PATTINSON JK, 1990, BLOOD, V76, P2242; ROTBLAT F, 1981, THROMB RES, V21, P931; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SURIN VL, 1990, NUCLEIC ACIDS RES, V18, P3432, DOI 10.1093/nar/18.11.3432; TANTRAVAHI U, 1986, CYTOGENET CELL GENET, V42, P75, DOI 10.1159/000132255; TAYLOR GR, 1989, LANCET, V2, P454; Tuddenham E G, 1989, Baillieres Clin Haematol, V2, P849, DOI 10.1016/S0950-3536(89)80049-6; WEBER JL, 1989, AM J HUM GENET, V44, P388; WION KL, 1986, NUCLEIC ACIDS RES, V14, P4535, DOI 10.1093/nar/14.11.4535; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; YOUSSOUFIAN H, 1987, NUCLEIC ACIDS RES, V15, P6312, DOI 10.1093/nar/15.15.6312	27	145	148	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					207	211		10.1016/0140-6736(91)90348-S	http://dx.doi.org/10.1016/0140-6736(91)90348-S			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676778				2022-12-01	WOS:A1991FY50400003
J	MAKELA, M; HELIOVAARA, M				MAKELA, M; HELIOVAARA, M			PREVALENCE OF PRIMARY FIBROMYALGIA IN THE FINNISH POPULATION	BRITISH MEDICAL JOURNAL			English	Article							FIBROSITIS; PAIN	Objective - To obtain descriptive epidemiological data on fibromyalgia and its components in a representative sample of the Finnish population. Design - Cross sectional study of 8000 Finns aged 30 or more invited for screening and a main examination for musculoskeletal disorders and other major disorders. Setting - A mobile clinic. Population - 7217 subjects who attended the screening phase; 3434 subjects positive on screening who attended the main examination for musculoskeletal disorders. Main outcome measures - Musculoskeletal, mental, and other symptoms detected by interview and questionnaire; results of standardised clinical examination of the musculoskeletal system; operational definition of fibromyalgia; mortality at 10 years. Results - The prevalence of fibromyalgia was low (54 cases; 0.75%) and related to age (peak prevalence at 55-64 years), female sex (twice as prevalent in women), occupation (no cases among 1596 white collar professionals), level of education (strong inverse gradient), and high levels of physical stress at work. No significant associations were found with body mass index, smoking, or mental stress at work. The prevalence of fibromyalgia was sensitive to even minor modifications of the definition. Fibromyalgia was strongly coincident with many other disorders, especially musculoskeletal conditions. Fibromyalgia did not predict mortality. Conclusion - Descriptive epidemiological data offer little support for the concept of fibromyalgia.			MAKELA, M (corresponding author), SOCIAL INSURANCE INST,SOCIAL SECUR RES INST,POB 78,SF-00381 HELSINKI,FINLAND.							AROMAA A, 1989, EXECUTION MINIFINL 1; CAMPBELL SM, 1983, ARTHRITIS RHEUM, V26, P817, DOI 10.1002/art.1780260701; CATHEY MA, 1986, AM J MED, V81, P78, DOI 10.1016/0002-9343(86)90882-X; COX DR, 1972, J R STAT SOC B, V34, P187; FORSLIND K, 1990, BRIT J RHEUMATOL, V29, P368; Goldberg DP, 1972, MAUDSLEY MONOGR, V21; GOLDENBERG DL, 1988, SEMIN ARTHRITIS RHEU, V18, P111, DOI 10.1016/0049-0172(88)90003-0; Haberman S. J., 1978, ANAL QUALITATIVE DAT, V1; HAWLEY DJ, 1988, J RHEUMATOL, V15, P1551; Kish L, 1965, SURVEY SAMPLING; MOLDOFSKY H, 1990, ADV PAIN RES THERAPY, V17; TAKALA J, 1979, ACTA PSYCHIAT SCAND, V59, P294, DOI 10.1111/j.1600-0447.1979.tb06968.x; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; YUNUS M, 1981, SEMIN ARTHRITIS RHEU, V11, P151, DOI 10.1016/0049-0172(81)90096-2; YUNUS MB, 1989, CLIN EXP RHEUMATOL, V7, P63	15	138	145	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					216	219		10.1136/bmj.303.6796.216	http://dx.doi.org/10.1136/bmj.303.6796.216			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ563	1884057	Green Published, Bronze			2022-12-01	WOS:A1991FZ56300020
J	OGRADY, JG; WENDON, J; TAN, KC; POTTER, D; COTTAM, S; COHEN, AT; GIMSON, AES; WILLIAMS, R				OGRADY, JG; WENDON, J; TAN, KC; POTTER, D; COTTAM, S; COHEN, AT; GIMSON, AES; WILLIAMS, R			LIVER-TRANSPLANTATION AFTER PARACETAMOL OVERDOSE	BRITISH MEDICAL JOURNAL			English	Article							FULMINANT HEPATIC-FAILURE	Objective - To evaluate the role of liver transplantation after paracetamol overdose. Design - Prospective study of consecutive candidates for transplantation and performance of transplantation over 18 months. Setting - Liver unit, King's College Hospital, London. Main outcome measures - Fulfilment of indicators of poor prognosis, selection for transplantation, transplantation, survival. Results - 30 of 37 patients considered to have a reasonable prognosis with intensive medical care survived. Of 14 of 29 patients considered to have a very poor prognosis and registered for urgent liver transplantation, six received liver transplants, four of whom survived, while seven died and one survived without a transplant. Three of 15 patients with poor prognostic indicators but not selected for transplantation survived. Conclusion - Liver transplantation will have a definite but limited role in the management of fulminant hepatic failure induced by paracetamol.	UNIV LONDON KINGS COLL HOSP,SCH MED & DENT,INST LIVER STUDIES,DENMARK HILL,LONDON SE5 8RX,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London				opoku, anita/0000-0001-7243-8157				BISMUTH H, 1989, TRANSPLANT REV, V3, P47; BREMS JJ, 1987, AM J SURG, V154, P137; EMOND JC, 1989, GASTROENTEROLOGY, V96, P1583, DOI 10.1016/0016-5085(89)90530-1; HARRISON PM, 1990, LANCET, V335, P1572, DOI 10.1016/0140-6736(90)91388-Q; HARRISON PM, 1990, BMJ-BRIT MED J, V301, P964, DOI 10.1136/bmj.301.6758.964; IWATSUKI S, 1989, TRANSPLANT P, V21, P2431; OGRADY JG, 1989, BAILLIERE CLIN GASTR, V3, P75, DOI 10.1016/0950-3528(89)90047-X; OGRADY JG, 1988, Q J MED, V69, P817; OGRADY JG, 1988, GASTROENTEROLOGY, V94, P1186, DOI 10.1016/0016-5085(88)90011-X; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; SCHAFER DF, 1989, SEMIN LIVER DIS, V9, P189, DOI 10.1055/s-2008-1040512; VICKERS C, 1988, J HEPATOL, V7, P143, DOI 10.1016/S0168-8278(88)80475-6; 1987, LANCET, V2, P1248	13	75	76	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					221	223		10.1136/bmj.303.6796.221	http://dx.doi.org/10.1136/bmj.303.6796.221			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ563	1884059	Green Published, Bronze			2022-12-01	WOS:A1991FZ56300023
J	ROSENSTOCK, L; KEIFER, M; DANIELL, WE; MCCONNELL, R; CLAYPOOLE, K				ROSENSTOCK, L; KEIFER, M; DANIELL, WE; MCCONNELL, R; CLAYPOOLE, K			CHRONIC CENTRAL-NERVOUS-SYSTEM EFFECTS OF ACUTE ORGANOPHOSPHATE PESTICIDE INTOXICATION	LANCET			English	Article							HEALTH	Acute organophosphate pesticide poisonings cause substantial morbidity and mortality world wide; however, whether organophosphates cause chronic neurological sequelae has not been established. To see whether single episodes of acute unintentional organophosphate intoxication lead to chronic neuropsychological dysfunction, we carried out a retrospective study of agricultural workers in Nicaragua who had been admitted to hospital between July 1, 1986, and July 31, 1988, for occupationally related organophosphate intoxication. This "poisoned" group (36 men) was tested on average about two years after the episode of pesticide poisoning and compared with a matched control group. The poisoned group did much worse than the control group on all neuropsychological subtests, with significantly worse performance on five of six subtests of a World Health Organisation neuropsychological test battery and on 3 of 6 additional tests that assessed verbal and visual attention, visual memory, visuomotor speed, sequencing and problem solving, and motor steadiness and dexterity. Differences in neuropsychological performance could not be explained by other factors. The findings of a persistent decrease in neuropsychological performance among individuals with previous intoxication emphasise the importance of prevention of even single episodes of organophosphate poisoning.	UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195; UNIV WASHINGTON,MT SINAI SCH MED,DIV OCCUPAT & ENVIRONM HLTH,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Icahn School of Medicine at Mount Sinai; University of Washington; University of Washington Seattle	ROSENSTOCK, L (corresponding author), UNIV WASHINGTON,OCCUPAT MED PROGRAM,ZA-66,SEATTLE,WA 98195, USA.							[Anonymous], 1990, PUBLIC HLTH IMPACT P; BURCHFIEL JL, 1976, TOXICOL APPL PHARM, V35, P365, DOI 10.1016/0041-008X(76)90296-9; COSTA LG, 1988, RECENT ADV NERVOUS S; Coye M J, 1985, J Public Health Policy, V6, P349, DOI 10.2307/3342402; Derogatis L.R., 1982, BRIEF SYMPTOM INVENT; DILLE JR, 1964, AEROSPACE MED, V35, P475; DUFFY FH, 1979, TOXICOL APPL PHARM, V47, P161, DOI 10.1016/0041-008X(79)90083-8; DURHAM WF, 1965, ARCH ENVIRON HEALTH, V10, P55, DOI 10.1080/00039896.1965.10663953; ESKANAZI B, 1988, MED NEUROPSYCHOLOGY, P223; GERCHON S, 1961, LANCET, V1, P1371; Hogstedt C, 1984, BIOL MONITORING SURV; HOLMES JH, 1957, T AM CLIN CLIMAT ASS, V68, P86; JEYARATNAM J, 1990, World Health Statistics Quarterly, V43, P139; JEYARATNAM J, 1985, SCAND J WORK ENV HEA, V11, P229, DOI 10.5271/sjweh.2230; JEYARATNAM J, 1985, BRIT J IND MED, V42, P505; KARCZMAR AG, 1984, FUND APPL TOXICOL, V4, pS1, DOI 10.1016/0272-0590(84)90133-7; LEWIS R, 1977, ANN M SE PSYCHOL ASS; MARONI M, 1986, TOXICOL LETT, V33, P115, DOI 10.1016/0378-4274(86)90076-7; MCCONNELL R, 1990, AM J PUBLIC HEALTH, V80, P1236, DOI 10.2105/AJPH.80.10.1236; Metcalf D R, 1969, Ann N Y Acad Sci, V160, P357, DOI 10.1111/j.1749-6632.1969.tb15857.x; MIDTLING JE, 1985, WESTERN J MED, V142, P514; Murphy DS, 1986, CASARETT DOULLS TOXI, P519; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reitan R.M., 1985, REITAN NEUROPSYCHOLO, V4; Rey A., 1964, LEXAMEN CLINIQUE PSY; Rosenstock L., 1987, Toxicology of pesticides: experimental, clinical and regulatory perspectives., P197; SAVAGE EP, 1988, ARCH ENVIRON HEALTH, V43, P38, DOI 10.1080/00039896.1988.9934372; SENANAYAKE N, 1987, NEW ENGL J MED, V316, P761, DOI 10.1056/NEJM198703263161301; TABERSHAW IR, 1966, JOM-J OCCUP MED, V8, P5; Wechsler D, 1981, ADULT INTELLIGENCE S; 1986, OPERATIONAL GUIDE WH; 1986, WHOVBC86926	32	364	381	0	29	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					223	227		10.1016/0140-6736(91)90356-T	http://dx.doi.org/10.1016/0140-6736(91)90356-T			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676786				2022-12-01	WOS:A1991FY50400011
J	ADLER, M; LAZARUS, RA; DENNIS, MS; WAGNER, G				ADLER, M; LAZARUS, RA; DENNIS, MS; WAGNER, G			SOLUTION STRUCTURE OF KISTRIN, A POTENT PLATELET-AGGREGATION INHIBITOR AND GP-IIB-IIIA ANTAGONIST	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; DISTANCE GEOMETRY; AQUEOUS-SOLUTION; CELL-ADHESION; GPIIB-IIIA; INTEGRINS; FAMILY; VENOMS	The structure of kistrin, which is a member of a homologous family of glycoprotein IIb-IIIa (GP IIb-IIIa) antagonists and potent protein inhibitors of platelet aggregation, has been determined by two-dimensional nuclear magnetic resonance (NMR) spectroscopy. The 68-residue protein consists of a series of tightly packed loops held together by six disulfide bonds and has almost no regular secondary structure. Kistrin has an Arg-Gly-Asp (RGD) adhesion site recognition sequence important for binding to GP IIb-IIIa that is located at the apex of a long loop across the surface of the protein.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; GENENTECH INC, DEPT PROT ENGN, SAN FRANCISCO, CA 94080 USA	Harvard University; Harvard Medical School; Roche Holding; Genentech					NIGMS NIH HHS [GM38608] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038608] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER M, UNPUB; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BARKER PL, 1991, Patent No. 1331; BECKER RC, 1991, CIRCULATION, V83, P1115, DOI 10.1161/01.CIR.83.3.1115; Carter P, UNPUB; DENNIS MR, UNPUB; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; GARSKY VM, 1989, P NATL ACAD SCI USA, V86, P4022, DOI 10.1073/pnas.86.11.4022; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; HAWIGER J, 1990, ATHER REV, V21, P165; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KLINE AD, 1988, J MOL BIOL, V204, P675, DOI 10.1016/0022-2836(88)90364-6; MAZUR P, UNPUB; MONTELIONE GT, 1986, J AM CHEM SOC, V108, P6765, DOI 10.1021/ja00281a051; NICHOLS A, 1990, EUR J PHARMACOL, V183, P2019, DOI 10.1016/0014-2999(90)92378-V; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SEYMOUR JL, 1990, J BIOL CHEM, V265, P10143; STEIN B, 1989, J AM COLL CARDIOL, V14, P813, DOI 10.1016/0735-1097(89)90453-1; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; YASUDA T, 1991, CIRCULATION, V83, P1038, DOI 10.1161/01.CIR.83.3.1038	24	249	260	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 26	1991	253	5018					445	448		10.1126/science.1862345	http://dx.doi.org/10.1126/science.1862345			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY288	1862345				2022-12-01	WOS:A1991FY28800040
J	AMAYA, E; MUSCI, TJ; KIRSCHNER, MW				AMAYA, E; MUSCI, TJ; KIRSCHNER, MW			EXPRESSION OF A DOMINANT NEGATIVE MUTANT OF THE FGF RECEPTOR DISRUPTS MESODERM FORMATION IN XENOPUS EMBRYOS	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; MESSENGER-RNA; SIGNAL TRANSDUCTION; CELL-LINE; TGF-BETA; INDUCTION; GENES; INVITRO; LAEVIS; IDENTIFICATION	Peptide growth factors may play a role in patterning of the early embryo, particularly in the induction of mesoderm. We have explored the role of fibroblast growth factor (FGF) in early Xenopus development by expressing a dominant negative mutant form of the FGF receptor. Using a functional assay in frog oocytes, we found that a truncated form of the receptor effectively abolished wild-type receptor function. Explants from embryos expressing this dominant negative mutant failed to induce mesoderm in response to FGF. In whole embryos the mutant receptor caused specific defects in gastrulation and in posterior development, and overexpression of a wild-type receptor could rescue these developmental defects. These results demonstrate that the FGF signaling pathway plays an important role in early embryogenesis, particularly in the formation of the posterior and lateral mesoderm.	UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	AMAYA, E (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1989, DEVELOPMENT, V106, P173; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; COOKE J, 1989, DEV BIOL, V131, P383, DOI 10.1016/S0012-1606(89)80012-0; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Holtfreter J., 1955, ANAL DEV, P230; HOLWILL S, 1987, DEVELOPMENT, V100, P735; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P D, 1973, Adv Morphog, V10, P1; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NIEUWKOOP PD, 1985, EPIGENETIC NATURE EA; PATERNO GD, 1989, DEVELOPMENT, V106, P79; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SASAVAGE NL, 1982, J BIOL CHEM, V257, P678; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SLACK JMW, 1989, DEVELOPMENT, V105, P147; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SYMES K, 1987, DEVELOPMENT, V101, P339; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WHITTAKER J, 1990, DIABETES CARE, V13, P576, DOI 10.2337/diacare.13.6.576; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939; WOODLAND HR, 1989, CELL, V59, P767, DOI 10.1016/0092-8674(89)90596-5	52	1026	1043	0	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					257	270		10.1016/0092-8674(91)90616-7	http://dx.doi.org/10.1016/0092-8674(91)90616-7			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1649700				2022-12-01	WOS:A1991FY71200007
J	COX, LS; LASKEY, RA				COX, LS; LASKEY, RA			DNA-REPLICATION OCCURS AT DISCRETE SITES IN PSEUDONUCLEI ASSEMBLED FROM PURIFIED DNA INVITRO	CELL			English	Article							CELL NUCLEAR ANTIGEN; XENOPUS EGGS; POLYMERASE-ALPHA; FREE-EXTRACT; CYCLE; INITIATION; PHASE	Bacteriophage-lambda DNA is assembled into pseudonuclei in Xenopus egg extract and replicated semiconservatively under temporal cell cycle control. Here, replication is shown to be regulated spatially and to occur at discrete sites that represent clustered replication forks. Clustered forks are visualized by incorporation of biotin-19-dUTP into nascent DNA. Pulse-label experiments show that discrete replication foci persist throughout S phase. We conclude that the organization of replication forks into discrete clusters, previously described in eukaryotic nuclei, is not dependent on specific eukaryotic DNA sequences or on a preexisting inherited chromosomal or nuclear structure.			COX, LS (corresponding author), WELLCOME CANC RES CAMPAIGN INST,CANC RES CAMPAIGN MOLEC EMBRYOL GRP,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Cox, Lynne/AAT-2047-2021	Cox, Lynne/0000-0002-5306-285X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLOW JJ, 1990, J CELL SCI, V95, P383; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1987, EMBO J, V6, P1997, DOI 10.1002/j.1460-2075.1987.tb02463.x; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; COOK PR, 1988, J CELL SCI, V90, P1; FORBES DJ, 1983, CELL, V34, P13, DOI 10.1016/0092-8674(83)90132-0; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; HUTCHISON C, 1989, J CELL SCI, V93, P605; LENO GH, 1991, J CELL BIOL, V112, P557, DOI 10.1083/jcb.112.4.557; MECHALI M, 1983, CELL, V35, P63, DOI 10.1016/0092-8674(83)90208-8; MECHALI M, 1984, CELL, V38, P55, DOI 10.1016/0092-8674(84)90526-9; MILLS AD, 1989, J CELL SCI, V94, P471; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAMURA H, 1984, EXP CELL RES, V151, P123, DOI 10.1016/0014-4827(84)90362-8; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; Sambrook J., 1989, MOL CLONING LAB MANU; VERHEIJEN R, 1988, J CELL SCI, V90, P11	21	70	71	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					271	275		10.1016/0092-8674(91)90617-8	http://dx.doi.org/10.1016/0092-8674(91)90617-8			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1830242				2022-12-01	WOS:A1991FY71200008
J	CYGLER, M; ROSE, DR; BUNDLE, DR				CYGLER, M; ROSE, DR; BUNDLE, DR			RECOGNITION OF A CELL-SURFACE OLIGOSACCHARIDE OF PATHOGENIC SALMONELLA BY AN ANTIBODY FAB FRAGMENT	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURES; COMBINING SITES; ANTIGEN COMPLEX; SEROGROUP-A; BINDING; PROTEINS; CONFORMATION; SPECIFICITY; LYSOZYME	The 2.05 angstrom (angstrom) resolution crystal structure of a dodecasaccharide-Fab complex revealed an unusual carbohydrate recognition site, defined by aromatic amino acids and a structured water molecule, rather than the carboxylic acid and amide side chains that are features of transport and other carbohydrate binding proteins. A trisaccharide epitope of a branched bacterial lipopolysaccharide fills this hydrophobic pocket (8 angstrom deep by 7 angstrom wide) in an entropy-assisted association (association constant = 2.05 x 10(5) liters per mole, enthalpy = -20.5 +/- 1.7 kilojoules per mole, and temperature times entropy = +10.0 +/- 2.9 kilojoules per mole). The requirement for the complementarity of van der Waals surfaces and the requirements of saccharide-saccharide and protein-saccharide hydrogen-bonding networks determine the antigen conformation adopted in the bound state.	NATL RES COUNCIL CANADA, INST BIOL SCI, OTTAWA K1A 0R6, ONTARIO, CANADA	National Research Council Canada	CYGLER, M (corresponding author), NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MONTREAL H4P 2R2, QUEBEC, CANADA.							AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; ANAND NN, IN PRESS GENE; ANAND NN, UNPUB J BIOL CHEM; BOCK K, 1984, CARBOHYD RES, V130, P35, DOI 10.1016/0008-6215(84)85268-4; BOCK K, 1984, CARBOHYD RES, V130, P23, DOI 10.1016/0008-6215(84)85267-2; BRUNGER AT, 1990, XPLOR SYSTEM CRYSTAL; BUNDLE DR, 1990, TOP CURR CHEM, V154, P1; BUNDLE DR, UNPUB; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; GLAUDEMANS CPJ, 1987, MOL IMMUNOL, V24, P371, DOI 10.1016/0161-5890(87)90179-9; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; JOHNSON LN, 1988, CURR TOP MICROBIOL, V139, P81; JONES AT, 1978, J APPL CRYSTALLOGR, V11, P614; Kauffmann F, 1966, BACTERIOLOGY ENTEROB; Lemieux R. U., 1979, ACS SYM SER, V87, P17, DOI DOI 10.1021/BK-1979-0087.CH002; LEMIEUX RU, 1988, CAN J CHEM, V66, P3083, DOI 10.1139/v88-477; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; LUDERITZ O, 1966, BACTERIOL REV, V30, P192; NASHED EM, 1990, J BIOL CHEM, V265, P20699; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1988, P NATL ACAD SCI USA, V85, P6885, DOI 10.1073/pnas.85.18.6885; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PEREZ S, 1978, CARBOHYD RES, V65, P114, DOI 10.1016/S0008-6215(00)84218-4; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; ROBBINS JB, 1978, IMMUNOCHEMISTRY, V15, P839, DOI 10.1016/0161-5890(78)90117-7; ROSE DR, 1990, J MOL BIOL, V215, P489, DOI 10.1016/S0022-2836(05)80161-5; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; THURIN J, 1988, CURR TOP MICROBIOL, V139, P59	33	258	264	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 26	1991	253	5018					442	445		10.1126/science.1713710	http://dx.doi.org/10.1126/science.1713710			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY288	1713710				2022-12-01	WOS:A1991FY28800039
J	DIXON, DA; KOWALCZYKOWSKI, SC				DIXON, DA; KOWALCZYKOWSKI, SC			HOMOLOGOUS PAIRING INVITRO STIMULATED BY THE RECOMBINATION HOTSPOT, CHI	CELL			English	Article							ESCHERICHIA-COLI RECA; HOT SPOT ACTIVITY; BACTERIOPHAGE-LAMBDA; GENERALIZED RECOMBINATION; STRAND EXCHANGE; RECBCD ENZYME; GENETIC-RECOMBINATION; BINDING-PROTEIN; PHAGE-LAMBDA; DNA	Genetic recombination in Escherichia coli is stimulated at DNA sequences known as Chi sites, 5'-GCTGGTGG-3'. We describe the in vitro formation of homologously paired joint molecules that is dependent upon this recombination hotspot. Chi-dependent joint molecule formation requires RecA, RecBCD, and SSB proteins and a Chi site in the donor linear dsDNA. The donor dsDNA is unwound by RecBCD enzyme, and the invasive strand is generated by nicking at Chi. This Chi-dependent invading strand must contain homology to the recipient supercoiled DNA substrate at its newly formed 3' end for efficient joint molecule formation. Action at Chi generates invasive ssDNA from the 5' but not the 3' side of Chi, suggesting that the nuclease activity of RecBCD enzyme is attenuated upon encountering a Chi site. These results support the view that RecBCD enzyme action can precede RecA protein action and reconcile the seemingly opposing degradative and recombination functions of RecBCD enzyme.			DIXON, DA (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, CHICAGO, IL 60611 USA.				NIGMS NIH HHS [GM-41347] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; Berger S. L., 1987, GUIDE MOL CLONING TE; BIANCHI M, 1983, CELL, V34, P931, DOI 10.1016/0092-8674(83)90550-0; BRAEDT G, 1989, P NATL ACAD SCI USA, V86, P871, DOI 10.1073/pnas.86.3.871; CHAUDHURY AM, 1984, P NATL ACAD SCI-BIOL, V81, P7850, DOI 10.1073/pnas.81.24.7850; CHENG KC, 1989, GENETICS, V123, P5; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; CONNOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476, DOI 10.1073/pnas.87.21.8476; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; EICHLER DC, 1977, J BIOL CHEM, V252, P499; FAULDS D, 1979, J MOL BIOL, V131, P681, DOI 10.1016/0022-2836(79)90197-9; GLASSBERG J, 1979, J BACTERIOL, V140, P14, DOI 10.1128/JB.140.1.14-19.1979; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; KONFORTI BB, 1987, P NATL ACAD SCI USA, V84, P690, DOI 10.1073/pnas.84.3.690; KONFORTI BB, 1990, J BIOL CHEM, V265, P6916; KOWALCZYKOWSKI SC, 1987, TRENDS BIOCHEM SCI, V12, P141, DOI 10.1016/0968-0004(87)90070-3; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE, V73, P289, DOI 10.1016/0300-9084(91)90216-N; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.biophys.20.1.539; KOWALCZYKOWSKI SC, 1990, UCLA S MOL CELLULAR, P357; LAM ST, 1974, GENETICS, V77, P425; LEBOWITZ J, 1985, THESIS J HOPKINS U B; LOVETT ST, 1988, GENETICS, V120, P37; MACKAY V, 1976, J BIOL CHEM, V251, P3716; MACKAY V, 1974, J BIOL CHEM, V249, P4286; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MESSING J, 1983, METHOD ENZYMOL, V101, P20; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; ROMAN LJ, 1989, J BIOL CHEM, V264, P18340; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1991, P NATL ACAD SCI USA, V88, P3367, DOI 10.1073/pnas.88.8.3367; RUYECHAN WT, 1975, BIOCHEMISTRY-US, V14, P5529, DOI 10.1021/bi00696a023; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; SMITH GR, 1984, COLD SPRING HARB SYM, V49, P485, DOI 10.1101/SQB.1984.049.01.055; SMITH GR, 1988, MICROBIOL REV, V52, P1; SMITH GR, 1983, CELL, V34, P709, DOI 10.1016/0092-8674(83)90525-1; SMITH GR, 1991, CELL, V64, P19, DOI 10.1016/0092-8674(91)90205-D; SMITH GR, 1990, NUCL ACIDS MOL BIOL, P78; SMITH JV, 1981, SCOT EDUC REV, V13, P25; STAHL FW, 1979, ANNU REV GENET, V13, P7, DOI 10.1146/annurev.ge.13.120179.000255; STAHL FW, 1975, J MOL BIOL, V94, P203, DOI 10.1016/0022-2836(75)90078-9; STAHL FW, 1990, GENETICS, V126, P519; STAHL FW, 1975, MOL GEN GENET, V140, P29, DOI 10.1007/BF00268986; STAHL FW, 1980, GENETICS, V94, P235; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; Telander-Muskavitch K.M, 1981, ENZYMES, P233; Thaler D.S., 1988, MECH CONSEQUENCES DN, P413; THALER DS, 1989, GENOME, V31, P53, DOI 10.1139/g89-013; WANG TCV, 1989, MOL GEN GENET, V216, P315, DOI 10.1007/BF00334370; WEST SC, 1988, TRENDS GENET, V4, P8, DOI 10.1016/0168-9525(88)90121-7; WIEGAND RC, 1977, J MOL BIOL, V116, P805, DOI 10.1016/0022-2836(77)90272-8; WILLIAMS JGK, 1981, J BIOL CHEM, V256, P7573	57	150	151	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 26	1991	66	2					361	371		10.1016/0092-8674(91)90625-9	http://dx.doi.org/10.1016/0092-8674(91)90625-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1855256				2022-12-01	WOS:A1991FY71200016
J	GLASS, DJ; NYE, SH; HANTZOPOULOS, P; MACCHI, MJ; SQUINTO, SP; GOLDFARB, M; YANCOPOULOS, GD				GLASS, DJ; NYE, SH; HANTZOPOULOS, P; MACCHI, MJ; SQUINTO, SP; GOLDFARB, M; YANCOPOULOS, GD			TRKB MEDIATES BDNF/NT-3-DEPENDENT SURVIVAL AND PROLIFERATION IN FIBROBLASTS LACKING THE LOW AFFINITY NGF RECEPTOR	CELL			English	Article							NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; MOLECULAR-CLONING; GENE-TRANSFER; FACTOR FAMILY; PC12 CELLS; MAMMALIAN-CELLS; EXPRESSION; BRAIN; DIFFERENTIATION	The neurotrophins (nerve growth factor [NGF], brain-derived neurotrophic factor [BDNF], neurotrophin-3 [NT-3], and neurotrophin-4 [NT-4]) have been defined by their ability to support neuronal survival. These factors utilize the Trk family of receptor tyrosine kinases, perhaps in conjunction with a second component known as the low affinity NGF receptor (LNGFR). Here we demonstrate that TrkB mediates survival and proliferation in response to both BDNF and NT-3 when expressed in a particular strain of NIH 3T3 fibroblasts, with BDNF the more potent ligand. Furthermore, the BDNF dose dependency displayed by these TrkB-expressing fibroblasts is similar to that required to support the survival of primary neurons. The LNGFR is not expressed in our fibroblast system, implying that this receptor is not essential for responses to physiological concentrations of the neurotrophins. We discuss our findings in the context of neurotrophin signaling pathways and mechanisms of neuronal cell death.	REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591	Regeneron	GLASS, DJ (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.		Glass, David/AAI-3910-2021					BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BERND P, 1984, J BIOL CHEM, V259, P5509; BOTHWELL M, 1991, CURR TOP MICROBIOL, V165, P63; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CAVALIERI F, 1987, MOL CELL BIOL, V7, P3554, DOI 10.1128/MCB.7.10.3554; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOLBOOK F, 1991, NEURON, V6, P845; HOSANG M, 1985, J BIOL CHEM, V260, P655; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; LINDSAY RM, 1985, DEV BIOL, V112, P30, DOI 10.1016/0012-1606(85)90116-2; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARUYAMA K, 1987, ONCOGENE, V1, P361; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MURPHY AJM, 1987, P NATL ACAD SCI USA, V84, P8277, DOI 10.1073/pnas.84.23.8277; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SEHGAL A, 1988, MOL CELL BIOL, V8, P2242, DOI 10.1128/MCB.8.5.2242; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SUTTER A, 1979, J BIOL CHEM, V254, P5972; SUTTER A, 1979, TRANSMEMBRANE SIGNAL, P659; TOGARI A, 1983, BIOCHEM BIOPH RES CO, V114, P1189, DOI 10.1016/0006-291X(83)90688-5; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	46	280	293	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					405	413		10.1016/0092-8674(91)90629-D	http://dx.doi.org/10.1016/0092-8674(91)90629-D			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1649703				2022-12-01	WOS:A1991FY71200020
J	GODDEN, JW; TURLEY, S; TELLER, DC; ADMAN, ET; LIU, MY; PAYNE, WJ; LEGALL, J				GODDEN, JW; TURLEY, S; TELLER, DC; ADMAN, ET; LIU, MY; PAYNE, WJ; LEGALL, J			THE 2.3 ANGSTROM X-RAY STRUCTURE OF NITRITE REDUCTASE FROM ACHROMOBACTER-CYCLOCLASTES	SCIENCE			English	Article							PROTEINS	The three-dimensional crystal structure of the copper-containing nitrite reductase (NIR) from Achromobacter cycloclastes has been determined to 2.3 angstrom (angstrom) resolution by isomorphous replacement. The monomer has two Greek key beta-barrel domains similar to that of plastocyanin and contains two copper sites. The enzyme is a trimer both in the crystal and in solution. The two copper atoms in the monomer comprise one type I copper site (Cu-I; two His, one Cys, and one Met ligands) and one putative type II copper site (Cu-II; three His and one solvent ligands). Although ligated by adjacent amino acids Cu-I and Cu-II are approximately 12.5 angstrom apart. Cu-II is bound with nearly perfect tetrahedral geometry by residues not within a single monomer, but from each of two monomers of the trimer. The Cu-II site is at the bottom of a 12 angstrom deep solvent channel and is the site to which the substrate (NO2-) binds, as evidenced by difference density maps of substrate-soaked and native crystals.	UNIV WASHINGTON, DEPT BIOL STRUCT SM20, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA; UNIV GEORGIA, DEPT MICROBIOL, ATHENS, GA 30602 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031770] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08268-02, GM31770] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adman E.T., 1985, METALLOPROTEINS ME 1, P1; BRANDEN CI, 1990, NATURE, V343, P687, DOI 10.1038/343687a0; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DENARIAZ G, 1991, BIOCHIM BIOPHYS ACTA, V1056, P225, DOI 10.1016/S0005-2728(05)80053-2; DOOLEY DM, 1988, J BIOL CHEM, V263, P14625; FENDERSON FF, 1991, BIOCHEMISTRY-US, V30, P7180, DOI 10.1021/bi00243a020; Golterman H. L., 1985, Denitrification in the nitrogen cycle, P1; HULSE CL, 1988, ANAL BIOCHEM, V172, P420, DOI 10.1016/0003-2697(88)90464-2; IWASAKI H, 1972, J BIOCHEM, V71, P645; IWASAKI H, 1975, J BIOCHEM-TOKYO, V78, P355, DOI 10.1093/oxfordjournals.jbchem.a130915; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAKUTANI T, 1981, J BIOCHEM-TOKYO, V89, P463, DOI 10.1093/oxfordjournals.jbchem.a133221; KASHEM MA, 1987, BIOCHEM BIOPH RES CO, V145, P563, DOI 10.1016/0006-291X(87)91357-X; LIU MY, 1986, J BACTERIOL, V166, P604, DOI 10.1128/jb.166.2.604-608.1986; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P513, DOI 10.1016/0022-2836(89)90498-1; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; Payne W. J., 1985, Denitrification in the nitrogen cycle, P47; SHAPLEIGH JP, 1987, BIOCHIM BIOPHYS ACTA, V911, P334, DOI 10.1016/0167-4838(87)90074-4; SHAPLEIGH JP, 1985, FEMS MICROBIOL LETT, V26, P275; SOLOMON EI, 1983, COPPER COORDINATION, P1; SUZUKI S, 1989, BIOCHEM BIOPH RES CO, V164, P1366, DOI 10.1016/0006-291X(89)91820-2; Teller D C, 1973, Methods Enzymol, V27, P346; TURLEY S, 1988, J MOL BIOL, V200, P417, DOI 10.1016/0022-2836(88)90251-3; WANG BC, 1985, METHOD ENZYMOL, V115, P90	26	344	348	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 26	1991	253	5018					438	442		10.1126/science.1862344	http://dx.doi.org/10.1126/science.1862344			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY288	1862344				2022-12-01	WOS:A1991FY28800038
J	KERPPOLA, TK; CURRAN, T				KERPPOLA, TK; CURRAN, T			FOS-JUN HETERODIMERS AND JUN HOMODIMERS BEND DNA IN OPPOSITE ORIENTATIONS - IMPLICATIONS FOR TRANSCRIPTION FACTOR COOPERATIVITY	CELL			English	Article							INTEGRATION HOST FACTOR; LEUCINE ZIPPER; FACTOR AP-1; PROTEIN COMPLEXES; BINDING; SITE; REPLICATION; ELECTROPHORESIS; RECOGNITION; ACTIVATION	Association of Fos and Jun with the AP-1 site results in a conformational change in the basic amino acid regions that constitute the DNA-binding domain. We show that Fos and Jun induce a corresponding alteration in the conformation of the DNA helix. Circular permutation analysis indicated that both Fos-Jun heterodimers and Jun homodimers induce flexure at the AP-1 site. Phasing analysis demonstrated that Fos-Jun heterodimers and Jun homodimers induce DNA bends that are directed in opposite orientations. Fos-Jun heterodimers bend DNA toward the major groove, whereas Jun homodimers bend DNA toward the minor groove. Fos and Jun peptides encompassing the dimerization and DNA-binding domains bend DNA in the same orientations as the full-length proteins. However, additional regions of both proteins influence the magnitude of the DNA bend angle. Thus, despite the amino acid sequence similarity in the basic region Fos-Jun heterodimers and Jun homodimers form topologically distinct DNA-protein complexes.			KERPPOLA, TK (corresponding author), ROCHE INST MOLEC BIOL,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110, USA.		Curran, Tom/F-5234-2018; Kerppola, Tom/AAG-4457-2022; Kerppola, Tom/AFK-6155-2022; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011; Curran, Tom/C-1164-2008	Curran, Tom/0000-0003-1444-7551; Kerppola, Tom/0000-0002-0611-9446; Kerppola, Tom/0000-0002-0611-9446; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BAUR CP, 1988, J MOL BIOL, V203, P1009, DOI 10.1016/0022-2836(88)90125-8; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN DR, 1990, ONCOGENE, V5, P929; CURRAN T, 1991, IN PRESS TRANSCRIPTI; DEVARGAS LM, 1991, P NATL ACAD SCI USA, V88, P588, DOI 10.1073/pnas.88.2.588; DEVARGAS LM, 1989, SCIENCE, V244, P1457; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LERMAN LS, 1982, BIOPOLYMERS, V21, P995, DOI 10.1002/bip.360210511; LEVENE SD, 1986, BIOCHEMISTRY-US, V25, P3988, DOI 10.1021/bi00362a003; LEVENE SD, 1989, SCIENCE, V245, P396, DOI 10.1126/science.2756426; LUMPKIN OJ, 1985, BIOPOLYMERS, V24, P1573, DOI 10.1002/bip.360240812; MCALLISTER CF, 1989, J BIOL CHEM, V264, P10451; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PECK LJ, 1981, NATURE, V292, P375, DOI 10.1038/292375a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RHODES D, 1981, NATURE, V292, P378, DOI 10.1038/292378a0; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROJO F, 1990, J MOL BIOL, V211, P713, DOI 10.1016/0022-2836(90)90072-T; RYSECK RP, 1991, ONCOGENE, V6, P533; SALVO JJ, 1987, NUCLEIC ACIDS RES, V15, P9771, DOI 10.1093/nar/15.23.9771; SALVO JJ, 1988, EMBO J, V7, P3609, DOI 10.1002/j.1460-2075.1988.tb03239.x; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VIGNAIS ML, 1989, J BIOL CHEM, V264, P8463; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WILLIAMS JS, 1988, MOL CELL BIOL, V8, P2763, DOI 10.1128/MCB.8.7.2763; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	56	296	297	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					317	326		10.1016/0092-8674(91)90621-5	http://dx.doi.org/10.1016/0092-8674(91)90621-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1906785				2022-12-01	WOS:A1991FY71200012
J	KLEIN, R; NANDURI, V; JING, SQ; LAMBALLE, F; TAPLEY, P; BRYANT, S; CORDONCARDO, C; JONES, KR; REICHARDT, LF; BARBACID, M				KLEIN, R; NANDURI, V; JING, SQ; LAMBALLE, F; TAPLEY, P; BRYANT, S; CORDONCARDO, C; JONES, KR; REICHARDT, LF; BARBACID, M			THE TRKB TYROSINE PROTEIN-KINASE IS A RECEPTOR FOR BRAIN-DERIVED NEUROTROPHIC FACTOR AND NEUROTROPHIN-3	CELL			English	Article							NERVE GROWTH-FACTOR; MOLECULAR-CLONING; FACTOR FAMILY; CHOLINERGIC NEURONS; MESSENGER-RNA; EXPRESSION; GENE; BDNF; IDENTIFICATION; SURVIVAL	trkB is a tyrosine protein kinase gene highly related to trk, a proto-oncogene that encodes a receptor for nerve growth factor (NGF) and neurotrophin-3 (NT-3). trkB expression is confined to structures of the central and peripheral nervous systems, suggesting it also encodes a receptor for neurotrophic factors. Here we show that brain-derived neurotrophic factor (BDNF) and NT-3, but not NGF, can induce rapid phosphorylation on tyrosine of gp145trkB, one of the receptors encoded by trkB. BDNF and NT-3 can induce DNA synthesis in quiescent NIH 3T3 cells that express gp145trkB. Cotransfection of plasmids encoding gp145trkB and BDNF or NT-3 leads to transformation of recipient NIH 3T3 cells. In these assays, BDNF elicits a response at least two orders of magnitude higher than NT-3. Finally, I-125-NT-3 binds to NIH 3T3 cells expressing gp145trkB; binding can be competed by NT-3 and BDNF but not by NGF. These findings indicate that gp145trkB may function as a neurotrophic receptor for BDNF and NT-3.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	KLEIN, R (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543, USA.		Lamballe, Fabienne/P-4293-2017; Klein, Ruediger/C-6147-2008; Lamballe, Fabienne/GLT-0820-2022	Klein, Ruediger/0000-0002-3109-0163; Lamballe, Fabienne/0000-0001-7631-942X; JONES, KEVIN/0000-0002-3802-7562	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016033] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS016033, P01 NS016033-230014] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; BARBACID M, 1991, IN PRESS BIOCH BIOPH; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KALCHEIM C, 1987, EMBO J, V6, P2871, DOI 10.1002/j.1460-2075.1987.tb02589.x; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KNUSEL B, 1991, P NATL ACAD SCI USA, V88, P961, DOI 10.1073/pnas.88.3.961; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LETWIN K, 1988, ONCOGENE, V3, P621; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0	38	818	848	2	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					395	403		10.1016/0092-8674(91)90628-C	http://dx.doi.org/10.1016/0092-8674(91)90628-C			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1649702	Green Accepted			2022-12-01	WOS:A1991FY71200019
J	KNIGHTON, DR; ZHENG, JH; TENEYCK, LF; XUONG, NH; TAYLOR, SS; SOWADSKI, JM				KNIGHTON, DR; ZHENG, JH; TENEYCK, LF; XUONG, NH; TAYLOR, SS; SOWADSKI, JM			STRUCTURE OF A PEPTIDE INHIBITOR BOUND TO THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE-MONOPHOSPHATE DEPENDENT PROTEIN-KINASE	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; ACTIVE-SITE; SECONDARY STRUCTURE; SUBSTRATE; BINDING; 3',5'-MONOPHOSPHATE; IDENTIFICATION; CONFORMATION; HOMOLOGY; DOMAINS	The structure of a 20-amino acid peptide inhibitor bound to the catalytic subunit of cyclic AMP-dependent protein kinase, and its interactions with the enzyme, are described. The x-ray crystal structure of the complex is the basis of the analysis. The peptide inhibitor, derived from a naturally occurring heat-stable protein kinase inhibitor, contains an amphipathic helix that is followed by a turn and an extended conformation. The extended region occupies the cleft between the two lobes of the enzyme and contains a five-residue consensus recognition sequence common to all substrates and peptide inhibitors of the catalytic subunit. The helical portion of the peptide binds to a hydrophobic groove and conveys high affinity binding. Loops from both domains converge at the active site and contribute to a network of conserved residues at the sites of magnesium adenosine triphosphate binding and catalysis. Amino acids associated with peptide recognition, nonconserved, extend over a large surface area.	UNIV CALIF SAN DIEGO,DEPT MED,9500 GILMAN DR,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093; SAN DIEGO SUPERCOMP CTR,SAN DIEGO,CA 92186; UNIV CALIF SAN DIEGO,DEPT PHYS,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [T32CA09523] Funding Source: Medline; NCRR NIH HHS [RR01644] Funding Source: Medline; NIDDK NIH HHS [T32DK07233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BHATNAGAR D, 1984, BIOCHEMISTRY-US, V23, P4350, DOI 10.1021/bi00314a016; BRAMSON HN, 1987, BIOCHEMISTRY-US, V26, P4466, DOI 10.1021/bi00388a042; BRAMSON HN, 1984, CRC CR REV BIOCH MOL, V15, P93, DOI 10.3109/10409238409102298; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P5997, DOI 10.1021/bi00393a008; BUECHLER JA, 1990, BIOCHEMISTRY-US, V29, P1937, DOI 10.1021/bi00459a039; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GLASS DB, 1989, J BIOL CHEM, V264, P14579; GRANOT J, 1981, BIOCHEMISTRY-US, V20, P602, DOI 10.1021/bi00506a024; GRANOT J, 1981, J BIOL CHEM, V255, P4569; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HJELMQUIST G, 1974, BIOCHEM BIOPH RES CO, V61, P559, DOI 10.1016/0006-291X(74)90993-0; HOFMANN F, 1980, J BIOL CHEM, V255, P1559; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JIMENEZ JS, 1982, BIOCHEMISTRY-US, V21, P1623, DOI 10.1021/bi00536a024; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Kemp BE, 1990, PEPTIDES PROTEIN PHO; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; NELSON NC, 1983, J BIOL CHEM, V258, P981; PARELLO J, IN PRESS J MOL BIOL; REED J, 1984, BIOCHEMISTRY-US, V23, P1357, DOI 10.1021/bi00302a004; REED J, 1985, BIOCHEMISTRY-US, V24, P2967, DOI 10.1021/bi00333a024; REED J, 1989, BIOCHEM J, V264, P371, DOI 10.1042/bj2640371; REED J, 1987, BIOCHEMISTRY-US, V26, P7641, DOI 10.1021/bi00398a017; ROSEVEAR PR, 1984, BIOCHEMISTRY-US, V23, P3161, DOI 10.1021/bi00309a009; SALERNO A, 1990, J BIOL CHEM, V265, P18079; SHOJI S, 1979, J BIOL CHEM, V254, P6211; THOMAS NE, 1987, BIOCHEMISTRY-US, V26, P4461, DOI 10.1021/bi00388a041; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; VANPATTEN SM, 1987, J BIOL CHEM, V262, P3398; VANPATTEN SM, 1986, J BIOL CHEM, V261, P5514; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WELDON SL, 1985, J BIOL CHEM, V260, P4203; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; YONEMOTO W, IN PRESS METHODS ENZ; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171; ZOLLER MN, 1981, J BIOL CHEM, V256, P10387	42	883	946	3	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 26	1991	253	5018					414	420		10.1126/science.1862343	http://dx.doi.org/10.1126/science.1862343			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY288	1862343				2022-12-01	WOS:A1991FY28800031
J	LASSAR, AB; DAVIS, RL; WRIGHT, WE; KADESCH, T; MURRE, C; VORONOVA, A; BALTIMORE, D; WEINTRAUB, H				LASSAR, AB; DAVIS, RL; WRIGHT, WE; KADESCH, T; MURRE, C; VORONOVA, A; BALTIMORE, D; WEINTRAUB, H			FUNCTIONAL-ACTIVITY OF MYOGENIC HLH PROTEINS REQUIRES HETERO-OLIGOMERIZATION WITH E12/E47-LIKE PROTEINS INVIVO	CELL			English	Article							MUSCLE-SPECIFIC ENHANCER; LOOP-HELIX PROTEINS; DNA-BINDING; NEGATIVE REGULATOR; 10T1/2 FIBROBLASTS; DETERMINATION GENE; SEX DETERMINATION; MYC HOMOLOGY; MYOD; EXPRESSION	In this report we provide four lines of evidence indicating that E12/E47-like proteins interact in vivo with the myogenic HLH proteins MyoD and myogenin. First, cotransfection of MyoD and E47 in COS cells indicates that these factors synergistically enhance transcription of a reporter gene containing an oligomerized MyoD-binding site. Second, mobility-shift assays of muscle cell nuclear extracts, "double shifted" with specific antisera, have identified complexes binding to the MEF1 site that contain either MyoD or myogenin in association with E12/E47-like proteins. Third, association with E47 alters the phosphorylation state of MyoD. Fourth, C3H10T1/2 cells expressing antisense E2A transcripts contain low levels of E2A gene products and display less terminal muscle differentiation when infected with retroviral MyoD or when challenged to differentiate with 5-azacytidine treatment. In addition we demonstrate that MyoD, in conjunction with E12/E47-like proteins, is functioning as a regulatory nodal point for activation of several other downstream muscle regulators.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98104; FRED HUTCHINSON CANC RES CTR,DEPT GENET,SEATTLE,WA 98104; UNIV TEXAS,SW MED SCH,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT HUMAN GENET,PHILADELPHIA,PA 19104; MIT,WHITEHEAD INST,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; Massachusetts Institute of Technology (MIT); Whitehead Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039458] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39458] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CAMPOSORTEGA JA, 1990, EUR J BIOCHEM, V190, P1, DOI 10.1111/j.1432-1033.1990.tb15538.x; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2827; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HARVEY RP, 1990, DEVELOPMENT, V108, P669; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCALES JB, 1990, MOL CELL BIOL, V10, P1516, DOI 10.1128/MCB.10.4.1516; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, IN PRESS GENES DEV; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	57	798	808	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					305	315		10.1016/0092-8674(91)90620-E	http://dx.doi.org/10.1016/0092-8674(91)90620-E			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1649701				2022-12-01	WOS:A1991FY71200011
J	LUPSKI, JR; DEOCALUNA, RM; SLAUGENHAUPT, S; PENTAO, L; GUZZETTA, V; TRASK, BJ; SAUCEDOCARDENAS, O; BARKER, DF; KILLIAN, JM; GARCIA, CA; CHAKRAVARTI, A; PATEL, PI				LUPSKI, JR; DEOCALUNA, RM; SLAUGENHAUPT, S; PENTAO, L; GUZZETTA, V; TRASK, BJ; SAUCEDOCARDENAS, O; BARKER, DF; KILLIAN, JM; GARCIA, CA; CHAKRAVARTI, A; PATEL, PI			DNA DUPLICATION ASSOCIATED WITH CHARCOT-MARIE-TOOTH DISEASE TYPE-1A	CELL			English	Article							NEUROPATHY TYPE-I; MULTILOCUS LINKAGE ANALYSIS; PERICENTROMERIC REGION; INTERSTITIAL DELETION; GEL-ELECTROPHORESIS; HEREDITARY MOTOR; GENETIC-LINKAGE; CHROMOSOME-17; RECEPTOR; LOCUS	Charcot-Marie-Tooth disease type 1A (CMT1A) was localized by genetic mapping to a 3 cM interval on human chromosome 17p. DNA markers within this interval revealed a duplication that is completely linked and associated with CMT1A. The duplication was demonstrated in affected individuals by the presence of three alleles at a highly polymorphic locus, by dosage differences at RFLP alleles, and by two-color fluorescence in situ hybridization. Pulsed-field gel electrophoresis of genomic DNA from patients of different ethnic origins showed a novel SacII fragment of 500 kb associated with CMT1A. A severely affected CMT1A offspring from a mating between two affected individuals was demonstrated to have this duplication present on each chromosome 17. We have demonstrated that failure to recognize the molecular duplication can lead to misinterpretation of marker genotypes for affected individuals, identification of false recombinants, and incorrect localization of the disease locus.	BAYLOR UNIV,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR UNIV,DEPT NEUROL,HOUSTON,TX 77030; LOUISIANA STATE UNIV,MED CTR,DEPT PATHOL,NEW ORLEANS,LA 70112; BAYLOR UNIV,CTR HUMAN GENOME,HOUSTON,TX 77030; UNIV PITTSBURGH,DEPT HUMAN GENET,PITTSBURGH,PA 15260; UNIV PITTSBURGH,DEPT PSYCHIAT,PITTSBURGH,PA 15260; UNIV CALIF LAWRENCE LIVERMORE NATL LAB,DIV BIOMED SCI,LIVERMORE,CA 94550; UNIV UTAH,SCH MED,DEPT MED INFORMAT,SALT LAKE CITY,UT 84130; LOUISIANA STATE UNIV,MED CTR,DEPT NEUROL,NEW ORLEANS,LA 70112	Baylor University; Baylor University; Louisiana State University System; Baylor University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Utah System of Higher Education; University of Utah; Louisiana State University System	LUPSKI, JR (corresponding author), BAYLOR UNIV,INST MOLEC GENET,HOUSTON,TX 77030, USA.		Patel, Pragna/H-9129-2017	Patel, Pragna/0000-0003-3584-1072; Barker, David/0000-0002-1438-4100	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K04HD000774] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000344, R01HG000256] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG-00256-01, HG 00344] Funding Source: Medline; NICHD NIH HHS [HD00774] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; BEDFORD MT, 1990, BIOTECHNIQUES, V9, P744; BEESON D, 1990, ANN HUM GENET, V54, P199, DOI 10.1111/j.1469-1809.1990.tb00378.x; BIRD TD, 1978, CLIN GENET, V14, P43; BIRD TD, 1982, AM J HUM GENET, V34, P388; BOULTER J, 1990, J BIOL CHEM, V265, P4472; Bridges CB, 1936, SCIENCE, V83, P210, DOI 10.1126/science.83.2148.210; CHANCE PF, 1990, AM J HUM GENET, V47, P915; Charcot JM, 1886, REV MED-PARIS, V6, P97; CONNEALLY PM, 1985, CYTOGENET CELL GENET, V40, P356, DOI 10.1159/000132186; DAUSSET J, 1986, PRESSE MED, V15, P1801; DEVLIN RH, 1990, AM J HUM GENET, V46, P112; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; FAIN P R, 1987, Genomics, V1, P340, DOI 10.1016/0888-7543(87)90034-6; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; FRANCO B, 1990, NUCLEIC ACIDS RES, V18, P7196, DOI 10.1093/nar/18.23.7196-a; GREEN MC, 1989, GENETIC VARIANTS STR; GRUNDY HO, 1989, IMMUNOGENETICS, V29, P331, DOI 10.1007/BF00352843; HERRMANN BG, 1987, CELL, V48, P813, DOI 10.1016/0092-8674(87)90078-X; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; KILLIAN JM, 1979, ANN NEUROL, V5, P515, DOI 10.1002/ana.410050604; KORNREICH R, 1990, J BIOL CHEM, V265, P9319; LATHROP GM, 1988, AM J HUM GENET, V42, P498; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LINDSLEY DL, 1985, DROS INF SERV, V62; LITT M, 1989, AM J HUM GENET, V44, P397; LUPSKI JR, 1991, CURRENT NEUROLOGY, P1; MAGENIS RE, 1986, AM J MED GENET, V24, P415, DOI 10.1002/ajmg.1320240304; MCALPINE PJ, 1990, GENOMICS, V7, P408, DOI 10.1016/0888-7543(90)90175-T; McKusick VA, 1990, MENDELIAN INHERITANC; MIDDLETONPRICE HR, 1990, AM J HUM GENET, V46, P92; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MORTON NE, 1956, AM J HUM GENET, V8, P80; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NAKAMURA Y, 1987, NUCLEIC ACIDS RES, V15, P10073, DOI 10.1093/nar/15.23.10073; Nakamura Y, 1988, GENOMICS, V2, P302, DOI 10.1016/0888-7543(88)90018-3; OTT J, 1978, ANN HUM GENET, V42, P255, DOI 10.1111/j.1469-1809.1978.tb00657.x; OTT J, 1985, ANAL HUMAN GENETIC L; PATEL PI, 1990, AM J HUM GENET, V47, P926; PATEL PI, 1990, AM J HUM GENET, V46, P801; RAEYMAEKERS P, 1989, AM J HUM GENET, V45, P953; RAY R, 1990, NUCLEIC ACIDS RES, V18, P4958, DOI 10.1093/nar/18.16.4958; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ CE, 1986, CYTOGENET CELL GENET, V43, P117, DOI 10.1159/000132307; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SHYAMALA V, 1990, EMBO J, V9, P939, DOI 10.1002/j.1460-2075.1990.tb08192.x; SKRE H, 1974, CLIN GENET, V6, P98; SMITH ACM, 1986, AM J MED GENET, V24, P393, DOI 10.1002/ajmg.1320240303; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRATTON RF, 1986, AM J MED GENET, V24, P421, DOI 10.1002/ajmg.1320240305; SULLIVAN DE, 1987, BIOTECHNIQUES, V5, P672; TIMMERMAN V, 1990, AM J HUM GENET, V47, P680; TRASK BJ, 1991, AM J HUM GENET, V48, P1; TSUBOTA SI, 1989, GENETICS, V122, P881; VANCE JM, 1989, EXP NEUROL, V104, P186, DOI 10.1016/S0014-4886(89)80013-5; VANCE JM, 1991, GENOMICS, V9, P623, DOI 10.1016/0888-7543(91)90355-I; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, GENOME ANAL, V1, P157; WESTERVELD A, 1971, NATURE-NEW BIOL, V234, P20, DOI 10.1038/newbio234020a0; WRIGHT EC, 1990, GENOMICS, V7, P103, DOI 10.1016/0888-7543(90)90524-X; ZOGHBI HY, 1989, AM J HUM GENET, V44, P255	62	1133	1152	0	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					219	232		10.1016/0092-8674(91)90613-4	http://dx.doi.org/10.1016/0092-8674(91)90613-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1677316				2022-12-01	WOS:A1991FY71200004
J	MUELLER, LD; GUO, PZ; AYALA, FJ				MUELLER, LD; GUO, PZ; AYALA, FJ			DENSITY-DEPENDENT NATURAL-SELECTION AND TRADE-OFFS IN LIFE-HISTORY TRAITS	SCIENCE			English	Article							FOOD-LIMITED ENVIRONMENTS; POPULATION-GROWTH; K-SELECTION; REGULATED SELECTION; DROSOPHILA MODEL; ESCHERICHIA-COLI; R-SELECTION; EVOLUTION; PLEIOTROPY	Theories of density-dependent natural selection state that at extreme population densities evolution produces alternative life histories due to trade-offs. The trade-offs are presumed to arise because those genotypes with highest fitness at high population densities will not also have high fitness at low density and vice-versa. These predictions were tested by taking samples from six populations of Drosophila melanogaster kept at low population densities (r-populations) for nearly 200 generations and placing them in crowded cultures (K-populations). After 25 generations in the crowded cultures, the derived K-populations showed growth rate and productivity that at high densities were elevated relative to the controls, but at low density were depressed.			MUELLER, LD (corresponding author), UNIV CALIF IRVINE,DEPT ECOL & EVOLUTIONARY BIOL,IRVINE,CA 92717, USA.				NCRR NIH HHS [S07 RR07008] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007008] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSON WW, 1971, AM NAT, V105, P489, DOI 10.1086/282741; ANDERSON WW, 1983, AM NAT, V121, P649, DOI 10.1086/284092; ASMUSSEN MA, 1983, GENETICS, V103, P335; BARCLAY HJ, 1981, AM NAT, V117, P944, DOI 10.1086/283779; BRADSHAW WE, 1989, AM NAT, V133, P869, DOI 10.1086/284957; CHARLESWORTH B, 1971, ECOLOGY, V52, P469, DOI 10.2307/1937629; CLARKE B, 1972, AM NAT, V106, P1, DOI 10.1086/282747; GUO P, UNPUB; HAYMER DS, 1983, GENETICS, V104, P343; LENSKI RE, 1988, EVOLUTION, V42, P433, DOI 10.1111/j.1558-5646.1988.tb04150.x; Loeschcke V, 1987, GENETIC CONSTRAINTS; LUCKINBILL LS, 1978, SCIENCE, V202, P1201, DOI 10.1126/science.202.4373.1201; MAC ARTHUR ROBERT H., 1967; MACARTHUR RH, 1962, P NATL ACAD SCI USA, V48, P1893, DOI 10.1073/pnas.48.11.1893; MUELLER LD, 1988, P NATL ACAD SCI USA, V85, P4383, DOI 10.1073/pnas.85.12.4383; MUELLER LD, 1988, AM NAT, V132, P786, DOI 10.1086/284890; MUELLER LD, 1990, EVOL ECOL, V4, P290, DOI 10.1007/BF02270928; MUELLER LD, 1981, P NATL ACAD SCI-BIOL, V78, P1303, DOI 10.1073/pnas.78.2.1303; MUELLER LD, 1986, EVOLUTION, V40, P1354, DOI 10.1111/j.1558-5646.1986.tb05761.x; MUELLER LD, 1988, EVOLUTION, V42, P1090; REZNICK D, 1985, OIKOS, V44, P257, DOI 10.2307/3544698; ROSE MR, 1985, THEOR POPUL BIOL, V28, P342, DOI 10.1016/0040-5809(85)90034-6; ROSE MR, 1984, EVOLUTION, V38, P1004, DOI 10.1111/j.1558-5646.1984.tb00370.x; ROUGHGARDEN J, 1971, ECOLOGY, V52, P453, DOI 10.2307/1937628; Roughgarden J., 1979, THEORY POPULATION GE; TAYLOR CE, 1980, EVOLUTION, V34, P1183, DOI 10.1111/j.1558-5646.1980.tb04064.x	26	95	95	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 26	1991	253	5018					433	435		10.1126/science.1907401	http://dx.doi.org/10.1126/science.1907401			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FY288	1907401	Green Submitted			2022-12-01	WOS:A1991FY28800036
J	SANDGREN, EP; PALMITER, RD; HECKEL, JL; DAUGHERTY, CC; BRINSTER, RL; DEGEN, JL				SANDGREN, EP; PALMITER, RD; HECKEL, JL; DAUGHERTY, CC; BRINSTER, RL; DEGEN, JL			COMPLETE HEPATIC REGENERATION AFTER SOMATIC DELETION OF AN ALBUMIN-PLASMINOGEN ACTIVATOR TRANSGENE	CELL			English	Article							GROWTH-HORMONE; MOLECULAR-GENETICS; LIVER NEOPLASIA; MAMMARY-GLAND; FUSION GENES; MOUSE MODEL; TGF-ALPHA; MICE; EXPRESSION; CELL	We previously demonstrated that expression of an albumin-urokinase-type plasminogen activator (Alb-uPA) fusion construct in transgenic mice resulted in elevated plasma uPA concentration, hypofibrinogenemia, and neonatal hemorrhaging. Two lines of Alb-uPA mice were established in which only one half of the transgenic pups died at birth; surprisingly, plasma uPA concentrations in survivors gradually returned to normal by 2 months of age. The basis for this phenomenon is DNA rearrangement within hepatocytes that affects the transgene tandem array and abolishes transgene expression. Transgene-deficient cells selectively proliferate relative to surrounding liver, and this process culminates in replacement of the entire liver by clonal hepatic nodules derived from transgene-deficient progenitor cells. In some cases as few as two nodules can reconstitute over 90% of liver mass, highlighting the remarkable regenerative capacity of individual liver cells.	UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	SANDGREN, EP (corresponding author), UNIV PENN,SCH VET MED,REPROD PHYSIOL LAB,PHILADELPHIA,PA 19104, USA.			Brinster, Ralph/0000-0003-1408-7656	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD009172, R01HD009172] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA038635, R29CA044611] Funding Source: NIH RePORTER; NCI NIH HHS [CA44611, CA38635] Funding Source: Medline; NICHD NIH HHS [HD09172] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAKKER E, 1987, NATURE, V329, P554, DOI 10.1038/329554a0; BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; BRAUN RE, 1990, BIOL REPROD, V43, P684, DOI 10.1095/biolreprod43.4.684; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Brodsky W Y, 1977, Int Rev Cytol, V50, P275; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; CHISARI FV, 1985, SCIENCE, V230, P1157, DOI 10.1126/science.3865369; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; COLLEN D, 1987, MOL BASIS BLOOD DISE, P662; DANO K, 1985, ADV CANCER RES, V44, P149; DARRAS BT, 1987, NATURE, V329, P556, DOI 10.1038/329556a0; DEGEN SJF, 1990, GENOMICS, V8, P49, DOI 10.1016/0888-7543(90)90225-J; DYCAICO MJ, 1988, SCIENCE, V242, P1409, DOI 10.1126/science.3264419; FAUSTO N, 1990, HEPATOLOGY TXB LIVER, P49; HAMMER RE, 1985, COLD SPRING HARB SYM, V50, P379, DOI 10.1101/SQB.1985.050.01.048; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HECKEL JL, 1990, CELL, V62, P447, DOI 10.1016/0092-8674(90)90010-C; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; HETHCOTE HW, 1978, P NATL ACAD SCI USA, V75, P2453, DOI 10.1073/pnas.75.5.2453; HIGGS DR, 1989, BLOOD, V73, P1081; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; LEHRMAN MA, 1987, CELL, V48, P827, DOI 10.1016/0092-8674(87)90079-1; LISKAY RM, 1984, COLD SPRING HARB SYM, V49, P183, DOI 10.1101/SQB.1984.049.01.021; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; PALMITER RD, 1984, CELL, V36, P869, DOI 10.1016/0092-8674(84)90036-9; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; QUAIFE CJ, 1989, ENDOCRINOLOGY, V124, P40, DOI 10.1210/endo-124-1-40; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1989, ONCOGENE, V4, P715; SELL S, 1990, CANCER RES, V50, P3811; SEPERACK PK, 1988, P NATL ACAD SCI USA, V85, P189, DOI 10.1073/pnas.85.1.189; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SODA R, 1984, BLOOD, V63, P270; STOLZ A, 1990, HEPATOLOGY TXB LIVER, P637; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; VNENCAKJONES CL, 1990, SCIENCE, V250, P1745, DOI 10.1126/science.1980158; WILKIE TM, 1987, MOL CELL BIOL, V7, P1646, DOI 10.1128/MCB.7.5.1646; WILKIE TM, 1991, GENE DEV, V5, P38, DOI 10.1101/gad.5.1.38; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q	46	306	325	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					245	256		10.1016/0092-8674(91)90615-6	http://dx.doi.org/10.1016/0092-8674(91)90615-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1713128				2022-12-01	WOS:A1991FY71200006
J	SCHOLER, HR; CIESIOLKA, T; GRUSS, P				SCHOLER, HR; CIESIOLKA, T; GRUSS, P			A NEXUS BETWEEN OCT-4 AND E1A - IMPLICATIONS FOR GENE-REGULATION IN EMBRYONIC STEM-CELLS	CELL			English	Article							EUKARYOTIC TRANSCRIPTIONAL ACTIVATORS; EARLY MOUSE EMBRYOGENESIS; F9 TERATOCARCINOMA CELLS; OCTAMER BINDING-PROTEINS; HEAVY-CHAIN ENHANCER; REGION 1A PROTEINS; CARCINOMA-CELLS; ADENOVIRUS INFECTION; CELLULAR PROTEINS; ESCHERICHIA-COLI	Oct-4 is a transcription factor expressed in the pluripotent progenitor cells of the early mouse embryo. Additional factors are required for the distal activation of genes in differentiated cells containing ectopically expressed Oct-4. Here we show that Oct-4 and E1A are sufficient for distance-independent activation of the basal transcription machinery. The ratio of Oct-4 to E1A is critical for transcriptional activation, because higher levels of either factor are less efficient. Activation depends on a transactivation domain linked to the POU domain of Oct-4 and also on the conserved domain 3 of the 289R E1A protein. This domain is required for binding to the C-terminal part of Oct-4 including the POU domain. Our results indicate that E1A can serve as a bridging factor between Oct-4 and the basal initiation complex, and we postulate that an E1A-like factor acts as a cellular bridging factor of Oct-4 in pluripotent cells.			SCHOLER, HR (corresponding author), MAX PLANCK INST BIOPHYS CHEM, DEPT MOLEC CELL BIOL, W-3400 GOTTINGEN, GERMANY.			Scholer, Hans/0000-0003-2643-5136				BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BORRELLI E, 1986, P NATL ACAD SCI USA, V83, P2846, DOI 10.1073/pnas.83.9.2846; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BRAITHWAITE AW, 1991, NEW BIOL, V3, P18; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHELLAPPAN SP, 1990, P NATL ACAD SCI USA, V87, P5878, DOI 10.1073/pnas.87.15.5878; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; CROCE CM, 1981, P NATL ACAD SCI-BIOL, V78, P5754, DOI 10.1073/pnas.78.9.5754; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; GULP JS, 1988, P NATL ACAD SCI USA, V85, P6450; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1988, ANTIBODIES LABORATOR; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HEN R, 1986, NATURE, V321, P249, DOI 10.1038/321249a0; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KELLY F, 1982, BIOCHIM BIOPHYS ACTA, V651, P105, DOI 10.1016/0304-419X(82)90009-9; KEMLER I, 1990, FASEB J, V4, P1444, DOI 10.1096/fasebj.4.5.2407588; KO JL, 1986, EMBO J, V5, P1645, DOI 10.1002/j.1460-2075.1986.tb04407.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LILY W, 1987, NATURE, V326, P512, DOI 10.1038/326512a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MORELLO D, 1982, NATURE, V296, P260, DOI 10.1038/296260a0; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; NELSON CC, 1990, P NATL ACAD SCI USA, V87, P8041, DOI 10.1073/pnas.87.20.8041; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHOLER HR, 1984, CELL, V36, P403, DOI 10.1016/0092-8674(84)90233-2; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SCHOLER HR, 1991, IN PRESS TRENDS GENE; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber E., 1989, TISSUE SPECIFIC GENE, P33; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SLEIGH MJ, 1985, TRENDS GENET, V1, P17, DOI 10.1016/0168-9525(85)90009-5; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; SVENSSON C, 1984, EMBO J, V3, P789, DOI 10.1002/j.1460-2075.1984.tb01886.x; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VELCICH A, 1989, ONCOGENE, V4, P707; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	77	175	176	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 26	1991	66	2					291	304		10.1016/0092-8674(91)90619-A	http://dx.doi.org/10.1016/0092-8674(91)90619-A			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1830243	hybrid			2022-12-01	WOS:A1991FY71200010
J	SOLDATI, T; PERRIARD, JC				SOLDATI, T; PERRIARD, JC			INTRACOMPARTMENTAL SORTING OF ESSENTIAL MYOSIN LIGHT-CHAINS - MOLECULAR DISSECTION AND INVIVO MONITORING BY EPITOPE TAGGING	CELL			English	Article							SMOOTH MUSCLE ACTIN; FUNCTIONAL DOMAINS; CELL-SURFACE; LIVING CELLS; ER PROTEINS; FIBROBLASTS; EXPRESSION; ANTIBODIES; TRANSPORT; DIFFERENTIATION	The isoprotein-specific intracompartmental sorting of the three essential myosin light chains (LCs), the skeletal muscle LC-1f and LC-3f and the nonmuscle LC-3nm, was investigated. Epitope tagging was used to monitor the intracellular localization to different cytoskeletal structures of the exogenously introduced constructs in adult rat cardiomyocytes (ARCs), which exhibit both stress fibers and regenerating myofibrils. LC-1f and LC-3f bind almost exclusively to the sarcomeric myosin heavy chain (MHC) with high affinity, while the LC-3nm interacts with stress fibers and sarcomeres equally well. Sorting appears to be directed by a hierarchical order of different affinities. Domain mapping by deletion and by construction of a LC-1f/3nm chimera suggests that the LCs are composed of three functionally distinct domains: a basal MHC binding site in the C-terminus; the central part, modulating the preferential interaction with MHC isoforms; and the isoprotein-specific N-terminus of the essential LC, which is probably not involved in the sorting process.	SWISS FED INST TECHNOL,INST CELL BIOL,CH-8093 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			SOLDATI, Thierry/A-2902-2009; SOLDATI, Thierry/U-6494-2019	SOLDATI, Thierry/0000-0002-2056-7931; SOLDATI, Thierry/0000-0002-2056-7931				ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; BARTON PJR, 1988, J BIOL CHEM, V263, P12669; BARTON PJR, 1985, BIOCHEM J, V231, P249, DOI 10.1042/bj2310249; BENDORI R, 1989, J CELL BIOL, V108, P2383, DOI 10.1083/jcb.108.6.2383; BILLETER R, 1988, MOL CELL BIOL, V8, P1361, DOI 10.1128/MCB.8.3.1361; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CHAUSSEPIED P, 1989, NATURE, V342, P950, DOI 10.1038/342950a0; ENDO T, 1984, J CELL BIOL, V99, P2322, DOI 10.1083/jcb.99.6.2322; EPPENBERGER ME, 1988, DEV BIOL, V130, P1, DOI 10.1016/0012-1606(88)90408-3; EPPENBERGEREBERHARDT M, 1990, DEV BIOL, V139, P269, DOI 10.1016/0012-1606(90)90296-U; FRIEDERICH E, 1989, CELL, V59, P461, DOI 10.1016/0092-8674(89)90030-5; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; GAUTHIER GF, 1990, J CELL BIOL, V110, P693, DOI 10.1083/jcb.110.3.693; GELI V, 1988, P NATL ACAD SCI USA, V85, P689, DOI 10.1073/pnas.85.3.689; GROVE BK, 1984, J CELL BIOL, V98, P518, DOI 10.1083/jcb.98.2.518; HAILSTONES DL, 1990, MOL CELL BIOL, V10, P1095, DOI 10.1128/MCB.10.3.1095; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; KREIS TE, 1980, CELL, V22, P555, DOI 10.1016/0092-8674(80)90365-7; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LAMSON G, 1989, DEV BIOL, V132, P62, DOI 10.1016/0012-1606(89)90204-2; LENNETTE DA, 1978, AM J CLIN PATHOL, V69, P647; MCKENNA N, 1985, J CELL BIOL, V100, P292, DOI 10.1083/jcb.100.1.292; MITTAL B, 1987, J CELL BIOL, V105, P1753, DOI 10.1083/jcb.105.4.1753; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MUNRO S, 1984, EMBO J, V3, P3087, DOI 10.1002/j.1460-2075.1984.tb02263.x; NGAI J, 1990, CELL, V60, P415, DOI 10.1016/0092-8674(90)90593-4; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; SANGER JM, 1986, J CELL BIOL, V102, P2053, DOI 10.1083/jcb.102.6.2053; SANGER JW, 1984, J CELL BIOL, V98, P825, DOI 10.1083/jcb.98.3.825; SCHAFER BW, 1988, J CELL BIOL, V106, P1161, DOI 10.1083/jcb.106.4.1161; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; SOLDATI T, 1990, J BIOL CHEM, V265, P4498; WEBER F, 1984, CELL, V36, P983, DOI 10.1016/0092-8674(84)90048-5; WEEDS AG, 1971, J MOL BIOL, V61, P701, DOI 10.1016/0022-2836(71)90074-X; YEE JK, 1987, GENE, V53, P97, DOI 10.1016/0378-1119(87)90096-5	37	80	81	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					277	289		10.1016/0092-8674(91)90618-9	http://dx.doi.org/10.1016/0092-8674(91)90618-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1713129	Green Published			2022-12-01	WOS:A1991FY71200009
J	AYANIAN, JZ; EPSTEIN, AM				AYANIAN, JZ; EPSTEIN, AM			DIFFERENCES IN THE USE OF PROCEDURES BETWEEN WOMEN AND MEN HOSPITALIZED FOR CORONARY HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; ARTERY BYPASS-SURGERY; LONG-TERM; SEX-DIFFERENCES; UNITED-STATES; MORTALITY; SURVIVAL; GENDER; CASS; TRANSPLANTATION	Background and Methods. Previous studies at individual hospitals have reported differences in the use of major diagnostic and therapeutic procedures for women and men with coronary heart disease. To assess whether these differences can be generalized, we performed retrospective analyses of coronary angiography and revascularization (coronary-artery bypass surgery or percutaneous transluminal coronary angioplasty) in women and men hospitalized for coronary heart disease in 1987, using abstract data on 49,623 discharges in Massachusetts and 33,159 discharges in Maryland. We used multiple logistic regression to estimate the adjusted odds of the use of a procedure, controlling for principal diagnosis, age, secondary diagnosis of congestive heart failure or diabetes mellitus, race, and insurance status. Results. The adjusted odds of undergoing angiography were 28 percent and 15 percent higher for men than for women in Massachusetts and Maryland, respectively (95 percent confidence intervals for the odds ratios, 1.22 to 1.35 and 1.08 to 1.22). The respective adjusted odds of undergoing revascularization were 45 percent and 27 percent higher for men than for women (95 percent confidence intervals, 1.35 to 1.55 and 1.16 to 1.40). Because these differences could be related to differing thresholds for hospital admission, we performed a second analysis limited to patients with diagnosed acute myocardial infarction (11,865 discharges in Massachusetts and 6894 discharges in Maryland), a group in which all patients would be expected to receive hospital care. The male-to-female odds ratios in both states remained similar in magnitude and were statistically significant for angiography and revascularization. Conclusions. These findings demonstrate that women who are hospitalized for coronary heart disease undergo fewer major diagnostic and therapeutic procedures than men. These differences may represent appropriate levels of care for men and women, but it is also possible that they reflect underuse in women or overuse in men. Further study should assess the cause of these differences and their effect on patients' outcomes.	HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B,1ST FLOOR,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health					AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P01HS006341] Funding Source: NIH RePORTER; AHRQ HHS [1 PO1 HS 06341] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADLER DS, 1986, AM J CARDIOL, V58, P195, DOI 10.1016/0002-9149(86)90046-9; BROGAN D, 1988, NEW ENGL J MED, V319, P55; BROOK RH, 1990, NEW ENGL J MED, V323, P1173, DOI 10.1056/NEJM199010253231705; CHAITMAN BR, 1981, CIRCULATION, V64, P360, DOI 10.1161/01.CIR.64.2.360; CHIRIKOS TN, 1984, WOMEN HEALTH, V9, P55, DOI 10.1300/J013v09n01_05; CHRISTAKIS GT, 1989, CIRCULATION, V80, P151; COWLEY MJ, 1985, CIRCULATION, V71, P90, DOI 10.1161/01.CIR.71.1.90; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; DOUGLAS JS, 1981, CIRCULATION, V64, P11; EAKER ED, 1989, AM HEART J, V117, P71, DOI 10.1016/0002-8703(89)90658-3; ELVEBACK LR, 1986, MAYO CLIN PROC, V61, P896, DOI 10.1016/S0025-6196(12)62612-3; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; FISHER LD, 1982, J THORAC CARDIOV SUR, V84, P334; GARDNER TJ, 1985, ANN SURG, V201, P780, DOI 10.1097/00000658-198506000-00016; GILLUM RF, 1987, AM HEART J, V113, P1255, DOI 10.1016/0002-8703(87)90952-5; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; HLATKY MA, 1988, AM J CARDIOL, V61, P515, DOI 10.1016/0002-9149(88)90756-4; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JOHANSSON S, 1984, EUR HEART J, V5, P374, DOI 10.1093/oxfordjournals.eurheartj.a061671; KANNEL WB, 1990, HEART ARTERIES VEINS, P627; KENNEDY RH, 1982, NEW ENGL J MED, V307, P986, DOI 10.1056/NEJM198210143071605; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KJELLSTRAND CM, 1987, NEPHRON, V45, P257, DOI 10.1159/000184160; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; PRYOR DB, 1983, ANN INTERN MED, V99, P528, DOI 10.7326/0003-4819-99-4-528; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; WENGER NK, 1990, ANN INTERN MED, V112, P557, DOI 10.7326/0003-4819-112-8-557	31	942	952	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 25	1991	325	4					221	225		10.1056/NEJM199107253250401	http://dx.doi.org/10.1056/NEJM199107253250401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX627	2057022				2022-12-01	WOS:A1991FX62700001
J	DAVIES, TF; MARTIN, A; CONCEPCION, ES; GRAVES, P; COHEN, L; BENNUN, A				DAVIES, TF; MARTIN, A; CONCEPCION, ES; GRAVES, P; COHEN, L; BENNUN, A			EVIDENCE OF LIMITED VARIABILITY OF ANTIGEN RECEPTORS ON INTRATHYROIDAL T-CELLS IN AUTOIMMUNE THYROID-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYELIN BASIC-PROTEIN; GRAVES-DISEASE; ANTITHYROID DRUGS; CLONES; LYMPHOCYTES; ENCEPHALOMYELITIS; THYROGLOBULIN; HETEROGENEITY; TRANSCRIPTS; LINES	Background. Patients with autoimmune thyroid diseases, including Graves' disease and Hashimoto's disease, have marked lymphocytic infiltration in their thyroid glands. We examined the gene for the variable regions of the alpha-chain of the human T-cell receptor (the V-alpha gene) in intrathyroidal T cells to determine whether the infiltration is a secondary heterogeneous immune response or a more restricted, and therefore primary and presumably pathogenetic, reaction to thyroid autoantigens. Methods. We used the polymerase chain reaction to detect small numbers of T cells expressing the variable region of the V-alpha gene. Different oligonucleotides were used to amplify complementary DNA for the 18 known families of the V-alpha gene in intrathyroidal T cells from 9 patients with autoimmune thyroid disease. We compared the findings with the results in patients with nonautoimmune thyroid disease as well as those in normal subjects. Results. We found marked restriction in the expression of T-cell-receptor V-alpha genes by T cells from the thyroid tissue of patients with autoimmune thyroid disease. An average of only 5 of the 18 V-alpha genes were expressed in such samples, as compared with 17 V-alpha genes expressed in peripheral-blood T cells from the same patients. No such restriction was found in thyroid tissue from patients with nonautoimmune thyroid disease. The predominantly expressed V-alpha genes differed from patient to patient, however, with no clear association with the type of disease. Conclusions. Intrathyroidal T-cell accumulation in autoimmune thyroid disease is highly restricted and points to the primacy of T cells in causing thyroid disorders. These results present the possibility of using antibodies to the T-cell receptor for the specific inhibition of abnormal T-cell function in autoimmune thyroid disease.	CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029; WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Weizmann Institute of Science					NIDDK NIH HHS [DK28243, DK35764] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035764, R01DK028243] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; BENNUN A, 1991, P NATL ACAD SCI USA, V88, P2466, DOI 10.1073/pnas.88.6.2466; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; FISFALEN ME, 1988, J CLIN ENDOCR METAB, V66, P776, DOI 10.1210/jcem-66-4-776; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOODMAN MG, 1982, B LYMPHOCYTES TODAY, P63; JANSSON R, 1983, J CLIN ENDOCR METAB, V56, P1164, DOI 10.1210/jcem-56-6-1164; KIMURA H, 1991, CLIN IMMUNOL IMMUNOP, V58, P195, DOI 10.1016/0090-1229(91)90136-X; LONDEI M, 1985, SCIENCE, V228, P85, DOI 10.1126/science.3871967; MACKENZIE WA, 1987, IMMUNOLOGY, V61, P101; MACKENZIE WA, 1987, J CLIN ENDOCR METAB, V64, P818, DOI 10.1210/jcem-64-4-818; MARGOLICK JB, 1984, AM J MED, V76, P815, DOI 10.1016/0002-9343(84)90992-6; MARON R, 1983, J IMMUNOL, V131, P2316; MARTIN A, 1990, AUTOIMMUNITY, V6, P269, DOI 10.3109/08916939008998419; MOEBIUS U, 1990, EUR J IMMUNOL, V20, P889, DOI 10.1002/eji.1830200426; OKSENBERG JR, 1990, NATURE, V345, P344, DOI 10.1038/345344a0; ROMAN SH, 1984, CLIN CHEM, V30, P246; ROMBALL CG, 1987, J IMMUNOL, V138, P1092; SPINELLA DG, 1987, J IMMUNOL, V138, P3991; VOLPE R, 1986, CLIN ENDOCRINOL, V25, P453, DOI 10.1111/j.1365-2265.1986.tb01712.x; WEISS I, 1981, J CLIN ENDOCR METAB, V53, P1223, DOI 10.1210/jcem-53-6-1223; WUCHERPFENNIG KW, 1990, SCIENCE, V248, P1016, DOI 10.1126/science.1693015	22	212	213	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 25	1991	325	4					238	244		10.1056/NEJM199107253250404	http://dx.doi.org/10.1056/NEJM199107253250404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX627	1829139	Bronze			2022-12-01	WOS:A1991FX62700004
J	DIETZ, HC; CUTTING, GR; PYERITZ, RE; MASLEN, CL; SAKAI, LY; CORSON, GM; PUFFENBERGER, EG; HAMOSH, A; NANTHAKUMAR, EJ; CURRISTIN, SM; STETTEN, G; MEYERS, DA; FRANCOMANO, CA				DIETZ, HC; CUTTING, GR; PYERITZ, RE; MASLEN, CL; SAKAI, LY; CORSON, GM; PUFFENBERGER, EG; HAMOSH, A; NANTHAKUMAR, EJ; CURRISTIN, SM; STETTEN, G; MEYERS, DA; FRANCOMANO, CA			MARFAN-SYNDROME CAUSED BY A RECURRENT DENOVO MISSENSE MUTATION IN THE FIBRILLIN GENE	NATURE			English	Article							DINUCLEOTIDE REPEAT POLYMORPHISM; POLYMERASE CHAIN-REACTION; DNA POLYMORPHISMS; CHROMOSOME-15; DUCHENNE; LOCUS	MARFAN syndrome is an inherited disorder of connective tissue manifested in the ocular, skeletal and cardiovascular systems. It is inherited as an autosomal dominant with high penetrance, but has great clinical variability 1. Linkage studies have mapped the Marfan locus to chromosome 15q15-21.3 (refs 2, 3). There have been no reports of genetic heterogeneity in the syndrome. Following the identification of fibrillin (a glycoprotein component of the extracellular microfibril 4), immunohistopathological quantification of the protein in skin and fibroblast culture 5, and examination of fibrillin synthesis, extracellular transport, and incorporation into the extracellular matrix (D. M. Milewicz, R.E.P., E. S. Crawford and P.H. Byers, manuscript in preparation) have demonstrated abnormalities of fibrillin metabolism in most patients. A portion of the complementary DNA encoding fibrillin has been cloned 6 and mapped by in situ hybridization to chromosome 15 (ref. 7). Here we report that the fibrillin gene is linked to the Marfan phenotYPe (theta = 0.00; logarithm of the odds (lod) = (3.9) and describe a de novo missense mutation in the fibrillin gene in two patients with sporadic disease. We thus implicate fibrillin as the protein defective in patients with the Marfan syndrome.	OREGON HLTH SCI UNIV, SHRINERS HOSP CRIPPLED CHILDREN, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, CTR MED GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, CTR MED GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT GYNECOL & OBSTET, CTR MED GENET, BALTIMORE, MD 21205 USA	Oregon Health & Science University; Oregon Health & Science University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	DIETZ, HC (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, DIV PEDIAT CARDIOL, BALTIMORE, MD 21205 USA.		Pyeritz, Reed/A-1364-2010	Puffenberger, Erik/0000-0002-6388-9148				BOUDOULAS H, 1988, MITRAL VALVE PROLAPS, P161; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; DENDUNNEN JT, 1987, NATURE, V329, P640, DOI 10.1038/329640a0; DIETZ HC, 1991, GENOMICS, V9, P355, DOI 10.1016/0888-7543(91)90264-F; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; FORREST SM, 1987, NATURE, V329, P638, DOI 10.1038/329638a0; HIGUCHI M, IN PRESS P NATN ACAD; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P152, DOI 10.1056/NEJM199007193230303; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; MAGENIS RE, IN PRESS GENOMICS; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; NAKAMURA Y, 1988, GENOMICS, V3, P342, DOI 10.1016/0888-7543(88)90125-5; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PYERITZ RE, 1979, NEW ENGL J MED, V300, P772, DOI 10.1056/NEJM197904053001406; SAIKI RK, 1988, NEW ENGL J MED, V319, P537, DOI 10.1056/NEJM198809013190903; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sambrook J., 1989, MOL CLONING; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4637, DOI 10.1093/nar/18.15.4637; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P2202	22	1479	1533	3	134	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					337	339		10.1038/352337a0	http://dx.doi.org/10.1038/352337a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852208				2022-12-01	WOS:A1991FY28900071
J	GOLDSTEIN, DJ; FINBOW, ME; ANDRESSON, T; MCLEAN, P; SMITH, K; BUBB, V; SCHLEGEL, R				GOLDSTEIN, DJ; FINBOW, ME; ANDRESSON, T; MCLEAN, P; SMITH, K; BUBB, V; SCHLEGEL, R			BOVINE PAPILLOMAVIRUS-E5 ONCOPROTEIN BINDS TO THE 16K COMPONENT OF VACUOLAR H+-ATPASES	NATURE			English	Article							OPEN READING FRAME; TRANSFORMING ACTIVITY; GAP-JUNCTIONS; E5; PROTEIN; GENE; LOCALIZATION; POLYPEPTIDE; MEMBRANES; ENCODES	THE major transforming protein of bovine papillomavirus type 1, E5 (refs 1-4), is mainly associated with endomembranes 5,6, specifically binding to a cellular protein of relative molecular mass 16,000 (16K) (ref. 7). At the same time as transformation, E5 causes the phosphorylation of tyrosine residues in epidermal and platelet-derived growth factor receptors 8,9. We show here that the 16K protein associated with E5 is the 16K component of vacuolar ATPases. This protein is known to be an integral membrane protein in endosomes, bovine chromaffin granules, synaptic vesicles, fungal and plant vacuoles and clathrin-coated vesicles 10-16, as well as a component of gap-junction-like membrane complexes 17. Because proton pumps are critical for the function of cellular compartments that process growth-factor receptors, the interaction of E5 with the 16K protein could explain the pleiomorphic features of cells transformed by E5.	BEATSON INST CANC RES,GLASGOW G61 1BD,SCOTLAND	Beatson Institute	GOLDSTEIN, DJ (corresponding author), GEORGETOWN UNIV,DEPT PATHOL,WASHINGTON,DC 20007, USA.							ARAI H, 1987, J BIOL CHEM, V262, P11006; BIRMAN S, 1990, FEBS LETT, V261, P303, DOI 10.1016/0014-5793(90)80577-6; BOWMAN EJ, 1983, J BIOL CHEM, V258, P5238; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; BUULTJENS TEJ, 1988, CELL TISSUE RES, V251, P571, DOI 10.1007/BF00214005; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; FINBOW ME, 1984, EMBO J, V3, P2271, DOI 10.1002/j.1460-2075.1984.tb02125.x; GOLDSTEIN DJ, 1990, EMBO J, V9, P137, DOI 10.1002/j.1460-2075.1990.tb08089.x; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEITCH B, 1990, EXP CELL RES, V190, P218, DOI 10.1016/0014-4827(90)90189-H; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MEAGHER L, 1990, NUCLEIC ACIDS RES, V18, P22; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; RANDALL SK, 1986, J BIOL CHEM, V261, P1364; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SETTLEMAN J, 1988, P NATL ACAD SCI USA, V85, P9007, DOI 10.1073/pnas.85.23.9007; SUN SZ, 1987, J BIOL CHEM, V262, P14790; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; YANG YC, 1985, P NATL ACAD SCI USA, V82, P1030, DOI 10.1073/pnas.82.4.1030	26	172	177	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					347	349		10.1038/352347a0	http://dx.doi.org/10.1038/352347a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1649407				2022-12-01	WOS:A1991FY28900075
J	HACK, M; BRESLAU, N; WEISSMAN, B; ARAM, D; KLEIN, N; BORAWSKI, E				HACK, M; BRESLAU, N; WEISSMAN, B; ARAM, D; KLEIN, N; BORAWSKI, E			EFFECT OF VERY-LOW-BIRTH-WEIGHT AND SUBNORMAL HEAD SIZE ON COGNITIVE-ABILITIES AT SCHOOL AGE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH ACHIEVEMENT; POSTNATAL-GROWTH; BRAIN GROWTH; INFANTS; CHILDREN; CIRCUMFERENCE; INTELLIGENCE; INTRAUTERINE; RETARDATION; FAILURE	Background. We tested the hypothesis that very-low-birth-weight (< 1.5 kg) infants with perinatal growth failure whose head size is not normal by eight months of age (corrected for prematurity) have significantly poorer growth and neurocognitive abilities at school age. than very-low-birth-weight children with a normal head size at eight months. We also hypothesized that these differences would persist even after control for major neurologic impairment and perinatal and sociodemographic risk factors. Methods. We have followed a cohort of very-low-birth-weight children since their birth during the period 1977 to 1979. At eight to nine years of age 249 children were evaluated with a neurologic examination and tests of intelligence; receptive and expressive language skills; speech, reading, mathematics, and spelling aptitude; visual and fine motor abilities; and behavior. Ages were corrected for premature birth. Results. Among these 249 very-low-birth-weight children, head size was subnormal (less than the mean -2 SD for age) at birth in 30 (12 percent), at term in 57 (23 percent), and at eight months in 33 (13 percent). As compared with the 216 children with normal head sizes, the 33 children with subnormal head sizes at the age of eight months had significantly lower mean birth weights (1.1 vs. 1.2 kg) and higher neonatal risk scores (71 vs. 53) and at the age of eight years had a higher incidence of neurologic impairment (21 percent vs. 8 percent) and lower IQ scores (mean verbal, 84 vs. 98). Even among the children without neurologic abnormalities, a subnormal head size at eight months of age was predictive of poorer verbal and performance IQ scores at eight years of age; lower scores for receptive language, speech, reading, mathematics, and spelling; and a higher incidence of hyperactivity. In multiple regression analyses to control for socioeconomic and neonatal risk factors, intrauterine growth failure, birth weight, and neurologic impairment, a subnormal head size at eight months of age had an independently adverse effect on IQ and on scores for receptive language, speech, reading, and spelling. Conclusions. In very-low-birth-weight infants, perinatal growth failure, as evidenced by a subnormal head circumference at eight months of age, is associated with poor cognitive function, academic achievement, and behavior at eight years of age.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PEDIAT, CLEVELAND, OH 44106 USA; HENRY FORD HOSP, DEPT PSYCHIAT, DETROIT, MI 48202 USA; HENRY FORD HOSP, DEPT BIOSTAT & RES EPIDEMIOL, DETROIT, MI 48202 USA; UNIV MICHIGAN, SCH MED, DEPT PSYCHIAT, ANN ARBOR, MI 48104 USA; EMORY UNIV, SCH MED, DEPT PEDIAT, ATLANTA, GA 30322 USA; CLEVELAND STATE UNIV, DEPT SPECIAL EDUC, CLEVELAND, OH 44115 USA	Case Western Reserve University; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; University of Michigan System; University of Michigan; Emory University; University System of Ohio; Cleveland State University			Breslau, Naomi/I-3196-2012; Borawski, Elaine/R-9959-2019	Borawski, Elaine/0000-0001-7629-6889; Aram, Dorit/0000-0002-0984-7297	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020057] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD20057] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ASTBURY J, 1986, DEV MED CHILD NEUROL, V28, P472; BABSON SG, 1969, AM J DIS CHILD, V117, P553, DOI 10.1001/archpedi.1969.02100030555009; BEARGIE RA, 1970, PEDIATR CLIN N AM, V17, P159; BERG AT, 1989, EARLY HUM DEV, V19, P271, DOI 10.1016/0378-3782(89)90062-5; BRANDT I, 1985, ACTA PAEDIATR SCAND, P38; BRAY PF, 1969, J PEDIATR, V75, P303, DOI 10.1016/S0022-3476(69)80404-X; Broman SH., 1975, PRESCHOOL IQ; Cravioto J., 1986, HUMAN GROWTH, V3, P501; DENCKLA MB, 1976, NEUROPSYCHOLOGIA, V14, P471, DOI 10.1016/0028-3932(76)90075-0; DiSimoni F., 1978, TOKEN TEST CHILDREN; DOBBING J, 1987, EARLY NUTRITION LATE; ELSON KB, 1970, DEV MED CHILD NEUROL, V12, P487; FANCOURT R, 1976, BMJ-BRIT MED J, V1, P1435, DOI 10.1136/bmj.1.6023.1435; Fletcher S.G., 1978, FLETCHER TIME BY COU; GALLER JR, 1984, HUMAN NUTRITION COMP, V5, P63; GILLBERG C, 1982, DEV MED CHILD NEUROL, V24, P752; GROSS RT, 1990, JAMA-J AM MED ASSOC, V263, P3035; HACK M, 1986, PEDIATRICS, V77, P196; HACK M, 1984, AM J DIS CHILD, V138, P370, DOI 10.1001/archpedi.1984.02140420036013; HACK M, 1991, PEDIATRICS, V87, P587; HACK M, 1989, AM J DIS CHILD, V143, P63, DOI 10.1001/archpedi.1989.02150130073018; HACK M, 1982, AM J OBSTET GYNECOL, V143, P693, DOI 10.1016/0002-9378(82)90117-X; HOBEL CJ, 1973, AM J OBSTET GYNECOL, V117, P1; Jastak S, 1984, WIDE RANGE ACHIEVEME; KOPPITZ EM, 1975, BENDER GESTALT TEST, V2; LIPPER E, 1981, PEDIATRICS, V67, P502; MARTIN HP, 1970, AM J DIS CHILD, V119, P128, DOI 10.1001/archpedi.1970.02100050130007; OUNSTED MK, 1984, EARLY HUM DEV, V9, P323, DOI 10.1016/0378-3782(84)90077-X; Pendergast K, 1969, PHOTO ARTICULATION T; PRYOR HB, 1967, CLIN PEDIATR, V6, P501, DOI 10.1177/000992286700600819; ROCHE AF, 1987, PEDIATRICS, V79, P706; ROSS G, 1983, J PEDIATR-US, V103, P105, DOI 10.1016/S0022-3476(83)80791-4; ROSS G, 1990, J PEDIATR-US, V117, P307, DOI 10.1016/S0022-3476(05)80552-9; SELLS CJ, 1977, PEDIATRICS, V59, P262; SEMELMINTZ E, 1982, CIN EVALUATION LANGU; SMITH RD, 1981, DEV MED CHILD NEUROL, V23, P626; STOCH MB, 1982, DEV MED CHILD NEUROL, V24, P419; TUDEHOPE DI, 1983, AUST PAEDIATR J, V19, P3; USHER R, 1969, J PEDIATR-US, V74, P901, DOI 10.1016/S0022-3476(69)80224-6; Wechsler D., 1997, WECHSLER INTELLIGENC; WEINBERG WA, 1974, J PEDIATR-US, V85, P482, DOI 10.1016/S0022-3476(74)80449-X; WILSON B C, 1982, Journal of Clinical Neuropsychology, V4, P19, DOI 10.1080/01688638208401113; WINGERD J, 1971, PEDIATRICS, V47, P818; WINICK M, 1969, J PEDIATR, V74, P667, DOI 10.1016/S0022-3476(69)80129-0; Woodcock R., 2011, WOODCOCK READING MAS, Vthird; Woodcock R.W., 1977, WOODCOCK JOHNSON PSY	47	386	394	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 25	1991	325	4					231	237		10.1056/NEJM199107253250403	http://dx.doi.org/10.1056/NEJM199107253250403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX627	2057024				2022-12-01	WOS:A1991FX62700003
J	HAMPTON, RY; GOLENBOCK, DT; PENMAN, M; KRIEGER, M; RAETZ, CRH				HAMPTON, RY; GOLENBOCK, DT; PENMAN, M; KRIEGER, M; RAETZ, CRH			RECOGNITION AND PLASMA-CLEARANCE OF ENDOTOXIN BY SCAVENGER RECEPTORS	NATURE			English	Article							LOW-DENSITY-LIPOPROTEIN; ESCHERICHIA-COLI LIPOPOLYSACCHARIDE; A-BINDING-SITES; CHOLESTEROL DEPOSITION; PERITONEAL-MACROPHAGES; RAT-LIVER; CELLS; PROTEIN; DEGRADATION; METABOLISM	LIPID A is the active moiety of lipopolysaccharide (LPS, also referred to as endotoxin), a surface component of Gram-negative bacteria that stimulates macrophage activation and causes endotoxic shock 1,2. Macrophages can bind, internalize and partially degrade LPS, lipid A and its bioactive precursor, lipid IV(A) (refs 3-7). We report here that lipid IV(A) binding and subsequent metabolism to a less active form by macrophage-like RAW 264.7 cells is mediated by the macrophage scavenger receptor. Scavenger-receptor ligands inhibit lipid IV(A) binding to, and metabolism by, RAW cells, and lipid IV(A) binds to type I and type II bovine scavenger receptors on transfected Chinese hamster ovary cells. Although in vitro competition studies with RAW cells indicate that scavenger receptor binding is not involved in LPS or lipid IV(A)-induced stimulation of macrophages, in vivo studies show that scavenger-receptor ligands greatly inhibit hepatic uptake of lipid IV(A) in mice. Thus, scavenger receptors expressed on macrophages may have an important role in the clearance and detoxification of endotoxin in animals.	MERCK SHARP & DOHME LTD,DEPT BIOCHEM,RAHWAY,NJ 07065; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Merck & Company; Massachusetts Institute of Technology (MIT)	HAMPTON, RY (corresponding author), UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706, USA.							BEUTLER B, 1988, BIOCHEMISTRY-US, V27, P7575, DOI 10.1021/bi00420a001; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; DRESEL HA, 1987, EMBO J, V6, P319, DOI 10.1002/j.1460-2075.1987.tb04757.x; DUNCAN RL, 1984, J IMMUNOL, V132, P1416; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; FREUDENBERG MA, 1984, REV INFECT DIS, V6, P483; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOLENBOCK DT, 1990, INFECT IMMUN, V58, P4069, DOI 10.1128/IAI.58.12.4069-4075.1990; HAMILTON TA, 1990, J IMMUNOL, V144, P2343; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; HARA H, 1987, BIOCHEM BIOPH RES CO, V146, P802, DOI 10.1016/0006-291X(87)90601-2; KAPLAN HM, 1983, MOUSE BIOMEDICAL RES, V3, P248; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; PETERSON AA, 1987, INFECT IMMUN, V55, P974, DOI 10.1128/IAI.55.4.974-978.1987; PITAS RE, 1985, J CELL BIOL, V100, P103, DOI 10.1083/jcb.100.1.103; PITAS RE, 1990, J BIOL CHEM, V265, P12722; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1988, COLD SPRING HARB SYM, V53, P973, DOI 10.1101/SQB.1988.053.01.112; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	30	474	491	2	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					342	344		10.1038/352342a0	http://dx.doi.org/10.1038/352342a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852209				2022-12-01	WOS:A1991FY28900073
J	HIGUCHI, H; GOLDMAN, YE				HIGUCHI, H; GOLDMAN, YE			SLIDING DISTANCE BETWEEN ACTIN AND MYOSIN-FILAMENTS PER ATP MOLECULE HYDROLYZED IN SKINNED MUSCLE-FIBERS	NATURE			English	Article							FROG-MUSCLE; STEP SIZE; FIBERS; RABBIT; ADENOSINE-5'-TRIPHOSPHATE; GENERATION; MOVEMENT; FORCE; ASSAY; RIGOR	MUSCLE contraction is generally thought to be driven by tilting 1,2 of the 19-nm-long myosin head 3, part of the thick filament, while attached to actin, part of the thin filament. This motion would produce about 12 nm of filament sliding 4,5. Recent estimates of the sliding distance per ATP molecule hydrolysed by actomyosin in vitro vary widely from 8 nm (ref. 6) to greater-than-or-equal-to 200 nm (ref. 7). The latter value is incompatible with a power stroke incorporating a single tilting motion of the head. We have measured the isotonic sliding distance per ATP molecule hydrolysed during the interaction between myosin and actin in skinned muscle fibres. We directly estimated the proportion of simultaneously attached actomyosin complexes and their ATP use. We report here that at low loads the interaction distance is at least 40 nm. This distance corresponds to the length of the power stroke plus the filament sliding while actomyosin crossbridges bear negative drag forces 5,8. If the power stroke is 12 nm, then our results indicate the drag distance to be at least 28 nm. Our results could also be explained by multiple power strokes per ATP molecule hydrolysed.	UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104; UNIV PENN,PENN MUSCLE INST,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania								Cecchi G, 1976, Boll Soc Ital Biol Sper, V52, P733; ELLIOTT A, 1978, J MOL BIOL, V123, P505, DOI 10.1016/0022-2836(78)90204-8; FERENCZI MA, 1984, J PHYSIOL-LONDON, V352, P575, DOI 10.1113/jphysiol.1984.sp015311; FORD LE, 1977, J PHYSIOL-LONDON, V269, P441, DOI 10.1113/jphysiol.1977.sp011911; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V354, P605, DOI 10.1113/jphysiol.1984.sp015395; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V354, P577, DOI 10.1113/jphysiol.1984.sp015394; GOLDMAN YE, 1987, BIOPHYS J, V52, P57, DOI 10.1016/S0006-3495(87)83188-0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY AF, 1973, COLD SPRING HARB SYM, V37, P669, DOI 10.1101/SQB.1973.037.01.081; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; TAWADA K, 1984, BIOPHYS J, V45, P593, DOI 10.1016/S0006-3495(84)84197-1; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0	20	92	92	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					352	354		10.1038/352352a0	http://dx.doi.org/10.1038/352352a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852212				2022-12-01	WOS:A1991FY28900077
J	ISHIJIMA, A; DOI, T; SAKURADA, K; YANAGIDA, T				ISHIJIMA, A; DOI, T; SAKURADA, K; YANAGIDA, T			SUB-PICONEWTON FORCE FLUCTUATIONS OF ACTOMYOSIN INVITRO	NATURE			English	Article							SINGLE KINESIN MOLECULES; ACTIN-FILAMENTS; MUSCLE-CONTRACTION; SLIDING FILAMENTS; MYOSIN; MOVEMENT; MECHANISM; MOTION; DIRECTION; VELOCITY	A new system has been developed for measuring the forces produced by a small number (< 5-150) of myosin molecules interacting with a single actin filament in vitro. The technique can resolve forces of less than a piconewton and has a time resolution in the submillisecond range. It can thus detect fluctuations of force caused by individual molecular interactions. From analysis of these force fluctuations, the coupling between the enzymatic ATPase activity of actomyosin and the resulting mechanical impulses can be elucidated.	OSAKA UNIV,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN; HONDA RES & DEV CO,WAKO RES CTR,WAKO,SAITAMA,JAPAN	Osaka University; Honda Motor Company			Yanagida, Toshio/D-1919-2009; Ishijima, Akihiko/F-4603-2012	Ishijima, Akihiko/0000-0002-8919-9268				BAGSHAW CR, 1990, J MUSCLE RES CELL M, V11, P533, DOI 10.1007/BF01745220; BAGSHAW CR, 1982, MUSCLE CONTRACTION; BERGER CL, 1989, P NATL ACAD SCI USA, V86, P8753, DOI 10.1073/pnas.86.22.8753; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BOREJDO J, 1977, BIOPHYS J, V20, P315, DOI 10.1016/S0006-3495(77)85552-5; BRENNER B, 1990, TOPICS MOL STRUCT BI, V13, P78; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; CRAWFORD AC, 1985, J PHYSIOL-LONDON, V364, P359, DOI 10.1113/jphysiol.1985.sp015750; EBASHI S, 1991, ANNU REV PHYSIOL, V53, P1, DOI 10.1146/annurev.ph.53.030191.000245; EISENBERG E, 1980, ANNU REV PHYSIOL, V42, P293, DOI 10.1146/annurev.ph.42.030180.001453; FUJME S, 1985, J CELL BIOL, V101, P2335; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HIBBERD MG, 1986, ANNU REV BIOPHYS BIO, V15, P119; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; IRVING M, 1985, NATURE, V316, P292, DOI 10.1038/316292a0; KAMIMURA S, 1989, NATURE, V340, P476, DOI 10.1038/340476a0; KATZ B, 1971, NATURE-NEW BIOL, V232, P124, DOI 10.1038/newbio232124b0; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KWAZUMI T, 1987, AM J PHYSIOL, V252, P253; LANDAU L, 1969, STATISTICAL PHYSICS, pCH4; LEE YW, 1969, STAT THEORY COMMUNIC, pCH8; MEISTER M, 1989, BIOPHYS J, V55, P904; MITSUI T, 1988, J MUSCLE RES CELL M, V9, P248, DOI 10.1007/BF01773895; OHNO T, IN PRESS J PHYOL; Oosawa F, 1986, Adv Biophys, V22, P151, DOI 10.1016/0065-227X(86)90005-5; Perrin F, 1934, J PHYS-PARIS, V5, P497, DOI 10.1051/jphysrad:01934005010049700; SELLERS JR, 1990, SCIENCE, V249, P406, DOI 10.1126/science.2377894; SPUDICH JA, 1990, NATURE, V348, P284, DOI 10.1038/348284a0; STEVENS CF, 1972, BIOPHYS J, V12, P1028, DOI 10.1016/S0006-3495(72)86141-1; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TONOMURA Y, 1986, ENERGY TRANSDUCING A; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I; YAMADA A, 1990, J BIOCHEM-TOKYO, V108, P341, DOI 10.1093/oxfordjournals.jbchem.a123203; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; YANAGIDA T, 1985, NATURE, V316, P369; YANOTOYOSHIMA Y, 1990, P NATL ACAD SCI USA, V87, P7130; YANOTOYOSHIMA Y, 1989, NATURE, V341, P154; YANOTOYOSHIMA Y, 1987, NATURE, V328, P536	49	228	230	1	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					301	306		10.1038/352301a0	http://dx.doi.org/10.1038/352301a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1830130				2022-12-01	WOS:A1991FY28900059
J	KOMIYAMA, NH; SHIH, DTB; LOOKER, D; TAME, J; NAGAI, K				KOMIYAMA, NH; SHIH, DTB; LOOKER, D; TAME, J; NAGAI, K			WAS THE LOSS OF THE D-HELIX IN ALPHA-GLOBIN A FUNCTIONALLY NEUTRAL MUTATION	NATURE			English	Article							ESCHERICHIA-COLI; HEMOGLOBIN; EXPRESSION; SEQUENCES; MYOGLOBIN	PROTEINS in the globin family are found in a variety of species from bacteria to man 1-3. From the many globin sequences known, evolutionary trees have been constructed showing that alpha and beta-globins diverged from a common ancestor between 425 and 500 million years ago, after vertebrate species had appeared and roughly when sharks and bony vertebrates diverged 4-6. The alpha and beta-globins assemble to form tetrameric haemoglobin, alpha-2-beta-2, which can switch between quaternary states having high and low oxygen affinity 7. This allows the protein to bind oxygen cooperatively and therefore efficiently transport oxygen from the lungs to respiring tissues. The alpha and beta-globins have closely related tertiary structures, being alpha-helical proteins with similar haem-binding sites. Most globins consist of eight helices, designated A to H from the N terminus, connected by short nonhelical segments, but all known vertebrate alpha-globins lack a D helix. Because the loss of this helix by alpha-globin occurred shortly before tetrameric haemoglobin appeared, it might be a functionally important mutation required for a tetramer assembly or allostery. We have now tested this idea by engineering human haemoglobins containing beta-subunits without a D helix and alpha-subunits with a D helix. Both of these mutations have little effect on the oxygen-binding properties of the molecule. Thus it is possible that deletion of the D helix in the alpha-subunit was caused by a neutral mutation 8.	MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND; OREGON HLTH SCI UNIV,DEPT BIOCHEM,PORTLAND,OR 97201; STOMATOGEN INC,BOULDER,CO 80301	MRC Laboratory Molecular Biology; Oregon Health & Science University				Tame, Jeremy/0000-0002-9341-7280				ARUTYUNYAN EG, 1980, SOV PHYS-CRYSTALLOGR, V25, P43; ASCHAUER H, 1985, BIOL CHEM H-S, V366, P589, DOI 10.1515/bchm3.1985.366.1.589; BRAUNITZER G, 1961, H-S Z PHYSIOL CHEM, V325, P283, DOI 10.1515/bchm2.1961.325.1.283; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V0005; Dickerson RE, 1983, HEMOGLOBIN STRUCTURE; DODSON G, 1988, PROTEIN ENG, V2, P233, DOI 10.1093/protein/2.3.233; FERMI G, 1981, ATLAS MOL STRUCTURES, V2; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; HUBER R, 1971, EUR J BIOCHEM, V19, P42, DOI 10.1111/j.1432-1033.1971.tb01285.x; Imai K, 1981, Methods Enzymol, V76, P438; KENDREW JC, 1960, NATURE, V185, P422, DOI 10.1038/185422a0; KIMURA M, 1979, SCI AM, V241, P94; KLEINSCHMIDT T, 1987, BIOL CHEM H-S, V368, P579; LESK AM, 1980, J MOL BIOL, V136, P225, DOI 10.1016/0022-2836(80)90373-3; LOVE WA, 1973, J MOL BIOL, V74, P331; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; PADLAN EA, 1974, J BIOL CHEM, V249, P4067; PERUTZ MF, 1983, MOL BIOL EVOL, V1, P1; PERUTZ MF, 1990, MECHANISMS COOPERATI; ROYER WE, 1989, J BIOL CHEM, V264, P21052; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; 1985, HEMOGLOBIN, V9, P229	22	21	21	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					349	351		10.1038/352349a0	http://dx.doi.org/10.1038/352349a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852211				2022-12-01	WOS:A1991FY28900076
J	LEE, B; GODFREY, M; VITALE, E; HORI, H; MATTEI, MG; SARFARAZI, M; TSIPOURAS, P; RAMIREZ, F; HOLLISTER, DW				LEE, B; GODFREY, M; VITALE, E; HORI, H; MATTEI, MG; SARFARAZI, M; TSIPOURAS, P; RAMIREZ, F; HOLLISTER, DW			LINKAGE OF MARFAN-SYNDROME AND A PHENOTYPICALLY RELATED DISORDER TO 2 DIFFERENT FIBRILLIN GENES	NATURE			English	Article							ABNORMALITIES; MICROFIBRILS; DEFECT	MARFAN Syndrome (MFS), one of the most common genetic disorders of connective tissue, is characterized by skeletal, cardiovascular and ocular abnormalities 1. The incidence of the disease is about 1 in 20,000, with life expectancy severely reduced because of cardiovascular complications. As the underlying defect is unknown, MFS diagnosis is based solely on clinical criteria. Certain phenotypic features of MFS are also shared by other conditions, which may be genetically distinct entities although part of a clinical continuum. Immunohistochemical studies have implicated fibrillin, a major component of elastin-associated microfibrils 2, in MFS aetiology 3,4. Genetic linkage analysis with random probes has independently localized the MFS locus to chromosome 15 (refs 5-7). Here we report that these two experimental approaches converge with the cloning and mapping of the fibrillin gene to chromosome 15q15-21, and with the establishment of linkage to MFS. We also isolated a second fibrillin gene and mapped it to chromosome 5q23-31. We linked this novel gene to a condition, congenital contractural arachnodactyly, that shares some of the features of MFS 1. Thus, the cosegregation of two related genes with two related syndromes implies that fibrillin mutations are likely to be responsible for different MFS phenotypes.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,1 GUSTAVE LEVY PL,NEW YORK,NY 10029; UNIV NEBRASKA,MED CTR,DEPT PEDIAT,MEYER REHABIL INST,MUNROE CTR HUMAN GENET,OMAHA,NE 68131; HOP ENFANTS LA TIMONE,INSERM,U242,F-13385 MARSEILLE,FRANCE; UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,MOLEC GENET LAB,FARMINGTON,CT 06030; TOKYO MED & DENT UNIV,MED RES INST,DEPT TISSUE PHYSIOL,TOKYO 101,JAPAN; UNIV NEBRASKA,MED CTR,DEPT PATHOL,OMAHA,NE 68131	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Nebraska System; University of Nebraska Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Connecticut; Tokyo Medical & Dental University (TMDU); University of Nebraska System; University of Nebraska Medical Center			vitale, emilia/A-5282-2011	Vitale, Emilia/0000-0003-4651-3875				BEALS RK, 1971, J BONE JOINT SURG AM, VA 53, P987, DOI 10.2106/00004623-197153050-00013; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; DIETZ HC, 1991, GENOMICS, V9, P355, DOI 10.1016/0888-7543(91)90264-F; GODFREY M, 1990, AM J HUM GENET, V46, P652; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P152, DOI 10.1056/NEJM199007193230303; INOUE S, 1986, AM J ANAT, V176, P121, DOI 10.1002/aja.1001760203; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEE B, 1991, J BIOL CHEM, V266, P5256; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; MADDOX BK, 1989, J BIOL CHEM, V264, P21382; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; OTT J, 1974, AM J HUM GENET, V26, P588; PYERITZ RE, 1990, PRINCIPLES PRACTICE, P1047; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TSIPOURAS P, P NATL ACAD SCI USA, V88, P4486; WALKER BA, 1969, ANN INTERN MED, V71, P349, DOI 10.7326/0003-4819-71-2-349	19	578	600	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					330	334		10.1038/352330a0	http://dx.doi.org/10.1038/352330a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852206				2022-12-01	WOS:A1991FY28900069
J	LOCALIO, AR; LAWTHERS, AG; BRENNAN, TA; LAIRD, NM; HEBERT, LE; PETERSON, LM; NEWHOUSE, JP; WEILER, PC; HIATT, HH				LOCALIO, AR; LAWTHERS, AG; BRENNAN, TA; LAIRD, NM; HEBERT, LE; PETERSON, LM; NEWHOUSE, JP; WEILER, PC; HIATT, HH			RELATION BETWEEN MALPRACTICE CLAIMS AND ADVERSE EVENTS DUE TO NEGLIGENCE - RESULTS OF THE HARVARD MEDICAL-PRACTICE STUDY-III	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY; CARE	Background and Methods. By matching the medical records of a random sample of 31,429 patients hospitalized in New York State in 1984 with statewide data on medical-malpractice claims, we identified patients who had filed claims against physicians and hospitals. These results were then compared with our findings, based on a review of the same medical records, regarding the incidence of injuries to patients caused by medical management (adverse events). Results. We identified 47 malpractice claims among 30,195 patients' records located on our initial visits to the hospitals, and 4 claims among 580 additional records located during follow-up visits. The overall rate of claims per discharge (weighted) was 0.13 percent (95 percent confidence interval, 0.076 to 0.18 percent). Of the 280 patients who had adverse events caused by medical negligence as defined by the study protocol, 8 filed malpractice claims (weighted rate, 1.53 percent; 95 percent confidence interval, 0 to 3.2 percent). By contrast, our estimate of the statewide ratio of adverse events caused by negligence (27,179) to malpractice claims (3570) is 7.6 to 1. This relative frequency overstates the chances that a negligent adverse event will produce a claim, however, because most of the events for which claims were made in the sample did not meet our definition of adverse events due to negligence. Conclusions. Medical-malpractice litigation infrequently compensates patients injured by medical negligence and rarely identifies, and holds providers accountable for, substandard care.	HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SOCIAL MED,DIV MED ETH,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH LAW,CAMBRIDGE,MA 02138	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard University	LOCALIO, AR (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,CTR BIOSTAT & EPIDEMIOL,POB 850,HERSHEY,PA 17033, USA.		Newhouse, Joseph/AGJ-5632-2022					ABEL, 1987, OHIO ST LJ, V48, P443; BELL PA, 1984, SYRACUSE LAW REV, V35, P939; BENNETT WI, 1988, NY TIMES MAGAZI 0724, P31; BOVBJERG RR, 1986, LAW CONTEMP PROBL, V49, P321, DOI 10.2307/1191431; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BROOK, 1975, DUKE LAW J, P1197; DANZON PM, 1985, MED MALPRACTICE THEO; DOHERTY EG, 1977, JAMA-J AM MED ASSOC, V238, P1656, DOI 10.1001/jama.238.15.1656; GAUMER GL, 1984, MILBANK FUND Q, V62, P380, DOI 10.2307/3349858; GUSTAFSON DH, 1973, ORGAN BEHAV HUM PERF, V9, P280, DOI 10.1016/0030-5073(73)90052-4; KUSSEROW RP, 1987, JAMA-J AM MED ASSOC, V257, P820; LEWIS R, 1985, AM MED NEWS, V1, P25; MEYERS AR, 1987, AM J PUBLIC HEALTH, V77, P1544, DOI 10.2105/AJPH.77.12.1544; Miller F H, 1986, Am J Law Med, V11, P433; NEWCOMBE HB, 1959, SCIENCE, V130, P954, DOI 10.1126/science.130.3381.954; RUBENSTEIN LV, 1990, JAMA-J AM MED ASSOC, V264, P1974, DOI 10.1001/jama.264.15.1974; SHAH BV, 1981, SESUDAAN STANDARD ER; SLOAN FA, 1989, JAMA-J AM MED ASSOC, V262, P3291, DOI 10.1001/jama.262.23.3291; 1988, SUDOC Y3T2222M4612; 1977, GAOHRD8755 GEN ACC O; 1988, 14 INS DEP CIRC LETT; 1980, 5 DEP COMM STAT POL, P12; 1977, REPORT MED INSURANCE; 1990, PATIENTS DOCTORS LAW	24	536	541	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 25	1991	325	4					245	251		10.1056/NEJM199107253250405	http://dx.doi.org/10.1056/NEJM199107253250405			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FX627	2057025				2022-12-01	WOS:A1991FX62700005
J	MASLEN, CL; CORSON, GM; MADDOX, BK; GLANVILLE, RW; SAKAI, LY				MASLEN, CL; CORSON, GM; MADDOX, BK; GLANVILLE, RW; SAKAI, LY			PARTIAL SEQUENCE OF A CANDIDATE GENE FOR THE MARFAN-SYNDROME	NATURE			English	Article							MICROFIBRILS; FIBRILLIN; COMPONENT; PROTEINS; COMPLEX	FIBRILLIN is a large (relative molecular mass 350,000) glycoprotein which can be isolated from fibroblast cell cultures and is a component of the microfibrils that are ubiquitous in the connective tissue space 1. The microfibrils of the suspensory ligament of the lens as well as the elastic fibre microfibrils of the blood vessel wall are composed of fibrillin. The ocular and cardiovascular manifestations of the Marfan syndrome are consistent with a defect in the gene coding for a structural constituent of these connective tissues. Immunohistological experiments have recently implicated fibrillin microfibrils in the pathogenesis of the Marfan syndrome 2. Genetic linkage data 3,4 localizing the Marfan gene to chromosome 15 and the in situ hybridization of fibrillin complementary DNA to 15q21.1 (ref. 5) together support fibrillin as a candidate Marfan gene. As a first step towards investigating the function of fibrillin in the architecture and development of connective tissues and its relationship to the Marfan syndrome, we report the cloning and partial sequencing of fibrillin cDNA.	SHRINERS HOSP CRIPPLED CHILDREN,3101 SW SAM JACKSON PK RD,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University								DIETZ HC, 1991, GENOMICS, V9, P355, DOI 10.1016/0888-7543(91)90264-F; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P152, DOI 10.1056/NEJM199007193230303; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; MAGENIS RE, IN PRESS GENOMICS; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SAKAI LY, IN PRESS J BIOL CHEM; STENFLO J, 1988, J BIOL CHEM, V263, P21; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585	14	289	298	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					334	337		10.1038/352334a0	http://dx.doi.org/10.1038/352334a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852207				2022-12-01	WOS:A1991FY28900070
J	PALMER, MS; DRYDEN, AJ; HUGHES, JT; COLLINGE, J				PALMER, MS; DRYDEN, AJ; HUGHES, JT; COLLINGE, J			HOMOZYGOUS PRION PROTEIN GENOTYPE PREDISPOSES TO SPORADIC CREUTZFELDT-JAKOB DISEASE	NATURE			English	Article							GERSTMANN-STRAUSSLER SYNDROME; GENE; DEMENTIA; MICE	THE human prion diseases, Creutzfeldt-Jakob disease (CJD) and Gerstmann-Straussler syndrome (GSS), are neurodegenerative diseases that are unique in being both infectious and genetic. Transmission of both diseases and the animal spongiform encephalopathies (for example, scrapie and bovine spongiform encephalopathy) to experimental animals by intracerebral inoculation with brain homogenates is well documented 1. Despite their experimental transmissibility, missense and insertional mutations in the prion protein gene are associated with both GSS and familial CJD, demonstrating that the human familial cases are autosomal dominant diseases 2-6. More that 80% of CJD cases occur sporadically, however, and are not known to be associated with mutations. Here we report that 21 of 22 sporadic CJD cases and a further 19 of 23 suspected sporadic CJD cases are homozygous at the polymorphic amino-acid residue 129; 51% of the normal population are heterozygous at this site. We argue that homozygosity predisposes towards sporadic CJD and that this directly supports the hypothesis that interaction between prion protein molecules underlies the disease process.	ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,PRION DIS GRP,NORFOLK PL,LONDON W2 1PG,ENGLAND; RADCLIFFE INFIRM,DEPT NEUROPATHOL,OXFORD OX2 6HE,ENGLAND	Imperial College London; Radcliffe Infirmary					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; COLLINGE J, 1989, LANCET, V2, P15, DOI 10.1016/S0140-6736(89)90256-0; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; DOHURA K, 1989, BIOCHEM BIOPH RES CO, V163, P974, DOI 10.1016/0006-291X(89)92317-6; GIBBS CJ, 1973, SCIENCE, V182, P67, DOI 10.1126/science.182.4107.67; GOLDFARB L G, 1989, American Journal of Human Genetics, V45, pA189; GOLDFARB LG, 1991, LANCET, V337, P15; GOLDGABER D, 1989, EXP NEUROL, V106, P204, DOI 10.1016/0014-4886(89)90095-2; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; KIMBERLIN RH, 1987, J GEN VIROL, V68, P1875, DOI 10.1099/0022-1317-68-7-1875; KITAMOTO T, 1989, J GEN VIROL, V70, P3371, DOI 10.1099/0022-1317-70-12-3371; MASTERS C L, 1987, P511; OWEN F, 1989, LANCET, V1, P51; PRUSINER SB, 1989, ANNU REV MICROBIOL, V43, P345, DOI 10.1146/annurev.mi.43.100189.002021; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0; WELLER RO, 1989, PSYCHOL MED, V19, P1, DOI 10.1017/S0033291700010965; WU Y, 1987, NUCLEIC ACIDS RES, V15, P3191, DOI 10.1093/nar/15.7.3191	21	736	757	0	43	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					340	342		10.1038/352340a0	http://dx.doi.org/10.1038/352340a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1677164				2022-12-01	WOS:A1991FY28900072
J	UYEDA, TQP; WARRICK, HM; KRON, SJ; SPUDICH, JA				UYEDA, TQP; WARRICK, HM; KRON, SJ; SPUDICH, JA			QUANTIZED VELOCITIES AT LOW MYOSIN DENSITIES IN AN INVITRO MOTILITY ASSAY	NATURE			English	Article							SINGLE KINESIN MOLECULES; STEP SIZE; ACTIN; MOVEMENT; MUSCLE	An in vitro motility assay has been developed in which single actin filaments move on one or a few heavy meromyosin (HMM) molecules. This movement is slower than when many HMM molecules are involved, in contrast to analogous experiments with microtubules and kinesin. Frequency analysis shows that sliding speeds distribute around integral multiples of a unitary velocity. This discreteness may be due to differences in the numbers of HMM molecules interacting with each actin filament, where the unitary velocity reflects the activity of one HMM molecule. The value of the unitary velocity predicts a step size of 5-20 nm per ATP, which is consistent with the conventional swinging crossbridge model for myosin function.	STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,FAIRCHILD CTR,STANFORD,CA 94305	Stanford University	UYEDA, TQP (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,FAIRCHILD CTR,STANFORD,CA 94305, USA.			Kron, Stephen/0000-0003-1518-2436				BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BRENNER B, 1982, P NATL ACAD SCI-BIOL, V79, P7288, DOI 10.1073/pnas.79.23.7288; DANTZIG JA, 1988, P NATL ACAD SCI USA, V85, P6716, DOI 10.1073/pnas.85.18.6716; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KRON SJ, 1991, J CELL SCI S, V14, P129; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; SCHUTT CE, 1989, J MOL BIOL, V209, P735, DOI 10.1016/0022-2836(89)90603-7; SHIMMEN T, 1988, BOT MAG TOKYO, V101, P533, DOI 10.1007/BF02488095; Taylor E W, 1989, Prog Clin Biol Res, V315, P9; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0	19	164	164	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					307	311		10.1038/352307a0	http://dx.doi.org/10.1038/352307a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852205				2022-12-01	WOS:A1991FY28900060
J	YONISHROUACH, E; RESNITZKY, D; LOTEM, J; SACHS, L; KIMCHI, A; OREN, M				YONISHROUACH, E; RESNITZKY, D; LOTEM, J; SACHS, L; KIMCHI, A; OREN, M			WILD-TYPE P53 INDUCES APOPTOSIS OF MYELOID LEUKEMIC-CELLS THAT IS INHIBITED BY INTERLEUKIN-6	NATURE			English	Article							TUMOR SUPPRESSION; C-MYC; GROWTH; DIFFERENTIATION; EXPRESSION; GENE; PROTEIN; ONCOGENE; SURVIVAL; BCL-2	WILD-TYPE p53 protein has many properties consistent with its being the product of a tumour suppressor gene 1-3. Although the normal roles of tumour suppressor genes are still largely unknown, it seems that they could be involved in promoting cell differentiation 4-6 as well as in mediating growth arrest by growth-inhibitory cytokines 7-9. Hence, the abrogation of wild-type p53 expression, which is a common feature of many tumours, could eliminate these activities. We have now tested this notion by restoring the expression of p53 in a murine myeloid leukaemic cell line that normally lacks p53. The use of a temperature-sensitive p53 mutant 10 allowed us to analyse cells in which the introduced p53 had either wild-type or mutant properties. Although there seemed to be no effect on differentiation, the introduction of wild-type p53 resulted in rapid loss of cell viability in a way characteristic of apoptosis (programmed cell death). The effect of wild-type p53 was counteracted by interleukin-6. Thus products of tumour suppressor genes could be involved in restricting precursor cell populations by mediating apoptosis.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT MOLEC GENET & VIROL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIBACH E, 1973, P NATL ACAD SCI USA, V70, P343, DOI 10.1073/pnas.70.2.343; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARRIS H, 1989, CIBA F SYMP, V142, P199; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LOTEM J, IN PRESS BLOOD; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINHASI O, 1984, MOL CELL BIOL, V4, P2180, DOI 10.1128/MCB.4.10.2180; PROKOCIMER M, 1986, BLOOD, V68, P113; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SACHS L, 1989, CIBA F SYMP, V142, P217; SACHS L, 1990, CANCER-AM CANCER SOC, V65, P2196, DOI 10.1002/1097-0142(19900515)65:10<2196::AID-CNCR2820651006>3.0.CO;2-Y; SHABO Y, 1988, BLOOD, V72, P2070; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; STANBRIDGE EJ, 1990, REV GENET, V24, P615; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790	41	2156	2201	2	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 25	1991	352	6333					345	347		10.1038/352345a0	http://dx.doi.org/10.1038/352345a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852210				2022-12-01	WOS:A1991FY28900074
J	HAYNES, BE; MENDOZA, A; MCNEIL, M; SCHROEDER, J; SMILEY, DR				HAYNES, BE; MENDOZA, A; MCNEIL, M; SCHROEDER, J; SMILEY, DR			A STATEWIDE EARLY DEFIBRILLATION INITIATIVE INCLUDING LAYPERSONS AND OUTCOME REPORTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AUTOMATIC EXTERNAL DEFIBRILLATOR; EMERGENCY MEDICAL TECHNICIANS; HOSPITAL CARDIAC ARRESTS; RECOMMENDATIONS; EXPERIENCE	Rapid delivery of defibrillatory shocks increases survival in patients with cardiac arrest. The automated external defibrillator interprets cardiac rhythms and delivers electrical shocks, permitting appropriate defibrillation by persons with minimal training. California initiated a program for early defibrillation by basic emergency medical technicians, using manual or automated external defibrillators, and by public safety personnel (fire fighters, peace officers, and public lifeguards), using automated external defibrillators. The program includes a system for reporting outcomes statewide. In the first 46 months under this program, 1487 patients received defibrillatory shocks; 1009 (68%) of these patients had witnessed ventricular fibrillation. Of the latter group, 191 were discharged from the hospital, representing 19% of those with witnessed ventricular fibrillation and 13% of all patients who had had shocks applied. California also implemented a framework of training and medical direction for defibrillation by laypersons using automated external defibrillators. Early defibrillation by basic emergency medical technicians and public safety personnel, encouraged by appropriate regulatory changes, results in gratifying survival rates.	CALIF EMERGENCY MED SERV AUTHOR,SACRAMENTO,CA		HAYNES, BE (corresponding author), KAISER PERMANENTE SAN DIEGO MED CTR,EMERGENCY SERV,4647 ZION AVE,SAN DIEGO,CA 92120, USA.							ADGEY AAJ, 1969, LANCET, V1, P1169; BACHMAN JW, 1986, JAMA-J AM MED ASSOC, V256, P477, DOI 10.1001/jama.256.4.477; CUMMINS RO, 1989, ANN EMERG MED, V18, P1269, DOI 10.1016/S0196-0644(89)80257-4; CUMMINS RO, 1990, JAMA-J AM MED ASSOC, V264, P1019, DOI 10.1001/jama.264.8.1019; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EISENBERG MS, 1990, ANN EMERG MED, V19, P1249, DOI 10.1016/S0196-0644(05)82283-8; EISENBERG MS, 1984, SUDDEN CARDIAC DEATH; GENTILE D, 1988, J TENN MED ASS   MAR, P144; GRAY AJ, 1987, BRIT MED J, V294, P1133, DOI 10.1136/bmj.294.6580.1133; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; STULTS KR, 1988, J EMERG MED SERV AUG, P39; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; 1991, INSTRUCTORS MANUAL A, P33	15	26	27	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	1991	266	4					545	547		10.1001/jama.266.4.545	http://dx.doi.org/10.1001/jama.266.4.545			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX021	2061982				2022-12-01	WOS:A1991FX02100029
J	MANSON, JE; STAMPFER, MJ; COLDITZ, GA; WILLETT, WC; ROSNER, B; SPEIZER, FE; HENNEKENS, CH				MANSON, JE; STAMPFER, MJ; COLDITZ, GA; WILLETT, WC; ROSNER, B; SPEIZER, FE; HENNEKENS, CH			A PROSPECTIVE-STUDY OF ASPIRIN USE AND PRIMARY PREVENTION OF CARDIOVASCULAR-DISEASE IN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; LOW-DOSE ASPIRIN; PROSTACYCLIN PRODUCTION; ACETYLSALICYLIC-ACID; PHYSICAL-ACTIVITY; HEALTHY-SUBJECTS; BLEEDING-TIME; INHIBITION; SEX; METABOLITES	Objective.-The aim of the study was to examine prospectively the association between regular aspirin use and the risk of a first myocardial infarction and other cardiovascular events in women. Design. - Prospective cohort study including 6 years of follow-up. Setting. -Registered nurses residing in 11 US states. Participants. - US registered nurses (n = 87 678) aged 34 to 65 years and free of diagnosed coronary heart disease, stroke, and cancer at baseline. Follow-up was 96.7% of total potential person-years of follow-up. Main Outcome Measures.-Incidence of myocardial infarction, stroke, cardiovascular death, and all important vascular events. Results. - During 475 265 person-years of follow-up, we documented 240 nonfatal myocardial infarctions, 146 nonfatal strokes, and 130 deaths due to cardiovascular disease (total, 516 important vascular events). Among women who reported taking one through six aspirin per week, the age-adjusted relative risk (RR) of a first myocardial infarction was 0.68 (95% confidence interval [Cl], 0.52 to 0.89; P = .005), as compared with those women who took no aspirin. After simultaneous adjustment for risk factors for coronary disease, the RR was 0.75 (95% Cl, 0.58 to 0.99; P = .04). For women aged 50 years and older, the age-adjusted RR was 0.61 (95% Cl, 0.45 to 0.84; P = .002) and the multivariate RR was 0.68 (95% Cl, 0.50 to 0.93; P = .02). We observed no alteration in the risk of stroke (multivariate RR = 0.99; P = .94). The multivariate RR of cardiovascular death was 0.89 (P = .56) and of important vascular events was 0.85 (P = .12). When examined separately, the results were nearly identical for the subgroups who took one through three and four though six aspirin per week. Among women who took seven or more aspirin per week, there were no apparent reductions in risk. Conclusions.-The use of one through six aspirin per week appears to be associated with a reduced risk of a first myocardial infarction among women. A randomized trial in women is necessary, however, to provide conclusive data on the role of aspirin in the primary prevention of cardiovascular disease in women.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	MANSON, JE (corresponding author), HARVARD UNIV, SCH MED, DEPT MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 07575, HL 34594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, BRIT MED J, V296, P320; [Anonymous], 1982, EPIDEMIOLOGIC RES; [Anonymous], 1989, GUIDE CLIN PREVENTIV; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; Boston, 1974, BMJ, V1, P440; ESCOLAR G, 1986, THROMB RES, V44, P837, DOI 10.1016/0049-3848(86)90029-0; HAMMOND EC, 1975, BMJ-BRIT MED J, V2, P269, DOI 10.1136/bmj.2.5965.269; HEAVEY DJ, 1985, NATURE, V318, P186, DOI 10.1038/318186a0; HENNEKENS CH, 1989, CIRCULATION, V80, P749, DOI 10.1161/01.CIR.80.4.749; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HO PC, 1985, BRIT J CLIN PHARMACO, V19, P675, DOI 10.1111/j.1365-2125.1985.tb02695.x; HUSTED SE, 1983, EUR J CLIN PHARMACOL, V24, P679, DOI 10.1007/BF00542222; KELTON JG, 1978, BLOOD, V52, P1073; MASOTTI G, 1979, LANCET, V2, P1213; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MONCADA S, 1979, NEW ENGL J MED, V300, P1142, DOI 10.1056/NEJM197905173002006; OBRIEN JR, 1968, LANCET, V1, P779; OGRADY J, 1978, LANCET, V2, P780; PAGANINIHILL A, 1989, BRIT MED J, V299, P1247, DOI 10.1136/bmj.299.6710.1247; PATRIGNANI P, 1982, J CLIN INVEST, V69, P1366, DOI 10.1172/JCI110576; PATRONO C, 1980, THROMB RES, V17, P317, DOI 10.1016/0049-3848(80)90066-3; PATRONO C, 1985, CIRCULATION, V72, P1177, DOI 10.1161/01.CIR.72.6.1177; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; PHILPOT VB, 1985, PROSTA LEUKOTR MED, V19, P123, DOI 10.1016/0262-1746(85)90077-0; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; SPRANGER M, 1989, STROKE, V20, P34, DOI 10.1161/01.STR.20.1.34; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; Walker AE, 1981, STROKE S1, V12, pI13; [No title captured]; 1988, PHS881114 US DEP HLT, V2, P170	32	240	246	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	1991	266	4					521	527		10.1001/jama.266.4.521	http://dx.doi.org/10.1001/jama.266.4.521			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX021	2061978				2022-12-01	WOS:A1991FX02100025
J	MORROW, JF; BRAINE, HG; KICKLER, TS; NESS, PM; DICK, JD; FULLER, AK				MORROW, JF; BRAINE, HG; KICKLER, TS; NESS, PM; DICK, JD; FULLER, AK			SEPTIC REACTIONS TO PLATELET TRANSFUSIONS - A PERSISTENT PROBLEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BACTERIAL PROLIFERATION; SALMONELLA SEPTICEMIA; ROOM-TEMPERATURE; STORAGE; SEPSIS; CONTAMINATION; FATALITIES; STERILITY	Objective.-To determine the medical and laboratory characteristics of bacteremia secondary to transfusion of microbiologically contaminated platelet concentrates. Design.-Febrile transfusion reactions were prospectively monitored over 42 months. Units involved in reactions were evaluated with Gram's stain and culture tests. Setting. -Comprehensive cancer center. Patients.- Patients receiving platelet transfusions for thrombocytopenia secondary to bone marrow failure. Result. - Seven cases of transfusion-associated sepsis were observed. Multidonor platelet products stored for 5 days resulted in an incidence of sepsis five times higher than those stored for 4 days or less (P < .01). Investigation indicates that contamination most likely occurred at the time of blood collection. Clinically, septic reactions were associated with greater temperature elevations (average increase, 2.0-degrees-C) than febrile reactions to sterile products. Conclusions.-Contamination of platelet concentrates remains a significant clinical problem. Septic episodes may be reduced by transfusion of platelets with shorter storage intervals.	JOHNS HOPKINS MED INST,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine								ANDERSON KC, 1986, AM J MED, V81, P405, DOI 10.1016/0002-9343(86)90290-1; ARNOW PM, 1986, ARCH INTERN MED, V146, P321, DOI 10.1001/archinte.146.2.321; BRAINE HG, 1986, TRANSFUSION, V26, P391, DOI 10.1046/j.1537-2995.1986.26486262752.x; BUCHHOLZ DH, 1971, NEW ENGL J MED, V285, P429, DOI 10.1056/NEJM197108192850803; BUCHHOLZ DH, 1973, TRANSFUSION, V13, P268, DOI 10.1111/j.1537-2995.1973.tb05488.x; CORDLE D, 1980, TRANSFUSION, V20, P105, DOI 10.1046/j.1537-2995.1980.20180125023.x; CUNNINGHAM M, 1973, J CLIN PATHOL, V26, P401, DOI 10.1136/jcp.26.6.401; DOUGLAS D, 1987, TRANSFUSION, V27, P512; GIBSON T, 1958, LANCET, V275, P983; HEAL JM, 1986, TRANSFUSION, V26, P388, DOI 10.1046/j.1537-2995.1986.26486262751.x; HEAL JM, 1987, TRANSFUSION, V27, P2, DOI 10.1046/j.1537-2995.1987.27187121466.x; HESS PM, 1980, TRANSFUSION, V20, P82; HONIG CL, 1980, TRANSFUSION, V20, P653, DOI 10.1046/j.1537-2995.1980.20681057154.x; INGELFINGER JA, 1987, BIOSTATISTICS CLIN M, V111, P123; Lennette E.H, 1985, MANUAL CLIN MICROBIO, V4th ed.; MURPHY S, 1969, NEW ENGL J MED, V280, P1094, DOI 10.1056/NEJM196905152802004; MYHRE BA, 1980, JAMA-J AM MED ASSOC, V244, P1333; MYHRE BA, 1974, TRANSFUSION, V14, P116, DOI 10.1111/j.1537-2995.1974.tb04502.x; PUNSALANG A, 1989, TRANSFUSION, V29, P596, DOI 10.1046/j.1537-2995.1989.29789369676.x; RHAME FS, 1973, ANN INTERN MED, V78, P633, DOI 10.7326/0003-4819-78-5-633; SAZAMA K, 1990, TRANSFUSION, V30, P583, DOI 10.1046/j.1537-2995.1990.30790385515.x; SIMON TL, 1983, TRANSFUSION, V23, P207, DOI 10.1046/j.1537-2995.1983.23383224896.x; SLICHTER SJ, 1976, BRIT J HAEMATOL, V34, P403, DOI 10.1111/j.1365-2141.1976.tb03587.x; SZYMANSKI IO, 1985, TRANSFUSION, V25, P290, DOI 10.1046/j.1537-2995.1985.25385219921.x; WALKER RH, 1990, TECHNICAL MANUAL	25	189	197	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	1991	266	4					555	558						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX021	2061984				2022-12-01	WOS:A1991FX02100031
J	ORENTLICHER, D				ORENTLICHER, D			GENDER DISPARITIES IN CLINICAL DECISION-MAKING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORONARY-BYPASS SURGERY; SEX-DIFFERENCES; LUNG-CANCER; MYOCARDIAL-INFARCTION; DETECTION BIAS; MEDICAL-CARE; WOMEN; MEN; MORTALITY; ILLNESS				ORENTLICHER, D (corresponding author), AMER MED ASSOC,COUNCIL ETH & JUDICIAL AFFAIRS,515 N STATE ST,CHICAGO,IL 60610, USA.							ARMITAGE KJ, 1979, JAMA-J AM MED ASSOC, V241, P2186, DOI 10.1001/jama.241.20.2186; BARKERBENFIELD B, 1973, AM FAMILY SOCIOHISTO; BERNSTEIN B, 1981, MED CARE, V19, P600, DOI 10.1097/00005650-198106000-00004; BROVERMA.IK, 1970, J CONSULT CLIN PSYCH, V34, P1, DOI 10.1037/h0028797; CLEARY PD, 1982, J HEALTH SOC BEHAV, V23, P106, DOI 10.2307/2136508; COLAMECO S, 1983, J FAM PRACTICE, V16, P1117; COTTON P, 1990, JAMA-J AM MED ASSOC, V263, P1051, DOI 10.1001/jama.263.8.1051; COTTON P, 1990, JAMA-J AM MED ASSOC, V263, P1049, DOI 10.1001/jama.263.8.1049; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; Eggers P W, 1984, Health Care Financ Rev, V5, P69; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; GOVE WR, 1979, AM SOCIOL REV, V44, P126, DOI 10.2307/2094822; Hamilton J, 1983, J Am Med Womens Assoc (1972), V38, P126; HAMILTON JA, 1985, WOMENS HLTH REPORT P, P2; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; HIBBARD JH, 1986, WOMEN HEALTH, V11, P21, DOI 10.1300/J013v11n02_03; KARLIN BG, 1988, ANN INTERN MED, V108, P149; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KJELLSTRAND CM, 1987, NEPHRON, V45, P257, DOI 10.1159/000184160; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; MARCUS AC, 1981, J HEALTH SOC BEHAV, V22, P174, DOI 10.2307/2136293; MCFARLANE MJ, 1986, ARCH INTERN MED, V146, P1695, DOI 10.1001/archinte.146.9.1695; MCFARLANE MJ, 1987, JAMA-J AM MED ASSOC, V258, P331, DOI 10.1001/jama.258.3.331; NATANSON CA, 1975, SOC SCI MED, V9, P57; RASKIN A, 1974, J NERV MENT DIS, V159, P120, DOI 10.1097/00005053-197408000-00006; SAVAGE WD, 1983, MED EDUC, V17, P159, DOI 10.1111/j.1365-2923.1983.tb00656.x; SCHOENBERG JB, 1989, AM J EPIDEMIOL, V130, P688, DOI 10.1093/oxfordjournals.aje.a115390; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOBIN JN, 1988, ANN INTERN MED, V108, P149; VERBRUGGE LM, 1982, PUBLIC HEALTH REP, V97, P417; VERBRUGGE LM, 1981, MED CARE, V19, P609, DOI 10.1097/00005650-198106000-00005; WAISBERG J, 1988, WOMEN HEALTH, V14, P3, DOI 10.1300/J013v14n01_02; WELLS CK, 1988, AM J EPIDEMIOL, V128, P1016; WENGER NK, 1990, ANN INTERN MED, V112, P557, DOI 10.7326/0003-4819-112-8-557; WENGER NK, 1985, ANNU REV MED, V36, P285; 1985, WOMENS HLTH REPORT P, P2	37	147	148	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	1991	266	4					559	562						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FX021	1843800				2022-12-01	WOS:A1991FX02100032
J	WHEELER, MC; ROE, MH; KAPLAN, EL; SCHLIEVERT, PM; TODD, JK				WHEELER, MC; ROE, MH; KAPLAN, EL; SCHLIEVERT, PM; TODD, JK			OUTBREAK OF GROUP-A STREPTOCOCCUS SEPTICEMIA IN CHILDREN - CLINICAL, EPIDEMIOLOGIC, AND MICROBIOLOGICAL CORRELATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE RHEUMATIC-FEVER; SHOCK-LIKE SYNDROME; STAPHYLOCOCCUS-AUREUS; OPACITY FACTOR; UNITED-STATES; TOXIN; RESURGENCE; MORTALITY; INFECTION; VARICELLA	Objective.-To determine the epidemiologic, clinical, and microbiological features of group A streptococcus septicemia in children. Design. - A descriptive series of 34 cases over an 11 -year period from 1980 through 1990. Setting.-An academically affiliated tertiary-care pediatric hospital, the principal referral center for the state of Colorado and surrounding states. Participants.-Thirty-four patients with positive blood cultures for group A streptococcus (33 medical records were available). Main Outcome Measures.-Yearly incidence and clinical features of cases; microbiological features of isolated organisms. Results. -There was a significant increase (P = .01) in the incidence of group A streptococcus bacteremia over an 11-year period, with 14 (41 %) of these cases occurring in 1989 and 1990. Patients had a rapidly progressing illness, usually without preceding pharyngitis. The prominent M and T types were 1 (4) and 12 (4). Eleven (73%) of the 15 strains produced pyrogenic exotoxin B that significantly correlated with production of proteinase. Conclusion.-There appears to be an increase in group A streptococcus bacteremia in children that is associated with a strain phenotype that suggests a change in organism virulence.	CHILDRENS HOSP,DEPT PEDIAT,DENVER,CO 80218; CHILDRENS HOSP,DEPT PATHOL,DENVER,CO 80218; UNIV COLORADO,SCH MED,DEPT PEDIAT,DENVER,CO 80202; UNIV COLORADO,SCH MED,DEPT MICROBIOL IMMUNOL,DENVER,CO 80202; WHO,COLLABORATING CTR REFERENCE & RES STREPTOCOCCI,MINNEAPOLIS,MN; UNIV MINNESOTA,SCH MED,DEPT PEDIAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT MICROBIOL,MINNEAPOLIS,MN 55455	Children's Hospital Colorado; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; World Health Organization; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	WHEELER, MC (corresponding author), CHILDRENS HOSP,EPIDEMIOL SECT,1056 E 19TH AVE,DENVER,CO 80218, USA.			Schlievert, Patrick/0000-0001-8314-9369				ALTEMEIER WA, 1978, SURGERY, V84, P534; ANDIMAN WA, 1979, CLIN PEDIATR PHILA, V19, P495; ARMITAGE P, 1971, STATISTICAL METHODS; BARTTER T, 1988, ARCH INTERN MED, V148, P1421, DOI 10.1001/archinte.148.6.1421; BELETSKAYA LV, 1981, 8TH P INT S STREPT S, P141; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CONE LA, 1987, NEW ENGL J MED, V317, P146, DOI 10.1056/NEJM198707163170305; CONGENI B, 1987, J PEDIATR-US, V111, P176, DOI 10.1016/S0022-3476(87)80063-X; DUDDING B, 1969, PEDIATRICS, V43, P359; FALCONE PA, 1988, CLIN PEDIATR, V27, P339, DOI 10.1177/000992288802700706; FISCHBACHER CM, 1987, SCAND J INFECT DIS, V19, P519, DOI 10.3109/00365548709032416; GAWORZEWSKA E, 1988, EPIDEMIOL INFECT, V100, P257, DOI 10.1017/S095026880006739X; GAWORZEWSKA ET, 1989, NEW ENGL J MED, V321, P1546; GERLACH D, 1983, ZBL BAKT-INT J MED M, V255, P221, DOI 10.1016/S0174-3031(83)80161-9; GOODER H, 1961, J GEN MICROBIOL, V25, P347, DOI 10.1099/00221287-25-3-347; HALLAS G, 1983, J MED MICROBIOL, V16, P13, DOI 10.1099/00222615-16-1-13; HANSMAN D, 1989, NEW ENGL J MED, V321, P1546; HOSIER DM, 1987, AM J DIS CHILD, V141, P730, DOI 10.1001/archpedi.1987.04460070032015; JOHNSON DR, 1988, J CLIN MICROBIOL, V26, P2025, DOI 10.1128/JCM.26.10.2025-2030.1988; JOHNSON LP, 1986, MOL GEN GENET, V203, P354, DOI 10.1007/BF00333979; KAVEY REW, 1989, PEDIATRICS, V84, P585; KOHLER W, 1987, ZBL BAKT-INT J MED M, V266, P104; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKENBACH JP, 1988, INT J EPIDEMIOL, V17, P618, DOI 10.1093/ije/17.3.618; MASSELL BF, 1988, NEW ENGL J MED, V318, P280, DOI 10.1056/NEJM198802043180504; MOLINA A M, 1985, European Journal of Epidemiology, V1, P37; RAPHAEL SA, 1989, PEDIATR INFECT DIS J, V8, P187; SCHLIEVERT PM, 1983, J INFECT DIS, V147, P236, DOI 10.1093/infdis/147.2.236; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; STOLLERMAN GH, 1982, ADV INTERNAL MED, V27, P373; Swift HF, 1943, J EXP MED, V78, P127, DOI 10.1084/jem.78.2.127; TODD JK, 1984, INFECT IMMUN, V45, P339, DOI 10.1128/IAI.45.2.339-344.1984; TOP FH, 1968, J HYG-CAMB, V66, P49, DOI 10.1017/S0022172400040936; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; WALD ER, 1987, PEDIATRICS, V80, P371; WINCHESTER PD, 1977, AM J DIS CHILD, V131, P753, DOI 10.1001/archpedi.1977.02120200035009; WONG VK, 1988, AM J DIS CHILD, V142, P831, DOI 10.1001/archpedi.1988.02150080037016; 1985, PEDIATRICS, V76, P322; 1990, MMWR, V39, P3; 1990, METHODS DILUTION ANT; 1989, STATISTICAL ABSTRACT, P22	41	122	123	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	1991	266	4					533	537		10.1001/jama.266.4.533	http://dx.doi.org/10.1001/jama.266.4.533			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX021	2061980				2022-12-01	WOS:A1991FX02100027
J	CROW, YJ; ALBERTI, KGMM; PARKIN, JM				CROW, YJ; ALBERTI, KGMM; PARKIN, JM			INSULIN-DEPENDENT DIABETES IN CHILDHOOD AND MATERIAL DEPRIVATION IN NORTHERN ENGLAND, 1977-86	BRITISH MEDICAL JOURNAL			English	Article							SOCIAL-CLASS; MELLITUS; IDDM	Objective - To determine the incidence of insulin dependent diabetes in the Northern region of England in children less than 16 years old in the period 1977 to 1986 and to relate the incidence data to an index of deprivation. Design - Retrospective analysis of hospital case records identified from the regional health authority's computer; validation of the primary source with hospital clinic registers and community paediatric registers. Setting - Northern region, excluding South Cumbria District Health Authority (659 300 children under 16 in 1981). Patients - All children diagnosed with insulin dependent diabetes before the age of 16 and resident in the region at time of diagnosis. Main outcome measures - Incidence rates for the 10 year period and analysis of incidence rates within categories of deprivation. Results - 919 incident cases were identified. The validation procedure covered 54% of all cases identified and gave 95% completeness of ascertainment. The average annual incidence over the 10 year period was 14.8/100 000 for girls and 13.4/100 000 for boys. The annual incidence for the most and least deprived areas of the region was 18.7/100 000 (95% confidence interval 16.2 to 21.5) for boys and 7/100 000 (5.6 to 8.8) for girls. There was a highly significant trend (p < 0.001) of decreasing incidence with decreasing level of deprivation. Conclusions - In the north of England the incidence of childhood diabetes is related to material deprivation.			CROW, YJ (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,HUMAN DIABET & METAB RES CTR,NEWCASTLE TYNE NE2 4HH,ENGLAND.		Crow, Yanick J/N-6120-2014	Crow, Yanick J/0000-0001-7211-7564				AKERBLOM HK, 1985, DIABETES CARE, V8, P10, DOI 10.2337/diacare.8.1.S10; ARMITAGE P, 1987, STATISTICAL METHODS, P372; BINGLEY PJ, 1989, BRIT MED J, V298, P558, DOI 10.1136/bmj.298.6673.558; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; HILL AB, 1984, SHORT TXB MED STATIS, P168; LAPORTE RE, 1981, AM J EPIDEMIOL, V114, P379, DOI 10.1093/oxfordjournals.aje.a113205; LILIENFELD AM, 1980, F EPIDEMIOLOGY, P337; SIEMIATYCKI J, 1988, DIABETES, V37, P1096, DOI 10.2337/diabetes.37.8.1096; STEWARTBROWN S, 1983, BRIT MED J, V286, P1855, DOI 10.1136/bmj.286.6381.1855; Townsend P, 1988, HLTH DEPRIVATION INE; WILSON RM, 1986, JAMA-J AM MED ASSOC, V256, P877, DOI 10.1001/jama.256.7.877; 1981, CENSUS 1981; 1990, DIABETES, V39, P858; 1987, BMJ, V295, P479	14	33	33	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1991	303	6795					158	160		10.1136/bmj.303.6795.158	http://dx.doi.org/10.1136/bmj.303.6795.158			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX578	1878639	Green Published, Bronze			2022-12-01	WOS:A1991FX57800021
J	HARPER, V; MACINNES, R; CAMPBELL, D; HALL, M				HARPER, V; MACINNES, R; CAMPBELL, D; HALL, M			INCREASED BIRTH-WEIGHT IN NORTHERLY ISLANDS - IS FISH CONSUMPTION A RED HERRING	BRITISH MEDICAL JOURNAL			English	Article									HLTH CTR,KIRKWALL,ORKNEY,SCOTLAND		HARPER, V (corresponding author), UNIV ABERDEEN,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZD,SCOTLAND.							BARBER SA, 1986, HUM NUTR-APPL NUTR, V40A, P462; OLSEN SF, 1985, J EPIDEMIOL COMMUN H, V39, P27, DOI 10.1136/jech.39.1.27; OLSEN SF, 1986, LANCET, V2, P367; PIRANI DH, 1978, OBSTET GYNECOL SURV, V33, P1	4	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1991	303	6795					166	166		10.1136/bmj.303.6795.166	http://dx.doi.org/10.1136/bmj.303.6795.166			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX578	1878642	Bronze, Green Published			2022-12-01	WOS:A1991FX57800024
J	PIALOUX, G; YOULE, M; DUPONT, B; GAZZARD, B; CAUWENBERGH, GFMJ; STOFFELS, PAM; DAVIES, S; DESAINTMARTIN, J; JANSSEN, PAJ				PIALOUX, G; YOULE, M; DUPONT, B; GAZZARD, B; CAUWENBERGH, GFMJ; STOFFELS, PAM; DAVIES, S; DESAINTMARTIN, J; JANSSEN, PAJ			PHARMACOKINETICS OF R-82913 IN PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX	LANCET			English	Article							REPLICATION	R 82913, a tetrahydroimidazobenzodiazepinthione (TIBO) derivative with potent activity against human immunodeficiency virus 1 (HIV-1) in vitro, was given to 22 patients with AIDS or AIDS-related complex in a dose-escalating pilot study. Doses of 10 to 300 mg administered daily by intravenous infusion were well tolerated for up to 50 weeks, with no haematological or biochemical evidence of toxicity. Mean OKT4 cell count rose slightly during the second month of treatment when higher steady-state plasma concentrations of the drug were achieved. Median p24 antigen concentration fell by 41% during the first month of therapy. When the rise in p24 antigen before therapy was compared to the fall during treatment, end-point analysis showed a significant difference (p < 0.03). The combination of potent antiretroviral activity in vitro and the observed effect on H IV p24 antigen and absence of toxicity in vivo indicate that R 82913 and related TIBO derivatives merit further study in the treatment of retroviral infections.	WESTMINSTER MED SCH & HOSP,DEAN RYLE ST,LONDON SW1P 2AP,ENGLAND; HOP INST PASTEUR,PARIS,FRANCE; CHU NECKER ENFANTS MALAD,F-75730 PARIS 15,FRANCE; ST STEPHENS HOSP,LONDON SW10 9TH,ENGLAND; JANSSEN RES FDN,BEERSE,BELGIUM; INST PASTEUR,IMMUNOHAEMATOL UNIT,F-75724 PARIS 15,FRANCE	Imperial College London; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Johnson & Johnson; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; NAKASHIMA H, 1986, ANTIMICROB AGENTS CH, V30, P9033; PAUUWELS R, 1990, DESIGN ANTIAIDS DRUG, P103; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; YARCHOAN R, 1986, LANCET, V1, P575	5	36	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1991	338	8760					140	143		10.1016/0140-6736(91)90135-C	http://dx.doi.org/10.1016/0140-6736(91)90135-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX424	1677064				2022-12-01	WOS:A1991FX42400003
J	BOLLINGER, JM; EDMONDSON, DE; HUYNH, BH; FILLEY, J; NORTON, JR; STUBBE, J				BOLLINGER, JM; EDMONDSON, DE; HUYNH, BH; FILLEY, J; NORTON, JR; STUBBE, J			MECHANISM OF ASSEMBLY OF THE TYROSYL RADICAL DINUCLEAR IRON CLUSTER COFACTOR OF RIBONUCLEOTIDE REDUCTASE	SCIENCE			English	Article							ESCHERICHIA-COLI; DIPHOSPHATE REDUCTASE; HYDROGEN-PEROXIDE; SMALL SUBUNIT; MOSSBAUER; SPECTROSCOPY; PROTEIN-B2; ACTIVATION; RESONANCE; ENZYME	Incubation of the apoB2 subunit of Escherichia coli ribonucleotide reductase with Fe2+ and O2 produces native B2, which contains the tyrosyl radical-dinuclear iron cluster cofactor required for nucleotide reduction. The chemical mechanism of this reconstitution reaction was investigated by stopped-flow absorption spectroscopy and by rapid freeze-quench EPR (electron paramagnetic resonance) spectroscopy. Two novel intermediates have been detected in the reaction. The first exhibits a broad absorption band centered at 565 nanometers. Based on known model chemistry, this intermediate is proposed to be a mu-peroxodiferric complex. The second intermediate exhibits a broad absorption band centered at 360 nanometers and a sharp, isotropic EPR signal with g = 2.00. When the reaction is carried out with Fe-57(2+), this EPR signal is broadened, demonstrating that the intermediate is an iron-coupled radical. Variation of the ratio of Fe2+ to B2 in the reaction and comparison of the rates of formation and decay of the intermediates to the rate of formation of the tyrosyl radical (.Y122) suggest that both intermediates can generate .Y122. This conclusion is supported by the fact that both intermediates exhibit an increased lifetime in a mutant B2 subunit (B2-Y122F) lacking the oxidizable Y122. Based on these kinetic and spectroscopic data, a mechanism for the reaction is proposed. Unlike reactions catalyzed by heme-iron peroxidases, oxygenases, and model complexes, the reconstitution reaction appears not to involve high-valent iron intermediates.	EMORY UNIV,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,DEPT PHYS,ATLANTA,GA 30322; COLORADO STATE UNIV,DEPT CHEM,FT COLLINS,CO 80523	Emory University; Emory University; Colorado State University	BOLLINGER, JM (corresponding author), MIT,DEPT CHEM & BIOL,CAMBRIDGE,MA 02139, USA.		Bollinger, Joseph/C-1425-2016; Filley, Jon/AAI-6208-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029595, R01GM032187, R01GM029433, R37GM029595] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32187, GM29595, GM29433] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BALLOU DP, 1974, ANAL CHEM, V46, P1248, DOI 10.1021/ac60345a034; BOLLINGER JM, IN PRESS J AM CHEM S; BUNKER G, 1987, BIOCHEMISTRY-US, V26, P4708, DOI 10.1021/bi00389a017; CHIN DH, 1980, J AM CHEM SOC, V102, P4344, DOI 10.1021/ja00533a009; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; FONTECAVE M, 1990, BIOCHEM BIOPH RES CO, V168, P659, DOI 10.1016/0006-291X(90)92371-6; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1989, J BIOL CHEM, V264, P17698; LYNCH JB, 1989, J BIOL CHEM, V264, P8091; MCCORMICK JM, IN PRESS NEW J CHEM; McMurry T. J., 1986, CYTOCHROME P450 STRU, P1; MENAGE S, 1990, J AM CHEM SOC, V112, P6423, DOI 10.1021/ja00173a055; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; OCHIAI EI, 1990, J BIOL CHEM, V265, P15758; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; QUE L, 1990, PROG INORG CHEM, V38, P97; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SAHLIN M, 1989, BIOCHEMISTRY-US, V28, P2618, DOI 10.1021/bi00432a039; SALOWE SP, 1986, J BACTERIOL, V165, P363, DOI 10.1128/jb.165.2.363-366.1986; SANDERSLOEHR J, 1988, OXIDASES RELATED RED, P193; SCARROW RC, 1987, J AM CHEM SOC, V109, P7857, DOI 10.1021/ja00259a039; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; SJOBERG BM, 1985, FEBS LETT, V183, P99, DOI 10.1016/0014-5793(85)80962-5; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; STUBBE J, 1983, J BIOL CHEM, V258, P1625; STUBBE J, 1989, ADV ENZYMOL RELAT AR, V63, P349; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004	36	342	343	1	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					292	298		10.1126/science.1650033	http://dx.doi.org/10.1126/science.1650033			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1650033				2022-12-01	WOS:A1991FX22400033
J	FARLEY, CT; TAYLOR, CR				FARLEY, CT; TAYLOR, CR			A MECHANICAL TRIGGER FOR THE TROT-GALLOP TRANSITION IN HORSES	SCIENCE			English	Article							FORCE PLATFORM; LOCOMOTION; GAITS; SPEED	It is widely thought that animals switch gaits at speeds that minimize energetic cost. Horses naturally switched from a trot to a gallop at a speed where galloping required more energy than trotting, and thus, the gait transition actually increased the energetic cost of running. However, by galloping at this speed, the peak forces on the muscles, tendons, and bones, and presumably the chance of injury, are reduced. When the horses carried weights, they switched from a trot to a gallop at a lower speed but at the same critical level of force. These findings suggest that the trot-gallop transition is triggered when musculoskeletal forces reach a critical level.			FARLEY, CT (corresponding author), HARVARD UNIV,MUSEUM COMPARAT ZOOL,CONCORD FIELD STN,OLD CAUSEWAY RD,BEDFORD,MA 01730, USA.				NIAMS NIH HHS [R01 AR 18140] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018140] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALEXANDER RM, 1989, PHYSIOL REV, V69, P1199, DOI 10.1152/physrev.1989.69.4.1199; BIEWENER AA, 1989, SCIENCE, V245, P45, DOI 10.1126/science.2740914; BIEWENER AA, 1983, J BIOMECH, V16, P565, DOI 10.1016/0021-9290(83)90107-0; BIEWENER AA, 1988, J EXP BIOL, V137, P191; BIEWENER AA, 1986, J EXP BIOL, V123, P383; BIEWENER AA, 1988, J ZOOL, V214, P547, DOI 10.1111/j.1469-7998.1988.tb03759.x; CAVAGNA GA, 1977, AM J PHYSIOL, V233, pR243, DOI 10.1152/ajpregu.1977.233.5.R243; CURREY J, 1984, MECH ADAPTATIONS BON, P80; FEDAK MA, 1981, J APPL PHYSIOL, V51, P772, DOI 10.1152/jappl.1981.51.3.772; HOYT DF, 1981, NATURE, V292, P239, DOI 10.1038/292239a0; KRAM R, 1989, J APPL PHYSIOL, V67, P1692, DOI 10.1152/jappl.1989.67.4.1692; MARGARIA R, 1938, ATTI ACCAD NAZ LINCE, V6, P7; MCMAHON TA, 1985, J EXP BIOL, V115, P263; PENNYCUICK CJ, 1975, J EXP BIOL, V63, P775; RUBIN CT, 1982, J EXP BIOL, V101, P187; SEEHERMAN HJ, 1981, RESP PHYSIOL, V44, P11, DOI 10.1016/0034-5687(81)90074-8	16	213	213	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					306	308		10.1126/science.1857965	http://dx.doi.org/10.1126/science.1857965			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857965				2022-12-01	WOS:A1991FX22400037
J	HAROUSE, JM; BHAT, S; SPITALNIK, SL; LAUGHLIN, M; STEFANO, K; SILBERBERG, DH; GONZALEZSCARANO, F				HAROUSE, JM; BHAT, S; SPITALNIK, SL; LAUGHLIN, M; STEFANO, K; SILBERBERG, DH; GONZALEZSCARANO, F			INHIBITION OF ENTRY OF HIV-1 IN NEURAL CELL-LINES BY ANTIBODIES AGAINST GALACTOSYL CERAMIDE	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY SYNDROME; PRODUCTIVE INFECTION; HTLV-III/LAV; MONOCLONAL-ANTIBODIES; ENVELOPE GLYCOPROTEIN; AIDS RETROVIRUS; CD4 RECEPTOR; T4 MOLECULE; SOLUBLE CD4	Although the CD4 molecule is the principal cellular receptor for the human immunodeficiency virus (HIV), several CD4-negative cell lines are susceptible to infection with one or more HIV strains. These findings indicate that there are alternate modes of viral entry, perhaps involving one or more receptor molecules. Antibodies against galactosyl ceramide (galactocerebroside, or GalC) inhibited viral internalization and infection in two CD4-negative cell lines derived from the nervous system: U373-MG and SK-N-MC. Furthermore, recombinant HIV surface glycoprotein gp120 bound to GalC but not to other glycolipids. These results suggest a role for GalC or a highly related molecule in HIV entry into neural cells.	UNIV PENN,MED CTR,DEPT NEUROL,CLIN RES BLDG,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT MICROBIOL,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania				Spitalnik, Steven/0000-0002-8528-4561	NCI NIH HHS [CA-45690] Funding Source: Medline; NINDS NIH HHS [NS-11037, NS-27405] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011037, F32NS011037, P01NS027405, P50NS027405] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANSAL R, 1989, J NEUROSCI RES, V24, P548, DOI 10.1002/jnr.490240413; BENJAMINS JA, 1987, J NEUROIMMUNOL, V14, P325, DOI 10.1016/0165-5728(87)90019-1; BERGER JR, 1989, NEUROLOGY, V39, P324, DOI 10.1212/WNL.39.3.324; BERMAN PW, 1985, SCIENCE, V227, P1490, DOI 10.1126/science.2983428; BHAT S, 1991, T AM SOC NEUROCHEM, V22, P183; BHAT S, IN PRESS P NATL ACAD; BHAT SA, UNPUB; CHIODI F, 1987, J VIROL, V61, P1244, DOI 10.1128/JVI.61.4.1244-1247.1987; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; COLLMAN R, 1990, J VIROL, V64, P4468, DOI 10.1128/JVI.64.9.4468-4476.1990; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEWHURST S, 1987, J VIROL, V61, P3774, DOI 10.1128/JVI.61.12.3774-3782.1987; DYER CA, 1988, J NEUROSCI, V8, P4307; GABUZDA DH, 1986, ANN NEUROL, V20, P289, DOI 10.1002/ana.410200304; GRAY F, 1991, NEUROLOGY, V41, P105, DOI 10.1212/WNL.41.1.105; GYORKEY F, 1987, J INFECT DIS, V155, P870, DOI 10.1093/infdis/155.5.870; HAROUSE JM, 1989, J VIROL, V63, P2527, DOI 10.1128/JVI.63.6.2527-2533.1989; HAROUSE JM, UNPUB; JAMESON BA, 1988, SCIENCE, V240, P1335, DOI 10.1126/science.2453925; JANSSEN RS, 1988, SCIENCE, V239, P586; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JOHNSON RT, 1986, TRENDS NEUROSCI, V9, P91, DOI 10.1016/0166-2236(86)90030-5; KIM SU, 1985, J NEUROIMMUNOL, V8, P255, DOI 10.1016/S0165-5728(85)80066-7; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; LARKIN M, 1989, AIDS, V3, P793, DOI 10.1097/00002030-198912000-00003; LASKY LA, 1984, BIO-TECHNOL, V2, P527, DOI 10.1038/nbt0684-527; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LI XL, 1990, J VIROL, V64, P1383, DOI 10.1128/JVI.64.3.1383-1387.1990; LIFSON JD, 1986, SCIENCE, V232, P1123, DOI 10.1126/science.3010463; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MAGNANI JL, 1987, METHOD ENZYMOL, V138, P195; MCCUNE JM, 1988, CELL, V55; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MOORE JP, 1990, AIDS, V4, P307, DOI 10.1097/00002030-199004000-00004; RAFF M, 1978, NATURE, V276, P813; RANCHST B, 1982, P NATL ACAD SCI USA, V79, P2709; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SHARPE AH, 1990, NATURE, V346, P181, DOI 10.1038/346181a0; SHAW GM, 1985, SCIENCE, V227, P177, DOI 10.1126/science.2981429; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SPITALNIK SL, 1985, BLOOD, V66, P319; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; WERNER A, 1990, AIDS, V4, P537, DOI 10.1097/00002030-199006000-00007; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; ZURBRIGGEN A, 1987, ACTA NEUROPATHOL, V74, P366, DOI 10.1007/BF00687214	51	497	514	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					320	323		10.1126/science.1857969	http://dx.doi.org/10.1126/science.1857969			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857969				2022-12-01	WOS:A1991FX22400042
J	PIEKEN, WA; OLSEN, DB; BENSELER, F; AURUP, H; ECKSTEIN, F				PIEKEN, WA; OLSEN, DB; BENSELER, F; AURUP, H; ECKSTEIN, F			KINETIC CHARACTERIZATION OF RIBONUCLEASE-RESISTANT 2'-MODIFIED HAMMERHEAD RIBOZYMES	SCIENCE			English	Article							SELF-CLEAVAGE; RNA; OLIGORIBONUCLEOTIDES	The incorporation of 2'-fluoro- and 2'-aminonucleotides into a hammerhead ribozyme was accomplished by automated chemical synthesis. The presence of 2'-fluorouridines, 2'-fluorocytidines, or 2'-aminouridines did not appreciably decrease catalytic efficiency. Incorporation of 2'-aminocytidines decreased ribozyme activity approximately by a factor of 20. The replacement of all adenosines with 2'-fluoroadenosines abolished catalysis in the presence of MgCl2 within the limits of detection, but some activity was retained in the presence of MnCl2. This effect on catalysis was localized to a specific group of adenines within the conserved single-stranded region of the ribozyme. The decrease in catalytic efficiency was caused by a decrease in the rate constant; the Michaelis constant was unaltered. The 2'-fluoro and 2'-amino modifications conferred resistance toward ribonuclease degradation. Ribozymes containing 2'-fluoro- or 2'-aminonucleotides at all uridine and cytidine positions were stabilized against degradation in rabbit serum by a factor of at least 10(3) compared to unmodified ribozyme.	MAX PLANCK INST EXPTL MED,CHEM ABT,HERMANN REIN STR 3,W-3400 GOTTINGEN,GERMANY	Max Planck Society				olsen, david/0000-0001-5521-0206				BEIJER B, 1990, NUCLEIC ACIDS RES, V18, P5143, DOI 10.1093/nar/18.17.5143; BENSELER F, UNPUB; CODINGTON JF, 1964, J ORG CHEM, V29, P558, DOI 10.1021/jo01026a009; COTTEN M, 1990, TRENDS BIOTECHNOL, V8, P174, DOI 10.1016/0167-7799(90)90168-W; DOERR IL, 1967, J ORG CHEM, V32, P1462, DOI 10.1021/jo01280a035; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; GUSCHLBAUER W, 1980, NUCLEIC ACIDS RES, V8, P1421, DOI 10.1093/nar/8.6.1421; HOBBS J, 1973, BIOCHEMISTRY-US, V12, P5138, DOI 10.1021/bi00749a018; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; IKEHARA M, 1978, CHEM PHARM BULL, V26, P2449; IMAZAWA M, 1979, J ORG CHEM, V44, P2039, DOI 10.1021/jo01326a037; JANIK B, 1972, BIOCHEM BIOPH RES CO, V46, P1153, DOI 10.1016/S0006-291X(72)80095-0; Mengel R., 1978, ANGEW CHEM, V90, P557; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9902, DOI 10.1021/bi00494a021; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; PIEKEN WA, UNPUB; ROSSI JJ, 1990, TRENDS BIOTECHNOL, V8, P179, DOI 10.1016/0167-7799(90)90169-X; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; VERHEYDEN JP, 1971, J ORG CHEM, V36, P250; WILLIAMS DM, 1991, BIOCHEMISTRY-US, V30, P4001, DOI 10.1021/bi00230a027	27	407	552	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					314	317		10.1126/science.1857967	http://dx.doi.org/10.1126/science.1857967			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857967				2022-12-01	WOS:A1991FX22400040
J	PINOLROMA, S; DREYFUSS, G				PINOLROMA, S; DREYFUSS, G			TRANSCRIPTION-DEPENDENT AND TRANSCRIPTION-INDEPENDENT NUCLEAR TRANSPORT OF HNRNP PROTEINS	SCIENCE			English	Article							RNA-BINDING PROTEINS; HELIX-DESTABILIZING PROTEIN; RIBONUCLEOPROTEIN-PARTICLES; MONOCLONAL-ANTIBODIES; CDNA CLONING; COMPLEXES; ENVELOPE; REVEALS; CELLS; SNRNA	Heterogeneous nuclear RNAs and specific nuclear proteins form heterogeneous nuclear ribonucleoprotein complexes (hnRNPs), one of the most abundant components of the nucleus. In mitosis, as the nuclear envelope breaks down, hnRNPs disperse throughout the cell. At the end of mitosis, hnRNPs dissociate and their proteins are transported into the daughter cell nuclei separately. Some are transported immediately (early group), white others are transported later (late group). Transport of the late group appears to require transcription by RNA polymerase II, in that inhibitors of this polymerase cause the late proteins to remain in the cytoplasm. Thus, there are two modes, transcription-dependent and transcription-independent, for the transport of nuclear proteins.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania	PINOLROMA, S (corresponding author), UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104, USA.		Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774				BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUVOLI M, 1988, NUCLEIC ACIDS RES, V16, P3751, DOI 10.1093/nar/16.9.3751; CHOI YD, 1984, P NATL ACAD SCI-BIOL, V81, P7471, DOI 10.1073/pnas.81.23.7471; CHOI YD, 1984, J CELL BIOL, V99, P1997; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; DEROBERTIS EM, 1982, NATURE, V295, P572, DOI 10.1038/295572a0; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cb.02.110186.002331; EGYHAZI E, 1982, EUR J BIOCHEM, V122, P445; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HARLOW E, 1988, ANTIBODIES LABORATOR; LAHIRI DK, 1985, J BIOL CHEM, V260, P598; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LESER GP, 1987, J CELL BIOL, V105, P2083, DOI 10.1083/jcb.105.5.2083; MARTIN TE, 1981, CELL NUCLEUS, V9, P119; MCKEON FD, 1983, P NATL ACAD SCI-BIOL, V80, P4374, DOI 10.1073/pnas.80.14.4374; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; PINOLROMA S, 1990, METHOD ENZYMOL, V181, P317; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PINOLROMA S, UNPUB; SAUTERER RA, 1988, EXP CELL RES, V176, P344, DOI 10.1016/0014-4827(88)90336-9; WILLIAMS KR, 1985, P NATL ACAD SCI USA, V82, P5666, DOI 10.1073/pnas.82.17.5666; ZELLER R, 1983, CELL, V32, P425, DOI 10.1016/0092-8674(83)90462-2; ZIEVE GW, 1986, J CELL PHYSIOL, V128, P85, DOI 10.1002/jcp.1041280114; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	31	188	189	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					312	314		10.1126/science.1857966	http://dx.doi.org/10.1126/science.1857966			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857966				2022-12-01	WOS:A1991FX22400039
J	QUE, L				QUE, L			OXYGEN ACTIVATION AT THE DIIRON CENTER OF RIBONUCLEOTIDE REDUCTASE	SCIENCE			English	Editorial Material							METHANE MONOOXYGENASE; HYDROGEN-PEROXIDE; IRON; COENZYME-B12; INTERMEDIATE; SPECTROSCOPY; MECHANISM; COBAMIDES; MOSSBAUER; PROTEIN				QUE, L (corresponding author), UNIV MINNESOTA,DEPT CHEM,MINNEAPOLIS,MN 55455, USA.							ANDERSON KK, 1991, NEW J CHEM, V15, P405; ASHLEY GW, 1986, J BIOL CHEM, V261, P3958; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BOLLINGER JM, IN PRESS J AM CHEM S; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; ERICSON A, 1988, J AM CHEM SOC, V110, P2330, DOI 10.1021/ja00215a070; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; FONTECAVE M, 1990, BIOCHEM BIOPH RES CO, V168, P659, DOI 10.1016/0006-291X(90)92371-6; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1989, J BIOL CHEM, V264, P10023; GROVES JT, 1985, J CHEM EDUC, V62, P928, DOI 10.1021/ed062p928; LEISING RA, 1991, J AM CHEM SOC, V113, P3988, DOI 10.1021/ja00010a050; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MENAGE S, 1990, J AM CHEM SOC, V112, P6423, DOI 10.1021/ja00173a055; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; ORMEJOHNSON WH, 1974, J BIOL CHEM, V249, P2338; QUE L, 1990, PROG INORG CHEM, V38, P97; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; STENKAMP RE, 1984, J AM CHEM SOC, V106, P618, DOI 10.1021/ja00315a027; STENKAMP RE, 1985, P NATL ACAD SCI USA, V82, P713, DOI 10.1073/pnas.82.3.713; STUBBE J, 1989, ADV ENZYMOL RELAT AR, V63, P349; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; TAMAO Y, 1973, BIOCHEMISTRY-US, V12, P24, DOI 10.1021/bi00725a005; WILLING A, 1988, EUR J BIOCHEM, V170, P603, DOI 10.1111/j.1432-1033.1988.tb13740.x	27	25	25	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					273	274		10.1126/science.1857963	http://dx.doi.org/10.1126/science.1857963			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857963				2022-12-01	WOS:A1991FX22400029
J	WIRAK, DO; BAYNEY, R; RAMABHADRAN, TV; FRACASSO, RP; HART, JT; HAUER, PE; HSIAU, P; PEKAR, SK; SCANGOS, GA; TRAPP, BD; UNTERBECK, AJ				WIRAK, DO; BAYNEY, R; RAMABHADRAN, TV; FRACASSO, RP; HART, JT; HAUER, PE; HSIAU, P; PEKAR, SK; SCANGOS, GA; TRAPP, BD; UNTERBECK, AJ			DEPOSITS OF AMYLOID-BETA PROTEIN IN THE CENTRAL-NERVOUS-SYSTEM OF TRANSGENIC MICE	SCIENCE			English	Article							ALTERNATIVELY SPLICED FORM; PRECURSOR MESSENGER-RNAS; CELL-SURFACE RECEPTOR; ALZHEIMERS-DISEASE; SENILE PLAQUES; GENE; EXPRESSION; BRAIN; LOCALIZATION; QUANTITATION	Alzheimer's disease is characterized by widespread deposition of amyloid in the central nervous system. The 4-kilodalton amyloid beta-protein is derived from a larger amyloid precursor protein and forms amyloid deposits in the brain by an unknown pathological mechanism. Except for aged nonhuman primates, there is no animal model for Alzheimer's disease. Transgenic mice expressing amyloid beta-protein in the brain could provide such a model. To investigate this possibility, the 4-kilodalton human amyloid beta-protein was expressed under the control of the promoter of the human amyloid precursor protein in two lines of transgenic mice. Amyloid beta-protein accumulated in the dendrites of some but not all hippocampal neurons in 1-year-old transgenic mice. Aggregates of the amyloid beta-protein formed amyloid-like fibrils that are similar in appearance to those in the brains of patients with Alzheimer's disease.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University	WIRAK, DO (corresponding author), MOLEC THERAPEUT INC,MILES RES CTR,400 MORGAN LANE,W HAVEN,CT 06516, USA.							BROECKHOVEN CV, 1990, SCIENCE, V248, P1120; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CORK LC, 1990, AM J PATHOL, V137, P1383; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; JOACHIM CL, 1989, AM J PATHOL, V135, P309; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEMAIRE HG, 1989, NUCLEIC ACIDS RES, V17, P517, DOI 10.1093/nar/17.2.517; LEVEY E, 1990, SCIENCE, V248, P1124; MANN DMA, 1988, NEW ENGL J MED, V318, P789; MARTIN LJ, 1991, P NATL ACAD SCI USA, V88, P1461, DOI 10.1073/pnas.88.4.1461; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRICE DL, 1986, ANNU REV NEUROSCI, V9, P489; RICHARDS SJ, 1990, EMBO J, V10, P297; ROBAKIS NK, 1987, LANCET, V1, P384; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SISODIA S, 1987, NUCLEIC ACIDS RES, V15, P1999; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TAGLIAVINI F, 1988, NEUROSCI LETT, V93, P191, DOI 10.1016/0304-3940(88)90080-8; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TRAPP BD, UNPUB; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WIRAK D, UPUB; WIRAK DO, 1991, EMBO J, V10, P289, DOI 10.1002/j.1460-2075.1991.tb07949.x; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V76, P541, DOI 10.1007/BF00689591; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	36	118	151	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					323	325		10.1126/science.1857970	http://dx.doi.org/10.1126/science.1857970			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857970				2022-12-01	WOS:A1991FX22400043
J	ASAKAI, R; CHUNG, DW; DAVIE, EW; SELIGSOHN, U				ASAKAI, R; CHUNG, DW; DAVIE, EW; SELIGSOHN, U			FACTOR-XI DEFICIENCY IN ASHKENAZI JEWS IN ISRAEL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOLECULAR-WEIGHT KININOGEN; THROMBOPLASTIN ANTECEDENT DEFICIENCY; TRANEXAMIC ACID; ORAL-SURGERY; HUMAN-PLASMA; GENE; PROTEINS; CHAIN; COMPLEX; SITE	Background and Methods. Severe factor XI deficiency, which is relatively common among Ashkenazi Jews, is associated with injury-related bleeding of considerable severity. Three point mutations - a splice-junction abnormality (Type 1), Glu117 --> Stop (Type 11), and Phe 283 --> Leu (Type III) - have been described in six patients with factor XI deficiency. Clinical correlations with these mutations have not been carried out. We determined the relative frequency of the mutations and their association with plasma levels of factor XI clotting activity and bleeding, analyzing the mutations with the polymerase chain reaction and restriction-enzyme digestion. Results. The Type 11 and Type III mutations had similar frequencies among 43 Ashkenazi Jewish probands with severe factor XI deficiency; these two mutations accounted for 49 percent and 47 percent, respectively, of a total of 86 analyzed alleles. Among 40 of the probands and 12 of their relatives with severe factor XI deficiency, patients homozygous for Type III mutation had a significantly higher level of factor XI clotting activity (mean [+/- SD] percentage of normal values, 9.7 +/- 3.8 percent; n = 13) than those homozygous for Type 11 mutation (1.2 +/- 0.5 percent, n = 16) or compound heterozygotes with Type 11/111 mutation (3.3 +/- 1.6 percent, n = 23), as well as significantly fewer episodes of injury-related bleeding. Each of these three groups had a similarly increased proportion of episodes, of bleeding complications after surgery at sites with enhanced local fibrinolysis, such as the urinary tract, or during tooth extraction. Conclusions. Type II and Type III mutations are the predominant causes of factor XI deficiency among Ashkenazi Jews. Genotypic analysis, assay for factor XI, and consideration of the type and location of surgery can be helpful in planning operations in patients with this disorder.	UNIV WASHINGTON, DEPT BIOCHEM, SJ-70, SEATTLE, WA 98195 USA; ICHILOV HOSP, INST HEMATOL, IL-64239 TEL AVIV, ISRAEL	University of Washington; University of Washington Seattle; Tel Aviv University			Sessum, Rachel/F-7312-2015	Sessum, Rachel/0000-0002-2444-7056; Asakai, Rei/0000-0002-1018-7556	NHLBI NIH HHS [HL-16919] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASAKAI R, 1987, BIOCHEMISTRY-US, V26, P7221, DOI 10.1021/bi00397a004; ASAKAI R, 1989, P NATL ACAD SCI USA, V86, P7667, DOI 10.1073/pnas.86.20.7667; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BIRN H, 1971, Scandinavian Journal of Dental Research, V79, P381; BOLTONMAGGS PHB, 1988, BRIT J HAEMATOL, V69, P521, DOI 10.1111/j.1365-2141.1988.tb02409.x; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; GOODMAN RM, 1979, GENETIC DISORDERS JE, P1; HARKER LA, 1974, HEMOSTASIS MANUAL, P28; KATO A, 1989, CYTOGENET CELL GENET, V52, P77, DOI 10.1159/000132844; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; MANNHALTER C, 1987, BLOOD, V70, P31; PAGE JD, 1989, BLOOD S, V74, pA291; RAGNI MV, 1985, BLOOD, V65, P719; RAPAPORT SI, 1961, BLOOD, V18, P149, DOI 10.1182/blood.V18.2.149.149; Rasmussen A B, 1966, Acta Otolaryngol, V61, P221, DOI 10.3109/00016486609127059; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAITO H, 1985, J LAB CLIN MED, V106, P718; SELIGSOHN U, 1978, BLOOD, V51, P1223; Siegel S., 1956, NONPARAMETRIC STAT, P96; SINDETPEDERSEN S, 1989, NEW ENGL J MED, V320, P840, DOI 10.1056/NEJM198903303201305; SINDETPEDERSEN S, 1986, J ORAL MAXIL SURG, V44, P703, DOI 10.1016/0278-2391(86)90039-X; SINDETPEDERSEN S, 1987, J DENT RES, V66, P1199, DOI 10.1177/00220345870660062101; STUMP DC, 1986, J BIOL CHEM, V261, P1267; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH PN, 1971, BRIT J HAEMATOL, V20, P463, DOI 10.1111/j.1365-2141.1971.tb07061.x	28	296	302	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 18	1991	325	3					153	158		10.1056/NEJM199107183250303	http://dx.doi.org/10.1056/NEJM199107183250303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW752	2052060				2022-12-01	WOS:A1991FW75200003
J	ASHBY, J; MORROD, RS				ASHBY, J; MORROD, RS			DETECTION OF HUMAN CARCINOGENS	NATURE			English	Editorial Material							RODENT CARCINOGENS; CHEMICALS; BIOASSAYS; MUTAGENS; TOO				ASHBY, J (corresponding author), ICI PLC,CENT TOXICOL LAB,MACCLESFIELD SK10 4TJ,ENGLAND.							AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; ASHBY J, 1991, MUTAT RES, V257, P229, DOI 10.1016/0165-1110(91)90003-E; ASHBY J, 1986, MUTAGENESIS, V1, P3, DOI 10.1093/mutage/1.1.3; BARTSCH H, 1989, CELL BIOL TOXICOL, V5, P115, DOI 10.1007/BF00122647; BRIDGES BA, 1976, MUTAT RES, V41, P71, DOI 10.1016/0027-5107(76)90075-0; BUTTERWORTH BE, 1990, MUTAT RES, V239, P117, DOI 10.1016/0165-1110(90)90033-8; CAGLIANO VJ, 1991, SCIENCE, V251, P606; CLAYSON DB, 1991, MUTAT RES, V257, P91, DOI 10.1016/0165-1110(91)90020-V; CLAYSON DB, 1989, MUTAT RES, V221, P53, DOI 10.1016/0165-1110(89)90045-6; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; DIETRICH DR, 1991, MUTAT RES, V248, P239, DOI 10.1016/0027-5107(91)90060-2; GRIESEMER RA, 1991, MUTAT RES, V257, P207, DOI 10.1016/0165-1110(91)90001-C; HASEMAN JK, 1987, CANCER LETT, V37, P125, DOI 10.1016/0304-3835(87)90154-6; HAY A, 1991, NATURE, V350, P555, DOI 10.1038/350555a0; HILL RN, 1989, FUND APPL TOXICOL, V12, P629, DOI 10.1016/0272-0590(89)90001-8; HUGG JE, 1991, CELL BIOL TOXIC, V7, P67; MALLING HV, 1974, CHEM CARCINOGENESIS; PETO R, 1985, ASSESSMENT RISK LOW, P3; ROBERTS L, 1991, SCIENCE, V252, P911, DOI 10.1126/science.2035022; SHELBY MD, 1990, MUTAT RES, V234, P257, DOI 10.1016/0165-1161(90)90022-G; TENNANT RW, 1990, MUTAGENESIS, V5, P3, DOI 10.1093/mutage/5.1.3; WEINSTEIN IB, 1991, SCIENCE, V251, P387, DOI 10.1126/science.1989073; WEISBURGER JH, 1981, FOOD COSMET TOXICOL, V19, P561, DOI 10.1016/0015-6264(81)90506-X; YAMASAKI H, 1988, TUMOUR PROMOTERS	25	89	89	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					185	186		10.1038/352185a0	http://dx.doi.org/10.1038/352185a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857407				2022-12-01	WOS:A1991FX18500022
J	BANDARA, LR; ADAMCZEWSKI, JP; HUNT, T; LATHANGUE, NB				BANDARA, LR; ADAMCZEWSKI, JP; HUNT, T; LATHANGUE, NB			CYCLIN-A AND THE RETINOBLASTOMA GENE-PRODUCT COMPLEX WITH A COMMON TRANSCRIPTION FACTOR	NATURE			English	Article							SV40 LARGE-T; E1A PROTEINS; CELL-CYCLE; BINDING; POLYPEPTIDES; ASSOCIATION; ANTIGEN	THE retinoblastoma gene (Rb) product is a negative regulator of cellular proliferation 1 an effect that could be mediated in part at the transcriptional level through its ability to complex with the sequence-specific transcription factor DRTF1 (ref. 2). This interaction is modulated by adenovirus E1a, which sequesters the Rb protein 3 and several other cellular proteins 3, including cyclin A (refs 4, 5), a molecule that undergoes cyclical accumulation and destruction during each cell cycle 6,7 and which is required for cell cycle progression 8. Cyclin A, which also complexes with DRTF1, facilitates the efficient assembly of the Rb protein into the complex. This suggests a role for cyclin A in regulating transcription and defines a transcription factor through which molecules that regulate the cell cycle in a negative fashion, such as Rb, and in a positive fashion, such as cyclin A, interact. Mutant loss-of-function Rb alleles, which occur in a variety of tumour cells, also fail to complex with E1a and large T antigen 9,10. Here we report on a naturally occurring loss-of-function Rb allele encoding a protein that fails to complex with DRTF1. This might explain how mutation in the Rb gene prevents negative growth control.	NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND; IMPERIAL CANC RES FUND,CLARE HALL LABS,POTTERS BAR EN6 3LD,HERTS,ENGLAND	MRC National Institute for Medical Research			Hunt, Tim/O-8544-2019	Hunt, Tim/0000-0001-5174-6038				BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SHIVJI MKK, 1991, MOL CELL BIOL, V11, P1686, DOI 10.1128/MCB.11.3.1686; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	22	287	298	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					249	251		10.1038/352249a0	http://dx.doi.org/10.1038/352249a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1830372				2022-12-01	WOS:A1991FX18500069
J	GREEN, DM; ZEVON, MA; LOWRIE, G; SEIGELSTEIN, N; HALL, B				GREEN, DM; ZEVON, MA; LOWRIE, G; SEIGELSTEIN, N; HALL, B			CONGENITAL-ANOMALIES IN CHILDREN OF PATIENTS WHO RECEIVED CHEMOTHERAPY FOR CANCER IN CHILDHOOD AND ADOLESCENCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ATOMIC-BOMB SURVIVORS; ANTI-NEOPLASTIC DRUGS; GLYCOPHORIN-A LOCUS; SALMONELLA-TYPHIMURIUM; WILMS TUMOR; MUTAGENIC ACTIVITY; MUTATIONS; AGENTS; PREGNANCY; MICROSOME	Background. Many patients who have been treated successfully for childhood cancer with regimens that contain one or more mutagenic chemotherapeutic agents are concerned that their own treatment during childhood or adolescence may adversely affect their children. Methods. To determine the effect of chemotherapy for cancer during childhood and adolescence on the outcome of subsequent pregnancies, we reviewed the records of 306 men and women who had been treated for pediatric cancer and who responded to our questionnaire. One hundred of the 306 patients reported 202 pregnancies. Among the patients who had received chemotherapy as part of their treatment for cancer, 60 patients or wives of patients had had one or more pregnancies of 20 or more weeks' gestation. The 60 former patients had a total of 100 live-born and 2 stillborn children. Results. The frequency of congenital anomalies was 8.1 percent (5 of 62) among the live-born children of the women and 7.9 percent (3 of 38) among the live-born children of the men. Structural congenital cardiac defects were identified in 10.0 percent (2 of 20) of the children of women who had been treated with dactinomycin, as compared with 0.6 percent (144 of 24,153) among the children in a multicenter survey of fetal anomalies (P = 0.0126). We found no relation between the number of mutagens received or the cumulative dose of any agent received and the frequency of congenital anomalies in the children. Conclusions. These data suggest that treatment of children and adolescents with mutagenic chemotherapeutic agents, in the dose ranges we examined, does not increase the frequency of congenital anomalies in the children subsequently born to the former patients. However, the possible adverse effect of dactinomycin on the children of such patients requires further study.	ROSWELL PK CANC INST, DEPT PSYCHOL, BUFFALO, NY 14263 USA; SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT PEDIAT, BUFFALO, NY 14260 USA; NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, ROSWELL PK GRAD DIV, DEPT NAT SCI, BUFFALO, NY 14263 USA	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Roswell Park Cancer Institute	GREEN, DM (corresponding author), ROSWELL PK CANC INST, DEPT PEDIAT, ELM & CARLTON ST, BUFFALO, NY 14263 USA.				NCI NIH HHS [CA-18201-15] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R25CA018201] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTINI RJ, 1985, MUTAT RES, V150, P411, DOI 10.1016/0027-5107(85)90138-1; ANDERSON D, 1978, BRIT J CANCER, V37, P924, DOI 10.1038/bjc.1978.134; AULETTA AE, 1978, J NATL CANCER I, V60, P1495, DOI 10.1093/jnci/60.6.1495; BENEDICT WF, 1977, CANCER RES, V37, P2209; BYRNE J, 1988, MED PEDIATR ONCOL, V16, P233, DOI 10.1002/mpo.2950160403; FRANZA BR, 1980, J NATL CANCER I, V65, P149; FREDERIC.PL, 1974, LANCET, V2, P707; GREEN DM, 1989, CANCER-AM CANCER SOC, V64, P2335, DOI 10.1002/1097-0142(19891201)64:11<2335::AID-CNCR2820641124>3.0.CO;2-7; GREEN DM, 1982, CANCER, V49, P2285, DOI 10.1002/1097-0142(19820601)49:11<2285::AID-CNCR2820491114>3.0.CO;2-N; GREEN DM, 1991, CANCER, V67, P206, DOI 10.1002/1097-0142(19910101)67:1<206::AID-CNCR2820670134>3.0.CO;2-2; HAKODA M, 1988, MUTAT RES, V201, P39, DOI 10.1016/0027-5107(88)90109-1; HAWKINS MM, 1988, J ROY COLL GEN PRACT, V38, P102; KYOIZUMI S, 1989, CANCER RES, V49, P581; LANGLOIS RG, 1987, SCIENCE, V236, P445, DOI 10.1126/science.3563520; LI FP, 1979, JNCI-J NATL CANCER I, V62, P1193; MATHESON D, 1978, DRUG CHEM TOXICOL, V1, P277, DOI 10.3109/01480547809105021; MATNEY TS, 1985, TERATOGEN CARCIN MUT, V5, P319, DOI 10.1002/tcm.1770050502; MULVIHILL JJ, 1983, MUTAT RES, V123, P345, DOI 10.1016/0165-1110(83)90028-3; MULVIHILL JJ, 1986, CLIN GENET, V39, P72; MYRIANTHOPOULOS NC, 1974, BIRTH DEFECTS ORI 11, V10; NEEL JV, 1988, AM J HUM GENET, V42, P663; NEEL JV, 1980, P NATL ACAD SCI-BIOL, V77, P4221, DOI 10.1073/pnas.77.7.4221; NGUYEN TV, 1982, CANCER RES, V42, P4792; PASTORFIDE GB, 1973, OBSTET GYNECOL, V42, P67; PREJEAN JD, 1984, DRUG METAB REV, V15, P619, DOI 10.3109/03602538409029975; PUEYO C, 1979, MUTAT RES, V67, P189, DOI 10.1016/0165-1218(79)90131-9; ROSS GT, 1976, CANCER, V37, P1043, DOI 10.1002/1097-0142(197602)37:2+<1043::AID-CNCR2820370809>3.0.CO;2-N; RUSTIN GJS, 1984, BRIT MED J, V288, P103, DOI 10.1136/bmj.288.6411.103; SEINO Y, 1978, CANCER RES, V38, P2148; STILLER CA, 1987, CARCINOGENESIS, V8, P129, DOI 10.1093/carcin/8.1.129; WILCOX AJ, 1984, AM J EPIDEMIOL, V120, P727, DOI 10.1093/oxfordjournals.aje.a113940; YAJIMA N, 1981, MUTAT RES, V88, P241, DOI 10.1016/0165-1218(81)90036-7; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C	33	83	87	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 18	1991	325	3					141	146		10.1056/NEJM199107183250301	http://dx.doi.org/10.1056/NEJM199107183250301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW752	2052058				2022-12-01	WOS:A1991FW75200001
J	HELMRICH, SP; RAGLAND, DR; LEUNG, RW; PAFFENBARGER, RS				HELMRICH, SP; RAGLAND, DR; LEUNG, RW; PAFFENBARGER, RS			PHYSICAL-ACTIVITY AND REDUCED OCCURRENCE OF NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLUCOSE-INTOLERANCE; RISK-FACTORS; EXERCISE; MEN; OBESITY; PREVALENCE; SENSITIVITY; MANAGEMENT; METABOLISM; MONOCYTES	Background. Physical activity is recommended by physicians to patients with non-insulin-dependent diabetes mellitus (NIDDM), because it increases sensitivity to insulin. Whether physical activity is effective in preventing this disease is not known. Methods. We used questionnaires to examine patterns of physical activity and other personal characteristics in relation to the subsequent development of NIDDM in 5990 male alumni of the University of Pennsylvania. The disease developed in a total of 202 men during 98,524 man-years of follow-up from 1962 to 1976. Results. Leisure-time physical activity, expressed in kilocalories expended per week in walking, stair climbing, and sports, was inversely related to the development of NIDDM. The incidence rates declined as energy expenditure increased from less than 500 kcal to 3500 kcal. For each 500-kcal increment in energy expenditure, the age-adjusted risk of NIDDM was reduced by 6 percent (relative risk, 0.94; 95 percent confidence interval, 0.90 to 0.98). This association remained the same when the data were adjusted for obesity, hypertension, and a parental history of diabetes. The association was weaker when we considered weight gain between the time of college attendance and 1962 (relative risk, 0.95; 95 percent confidence interval, 0.90 to 1.00). The protective effect of physical activity was strongest in persons at highest risk for NIDDM, defined as those with a high body-mass index, a history of hypertension, or a parental history of diabetes. These factors, in addition to weight gain since college, were also independent predictors of the disease. Conclusions. Increased physical activity is effective in preventing NIDDM, and the protective benefit is especially pronounced in persons at the highest risk for the disease.	STANFORD UNIV,MED CTR,SCH MED,DEPT HLTH RES & POLICY,STANFORD,CA 94305; UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720	Stanford University; University of California System; University of California Berkeley			Ragland, David R/G-6302-2017	Ragland, David R/0000-0002-8996-1320	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007365, R01HL034174] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL34174, T32 HL07365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AINSWORTH BE, IN PRESS MED SCI SPO; BARRETTCONNOR E, 1989, EPIDEMIOL REV, V11, P172, DOI 10.1093/oxfordjournals.epirev.a036035; BARRETTCONNOR E, 1981, AM J EPIDEMIOL, V113, P276, DOI 10.1093/oxfordjournals.aje.a113097; BEATY TH, 1982, AM J EPIDEMIOL, V115, P380, DOI 10.1093/oxfordjournals.aje.a113316; BJORNTORP P, 1970, METABOLIS, V19, P631, DOI 10.1016/0026-0495(70)90020-X; BLAIR SN, 1985, PUBLIC HEALTH REP, V100, P172; COX DR, 1972, J R STAT SOC B, V34, P187; DeFronzo R A, 1983, Am J Med, V74, P52, DOI 10.1016/0002-9343(83)90654-X; DEVLIN JT, 1985, DIABETES, V34, P973, DOI 10.2337/diabetes.34.10.973; DEVLIN JT, 1987, DIABETES, V36, P434, DOI 10.2337/diabetes.36.4.434; DONAHUE RP, 1990, AM J EPIDEMIOL, V132, P827, DOI 10.1093/oxfordjournals.aje.a115725; FRISCH RE, 1986, DIABETES, V35, P1101, DOI 10.2337/diabetes.35.10.1101; HORTON ES, 1988, DIABETES CARE, V11, P201, DOI 10.2337/diacare.11.2.201; JARRETT RJ, 1986, DIABETIC MED, V3, P549, DOI 10.1111/j.1464-5491.1986.tb00813.x; KAHN HA, 1971, J CHRON DIS, V23, P617, DOI 10.1016/0021-9681(71)90158-5; KANNEL WB, 1982, DIABETES MELLITUS OB, P734; KARAM JH, 1982, DIABETES MELLITUS OB, P294; KING H, 1984, AM J EPIDEMIOL, V119, P396, DOI 10.1093/oxfordjournals.aje.a113758; KOIVISTO VA, 1979, J CLIN INVEST, V64, P1011, DOI 10.1172/JCI109537; KOVAR MG, 1987, AM J PUBLIC HEALTH, V77, P1549, DOI 10.2105/AJPH.77.12.1549; KROTKIEWSKI M, 1983, SCAND J REHABIL ME S, V9, P55; LEON AS, 1979, AM J CLIN NUTR, V32, P1776, DOI 10.1093/ajcn/32.9.1776; LINGARDE F, 1981, DIABETOLOGIA, V20, P134; LOHMANN D, 1978, METABOLISM, V27, P521, DOI 10.1016/0026-0495(78)90017-3; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MODAN M, 1986, DIABETOLOGIA, V29, P82, DOI 10.1007/BF00456115; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1973, AM J EPIDEMIOL, V97, P314, DOI 10.1093/oxfordjournals.aje.a121511; PASSMORE R, 1955, PHYSIOL REV, V35, P801, DOI 10.1152/physrev.1955.35.4.801; RAURAMAA R, 1984, PREV MED, V13, P37, DOI 10.1016/0091-7435(84)90039-2; REITMAN JS, 1984, DIABETES CARE, V7, P434, DOI 10.2337/diacare.7.5.434; SOMAN VR, 1979, NEW ENGL J MED, V301, P1200, DOI 10.1056/NEJM197911293012203; TAYLOR R, 1984, DIABETOLOGIA, V27, P578, DOI 10.1007/BF00276971; THORNE MC, 1968, AM J EPIDEMIOL, V87, P520, DOI 10.1093/oxfordjournals.aje.a120843; WEST KM, 1978, EPIDEMIOLOGY DIABETE; WILSON PW, 1981, AM J EPIDEMIOL, V114, P697, DOI 10.1093/oxfordjournals.aje.a113240; 1987, DIABETES CARE, V10, P639; 1985, NIH851468 DEP HLTH H; [No title captured]	39	1164	1195	1	122	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 18	1991	325	3					147	152		10.1056/NEJM199107183250302	http://dx.doi.org/10.1056/NEJM199107183250302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW752	2052059				2022-12-01	WOS:A1991FW75200002
J	INOUE, I; NAGASE, H; KISHI, K; HIGUTI, T				INOUE, I; NAGASE, H; KISHI, K; HIGUTI, T			ATP-SENSITIVE K+ CHANNEL IN THE MITOCHONDRIAL INNER MEMBRANE	NATURE			English	Article							OXIDATIVE-PHOSPHORYLATION; ENERGY TRANSDUCTION; CATIONIC CHANNEL; TRANSPORT; PROTEINS; IMPORT	MITOCHONDRIA take up and extrude various inorganic and organic ions, as well as larger substances such as proteins 1-4. The technique of patch clamping should provide real-time information on such transport and on energy transduction in oxidative phosphorylation. It has been applied to detect microscopic currents from mitochondrial membranes and conductances of ion channels in the 5-1,000 pS range in the outer and inner membranes 5-10. These pores are not, however, selective for particular ions. Here we use fused giant mitoplasts prepared from rat liver mitochondria to identify a small conductance channel highly selective for K+ in the inner mitochondrial membrane. This channel can be reversibly inactivated by ATP applied to the matrix side under inside-out patch configuration; it is also inhibited by 4-aminopyridine and by glybenclamide. The slope conductance of the unitary currents measured at negative membrane potentials was 9.7 +/- 1.0 pS (mean +/- s.d., n = 6) when the pipette solution contained 100 mM K+ and the bathing solution 33.3 mM K+. Our results indicate that mitochondria depolarize by generating a K+ conductance when ATP in the matrix is deficient.	UNIV TOKUSHIMA,FAC PHARMACEUT SCI,TOKUSHIMA 770,JAPAN	Tokushima University	INOUE, I (corresponding author), UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN.							ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; CHAN TL, 1970, J CELL BIOL, V45, P291, DOI 10.1083/jcb.45.2.291; CHAZOTTE B, 1985, BIOCHIM BIOPHYS ACTA, V818, P87, DOI 10.1016/0005-2736(85)90142-7; CROMPTON M, 1985, CURR TOP MEMBR TRANS, V25, P231; DIWAN JJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P155, DOI 10.1016/S0304-4173(87)80001-0; Garlid K.D., 1988, INTEGRATION MITOCHON, P259; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAY R, 1984, BIOCHIM BIOPHYS ACTA, V779, P65, DOI 10.1016/0304-4157(84)90004-2; HENRY JP, 1989, J MEMBRANE BIOL, V112, P139, DOI 10.1007/BF01871275; HIGUTI T, 1983, BIOCHIM BIOPHYS ACTA, V725, P1, DOI 10.1016/0005-2728(83)90217-7; HIGUTI T, 1985, P NATL ACAD SCI USA, V82, P1331, DOI 10.1073/pnas.82.5.1331; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; LEHNINGER AL, 1964, MITOCHONDRION, P180; MEVES H, 1977, J PHYSIOL-LONDON, V268, P511, DOI 10.1113/jphysiol.1977.sp011869; MORAN O, 1990, J BIOL CHEM, V265, P980; Rottenberg H, 1979, Methods Enzymol, V55, P547; SCHNAITMAN C, 1967, J CELL BIOL, V32, P719, DOI 10.1083/jcb.32.3.719; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SORGATO MC, 1989, J BIOENERG BIOMEMBR, V21, P485, DOI 10.1007/BF00762520; STURGESS NC, 1985, LANCET, V2, P474; THIEFFRY M, 1988, EMBO J, V7, P1449, DOI 10.1002/j.1460-2075.1988.tb02962.x	23	632	681	1	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					244	247		10.1038/352244a0	http://dx.doi.org/10.1038/352244a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857420				2022-12-01	WOS:A1991FX18500067
J	JAHN, M; ROGERS, MJ; SOLL, D				JAHN, M; ROGERS, MJ; SOLL, D			ANTICODON AND ACCEPTOR STEM NUCLEOTIDES IN TRANSFER RNAGLN ARE MAJOR RECOGNITION ELEMENTS FOR ESCHERICHIA-COLI GLUTAMINYL-TRANSFER RNA-SYNTHETASE	NATURE			English	Article							IDENTITY; AMINOACYLATION; METHIONINE; INVITRO; SPECIFICITY; PARAMETERS; INVIVO; GLN	THE correct attachment of amino acids to their corresponding (cognate) transfer RNA catalysed by aminoacyl-tRNA synthetases is a key factor in ensuring the fidelity of protein biosynthesis. Previous studies have demonstrated that the interaction of Escherichia coli tRNA(Gln) with glutaminyl-tRNA synthetase (GlnRS) provides an excellent system 1 to study this highly specific recognition process, also referred to as 'tRNA identity' 2. Accurate acylation of tRNA depends mainly on two principles: a set of nucleotides in the tRNA molecule (identity elements) responsible for proper discrimination by aminoacyl-tRNA synthetases 1-3 and competition between different synthetases for tRNAs 4-6. Elements of glutamine identity are located in the anticodon 2,7-9 and in the acceptor stem region, including the discriminator base 5,10-13. We report here the production of more than 20 tRNA2Gln mutants at positions likely to be involved in tRNA discrimination by the enzyme. Unmodified tRNA, containing the wild-type anticodon and U or G at its 5'-terminus, can be aminocylated by GlnRS with similar kinetic parameters to native tRNA2Gln. By in vitro aminoacylation the mutant tRNAs showed decreases of up to 3 x 10(5)-fold in the specificity constant (k(cat)/K(M)) 14 with the major contribution of k(cat). Despite these large changes, some of these mutant tRNAs are efficient amber suppressors in vivo. Our results show that strong elements for glutamine identity reside in the anticodon region and in positions 2 and 3 of the acceptor stem, and that the contribution of different identity elements to the overall discrimination varies significantly. We discuss our data in the light of the crystal structure of the GlnRS:tRNA(Gln) complex 15,16.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Yale University								CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; Fersht A., 1985, ENZYME STRUCTURE MEC; HALL KB, 1989, BIOCHEMISTRY-US, V28, P5794, DOI 10.1021/bi00440a014; HASEGAWA T, 1989, BIOCHEM BIOPH RES CO, V163, P1534, DOI 10.1016/0006-291X(89)91154-6; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; HIMENO H, 1990, NUCLEIC ACIDS RES, V18, P6815, DOI 10.1093/nar/18.23.6815; HOBEN PJ, 1984, THESIS YALE U; HOOPER ML, 1972, FEBS LETT, V22, P149, DOI 10.1016/0014-5793(72)80241-2; HOU YM, 1989, BIOCHEMISTRY-US, V28, P4942, DOI 10.1021/bi00438a005; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; INOKUCHI H, 1984, P NATL ACAD SCI-BIOL, V81, P5076, DOI 10.1073/pnas.81.16.5076; JAHN MJ, 1991, NUCLEIC ACIDS RES, V19, P2786, DOI 10.1093/nar/19.10.2786; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PERONA JJ, 1988, J MOL BIOL, V202, P121, DOI 10.1016/0022-2836(88)90524-4; PERONA JJ, 1989, SCIENCE, V246, P1152, DOI 10.1126/science.2686030; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; REDFIELD AG, 1986, STRUCTURE DYNAMICS R, P99; ROGERS MJ, 1988, P NATL ACAD SCI USA, V85, P6627, DOI 10.1073/pnas.85.18.6627; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; SENO T, 1974, BIOCHIM BIOPHYS ACTA, V349, P328, DOI 10.1016/0005-2787(74)90120-8; SEONG BL, 1989, J BIOL CHEM, V246, P6504; SHIMURA Y, 1972, FEBS LETT, V22, P144, DOI 10.1016/0014-5793(72)80240-0; SOLL D, 1990, EXPERIENTIA, V46, P1089; SWANSON R, 1988, SCIENCE, V242, P1548, DOI 10.1126/science.3144042; YANIV M, 1974, J MOL BIOL, V86, P245, DOI 10.1016/0022-2836(74)90016-3; YARUS M, 1988, CELL, V55, P739, DOI 10.1016/0092-8674(88)90127-4	35	189	191	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					258	260		10.1038/352258a0	http://dx.doi.org/10.1038/352258a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857423				2022-12-01	WOS:A1991FX18500072
J	KESSLER, DA				KESSLER, DA			DRUG PROMOTION AND SCIENTIFIC EXCHANGE - THE ROLE OF THE CLINICAL INVESTIGATOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											KESSLER, DA (corresponding author), US FDA,ROCKVILLE,MD 20857, USA.								0	55	55	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 18	1991	325	3					201	203		10.1056/NEJM199107183250310	http://dx.doi.org/10.1056/NEJM199107183250310			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW752	2052064				2022-12-01	WOS:A1991FW75200010
J	KRAMER, H; CAGAN, RL; ZIPURSKY, SL				KRAMER, H; CAGAN, RL; ZIPURSKY, SL			INTERACTION OF BRIDE OF SEVENLESS MEMBRANE-BOUND LIGAND AND THE SEVENLESS TYROSINE-KINASE RECEPTOR	NATURE			English	Article							HOMOPHILIC ADHESION MOLECULE; GROWTH-FACTOR RECEPTOR; DROSOPHILA RETINA; EGF RECEPTOR; CELL FATE; SIGNAL TRANSDUCTION; MESODERM INDUCTION; PUTATIVE RECEPTOR; PATTERN-FORMATION; FASCICLIN-III	During development of the Drosophila retina, the R8 photoreceptor neuron induces a neighbouring cell to assume an R7 cell fate. Genetic data suggest that the induction is mediated by two transmembrane proteins encoded by bride of sevenless and sevenless. A direct interaction between these two proteins was demonstrated by the heterotypic aggregation of cell lines expressing them. In the developing eye the sevenless-dependent internalization of bride of sevenless by the R7 precursor cell provides evidence for a direct interaction between these two proteins in vivo.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	KRAMER, H (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA.		Cagan, Ross Leigh/AAV-9528-2021	Kramer, Helmut/0000-0002-1167-2676; Zipursky, Stephen/0000-0001-5630-7181; Cagan, Ross/0000-0001-5297-450X				ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BOWTELL DDL, 1989, CELL, V56, P931, DOI 10.1016/0092-8674(89)90626-0; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CAMPOSORTEGA JA, 1979, ROUX ARCH DEV BIOL, V186, P27, DOI 10.1007/BF00848106; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; NAGAFUCHI A, 1987, NATURE, V308, P693; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OTTE AP, 1991, SCIENCE, V251, P570, DOI 10.1126/science.1990433; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; RIO DC, 1986, CELL, V44, P21, DOI 10.1016/0092-8674(86)90481-2; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SORACCIA P, 1990, J BIOL CHEM, V265, P4902; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Spemann H., 1938, EMBRYONIC DEV INDUCT; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	55	287	294	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 18	1991	352	6332					207	212		10.1038/352207a0	http://dx.doi.org/10.1038/352207a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857416				2022-12-01	WOS:A1991FX18500053
J	MISSIAEN, L; TAYLOR, CW; BERRIDGE, MJ				MISSIAEN, L; TAYLOR, CW; BERRIDGE, MJ			SPONTANEOUS CALCIUM RELEASE FROM INOSITOL TRISPHOSPHATE-SENSITIVE CALCIUM STORES	NATURE			English	Article							INTRACELLULAR CALCIUM; CA-2+ RELEASE; FURA-2-LOADED HEPATOCYTES; OSCILLATIONS; CELLS; 1,4,5-TRISPHOSPHATE; MITOCHONDRIA; PHOSPHATES; RETICULUM; BINDING	Inositol 1,4,5-trisphosphate (InsP3) functions as a second messenger to mobilize Ca2+ from intracellular reservoirs 1. The release mechanism displays all-or-none characteristics 2,3, that may account for other observations that the InsP3-induced mobilization of Ca2+ is quantal 4-6. Quantal release may depend on the sensitivity of the InsP3 receptor being regulated by the Ca2+ concentration in the lumen of the endoplasmic reticulum 7. We report here that the InsP3-sensitive store in hepatocytes discharges spontaneously when overloaded with Ca2+. The release, which is blocked by heparin, is preceded by an increasing sensitivity of the InsP3 receptor to endogenous InsP3, and is promoted by those sulphydryl reagents (oxidized glutathione and thimerosal) that induce Ca2+ oscillations in intact cells (ref. 8, and T. A. Rooney, D. C. Renard, E. J. Sass and A. P. Thomas, manuscript in preparation). This novel process could have a role in generating both Ca2+ oscillations and Ca2+ waves.	UNIV CAMBRIDGE, DEPT PHARMACOL, CAMBRIDGE CB2 1QJ, ENGLAND	University of Cambridge	MISSIAEN, L (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, AFRC, MOLEC SIGNALLING LAB, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.		Taylor, Colin/G-2447-2010	Taylor, Colin/0000-0001-7771-1044	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BECKER GL, 1980, J BIOL CHEM, V255, P9009; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAROOTUNIAN AT, 1988, COLD SPRING HARB SYM, V53, P935, DOI 10.1101/SQB.1988.053.01.108; IGUSA Y, 1983, J PHYSIOL-LONDON, V340, P611, DOI 10.1113/jphysiol.1983.sp014783; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; KAWANISHI T, 1989, J BIOL CHEM, V264, P12859; KURTZ A, 1989, P NATL ACAD SCI USA, V86, P3423, DOI 10.1073/pnas.86.9.3423; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NUNN DL, 1990, BIOCHEM J, V270, P227, DOI 10.1042/bj2700227; OHNISHI ST, 1979, J BIOCHEM, V86, P1147, DOI 10.1093/oxfordjournals.jbchem.a132609; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PERES A, 1990, FEBS LETT, V275, P213, DOI 10.1016/0014-5793(90)81474-3; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; STUENKEL EL, 1990, AM J PHYSIOL, V258, pC289, DOI 10.1152/ajpcell.1990.258.2.C289; SWANN K, 1991, FEBS LETT, V278, P175, DOI 10.1016/0014-5793(91)80110-O; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; WOODS NM, 1990, CELL CALCIUM, V11, P353, DOI 10.1016/0143-4160(90)90038-V; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; ZHAO H, 1990, J BIOL CHEM, V265, P14822	28	335	340	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 18	1991	352	6332					241	244		10.1038/352241a0	http://dx.doi.org/10.1038/352241a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857419				2022-12-01	WOS:A1991FX18500066
J	QUON, D; WANG, Y; CATALANO, R; SCARDINA, JM; MURAKAMI, K; CORDELL, B				QUON, D; WANG, Y; CATALANO, R; SCARDINA, JM; MURAKAMI, K; CORDELL, B			FORMATION OF BETA-AMYLOID PROTEIN DEPOSITS IN BRAINS OF TRANSGENIC MICE	NATURE			English	Article							PRECURSOR MESSENGER-RNA; ALZHEIMERS-DISEASE; DIFFERENTIAL EXPRESSION; SENILE PLAQUES; RAT-BRAIN; ANTIBODY; NEURONS; CORTEX; GENE; DNA	DEPOSITS of beta-amyloid are one of the main pathological characteristics of Alzheimer's disease. The beta-amyloid peptide constituent (relative molecular mass 4,200) of the deposits is derived from the beta-amyloid precursor protein (beta-APP) which is expressed in several different isoforms 1-6. The two most prevalent beta-APP isoforms are distinguished by either the presence (beta-APP751) or absence (beta-APP695) of a Kunitz serine protease inhibitor domain. Changes in the abundance of different beta-APP messenger RNAs in brains of Alzheimer's disease victims have been widely reported 7-12. Although these results have been controversial, most evidence favours an increase in the mRNAs encoding protease inhibitor-containing isoforms of beta-APP and it is proposed that this change contributes to beta-amyloid formation 9-12. We have now produced an imbalance in the normal neuronal ratio of beta-APP isoforms by preparing transgenic mice expressing additional beta-APP751 under the control of a neural-specific promoter. The cortical and hippocampal brain regions of the transgenic mice display extracellular beta-amyloid immunoreactive deposits varying in size (< 5-50-mu-m) and abundance. These results suggest that one mechanism of beta-amyloid formation may involve a disruption of the normal ratio of neuronal beta-APP isoform expression and support a direct relationship between increased expression of Kunitz inhibitor-bearing beta-APP isoforms and beta-amyloid deposition.	CALIF BIOTECHNOL INC,2450 BAYSHORE PKWY,MT VIEW,CA 94043									ALLSOP D, 1989, NEUROPATH APPL NEURO, V15, P531, DOI 10.1111/j.1365-2990.1989.tb01252.x; BUGIANI O, 1989, NEUROSCI LETT, V103, P263, DOI 10.1016/0304-3940(89)90110-9; EKLUND J, 1976, ANIM PROD, V22, P127, DOI 10.1017/S0003356100035509; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; IKEDA S, 1989, LAB INVEST, V60, P113; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; JOHNSON SA, 1988, EXP NEUROL, V102, P264, DOI 10.1016/0014-4886(88)90104-5; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MURPHY GM, 1990, PROG NEURO-PSYCHOPH, V14, P309, DOI 10.1016/0278-5846(90)90019-D; NEVE RL, 1990, NEURON, V5, P329, DOI 10.1016/0896-6273(90)90169-G; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PALMERT MR, 1988, SCIENCE, V241, P1080, DOI 10.1126/science.2457949; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKIMURA K, 1987, GENE, V60, P103, DOI 10.1016/0378-1119(87)90218-6; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAGGART RT, 1983, SCIENCE, V219, P1228, DOI 10.1126/science.6402815; TAGLIAVINI F, 1988, NEUROSCI LETT, V93, P191, DOI 10.1016/0304-3940(88)90080-8; TAKIO K, 1989, BIOCHEM BIOPH RES CO, V160, P1296, DOI 10.1016/S0006-291X(89)80144-5; TANAKA S, 1988, BIOCHEM BIOPH RES CO, V157, P472, DOI 10.1016/S0006-291X(88)80273-0; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; Towbin H, 1979, 10 1073 PNAS 76 9 43, V76, P4350, DOI [10.1073/pnas.76.9.4350, DOI 10.1073/PNAS.76.9.4350]; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V76, P541, DOI 10.1007/BF00689591	30	356	401	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					239	241		10.1038/352239a0	http://dx.doi.org/10.1038/352239a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1906990				2022-12-01	WOS:A1991FX18500065
J	ROULD, MA; PERONA, JJ; STEITZ, TA				ROULD, MA; PERONA, JJ; STEITZ, TA			STRUCTURAL BASIS OF ANTICODON LOOP RECOGNITION BY GLUTAMINYL-TRANSFER RNA-SYNTHETASE	NATURE			English	Article							PHENYLALANINE TRANSFER-RNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; 2.8-A RESOLUTION; TRANSLATION; REFINEMENT; ATP	The refined crystal structure of Escherichia coli glutaminyl transfer RNA synthetase complexed with transfer RNA(Gln) and ATP reveals that the structure of the anticodon loop of the enzyme-bound tRNA(Gln) differs extensively from that of the known crystal structures of uncomplexed tRNA molecules. The anticodon stem is extended by two non-Watson-Crick base pairs, leaving the three anticodon bases unpaired and splayed out to bind snugly into three separate complementary pockets in the protein. These interactions suggest that the entire anticodon loop provides essential sites for glutaminyl tRNA synthetase discrimination among tRNA molecules.	YALE UNIV, DEPT CHEM, NEW HAVEN, CT 06511 USA; YALE UNIV, HOWARD HUGHES MED INST, NEW HAVEN, CT 06511 USA	Yale University; Howard Hughes Medical Institute; Yale University	ROULD, MA (corresponding author), YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, POB 6666, NEW HAVEN, CT 06511 USA.		Steitz, Thomas A./C-6559-2009					BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FINZEL BC, 1990, CRYSTALLOGRAPHIC MOD, P175; HOLBROOK SR, 1978, J MOL BIOL, V123, P631, DOI 10.1016/0022-2836(78)90210-3; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; NROMANLY J, 1989, A REV BIOCH, V58, P1029; PERONA JJ, 1989, SCIENCE, V246, P1152, DOI 10.1126/science.2686030; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; RAVEL JM, 1965, J BIOL CHEM, V240, P432; REDFIELD AG, 1986, STRUCTURE DYNAMICS R; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SENO T, 1974, BIOCHIM BIOPHYS ACTA, V349, P328, DOI 10.1016/0005-2787(74)90120-8; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; WESTHOF E, 1988, ACTA CRYSTALLOGR A, V44, P112, DOI 10.1107/S010876738700446X; WOO NH, 1980, NATURE, V286, P346, DOI 10.1038/286346a0; YANIV M, 1974, J MOL BIOL, V86, P245, DOI 10.1016/0022-2836(74)90016-3; YARUS M, 1986, J MOL BIOL, V192, P235, DOI 10.1016/0022-2836(86)90362-1; YARUS M, 1977, NUCLEIC ACID PROTEIN, P391	26	349	353	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 18	1991	352	6332					213	218		10.1038/352213a0	http://dx.doi.org/10.1038/352213a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857417				2022-12-01	WOS:A1991FX18500054
J	SLEZAK, SE; MUIRHEAD, KA				SLEZAK, SE; MUIRHEAD, KA			RADIOACTIVE CELL-MEMBRANE LABELING	NATURE			English	Article							FLUORESCENT				SLEZAK, SE (corresponding author), ZYNAXIS CELL SCI,371 PHOENIXVILLE PIKE,MALVERN,PA 19355, USA.							GRAY G, 1991, J NUCL MED, V32, P1092; HOFER KH, 1984, BLOOD CELLS NUCL M 2, P224; HORAN PK, 1990, FLOW CYTOMETRY, V30, P469; KOPIA GA, 1990, CIRCULATION, V82, P175; MEINICOFF MJ, 1988, J LEUKOCYTE BIOL, V43, P387; OLZEWSKI WL, 1987, IN VIVO MIGRATION IM, P223; PALMER LD, 1991, FASEB J, V5, pA639; ROWLINSONBUSZA G, 1991, CANCER RES, V51, P3251; SLEZAK SE, 1989, J IMMUNOL METHODS, V117, P205, DOI 10.1016/0022-1759(89)90142-7; SLEZAK SE, 1989, BLOOD, V74, P2171; TEARE GF, 1991, CELL IMMUNOL, V134, P157, DOI 10.1016/0008-8749(91)90339-D; YUAN Y, 1990, MICROVASC RES, V40, P218, DOI 10.1016/0026-2862(90)90021-I	12	20	21	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					261	262		10.1038/352261a0	http://dx.doi.org/10.1038/352261a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857424				2022-12-01	WOS:A1991FX18500073
J	SZER, IS; TAYLOR, E; STEERE, AC				SZER, IS; TAYLOR, E; STEERE, AC			THE LONG-TERM COURSE OF LYME ARTHRITIS IN CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BILATERAL KERATITIS; ANTIBODY-RESPONSE; DISEASE; MANIFESTATIONS; NEUROBORRELIOSIS; PENICILLIN; CHILDHOOD; THERAPY	Background and Methods. The natural history of Lyme disease is not completely known. We studied the long-term course of Lyme arthritis in 46 children in whom the onset of the disease occurred between 1976 and 1979 and who received no antibiotic therapy for at least the first four years of the illness. Results. Of the 46 children-(age range, 2 to 15 years), 33 (72 percent) initially had erythema migrans, 7 (15 percent) had influenza-like symptoms, and 6 (13 percent) had migratory joint pain. These manifestations were followed by brief attacks of arthritis, particularly affecting the knee. The percentage of children with recurrent episodes of arthritis declined each year. By year 4, only 10 children still had a mean of two episodes of arthritis per year; the duration of arthritis was generally longer in older children (P < 0.05). During the sixth year of illness, two children (4 percent) had keratitis, and more than 10 years after the onset of disease, a subtle encephalopathy developed in two other children. Of the 39 children whom we were able to contact in 1988-1989, 12 (31 percent) still had occasional brief episodes of joint pain and 1 (3 percent) had marked fatigue. All 46 children had positive IgG antibody responses to Borrelia burgdorferi throughout the illness and on long-term follow-up. As compared with those who became asymptomatic, the children with recurrent symptoms more often had IgM responses to the spirochete and had significantly higher IgG titers-(P < 0.05). Conclusions. The course of initially untreated Lyme disease in children may include acute infection followed by attacks of arthritis and then by keratitis, subtle joint pain, or chronic encephalopathy.	TUFTS UNIV,NEW ENGLAND MED CTR,FLOATING HOSP INFANTS & CHILDREN,SCH MED,DEPT PEDIAT,BOSTON,MA 02111; TUFTS UNIV,NEW ENGLAND MED CTR,FLOATING HOSP INFANTS & CHILDREN,SCH MED,DEPT MED,BOSTON,MA 02111	Floating Hospital For Children; Tufts Medical Center; Tufts University; Floating Hospital For Children; Tufts Medical Center; Tufts University				Steere, Allen/0000-0002-5268-9853	NIAMS NIH HHS [AR-20358] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR020358] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON LJ, 1987, PEDIATR INFECT DIS J, V6, P711, DOI 10.1097/00006454-198708000-00003; BAUM J, 1988, AM J OPHTHALMOL, V105, P75, DOI 10.1016/0002-9394(88)90124-9; CRAFT JE, 1984, J INFECT DIS, V149, P789, DOI 10.1093/infdis/149.5.789; CULP RW, 1987, J BONE JOINT SURG AM, V69A, P96, DOI 10.2106/00004623-198769010-00016; EICHENFIELD AH, 1986, J PEDIATR-US, V109, P753, DOI 10.1016/S0022-3476(86)80688-6; HALPERIN JJ, 1989, NEUROLOGY, V39, P753, DOI 10.1212/WNL.39.6.753; KORNMEHL EW, 1989, OPHTHALMOLOGY, V96, P1194; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; STEER AC, 1983, ANN INTERN MED, V99, P767, DOI 10.7326/0003-4819-99-6-767; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1985, NEW ENGL J MED, V312, P869, DOI 10.1056/NEJM198504043121401; STEERE AC, 1980, ANN INTERN MED, V93, P1, DOI 10.7326/0003-4819-93-1-1; STEERE AC, 1990, J INFECT DIS, V161, P1203, DOI 10.1093/infdis/161.6.1203; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; SWARTZ TA, 1971, AM J EPIDEMIOL, V94, P246, DOI 10.1093/oxfordjournals.aje.a121318; WILLIAMS CL, 1990, PEDIATR INFECT DIS J, V9, P10, DOI 10.1097/00006454-199001000-00003; YANEZ JE, 1966, ANN INTERN MED, V64, P772, DOI 10.7326/0003-4819-64-4-772	20	131	132	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 18	1991	325	3					159	163		10.1056/NEJM199107183250304	http://dx.doi.org/10.1056/NEJM199107183250304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW752	2052061				2022-12-01	WOS:A1991FW75200004
J	WATANABE, N; HUNT, T; IKAWA, Y; SAGATA, N				WATANABE, N; HUNT, T; IKAWA, Y; SAGATA, N			INDEPENDENT INACTIVATION OF MPF AND CYTOSTATIC FACTOR (MOS) UPON FERTILIZATION OF XENOPUS EGGS	NATURE			English	Article							MATURATION-PROMOTING FACTOR; PROTO-ONCOGENE PRODUCT; CELL-CYCLE; OOCYTES; ARREST; METAPHASE; COMPONENT	IN vertebrates, mature eggs are arrested at the second meiotic metaphase by the cytostatic factor (CSF) 1, now known to be the c-mos proto-oncogene product (Mos) 2,3. Fertilization or egg activation triggers a transient increase in the cytoplasmic free calcium 4,5 and releases the meiotic arrest by inactivating maturation/mitosis-promoting factor (MPF) 6,7. CSF or Mos, which is also inactivated by the calcium transient 8,9, seems to stabilize MPF in mature eggs and CSF-injected embryos. Thus, it was assumed that CSF inactivation is the primary cause of MPF inactivation on meiotic release 2,6,8,10-14. We have directly compared the degradation kinetics of CSF (Mos) and MPF during meiotic release, using the same batch of Xenopus eggs. We report here that, at the molecular level, cyclin subunits of MPF are degraded before Mos is degraded and, at the physiological level, that MPF activity is inactivated before CSF activity during activation of Xenopus eggs. These results, in conjunction with circumstantial evidence, support the novel view that a calcium transient on fertilization induces a CSF-independent pathway for MPF inactivation, whereas CSF inactivation during meiotic release serves only to allow the fertilized egg to enter mitosis.	KURUME UNIV,INST LIFE SCI,DIV MOLEC GENET,2432-3 AIKAWA,KURUME,FUKUOKA 830,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; TOKYO MED & DENT UNIV,BUNKYO KU,TOKYO 113,JAPAN	Kurume University; RIKEN; Tokyo Medical & Dental University (TMDU)			Hunt, Tim/O-8544-2019; Watanabe, Nobumoto/N-6959-2015	Hunt, Tim/0000-0001-5174-6038; Watanabe, Nobumoto/0000-0002-2130-1334				BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HUNT T, 1989, NATURE, V342, P483, DOI 10.1038/342483a0; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; KUBOTA HY, 1987, DEV BIOL, V119, P129, DOI 10.1016/0012-1606(87)90214-4; LORCA T, 1991, MOL CELL BIOL, V11, P1171, DOI 10.1128/MCB.11.2.1171; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MEYERHOF PG, 1977, DEV BIOL, V61, P214, DOI 10.1016/0012-1606(77)90293-7; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P319; SHIBUYA EK, 1988, DEV BIOL, V129, P253, DOI 10.1016/0012-1606(88)90179-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604	24	159	164	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					247	248		10.1038/352247a0	http://dx.doi.org/10.1038/352247a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1830371				2022-12-01	WOS:A1991FX18500068
J	HAVAS, S; KOUMJIAN, L; REISMAN, J; HSU, L; WOZENSKI, S				HAVAS, S; KOUMJIAN, L; REISMAN, J; HSU, L; WOZENSKI, S			RESULTS OF THE MASSACHUSETTS MODEL SYSTEMS FOR BLOOD CHOLESTEROL SCREENING PROJECT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROGRAM; HYPERTENSION; COMMUNITY; MORTALITY; IMPACT	Objective. - To evaluate the effectiveness of a model blood cholesterol screening program. Design. - Principal components included physician education, community-based screenings, and follow-up. A lay or professional educator provided counseling and referral advice. Half of the subjects with high blood cholesterol levels received a reminder to see their physician. Setting. - 135 sites in four Massachusetts communities. Participants. - 10 428 adults. Males, the young, the poor, the less educated, and minorities were underrepresented. Main Outcome Measures.-Referral completion rates, blood cholesterol changes. Results. - 51.5% of those referred had visited their physicians within 2 to 4 months, increasing to 65.6% within 6 to 12 months. Older age (odds ratio [OR], 1.17 per additional decade), more education (OR, 1.17 per additional level), higher blood cholesterol levels (OR, 1.19 per additional 0.51 mmol/L), previous knowledge of level (OR, 1.34), and receiving a reminder (OR, 1.24) were significantly associated with greater likelihood of referral completion, whereas the type of educator providing counseling was not. Physicians had remeasured the blood cholesterol level of 76% of those seen, given dietary counseling to 70%, and prescribed medication to 15%. Significant changes in dietary fat were reported by both compliers and noncompliers with advice to follow up with their physicians. Six months after screening, blood cholesterol levels were 3.6% lower in noncompliers, 4.4% lower in compliers not taking cholesterol-lowering medications, and 8.8% in compliers taking such medications. Conclusions. - An effective, community-based blood cholesterol screening program can attract diverse populations and can result in most participants with high levels following up with their physicians, making dietary changes, and lowering their cholesterol levels. Additional strategies may be needed to attract underrepresented groups and to reduce the apparent overuse of cholesterol-lowering medications.	MASSACHUSETTS DEPT PUBL HLTH,BOSTON,MA 02130; UNIV LOWELL,COLL HLTH PROFESS,LOWELL,MA 01854	Massachusetts Department of Public Health; University of Massachusetts System; University of Massachusetts Lowell	HAVAS, S (corresponding author), UNIV MARYLAND,SCH MED,DEPT EPIDEMIOL & PREVENT MED,655 W BALTIMORE ST,BALTIMORE,MD 21201, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037832] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL37832] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOCK G, 1985, AM J EPIDEMIOL, V122, P27, DOI 10.1093/oxfordjournals.aje.a114084; DAVIS CE, 1976, AM J EPIDEMIOL, V104, P493, DOI 10.1093/oxfordjournals.aje.a112321; FISCHER PM, 1990, ARCH INTERN MED, V150, P2567, DOI 10.1001/archinte.150.12.2567; GARRAWAY WM, 1987, JAMA-J AM MED ASSOC, V258, P214, DOI 10.1001/jama.258.2.214; GREENLAND P, 1987, AM J PUBLIC HEALTH, V77, P73, DOI 10.2105/AJPH.77.1.73; HAVAS S, 1989, AM J PREV MED, V5, P337, DOI 10.1016/S0749-3797(18)31054-7; KOTCHEN JM, 1986, JAMA-J AM MED ASSOC, V255, P2177, DOI 10.1001/jama.255.16.2177; LEFEBVRE RC, 1987, PREV MED, V16, P80, DOI 10.1016/0091-7435(87)90008-9; LEVY RI, 1984, AM J CARDIOL, V54, pC7, DOI 10.1016/0002-9149(84)90850-6; NAUGHTON MJ, 1990, JAMA-J AM MED ASSOC, V263, P1213, DOI 10.1001/jama.263.9.1213; RASTAM L, 1988, AM J PREV MED, V4, P244, DOI 10.1016/S0749-3797(18)31156-5; ROCHELLA E, 1984, HLTH ED Q, V11, P225; WYNDER EL, 1989, AM HEART J, V117, P649, DOI 10.1016/0002-8703(89)90741-2; WYNDER EL, 1986, JAMA-J AM MED ASSOC, V256, P2839, DOI 10.1001/jama.256.20.2839; 1968, NATIONAL DIET HEART, V18; 1985, JAMA-J AM MED ASSOC, V253, P2080; 1988, ARCH INTERN MED, V148, P36; 1990, MMWR, V39, P633; 1990, PREVENTION 89 90 FED, P34; 1986, HOME GARDEN B    APR, V232, P1; 1990, US PHS NIH902964 PUB	21	16	16	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1991	266	3					375	381		10.1001/jama.266.3.375	http://dx.doi.org/10.1001/jama.266.3.375			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV960	2056647				2022-12-01	WOS:A1991FV96000027
J	TIELSCH, JM; SOMMER, A; KATZ, J; ROYALL, RM; QUIGLEY, HA; JAVITT, J				TIELSCH, JM; SOMMER, A; KATZ, J; ROYALL, RM; QUIGLEY, HA; JAVITT, J			RACIAL VARIATIONS IN THE PREVALENCE OF PRIMARY OPEN-ANGLE GLAUCOMA - THE BALTIMORE EYE SURVEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FRAMINGHAM EYE; RISK-FACTORS	Objective. - To compare the prevalence of primary open-angle glaucoma between black and white Americans. Design, Setting, and Participants. - The design was a population-based prevalence survey of a noninstitutionalized black and white population aged 40 years or older from the eastern and southeastern health districts of Baltimore, Md. A multistage random sampling strategy was used to identify 7104 eligible participants, of whom 5308 (2395 blacks, 2913 whites) received an ophthalmologic screening examination. Those with abnormalities were referred for definitive diagnostic evaluation. Main Outcome Measure. - Primary open-angle glaucoma was defined based on evidence of glaucomatous optic nerve damage, including abnormal visual fields and/or severe optic disc cupping, and was independent of intraocular pressure. Main Results. - Age-adjusted prevalence rates for primary open-angle glaucoma were four to five times higher in blacks as compared with whites. Rates among blacks ranged from 1.23% in those aged 40 through 49 years to 11.26% in those 80 years or older, whereas rates for whites ranged from 0.92% to 2.16%, respectively. There was no difference in rates of primary open-angle glaucoma between men and women for either blacks or whites in this population. Based on these data, an estimated 1.6 million persons aged 40 years or older in the United States have primary open-angle glaucoma. Conclusions. - Black Americans are at higher risk of primary open-angle glaucoma than their white neighbors. This may reflect an underlying genetic susceptibility to this disease and indicates that additional efforts are needed to identify and treat this sight-threatening disorder in high-risk communities.	JOHNS HOPKINS UNIV HOSP,WILMER OPHTHALMOL INST,DANA CTR PREVENT OPHTHALMOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University			Javitt, Jonathan/AAJ-5574-2021	Javitt, Jonathan/0000-0003-2371-1609; Katz, Joanne/0000-0002-5997-7823; Tielsch, James/0000-0002-1151-060X	NCRR NIH HHS [RR-04060] Funding Source: Medline; NEI NIH HHS [EY-05091, EY-03605] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004060] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY003605] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BENGTSSON B, 1981, BRIT J OPHTHALMOL, V65, P46, DOI 10.1136/bjo.65.1.46; BENGTSSON B, 1989, BRIT J OPHTHALMOL, V73, P483, DOI 10.1136/bjo.73.7.483; COULEHAN JL, 1980, AM J EPIDEMIOL, V111, P759, DOI 10.1093/oxfordjournals.aje.a112954; FRYDMAN JE, 1966, J AMER MED ASSOC, V198, P1237, DOI 10.1001/jama.198.12.1237; HOLLOWS FC, 1966, BRIT J OPHTHALMOL, V50, P570, DOI 10.1136/bjo.50.10.570; KAHN HA, 1980, AM J EPIDEMIOL, V111, P769, DOI 10.1093/oxfordjournals.aje.a112955; KAHN HA, 1980, ARCH OPHTHALMOL-CHIC, V98, P2172, DOI 10.1001/archopht.1980.01020041024003; KAHN HA, 1973, DHEW NIH73427 NAT EY; KAHN HA, 1989, STATISTICAL METHODS; KOSOKO O, 1986, OPHTHALMOLOGY, V93, P882; Leibowitz H M, 1980, Surv Ophthalmol, V24, P335; MARTIN MJ, 1985, AM J OPHTHALMOL, V99, P383, DOI 10.1016/0002-9394(85)90001-7; MASON RP, 1989, OPHTHALMOLOGY, V96, P1363; SOMMER A, 1984, ARCH OPHTHALMOL-CHIC, V102, P1766; TIELSCH JM, 1988, OPHTHALMOLOGY, V95, P350; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; VIGGOSSON G, 1986, ACTA OPHTHALMOL, V64, P138; WALLACE J, 1969, AM J OPHTHALMOL, V67, P93, DOI 10.1016/0002-9394(69)90013-0; WILENSKY JT, 1978, ANN OPHTHALMOL, V10, P1398; WILSON MR, 1987, ARCH OPHTHALMOL-CHIC, V105, P1066	20	997	1036	0	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1991	266	3					369	374		10.1001/jama.266.3.369	http://dx.doi.org/10.1001/jama.266.3.369			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV960	2056646				2022-12-01	WOS:A1991FV96000026
J	ZEMEL, G; KATZEN, BT; BECKER, GJ; BENENATI, JF; SALLEE, DS				ZEMEL, G; KATZEN, BT; BECKER, GJ; BENENATI, JF; SALLEE, DS			PERCUTANEOUS TRANSJUGULAR PORTOSYSTEMIC SHUNT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THERAPEUTIC PORTACAVAL-SHUNT; ENDOSCOPIC SCLEROTHERAPY; RANDOMIZED TRIAL; VARICEAL HEMORRHAGE; PORTAL-HYPERTENSION; BLEEDING VARICES; CIRRHOSIS; DISEASE; STENTS	Objective. - To determine the effectiveness of the Palmaz balloon expandable stent for the creation of a transjugular intrahepatic portosystemic shunt. The device is designed to achieve portal decompression in patients with variceal hemorrhage secondary to portal hypertension. Design. - Transjugular intrahepatic portosystemic shunting was performed in eight patients during a 9-month period. Mean follow-up was 5 months. Patients. - All patients had cirrhosis with portal hypertension and varices. Bleeding occurred in seven patients from esophageal varices and in one patient from hemorrhoids. Main Outcome Measures. - Shunt patency and recurrent variceal hemorrhage. Results. - Shunts created from a transjugular approach between a hepatic and a portal vein (diameters of 8 to 12 mm) lowered the average portosystemic pressure gradient from 36 to 11 mm Hg. Mean postoperative hospital stay was 7.7 days. Complete variceal decompression after transjugular intrahepatic portosystemic shunt placement was identified endoscopically in all eight patients. The patient treated for hemorrhoids rebled and was treated successfully by transfemoral balloon expansion of the shunt diameter from 8 to 12 mm. All shunts were patent at 1 to 9 months (mean, 5 months) of follow-up. Conclusion. - Initial results suggest that transjugular intrahepatic portosystemic shunt is a safe and effective method of portal decompression for the treatment of variceal hemorrhage.			ZEMEL, G (corresponding author), BAPTIST HOSP MIAMI,MIAMI VASC INST,8900 N KENDALL DR,MIAMI,FL 33176, USA.							CASTANEDAZUNIGA WR, 1988, INTERVENTIONAL RADIO, P167; CELLO JP, 1987, NEW ENGL J MED, V316, P11, DOI 10.1056/NEJM198701013160103; COLAPINTO RF, 1982, CAN MED ASSOC J, V126, P267; COLDWELL DM, 1991, RADIOLOGY, V178, P249, DOI 10.1148/radiology.178.1.1984312; JACKSON FC, 1971, ANN SURG, V174, P672, DOI 10.1097/00000658-197110000-00012; JOHANSEN K, 1989, AM J SURG, V157, P479, DOI 10.1016/0002-9610(89)90639-9; PALMAZ JC, 1986, AM J ROENTGENOL, V147, P1251, DOI 10.2214/ajr.147.6.1251; PALMAZ JC, 1985, AJR, V145, P820; RESNICK RH, 1974, GASTROENTEROLOGY, V67, P843; REYNOLDS TB, 1981, GASTROENTEROLOGY, V80, P1005; RICHTER GM, 1990, RADIOLOGY, V174, P1027, DOI 10.1148/radiology.174.3.174-3-1027; RIKKERS LF, 1987, ANN SURG, V206, P261, DOI 10.1097/00000658-198709000-00004; RIKKERS LF, 1983, SURGERY, V94, P126; ROSCH J, 1987, RADIOLOGY, V162, P481; ROSCH J, 1969, RADIOLOGY, V92, P1112; RUEFF B, 1976, LANCET, V1, P655; RUTHERFORD RB, 1991, CIRCULATION, V83, P6; VIALLET A, 1975, GASTROENTEROLOGY, V69, P1297; WARREN WD, 1986, ANN SURG, V203, P454, DOI 10.1097/00000658-198605000-00002; WARREN WD, 1983, AM J SURG, V145, P8, DOI 10.1016/0002-9610(83)90159-9	20	169	186	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1991	266	3					390	393		10.1001/jama.266.3.390	http://dx.doi.org/10.1001/jama.266.3.390			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV960	1829120				2022-12-01	WOS:A1991FV96000029
J	FRAZIER, LM; BROWN, JT; DIVINE, GW; FLEMING, GR; PHILIPS, NM; SIEGAL, WC; KHAYRALLAH, MA				FRAZIER, LM; BROWN, JT; DIVINE, GW; FLEMING, GR; PHILIPS, NM; SIEGAL, WC; KHAYRALLAH, MA			CAN PHYSICIAN EDUCATION LOWER THE COST OF PRESCRIPTION DRUGS - A PROSPECTIVE, CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							GENERIC PHARMACEUTICALS; MILD HYPERTENSION; LIPID PROFILE; THERAPY; PRICE	Objective: To determine whether an educational program featuring a drug cost manual can assist physicians in reducing their patients' out-of-pocket prescription drug expenses. Design: Prospective controlled trial. Setting: A general internal medicine-teaching clinic in a university hospital. Participants: Fifty-one medical interns. Intervention: Thirty-one interns received a manual of comparative drug prices annotated with prescribing advice, two feedback reports, and weekly cost-oriented prescribing reminders. A control group concurrently participated in a manual-based educational program on cholesterol management. Measurements: Copies of 3012 prescriptions written over 8 months were analyzed. Main Results: Intervention group physicians prescribed less expensive drugs within classes of drugs. The change in drug price score per prescription was -0.15 (95% Cl, - 0.27 to - 0.04; P = 0.01). A score of 3 was assigned to the most expensive, 2 was assigned to intermediate-priced, and 1 was assigned to the least expensive drug or drugs in the class. An increase of 0.74 months' (Cl, 0.49 to 0.98; P < 0.001) supply of medication was dispensed per prescription, reducing dispensing fees. The program was well accepted by the physicians. Conclusion: This relatively simple educational intervention can help physicians to reduce their patients' drug expenses and may serve as a model for incorporating cost information into the routine practice of medicine.	UNIV N CAROLINA, SCH EDUC, CHAPEL HILL, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill	FRAZIER, LM (corresponding author), DUKE UNIV, MED CTR, BOX 2914, DURHAM, NC 27710 USA.							AMES RP, 1987, AM HEART J, V114, P998, DOI 10.1016/0002-8703(87)90599-0; [Anonymous], 1981, JAMA, V246, P2073; [Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; [Anonymous], 1980, LANCET, V1, P1261; [Anonymous], 1970, JAMA, V213, P1143; AVORN J, 1986, JAMA-J AM MED ASSOC, V255, P357, DOI 10.1001/jama.255.3.357; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; BLOOM BS, 1986, JAMA-J AM MED ASSOC, V256, P2523, DOI 10.1001/jama.256.18.2523; BRICELAND LL, 1988, ARCH INTERN MED, V148, P2019, DOI 10.1001/archinte.148.9.2019; BRITTON HL, 1981, AM J HOSP PHARM, V38, P1897, DOI 10.1093/ajhp/38.12.1897; CARDINALE VA, 1988, DRUG TOPICS RED BOOK; CLAPHAM CE, 1988, AM J HOSP PHARM, V45, P2329, DOI 10.1093/ajhp/45.11.2329; CRAIG WA, 1978, ANN INTERN MED, V89, P793, DOI 10.7326/0003-4819-89-5-793; DURBIN WA, 1981, JAMA-J AM MED ASSOC, V246, P1796, DOI 10.1001/jama.246.16.1796; FAICH GA, 1987, NEW ENGL J MED, V316, P1473, DOI 10.1056/NEJM198706043162309; FRAZIER LM, 1986, N C MED J, V47, P115; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; GEHLBACH SH, 1984, MED CARE, V22, P193, DOI 10.1097/00005650-198403000-00002; GROOP L, 1985, EUR J CLIN PHARMACOL, V28, P697, DOI 10.1007/BF00607919; HELGELAND A, 1980, AM J MED, V69, P725, DOI 10.1016/0002-9343(80)90438-6; HOLTZMAN E, 1987, J CARDIOVASC PHARM, V10, pS86, DOI 10.1097/00005344-198706102-00026; Hypertension Detection Follow-up Program Cooperative Group, 1979, JAMA-J AM MED ASSOC, V242, P2562, DOI DOI 10.1001/JAMA.1979.03300230018021; KAPLAN NM, 1987, AM J MED, V82, P9, DOI 10.1016/0002-9343(87)90137-9; KLEIN LE, 1981, J MED EDUC, V56, P504; Kreling D H, 1989, Health Care Financ Rev, V10, P67; LASAGNA L, 1986, JAMA-J AM MED ASSOC, V256, P2566, DOI 10.1001/jama.1986.03380180128035; MARTON KI, 1985, ARCH INTERN MED, V145, P816, DOI 10.1001/archinte.145.5.816; NIGHTINGALE SL, 1987, JAMA-J AM MED ASSOC, V258, P1200, DOI 10.1001/jama.258.9.1200; PROSSER PR, 1985, AM J MED SCI, V289, P179, DOI 10.1097/00000441-198505000-00001; ROBERTS WC, 1987, AM J CARDIOL, V60, pE33; SAMUEL P, 1986, AM J CARDIOL, V57, pC24, DOI 10.1016/0002-9149(86)91023-4; SCHAFFNER W, 1983, JAMA-J AM MED ASSOC, V250, P1728, DOI 10.1001/jama.250.13.1728; SKILLMAN TG, 1981, AM J MED, V70, P361, DOI 10.1016/0002-9343(81)90773-7; SMITH WM, 1977, CIRC RES, V40, P98; Snedecor G W, 1967, STAT METHODS, P327; Stoudemire A, 1984, Psychiatr Med, V2, P211; STROM BL, 1987, NEW ENGL J MED, V316, P1456, DOI 10.1056/NEJM198706043162306; WALDO DR, 1989, HLTH CARE FINANC REV, V9, P83; WALLIN JD, 1987, ARCH INTERN MED, V147, P654, DOI 10.1001/archinte.147.4.654; WOODWARD RS, 1987, AM J MED, V83, P817, DOI 10.1016/0002-9343(87)90636-X; 1987, APPROVED DRUG PRODUC, P1	41	61	61	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1991	115	2					116	121		10.7326/0003-4819-115-2-116	http://dx.doi.org/10.7326/0003-4819-115-2-116			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW091	2058859				2022-12-01	WOS:A1991FW09100008
J	PERRILLO, RP; BRUNT, EM				PERRILLO, RP; BRUNT, EM			HEPATIC HISTOLOGIC AND IMMUNOHISTOCHEMICAL CHANGES IN CHRONIC HEPATITIS-B AFTER PROLONGED CLEARANCE OF HEPATITIS-B E-ANTIGEN AND HEPATITIS-B SURFACE-ANTIGEN	ANNALS OF INTERNAL MEDICINE			English	Note							POLYMERASE CHAIN-REACTION; ANTIVIRAL THERAPY; CONTROLLED TRIAL; PREDNISONE WITHDRAWAL; ALPHA-INTERFERON; DNA; LIVER; SERUM		WASHINGTON UNIV, SCH MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	PERRILLO, RP (corresponding author), VET AFFAIRS MED CTR, 111 JC, 915 N GRAND BLVD, ST LOUIS, MO 63106 USA.							BROOK MG, 1988, VIRAL HEPATITIS LIVE, P906; DIBISCEGLIE AM, 1987, GASTROENTEROLOGY, V93, P1236, DOI 10.1016/0016-5085(87)90250-2; HOOFNAGLE JH, 1988, GASTROENTEROLOGY, V95, P1318, DOI 10.1016/0016-5085(88)90367-8; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KORENMAN J, 1991, ANN INTERN MED, V114, P629, DOI 10.7326/0003-4819-114-8-629; KUHNS M, 1990, HEPATOLOGY, V12, P904; KUHNS MC, 1989, J MED VIROL, V27, P274, DOI 10.1002/jmv.1890270404; MARCELLIN P, 1990, ANN INTERN MED, V112, P227, DOI 10.7326/0003-4819-112-3-227; PERRILLO RP, 1988, ANN INTERN MED, V109, P95, DOI 10.7326/0003-4819-109-2-95; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503	10	66	66	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1991	115	2					113	115		10.7326/0003-4819-115-2-113	http://dx.doi.org/10.7326/0003-4819-115-2-113			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW091	2058858				2022-12-01	WOS:A1991FW09100007
J	WRIGHT, TL; HSU, H; DONEGAN, E; FEINSTONE, S; GREENBERG, H; READ, A; ASCHER, NL; ROBERTS, JP; LAKE, JR				WRIGHT, TL; HSU, H; DONEGAN, E; FEINSTONE, S; GREENBERG, H; READ, A; ASCHER, NL; ROBERTS, JP; LAKE, JR			HEPATITIS-C VIRUS NOT FOUND IN FULMINANT NON-A, NON-B HEPATITIS	ANNALS OF INTERNAL MEDICINE			English	Note							FAILURE		DEPT VET AFFAIRS MED CTR, PALO ALTO, CA 94304 USA; US FDA, HEPATITIS RES LAB, SAN FRANCISCO, CA 94102 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; STANFORD UNIV, STANFORD, CA 94305 USA	US Food & Drug Administration (FDA); University of California System; University of California San Francisco; Stanford University	WRIGHT, TL (corresponding author), VET AFFAIRS MED CTR, GASTROENTEROL UNIT, 111B, 4150 CLEMENT ST, SAN FRANCISCO, CA 94121 USA.			greenberg, harry/0000-0002-2128-9080; Lake, John/0000-0002-4332-0528	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-26743] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; CRISTIANO K, IN PRES HEPATOLOGY; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MUTO Y, 1990, Gastroenterologia Japonica, V25, P32; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4	7	131	132	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1991	115	2					111	112		10.7326/0003-4819-115-2-111	http://dx.doi.org/10.7326/0003-4819-115-2-111			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW091	1647717				2022-12-01	WOS:A1991FW09100006
J	BHATTI, N; GILSON, RJC; BEECHAM, M; WILLIAMS, P; MATTHEWS, MP; TEDDER, RS; WELLER, IVD				BHATTI, N; GILSON, RJC; BEECHAM, M; WILLIAMS, P; MATTHEWS, MP; TEDDER, RS; WELLER, IVD			FAILURE TO DELIVER HEPATITIS-B VACCINE - CONFESSIONS FROM A GENITOURINARY MEDICINE CLINIC	BRITISH MEDICAL JOURNAL			English	Article							HOMOSEXUAL MEN; VIRAL-HEPATITIS; VIRUS-INFECTION; EFFICACY; DISEASE; TRIAL; POPULATION; PREVALENCE; ANTIBODIES; CARRIERS	Objective-To audit hepatitis B immunisation of homosexual or bisexual men in a genitourinary medicine clinic. Design-Retrospective case note review of all homosexual and bisexual men presenting to a genitourinary clinic as new patients during 12 months in 1988 and follow up review of notes to May 1990. Setting-One department of genitourinary medicine, Middlesex Hospital. Patients-758 homosexual or bisexual men, of whom 207 started a course of hepatitis B vaccine in 1988. Case notes were unavailable for one patient. Main outcome measures-The proportion of patients screened for hepatitis B virus markers, the proportion of susceptible patients immunised, the proportion completing the vaccine course, and the proportion rendered immune. Results-25 men had been previously tested for hepatitis markers; of the 732 not previously tested, 440 (60.1%) were screened for hepatitis B markers. 207 (69%) of the 300 patients without hepatitis B serological markers started the vaccine course, and 141 (68%) completed it, with 75 (84%) of the 89 tested after immunisation being immune. An estimated 24% of susceptible new patients were rendered immune as a result of the immunisation policy. Patients who presented with a further episode of a sexually transmitted disease were more likely to have been screened (25% v 12%, p < 0.0001) and immunised (31% v 18% p = 0.02); those known or found to be positive for HIV antibody were more likely to have been screened (23% v 14%, p = 0.047) but less likely to have been immunised (6% v 17%, p = 0.004). Conclusions-The major failure was that in not screening; failure to immunise patients found to be susceptible and failure of compliance with the vaccine course contributed. Non-response to the vaccine was of minor importance. Improvements in vaccine delivery are required. Implications-Other providers should be encouraged to review their performance.	UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON W1N 8AA,ENGLAND; UNIV COLL & MIDDLESEX SCH MED,DEPT MED MICROBIOL,DIV VIROL,LONDON WC1E 6BT,ENGLAND; MIDDLESEX HOSP,DEPT GENITOURINARY MED,LONDON W1N 8AA,ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London			Gilson, Richard J C/C-5123-2009	Tedder, Richard/0000-0002-9672-5721				ADLER MW, 1983, BRIT MED J, V266, P1621; ANDRE FE, 1987, POSTGRAD MED J, V63, P169; BODSWORTH N, 1989, J INFECT DIS, V160, P577, DOI 10.1093/infdis/160.4.577; CARNE CA, 1987, BRIT MED J, V294, P866, DOI 10.1136/bmj.294.6576.866; CHRISTOPHER PJ, 1984, AUST NZ J MED, V14, P491, DOI 10.1111/j.1445-5994.1984.tb03624.x; COLEMAN JC, 1979, J INFECTION, V1, P61, DOI 10.1016/S0163-4453(79)80055-9; COLLIER AC, 1988, ANN INTERN MED, V109, P101, DOI 10.7326/0003-4819-109-2-101; COUTINHO RA, 1983, BRIT MED J, V286, P1305, DOI 10.1136/bmj.286.6374.1305; ELLIS WR, 1979, LANCET, V1, P903; FEFFRIES DJ, 1973, BMJ, V2, P455; FRANCIS DP, 1982, ANN INTERN MED, V97, P362, DOI 10.7326/0003-4819-97-3-362; FULFORD KWM, 1973, LANCET, V1, P1470; GILSON RJC, 1990, HEPATITIS B SEXUALLY, V919, P45; HENTZER B, 1980, SCAND J INFECT DIS, V12, P245, DOI 10.3109/inf.1980.12.issue-4.02; KANE MA, 1989, AM J MED, V87; KROGSGAARD K, 1987, HEPATOLOGY, V7, P37, DOI 10.1002/hep.1840070109; LOKE RHT, 1989, BRIT MED J, V298, P234, DOI 10.1136/bmj.298.6668.234; LOVEDAY C, 1989, BRIT MED J, V298, P419, DOI 10.1136/bmj.298.6671.419; MCCUSKER J, 1990, PUBLIC HEALTH REP, V105, P59; MULLEY AG, 1982, NEW ENGL J MED, V307, P644, DOI 10.1056/NEJM198209093071103; POLAKOFF S, 1990, J INFECTION, V20, P163, DOI 10.1016/0163-4453(90)93522-T; SCHREEDER MT, 1982, J INFECT DIS, V146, P7, DOI 10.1093/infdis/146.1.7; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; Taylor PE, 1988, VIRAL HEPATITIS LIVE, P198; TEDDER RS, 1980, J MED VIROL, V6, P323, DOI 10.1002/jmv.1890060407; WELLER IVD, 1986, J HEPATOL, V3, pS9, DOI 10.1016/S0168-8278(86)80095-2; 1985, MMWR, V34, P313; 1988, MMWR, V37, P429; 1987, MMWR, V36, P353; 1989, MMWR, V38, P37; 1988, IMMUNISATION INFECTI, P75	31	40	40	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1991	303	6794					97	101		10.1136/bmj.303.6794.97	http://dx.doi.org/10.1136/bmj.303.6794.97			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW586	1830505	Green Published, Bronze			2022-12-01	WOS:A1991FW58600024
J	BOLLAG, U; BOLLAGALBRECHT, E				BOLLAG, U; BOLLAGALBRECHT, E			RECOMMENDATIONS DERIVED FROM PRACTICE AUDIT FOR THE TREATMENT OF ACUTE OTITIS-MEDIA	LANCET			English	Article							DOUBLE-BLIND; CHILDREN; MANAGEMENT	There is much disagreement about diagnostic criteria and optimum treatment for acute otitis media (OM). From a practice audit of the management of OM, we went on to develop and test a protocol in which we defined criteria for the diagnosis and treatment of this disorder. In a two-year study of 168 children aged 0-16 years with acute OM (and confirmed in a second study of another 62 children during the following year), we found that the main feature of otitis media is intense pain in the ear and is accompanied in 90% of cases by upper respiratory tract infection (URTI) at presentation. Hearing loss is common and otorrhoea develops in about 10% of children. Antibiotics, which are prescribed by most physicians, are not needed in the first instance, but we recommend vigorous treatment with analgesics. Supportive measures are similar to those used for the management of URTI. Follow-up evaluation is essential to detect the few refractory cases that must be referred to the specialist.										ARMSTRONG D, 1990, RES METHODS GENERAL; BLUESTONE CD, 1983, PEDIATRIC OTOLARYNGO; Bluestone CD., 2007, OTITIS MEDIA INFANTS, V4th; BOLLAG U, 1990, CLIN PEDIATR, V29, P244, DOI 10.1177/000992289002900410; BOLLAG U, 1984, HELV PAEDIATR ACTA, V39, P341; BOLLAG U, 1986, SPECTRUM, V27, P52; CANTEKIN EI, 1983, NEW ENGL J MED, V308, P297, DOI 10.1056/NEJM198302103080601; Chalmers D, 1989, CLIN DEV MED, V108, P1; FLEMING DM, 1989, INFLUENZA INFLUENZA, P213; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; FROOM J, 1982, J FAM PRACTICE, V15, P743; FRY J, 1961, CATARRHAL CHILD; HAYDEN GF, 1981, CLIN PEDIATR, V20, P99, DOI 10.1177/000992288102000203; KETTLETY A, 1907, BR J AUDIO, V21, P73; LOWE JF, 1963, LANCET, V2, P1129; PUKANDER J, 1983, ACTA OTO-LARYNGOL, V95, P117, DOI 10.3109/00016488309130924; SCHWARTZ DM, 1980, ANN OTOL RHINOL S68, V68, P211; SCHWARTZ RH, 1981, CLIN PEDIATR, V20, P549, DOI 10.1177/000992288102000901; SKINNER WM, 1978, OTOLARYNGOL CLIN N A, V11, P631; STOOL S, 1989, POSTGRAD MED, V85, P40; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; VANBUCHEM FL, 1981, LANCET, V2, P883	22	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					96	99		10.1016/0140-6736(91)90086-5	http://dx.doi.org/10.1016/0140-6736(91)90086-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676479				2022-12-01	WOS:A1991FW16100014
J	NAROD, SA; FEUNTEUN, J; LYNCH, HT; WATSON, P; CONWAY, T; LYNCH, J; LENOIR, GM				NAROD, SA; FEUNTEUN, J; LYNCH, HT; WATSON, P; CONWAY, T; LYNCH, J; LENOIR, GM			FAMILIAL BREAST-OVARIAN CANCER LOCUS ON CHROMOSOME-17Q12-Q23	LANCET			English	Note							LINKAGE ANALYSIS	Familial breast cancer has been linked to the D17S74 locus on chromosome 17q. To confirm this finding and to investigate whether ovarian cancer is also linked to this locus, five large families with a hereditary predisposition to cancer of the breast and ovary were investigated. Three families were positive for linkage. For the largest family the lod score was 2.72. These findings suggest that the chromosomal region 17q12-q23, previously shown to contain a gene for early-onset breast cancer, is also associated with a proportion of hereditary ovarian cancers.	INT AGCY RES CANC,150 COURS ALBERT THOMAS,F-69372 LYONS,FRANCE; MCGILL UNIV,DEPT ONCOL,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3G 1A4,QUEBEC,CANADA; CREIGHTON UNIV,SCH MED,DEPT PREVENT MED,OMAHA,NE 68178; MCGILL UNIV,CTR HUMAN GENET,MONTREAL H3G 1A4,QUEBEC,CANADA; INST GUSTAVE ROUSSY,CNRS,UA 1158,F-94805 VILLEJUIF,FRANCE	World Health Organization; International Agency for Research on Cancer (IARC); McGill University; McGill University; Creighton University; McGill University; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy			Narod, Steven A/AAA-6112-2022; Feunteun, Jean/AAZ-1267-2020	Feunteun, Jean/0000-0003-1212-9189				BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; FERRELL RE, 1989, CANCER GENET CYTOGEN, V38, P241, DOI 10.1016/0165-4608(89)90665-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LYNCH HT, 1981, GENETICS BREAST CANC; Nakamura Y, 1988, GENOMICS, V2, P302, DOI 10.1016/0888-7543(88)90018-3; NAROD SA, 1989, HUM GENET, V83, P353, DOI 10.1007/BF00291380; OTT J, 1985, ANAL HUMAN GENETIC L; ROBERTSON M, 1989, NATURE, V342, P222, DOI 10.1038/342222a0	10	522	535	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					82	83						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676470				2022-12-01	WOS:A1991FW16100005
J	SETH, R; RAYMOND, FD; MAKGOBA, MW				SETH, R; RAYMOND, FD; MAKGOBA, MW			CIRCULATING ICAM-1 ISOFORMS - DIAGNOSTIC PROSPECTS FOR INFLAMMATORY AND IMMUNE DISORDERS	LANCET			English	Note							INTERCELLULAR-ADHESION MOLECULE-1; EXPRESSION; LIGAND; CELLS	Intercellular adhesion molecule-1 (ICAM-1, CD54) is an important early marker of immune activation and response. Evidence on its role has come from immunohistological staining of tissues, since no free circulating ICAM-1 has been detected. By means of monoclonal antibodies against ICAM-1 and a sensitive chemiluminescence technique, free circulating ICAM-1 was detected in serum from sixteen healthy young volunteers. The concentrations varied among the subjects. Non-denaturing gel separation methods showed that ICAM-1 circulates in at least three isoforms, the proportions of which also varied. These findings have important implications for the investigation, diagnosis, and therapeutic monitoring of various inflammatory, neoplastic, and immune disorders.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CHEM PATHOL,DIV MOLEC ENDOCRINOL,DU CANE RD,LONDON W12 0NN,ENGLAND	Imperial College London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS DH, 1989, LANCET, V2, P1122; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; GRIFFITHS CEM, 1989, J AM ACAD DERMATOL, V20, P617, DOI 10.1016/S0190-9622(89)70073-6; HILDRETH JEK, 1985, J IMMUNOL, V134, P3272; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MARLIN SD, 1987, CELL, V51, P831; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; VOGETSEDER W, 1989, INT J CANCER, V43, P768, DOI 10.1002/ijc.2910430504; WAWRYK SO, 1989, IMMUNOL REV, V108, P135, DOI 10.1111/j.1600-065X.1989.tb00016.x; WEETMAN AP, 1989, J ENDOCRINOL, V122, P185, DOI 10.1677/joe.0.1220185	10	391	401	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					83	84		10.1016/0140-6736(91)90077-3	http://dx.doi.org/10.1016/0140-6736(91)90077-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676471				2022-12-01	WOS:A1991FW16100006
J	SHIPLEY, MJ; POCOCK, SJ; MARMOT, MG				SHIPLEY, MJ; POCOCK, SJ; MARMOT, MG			DOES PLASMA-CHOLESTEROL CONCENTRATION PREDICT MORTALITY FROM CORONARY HEART-DISEASE IN ELDERLY PEOPLE - 18 YEAR FOLLOW-UP IN WHITEHALL STUDY	BRITISH MEDICAL JOURNAL			English	Article								Objective-To explore the extent to which the relation between plasma cholesterol concentration and risk of death from coronary heart disease in men persists into old age. Design - 18 year follow up of male Whitehall civil servants. Plasma cholesterol concentrations and other risk factors were determined at first examination in 1967-9 when they were aged 40-69. Death of men up to 31 january 1987 was recorded. Subjects-18296 male civil servants, 4155 of whom died during follow up. Main outcome measures - Cause and age of death. Cholesterol concentration in 1967-9 and number of years elapsed between testing and death. Results - 1676 men died of coronary heart disease. The mean cholesterol concentration in these men was 0.32 mmol/l higher than that in all other men (95% confidence interval 0.26 to 0.37 mmol/l). This difference in cholesterol concentrations fell 0.15 mmol/l with every 10 years' increase in age at screening. The risk of raised cholesterol concentration fell with age at death. Compared with other men cholesterol concentration in those who died of coronary heart disease was 0.44 mmol/l higher in those who died aged < 60 and 0.26 mmol/l higher in those aged 60-79 (p = 0.03). For a given age at death the longer the gap between cholesterol measurement and death the more predictive the cholesterol concentration, both for coronary heart disease and all cause mortality (trend test p = 0.06 and 0.03 respectively). Conclusion-Reducing plasma cholesterol concentrations in middle age may influence the risk of death from coronary heart disease in old age.	UCL, DEPT COMMUNITY MED, LONDON WC1E 6EA, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND	University of London; University College London; University of London; London School of Hygiene & Tropical Medicine			Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; BLOCK WD, 1966, CLIN CHEM, V10, P681; COX DR, 1972, J R STAT SOC B, V34, P187; MARMOT MG, 1986, LANCET, V2, P274; REID DD, 1974, LANCET, V1, P469; ROSE G, 1982, BRIT MED J, V284, P1600, DOI 10.1136/bmj.284.6329.1600; ROSE G, 1980, LANCET, V1, P523; 1982, JAMA-J AM MED ASSOC, V248, P2853	9	86	86	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 13	1991	303	6794					89	92		10.1136/bmj.303.6794.89	http://dx.doi.org/10.1136/bmj.303.6794.89			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW586	1860009	Green Published, Bronze			2022-12-01	WOS:A1991FW58600020
J	WILLIAMS, DRR; BYRNE, C; CLARK, PMS; COX, L; DAY, NE; RAYMAN, G; WANG, T; HALES, CN				WILLIAMS, DRR; BYRNE, C; CLARK, PMS; COX, L; DAY, NE; RAYMAN, G; WANG, T; HALES, CN			RAISED PROINSULIN CONCENTRATION AS EARLY INDICATOR OF BETA-CELL DYSFUNCTION	BRITISH MEDICAL JOURNAL			English	Article							INSULIN		ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QQ,ENGLAND; ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge; Addenbrooke's Hospital; University of Cambridge	WILLIAMS, DRR (corresponding author), ADDENBROOKES HOSP,DEPT COMMUNITY MED,CAMBRIDGE CB2 2QQ,ENGLAND.			Byrne, Christopher D/0000-0001-6322-7753				SOBEY WJ, 1989, BIOCHEM J, V260, P535, DOI 10.1042/bj2600535; TEMPLE RC, 1989, LANCET, V1, P293, DOI 10.1016/S0140-6736(89)91306-8; YUDKIN JS, 1990, BRIT MED J, V301, P397, DOI 10.1136/bmj.301.6749.397; 1985, WHO TECH REP SER, V727	4	51	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1991	303	6794					95	96		10.1136/bmj.303.6794.95-a	http://dx.doi.org/10.1136/bmj.303.6794.95-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW586	1860012	Green Published, Bronze			2022-12-01	WOS:A1991FW58600023
J	ALLEN, PN; NOLLER, HF				ALLEN, PN; NOLLER, HF			A SINGLE BASE SUBSTITUTION IN 16S RIBOSOMAL-RNA SUPPRESSES STREPTOMYCIN DEPENDENCE AND INCREASES THE FREQUENCY OF TRANSLATIONAL ERRORS	CELL			English	Article							ESCHERICHIA-COLI; MUTATIONS; PROTEIN; MUTANTS; RESISTANT; SUBUNITS; DOMAIN	A C to U substitution at position 1469 of 16S ribosomal RNA (rRNA) from Escherichia coli suppresses streptomycin dependence and causes increased translational error frequencies. Strains containing the rpsL252 or StrM287 streptomycin-dependent alleles are able to grow in the absence of streptomycin when transformed with plasmids containing the U1469 mutation in 16S rRNA. Ribosomes containing wild-type proteins and U1469 mutant 16S rRNA misincorporate leucine in vitro at elevated levels, comparable to that of some typical S4 ram ribosomes. These results provide additional support for the participation of 16S rRNA in maintaining translational accuracy.			ALLEN, PN (corresponding author), UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, SANTA CRUZ, CA 95064 USA.				NIGMS NIH HHS [GM-17129] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017129, R37GM017129] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN PN, 1989, J MOL BIOL, V208, P457, DOI 10.1016/0022-2836(89)90509-3; ANDERSSON DI, 1982, MOL GEN GENET, V187, P467, DOI 10.1007/BF00332630; ANDERSSON DI, 1983, MOL GEN GENET, V191, P378, DOI 10.1007/BF00425749; BIRGE EA, 1970, MOL GEN GENET, V109, P356, DOI 10.1007/BF00267704; BJARE U, 1971, J MOL BIOL, V57, P423, DOI 10.1016/0022-2836(71)90101-X; BOHMAN K, 1984, MOL GEN GENET, V198, P90, DOI 10.1007/BF00328706; DAHLBERG AE, 1989, CELL, V57, P525, DOI 10.1016/0092-8674(89)90122-0; DOUTHWAITE S, 1985, P NATL ACAD SCI USA, V82, P8330, DOI 10.1073/pnas.82.24.8330; GREEN M, 1971, NATURE-NEW BIOL, V234, P273, DOI 10.1038/newbio234273a0; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HASENBANK R, 1973, MOL GEN GENET, V127, P1, DOI 10.1007/BF00267778; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; JELENC PC, 1980, ANAL BIOCHEM, V105, P369, DOI 10.1016/0003-2697(80)90472-8; JEMIOLO DK, 1985, NUCLEIC ACIDS RES, V13, P8631, DOI 10.1093/nar/13.23.8631; KIRSEBOM LA, 1985, P NATL ACAD SCI USA, V82, P717, DOI 10.1073/pnas.82.3.717; KORN AP, 1985, EUR J CELL BIOL, V39, P56; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KURLAND CG, 1990, RIBOSOME, P513; MOAZED D, 1986, J MOL BIOL, V191, P483, DOI 10.1016/0022-2836(86)90143-9; MOORE PB, 1986, STRUCTURE FUNCTION G, P87; MURGOLA EJ, 1988, P NATL ACAD SCI USA, V85, P4162, DOI 10.1073/pnas.85.12.4162; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; NOLLER HF, 1990, RIBOSOME STRUCTURE F, P513; NOMURA M, 1969, COLD SPRING HARB SYM, V34, P49, DOI 10.1101/SQB.1969.034.01.009; OLSSON MO, 1979, MOL GEN GENET, V169, P251, DOI 10.1007/BF00382271; POWERS T, 1990, P NATL ACAD SCI USA, V87, P1042, DOI 10.1073/pnas.87.3.1042; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; ROSSET R, 1969, J MOL BIOL, V39, P95, DOI 10.1016/0022-2836(69)90336-2; RUUSALA T, 1984, EMBO J, V3, P2575, DOI 10.1002/j.1460-2075.1984.tb02176.x; SANCHEZANZALDO FJ, 1974, MOL GEN GENET, V130, P47, DOI 10.1007/BF00270518; SCHROEDER AL, 1983, CAN J GENET CYTOL, V25, P16, DOI 10.1139/g83-003; SHEN ZH, 1989, NUCLEIC ACIDS RES, V17, P4535, DOI 10.1093/nar/17.12.4535; SIGMUND CD, 1988, METHOD ENZYMOL, V164, P673; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; Traub P, 1971, METHOD ENZYMOL, V20, P391; TRIMAN K, 1989, J MOL BIOL, V209, P645, DOI 10.1016/0022-2836(89)92000-7; WEISSBRUMMER B, 1989, MOL GEN GENET, V217, P362, DOI 10.1007/BF02464905; WOOD WB, 1962, P NATL ACAD SCI USA, V48, P94, DOI 10.1073/pnas.48.1.94	39	50	50	1	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1991	66	1					141	148		10.1016/0092-8674(91)90146-P	http://dx.doi.org/10.1016/0092-8674(91)90146-P			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	2070415				2022-12-01	WOS:A1991FW91300016
J	ANDERSON, MP; GREGORY, RJ; THOMPSON, S; SOUZA, DW; PAUL, S; MULLIGAN, RC; SMITH, AE; WELSH, MJ				ANDERSON, MP; GREGORY, RJ; THOMPSON, S; SOUZA, DW; PAUL, S; MULLIGAN, RC; SMITH, AE; WELSH, MJ			DEMONSTRATION THAT CFTR IS A CHLORIDE CHANNEL BY ALTERATION OF ITS ANION SELECTIVITY	SCIENCE			English	Article							CYSTIC-FIBROSIS GENE; TRANSMEMBRANE CONDUCTANCE REGULATOR; ION CHANNEL; PATCH-CLAMP; TRANSPORT; IDENTIFICATION; EXPRESSION; CELLS; CAMP	Expression of the cystic fibrosis transmembrane conductance regulator (CFTR) generates adenosine 3',5'-monophosphate (cAMP)-regulated chloride channels, indicating that CFTR is either a chloride channel or a chloride channel regulator. To distinguish between these possibilities, basic amino acids in the putative transmembrane domains were mutated. The sequence of anion selectivity of cAMP-regulated channels in cells containing either endogenous or recombinant CFTR was bromide > chloride > iodide > fluoride. Mutation of the lysines at positions 95 or 335 to acidic amino acids converted the selectivity sequence to iodide > bromide > chloride > fluoride. These data indicate that CFTR is a cAMP-regulated chloride channel and that lysines 95 and 335 determine anion selectivity.	GENZYME CORP,FRAMINGHAM,MA 01701; MIT,WHITEHEAD INST,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Sanofi-Aventis; Genzyme Corporation; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; University of Iowa	ANDERSON, MP (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.			Welsh, Michael/0000-0002-1646-6206; Anderson, Matthew/0000-0003-4602-1811				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ANDERSON MP, IN PRESS P NATL ACAD; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CARSON MR, 1989, AM J PHYSIOL, V257, pL259, DOI 10.1152/ajplung.1989.257.4.L259; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DENNING G, 1991, FASEB J, V5, pA1760; DIAMOND G, 1991, AM ASS CANCER RES A, V33; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GRZELCZAK Z, 1990, Journal of Cell Biology, V111, p310A; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B, 1984, IONIC CHANNELS EXCIT; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; MADARA JL, 1987, GASTROENTEROLOGY, V92, P1133, DOI 10.1016/S0016-5085(87)91069-9; OSTEDGAARD LS, UNPUB; QUINTON PM, 1989, ANN NY ACAD SCI, V574, P438; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WRIGHT EM, 1977, PHYSIOL REV, V57, P109, DOI 10.1152/physrev.1977.57.1.109; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	36	988	1005	3	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					202	205		10.1126/science.1712984	http://dx.doi.org/10.1126/science.1712984			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1712984				2022-12-01	WOS:A1991FW16000039
J	BARROW, CJ; ZAGORSKI, MG				BARROW, CJ; ZAGORSKI, MG			SOLUTION STRUCTURES OF BETA PEPTIDE AND ITS CONSTITUENT FRAGMENTS - RELATION TO AMYLOID DEPOSITION	SCIENCE			English	Article							PAIRED HELICAL FILAMENTS; X-RAY-DIFFRACTION; ALZHEIMERS-DISEASE; PROTEIN-PRECURSOR; MESSENGER-RNA; SENILE PLAQUES; BRAIN; INHIBITOR; IDENTIFICATION; LOCALIZATION	The secondary structures in solution of the synthetic, naturally occurring, amyloid beta-peptides, residues 1 to 42 [beta(1-42)] and beta(1-39), and related fragments, beta(1-28) and beta(29-42), have been studied by circular dichroism and two-dimensional nuclear magnetic resonance spectroscopy. In patients with Alzheimer's disease, extracellular amyloid plaque core is primarily composed of beta(1-42), whereas cerebrovascular amyloid contains the more soluble beta(1-39). In aqueous trifluoroethanol solution, the beta(1-28), beta(1-39), and beta(1-42) peptides adopt monomeric alpha-helical structures at both low and high pH, whereas at intermediate pH (4 to 7) an oligomeric beta-structure (the probable structure in plaques) predominates. Thus, beta-peptide is not by itself an insoluble protein (as originally thought), and localized or normal age-related alterations of pH may be necessary for the self-assembly and deposition of beta-peptide. The hydrophobic carboxyl-terminal segment, beta(29-42), exists exclusively as an oligomeric beta-sheet in solution, regardless of differences in solvent, pH, or temperature, suggesting that this segment directs the folding of the complete beta(1-42) peptide to produce the beta-pleated sheet found in amyloid plaques.	SUNTORY INST BIOORGAN RES,SHIMAMOTO,OSAKA 618,JAPAN	Suntory Holdings Ltd								BAX A, 1989, ANNU REV BIOCHEM, V58, P223; BEHROUZ N, 1989, LAB INVEST, V61, P576; BEYREUTHER K, 1988, ETIOLOGY DEMENTIA AL, P125; CANDY JM, 1986, LANCET, V1, P354; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; EANES ED, 1968, J HISTOCHEM CYTOCHEM, V16, P673, DOI 10.1177/16.11.673; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GILBOE DD, 1986, PHARM CEREBRAL ISCHE, P119; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1988, CELL, V52, P307, DOI 10.1016/S0092-8674(88)80021-7; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOREVIC PD, 1987, BIOCHEM BIOPH RES CO, V147, P854, DOI 10.1016/0006-291X(87)91008-4; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GRONENBORN AM, 1990, ANAL CHEM, V62, P2, DOI 10.1021/ac00200a003; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; Hollosi M, 1989, Pept Res, V2, P109; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KITAGUCHI N, 1990, BIOCHIM BIOPHYS ACTA, V1038, P105, DOI 10.1016/0167-4838(90)90017-A; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LEWIS PN, 1971, P NATL ACAD SCI USA, V68, P2293, DOI 10.1073/pnas.68.9.2293; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; MUNCKATA K, 1987, STROKE, V18, P412; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; OSTERHOUT JJ, 1989, BIOCHEMISTRY-US, V28, P7059, DOI 10.1021/bi00443a042; PALMERT MR, 1988, SCIENCE, V241, P1080, DOI 10.1126/science.2457949; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; PRICE DL, 1986, ANNU REV NEUROSCI, V9, P489; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P75; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SPILLANTINI MG, 1990, P NATL ACAD SCI USA, V87, P3947, DOI 10.1073/pnas.87.10.3947; Stewart JM, 1984, SOLID PHASE PEPTIDE; TAGLIAVINI F, 1988, NEUROSCI LETT, V93, P191, DOI 10.1016/0304-3940(88)90080-8; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WISNIEWSKI HM, 1976, J NEUROL SCI, V27, P173, DOI 10.1016/0022-510X(76)90059-9; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V77, P113; YATES CM, 1990, J NEUROCHEM, V55, P1624, DOI 10.1111/j.1471-4159.1990.tb04948.x; ZHANG H, 1989, P NATL ACAD SCI USA, V86, P8045, DOI 10.1073/pnas.86.20.8045	53	554	575	0	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					179	182		10.1126/science.1853202	http://dx.doi.org/10.1126/science.1853202			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1853202				2022-12-01	WOS:A1991FW16000031
J	BLUMBERG, B; WRIGHT, CVE; DEROBERTIS, EM; CHO, KWY				BLUMBERG, B; WRIGHT, CVE; DEROBERTIS, EM; CHO, KWY			ORGANIZER-SPECIFIC HOMEOBOX GENES IN XENOPUS-LAEVIS EMBRYOS	SCIENCE			English	Article							DNA-BINDING SPECIFICITY; EARLY DROSOPHILA EMBRYO; BICOID PROTEIN; HOMEODOMAIN PROTEINS; ANTERIOR STRUCTURES; EXPRESSION VECTOR; GROWTH-FACTORS; MESODERM; AXIS; TRANSCRIPTION	The dorsal blastopore lip of the early Xenopus laevis gastrula can organize a complete secondary body axis when transplanted to another embryo. A search for potential gene regulatory components specifically expressed in the organizer was undertaken that resulted in the identification of four types of complementary DNAs from homeobox-containing genes that fulfill this criterion. The most abundant of these encodes a DNA-binding specificity similar to that of the Drosophila melanogaster anterior morphogen bicoid. The other three are also homologous to developmentally significant Drosophila genes. These four genes may participate in the regulation of the developmental potential of the organizer.	UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles				De Robertis, Edward/0000-0002-7843-1869	NICHD NIH HHS [HD-21502, HD-07273] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD007273, R37HD021502, R01HD021502] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1990, TRENDS GENET, V6, P57; ALTABA ARI, 1989, DEVELOPMENT, V106, P173; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURGLIN TR, 1987, EMBO J, V6, P2617, DOI 10.1002/j.1460-2075.1987.tb02552.x; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; Cho K., UNPUB; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; Dawid I.B., 1990, Current Topics in Developmental Biology, V24, P261, DOI 10.1016/S0070-2153(08)60090-3; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GURDON JB, 1987, DEVELOPMENT, V99, P285; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HAN JH, 1988, NUCLEIC ACIDS RES, V16, P11837, DOI 10.1093/nar/16.24.11837; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARVEY RP, 1986, EMBO J, V5, P1237, DOI 10.1002/j.1460-2075.1986.tb04352.x; HOLTFRETER HB, 1965, THESIS U ROCHESTER; JAYNES JB, 1990, GENETICS OF PATTERN FORMATION AND GROWTH CONTROL, P47; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; NAKAMURA O, 1978, ORG MILESTONE HALF C; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH JC, 1989, DEVELOPMENT, V105, P665; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; Spemann H, 1931, Wilhelm Roux Arch Entwickl Mech Org, V123, P389, DOI 10.1007/BF01380646; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STEWART RM, 1990, DEVELOPMENT, V109, P363; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TREISMAN J, 1989, CELL, V59, P553; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; WRIGHT CVE, 1989, TRENDS BIOCHEM SCI, V14, P52, DOI 10.1016/0968-0004(89)90043-1	45	341	348	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	1991	253	5016					194	196		10.1126/science.1677215	http://dx.doi.org/10.1126/science.1677215			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1677215				2022-12-01	WOS:A1991FW16000036
J	CASANOVA, JE; APODACA, G; MOSTOV, KE				CASANOVA, JE; APODACA, G; MOSTOV, KE			AN AUTONOMOUS SIGNAL FOR BASOLATERAL SORTING IN THE CYTOPLASMIC DOMAIN OF THE POLYMERIC IMMUNOGLOBULIN RECEPTOR	CELL			English	Article							CANINE KIDNEY-CELLS; POLARIZED EPITHELIAL-CELLS; INFLUENZA-VIRUS HEMAGGLUTININ; COATED PIT LOCALIZATION; MDCK CELLS; MEMBRANE GLYCOPROTEIN; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; G-PROTEIN; SURFACE	The polymeric immunoglobulin receptor is normally delivered from the Golgi to the basolateral surface of epithelial cells and then transports polymeric IgA and IgM to the apical surface. We now report that a 14 residue segment of the 103 amino acid cytoplasmic domain, proximal to the plasma membrane, directs the receptor to the basolateral surface. A mutant receptor lacking these 14 amino acids is sorted directly to the apical surface from the Golgi. Furthermore, this sequence is sufficient to redirect an apical membrane protein, placental alkaline phosphatase, to the basolateral plasma membrane. We conclude that this sequence contains an autonomous signal, which specifies sorting from the Golgi to the basolateral surface, a process previously postulated to occur by default.	UNIV CALIF SAN FRANCISCO, SCH MED, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	CASANOVA, JE (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT ANAT, SAN FRANCISCO, CA 94143 USA.		Apodaca, Gerard/HCJ-0048-2022	mostov, keith/0000-0002-8123-6247	PHS HHS [A1 RO1 25144] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BALCAROVASTANDER J, 1984, EMBO J, V3, P2687, DOI 10.1002/j.1460-2075.1984.tb02194.x; BARTLES JR, 1988, TRENDS BIOCHEM SCI, V13, P181, DOI 10.1016/0968-0004(88)90147-8; BERGER J, 1988, J BIOL CHEM, V263, P10016; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CAPLAN M, 1989, FUNCTIONAL EPITHELIA, P71; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHOUDARY PV, 1986, COLD SPRING HARB SYM, V51, P1047, DOI 10.1101/SQB.1986.051.01.121; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COMPTON T, 1989, P NATL ACAD SCI USA, V86, P4112, DOI 10.1073/pnas.86.11.4112; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; GERSTEN DM, 1978, J IMMUNOL METHODS, V24, P305, DOI 10.1016/0022-1759(78)90133-3; GONZALEZ A, 1987, P NATL ACAD SCI USA, V84, P3738, DOI 10.1073/pnas.84.11.3738; HOWARD AD, 1987, P NATL ACAD SCI USA, V84, P6055, DOI 10.1073/pnas.84.17.6055; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JONES LV, 1985, MOL CELL BIOL, V5, P2181, DOI 10.1128/MCB.5.9.2181; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MOSTOV KE, 1985, CELL, V43, P389, DOI 10.1016/0092-8674(85)90166-7; MOSTOV KE, 1987, J CELL BIOL, V105, P2031, DOI 10.1083/jcb.105.5.2031; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUSIL LS, 1987, J CELL BIOL, V104, P1725, DOI 10.1083/jcb.104.6.1725; PUDDINGTON L, 1987, P NATL ACAD SCI USA, V84, P2756; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; ROMAN LM, 1986, J CELL BIOL, V103, P2607, DOI 10.1083/jcb.103.6.2607; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAERER E, 1990, J CELL BIOL, V110, P987, DOI 10.1083/jcb.110.4.987; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; SOLARI R, 1984, CELL, V36, P61, DOI 10.1016/0092-8674(84)90074-6; STEPHENS EB, 1986, CELL, V47, P1053, DOI 10.1016/0092-8674(86)90820-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VENKATAKRISHNAN G, 1991, BIOCHEMISTRY-US, V30, P2748, DOI 10.1021/bi00225a002; VONBONSDORFF CH, 1985, EMBO J, V4, P2781, DOI 10.1002/j.1460-2075.1985.tb04004.x; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	53	278	281	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1991	66	1					65	75		10.1016/0092-8674(91)90139-P	http://dx.doi.org/10.1016/0092-8674(91)90139-P			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	2070419				2022-12-01	WOS:A1991FW91300009
J	CASTRILLO, JL; THEILL, LE; KARIN, M				CASTRILLO, JL; THEILL, LE; KARIN, M			FUNCTION OF THE HOMEODOMAIN PROTEIN GHF1 IN PITUITARY CELL-PROLIFERATION	SCIENCE			English	Article							HORMONE-RELEASING FACTOR; GENE; MICE; OLIGODEOXYNUCLEOTIDE; SOMATOTROPHS; REPLICATION; EXPRESSION; INHIBITION; ELEMENTS; INVITRO	Mutations that cause pituitary dwarfism in the mouse reside in the gene encoding the transcription factor growth hormone factor 1 (GHF1 or pit1). These dwarf mice (dw and dw(J)) are deficient in growth hormone (GH) and prolactin (PRL) synthesis and exhibit pituitary hypoplasia, suggesting a stem cell defect. With antisense oligonucleotide technology, a cell culture model of this genetic defect was developed. Specific inhibition of GHF1 synthesis by complementary oligonucleotides led to a marked decrease in GH and PRL expression and to a marked decrease in proliferation of somatotrophic cell lines. These results provide direct evidence that the homeodomain protein GHF1 is required not only for the establishment and maintenance of the differentiated phenotype but for cell proliferation as well.	UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038527] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38527] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTKE A, 1964, ANAT RECORD, V149, P225, DOI 10.1002/ar.1091490206; BILEZIKJIAN LM, 1983, ENDOCRINOLOGY, V113, P1726, DOI 10.1210/endo-113-5-1726; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CARACCIOLO D, 1989, SCIENCE, V245, P1107, DOI 10.1126/science.2672339; CASTRILLO JL, UNPUB; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; EICHER EM, 1976, J HERED, V67, P87, DOI 10.1093/oxfordjournals.jhered.a108682; Francis Torben, 1944, ACTA PATH ET MICROBIOL SCAND, V21, P928; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; ISHIKAWA K, 1986, NEUROENDOCRINOLOGY, V43, P537, DOI 10.1159/000124579; Karin M, 1990, CURR OPIN CELL BIOL, V2, P996, DOI 10.1016/0955-0674(90)90148-8; KARIN M, 1990, TRENDS GENET, V6, P92, DOI 10.1016/0168-9525(90)90100-K; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAYO KE, 1988, MOL ENDOCRINOL, V2, P606, DOI 10.1210/mend-2-7-606; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; REYMOND MJ, 1984, ACTA ENDOCRINOL-COP, V106, P459, DOI 10.1530/acta.0.1060459; ROUX M, 1982, CELL TISSUE RES, V223, P415, DOI 10.1007/BF01258498; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; Snell GD, 1929, P NATL ACAD SCI USA, V15, P274, DOI 10.1073/pnas.15.3.274; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; WILSON DB, 1981, J ANAT, V133, P407; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280	32	236	239	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	1991	253	5016					197	199		10.1126/science.1677216	http://dx.doi.org/10.1126/science.1677216			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1677216				2022-12-01	WOS:A1991FW16000037
J	CHAILLET, JR; VOGT, TF; BEIER, DR; LEDER, P				CHAILLET, JR; VOGT, TF; BEIER, DR; LEDER, P			PARENTAL-SPECIFIC METHYLATION OF AN IMPRINTED TRANSGENE IS ESTABLISHED DURING GAMETOGENESIS AND PROGRESSIVELY CHANGES DURING EMBRYOGENESIS	CELL			English	Article							DNA METHYLATION; DETERMINES METHYLATION; PATERNAL GENOMES; MOUSE; EXPRESSION; MICE; REGION; CELLS	Genomic imprinting is a regulatory process that requires a cell to recognize the parental origin of alleles. To understand how these alleles are distinguished, we have assessed changes in the DNA methylation of an imprinted transgene as it switches from one inheritance pattern to another while moving through gametogenesis and embryogenesis. We find that both maternally and paternally inherited methylation patterns are erased in primordial germ cells and that distinctive patterns emerge during germ cell maturation. In the case of the maternal allele, the methylation pattern is fully acquired during oogenesis. In the case of the paternal allele, the methylation pattern found in sperm undergoes further modification during embryogenesis. Thus, the distinction between "erased" maternal and paternal alleles is first established during their residence in different germ cells and then may be maintained by the recognition of the distinctive patterns that each allele displays in the zygote.			CHAILLET, JR (corresponding author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115, USA.							ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; HEATH JK, 1978, DEV MAMMALS, V3; Hogan B., 1986, MANIPULATING MOUSE E; KIRSCH IR, 1981, NATURE, V293, P585, DOI 10.1038/293585a0; MCGOWAN R, 1989, GENE DEV, V3, P1669, DOI 10.1101/gad.3.11.1669; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; MONK M, 1987, DEVELOPMENT, V99, P371; NEBEL BR, 1961, SCIENCE, V134, P832, DOI 10.1126/science.134.3482.832; PEDERSEN RA, 1988, PHYSL REPRODUCTION; QUINN P, 1982, J REPROD FERTIL, V66, P161; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; REIK W, 1990, DEVELOPMENT, P99; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SAPIENZA C, 1987, NATURE, V328, P251, DOI 10.1038/328251a0; SASAKI H, 1991, DEVELOPMENT, V111, P573; SEARLE AG, 1978, CYTOGENET CELL GENET, V20, P282, DOI 10.1159/000130859; SOLTER D, 1988, ANNU REV GENET, V22, P127; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SURANI MA, 1990, PHILOS T ROY SOC B, V326, P313, DOI 10.1098/rstb.1990.0014; SURANI MA, 1988, TRENDS GENET, V4, P59, DOI 10.1016/0168-9525(88)90040-6; SURANI MAH, 1986, CELL, V45, P127, DOI 10.1016/0092-8674(86)90544-1; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; WASSERMAN PM, 1988, PHYSL REPRODUCTION; Whittingham D G, 1971, J Reprod Fertil Suppl, V14, P7; YAMAMOTO T, 1980, P NATL ACAD SCI-BIOL, V77, P176, DOI 10.1073/pnas.77.1.176	34	214	221	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1991	66	1					77	83		10.1016/0092-8674(91)90140-T	http://dx.doi.org/10.1016/0092-8674(91)90140-T			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1649008				2022-12-01	WOS:A1991FW91300010
J	CHAUDHARY, PM; RONINSON, IB				CHAUDHARY, PM; RONINSON, IB			EXPRESSION AND ACTIVITY OF P-GLYCOPROTEIN, A MULTIDRUG EFFLUX PUMP, IN HUMAN HEMATOPOIETIC STEM-CELLS	CELL			English	Article							BONE-MARROW-CELLS; RESISTANCE GENE; ANTIGENIC ANALYSIS; PROGENITOR CELLS; CFU-S; RHODAMINE-123 FLUORESCENCE; MONOCLONAL-ANTIBODY; TUMOR-CELLS; RAT-LIVER; PURIFICATION	Hematopoietic stem cells show reduced staining with a mitochondrial fluorescent dye, rhodamine 123 (Rh123), which was supposed to indicate decreased mitochondrial activity in these cells. Rhl23 and several other fluorescent dyes are substrates for transport mediated by P-glycoprotein (P-gp), an efflux pump responsible for multidrug resistance in tumor cells. We have found that staining of human bone marrow cells with fluorescent dyes is potentiated by P-gp inhibitors and inversely correlated with P-gp expression. P-gp is expressed in practically all hematopoietic progenitor cells, including long-term culture-initiating cells. The highest levels of P-gp among the progenitors are associated with cells displaying characteristics of pluripotent stem cells. These results have implications for stem cell purification and bone marrow resistance to cancer chemotherapy.			CHAUDHARY, PM (corresponding author), UNIV ILLINOIS, DEPT GENET, CHICAGO, IL 60612 USA.		Chaudhary, Preet/E-1970-2018; Roninson, Igor/K-1310-2017	Roninson, Igor/0000-0002-9211-1327	NATIONAL CANCER INSTITUTE [R01CA040333, R37CA040333] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40333] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS RG, 1989, J EXP MED, V169, P1721, DOI 10.1084/jem.169.5.1721; BERENSON RJ, 1988, J CLIN INVEST, V81, P951, DOI 10.1172/JCI113409; BERENSON RJ, 1991, BLOOD, V77, P1717; BERTONCELLO I, 1985, EXP HEMATOL, V13, P999; BRANDT J, 1988, J CLIN INVEST, V82, P1017, DOI 10.1172/JCI113658; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; BURT RK, 1988, J NATL CANCER I, V80, P1383, DOI 10.1093/jnci/80.17.1383; CIVIN CI, 1984, J IMMUNOL, V133, P157; CIVIN CI, 1987, EXP HEMATOL, V15, P10; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415; FORD JM, 1990, PHARMACOL REV, V42, P155; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GARTNER S, 1980, P NATL ACAD SCI-BIOL, V77, P4756, DOI 10.1073/pnas.77.8.4756; GELLER RB, 1990, BRIT J HAEMATOL, V76, P340, DOI 10.1111/j.1365-2141.1990.tb06365.x; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HAUGHLAND RP, 1989, MOL PROBES HDB FLUOR; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KASTAN MB, 1990, BLOOD, V75, P1947; LALANDE ME, 1981, P NATL ACAD SCI-BIOL, V78, P363, DOI 10.1073/pnas.78.1.363; LAMPIDIS TJ, 1985, CANCER RES, V45, P2626; MCCARTHY KF, 1990, INT J CELL CLONING, V8, P184, DOI 10.1002/stem.5530080305; MULDER AH, 1987, EXP HEMATOL, V15, P99; NEYFAKH AA, 1989, EXP CELL RES, V185, P496, DOI 10.1016/0014-4827(89)90318-2; NEYFAKH AA, 1988, EXP CELL RES, V174, P168, DOI 10.1016/0014-4827(88)90152-8; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; PALLAVICINI MG, 1985, EXP HEMATOL, V13, P1173; Pirker R, 1989, Cancer Commun, V1, P141; PLOEMACHER RE, 1988, J CELL PHYSIOL, V136, P531, DOI 10.1002/jcp.1041360320; PLOEMACHER RE, 1989, EXP HEMATOL, V17, P263; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SHUDO N, 1990, CANCER RES, V50, P3055; SKIYSMS D, 1985, DOMSYIV VRLL MOL HRN, V11, P117; SNFTRED TH, 1986, NLOOF, V67, P842; SNFTRED TH, 1986, NLOOF, V68, P1030; SPANGRUDE GJ, 1990, P NATL ACAD SCI USA, V87, P7433, DOI 10.1073/pnas.87.19.7433; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SROUR EF, 1991, CYTOMETRY, V12, P179, DOI 10.1002/cyto.990120213; STRAUSS LC, 1986, EXP HEMATOL, V14, P878; SUGAWARA I, 1988, CANCER RES, V48, P1926; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; VANDERSLUIJS JP, 1990, EXP HEMATOL, V18, P893; VISSER JWM, 1990, EXP HEMATOL, V18, P248	47	926	966	0	52	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1991	66	1					85	94		10.1016/0092-8674(91)90141-K	http://dx.doi.org/10.1016/0092-8674(91)90141-K			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1712673				2022-12-01	WOS:A1991FW91300011
J	CORDONCARDO, C; TAPLEY, P; JING, SQ; NANDURI, V; OROURKE, E; LAMBALLE, F; KOVARY, K; KLEIN, R; JONES, KR; REICHARDT, LF; BARBACID, M				CORDONCARDO, C; TAPLEY, P; JING, SQ; NANDURI, V; OROURKE, E; LAMBALLE, F; KOVARY, K; KLEIN, R; JONES, KR; REICHARDT, LF; BARBACID, M			THE TRK TYROSINE PROTEIN-KINASE MEDIATES THE MITOGENIC PROPERTIES OF NERVE GROWTH-FACTOR AND NEUROTROPHIN-3	CELL			English	Article							FACTOR NGF RECEPTORS; MOLECULAR-CLONING; FACTOR FAMILY; GENE-TRANSFER; HIGH-AFFINITY; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; DIFFERENTIATION; EXPRESSION; ONCOGENE	The product of the trk proto-oncogene encodes a receptor for nerve growth factor (NGF). Here we show that NGF is a powerful mitogen that can induce resting NIH 3T3 cells to enter S phase, grow in semisolid medium, and become morphologically transformed. These mitogenic effects are absolutely dependent on expression of gp140trk receptors, but do not require the presence of the previously described low affinity NGF receptor. gp140trk also serves as a receptor for the related factor neurotrophin-3 (NT-3), but not for brain-derived neurotrophic factor. Both NGF and NT-3 induce the rapid phosphorylation of gp140trk receptors and the transient expression of c-Fos proteins. However, NT-3 appears to elicit more limited mitogenic responses than NGF. These results indicate that the product of the trk proto-oncogene is sufficient to mediate signal transduction processes induced by NGF and NT-3, at least in proliferating cells.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,GROWTH REGULAT LAB,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,BIOTECHNOL LAB,PRINCETON,NJ 08543; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	Bristol-Myers Squibb; Bristol-Myers Squibb; Howard Hughes Medical Institute; University of California System; University of California San Francisco	CORDONCARDO, C (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,MOLEC ONCOL LAB,POB 4000,PRINCETON,NJ 08543, USA.		Klein, Ruediger/C-6147-2008; Kovary, Karla/E-3979-2013; Lamballe, Fabienne/GLT-0820-2022; Lamballe, Fabienne/P-4293-2017	Klein, Ruediger/0000-0002-3109-0163; Lamballe, Fabienne/0000-0001-7631-942X; JONES, KEVIN/0000-0002-3802-7562	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016033] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS016033-190014, P01 NS016033] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ALOE L, 1977, BRAIN RES, V133, P358, DOI 10.1016/0006-8993(77)90772-7; BARBACID M, 1991, IN PRESS ACTA REV CA; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURSTEIN DE, 1982, DEV BIOL, V94, P477, DOI 10.1016/0012-1606(82)90364-5; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEMPSTEAD B, 1988, COLD SPRING HARB SYM, V53, P477, DOI 10.1101/SQB.1988.053.01.055; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1985, J BIOL CHEM, V260, P655; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON EM, 1987, BIOCHEM PHARMACOL, V36, P4189, DOI 10.1016/0006-2952(87)90658-7; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAISHO Y, 1991, BIOCHEM BIOPH RES CO, V174, P379, DOI 10.1016/0006-291X(91)90531-B; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1991, IN PRESS CELL, V66; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MASSAGUE J, 1981, J BIOL CHEM, V256, P9419; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PLEASURE SJ, 1990, P NATL ACAD SCI USA, V87, P8496, DOI 10.1073/pnas.87.21.8496; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; REPRESA J, 1989, DEV BIOL, V134, P21, DOI 10.1016/0012-1606(89)90074-2; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; ROSS R, 1987, ANNU REV MED, V38, P71, DOI 10.1146/annurev.med.38.1.71; SUTTER A, 1979, J BIOL CHEM, V254, P5972; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551	59	499	513	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1991	66	1					173	183		10.1016/0092-8674(91)90149-S	http://dx.doi.org/10.1016/0092-8674(91)90149-S			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1649007	Green Accepted			2022-12-01	WOS:A1991FW91300019
J	DARST, SA; EDWARDS, AM; KUBALEK, EW; KORNBERG, RD				DARST, SA; EDWARDS, AM; KUBALEK, EW; KORNBERG, RD			3-DIMENSIONAL STRUCTURE OF YEAST RNA POLYMERASE-II AT 16-A RESOLUTION	CELL			English	Article							TWO-DIMENSIONAL CRYSTALS; ELECTRON-MICROSCOPY; LARGEST SUBUNIT; TRANSCRIPTION; DNA; HOLOENZYME; PROMOTER; INVITRO; VIEW; GENE	The structure of yeast RNA polymerase II has been determined by three-dimensional reconstruction from electron micrographs of two-dimensional crystals at approximately 16 angstrom resolution. The most prominent feature of the structure is an arm of protein density surrounding a channel about 25 angstrom in diameter, similar to that found previously for E. coli RNA polymerase. The 25 angstrom-diameter channel bifurcates on one face of the protein, connecting with a 25 angstrom-wide groove and with a channel about half as wide. The 25 angstrom channel and groove, and the narrow channel, may bind double- and single-stranded nucleic acids, respectively. A finger of protein density projecting from the molecule adjacent to the arm-like feature may represent the C-terminal domain of the largest subunit. These results provide a structural basis for analyses of the transcription process and its regulation.			DARST, SA (corresponding author), STANFORD UNIV,BECKMAN LABS STRUCT BIOL,DEPT CELL BIOL,STANFORD,CA 94305, USA.			Edwards, Aled/0000-0002-4782-6016	NIAID NIH HHS [AI21144] Funding Source: Medline; NIGMS NIH HHS [GM36659] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARD DA, 1983, J MOL BIOL, V167, P849, DOI 10.1016/S0022-2836(83)80114-4; AHEARN JM, 1987, J BIOL CHEM, V262, P10695; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; BERNHARD SL, 1986, BIOCHEMISTRY-US, V25, P6397, DOI 10.1021/bi00369a009; BIGGS J, 1985, CELL, V42, P611, DOI 10.1016/0092-8674(85)90118-7; CHUNG YJ, 1990, GENE REGULATION AIDS, P3; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1988, J MOL BIOL, V203, P269, DOI 10.1016/0022-2836(88)90107-6; DARST SA, 1991, IN PRESS J MOL BIOL; DEZELEE S, 1976, EUR J BIOCHEM, V65, P543, DOI 10.1111/j.1432-1033.1976.tb10372.x; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; GOODSELL DS, 1989, J MOL GRAPHICS, V7, P41, DOI 10.1016/0263-7855(89)80055-4; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; HEUMANN H, 1988, EMBO J, V7, P4379, DOI 10.1002/j.1460-2075.1988.tb03336.x; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KUHNKE G, 1987, EMBO J, V6, P507, DOI 10.1002/j.1460-2075.1987.tb04782.x; KUMAR S A, 1975, Journal of Biological Chemistry, V250, P2878; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MONFORTE JA, 1990, BIOCHEMISTRY-US, V29, P7882, DOI 10.1021/bi00486a015; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; RUET A, 1980, J BIOL CHEM, V255, P6450; SCHULTZ P, 1990, J MOL BIOL, V216, P353, DOI 10.1016/S0022-2836(05)80326-2; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313	30	144	144	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1991	66	1					121	128		10.1016/0092-8674(91)90144-N	http://dx.doi.org/10.1016/0092-8674(91)90144-N			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	2070414				2022-12-01	WOS:A1991FW91300014
J	EPHRUSSI, A; DICKINSON, LK; LEHMANN, R				EPHRUSSI, A; DICKINSON, LK; LEHMANN, R			OSKAR ORGANIZES THE GERM PLASM AND DIRECTS LOCALIZATION OF THE POSTERIOR DETERMINANT NANOS	CELL			English	Article							DROSOPHILA POLAR GRANULES; MATERNAL-EFFECT MUTATIONS; ANTEROPOSTERIOR POLARITY; GENE; EMBRYOS; SEGMENTATION; COMPONENT; SEQUENCE; PROTEIN; VASA	oskar is one of seven Drosophila maternal-effect genes that are necessary for germline and abdomen formation. We have cloned oskar and show that oskar RNA is localized to the posterior pole of the oocyte when germ plasm forms. This polar distribution of oskar RNA is established during oogenesis in three phases: accumulation in the oocyte, transport toward the posterior, and finally maintenance at the posterior pole of the oocyte. The colocalization of oskar and nanos in wild-type and bicaudal embryos suggests that oskar directs localization of the posterior determinant nanos. We propose that the pole plasm is assembled stepwise and that continued interaction among its components is required for germ cell determination.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	EPHRUSSI, A (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.		Ephrussi, Anne/ABD-4393-2021; Ephrussi, Anne/AAG-4075-2020	Ephrussi, Anne/0000-0002-5061-4620; 	NICHD NIH HHS [R01 HD27549-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027549] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEAMS HW, 1974, INT REV CYTOL, V139, P413; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; EDDY EM, 1975, INT REV CYTOL, V43, P229; Ephrussi B, 1936, AM NAT, V70, P218, DOI 10.1086/280658; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HAENLIN M, 1985, CELL, V40, P827, DOI 10.1016/0092-8674(85)90342-3; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HUETNER AF, 1923, J MORPHOL, V39, P249; ILLMENSEE K, 1976, DEV BIOL, V49, P40, DOI 10.1016/0012-1606(76)90257-8; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MAHOWALD AP, 1962, J EXP ZOOL, V151, P201, DOI 10.1002/jez.1401510302; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOHLER J, 1986, GENETICS, V112, P808; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1979, S SOC DEV BIOL, V37, P185; RAFF JW, 1990, DEVELOPMENT, V110, P1249; SAMBROOK G, 1989, MOL CLONING LABORATO; SCHUPBACH T, 1989, GENETICS, V121, P101; SCHUPBACH T, 1986, DEV BIOL, V113, P443, DOI 10.1016/0012-1606(86)90179-X; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; Suzuki D.T., 1989, INTRO GENETIC ANAL; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WANG C, 1991, IN PRESS CELL; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHITFIELD WGF, 1989, NATURE, V338, P337, DOI 10.1038/338337a0	41	663	671	1	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1991	66	1					37	50		10.1016/0092-8674(91)90137-N	http://dx.doi.org/10.1016/0092-8674(91)90137-N			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	2070417				2022-12-01	WOS:A1991FW91300007
J	HEUS, HA; PARDI, A				HEUS, HA; PARDI, A			STRUCTURAL FEATURES THAT GIVE RISE TO THE UNUSUAL STABILITY OF RNA HAIRPINS CONTAINING GNRA LOOPS	SCIENCE			English	Article							SECONDARY STRUCTURE; CONFORMATIONAL-ANALYSIS; RIBOSOMAL-RNA; SRP RNA; ACID; REGION; DNA	The most frequently occurring RNA hairpins in 16S and 23S ribosomal RNA contain a tetranucleotide loop that has a GNRA consensus sequence. The solution structures of the GCAA and GAAA hairpins have been determined by nuclear magnetic resonance spectroscopy. Both loops contain an unusual G-A base pair between the first and last residue in the loop, a hydrogen bond between a G base and a phosphate, extensive base stacking, and a hydrogen bond between a sugar 2'-end OH and a base. These interactions explain the high stability of these hairpins and the sequence requirements for the variant and invariant nucleotides in the GNRA tetranucleotide loop family.	UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder			Heus, Hans/F-9696-2015	Heus, Hans/0000-0001-7256-4241	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030726, R01AI027026, R01AI030726] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03283] Funding Source: Medline; NIAID NIH HHS [AI 27026, AI 30726] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADHIN MR, 1990, BIOCHIM BIOPHYS ACTA, V1050, P110, DOI 10.1016/0167-4781(90)90150-Z; ALTONA C, 1982, RECL TRAV CHIM PAY B, V101, P413; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; ENDO Y, 1988, J BIOL CHEM, V263, P7917; GUTELL RR, 1985, PROG NUCLEIC ACID RE, V32, P155, DOI 10.1016/S0079-6603(08)60348-7; HANEY J, COMMUNICATION; HEUS HA, 1991, J MOL BIOL, V217, P113, DOI 10.1016/0022-2836(91)90615-D; HEUS HA, UNPUB; JAQUIR A, 1987, CELL, V54, P17; LANKHORST PP, 1984, J BIOMOL STRUCT DYN, V1, P1387, DOI 10.1080/07391102.1984.10507527; LI Y, 1991, P NATL ACAD SCI USA, V88, P26, DOI 10.1073/pnas.88.1.26; LIAO X, 1989, P NATL ACAD SCI USA, V86, P4837; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PACE NR, 1989, GENE, V82, P65, DOI 10.1016/0378-1119(89)90031-0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P55; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; UHLENBECK OC, 1990, NATURE, V346, P613, DOI 10.1038/346613a0; van Knippenberg PH, 1986, STRUCTURE FUNCTION G, P412; WARING RB, 1984, GENE, V28, P277, DOI 10.1016/0378-1119(84)90145-8; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; WUTHRICH K, 1986, NMR PROTEINS NUCL AC, P44	23	613	631	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					191	194		10.1126/science.1712983	http://dx.doi.org/10.1126/science.1712983			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1712983				2022-12-01	WOS:A1991FW16000035
J	KIMHA, J; SMITH, JL; MACDONALD, PM				KIMHA, J; SMITH, JL; MACDONALD, PM			OSKAR MESSENGER-RNA IS LOCALIZED TO THE POSTERIOR POLE OF THE DROSOPHILA OOCYTE	CELL			English	Article							MATERNAL-EFFECT MUTATIONS; ANTEROPOSTERIOR POLARITY; ANTERIOR LOCALIZATION; BICOID RNA; GENE; EMBRYO; SEGMENTATION; SEQUENCE; PATTERN; MELANOGASTER	Mutants of the maternal posterior-group genes of Drosophila lack posterior body pattern elements and germ cells, both of which form through the action of determinants localized to the posterior pole of the oocyte. We report that transcripts of one of these genes, oskar, become localized to the posterior pole of oocytes shortly after the oocyte begins to differentiate visibly. Analysis of various posterior-group mutants reveals that localization of oskar mRNA is an early step in the posterior localization pathway. In addition, we find that nonsense oskar mutations disrupt osk mRNA localization, while missense oskar mutations do not.			KIMHA, J (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042612] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42612] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; GUTZEIT HO, 1982, J EMBRYOL EXP MORPH, V67, P101; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; Innis MA, 1990, PCR PROTOCOLS GUIDE; King RC., 1970, OVARIAN DEV DROSOPHI; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MACDONALD PM, 1986, CELL, V47, P721, DOI 10.1016/0092-8674(86)90515-5; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MAHOWALD AP, 1968, J EXP ZOOL, V167, P237, DOI 10.1002/jez.1401670211; MAHOWALD AP, 1962, J EXP ZOOL, V151, P201, DOI 10.1002/jez.1401510302; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOHLER J, 1986, GENETICS, V112, P803; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANDER K, 1988, NATURE, V335, P68, DOI 10.1038/335068a0; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEPHENSON EC, 1988, GENE DEV, V2, P1655, DOI 10.1101/gad.2.12a.1655; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRECKER TR, 1989, SCIENCE, V243, P1062, DOI 10.1126/science.2922596; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9	41	483	488	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1991	66	1					23	34		10.1016/0092-8674(91)90136-M	http://dx.doi.org/10.1016/0092-8674(91)90136-M			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	2070416				2022-12-01	WOS:A1991FW91300006
J	LIAO, NS; BIX, M; ZIJLSTRA, M; JAENISCH, R; RAULET, D				LIAO, NS; BIX, M; ZIJLSTRA, M; JAENISCH, R; RAULET, D			MHC CLASS-I DEFICIENCY - SUSCEPTIBILITY TO NATURAL-KILLER (NK) CELLS AND IMPAIRED NK ACTIVITY	SCIENCE			English	Article							BONE-MARROW ALLOGRAFTS; T-CELLS; INTERFERON INDUCERS; ANTIGEN EXPRESSION; LYMPHOMA VARIANTS; MICE; REJECTION; GENE; LYSIS; TRANSFECTION	The role of major histocompatibility complex (MHC) class I expression in natural killer (NK) cell target recognition is controversial. Normal T cell blasts from MHC class I-deficient mutant mice were found to serve as target cells for NK cells in vitro, which suggests that MHC class I molecules are directly involved in NK cell recognition. Spleen cells from the mutant mice were deficient in their ability to lyse MHC class I-deficient target cells or NK-susceptible tumor targets, and mutant mice could not reject allogeneic bone marrow. Thus, class I molecules may participate in the positive selection or tolerance induction of NK cells.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,BERKELEY,CA 94720; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	University of California System; University of California Berkeley; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Liao, Nan-Shih/ABE-7580-2020	Liao, Nan-Shih/0000-0003-3707-4145; Raulet, David/0000-0002-1257-8649; Bix, Mark/0000-0003-4617-0497	NCI NIH HHS [R35 CA44339] Funding Source: Medline; NIAID NIH HHS [R01 AI30171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; CICCONE E, 1990, J EXP MED, V172, P47, DOI 10.1084/jem.172.1.47; CUDKOWICZ G, 1964, NATURE, V204, P450, DOI 10.1038/204450a0; CUDKOWICZ G, 1971, J EXP MED, V134, P1513, DOI 10.1084/jem.134.6.1513; DEGLIANTONI G, 1985, J EXP MED, V162, P1512, DOI 10.1084/jem.162.5.1512; DENNERT G, 1988, J IMMUNOL, V140, P2472; DJEU JY, 1979, J IMMUNOL, V122, P175; DORSHKIND K, 1985, J IMMUNOL, V134, P3798; GIDLUND M, 1978, NATURE, V273, P759, DOI 10.1038/273759a0; HARELBELLAN A, 1986, P NATL ACAD SCI USA, V83, P5688, DOI 10.1073/pnas.83.15.5688; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KOO GC, 1984, HYBRIDOMA, V3, P301, DOI 10.1089/hyb.1984.3.301; KRIMPENFORT P, 1987, EMBO J, V6, P1673, DOI 10.1002/j.1460-2075.1987.tb02416.x; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEVITSKY HI, 1991, J IMMUNOL, V146, P1113; LJUNGGREN HG, 1990, J IMMUNOL, V145, P380; MASON LH, 1990, J IMMUNOL, V145, P751; MURPHY WJ, 1987, J EXP MED, V166, P1499, DOI 10.1084/jem.166.5.1499; NISHIMURA MI, 1988, J IMMUNOL, V141, P4403; OHLEN C, 1989, J IMMUNOL, V142, P3336; OHLEN C, 1989, SCIENCE, V246, P666, DOI 10.1126/science.2814488; RAULET DH, 1982, J EXP MED, V155, P1766, DOI 10.1084/jem.155.6.1766; RAULET DH, 1980, J IMMUNOL, V125, P1136; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SENTMAN CL, 1989, J IMMUNOL, V142, P1847; SHIMIZU Y, 1989, EUR J IMMUNOL, V19, P447, DOI 10.1002/eji.1830190306; STORKUS WJ, 1989, J IMMUNOL, V143, P3853; STURMHOFEL K, 1990, EUR J IMMUNOL, V20, P171, DOI 10.1002/eji.1830200125; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZIJLSTRA M, UNPUB	32	423	430	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					199	202		10.1126/science.1853205	http://dx.doi.org/10.1126/science.1853205			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1853205				2022-12-01	WOS:A1991FW16000038
J	LIVDAHL, TP; WILLEY, MS				LIVDAHL, TP; WILLEY, MS			PROSPECTS FOR AN INVASION - COMPETITION BETWEEN AEDES-ALBOPICTUS AND NATIVE AEDES-TRISERIATUS	SCIENCE			English	Article							TREE-HOLE MOSQUITOS; NORTH-AMERICA; UNITED-STATES; CULICIDAE; DIPTERA	Competition between larval populations of the native North American treehole mosquito Aedes triseriatus and Aedes albopictus, recently introduced from Asia to North America, was assessed by comparing per capita growth rate estimates for experimental cohorts of larvae developing under a variety of initial density combinations in fluid obtained from tires or from treeholes. Estimates of carrying capacities and competition coefficients indicate that competition between the two species will result in stable coexistence in treehole communities but local extinction of A. triseriatus in tire habitats.			LIVDAHL, TP (corresponding author), CLARK UNIV,DEPT BIOL,WORCESTER,MA 01610, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI027940] Funding Source: NIH RePORTER; NIAID NIH HHS [R15AI27940] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLACK WC, 1989, J MED ENTOMOL, V26, P260, DOI 10.1093/jmedent/26.4.260; BRADSHAW WE, 1988, OECOLOGIA, V74, P507, DOI 10.1007/BF00380047; BRADSHAW WE, 1983, OECOLOGIA, V57, P239, DOI 10.1007/BF00379586; COPELAND RS, 1990, ANN ENTOMOL SOC AM, V83, P1063, DOI 10.1093/aesa/83.6.1063; HARD JJ, 1989, OIKOS, V54, P137, DOI 10.2307/3565259; HAWLEY WA, 1987, SCIENCE, V236, P1114, DOI 10.1126/science.3576225; HO C, 1989, J MED ENTOMOL, V26, P615; LIVDAHL TP, 1984, J ANIM ECOL, V53, P573, DOI 10.2307/4535; OMEARA G, 1990, 1990 ANN M ENT WOC A; PETERSEN JJ, 1969, MOSQ NEWS, V29, P134; SCHREIBER ET, 1988, J AM MOSQUITO CONTR, V4, P9; SHROYER DA, 1986, J AM MOSQUITO CONTR, V2, P424; SOKAL RR, 1981, BIOMETRY, P795; SPRENGER D, 1986, J AM MOSQUITO CONTR, V2, P217; WALKER ED, 1988, ENVIRON ENTOMOL, V17, P199, DOI 10.1093/ee/17.2.199; 1989, AM MOSQ CONTROL ASS, V15, P15; 1990, AM MOSQ CONTROL ASS, V16, P13; 1990, AM MOSQ CONTROL ASS, V16, P5	18	156	158	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					189	191		10.1126/science.1853204	http://dx.doi.org/10.1126/science.1853204			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1853204				2022-12-01	WOS:A1991FW16000034
J	METZ, T; GRAF, T				METZ, T; GRAF, T			FUSION OF THE NUCLEAR ONCOPROTEINS V-MYB AND V-ETS IS REQUIRED FOR THE LEUKEMOGENICITY OF E26 VIRUS	CELL			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; HEMATOPOIETIC TARGET-CELLS; LONG TERMINAL REPEAT; RECEPTOR-ALPHA-GENE; DNA-BINDING DOMAIN; TRANSCRIPTIONAL ACTIVATION; T(15-17) TRANSLOCATION; TRANS-ACTIVATION; PROTO-ONCOGENE; MYELOID CELLS	The highly leukemogenic avian retrovirus E26 expresses the two transcriptional activator-type oncogenes v-myb and v-ets as a nuclear fusion protein. Previous studies have shown that both oncogenes cooperate in the transformation of erythroid cells in vitro and that the phenotypes of transformed cells differ, depending on whether the oncogenes are coexpressed as separate proteins or as a fusion protein. Here we show that virus constructs encoding either v-Myb or v-Ets as their only oncoprotein are nonleukemogenic and that constructs coexpressing nonfused v-Myb and v-Ets proteins appear to be weakly leukemogenic. Surprisingly, leukemic animals injected with the latter contain highly leukemogenic variant viruses that exhibit internal deletions in their genome, resulting in the synthesis of novel Myb-Ets fusion proteins. These results show that v-Myb and v-Ets must be fused to cause leukemia and establish a new mechanism of oncogene activation and cooperation.			METZ, T (corresponding author), EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, W-6900 HEIDELBERG, GERMANY.		Graf, Thomas/B-4252-2015	Graf, Thomas/0000-0003-2774-4117				BARTLETT JA, 1986, BIOTECHNIQUES, V4, P208; BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1982, EMBO J, V1, P1069, DOI 10.1002/j.1460-2075.1982.tb01298.x; BISTER K, 1982, P NATL ACAD SCI-BIOL, V79, P3677, DOI 10.1073/pnas.79.12.3677; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GRAF T, 1981, EXP CELL RES, V131, P331, DOI 10.1016/0014-4827(81)90236-6; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; Ivanov X, 1962, B I PATHOL COMP ANIM, V9, P5; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; LEMONS RS, 1990, GENE CHROMOSOME CANC, V2, P79, DOI 10.1002/gcc.2870020202; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Maniatis T., 1982, MOL CLONING; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WEISS R, 1985, RNA TUMOR VIRUSES MO, V2, P657; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	44	98	98	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1991	66	1					95	105		10.1016/0092-8674(91)90142-L	http://dx.doi.org/10.1016/0092-8674(91)90142-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	2070421				2022-12-01	WOS:A1991FW91300012
J	MIZUUCHI, K; ADZUMA, K				MIZUUCHI, K; ADZUMA, K			INVERSION OF THE PHOSPHATE CHIRALITY AT THE TARGET SITE OF MU-DNA STRAND TRANSFER - EVIDENCE FOR A ONE-STEP TRANSESTERIFICATION MECHANISM	CELL			English	Article							DIASTEREOMERIC PHOSPHOROTHIOATE ANALOGS; BACTERIOPHAGE-MU; DEOXYADENOSINE TRIPHOSPHATE; POLYMERASE-I; TRANSPOSITION; PROTEIN; RECOMBINATION; CLEAVAGE; GENE; PURIFICATION	Central to transposition of phage Mu are two reactions mediated by the MuA protein. First, MuA introduces single-stranded cuts at the ends of the Mu DNA to generate 3'OH termini. In the subsequent strand-transfer step, the MuA-Mu DNA end complex cuts a target DNA and joins the Mu 3 'ends to the 5' ends of the target. DNA containing chiral phosphorothioates was used to demonstrate inversion of the chirality during the course of strand transfer. This result strongly supports a one-step transesterification mechanism in which the 3'OH of the cleaved donor DNA is the attacking nucleophile. Furthermore, this donor 3'OH group was essential for target DNA cleavage. In contrast, during lambda-integration the phosphate chirality was retained, as expected for a two-step transesterification involving a covalent protein-DNA intermediate.			MIZUUCHI, K (corresponding author), NIADDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.							BAKER TA, 1991, IN PRESS CELL, V65; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; Berg D. E., 1989, MOBILE DNA; BUCHWALD SL, 1982, METHOD ENZYMOL, V87, P279; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; BURGERS PMJ, 1979, BIOCHEMISTRY-US, V18, P592, DOI 10.1021/bi00571a007; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CRAIG NL, 1988, ANNU REV GENET, V22, P77; CRAIGIE R, 1985, J BIOL CHEM, V260, P1832; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; HANIFORD DB, 1991, CELL, V64, P171; HERSCHLAG D, 1991, IN PRESS BIOCHEMISTR, V30; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; KITTS PA, 1988, NUCLEIC ACIDS RES, V16, P6839, DOI 10.1093/nar/16.14.6839; KITTS PA, 1988, J MOL BIOL, V204, P95, DOI 10.1016/0022-2836(88)90602-X; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MIZUUCHI K, 1986, ANNU REV GENET, V20, P385; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; ROMANIUK PJ, 1982, J BIOL CHEM, V257, P7684; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; VANMANSFELD ADM, 1986, NUCLEIC ACIDS RES, V14, P4229, DOI 10.1093/nar/14.10.4229	32	139	141	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1991	66	1					129	140		10.1016/0092-8674(91)90145-O	http://dx.doi.org/10.1016/0092-8674(91)90145-O			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1649006				2022-12-01	WOS:A1991FW91300015
J	PENDERGAST, AM; MULLER, AJ; HAVLIK, MH; MARU, Y; WITTE, ON				PENDERGAST, AM; MULLER, AJ; HAVLIK, MH; MARU, Y; WITTE, ON			BCR SEQUENCES ESSENTIAL FOR TRANSFORMATION BY THE BCR-ABL ONCOGENE BIND TO THE ABL-SH2 REGULATORY DOMAIN IN A NON-PHOSPHOTYROSINE-DEPENDENT MANNER	CELL			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; TYROSINE KINASE-ACTIVITY; C-ABL; PHILADELPHIA-CHROMOSOME; NUCLEOTIDE-SEQUENCE; MEMBRANE-PROTEINS; FUSED TRANSCRIPT; PHOSPHOLIPASE-C; LYMPHOID-CELLS	BCR-ABL is a chimeric oncogene implicated in the pathogenesis of Philadelphia chromosome-positive human leukemias. BCR first exon sequences specifically activate the tyrosine kinase and transforming potential of BCR-ABL. We have tested the hypothesis that activation of BCR-ABL may involve direct interaction between BCR sequences and the tyrosine kinase regulatory domains of ABL. Full-length c-BCR as well as BCR sequences retained in BCR-ABL bind specifically to the SH2 domain of ABL. The binding domain has been localized within the first exon of BCR and consists of at least two SH2-binding sites. This domain is essential for BCR-ABL-mediated transformation. Phosphoserine/phosphothreonine but not phosphotyrosine residues on BCR are required for interaction with the ABL SH2 domain. These findings extend the range of potential SH2-protein interactions in growth control pathways and suggest a function for SH2 domains in the activation of the BCR-ABL oncogene as well as a role for BCR in cellular signaling pathways.	UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	PENDERGAST, AM (corresponding author), UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA.			Pendergast, Ann Marie/0000-0002-1250-6880; Muller, Alexander/0000-0001-7854-6933				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CAMPBELL ML, 1990, ONCOGENE, V5, P773; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ELLIS C, 1991, IN PRESS ONCOGENE; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LEHTO VP, 1988, NATURE, V334, P388, DOI 10.1038/334388a0; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUO K, 1900, MOL CELL BIOL, V10, P5305; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MOTSN MG, 1990, P NSYL SVSF DVI UD, V87, P8622; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1988, ONCOGENE, V3, P491; Pendergast A M, 1987, Baillieres Clin Haematol, V1, P1001, DOI 10.1016/S0950-3536(87)80036-7; PENDERGAST AM, 1989, ONCOGENE, V4, P759; PENDERGAST AM, 1991, IN PRESS P NATL ACAD; QUILLIAM LA, 1990, MOL CELL BIOL, V11, P1804; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; Summers MD, 1987, MANUAL METHODS BACUL; TIMMONS MS, 1989, ONCOGENE, V4, P559; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079	55	325	339	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1991	66	1					161	171		10.1016/0092-8674(91)90148-R	http://dx.doi.org/10.1016/0092-8674(91)90148-R			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1712671				2022-12-01	WOS:A1991FW91300018
J	RICH, DP; GREGORY, RJ; ANDERSON, MP; MANAVALAN, P; SMITH, AE; WELSH, MJ				RICH, DP; GREGORY, RJ; ANDERSON, MP; MANAVALAN, P; SMITH, AE; WELSH, MJ			EFFECT OF DELETING THE R-DOMAIN ON CFTR-GENERATED CHLORIDE CHANNELS	SCIENCE			English	Article							CYSTIC-FIBROSIS GENE; TRANSMEMBRANE CONDUCTANCE REGULATOR; BACTERIAL TRANSPORT PROTEINS; MULTIDRUG RESISTANCE; PATCH-CLAMP; CELLS; IDENTIFICATION; EXPRESSION; MUTATIONS; INACTIVATION	The cystic fibrosis transmembrane conductance regulator (CFTR), which forms adenosine 3',5'-monophosphate (cAMP)-regulated chloride channels, is defective in patients with cystic fibrosis. This protein contains two putative nucleotide binding domains (NBD1 and NBD2) and an R domain. CFTR in which the R domain was deleted (CFTR-DELTA-R) conducted chloride independently of the presence of cAMP. However, sites within CFTR other than those deleted also respond to cAMP, because the chloride current of CFTR-DELTA-R increased further in response to cAMP stimulation. In addition, deletion of the R domain suppressed the inactivating effect of a mutation in NBD2 (but not NBD1), a result which suggests that NBD2 interacts with the channel through the R domain.	GENZYME CORP, FRAMINGHAM, MA 01701 USA; MIT, HOWARD HUGHES MED INST, DEPT PHYSIOL & BIOPHYS, CAMBRIDGE, MA 02142 USA	Sanofi-Aventis; Genzyme Corporation; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	RICH, DP (corresponding author), MIT, HOWARD HUGHES MED INST, DEPT INTERNAL MED, CAMBRIDGE, MA 02142 USA.			Anderson, Matthew/0000-0003-4602-1811; Welsh, Michael/0000-0002-1646-6206				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BOAT TF, 1989, METABOLIC BASIS INHE; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DENNING G, 1991, FASEB J, V5, pA1760; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; FERROLUZZIAMES G, 1976, P NATL ACAD SCI USA, V73, P1877, DOI 10.1073/pnas.73.6.1877; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, IN PRESS MOL CELL BI; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; OSTEDGAARD LS, UNPUB; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	31	250	261	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	1991	253	5016					205	207		10.1126/science.1712985	http://dx.doi.org/10.1126/science.1712985			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1712985				2022-12-01	WOS:A1991FW16000040
J	ROSNER, MH; VIGANO, MA; RIGBY, PWJ; ARNHEITER, H; STAUDT, LM				ROSNER, MH; VIGANO, MA; RIGBY, PWJ; ARNHEITER, H; STAUDT, LM			OCT-3 AND THE BEGINNING OF MAMMALIAN DEVELOPMENT	SCIENCE			English	Editorial Material							EMBRYONAL CARCINOMA-CELLS; DNA-BINDING DOMAIN; TRANSCRIPTION FACTOR; POU-DOMAIN; IMMUNOGLOBULIN GENES; NUCLEAR FACTOR; STEM-CELLS; MOUSE EMBRYOGENESIS; PROTEIN-BINDING; LEUKEMIA-VIRUS		NCI, METAB BRANCH, BETHESDA, MD 20892 USA; NATL INST MED RES, EUKARYOT MOLEC GENET LAB, LONDON NW7 1AA, ENGLAND; NINCDS, VIRAL & MOLEC PATHOGENESIS LAB, BETHESDA, MD 20892 USA; GEORGETOWN UNIV, SCH MED, DEPT PATHOL, WASHINGTON, DC 20057 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); MRC National Institute for Medical Research; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Georgetown University			Staudt, Louis/AAC-5324-2019	vigano, maria alessandra/0000-0003-2009-0384				BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DWORKIN MB, 1990, MOL REPROD DEV, V26, P261, DOI 10.1002/mrd.1080260310; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; HAAS MW, 1991, VIROLOGY, V180, P41, DOI 10.1016/0042-6822(91)90007-X; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JOHNSON MH, 1981, BIOL REV, V56, P463, DOI 10.1111/j.1469-185X.1981.tb00356.x; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; LOH TP, 1990, MOL CELL BIOL, V10, P4045, DOI 10.1128/MCB.10.8.4045; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; REICHEL R, 1987, CELL, V48, P501, DOI 10.1016/0092-8674(87)90200-5; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; ROSNER MH, 1991, CELL, V64, P1103, DOI 10.1016/0092-8674(91)90265-Z; ROSNER MH, UNPUB; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SIVE HL, 1986, P NATL ACAD SCI USA, V83, P6382, DOI 10.1073/pnas.83.17.6382; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TSUKIYAMA T, 1989, MOL CELL BIOL, V9, P4670, DOI 10.1128/MCB.9.11.4670; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	48	11	11	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	1991	253	5016					144	145		10.1126/science.1853199	http://dx.doi.org/10.1126/science.1853199			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1853199				2022-12-01	WOS:A1991FW16000023
J	STJOHNSTON, D; BEUCHLE, D; NUSSLEINVOLHARD, C				STJOHNSTON, D; BEUCHLE, D; NUSSLEINVOLHARD, C			STAUFEN, A GENE REQUIRED TO LOCALIZE MATERNAL RNAS IN THE DROSOPHILA EGG	CELL			English	Article							POLAR GRANULES; EFFECT MUTATIONS; ANTEROPOSTERIOR POLARITY; BICOID PROTEIN; EMBRYO; PATTERN; MELANOGASTER; SEGMENTATION; VASA; EXPRESSION	The posterior group gene staufen is required both for the localization of maternal determinants to the posterior pole of the Drosophila egg and for bicoid RNA to localize correctly to the anterior pole. We report the cloning and sequencing of staufen and show that staufen protein is one of the first molecules to localize to the posterior pole of the oocyte, perhaps in association with oskar RNA. Once localized, staufen is found in the polar granules and is required to hold other polar granule components at the posterior pole. By the time the egg is laid, staufen protein is also concentrated at the anterior pole, in the same region as bicoid RNA.	MAX PLANCK INST ENTWICKLUNGSBIOL,GENET ABT 3,W-7400 TUBINGEN,GERMANY	Max Planck Society			St Johnston, Daniel/C-9568-2009	St Johnston, Daniel/0000-0001-5582-3301				AKAM M, 1987, DEVELOPMENT, V101, P1; BERG CA, 1991, GENETICS, V127, P515; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COUNCE SJ, 1963, J MORPHOL, V112, P129, DOI 10.1002/jmor.1051120203; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DUNCAN IM, 1982, GENETICS, V102, P49; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; King RC., 1970, OVARIAN DEV DROSOPHI; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; LEHMANN R, 1991, IN PRESS DEVELOPMENT; LEPTIN M, 1990, DEVELOPMENT, V110, P73; MAHOWALD AP, 1968, J EXP ZOOL, V167, P237, DOI 10.1002/jez.1401670211; MAHOWALD AP, 1971, J EXP ZOOL, V176, P329, DOI 10.1002/jez.1401760308; MAHOWALD AP, 1962, J EXP ZOOL, V151, P201, DOI 10.1002/jez.1401510302; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOHLER J, 1986, GENETICS, V112, P803; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; RAFF JW, 1990, DEVELOPMENT, V110, P1249; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANDER K, 1988, NATURE, V335, P68, DOI 10.1038/335068a0; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SCHUPBACH T, 1986, DEV BIOL, V113, P443, DOI 10.1016/0012-1606(86)90179-X; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9	49	524	529	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1991	66	1					51	63		10.1016/0092-8674(91)90138-O	http://dx.doi.org/10.1016/0092-8674(91)90138-O			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1712672				2022-12-01	WOS:A1991FW91300008
J	VLEMINCKX, K; VAKAET, L; MAREEL, M; FIERS, W; VANROY, F				VLEMINCKX, K; VAKAET, L; MAREEL, M; FIERS, W; VANROY, F			GENETIC MANIPULATION OF E-CADHERIN EXPRESSION BY EPITHELIAL TUMOR-CELLS REVEALS AN INVASION SUPPRESSOR ROLE	CELL			English	Article							ADHESION MOLECULE UVOMORULIN; CYTOPLASMIC DOMAIN; CANCER METASTASIS; SORTING-OUT; TRANSFECTION; DIFFERENTIATION; INVITRO; IDENTIFICATION; CARCINOMAS; PHENOTYPES	A cDNA encoding the cell-cell adhesion molecule E-cadherin was transfected into highly invasive epithelial tumor cell lines of dog kidney or mouse mammary gland origin. Transfectants with a homogeneously high expression of E-cadherin showed a reproducible loss of activity in two types of in vitro invasion assays. invasiveness of these transfectants could be reinduced specifically by treatment with anti-E-cadherin antibodies. In vivo, they formed partly differentiated tumors, instead of fully undifferentiated tumors. Alternatively, a plasmid encoding E-cadherin-specific anti-sense RNA was introduced into noninvasive ras-transformed cells with high endogenous E-cadherin expression. The resulting down-regulation, albeit partial, rendered the cells invasive. These data provide direct evidence that E-cadherin acts as an invasion suppressor molecule.	STATE UNIV GHENT,EXPTL CANCEROL LAB,B-9000 GHENT,BELGIUM	Ghent University	VLEMINCKX, K (corresponding author), STATE UNIV GHENT,MOLEC BIOL LAB,B-9000 GHENT,BELGIUM.		Vakaet, Luc/A-6467-2010; Vleminckx, Kris/J-5699-2013; van Roy, Frans M/C-6123-2009	van Roy, Frans M/0000-0003-4358-1039				BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; EDELMAN GM, 1987, P NATL ACAD SCI USA, V84, P8502, DOI 10.1073/pnas.84.23.8502; EIDELMAN S, 1989, AM J PATHOL, V135, P101; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FIDLER IJ, 1987, CURR PROB SURG, V24, P137, DOI 10.1016/0011-3840(87)90002-5; FRIEDLANDER DR, 1989, P NATL ACAD SCI USA, V86, P7043, DOI 10.1073/pnas.86.18.7043; GARBISA S, 1987, CANCER RES, V47, P1523; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HASHIMOTO M, 1989, JPN J CANCER RES, V80, P459, DOI 10.1111/j.1349-7006.1989.tb02336.x; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; LIOTTA LA, 1986, CANCER RES, V46, P1; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MAREEL M, 1979, VIRCHOWS ARCH B, V30, P95; MAREEL M, 1988, UCLA S MOL CELLULAR, V78, P179; MAREEL M M, 1981, Invasion and Metastasis, V1, P195; MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623; MAREEL MM, 1983, CANCER METAST REV, V2, P201, DOI 10.1007/BF00048970; MAREEL MM, 1990, CANCER METAST REV, V9, P45, DOI 10.1007/BF00047588; MAREEL MM, 1991, MECHANISMS INVASION; MAREEL MM, 1986, NEW FRONTIERS MAMMAR, P351; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OWENS RB, 1974, J NATL CANCER I, V53, P261, DOI 10.1093/jnci/53.1.261; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PIERCE GB, 1988, CANCER RES, V48, P1996; SACHS L, 1987, CANCER RES, V47, P1981; Sambrook J., 1989, MOL CLONING LAB MANU; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; SOBEL ME, 1990, JNCI-J NATL CANCER I, V82, P267, DOI 10.1093/jnci/82.4.267; SONNENBERG A, 1986, CANCER RES, V46, P5913; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEEG PS, 1988, CANCER RES, V48, P6550; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; VANROY FM, 1989, ANTICANCER RES, V9, P1553; VANROY FM, 1986, CANCER RES, V46, P4787	46	1501	1554	1	42	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1991	66	1					107	119		10.1016/0092-8674(91)90143-M	http://dx.doi.org/10.1016/0092-8674(91)90143-M			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	2070412				2022-12-01	WOS:A1991FW91300013
J	WASHBURN, JO; MERCER, DR; ANDERSON, JR				WASHBURN, JO; MERCER, DR; ANDERSON, JR			REGULATORY ROLE OF PARASITES - IMPACT ON HOST POPULATION SHIFTS WITH RESOURCE AVAILABILITY	SCIENCE			English	Article							LAMBORNELLA-CLARKI CILIOPHORA; AEDES-SIERRENSIS DIPTERA; CALIFORNIA TREEHOLES; MOSQUITO; CILIATE; TETRAHYMENIDAE; CULICIDAE	Effects of infections by the ciliate Lambornella clarki on larval populations of its mosquito host Aedes sierrensis were examined in laboratory and field studies. When host populations developed with sufficient food, mortality from parasites was additive and reduced the number of emerging mosquitoes. For food-limited populations, mortality was compensatory or depensatory; emerging adults were as or more abundant with higher average fitness than those from uninfected control populations. When nutrients were scarce, parasitic infections relaxed larval competition and increased per capita food by reducing host abundance. Food limitation altered larval feeding behavior, reducing horizontal transmission and subsequent mortality from parasitism.			WASHBURN, JO (corresponding author), UNIV CALIF BERKELEY, DEPT ENTOMOL, BERKELEY, CA 94720 USA.				NIAID NIH HHS [AI20245] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020245] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUDELOSILVA F, 1984, AM J TROP MED HYG, V33, P1267, DOI 10.4269/ajtmh.1984.33.1267; ANDERSON RM, 1979, NATURE, V279, P150, DOI 10.1038/279150a0; ANDERSON RM, 1978, J ANIM ECOL, V47, P219, DOI 10.2307/3933; CARPENTER SR, 1982, OIKOS, V39, P17, DOI 10.2307/3544526; CARPENTER SR, 1983, ECOLOGY, V64, P219, DOI 10.2307/1937068; CLARK TB, 1976, J INVERTEBR PATHOL, V28, P341, DOI 10.1016/0022-2011(76)90009-4; CORLISS JO, 1976, T AM MICROSC SOC, V95, P725, DOI 10.2307/3225400; EGERTER DE, 1985, J INVERTEBR PATHOL, V46, P296, DOI 10.1016/0022-2011(85)90072-2; EGERTER DE, 1986, P NATL ACAD SCI USA, V83, P7335, DOI 10.1073/pnas.83.19.7335; Esch G. W., 1990, PARASITE COMMUNITIES; Hassell M. P, 1982, POPULATION BIOL INFE, P15; Hawley W.A., 1985, P167; HAWLEY WA, 1985, J ANIM ECOL, V54, P955, DOI 10.2307/4389; Holmes J.C., 1982, Life Sciences Research Report, P37; Lounibos L. P., 1985, ECOLOGY MOSQUITOES; SCOTT ME, 1989, PROTOZOOL TODAY, V5, P179; Washburn J., UNPUB; WASHBURN JO, 1988, SCIENCE, V240, P1193, DOI 10.1126/science.3131877; WASHBURN JO, 1986, J INVERTEBR PATHOL, V48, P296, DOI 10.1016/0022-2011(86)90058-3; WASHBURN JO, 1989, J MED ENTOMOL, V26, P173, DOI 10.1093/jmedent/26.3.173; WASHBURN JO, IN PRESS J INVERT PA; WOODWARD DL, 1988, B SOC VECTOR ECOL, V13, P1	22	79	80	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	1991	253	5016					185	188		10.1126/science.1906637	http://dx.doi.org/10.1126/science.1906637			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1906637				2022-12-01	WOS:A1991FW16000033
J	BAICHWAL, VR; PARK, A; TJIAN, R				BAICHWAL, VR; PARK, A; TJIAN, R			V-SRC AND EJ RAS ALLEVIATE REPRESSION OF C-JUN BY A CELL-SPECIFIC INHIBITOR	NATURE			English	Article							PROTO-ONCOGENE; FIBROBLASTS; AP-1; GENE; TPA; TRANSCRIPTION	THE AP-1 family of transcription factors, which includes the proto-oncogene products c-Jun and c-Fos 1, controls the stimulation of cellular genes by growth factors and the expression of oncogenes, including src and ras 2-8. Transcriptional activation by c-Jun is regulated by a cell-type-specific inhibitor that represses the activity of a transcriptional activation domain (A1) of c-Jun by operating through the adjacent negative regulatory region (delta) (refs 9-11). Here we show that cotransfection of the src or ras oncogene enhances the transcriptional activity of a GAL4:c-Jun hybrid that includes the delta-A1 region of c-Jun, suggesting that the DNA binding and dimerization domain of c-Jun is not required for stimulation by Src or Ras. Moreover, induction of c-Jun activity by Src and Ras occurs in cell lines containing the c-Jun inhibitor but not in a cell line lacking it. The region in c-Jun essential for the stimulatory action of these oncogenes maps to domain A1. These findings suggest the existence of signal-transduction pathways that result in an increase in transcriptional activity of c-Jun and AP-1 by disrupting the c-Jun:inhibitor interaction.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	BAICHWAL, VR (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.							ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BOHMANN D, 1989, CELL, V59, P909; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x	17	84	88	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1991	352	6331					165	168		10.1038/352165a0	http://dx.doi.org/10.1038/352165a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW097	1906140				2022-12-01	WOS:A1991FW09700060
J	BIRD, GS; ROSSIER, MF; HUGHES, AR; SHEARS, SB; ARMSTRONG, DL; PUTNEY, JW				BIRD, GS; ROSSIER, MF; HUGHES, AR; SHEARS, SB; ARMSTRONG, DL; PUTNEY, JW			ACTIVATION OF CA2+ ENTRY INTO ACINAR-CELLS BY A NON-PHOSPHORYLATABLE INOSITOL TRISPHOSPHATE	NATURE			English	Article							RAT-LIVER CELLS; 1,4,5-TRISPHOSPHATE 3-KINASE; INTRACELLULAR CA-2+; CALCIUM RELEASE; 1,3,4,5-TETRAKISPHOSPHATE; PHOSPHATES; RECEPTOR; MEMBRANE; THAPSIGARGIN; PURIFICATION	IN many cell types, receptor activation of phosphoinositidase C results in an initial release of intracellular Ca2+ stores followed by sustained Ca2+ entry across the plasma membrane. Inositol 1,4,5-trisphosphate is the mediator of the initial Ca2+ release 1, although its role in the mechanism underlying Ca2+ entry remains controversial 2-6. We have now used two techniques to introduce inositol phosphates into mouse lacrimal acinar cells and measure their effects on Ca2+ entry: microinjection into cells loaded with Fura-2, a fluorescent dye which allows the measurement of intracellular free calcium concentration by microspectrofluorimetry, and perfusion of patch clamp pipettes in the whole-cell configuration while monitoring the activity of Ca2+-activated K+ channels as an indicator of intracellular Ca2+. We report here that inositol 1,4,5-trisphosphate serves as a signal that is both necessary and sufficient for receptor activation of Ca2+ entry across the plasma membrane in these cells.			BIRD, GS (corresponding author), NIEHS, CELLULAR & MOLEC PHARMACOL LAB, CALCIUM REGULAT SECT, RES TRIANGLE PK, NC 27709 USA.		Shears, Stephen B/C-6335-2019; Rossier, Michel/AAW-2895-2021; Bird, Gary/AAI-8186-2021; Putney, James W/F-7247-2019	Shears, Stephen B/0000-0001-7309-8916; Bird, Gary/0000-0003-1389-8748; Putney, James W/0000-0002-3379-4789				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BURGESS GM, IN PRESS J BIOL CHEM; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; DEAN NM, 1987, BIOCHEM J, V242, P361, DOI 10.1042/bj2420361; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILL TD, 1987, BIOCHEM BIOPH RES CO, V149, P897, DOI 10.1016/0006-291X(87)90492-X; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; IRVINE RF, 1984, BIOCHEM J, V222, P269, DOI 10.1042/bj2220269; IRVINE RF, 1989, BIOCHEM SOC T, V17, P6, DOI 10.1042/bst0170006; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KENNEDY ED, 1989, J NEUROCHEM, V53, P1652, DOI 10.1111/j.1471-4159.1989.tb08566.x; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LLANO I, 1987, PFLUG ARCH EUR J PHY, V409, P499, DOI 10.1007/BF00583807; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; MORRIS AJ, 1988, BIOCHEM J, V251, P157, DOI 10.1042/bj2510157; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; PAROD RJ, 1978, J PHYSIOL-LONDON, V281, P371, DOI 10.1113/jphysiol.1978.sp012428; PAROD RJ, 1980, AM J PHYSIOL, V239, pG99, DOI 10.1152/ajpgi.1980.239.2.G99; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RYU SH, 1987, FASEB J, V1, P388, DOI 10.1096/fasebj.1.5.2824270; SHEARS SB, 1988, BIOCHEM J, V256, P363, DOI 10.1042/bj2560363; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; SPAT A, 1986, NATURE, V319, P514, DOI 10.1038/319514a0; STEPHENS LR, 1989, BIOCHEM J, V262, P727, DOI 10.1042/bj2620727; TANG JM, 1990, PFLUG ARCH EUR J PHY, V416, P347, DOI 10.1007/BF00392072; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; YAMAGUCHI K, 1988, BIOCHEM J, V251, P129, DOI 10.1042/bj2510129	32	175	177	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 11	1991	352	6331					162	165		10.1038/352162a0	http://dx.doi.org/10.1038/352162a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW097	1648669				2022-12-01	WOS:A1991FW09700059
J	DEANGELIS, GC; OHZAWA, I; FREEMAN, RD				DEANGELIS, GC; OHZAWA, I; FREEMAN, RD			DEPTH IS ENCODED IN THE VISUAL-CORTEX BY A SPECIALIZED RECEPTIVE-FIELD STRUCTURE	NATURE			English	Article							CAT STRIATE CORTEX; SPATIAL-FREQUENCY; LOCAL STEREOPSIS; BINOCULAR INTERACTION; SIMPLE CELLS; VISION; MODEL; DISCRIMINATION; ORGANIZATION; SELECTIVITY	BINOCULAR neurons in the visual cortex are thought to perform the first stage of processing for the fine stereoscopic depth discrimination exhibited by animals with frontally located eyes. Because lateral separation of the eyes gives a slightly different view to each eye, there are small variations in position (disparities), mainly along the horizontal dimension, between corresponding features in the two retinal images. The visual system uses these disparities to gauge depth. We studied neurons in the cat's visual cortex to determine whether the visual system uses the anisotropy in the range of horizontal and vertical disparities. We report here that there is a corresponding anisotropy in the cortical representation of binocular information: receptive-field profiles for left and right eyes are matched for cells that are tuned to horizontal orientations of image contours. For neurons tuned to vertical orientations, left and right receptive fields are predominantly dissimilar. Therefore, a major modification is required of the conventional notion of disparity processing. The modified scheme allows a unified encoding of monocular form and binocular disparity information.	UNIV CALIF BERKELEY,SCH OPT,BIOENGN GRP,BERKELEY,CA 94720; UNIV CALIF BERKELEY,SCH OPT,NEUROBIOL GRP,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley				DeAngelis, Gregory/0000-0002-1635-1273; Ohzawa, Izumi/0000-0002-7123-7318				BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; DAUGMAN JG, 1985, J OPT SOC AM A, V2, P1160, DOI 10.1364/JOSAA.2.001160; DEVALOIS RL, 1982, VISION RES, V22, P545, DOI 10.1016/0042-6989(82)90113-4; FERSTER D, 1981, J PHYSIOL-LONDON, V311, P623, DOI 10.1113/jphysiol.1981.sp013608; FREEMAN RD, 1990, VISION RES, V30, P1661, DOI 10.1016/0042-6989(90)90151-A; FREEMAN RD, 1982, EXP BRAIN RES, V48, P296; Gabor D., 1946, IEEE J I ELECT ENG, V93, P429, DOI DOI 10.1049/JI-3-2.1946.0074; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; HUBEL DH, 1973, J PHYSL, V232, P29; JONES JP, 1987, J NEUROPHYSIOL, V58, P1187, DOI 10.1152/jn.1987.58.6.1187; JONES JP, 1987, J NEUROPHYSIOL, V58, P1233, DOI 10.1152/jn.1987.58.6.1233; JOSHUA DE, 1970, EXP BRAIN RES, V10, P389, DOI 10.1007/BF02324766; LEVAY S, 1988, VISUAL NEUROSCI, V1, P395, DOI 10.1017/S0952523800004168; MARCELJA S, 1980, J OPT SOC AM, V70, P1297, DOI 10.1364/JOSA.70.001297; MARR D, 1979, PROC R SOC SER B-BIO, V204, P301, DOI 10.1098/rspb.1979.0029; MASKE R, 1984, VISION RES, V24, P1921, DOI 10.1016/0042-6989(84)90026-9; NOMURA M, 1990, BIOL CYBERN, V63, P237, DOI 10.1007/BF00195863; OHZAWA I, 1986, J NEUROPHYSIOL, V56, P221, DOI 10.1152/jn.1986.56.1.221; OHZAWA I, 1990, SCIENCE, V249, P1037, DOI 10.1126/science.2396096; POGGIO GF, 1988, J NEUROSCI, V8, P4531; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; SAKITT B, 1982, BIOL CYBERN, V43, P97, DOI 10.1007/BF00336972; SCHOR CM, 1984, VISION RES, V24, P573, DOI 10.1016/0042-6989(84)90111-1; SCHOR CM, 1983, VISION RES, V23, P1649, DOI 10.1016/0042-6989(83)90179-7; von der Heydt R, 1978, Exp Brain Res, V31, P523	25	210	211	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1991	352	6331					156	159		10.1038/352156a0	http://dx.doi.org/10.1038/352156a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW097	2067576				2022-12-01	WOS:A1991FW09700057
J	FARCI, P; ALTER, HJ; WONG, D; MILLER, RH; SHIH, JW; JETT, B; PURCELL, RH				FARCI, P; ALTER, HJ; WONG, D; MILLER, RH; SHIH, JW; JETT, B; PURCELL, RH			A LONG-TERM STUDY OF HEPATITIS-C VIRUS-REPLICATION IN NON-A, NON-B HEPATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIBODIES; GENOME; BLOOD; CDNA; CHIMPANZEES; SEQUENCE; ANTIGEN; RNA; PCR	Background. Although antibodies to the hepatitis C virus (HCV) are known to be associated with non-A, non-B hepatitis, little is known about the pattern of HCV replication, its relation to antibody levels, and the clinical course of non-A, non-B hepatitis. Methods. We measured HCV RNA in serial serum samples from five patients with post-transfusion non-A, non-B hepatitis who were followed for 1 0 to 14 years after transfusion. We also studied four chimpanzees that were experimentally infected with serum from four of these patients. Serum HCV RNA was detected by a "nested" polymerase-chain-reaction (PCR) assay that used two sets of primers derived from the third (NS3) and fourth (NS4) nonstructural gene regions of the HCV genome. Results. HCV sequences were detected by PCR in only two of the five patients and two of the four chimpanzees with the set of primers corresponding to the NS3 region, but in all five patients (and in all four chimpanzees) with the primers from the NS4 region. Serum HCV RNA was first detected within three weeks of transfusion in all five patients and within one week in three patients. The viremia lasted less than 4 months in the patient (and two chimpanzees) with acute, self-limited hepatitis, whereas it persisted for 10 to 14 years in the four patients (and for 1 and 3 years in two chimpanzees) with chronic non-A, non-B hepatitis. Antibodies to HCV were first detected at week 12 to 14; they disappeared after nine years in the patient with self-limited disease and became borderline after five years in one of the patients with chronic disease. Conclusions. During the early phase of primary HCV infection, there is a period of several months of seronegativity during which HCV RNA is the only diagnostic marker of infection. The disappearance of HCV RNA from serum appears to correlate with the resolution of non-A, non-B hepatitis, whereas viremia persists in patients whose disease progresses to chronic hepatitis. In contrast, antibody levels do not necessarily remain elevated in patients with chronic disease.	NIH,BIOMED ENGN & INSTRUMENTAT BRANCH,WARREN G MAGNUSON CLIN CTR,DEPT TRANSFUS MED,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	FARCI, P (corresponding author), NIAID,INFECT DIS LAB,HEPATITIS VIRUSES SECT,BLDG 7,RM 202,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		Jett, Betsy/AAT-5154-2021					ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1978, LANCET, V1, P459; ALTER HJ, 1989, CURRENT PERSPECTIVES, P83; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1989, LANCET, V2, P294; FEINSTONE SM, 1981, J INFECT DIS, V144, P588, DOI 10.1093/infdis/144.6.588; GARSON JA, 1990, LANCET, V336, P1022, DOI 10.1016/0140-6736(90)92487-3; HOUGHTON M, 1988, Patent No. 883109225; KANEKO S, 1990, LANCET, V335, P976, DOI 10.1016/0140-6736(90)91042-9; KATO N, 1989, P JPN ACAD B-PHYS, V65, P219, DOI 10.2183/pjab.65.219; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUBO Y, 1989, NUCLEIC ACIDS RES, V17, P10367, DOI 10.1093/nar/17.24.10367; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; KWOK S, 1989, NATURE, V339, P490; MAKRIS M, 1990, LANCET, V335, P1117, DOI 10.1016/0140-6736(90)91124-S; MIYAMURA T, 1990, P NATL ACAD SCI USA, V87, P983, DOI 10.1073/pnas.87.3.983; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; SHIMIZU YK, 1990, P NATL ACAD SCI USA, V87, P6441, DOI 10.1073/pnas.87.16.6441; VANDERPOEL CL, 1989, LANCET, V2, P297; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266	25	494	511	1	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	1991	325	2					98	104		10.1056/NEJM199107113250205	http://dx.doi.org/10.1056/NEJM199107113250205			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV522	1646962				2022-12-01	WOS:A1991FV52200005
J	GREENBERG, AE; NSA, W; RYDER, RW; MEDI, M; NZEZA, M; KITADI, N; BAANGI, M; MALANDA, N; DAVACHI, F; HASSIG, SE				GREENBERG, AE; NSA, W; RYDER, RW; MEDI, M; NZEZA, M; KITADI, N; BAANGI, M; MALANDA, N; DAVACHI, F; HASSIG, SE			PLASMODIUM-FALCIPARUM MALARIA AND PERINATALLY ACQUIRED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION IN KINSHASA, ZAIRE - A PROSPECTIVE, LONGITUDINAL COHORT STUDY OF 587 CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIV SEROPOSITIVITY; ASSOCIATION; DISEASES; INFANTS; QUININE; AIDS	Background. It is uncertain whether Plasmodium falciparum malaria is more frequent or more severe in children with perinatally acquired human immunodeficiency virus type 1 (HIV-1) infection and whether P. falciparum infection accelerates the progression of HIV-related disease. Methods. We conducted a prospective, longitudinal cohort study in Kinshasa, Zaire. Two hundred sixty children 5 to 9 months of age who had been born to HIV-1-seropositive mothers and 327 children of the same age who had been born to seronegative mothers were monitored intensively for malaria over a 13-month period. All episodes of fever were evaluated with blood smears for malaria, and children found to be infected with P. falciparum were treated with a standard regimen of oral quinine. Results. A total of 2899 fevers were evaluated, with 271 cases of malaria identified. No statistically significant differences were found in the incidence, severity, or response to therapy of malaria among four well-defined groups of children: those with the acquired immunodeficiency syndrome (AIDS), those who were HIV-1-seropositive throughout the study, those who were born to HIV-1-seropositive mothers but reverted to seronegative, and those who were seronegative throughout the study. During the 13-month period the incidence of malaria in the 36 children with HIV infection in whom AIDS developed was lower, although not significantly so, than in the 37 in whom AIDS did not develop. Conclusions. In this study malaria was not more frequent or more severe in children with progressive HIV-1 infection and malaria did not appear to accelerate the rate of progression of HIV-1 disease.	PROJET SIDA, KINSHASA, DEM REP CONGO; CTR DIS CONTROL, CTR INFECT DIS, DIV PARASIT DIS, MALARIA BRANCH, ATLANTA, GA 30333 USA; MAMA YEMO HOSP, DEPT PEDIAT, KINSHASA, DEM REP CONGO	Centers for Disease Control & Prevention - USA	GREENBERG, AE (corresponding author), CTR DIS CONTROL, CTR INFECT DIS, DIV HIV AIDS, MAILSTOP E-45, ATLANTA, GA 30333 USA.							BADI N, 1989, 5TH INT C AIDS MONTR; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; COLEBUNDERS R, 1990, J INFECTION, V21, P167, DOI 10.1016/0163-4453(90)91701-E; COLEBUNDERS RI, 1987, AIDS, V1, P151; FEORINO PM, 1984, SCIENCE, V225, P69, DOI 10.1126/science.6328663; GOODGAME RW, 1990, NEW ENGL J MED, V323, P383, DOI 10.1056/NEJM199008093230605; GREENBERG AE, 1988, JAMA-J AM MED ASSOC, V259, P545, DOI 10.1001/jama.259.4.545; GREENBERG AE, 1989, B WORLD HEALTH ORGAN, V67, P189; GREENBERG AE, 1989, AM J TROP MED HYG, V40, P360, DOI 10.4269/ajtmh.1989.40.360; HO M, 1989, PARASITE IMMUNOL, V11, P105, DOI 10.1111/j.1365-3024.1989.tb00652.x; MARGOLICK JB, 1987, J IMMUNOL, V138, P1719; MCGREGOR IA, 1971, T ROY SOC TROP MED H, V65, P136, DOI 10.1016/0035-9203(71)90211-2; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; MORROW RH, 1989, AIDS, V3, pS79, DOI 10.1097/00002030-198901001-00012; NGIMBI NP, 1982, ANN SOC BELG MED TR, V62, P121; NGUYENDINH P, 1981, B WORLD HEALTH ORGAN, V59, P641; NGUYENDINH P, 1987, AM J TROP MED HYG, V37, P217, DOI 10.4269/ajtmh.1987.37.217; NGUYENDINH P, 1987, B WORLD HEALTH ORGAN, V65, P607; NGUYENDINH P, 1987, 36TH ANN M AM SOC TR; NGUYENDINH P, 1987, 3RD INT C AIDS WASH; NSA W, 1989, 5TH P INT C AIDS MON; NSA W, 1988, 4TH INT C AIDS STOCK; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SHAFFER N, 1990, AIDS, V4, P1231, DOI 10.1097/00002030-199012000-00008; SIMOOYA OO, 1988, BRIT MED J, V297, P30, DOI 10.1136/bmj.297.6640.30; SMITH PG, 1988, INT J EPIDEMIOL, V17, P705, DOI 10.1093/ije/17.4.705; SULZER A, 1986, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V24, P159; TROYEBLOMBERG M, 1988, PROG ALLERGY, V41, P253; World health organization malaria action program, 1986, T R SOC TROP MED H S, V80, P3; 1987, MMWR S1S, V36, pS1; 1986, T R SOC TROP MED HYG, V80, P571; 1986, WEEKLY EPIDEMIOLOGIC, V61, P69	33	93	95	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 11	1991	325	2					105	109		10.1056/NEJM199107113250206	http://dx.doi.org/10.1056/NEJM199107113250206			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV522	2052043	Bronze			2022-12-01	WOS:A1991FV52200006
J	HOWARD, JB; MCKINNON, JT; MAKAROVSKY, Y; LAFLEUR, AL; JOHNSON, ME				HOWARD, JB; MCKINNON, JT; MAKAROVSKY, Y; LAFLEUR, AL; JOHNSON, ME			FULLERENES C60 AND C70 IN FLAMES	NATURE			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; PERFORMANCE LIQUID-CHROMATOGRAPHY; CARBON; C-60; SOOT; BUCKMINSTERFULLERENE; FORM	THE fullerenes C60 and C70 were first identified 1 in carbon vapour produced by laser irradiation of graphite, and have recently been produced in macroscopic quantities 2-5 by vaporization of graphite with resistive heating. It has also been suggested 6-9 that fullerenes might be formed in sooting flames, and indeed all-carbon ions with mass/charge ratios suggestive of fullerenes have been detected in flames 10-12. These species were assumed to have the cage structures of fullerenes, but the mass spectroscopic evidence could not establish this conclusively. We have now collected samples of condensible compounds and soot from hydrocarbon combustion under a range of conditions, and analysed these using conventional techniques in an effort to detect fullerenes. Spectroscopic studies reveal the presence of C60 and C70 in yields and ratios that depend on temperature, pressure, carbon/oxygen ratio and residence time in the flame. Control of these conditions allows optimal yields of 3 g of fullerenes per kilogram of fuel carbon burned, and variation of the C70/C60 ratio over the range 0.26-5.7.	MIT,CTR ENVIRONM HLTH SCI,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	HOWARD, JB (corresponding author), MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139, USA.							AJIE H, 1990, J PHYS CHEM-US, V94, P8630, DOI 10.1021/j100387a004; Bittner J.D., 1983, SOOT COMBUSTION SYST, P57, DOI 10.1007/978-1-4684- 4463-6_5; BITTNER JD, 1981, 18 S INT COMB COMB I, P1105; BOCKHORN H, 1983, BER BUNSEN PHYS CHEM, V87, P1067, DOI 10.1002/bbpc.19830871121; CURL RF, 1988, SCIENCE, V242, P1017, DOI 10.1126/science.242.4881.1017; FETZER JC, 1985, J CHROMATOGR, V346, P81, DOI 10.1016/S0021-9673(00)90496-5; FETZER JC, 1985, J CHROMATOGR, V322, P275, DOI 10.1016/S0021-9673(01)97687-3; FETZER JC, 1984, J CHROMATOGR, V295, P161, DOI 10.1016/S0021-9673(01)87607-X; GERHARDT P, 1987, CHEM PHYS LETT, V137, P306, DOI 10.1016/0009-2614(87)80889-8; GERHARDT P, 1989, 22ND S INT COMB PITT, P395; HAUFLER RE, 1990, J PHYS CHEM-US, V94, P8634, DOI 10.1021/j100387a005; Homann K -H, 1963, Z PHYS CHEM NF, V37, P299; HOMANN KH, 1973, P COMBUSTION I EUROP, P394; HOWARD JB, IN PRESS 23RD INT S; Kraschmer W., 1990, CHEM PHYS LETT, V170, P167; KRATSCHMER W, 1990, NATURE, V347, P354, DOI 10.1038/347354a0; KROTO H, 1988, SCIENCE, V242, P1139, DOI 10.1126/science.242.4882.1139; KROTO HW, 1988, NATURE, V331, P328, DOI 10.1038/331328a0; KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0; LAFLEUR AL, 1987, ANAL LETT, V20, P1171; LOFFLER S, 1990, 23 S INT COMB COMB I, P355; LUFFER DR, 1990, RAPID COMMUN MASS SP, V4, P552, DOI 10.1002/rcm.1290041218; McKinnon J.T, 1989, THESIS MIT; MCKINNON JT, 1990, COMBUST SCI TECHNOL, V74, P175, DOI 10.1080/00102209008951687; OLSON DB, 1981, 18TH S INT COMB PITT, P453; TAYLOR R, 1990, J CHEM SOC CHEM COMM, P1423, DOI 10.1039/c39900001423; ZHANG QL, 1986, J PHYS CHEM-US, V90, P525, DOI 10.1021/j100276a001	27	465	492	3	124	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1991	352	6331					139	141		10.1038/352139a0	http://dx.doi.org/10.1038/352139a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW097	2067575				2022-12-01	WOS:A1991FW09700049
J	THERIOT, JA; MITCHISON, TJ				THERIOT, JA; MITCHISON, TJ			ACTIN MICROFILAMENT DYNAMICS IN LOCOMOTING CELLS	NATURE			English	Article							HEAVY-CHAIN GENE; ELECTRIC-FIELDS; MICROTUBULES; FLUORESCENCE; FIBROBLASTS; MOTILITY; MYOSIN; ORGANIZATION; LAMELLIPODIA; CYTOSKELETON	The dynamic behaviour of actin filaments has been directly observed in living, motile cells using fluorescence photoactivation. In goldfish epithelial keratocytes, the actin microfilaments in the lamellipodium remain approximately fixed relative to the substrate as the cell moves over them, regardless of cell speed. The rate of turnover of actin subunits in the lamellipodium is remarkably rapid. Cell movement is directly and tightly coupled to the formation of new actin filaments at the leading edge.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	THERIOT, JA (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL & BIOPHYS, SAN FRANCISCO, CA 94143 USA.			Theriot, Julie/0000-0002-2334-2535				AMATO PA, 1986, J CELL BIOL, V102, P1074, DOI 10.1083/jcb.102.3.1074; BEREITERHAHN J, 1988, CELL MOTIL CYTOSKEL, V10, P528, DOI 10.1002/cm.970100409; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; COOPER MS, 1985, J NEUROSCI RES, V13, P223, DOI 10.1002/jnr.490130116; COOPER MS, 1986, J CELL BIOL, V102, P1384, DOI 10.1083/jcb.102.4.1384; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DOSREMEDIOS CG, 1987, J MUSCLE RES CELL M, V8, P97, DOI 10.1007/BF01753986; EGELHOFF TT, 1991, TRENDS GENET, V7, P161, DOI 10.1016/0168-9525(91)90380-9; EUTENEUER U, 1984, NATURE, V310, P58, DOI 10.1038/310058a0; FISHER GW, 1988, CELL MOTIL CYTOSKEL, V11, P235, DOI 10.1002/cm.970110403; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; HAUGLAND RP, 1989, MIL PROBES HDB FLUOR; HEGYI G, 1974, EUR J BIOCHEM, V44, P7, DOI 10.1111/j.1432-1033.1974.tb03452.x; HILL TL, 1982, P NATL ACAD SCI-BIOL, V79, P490, DOI 10.1073/pnas.79.2.490; HUXLEY HE, 1973, NATURE, V244, P445, DOI 10.1038/243445a0; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KOLEGA J, 1986, J CELL BIOL, V102, P1400, DOI 10.1083/jcb.102.4.1400; Korn ED, 1990, CURR OPIN CELL BIOL, V2, P57, DOI 10.1016/S0955-0674(05)80031-6; KREIS TE, 1982, CELL, V29, P835, DOI 10.1016/0092-8674(82)90445-7; KUCIK DF, 1989, NATURE, V340, P315, DOI 10.1038/340315a0; KUCIK DF, 1990, J CELL BIOL, V111, P1617, DOI 10.1083/jcb.111.4.1617; LEE J, 1990, SCIENCE, V247, P1229, DOI 10.1126/science.2315695; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; OSTER GF, 1987, J CELL SCI, P35; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Pollard TD, 1990, CURR OPIN CELL BIOL, V2, P33, DOI 10.1016/S0955-0674(05)80028-6; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; RINNERTHALER G, 1988, J CELL BIOL, V106, P747, DOI 10.1083/jcb.106.3.747; RINNERTHALER G, 1991, J STRUCT BIOL, V106, P1, DOI 10.1016/1047-8477(91)90058-5; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; Small J V, 1988, Electron Microsc Rev, V1, P155; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; SVITKINA TM, 1986, J CELL SCI, V82, P235; SYMONS M, IN PRESS J CELL BIOL; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Taylor D L, 1979, Int Rev Cytol, V56, P57, DOI 10.1016/S0074-7696(08)61821-5; TRINKAUS JP, 1984, CELLS ORGANS FORCES, P202; WALKER JW, 1989, METHOD ENZYMOL, V172, P288; WANG YL, 1980, J HISTOCHEM CYTOCHEM, V28, P1198, DOI 10.1177/28.11.6107318; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; YIN HL, 1988, J CELL SCI, P169	41	672	681	1	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 11	1991	352	6331					126	131		10.1038/352126a0	http://dx.doi.org/10.1038/352126a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW097	2067574				2022-12-01	WOS:A1991FW09700045
J	VARADI, G; LORY, P; SCHULTZ, D; VARADI, M; SCHWARTZ, A				VARADI, G; LORY, P; SCHULTZ, D; VARADI, M; SCHWARTZ, A			ACCELERATION OF ACTIVATION AND INACTIVATION BY THE BETA SUBUNIT OF THE SKELETAL-MUSCLE CALCIUM-CHANNEL	NATURE			English	Article							DIHYDROPYRIDINE RECEPTOR; FUNCTIONAL EXPRESSION; MAMMALIAN-CELLS; MESSENGER-RNA; CDNA CLONING; ALPHA-1-SUBUNIT; RESOLUTION; INDUCTION; EXISTENCE; CURRENTS	THE L-type voltage-dependent calcium channel is an important link in excitation-contraction coupling of muscle cells 1 (reviewed in refs 2 and 3). The channel has two functional characteristics: calcium permeation and receptor sites for calcium antagonists. In skeletal muscle the channel is a complex of five subunits, alpha-1, alpha-2, beta, gamma and delta (ref. 4). Complementary DNAs to these subunits have been cloned and their amino-acid sequences deduced 5-8. The skeletal muscle alpha-1 subunit cDNA expressed in L cells manifests as specific calcium-ion permeation, as well as sensitivity to the three classes of organic calcium-channel blockers 9,10. We report here that coexpression of the alpha-1 subunit with other subunits results in significant changes in dihydropyridine binding and gating properties. The available number of drug receptor sites increases 10-fold with an alpha-1-beta combination, whereas the affinity of the dihydropyridine binding site remains unchanged. Also, the presence of the beta-subunit accelerates activation and inactivation kinetics of the calcium-channel current.	UNIV CINCINNATI,DEPT PHARMACOL & CELL BIOPHYS,231 BETHESDA AVE,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati				LORY, philippe/0000-0002-1638-7604				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; CAFFREY JM, 1987, SCIENCE, V236, P570, DOI 10.1126/science.2437651; CAFFREY JM, 1989, J NEUROSCI, V9, P3443; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; Janis R.A., 1987, ADV DRUG RES, V16, P309; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KIM HS, 1990, J BIOL CHEM, V265, P11858; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LORY P, 1990, J PHYSIOL-LONDON, V429, P95, DOI 10.1113/jphysiol.1990.sp018246; MCPHERSON GA, 1985, KINETIC EBDA LIGAND; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PRAGNELL M, 1985, NATURE, V314, P747; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Sambrook J., 1989, MOL CLONING LAB MANU; SLISH DF, 1989, FEBS LETT, V250, P509, DOI 10.1016/0014-5793(89)80786-0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VAGHY PL, 1988, TRENDS PHARMACOL SCI, V9, P398, DOI 10.1016/0165-6147(88)90066-1	28	270	273	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1991	352	6331					159	162		10.1038/352159a0	http://dx.doi.org/10.1038/352159a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW097	1712427				2022-12-01	WOS:A1991FW09700058
J	CONNOR, CD; SHULKIN, DJ				CONNOR, CD; SHULKIN, DJ			MEASLES - AN INCREASING OCCUPATIONAL RISK FOR PHYSICIANS-IN-TRAINING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											CONNOR, CD (corresponding author), UNIV PENN,SCH MED,PHILADELPHIA,PA 19104, USA.							POLAND GA, 1990, ANN INTERN MED, V113, P628, DOI 10.7326/0003-4819-113-8-628; 1990, HOSPITAL IMMUNIZATIO, P1; 1990, MMWR, V39, P430; 1989, MMWR, V38, P5	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					220	220						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU896	2056623				2022-12-01	WOS:A1991FU89600029
J	ESKENAZI, B; FENSTER, L; SIDNEY, S				ESKENAZI, B; FENSTER, L; SIDNEY, S			A MULTIVARIATE-ANALYSIS OF RISK-FACTORS FOR PREECLAMPSIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREGNANCY-INDUCED HYPERTENSION; 6TH PERIODIC REPORT; LOW-DOSE ASPIRIN; REMOTE PROGNOSIS; PRE-ECLAMPSIA; GESTATIONAL HYPERTENSION; WOMEN; DISEASES; MANAGEMENT; DIAGNOSIS	Objective.- To determine, in a multivariate analysis, risk factors for preeclampsia that could be observed early in pregnancy and to establish whether these risk factors are different for nulliparas and multiparas. Design.- A case-control study of preeclampsia. Setting.- Women who gave birth at Northern California Kaiser Permanente Medical Centers in 1984 and 1985. Participants.- Preeclamptic cases (n = 139) were determined from discharge diagnosis of severe preeclampsia and by confirmation of blood pressures and proteinuria from medical records. Controls (n = 132) were randomly selected women who had no discharge diagnosis of any hypertensive disorder of pregnancy and who had no evidence of hypertension or proteinuria from medical record review. Main Variables Examined.- Medical records were abstracted for information regarding maternal age, race, previous pregnancy history, family medical history, socioeconomic status, employment during pregnancy, body mass, and smoking and alcohol consumption. Results.- Multiple logistic regression analyses confirmed that case patients were more likely than control patients to be nulliparous (adjusted odds ratio [OR], 5.4; 95% confidence interval [Cl], 2.8 to 10.3) and that preeclampsia in a previous pregnancy greatly increased the risk in a subsequent one (adjusted OR, 10.8; 95% Cl, 1.2 to 29.1). However, regardless of parity, preeclamptic women were also more likely to be of high body mass (adjusted OR, 2.7; 95% Cl, 1.2 to 6.2), to work during pregnancy (adjusted OR, 2.1; 95% Cl, 1.1 to 4.4), and to have a family history of hypertension (adjusted OR, 1.7; 95% Cl, 0.92 to 3.2). Having a previous history of a spontaneous abortion was protective but only in multiparous women (adjusted OR for multiparas, 0.09; 95% Cl, 0.02 to 0.48). In contrast, being black was a significant risk for preeclampsia but only in nulliparous women (adjusted OR for nulliparas, 12.3; 95% Cl, 1.6 to 100.8). Conclusions.- There are a number of risk factors for preeclampsia that may be determined early in a woman's pregnancy Multiparas and nulliparas share certain risk factors but not others. A cohort investigation is needed to determine the ability of these risk factors to predict who develops preeclampsia.	UNIV CALIF BERKELEY,SCH PUBL HLTH,NO CALIF OCCUPAT HLTH CTR,BERKELEY,CA 94720; KAISER PERMANENTE MED CTR,DIV RES,OAKLAND,CA; UNIV CALIF BERKELEY,SCH PUBL HLTH,PROGRAM EPIDEMIOL,BERKELEY,CA 94720; CALIF DEPT HLTH SERV,REPROD ENDOCRINOL PROGRAM,BERKELEY,CA 94704	University of California System; University of California Berkeley; Kaiser Permanente; University of California System; University of California Berkeley; California Department of Health Care Services	ESKENAZI, B (corresponding author), UNIV CALIF BERKELEY,SCH PUBL HLTH,PROGRAM MATERNAL & CHILD HLTH,312 EARL WARREN HALL,BERKELEY,CA 94720, USA.							BAIRD D, 1949, LANCET, V1, P1070; BARRON SL, 1968, P ROY SOC MED, V61, P120; BEAUFILS M, 1985, LANCET, V1, P840, DOI 10.1016/S0140-6736(85)92207-X; BENIGNI A, 1989, NEW ENGL J MED, V321, P357, DOI 10.1056/NEJM198908103210604; CHESLEY LC, 1976, AM J OBSTET GYNECOL, V124, P446, DOI 10.1016/0002-9378(76)90168-X; CHESLEY LC, 1984, CLIN OBSTET GYNECOL, V27, P801, DOI 10.1097/00003081-198412000-00004; Chiang CL, 1980, INTRO STOCHASTIC PRO; DAVIES AM, 1970, ISRAEL J MED SCI, V6, P253; DENMAN T, 1821, INTRO PRACTICE MIDWI; DUFFUS GM, 1968, LANCET, V1, P994; ESKENAZI B, 1988, AM J IND MED, V14, P177, DOI 10.1002/ajim.4700140208; FITZGIBBON G, 1922, J OBSTET GYN BR COMM, V29, P402; FRIEDMAN GD, 1982, HYPERTENSION, V4, P143; GLEICHER N, 1986, AM J OBSTET GYNECOL, V154, P1044, DOI 10.1016/0002-9378(86)90747-7; Goldhaber M K, 1991, Epidemiology, V2, P33; HERTZPICCIOTTO I, 1990, EPIDEMIOL REV, V12, P108, DOI 10.1093/oxfordjournals.epirev.a036049; HIATT RA, 1982, KIDNEY INT, V22, P63, DOI 10.1038/ki.1982.133; Klatsky A L, 1978, Compr Ther, V4, P60; KLEBANOFF MA, 1990, NEW ENGL J MED, V323, P1040, DOI 10.1056/NEJM199010113231506; KRIEGER N, 1991, J EPIDEMIOL COMMUN H, V45, P35, DOI 10.1136/jech.45.1.35; LEHMANN K, 1983, EKLAMPSIEN DANMARK A; MACGILLIVRAY I, 1961, J OBSTET GYN BR COMM, V68, P557; MARCOUX S, 1989, AM J EPIDEMIOL, V130, P950, DOI 10.1093/oxfordjournals.aje.a115427; MARCOUX S, 1989, J EPIDEMIOL COMMUN H, V43, P147, DOI 10.1136/jech.43.2.147; NELSON TR, 1955, J OBSTET GYNAECOL, V62, P48; Niswander K. R., 1972, DHEW PUBL; PALMGREN B, 1973, ACTA OBSTET GYN SCAN, V52, P183, DOI 10.3109/00016347309158310; Roberts JM, 1984, MATERNAL FETAL MED P, P703; SCHIFF E, 1989, NEW ENGL J MED, V321, P351, DOI 10.1056/NEJM198908103210603; SIBAI BM, 1988, AM J OBSTET GYNECOL, V159, P1; SIBAI BM, 1986, AM J OBSTET GYNECOL, V155, P1011, DOI 10.1016/0002-9378(86)90336-4; WALLENBURG HCS, 1986, LANCET, V1, P1; 1980, 1980 CENSUS POPULATI; 1987, WHO TECHNICAL REPORT, V758; 1985, SAS USERS GUIDE VERS	35	362	366	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					237	241						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU896	2056625				2022-12-01	WOS:A1991FU89600032
J	HOLT, VL; CHU, J; DALING, JR; STERGACHIS, AS; WEISS, NS				HOLT, VL; CHU, J; DALING, JR; STERGACHIS, AS; WEISS, NS			TUBAL-STERILIZATION AND SUBSEQUENT ECTOPIC PREGNANCY - A CASE-CONTROL STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; POPULATION; FAILURES	Objective.- To assess the relative risk of ectopic pregnancy associated with postpartum or interval tubal sterilization. Design.- Case-control study using a comparison group of women of reproductive age at risk of pregnancy. Setting.- Group Health Cooperative of Puget Sound, a health maintenance organization based in Seattle, Wash. Participants.- Cases were 249 enrollees diagnosed as having an ectopic pregnancy between October 1, 1981, and September 30, 1986. Controls were 835 randomly selected enrollees matched to cases on age and county of residence. Measurements.- Information on interval sterilization history was obtained from interviews, examination of medical records, automated hospitalization files, and a previously validated algorithm. A logistic regression model was used to estimate relative risks (RRs) for sterilized women compared with women using other types of or no contraception at the reference date. Results.- Controlling for age, county, race, smoking, income, gravidity, and prior use of a Dalkon Shield intrauterine device, the risk of ectopic pregnancy in women who had undergone interval sterilization was 3.7 (95% confidence interval [Cl], 1.7 to 8.0) times that of women currently using oral contraception and 2.8 (95% Cl, 1.5 to 5.5) times that of women currently using barrier contraceptive methods. Use of interval sterilization was associated with a risk of ectopic pregnancy similar to that of women using intrauterine devices (RR, 0.8; 95% Cl, 0.4 to 1.7) and a risk lower than that of women who were not using contraception (RR, 0.2; 95% Cl, 0.1 to 0.3). The corresponding RRs associated with postpartum sterilization were lower: 1.2 (95% Cl, 0.3 to 3.9), 0.9 (95% Cl, 0.3 to 2.8), 0.3 (95% Cl, 0.1 to 0.8), and 0. 1 (95% Cl, 0.0 to 0.2), respectively. Conclusion.- Tubal sterilization provides some protection against extrauterine as well as intrauterine pregnancy. It is likely that postpartum sterilization can be a safe alternative to all types of temporary contraception in terms of risk of ectopic pregnancy, while some types of interval sterilization may lead to an increased risk, in comparison with use of oral contraceptives or barrier methods.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,DIV PUBL HLTH SCI,SEATTLE,WA 98104; UNIV WASHINGTON,SCH MED,DEPT OBSTET & GYNECOL,SEATTLE,WA 98195; GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,SEATTLE,WA; UNIV WASHINGTON,SCH PHARM,DEPT PHARM PRACTICE,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Group Health Cooperative; University of Washington; University of Washington Seattle					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017657] Funding Source: NIH RePORTER; NICHD NIH HHS [3RO1HD17657-S1, 1RO1HD17657] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1985, Clin Reprod Fertil, V3, P131; BACHRACH CA, 1984, FAM PLANN PERSPECT, V16, P253, DOI 10.2307/2134914; BRESLOW N. E., 1980, STATISTICAL METHODS; CHENG MCE, 1977, STUD FAMILY PLANN, V8, P109, DOI 10.2307/1966115; CHI IC, 1980, AM J OBSTET GYNECOL, V136, P768, DOI 10.1016/0002-9378(80)90454-8; CHI IC, 1981, ADV PLANNED PARENT, V16, P52; DESTEFANO F, 1982, OBSTET GYNECOL, V60, P326; DESTEFANO F, 1984, JAMA-J AM MED ASSOC, V251, P1432; GRAY RH, 1984, INTRAUTERINE CONTRAC, P354; HOLT VL, 1989, AM J PUBLIC HEALTH, V79, P1234, DOI 10.2105/AJPH.79.9.1234; KJER JJ, 1989, AM J OBSTET GYNECOL, V160, P1202, DOI 10.1016/0002-9378(89)90190-7; Loffer F D, 1975, Obstet Gynecol Surv, V30, P407, DOI 10.1097/00006254-197507000-00001; MARCHBANKS PA, 1988, JAMA-J AM MED ASSOC, V259, P1823, DOI 10.1001/jama.259.12.1823; MCCAUSLAND A, 1980, AM J OBSTET GYNECOL, V136, P97, DOI 10.1016/0002-9378(80)90573-6; MOSHER WD, 1990, ADV DATA VITAL HLTH, V182; PEARSON DC, 1987, PREV MED, V16, P783, DOI 10.1016/0091-7435(87)90018-1; STERGACHIS A, 1990, JAMA-J AM MED ASSOC, V264, P2893, DOI 10.1001/jama.264.22.2893; TATUM HJ, 1977, FERTIL STERIL, V28, P407; WEISS NS, 1988, JAMA-J AM MED ASSOC, V260, P1553, DOI 10.1001/jama.1988.03410110061019; WEISS NS, 1985, AM J PUBLIC HEALTH, V75, P67, DOI 10.2105/AJPH.75.1.67; 1988, MMWR, V37, P637	21	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					242	246		10.1001/jama.266.2.242	http://dx.doi.org/10.1001/jama.266.2.242			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU896	2056626				2022-12-01	WOS:A1991FU89600033
J	HUTCHINSON, CM; WILSON, C; REICHART, CA; MARSIGLIA, VC; ZENILMAN, JM; HOOK, EW				HUTCHINSON, CM; WILSON, C; REICHART, CA; MARSIGLIA, VC; ZENILMAN, JM; HOOK, EW			LYMPHOCYTE-CD4 CONCENTRATIONS IN PATIENTS WITH NEWLY IDENTIFIED HIV-INFECTION ATTENDING STD CLINICS - POTENTIAL IMPACT ON PUBLICLY FUNDED HEALTH-CARE RESOURCES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; HOMOSEXUAL MEN; SEXUAL-BEHAVIOR; UNITED-STATES; MEDICAL-CARE; AIDS; COHORT; ANTIBODY; COSTS	Since January 1990, human immunodeficiency virus (HIV)-infected patients attending two sexually transmitted disease clinics in Baltimore, Md, have been offered T-lymphocyte subset evaluations. From January through September, CD4+ lymphocyte concentrations were measured in 223 newly diagnosed HIV-infected patients; 50% had fewer than 500 CD4+ T cells and 12% had fewer than 200 CD4+ T cells per cubic millimeter. Most patients were asymptomatic, and, even among patients with fewer than 200 CD4+ T cells, 54% had no symptoms or signs suggestive of advanced HIV infection. Homosexually active men had significantly lower mean CD4+ lymphocyte concentrations than intravenous drug users. Given the substantial numbers of patients with CD4+ concentrations that qualified them for zidovudine therapy, we also assessed their mechanisms of paying for health care. Only 24% of HIV-infected patients had private insurance. Seventy-two percent of patients with fewer than 200 CD4+ T cells either had no insurance or relied on public assistance for health care. Thus, although 50% of asymptomatic individuals identified by routine voluntary HIV screening in an inner-city sexually transmitted disease clinic may benefit from therapy for their disease, 75% of those qualifying for presently recommended therapy either depend on publicly funded health care or have no means of payment for care.	JOHNS HOPKINS UNIV HOSP,DEPT MED,600 N WOLFE ST,BALTIMORE,MD 21205; BALTIMORE MARYLAND CITY HLTH DEPT,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University								ARNO PS, 1989, JAMA-J AM MED ASSOC, V262, P1493, DOI 10.1001/jama.262.11.1493; BUCHANAN RJ, 1988, AM J PUBLIC HEALTH, V78, P462; CATES W, 1988, AM J PUBLIC HEALTH, V78, P1533, DOI 10.2105/AJPH.78.12.1533; CHEUNG TW, 1990, JAMA-J AM MED ASSOC, V263, P1067, DOI 10.1001/jama.1990.03440080039013; COATES T, 1988, AIDS S1, V2, P239; DROTMAN DP, 1989, ANN INTERN MED, V110, P680, DOI 10.7326/0003-4819-110-9-680; ERICKSON B, 1990, SEX TRANSM DIS, V17, P194, DOI 10.1097/00007435-199010000-00009; EYSTER ME, 1989, ANN INTERN MED, V110, P963, DOI 10.7326/0003-4819-110-12-963; FOX R, 1987, AIDS, V1, P241; FRIEDLAND GH, 1990, NEW ENGL J MED, V322, P1000, DOI 10.1056/NEJM199004053221409; GIORGI JV, 1989, CLIN IMMUNOL IMMUNOP, V52, P10, DOI 10.1016/0090-1229(89)90188-8; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; GOEDERT JJ, 1984, LANCET, V2, P711; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; JACOBSEN PB, 1990, J CONSULT CLIN PSYCH, V58, P31, DOI 10.1037/0022-006X.58.1.31; LO B, 1989, ANN INTERN MED, V110, P727; MAKADON HJ, 1990, J ACQ IMMUN DEF SYND, V3, P123; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P462, DOI 10.2105/AJPH.78.4.462; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; QUINN TC, 1990, ARCH INTERN MED, V150, P1297, DOI 10.1001/archinte.150.6.1297; RANGO NA, 1990, NEW YORK STATE J MED, V90, P116; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; ROGERS MF, 1983, ANN INTERN MED, V99, P151, DOI 10.7326/0003-4819-99-2-151; SCHECHTER MT, 1988, AM J PUBLIC HEALTH, V78, P1535, DOI 10.2105/AJPH.78.12.1535; SCITOVSKY AA, 1987, PUBLIC HEALTH REP, V102, P5; SCITOVSKY AA, 1990, J ACQ IMMUN DEF SYND, V3, P904; STEVENS CE, 1986, JAMA-J AM MED ASSOC, V255, P2167, DOI 10.1001/jama.255.16.2167; VANGRIENSVEN GJP, 1988, AM J PUBLIC HEALTH, V78, P1575, DOI 10.2105/AJPH.78.12.1575; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; ZENILMAN JM, 1990, 30TH INT C ANT AG CH; 1990, AM J MED, V89, P335; 1990, MMWR, V39, P137; 1989, MMWR, V381, P1; [No title captured]; 1990, MMWR, V39, P1	41	27	27	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					253	256		10.1001/jama.266.2.253	http://dx.doi.org/10.1001/jama.266.2.253			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FU896	1676076				2022-12-01	WOS:A1991FU89600035
J	LAUER, MS; ANDERSON, KM; KANNEL, WB; LEVY, D				LAUER, MS; ANDERSON, KM; KANNEL, WB; LEVY, D			THE IMPACT OF OBESITY ON LEFT-VENTRICULAR MASS AND GEOMETRY - THE FRAMINGHAM-HEART-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AORTIC REGURGITATION; GLUCOSE-INTOLERANCE; BLOOD-PRESSURE; BODY BUILD; HYPERTROPHY; HYPERTENSION; DISEASE; CARDIOMYOPATHY; REDUCTION; CRITERIA	Objective.- To determine the relationship of varying degrees of obesity with left ventricular mass and geometry. Design.- Survey. Setting.- Population-based epidemiologic study. Participants and Methods.- M-mode echocardiograms, which were adequate for estimation of left ventricular mass, were obtained in 3922 healthy participants of the Framingham Heart Study Measured height and weight were used to calculate body-mass index, a measure of obesity. Results.- Body-mass index was strongly correlated with left ventricular mass. After adjusting for age and blood pressure, body-mass index remained a strong independent predictor of left ventricular mass, left ventricular wall thickness, and left ventricular internal dimension (P < .01 for all). Body-mass index was associated with prevalence of echocardiographic left ventricular hypertrophy, particularly in subjects with a body-mass index exceeding 30 kg/m2. Conclusions.- Obesity is significantly correlated with left ventricular mass, even after controlling for age and blood pressure. The increase in left ventricular mass associated with increasing adiposity reflects increases in both left ventricular wall thickness and left ventricular internal dimension.	BETH ISRAEL HOSP, CHARLES A DANA RES INST, BOSTON, MA 02215 USA; BOSTON UNIV, SCH MED, DIV EPIDEMIOL & PREVENT MED, BOSTON, MA 02118 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT MED, DIV CLIN EPIDEMIOL, BOSTON, MA 02215 USA; HARVARD UNIV, BETH ISRAEL HOSP,DEPT MED,DIV CARDIOL, THORNDIKE LAB, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Boston University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	LAUER, MS (corresponding author), NHLBI, FRAMINGHAM HEART STUDY, 5 THURBER ST, FRAMINGHAM, MA 02215 USA.		Lauer, Michael S/L-9656-2013; Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021	Lauer, Michael S/0000-0002-9217-8177; Levy, Daniel/0000-0003-1843-8724	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007374] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07374, N01-HC-38038] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER J K, 1962, Cardiovasc Res Cent Bull, V1, P39; ALEXANDER JK, 1985, PROG CARDIOVASC DIS, V27, P325, DOI 10.1016/S0033-0620(85)80002-5; BOROW K, 1989, TXB ADULT PEDIATRIC, P108; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DEDIVITIIS O, 1981, CIRCULATION, V64, P477, DOI 10.1161/01.CIR.64.3.477; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; FEIGENBAUM H, 1981, ECHOCARDIOGR-J CARD, P51; GARDIN JM, 1987, HYPERTENSION, V9, P36; GROSSMAN W, 1975, J CLIN INVEST, V56, P56, DOI 10.1172/JCI108079; HAMMOND IW, 1988, J AM COLL CARDIOL, V12, P996, DOI 10.1016/0735-1097(88)90467-6; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1967, ANN INTERN MED, V67, P48, DOI 10.7326/0003-4819-67-1-48; KANNEL WB, 1969, ANN INTERN MED, V71, P89, DOI 10.7326/0003-4819-71-1-89; KATZ AM, 1990, NEW ENGL J MED, V322, P100; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; MACMAHON SW, 1986, NEW ENGL J MED, V314, P334, DOI 10.1056/NEJM198602063140602; MESSERLI FH, 1981, ARCH INTERN MED, V141, P81, DOI 10.1001/archinte.141.1.81; MESSERLI FH, 1983, ANN INTERN MED, V99, P757, DOI 10.7326/0003-4819-99-6-757; MESSERLI FH, 1982, LANCET, V1, P1165; OSTLUND RE, 1990, NEW ENGL J MED, V322, P229, DOI 10.1056/NEJM199001253220404; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SAVAGE DD, 1990, AM J CARDIOL, V65, P371, DOI 10.1016/0002-9149(90)90304-J; SAVAGE DD, 1987, CIRCULATION, V75, P26; SAVAGE DD, 1979, CIRCULATION, V59, P623, DOI 10.1161/01.CIR.59.4.623; SORLIE P, 1980, JAMA-J AM MED ASSOC, V243, P1828, DOI 10.1001/jama.243.18.1828; TOBIAN L, 1978, NEW ENGL J MED, V298, P46, DOI 10.1056/NEJM197801052980110; VANDENBOSSCHE JL, 1984, J AM COLL CARDIOL, V4, P1195, DOI 10.1016/S0735-1097(84)80138-2; WILSON JR, 1980, AM J MED, V68, P664, DOI 10.1016/0002-9343(80)90252-1; WILSON PW, 1981, AM J EPIDEMIOL, V114, P697, DOI 10.1093/oxfordjournals.aje.a113240	37	457	478	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					231	236		10.1001/jama.266.2.231	http://dx.doi.org/10.1001/jama.266.2.231			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU896	1829117				2022-12-01	WOS:A1991FU89600031
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW THERAPY FOR CHRONIC LYMPHOCYTIC-LEUKEMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1990, JAMA-J AM MED ASSOC, V263, P793	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					190	190						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU896	1711593				2022-12-01	WOS:A1991FU89600004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			POSSIBILITY OF YERSINIA-ENTEROCOLITICA BACTEREMIA DUE TO TRANSFUSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1991, MMWR, V40, P176	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					190	190						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU896	1711593				2022-12-01	WOS:A1991FU89600005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			IMPRINTING OF ORAL SOLID DOSAGE FORM-DRUG PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1991, FED REG         0515, V56, P22370	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					190	190						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU896	1711593				2022-12-01	WOS:A1991FU89600003
J	SISK, JE; GIANFRANCESCO, FD; COSTER, JM				SISK, JE; GIANFRANCESCO, FD; COSTER, JM			RECOMBINANT ERYTHROPOIETIN AND MEDICARE PAYMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANEMIA	The biologic recombinant human erythropoietin provides a recent case study of the great influence federal policies, especially Medicare payment, exert over the use and cost of medical technologies. By covering most dialysis patients, Medicare has been the predominant payer for recombinant erythropoietin, which corrects anemia associated with chronic renal disease. Medicare's leverage seems to have produced a low US price for the product. Paying a fixed rate per treatment with the biologic agent gave dialysis facilities a financial incentive to use low doses, but Medicare did not routinely monitor patients' responses. By August 1990, average and modal doses were low, and fewer than 45% of patients who had been treated for 6 months or more had ever attained the target hematocrit. Medicare should recognize the financial incentives of its payment policies and routinely evaluate the quality of care for beneficiaries.	US CONGRESS,OFF TECHNOL ASSESSMENT,WASHINGTON,DC									BERKOW R, 1987, MERCK MANUAL, P1096; ESCHBACH J, 1990, CURRENT NEPHROLOGY, P14; ESCHBACH J, IN PRESS AM J KIDNEY; ESCHBACH JW, 1989, NEW ENGL J MED, V321, P158, DOI 10.1056/NEJM198907203210305; GIBBONS A, 1990, SCIENCE, V250, P905, DOI 10.1126/science.2237437; KLEINMAN K, 1988, AM SOC NEPHR ABSTR; LIM VS, 1989, ANN INTERN MED, V110, P108, DOI 10.7326/0003-4819-110-2-108; RAINE AEG, IN PRESS AM J KIDNEY; SINAITRIEMAN L, 1989, J PEDIATR, V114, P530; SOBOTA J, 1990, ERYTHROPOIETIN CLIN; SOBOTA JT, 1989, CONTRIB NEPHROL, V76, P166; STEVEN JM, 1988, DIALYSIS TRANSPLANT, V3, P33; TEEHAN BP, 1989, TRANSPL P, V21, P63; 1991, HHS NEWS        0102; 1989, MEDICARE PROVIDER 1, pCH27; 1990, RECOMBINANT ERYTHROP; 1989, KIDN INT ABSTR, V35, P195; 1990, EFFECT INTERIM PAYME; 1986, LISTING PROVIDERS FU; 1989, MEDICARE CARRIERS MA; 1989, SUMMARY BASIS APPROV	21	25	25	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					247	252		10.1001/jama.266.2.247	http://dx.doi.org/10.1001/jama.266.2.247			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU896	2056627				2022-12-01	WOS:A1991FU89600034
J	CUSICK, EL; KRUKOWSKI, ZH; MACINTOSH, CA; MATHESON, NA				CUSICK, EL; KRUKOWSKI, ZH; MACINTOSH, CA; MATHESON, NA			RISK OF NEOPLASIA AND MALIGNANCY IN DOMINANT THYROID SWELLINGS	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; DIAGNOSIS; NODULE	Objective - To determine the risk of neoplasia and malignancy in "dominant" thyroid swellings. Design - Prospective analysis during six years. Setting-Thyroid clinic serving the Grampian region. Patients-574 consecutive patients presenting with a discrete thyroid swelling, of whom 179 (31%) were classified clinically as having a dominant area of enlargement within a multinodular gland. Results-After clinical and cytological assessment 77 dominant swellings were excised. Of the excised swellings, 45 were non-neoplastic and 32 neoplastic, including 11 malignant lesions. The minimum incidence of neoplasia and malignancy in all 179 dominant swellings was therefore 18% and 6% respectively. Conclusion-Dominant thyroid swellings should be regarded with greater clinical suspicion than has been traditional.	UNIV ABERDEEN,DEPT SURG,ABERDEEN AB9 1FX,SCOTLAND	University of Aberdeen								BEIERWALTES WH, 1983, ENDOCRINE SURGERY UP, P18; COLE WH, 1945, JAMA-J AM MED ASSOC, V127, P883, DOI 10.1001/jama.1945.02860140001001; COPE O, 1949, CLIN ENDOCRINOL META, V9, P1012; CUSICK EL, 1991, BRIT J SURG, V78, P94, DOI 10.1002/bjs.1800780129; CUSICK EL, 1990, BMJ-BRIT MED J, V301, P318, DOI 10.1136/bmj.301.6747.318; HOFFMAN GL, 1972, ARCH SURG-CHICAGO, V105, P379; LENNQUIST S, 1987, SURG CLIN N AM, V67, P213; ROHER HD, 1987, SURG CLIN N AM, V67, P233; THOMAS CG, 1976, ANN SURG, V183, P463, DOI 10.1097/00000658-197605000-00002	9	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1991	303	6793					20	22		10.1136/bmj.303.6793.20	http://dx.doi.org/10.1136/bmj.303.6793.20			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW128	1859949	Green Published, Bronze			2022-12-01	WOS:A1991FW12800020
J	FRIBERG, L; OLESEN, J; IVERSEN, HK; SPERLING, B				FRIBERG, L; OLESEN, J; IVERSEN, HK; SPERLING, B			MIGRAINE PAIN ASSOCIATED WITH MIDDLE CEREBRAL-ARTERY DILATATION - REVERSAL BY SUMATRIPTAN	LANCET			English	Article							BLOOD-FLOW; CLASSIC MIGRAINE; 5-HT1-LIKE RECEPTOR; COMMON MIGRAINE; ATTACKS; GR43175; ISCHEMIA; TOMOGRAPHY; HEADACHE; AGONIST	The combination of measurements of regional cerebral blood flow (rCBF) and blood velocity in the middle cerebral arteries (MCA) by transcranial doppler sonography was used to investigate cerebrovascular involvement in migraine. Ten migraine patients with unilateral headache were studied during an attack and when they had been free of attacks for 5 days (non-attack). On both occasions they were given an intravenous infusion of sumatriptan (2 mg), a 5-HT1-like receptor agonist, which relieved the symptoms within 30 min without affecting rCBF. The MCA velocity was normal on both sides on the non-attack day and on the unaffected side during the attack. However, during the attack the MCA velocity on the headache side was significantly lower than that on the nonheadache side (45 vs 61 cm/s:mean difference 16.3 [95% confidence interval 10.3-22.3]; p = 0.02). The MCA velocity on the headache side returned to normal after treatment with sumatriptan and recovery. Since rCBF in the MCA supply territory was unaffected, the lower velocity can be explained only by dilatation of the MCA. The mean MCA diameter increase was estimated to be 20%. Thus, headache was associated with intracranial large arterial dilatation on the headache side. Sumatriptan predominantly had effects on the distended artery, which suggests that the 5-HT receptor system has a role in the pathogenesis of migraine.	GENTOFTE HOSP,DEPT NEUROL,DK-2900 COPENHAGEN,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital	FRIBERG, L (corresponding author), BISWAS & ASSOCIATES,DEPT CLIN PHYSIOL & NUCL MED,OTTAWA K2H 5Y6,ONTARIO,CANADA.		Iversen, Helle Klingenberg/B-9154-2009; Iversen, Helle Klingenberg/P-5726-2019	Iversen, Helle Klingenberg/0000-0002-5880-6352; Olesen, Jes/0000-0002-6712-2702				AASLID R, TRANSCRANIAL DOPPLER, P19; ANDERSEN AR, 1988, ARCH NEUROL-CHICAGO, V45, P154, DOI 10.1001/archneur.1988.00520260040017; ATKINS HL, 1980, J NUCL MED, V21, P459; CELSIS P, 1981, J COMPUT ASSIST TOMO, V5, P641, DOI 10.1097/00004728-198110000-00006; DECLERCK F, 1985, SEROTONIN CARDIOVASC, P155; DOENICKE A, 1988, LANCET, V1, P1309; EDVINSSON L, 1989, CEPHALALGIA S10, V9, P39; FENIUK W, 1989, BRIT J PHARMACOL, V96, P83, DOI 10.1111/j.1476-5381.1989.tb11787.x; FRIBERG L, 1987, BRAIN, V110, P917, DOI 10.1093/brain/110.4.917; FRIBERG L, 1989, CEPHALALGIA S10, V9, P29; HARPER AM, 1977, J PHYSIOL-LONDON, V271, P735, DOI 10.1113/jphysiol.1977.sp012023; HUMPHREY PPA, 1988, BRIT J PHARMACOL, V94, P1123, DOI 10.1111/j.1476-5381.1988.tb11630.x; IVERSEN HK, 1990, LANCET, V336, P837, DOI 10.1016/0140-6736(90)92339-J; JENSEN K, 1985, ACTA NEUROL SCAND, V72, P561; JENSEN K, 1987, ACTA NEUROL SCAND, V75, P310, DOI 10.1111/j.1600-0404.1987.tb05452.x; LASSEN NA, 1978, J COMPUT ASSIST TOMO, V2, P661, DOI 10.1097/00004728-197811000-00047; LAURITZEN M, 1983, ANN NEUROL, V13, P633, DOI 10.1002/ana.410130609; LAURITZEN M, 1984, BRAIN, V107, P447, DOI 10.1093/brain/107.2.447; Moskowitz M., 1988, BASIC MECH HEADACHE, P429; OLESEN J, 1990, ANN NEUROL, V28, P791, DOI 10.1002/ana.410280610; OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406; OLESEN J, 1981, LANCET, V2, P438; OLSEN TS, 1987, ARCH NEUROL-CHICAGO, V44, P156, DOI 10.1001/archneur.1987.00520140028013; PARSONS AA, 1989, BRIT J PHARMACOL, V96, P434, DOI 10.1111/j.1476-5381.1989.tb11835.x; SKINHOJ E, 1973, ARCH NEUROL-CHICAGO, V29, P95, DOI 10.1001/archneur.1973.00490260039007; TFELTHANSEN P, 1989, CEPHALALGIA, V9, P73; THIE A, 1990, HEADACHE, V30, P209, DOI 10.1111/j.1526-4610.1990.hed3004209.x; YOUNG AR, 1987, NEURONAL MESSENGERS, P57; 1988, CEPHALALGIA S7, V8, P1	29	337	337	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					13	17		10.1016/0140-6736(91)90005-A	http://dx.doi.org/10.1016/0140-6736(91)90005-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676084				2022-12-01	WOS:A1991FV29600004
J	STOUT, RW; CRAWFORD, V				STOUT, RW; CRAWFORD, V			SEASONAL-VARIATIONS IN FIBRINOGEN CONCENTRATIONS AMONG ELDERLY PEOPLE	LANCET			English	Article							PLASMA; MORTALITY; PRESSURE; CORONARY; WINTER	Mortality and morbidity in elderly people are higher in winter than in summer months, with seasonal variations in rates of both fatal and non-fatal myocardial infarction and stroke. To identify factors that might contribute to the excess winter frequency of cardiovascular disease in the elderly, we studied 100 subjects aged 75 and over who lived in either their own homes or in sheltered or residential accommodation. Each person was visited each month for one year, body and environmental temperatures were noted, and cardiovascular risk factors were measured. 32 subjects withdrew from the study. Significant seasonal effects were found for fibrinogen, plasma viscosity, and HDL cholesterol (p < 0.003, Bonferroni adjustment). Plasma fibrinogen concentrations showed the greatest seasonal change and were 23% higher in the coldest six months compared with summer months. Fibrinogen was significantly (p < 0.05) and negatively related to core body temperature and all measures of environmental temperature. Those living in institutions had greater changes in plasma fibrinogen than those living in the community. The seasonal variation in plasma fibrinogen concentration is large enough to increase the risk of both myocardial infarction and stroke in winter.			STOUT, RW (corresponding author), QUEENS UNIV BELFAST, DEPT GERIATR MED, BELFAST BT7 9BL, NORTH IRELAND.							Alderson M. R., 1985, Health Trends, V4, P87; BASTOW MD, 1983, LANCET, V1, P143; BRENNAN PJ, 1982, BMJ-BRIT MED J, V285, P919, DOI 10.1136/bmj.285.6346.919; BROOKE OG, 1973, J PHYSIOL-LONDON, V231, pP91; BULL G M, 1975, Age and Ageing, V4, P232, DOI 10.1093/ageing/4.4.232; BULL G M, 1975, Age and Ageing, V4, P19, DOI 10.1093/ageing/4.1.19; BULL G M, 1978, Age and Ageing, V7, P210, DOI 10.1093/ageing/7.4.210; BULL GM, 1979, J CLIN PATHOL, V32, P16, DOI 10.1136/jcp.32.1.16; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COLLINS KJ, 1986, AGE AGEING, V15, P212, DOI 10.1093/ageing/15.4.212; DIMINNO G, 1990, ARTERIOSCLEROSIS, V10, P1, DOI 10.1161/01.ATV.10.1.1; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GORDON DJ, 1988, J CLIN EPIDEMIOL, V41, P679, DOI 10.1016/0895-4356(88)90120-5; JARRETT RJ, 1984, DIABETOLOGIA, V27, P574, DOI 10.1007/BF00276970; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KEATINGE WR, 1984, BMJ-BRIT MED J, V289, P1405, DOI 10.1136/bmj.289.6456.1405; KEATINGE WR, 1986, BRIT MED J, V293, P732, DOI 10.1136/bmj.293.6549.732-a; KEATINGE WR, 1989, INT J BIOMETEOROL, V33, P71, DOI 10.1007/BF01686280; MACMILLAN AL, 1967, LANCET, V2, P165; MARSHALL RJ, 1988, INT J EPIDEMIOL, V17, P325, DOI 10.1093/ije/17.2.325; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MCKEE CM, 1989, EUR J EPIDEMIOL, V5, P178, DOI 10.1007/BF00156826; MEADE TW, 1980, LANCET, V1, P1050; WASSERTHEILSMOL.S, 1990, BIOSTATISTICS EPIDEM, P49	24	231	236	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	1991	338	8758					9	13		10.1016/0140-6736(91)90004-9	http://dx.doi.org/10.1016/0140-6736(91)90004-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676131				2022-12-01	WOS:A1991FV29600003
J	THALER, MM; PARK, CK; LANDERS, DV; WARA, DW; HOUGHTON, M; VEEREMANWAUTERS, G; SWEET, RL; HAN, JH				THALER, MM; PARK, CK; LANDERS, DV; WARA, DW; HOUGHTON, M; VEEREMANWAUTERS, G; SWEET, RL; HAN, JH			VERTICAL TRANSMISSION OF HEPATITIS-C VIRUS	LANCET			English	Note							INFANT TRANSMISSION	There is evidence that hepatitis C virus (HCV) may be vertically transmitted from infected mothers to their children. To test this hypothesis, we prospectively studied 10 pregnant women at high risk from parenterally or sexually transmitted diseases with the polymerase chain reaction. HCV RNA was found in 8 newborn babies delivered by women who were anti-HCV seropositive, and persisted for 2-19 months of follow-up. Anti-HCV detected in 7 infants cleared by 9 months and remained undetectable thereafter. Serum alanine aminotransferase was raised in 3 infants. The findings provide evidence of vertical transmission of HCV and suggest that perinatal infection may initiate a silent disease process or chronic carrier state.	CHIRON CORP,EMERYVILLE,CA; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; HALLYM UNIV,COLL MED,DEPT INTERNAL MED,CHUNCHON,SOUTH KOREA	Novartis; University of California System; University of California San Francisco; Hallym University	THALER, MM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,M680,BOX 0136,SAN FRANCISCO,CA 94143, USA.			Houghton, Michael/0000-0003-3762-6771	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001271] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 01271] Funding Source: Medline; NICHD NIH HHS [NICHD 24640] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTER MJ, 1989, NEW ENGL J MED, V321, P1538, DOI 10.1056/NEJM198911303212208; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; CHOO QL, 1990, BRIT MED BULL, V46, P423, DOI 10.1093/oxfordjournals.bmb.a072408; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; REESINK HW, 1990, LANCET, V335, P1216, DOI 10.1016/0140-6736(90)92734-Y; WEINTRAUB S, 1990, J CLIN EXP NEUROPSYC, V12, P49	7	244	246	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					17	18		10.1016/0140-6736(91)90006-B	http://dx.doi.org/10.1016/0140-6736(91)90006-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676085				2022-12-01	WOS:A1991FV29600005
J	TREGASKIS, B; MAYBERRY, JF				TREGASKIS, B; MAYBERRY, JF			ELDERLY PEOPLE AT HOME WHO CANNOT COPE	LANCET			English	Editorial Material											TREGASKIS, B (corresponding author), LEICESTER GEN HOSP,LEICESTER LE5 4PW,ENGLAND.		Mayberry, John/AAP-2392-2020					FORSTER DP, 1980, BRIT MED J, V280, P739, DOI 10.1136/bmj.280.6215.739; GRAY JAM, 1990, J PUBLIC HEALTH MED, V12, P28, DOI 10.1093/oxfordjournals.pubmed.a042502; GRAY JAM, 1980, PUBLIC HEALTH, V94, P296, DOI 10.1016/S0033-3506(80)80078-3; Hoggett B., 1984, MENTAL HLTH LAW; MAYBERRY JF, 1991, THESIS U WALES; TOWLER JN, 1988, PUBLIC HEALTH, V102, P485, DOI 10.1016/S0033-3506(88)80087-8	6	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					47	47		10.1016/0140-6736(91)90026-L	http://dx.doi.org/10.1016/0140-6736(91)90026-L			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676095				2022-12-01	WOS:A1991FV29600019
J	VEEN, S; ENSDOKKUM, MH; SCHREUDER, AM; VERLOOVEVANHORICK, SP; BRAND, R; RUYS, JH				VEEN, S; ENSDOKKUM, MH; SCHREUDER, AM; VERLOOVEVANHORICK, SP; BRAND, R; RUYS, JH			IMPAIRMENTS, DISABILITIES, AND HANDICAPS OF VERY PRETERM AND VERY-LOW-BIRTH-WEIGHT INFANTS AT 5 YEARS OF AGE	LANCET			English	Article							BIRTH-WEIGHT INFANTS; NEONATAL INTENSIVE-CARE; PERIVENTRICULAR-INTRAVENTRICULAR HEMORRHAGE; NATIONAL COLLABORATIVE SURVEY; FOLLOW-UP; GESTATIONAL-AGE; NETHERLANDS; MORTALITY; MORBIDITY; RESIDENTS	The Project On Preterm and Small for gestational age infants (POPS) was started in the Netherlands in 1983 to investigate the relation between prenatal/perinatal factors and mortality/morbidity in very preterm and very-low-birthweight infants. Of the 1338 liveborn infants (< 32 weeks and/or < 1500 g) 966 were enrolled in the five-year (chronological age) follow-up programme; 96% of these children were assessed during a home visit. The overall outcome was expressed as impairments, disabilities, and handicaps according to World Health Organisation criteria. Of the assessed children, 13% had a disability and 14% were handicapped, which are much higher frequencies than those found in the general population. Handicaps were due mainly to abnormalities of neuromotor function, mental development, or language and speech development. Compared with the handicap frequency in the same cohort at two years of age, a more favourable outcome at five years of age was seen in 10%, and a less favourable outcome in 7% of the children. The findings show that most of those high-risk children survived without handicap or serious disability at preschool age.	UNIV HOSP LEIDEN, DEPT PAEDIAT, NEONATAL UNIT, POB 9600, 2300 RC LEIDEN, NETHERLANDS; TNO, INST PREVENT HLTH CARE, 2313 AD LEIDEN, NETHERLANDS; LEIDEN UNIV, DEPT MED STAT, 2300 RA LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Netherlands Organization Applied Science Research; Leiden University; Leiden University - Excl LUMC								AYLWARD GP, 1989, J PEDIATR-US, V115, P515, DOI 10.1016/S0022-3476(89)80273-2; BAUCHNER H, 1988, PEDIATR CLIN N AM, V35, P1207; BEGANOVIC N, 1988, ARCH DIS CHILD, V63, P66, DOI 10.1136/adc.63.1.66; DENOUDEN L, 1990, NEUROPEDIATRICS, V21, P66, DOI 10.1055/s-2008-1071463; EHRENHAFT PM, 1989, OBSTET GYNECOL, V74, P528; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; HORWOOD SP, 1982, PEDIATRICS, V69, P613; HUNT JV, 1988, PEDIATRICS, V82, P596; JOHNSON M A, 1987, Canadian Medical Association Journal, V136, P1157; KITCHEN WH, 1987, J PEDIATR-US, V110, P283, DOI 10.1016/S0022-3476(87)80174-9; KITCHEN WH, 1982, SEMIN PERINATOL, V6, P373; KOLLEE LAA, 1988, OBSTET GYNECOL, V72, P729; MCCORMICK MC, 1989, JAMA-J AM MED ASSOC, V261, P1767, DOI 10.1001/jama.261.12.1767; PIEKKALA P, 1988, NEUROPEDIATRICS, V19, P33, DOI 10.1055/s-2008-1052398; POWELL TG, 1986, LANCET, V1, P539; ROSS G, 1985, PEDIATRICS, V76, P885; SAIGAL S, 1982, J PEDIATR-US, V100, P606, DOI 10.1016/S0022-3476(82)80767-1; TOUWEN BCL, 1986, EUR J PEDIATR, V145, P460, DOI 10.1007/BF02429042; van de Bor M, 1988, Paediatr Perinat Epidemiol, V2, P328; VANDEBOR M, 1987, J PERINAT MED, V15, P333, DOI 10.1515/jpme.1987.15.4.333; VANDEBOR M, 1988, NEUROPEDIATRICS, V19, P183, DOI 10.1055/s-2008-1052442; VANDEBOR M, 1989, PEDIATRICS, V83, P915; VANDERAA DMC, 1989, THESIS STATE U LEIDE, P185; VANDERAA DMV, 1991, EUR J OBSTET GYN R B, V39, P87, DOI 10.1016/0028-2243(91)90069-W; VANDERAA DMV, 1991, PAEDIATR PERINAT EP, V5, P11; VANDERAA DMZ, 1990, NEUROPEDIATRICS, V21, P62; VANDERAA TMZ, 1989, LANCET, V1, P253; VERLOOVEVANHORICK SP, 1988, PEDIATRICS, V81, P404; VERLOOVEVANHORICK SP, 1986, LANCET, V1, P55; VERLOOVEVANHORICK SP, 1989, EUR J PEDIATR, V149, P197, DOI 10.1007/BF01958281; Walther F J, 1989, Paediatr Perinat Epidemiol, V3, P53, DOI 10.1111/j.1365-3016.1989.tb00369.x; WIERENGA H, 1990, EARLY HUM DEV, V23, P15, DOI 10.1016/0378-3782(90)90125-3; 1990, LICHAMELIJKE BEPERKI, P67; 1990, MANAGEMENT GROUP OXF, P15; 1980, INT CLASSIFICATION I, P207	35	177	178	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					33	36		10.1016/0140-6736(91)90015-H	http://dx.doi.org/10.1016/0140-6736(91)90015-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1711644				2022-12-01	WOS:A1991FV29600014
J	BROOKMEYER, R				BROOKMEYER, R			RECONSTRUCTION AND FUTURE-TRENDS OF THE AIDS EPIDEMIC IN THE UNITED-STATES	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; SHORT-TERM PROJECTIONS; LYMPHOCYTE-T COUNTS; HIV-INFECTION; SAN-FRANCISCO; YOUNG-ADULTS; ZIDOVUDINE; MODELS; PROGRESSION; PREVALENCE	There has been considerable uncertainty in estimates of past and current human immunodeficiency virus (HIV) infection rates in the United States. Statistical estimates of historical infection rates can be obtained from acquired immunodeficiency syndrome (AIDS) incidence data and the incubation period. However, this approach is subject to a number of sources of uncertainty and two other approaches, epidemic models of HIV transmission and surveys of HIV prevalence, are used to corroborate and refine the statistical estimates. Analyses suggest the HIV infection rate in the United States grew rapidly in the early 1980s, peaked in the mid-1980s, and subsequently declined markedly. Due both to the decline in the underlying infection rate and to the development of effective therapies that may delay AIDS diagnosis, overall AIDS incidence may plateau during the next 5 years. However, the number of individuals with advanced HIV disease without a diagnosis of AIDS who could potentially benefit from therapy is expected to increase 40% by 1995 as infected individuals progress to more advanced stages of HIV disease. Thus, although the overall HIV infection rate has declined, the demands on the U.S. health care system for treatment and care of HIV-infected individuals remain enormous.			BROOKMEYER, R (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT BIOSTAT, BALTIMORE, MD 21205 USA.				NCI NIH HHS [CA-48723] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048723] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS EB, 1990, J ACQ IMMUN DEF SYND, V3, P460; BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0; BACCHETTI P, 1990, J AM STAT ASSOC, V85, P1001; BROOKMEYER R, 1990, BIOMETRICS, V46, P1151, DOI 10.2307/2532455; BROOKMEYER R, 1989, BIOMETRICS, V45, P325, DOI 10.2307/2532057; BROOKMEYER R, 1989, STAT MED, V8, P23, DOI 10.1002/sim.4780080105; BROOKMEYER R, 1988, J AM STAT ASSOC, V83, P301, DOI 10.2307/2288844; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P1168; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P92; CURRAN JW, 1985, SCIENCE, V229, P1352, DOI 10.1126/science.2994217; DAY NE, 1989, PHILOS T ROY SOC B, V325, P123, DOI 10.1098/rstb.1989.0077; DEGRUTTOLA V, 1989, STAT MED, V8, P35, DOI 10.1002/sim.4780080106; DONDERO TJ, 1989, 5TH INT C AIDS MONTR; FOX RJ, UNPUB; GAIL MH, 1988, J NATL CANCER I, V80, P900, DOI 10.1093/jnci/80.12.900; GAIL MH, 1989, STAT MED, V8, P59, DOI 10.1002/sim.4780080108; GAIL MH, 1990, J ACQ IMMUN DEF SYND, V3, P296; GAIL MH, 1990, JAMA-J AM MED ASSOC, V263, P1538; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267; HARDY AM, 1987, PUBLIC HEALTH REP, V102, P386; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; HETHCOTE HW, 1984, LECT NOTES BIOMATHEM, V56; HYMAN JM, 1988, MATH BIOSCI, V90, P415, DOI 10.1016/0025-5564(88)90078-8; KARON JM, 1988, J ACQ IMMUN DEF SYND, V1, P542; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LONGINI IM, 1990, J ACQ IMMUN DEF SYND, V3, P930; LONGINI IM, 1989, STAT MED, V8, P831, DOI 10.1002/sim.4780080708; MAY RM, 1987, NATURE, V326, P137, DOI 10.1038/326137a0; MCKUSICK L, 1985, AM J PUBLIC HEALTH, V75, P493, DOI 10.2105/AJPH.75.5.493; MCNEIL JG, 1989, NEW ENGL J MED, V320, P1581, DOI 10.1056/NEJM198906153202403; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; O'Sullivan, 1986, STAT SCI, V1, P502, DOI DOI 10.1214/ss/1177013525; OSULLIVAN F, 1986, J AM STAT ASSOC, V81, P96, DOI 10.2307/2287973; PHILLIPS DL, 1962, J ACM, V9, P84, DOI 10.1145/321105.321114; PICKERING J, 1986, MATH MODELLING, V7, P661, DOI 10.1016/0270-0255(86)90127-2; Rosenberg Philip S., 1990, Annals of Epidemiology, V1, P105; ROSENBERG PS, 1991, J ACQ IMMUN DEF SYND, V4, P392; ROSENBERG PS, 1991, AM J EPIDEMIOL, V133, P276, DOI 10.1093/oxfordjournals.aje.a115872; ROSENBERG PS, 1991, APPL STAT-J ROY ST C, V40, P269; ROSENBERG PS, IN PRESS STAT MED; SCHECHTER MT, 1989, LANCET, V1, P1026; Segal M, 1990, J Acquir Immune Defic Syndr (1988), V3, P832; TAYLOR JMG, 1989, STAT MED, V8, P45, DOI 10.1002/sim.4780080107; TAYLOR JMG, 1991, J ACQ IMMUN DEF SYND, V4, P69; Tikhonov A., 1963, SOV MATH DOKL, V4, P1035; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1988, MORB MORTAL WKLY REP, V37, P294; 1990, MORB MORTAL WKLY REP, V39, P112; 1991, MORB MORTAL WKLY S6, V40, P1; 1987, MORB MORTAL WKLY S6, V36	50	227	233	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 5	1991	253	5015					37	42		10.1126/science.2063206	http://dx.doi.org/10.1126/science.2063206			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	2063206				2022-12-01	WOS:A1991FV17700028
J	CLEVENGER, CV; ALTMANN, SW; PRYSTOWSKY, MB				CLEVENGER, CV; ALTMANN, SW; PRYSTOWSKY, MB			REQUIREMENT OF NUCLEAR PROLACTIN FOR INTERLEUKIN-2 - STIMULATED PROLIFERATION OF LYMPHOCYTES-T	SCIENCE			English	Article							NB2 LYMPHOMA-CELLS; DNA-TRANSFECTION; TREATED-CELLS; C-MYC; GROWTH; EXPRESSION; PROTEIN; GENE; RECEPTOR; LOCATION	Prolactin (PRL) is necessary for the proliferation of cloned T lymphocytes in response to interleukin-2 (IL-2). Translocation of PRL into the nucleus occurs during IL-2-stimulated mitogenesis. Therefore, the function of intranuclear PRL in T cell proliferation was tested. Eukaryotic expression vectors were prepared to express wild-type PRL [PRL(WT)], PRL that lacks the signal sequence for translocation into the endoplasmic reticulum [PRL(ER-)], and chimeric PRL in which the signal peptide was replaced with the sequence that directs the nuclear translocation of the SV40 large T antigen [PRL(NT+)]. Expression of these constructs in a T cell line (Nb2) responsive to PRL and IL-2 resulted in localization of PRL in the extracellular milieu, cytoplasm, or nucleus, respectively. Stimulation with IL-2 alone resulted in a five- to tenfold increase in the incorporation of [H-3]thymidine by cells expressing PRL(NT+) or PRL(WT) as compared to PRL(ER-) or the parental Nb2 cells. Only the PRL(NT+) clone proliferated continuously with IL-2 stimulation in the presence of antiserum to PRL. These results demonstrate that nuclear PRL is necessary for IL-2-stimulated proliferation and suggest that a peptide hormone can function in the nucleus without binding to its cell surface receptor.			CLEVENGER, CV (corresponding author), UNIV PENN,DEPT PATHOL & LAB MED,545 CLIN RES BLDG,422 CURIE BLVD,PHILADELPHIA,PA 19104, USA.				NIGMS NIH HHS [GM-36962, GM-13901] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036962] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS GK, 1987, BIOCHIM BIOPHYS ACTA, V909, P231, DOI 10.1016/0167-4781(87)90082-0; BERCZI I, 1981, ACTA ENDOCRINOL-COP, V98, P506, DOI 10.1530/acta.0.0980506; BERNTON EW, 1988, SCIENCE, V239, P401, DOI 10.1126/science.3122324; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; BUCKLEY AR, 1988, P NATL ACAD SCI USA, V85, P8649, DOI 10.1073/pnas.85.22.8649; CLEVENGER CV, 1990, ENDOCRINOLOGY, V127, P3151, DOI 10.1210/endo-127-6-3151; CLEVENGER CV, 1990, P NATL ACAD SCI USA, V87, P6460, DOI 10.1073/pnas.87.16.6460; CONNORS RW, 1988, DNA-J MOLEC CELL BIO, V7, P651, DOI 10.1089/dna.1988.7.651; CROZE F, 1988, MOL CELL ENDOCRINOL, V55, P253, DOI 10.1016/0303-7207(88)90140-2; DAVIS JA, 1988, MOL ENDOCRINOL, V2, P740, DOI 10.1210/mend-2-8-740; EMR SD, 1980, NATURE, V285, P82, DOI 10.1038/285082a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GOUT PW, 1980, CANCER RES, V40, P2433; GRENFELL S, 1989, BIOCHEM J, V264, P813, DOI 10.1042/bj2640813; GUBBINS EJ, 1980, J BIOL CHEM, V255, P8655; HARTMANN DP, 1989, FASEB J, V3, P2194, DOI 10.1096/fasebj.3.10.2787766; HIGUCHI R, 1990, PCR PROTOCOLS, pCH22; IMMAMURA T, 1990, SCIENCE, V249, P1567; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; LANFORD RE, 1990, EXP CELL RES, V186, P32, DOI 10.1016/0014-4827(90)90206-P; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MAHER DW, 1989, MOL CELL BIOL, V9, P2251, DOI 10.1128/MCB.9.5.2251; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MURPHY PR, 1988, ENDOCRINOLOGY, V122, P2476, DOI 10.1210/endo-122-6-2476; NAGY E, 1978, ACTA ENDOCRINOL-COP, V89, P530; NAGY E, 1983, IMMUNOPHARMACOLOGY, V6, P231, DOI 10.1016/0162-3109(83)90023-1; NICOLL CS, 1974, HDB PHYSL 2, V4, pCH32; NOBLE RL, 1980, CANCER RES, V40, P2437; RILLEMA JA, 1989, BIOCHIM BIOPHYS ACTA, V1014, P78, DOI 10.1016/0167-4889(89)90243-7; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; SMITH RM, 1988, J HISTOCHEM CYTOCHEM, V36, P359, DOI 10.1177/36.4.3279110; SOLER AP, 1989, P NATL ACAD SCI USA, V86, P6640, DOI 10.1073/pnas.86.17.6640; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; YULEE LY, 1990, MOL CELL ENDOCRINOL, V68, P21; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087	39	160	165	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					77	79		10.1126/science.2063207	http://dx.doi.org/10.1126/science.2063207			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	2063207				2022-12-01	WOS:A1991FV17700038
J	DAAR, I; NEBREDA, AR; YEW, N; SASS, P; PAULES, R; SANTOS, E; WIGLER, M; VANDEWOUDE, GF				DAAR, I; NEBREDA, AR; YEW, N; SASS, P; PAULES, R; SANTOS, E; WIGLER, M; VANDEWOUDE, GF			THE RAS ONCOPROTEIN AND M-PHASE ACTIVITY	SCIENCE			English	Article							MOS PROTO-ONCOGENE; MATURATION-PROMOTING FACTOR; MURINE SARCOMA-VIRUS; XENOPUS OOCYTES; CELL-CYCLE; MEIOTIC MATURATION; GENE-PRODUCT; ARREST; P21; EGGS	The endogenous mos proto-oncogene product (Mos) is required for meiotic maturation In Xenopus oocytes, the ras oncogene product (Ras) can induce meiotic maturation and high levels of M-phase-promoting factor (MPF) independent of endogenous Mos, indicating that a parallel pathway to metaphase exists. In addition, Ras, like Mos and cytostatic factor, can arrest Xenopus embryonic cell cleavage in mitosis and maintain high levels of MPF. Thus, in the Xenopus oocyte and embryo systems Ras functions in the M phase of the cell cycle. The embryonic cleavage arrest assay is a rapid and sensitive test for Ras function.	NCI,FREDERIK CANC RES & DEV CTR,BASIC RES PROGRAM,ABL,FREDERICK,MD 21701; NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892; LEDERLE LAB,PEARL RIVER,NY 10965; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Cold Spring Harbor Laboratory			Nebreda, Angel Rodriguez/R-9594-2019	Paules, Richard S/0000-0001-9106-7486; Daar, Ira/0000-0003-2657-526X; Wigler, Michael/0000-0003-4396-1971	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLENDE CC, 1988, FEBS LETT, V234, P426, DOI 10.1016/0014-5793(88)80130-3; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHAKALAPARAMPIL I, 1988, CELL, V52, P801; DAAR IO, UNPUB; DESPHANDE AK, 1987, MOL CELL BIOL, V7, P1285; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURKIN JP, 1987, MOL CELL BIOL, V7, P444, DOI 10.1128/MCB.7.1.444; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FISCHINGER PJ, 1971, J GEN VIROL, V13, P203, DOI 10.1099/0022-1317-13-2-203; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HAYAG N, 1990, ONCOGENE, V5, P1481; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; KIM R, 1990, MOL CELL BIOL, V10, P5945, DOI 10.1128/MCB.10.11.5945; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; Masui Y, 1979, Int Rev Cytol, V57, P185, DOI 10.1016/S0074-7696(08)61464-3; MEYERHOF PG, 1977, DEV BIOL, V61, P214, DOI 10.1016/0012-1606(77)90293-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NEBREDA AR, UNPUB; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARK M, 1989, METABOLIC BASIS INHE, V1, P251; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANTOS E, 1988, J BIOL CHEM, V263, P9853; SHIBUYA E, 1989, DEVELOPMENT CAMBRIDG, V106, P779; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x	42	73	73	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					74	76		10.1126/science.1829549	http://dx.doi.org/10.1126/science.1829549			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1829549				2022-12-01	WOS:A1991FV17700037
J	DAVIS, S; ALDRICH, TH; VALENZUELA, DM; WONG, V; FURTH, ME; SQUINTO, SP; YANCOPOULOS, GD				DAVIS, S; ALDRICH, TH; VALENZUELA, DM; WONG, V; FURTH, ME; SQUINTO, SP; YANCOPOULOS, GD			THE RECEPTOR FOR CILIARY NEUROTROPHIC FACTOR	SCIENCE			English	Article							NERVE GROWTH-FACTOR; CELL EXPRESSION SYSTEM; MOLECULAR-CLONING; CHOLINERGIC DIFFERENTIATION; NEURONAL DIFFERENTIATION; SYMPATHETIC NEURONS; BETA-CHAIN; INTERLEUKIN-6; PURIFICATION; FAMILY	Although neurotrophic factors were originally isolated on the basis of their ability to support the survival of neurons, these molecules are now thought to influence many aspects of the development and maintenance of the nervous system. Identifying the receptors for these neurotrophic factors should aid in identifying the cells on which these factors act and in understanding their precise mechanisms of action. A "tagged-ligand panning" procedure was used to clone a receptor for ciliary neurotrophic factor (CNTF). This receptor is expressed exclusively within the nervous system and skeletal muscle. The CNTF receptor has a structure unrelated to the receptors utilized by the nerve growth factor family of neurotrophic molecules, but instead is most homologous to the receptor for a cytokine, interleukin-6. This similarity suggests that the CNTF receptor, like the interleukin-6 receptor, requires a second, signal-transducing component. In contrast to all known receptors, the CNTF receptor is anchored to cell membranes by a glycosyl-phosphatidylinositol linkage.			DAVIS, S (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.							ADLER JE, 1989, P NATL ACAD SCI USA, V86, P1080, DOI 10.1073/pnas.86.3.1080; ADLER R, 1979, SCIENCE, V204, P1434, DOI 10.1126/science.451576; ARUFFO A, 1987, EMBO J, V6, P3313, DOI 10.1002/j.1460-2075.1987.tb02651.x; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARBET AF, 1978, P NATL ACAD SCI USA, V75, P1989, DOI 10.1073/pnas.75.4.1989; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BAZAN JF, IN PRESS NEURON; BOULTON TG, IN PRESS CELL; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; Davis S.M, UNPUB; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FANDL J, UNPUB; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FUKUDA K, 1985, P NATL ACAD SCI USA, V82, P8795; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEMPSTEAD D, 1991, NATURE, V350, P678; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HUGHES SM, 1988, NATURE, V335, P70, DOI 10.1038/335070a0; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; LOW MG, 1987, BIOCHEM J, V244, P1; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MANTHORPE M, 1989, NERVE GROWTH FACTORS, P31; MANTHORPE M, 1984, GROWTH MATURATION FA; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MEAKIN SO, IN PRESS P NATL ACAD; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; RAO MS, 1990, DEV BIOL, V139, P654; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SENDTNER M, 1989, NATURE, V345, P920; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; SQUINTO SP, IN PRESS CELL; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; WEBER MJ, 1985, J NEUROCHEM, V45, P1541, DOI 10.1111/j.1471-4159.1985.tb07225.x; WONG V, 1987, P NATL ACAD SCI USA, V84, P8726, DOI 10.1073/pnas.84.23.8726; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	56	603	628	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					59	63		10.1126/science.1648265	http://dx.doi.org/10.1126/science.1648265			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1648265				2022-12-01	WOS:A1991FV17700032
J	GOODMAN, B				GOODMAN, B			HOLY PHYLOGENY - DID BATS EVOLVE TWICE	SCIENCE			English	Editorial Material																		PETTIGREW, SYSTEMATIC ZOOLO JUN; 1986, SCIENCE, V23, P1304	2	2	2	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					36	36		10.1126/science.2063205	http://dx.doi.org/10.1126/science.2063205			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	2063205				2022-12-01	WOS:A1991FV17700027
J	HATANO, M; ROBERTS, CWM; MINDEN, M; CRIST, WM; KORSMEYER, SJ				HATANO, M; ROBERTS, CWM; MINDEN, M; CRIST, WM; KORSMEYER, SJ			DEREGULATION OF A HOMEOBOX GENE, HOX11, BY THE T(10-14) IN T-CELL LEUKEMIA	SCIENCE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING MOTIF; CHROMOSOME-TRANSLOCATION; MESSENGER-RNA; PROTEINS; SEQUENCE; DROSOPHILA; REGION; HELIX; BREAKPOINTS	Molecular cloning of the t(10;14)(q24;q11) recurrent breakpoint of T cell acute lymphoblastic leukemia has demonstrated a transcript for the candidate gene TCL3. Characterization of this gene from chromosome segment l0q24 revealed it to be a new homeobox, HOX11. The HOX11 homeodomain is most similar to that of the murine gene Hlx and possesses a markedly glycine-rich variable region and an acidic carboxyl terminus. HOX11, while expressed in liver, was not detected in normal thymus or T cells. This lineage-restricted homeobox gene is deregulated upon translocation into the T cell receptor locus where it may act as an oncogene.	WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA; PRINCESS MARGARET HOSP, TORONTO M4X 1K9, ONTARIO, CANADA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; PEDIAT ONCOL GRP, ST LOUIS, MO USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Roberts, Charles/N-2541-2018	Roberts, Charles/0000-0003-1135-1896	NATIONAL CANCER INSTITUTE [U10CA030969, P30CA021765, P01CA049712] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765, CA 30969, 1 PO1 CA49712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; BAKHSHI A, 1985, CELL, V41, P89; BEACHY PA, 1985, NATURE, V313, P545, DOI 10.1038/313545a0; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUBE ID, 1986, BLOOD, V67, P1181; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; HANES S, 1990, CELL, V57, P1275; HATANO M, UNPUB; HAVILAND DL, 1991, J IMMUNOL, V146, P362; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LU M, 1990, GENE CHROMOSOME CANC, V2, P217, DOI 10.1002/gcc.2870020309; MAUILIO F, 1986, NATURE, V324, P664; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; RAIMONDI SC, 1988, BLOOD, V72, P1560; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; ROWLEY JD, 1982, SCIENCE, V216, P749, DOI 10.1126/science.7079737; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; VISVADER J, 1991, ONCOGENE, V6, P187; WHARTON RP, 1985, NATURE, V316, P601, DOI 10.1038/316601a0; WRIGHT CVE, 1989, TRENDS BIOCHEM SCI, V14, P52, DOI 10.1016/0968-0004(89)90043-1; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	43	392	397	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 5	1991	253	5015					79	82		10.1126/science.1676542	http://dx.doi.org/10.1126/science.1676542			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1676542				2022-12-01	WOS:A1991FV17700039
J	HUNTLEY, ME; LOPEZ, MDG; KARL, DM				HUNTLEY, ME; LOPEZ, MDG; KARL, DM			TOP PREDATORS IN THE SOUTHERN-OCEAN - A MAJOR LEAK IN THE BIOLOGICAL CARBON PUMP	SCIENCE			English	Article							MARGINAL ICE-ZONE; PHYTOPLANKTON GROWTH; WEDDELL SEA; AUTUMN	Primary productivity in the Southern Ocean is approximately 3.5 gigatons of carbon per year, which accounts for nearly 15 percent of the global total. The presence of high concentrations of nitrate in Antarctic waters suggests that it might be possible to increase primary production significantly and thereby alleviate the net accumulation of atmospheric carbon dioxide. An analysis of the food web for these waters implies that the Southern Ocean may be remarkably inefficient as a carbon sink. This inefficiency is caused by the large flux of carbon respired to the atmosphere by air-breathing birds and mammals, dominant predators in the unusually simple food web of Antarctic waters. These top predators may transfer into the atmosphere as much as 20 to 25 percent of photosynthetically fixed carbon.	UNIV HAWAII,SCH OCEAN & EARTH SCI & TECHNOL,HONOLULU,HI 96822	University of Hawaii System	HUNTLEY, ME (corresponding author), UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093, USA.		Karl, David/AFP-3837-2022	Karl, David/0000-0002-6660-6721				BERGER WH, 1989, PRODUCTIVITY OCEAN P, P1; BROWN SG, 1984, ANTARCT ECOL, V2, P717; Conover R.J., 1978, Marine Ecology (London), V4, P221; CONOVER RJ, IN PRESS J MAR SYSTE; COTA GF, 1990, DEEP-SEA RES, V37, P1145, DOI 10.1016/0198-0149(90)90056-2; CROXALL JP, 1984, ANTARCT ECOL, V2, P533; DUCKLOW H, 1988, PROTOZOA THEIR ROLE, P431; EPPLEY RW, 1979, NATURE, V282, P677, DOI 10.1038/282677a0; Everson I., 1984, ANTARCT ECOL, V1, P783; Gordon AL, 1982, SO OCEAN ATLAS; HUMPHREYS WF, 1979, J ANIM ECOL, V48, P427, DOI 10.2307/4171; HUNTLEY ME, IN PRESS DEEP SEA RE; KARL DM, IN PRESS DEEP SEA RE; KARL DM, 1990, DEEP-SEA RES, V37, P1145; Kawamura A., 1970, Scient. Rep. Whales Res. Inst., Tokyo, VNo. 22, P127; Knox G. A., 1970, ANTARCT ECOL, V1, P69; LANCELOT C, 1989, BELGIAN SCI RES PROG, V1; Laws R.M., 1984, P621; LAWS RM, 1985, AM SCI, V73, P26; LWAS RM, 1984, ANTARCTIC ECOLOGY, V2; MARTIN JH, 1988, NATURE, V331, P341, DOI 10.1038/331341a0; Martin JH, 1990, PALEOCEANOGRAPHY, V5, P1, DOI 10.1029/PA005i001p00001; Redfield AC., 1963, SEA, DOI DOI 10.1016/J.ORGGEOCHEM.2014.06.002; Ricklefs RE, 1973, ECOLOGY; Romankevich E. A., 1984, GEOCHEMISTRY ORGANIC; SMETACEK V, COMMUNICATION; SMITH WO, 1990, LIMNOL OCEANOGR, V35, P809, DOI 10.4319/lo.1990.35.4.0809; SMITH WO, 1988, ANTARCTIC OCEAN RESO, P131, DOI DOI 10.1007/978-3-642-73724-4_10; Sundquist E.T., 1985, GEOPHYS MONOGR SER, V32, P5; TANS PP, 1990, SCIENCE, V247, P1431, DOI 10.1126/science.247.4949.1431; VERNET M, IN PRESS ANTARCT J U; VEZINA AF, 1989, MAR ECOL-PROG SER, V42, P269	32	87	88	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					64	66		10.1126/science.1905841	http://dx.doi.org/10.1126/science.1905841			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1905841				2022-12-01	WOS:A1991FV17700033
J	HWANG, SS; BOYLE, TJ; LYERLY, HK; CULLEN, BR				HWANG, SS; BOYLE, TJ; LYERLY, HK; CULLEN, BR			IDENTIFICATION OF THE ENVELOPE V3 LOOP AS THE PRIMARY DETERMINANT OF CELL TROPISM IN HIV-1	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY SYNDROME; CENTRAL NERVOUS-SYSTEM; T-CELL; MONONUCLEAR PHAGOCYTES; NEUTRALIZING DETERMINANT; AIDS PATIENTS; CD4 ANTIGEN; SOLUBLE CD4; INFECTION	Cells of the monocyte-macrophage lineage are targets for human immunodeficiency virus-1 (HIV-1) infection in vivo. However, many laboratory strains of HIV-l that efficiently infect transformed T cell lines replicate poorly in macrophages. A 20-amino acid sequence from the macrophage-tropic BaL isolate of HIV-1 was sufficient to confer macrophage tropism on HTLV-IIIB, a T cell line-tropic isolate. This small sequence element is in the V3 loop, the envelope domain that is the principal neutralizing determinant of HIV-1. Thus, the V3 loop not only serves as a target of the host immune response but is also pivotal in determining HIV-l tissue tropism.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT HISTOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lyerly, Herbert Kim/AAX-4925-2020; Lyerly, Herbert K/B-6528-2014	Lyerly, Herbert Kim/0000-0002-0063-4770; Lyerly, Herbert K/0000-0002-0063-4770				ANDERSEN KB, 1987, J GEN VIROL, V68, P2193, DOI 10.1099/0022-1317-68-8-2193; ANDERSEN KB, 1989, J GEN VIROL, V70, P1921, DOI 10.1099/0022-1317-70-7-1921; APPLEYARD G, 1985, J GEN VIROL, V66, P363, DOI 10.1099/0022-1317-66-2-363; BALDWIN GC, 1990, P NATL ACAD SCI USA, V87, P3933, DOI 10.1073/pnas.87.10.3933; BOYLE TJ, UNPUB; Boyum A, 1968, SCAND J CLIN LAB I S, V97, P51; CAMERINI D, 1990, CELL, V60, P747, DOI 10.1016/0092-8674(90)90089-W; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CHOPPIN PW, 1980, REV INFECT DIS, V2, P40; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; COLLMAN R, 1989, J EXP MED, V170, P1149, DOI 10.1084/jem.170.4.1149; COLLMAN R, 1990, J VIROL, V64, P4468, DOI 10.1128/JVI.64.9.4468-4476.1990; CROWL R, 1985, CELL, V41, P979, DOI 10.1016/S0092-8674(85)80078-7; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; EVANS LA, 1987, J IMMUNOL, V138, P3415; FENYO EM, 1988, J VIROL, V62, P4414; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GARRETT ED, 1991, J VIROL, V65, P1653, DOI 10.1128/JVI.65.3.1653-1657.1991; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; HATTORI T, 1989, FEBS LETT, V248, P48, DOI 10.1016/0014-5793(89)80429-6; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; KIM SY, 1990, J VIROL, V64, P5600, DOI 10.1128/JVI.64.11.5600-5604.1990; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MADDON PJ, 1988, CELL, V54, P865, DOI 10.1016/S0092-8674(88)91241-X; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MCCLURE MO, 1988, EMBO J, V7, P513, DOI 10.1002/j.1460-2075.1988.tb02839.x; MCCLURE MO, 1990, J GEN VIROL, V71, P767, DOI 10.1099/0022-1317-71-4-767; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MELTZER MS, 1990, ANNU REV IMMUNOL, V8, P169, DOI 10.1146/annurev.iy.08.040190.001125; MOORE JP, 1991, J VIROL, V65, P1133, DOI 10.1128/JVI.65.3.1133-1140.1991; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; Nowell P.C, 1960, CANCER RES, V20, P562; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; OTSUKI K, 1981, ARCH VIROL, V70, P315, DOI 10.1007/BF01320246; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PAUZA CD, 1988, J CELL BIOL, V107, P959, DOI 10.1083/jcb.107.3.959; PERTOFT H, 1980, J IMMUNOL METHODS, V33, P221, DOI 10.1016/S0022-1759(80)80012-3; POMERANTZ RJ, 1991, J VIROL, V65, P1041, DOI 10.1128/JVI.65.2.1041-1045.1991; POTTS BJ, 1990, VIROLOGY, V175, P465, DOI 10.1016/0042-6822(90)90431-P; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SCHEID A, 1976, VIROLOGY, V69, P265, DOI 10.1016/0042-6822(76)90213-0; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3; STEPHENS PE, 1990, NATURE, V343, P219, DOI 10.1038/343219b0; STOLER MH, 1986, JAMA-J AM MED ASSOC, V256, P2360, DOI 10.1001/jama.256.17.2360; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TOTH TE, 1982, AM J VET RES, V43, P967; ULMER AJ, 1979, J IMMUNOL METHODS, V30, P1, DOI 10.1016/0022-1759(79)90268-0; WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WILLEY RL, 1989, J VIROL, V63, P3595, DOI 10.1128/JVI.63.9.3595-3600.1989; WOLFS TFW, 1990, P NATL ACAD SCI USA, V87, P9938, DOI 10.1073/pnas.87.24.9938; YOSHIKURA H, 1981, VIROLOGY, V113, P503, DOI 10.1016/0042-6822(81)90178-1	66	806	844	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					71	74		10.1126/science.1905842	http://dx.doi.org/10.1126/science.1905842			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1905842				2022-12-01	WOS:A1991FV17700036
J	KNUDSEN, EI; BRAINARD, MS				KNUDSEN, EI; BRAINARD, MS			VISUAL INSTRUCTION OF THE NEURAL MAP OF AUDITORY SPACE IN THE DEVELOPING OPTIC TECTUM	SCIENCE			English	Article							PRIMATE SUPERIOR COLLICULUS; BARN OWL; GUINEA-PIG; SENSORIMOTOR INTEGRATION; RESPONSE PROPERTIES; SOUND LOCALIZATION; EYE-MOVEMENTS; SENSITIVITY; DEPRIVATION; MATURATION	Neural maps of visual and auditory space are aligned in the adult optic tectum. In barn owls, this alignment of sensory maps was found to be controlled during ontogeny by visual instruction of the auditory spatial tuning of neurons. Large adaptive changes in auditory spatial tuning were induced by raising owls with displacing prisms mounted in spectacle frames in front of the eyes; neurons became tuned to sound source locations corresponding to their optically displaced, rather than their normal, visual receptive field locations. The results demonstrate that visual experience during development calibrates the tectal auditory space map in a site-specific manner, dictating its topography and alignment with the visual space map.			KNUDSEN, EI (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,SHERMAN FAIRCHILD SCI BLDG,STANFORD,CA 94305, USA.			Brainard, Michael/0000-0002-9425-9907	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000155] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC00155-12] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		DULAC S, 1990, J NEUROPHYSIOL, V63, P131, DOI 10.1152/jn.1990.63.1.131; JAY MF, 1987, J NEUROPHYSIOL, V57, P35, DOI 10.1152/jn.1987.57.1.35; JAY MF, 1987, J NEUROPHYSIOL, V57, P22, DOI 10.1152/jn.1987.57.1.22; KALIL R, 1967, PERCEPT MOTOR SKILL, V24, P475, DOI 10.2466/pms.1967.24.2.475; KING AJ, 1983, J PHYSIOL-LONDON, V342, P361, DOI 10.1113/jphysiol.1983.sp014856; KING AJ, 1988, NATURE, V332, P73, DOI 10.1038/332073a0; KING AJ, 1987, J NEUROPHYSIOL, V57, P596, DOI 10.1152/jn.1987.57.2.596; KNUDSEN EI, 1983, SCIENCE, V222, P939, DOI 10.1126/science.6635667; KNUDSEN EI, 1985, J NEUROSCI, V5, P3094; KNUDSEN EI, 1982, J NEUROSCI, V2, P1177; KNUDSEN EI, 1991, J NEUROSCI, V11, P1727; KNUDSEN EI, 1989, J NEUROSCI, V9, P3306; KNUDSEN EI, 1990, J NEUROSCI, V10, P222; KNUDSEN EI, 1988, P NATL ACAD SCI USA, V85, P6211, DOI 10.1073/pnas.85.16.6211; KNUDSEN EI, 1989, VISUAL NEUROSCI, V2, P35, DOI 10.1017/S0952523800004302; MIDDLEBROOKS JC, 1984, J NEUROSCI, V4, P2621; MOISEFF A, 1981, J NEUROSCI, V1, P40, DOI 10.1523/JNEUROSCI.01-01-00040.1981; OLSEN JF, 1989, J NEUROSCI, V9, P2591; SPARKS DL, 1986, PHYSIOL REV, V66, P118, DOI 10.1152/physrev.1986.66.1.118; STEINBACH MJ, 1973, VISION RES, V13, P889, DOI 10.1016/0042-6989(73)90055-2; WISE LZ, 1985, J NEUROPHYSIOL, V54, P185, DOI 10.1152/jn.1985.54.2.185; WITHINGTONWRAY DJ, 1990, EUR J NEUROSCI, V2, P682, DOI 10.1111/j.1460-9568.1990.tb00458.x; WITHINGTONWRAY DJ, 1990, EUR J NEUROSCI, V2, P693, DOI 10.1111/j.1460-9568.1990.tb00459.x	23	162	162	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					85	87		10.1126/science.2063209	http://dx.doi.org/10.1126/science.2063209			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	2063209				2022-12-01	WOS:A1991FV17700041
J	MITRAKI, A; FANE, B; HAASEPETTINGELL, C; STURTEVANT, J; KING, J				MITRAKI, A; FANE, B; HAASEPETTINGELL, C; STURTEVANT, J; KING, J			GLOBAL SUPPRESSION OF PROTEIN FOLDING DEFECTS AND INCLUSION BODY FORMATION	SCIENCE			English	Article							TAIL-SPIKE PROTEIN; AMINO-ACID SUBSTITUTIONS; P22 TAILSPIKE PROTEIN; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; PHAGE-P22 TAILSPIKE; RAMAN-SPECTROSCOPY; POLYPEPTIDE-CHAIN; GENETIC-ANALYSIS; WILD-TYPE	Amino acid substitutions at a site in the center of the bacteriophage protein P22 tailspike polypeptide chain suppress temperature-sensitive folding mutations at many sites throughout the chain. Characterization of the intracellular folding and chain assembly process reveals that the suppressors act in the folding pathway, inhibiting the aggregation of an early folding intermediate into the kinetically trapped inclusion body state. The suppressors alone increase the folding efficiency of the otherwise wild-type polypeptide chain without altering the stability or activity of the native state. These amino acid substitutions identify an unexpected aspect of the protein folding grammar-sequences within the chain that carry information inhibiting unproductive off-pathway conformations. Such mutations may serve to increase the recovery of protein products of cloned genes.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511	Yale University	MITRAKI, A (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.		MITRAKI, Anna/A-6034-2014	MITRAKI, Anna/0000-0001-5072-1939	NIGMS NIH HHS [GMS17,980] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BERGET PB, 1980, J VIROL, V34, P234, DOI 10.1128/JVI.34.1.234-243.1980; BOWDEN GA, 1990, J BIOL CHEM, V265, P16760; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BREMS DN, 1986, BIOCHEMISTRY-US, V25, P6539, DOI 10.1021/bi00369a030; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; FANE B, 1991, GENETICS, V127, P263; FANE B, IN PRESS J BIOL CHEM; FUCHS A, IN PRESS BIOCHEMISTR; GEORGIOU G, 1986, APPL ENVIRON MICROB, V52, P1152; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; GOLDENBERG DP, 1989, NATURE, V338, P127, DOI 10.1038/338127a0; GOLDENBERG DP, 1988, ANNU REV BIOPHYS BIO, V17, P481; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HARRINGT.WF, 1970, BIOCHEMISTRY-US, V9, P3714, DOI 10.1021/bi00821a010; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.bi.59.070190.003215; KING J, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P225; KING J, 1986, BIO-TECHNOL, V4, P297, DOI 10.1038/nbt0486-297; Lee S. J., COMMUNICATION; LONDON J, 1974, EUR J BIOCHEM, V47, P409, DOI 10.1111/j.1432-1033.1974.tb03707.x; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MAURIDES PA, 1990, GENETICS, V125, P673; MITRAKI A, 1987, EUR J BIOCHEM, V163, P29, DOI 10.1111/j.1432-1033.1987.tb10732.x; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MITRAKI A, UNPUB; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RICHARDSON J, 1988, SCIENCE, V240, P4859; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SARGENT D, 1988, J MOL BIOL, V199, P491, DOI 10.1016/0022-2836(88)90620-1; SATHER S, UNPUB; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; SECKLER R, 1989, J BIOL CHEM, V264, P11750; SHORTLE D, 1989, J BIOL CHEM, V264, P5315; SMITH DH, 1981, J MOL BIOL, V145, P653, DOI 10.1016/0022-2836(81)90308-9; SMITH DH, 1980, GENETICS, V96, P331; STROUP AN, 1990, BIOCHEMISTRY-US, V29, P9765, DOI 10.1021/bi00494a002; STURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; THOMAS GJ, 1990, BIOCHEMISTRY-US, V29, P4181, DOI 10.1021/bi00469a022; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WETZEL R, IN PRESS BIOTECHNOLO; WETZEL R, 1990, PROTEIN DESIGN DEV N, P79; YU MH, 1988, J BIOL CHEM, V263, P1424; YU MH, 1984, P NATL ACAD SCI-BIOL, V81, P6584, DOI 10.1073/pnas.81.21.6584; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007	57	186	201	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					54	58		10.1126/science.1648264	http://dx.doi.org/10.1126/science.1648264			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1648264				2022-12-01	WOS:A1991FV17700031
J	BARASCH, J; KISS, B; PRINCE, A; SAIMAN, L; GRUENERT, D; ALAWQATI, Q				BARASCH, J; KISS, B; PRINCE, A; SAIMAN, L; GRUENERT, D; ALAWQATI, Q			DEFECTIVE ACIDIFICATION OF INTRACELLULAR ORGANELLES IN CYSTIC-FIBROSIS	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CHLORIDE CONDUCTANCE; GOLGI-APPARATUS; RAT-LIVER; GLYCOPROTEINS; GANGLIOSIDES; BIOSYNTHESIS; FIBROBLASTS; EPITHELIUM; CHANNELS	THE phenotype of cystic fibrosis (CF) includes abnormalities in transepithelial transport of Cl- (refs 1-5), decreased sialylation and increased sulphation and fucosylation of glycoproteins 6-9, and lung colonization with Pseudomonas. It is not apparent how these abnormalities are interrelated, nor how they result from loss of function of the CF gene-encoded transmembrane regulator (CFTR) 10. We have previously shown that that the pH of a secretory granule is regulated by the vesicular conductance for Cl- (ref. 11). Here we find defective acidification in CF cells of the trans-Golgi/trans-Golgi network, of prelysosomes and of endosomes as a result of diminished Cl- conductance. Sialylation of proteins and lipids is reduced and ligand traffic altered. These abnormalities can result from defective acidification because vacuolar pH regulates glycoprotein processing and ligand transport. The CF phenotype is similar to that of alkalinized cells 12 and acidification-defective mutatants 13.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PEDIAT,NEW YORK,NY 10032; UNIV CALIF SAN FRANCISCO,CYST FIBROSIS RES CTR,SAN FRANCISCO,CA 94143	Columbia University; Columbia University; University of California System; University of California San Francisco	BARASCH, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032, USA.		Al-Awqati, Qais/B-2465-2009	Al-Awqati, Qais/0000-0001-7141-1040				ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; BOAT TF, 1974, AM REV RESPIR DIS, V110, P428; BUSAM K, 1986, EUR J BIOCHEM, V160, P23, DOI 10.1111/j.1432-1033.1986.tb09934.x; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DICKSON RB, 1981, J CELL BIOL, V89, P29, DOI 10.1083/jcb.89.1.29; FISHMAN PH, 1976, J BIOL CHEM, V251, P4490; FISHMAN PH, 1976, SCIENCE, V194, P906, DOI 10.1126/science.185697; FRATES RC, 1983, PEDIATR RES, V17, P30, DOI 10.1203/00006450-198301000-00006; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JOHNSON RG, 1979, J BIOL CHEM, V254, P3750; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KRIVAN HC, 1988, ARCH BIOCHEM BIOPHYS, V260, P493, DOI 10.1016/0003-9861(88)90473-0; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROFF CF, 1986, J CELL BIOL, V103, P2283, DOI 10.1083/jcb.103.6.2283; Roseman S., 1966, METHOD ENZYMOL, V8, P354; ROSNER H, 1973, J NEUROCHEM, V21, P655, DOI 10.1111/j.1471-4159.1973.tb06010.x; SCANLIN TF, 1985, PEDIATR RES, V19, P368, DOI 10.1203/00006450-198519040-00011; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; TAATJES DJ, 1986, EUR J CELL BIOL, V42, P344; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WESLEY A, 1983, PEDIATR RES, V17, P65, DOI 10.1203/00006450-198301000-00013; WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8	36	466	469	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					70	73		10.1038/352070a0	http://dx.doi.org/10.1038/352070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	1712081				2022-12-01	WOS:A1991FV17800073
J	BUSCH, MP; EBLE, BE; KHAYAMBASHI, H; HEILBRON, D; MURPHY, EL; KWOK, S; SNINSKY, J; PERKINS, HA; VYAS, GN				BUSCH, MP; EBLE, BE; KHAYAMBASHI, H; HEILBRON, D; MURPHY, EL; KWOK, S; SNINSKY, J; PERKINS, HA; VYAS, GN			EVALUATION OF SCREENED BLOOD DONATIONS FOR HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION BY CULTURE AND DNA AMPLIFICATION OF POOLED CELLS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; LOW COPY NUMBERS; MONONUCLEAR-CELLS; HOMOSEXUAL MEN; WESTERN BLOT; HIV; TRANSFUSION; TRANSMISSION; ANTIBODY; INDIVIDUALS	Background. Reports of transmission of the human immunodeficiency virus type 1 (HIV-1) from transfusions of screened blood and reports of silent, antibody-negative HIV-1 infections in persons at high risk continue to foster concern about the safety of the blood supply. Previous estimates of the risk of HIV-1 range from 1 in 38,000 to 1 in 300,000 per unit of blood but are based on either epidemiologic models or the demonstration of seroconversion in recipients. Methods. We isolated peripheral-blood mononuclear cells from blood that was fully screened and found to be seronegative, combined them into pools of cells from 50 donors, and tested them for HIV-1 by viral culture and the polymerase chain reaction, using protocols specifically adapted for this analysis. Results. The 1530 pools of mononuclear cells were prepared from 76,500 blood donations made in San Francisco between November 1987 and December 1989. Of these pools, 1436 (representing 71,800 donations) were cultured successfully; 873 (43,650 donations) were evaluated by the polymerase chain reaction. Only one pool was confirmed as HIV-1-infected by both methods. After adjustment for sample-based estimates of the sensitivity of the detection systems using culture and the polymerase chain reaction, the probability that a screened donor will be positive for HIV-1 was estimated as 1 in 61,171 (95 percent upper confidence bound, 1 in 10,695). Conclusions. Silent HIV-1 infections are exceedingly rare among screened blood donors, so the current risk of HIV-1 transmission from blood transfusions, even in high-prevalence metropolitan areas, is extremely low.	UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; IRWIN MEM BLOOD CTR,SAN FRANCISCO,CA; CETUS CORP,EMERYVILLE,CA 94608	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Vyas, Girish/0000-0003-1090-4911	NHLBI NIH HHS [N01-HB-86-7024] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUGAWAN TL, 1988, BIO-TECHNOL, V6, P943, DOI 10.1038/nbt0888-943; BUSCH MP, 1987, AM J CLIN PATHOL, V88, P673, DOI 10.1093/ajcp/88.6.673; BUSCH MP, 1991, TRANSFUSION, V31, P4, DOI 10.1046/j.1537-2995.1991.31191096183.x; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COHEN ND, 1989, NEW ENGL J MED, V320, P1172, DOI 10.1056/NEJM198905043201803; Cox DR, 2018, ANAL BINARY DATA; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DONAHUE JG, 1990, NEW ENGL J MED, V323, P1709; EBLE BE, 1990, 14TH INT C CLIN CHEM; EISENSTEIN BI, 1990, NEW ENGL J MED, V322, P178; GALLO D, 1987, J CLIN MICROBIOL, V25, P1291, DOI 10.1128/JCM.25.7.1291-1294.1987; GUATELLI JC, 1989, CLIN MICROBIOL REV, V2, P217, DOI 10.1128/CMR.2.2.217-226.1989; HWANG LY, 1989, TRANSFUSION, V29, P113, DOI 10.1046/j.1537-2995.1989.29289146827.x; IMAGAWA DT, 1989, NEW ENGL J MED, V320, P1458, DOI 10.1056/NEJM198906013202205; JACKSON JB, 1990, J CLIN MICROBIOL, V28, P16, DOI 10.1128/JCM.28.1.16-19.1990; JACKSON JB, 1990, NEW ENGL J MED, V322, P217, DOI 10.1056/NEJM199001253220402; JACKSON JB, 1988, J CLIN MICROBIOL, V26, P1416, DOI 10.1128/JCM.26.7.1416-1418.1988; JULIEN AM, 1988, LANCET, V2, P1248; KELLOGG DE, 1990, ANAL BIOCHEM, V189, P202, DOI 10.1016/0003-2697(90)90108-L; KELLOGG DE, 1990, PCR PROTOCOLS GUIDE, P337; KLEINMAN S, 1988, TRANSFUSION, V28, P499, DOI 10.1046/j.1537-2995.1988.28588337347.x; KLEINMAN SH, 1989, TRANSFUSION, V29, P572, DOI 10.1046/j.1537-2995.1989.29789369672.x; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LEE TH, IN PRESS AIDS; LIFSON AR, 1990, J INFECT DIS, V161, P436, DOI 10.1093/infdis/161.3.436; LOCHE M, 1988, LANCET, V2, P418; NETER J, 1974, APPLIED LINEAR STATI; PERKINS HA, 1987, TRANSFUSION, V27, P502, DOI 10.1046/j.1537-2995.1987.27688071706.x; PERKINS HA, 1989, NEW ENGL J MED, V320, P463; SHEPPARD HW, 1991, J ACQ IMMUN DEF SYND, V4, P277; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SOBEL M, 1975, BIOMETRIKA, V62, P181, DOI 10.2307/2334502; ULRICH PP, 1988, J MED VIROL, V25, P1, DOI 10.1002/jmv.1890250102; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; WOLINSKY SM, 1989, ANN INTERN MED, V111, P961, DOI 10.7326/0003-4819-111-12-961	36	129	130	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1991	325	1					1	5		10.1056/NEJM199107043250101	http://dx.doi.org/10.1056/NEJM199107043250101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU342	2046708				2022-12-01	WOS:A1991FU34200001
J	CHRISTINCK, ER; LUSCHER, MA; BARBER, BH; WILLIAMS, DB				CHRISTINCK, ER; LUSCHER, MA; BARBER, BH; WILLIAMS, DB			PEPTIDE BINDING TO CLASS-I MHC ON LIVING CELLS AND QUANTITATION OF COMPLEXES REQUIRED FOR CTL LYSIS	NATURE			English	Article							MONOCLONAL-ANTIBODIES; HLA MOLECULES; RECOGNITION; ANTIGENS; BETA-2-MICROGLOBULIN; INVITRO; H-2	ANTIGENIC peptides are presented to CD8+ T lymphocytes by class I major histocompatibility complex (MHC) molecules 1,2. Peptides specifically bind to purified class I molecules in vitro 3-7, and to class I molecules on cells at nonphysiological temperatures 8. We report here the kinetic and equilibrium parameters for the binding of radiolabelled influenza nucleoprotein peptides (NP-Y365-380 and shorter homologues) to the murine H-2D(b) molecule on intact, viable cells at 37-degrees-C. In contrast to earlier reports, we show that peptide binding is rapid and reversible, with dissociation constants ranging from nanomolar to micromolar, suggestive of typical ligand-receptor interactions. Only 10% of cell-surface D(b) molecules can bind these peptides. To address the relationship between peptide binding and T-cell recognition of the antigen-MHC complex, we determined the minimum number of complexes required to sensitize a target cell for lysis by class I-restricted cytotoxic T-lymphocytes. Our data indicate that EL4 thymoma cells (H-2b) can be sensitized for lysis by cytotoxic T-lymphocytes when as few as 200 class I-peptide complexes (less than 0.08% of surface D(b) molecules) are present per cell.	UNIV TORONTO,DEPT IMMUNOL,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto	CHRISTINCK, ER (corresponding author), UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA.							BODMER HC, 1989, IMMUNOLOGY, V66, P163; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CARRENO BM, 1990, P NATL ACAD SCI USA, V87, P3420, DOI 10.1073/pnas.87.9.3420; CEPPELLINI R, 1989, NATURE, V339, P392, DOI 10.1038/339392a0; CHEN BP, 1990, J EXP MED, V172, P931, DOI 10.1084/jem.172.3.931; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CHOPPIN J, 1990, J EXP MED, V172, P889, DOI 10.1084/jem.172.3.889; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; FRELINGER JA, 1990, J EXP MED, V172, P827, DOI 10.1084/jem.172.3.827; GORER PA, 1950, BRIT J CANCER, V4, P372, DOI 10.1038/bjc.1950.36; HAMMERLING GJ, 1982, P NATL ACAD SCI-BIOL, V79, P4737, DOI 10.1073/pnas.79.15.4737; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HYMAN R, 1976, IMMUNOGENETICS, V3, P75, DOI 10.1007/BF01576940; KILBOURN.ED, 1969, B WORLD HEALTH ORGAN, V41, P643; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; LAGARDE AE, 1984, SOMAT CELL MOLEC GEN, V10, P503, DOI 10.1007/BF01534855; LEMKE H, 1979, IMMUNOL REV, V47, P175, DOI 10.1111/j.1600-065X.1979.tb00293.x; OZATO K, 1980, J IMMUNOL, V124, P533; OZATO K, 1982, TRANSPLANTATION, V34; ROCK KL, 1990, P NATL ACAD SCI USA, V87, P7517, DOI 10.1073/pnas.87.19.7517; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P301, DOI 10.1073/pnas.88.1.301; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SMITH MH, 1986, MOL IMMUNOL, V23, P1077, DOI 10.1016/0161-5890(86)90006-4; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANBLEEK GM, 1990, NATURE, V348, P213; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002	29	340	350	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					67	70		10.1038/352067a0	http://dx.doi.org/10.1038/352067a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	2062379				2022-12-01	WOS:A1991FV17800072
J	ENDO, I; SOEDA, E; MURAKAMI, Y; NISHI, K				ENDO, I; SOEDA, E; MURAKAMI, Y; NISHI, K			HUMAN GENOME ANALYSIS SYSTEM	NATURE			English	Article											ENDO, I (corresponding author), INST PHYS & CHEM RES,DIV GENOME RES,TSUKUBAO,IBARAKI 305,JAPAN.							DEININGER PL, 1983, ANAL BIOCHEM, V129, P216, DOI 10.1016/0003-2697(83)90072-6; SAKABE M, 1990, REV SCI INSTRUM, V61, P1966; WADA A, 1984, NATURE, V305, P193	3	7	8	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					89	90		10.1038/352089a0	http://dx.doi.org/10.1038/352089a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	2062384				2022-12-01	WOS:A1991FV17800080
J	KUNTZ, RE; TOSTESON, ANA; BERMAN, AD; GOLDMAN, L; GORDON, PC; LEONARD, BM; MCKAY, RG; DIVER, DJ; SAFIAN, RD				KUNTZ, RE; TOSTESON, ANA; BERMAN, AD; GOLDMAN, L; GORDON, PC; LEONARD, BM; MCKAY, RG; DIVER, DJ; SAFIAN, RD			PREDICTORS OF EVENT-FREE SURVIVAL AFTER BALLOON AORTIC VALVULOPLASTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANS-LUMINAL VALVULOPLASTY; LEFT-VENTRICULAR FUNCTION; VALVE-REPLACEMENT; FOLLOW-UP; ELDERLY PATIENTS; NONCARDIAC SURGERY; NATURAL-HISTORY; STENOSIS; RISK; OCTOGENARIANS	Background. Balloon aortic valvuloplasty was developed as an alternative to aortic-valve replacement in selected elderly patients with aortic stenosis. The use of this procedure is limited, however, by a high incidence of restenosis. Methods. Between December 1985 and April 1989, valvuloplasty was performed in 205 patients. We evaluated 40 demographic and hemodynamic variables as univariate predictors of event-free survival by Cox regression analysis and identified independent predictors of event-free survival by stepwise multivariate analysis. Results. Early hemodynamic results indicated a decrease in the peak transaortic-valve pressure gradient from 67 +/- 28 to 33 +/- 15 mm Hg after valvuloplasty and an increase in aortic-valve area from 0.6 +/- 0.2 to 0.9 +/- 0.3 cm2 (P < 0.001 for both comparisons). The rate of event-free survival (defined as survival without recurrent symptoms, repeated valvuloplasty, or aortic-valve replacement) was 18 percent over the mean (+/- SD) follow-up period of 24 +/- 12 months (range, 1 to 47). Significant predictors of event-free survival included the left ventricular ejection fraction and the left ventricular and aortic systolic pressure before valvuloplasty, and the percent reduction in the aortic-valve pressure gradient; the pulmonary-capillary wedge pressure was inversely associated with event-free survival. Although the predicted event-free survival rate for the entire patient group was 50 percent at one year (95 percent confidence interval, 43 to 57 percent) and 25 percent at two years (95 percent confidence interval, 19 to 31 percent), the probability of event-free survival at one year varied between 23 and 65 percent when patients were stratified according to three independent predictors: the aortic systolic pressure, the pulmonary-capillary wedge pressure, and the percent reduction in the peak aortic-valve gradient. Conclusions. The most important predictors of event-free survival after balloon aortic valvuloplasty were related to base-line left ventricular performance. The best long-term results after valvuloplasty were observed among patients who would also have been expected to have excellent long-term results after aortic-valve replacement.	CHARLES A DANA RES INST,BOSTON,MA; HARVARD UNIV,BETH ISRAEL HOSP,THORNDIKE LAB,DIV CARDIOVASC,BOSTON,MA 02215; BETH ISRAEL HOSP,DIV CLIN EPIDEMIOL,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School					NHLBI NIH HHS [IF32 HL07987-01A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL007987] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACAR J, 1981, J THORAC CARDIOV SUR, V82, P114; BERLAND J, 1989, CIRCULATION, V79, P1189, DOI 10.1161/01.CIR.79.6.1189; BERMAN AD, 1988, J AM COLL CARDIOL, V11, P1213, DOI 10.1016/0735-1097(88)90284-7; BLOCK PC, 1988, AM J CARDIOL, V62, P760, DOI 10.1016/0002-9149(88)91218-0; BLOCK PC, 1987, AM J CARDIOL, V60, P659, DOI 10.1016/0002-9149(87)90377-8; COPELAND JG, 1977, J THORAC CARDIOV SUR, V74, P875; CORMIER B, 1988, EUR HEART J, V9, P113, DOI 10.1093/eurheartj/9.suppl_E.113; CRIBIER A, 1986, LANCET, V1, P63; DEAN LS, 1989, CATHETER CARDIO DIAG, V16, P130, DOI 10.1002/ccd.1810160213; DESNOYERS MR, 1988, AM J CARDIOL, V62, P1078, DOI 10.1016/0002-9149(88)90552-8; DORROS G, 1987, CATHETER CARDIO DIAG, V13, P151, DOI 10.1002/ccd.1810130302; EDMUNDS LH, 1988, NEW ENGL J MED, V319, P131, DOI 10.1056/NEJM198807213190302; FRANK S, 1973, BRIT HEART J, V35, P41; FREMES SE, 1989, CIRCULATION, V80, P77; ISNER JM, 1988, AM J CARDIOL, V61, P583, DOI 10.1016/0002-9149(88)90769-2; ISNER JM, 1987, AM J CARDIOL, V59, P313, DOI 10.1016/0002-9149(87)90805-8; ISNER JM, 1988, ANN INTERN MED, V108, P377, DOI 10.7326/0003-4819-108-3-377; JOHNSON RG, 1990, ANN THORAC SURG, V49, P740, DOI 10.1016/0003-4975(90)90013-V; KENNEDY JW, 1977, CIRCULATION, V56, P944, DOI 10.1161/01.CIR.56.6.944; LEMBO NJ, 1987, AM J CARDIOL, V60, P733, DOI 10.1016/0002-9149(87)90397-3; LETAC B, 1988, AM J CARDIOL, V62, P598, DOI 10.1016/0002-9149(88)90663-7; LEVINE MJ, 1988, AM J CARDIOL, V62, P1309, DOI 10.1016/0002-9149(88)90284-6; LEVINSON JR, 1989, CIRCULATION, V80, P49; LEWIN RF, 1989, CATHETER CARDIO DIAG, V16, P123, DOI 10.1002/ccd.1810160212; LEWIN RF, 1989, J AM COLL CARDIOL, V14, P1210, DOI 10.1016/0735-1097(89)90419-1; LOMBARD JT, 1987, ANN INTERN MED, V106, P292, DOI 10.7326/0003-4819-106-2-292; LYTLE BW, 1983, CIRCULATION, V68, P1149, DOI 10.1161/01.CIR.68.6.1149; MAGOVERN JA, 1987, J AM COLL CARDIOL, V9, P38, DOI 10.1016/S0735-1097(87)80079-7; MCKAY RG, 1987, CIRCULATION, V75, P192, DOI 10.1161/01.CIR.75.1.192; MCKAY RG, 1986, CIRCULATION, V74, P119, DOI 10.1161/01.CIR.74.1.119; MCKAY RG, 1988, CIRCULATION, V76, P1298; MIRSKY I, 1981, AM J CARDIOL, V48, P295, DOI 10.1016/0002-9149(81)90610-X; OKEEFE JH, 1987, MAYO CLIN PROC, V62, P986, DOI 10.1016/S0025-6196(12)65068-X; PANTELY G, 1978, J THORAC CARDIOV SUR, V75, P383; RIOUX C, 1988, EUR HEART J, V9, P121, DOI 10.1093/eurheartj/9.suppl_E.121; ROBICSEK F, 1988, ANN THORAC SURG, V45, P515, DOI 10.1016/S0003-4975(10)64524-9; Ross J Jr, 1968, Circulation, V38, P61; ROTH RB, 1989, J AM COLL CARDIOL, V13, P1039, DOI 10.1016/0735-1097(89)90258-1; SAFIAN RD, 1987, J AM COLL CARDIOL, V9, P655, DOI 10.1016/S0735-1097(87)80061-X; SAFIAN RD, 1988, NEW ENGL J MED, V319, P125, DOI 10.1056/NEJM198807213190301; SHERMAN W, 1989, ANN INTERN MED, V110, P421, DOI 10.7326/0003-4819-110-6-421; SMITH N, 1978, CIRCULATION, V58, P255, DOI 10.1161/01.CIR.58.2.255; TURINA J, 1987, EUR HEART J, V8, P471, DOI 10.1093/oxfordjournals.eurheartj.a062307	43	53	59	1	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1991	325	1					17	23		10.1056/NEJM199107043250104	http://dx.doi.org/10.1056/NEJM199107043250104			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU342	2046709				2022-12-01	WOS:A1991FU34200004
J	LASPADA, AR; WILSON, EM; LUBAHN, DB; HARDING, AE; FISCHBECK, KH				LASPADA, AR; WILSON, EM; LUBAHN, DB; HARDING, AE; FISCHBECK, KH			ANDROGEN RECEPTOR GENE-MUTATIONS IN X-LINKED SPINAL AND BULBAR MUSCULAR-ATROPHY	NATURE			English	Article							LOCALIZATION; EXPRESSION; CLONING; FAMILY; LOCUS; ACID; OPA	X-LINKED spinal and bulbar muscular atrophy (Kennedy's disease) is an adult-onset form of motorneuron disease which may be associated with signs of androgen insensitivity. We have now investigated whether the androgen receptor gene on the proximal long arm of the X chromosome is a candidate gene for this disease. In patient samples we found androgen receptor gene mutations with increased size of a polymorphic tandem CAG repeat in the coding region. These amplified repeats were absolutely associated with the disease, being present in 35 unrelated patients and none of 75 controls. They segregated with the disease in 15 families, with no recombination in 61 meioses (the maximum log likelihood ratio (lod score) is 13.2 at a recombination rate of 0). The association is unlikely to be due to linkage disequilibrium, because 11 different disease alleles were observed. We conclude that enlargement of the CAG repeat in the androgen receptor gene is probably the cause of this disorder.	UNIV N CAROLINA,REPROD BIOL LABS,CHAPEL HILL,NC 27599; NATL HOSP,INST NEUROL,LONDON WC1N 3BG,ENGLAND	University of North Carolina; University of North Carolina Chapel Hill; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	LASPADA, AR (corresponding author), UNIV PENN,SCH MED,DEPT NEUROL,PHILADELPHIA,PA 19104, USA.		La Spada, Albert/AAG-8809-2020					ARBIZU T, 1983, J NEUROL SCI, V59, P371, DOI 10.1016/0022-510X(83)90022-9; BROWN CJ, 1989, AM J HUM GENET, V44, P264; DUBOULE D, 1987, MOL CELL BIOL, V7, P2003, DOI 10.1128/MCB.7.5.2003; EDWARDS A, UNPUB GENOMICS; FISCHBECK KH, 1991, ADV NEUROL, V56, P209; FISCHBECK KH, 1986, NEUROLOGY, V36, P1595, DOI 10.1212/WNL.36.12.1595; HARDING AE, 1982, J NEUROL NEUROSUR PS, V45, P1012, DOI 10.1136/jnnp.45.11.1012; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KURZ EM, 1986, SCIENCE, V232, P395, DOI 10.1126/science.3961488; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OTT J, 1974, AM J HUM GENET, V26, P588; SAR M, 1977, SCIENCE, V197, P77, DOI 10.1126/science.867053; TAN JA, 1988, MOL ENDOCRINOL, V2, P1276, DOI 10.1210/mend-2-12-1276; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; WARNER C L, 1991, Neurology, V41, P313; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; YANDELL DW, 1989, AM J HUM GENET, V45, P547; YU WHA, 1989, J NEUROSCI, V9, P3908	19	2014	2074	2	67	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					77	79		10.1038/352077a0	http://dx.doi.org/10.1038/352077a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	2062380				2022-12-01	WOS:A1991FV17800075
J	MARTIN, J; LANGER, T; BOTEVA, R; SCHRAMEL, A; HORWICH, AL; HARTL, FU				MARTIN, J; LANGER, T; BOTEVA, R; SCHRAMEL, A; HORWICH, AL; HARTL, FU			CHAPERONIN-MEDIATED PROTEIN FOLDING AT THE SURFACE OF GROEL THROUGH A MOLTEN GLOBULE-LIKE INTERMEDIATE	NATURE			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; LIVER DIHYDROFOLATE-REDUCTASE; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; PRECURSOR PROTEINS; RIBULOSEBISPHOSPHATE-CARBOXYLASE; ATP HYDROLYSIS; RHODANESE; HSP60; MITOCHONDRIA	Folding of two monomeric enzymes mediated by groE has been reconstituted in vitro. The groEL protein stabilizes the polypeptides in a conformation resembling the 'molten globule' state. Mg-ATP and groES then promote the acquisition of ordered tertiary structure at the surface of groEL. Folding requires the hydrolysis of about 100 ATP molecules per protein monomer. This active process of surface-mediated chain folding might represent a general mechanism for the formation of protein structure in vivo.	UNIV MUNICH,INST PHYSIOL CHEM,GOETHESTR 33,W-8000 MUNICH 2,GERMANY; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT HUMAN GENET,NEW HAVEN,CT 06510; UNIV MUNICH,INST ZOOL,W-8000 MUNICH 2,GERMANY	University of Munich; Howard Hughes Medical Institute; Yale University; Yale University; University of Munich			Hartl, F. Ulrich/Y-8206-2019	Langer, Thomas/0000-0003-1250-1462				BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P327; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; FAYET O, 1986, MOL GEN GENET, V202, P35; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2206; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GARVEY EP, 1989, PROTEINS, V6, P259, DOI 10.1002/prot.340060308; GATENBY AA, 1990, ANNU REV CELL BIOL, V6, P125; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HARTL FU, IN PRESS SEMIN IMMUN; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HUANG SM, 1989, BIOCHEMISTRY-US, V28, P471, DOI 10.1021/bi00428a010; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KUMAR AA, 1980, BIOCHEMISTRY-US, V19, P667, DOI 10.1021/bi00545a010; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MATTHEWS DA, 1985, J BIOL CHEM, V260, P381; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; OSTOASALOMA P, 1990, BIOCHIM BIOPHYS ACTA, V1041, P140; PELHAM H, 1988, NATURE, V332, P776, DOI 10.1038/332776a0; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SEMISOTNOV GV, 1987, FEBS LETT, V224, P9, DOI 10.1016/0014-5793(87)80412-X; STERNBERG N, 1973, J MOL BIOL, V76, P25, DOI 10.1016/0022-2836(73)90079-X; TANDON S, 1989, J BIOL CHEM, V264, P9859; TANDON S, 1986, J BIOL CHEM, V261, P5615; TANDON S, 1990, J BIOL CHEM, V265, P5967; TOUCHETTE NA, 1986, BIOCHEMISTRY-US, V25, P5445, DOI 10.1021/bi00367a015; VACHEREAU A, 1989, ANAL BIOCHEM, V179, P206, DOI 10.1016/0003-2697(89)90227-3; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257	54	810	817	0	38	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					36	42		10.1038/352036a0	http://dx.doi.org/10.1038/352036a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	1676490				2022-12-01	WOS:A1991FV17800061
J	PLATT, OS; THORINGTON, BD; BRAMBILLA, DJ; MILNER, PF; ROSSE, WF; VICHINSKY, E; KINNEY, TR				PLATT, OS; THORINGTON, BD; BRAMBILLA, DJ; MILNER, PF; ROSSE, WF; VICHINSKY, E; KINNEY, TR			PAIN IN SICKLE-CELL DISEASE - RATES AND RISK-FACTORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-GLOBIN GENE; FETAL HEMOGLOBIN; CRISIS; ANEMIA; THALASSEMIA; SEVERITY; GELATION; MODELS	Background and Methods. Acute episodes of pain are the principal symptom of sickle cell disease, but little is known about the epidemiologic features of these episodes or risk factors for them, nor is it known whether patients with high rates of such episodes die prematurely. We prospectively studied the natural history of sickle cell disease in 3578 patients ranging from newborns to persons up to 66 years old who were followed at clinical centers across the United States. Results. There were 12,290 episodes of pain in 18,356 patient-years. The average rate was 0.8 episode per patient-year in sickle cell anemia, 1.0 episode per patient-year in sickle beta-0-thalassemia, and 0.4 episode per patient-year in hemoglobin SC disease and sickle beta+-thalassemia. The rate varied widely within each of thesefour groups - e.g., 39 percent of patients with sickle cell anemia had no episodes of pain, and 1 percent had more than six episodes per year. The 5.2 percent of patients with 3 to 10 episodes per year had 32.9 percent of all episodes. Among patients with sickle cell anemia who were more than 20 years old, those with high rates of pain episodes tended to die earlier than those with low rates. High rates were associated with a high hematocrit and low fetal hemoglobin levels. Alpha-Thalassemia had no effect on pain apart from its association with an increased hematocrit. Conclusions. The "pain rate" (episodes per year) is a measure of clinical severity and correlates with early death in patients with sickle cell anemia over the age of 20. Even when the fetal hemoglobin level is low, one can predict that small increments in the level may have an ameliorating effect on the pain rate and may ultimately improve survival. This outcome is particularly encouraging to investigators studying hydroxyurea and other treatments designed to increase the fetal hemoglobin level.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; NEW ENGLAND RES INST, WATERTOWN, MA USA; MED COLL GEORGIA, AUGUSTA, GA 30912 USA; DUKE UNIV, SCH MED, DURHAM, NC 27706 USA; OAKLAND CHILDRENS MED CTR, OAKLAND, CA USA	Harvard University; Harvard Medical School; HealthCore, Inc; University System of Georgia; Augusta University; Duke University	PLATT, OS (corresponding author), CHILDRENS HOSP MED CTR, DANA FARBER CANC INST, DIV HEMATOL ONCOL, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.		Vichinsky, Elliott P/F-8541-2011	Vichinsky, Elliott P/0000-0002-0500-9579				AITKIN M, 1989, STATISTICAL MODELLIN; BAKER RJ, 1978, GLIM SYSTEM; BALLAS SK, 1988, BLOOD, V72, P1216; BAUM KF, 1987, ARCH INTERN MED, V147, P1231, DOI 10.1001/archinte.147.7.1231; BILLETT HH, 1986, BLOOD, V68, P301; BRESLOW N, 1990, J AM STAT ASSOC, V85, P565, DOI 10.2307/2289799; BRESLOW NE, 1984, J R STAT SOC C-APPL, V33, P38; CHARACHE S, 1967, ANN INTERN MED, V67, P1195, DOI 10.7326/0003-4819-67-6-1195; CHARACHE S, 1987, BLOOD, V69, P109; CNAAN A, 1989, STAT MED, V8, P1255, DOI 10.1002/sim.4780081009; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2; DOZY AM, 1979, NATURE, V280, P605, DOI 10.1038/280605a0; EMBURY SH, 1980, J CLIN INVEST, V66, P1319, DOI 10.1172/JCI109984; FARBER MD, 1985, J CHRON DIS, V38, P495, DOI 10.1016/0021-9681(85)90033-5; GASTON M, 1982, AM J PEDIAT HEMATOL, V4, P197; KONOTEYA.FI, 1974, ARCH INTERN MED, V133, P611, DOI 10.1001/archinte.133.4.611; LANDE WM, 1988, BLOOD, V72, P2056; LEIKIN SL, 1989, PEDIATRICS, V84, P500; MANKAD VN, 1990, BLOOD, V75, P274; Powars D R, 1987, Prog Clin Biol Res, V240, P393; POWARS DR, 1984, BLOOD, V63, P921, DOI 10.1182/blood.V63.4.921.921; Seber G.A.F., 1977, LINEAR REGRESSION AN; STEINBERG MH, 1984, BLOOD, V63, P1353; SUNSHINE HR, 1979, J MOL BIOL, V133, P435, DOI 10.1016/0022-2836(79)90402-9; SUNSHINE HR, 1978, NATURE, V275, P238, DOI 10.1038/275238a0; VICHINSKY EP, 1982, AM J PEDIAT HEMATOL, V4, P328	26	1144	1160	1	58	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1991	325	1					11	16		10.1056/NEJM199107043250103	http://dx.doi.org/10.1056/NEJM199107043250103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU342	1710777				2022-12-01	WOS:A1991FU34200003
J	RUDOLPH, AS; RATNA, BR; KAHN, B				RUDOLPH, AS; RATNA, BR; KAHN, B			SELF-ASSEMBLING PHOSPHOLIPID FILAMENTS	NATURE			English	Article							MEMBRANES; FLUCTUATIONS; SHAPES	AQUEOUS dispersions of double-chain phospholipids spontaneously assemble into closed bilayers called vesicles (or liposomes). Although the vesicles are in general topologically spherical, cylindrical 1 and helical 2 liposomes have sometimes been observed. We present here video-enhanced microscopic studies of a diacetylenic phospholipid dispersed in ethanol/water, which reveal the existence of unusual bilayer morphologies. On cooling the dispersion from the isotropic phase, we have observed the formation of long (of the order of hundreds of micrometres), thin (0.2-2-mu-m) filaments, which fluctuate strongly. When the temperature is decreased further, the filaments rapidly retract into a mass of lipid. At constant temperature, on the other hand, the filaments transform into torus or ring-like vesicles. Such nonspherical structures have been predicted theoretically 3,4 but not previously observed experimentally.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM,WASHINGTON,DC 20007; GEOCENTERS INC,FT WASHINGTON,MD 20744	Georgetown University	RUDOLPH, AS (corresponding author), USN,RES LAB,CTR BIOMOLEC SCI & ENGN,CODE 6090,WASHINGTON,DC 20375, USA.							BESSIS M, 1973, LIVING BLOOD CELLS T, P61; Cevc G, 1987, PHOSPHOLIPID BILAYER; CHAPMAN D, 1982, Patent No. 4348329; CULLIS PR, 1986, CHEM PHYS LIPIDS, V40, P127, DOI 10.1016/0009-3084(86)90067-8; CULLIS PR, 1985, PHOSPHOLIPIDS CELLUL, V1; DEKRUIJFF B, 1987, NATURE, V329, P587, DOI 10.1038/329587a0; DEULING HJ, 1976, J PHYS-PARIS, V37, P1335, DOI 10.1051/jphys:0197600370110133500; DEULING HJ, 1977, BLOOD CELLS, V3, P713; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P7132, DOI 10.1073/pnas.83.19.7132; HUB HH, 1980, ANGEW CHEM INT EDIT, V19, P938, DOI 10.1002/anie.198009381; Israelachvili J.N., 1985, INTERMOLECULAR SURFA; LIN KC, 1982, NATURE, V296, P164, DOI 10.1038/296164a0; OUYANG ZC, 1990, PHYS REV A, V41, P4517, DOI 10.1103/PhysRevA.41.4517; SCHNEIDER MB, 1984, BIOPHYS J, V45, P891, DOI 10.1016/S0006-3495(84)84235-6; SINGH A, 1986, SYNTHETIC COMMUN, V16, P847, DOI 10.1080/00397918608059667; Zhong-can, 1989, Phys Rev A Gen Phys, V39, P5280, DOI 10.1103/PhysRevA.39.5280	16	42	43	2	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					52	55		10.1038/352052a0	http://dx.doi.org/10.1038/352052a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	2062377				2022-12-01	WOS:A1991FV17800066
J	STEWART, LMD; HIRST, M; FERBER, ML; MERRYWEATHER, AT; CAYLEY, PJ; POSSEE, RD				STEWART, LMD; HIRST, M; FERBER, ML; MERRYWEATHER, AT; CAYLEY, PJ; POSSEE, RD			CONSTRUCTION OF AN IMPROVED BACULOVIRUS INSECTICIDE CONTAINING AN INSECT-SPECIFIC TOXIN GENE	NATURE			English	Article							ANDROCTONUS-AUSTRALIS HECTOR; NUCLEAR POLYHEDROSIS-VIRUS; EXPRESSION VECTORS; BACILLUS-THURINGIENSIS; CELLS; VENOM	BACULOVIRUSES provide alternatives to chemicals for controlling insect pests 1-4 and can be applied by spraying. Baculoviruses have a limited host range, but work relatively slowly. They are dissolved in the midgut of insect larvae to release infectious virions which enter gut epithelial cells and begin to replicate. Replication in other organs causes extensive tissue damage and eventually death. This process can take 4-5 days, but in the field may last for more than a week, allowing the larvae to feed for longer and thereby damaging the host plant. Baculovirus expression vectors expreSSing foreign genes 5,6, such as those for insect-specific toxins, hormones or enzymes, might alleviate this problem 7-11. We have now constructed a recombinant baculovirus derived from Autographa californica nuclear polyhedrosis virus containing an insect-specific neurotoxin from the venom of the North African (Algerian) scorpion, Androctonus australis Hector 12. The neurotoxin acts by causing specific modifications to the Na+ conductance of neurons, producing a presynaptic excitatory effect leading to paralysis and death 15,16; it has no effect in mice 17,18. Expression of the neurotoxin by the virus causes a reduction in the time required to kill the host insect.	WELLCOME ENVIRONM HLTH,BERKHAMSTED HP4 2DY,HERTS,ENGLAND	GlaxoSmithKline	STEWART, LMD (corresponding author), NERC,INST VIROL & ENVIRONM MICROBIOL,MANSFIELD RD,OXFORD OX1 3SR,ENGLAND.		Possee, Robert/E-7034-2012; Lopez-Ferber, Miguel/F-5465-2012; GUO, Zhaoyu/AAS-5699-2020	Possee, Robert/0000-0002-9575-6040; Lopez-Ferber, Miguel/0000-0002-3850-1703; 				[Anonymous], 1971, PROBIT ANAL; BOUGIS PE, 1989, J BIOL CHEM, V264, P19259; CARBONELL LF, 1988, GENE, V73, P409, DOI 10.1016/0378-1119(88)90505-7; COOK RF, 1977, INFECT IMMUN, V25, P396; Cunningham J.C., 1982, P335; DARBON H, 1982, INT J PEPT PROT RES, V20, P320; DEDIANOUS S, 1987, TOXICON, V25, P411, DOI 10.1016/0041-0101(87)90074-2; Entwistle P.F., 1985, P347; Evans H.F., 1987, P257; HAMMOCK BD, 1990, NATURE, V344, P458, DOI 10.1038/344458a0; HARAP KA, 1977, VIROLOGY, V79, P14; HUBER J, 1986, BIOL BACULOVIRUSES, V2, P182; HUGHES PR, 1986, J INVERTEBR PATHOL, V48, P187, DOI 10.1016/0022-2011(86)90122-9; HUGHES PR, 1981, J INVERTEBR PATHOL, V37, P154, DOI 10.1016/0022-2011(81)90069-0; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIVINGSTONE C, 1989, NUCLEIC ACIDS RES, V17, P2366, DOI 10.1093/nar/17.6.2366; MAEDA S, 1989, BIOCHEM BIOPH RES CO, V165, P1177, DOI 10.1016/0006-291X(89)92726-5; MARTENS JWM, 1990, APPL ENVIRON MICROB, V56, P2748; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MERRYWEATHER AT, 1990, J GEN VIROL, V71, P1535, DOI 10.1099/0022-1317-71-7-1535; PENNOCK GD, 1984, MOL CELL BIOL, V4, P399, DOI 10.1128/MCB.4.3.399; POSSEE RD, 1986, VIRUS RES, V5, P43, DOI 10.1016/0168-1702(86)90064-X; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; TEITELBAUM Z, 1979, INSECT BIOCHEM, V9, P343, DOI 10.1016/0020-1790(79)90080-5; WALTHER C, 1976, J INSECT PHYSIOL, V22, P1187, DOI 10.1016/0022-1910(76)90092-5; WEYER U, 1990, J GEN VIROL, V71, P1525, DOI 10.1099/0022-1317-71-7-1525; WHITFORD M, 1989, J VIROL, V63, P1393, DOI 10.1128/JVI.63.3.1393-1399.1989; ZLOTKIN E, 1971, BIOCHIMIE, V53, P1073, DOI 10.1016/S0300-9084(71)80195-5; ZLOTKIN E, 1983, INSECT BIOCHEM, V13, P219, DOI 10.1016/0020-1790(83)90043-4	30	303	346	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					85	88		10.1038/352085a0	http://dx.doi.org/10.1038/352085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	2062383				2022-12-01	WOS:A1991FV17800078
J	SUN, XJ; ROTHENBERG, P; KAHN, CR; BACKER, JM; ARAKI, E; WILDEN, PA; CAHILL, DA; GOLDSTEIN, BJ; WHITE, MF				SUN, XJ; ROTHENBERG, P; KAHN, CR; BACKER, JM; ARAKI, E; WILDEN, PA; CAHILL, DA; GOLDSTEIN, BJ; WHITE, MF			STRUCTURE OF THE INSULIN-RECEPTOR SUBSTRATE IRS-1 DEFINES A UNIQUE SIGNAL TRANSDUCTION PROTEIN	NATURE			English	Article							GROWTH FACTOR-I; TYROSINE-PHOSPHORYLATION; PHOSPHATIDYLINOSITOL KINASE; CELLS; ADIPOCYTES; COMMON; PHOSPHOPROTEIN; PURIFICATION; 3-KINASE; BINDING	SINCE the discovery of insulin nearly 70 years ago, there has been no problem more fundamental to diabetes research than understanding how insulin works at the cellular level. Insulin binds to the alpha-subunit of the insulin receptor which activates the tyrosine kinase in the beta-subunit, but the molecular events linking the receptor kinase to insulin-sensitive enzymes and transport processes are unknown 1,2. Our discovery that insulin stimulates tyrosine phosphorylation of a protein of relative molecular mass between 165,000 and 185,000, collectively called pp185, showed that the insulin receptor kinase has specific cellular substrates 3. The pp185 is a minor cytoplasmic phosphoprotein found in most cells and tissues 4-10; its phosphorylation is decreased in cells expressing mutant receptors defective in signalling 6,11. We have now cloned IRS-1, which encodes a component of the pp185 band. IRS-1 contains over ten potential tyrosine phosphorylation sites, six of which are in Tyr-Met-X-Met motifs. During insulin stimulation, the IRS-1 protein undergoes tyrosine phosphorylation and binds phosphatidylinositol 3-kinase, suggesting that IRS-1 acts as a multisite 'docking' protein to bind signal-transducing molecules containing Src-homology 2 and Src-homology-3 domains 12-14. Thus IRS-1 may link the insulin receptor kinase and enzymes regulating cellular growth and metabolism.			SUN, XJ (corresponding author), HARVARD UNIV,SCH MED,DEPT MED,JOSLIN DIABET CTR,DIV RES,1 JOSLIN PL,BOSTON,MA 02115, USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BACKER JM, IN PRESS BIOCHEMISTR; BRINDLE NPJ, 1990, BIOCHEM J, V268, P615, DOI 10.1042/bj2680615; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; ESCOBEDO JA, 1991, CELL, V65; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HJOLLUND E, 1988, ACTA ENDOCRINOL-COP, V118, P59; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; LATHE R, 1985, J MOL BIOL, V83, P1; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PINES J, 1990, New Biologist, V2, P389; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHEMER J, 1987, J BIOL CHEM, V262, P15476; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358	31	1412	1447	1	59	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					73	77		10.1038/352073a0	http://dx.doi.org/10.1038/352073a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	1648180				2022-12-01	WOS:A1991FV17800074
J	TOMALSKI, MD; MILLER, LK				TOMALSKI, MD; MILLER, LK			INSECT PARALYSIS BY BACULOVIRUS-MEDIATED EXPRESSION OF A MITE NEUROTOXIN GENE	NATURE			English	Article							PYEMOTES-TRITICI; TRANSCRIPTION; VECTORS; TOXINS	FEMALE mites of the species Pyemotes tritici inject an extremely potent venom into their insect prey that causes muscle-contraction and paralysis 1-4. These mites are able to paralyse insects 150,000 times their size 5 and their venom is effective in a broad range of insect species 4. A toxin (TxP-I) associated with the mite venom apparatus causes immediate muscle-contractive paralysis when injected into insects but not mice 6. In this report, we describe the cloning, sequencing and expression of a complementary DNA (Tox-34) encoding TxP-I. Insect cells infected with a recombinant baculovirus (vEV-Tox34) expressing Tox-34 secrete three polypeptides related to TxP-I which cause paralysis on injection. Larvae infected with vEV-Tox34 become paralysed during infection, thus reflecting the potential application of this toxin gene in insect biocontrol methods. The toxin gene expression system will also allow further exploration of the neurophysiological basis of its insect-specific effects.	UNIV GEORGIA,DEPT GENET,ATHENS,GA 30602	University System of Georgia; University of Georgia	TOMALSKI, MD (corresponding author), UNIV GEORGIA,DEPT ENTOMOL,ATHENS,GA 30602, USA.							Battey, 1986, BASIC METHODS MOL BI; BISHOP DHL, 1988, RELEASE GENETICALLY, P143; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CARBONELL LF, 1988, GENE, V73, P409, DOI 10.1016/0378-1119(88)90505-7; KRCZAL H, 1959, ACARINA, V1, P385; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER DW, 1986, GENETIC ENG PRINCIPL, V8, P277; MILLER LK, 1983, SCIENCE, V219, P715, DOI 10.1126/science.219.4585.715; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MOSER JC, 1975, T ROY ENT SOC LONDON, V127, P185; OOI BG, 1989, J MOL BIOL, V210, P721, DOI 10.1016/0022-2836(89)90105-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOMALSKI MD, 1989, TOXICON, V27, P1151, DOI 10.1016/0041-0101(89)90009-3; TOMALSKI MD, 1988, VIROLOGY, V167, P591, DOI 10.1016/S0042-6822(88)90122-5; TOMALSKI MD, 1988, TOXICON, V26, P127, DOI 10.1016/0041-0101(88)90164-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAIVANIJKUL P, 1968, P HAWAII ENTOMOL SOC, V20, P443; WANG XZ, 1991, GENE, V100, P131, DOI 10.1016/0378-1119(91)90358-I; WEISER JAROSLAV, 1964, ANN ENTOMOL SOC AMER, V57, P479	19	227	267	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					82	85		10.1038/352082a0	http://dx.doi.org/10.1038/352082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	1840646				2022-12-01	WOS:A1991FV17800077
J	WALLER, DK; LUSTIG, LS; CUNNINGHAM, GC; GOLBUS, MS; HOOK, EB				WALLER, DK; LUSTIG, LS; CUNNINGHAM, GC; GOLBUS, MS; HOOK, EB			2ND-TRIMESTER MATERNAL SERUM ALPHA-FETOPROTEIN LEVELS AND THE RISK OF SUBSEQUENT FETAL DEATH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEURAL-TUBE DEFECTS; PREGNANCIES; OUTCOMES; VALUES	Background. The finding of an elevated level of maternal serum alpha-fetoprotein during the second trimester of pregnancy may indicate that the fetus has died or is about to die. It is uncertain, however, whether the finding is associated with an increased risk of fetal death later in gestation independent of known causes of elevation, such as the presence of neural-tube defects or multiple gestation. Methods. To address this question, we performed a case-control study of 612 women whose pregnancies ended in fetal death and 2501 women who gave birth to live infants, using reports from California vital statistics for 1987. All the women had singleton pregnancies and alpha-fetoprotein screening in the second trimester. Results. Women with elevated levels of serum alpha-fetoprotein in the second trimester of pregnancy had an increased risk of fetal death, and the risk was increased until term. Women with the highest levels of serum alpha-fetoprotein - greater-than-or-equal-to 3.0 times the median value - had a very high risk of fetal death (odds ratio, 10.4; 95 percent confidence interval, 4.9 to 22.0) as compared with women who had normal levels of alpha-fetoprotein. Maternal serum alpha-fetoprotein levels that were 2.0 to 2.9 times the median were also associated with an elevated risk of fetal death (odds ratio, 2.4; 95 percent confidence interval, 1.7 to 3.4). Elevated levels of alpha-fetoprotein were especially likely to be associated with fetal death in cases in which maternal hypertension or placental infarction was also present. Conclusions. An unexplained elevated level of maternal serum alpha-fetoprotein in the second trimester of pregnancy is associated with an increased risk of subsequent fetal death, up to four to five months after alpha-fetoprotein screening.	UNIV CALIF BERKELEY,SCH PUBL HLTH,WARREN HALL,BERKELEY,CA 94720; CALIF DEPT HLTH SERV,GENET DIS BRANCH,CALIF ALPHA FETOPROT SCREENING PROGRAM,BERKELEY,CA 94704; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143	University of California System; University of California Berkeley; California Department of Health Care Services; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Waller, Dorothy/0000-0003-2211-4773				ADAMS MJ, 1984, AM J OBSTET GYNECOL, V148, P241, DOI 10.1016/S0002-9378(84)80062-9; ANDERSON GD, 1986, OBSTETRICS NORMAL PR, P819; Bakketeig L. S., 1984, PERINATAL EPIDEMIOLO, P99; BAULD R, 1974, ARCH DIS CHILD, V49, P782, DOI 10.1136/adc.49.10.782; BENNETT MJ, 1979, AM J OBSTET GYNECOL, V135, P545, DOI 10.1016/0002-9378(79)90449-6; BERKELEY AS, 1983, AM J OBSTET GYNECOL, V146, P859, DOI 10.1016/0002-9378(83)91091-8; BOYD PA, 1986, PRENATAL DIAG, V6, P369, DOI 10.1002/pd.1970060505; BROCK DJH, 1979, LANCET, V1, P1281; BURTON BK, 1988, OBSTET GYNECOL, V72, P709; BYRNE J, 1986, AM J MED GENET, V25, P327, DOI 10.1002/ajmg.1320250219; CRANDALL BF, 1983, WESTERN J MED, V138, P524; DAVENPORT DM, 1983, AM J OBSTET GYNECOL, V146, P657, DOI 10.1016/0002-9378(83)91008-6; EVANS MI, 1988, OBSTET GYNECOL, V72, P342; FAROOQUI MO, 1973, OBSTET GYNECOL SURV, V28, P144; LAMMER EJ, 1989, JAMA-J AM MED ASSOC, V261, P1757, DOI 10.1001/jama.261.12.1757; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; MILUNSKY A, 1989, AM J OBSTET GYNECOL, V161, P291, DOI 10.1016/0002-9378(89)90501-2; MOORE TR, 1989, AM J OBSTET GYNECOL, V160, P1075, DOI 10.1016/0002-9378(89)90164-6; NELSON LH, 1987, AM J OBSTET GYNECOL, V157, P572, DOI 10.1016/S0002-9378(87)80009-1; ROBINSON L, 1989, OBSTET GYNECOL, V74, P17; SALAFIA CM, 1988, AM J OBSTET GYNECOL, V158, P1064, DOI 10.1016/0002-9378(88)90220-7; SEPPALA M, 1976, LANCET, V2, P123; SEPPALA M, 1972, BMJ-BRIT MED J, V4, P769, DOI 10.1136/bmj.4.5843.769; SIMPSON JL, 1987, AM J OBSTET GYNECOL, V156, P852, DOI 10.1016/0002-9378(87)90341-3; SIMPSON JL, 1986, OBSTETRICS NORMAL PR, P651; WARBURTON D, 1964, AM J HUM GENET, V16, P1; 1977, LANCET, V1, P1323	27	71	71	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1991	325	1					6	10		10.1056/NEJM199107043250102	http://dx.doi.org/10.1056/NEJM199107043250102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU342	1710779				2022-12-01	WOS:A1991FU34200002
J	WERY, JP; SCHEVITZ, RW; CLAWSON, DK; BOBBITT, JL; DOW, ER; GAMBOA, G; GOODSON, T; HERMANN, RB; KRAMER, RM; MCCLURE, DB; MIHELICH, ED; PUTNAM, JE; SHARP, JD; STARK, DH; TEATER, C; WARRICK, MW; JONES, ND				WERY, JP; SCHEVITZ, RW; CLAWSON, DK; BOBBITT, JL; DOW, ER; GAMBOA, G; GOODSON, T; HERMANN, RB; KRAMER, RM; MCCLURE, DB; MIHELICH, ED; PUTNAM, JE; SHARP, JD; STARK, DH; TEATER, C; WARRICK, MW; JONES, ND			STRUCTURE OF RECOMBINANT HUMAN RHEUMATOID ARTHRITIC SYNOVIAL-FLUID PHOSPHOLIPASE-A2 AT 2.2 A RESOLUTION	NATURE			English	Article							BOVINE PANCREATIC PHOSPHOLIPASE-A2; TRANSITION-STATE ANALOG; CRYSTAL-STRUCTURE; EXTRACELLULAR PHOSPHOLIPASE-A2; VENOM PHOSPHOLIPASE-A2; NUCLEIC-ACIDS; FORCE-FIELD; PURIFICATION; EXPRESSION; REFINEMENT	PHOSPHOLIPASES A2 (PLA2s) may be grouped into distinct families of proteins that catalyse the hydrolysis of the 2-acyl bond of phospholipids and perform a variety of biological functions. The best characterized are the small (relative molecular mass approximately 14,000) calcium-dependent, secretory enzymes of diverse origin, such as pancreatic and venom PLA2s 1. The structures and functions of several PLA2s are known 2. Recently, high-resolution crystal structures of complexes of secretory PLA2s with phosphonate phospholipid analogues have provided information about the detailed stereochemistry of transition-state binding 3, confirming the proposed catalytic mechanism of esterolysis 4. By contrast, studies on mammalian nonpancreatic secretory PLA2S (s-PLA2S) have only recently begun; s-PLA2S are scarce in normal cells and tissues but large amounts are found in association with local and systemic inflammatory processes and tissue injury in animals and man 5-7. Such s-PLAs have been purified from rabbit and rat inflammatory exudate 8,9, from synovial fluid from patients with rheumatoid arthritis 10,11 and from human platelets 11. Cloning and sequencing shows that the primary structure of the human s-PLA2 11,12 has about 37% homology with that of bovine pancreatic PLA2 13 and 44% homology with that of Crotalus atrox PLA2 14. The human s-PLA2 is an unusually basic protein, yet contains most of the highly conserved amino-acid residues and sequences characteristic of the PLA2S sequenced so far 1,15. Here we report the refined, three-dimensional crystal structure at 2.2 angstrom resolution of recombinant human rheumatoid arthritic synovial fluid PLA2. This may aid the development of potent and specific inhibitors of this enzyme using structure-based design.			WERY, JP (corresponding author), ELI LILLY & CO,LILLY RES LAB,LILLY CORP CTR,INDIANAPOLIS,IN 46285, USA.							BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNIE S, 1985, J BIOL CHEM, V260, P9742; CHANG HW, 1987, J BIOCHEM, V102, P147, DOI 10.1093/oxfordjournals.jbchem.a122026; CHANG J, 1987, BIOCHEM PHARMACOL, V36, P2429, DOI 10.1016/0006-2952(87)90512-0; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; FLEER EAM, 1978, EUR J BIOCHEM, V82, P261, DOI 10.1111/j.1432-1033.1978.tb12019.x; FORST S, 1986, BIOCHEMISTRY-US, V25, P8381, DOI 10.1021/bi00374a008; GRINNELL BW, 1987, BIO-TECHNOL, V5, P1189, DOI 10.1038/nbt1187-1189; HEINRIKSON RL, 1991, METHOD ENZYMOL, V197, P210; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kramer R M, 1990, Adv Exp Med Biol, V275, P35; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; RANDOLPH A, 1982, J BIOL CHEM, V257, P2155; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; STEFANSKI E, 1986, J BIOCHEM-TOKYO, V100, P1297, DOI 10.1093/oxfordjournals.jbchem.a121836; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; VADAS P, 1986, LAB INVEST, V55, P391; VADAS P, 1988, AGENTS ACTIONS, V24, P320, DOI 10.1007/BF02028289; VERHEIJ HM, 1980, BIOCHEMISTRY-US, V19, P743, DOI 10.1021/bi00545a021; WAITE M, 1987, PHOSPHOLIPASES, P155; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787	29	228	242	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					79	82		10.1038/352079a0	http://dx.doi.org/10.1038/352079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	2062381				2022-12-01	WOS:A1991FV17800076
J	YU, XM; HALL, ZW				YU, XM; HALL, ZW			EXTRACELLULAR DOMAINS MEDIATING EPSILON SUBUNIT INTERACTIONS OF MUSCLE ACETYLCHOLINE-RECEPTOR	NATURE			English	Article							ENDOPLASMIC-RETICULUM; ION CHANNELS; TRANSMEMBRANE; MUTAGENESIS; BINDING; CELLS	LIGAND-gated ion channels, a major class of cell-surface proteins, have a pseudosymmetric structure with five highly homologous subunits arranged around a central ion pore 1. The correct assembly of each channel, whose subunit composition varies with cell type and stage of development, requires specific recognition between the subunits 2-4. Assembly of the pentameric form of the acetylcholine receptor from adult muscle (AChR; alpha-2-beta-epsilon-delta) proceeds by a stepwise pathway starting with the formation of the heterodimers, alpha-epsilon and alpha-delta. The heterodimers then associate with the beta-subunit and with each other to form the complete receptor 5-7,21. We have now determined which parts of the subunits mediate the interactions during assembly of the adult form of the receptor from mouse muscle by using a chimaeric subunit in which the N-terminal and C-terminal extracellular domains are derived from the E subunit with the remainder from the beta-subunit. The epsilon and beta-subunits were chosen because the epsilon-subunit forms a heterodimer with the alpha-subunit in the pathway for assembly of the receptor, whereas the beta-subunit does not. The epsilon-beta chimaera can substitute for the epsilon but not the beta-subunit in the oligomeric receptor, indicating that the alpha-subunit specifically recognizes an extracellular domain of the epsilon-subunit.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BUONANNO A, 1989, J BIOL CHEM, V264, P7611; CLAUDIO T, 1989, FRONTIERS MOL BIOL M, P63; DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GU Y, 1988, NEURON, V1, P117, DOI 10.1016/0896-6273(88)90195-X; GU Y, 1990, NEURON, V5, P147, DOI 10.1016/0896-6273(90)90305-Y; GU Y, IN PRESS NEURON; GU Y, IN PRESS J CELL BIOL; GULLICK WJ, 1983, BIOCHEMISTRY-US, V22, P3312, DOI 10.1021/bi00283a003; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JOHNSON JD, 1988, P NATL ACAD SCI USA, V85, P7516, DOI 10.1073/pnas.85.20.7516; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NUMA S, 1983, COLD SPRING HARB SYM, V48, P57, DOI 10.1101/SQB.1983.048.01.008; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0	21	80	80	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					64	67		10.1038/352064a0	http://dx.doi.org/10.1038/352064a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	1712080				2022-12-01	WOS:A1991FV17800071
J	FRIEDMAN, Y; FRANKLIN, C; FREELS, S; WEIL, MH				FRIEDMAN, Y; FRANKLIN, C; FREELS, S; WEIL, MH			LONG-TERM SURVIVAL OF PATIENTS WITH AIDS, PNEUMOCYSTIS-CARINII PNEUMONIA, AND RESPIRATORY-FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; LIFE-SUSTAINING TREATMENT; INTENSIVE-CARE UNIT; MECHANICAL VENTILATION; PROGNOSTIC FACTORS; CORTICOSTEROIDS; EXPERIENCE; ADMISSION	Objective. - To evaluate the long-term survival of patients admitted to the medical intensive care unit, Cook County Hospital, Chicago, Ill, with Pneumocystis carinii pneumonia and acute respiratory failure. Design. - Cohort study over a 4-year period. Setting. - Municipal teaching hospital. Patients. - Seventy-three consecutive patients who had 75 episodes of P carinii pneumonia and acute respiratory failure were followed up from the time of hospital admission until their deaths or the termination of the study. Outcome Measures. - Duration of survival from the time of initial hospital admission with diagnoses of P carinii pneumonia and acute respiratory failure. Results. - Consistent with recent reports of improved short-term outcome, the immediate hospital survival was 47% (35/75). The 1-year survival was 37% (95% confidence interval, 26% to 49%). Two patients have survived for 40 months. Almost three quarters of the patients who survived hospitalization lived for at least 1 year. Conclusions. - The long-term prognosis for patients with the acquired immunodeficiency syndrome, P carinii pneumonia, and acute respiratory failure is now substantially better than anticipated. Respiratory failure due to P carinii pneumonia does not necessarily signify the terminal phase of human immunodeficiency virus infection. Accordingly, patients with the acquired immunodeficiency syndrome, P carinii pneumonia, and acute respiratory failure can be appropriate candidates for life support in medical intensive care units.	UNIV HLTH SCI CHICAGO MED SCH,N CHICAGO,IL 60064; UNIV ILLINOIS,SCH PUBL HLTH,DEPT EPIDEMIOL BIOSTAT,CHICAGO,IL 60680	Chicago Medical School; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	FRIEDMAN, Y (corresponding author), COOK CTY HOSP,DEPT MED,DIV CRIT CARE MED,1835 W HARRISON ST,CHICAGO,IL 60612, USA.							ALLEGRA CJ, 1987, NEW ENGL J MED, V317, P978, DOI 10.1056/NEJM198710153171602; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; EFFEREN LS, 1989, AM J MED, V87, P401, DOI 10.1016/S0002-9343(89)80821-6; ELSADR W, 1988, AM REV RESPIR DIS, V137, P1264, DOI 10.1164/ajrccm/137.6.1264; ENGELHARDT HT, 1986, JAMA-J AM MED ASSOC, V255, P1159, DOI 10.1001/jama.255.9.1159; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRIEDMAN Y, 1990, CRIT CARE MED, V18, P346, DOI 10.1097/00003246-199003000-00027; FRIEDMAN Y, 1989, CHEST, V96, P862, DOI 10.1378/chest.96.4.862; HARDY WD, 1989, 1989 AIDS CLIN REV, P125; KAPLAN RM, 1989, MED CARE, V27, pS27, DOI 10.1097/00005650-198903001-00003; LUCE JM, 1988, AM REV RESPIR DIS, V137, P1261, DOI 10.1164/ajrccm/137.6.1261; MACFADDEN DK, 1987, LANCET, V1, P1477, DOI 10.1016/S0140-6736(87)92219-7; MONTANER JSG, 1989, CHEST, V95, P881, DOI 10.1378/chest.95.4.881; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; ROGERS PL, 1989, CRIT CARE MED, V17, P113, DOI 10.1097/00003246-198902000-00001; ROSEN MJ, 1986, J INTENSIVE CARE MED, V1, P55; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SCHEIN RMH, 1986, CRIT CARE MED, V14, P1026, DOI 10.1097/00003246-198612000-00006; STEINBROOK R, 1986, NEW ENGL J MED, V314, P457, DOI 10.1056/NEJM198602133140730; STOVER DE, 1985, AM J MED, V78, P429, DOI 10.1016/0002-9343(85)90334-1; VEACH L, 1990, CHEST, V97, P1499, DOI 10.1378/chest.97.6.1499-b; WACHTER RM, 1990, CHEST, V97, P1499, DOI 10.1378/chest.97.6.1499-b; WACHTER RM, 1989, CHEST, V96, P714, DOI 10.1378/chest.96.4.714; WACHTER RM, 1988, ARCH INTERN MED, V148, P149, DOI 10.1001/archinte.148.1.149; WACHTER RM, 1989, CHEST, V95, P647, DOI 10.1378/chest.95.3.647; WACHTER RM, 1986, AM REV RESPIR DIS, V134, P891, DOI 10.1164/arrd.1986.134.5.891; WACHTER RM, 1989, 5TH INT C AIDS MONTR; 1985, MMWR, V34, P373	29	35	35	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1991	266	1					89	92		10.1001/jama.266.1.89	http://dx.doi.org/10.1001/jama.266.1.89			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT934	2046133				2022-12-01	WOS:A1991FT93400033
J	HEALY, B				HEALY, B			GENETIC-MARKER FOR LONG QT SYNDROME IDENTIFIED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, SCIENCE, V252, P704	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1991	266	1					19	19						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT934	2046123				2022-12-01	WOS:A1991FT93400005
J	HEALY, B				HEALY, B			REPLACEMENT THERAPY EFFECTIVE FOR PATIENTS WITH GAUCHERS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, NEW ENGL J MED, V324, P1464	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1991	266	1					19	19						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT934	2046123				2022-12-01	WOS:A1991FT93400003
J	HEALY, B				HEALY, B			ALLELIC LOSS CORRELATED WITH PRIMARY BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, P NATL ACAD SCI USA, V88, P3847	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1991	266	1					19	19						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT934	2046123				2022-12-01	WOS:A1991FT93400004
J	HEIDRICH, FE; STERGACHIS, A; GROSS, KM				HEIDRICH, FE; STERGACHIS, A; GROSS, KM			DIURETIC DRUG-USE AND THE RISK FOR HIP FRACTURE	ANNALS OF INTERNAL MEDICINE			English	Article						DIURETICS, THIAZIDE; FUROSEMIDE; HIP FRACTURES; THIAZIDES; OSTEOPOROSIS	BONE-MINERAL CONTENT; THIAZIDE DIURETICS; ELDERLY WOMEN; FALLS; PREVENTION; ESTROGEN	Objective: To test the hypothesis that use of thiazide diuretics prevents hip fracture and to study the risk for hip fracture associated with furosemide use. Design: A case-control study. Setting: Hospitals owned by a health maintenance organization in Washington. Patients: Elderly patients (n = 462) hospitalized because of a hip fracture between 1977 and 1983 and an equal number of age- and sex-matched population-based control patients. Measurements: Use of thiazide diuretics and furosemide was ascertained from medical records and computerized pharmacy records. The relative risk for hip fracture associated with diuretic use was calculated and adjusted for the potentially confounding effects of nursing home residence; previous hospitalizations; a history of stroke, alcoholism, or the organic brain syndrome; body weight; leg paralysis; and use of phenobarbital, corticosteroids, or other diuretics. Current and former users of diuretics were analyzed separately. Main Results: The adjusted risk for hip fracture was 1.6 (95% Cl, 1.0 to 2.5) for current thiazide users. The adjusted risk for hip fracture for current furosemide use was 3.9 (Cl, 1.5 to 10.4). Conclusions: According to this study, use of thiazide diuretics did not protect against hip fracture and cannot be recommended for fracture prevention. Current furosemide use was also associated with hip fracture.	UNIV WASHINGTON, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	HEIDRICH, FE (corresponding author), GRP HLTH COOPERAT PUGET SOUND, 200 15TH AVE E, SEATTLE, WA 98112 USA.							ADLANDDAVENPORT P, 1985, AM J OBSTET GYNECOL, V152, P630, DOI 10.1016/S0002-9378(85)80035-1; CAMPBELL AJ, 1989, J GERONTOL, V44, pM112, DOI 10.1093/geronj/44.4.m112; HALE WE, 1984, J AM GERIATR SOC, V32, P5, DOI 10.1111/j.1532-5415.1984.tb05142.x; HUNT I, 1988, AM J EPIDEMIOL, V128, P903; JICK H, 1980, AM J EPIDEMIOL, V112, P577, DOI 10.1093/oxfordjournals.aje.a113030; JOHNSON RE, 1981, AM J PUBLIC HEALTH, V71, P138, DOI 10.2105/AJPH.71.2.138; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LINDSAY R, 1987, J BONE MINER RES  S1, V2, P529; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MANTEL N, 1959, J NATL CANCER I, V22, P719; MELTON LJ, 1983, OSTEOPOROSIS SYNDROM; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; PEARSON DC, 1987, PREV MED, V16, P783, DOI 10.1016/0091-7435(87)90018-1; RASHIQ S, 1986, BRIT MED J, V292, P861, DOI 10.1136/bmj.292.6524.861; RAY WA, 1989, LANCET, V1, P687; RESNICK NM, 1989, JAMA-J AM MED ASSOC, V261, P1025, DOI 10.1001/jama.261.7.1025; ROSS RT, 1989, NEW ENGL J MED, V321, P1614; Sernbo I, 1987, Compr Gerontol A, V1, P93; SHELDON JH, 1960, BRIT MED J, V2, P1685, DOI 10.1136/bmj.2.5214.1685; SOWERS JR, 1989, J LAB CLIN MED, V114, P338; STERGACHIS A, 1989, PHARMACOEPIDEMIOLOGY; Stergachis AS, 1991, PHARMACOEPIDEMIOLOGY; SUKI WN, 1970, NEW ENGL J MED, V283, P836, DOI 10.1056/NEJM197010152831603; TAGGART HM, 1988, J AM GERIATR SOC, V36, P1006, DOI 10.1111/j.1532-5415.1988.tb04367.x; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; TRANSBOL I, 1982, METABOLISM, V31, P383, DOI 10.1016/0026-0495(82)90115-9; WASNICH RD, 1986, OBSTET GYNECOL, V67, P457; WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605; WASNICH RD, 1987, OSTEOPOROSIS UPDATE; 1985, SAS RELEASE 5 18	32	110	111	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1991	115	1					1	6		10.7326/0003-4819-115-1-1	http://dx.doi.org/10.7326/0003-4819-115-1-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT937	2048857				2022-12-01	WOS:A1991FT93700001
J	HILTON, E; SINGER, C; KOZARSKY, P; SMITH, MA; LARDIS, MP; BORENSTEIN, MT				HILTON, E; SINGER, C; KOZARSKY, P; SMITH, MA; LARDIS, MP; BORENSTEIN, MT			STATUS OF IMMUNITY TO TETANUS, MEASLES, MUMPS, RUBELLA, AND POLIO AMONG UNITED-STATES TRAVELERS	ANNALS OF INTERNAL MEDICINE			English	Note						RUBELLA; POLIOMYELITIS; MUMPS; MEASLES; TETANUS	DIPHTHERIA	Objective: To assess the susceptibility of travelers to vaccine-preventable diseases, including tetanus, polio, measles, mumps, and rubella. Design: Serologic testing in a cohort of persons before travel. Setting: Travel health centers at two university hospitals. Patients: Two hundred and thirty-three U.S. residents traveling to developing countries. Measurements: Tetanus titers were measured by passive hemagglutination; polio antibodies, by neutralization; and antibody levels to measles, mumps, and rubella, by indirect enzyme-linked immunosorbent assay. Main Results: Tetanus titers were negative in 22 travelers (9%), with the elderly and women more likely to be unprotected (P = 0.003). Twenty-eight travelers (twelve percent) were not protected against polio serotypes 1, 3, or both. Measles antibodies were absent in 4% of travelers, with men more likely than women to be seronegative (7% compared with 2%; P = 0.06). Those born after 1956 were more likely to be seronegative for measles (9% compared with 2%; P = 0.02). Mumps antibody titers were absent in 6% of travelers overall and in 20% of travelers in their twenties. Rubella titers were negative in 19 patients (8%), 5 of whom were women of child-bearing age. Conclusions: Many U.S. travelers are at risk for vaccine-preventable diseases.	EMORY UNIV, SCH MED, ATLANTA, GA 30322 USA	Emory University	HILTON, E (corresponding author), LONG ISL JEWISH MED CTR, LAKEVILLE RD, ROOM B-202, NEW HYDE PK, NY 11042 USA.							FEDSON DS, 1990, GUIDE ADULT IMMUNIZA, P51; GERSHON AA, 1979, DIAGNOSTIC PROCEDURE, P655; HARDEGREE M C, 1970, Bulletin of the World Health Organization, V43, P461; KLEIN EB, 1980, ARCH VIROL, V66, P321, DOI 10.1007/BF01320628; KOBLIN BA, 1989, AM J PUBLIC HEALTH, V79, P1297, DOI 10.2105/AJPH.79.9.1297; MARKOWITZ LE, 1988, INT J EPIDEMIOL, V17, P187, DOI 10.1093/ije/17.1.187; MELNICK JL, 1979, DIAGNOSTIC PROCEDURE, P65; PEEL MM, 1980, J BIOL STAND, V8, P177, DOI 10.1016/S0092-1157(80)80034-5; WEISS BP, 1983, AM J PUBLIC HEALTH, V73, P802, DOI 10.2105/AJPH.73.7.802	9	17	17	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1991	115	1					32	33		10.7326/0003-4819-115-1-32	http://dx.doi.org/10.7326/0003-4819-115-1-32			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT937	2048860				2022-12-01	WOS:A1991FT93700007
J	LIANG, MH; DALTROY, LH; LARSON, MG; PARTRIDGE, AJ; ABELES, M; TAYLOR, C; FOSSEL, AH				LIANG, MH; DALTROY, LH; LARSON, MG; PARTRIDGE, AJ; ABELES, M; TAYLOR, C; FOSSEL, AH			EVALUATION OF SOCIAL-SECURITY DISABILITY IN CLAIMANTS WITH RHEUMATIC DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						ARTHRITIS; RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; SOCIAL SECURITY, DISABILITY; DISABILITY EVALUATION	ARTHRITIS; PATIENT	We compared the Social Security Administration's (SSA) judgment of disability with uninvolved rheumatologists' evaluations of ability to work. With the cooperation of the SSA, 52 new disability claimants who alleged rheumatoid arthritis, osteoarthritis, or systemic lupus erythematosus were identified at the beginning of their claim. At the same time that their claim was being formally reviewed, they had a standardized examination by an independent rheumatologist who was not involved with their care, and they had a standardized test of observed performance. Rheumatologists' judgments of ability to work were compared with the SSA judgments. Rheumatologist and SSA judgments were in agreement for 35 of the 52 claimants (67%). All 11 claimants who met or equaled the SSA medical evaluation criteria were judged work-disabled by the rheumatologist. Of 27 judged able to work by the SSA, the rheumatologist judged 11 to be unable. Agreement between the SSA judgment of residual functional capacity and observed performance was no more than would be expected by chance. Most SSA judgments agree with a clinician's evaluation but a standardized physical evaluation by a rheumatologist and performance-based tests appear to add important information.	UNIV CONNECTICUT, CTR HLTH, FARMINGTON, CT 06032 USA	University of Connecticut	LIANG, MH (corresponding author), BRIGHAM & WOMENS HOSP, CTR MULTIPURPOSE ARTHRITIS, PPB-B2, 75 FRANCIS ST, BOSTON, MA 02115 USA.			Larson, Martin/0000-0002-9631-1254	NCRR NIH HHS [RR-05669] Funding Source: Medline; NIADDK NIH HHS [AM-20580] Funding Source: Medline; NIAMS NIH HHS [AR-20621] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020621] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CAREY TS, 1988, J CLIN EPIDEMIOL, V41, P691, DOI 10.1016/0895-4356(88)90121-7; CAREY TS, 1986, ANN INTERN MED, V104, P706, DOI 10.7326/0003-4819-104-5-706; CAREY TS, 1987, MED CARE, V25, P267, DOI 10.1097/00005650-198704000-00001; HADLER NM, 1984, SEMIN ARTHRITIS RHEU, V14, P45, DOI 10.1016/0049-0172(84)90008-8; HOLLINGSHEAD AB, 1958, SOCIAL CLASS MENTAL, P387; KELLOR M, 1977, SISTER KENNY I PUBLI, V721; LIANG MH, 1988, SUPPLEMENTARY ANAL D; LUDWIG AM, 1981, AM J PSYCHOTHER, V35, P5, DOI 10.1176/appi.psychotherapy.1981.35.1.5; MCCOY JL, 1989, SOC SECUR BULL, V52, P16; MEENAN RF, 1983, B RHEUM DIS, V33, P1; NAGI SZ, 1969, IND MED SURG, V38, P27; Osterweis M., 1987, PAIN DISABILITY CLIN; Paik, 2003, STAT METHODS RATES P, P598; PARTRIDGE AJ, 1984, CLIN RHEUMATOLOGY PR, V2, P275; Stone D., 1984, DISABLED STATE; TURK DC, 1988, PAIN, V34, P217, DOI 10.1016/0304-3959(88)90117-0; YELIN E, 1980, ANN INTERN MED, V93, P551, DOI 10.7326/0003-4819-93-4-551; 1977, SELECTED CHARACTERIS; 1987, SSA64031 US DEP HLTH; 1982, DICT RHEUMATIC DISEA, V1, P73; 1986, SSA64014 US DEP HLTH	21	10	10	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1991	115	1					26	31		10.7326/0003-4819-115-1-26	http://dx.doi.org/10.7326/0003-4819-115-1-26			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT937	2048859				2022-12-01	WOS:A1991FT93700006
J	SAFRIN, S; BERGER, TG; GILSON, I; WOLFE, PR; WOFSY, CB; MILLS, J; BIRON, KK				SAFRIN, S; BERGER, TG; GILSON, I; WOLFE, PR; WOFSY, CB; MILLS, J; BIRON, KK			FOSCARNET THERAPY IN 5 PATIENTS WITH AIDS AND ACYCLOVIR-RESISTANT VARICELLA-ZOSTER VIRUS-INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						VARICELLA ZOSTER VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; FOSCARNET; ACYCLOVIR; HUMAN IMMUNODEFICIENCY VIRUS	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HERPES-ZOSTER	Objective: To determine whether foscarnet has potential efficacy in the treatment of acyclovir-resistant mucocutaneous varicella-zoster infection in patients with the acquired immunodeficiency syndrome (AIDS). Design: Open-label study. Setting. Three university medical centers. Patients: Five patients with AIDS who were infected with thymidine-kinase-deficient or -altered strains of varicella-zoster virus. Intervention: Foscarnet, 40 mg/kg body weight every 8 hours in 1-hour infusions for 10 or more days. Main Results: Four patients had healing in response to foscarnet therapy, and each of four tested patients became culture negative for virus during foscarnet therapy. Results of fluorescent antigen testing remained positive during therapy in two patients; one of these patients had concomitant clinical failure but the other patient healed fully. One patient had complete healing despite the emergence of resistance to foscarnet in serial specimens obtained during foscarnet therapy. Conclusion: Foscarnet is a potentially effective and tolerable antiviral agent for patients with acyclovir-resistant, varicella-zoster virus infection; however, the optimal dosage and duration of therapy require further study, as does the relation between clinical findings and in-vitro susceptibility results.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94110 USA; BURROUGHS WELLCOME CO, RES TRIANGLE PK, NC 27709 USA	University of California System; University of California San Francisco; Burroughs Wellcome Fund								BABA M, 1986, TOHOKU J EXP MED, V148, P275, DOI 10.1620/tjem.148.275; FRIEDMANKIEN AE, 1986, J AM ACAD DERMATOL, V14, P1023, DOI 10.1016/S0190-9622(86)70127-8; GILSON IH, 1989, J AM ACAD DERMATOL, V20, P637, DOI 10.1016/S0190-9622(89)70076-1; HOPPENJANS WB, 1990, ARCH DERMATOL, V126, P1048, DOI 10.1001/archderm.126.8.1048; JACOBSON MA, 1990, ANN INTERN MED, V112, P187, DOI 10.7326/0003-4819-112-3-187; JANIER M, 1988, J AM ACAD DERMATOL, V18, P584, DOI 10.1016/S0190-9622(88)80295-0; LINNEMANN CC, 1990, AIDS, V4, P577, DOI 10.1097/00002030-199006000-00014; PAHWA S, 1988, JAMA-J AM MED ASSOC, V260, P2879, DOI 10.1001/jama.260.19.2879; SAFRIN S, 1990, J INFECT DIS, V161, P1078, DOI 10.1093/infdis/161.6.1078; WEIGLE KA, 1983, J INFECT DIS, V148, P630, DOI 10.1093/infdis/148.4.630	10	165	168	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1991	115	1					19	21		10.7326/0003-4819-115-1-19	http://dx.doi.org/10.7326/0003-4819-115-1-19			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT937	1646585				2022-12-01	WOS:A1991FT93700004
J	SHEIKH, KH; DAVIDSON, CJ; NEWMAN, GE; KISSLO, KB; SCHWAB, SJ				SHEIKH, KH; DAVIDSON, CJ; NEWMAN, GE; KISSLO, KB; SCHWAB, SJ			INTRAVASCULAR ULTRASOUND ASSESSMENT OF THE RENAL-ARTERY	ANNALS OF INTERNAL MEDICINE			English	Article						RENAL ARTERY; HYPERTENSION; ANGIOPLASTY; ANGIOGRAPHY; ULTRASONOGRAPHY	RENOVASCULAR HYPERTENSION; ANGIOPLASTY; DISEASE; SIZE	Objective: To determine the feasibility and diagnostic value of catheter-based intravascular ultrasound imaging compared with angiography for visualizing renal artery structure. Design: Renal artery images were obtained in patients with renal artery stenosis having percutaneous balloon angioplasty and in normal subjects by digital angiography and by a 20-MHz, mechanically driven, catheter-based, intravascular ultrasound imaging system. Setting. A referral-based university hospital. Patients: Four randomly selected normal subjects without known renal disease and four consecutive patients with known renal artery stenosis referred for percutaneous balloon angioplasty. Interventions: Digital angiograms and intravascular ultrasound images of nine renal artery segments were obtained. In patients with renal artery stenosis, imaging was done before and after balloon angioplasty. Main Results: Digital angiography and ultrasonography correlated closely in the determination of arterial lumen diameter (r = 0.81) and cross-sectional area (r = 0.83). However, ultrasonography provided structural information not shown by angiography. All normal arteries showed discrete intimal, medial, and adventitial wall layers by ultrasonography. In the five stenotic segments, angiography identified the cause of stenosis to be atherosclerosis in four patients and fibromuscular dysplasia in one patient. Ultrasound imaging, however, identified the disease process as atherosclerosis in three patients and as fibromuscular dysplasia in two patients. After renal angioplasty, ultrasonography identified three arterial dissections, only one of which was shown by angiography. Conclusions: These preliminary data indicate that catheter-based intravascular ultrasound imaging of the renal artery is feasible and correlates well with angiography in assessing renal artery size and also provides potentially important additional structural information that permits a better characterization of arterial pathology.	DUKE UNIV, MED CTR, DURHAM, NC 27710 USA	Duke University					NATIONAL CANCER INSTITUTE [R01CA037586] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DAVIDSON CJ, 1990, J AM COLL CARDIOL, V16, P633, DOI 10.1016/0735-1097(90)90354-R; FOSTER JH, 1975, JAMA-J AM MED ASSOC, V231, P1043, DOI 10.1001/jama.231.10.1043; GUSSENHOVEN EJ, 1989, J AM COLL CARDIOL, V14, P947, DOI 10.1016/0735-1097(89)90471-3; HARRISON EG, 1971, MAYO CLIN PROC, V46, P161; HARRISON JK, 1990, J AM COLL CARDIOL, V15, P906, DOI 10.1016/0735-1097(90)90291-V; MCCORMAC.LJ, 1966, AM HEART J, V72, P188, DOI 10.1016/0002-8703(66)90442-X; NICHOLS AB, 1989, J AM COLL CARDIOL, V13, P1094, DOI 10.1016/0735-1097(89)90267-2; PANDIAN NG, 1990, AM J CARDIOL, V65, P1278, DOI 10.1016/0002-9149(90)90993-B; PICKERING TG, 1984, AM J MED, V77, P61, DOI 10.1016/S0002-9343(84)80059-5; SOS TA, 1986, HYPERTENSION KIDNEY, P251; TEGTMEYER CJ, 1984, RADIOLOGY, V153, P77, DOI 10.1148/radiology.153.1.6236477	11	15	15	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1991	115	1					22	25		10.7326/0003-4819-115-1-22	http://dx.doi.org/10.7326/0003-4819-115-1-22			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT937	1828655				2022-12-01	WOS:A1991FT93700005
J	DONE, DJ; JOHNSTONE, EC; FRITH, CD; GOLDING, J; SHEPHERD, PM; CROW, TJ				DONE, DJ; JOHNSTONE, EC; FRITH, CD; GOLDING, J; SHEPHERD, PM; CROW, TJ			COMPLICATIONS OF PREGNANCY AND DELIVERY IN RELATION TO PSYCHOSIS IN ADULT LIFE - DATA FROM THE BRITISH PERINATAL-MORTALITY SURVEY SAMPLE	BRITISH MEDICAL JOURNAL			English	Article							OBSTETRIC COMPLICATIONS; SCHIZOPHRENIC MOTHERS; EPIDEMIOLOGY; CHILDREN; ILLNESS; TWIN; RISK	Objective - To evaluate whether events occurring at or around the time of birth contribute to the onset of psychotic illness in adult life. Design - Pregnancy and birth complications as possible causes of adult mental illness were studied in the population sample of the British perinatal mortality survey. Subsequent psychiatric admissions were independently identified through the Mental Health Enquiry and records of regional and special health authorities. Logistic regression was used to compare data on perinatal deaths with those on survivors to determine factors independently associated with perinatal death, and this equation was then used to calculate the risk of perinatal death for each survivor. Subjects - 16 980 people born in a single week in 1958 (the British perinatal mortality survey sample), including 252 patients admitted to psychiatric care; case notes of 235 patients were supplied. Main outcome measures and results - Patients with a schizophrenic illness (whether defined by "broad" (n = 57) or "narrow" (n = 35) diagnostic criteria) did not have a greater mean risk of perinatal death than the population in general, but there was some evidence of increased liability (relative risk 2.43; 95% confidence interval 1.17 to 5.05) for those with affective psychosis (n = 32). Specific high risk variables for affective psychosis were decreased gestation time (273.9 v 281.2 days; mean difference 7.3 days, 95% confidence interval 3.1 to 11.5; p < 0.002) and prescription of vitamin K to the child in the first week of life (19% of patients v 5% of controls, p = 0.016). Conclusions - The findings give no support to theories that factors predicting perinatal mortality contribute significantly to causation of schizophrenic illness. Further investigation of decreased gestation length in relation to affective disorder is required.	ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,BRISTOL BS2 8BJ,ENGLAND; CITY UNIV LONDON,SOCIAL STAT RES UNIT,LONDON EC1V 0BH,ENGLAND	Bristol Royal Hospital For Children; University of Bristol; City University London	DONE, DJ (corresponding author), CLIN RES CTR,DIV PSYCHIAT,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.		crow, timothy J/M-8327-2014; Frith, Chris D/A-2171-2009	crow, timothy J/0000-0002-5482-6655; Frith, Chris D/0000-0002-8665-0690; Golding, Jean/0000-0003-2826-3307				BERTELSEN A, 1977, BRIT J PSYCHIAT, V130, P330, DOI 10.1192/bjp.130.4.330; BUTLER N, 1971, BMJ, V1, P127; BUTLER NR, 1969, PERINATAL PROBLEMS; DALEN P, 1965, ACTA PSYCHIAT SCAND, V41, P527, DOI 10.1111/j.1600-0447.1965.tb06169.x; DER G, 1990, LANCET, V335, P513, DOI 10.1016/0140-6736(90)90745-Q; EAGLES JM, 1990, LANCET, V336, P1139; EATON WW, 1985, EPIDEMIOL REV, V7, P105, DOI 10.1093/oxfordjournals.epirev.a036278; Gottesman I.I., 1972, SCHIZOPHRENIA GENETI; HARE EH, 1987, BRIT MED BULL, V43, P514, DOI 10.1093/oxfordjournals.bmb.a072199; JACOBSEN B, 1980, ACTA PSYCHIAT SCAND, V62, P337, DOI 10.1111/j.1600-0447.1980.tb07709.x; JOFFE M, 1985, J BIOSOC SCI, V17, P113, DOI 10.1017/S0021932000015522; KENDLER KS, 1983, AM J PSYCHIAT, V140, P1551; KETY SS, 1983, AM J PSYCHIAT, V140, P720; LANE EA, 1966, J PSYCHOL, V64, P227, DOI 10.1080/00223980.1966.10544847; LEWIS SW, 1989, PSYCHOL MED, V19, P5, DOI 10.1017/S0033291700010977; LEWIS SW, 1987, J PSYCHIAT RES, V21, P413, DOI 10.1016/0022-3956(87)90088-4; MCNEIL TF, 1973, BRIT J PSYCHIAT, V123, P341, DOI 10.1192/bjp.123.3.341; McNeil TF, 1978, NATURE SCHIZOPHRENIA, P401; MEDNICK SA, 1971, SOC BIOL, V18, P103; MEDNICK SA, 1978, NATURE SCHIZOPHRENIA, P442; MENDLEWICZ J, 1977, NATURE, V268, P327, DOI 10.1038/268327a0; MIRDAL GKM, 1974, ACTA PSYCHIAT SCAND, V50, P553; OLSON SC, 1989, BIOL PSYCHIAT, V25, pA93; OWEN MJ, 1988, PSYCHOL MED, V18, P331, DOI 10.1017/S003329170000787X; PARNAS J, 1982, BRIT J PSYCHIAT, V140, P416, DOI 10.1192/bjp.140.4.416; POLLACK M, 1966, AM J ORTHOPSYCHIAT, V36, P510, DOI 10.1111/j.1939-0025.1966.tb02394.x; POLLACK M, 1968, AM J ORTHOPSYCHIAT, V38, P94, DOI 10.1111/j.1939-0025.1968.tb00560.x; REDDY R, 1989, BIOL PSYCHIAT, V25, pA93; SHEPHERD PM, 1985, 1 CITY U SOC STAT RE; Shields J, 1982, SCHIZOPHRENIA EPIGEN; WEISSMAN MM, 1984, NEUROBIOLOGY MOOD DI, P60; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; WOERNER MG, 1973, ACTA PSYCHIAT SCAND, V49, P712, DOI 10.1111/j.1600-0447.1973.tb04460.x; WREDE G, 1980, ACTA PSYCHIAT SCAND, V62, P369, DOI 10.1111/j.1600-0447.1980.tb00623.x	34	193	193	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1576	1580		10.1136/bmj.302.6792.1576	http://dx.doi.org/10.1136/bmj.302.6792.1576			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FU549	1855042	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1991FU54900026
J	KOLETZKO, S; GRIFFITHS, A; COREY, M; SMITH, C; SHERMAN, P				KOLETZKO, S; GRIFFITHS, A; COREY, M; SMITH, C; SHERMAN, P			INFANT-FEEDING PRACTICES AND ULCERATIVE-COLITIS IN CHILDHOOD	BRITISH MEDICAL JOURNAL			English	Article							CROHNS-DISEASE		UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DIV GASTROENTEROL,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT PAEDIAT,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT NURSING,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Sherman, Philip/0000-0002-4733-6690				ACHESON ED, 1961, BRIT MED J, V2, P929, DOI 10.1136/bmj.2.5257.929; CHANDRA RK, 1989, NUTR RES, V9, P1, DOI 10.1016/S0271-5317(89)80098-3; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; KOLETZKO S, 1989, BRIT MED J, V298, P1617, DOI 10.1136/bmj.298.6688.1617; WHORWELL PJ, 1979, BRIT MED J, V1, P382, DOI 10.1136/bmj.1.6160.382	5	49	50	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1580	1581		10.1136/bmj.302.6792.1580	http://dx.doi.org/10.1136/bmj.302.6792.1580			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU549	1855043	Green Published, Bronze			2022-12-01	WOS:A1991FU54900027
J	KUCK, KH; SCHLUTER, M; GEIGER, M; SIEBELS, J; DUCKECK, W				KUCK, KH; SCHLUTER, M; GEIGER, M; SIEBELS, J; DUCKECK, W			RADIOFREQUENCY CURRENT CATHETER ABLATION OF ACCESSORY ATRIOVENTRICULAR PATHWAYS	LANCET			English	Article							PARKINSON-WHITE SYNDROME; ELECTRODE CONFIGURATION; CONDUCTION; TACHYCARDIA; BLOCK	Tachyarrhythmias mediated by an accessory atrioventricular pathway and which are refractory to drug therapy have been treated surgically with variable success. Early results of direct-current catheter ablation were encouraging but were associated with complications such as barotrauma and the need for a general anaesthetic. We have investigated the endocardial application of radiofrequency current which is a potentially safer technique. Of 105 patients with an accessory atrioventricular pathway, 79 were located on the left side of the heart and 32 on the right side. Accessory pathway conduction was permanently abolished in 93 (89%) patients. Complications developed in 3 patients: thrombotic occlusion of a femoral artery, arteriovenous fistula formation at the site of groin puncture, and left ventricular rupture with cardiac tamponade after direct-current shocks. There were no deaths from the procedure. We conclude that radiofrequency current catheter ablation is both effective and safe for patients with symptomatic tachyarrhythmias mediated by accessory atrioventricular pathways.			KUCK, KH (corresponding author), UNIV HAMBURG,HOSP EPPENDORF,DEPT CARDIOL,W-2000 HAMBURG 20,GERMANY.		Poposka, Lidija/N-6851-2019	Poposka, Lidija/0000-0002-2539-6828				BECKER AE, 1978, CIRCULATION, V57, P870, DOI 10.1161/01.CIR.57.5.870; BORGGREFE M, 1987, J AM COLL CARDIOL, V10, P576, DOI 10.1016/S0735-1097(87)80200-0; COX JL, 1985, J THORAC CARDIOV SUR, V90, P490; EVANS GT, 1988, PACE, V11, P1621, DOI 10.1111/j.1540-8159.1988.tb06284.x; GALLAGHER JJ, 1982, NEW ENGL J MED, V306, P194, DOI 10.1056/NEJM198201283060402; JACKMAN W, 1990, CIRCULATION, V82, P689; JACKMAN WM, 1983, CIRCULATION, V68, P906, DOI 10.1161/01.CIR.68.5.906; JACKMAN WM, 1988, CIRCULATION, V78, P1288, DOI 10.1161/01.CIR.78.5.1288; JACKMAN WM, IN PRESS CIRCULATION; KUCK KH, 1990, CIRCULATION, V82, P407, DOI 10.1161/01.CIR.82.2.407; KUCK KH, 1989, PACE, V12, P1681, DOI 10.1111/j.1540-8159.1989.tb01847.x; KUCK KH, 1988, EUR HEART J, V9, P927, DOI 10.1093/oxfordjournals.eurheartj.a062589; KUCK KH, IN PRESS PACE; KUNZE KP, 1985, J AM COLL CARDIOL, V6, P1428, DOI 10.1016/S0735-1097(85)80236-9; LANGBERG JJ, 1991, AM J CARDIOL, V67, P142, DOI 10.1016/0002-9149(91)90436-O; MORADY F, 1990, CIRCULATION, V82, P689; MORADY F, 1989, CIRCULATION, V79, P1160, DOI 10.1161/01.CIR.79.6.1160; NATHAN AW, 1984, LANCET, V1, P1280; SCHEINMAN MM, 1982, JAMA-J AM MED ASSOC, V248, P851, DOI 10.1001/jama.248.7.851; WARD DE, 1985, BRIT HEART J, V53, P64	20	333	343	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1991	337	8757					1557	1561		10.1016/0140-6736(91)93258-B	http://dx.doi.org/10.1016/0140-6736(91)93258-B			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU551	1675706				2022-12-01	WOS:A1991FU55100002
J	NICHOLAS, AS; DEBIAS, DA; GREENE, CH				NICHOLAS, AS; DEBIAS, DA; GREENE, CH			SOMATIC COMPONENT TO MYOCARDIAL-INFARCTION - 3 YEAR FOLLOW-UP	BRITISH MEDICAL JOURNAL			English	Article							CORONARY-ARTERY DISEASE; DYSFUNCTION		PHILADELPHIA COLL OSTEOPATH MED,PHYSIOL & PHARMACOL,PHILADELPHIA,PA 19131; PHILADELPHIA COLL OSTEOPATH MED,OSTEOPATH PRINCIPLES & PRACTICE,PHILADELPHIA,PA 19131; PHILADELPHIA COLL OSTEOPATH MED,PHYSIOL,PHILADELPHIA,PA 19131									BEAL MC, 1985, J AM OSTEOPATH ASSOC, V85, P302; BEAL MC, 1983, J AM OSTEOPATH ASSOC, V82, P822; COX JM, 1983, J AM OSTEOPATH ASSOC, V82, P832; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; NICHOLAS AS, 1985, BRIT MED J, V291, P13, DOI 10.1136/bmj.291.6487.13	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1581	1581		10.1136/bmj.302.6792.1581	http://dx.doi.org/10.1136/bmj.302.6792.1581			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU549	1855044	Bronze, Green Published			2022-12-01	WOS:A1991FU54900028
J	POUNGVARIN, N; VIRIYAVEJAKUL, A; KOMONTRI, C				POUNGVARIN, N; VIRIYAVEJAKUL, A; KOMONTRI, C			SIRIRAJ STROKE SCORE AND VALIDATION-STUDY TO DISTINGUISH SUPRATENTORIAL INTRACEREBRAL HEMORRHAGE FROM INFARCTION	BRITISH MEDICAL JOURNAL			English	Article							HEMORRHAGE	Objectives - To develop a simple, reliable, and safe diagnostic tool for acute stroke syndromes in a setting where computerised brain scanning was not readily available and to validate its accuracy with regard to pathological types of stroke. Design - 13 clinical variables that potentially might differentiate supratentorial cerebral haemorrhage from infarction were recorded and tested by multivariate analysis in a prospective study of 174 patients with acute stroke. In developing the Siriraj stroke score stepwise discriminant analysis of the variables was followed by a linear discriminant equation to differentiate between supratentorial haemorrhage and infarction. The score obtained was validated against scores in 206 other patients with stroke, computerised brain scans being used for definitive diagnosis. Setting - Siriraj Hospital Medical School, Mahidol University, Bangkok. Subjects - Prospective study: 174 consecutive patients with acute supratentorial stroke syndrome (not subarachnoid haemorrhage) admitted to Siriraj Hospital during 1984-5; validation study: 206 patients admitted to Siriraj Hospital or another hospital for supratentorial intracerebral haemorrhage or infarction. Results - The Siriraj stroke score was developed and calculated as (2.5 x level of consciousness) + (2 x vomiting) + (2 x headache) + (0.1 x diastolic blood pressure) - (3 x atheroma markers) - 12. A score above 1 indicates supratentorial intracerebral haemorrhage, while a score below -1 indicates infarction. The score between 1 and -1 represents an equivocal result needing a computerised brain scan or probability curve to verify the diagnosis. In the validation study of the Siriraj stroke score the diagnostic sensitivities of the score for cerebral haemorrhage and cerebral infarction were 89.3% and 93.2% respectively, with an overall predictive accuracy of 90.3%. Conclusion - The Siriraj stroke score is widely accepted and applied in hospitals throughout Thailand as a simple and reliable bedside method for diagnosing acute stroke.	MAHIDOL UNIV,SIRIRAJ HOSP,FAC MED,DEPT MED,CLIN EPIDEMIOL UNIT,BANGKOK 10700,THAILAND	Mahidol University	POUNGVARIN, N (corresponding author), MAHIDOL UNIV,SIRIRAJ HOSP,FAC MED,DEPT MED,DIV NEUROL,BANGKOK 10700,THAILAND.							ALLAN CMC, 1983, Q J MED, V42, P515; ALLAN CMC, 1984, THESIS U CAMBRIDGE C; HARRISON MJG, 1980, POSTGRAD MED J, V56, P629, DOI 10.1136/pgmj.56.659.629; Kurtzke J.F., 1985, CEREBROVASCULAR SURV, P1; SANDERCOCK PAG, 1985, BRIT MED J, V291, P1675, DOI 10.1136/bmj.291.6510.1675; SANDERCOCK PAG, 1986, BRIT MED J, V292, P173; SCHAAFSMA S, 1968, J NEUROL SCI, V7, P83, DOI 10.1016/0022-510X(68)90005-1; VANARBIN M, 1981, STROKE, V12, P288; VIRIYAVEJAKUL A, 1990, CLIN NEUROPHARMACOL, V13, pS26, DOI 10.1097/00002826-199013003-00003; VIRIYAVEJAKUL A, 1976, SIRIRAJ HOSP GAZETTE, V28, P1648; VIRIYAVEJAKUL A, 1982, SIRIRAJ HOSPITAL GAZ, V34, P501	11	95	98	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1565	1567		10.1136/bmj.302.6792.1565	http://dx.doi.org/10.1136/bmj.302.6792.1565			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU549	1855041	Bronze, Green Published			2022-12-01	WOS:A1991FU54900023
J	ARNOLD, FH; HAYMORE, BL				ARNOLD, FH; HAYMORE, BL			ENGINEERED METAL-BINDING PROTEINS - PURIFICATION TO PROTEIN FOLDING	SCIENCE			English	Editorial Material							RECOMBINANT PROTEINS; DENOVO DESIGN; PEPTIDES		MONSANTO CO,DEPT CHEM SCI,CENT RES LABS,ST LOUIS,MO 63167	Monsanto	ARNOLD, FH (corresponding author), CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125, USA.			Arnold, Frances H./0000-0002-4027-364X				ARNOLD FH, 1991, BIO-TECHNOL, V9, P151, DOI 10.1038/nbt0291-151; BREWER SJ, 1991, PURIFICATION ANAL RE, P239; GHADIRI MR, 1990, J AM CHEM SOC, V112, P1630, DOI 10.1021/ja00160a054; HANDEL T, 1990, J AM CHEM SOC, V112, P6710, DOI 10.1021/ja00174a039; HAYMORE BL, UNPUB; HIGAKI JN, 1990, BIOCHEMISTRY-US, V29, P8582, DOI 10.1021/bi00489a012; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; IVERSON BL, 1990, SCIENCE, V249, P659, DOI 10.1126/science.2116666; KELLIS JT, UNPUB; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; SMITH MC, 1988, J BIOL CHEM, V263, P7211; SUH SS, 1991, PROTEIN ENG, V4, P301, DOI 10.1093/protein/4.3.301; TODD RJ, 1991, PROTEINS, V10, P156, DOI 10.1002/prot.340100209	13	204	215	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1991	252	5014					1796	1797		10.1126/science.1648261	http://dx.doi.org/10.1126/science.1648261			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	1648261				2022-12-01	WOS:A1991FU06100027
J	BIALEK, W; RIEKE, F; VANSTEVENINCK, RRD; WARLAND, D				BIALEK, W; RIEKE, F; VANSTEVENINCK, RRD; WARLAND, D			READING A NEURAL CODE	SCIENCE			English	Article								Traditional approaches to neural coding characterize the encoding of known stimuli in average neural responses. Organisms face nearly the opposite task - extracting information about an unknown time-dependent stimulus from short segments of a spike train. Here the neural code was characterized from the point of view of the organism, culminating in algorithms for real-time stimulus estimation based on a single example of the spike train. These methods were applied to an identified movement-sensitive neuron in the fly visual system. Such decoding experiments determined the effective noise level and fault tolerance of neural computation, and the structure of the decoding algorithms suggested a simple model for real-time analog signal processing with spiking neurons.	UNIV CALIF BERKELEY, DEPT PHYS, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; STATE UNIV GRONINGEN, DEPT BIOPHYS, 9700 AB GRONINGEN, NETHERLANDS	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Groningen								Adrian ED, 1926, J PHYSIOL-LONDON, V61, P49, DOI 10.1113/jphysiol.1926.sp002273; BIALEK W, 1990, J STAT PHYS, V59, P103, DOI 10.1007/BF01015565; BIALEK W, 1990, 1989 LECT COMPL SYST, V2, P513; FITZHUGH R, 1958, J GEN PHYSIOL, V41, P675, DOI 10.1085/jgp.41.4.675; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; Hausen K., 1984, PHOTORECEPTION VISIO; KOCH C, 1983, P NATL ACAD SCI-BIOL, V80, P2799, DOI 10.1073/pnas.80.9.2799; LAND MF, 1974, J COMP PHYSIOL, V89, P331, DOI 10.1007/BF00695351; Marmarelis P.Z., 1978, ANAL PHYSL SYSTEMS; MILLER MI, 1987, J ACOUST SOC AM, V81, P665, DOI 10.1121/1.394835; Perkel D.H., 1968, NEUROSCI RES PROGRAM, V6, P221; Reichardt W., 1961, PRINCIPLES SENSORY C; RICHMOND BJ, 1990, J NEUROPHYSIOL, V64, P351, DOI 10.1152/jn.1990.64.2.351; RIEKE F, IN PRESS 1991 P EUR; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; SZEKELY G, 1981, ADV PHYSL SCI, V30, P103; VANSTEVENINCK RD, 1988, PROC R SOC SER B-BIO, V234, P379; VANSTEVENINCK RRD, 1986, REAL TIME PERFORMANC; WARLAND D, IN PRESS ANAL MODELI; WESTHEIMER G, 1975, INVEST OPHTH VISUAL, V14, P570	20	695	722	0	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 28	1991	252	5014					1854	1857		10.1126/science.2063199	http://dx.doi.org/10.1126/science.2063199			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	2063199				2022-12-01	WOS:A1991FU06100042
J	BLOOM, DE; GLIED, S				BLOOM, DE; GLIED, S			BENEFITS AND COSTS OF HIV TESTING	SCIENCE			English	Article							IMMUNODEFICIENCY VIRUS HIV; UNITED-STATES; AIDS; MEN; PREVENTION; KNOWLEDGE; IMPACT; COHORT; TRIAL	The benefits and costs of human immunodeficiency virus (HIV) testing in employment settings are examined from two points of view: that of private employers whose profitability may be affected by their testing policies and that of public policy-makers who may affect social welfare through their design of regulations related to HIV testing. The results reveal that HIV testing is clearly not cost-beneficial for most firms, although the benefits of HIV testing may outweigh the costs for some large firms that offer generous fringe-benefit packages and that recruit workers from populations in which the prevalence of HIV infection is high. The analysis also indicates that the testing decisions of unregulated employers are not likely to yield socially optimal economic outcomes and that existing state and federal legislation related to HIV testing in employment settings has been motivated primarily by concerns over social equity.	COLUMBIA UNIV,SCH PUBL HLTH,NEW YORK,NY 10027; COLUMBIA UNIV,DEPT ECON,NEW YORK,NY 10027	Columbia University; Columbia University	BLOOM, DE (corresponding author), COLUMBIA UNIV,DEPT ECON,NEW YORK,NY 10027, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025914] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25914-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANTA WF, 1989, COMPLETE HDB COMBATT; BLOOM DE, 1988, SCIENCE, V239, P604, DOI 10.1126/science.3277273; BLOOM DE, 1989, HEALTH POLICY, V11, P187, DOI 10.1016/0168-8510(89)90035-3; BODEN LI, 1986, J OCCUP ENVIRON MED, V28, P751, DOI 10.1097/00043764-198608000-00040; BOWLEG IA, 1989, SUMMARY AIDS LAWS 19; Brown C., 1990, EMPLOYERS LARGE SMAL; BURKE DS, 1988, NEW ENGL J MED, V319, P961, DOI 10.1056/NEJM198810133191501; CATES W, 1988, AM J PUBLIC HEALTH, V78, P1533, DOI 10.2105/AJPH.78.12.1533; DECRESCE RP, 1989, DRUG TESTING WORKPLA; EDEN J, 1988, AIDS HLTH INSURANCE; FEHRS LJ, 1988, LANCET, V2, P379; GAIL MH, 1989, STAT MED, V8, P59, DOI 10.1002/sim.4780080108; GLIED S, 1990, THESIS HARVARD U; GOLDEN JA, 1989, LANCET, V1, P654; HAY JW, 1988, J ACQ IMMUN DEF SYND, V1, P466; KOTLIKOFF LJ, 1983, PENSIONS AM EC; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P1499; LEONARD AS, 1987, AIDS LAW GUIDE PUBLI, P109; LONG JE, 1982, REV ECON STAT, V64, P211, DOI 10.2307/1924300; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P462, DOI 10.2105/AJPH.78.4.462; MIIKE L, 1987, COMMUNICATION   1019; Ostrow D G, 1989, AIDS Educ Prev, V1, P1; Parsons D. O., 1986, HDB LABOR EC, V2, P789; RATCLIFFE JM, 1986, J OCCUP  MED, V28, P907; RUTHERFORD W, 1987, DEC PRES COMM HUM IM; SCITOVSKY AA, 1987, PUBLIC HEALTH REP, V102, P5; TEWKSBURY RL, 1984, HDB EMPLOYEE BENEFIT, P678; TURNOCK BJ, 1989, JAMA-J AM MED ASSOC, V261, P23; VALDISERRI RO, 1988, AM J PUBLIC HEALTH, V78, P801, DOI 10.2105/AJPH.78.7.801; VANDENHOEK JAR, 1989, AM J PUBLIC HEALTH, V79, P1355, DOI 10.2105/AJPH.79.10.1355; VANGRIENSVEN GJP, 1989, AM J EPIDEMIOL, V129, P596; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1987, MORB MORTAL WKLY REP, V38, pS6; 1990, SCIENCE, V249, P20; 1988, HLTH US 1987; 1989, PROTECTION AIDS RELA; 1990, HIV AIDS SURVEIL NOV; NIH ND2591401 GRANT; 1988, FORTUNE; 1987, HOUSEHD EC STUD P70; 1988, JAMA-J AM MED ASSOC, V260, P935; 1986, BUR LABOR STAT B, V2262; 1990, STATISTICAL ABSTRACT; 1989, MORB MORTAL WKLY REP, V38, pS4; 1987, HLTH CARE COVERAGE C	45	30	30	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1991	252	5014					1798	1804		10.1126/science.1829547	http://dx.doi.org/10.1126/science.1829547			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FU061	1829547				2022-12-01	WOS:A1991FU06100028
J	CALIGIURI, MG; BAUERLE, R				CALIGIURI, MG; BAUERLE, R			SUBUNIT COMMUNICATION IN THE ANTHRANILATE SYNTHASE COMPLEX FROM SALMONELLA-TYPHIMURIUM	SCIENCE			English	Article								The anthranilate synthase - phosphoribosyl transferase complex of the tryptophan biosynthetic pathway in Salmonella typhimurium is an allosteric, heterotetrameric (TrpE2-TrpD2) enzyme whose multiple activities are negatively feedback-regulated by L-tryptophan. A hybrid complex containing one catalytically active, feedback-insensitive and one catalytically inactive, feedback-sensitive mutant TrpE subunit was assembled in vitro and used to investigate communication between regulatory and catalytic sites located on different subunits. The properties of the hybrid complex demonstrate that the binding of a single inhibitor molecule to one TrpE subunit is sufficient for the propagation of a conformational change that affects the active site of the companion subunit.	UNIV VIRGINIA, DEPT BIOL, CHARLOTTESVILLE, VA 22901 USA; UNIV VIRGINIA, INST MOLEC BIOL, CHARLOTTESVILLE, VA 22901 USA	University of Virginia; University of Virginia					NIGMS NIH HHS [GM07082, GM35889] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035889] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUERLE R, 1987, METHOD ENZYMOL, V142, P366; CALIGIURI M, UNPUB; CALIGIURI MG, 1991, J BIOL CHEM, V266, P8328; CRICK FHC, 1964, J MOL BIOL, V8, P161, DOI 10.1016/S0022-2836(64)80156-X; FOOTE J, 1985, J MOL BIOL, V186, P175, DOI 10.1016/0022-2836(85)90267-0; FOREMAN JE, 1985, J BIOL CHEM, V260, P19; GRIESHABER M, 1978, Z NATURFORSCH C, V33, P235; GRIESHABER M, 1972, NATURE-NEW BIOL, V236, P232, DOI 10.1038/newbio236232a0; HENDERSON EJ, 1970, J BIOL CHEM, V245, P1416; HENDERSON EJ, 1971, J BIOL CHEM, V246, P6891; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KUO LC, 1982, P NATL ACAD SCI-BIOL, V79, P2250, DOI 10.1073/pnas.79.7.2250; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAGANO H, 1970, J BIOL CHEM, V245, P3097; Segel I. H, 1993, ENZYME KINETICS; SENNEWALD J, UNPUB; SMITH D, 1969, BIOCHEMISTRY-US, V8, P1451, DOI 10.1021/bi00832a021; VALDEZ BC, 1989, J BIOL CHEM, V264, P131; ZABIN I, 1975, ANNU REV BIOCHEM, V44, P295, DOI 10.1146/annurev.bi.44.070175.001455; ZALKIN H, 1968, BIOCHEMISTRY-US, V7, P3566, DOI 10.1021/bi00850a034; ZALKIN H, 1980, MULTIFUNCTIONAL PROT, P123	21	33	35	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 28	1991	252	5014					1845	1848		10.1126/science.2063197	http://dx.doi.org/10.1126/science.2063197			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	2063197				2022-12-01	WOS:A1991FU06100039
J	CHANT, J; HERSKOWITZ, I				CHANT, J; HERSKOWITZ, I			GENETIC-CONTROL OF BUD SITE SELECTION IN YEAST BY A SET OF GENE-PRODUCTS THAT CONSTITUTE A MORPHOGENETIC PATHWAY	CELL			English	Article							CEREVISIAE CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; CAENORHABDITIS-ELEGANS; MATING TYPES; CDC24 GENE; ACTIN; CDC42; LOCALIZATION; BINDING; MUTANTS	Yeast cells choose bud sites on their surface in two distinct spatial patterns: axial for a and alpha-cells and bipolar for a/alpha-cells. We have identified four genes, BUD1-BUD4, necessary for the axial pattern by isolating mutants of alpha-cells that do not exhibit this pattern. Mutations in BUD1 (which is the same as the previously identified gene RSR1) or BUD2 lead to a random budding pattern in all cell types; mutations in BUD3 or BUD4 lead to a bipolar pattern in all cell types. These observations indicate the existence of a basal budding pattern, requiring no BUD products, that is random; BUD1 and BUD2 act on this basal pattern to create the bipolar pattern; the further action of BUD3 and BUD4 leads to the axial pattern. These studies thus identify a set of gene products that directs cell morphogenesis to a genetically programmed site.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, PROGRAM CELL BIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	CHANT, J (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, PROGRAM GENET, SAN FRANCISCO, CA 94143 USA.							ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CHANT J, 1991, CELL, V65; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; FIELD C, 1980, J CELL BIOL, V86, P123, DOI 10.1083/jcb.86.1.123; FINEGOLD AA, 1991, IN PRESS P NATL ACAD; FREIFELDER D, 1960, J BACTERIOL, V80, P567, DOI 10.1128/JB.80.4.567-568.1960; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; Gunning B.E.S., 1982, DEV ORDER ITS ORIGIN, P379; HAARER BK, 1987, MOL CELL BIOL, V7, P3678, DOI 10.1128/MCB.7.10.3678; HAYASHIBE M, 1973, J GEN APPL MICROBIOL, V19, P23, DOI 10.2323/jgam.19.23; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HICKS JB, 1977, GENETICS, V85, P373; HICKS JB, 1976, GENETICS, V83, P245; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; JOHNSON DE, 1991, J CELL BIOL, V113, P339, DOI 10.1083/jcb.113.2.339; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KLAPHOLZ S, 1982, GENETICS, V100, P387; Luria SE, 1943, GENETICS, V28, P491; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RINE J, 1987, GENETICS, V116, P9; ROBERTS RL, 1983, MOL CELL BIOL, V3, P922, DOI 10.1128/MCB.3.5.922; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sherman F., 1982, METHODS YEAST GENETI; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SLOAT BF, 1978, SCIENCE, V200, P1171, DOI 10.1126/science.349694; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; SNYDER M, 1991, IN PRESS J CELL BIOL; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STRATHERN J, 1981, J MOL BIOL, V147, P357, DOI 10.1016/0022-2836(81)90488-5; TKACZ JS, 1972, J GEN MICROBIOL, V72, P243, DOI 10.1099/00221287-72-2-243; TKACZ JS, 1973, J BACTERIOL, V113, P1073, DOI 10.1128/JB.113.2.1073-1075.1973	43	340	343	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1991	65	7					1203	1212		10.1016/0092-8674(91)90015-Q	http://dx.doi.org/10.1016/0092-8674(91)90015-Q			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	2065354				2022-12-01	WOS:A1991FU89900012
J	CHANT, J; CORRADO, K; PRINGLE, JR; HERSKOWITZ, I				CHANT, J; CORRADO, K; PRINGLE, JR; HERSKOWITZ, I			YEAST BUD5, ENCODING A PUTATIVE GDP-GTP EXCHANGE FACTOR, IS NECESSARY FOR BUD SITE SELECTION AND INTERACTS WITH BUD FORMATION GENE BEM1	CELL			English	Article							MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; CDC25 GENE; CELLULAR MORPHOGENESIS; BINDING PROTEINS; WILD-TYPE; RAS; ACTIN; PRODUCT; MUTANTS	Cells of the yeast S. cerevisiae choose bud sites in an axial or bipolar spatial pattern depending on their cell type. We have identified a gene, BUD5, that resembles BUD1 and BUD2 in being required for both patterns; bud5- mutants also exhibit random budding in all cell types. The BUD5 nucleotide sequence predicts a protein of 538 amino acids that has similarity to the S. cerevisiae CDC25 product, an activator of RAS proteins that catalyzes GDP-GTP exchange. Two potential targets of BUD5 are known: BUD1 (RSR1) and CDC42, proteins involved in bud site selection and bud formation, respectively, that have extensive similarity to RAS. We also show that BUD5 interacts functionally with a gene, BEM1, that is required for bud formation. This interaction provides further support for the view that products involved in bud site selection guide the positioning of a complex necessary for bud formation.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, PROGRAM CELL BIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, PROGRAM GENET, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	CHANT, J (corresponding author), UNIV MICHIGAN, DEPT BIOL, ANN ARBOR, MI 48109 USA.				NIGMS NIH HHS [GM31006, GM07544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031006, R01GM031006] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ASTELL CR, 1981, CELL, V27, P15, DOI 10.1016/0092-8674(81)90356-1; BANUETT F, 1987, J BACTERIOL, V169, P4076, DOI 10.1128/jb.169.9.4076-4085.1987; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BENDER A, 1989, GENETICS, V121, P463; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CHANT J, 1991, CELL, V65; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DANIEL J, 1987, MOL CELL BIOL, V7, P3857, DOI 10.1128/MCB.7.10.3857; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; FINEGOLD AA, 1991, IN PRESS P NATL ACAD; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HERSKOWITZ IH, 1965, GENETICS; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; HUTTER KJ, 1978, A VAN LEEUW J MICROB, V44, P269, DOI 10.1007/BF00394305; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LEVITZKI A, 1990, SCIENCE, V248, P794, DOI 10.1126/science.2188357; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; MEEKSWAGNER D, 1986, CELL, V44, P43, DOI 10.1016/0092-8674(86)90483-6; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; Pringle J R, 1975, Methods Cell Biol, V11, P131, DOI 10.1016/S0091-679X(08)60320-9; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1987, METHOD ENZYMOL, V152, P481; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1982, METHODS YEAST GENETI; SLOAT BF, 1978, SCIENCE, V200, P1171, DOI 10.1126/science.349694; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STRATHERN J, 1981, J MOL BIOL, V147, P357, DOI 10.1016/0022-2836(81)90488-5; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WICKNER RB, 1987, YEAST, V3, P51, DOI 10.1002/yea.320030108; WILKINSON LE, 1974, EXP CELL RES, V89, P175, DOI 10.1016/0014-4827(74)90200-6	52	222	225	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1991	65	7					1213	1224		10.1016/0092-8674(91)90016-R	http://dx.doi.org/10.1016/0092-8674(91)90016-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1905981	Green Published			2022-12-01	WOS:A1991FU89900013
J	DOERING, TL; RAPER, J; BUXBAUM, LU; ADAMS, SP; GORDON, JI; HART, GW; ENGLUND, PT				DOERING, TL; RAPER, J; BUXBAUM, LU; ADAMS, SP; GORDON, JI; HART, GW; ENGLUND, PT			AN ANALOG OF MYRISTIC ACID WITH SELECTIVE TOXICITY FOR AFRICAN TRYPANOSOMES	SCIENCE			English	Article							VARIANT SURFACE GLYCOPROTEIN; PHOSPHATIDYLINOSITOL MEMBRANE ANCHORS; GLYCOSYL-PHOSPHATIDYLINOSITOL; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS; BRUCEI; BIOSYNTHESIS; PROTEIN; IDENTIFICATION; PURIFICATION	Trypanosoma brucei, the protozoan parasite responsible for African sleeping sickness, evades the host immune response through the process of antigenic variation. The variant antigen, known as the variant surface glycoprotein (VSG), is anchored to the cell surface by a glycosyl phosphatidylinositol (GPI) structure that contains myristate (n-tetradecanoate) as its only fatty acid component. The utilization of heteroatom-containing analogs of myristate was studied both in a cell-free system and in vivo. Results indicated that the specificity of fatty acid incorporation depends on chain length rather than on hydrophobicity. One analog, 10-(propoxy)decanoic acid, was highly toxic to trypanosomes in culture although it is nontoxic to mammalian cells.	MONSANTO CO,ST LOUIS,MO 64167; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Monsanto; Washington University (WUSTL)	DOERING, TL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21210, USA.			Raper, Jayne/0000-0002-8723-9748; Hart, Gerald/0000-0001-7812-4351	NIAID NIH HHS [AI27179, AI21334] Funding Source: Medline; NIGMS NIH HHS [5T32GM07309] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, R01AI021334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007309] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITMAN C, 1990, TROP DIS RES NEWS, V31, P3; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BRYANT ML, 1991, P NATL ACAD SCI USA, V88, P2055, DOI 10.1073/pnas.88.6.2055; BRYANT ML, 1989, P NATL ACAD SCI USA, V86, P8655, DOI 10.1073/pnas.86.22.8655; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; DIXON H, 1967, T ROY SOC TROP MED H, V61, P12; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOERING TL, 1990, J BIOL CHEM, V265, P611; DOERING TL, UNPUB; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HAJDUK SL, 1989, TROPICAL GEOGRAPHIC, P268; HAMM B, 1990, MOL BIOCHEM PARASIT, V40, P13, DOI 10.1016/0166-6851(90)90075-W; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P8511, DOI 10.1073/pnas.87.21.8511; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MELLORS A, 1989, PARASITOL TODAY, V5, P239, DOI 10.1016/0169-4758(89)90255-X; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; RABEN DM, UNPUB; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001	32	74	76	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1991	252	5014					1851	1854		10.1126/science.1829548	http://dx.doi.org/10.1126/science.1829548			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	1829548				2022-12-01	WOS:A1991FU06100041
J	DORVAL, BC; CARAFA, YD; SIRANDPUGNET, P; GALLEGO, M; BRODY, E; MARIE, J				DORVAL, BC; CARAFA, YD; SIRANDPUGNET, P; GALLEGO, M; BRODY, E; MARIE, J			RNA SECONDARY STRUCTURE REPRESSION OF A MUSCLE-SPECIFIC EXON IN HELA-CELL NUCLEAR EXTRACTS	SCIENCE			English	Article								The chicken beta-tropomyosin pre-messenger RNA (pre-mRNA) is spliced in a tissue-specific manner to yield messenger RNA's (mRNA's) coding for different isoforms of this protein. Exons 6A and 6B are spliced in a mutually exclusive manner; exon 6B was included in skeletal muscle, whereas exon 6A was preferred in all other tissues. The distal portion of the intron upstream of exon 6B was shown to form stable double-stranded regions with part of the intron downstream of exon 6B and with sequences in exon 6B. This structure repressed splicing of exon 6B to exon 7 in a HeLa cell extract. Derepression of splicing occurred on disruption of this structure and repression followed when the structure was re-formed, even if the structure was formed between two different RNA molecules. Repression leads to inhibition of formation of spliceosomes. Disrupting either of the two double-stranded regions could lead to derepression, whereas re-forming the helices by suppressor mutations reestablished repression. These results support a simple model of tissue-specific splicing in this region of the pre-mRNA.			DORVAL, BC (corresponding author), UNIV PARIS 06, CNRS, CTR GENET MOLEC, F-91198 GIF SUR YVETTE, FRANCE.		Gallego, Maria E/F-1044-2011	Gallego, Maria E/0000-0001-5588-9116; SIRAND-PUGNET, Pascal/0000-0003-2613-0762; Clouet-d'Orval, Beatrice/0000-0002-3591-8538				BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; BRODY E, 1989, EVOLUTIONARY TINKERI, P203; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; DORVAL BC, IN PRESS J MOL BIOL; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FU XY, 1988, EMBO J, V7, P809, DOI 10.1002/j.1460-2075.1988.tb02879.x; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; HALL KB, 1988, P NATL ACAD SCI USA, V85, P704, DOI 10.1073/pnas.85.3.704; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; HODGKIN J, 1989, CELL, V56, P905, DOI 10.1016/0092-8674(89)90619-3; KAKIZUKA A, 1990, J BIOL CHEM, V265, P10102; KONARSKA MM, 1989, METHOD ENZYMOL, V180, P442; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LEAR AL, 1990, J MOL BIOL, V211, P103, DOI 10.1016/0022-2836(90)90014-D; LIBRI D, 1989, J BIOL CHEM, V264, P2935; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; LIBRI D, 1989, NUCLEIC ACIDS RES, V17, P6449; MUNROE SH, 1988, EMBO J, V7, P2523, DOI 10.1002/j.1460-2075.1988.tb03100.x; NASIM FH, 1990, GENE DEV, V4, P1172, DOI 10.1101/gad.4.7.1172; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; NOBLE JCS, 1988, GENE DEV, V2, P1460, DOI 10.1101/gad.2.11.1460; PACE NR, 1989, GENE, V82, P65, DOI 10.1016/0378-1119(89)90031-0; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; SAMBOOK J, 1989, MOL CLONING LABORATO; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SKINNER MA, 1989, J MOL BIOL, V207, P379, DOI 10.1016/0022-2836(89)90261-1; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOLNICK D, 1985, CELL, V43, P667, DOI 10.1016/0092-8674(85)90239-9; SOLNICK D, 1987, MOL CELL BIOL, V7, P3194, DOI 10.1128/MCB.7.9.3194; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	46	132	132	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 28	1991	252	5014					1823	1828		10.1126/science.2063195	http://dx.doi.org/10.1126/science.2063195			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	2063195				2022-12-01	WOS:A1991FU06100032
J	HENDERSON, S; ROWE, M; GREGORY, C; CROOMCARTER, D; WANG, F; LONGNECKER, R; KIEFF, E; RICKINSON, A				HENDERSON, S; ROWE, M; GREGORY, C; CROOMCARTER, D; WANG, F; LONGNECKER, R; KIEFF, E; RICKINSON, A			INDUCTION OF BCL-2 EXPRESSION BY EPSTEIN-BARR-VIRUS LATENT MEMBRANE PROTEIN-1 PROTECTS INFECTED B-CELLS FROM PROGRAMMED CELL-DEATH	CELL			English	Article							POSITIVE BURKITTS-LYMPHOMA; ANTIGEN-DRIVEN SELECTION; ENDONUCLEASE ACTIVATION; FOLLICULAR LYMPHOMA; DEREGULATED BCL2; TRANSGENIC MICE; GENE-EXPRESSION; GROWTH; TRANSLOCATION; APOPTOSIS	Epstein-Barr virus (EBV) not only induces growth transformation in human B lymphocytes, but has more recently been shown to enhance B cell survival under suboptimal conditions where growth is inhibited; both effects are mediated through the coordinate action of eight virus-coded latent proteins. The effect upon cell survival is best recognized in EBV-positive Burkitt's lymphoma cell lines where activation of full virus latent gene expression protects the cells from programmed cell death (apoptosis). Here we show by DNA transfection into human B cells that protection from apoptosis is conferred through expression of a single EBV latent protein, the latent membrane protein LMP 1. Furthermore, we demonstrate that LMP 1 mediates this effect by up-regulating expression of the cellular oncogene bcl-2. The interplay between EBV infection and expression of this cellular oncogene has important implications for virus persistence and for the pathogenesis of virus-associated malignant disease.	BRIGHAM & WOMENS HOSP,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital	HENDERSON, S (corresponding author), UNIV BIRMINGHAM,DEPT CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.		Rowe, Martin/B-2880-2009	Rowe, Martin/0000-0003-4139-7326; Hope, Sheila/0000-0002-3608-4379	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], EPSTEIN BARR VIRUS; BAKHSHI A, 1985, CELL, V41, P889; CHEAH MSC, 1986, NATURE, V319, P239; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KIEFF E, 1990, VIROLOGY, P1889; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LONGNECKER R, 1990, J VIROL, V64, P2319, DOI 10.1128/JVI.64.5.2319-2326.1990; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NILSSON K, 1971, INT J CANCER, V8, P443, DOI 10.1002/ijc.2910080312; NUNEZ G, 1990, J IMMUNOL, V144, P3602; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; PEZZELLA F, 1990, AM J PATHOL, V137, P225; REED JC, 1989, ONCOGENE, V4, P1123; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; ROONEY CM, 1986, J NATL CANCER I, V77, P681, DOI 10.1093/jnci/77.3.681; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; ROWE M, 1986, INT J CANCER, V37, P363; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; THORLEYLAWSON DA, 1985, J EXP MED, V162, P45, DOI 10.1084/jem.162.1.45; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAO QY, 1989, INT J CANCER, V43, P67, DOI 10.1002/ijc.2910430115; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	50	1129	1155	0	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1107	1115		10.1016/0092-8674(91)90007-L	http://dx.doi.org/10.1016/0092-8674(91)90007-L			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1648447				2022-12-01	WOS:A1991FU89900004
J	JUSTEMENT, LB; CAMPBELL, KS; CHIEN, NC; CAMBIER, JC				JUSTEMENT, LB; CAMPBELL, KS; CHIEN, NC; CAMBIER, JC			REGULATION OF B-CELL ANTIGEN RECEPTOR SIGNAL TRANSDUCTION AND PHOSPHORYLATION BY CD45	SCIENCE			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; LEUKOCYTE-COMMON ANTIGEN; MURINE LYMPHOCYTES-B; HUMAN T-CELLS; MOLECULAR-COMPONENTS; ACTIVATION; IGM; PHOSPHATASE; ANTIBODIES; T200	CD45 is a member of a family of membrane proteins that possess phosphotyrosine phosphatase activity, and is the source of much of the tyrosine phosphatase activity in lymphocytes. In view of its enzymatic activity and high copy number, it seems likely that CD45 functions in transmembrane signal transduction by lymphocyte receptors that arc coupled to activation of tyrosine kinases. The B cell antigen receptor was found to transduce a Ca2+-mobilizing signal only if cells expressed CD45. Also, both membrane immunoglobulin M (mIgM) and CD45 were lost from the surface of cells treated with antibody to CD45, suggesting a physical interaction between these proteins. Finally, CD45 dephosphorylated a complex of mIg-associated proteins that appears to function in signal transduction by the antigen receptor. These data indicate that CD45 occurs as a component of a complex of proteins associated with the antigen receptor, and that CD45 may regulate signal transduction by modulating the phosphorylation state of the antigen receptor subunits.	UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80206	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Campbell, Kerry S./T-1381-2019	Cambier, John/0000-0002-7803-242X; Justement, Louis/0000-0001-7058-867X	NIAID NIH HHS [AI20519, AI21768] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021768, R01AI020519] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVRAMEAS S, 1979, J IMMUNOL, V122, P648; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P399; CAMBIER JC, 1991, J IMMUNOL, V146, P2075; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, IN PRESS P NATL ACAD; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GRUBER MF, 1989, J IMMUNOL, V142, P4144; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; JOHNSON P, 1989, J EXP MED, V169, P1179, DOI 10.1084/jem.169.3.1179; JUSTEMENT LB, 1990, J IMMUNOL, V144, P3272; JUSTEMENT LB, UNPUB; KIENER PA, 1989, J IMMUNOL, V143, P23; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LANE PJL, 1990, J IMMUNOL, V144, P3684; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; MIRE AR, 1985, BIOCHIM BIOPHYS ACTA, V847, P159, DOI 10.1016/0167-4889(85)90169-7; MITTLER RS, 1987, J IMMUNOL, V138, P3159; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NISHIBE S, 1990, SCIENCE, V250, P153; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.iy.07.040189.002011; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; WADE WF, 1989, P NATL ACAD SCI USA, V86, P6297, DOI 10.1073/pnas.86.16.6297; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	35	308	314	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1991	252	5014					1839	1842		10.1126/science.1648262	http://dx.doi.org/10.1126/science.1648262			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	1648262				2022-12-01	WOS:A1991FU06100037
J	KARESS, RE; CHANG, XJ; EDWARDS, KA; KULKARNI, S; AGUILERA, I; KIEHART, DP				KARESS, RE; CHANG, XJ; EDWARDS, KA; KULKARNI, S; AGUILERA, I; KIEHART, DP			THE REGULATORY LIGHT CHAIN OF NONMUSCLE MYOSIN IS ENCODED BY SPAGHETTI-SQUASH, A GENE REQUIRED FOR CYTOKINESIS IN DROSOPHILA	CELL			English	Article							HEAVY-CHAIN; CELL-CYCLE; CHROMOSOME MOVEMENT; SEQUENCE-ANALYSIS; DICTYOSTELIUM; MELANOGASTER; INVITRO; MUSCLE; ACTIN; DISSECTION	Two independent approaches to understanding the molecular mechanism of cytokinesis have converged on the gene spaghetti-squash (sqh). A genetic screen for mitotic mutants identified sqh1, a mutation that disrupts cytokinesis, which was then cloned by transposon tagging. Independently, the gene that encodes the regulatory light chain of the biochemically defined nonmuscle myosin (MRLC-C) was also cloned. We show here that sqh encodes MRLC-C and that in sqh1 mutants, the level of stable light chain transcript is greatly reduced. Reversion by transposon excision or transformation with a wild-type copy of the sqh transcription unit rescues cytokinesis failure and other defects in sqh1. Vertebrate homologs of MRLC-C are phosphorylatable and regulate myosin activity in vitro. These studies provide genetic proof that MRLC-C is required for cytokinesis, suggest a role for the protein in regulating contractile ring function, and establish a genetic system to evaluate its function.	HARVARD UNIV, DEPT CELLULAR & DEV IMMUNOL, CAMBRIDGE, MA 02138 USA	Harvard University	KARESS, RE (corresponding author), NYU MED CTR, DEPT BIOCHEM, NEW YORK, NY 10016 USA.		Aguilera, Isabel/K-2680-2017; Edwards, Kevin Andrew/GOE-3539-2022	Aguilera, Isabel/0000-0003-2165-4954; Edwards, Kevin Andrew/0000-0003-4721-5626; Karess, Roger/0000-0002-7299-0600	NIGMS NIH HHS [GM33830, GM37979] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033830, R01GM037979] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BAKER BS, 1987, ANEUPLOIDY A; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; CITI S, 1987, BIOESSAYS, V7, P155, DOI 10.1002/bies.950070404; Conrad G. W., 1981, MITOSIS CYTOKINESIS, P365; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Engels W.R, 1989, MOBILE DNA, P437; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIWARA K, 1976, J CELL BIOL, V71, P848, DOI 10.1083/jcb.71.3.848; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; HATZFELD J, 1975, CELL, V5, P123, DOI 10.1016/0092-8674(75)90020-3; KARESS RE, 1989, J CELL BIOL, V109, P2951, DOI 10.1083/jcb.109.6.2951; KETCHUM AS, 1990, P NATL ACAD SCI USA, V87, P6316, DOI 10.1073/pnas.87.16.6316; KIEHART DP, 1982, J CELL BIOL, V94, P165, DOI 10.1083/jcb.94.1.165; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; KIEHART DP, 1986, J CELL BIOL, V103, P1517, DOI 10.1083/jcb.103.4.1517; KIEHART DP, 1989, EMBO J, V8, P913, DOI 10.1002/j.1460-2075.1989.tb03452.x; KIEHART DP, 1990, ANN NY ACAD SCI, V582, P233; KITANISHIYUMURA T, 1989, CELL MOTIL CYTOSKEL, V12, P78, DOI 10.1002/cm.970120203; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1986, DROS INF SERV, V64; LINDSLEY DL, 1985, DROS INF SERV, V62; MABUCHI I, 1986, INT REV CYTOL, V101, P175, DOI 10.1016/S0074-7696(08)60249-1; MABUCHI I, 1977, J CELL BIOL, V74, P251, DOI 10.1083/jcb.74.1.251; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; POLLARD TD, 1990, ANN NY ACAD SCI, V582, P120; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; RIPOLL P, 1987, BIOESSAYS, V7, P204, DOI 10.1002/bies.950070504; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P463; SATTERWHITE L, 1990, ANN NY ACAD SCI, V582, P307; SCHROEDER T, 1989, ANN NY ACAD SCI, V582, P78; SCHROEDER TE, 1973, P NATL ACAD SCI USA, V70, P1688, DOI 10.1073/pnas.70.6.1688; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; Snedecor G.W., 1980, STAT METHODS, V7; SPUDICH JA, 1989, CELL REGUL, V1, P1; SUBBIAH S, 1989, J MOL BIOL, V209, P539, DOI 10.1016/0022-2836(89)90592-5; TRYBUS KM, 1991, CELL MOTIL CYTOSKEL, V18, P81, DOI 10.1002/cm.970180202; UMEMOTO S, 1989, J BIOL CHEM, V264, P1431; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cellbio.3.1.379; YOUNG PE, 1991, DEVELOPMENT, V111, P1; ZAVODNY P, 1988, NUCLEIC ACIDS RES, V16, P214	56	238	240	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1991	65	7					1177	1189		10.1016/0092-8674(91)90013-O	http://dx.doi.org/10.1016/0092-8674(91)90013-O			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1905980				2022-12-01	WOS:A1991FU89900010
J	LIBRI, D; PISERI, A; FISZMAN, MY				LIBRI, D; PISERI, A; FISZMAN, MY			TISSUE-SPECIFIC SPLICING INVIVO OF THE BETA-TROPOMYOSIN GENE - DEPENDENCE ON AN RNA SECONDARY STRUCTURE	SCIENCE			English	Article								The beta-tropomyosin gene in chicken contains two mutually exclusive exons (exons 6A and 6B) which are used by the splicing apparatus in myogenic cells, respectively, before (myoblast stage) and after (myotube stage) differentiation. The myoblast splicing pattern is shown to depend on multiple sequence elements that are located in the upstream intron and in the exon 6B and that exert a negative control over exon 6B splicing. This regulation of splicing is due, at least in part, to a secondary structure of the primary transcript, which limits in vivo the accessibility of exon 6B in myoblasts.	DIPARTIMENTO GENET & BIOL MICROORGANISMI, I-20131 MILAN, ITALY		LIBRI, D (corresponding author), INST PASTEUR, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.							CHEBLI K, 1989, MOL CELL BIOL, V9, P4852, DOI 10.1128/MCB.9.11.4852; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; ERSTER SH, 1988, NUCLEIC ACIDS RES, V16, P5999, DOI 10.1093/nar/16.13.5999; FISZMAN MY, UNPUB; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FU XY, 1987, MOL CELL BIOL, V7, P738, DOI 10.1128/MCB.7.2.738; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEMONNIER M, 1989, NUCLEIC ACIDS RES, V17, P5400, DOI 10.1093/nar/17.13.5400; LIBRI D, 1989, J BIOL CHEM, V264, P2935; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; LIBRI D, 1989, NUCLEIC ACIDS RES, V17, P6449; LIBRI D, UNPUB; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; SOLNICK D, 1985, CELL, V43, P667, DOI 10.1016/0092-8674(85)90239-9; SOLNICK D, 1987, MOL CELL BIOL, V7, P3194, DOI 10.1128/MCB.7.9.3194; WATAKABE A, 1989, NUCLEIC ACIDS RES, V17, P8159, DOI 10.1093/nar/17.20.8159; WILSON WD, 1988, NUCLEIC ACIDS RES, V16, P5137, DOI 10.1093/nar/16.11.5137; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	24	142	143	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 28	1991	252	5014					1842	1845		10.1126/science.2063196	http://dx.doi.org/10.1126/science.2063196			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	2063196				2022-12-01	WOS:A1991FU06100038
J	LINCHAO, S; COHEN, SN				LINCHAO, S; COHEN, SN			THE RATE OF PROCESSING AND DEGRADATION OF ANTISENSE RNAI REGULATES THE REPLICATION OF COIE1-TYPE PLASMIDS INVIVO	CELL			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; PRIMER TRANSCRIPT; RIBONUCLEASE-E; DNA-REPLICATION; COPY-NUMBER; PMB1 REPLICATION; RIBOSOMAL-RNA; GROWTH-RATE; STABILITY	We show that the rate of degradation of RNAI, an antisense repressor of the replication primer RNAII, is a key element of control in the replication of ColE1-type plasmids in vivo. Cleavage of RNAI by RNAase E, a ribosomal RNA-processing enzyme encoded or controlled by the rne (also known as ams) locus, relieves repression by endonucleolytically converting RNAI to a very rapidly decaying product, pRNAl-5. A 5' triphosphate-terminated homolog of pRNAI-5 is degraded slowly and consequently inhibits replication. Nucleotide substitutions within the RNAase E cleavage sequence alter RNAI half-life and plasmid copy number, changing also the incompatibility phenotype. RNAI variants lacking the sequence cleaved by RNAase E are eliminated by growth rate-dependent degradation, resulting in growth-responsive control of plasmid replication and copy number.	STANFORD UNIV, MED CTR, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT MED, STANFORD, CA 94305 USA	Stanford University; Stanford University	LINCHAO, S (corresponding author), ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN.		Lin-Chao, Sue/AAZ-8246-2021; Lin-Chao, Sue/AGI-2030-2022	Lin-Chao, Sue/0000-0002-8415-9304; Lin-Chao, Sue/0000-0002-8415-9304	NIGMS NIH HHS [GM27241] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027241] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BIEK DP, 1986, J BACTERIOL, V167, P594, DOI 10.1128/jb.167.2.594-603.1986; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; CABELLO F, 1976, NATURE, V259, P285, DOI 10.1038/259285a0; CESARENI G, 1985, TRENDS BIOCHEM SCI, V10, P303, DOI 10.1016/0968-0004(85)90168-9; CESARENI G, 1984, EMBO J, V3, P1365, DOI 10.1002/j.1460-2075.1984.tb01978.x; CESARENI G, 1982, P NATL ACAD SCI-BIOL, V79, P6313, DOI 10.1073/pnas.79.20.6313; CHANDA PK, 1985, J BACTERIOL, V161, P446, DOI 10.1128/JB.161.1.446-449.1985; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; DAVISON J, 1984, GENE, V28, P1, DOI 10.1016/0378-1119(84)90082-9; DOOLEY TP, 1985, J MOL BIOL, V186, P87, DOI 10.1016/0022-2836(85)90259-1; ELBLE RC, 1983, MECHANISMS DNA REPLI, P303; FITZWATER T, 1988, EMBO J, V7, P3289, DOI 10.1002/j.1460-2075.1988.tb03196.x; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; JAURIN B, 1982, EMBO J, V1, P875, DOI 10.1002/j.1460-2075.1982.tb01263.x; KADO CI, 1981, J BACTERIOL, V145, P1365, DOI 10.1128/JB.145.3.1365-1373.1981; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUWANO M, 1977, MOL GEN GENET, V154, P279, DOI 10.1007/BF00571283; LACATENA RM, 1981, NATURE, V294, P623, DOI 10.1038/294623a0; LACATENA RM, 1984, CELL, V37, P1009, DOI 10.1016/0092-8674(84)90435-5; LACATENA RM, 1983, J MOL BIOL, V170, P635, DOI 10.1016/S0022-2836(83)80125-9; LINCHAO S, 1986, MOL GEN GENET, V203, P143, DOI 10.1007/BF00330395; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; Maniatis T., 1982, MOL CLONING; MASUKATA H, 1986, CELL, V44, P125, DOI 10.1016/0092-8674(86)90491-5; MASUKATA H, 1984, CELL, V36, P513, DOI 10.1016/0092-8674(84)90244-7; MASUKATA H, 1990, CELL, V62, P331, DOI 10.1016/0092-8674(90)90370-T; MELEFORS O, 1988, CELL, V52, P893, DOI 10.1016/0092-8674(88)90431-X; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORITA M, 1979, EUR J BIOCHEM, V97, P435, DOI 10.1111/j.1432-1033.1979.tb13131.x; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; NILSSON G, 1984, NATURE, V312, P75, DOI 10.1038/312075a0; NUGENT ME, 1986, J GEN MICROBIOL, V132, P1021; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PEDERSEN S, 1978, CELL, V14, P179, DOI 10.1016/0092-8674(78)90312-4; POLISKY B, 1988, CELL, V55, P929, DOI 10.1016/0092-8674(88)90235-8; RAY BK, 1982, EUR J BIOCHEM, V125, P283, DOI 10.1111/j.1432-1033.1982.tb06680.x; RESNEKOV O, 1990, P NATL ACAD SCI USA, V87, P8355, DOI 10.1073/pnas.87.21.8355; ROTH JR, 1970, METHODS ENZYMOL    A, V17, P3; ROY MK, 1983, BIOCHIM BIOPHYS ACTA, V747, P200, DOI 10.1016/0167-4838(83)90098-5; SCOTT JR, 1984, MICROBIOL REV, V48, P1; SELZER G, 1983, CELL, V32, P119, DOI 10.1016/0092-8674(83)90502-0; SIMONS RW, 1988, GENE, V72, P35, DOI 10.1016/0378-1119(88)90125-4; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; SZEBERENYI J, 1983, J MOL BIOL, V168, P525, DOI 10.1016/S0022-2836(83)80300-3; TAMM J, 1985, P NATL ACAD SCI USA, V82, P2257, DOI 10.1073/pnas.82.8.2257; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TOMIZAWA J, 1986, CELL, V47, P89, DOI 10.1016/0092-8674(86)90369-7; TOMIZAWA J, 1985, CELL, V40, P527, DOI 10.1016/0092-8674(85)90201-6; TOMIZAWA J, 1984, CELL, V38, P871, DOI 10.1016/0092-8674(84)90282-4; TOMIZAWA JI, 1981, P NATL ACAD SCI-BIOL, V78, P6096, DOI 10.1073/pnas.78.10.6096; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; WONG EM, 1985, CELL, V42, P959, DOI 10.1016/0092-8674(85)90292-2	60	188	190	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1991	65	7					1233	1242		10.1016/0092-8674(91)90018-T	http://dx.doi.org/10.1016/0092-8674(91)90018-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1712252				2022-12-01	WOS:A1991FU89900015
J	MUDRYJ, M; DEVOTO, SH; HIEBERT, SW; HUNTER, T; PINES, J; NEVINS, JR				MUDRYJ, M; DEVOTO, SH; HIEBERT, SW; HUNTER, T; PINES, J; NEVINS, JR			CELL-CYCLE REGULATION OF THE E2F TRANSCRIPTION FACTOR INVOLVES AN INTERACTION WITH CYCLIN-A	CELL			English	Article							DNA-BINDING ACTIVITY; ADENOVIRUS-INFECTED CELLS; SERUM RESPONSE ELEMENT; C-FOS GENE; TRANS-ACTIVATION; MESSENGER-RNA; E1A PROTEINS; E4 GENE; EXPRESSION; IDENTIFICATION	We have examined E2F binding activity in extracts of synchronized NIH 3T3 cells. During the GO to Gl transition, there is a marked increase in the level of active E2F. Subsequently, there are changes in the nature of E2F-containing complexes. A G1-specific complex increases in abundance, disappears, and is then replaced by another complex as S phase begins. Analysis of extracts of thymidine-blocked cells confirms that the complexes are cell cycle regulated. We also show that the cyclin A protein is a component of the S phase complex. Each complex can be dissociated by the adenovirus E1A 12S product, releasing free E2F. The release of E2F from the cyclin A complex coincides with the stimulation of an E2F-dependent promoter. We suggest that these interactions control the activity of E2F and that disruption of the complexes by E1A contributes to a loss of cellular proliferation control.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037	Salk Institute	MUDRYJ, M (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MICROBIOL & IMMUNOL,GENET SECT,DURHAM,NC 27710, USA.			Pines, Jonathon/0000-0002-5227-6004; Devoto, Stephen/0000-0001-9513-3962	NATIONAL CANCER INSTITUTE [R35CA039780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS008790] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780] Funding Source: Medline; NIGMS NIH HHS [GM26765] Funding Source: Medline; NINDS NIH HHS [NS08790] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABISS LE, 1989, J VIROL, V63, P2709, DOI 10.1128/JVI.63.6.2709-2717.1989; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P43532; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FARNHAM PJ, 1985, J BIOL CHEM, V260, P7675; FELTCHER C, 1987, CELL, V51, P773; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GILMARTIN GM, 1988, GENE DEV, V2, P578, DOI 10.1101/gad.2.5.578; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NAGARAJAN M, 1989, EXP CELL RES, V181, P289, DOI 10.1016/0014-4827(89)90203-6; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; REICHEL R, 1989, J VIROL, V63, P3643, DOI 10.1128/JVI.63.9.3643-3650.1989; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	49	360	371	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1243	1253		10.1016/0092-8674(91)90019-U	http://dx.doi.org/10.1016/0092-8674(91)90019-U			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1829647				2022-12-01	WOS:A1991FU89900016
J	NAAR, AM; BOUTIN, JM; LIPKIN, SM; YU, VC; HOLLOWAY, JM; GLASS, CK; ROSENFELD, MG				NAAR, AM; BOUTIN, JM; LIPKIN, SM; YU, VC; HOLLOWAY, JM; GLASS, CK; ROSENFELD, MG			THE ORIENTATION AND SPACING OF CORE DNA-BINDING MOTIFS DICTATE SELECTIVE TRANSCRIPTIONAL RESPONSES TO 3 NUCLEAR RECEPTORS	CELL			English	Article							THYROID-HORMONE RECEPTOR; RAT GROWTH-HORMONE; RETINOIC ACID RECEPTORS; SUBUNIT GENE PROMOTER; 5' FLANKING REGION; ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; NEGATIVE REGULATION; PITUITARY-CELLS; AMINO-ACIDS	Characterization of several thyroid hormone (T3), retinoic acid, and estrogen response elements has led to the identification of conserved DNA half-sites (core binding motifs). We present evidence that differences in both the relative orientation and spacing of these motifs within hormone response elements determine the distinct transcriptional responses of three members of the nuclear receptor superfamily. When separated by 3 bp, direct repeat, palindromic, and inverted palindromic arrangements of these motifs impart selective transcriptional responses to retinoic acid, estrogen, and T3 receptors, respectively. Varying the spacing between core motifs alters the specificity. Without spacing, a direct repeat of the core motif paradoxically configures the T3 receptor to confer transactivation in the absence of T3 and repression in its presence. Such an element occurs naturally in the mouse beta-thyrotropin promoter, physiologically under negative regulation by T3. The orientation and spacing of core binding motifs may thus function in concert as a code that accounts for the selective patterns of transcriptional responses of hormonally regulated promoters.	UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,MOLEC PATHOL GRP,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,NEUROSCI GRP,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	NAAR, AM (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,EUKARYOT REGULATORY BIOL PROGRAM,LA JOLLA,CA 92093, USA.		Glass, Christopher/AAI-3933-2021; Yu, Victor/A-7899-2015	Glass, Christopher/0000-0003-4344-3592; Yu, Victor/0000-0003-3270-4734				BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CARR FE, 1987, J BIOL CHEM, V262, P981; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HEARING P, 1983, CELL, V33, P695, DOI 10.1016/0092-8674(83)90012-0; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; JONAT G, 1990, CELL, V62, P1189; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MORITA S, 1990, J ENDOCRINOL, V125, P251, DOI 10.1677/joe.0.1250251; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SHUPNIK MA, 1987, ENDOCRINOLOGY, V121, P619, DOI 10.1210/endo-121-2-619; SLATER EP, 1991, MOL ENDOCRINOL, V5, P386, DOI 10.1210/mend-5-3-386; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WATERMAN ML, 1988, MOL ENDOCRINOL, V2, P14, DOI 10.1210/mend-2-1-14; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	53	573	578	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1267	1279		10.1016/0092-8674(91)90021-P	http://dx.doi.org/10.1016/0092-8674(91)90021-P			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1648451				2022-12-01	WOS:A1991FU89900018
J	ORCHINIK, M; MURRAY, TF; MOORE, FL				ORCHINIK, M; MURRAY, TF; MOORE, FL			A CORTICOSTEROID RECEPTOR IN NEURONAL MEMBRANES	SCIENCE			English	Article								Steroids may rapidly alter neuronal function and behavior through poorly characterized, direct actions on neuronal membranes. The membrane-bound receptors mediating these behavioral responses have not been identified. [H-3]Corticosterone labels a population of specific, high-affinity recognition sites (dissociation constant = 0.51 nanomolar) in synaptic membranes from an amphibian brain. These binding sites were localized by receptor autoradiography in the neuropil, outside the regions of perikarya. The affinities of corticoids for this [H-3]corticosterone binding site were linearly related to their potencies in rapidly suppressing male reproductive behavior. Thus, it appears that brain membranes contain a corticosteroid receptor that could participate in the regulation of behavior.	OREGON STATE UNIV, DEPT PHARM, CORVALLIS, OR 97331 USA	Oregon State University	ORCHINIK, M (corresponding author), OREGON STATE UNIV, DEPT ZOOL, CORVALLIS, OR 97331 USA.							BOYD SK, 1990, HORM BEHAV, V24, P128, DOI 10.1016/0018-506X(90)90032-S; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; COZZA EN, 1990, J STEROID BIOCHEM, V35, P511, DOI 10.1016/0022-4731(90)90261-P; DEKLOET ER, 1987, PSYCHONEUROENDOCRINO, V12, P83, DOI 10.1016/0306-4530(87)90040-0; FEYEREISEN R, 1985, COMP BIOCHEM PHYS B, V82, P559, DOI 10.1016/0305-0491(85)90023-9; FUNDER JW, 1987, ANNU REV PHYSIOL, V49, P397; GEE KW, 1987, EUR J PHARMACOL, V136, P419, DOI 10.1016/0014-2999(87)90317-7; GEE KW, 1988, MOL NEUROBIOL, V2, P291, DOI 10.1007/BF02935636; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; HARRISON NL, 1987, J PHARMACOL EXP THER, V241, P346; HUA SY, 1989, ENDOCRINOLOGY, V124, P687, DOI 10.1210/endo-124-2-687; KE FC, 1990, J NEUROCHEM, V54, P467, DOI 10.1111/j.1471-4159.1990.tb01895.x; KELLY MJ, 1977, EXP BRAIN RES, V30, P53; KUBLIGARFIAS C, 1990, HORM BEHAV, V24, P443, DOI 10.1016/0018-506X(90)90033-T; LANGE CB, 1988, GEN COMP ENDOCR, V71, P141; LESHCHENKO MV, 1987, FARMAKOL TOKSIKOL MO, V3, P60; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P60; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MAJEWSKA MD, 1990, BRAIN RES, V526, P143, DOI 10.1016/0006-8993(90)90261-9; MCEWEN BS, 1986, PHYSIOL REV, V66, P1121, DOI 10.1152/physrev.1986.66.4.1121; MEDHI AD, 1984, GEN COMP ENDOCR, V53, P475; MOORE FL, 1990, J EXP ZOOL, P157; MOORE FL, 1984, HORM BEHAV, V18, P400, DOI 10.1016/0018-506X(84)90026-6; MORROW AL, 1990, MOL PHARMACOL, V37, P263; NABEKURA J, 1986, SCIENCE, V233, P226, DOI 10.1126/science.3726531; ORCHINIK M, 1989, Society for Neuroscience Abstracts, V15, P759; PUIA G, 1990, NEURON, V4, P759, DOI 10.1016/0896-6273(90)90202-Q; RIKER WF, 1982, ADRENAL ACTIONS BRAI, P69; SAPHIER D, 1988, BRAIN RES, V453, P183, DOI 10.1016/0006-8993(88)90157-6; SATRE M, 1974, BIOCHEMISTRY-US, V13, P2201, DOI 10.1021/bi00707a029; SCHUMACHER M, 1990, SCIENCE, V13, P359; SMITH SS, 1987, BRAIN RES, V422, P40, DOI 10.1016/0006-8993(87)90538-5; TALLARIDA RJ, 1979, DOSE RESPONSE RELATI, P107; TOWLE AC, 1983, J STEROID BIOCHEM, V18, P135, DOI 10.1016/0022-4731(83)90079-1; TURNER DM, 1989, J PHARMACOL EXP THER, V248, P960; WEILAND GA, 1981, LIFE SCI, V29, P313, DOI 10.1016/0024-3205(81)90324-6; Whittaker VP, 1969, HDB NEUROCHEMISTRY, VII, P327, DOI DOI 10.1007/978-1-4899-7321-4_14; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	38	460	468	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 28	1991	252	5014					1848	1851		10.1126/science.2063198	http://dx.doi.org/10.1126/science.2063198			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	2063198				2022-12-01	WOS:A1991FU06100040
J	PONS, TP; GARRAGHTY, PE; OMMAYA, AK; KAAS, JH; TAUB, E; MISHKIN, M				PONS, TP; GARRAGHTY, PE; OMMAYA, AK; KAAS, JH; TAUB, E; MISHKIN, M			MASSIVE CORTICAL REORGANIZATION AFTER SENSORY DEAFFERENTATION IN ADULT MACAQUES	SCIENCE			English	Article							SOMATOSENSORY CORTEX; OWL MONKEYS; AREA 3B; ORGANIZATION; REPRESENTATIONS; CONNECTIONS; MAMMALS; LESIONS; HAND; BODY	After limited sensory deafferentations in adult primates, somatosensory cortical maps reorganize over a distance of 1 to 2 millimeters mediolaterally, that is, in the dimension along which different body parts are represented. This amount of reorganization was considered to be an upper limit imposed by the size of the projection zones of individual thalamocortical axons, which typically also extend a mediolateral distance of 1 to 2 millimeters. However, after extensive long-term deafferentations in adult primates, changes in cortical maps were found to be an order of magnitude greater than those previously described. These results show the need for a reevaluation of both the upper limit of cortical reorganization in adult primates and the mechanisms responsible for it.	UNIV ALABAMA,DEPT PSYCHOL,BIRMINGHAM,AL 35294; VANDERBILT UNIV,DEPT PSYCHOL,NASHVILLE,TN 37240	University of Alabama System; University of Alabama Birmingham; Vanderbilt University	PONS, TP (corresponding author), NIMH,NEUROPSYCHOL LAB,BLDG 9,ROOM 1N107,BETHESDA,MD 20892, USA.							CONLEY M, 1984, Society for Neuroscience Abstracts, V10, P495; Darian-Smith, 1984, HDB PHYSL 2 1, V3, P789; EL-BOHY A, 1990, Society for Neuroscience Abstracts, V16, P1162; FRIEDMAN DP, 1986, J COMP NEUROL, V252, P323, DOI 10.1002/cne.902520304; GARRAGHTY PE, 1989, SOMATOSENS MOT RES, V6, P401, DOI 10.3109/08990228909144683; GARRAGHTY PE, 1990, J COMP NEUROL, V294, P583, DOI 10.1002/cne.902940406; GARRAGHTY PE, IN PRESS P NATL ACAD; GOLDBERGER ME, 1988, PHYSL BASIS FUNCTION, P361; HEINEN S J, 1988, Investigative Ophthalmology and Visual Science, V29, P23; JONES EG, 1978, J COMP NEUROL, V181, P297; Kaas J.H., 1988, P421; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; KAAS JH, 1983, PHYSIOL REV, V63, P206, DOI 10.1152/physrev.1983.63.1.206; KAAS JH, 1979, SCIENCE, V204, P521, DOI 10.1126/science.107591; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; Killackey H P, 1989, J Cogn Neurosci, V1, P3, DOI 10.1162/jocn.1989.1.1.3; MERZENICH MM, 1983, NEUROSCIENCE, V10, P639, DOI 10.1016/0306-4522(83)90208-7; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; MERZENICH MM, 1982, TRENDS NEUROSCI, V5, P434, DOI 10.1016/0166-2236(82)90235-1; MERZENICH MM, 1988, NEUROBIOLOGY NEOCORT, P41; NELSON RJ, 1980, J COMP NEUROL, V192, P611, DOI 10.1002/cne.901920402; PONS TP, 1986, J COMP NEUROL, V248, P313, DOI 10.1002/cne.902480303; PONS TP, 1985, J COMP NEUROL, V241, P445, DOI 10.1002/cne.902410405; PONS TP, 1987, SOMATOSENS MOT RES, V4, P309, DOI 10.3109/07367228709144612; RHOADES RW, 1987, J NEUROPHYSIOL, V57, P1577, DOI 10.1152/jn.1987.57.5.1577; ROE AW, 1990, SCIENCE, V250, P818, DOI 10.1126/science.2237432; SHERMAN SM, 1982, PHYSIOL REV, V62, P738, DOI 10.1152/physrev.1982.62.2.738; SUR M, 1980, J NEUROPHYSIOL, V44, P295, DOI 10.1152/jn.1980.44.2.295; Taub E., 1980, CLIN APPL, P371; WERNER G, 1968, J NEUROPHYSIOL, V31, P856, DOI 10.1152/jn.1968.31.6.856; WOOLSEY CN, 1942, B J HOPKINS HOSP, V70, P339	31	823	854	1	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1991	252	5014					1857	1860		10.1126/science.1843843	http://dx.doi.org/10.1126/science.1843843			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	1843843				2022-12-01	WOS:A1991FU06100043
J	POWERS, S; GONZALES, E; CHRISTENSEN, T; CUBERT, J; BROEK, D				POWERS, S; GONZALES, E; CHRISTENSEN, T; CUBERT, J; BROEK, D			FUNCTIONAL CLONING OF BUD5, A CDC25-RELATED GENE FROM SACCHAROMYCES-CEREVISIAE THAT CAN SUPPRESS A DOMINANT-NEGATIVE RAS2 MUTANT	CELL			English	Article							DEPENDENT PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; ADENYLATE-CYCLASE; CDC25 GENE; CATALYTIC SUBUNITS; BUDDING YEAST; WILD-TYPE; ACTIVATION; SEQUENCE; DNA	By searching for genes that behave like CDC25 of S. cerevisiae in their ability to counteract a dominant-negative RAS2 mutant in a wild-type RAS-dependent manner, we have isolated a CDC25-like homolog, BUD5. BUD5 is tightly linked to the MAT locus. Although overexpressed BUD5 cannot substitute for CDC25 function, we present evidence that its gene product can bind to the guanine nucleotide binding-deficient RAS2val19ala22 gene product and thereby counteract its dominant-negative effect. We propose that BUD5 is a member of a family of CDC25-related genes that encode activators of RAS and RAS-like proteins.	UNIV SO CALIF,SCH MED,DEPT BIOCHEM,LOS ANGELES,CA 90033	University of Southern California	POWERS, S (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.			Powers, Scott/0000-0003-2769-1932	NCI NIH HHS [CA50261] Funding Source: Medline; NIGMS NIH HHS [GM41258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTELL CR, 1981, CELL, V27, P15, DOI 10.1016/0092-8674(81)90356-1; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; BURNE HR, 1990, NATURE, V348, P125; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CHANT J, 1991, CELL, V65; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DANIEL J, 1987, MOL CELL BIOL, V7, P3857, DOI 10.1128/MCB.7.10.3857; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON KE, 1987, J BIOL CHEM, V262, P8636; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MARTEGANI E, 1984, EUR J BIOCHEM, V144, P205, DOI 10.1111/j.1432-1033.1984.tb08450.x; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TODA T, 1988, GENE DEV, V2, P517, DOI 10.1101/gad.2.5.517; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WEST M, 1990, FEBS LETT, V259, P2465; WICKNER RB, 1987, YEAST, V3, P51, DOI 10.1002/yea.320030108; WIGLER M, 1988, COLD SPRING HARB SYM, V53, P649, DOI 10.1101/SQB.1988.053.01.074; WIGLER MH, 1990, NATURE, V346, P696, DOI 10.1038/346696a0	29	93	95	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1225	1231		10.1016/0092-8674(91)90017-S	http://dx.doi.org/10.1016/0092-8674(91)90017-S			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1905982				2022-12-01	WOS:A1991FU89900014
J	SCHENKMAN, S; JIANG, MS; HART, GW; NUSSENZWEIG, V				SCHENKMAN, S; JIANG, MS; HART, GW; NUSSENZWEIG, V			A NOVEL CELL-SURFACE TRANS-SIALIDASE OF TRYPANOSOMA-CRUZI GENERATES A STAGE-SPECIFIC EPITOPE REQUIRED FOR INVASION OF MAMMALIAN-CELLS	CELL			English	Article							ALTERNATIVE COMPLEMENT PATHWAY; MONOCLONAL-ANTIBODIES; SIALYL-LEX; ACID; ADHESION; TRYPOMASTIGOTES; NEURAMINIDASE; RECOGNITION; FORMS; GLYCOSYLTRANSFERASES	When trypomastigotes of T. cruzi emerge from cells of the mammalian host, they contain little or no sialic acids on their surfaces. However, rapidly upon entering the circulation, they express a unique cell surface trans-sialidase activity. This enzyme specifically transfers alpha(2-3)-linked sialic acid from extrinsic host-derived macromolecules to parasite surface molecules, leading to the assembly of Ssp-3, a trypomastigote-specific epitope. The T. cruzi trans-sialidase does not utilize cytidine 5' monophospho-N-acetylneuraminic acid as a donor substrate, but readily transfers sialic acid from exogenously supplied alpha(2-3)-sialyllactose. Monoclonal antibodies that recognize sialic acid residues of Ssp-3 inhibit attachment of trypomastigotes to host cells, suggesting that the unusual trans-sialidase provides Ssp-3 with structural features required for target cell recognition.	NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; JOHNS HOPKINS UNIV,DEPT BIOL CHEM,BALTIMORE,MD 21218	New York University; Johns Hopkins University	SCHENKMAN, S (corresponding author), NYU MED CTR,DEPT PATHOL,NEW YORK,NY 10016, USA.		Schenkman, Sergio/A-9227-2013	Schenkman, Sergio/0000-0001-9353-8480; Hart, Gerald/0000-0001-7812-4351	NATIONAL CANCER INSTITUTE [R01CA042486] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42486] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABUIN G, 1989, MOL BIOCHEM PARASIT, V35, P229, DOI 10.1016/0166-6851(89)90209-0; ANDREWS NW, 1987, EXP PARASITOL, V64, P474, DOI 10.1016/0014-4894(87)90062-2; BOSCHETTI MA, 1987, MOL BIOCHEM PARASIT, V24, P175, DOI 10.1016/0166-6851(87)90104-6; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CROWELL RL, 1986, VIRAL ATTACHMENT ENT; DEARAUJOJORGE TC, 1989, MEM I OSWALDO CRUZ, V84, P441, DOI 10.1590/S0074-02761989000400001; DEARRUDA MV, 1989, EUR J BIOCHEM, V182, P413, DOI 10.1111/j.1432-1033.1989.tb14847.x; DESOUZA W, 1984, INT REV CYTOL, V86, P197, DOI 10.1016/S0074-7696(08)60180-1; DETITTO EH, 1987, ACTA TROP, V44, P273; EDWARDS MS, 1982, J IMMUNOL, V128, P1278; HADLEY LH, 1987, ANNU REV MICROBIOL, V40, P415; HARTH G, 1987, P NATL ACAD SCI USA, V84, P8320, DOI 10.1073/pnas.84.23.8320; JARVIS GA, 1987, INFECT IMMUN, V55, P174, DOI 10.1128/IAI.55.1.174-180.1987; KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75; KIPNIS TL, 1981, P NATL ACAD SCI-BIOL, V78, P602, DOI 10.1073/pnas.78.1.602; Kirchhoff L. V., 1990, Principles and practice of infectious diseases., P2077; LEY V, 1988, J EXP MED, V168, P649, DOI 10.1084/jem.168.2.649; Marsden P. D., 1988, The biology of parasitism. A molecular and immunological approach., P77; NAIRN CA, 1988, J GEN MICROBIOL, V134, P3295; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OUAISSI MA, 1986, SCIENCE, V234, P603, DOI 10.1126/science.3094145; PASSANITI A, 1988, J BIOL CHEM, V263, P7591; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEREIRA MEA, 1983, SCIENCE, V219, P1444, DOI 10.1126/science.6338592; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PIRAS MM, 1987, MOL BIOCHEM PARASIT, V22, P135, DOI 10.1016/0166-6851(87)90043-0; POWELL LD, 1986, ANAL BIOCHEM, V157, P179, DOI 10.1016/0003-2697(86)90211-3; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; PRIOLI RP, 1990, J IMMUNOL, V144, P4384; RIMOLDI MT, 1989, J CLIN INVEST, V84, P1982, DOI 10.1172/JCI114388; ROBERTS DD, 1989, J BIOL CHEM, V264, P9289; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; ROTH S, 1971, J CELL BIOL, V51, P536, DOI 10.1083/jcb.51.2.536; RUNYAN RB, 1986, J CELL BIOL, V102, P432, DOI 10.1083/jcb.102.2.432; SCHAUER R, 1983, H-S Z PHYSIOL CHEM, V364, P1053, DOI 10.1515/bchm2.1983.364.2.1053; SCHENKMAN S, 1988, CELL, V55, P157, DOI 10.1016/0092-8674(88)90018-9; SCHENKMAN S, 1991, EXP PARASITOL, V72, P76, DOI 10.1016/0014-4894(91)90123-E; SCHENKMAN S, 1991, INFECT IMMUN, V59, P645, DOI 10.1128/IAI.59.2.645-654.1991; Silva LHP, 1953, FOLIA CLIN BIOL, V20, P191; TEIXEIRA MMG, 1986, MOL BIOCHEM PARASIT, V18, P271, DOI 10.1016/0166-6851(86)90085-X; VEH RW, 1981, J CHROMATOGR, V212, P313, DOI 10.1016/S0021-9673(01)84044-9; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WASSARMAN PM, 1987, ANNU REV CELL BIOL, V3, P109, DOI 10.1146/annurev.cellbio.3.1.109; YOSHIDA N, 1989, INFECT IMMUN, V57, P1663, DOI 10.1128/IAI.57.6.1663-1667.1989; ZINGALES B, 1985, CURR TOP MICROBIOL, V117, P129; ZINGALES B, 1987, MOL BIOCHEM PARASIT, V26, P135, DOI 10.1016/0166-6851(87)90137-X	46	385	393	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1117	1125		10.1016/0092-8674(91)90008-M	http://dx.doi.org/10.1016/0092-8674(91)90008-M			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1712251				2022-12-01	WOS:A1991FU89900005
J	SCHWARTZBERG, PL; STALL, AM; HARDIN, JD; BOWDISH, KS; HUMARAN, T; BOAST, S; HARBISON, ML; ROBERTSON, EJ; GOFF, SP				SCHWARTZBERG, PL; STALL, AM; HARDIN, JD; BOWDISH, KS; HUMARAN, T; BOAST, S; HARBISON, ML; ROBERTSON, EJ; GOFF, SP			MICE HOMOZYGOUS FOR THE ABLM1 MUTATION SHOW POOR VIABILITY AND DEPLETION OF SELECTED B-CELL AND T-CELL POPULATIONS	CELL			English	Article							MURINE LEUKEMIA-VIRUS; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM-CELLS; TARGETED GENE DISRUPTION; C-ABL; HOMOLOGOUS RECOMBINATION; PHILADELPHIA-CHROMOSOME; DIFFERENTIAL EXPRESSION; KINASE-ACTIVITY	The c-abl gene, originally identified as the cellular homolog of the transforming gene of the Abelson murine leukemia virus, encodes a protein-tyrosine kinase of unknown function that is expressed in all mammalian tissues. We have previously described the introduction of a mutation in the c-abl gene into the mouse germline via targeted gene disruption of embryonic stem cells. We now show that mice homozygous for this mutation are severely affected, displaying increased perinatal mortality, runtedness, and abnormal spleen, head, and eye development. We have examined components of the immune system and have found major reductions in B cell progenitors in the adult bone marrow, with less dramatic reductions in developing T cell compartments.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MICROBIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA; HOFFMANN LA ROCHE INC, DEPT TOXICOL & PATHOL, NUTLEY, NJ 07110 USA	Columbia University; Columbia University; Roche Holding	SCHWARTZBERG, PL (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.				NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA23767] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1970, CANCER RES, V30, P2213; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOULTER CA, 1988, EXP CELL RES, V179, P214, DOI 10.1016/0014-4827(88)90360-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; GERSHWIN ME, 1975, CLIN IMMUNOL IMMUNOP, V4, P324, DOI 10.1016/0090-1229(75)90002-1; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HARDY RR, 1984, J EXP MED, V159, P1169, DOI 10.1084/jem.159.4.1169; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; Hogan B., 1986, MANIPULATING MOUSE E; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KINCADE PW, 1989, ANNU REV IMMUNOL, V7, P111, DOI 10.1146/annurev.iy.07.040189.000551; KINCADE PW, 1981, J IMMUNOL METHODS, V13, P215; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LANE PW, 1968, J HERED, V59, P300, DOI 10.1093/oxfordjournals.jhered.a107725; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; MACKENSEN JUDITH A., 1960, JOUR HEREDITY, V51, P188; Maniatis T., 1982, MOL CLONING; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MELCHERS F, 1975, TRANSPLANT REV, V25, P26; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NISHIKAWA SI, 1988, EUR J IMMUNOL, V18, P1767, DOI 10.1002/eji.1830181117; PARKS DR, 1986, HDB EXPT IMMUNOLOGY; PEI YF, 1970, ANAT REC, V168, P105, DOI 10.1002/ar.1091680109; PONZETTO C, 1989, ONCOGENE, V4, P685; PREMKUMAR E, 1975, CELL, V6, P149, DOI 10.1016/0092-8674(75)90005-7; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHWARTZBERG PL, 1990, P NATL ACAD SCI USA, V87, P3210, DOI 10.1073/pnas.87.8.3210; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; SEFTON BM, 1981, P NATL ACAD SCI-BIOL, V78, P1552, DOI 10.1073/pnas.78.3.1552; SIDEN EJ, 1979, CELL, V16, P389, DOI 10.1016/0092-8674(79)90014-X; SIRACUSA LD, 1990, GENOMICS, V6, P491, DOI 10.1016/0888-7543(90)90479-E; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; STEIN KF, 1967, DEV BIOL, V16, P315, DOI 10.1016/0012-1606(67)90045-0; Strickberger MW., 1976, GENETICS; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WILDE DB, 1983, J IMMUNOL, V131, P2178; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0	61	313	322	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1991	65	7					1165	1175		10.1016/0092-8674(91)90012-N	http://dx.doi.org/10.1016/0092-8674(91)90012-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	2065353				2022-12-01	WOS:A1991FU89900009
J	THISSE, C; PERRINSCHMITT, F; STOETZEL, C; THISSE, B				THISSE, C; PERRINSCHMITT, F; STOETZEL, C; THISSE, B			SEQUENCE-SPECIFIC TRANSACTIVATION OF THE DROSOPHILA TWIST GENE BY THE DORSAL GENE-PRODUCT	CELL			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; VENTRAL POLARITY; BICOID PROTEIN; NUCLEAR-LOCALIZATION; DORSOVENTRAL PATTERN; REL ONCOGENE; EMBRYO; CELLS; EXPRESSION	The maternal gene dorsal encodes a nuclear protein acting as a morphogen that determines the size and fate of regions along the dorsal-ventral axis of the Drosophila embryo. From previous genetic and biochemical studies it was hypothesized that dorsal might be responsible for the activation of the zygotic gene twist. In this report, regulatory sequences required for correct spatial and quantitative expression of twist are defined, by using phenotypic rescue and studying twist-beta-galactosidase expression. In addition, by transient cotransfection assays, we show that the dorsal protein specifically activates expression from the twist promoter. We demonstrate that dorsal is a sequence-specific DNA-binding protein that recognizes a motif similar to that recognized by the mammalian transcriptional activator NF-kappa-B.			THISSE, C (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM,U184, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE.			THISSE, Christine/0000-0002-8684-1681				ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; BOUROUIS M, 1983, EMBO J, V2, P1099, DOI 10.1002/j.1460-2075.1983.tb01552.x; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELMESSAL M, 1987, THESIS U L PASTEUR S; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IP YT, 1991, CELL, V64, P439; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEPTIN M, 1990, DEVELOPMENT, V110, P73; LEVINE M, 1988, CELL, V52, P785, DOI 10.1016/0092-8674(88)90418-7; LIN HC, 1985, ANAL BIOCHEM, V147, P114, DOI 10.1016/0003-2697(85)90016-8; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MARTIN M, 1988, J INSECT PHYSIOL, V34, P691, DOI 10.1016/0022-1910(88)90079-0; N?sslein-Volhard C., 1979, DETERMINANTS SPATIAL, P185; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1989, CIBA F SYMP, V144, P37; RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW C, 1987, NATURE, V330, P583, DOI 10.1038/330583a0; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTAMARIA P, 1983, EMBO J, V2, P1695, DOI 10.1002/j.1460-2075.1983.tb01644.x; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SCHUPBACH T, 1986, DEV BIOL, V113, P443, DOI 10.1016/0012-1606(86)90179-X; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIMPSON P, 1983, GENETICS, V105, P615; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STEWARD R, 1984, NATURE, V311, P262, DOI 10.1038/311262a0; STEWARD R, 1985, COLD SPRING HARB SYM, V50, P223, DOI 10.1101/SQB.1985.050.01.028; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; VAUGHN JL, 1986, TCA MANUAL, V3, P527; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9	55	214	215	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1991	65	7					1191	1201		10.1016/0092-8674(91)90014-P	http://dx.doi.org/10.1016/0092-8674(91)90014-P			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1648449				2022-12-01	WOS:A1991FU89900011
J	TYBULEWICZ, VLJ; CRAWFORD, CE; JACKSON, PK; BRONSON, RT; MULLIGAN, RC				TYBULEWICZ, VLJ; CRAWFORD, CE; JACKSON, PK; BRONSON, RT; MULLIGAN, RC			NEONATAL LETHALITY AND LYMPHOPENIA IN MICE WITH A HOMOZYGOUS DISRUPTION OF THE C-ABL PROTOONCOGENE	CELL			English	Article							GERM-LINE TRANSMISSION; TYROSINE KINASE; STEM-CELLS; DIFFERENTIAL EXPRESSION; NUCLEOTIDE-SEQUENCE; CATALYTIC DOMAINS; PHOSPHOLIPASE-C; MESSENGER-RNAS; MOUSE; GENE	The c-abl proto-oncogene, which encodes a cytoplasmic protein-tyrosine kinase, is expressed throughout murine gestation and ubiquitously in adult mouse tissues. However, its levels are highest in thymus, spleen, and testes. To examine the in vivo role of c-abl, the gene was disrupted in embryonic stem cells, and the resulting genetically modified cells were used to establish a mouse strain carrying the mutation. Most mice homozygous for the c-abl mutation became runted and died 1 to 2 weeks after birth. In addition, many showed thymic and splenic atrophy and a T and B cell lymphopenia.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; TUFTS UNIV,SCH VET MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111	Massachusetts Institute of Technology (MIT); Tufts University; Tufts University	TYBULEWICZ, VLJ (corresponding author), MIT,WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02139, USA.		Esguerra, Camila/D-7657-2014	Esguerra, Camila/0000-0001-7891-1427; Jackson, Peter/0000-0002-1742-2539	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037569] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37569] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ARRUSHDI A, 1988, ONCOGENE, V2, P353; BARTRAM CR, 1985, EMBO J, V4, P683, DOI 10.1002/j.1460-2075.1985.tb03683.x; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNARDS A, 1988, ONCOGENE, V2, P297; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PAWSON T, 1988, ONCOGENE, V3, P491; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SHTIVELMAN E, 1986, CELL, V47, P227; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773	39	1194	1248	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1153	1163		10.1016/0092-8674(91)90011-M	http://dx.doi.org/10.1016/0092-8674(91)90011-M			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	2065352				2022-12-01	WOS:A1991FU89900008
J	UMESONO, K; MURAKAMI, KK; THOMPSON, CC; EVANS, RM				UMESONO, K; MURAKAMI, KK; THOMPSON, CC; EVANS, RM			DIRECT REPEATS AS SELECTIVE RESPONSE ELEMENTS FOR THE THYROID-HORMONE, RETINOIC ACID, AND VITAMIN-D3 RECEPTORS	CELL			English	Article							DNA-BINDING DOMAIN; HUMAN OSTEOCALCIN GENE; GLUCOCORTICOID RECEPTOR; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; NEGATIVE REGULATION; PROMOTER ELEMENTS; ESTROGEN-RECEPTOR; TRANS-ACTIVATION; NUCLEAR-PROTEIN; AMINO-ACIDS	We report here the identification of thyroid hormone response elements (TREs) that consist of a direct repeat, not a palindrome, of the half-sites. Unlike palindromic TREs, direct repeat TREs do not confer a retinoic acid response. The tandem TRE can be converted into a retinoic acid response element by increasing the spacing between the half-sites by 1 nucleotide, and the resulting retinoic acid response element is no longer a TRE. Decreasing the half-site spacing by 1 nucleotide converts the TRE to a vitamin D3 response element, while eliminating response to T3. These results correlate well with DNA-binding affinities of the thyroid hormone, retinoic acid, and vitamin D3 receptors. This study points to the general importance of tandem repeat hormone response elements and suggests a simple physiologic code exists in which half-site spacing plays a critical role in achieving selective hormonal response.			UMESONO, K (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,GENE EXPRESS LAB,POB 85800,SAN DIEGO,CA 92186, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CRONE DE, 1990, J BIOL CHEM, V265, P10851; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GREEN S, 1988, TRENDS GENET, V249, P157; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; HU MCT, 1986, MOL CELL BIOL, V6, P15, DOI 10.1128/MCB.6.1.15; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKOSE ER, 1990, P NATL ACAD SCI USA, V87, P1701, DOI 10.1073/pnas.87.5.1701; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; MUNOZCANOVES P, 1990, J BIOL CHEM, V265, P20065; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OZONO K, 1991, IN PRESS J BIOL CHEM; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TRASK RV, 1988, J BIOL CHEM, V263, P17142; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WEINBERGER C, 1990, ANNU REV PHYSIOL, V52, P823; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	72	1613	1654	0	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1255	1266		10.1016/0092-8674(91)90020-Y	http://dx.doi.org/10.1016/0092-8674(91)90020-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1648450	Green Accepted			2022-12-01	WOS:A1991FU89900017
J	WILSON, C; WARDELL, MR; WEISGRABER, KH; MAHLEY, RW; AGARD, DA				WILSON, C; WARDELL, MR; WEISGRABER, KH; MAHLEY, RW; AGARD, DA			3-DIMENSIONAL STRUCTURE OF THE LDL RECEPTOR-BINDING DOMAIN OF HUMAN APOLIPOPROTEIN-E	SCIENCE			English	Article							CYSTEINE-ARGININE INTERCHANGE; HUMAN-PLASMA-LIPOPROTEINS; E APOPROTEIN; AQUEOUS-SOLUTION; LEUCINE ZIPPER; TAU-PROTEIN; SITE; EVOLUTION; FIBROBLASTS; REFINEMENT	Human apolipoprotein E, a blood plasma protein, mediates the transport and uptake of cholesterol and lipid by way of its high affinity interaction with different cellular receptors, including the low-density lipoprotein (LDL) receptor. The three-dimensional structure of the LDL receptor-binding domain of apoE has been determined at 2.5 angstrom resolution by x-ray crystallography. The protein forms an unusually elongated (65 angstroms) four-helix bundle, with the helices apparently stabilized by a tightly packed hydrophobic core that includes leucine zipper-type interactions and by numerous salt bridges on the mostly charged surface. Basic amino acids important for LDL receptor binding are clustered into a surface patch on one long helix. This structure provides the basis for understanding the behavior of naturally occurring mutants that can lead to atherosclerosis.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,GRAD GRP BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,CARDIOVASC RES INST,GLADSTONE FDN LABS CARDIOVASC DIS,SAN FRANCISCO,CA 94140; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J MOL BIOL, V202, P179, DOI 10.1016/0022-2836(88)90531-1; AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BOGUSKI MS, 1986, J LIPID RES, V27, P1011; BOGUSKI MS, 1986, J BIOL CHEM, V261, P6398; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; BRUNGER AT, 1987, SCIENCE, V235, P4558; CROWTHER RA, 1971, MOL REPLACEMENT METH; DAS HK, 1985, J BIOL CHEM, V260, P6240; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; GIANTURCO SH, 1983, J BIOL CHEM, V258, P4526; GILSON MK, 1987, NATURE, V330, P84, DOI 10.1038/330084a0; GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645; HOPE H, 1990, ANNU REV BIOPHYS BIO, V19, P197; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1984, J BIOL CHEM, V259, P7261; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; KANOST MR, 1988, J BIOL CHEM, V263, P10568; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KUNDROT CE, 1988, PROTEINS, V3, P71; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LUO CC, 1986, J MOL BIOL, V187, P325, DOI 10.1016/0022-2836(86)90436-5; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MANN WA, 1989, BIOCHIM BIOPHYS ACTA, V1005, P239, DOI 10.1016/0005-2760(89)90043-X; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; POWNALL HJ, 1982, BIOPHYS J, V37, P175, DOI 10.1016/S0006-3495(82)84658-4; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SPARROW JT, 1985, BIOCHEMISTRY-US, V24, P6984, DOI 10.1021/bi00345a035; SUSSMAN JL, 1985, METHOD ENZYMOL, V115, P271; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, UNPUB; WETTERAU J, UNPUB; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0	45	630	644	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1991	252	5014					1817	1822		10.1126/science.2063194	http://dx.doi.org/10.1126/science.2063194			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	2063194				2022-12-01	WOS:A1991FU06100031
J	BEZPROZVANNY, I; WATRAS, J; EHRLICH, BE				BEZPROZVANNY, I; WATRAS, J; EHRLICH, BE			BELL-SHAPED CALCIUM-RESPONSE CURVES OF INS(1,4,5)P3-GATED AND CALCIUM-GATED CHANNELS FROM ENDOPLASMIC-RETICULUM OF CEREBELLUM	NATURE			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; MUSCLE SARCOPLASMIC-RETICULUM; PANCREATIC ACINAR-CELLS; SMOOTH-MUSCLE; TRISPHOSPHATE RECEPTOR; SINGLE CHANNEL; ADENINE-NUCLEOTIDES; RELEASE CHANNEL; SKELETAL-MUSCLE; CA-2+ RELEASE	RELEASE of calcium from intracellular stores occurs by two pathways, an inositol 1,4,5-trisphosphate (InsP3)-gated channel 1-3 and a calcium-gated channel (ryanodine receptor) 4-6. Using specific antibodies, both receptors were found in Purkinje cells of cerebellum 7,8. We have now Compared the functional properties of the channels corresponding to the two receptors by incorporating endoplasmic reticulum vesicles from canine cerebellum into planar bilayers. InsP3-gated channels were observed most frequently. Another channel type was activated by adenine nucleotides or caffeine, inhibited by ruthenium red, and modified by ryanodine, characteristics of the ryanodine receptor/channel 6. The open probability of both channel types displayed a bell-shaped curve for dependence on calcium. For the InsP3-gated channel, the maximum probability of opening occurred at 0.2-mu-M free calcium, with sharp decreases on either side of the maximum. Maximum activity for the ryanodine receptor/channel was maintained between 1 and 100-mu-M calcium. Thus, within the physiological range of cytoplasmic calcium, the InsP3-gated channel itself allows positive feedback and then negative feedback for calcium release, whereas the ryanodine receptor/channel behaves solely as a calcium-activated channel. The existence in the same cell of two channels with different responses to calcium and different ligand sensitivities provides a basis for complex patterns of intracellular calcium regulation.	UNIV CONNECTICUT, CTR HLTH, DEPT MED, FARMINGTON, CT 06032 USA; UNIV CONNECTICUT, CTR HLTH, DEPT PHYSIOL, FARMINGTON, CT 06032 USA; ACAD SCI USSR, INST CYTOL, LENINGRAD 194064, USSR	University of Connecticut; University of Connecticut; Russian Academy of Sciences			Oka, Yoshitaka/C-9670-2010; /AAX-8408-2021	Oka, Yoshitaka/0000-0002-3482-3051; /0000-0001-9657-9704				AIREY JA, 1990, J BIOL CHEM, V265, P14187; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BORGATTA L, 1991, P NATL ACAD SCI USA, V88, P2486, DOI 10.1073/pnas.88.6.2486; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HARTOONIAN AT, 1991, SCIENCE, V251, P75; HERRMANNFRANK A, 1990, BIOPHYS J, V57, pA156; HINGORANI S R, 1990, Society for Neuroscience Abstracts, V16, P1018; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; ORELLANA S, 1987, J BIOL CHEM, V262, P1638; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; SHOSHANBARMATZ V, 1990, BIOCHEM J, V268, P699, DOI 10.1042/bj2680699; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; VARNEY MA, 1990, BIOCHEM J, V269, P211, DOI 10.1042/bj2690211; VOLPE P, 1990, AM J PHYSIOL, V258, pC1077, DOI 10.1152/ajpcell.1990.258.6.C1077; WATRAS J, 1987, BIOCHIM BIOPHYS ACTA, V931, P354, DOI 10.1016/0167-4889(87)90227-8; WATRAS J, IN PRESS J NEUROSCI; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	35	1537	1560	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 27	1991	351	6329					751	754		10.1038/351751a0	http://dx.doi.org/10.1038/351751a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1648178				2022-12-01	WOS:A1991FU20100066
J	DIRICK, L; NASMYTH, K				DIRICK, L; NASMYTH, K			POSITIVE FEEDBACK IN THE ACTIVATION OF G1 CYCLINS IN YEAST	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; HO GENE; MATING-PHEROMONE; CELL; ARREST; SIZE	YEAST cells become committed to the mitotic cell cycle at a stage during G1 called Start 1. To enter Start, cells must grow to a critical size. They also require the CDC28 protein kinase and at least one of three G1-specific cyclins encoded by CLN1, 2, and 3 (refs 2-4). It is thought that Start is triggered by the accumulation of G1 cyclins that bind to the CDC28 kinase and activate it. So what determines the accumulation of G1 cyclins? For CLN1 and CLN2, transcriptional activation could be involved because their RNAs appear transiently during the cell cycle as cells undergo Start 5. Here we report that the appearance of CLN1 and CLN2 RNAs depends on an active CDC28 kinase and is stimulated by CLN3 activity. We propose that CDC28 kinase activity due to CLN1 and CLN2 proteins arises through a positive feedback loop which allows CLN proteins to promote their own synthesis.			DIRICK, L (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nasmyth, Kim/0000-0001-7030-4403				ANDREWS BJ, 1989, NATURE, V342, P803; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; NASMYTH KA, IN PRESS CELL; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	19	173	176	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					754	757		10.1038/351754a0	http://dx.doi.org/10.1038/351754a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1829507				2022-12-01	WOS:A1991FU20100067
J	EGEBJERG, J; BETTLER, B; HERMANSBORGMEYER, I; HEINEMANN, S				EGEBJERG, J; BETTLER, B; HERMANSBORGMEYER, I; HEINEMANN, S			CLONING OF A CDNA FOR A GLUTAMATE RECEPTOR SUBUNIT ACTIVATED BY KAINATE BUT NOT AMPA	NATURE			English	Article							AMINO-ACID RECEPTORS; FUNCTIONAL EXPRESSION; XENOPUS-OOCYTES; KAINIC ACID; NERVOUS-SYSTEM; BINDING-SITES; PHARMACOLOGY; QUISQUALATE; FAMILY; SEQUENCE	FAST excitatory transmission in the vertebrate central nervous system is mediated mainly by L-glutamate. On the basis of pharmacological, physiological and agonist binding properties, the ionotropic glutamate receptors are classified into NMDA (N-methyl-D-aspartate), AMPA (alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionate) and kainate subtypes 1. Sequence homology between complementary DNA clones encoding non-NMDA glutamate receptor subunits reveals at least two subunit classes: the GluR1 to GluR4 class 2-6 and the GluR5 class 7. Here we report the cloning and expression of a functional rat glutamate receptor subunit cDNA, GluR6, which has a very different pharmacology from that of the GluR1-GluR4 class. Receptors generated from the GluR1-GluR4 class have a higher apparent affinity for AMPA than for kainate 3-6. When expressed in Xenopus oocytes the homomeric GluR6 receptor is activated by kainate, quisqualate and L-glutamate but not by AMPA, and the apparent affinity for kainate is higher than for receptors from the GluR1-GluR4 class. Desensitization of the receptor was observed with continuous application of agonist. The homomeric GluR6 glutamate receptor exhibits an outwardly rectifying current-voltage relationship. In situ hybridizations reveal a pattern of GluR6 gene expression reminiscent of the binding pattern obtained with [H-3]kainate.			EGEBJERG, J (corresponding author), SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA.		bettler, bernhard/AAO-8018-2020	Bettler, Bernhard/0000-0003-0842-8207				BENARI Y, 1988, J PHYSIOL-LONDON, V404, P365, DOI 10.1113/jphysiol.1988.sp017294; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DAWSON TL, 1990, MOL PHARMACOL, V38, P779; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FOSTER AC, 1984, BRAIN RES REV, V7, P103, DOI 10.1016/0165-0173(84)90020-1; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; MEYER ML, 1989, P NATL ACAD SCI USA, V86, P1411; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONAGHAN DT, 1982, BRAIN RES, V252, P91, DOI 10.1016/0006-8993(82)90981-7; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; ROBINSON JH, 1981, BRAIN RES, V221, P117, DOI 10.1016/0006-8993(81)91067-2; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; VERDOORN TA, 1988, MOL PHARMACOL, V34, P298; VERDOORN TA, 1989, MOL PHARMACOL, V35, P360; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0	22	581	593	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					745	748		10.1038/351745a0	http://dx.doi.org/10.1038/351745a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1648177				2022-12-01	WOS:A1991FU20100064
J	ISSARTEL, JP; KORONAKIS, V; HUGHES, C				ISSARTEL, JP; KORONAKIS, V; HUGHES, C			ACTIVATION OF ESCHERICHIA-COLI PROHAEMOLYSIN TO THE MATURE TOXIN BY ACYL CARRIER PROTEIN-DEPENDENT FATTY ACYLATION	NATURE			English	Article							MULTIDRUG RESISTANCE; BACTERIAL TRANSPORT; HEMOLYSIN HLYA; GENE; SECRETION; BINDING; RECEPTOR	HAEMOLYSIN secreted by pathogenic Escherichia coli binds to mammalian cell membranes, disrupting cellular activities and lysing cells by pore-formation. It is synthesized as nontoxic prohaemolysin (proHlyA), which is activated intracellularly by a mechanism dependent on the cosynthesized HlyC. Haemolysin is one of a family of membrane-targeted toxins, including the leukotoxins of Pasteurella and Actinobacillus and the bifunctional adenylate cyclase haemolysin of Bordetella pertussis, which require this protoxin activation 1-5. HlyC alone cannot activate proHlyA, but requires a cytosolic activating factor 6. Here we report the cytosolic activating factor is identical to the acyl carrier protein and that activation to mature toxin is achieved by the transfer of a fatty acyl group from acyl carrier protein to proHlyA. Only acyl carrier protein, not acyl-CoA, can promote HlyC-directed proHlyA acylation, but a range of acyl groups are effective.			ISSARTEL, JP (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.		ISSARTEL, Jean-Paul/B-8727-2014	Koronakis, Vassilis/0000-0002-1353-1092	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BOEHM DF, 1990, INFECT IMMUN, V58, P1959, DOI 10.1128/IAI.58.6.1959-1964.1990; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; FORESTIER C, 1990, INFECT IMMUN, V58, P828, DOI 10.1128/IAI.58.3.828-832.1990; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GYGI D, 1990, MOL MICROBIOL, V4, P123, DOI 10.1111/j.1365-2958.1990.tb02021.x; HARDIE KR, IN PRESS MOL MICROBI, V5; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HEDO JA, 1987, J BIOL CHEM, V262, P954; HIGGINS C, 1989, NATURE, V340, P342, DOI 10.1038/340342a0; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JACKOWSKI S, 1987, J BACTERIOL, V169, P1469, DOI 10.1128/jb.169.4.1469-1473.1987; KORONAKIS V, 1987, J BACTERIOL, V169, P1509, DOI 10.1128/jb.169.4.1509-1515.1987; LUDWIG A, 1988, MOL GEN GENET, V214, P553, DOI 10.1007/BF00330494; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; NICAUD JM, 1985, FEBS LETT, V187, P339, DOI 10.1016/0014-5793(85)81272-2; OLSON EN, 1984, J BIOL CHEM, V259, P5364; PELLETT S, 1990, INFECT IMMUN, V58, P822, DOI 10.1128/IAI.58.3.822-827.1990; PILLAI S, 1987, P NATL ACAD SCI USA, V84, P7654, DOI 10.1073/pnas.84.21.7654; ROCK CO, 1979, J BIOL CHEM, V254, P7123; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; THERISOD H, 1987, P NATL ACAD SCI USA, V84, P8235, DOI 10.1073/pnas.84.23.8235; VANAMAN TC, 1968, J BIOL CHEM, V243, P6420; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x	27	268	276	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					759	761		10.1038/351759a0	http://dx.doi.org/10.1038/351759a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	2062368				2022-12-01	WOS:A1991FU20100069
J	KEMP, JS; THACH, BT				KEMP, JS; THACH, BT			SUDDEN-DEATH IN INFANTS SLEEPING ON POLYSTYRENE-FILLED CUSHIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COT DEATH; HONG-KONG; AROUSAL; RESPONSES; MECHANISM; POSITION; SIDS	Background. Infants are at risk for both the sudden infant death syndrome (SIDS) and accidental suffocation. On postmortem examination, however, it is difficult to distinguish one from the other without information from the scene of death. Healthy infants are assumed to be able to turn their heads and, if not otherwise restrained, to obtain fresh air. We assessed this assumption in an investigation of infant deaths that occurred during sleep on cushions filled with polystyrene beads. Methods. We obtained data on 25 deaths from the U.S. Consumer Product Safety Commission. We also used mechanical and animal models to study physiologic aspects of ventilation relevant to these results, by simulating the effects on an infant of breathing into a cushion. We measured the effects of softness, malleability (molding of the cushion about an infant's head), airflow resistance, and rebreathing of expired gases. Results. All 25 study infants were prone when found dead, and at least 88 percent were face down with nose and mouth obstructed by the cushion. SIDS was the diagnosis in 19 of the 23 infants who underwent autopsy. Our findings show, however, that the cushion would have limited movement of the infant's head to obtain fresh air, and the amount of rebreathing we estimated to have occurred in the infants was lethal in a rabbit model. Conclusions. Accidental suffocation by rebreathing was the most likely cause of death in most of the 25 infants studied. Consequently, there is a need to reassess the cause of death in the 28 to 52 percent of the victims of SIDS who are found with their faces straight down. Safety regulations setting standards for softness, malleability, and the potential for rebreathing are needed for infant bedding.	WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT PEDIAT, DIV PULM, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT PEDIAT, DIV NEWBORN MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)					NICHD NIH HHS [HD-10993] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD010993, R01HD010993] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADELSON L, 1956, PEDIATRICS, V17, P663; BASS M, 1986, NEW ENGL J MED, V315, P100, DOI 10.1056/NEJM198607103150206; Batchelor G.K., 1967, INTRO FLUID DYNAMICS, P233; BECKWITH JB, 1988, ANN NY ACAD SCI, V533, P37, DOI 10.1111/j.1749-6632.1988.tb37232.x; BECKWITH JB, 1967, HOSP PRACT, V2, P44; BECKWITH JB, 1988, SUDDEN INFANT DEATH, P48; BOWDEN K, 1950, Med J Aust, V1, P65; CAMPS FE, 1970, SUDDEN UNEXPECTED DE, P1; DAVIES DP, 1985, LANCET, V2, P1346; DEJONGE GA, 1989, BRIT MED J, V298, P722, DOI 10.1136/bmj.298.6675.722; EMERY JL, 1970, SUDDEN UNEXPECTED DE, P124; FEWELL JE, 1989, J DEV PHYSIOL, V11, P77; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; GESELL A, 1934, INFANT BEHAV, P61; GOLIN M, 1959, JAMA-J AM MED ASSOC, V169, P2021; GORDON I, 1982, FORENSIC MED GUIDE P, P31; GUGGER M, 1989, AM REV RESPIR DIS, V140, P1301, DOI 10.1164/ajrccm/140.5.1301; GUNTHEROTH WG, 1989, CRIB DEATH SUDDEN IN, P21; HATCH DJ, 1982, ARCH DIS CHILD, V57, P443, DOI 10.1136/adc.57.6.443; HOFFMAN HJ, 1988, ANN NY ACAD SCI, V533, P13, DOI 10.1111/j.1749-6632.1988.tb37230.x; HUNT CE, 1981, J APPL PHYSIOL, V50, P1313, DOI 10.1152/jappl.1981.50.6.1313; ILLINGWORTH RS, 1980, DEV INFANT YOUNG CHI, P117; Jones A M, 1976, J Forensic Sci, V21, P833; KEMP J, 1990, PEDIATR RES, V27, pA358; KRAUS JF, 1985, PUBLIC HEALTH REP, V100, P231; KROUS HF, 1988, SUDDEN INFANT DEATH, P18; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; MCGLASHAN ND, 1988, LANCET, V2, P106; MOUNTCASTLE VB, 1980, MED PHYSL, P1369; NELSON EAS, 1989, AUST PAEDIATR J, V25, P202; PETERSON DR, 1988, ANN NY ACAD SCI, V533, P6, DOI 10.1111/j.1749-6632.1988.tb37229.x; PHILLIPSON EA, 1978, AM REV RESPIR DIS, V118, P807; POLSON CJ, 1985, ESSENTIALS FORENSIC, P583; SMIALEK J E, 1988, Pediatrician, V15, P191; Sturner W Q, 1976, J Forensic Sci, V21, P483; STURNER WQ, 1977, FORENSIC MED, V2, P1015; SULLIVAN CE, 1979, J APPL PHYSIOL, V47, P1304, DOI 10.1152/jappl.1979.47.6.1304; TAN S, 1989, PEDIATR RES, V25, pA328; THACH BT, 1988, ANN NY ACAD SCI, V533, P314, DOI 10.1111/j.1749-6632.1988.tb37261.x; VALDESDAPENA MA, 1967, PEDIATRICS, V39, P123; WINN K, 1986, Pediatric Pathology, V5, P325; WOOLLEY PV, 1945, J PEDIATR-US, V26, P572, DOI 10.1016/S0022-3476(45)80085-9; 1990, FED REGISTER, V55, P42202; 1970, BS4578 BRIT STAND I	44	132	137	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1991	324	26					1858	1864		10.1056/NEJM199106273242605	http://dx.doi.org/10.1056/NEJM199106273242605			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT580	2041551				2022-12-01	WOS:A1991FT58000005
J	LISSNER, L; ODELL, PM; DAGOSTINO, RB; STOKES, J; KREGER, BE; BELANGER, AJ; BROWNELL, KD				LISSNER, L; ODELL, PM; DAGOSTINO, RB; STOKES, J; KREGER, BE; BELANGER, AJ; BROWNELL, KD			VARIABILITY OF BODY-WEIGHT AND HEALTH OUTCOMES IN THE FRAMINGHAM POPULATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK; MEN	Background. Fluctuation in body weight is a common phenomenon, due in part to the high prevalence of dieting. In this study we examined the associations between variability in body weight and health end points in subjects participating in the Framingham Heart Study, which involves follow-up examinations every two years after entry. Methods. The degree of variability of body weight was expressed as the coefficient of variation of each subject's measured body-mass-index values at the first eight biennial examinations during the study and on their recalled weight at 25 years of age. Using the 32-year follow-up data, we analyzed total mortality, mortality from coronary heart disease, and morbidity due to coronary heart disease and cancer in relation to intraindividual variation in body weight, including only end points that occurred after the 10th biennial examination. We used age-adjusted proportional-hazards regression for the data analysis. Results. Subjects with highly variable body weights had increased total mortality (P = 0.005 for men, P = 0.01 for women), mortality from coronary heart disease (P = 0.009 for men, P = 0.009 for women), and morbidity due to coronary heart disease (P = 0.0009 for men, P = 0.006 for women). Using a multivariate analysis that also controlled for obesity, trends in weight over time, and five indicators of cardiovascular risk, we found that the positive associations between fluctuations in body weight and end points related to mortality and coronary heart disease could not be attributed to these potential confounding factors. The relative risks of these end points in subjects whose weight varied substantially, as compared with those whose weight was relatively stable, ranged from 1.27 to 1.93. Conclusions. Fluctuations in body weight may have negative health consequences, independent of obesity and the trend of body weight over time.	YALE UNIV, DEPT PSYCHOL, 2 HILLHOUSE AVE, BOX 11A, NEW HAVEN, CT 06520 USA; BRYANT COLL, DEPT MATH, SMITHFIELD, RI 02917 USA; BOSTON UNIV, DEPT MATH, BOSTON, MA 02215 USA; DEPT PRIMARY HLTH CARE, GOTHENBURG, SWEDEN; BOSTON UNIV, MED CTR, DEPT PREVENT MED & EPIDEMIOL, BOSTON, MA 02215 USA	Yale University; Bryant University; Boston University; Boston University				Kreger, Bernard/0000-0002-8593-3795	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009430] Funding Source: NIH RePORTER; NCI NIH HHS [S-232-CA09430] Funding Source: Medline; NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NIMH NIH HHS [MH00319] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		[Anonymous], 1976, INT CLASSIFICATION D; ASHLEY FW, 1974, J CHRON DIS, V27, P103, DOI 10.1016/0021-9681(74)90079-4; BROWNELL KD, 1986, AM PSYCHOL, V41, P765, DOI 10.1037/0003-066X.41.7.765; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; HAMM P, 1989, AM J EPIDEMIOL, V129, P312, DOI 10.1093/oxfordjournals.aje.a115135; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; Lissner L., 1989, Obesity in Europe 88. Proceedings of the 1st European Congress on Obesity, 5-6 June, 1988, Stockholm, Sweden., P55; LISSNER L, 1990, INT J OBESITY, V14, P373; Marlatt GA., 1985, RELAPSE PREVENTION; PERCY C, 1984, CANCER-AM CANCER SOC, V54, P1435, DOI 10.1002/1097-0142(19841001)54:7<1435::AID-CNCR2820540734>3.0.CO;2-O; STEVENS J, 1990, INT J OBESITY, V14, P385; STUNKARD AJ, 1981, AM J CLIN NUTR, V34, P1593, DOI 10.1093/ajcn/34.8.1593; 1986, STATISTICAL ANAL SYS; 1985, ADV DATA VITAL HLTH, V113, P2	15	534	543	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1991	324	26					1839	1844		10.1056/NEJM199106273242602	http://dx.doi.org/10.1056/NEJM199106273242602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT580	2041550				2022-12-01	WOS:A1991FT58000002
J	MERCIER, N; VALLADAS, H; JORON, JL; REYSS, JL; LEVEQUE, F; VANDERMEERSCH, B				MERCIER, N; VALLADAS, H; JORON, JL; REYSS, JL; LEVEQUE, F; VANDERMEERSCH, B			THERMOLUMINESCENCE DATING OF THE LATE NEANDERTHAL REMAINS FROM SAINT-CESAIRE	NATURE			English	Article							SYSTEM; DATES	ANATOMICALLY modern humans have long been thought to have been responsible for the Aurignacian and Chatelperronian industries of the early Upper Palaeolithic of Western Europe, whereas the Middle Palaeolithic Mousterian industry has been attributed to Neanderthals. The presence of both Middle and Upper Palaeolithic strata at Saint-Cesaire in France offers an excellent opportunity for studying the cultural transition between the two. Saint-Cesaire is the only Chatelperronian site that has yielded really diagnostic hominid fossils, and the discovery there of Neanderthal remains 1 alongside Chatelperronian tools cast doubt on the exclusive association between industries and taxon. We report thermoluminescence dates for 20 burnt flints from the site. Those found near the Neanderthal remains were dated at 36,300 +/- 2,700 years BP (before present), making this specimen the youngest Neanderthal dated so far. This date places the stratum close in age to several French 2,3 but much younger than some Spanish 4,5 Aurignacian sites believed to have been occupied by modern humans. The possibility of contact between the West European Neanderthals and the intrusive modern humans who replaced them cannot therefore be excluded.	CENS,LAB PIERRE SUE,SCI TERRE GRP,F-91191 GIF SUR YVETTE,FRANCE; HOTEL ROCHEFORT,DIRECT ANTIQUITES REG POITOU CHARENTES,F-86020 POITIERS,FRANCE; UNIV BORDEAUX 1,ANTHROPOL LAB,CNRS,UA 376,F-33405 TALENCE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	MERCIER, N (corresponding author), CEA,CNRS LAB,CTR FAIBLES RADIOACT,AVE TERRASSE,F-91198 GIF SUR YVETTE,FRANCE.		Klein, Richard G/B-5910-2009	Mercier, Norbert/0000-0002-6375-9108				Aitken M. J., 1985, THERMOLUMINESCENCE D; AITKEN MJ, 1976, ARCHAEOMETRY, V18, P233, DOI 10.1111/j.1475-4754.1976.tb00168.x; APSIMON AM, 1980, NATURE, V287, P272; BARD E, 1990, NATURE, V345, P405, DOI 10.1038/345405a0; BELL WT, 1979, ARCHAEOMETRY, V21, P243, DOI 10.1111/j.1475-4754.1979.tb00258.x; BELL WT, 1991, ARCHAEOMETRY, V33, P43, DOI 10.1111/j.1475-4754.1991.tb00684.x; BISCHOFF JL, 1989, J ARCHAEOL SCI, V16, P563, DOI 10.1016/0305-4403(89)90022-8; Bordes F., 1968, PALEOLITHIQUE MONDE; Cabrera-Valdes V., 1989, J ARCHAEOL SCI, V16, P577, DOI [10.1016/0305-4403(89)90023-X, DOI 10.1016/0305-4403(89)90023-X]; CHAYLA B, 1973, CR ACAD SCI D NAT, V277, P273; DEMARS PY, 1989, HOMME NEANDERTAL, V3, P23; GAMBIER D, 1989, HOMME NEANDERTAL, V3, P67; Girard M., 1990, MEM MUS PREHIST ILE, V3, P295; GOWLETT JAJ, 1986, ARCHAEOMETRY, V28, P206, DOI 10.1111/j.1475-4754.1986.tb00389.x; HUXTABLE J, 1982, ARCHAEOMETRY, V24, P164; Leroi-Gourhan A., 1965, PREHISTOIRE ART OCCI; Leroi-Gourhan A, 1984, B SOC PREHISTORIQUE, V81, P196; LEROIGOURHAN A, 1963, B SOC MERID SPELEO P, P6; LEVEQUE F, 1980, CR ACAD SCI D NAT, V291, P187; LEVEQUE F, 1983, ANTHROPOLOGIE, V87, P369; LEVEQUE F, 1989, HOMME NEANDERTAL, V3, P99; MELLARS P, 1989, CURR ANTHROPOL, V30, P349, DOI 10.1086/203755; Mellars P, 1989, HUMAN REVOLUTION; Prescott JR., 1982, LATITUDE, V6, P17; VALLADAS H, 1986, NATURE, V322, P452, DOI 10.1038/322452a0; VALLADAS H, 1987, ARCHAEOMETRY, V27, P214; Valladas H., 1982, PACT, V6, P171; VANDERMEERSCH B, 1984, Bulletins et Memoires de la Societe d'Anthropologie de Paris, V1, P191, DOI 10.3406/bmsap.1984.3932; VANDERMEERSCH B, 1990, MEMOIRES MUSEE PREHI, V3, P25; VOGGEL JC, 1967, RADIOCARBON, V9, P107; WOLPOFF MH, 1981, NATURE, V289, P823, DOI 10.1038/289823a0	31	71	73	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					737	739		10.1038/351737a0	http://dx.doi.org/10.1038/351737a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FU201	2062366				2022-12-01	WOS:A1991FU20100061
J	PRICE, M; LEMAISTRE, M; PISCHETOLA, M; DILAURO, R; DUBOULE, D				PRICE, M; LEMAISTRE, M; PISCHETOLA, M; DILAURO, R; DUBOULE, D			A MOUSE GENE RELATED TO DISTAL-LESS SHOWS A RESTRICTED EXPRESSION IN THE DEVELOPING FOREBRAIN	NATURE			English	Article							LIMB DEVELOPMENT; DROSOPHILA; MURINE; HOMEODOMAIN; EMBRYOGENESIS; ORGANIZATION; HINDBRAIN; PATTERN; EN-1	MANY genes known to be involved in embryogenesis and morphogenesis of the fruitfly Drosophila melanogaster encode proteins with a highly conserved region of 60 amino acids called the homeodomain 1. Mammalian counterparts for most of these genes have been identified, including those homologous to the Drosophila homeotic genes 2,3 or to genes such as evenskipped 4, engrailed 5,6 or caudal 7. We have isolated a murine homeobox gene that encodes a homeodomain similar to that encoded by the Drosophila Distalless (Dll) gene 8. Dll has a crucial role in Drosophila limb morphogenesis, partially specifying pattern along the proximo-distal axis of the limb 8,9. The murine counterpart is expressed in a restricted region of the developing brain, within the diencephalon and the adjacent telencephalic regions.			PRICE, M (corresponding author), EUROPEAN MOLEC BIOL LAB,POSTFACH 102209,W-6900 HEIDELBERG,GERMANY.		Di Lauro, Roberto/A-2746-2012	Di Lauro, Roberto/0000-0001-9493-3036; duboule, denis/0000-0001-9961-2960				BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; GAUNT SJ, 1988, DEVELOPMENT S, V104, P71; GLOVER DM, 1989, DNA CLONING PRACTICA; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; LUMSDEN A, 1990, TRENDS NEUROSCI, V8, P335; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; Niimi K, 1962, TOKUSHIMA J EXP MED, V8, P203; PUELLES L, 1987, J COMP NEUROL, V266, P247, DOI 10.1002/cne.902660210; RUGH R, 1968, MOUSE ITS REPRODUCTI; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; WILKINSON DG, 1990, TRENDS NEUROSCI, V13, P335, DOI 10.1016/0166-2236(90)90145-Z; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0	22	276	286	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					748	751		10.1038/351748a0	http://dx.doi.org/10.1038/351748a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1676488				2022-12-01	WOS:A1991FU20100065
J	ROGERS, DJ; RANDOLPH, SE				ROGERS, DJ; RANDOLPH, SE			MORTALITY-RATES AND POPULATION-DENSITY OF TSETSE-FLIES CORRELATED WITH SATELLITE IMAGERY	NATURE			English	Article							AFRICA; GLOSSINA; KENYA	TSETSE flies are a major constraint on animal production in about 10 million km 2 of Africa through their transmission of animal trypanosomiasis 1. Up to 25 million people are at risk from human trypanosomiasis, or sleeping sickness 2. Tsetse research has been concentrated on the factors that control the distribution and abundance of these vectors and the means by which their numbers can be reduced 3. Eradication successes in some countries are insignificant compared with the continental scale of the problem and the long-term reduction in the area infested by tsetse has been negligible 4. We report here that the mortality rates of tsetse from sites in both West and East Africa, the size of male and female tsetse (related to the mortality rate of the parental female population) along a north-south transect in West Africa, and the abundance of two species of tsetse over the northern half of Cote d'lvoire, are significantly correlated with data from meteorological satellites. This information could be used to predict both the mortality rate and the abundance (key determinants of disease transmission potential) of tsetse over very large areas of the continent and to produce maps of high risk areas of disease transmission for the African trypanosomiases and, by implication, for many other vector-borne diseases.			ROGERS, DJ (corresponding author), DEPT ZOOL,S PARKS RD,OXFORD OX1 3PS,ENGLAND.		Randolph, Sarah/AAR-9346-2021					[Anonymous], 2005, AFRICA BUSINESS APR; AVERY MI, 1990, NATURE, V344, P860, DOI 10.1038/344860a0; BARRETT EC, 1986, 20TH P INT S REM SEN, V3, P955; BARTHOLOME E, 1988, INT J REMOTE SENS, V9, P1539, DOI 10.1080/01431168808954959; Bourn D., 1983, THESIS OXFORD U; BUXTON PA, 1955, LONDON SCH HYGIENE T, V10; CHALLIER A, 1973, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V11, P251; CROSS ER, 1984, MIL MED, V149, P28; DEMUYNCK A, 1989, ANN SOC BELGE MED TR, V69; DRANSFIELD RD, 1989, MED VET ENTOMOL, V3, P83, DOI 10.1111/j.1365-2915.1989.tb00478.x; HIELKEMA JU, 1986, INT J REMOTE SENS, V7, P1609, DOI 10.1080/01431168608948956; HUETE AR, 1987, REMOTE SENS ENVIRON, V23, P213, DOI 10.1016/0034-4257(87)90038-1; HUGHJONES ME, 1988, ACTA VET SCAND, V84, P256; HUTCHINSON CF, IN PRESS INT J REM S; LINTHICUM KJ, 1987, SCIENCE, V235, P1656, DOI 10.1126/science.3823909; MILFORD JR, 1986, RAINFALL MAPPING W A; MORAN PAP, 1950, BIOMETRICS, V6, P250, DOI 10.2307/3001822; MULLIGAN HW, 1970, AFRICAN TRYPANOSOMIA; MURRAY M, 1984, PREV VET MED, V2, P23, DOI 10.1016/0167-5877(84)90045-X; NICHOLSON SE, 1990, CLIMATIC CHANGE, V17, P209, DOI 10.1007/BF00138369; RANDOLPH SE, 1978, B ENTOMOL RES, V68, P655, DOI 10.1017/S0007485300009627; ROGERS D, 1979, J ANIM ECOL, V48, P825, DOI 10.2307/4197; ROGERS DJ, 1988, PARASITOLOGY, V97, P193, DOI 10.1017/S0031182000066853; ROGERS DJ, 1986, J ANIM ECOL, V55, P1007, DOI 10.2307/4430; ROGERS DJ, 1984, INSECT SCI APPL, V5, P397, DOI 10.1017/S1742758400008729; TUCKER CJ, 1986, INT J REMOTE SENS, V7, P1395, DOI 10.1080/01431168608948944; TUCKER CJ, 1985, SCIENCE, V227, P369, DOI 10.1126/science.227.4685.369; Varley G.C., 1973, INSECT POPULATION EC; WASHINO RK, 1987, 1987 U CAL DIV AGR N; 1983, HMSO TABLES TEMPER 4; 1982, CARTOGRAPHIE REPARTI	31	138	141	1	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					739	741		10.1038/351739a0	http://dx.doi.org/10.1038/351739a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	2062367				2022-12-01	WOS:A1991FU20100062
J	SOLOMON, A; WEISS, DT; KATTINE, AA				SOLOMON, A; WEISS, DT; KATTINE, AA			NEPHROTOXIC POTENTIAL OF BENCE-JONES PROTEINS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIGHT-CHAIN DEPOSITION; MOLECULAR-WEIGHT PROTEINS; MULTIPLE-MYELOMA; ISOELECTRIC POINT; RENAL-FAILURE; LYMPHOPLASMACYTIC DISORDERS; AMYLOID DEPOSITS; BETA-FIBRILLOSES; CAST NEPHROPATHY; RAT	Background. The renal manifestations of diseases associated with the production of monoclonal light chains - myeloma (cast) nephropathy, light-chain deposition disease, and amyloidosis AL - result from the deposition of certain Bence Jones proteins as tubular casts, basement-membrane precipitates, or fibrils, respectively. For unknown reasons, the severity of the renal manifestations of these diseases varies greatly from patient to patient. We employed an experimental in vivo model to determine the pathologic importance of various Bence Jones proteins. Methods. Mice were injected intraperitoneally with 300 mg of Bence Jones protein from 40 patients with multiple myeloma or amyloidosis AL and killed 48 hours later. The mouse kidneys were examined by light and electron microscopy, and light-chain deposits were identified immunohistochemically with highly specific antihuman lightchain antiserum. Results. Of the 40 different human Bence Jones proteins studied, 26 were deposited in the mouse kidneys predominantly as tubular casts, basement-membrane precipitates, or crystals; no light-chain deposits were detected in the kidneys of the mice that received the other 14 Bence Jones proteins. Of the 18 patients for whom renal tissue was available for study, the findings in 14 were comparable to those in the mice. Furthermore, the proteins obtained from 22 of the 27 patients whose serum creatinine concentrations equaled or exceeded 168-mu-mol per liter (1.9 mg per deciliter) were deposited in the mouse kidneys, whereas protein deposition occurred after the injection of proteins from only 4 of the 13 patients with serum creatinine concentrations below 168-mu-mol per liter. The repeated injection of Bence Jones proteins from two patients who had amyloidosis AL resulted in deposition of the protein in the mouse kidneys as amyloid. Conclusions. Particular Bence Jones proteins are primarily responsible for producing the distinctive types of protein deposition in renal tissue and the clinical manifestations that occur in patients with light-chain - associated diseases. This experimental model has potential value for the identification of nephrotoxic or amyloidogenic light chains.	UNIV TENNESSEE, MED CTR, GRAD SCH MED, DEPT PATHOL, KNOXVILLE, TN 37920 USA	University of Tennessee System; University of Tennessee Health Science Center	SOLOMON, A (corresponding author), UNIV TENNESSEE, MED CTR,GRAD SCH MED,DEPT MED, HUMAN IMMUNOL & CANC PROGRAM, 1924 ALCOA HWY, KNOXVILLE, TN 37920 USA.				NCI NIH HHS [CA-10056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA010056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANIAN R, 1990, ARCH INTERN MED, V150, P1693; BUXBAUM J, 1986, J CLIN INVEST, V78, P798, DOI 10.1172/JCI112643; BUXBAUM JN, 1990, ANN INTERN MED, V112, P455, DOI 10.7326/0003-4819-76-3-112-6-455; Clyne D H, 1981, Contrib Nephrol, V24, P78; CLYNE DH, 1979, KIDNEY INT, V16, P345, DOI 10.1038/ki.1979.137; COOPER EH, 1984, J CLIN PATHOL, V37, P852, DOI 10.1136/jcp.37.8.852; COWARD RA, 1984, CLIN SCI, V66, P229, DOI 10.1042/cs0660229; FANG LST, 1985, KIDNEY INT, V27, P582, DOI 10.1038/ki.1985.50; GALLO G, 1989, SEMIN HEMATOL, V26, P234; GALLO GR, 1982, PATHOL ANNU, V17, P291; GANEVAL D, 1984, KIDNEY INT, V26, P1, DOI 10.1038/ki.1984.126; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; HILL GS, 1983, AM J KIDNEY DIS, V2, P423, DOI 10.1016/S0272-6386(83)80075-4; HILL GS, 1983, PATHOLOGY KIDNEY, V2, P993; JOHNS EA, 1986, J CLIN PATHOL, V39, P833, DOI 10.1136/jcp.39.8.833; JOHNSON WJ, 1990, ARCH INTERN MED, V150, P863, DOI 10.1001/archinte.150.4.863; KOSS MN, 1976, LAB INVEST, V34, P579; KYLE RA, 1989, ANNU REV MED, V40, P53; MELCION C, 1984, CLIN NEPHROL, V22, P138; NORDEN AGW, 1989, J CLIN PATHOL, V42, P59, DOI 10.1136/jcp.42.1.59; PALANT CE, 1986, AM J MED, V80, P98, DOI 10.1016/0002-9343(86)90055-0; PIRANI CL, 1982, CONTEMP ISS NEPHROL, V10, P287; PREUDHOMME JL, 1980, AM J MED, V69, P703, DOI 10.1016/0002-9343(80)90421-0; RANDALL RE, 1976, AM J MED, V60, P293, DOI 10.1016/0002-9343(76)90440-X; ROTA S, 1987, MEDICINE, V66, P126, DOI 10.1097/00005792-198703000-00004; SANDERS PW, 1987, KIDNEY INT, V32, P851, DOI 10.1038/ki.1987.286; SANDERS PW, 1988, J CLIN INVEST, V82, P2086, DOI 10.1172/JCI113830; SANDERS PW, 1990, J CLIN INVEST, V85, P570, DOI 10.1172/JCI114474; SMOLENS P, 1983, KIDNEY INT, V24, P192, DOI 10.1038/ki.1983.144; SMOLENS P, 1986, KIDNEY INT, V30, P874, DOI 10.1038/ki.1986.267; SOLLING K, 1984, ACTA MED SCAND, V216, P495; SOLOMON A, 1975, J CLIN INVEST, V55, P579, DOI 10.1172/JCI107965; SOLOMON A, 1986, SEMIN ONCOL, V13, P341; SOLOMON A, 1990, AM J PATHOL, V137, P855; SOLOMON A, 1982, J CLIN INVEST, V70, P453, DOI 10.1172/JCI110635; SOLOMON A, 1985, METHOD ENZYMOL, V116, P101; SOLOMON A, 1982, NEW ENGL J MED, V306, P605, DOI 10.1056/NEJM198203113061010; STURGILL BC, 1987, PATHOL ANNU, V22, P133; TUBBS RR, 1981, AM J MED, V71, P263, DOI 10.1016/0002-9343(81)90127-3; WEISS JH, 1981, KIDNEY INT, V20, P198, DOI 10.1038/ki.1981.122; WOCHNER RD, 1967, J EXP MED, V126, P207, DOI 10.1084/jem.126.2.207	42	218	222	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1991	324	26					1845	1851		10.1056/NEJM199106273242603	http://dx.doi.org/10.1056/NEJM199106273242603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT580	1904132				2022-12-01	WOS:A1991FT58000003
J	BRENNAN, TA; HEBERT, LE; LAIRD, NM; LAWTHERS, A; THORPE, KE; LEAPE, LL; LOCALIO, AR; LIPSITZ, SR; NEWHOUSE, JP; WEILER, PC; HIATT, HH				BRENNAN, TA; HEBERT, LE; LAIRD, NM; LAWTHERS, A; THORPE, KE; LEAPE, LL; LOCALIO, AR; LIPSITZ, SR; NEWHOUSE, JP; WEILER, PC; HIATT, HH			HOSPITAL CHARACTERISTICS ASSOCIATED WITH ADVERSE EVENTS AND SUBSTANDARD CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY DATA; DEATH RATES; QUALITY; ILLNESS; DISEASE; COST; SEVERITY	To explore the epidemiology of adverse events (AEs), which were defined as injuries due to medical treatment, and that subset of AEs caused by negligence, we studied interhospital variation in these outcomes in a sample of 31 000 medical records drawn from a random selection of 51 hospitals in New York in 1984. We found a substantial variation in both AE rates (0.2% to 7.9%; mean, 3.2%) and the percentage of AEs due to negligence (1% to 60%; mean, 24.9%) among hospitals. Univariate analyses of AEs revealed that primary teaching institutions had significantly higher rates (4.1%) and rural hospitals had significantly lower ones (1.0%). The percentage of AEs due to negligence was lower in primary teaching (10.7%) and for-profit (9.5%) hospitals and was significantly higher in hospitals with predominantly (> 80%) minority patients who had been discharged (37%). These findings were corroborated by multivariate analysis. Our results suggest that AEs and negligence are not randomly distributed and that certain types of hospitals have significantly higher rates of injuries due to substandard care. These observations may represent an important improvement on existing measures of quality because they take into account the fact that some hospitals' populations may be at risk of suffering a poor outcome.	HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,SCH LAW,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	BRENNAN, TA (corresponding author), BRIGHAM & WOMENS HOSP,DIV GEN MED,BOSTON,MA 02115, USA.		Newhouse, Joseph/AAD-9763-2019; Newhouse, Joseph/AGJ-5632-2022					ABRAMSON NS, 1980, JAMA-J AM MED ASSOC, V244, P582; BERWICK DM, 1990, JAMA-J AM MED ASSOC, V263, P247, DOI 10.1001/jama.263.2.247; BIGBY J, 1986, AM J MED, V83, P1031; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1989, MED CARE, V29, P505; BURSTIN H R, 1991, Clinical Research, V39, p189A; CLEARY PD, 1988, INQUIRY-J HEALTH CAR, V25, P25; COUCH NP, 1981, NEW ENGL J MED, V304, P634, DOI 10.1056/NEJM198103123041103; DONABEDIAN A, 1985, INQUIRY-J HEALTH CAR, V22, P282; DUBOIS RW, 1987, AM J PUBLIC HEALTH, V77, P1162, DOI 10.2105/AJPH.77.9.1162; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; FEIGENSON JS, 1978, JAMA-J AM MED ASSOC, V240, P1878; FINK A, 1989, MED CARE, V27, P315, DOI 10.1097/00005650-198904000-00001; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; HIATT HH, 1989, NEW ENGL J MED, V321, P480, DOI 10.1056/NEJM198908173210725; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; JOST TS, 1989, OHIO ST LJ, V50, P1; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1953, DOI 10.1001/jama.264.15.1953; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; LAKSHMANAN MC, 1986, ARCH INTERN MED, V146, P1931, DOI 10.1001/archinte.146.10.1931; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MASON WB, 1980, MED CARE, V18, P147, DOI 10.1097/00005650-198002000-00002; MOREHEAD MA, 1964, STUDY HOSPITAL CARE; PALMER RH, 1983, AMBULATORY HLTH CARE; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; SAFRAN C, 1989, MED CARE, V27, P204, DOI 10.1097/00005650-198902000-00010; SHAH BV, 1981, SESUDAAN STANDARD ER; SHAH BV, 1984, RTI LOGIT PROCEDURE; SHORTELL SM, 1981, MED CARE, V19, P1041, DOI 10.1097/00005650-198110000-00006; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; YERGAN J, 1987, MED CARE, V25, P592, DOI 10.1097/00005650-198707000-00003; 1985, 1984 NEW YORK STAT D; 1975, MED INSURANCE FEASIB	36	195	197	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3265	3269		10.1001/jama.265.24.3265	http://dx.doi.org/10.1001/jama.265.24.3265			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FR835	2046108				2022-12-01	WOS:A1991FR83500032
J	BROWNER, WS; WESTENHOUSE, J; TICE, JA				BROWNER, WS; WESTENHOUSE, J; TICE, JA			WHAT IF AMERICANS ATE LESS FAT - A QUANTITATIVE ESTIMATE OF THE EFFECT ON MORTALITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MAMMARY CARCINOGENESIS; SERUM-CHOLESTEROL; RISK-FACTORS; DIETARY-FAT; BREAST-CANCER; FOLLOW-UP; CARDIOVASCULAR-DISEASE; PROSTATE-CANCER; PLASMA-LIPIDS	Americans consume an average of 37% of their energy intake as fat. Many authorities recommend restricting fat intake to 30% of energy intake to reduce the rates of coronary heart disease and perhaps of cancers of the breast, colon, and prostate. Based on the assumptions that underlie those recommendations, we estimated the effect of this dietary change on mortality. If all Americans restricted their intake of dietary fat by reducing consumption of saturated fat and accompanying dietary cholesterol, the corresponding reductions in serum cholesterol levels could reduce coronary heart disease mortality rates by 5% to 20%, depending on age. If the relationship between dietary fat and cancer is as strong as has been observed in some studies, the proportional effects on mortality from fat-related cancers could be even greater, although the absolute effects - given the lower mortality rates - would be smaller. Overall, if the assumptions are correct, about 42 000 of the 2.3 million deaths that would have occurred in adults each year in the United States could be deferred. This 2% benefit, equivalent to an increase in average life expectancy of 3 to 4 months, would accrue chiefly to people over the age of 65 years. If recent concerns about the possibly harmful effects of cholesterol lowering on mortality from noncardiovascular causes - which mainly affect younger persons - are valid, these relatively modest benefits would be overestimates of the actual effect.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT EPIDEMIOL & BIOSTAT, DIV CLIN EPIDEMIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	BROWNER, WS (corresponding author), VET AFFAIRS MED CTR, DEPT MED, GEN INTERNAL MED SECT, SAN FRANCISCO, CA 94121 USA.			Tice, Jeffrey/0000-0002-9857-2028				ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; BANSAL BR, 1978, CANCER RES, V38, P3293; BOISSONNEAULT GA, 1986, J NATL CANCER I, V76, P335; BRADEN LM, 1986, LIPIDS, V21, P285, DOI 10.1007/BF02536414; BROWNER WS, 1986, AM J EPIDEMIOL, V123, P143, DOI 10.1093/oxfordjournals.aje.a114208; BULL AW, 1979, CANCER RES, V39, P4956; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CHAN PC, 1983, CANCER RES, V43, P1079; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COWAN LD, 1990, AM J EPIDEMIOL, V131, P468, DOI 10.1093/oxfordjournals.aje.a115521; DAO TL, 1983, J NATL CANCER I, V71, P201; ERNST N, 1980, LANCET, V2, P111; FISHER M, 1989, ARCH INTERN MED, V149, P1726, DOI 10.1001/archinte.149.8.1726; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GRAHAM S, 1978, JNCI-J NATL CANCER I, V61, P709; GRAHAM S, 1983, JNCI-J NATL CANCER I, V70, P687; GRAY GE, 1979, BRIT J CANCER, V39, P1, DOI 10.1038/bjc.1979.1; HAENSZEL W, 1973, J NATL CANCER I, V51, P1765, DOI 10.1093/jnci/51.6.1765; HARRIS T, 1988, J AM GERIATR SOC, V36, P1023, DOI 10.1111/j.1532-5415.1988.tb04370.x; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; HESHMAT MY, 1985, PROSTATE, V6, P7, DOI 10.1002/pros.2990060103; HIATT RA, 1986, J CHRON DIS, V39, P861, DOI 10.1016/0021-9681(86)90034-2; HILL AB, 1971, PRINCIPLES MED STATI, P220; HOPKINS GJ, 1981, J NATL CANCER I, V66, P517; INGRAM D M, 1981, Nutrition and Cancer, V3, P75; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; JAIN M, 1980, INT J CANCER, V26, P757, DOI 10.1002/ijc.2910260609; JOHNSON JL, 1986, AM J EPIDEMIOL, V123, P209, DOI 10.1093/oxfordjournals.aje.a114230; JONES DY, 1987, AM J CLIN NUTR, V45, P1451, DOI 10.1093/ajcn/45.6.1451; KANNEL WB, 1988, CLIN CHEM, V34, pB53; KANNEL WB, 1986, AM HEART J, V112, P825, DOI 10.1016/0002-8703(86)90481-3; KANNEL WB, 1987, AM HEART J, V114, P413, DOI 10.1016/0002-8703(87)90511-4; KEYS A, 1974, AM J CLIN NUTR, V27, P188, DOI 10.1093/ajcn/27.2.188; KEYS A, 1965, METABOLIS, V14, P759, DOI 10.1016/0026-0495(65)90002-8; KNEKT P, 1988, J CLIN EPIDEMIOL, V41, P519, DOI 10.1016/0895-4356(88)90056-X; KRITCHEVSKY D, 1984, CANCER RES, V44, P3174; MACQUARTMOULIN G, 1986, INT J CANCER, V38, P183, DOI 10.1002/ijc.2910380207; MARTIN MJ, 1986, LANCET, V2, P933; MILLER AB, 1978, AM J EPIDEMIOL, V107, P499, DOI 10.1093/oxfordjournals.aje.a112569; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEWMAN TB, 1990, JAMA-J AM MED ASSOC, V264, P3039, DOI 10.1001/jama.264.23.3039; PAGE IH, 1961, CIRCULATION, V23, P133, DOI 10.1161/01.CIR.23.1.133; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; POTTER JD, 1986, JNCI-J NATL CANCER I, V76, P557, DOI 10.1093/jnci/76.4.557; PRENTICE RL, 1988, JNCI-J NATL CANCER I, V80, P802, DOI 10.1093/jnci/80.11.802; Ravenholt R T, 1985, Am J Prev Med, V1, P4; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROBERTSON L, 1983, INJUIRES CAUSES CONT, P9; ROHAN TE, 1988, AM J EPIDEMIOL, V128, P478, DOI 10.1093/oxfordjournals.aje.a114996; ROSE DP, 1986, CANCER-AM CANCER SOC, V58, P2363, DOI 10.1002/1097-0142(19861201)58:11<2363::AID-CNCR2820581102>3.0.CO;2-#; SCHATZKIN A, 1987, LANCET, V2, P298; SHERWIN RW, 1987, JAMA-J AM MED ASSOC, V257, P943; SNOWDON DA, 1984, AM J EPIDEMIOL, V120, P244, DOI 10.1093/oxfordjournals.aje.a113886; TAYLOR WC, 1987, ANN INTERN MED, V106, P605, DOI 10.7326/0003-4819-106-4-605; TYROLER HA, 1987, CIRCULATION, V76, P515, DOI 10.1161/01.CIR.76.3.515; VANTVEER P, 1990, INT J EPIDEMIOL, V19, P12, DOI 10.1093/ije/19.1.12; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; WILLETT WC, 1984, NEW ENGL J MED, V310, P633, DOI 10.1056/NEJM198403083101006; WILLETT WC, 1984, NEW ENGL J MED, V310, P697, DOI 10.1056/NEJM198403153101106; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; 1988, NCI NIH882789 US DEP; 1966, DIETARY FAT HUMAN HL; 1988, SURGEON GENERALS REP; 1984, NUTRITION CANCER CAU; 1988, US BUREAU CENSUS P25, V1000; 1984, NCI NIH842671 US DEP; 1985, KJAMA, V253, P2080; [No title captured]; 1983, DHHHS PHS831681 US D; 1977, 052070039132 PUBL; 1985, INJURY AM CONTINUING, P23; 1979, DHEW PHS7955071 PUBL; 1984, CIRCULATION, V70, pA153; 1988, VITAL STATISTICS U A, V2	77	79	81	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3285	3291		10.1001/jama.265.24.3285	http://dx.doi.org/10.1001/jama.265.24.3285			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR835	1801770				2022-12-01	WOS:A1991FR83500036
J	CHAVEZ, GF; MULINARE, J; EDMONDS, LD				CHAVEZ, GF; MULINARE, J; EDMONDS, LD			EPIDEMIOLOGY OF RH HEMOLYTIC-DISEASE OF THE NEWBORN IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNE GLOBULIN; IMMUNOGLOBULIN UTILIZATION; RHESUS ISOIMMUNIZATION; PREVENTION; IDENTIFICATION; SURVEILLANCE; MANAGEMENT	Nationwide surveillance of Rh hemolytic disease of the newborn (RhHDN) indicates that, after a substantial decline in incidence, reported rates reached a plateau in the late 1970s. We conducted a study designed to validate RhHDN surveillance data, to obtain corrected incidence estimates, and to identify potential reasons for the reported plateau. We obtained data from the Birth Defects Monitoring Program, a national surveillance system that collects data from public and private hospitals participating voluntarily. We asked hospitals for copies of the medical records for all infants discharged with a code for RhHDN and for a sample of the medical records of infants discharged with a code for other and unspecified hemolytic disease during 1986. The estimated incidence rate of RhHDN was 10.6 per 10 000 total births, with some regional variations. Our findings indicate that, despite the availability of an effective preventive measure, RhHDN continues to contribute significantly to infant morbidity and mortality in the United States.	CTR DIS CONTROL,CTR ENVIRONM HLTH & INJURY CONTROL,DIV BIRTH DEFECTS & DEV DISABIL,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								ADAMS MM, 1981, AM J PUBLIC HEALTH, V71, P1031, DOI 10.2105/AJPH.71.9.1031; ADAMS MM, 1984, AM J OBSTET GYNECOL, V149, P633, DOI 10.1016/0002-9378(84)90248-5; BEHRMAN RE, 1987, NELSON TXB PEDIATRIC, P384; BOWMAN JM, 1983, CAN MED ASSOC J, V129, P343; BOWMAN JM, 1984, AM J OBSTET GYNECOL, V148, P1151, DOI 10.1016/0002-9378(84)90651-3; Bowman JM., 1978, PERINATAL CARE, V2, P24; Caiola G, 1984, Obstet Gynecol Surv, V39, P55, DOI 10.1097/00006254-198401000-00021; CLARKE CA, 1985, BRIT MED J, V291, P17, DOI 10.1136/bmj.291.6487.17; EDMONDS LD, 1981, INT J EPIDEMIOL, V10, P247, DOI 10.1093/ije/10.3.247; FREDA VJ, 1975, NEW ENGL J MED, V292, P1014, DOI 10.1056/NEJM197505082921906; FRIGOLETTO FD, 1979, CLIN PERINATOL, V6, P321, DOI 10.1016/S0095-5108(18)31150-3; GRIMES DA, 1983, SOUTHERN MED J, V76, P743, DOI 10.1097/00007611-198306000-00017; GRIMES DA, 1977, OBSTET GYNECOL, V50, P261; GRIMES DA, 1981, AM J OBSTET GYNECOL, V140, P246, DOI 10.1016/0002-9378(81)90268-4; HENRY G, 1976, OBSTET GYNECOL, V48, P557; HENSLEIGH PA, 1983, AM J OBSTET GYNECOL, V146, P749, DOI 10.1016/0002-9378(83)91071-2; KEITH L, 1978, PERINATAL CARE, V2, P37; KORNSTAD L, 1987, NIPH (National Institute of Public Health) Annals (Oslo), V10, P3; LIM OW, 1982, OBSTET GYNECOL, V59, P477; POLLACK W, 1978, PERINATAL CARE, V2, P8; WIBLEKANT J, 1983, CLIN PERINATOL, V10, P343, DOI 10.1016/S0095-5108(18)30970-9; WYSOWSKI DK, 1979, JAMA-J AM MED ASSOC, V242, P1376, DOI 10.1001/jama.242.13.1376; 1988, MONTHLY VITAL STATIS, V37; 1989, GUIDE CLIN PREVENTIV, P221; 1988, MMWR S5, V37, P1; 1981, MMWR, V30, P13; 1985, MMWR, V34, pSS1	27	94	98	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3270	3274		10.1001/jama.265.24.3270	http://dx.doi.org/10.1001/jama.265.24.3270			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR835	1904504				2022-12-01	WOS:A1991FR83500033
J	GOODWIN, FK				GOODWIN, FK			PEER-REARED MONKEYS ALCOHOL-PRONE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							HIGHLEY JD, IN PRESS P NATL ACAD	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3221	3221						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR835	1646339				2022-12-01	WOS:A1991FR83500007
J	GOODWIN, FK				GOODWIN, FK			COCAINE ANALOGS AND BRAIN IMAGING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							KUHAR MJ, 1991, EUR J PHARMACOL, V194, P133; 1991, MOL PHARMACOL, V39, P339; IN PRESS PHARM EXP T	3	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3221	3221						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FR835	1646339				2022-12-01	WOS:A1991FR83500006
J	GOODWIN, FK				GOODWIN, FK			TRICYCLICS AND HEART-TRANSPLANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							SHAPIRO PA, 1991, AM J PSYCHIAT, V148, P371; DIAGNOSTIC STATISTIC	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3221	3221						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FR835	1646339				2022-12-01	WOS:A1991FR83500005
J	LEW, JF; GLASS, RI; GANGAROSA, RE; COHEN, IP; BERN, C; MOE, CL				LEW, JF; GLASS, RI; GANGAROSA, RE; COHEN, IP; BERN, C; MOE, CL			DIARRHEAL DEATHS IN THE UNITED-STATES, 1979 THROUGH 1987 - A SPECIAL PROBLEM FOR THE ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GASTROENTERITIS; COMMUNITY	Objective. - Diarrhea is an important cause of death among young children in both developing and developed countries, but little is known about diarrheal deaths among adults. In this study, we examined trends in diarrheal deaths among all age groups in the United States. Design/Setting/Participants. - We reviewed national mortality data compiled by the National Center for Health Statistics, Hyattsville, Md, which consist of information from all death certificates filed in the United States for the period 1979 through 1987. A death for which diarrhea was listed as an immediate or underlying cause was considered a "diarrheal death" and included in the analysis. Results. - We found that 28 538 persons died of diarrhea cited as either an immediate or the underlying cause of death during the 9-year period. A majority of diarrheal deaths occurred among the elderly (older than 74 years of age, 51%), followed by adults 55 to 74 years of age (27%), and young children (younger than 5 years of age, 11 %). For the elderly, adjusted risk factors for dying of diarrhea included being white, female, and residing in a long-term care facility. Only the elderly and young children had clear, distinct winter peaks of diarrheal deaths, suggesting that the diarrhea may, in part, be infectious in origin. Conclusion. - For the elderly, more directed studies of those at risk, such as nursing home residents, are needed to determine if oral rehydration therapy, vaccines, or other preventive measures might benefit this population.	EMORY UNIV,SCH PUBL HLTH,ATLANTA,GA 30322; LYCEE ST LOUIS,PARIS,FRANCE	Emory University	LEW, JF (corresponding author), CTR DIS CONTROL,DIV VIRAL & RICKETTSIAL DIS,RESP & ENTER VIRUS BRANCH,ATLANTA,GA 30333, USA.		Moe, Christine L/G-6118-2012					AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BRESLOW L, 1990, ANNU REV PUBL HEALTH, V11, P1; FITZGERALD JF, 1989, PEDIATR INFECT DIS J, V8, P564, DOI 10.1097/00006454-198908000-00044; GELLERT GA, 1990, INFECT CONT HOSP EP, V11, P459; GORDON SM, 1990, AM J EPIDEMIOL, V131, P702, DOI 10.1093/oxfordjournals.aje.a115554; HING E, 1989, VITA HLTH STAT, V102, P24; HING E, 1987, PHS871270 US DEP HLT; HO MS, 1988, J INFECT DIS, V158, P1112, DOI 10.1093/infdis/158.5.1112; HO MS, 1988, JAMA-J AM MED ASSOC, V260, P3281, DOI 10.1001/jama.260.22.3281; ISRAEL RA, 1986, AM J EPIDEMIOL, V124, P161, DOI 10.1093/oxfordjournals.aje.a114375; LEBARON CW, 1990, JAMA-J AM MED ASSOC, V264, P983, DOI 10.1001/jama.264.8.983; MAASDAM CF, 1981, GERIATRICS, V36, P127; MATSON DO, 1990, J INFECT DIS, V162, P598, DOI 10.1093/infdis/162.3.598; Smith P W, 1989, Infect Dis Clin North Am, V3, P763; WING S, 1985, J GERONTOL, V40, P78, DOI 10.1093/geronj/40.1.78; 1990, PHS901232 US DEP HLT; [No title captured]; 1982, US BUREAU CENSUS P25, V917; 1987, MMWR, V36, P1; 1988, US BUREAU CENSUS P25, V1022; 1990, STATE WORLDS CHILDRE	21	118	120	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3280	3284		10.1001/jama.265.24.3280	http://dx.doi.org/10.1001/jama.265.24.3280			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR835	2046110				2022-12-01	WOS:A1991FR83500035
J	OBRIEN, RJ				OBRIEN, RJ			HEPATOXIC REACTION TO ANTITUBERCULOUS DRUGS - ADJUSTMENTS TO THERAPEUTIC REGIMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											OBRIEN, RJ (corresponding author), CTR DIS CONTROL,ATLANTA,GA 30333, USA.								0	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3323	3323		10.1001/jama.265.24.3323	http://dx.doi.org/10.1001/jama.265.24.3323			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR835	2046117				2022-12-01	WOS:A1991FR83500045
J	SCHUCHAT, A; BROOME, CV; HIGHTOWER, A; COSTA, SJ; PARKIN, W				SCHUCHAT, A; BROOME, CV; HIGHTOWER, A; COSTA, SJ; PARKIN, W			USE OF SURVEILLANCE FOR INVASIVE PNEUMOCOCCAL DISEASE TO ESTIMATE THE SIZE OF THE IMMUNOSUPPRESSED HIV-INFECTED POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY SYNDROME; PERSISTENT GENERALIZED LYMPHADENOPATHY; INTRAVENOUS DRUG-USERS; AIDS-RELATED COMPLEX; BACTERIAL PNEUMONIA; ANTIBODY-RESPONSES; BACTEREMIA; VACCINE	We used population-based surveillance in New Jersey in 1986 to quantify the risk of invasive pneumococcal disease in persons with the acquired immunodeficiency syndrome (AIDS) and in those who went on to develop AIDS. Using pneumococcal surveillance, we also devised a method to estimate the size of the immunosuppressed population infected with the human immunodeficiency virus (HIV), the so-called pre-AIDS population. From rates of pneumococcal disease that occurred in areas with a low incidence of AIDS, we calculated the number of patients expected to contract pneumococcal disease in areas with a high incidence of AIDS. There were 59 more cases of pneumococcal disease observed than expected; 14 of these patients had AIDS by the time of pneumococcal infection. We attributed the remaining 45 cases to the increased risk of pneumococcal infection in pre-AIDS. The pre-AIDS pneumococcal cases and the attack rate of pneumococcal disease in pre-AIDS were used to estimate the size of the 1986 pre-AIDS New Jersey population as 8823 pre-AIDS cases (95% confidence interval, 7377 to 10 714) or 0.37% of the adult New Jersey population. Surveillance for marker diseases may provide a simple, independent method of estimating the pre-AIDS population.	CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,STAT SERV,ATLANTA,GA 30333; NEW JERSEY STATE DEPT HLTH,DIV AIDS PREVENT & CONTROL,DATA ANAL UNIT,TRENTON,NJ; NEW JERSEY STATE DEPT HLTH,DIV EPIDEMIOL & DIS CONTROL,TRENTON,NJ	Centers for Disease Control & Prevention - USA; New Jersey Department of Health & Senior Services; New Jersey Department of Health & Senior Services	SCHUCHAT, A (corresponding author), CTR DIS CONTROL,MENINGITIS & SPECIAL PATHOGENS BRANCH,BLDG 1,ROOM 4415,ATLANTA,GA 30333, USA.							AMMANN AJ, 1984, JAMA-J AM MED ASSOC, V251, P1447, DOI 10.1001/jama.251.11.1447; [Anonymous], MMWR MORB MORTAL WKL; [Anonymous], MMWR MORB MORTAL WKL; ARMITAGE P, 1987, STATISTICAL METHODS, P118; BALLET JJ, 1987, CLIN EXP IMMUNOL, V68, P479; BURKE DS, 1987, NEW ENGL J MED, V317, P131, DOI 10.1056/NEJM198707163170302; JANOFF EN, 1988, J INFECT DIS, V158, P983, DOI 10.1093/infdis/158.5.983; KLEIN RS, 1989, J INFECT DIS, V160, P826, DOI 10.1093/infdis/160.5.826; OCHS HD, 1988, J CLIN IMMUNOL, V8, P57, DOI 10.1007/BF00915157; PARKIN JM, 1989, AIDS, V3, P37, DOI 10.1097/00002030-198903010-00008; POLSKY B, 1986, ANN INTERN MED, V104, P38, DOI 10.7326/0003-4819-104-1-38; RAGNI MV, 1987, J LAB CLIN MED, V109, P545; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SIMBERKOFF MS, 1984, AM REV RESPIR DIS, V130, P1174; STONEBURNER R, 1988, 4 INT C AIDS STODKH; WHIMBEY E, 1986, ANN INTERN MED, V104, P511, DOI 10.7326/0003-4819-104-4-511; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; 1988, SAS STAT USERS GUIDE, P690; 1988, MMWR, V37, P593	20	69	69	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3275	3279		10.1001/jama.265.24.3275	http://dx.doi.org/10.1001/jama.265.24.3275			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR835	2046109				2022-12-01	WOS:A1991FR83500034
J	COBBE, SM; REDMOND, MJ; WATSON, JM; HOLLINGWORTH, J; CARRINGTON, DJ				COBBE, SM; REDMOND, MJ; WATSON, JM; HOLLINGWORTH, J; CARRINGTON, DJ			HEARTSTART SCOTLAND - INITIAL EXPERIENCE OF A NATIONAL SCHEME FOR OUT OF HOSPITAL DEFIBRILLATION	BRITISH MEDICAL JOURNAL			English	Article							EMERGENCY MEDICAL TECHNICIANS; AUTOMATIC EXTERNAL DEFIBRILLATOR; CARDIAC-ARREST; CLINICAL-EXPERIENCE; MANAGEMENT; RESUSCITATION; CARE	Objective - To determine the outcome of out of hospital defibrillation in Scotland during the year after the introduction of automated external defibrillators in October 1988. Design - Retrospective analysis of ambulance service reports and hospital records. Setting - Scottish Ambulance Service and acute receiving hospitals throughout Scotland. Main outcome measures - Delay from cardiac arrest to first defibrillator shock; vital state on arrival at hospital accident and emergency department; survival to hospital discharge. Results - During the study period 268 defibrillators were purchased by public subscription and 96% of the 2000 ambulance crew underwent an eight hour training programme in cardiopulmonary resuscitation and defibrillation. A total of 1111 cardiac arrests were recorded, and defibrillation was indicated and undertaken in 602 (54%) patients, mean age 63 (range 14-92) years. A spontaneous pulse was present on arrival at hospital in 180 (30%) of the defibrillated patients, and 75 (12.5%) were subsequently discharged alive. As expected, the likelihood of survival was inversely related to the delay from the onset of cardiac arrest to the time of the first shock and was greater in the case of witnessed arrest. If ventricular fibrillation occurred after the arrival of the ambulance, survival to discharge was 33%. Conclusions - An effective scheme for out of hospital defibrillation can be introduced rapidly, and with limited training implications and costs, by the use of automated external defibrillators in ambulances.	FIFE LOTHIAN & BORDERS SCOTTISH AMBULANCE SERV,EDINBURGH EH10 5SA,SCOTLAND		COBBE, SM (corresponding author), ROYAL INFIRM,DEPT MED CARDIOL,GLASGOW G31 2ER,SCOTLAND.							ANDERSON IWR, 1987, BRIT MED J, V294, P228, DOI 10.1136/bmj.294.6566.228; BEAGLEHOLE R, 1986, BMJ-BRIT MED J, V292, P33, DOI 10.1136/bmj.292.6512.33; COBB LA, 1986, MANAGEMENT ACUTE COR, P105; COBB LA, 1975, CIRCULATION       S3, V51, P223; CUMMINS RO, 1987, JAMA-J AM MED ASSOC, V257, P1605, DOI 10.1001/jama.257.12.1605; CUMMINS RO, 1989, ANN EMERG MED, V18, P1269, DOI 10.1016/S0196-0644(89)80257-4; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1982, NEW ENGL J MED, V306, P1340, DOI 10.1056/NEJM198206033062206; GRAY AJ, 1987, BMJ, V295, P1133; HAMPTON JR, 1978, BRIT MED J, V1, P1118, DOI 10.1136/bmj.1.6120.1118; JAKOBSSON J, 1987, ACTA MED SCAND, V222, P123; MACKINTOSH AF, 1978, BRIT MED J, V1, P1115, DOI 10.1136/bmj.1.6120.1115; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; PANTRIDG.JF, 1967, LANCET, V2, P271; ROWLEY JM, 1987, BRIT MED J, V295, P1387, DOI 10.1136/bmj.295.6610.1387; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; VUKOV LF, 1988, ANN EMERG MED, V17, P318, DOI 10.1016/S0196-0644(88)80771-6; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; 1990, 1989 GEN REG OFF ANN; 1976, HN76204 DHSS DEP HLT; 1987, EXTENDED TRAINING AM; 1984, DA8412 DHSS DEP HLTH	25	78	78	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1517	1520		10.1136/bmj.302.6791.1517	http://dx.doi.org/10.1136/bmj.302.6791.1517			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855025	Green Published, Bronze			2022-12-01	WOS:A1991FT50500028
J	DEDOMBAL, FT; DALLOS, V; MCADAM, WAF				DEDOMBAL, FT; DALLOS, V; MCADAM, WAF			CAN COMPUTER-AIDED TEACHING PACKAGES IMPROVE CLINICAL CARE IN PATIENTS WITH ACUTE ABDOMINAL-PAIN	BRITISH MEDICAL JOURNAL			English	Article							ACUTE ABDOMEN; DIAGNOSIS	Objective - To compare three methods of support for inexperienced staff in their diagnosis and management of patients with acute abdominal pain -namely, with (a) structured data collection forms, (b) real time computer aided decision support, and (c) computer based teaching packages. Design - Prospective assessment of effects of methods of support on groups of doctors in one. urban hospital and one rural hospital. Setting - Accident and emergency department at Whipps Cross Hospital, London, and surgical wards of Airedale General Hospital, West Yorkshire. Patients - Consecutive prospective series of all patients presenting to each hospital in specified time periods with acute abdominal pain; total patients in the various periods were 12 506. Main outcome measures - Diagnostic accuracy of participating doctors, admission rates of patients with non-specific abdominal pain, perforation rates in patients with appendicitis, negative laparotomy rates. Results - Use of any one modality resulted in improved diagnostic accuracy and decision making performance. Use of structured forms plus computer feedback resulted in better performance than use of forms alone. Use of structured forms plus a computer teaching package gave results at least as good as those with direct feedback by computer. Conclusions - The results confirm earlier studies in suggesting that the use of computer aided decision support improves diagnostic and decision making performance when dealing with patients suffering from acute abdominal pain. That use of the computer for teaching gave results at least as good as with its use for direct feedback may be highly relevant for those who are apprehensive about the real time use of diagnostic computers in a clinical setting.	WHIPPS CROSS HOSP & CHEST CLIN,DEPT ACCID & EMERGENCY,LONDON E11,ENGLAND; AIREDALE DIST GEN HOSP,STEETON BD20 6TD,W YORKSHIRE,ENGLAND		DEDOMBAL, FT (corresponding author), UNIV LEEDS,CLIN INFORMAT SCI UNIT,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.							ADAMS ID, 1986, BRIT MED J, V293, P800, DOI 10.1136/bmj.293.6550.800; BALLA JI, 1989, BRIT MED J, V298, P579, DOI 10.1136/bmj.298.6673.579; BOOM R, 1980, P MEDINFO 80 AMSTERD, P1760; CLIFFORD PC, 1986, ANN ROY COLL SURG, V68, P182; DEDOMBAL FT, 1988, SCAND J GASTROENTERO, V23, P35; DEDOMBAL FT, 1972, BMJ-BRIT MED J, V2, P9, DOI 10.1136/bmj.2.5804.9; Gunn A A, 1976, J R Coll Surg Edinb, V21, P170; Hancock DM, 1987, THEOR SURG, V2, P99; HEWETT DJ, 1990, HOSPITAL UPDATE, V16, P283; HOFFMANN J, 1989, BRIT J SURG, V76, P774, DOI 10.1002/bjs.1800760803; LEAPER DJ, 1973, BMJ-BRIT MED J, V3, P569, DOI 10.1136/bmj.3.5880.569; MASSEY FJ, 1951, J AM STAT ASSOC, V46, P68, DOI 10.2307/2280095; MCADAM WAF, 1990, ANN ROY COLL SURG, V72, P140; MCADAM WAF, 1981, 6 YEARS EXPERIENCE C; MORRIS F, 1990, BRIT MED J, V300, P165, DOI 10.1136/bmj.300.6718.165; PATERSONBROWN S, 1990, BRIT J SURG, V77, P13, DOI 10.1002/bjs.1800770105; ROWSELL KV, IN PRESS THEORETICAL; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; STANILAND JR, 1972, BMJ-BRIT MED J, V3, P393, DOI 10.1136/bmj.3.5823.393; WILSON PD, 1975, BMJ-BRIT MED J, V2, P73, DOI 10.1136/bmj.2.5962.73	20	50	50	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1495	1497		10.1136/bmj.302.6791.1495	http://dx.doi.org/10.1136/bmj.302.6791.1495			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855017	Green Published, Bronze			2022-12-01	WOS:A1991FT50500019
J	DYE, S; ISAACS, C				DYE, S; ISAACS, C			INTRAVENOUS DRUG MISUSE AMONG PRISON-INMATES - IMPLICATIONS FOR SPREAD OF HIV	BRITISH MEDICAL JOURNAL			English	Article											DYE, S (corresponding author), ST MARYS HOSP,SCH MED,DEPT IMMUNOL,LONDON W2 1PG,ENGLAND.			Dye, Stephen/0000-0002-0535-5332				CARVELL ALM, 1990, BRIT MED J, V300, P1383, DOI 10.1136/bmj.300.6736.1383; SKIDMORE CA, 1990, BRIT MED J, V300, P219, DOI 10.1136/bmj.300.6719.219; 1989, HIV AIDS PRISONS; 1988, HIV AIDS PRISONS	4	28	28	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1506	1506		10.1136/bmj.302.6791.1506	http://dx.doi.org/10.1136/bmj.302.6791.1506			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FT505	1855020	Bronze, Green Published			2022-12-01	WOS:A1991FT50500023
J	HART, JT; THOMAS, C; GIBBONS, B; EDWARDS, C; HART, M; JONES, J; JONES, M; WALTON, P				HART, JT; THOMAS, C; GIBBONS, B; EDWARDS, C; HART, M; JONES, J; JONES, M; WALTON, P			25 YEARS OF CASE FINDING AND AUDIT IN A SOCIALLY DEPRIVED COMMUNITY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; GENERAL-PRACTICE; BLOOD-PRESSURE; DIETARY-SODIUM; INVERSE CARE; HEALTH CHECK; INEQUALITIES; HYPERTENSION; SATISFACTION; ATTENDERS	Objective - To evaluate audit and case finding (whole population care) in a community over 25 years. Design - Contemporary screening for and audits of care of chronic disease and risk factors; retrospective review of computerised practice records; and comparisons of mortality and social indices with neighbouring communities. Setting - One general practice in Glyncorrwg, West Glamorgan. Subjects - 1800 people registered with the practice in 1987 and 558 people who died from 1964 to 1987, whose records had been retained. Main outcome measures - Detection of high blood pressure, smoking, airways obstruction, obesity, diabetes, and alcohol problems in adults aged 20-79; prevalence of smoking in this population and in hypertensive and diabetic groups; age standardised mortality ratios in relation to indices of social deprivation. Results - In the population aged 20-79 (1207 patients) 249 (21%) had peak expiratory flow rate less than 50% of expected value or which improved by 15% or more with an inhaled beta-agonist, 207 (17%) had body mass index at or over 30 kg/m2, 118 (10%) had untreated mean arterial pressures greater than 159/104 mm Hg (three readings), 80 (7%) (65 (16%) men, 15 (4%) women) had recognised alcohol problems, and 35 (3%) had diabetes. The proportion of men aged 20-64 who said they smoked fell from 61% (290/476) in 1968-70 to 36% (162/456) in 1985 whereas that of women who smoked was unchanged (43%, 187/436 v 42%, 190/448 respectively). In 116 screened hypertensive patients group mean blood pressure fell from 186/110 mm Hg before treatment to 146/84 mm Hg at 1987 audit, as did the proportion of smokers (56% v 20%), but body mass index and total cholesterol concentration showed no significant change. In 34 diabetic patients mean blood pressure and the proportion of smokers fell (171/93 mm Hg v 155/81 mm Hg; 44% v 12%). The age standardised mortality ratio in 1981-6 was lower than in a neighbouring village without a developed case finding programme (actual to expected deaths < 65 = 21 to 22 in Glyncorrwg, 48 to 30 in control village). Conclusions - Whole population care through organised case finding and audit is feasible but only with a labour intensive approach combining accessibility, flexibility, and continuity, as well as a planned and structured approach, which requires substantial expansion of staff numbers and assiduous recording. It may reduce risks for at least some high risk groups. Despite their shortcomings the available data are consistent with the hypothesis that whole population care helps reduce mortality. Incentives in the new contract, which encourage the uncritical development of structured process, may diminish health outputs.	UNIV SWANSEA, DEPT GEOG, SWANSEA SA2 8PP, WALES; ABER BLAENGWYNFI HLTH CTR, BLAENGWYNFI, W GLAM, WALES; GLYNCORRWG HLTH CTR, GLYNCORRWYG, W GLAM, WALES	Swansea University	HART, JT (corresponding author), ST MARYS HOSP, SCH MED, DEPT GEN PRACTICE, LONDON W2 1PG, ENGLAND.							ALBASHIR MM, 1991, BRIT J GEN PRACT, V41, P6; AMIEL S, 1991, BRIT MED J, V302, P527, DOI 10.1136/bmj.302.6775.527; [Anonymous], 1970, JAMA, V213, P1143; BALLARD DJ, 1988, AM J PREV MED, V4, P133, DOI 10.1016/S0749-3797(18)31185-1; BOSANQUET N, 1988, BMJ-BRIT MED J, V296, P157; BUCHAN IC, 1973, SCOTTISH HLTH STUDIE, V27; CATFORD JC, 1984, BRIT MED J, V289, P1668, DOI 10.1136/bmj.289.6459.1668; Coope J, 1974, J R Coll Gen Pract, V24, P161; DAY JL, 1987, BRIT MED J, V294, P1590, DOI 10.1136/bmj.294.6587.1590; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HAMILTON M, 1964, LANCET, V1, P235; Hart J T, 1974, J R Coll Physicians Lond, V8, P299; Hart J T, 1976, J R Coll Gen Pract, V26, P885; HART JT, 1987, BRIT MED J, V294, P871, DOI 10.1136/bmj.294.6576.871; HART JT, 1970, LANCET, V2, P223; HART JT, 1990, BRIT J GEN PRACT, V40, P4; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; HART JT, 1982, BRIT MED J, V284, P1686, DOI 10.1136/bmj.284.6330.1686; HART JT, 1987, HYPERTENSION COMMUNI; Hart JT, 1988, PREVENTION CORONARY; HARTLAGE JA, 1984, SOAP COSMET CHEM SPE, V60, P42; HAYES TM, 1984, BRIT MED J, V289, P728, DOI 10.1136/bmj.289.6447.728; JAMROZIK K, 1984, BRIT MED J, V288, P1499, DOI 10.1136/bmj.288.6429.1499; Kark SL, 1989, PRACTICE COMMUNITY O; KAUL SA, 1988, STUDY SMALL AREA STA; LEESE B, 1989, BRIT MED J, V298, P932, DOI 10.1136/bmj.298.6678.932; LITTLEPAGE BNC, 1988, STUDY SMALL AREA STA; MAIN J, 1990, RCGP CONNECTION  SEP, P4; MARMOT MG, 1984, LANCET, V1, P1003; MORRELL DC, 1986, BMJ-BRIT MED J, V292, P870, DOI 10.1136/bmj.292.6524.870; PILL R, 1988, J ROY COLL GEN PRACT, V38, P53; PILL R, 1988, J ROY COLL GEN PRACT, V38, P57; PRINGLE M, 1989, BRIT MED J, V299, P470, DOI 10.1136/bmj.299.6697.470; RIDSDALE L, 1989, J ROY COLL GEN PRACT, V39, P488; RIDSDALE L, 1990, BRIT MED J, V301, P455, DOI 10.1136/bmj.301.6750.455; ROBSON J, 1989, BMJ-BRIT MED J, V298, P433, DOI 10.1136/bmj.298.6671.433; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; SAVAGE R, 1990, BRIT MED J, V301, P968, DOI 10.1136/bmj.301.6758.968; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; Stott N C, 1979, J R Coll Gen Pract, V29, P201; THOMAS K, 1989, J ROY COLL GEN PRACT, V39, P509; THOMPSON NF, 1990, BRIT J GEN PRACT, V40, P16; Townsend P, 1988, HLTH DEPRIVATION INE; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; WALLACE PG, 1987, J ROY COLL GEN PRACT, V37, P354; WALLER D, 1990, BRIT MED J, V300, P1115, DOI 10.1136/bmj.300.6732.1115; WATT GCM, 1983, LANCET, V1, P1245; WATT GCM, 1983, BMJ-BRIT MED J, V286, P432, DOI 10.1136/bmj.286.6363.432; WATT GCM, 1985, BMJ-BRIT MED J, V291, P1525, DOI 10.1136/bmj.291.6508.1525; 1980, INEQUALITIES HLTH; 1987, 7 HEARTB WAL; 1986, 24 ROYAL COLL GEN PR; 1985, 1 HEARTB WAL	54	60	59	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 22	1991	302	6791					1509	1513		10.1136/bmj.302.6791.1509	http://dx.doi.org/10.1136/bmj.302.6791.1509			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855023	Green Published, Bronze			2022-12-01	WOS:A1991FT50500026
J	KENNEDY, DH; NAIR, G; ELLIOTT, L; DITTON, J				KENNEDY, DH; NAIR, G; ELLIOTT, L; DITTON, J			DRUG MISUSE AND SHARING OF NEEDLES IN SCOTTISH PRISONS	BRITISH MEDICAL JOURNAL			English	Article									UNIV GLASGOW,CTR HIV & AIDS RESOURCE,GLASGOW G12 8QQ,SCOTLAND; RUCHILL HOSP,DEPT INFECT & TROP MED,GLASGOW G20 9NB,SCOTLAND; UNIV GLASGOW,CRIMINOL RES UNIT,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow; University of Glasgow								CARVELL ALM, 1990, BRIT MED J, V300, P1383, DOI 10.1136/bmj.300.6736.1383; DOLAN KA, 1990, HOWARD J, V29, P177; HARDING TW, 1990, HIV AIDS EUORPEAN PR; Stimson GV, 1988, INJECTING EQUIPMENT; 1990, ANSWER AIDS NEWS S	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1507	1507		10.1136/bmj.302.6791.1507	http://dx.doi.org/10.1136/bmj.302.6791.1507			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FT505	1855021	Green Published, Bronze			2022-12-01	WOS:A1991FT50500024
J	MCARDLE, CS; HOLE, D				MCARDLE, CS; HOLE, D			IMPACT OF VARIABILITY AMONG SURGEONS ON POSTOPERATIVE MORBIDITY AND MORTALITY AND ULTIMATE SURVIVAL	BRITISH MEDICAL JOURNAL			English	Article							LARGE-BOWEL-CANCER; LOCAL RECURRENCE	Objective - To assess the differences among surgeons in postoperative complications, postoperative mortality, and survival in patients undergoing surgery for colorectal cancer. Design - Prospective study of patients with colorectal cancer managed by one of 13 consultant surgeons, none of whom had a special interest in colorectal surgery. Setting - Royal Infirmary, Glasgow. Patients - 645 sequential patients with colorectal cancer presenting over the six years from 1974 to 1979. Main outcome measures - Postoperative complications, postoperative mortality (within 30 days), and survival (up to 10 years); predictive factors for postoperative mortality and survival; and relative hazard rate ratios for individual surgeons. Results - The proportion of patients undergoing apparently curative resection varied among surgeons from 40% to 76%; overall postoperative mortality varied from 8% to 30%. After curative resection postoperative mortality varied from 0% to 20%, local recurrence from 0% to 21%, and the rate of anastomotic leak from 0% to 25%. Survival at 10 years in patients who underwent curative resection varied from 20% to 63%, two year survival in those who underwent palliative resection varied from 7% to 32%, and median survival in those who underwent palliative diversion varied from one to eight months. The hazard rate ratios among individual surgeons, taking into account the identified risk factors, varied from 0.56 to 2.03, from 0.17 to 1.92, and from 0.57 to 1.50 for curative resection, palliative resection, and palliative diversion, respectively. Conclusion - There were significant variations in patient outcome among surgeons after surgery for colorectal cancer; such differences compromise survival. A considerable improvement in overall survival might be achieved if such surgery were undertaken by surgeons with a special interest in colorectal surgery or surgical oncology.	RUCHILL HOSP,CANC SURVEILLANCE UNIT,GLASGOW G20,SCOTLAND		MCARDLE, CS (corresponding author), UNIV GLASGOW,ROYAL INFIRM,DEPT SURG,GLASGOW G31 2ER,SCOTLAND.							AUSOBSKY JR, 1985, ANN ROY COLL SURG, V67, P159; Breslow NE, 1987, SCI PUBLICATION INT, V2; Buck N, 1987, REPORT CONFIDENTIAL; COX DR, 1972, J R STAT SOC B, V34, P187; FIELDING LP, 1980, BRIT MED J, V281, P411, DOI 10.1136/bmj.281.6237.411; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MCARDLE CS, 1990, BRIT J SURG, V77, P280, DOI 10.1002/bjs.1800770314; PHILLIPS RKS, 1984, BRIT J SURG, V71, P12, DOI 10.1002/bjs.1800710104; QUIRKE P, 1986, LANCET, V2, P996, DOI 10.1016/s0140-6736(86)92612-7; SHANDALL A, 1985, BRIT J SURG, V72, P606, DOI 10.1002/bjs.1800720808	10	474	479	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1501	1505		10.1136/bmj.302.6791.1501	http://dx.doi.org/10.1136/bmj.302.6791.1501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1713087	Green Published, Bronze			2022-12-01	WOS:A1991FT50500021
J	RAMSAY, MEB; CORBEL, MJ; REDHEAD, K; ASHWORTH, LAE; BEGG, NT				RAMSAY, MEB; CORBEL, MJ; REDHEAD, K; ASHWORTH, LAE; BEGG, NT			PERSISTENCE OF ANTIBODY AFTER ACCELERATED IMMUNIZATION WITH DIPHTHERIA TETANUS PERTUSSIS-VACCINE	BRITISH MEDICAL JOURNAL			English	Article							LINKED IMMUNOSORBENT-ASSAY; TOXIN NEUTRALIZATION TEST; HUMAN-SERA; POLIOMYELITIS; ANTITOXIN; EFFICACY	Objective - To determine the persistence of antibody to diphtheria, tetanus, and pertussis in children receiving an accelerated schedule of primary immunisation. Design - Controlled study of antibody testing of blood samples from children immunised according to various schedules: three doses of triple vaccine completed at 8-13 calendar months, 6-7 calendar months, before 6 calendar months, or three doses followed by diphtheria/tetanus before age 2. Setting - Plymouth Health Authority. Subjects - 129 children aged 4 years who had received three doses of diphtheria/tetanus/pertussis vaccine with or without a diphtheria/tetanus booster. Main outcome measures-Diphtheria and tetanus antitoxin concentrations and antibody titres to pertussis toxin, filamentous haemagglutinin, and agglutinogens 2 and 3. Results - All children had protective concentrations of antitoxin to diphtheria and tetanus (greater-than-or-equal-to 0.01 IU/ml). There was no evidence of a significant difference in diphtheria or tetanus antitoxin concentrations and pertussis antibody titres in children immunised with an accelerated course (third dose of triple vaccine before 6 months) compared with those who received a longer course (third dose at 8-13 months) with no booster (geometric mean antitoxin concentration 0.411 (95% confidence interval 0.273 to 0.618) v 0.426 (0.294 to 0.616) for diphtheria and 0.358 (0.231 to 0.556) v 0.299 (0.197 to 0.453) for tetanus; geometric mean antibody titres 903 (500 to 1631) v 1386 (848 to 2266) for pertussis filamentous haemagglutinin, 179 (130 to 248) v 232 (167 to 322) for pertussis toxin, and 2002 (1276 to 3142) v 3591 (2220 to 5809) for agglutinogens 2 and 3). Conclusion - Immunisation with three doses of triple vaccine at monthly intervals completed before 6 months of age probably provides adequate protection against diphtheria, tetanus, and whooping cough which will persist until the age of the preschool booster.	PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND; PUBL HLTH LAB SERV,CTR APPL MICROBIOL & RES,IMMUNOL & PATHOL GRP,SALISBURY SP4 0JG,WILTS,ENGLAND	Public Health England			Corbel, Michael/AAI-5520-2020; Ramsay, Mary Elizabeth/S-8281-2016	Ramsay, Mary Elizabeth/0000-0002-7156-7640				AGNESE PAD, 1949, PEDIATRICS, V3, P333; BARRETT CD, 1962, PEDIATRICS, V30, P720; CANNON DA, 1960, P S IMMUNISATION CHI; CHURCH MA, 1979, LANCET, V2, P188; COLLIER LH, 1979, LANCET, V1, P1364; HALSEY N, 1985, B WORLD HEALTH ORGAN, V63, P1151; JONES AE, 1989, VACCINE, V7, P300, DOI 10.1016/0264-410X(89)90189-8; MELVILLESMITH M, 1988, J MED MICROBIOL, V25, P279, DOI 10.1099/00222615-25-4-279; MELVILLESMITH ME, 1983, J BIOL STAND, V11, P137, DOI 10.1016/S0092-1157(83)80038-9; MILLER E, 1991, LANCET, P70; MILLER JJ, 1949, PEDIATRICS, V3, P468; NOAH N, 1976, BMJ, V1, P357; SMITH JWG, 1969, BRIT MED BULL, V25, P177, DOI 10.1093/oxfordjournals.bmb.a070689; 1984, IMMUNISATION INFECTI; 1982, BMJ, V285, P357; 1990, CONTROL DIPHTHERIA E; 1990, IMMUNISATION INFECTI; 1988, IMMUNISATION INFECTI; 1951, BMJ, V1, P1463; 1968, STATE PUBLIC HLTH YE	20	31	31	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1489	1491		10.1136/bmj.302.6791.1489	http://dx.doi.org/10.1136/bmj.302.6791.1489			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855015	Bronze, Green Published			2022-12-01	WOS:A1991FT50500017
J	SMITH, RA; LING, S; ALEXANDER, FW				SMITH, RA; LING, S; ALEXANDER, FW			GOLF RELATED HEAD-INJURIES IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article									NEWCASTLE GEN HOSP,DEPT PAEDIAT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital								JENNETT B, 1977, Lancet, V2, P696; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; MILLER JD, 1968, LANCET, V2, P991; STRANG I, 1978, INJURY, V10, P154	4	10	10	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1505	1506		10.1136/bmj.302.6791.1505	http://dx.doi.org/10.1136/bmj.302.6791.1505			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855019	Green Published, Bronze			2022-12-01	WOS:A1991FT50500022
J	VANDUIJN, CM; HOFMAN, A				VANDUIJN, CM; HOFMAN, A			RELATION BETWEEN NICOTINE INTAKE AND ALZHEIMERS-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							PARKINSONS-DISEASE; RISK-FACTORS; BINDING-SITES; CEREBRAL-CORTEX; HUMAN-BRAIN; DEMENTIA; SMOKING	Objective - To study the association between Alzheimer's disease and nicotine intake through smoking. Design - Population based case-control study. Setting - City of Rotterdam and four northern provinces of The Netherlands. Subjects - 198 patients with early onset Alzheimer's disease, 198 controls matched for age and sex, and families of 17 patients in whom Alzheimer's disease was apparently inherited as an autosomal dominant disorder. Main outcome measures - Age of onset of dementia, relative risk of Alzheimer's disease. Results - 89 of 193 patients with Alzheimer's disease had a history of smoking compared with 102 of 195 controls. Among the patients and controls with a family history of dementia, smoking was significantly less common in those with dementia (40/95 with dementia v 55/96 controls; relative risk 0.35; 95% confidence interval 0.16 to 0.78). The risk of Alzheimer's disease decreased with increasing daily number of cigarettes smoked before onset of disease (relative risk 0.3 in those smoking > 21/day v 1 in non-smokers). In six families in which the disease was apparently inherited as an autosomal dominant disorder, the mean age of onset was 4.17 years later in smoking patients than in non-smoking patients from the same family (p = 0.03). Conclusions - These findings suggest an inverse association between smoking and Alzheimer's disease, although smoking cannot be advocated for other health reasons. We speculate that nicotine may have a role in the aetiology of both Alzheimer's disease and Parkinson's disease.			VANDUIJN, CM (corresponding author), ERASMUS UNIV,SCH MED,DEPT EPIDEMIOL & BIOSTAT,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.							AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; APPEL SH, 1981, BRAIN NEUROTRANSMITT, P203; Barclay L, 1989, Prog Clin Biol Res, V317, P189; BARON JA, 1986, NEUROLOGY, V36, P1490, DOI 10.1212/WNL.36.11.1490; BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/j.1471-4159.1988.tb10600.x; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; CALNE DB, 1986, LANCET, V2, P1067, DOI 10.1016/S0140-6736(86)90469-1; CHANDRA V, 1987, NEUROLOGY, V37, P1295, DOI 10.1212/WNL.37.8.1295; DITTER SM, 1987, NEUROLOGY, V37, P754, DOI 10.1212/WNL.37.5.754; FARRER LA, 1990, NEUROLOGY, V40, P395, DOI 10.1212/WNL.40.3_Part_1.395; FERRINISTRAMBI L, 1990, NEUROEPIDEMIOLOGY, V9, P39; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; GRAVES AB, 1990, ANN NEUROL, V28, P766, DOI 10.1002/ana.410280607; GRAVES AB, IN PRESS INT J EPIDE; GROSSBERG GT, 1989, J AM GERIATR SOC, V37, P822; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; HOFMAN A, 1989, NEUROLOGY, V39, P1589, DOI 10.1212/WNL.39.12.1589; HOFMAN A, 1989, NEUROEPIDEMIOLOGY, V8, P296, DOI 10.1159/000110197; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; JONES GMM, 1987, J NEUROL NEUROSUR PS, V50, P1383, DOI 10.1136/jnnp.50.10.1383; JOYA CJ, 1990, NEUROBIOL AGING, V11, P296; KELLAR KJ, 1987, BRAIN RES, V436, P62, DOI 10.1016/0006-8993(87)91556-3; LONDON ED, 1989, NEUROCHEM RES, V14, P745, DOI 10.1007/BF00964952; MARSDEN CD, 1990, LANCET, V335, P948, DOI 10.1016/0140-6736(90)91006-V; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; NEWHOUSE PA, 1988, PSYCHOPHARMACOLOGY, V95, P171; PERRY EK, 1989, NEUROSCI RES COMMUN, V5, P117; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; PRICE DL, 1986, TRENDS NEUROSCI, V9, P29, DOI 10.1016/0166-2236(86)90011-1; SAHAKIAN B, 1989, BRIT J PSYCHIAT, V154, P797, DOI 10.1192/bjp.154.6.797; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SHALAT SL, 1987, NEUROLOGY, V37, P1630, DOI 10.1212/WNL.37.10.1630; WHITEHOUSE PJ, 1988, NEUROLOGY, V38, P720, DOI 10.1212/WNL.38.5.720	34	161	175	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1491	1494		10.1136/bmj.302.6791.1491	http://dx.doi.org/10.1136/bmj.302.6791.1491			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855016	Green Published, Bronze			2022-12-01	WOS:A1991FT50500018
J	ADAMS, MD; KELLEY, JM; GOCAYNE, JD; DUBNICK, M; POLYMEROPOULOS, MH; XIAO, H; MERRIL, CR; WU, A; OLDE, B; MORENO, RF; KERLAVAGE, AR; MCCOMBIE, WR; VENTER, JC				ADAMS, MD; KELLEY, JM; GOCAYNE, JD; DUBNICK, M; POLYMEROPOULOS, MH; XIAO, H; MERRIL, CR; WU, A; OLDE, B; MORENO, RF; KERLAVAGE, AR; MCCOMBIE, WR; VENTER, JC			COMPLEMENTARY-DNA SEQUENCING - EXPRESSED SEQUENCE TAGS AND HUMAN GENOME PROJECT	SCIENCE			English	Article								Automated partial DNA sequencing was conducted on more than 600 randomly selected human brain complementary DNA (cDNA) clones to generate expressed sequence tags (ESTs). ESTs have applications in the discovery of new human genes, mapping of the human genome, and identification of coding regions in genomic sequences. Of the sequences generated, 337 represent new genes, including 48 with significant similarity to genes from other organisms, such as a yeast RNA polymerase II subunit; Drosophila kinesin, Notch, and Enhancer of split; and a murine tyrosine kinase receptor. Forty-six ESTs were mapped to chromosomes after amplification by the polymerase chain reaction. This fast approach to cDNA characterization will facilitate the tagging of most human genes in a few years at a fraction of the cost of complete genomic sequencing, provide new genetic markers, and serve as a resource in diverse biological research fields.	NINCDS, RECEPTOR BIOCHEM & MOLEC BIOL SECT, BETHESDA, MD 20892 USA; ST ELIZABETH HOSP, NIMH, CTR NEUROSCI, BIOCHEM GENET LAB, WASHINGTON, DC 20032 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Martinez, Octavio/B-7375-2009	McCombie, W. Richard/0000-0003-1899-0682				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BALTIMORE D, 1988, REPORT AD HOC PROGRA; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BRENNER S, 1990, CIBA F SYMP, V149, P6; CAMPOSORTEGA JA, 1988, TRENDS NEUROSCI, V11, P400, DOI 10.1016/0166-2236(88)90077-X; CATHCART R, 1990, NATURE, V347, P310, DOI 10.1038/347310a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUGUID JR, 1990, NUCLEIC ACIDS RES, V18, P2789, DOI 10.1093/nar/18.9.2789; FARGNOLI J, 1990, ANAL BIOCHEM, V187, P364, DOI 10.1016/0003-2697(90)90471-K; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; FUCHS R, 1991, COMPUT APPL BIOSCI, V7, P105; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; KATO K, 1990, EUR J NEUROSCI, V2, P704, DOI 10.1111/j.1460-9568.1990.tb00460.x; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KOCH MSH, 1990, NUCLEIC ACIDS RES, V18, P5705; McKusick VA., ONLINE MENDELIAN INH; NISHI S, 1988, BIOCHEM BIOPH RES CO, V157, P937, DOI 10.1016/S0006-291X(88)80964-1; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; PALAZZOLO MJ, 1989, NEURON, V3, P527, DOI 10.1016/0896-6273(89)90211-0; PATANJALI SR, 1991, P NATL ACAD SCI USA, V88, P1943, DOI 10.1073/pnas.88.5.1943; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PUTNEY SD, 1983, NATURE, V302, P718, DOI 10.1038/302718a0; SCHMID DW, 1987, J NEUROCHEM, V48, P307, DOI 10.1111/j.1471-4159.1987.tb13163.x; Schwartz RM, 1979, ATLAS PROTEIN SEQUEN, P353, DOI DOI 10.2307/2408678; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; SUTCLIFFE JG, 1988, ANNU REV NEUROSCI, V11, P157, DOI 10.1146/annurev.ne.11.030188.001105; TRAVIS GH, 1988, P NATL ACAD SCI USA, V85, P1696, DOI 10.1073/pnas.85.5.1696; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WAGSTAFF J, IN PRESS AM J HUM GE; 1991, HUM GENOME NEWS, V2, P1; 1988, REPORT COMMITTEE MAP	34	1737	2118	6	168	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	1991	252	5013					1651	1656		10.1126/science.2047873	http://dx.doi.org/10.1126/science.2047873			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	2047873				2022-12-01	WOS:A1991FT11400035
J	FAUSTMAN, D; COE, C				FAUSTMAN, D; COE, C			PREVENTION OF XENOGRAFT REJECTION BY MASKING DONOR HLA CLASS-I ANTIGENS	SCIENCE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; ISLET ALLOGRAFT SURVIVAL; T-CELL RECEPTORS; AUTOIMMUNE ENCEPHALOMYELITIS; MONOCLONAL-ANTIBODY; RENAL-ALLOGRAFTS; ADHESION; INVIVO; MICE; PROLONGATION	Destruction of target cells by cytotoxic T lymphocytes requires the presence of HLA (human lymphocyte antigen) class I antigens on the target cells for adhesion as well as for triggering of the antigen-specific T cell receptor. Rejection of xenogeneic human pancreatic islets and liver was circumvented by masking, before transplantation, donor antigens with F(ab')2 antibody fragments to HLA class I or tissue-specific epitopes. This strategy eliminated the need for recipient immunosuppression and allowed islet xenograft survival beyond 200 days, as demonstrated functionally by C peptide secretion as well as by histology. These in vivo observations are consistent with the importance of donor HLA class I in eliciting graft rejection and have potential applicability to the successful transplantation of other HLA class I-bearing donor tissues.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DIABET UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital								ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ADORINI L, 1988, NATURE, V334, P623, DOI 10.1038/334623a0; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BOITARD C, 1988, P NATL ACAD SCI USA, V85, P9719, DOI 10.1073/pnas.85.24.9719; BROSTOFF SW, 1984, J IMMUNOL, V133, P1938; CAMPBELL IL, 1989, P NATL ACAD SCI USA, V86, P4282, DOI 10.1073/pnas.86.11.4282; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; DOHERTY PC, 1984, ADV CANCER RES, V42, P1, DOI 10.1016/S0065-230X(08)60455-8; FABRE JW, 1975, TRANSPLANTATION, V20, P269; FAUSTMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P5156, DOI 10.1073/pnas.78.8.5156; FAUSTMAN DL, 1984, P NATL ACAD SCI-BIOL, V81, P3864, DOI 10.1073/pnas.81.12.3864; FRENCH ME, 1972, TRANSPLANT REV-DENMA, V13, P115; GOODFELLOW PN, 1976, TRANSPLANTATION, V22, P595, DOI 10.1097/00007890-197612000-00009; KRENSKY AM, 1983, J IMMUNOL, V131, P611; LACY PE, 1979, SCIENCE, V204, P312, DOI 10.1126/science.107588; LAFFERTY KJ, 1975, SCIENCE, V188, P259, DOI 10.1126/science.1118726; LIDER O, 1988, SCIENCE, V239, P181, DOI 10.1126/science.2447648; MARON R, 1983, J IMMUNOL, V131, P2316; OWHASHI M, 1988, J EXP MED, V168, P2153, DOI 10.1084/jem.168.6.2153; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SPITS H, 1986, SCIENCE, V232, P403, DOI 10.1126/science.3485822; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STEINMAN L, 1981, P NATL ACAD SCI-BIOL, V78, P7111, DOI 10.1073/pnas.78.11.7111; VIVES M, 1990, IMMUNOLOGY DIABETES, P5; Wang Y, 1987, DIABETES, V36, P535, DOI 10.2337/diabetes.36.4.535; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	26	107	146	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1991	252	5013					1700	1702		10.1126/science.1710828	http://dx.doi.org/10.1126/science.1710828			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1710828				2022-12-01	WOS:A1991FT11400044
J	FINBERG, RW; WAHL, SM; ALLEN, JB; SOMAN, G; STROM, TB; MURPHY, JR; NICHOLS, JC				FINBERG, RW; WAHL, SM; ALLEN, JB; SOMAN, G; STROM, TB; MURPHY, JR; NICHOLS, JC			SELECTIVE ELIMINATION OF HIV-1-INFECTED CELLS WITH AN INTERLEUKIN-2 RECEPTOR SPECIFIC CYTOTOXIN	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED CELLS; FUSION PROTEIN; DIPHTHERIA-TOXIN; ENVELOPE GLYCOPROTEIN; LYMPHOCYTES; ACTIVATION; ENTRY; MONOCYTES; CD4	Infection by human immunodeficiency virus type 1 (HIV-1) is associated with cellular activation and expression of the interleukin-2 (IL-2) receptor. A genetically engineered fusion toxin, DAB486 IL-2, that contains the enzymatic site and translocation domain of diphtheria toxin and the receptor binding domain of IL-2 specifically kills cells that express high-affinity IL-2 receptors. This toxin selectively eliminated the HIV-1-infected cells from mixed cultures of infected and uninfected cells and inhibited production of viral proteins and infectious virus. Thus, cellular activation antigens present a target for early antiviral intervention.	SERAGEN,HOPKINTON,MA 01748; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; NIDR,IMMUNOL LAB,BETHESDA,MD 20892; BETH ISRAEL HOSP,CHARLES A DANA RES INST,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL HOSP,THORNDIKE LAB,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; BOSTON UNIV MED,BOSTON UNIV HOSP,BOSTON,MA 02118	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Boston University	FINBERG, RW (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,INFECT DIS LAB,BOSTON,MA 02115, USA.		Finberg, Robert W/E-3323-2010					ALLEN JB, 1990, J CLIN INVEST, V85, P192, DOI 10.1172/JCI114412; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FIELDS AP, 1988, NATURE, V333, P278, DOI 10.1038/333278a0; FINBERG RW, UNPUB; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GEYER SJ, 1989, 5TH INT C AIDS INT A, P636; GOWDA SD, 1989, J IMMUNOL, V142, P773; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; HORAK ID, 1990, NATURE, V348, P557, DOI 10.1038/348557a0; KIRKMAN RL, 1989, TRANSPLANTATION, V47, P327, DOI 10.1097/00007890-198902000-00028; KIYOKAWA T, 1989, CANCER RES, V49, P4042; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; LEMAISTRE F, 1990, BLOOD, V76, pA314; MIOSSEC P, 1990, ARTHRITIS RHEUM, V33, P1688, DOI 10.1002/art.1780331112; MITTLER RS, 1989, SCIENCE, V245, P1380, DOI 10.1126/science.2571187; Nichols Johanna, UNPUB; PANKEWYCZ O, 1989, TRANSPLANTATION, V47, P318, DOI 10.1097/00007890-198902000-00026; RIECKMANN P, 1991, J EXP MED, V173, P1, DOI 10.1084/jem.173.1.1; SPIRA TJ, 1987, J CLIN MICROBIOL, V25, P97, DOI 10.1128/JCM.25.1.97-99.1987; TILL MA, 1988, SCIENCE, V242, P1166, DOI 10.1126/science.2847316; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WAHL SM, 1989, J IMMUNOL, V142, P3553; WATERS CA, 1990, EUR J IMMUNOL, V20, P785, DOI 10.1002/eji.1830200412; WILLIAMS DP, 1987, PROTEIN ENG, V1, P493, DOI 10.1093/protein/1.6.493; WOODWORTH T, 1991, 4TH INT C HUM RETR M; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	28	49	52	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1991	252	5013					1703	1705		10.1126/science.1904628	http://dx.doi.org/10.1126/science.1904628			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1904628				2022-12-01	WOS:A1991FT11400045
J	KERN, SE; KINZLER, KW; BRUSKIN, A; JAROSZ, D; FRIEDMAN, P; PRIVES, C; VOGELSTEIN, B				KERN, SE; KINZLER, KW; BRUSKIN, A; JAROSZ, D; FRIEDMAN, P; PRIVES, C; VOGELSTEIN, B			IDENTIFICATION OF P53 AS A SEQUENCE-SPECIFIC DNA-BINDING PROTEIN	SCIENCE			English	Article							WILD-TYPE P53; GENE-MUTATIONS; LAC REPRESSOR; LUNG-CANCER; CELL-LINE; DELETIONS; ONCOGENE; TRANSFORMATION; ABNORMALITIES; REPLICATION	The tumor-suppressor gene p53 is altered by missense mutation in numerous human malignancies. However, the biochemical properties of p53 and the effect of mutation on these properties are unclear. A human DNA sequence was identified that binds specifically to wild-type human p53 protein in vitro. As few as 33 base pairs were sufficient to confer specific binding. Certain guanines within this 33-base pair region were critical, as methylation of these guanines or their substitution with thymine-abrogated binding. Human p53 proteins containing either of two missense mutations commonly found in human tumors were unable to bind significantly to this sequence. These data suggest that a function of p53 may be mediated by its ability to bind to specific DNA sequences in the human genome, and that this activity is altered by mutations that occur in human tumors.	JOHNS HOPK UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21231; APPL BIOTECHNOL,CAMBRIDGE,MA 02142; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Johns Hopkins University; Johns Hopkins University; Columbia University					NATIONAL CANCER INSTITUTE [R01CA043460, P01CA033620, P30CA006973, R37CA043460] Funding Source: NIH RePORTER; NCI NIH HHS [CA43460, CA33620, CA06973] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ANACHKOVA B, 1989, MOL CELL BIOL, V9, P532, DOI 10.1128/MCB.9.2.532; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; HUBERMAN JA, COMMUNICATION; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; KERN SE, 1991, ONCOGENE, V6, P131; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; LYONS J, 1990, INFECT IMMUN, V58, P4089, DOI 10.1128/IAI.58.12.4089-4098.1990; MANIATIS T, 1982, MOL CLONING LABORATO, P477; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MISRA R, 1989, NUCLEIC ACIDS RES, V17, P8327, DOI 10.1093/nar/17.20.8327; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROMANO JW, 1989, ONCOGENE, V4, P1483; STEINMEYER K, 1988, ONCOGENE, V3, P501; STRATTON MR, 1990, ONCOGENE, V5, P1297; SYLVESTER JE, 1989, GENE, V84, P193, DOI 10.1016/0378-1119(89)90155-8; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; ZIMARINO V, 1990, SCIENCE, V249, P546, DOI 10.1126/science.2200124	35	1076	1109	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1991	252	5013					1708	1711		10.1126/science.2047879	http://dx.doi.org/10.1126/science.2047879			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	2047879				2022-12-01	WOS:A1991FT11400047
J	KREMER, EJ; PRITCHARD, M; LYNCH, M; YU, S; HOLMAN, K; BAKER, E; WARREN, ST; SCHLESSINGER, D; SUTHERLAND, GR; RICHARDS, RI				KREMER, EJ; PRITCHARD, M; LYNCH, M; YU, S; HOLMAN, K; BAKER, E; WARREN, ST; SCHLESSINGER, D; SUTHERLAND, GR; RICHARDS, RI			MAPPING OF DNA INSTABILITY AT THE FRAGILE-X TO A TRINUCLEOTIDE REPEAT SEQUENCE P(CCG)N	SCIENCE			English	Article							NUCLEOTIDES; EXPRESSION	The sequence of a Pst I restriction fragment was determined that demonstrates instability in fragile X syndrome pedigrees. The region of instability was localized to a trinucleotide repeat p(CCG)n. The sequences flanking this repeat were identical in normal and affected individuals. The breakpoints in two somatic cell hybrids constructed to break at the fragile site also mapped to this repeat sequence. The repeat exhibits instability both when cloned in a nonhomologous host and after amplification by the polymerase chain reaction. These results suggest variation in the trinucleotide repeat copy number as the molecular basis for the instability and possibly the fragile site. This would account for the observed properties of this region in vivo and in vitro.	WASHINGTON UNIV,SCH MED,CTR GENET MED,ST LOUIS,MO 63110; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322	Washington University (WUSTL); Emory University; Emory University			Kremer, EJ/P-9838-2019; Richards, Robert/ABE-6423-2020; Sutherland, Grant Robert/D-2606-2012; Kremer, Eric J/D-3734-2013; Warren, Stephen T/A-2498-2012	Kremer, EJ/0000-0001-6114-7530; Richards, Robert Ian/0000-0002-5978-6453				BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; KREMER E, UNPUB; KREMER EJ, IN PRESS AM J HUM GE; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; Sutherland G, 1985, FRAGILE SITES HUMAN; SUTHERLAND GR, 1986, AM J MED GENET, V23, P409, DOI 10.1002/ajmg.1320230133; SUTHERLAND GR, 1988, MUTAT RES, V200, P207, DOI 10.1016/0027-5107(88)90084-X; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WILLIAMSON R, 1990, CYTOGENET CELL GENET, V55, P457, DOI 10.1159/000133027; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; [No title captured]	13	834	866	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1991	252	5013					1711	1714		10.1126/science.1675488	http://dx.doi.org/10.1126/science.1675488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1675488				2022-12-01	WOS:A1991FT11400048
J	MOTT, DD; LEWIS, DV				MOTT, DD; LEWIS, DV			FACILITATION OF THE INDUCTION OF LONG-TERM POTENTIATION BY GABA-B RECEPTORS	SCIENCE			English	Article							RAT DENTATE GYRUS; HIPPOCAMPAL-NEURONS; BACLOFEN; INHIBITION; DEPRESSION; 2-HYDROXY-SACLOFEN; INVITRO; STIMULATION; ANTAGONISTS; RESPONSES	Long-term potentiation (LTP), an in vitro model of learning, was induced in hippocampal slices by 5-hertz stimulation. During induction, gamma-aminobutyric acid A (GABA(A)) inhibition decreased, causing the N-methyl-D-aspartate receptor-mediated excitation to increase. 2-OH Saclofen, a GABA(B) receptor antagonist, prevented the reduction of inhibition, the increase of excitation, and the induction of LTP. Therefore, disinhibition caused by GABA(B) receptors is required for induction of LTP by 5-hertz stimulation. GABA(B) receptor modulation of synaptic plasticity occurs at frequencies in the range of the endogenous hippocampal theta rhythm, which has been shown to modulate LTP in vivo.	DUKE UNIV,MED CTR,DEPT PEDIAT NEUROL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710	Duke University; Duke University	MOTT, DD (corresponding author), DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710, USA.			Mott, David/0000-0003-0758-8006	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027488] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27488] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDAHAN MI, 1990, BRAIN RES, V526, P308, DOI 10.1016/0006-8993(90)91237-B; BONANNO G, 1989, EUR J PHARM-MOLEC PH, V172, P41, DOI 10.1016/0922-4106(89)90043-6; COLLINGRIDGE GL, 1989, NMDA RECEPTOR, pCH9; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DEISZ RA, 1989, J PHYSIOL-LONDON, V412, P513, DOI 10.1113/jphysiol.1989.sp017629; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; DUNWIDDIE T, 1978, J PHYSIOL-LONDON, V276, P353, DOI 10.1113/jphysiol.1978.sp012239; HARRISON NL, 1990, J PHYSIOL-LONDON, V422, P433, DOI 10.1113/jphysiol.1990.sp017993; HERRON CE, 1985, NEUROSCI LETT, V60, P19, DOI 10.1016/0304-3940(85)90375-1; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; KERR DIB, 1988, NEUROSCI LETT, V92, P92, DOI 10.1016/0304-3940(88)90748-3; LAMBERT NA, 1989, NEUROSCI LETT, V107, P125, DOI 10.1016/0304-3940(89)90803-3; LARSON J, 1988, BRAIN RES, V441, P111, DOI 10.1016/0006-8993(88)91388-1; MISGELD U, 1989, PFLUG ARCH EUR J PHY, V414, P139, DOI 10.1007/BF00580955; MORRISETT RA, 1991, J NEUROSCI, V11, P203; MOTT D D, 1990, Society for Neuroscience Abstracts, V16, P945; MOTT DD, 1989, J PHARMACOL EXP THER, V249, P721; MOTT DD, 1990, NEUROSCI LETT, V113, P222, DOI 10.1016/0304-3940(90)90307-U; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLPE HR, 1990, N-S ARCH PHARMACOL, V342, P194, DOI 10.1007/BF00166964; PACELLI GJ, 1989, BRAIN RES, V486, P26, DOI 10.1016/0006-8993(89)91273-0; PAVLIDES C, 1988, BRAIN RES, V439, P383, DOI 10.1016/0006-8993(88)91499-0; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P524, DOI 10.1152/jn.1989.61.3.524; WIGSTROM H, 1983, NATURE, V301, P603, DOI 10.1038/301603a0	25	261	263	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1991	252	5013					1718	1720		10.1126/science.1675489	http://dx.doi.org/10.1126/science.1675489			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1675489				2022-12-01	WOS:A1991FT11400050
J	PUTZ, J; PUGLISI, JD; FLORENTZ, C; GIEGE, R				PUTZ, J; PUGLISI, JD; FLORENTZ, C; GIEGE, R			IDENTITY ELEMENTS FOR SPECIFIC AMINOACYLATION OF YEAST TRANSFER RNAASP BY COGNATE ASPARTYL-TRANSFER RNA-SYNTHETASE	SCIENCE			English	Article								The nucleotides crucial for the specific aminoacylation of yeast tRNA(Asp) by its cognate synthetase have been identified. Steady-state aminoacylation kinetics of unmodified tRNA transcripts indicate that G34, U35, C36, and G73 are important determinants of tRNA(Asp) identity. Mutations at these positions result in a large decrease (19- to 530-fold) of the kinetic specificity constant (ratio of the catalytic rate constant k(cat) and the Michaelis constant K(m)) for aspartylation relative to wild-type tRNA(Asp). Mutation to G10-C25 within the D-stem reduced k(cat)/K(m) eightfold. This fifth mutation probably indirectly affects the presentation of the highly conserved G10 nucleotide to the synthetase. A yeast tRNA(Phe) was converted into an efficient substrate for aspartyl-tRNA synthetase through introduction of the five identity elements. The identity nucleotides are located in regions of tight interaction between tRNA and synthetase as shown in the crystal structure of the complex and suggest sites of base-specific contacts.	CNRS, INST BIOL MOLEC & CELLULAIRE, BIOCHIM LAB, 15 RUE RENE DESCARTES, F-67084 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								BRUCE AG, 1982, BIOCHEMISTRY-US, V21, P3921, DOI 10.1021/bi00260a003; CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; EBEL JP, 1973, BIOCHIMIE, V55, P547, DOI 10.1016/S0300-9084(73)80415-8; FLORENTZ C, 1991, EUR J BIOCHEM, V195, P229, DOI 10.1111/j.1432-1033.1991.tb15698.x; FREIST W, 1989, BIOCHEMISTRY-US, V28, P6787, DOI 10.1021/bi00443a001; GANGLOFF J, 1971, NATURE, V230, P726; GARCIA A, 1990, NUCLEIC ACIDS RES, V18, P89, DOI 10.1093/nar/18.1.89; GARCIA A, UNPUB; HASEGAWA T, 1989, BIOCHEM BIOPH RES CO, V163, P1534, DOI 10.1016/0006-291X(89)91154-6; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; LORBER B, 1983, BIOCHEM BIOPH RES CO, V117, P259, DOI 10.1016/0006-291X(83)91569-3; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; NICHOLAS HB, 1987, COMPUT APPL BIOSCI, V3, P177; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; PERRET V, 1990, BIOCHIMIE, V72, P735, DOI 10.1016/0300-9084(90)90158-D; PUGLISI J, UNPUB; RAJBHANDARY UL, 1968, J BIOL CHEM, V243, P598; ROGERS MJ, 1988, P NATL ACAD SCI USA, V85, P6627, DOI 10.1073/pnas.85.18.6627; ROMBY P, 1985, J MOL BIOL, V184, P455, DOI 10.1016/0022-2836(85)90294-3; ROMBY P, 1986, THESIS U L PASTEUR S; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAMPSON JR, 1989, SCIENCE, V243, P1363; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SAYERS JR, 1989, PROTEIN FUNCTION PRA, P279; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SEKIYA T, 1980, NUCLEIC ACIDS RES, V8, P3809, DOI 10.1093/nar/8.17.3809; SHI JP, 1990, BIOCHEMISTRY-US, V29, P3621, DOI 10.1021/bi00467a005; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; YARUS M, 1988, CELL, V55, P739, DOI 10.1016/0092-8674(88)90127-4	36	166	168	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	1991	252	5013					1696	1699		10.1126/science.2047878	http://dx.doi.org/10.1126/science.2047878			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	2047878				2022-12-01	WOS:A1991FT11400043
J	RAPRAEGER, AC; KRUFKA, A; OLWIN, BB				RAPRAEGER, AC; KRUFKA, A; OLWIN, BB			REQUIREMENT OF HEPARAN-SULFATE FOR BFGF-MEDIATED FIBROBLAST GROWTH AND MYOBLAST DIFFERENTIATION	SCIENCE			English	Article							PLASMINOGEN-ACTIVATOR PRODUCTION; SKELETAL-MUSCLE MYOBLASTS; PROTEIN-TYROSINE KINASE; EXTRACELLULAR-MATRIX; SWISS-3T3 CELLS; FACTOR RECEPTOR; AFFINITY; BINDING; CLONING; IDENTIFICATION	Basic fibroblast growth factor (bFGF) binds to heparan sulfate proteoglycans at the cell surface and to receptors with tyrosine kinase activity. Prevention of binding between cell surface heparan sulfate and bFGF (i) substantially reduces binding of fibroblast growth factor to its cell-surface receptors, (ii) blocks the ability of bFGF to support the growth of Swiss 3T3 fibroblasts, and (iii) induces terminal differentiation of MM14 skeletal muscle cells, which is normally repressed by fibroblast growth factor. These results indicate that cell surface heparan sulfate is directly involved in bFGF cell signaling.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	RAPRAEGER, AC (corresponding author), UNIV WISCONSIN,DEPT PATHOL,MADISON,WI 53706, USA.		Olwin, Bradley B/A-1333-2014	Krufka, Alison/0000-0002-8921-6291	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R23HD021881, R01HD021881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039467, R01AR039467] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR039467, AR39467] Funding Source: Medline; NICHD NIH HHS [HD21881] Funding Source: Medline; PHS HHS [5T32H007118] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURRUS LW, 1989, J BIOL CHEM, V264, P18647; CARPENTER G, 1976, J CELL PHYSIOL, V88, P227, DOI 10.1002/jcp.1040880212; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FARLEY JR, 1978, ARCH BIOCHEM BIOPHYS, V185, P376, DOI 10.1016/0003-9861(78)90180-7; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HUANG SS, 1986, BIOCHEM BIOPH RES CO, V139, P619, DOI 10.1016/S0006-291X(86)80035-3; KELLER JM, 1987, BIOCHIM BIOPHYS ACTA, V926, P139, DOI 10.1016/0304-4165(87)90230-3; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KRUFKA A, 1990, Journal of Cell Biology, V111, p223A; KRUFKA A, UNPUB; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LORIES V, 1989, J BIOL CHEM, V264, P7009; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; OLWIN BB, UNPUB; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; RAPRAEGER AC, UNPUB; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SENO M, 1990, EUR J BIOCHEM, V188, P239, DOI 10.1111/j.1432-1033.1990.tb15395.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	39	1419	1461	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1991	252	5013					1705	1708		10.1126/science.1646484	http://dx.doi.org/10.1126/science.1646484			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1646484				2022-12-01	WOS:A1991FT11400046
J	RUFF, M; KRISHNASWAMY, S; BOEGLIN, M; POTERSZMAN, A; MITSCHLER, A; PODJARNY, A; REES, B; THIERRY, JC; MORAS, D				RUFF, M; KRISHNASWAMY, S; BOEGLIN, M; POTERSZMAN, A; MITSCHLER, A; PODJARNY, A; REES, B; THIERRY, JC; MORAS, D			CLASS-II AMINOACYL TRANSFER-RNA SYNTHETASES - CRYSTAL-STRUCTURE OF YEAST ASPARTYL-TRANSFER RNA-SYNTHETASE COMPLEXED WITH TRANSFER RNAASP	SCIENCE			English	Article								The crystal structure of the binary complex tRNA(Asp)-aspartyl tRNA synthetase from yeast was solved with the use of multiple isomorphous replacement to 3 angstrom resolution. The dimeric synthetase, a member of class II aminoacyl tRNA synthetases (aaRS's) exhibits the characteristic signature motifs conserved in eight aaRS's. These three sequence motifs are contained in the catalytic site domain, built around an antiparallel beta-sheet, and flanked by three alpha-helices that form the pocket in which adenosine triphosphate (ATP) and the CCA end of tRNA bind. The tRNA(Asp) molecule approaches the synthetase from the variable loop side. The two major contact areas are with the acceptor end and the anticodon stem and loop. In both sites the protein interacts with the tRNA from the major groove side. The correlation between aaRS class II and the initial site of aminoacylation at 3'-OH can be explained by the structure. The molecular association leads to the following features: (i) the backbone of the GCCA single-stranded portion of the acceptor end exhibits a regular helical conformation; (ii) the loop between residues 320 and 342 in motif 2 interacts with the acceptor stem in the major groove and is in contact with the discriminator base G and the first base pair UA; and (iii) the anticodon loop undergoes a large conformational change in order to bind the protein. The conformation of the tRNA molecule in the complex is dictated more by the interaction with the protein than by its own sequence.	UNIV STRASBOURG 1, CNRS,INST BIOL MOLEC & CELLULAIRE, CRISTALLOG BIOL LAB,15 RUE RENE DESCARTES, F-67084 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			ruff, marc/J-3011-2013	ruff, marc/0000-0001-5451-6377; Podjarny, Alberto/0000-0002-7685-1077; POTERSZMAN, Arnaud/0000-0002-6702-5777; Krishnaswamy, Sankaran/0000-0002-6797-4614				AMIRI I, 1985, BIOCHIMIE, V67, P607, DOI 10.1016/S0300-9084(85)80200-5; ANSELME J, 1989, GENE, V84, P481, DOI 10.1016/0378-1119(89)90524-6; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DIETRICH A, 1980, J MOL BIOL, V138, P129, DOI 10.1016/S0022-2836(80)80008-8; DOCK AC, 1984, BIOCHIMIE, V66, P179, DOI 10.1016/0300-9084(84)90063-4; DOCKBREGEON AC, 1990, EUR J BIOCHEM, V188, P283, DOI 10.1111/j.1432-1033.1990.tb15401.x; ERIANI G, 1990, NUCLEIC ACIDS RES, V18, P7109, DOI 10.1093/nar/18.23.7109; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ERIANI G, IN PRESS NUCLEIC ACI; FRASER TH, 1975, P NATL ACAD SCI USA, V72, P3044, DOI 10.1073/pnas.72.8.3044; FREIST W, 1981, H-S Z PHYSIOL CHEM, V362, P1247, DOI 10.1515/bchm2.1981.362.2.1247; FREIST W, 1988, ANGEW CHEM INT EDIT, V27, P773, DOI 10.1002/anie.198807731; GANGLOFF J, 1971, NATURE, V230, P726; GIEGE R, 1980, CR ACAD SCI D NAT, V291, P393; HECK JD, 1988, J BIOL CHEM, V263, P868; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; HOUNTONDJI C, 1985, BIOCHEMISTRY-US, V24, P1175, DOI 10.1021/bi00326a018; HOUNTONDJI C, 1986, BIOCHIMIE, V68, P1071, DOI 10.1016/S0300-9084(86)80181-X; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KERN D, 1990, EUR J BIOCHEM, V193, P97, DOI 10.1111/j.1432-1033.1990.tb19309.x; KERN D, 1981, BIOCHIM BIOPHYS ACTA, V653, P83, DOI 10.1016/0005-2787(81)90106-4; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; LEVEQUE F, 1990, NUCLEIC ACIDS RES, V18, P305, DOI 10.1093/nar/18.2.305; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MORAS D, 1986, P NATL ACAD SCI USA, V83, P932, DOI 10.1073/pnas.83.4.932; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; NICHOLAS HB, 1987, COMPUT APPL BIOSCI, V3, P53; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; PODJARNY A, 1987, J BIOMOL STRUCT DYN, V5, P187, DOI 10.1080/07391102.1987.10506389; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; RICH A, 1977, NUCLEIC ACIDS RES, V4, P1649, DOI 10.1093/nar/4.5.1649; Rich A., 1962, HORIZONS BIOCH, P103; RISLER JL, 1981, NATURE, V292, P384, DOI 10.1038/292384a0; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1988, J MOL BIOL, V201, P235, DOI 10.1016/0022-2836(88)90450-0; RUFF M, UNPUB; SELLAMI M, 1986, NUCLEIC ACIDS RES, V14, P1657, DOI 10.1093/nar/14.4.1657; SHARP KA, 1990, BIOCHEMISTRY-US, V29, P340, DOI 10.1021/bi00454a006; VONDERHAAR F, 1975, BIOCHEMISTRY-US, V15, P4131; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8	48	657	667	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	1991	252	5013					1682	1689		10.1126/science.2047877	http://dx.doi.org/10.1126/science.2047877			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	2047877				2022-12-01	WOS:A1991FT11400040
J	VERDOORN, TA; BURNASHEV, N; MONYER, H; SEEBURG, PH; SAKMANN, B				VERDOORN, TA; BURNASHEV, N; MONYER, H; SEEBURG, PH; SAKMANN, B			STRUCTURAL DETERMINANTS OF ION FLOW THROUGH RECOMBINANT GLUTAMATE RECEPTOR CHANNELS	SCIENCE			English	Article								Functional glutamate receptors (GluRs) were transiently expressed in cultured mammalian cells from cloned complementary DNAs encoding GluR-A, -B, -C, or -D polypeptides. The steady-state current-voltage (I-V) relations of glutamate- and kainate-induced currents through homomeric channels fell into two classes: channels composed of either the GluR-A, -C, and -D subunits showed doubly rectifying I-V curves, and channels composed of the GluR-B subunits displayed simple outward rectification. The presence of GluR-B subunits in heteromeric GluRs determined the I-V behavior of the resulting channels. Site-directed mutagenesis identified a single amino acid difference (glutamine to arginine) in the putative transmembrane segment TM2 responsible for subunit-specific I-V relationships. The properties of heteromeric wild-type and mutant GluRs revealed that the dominance of GluR-B is due to the arginine residue in the TM2 region.	MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, JAHNSTR 29, W-6900 HEIDELBERG 1, GERMANY; UNIV HEIDELBERG, CTR MOLEC BIOL, MOLEC NEUROENDOCRINOL LAB, W-6900 HEIDELBERG 1, GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg			Burnashev, Nail/G-4056-2013	Monyer, Hannah/0000-0002-9332-5749				ADAMS PR, 1975, BRIT J PHARMACOL, V53, P308, DOI 10.1111/j.1476-5381.1975.tb07364.x; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; DAWSON TL, 1990, MOL PHARMACOL, V38, P779; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JONAS P, IN PRESS J PHYSL LON; JONAS P, UNPUB; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MONGHAN DT, 1989, ANN REV PHARM TOXICO, V21, P165; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NEHER E, 1975, P NATL ACAD SCI USA, V72, P2140, DOI 10.1073/pnas.72.6.2140; SAH P, 1990, J PHYSIOL-LONDON, V430, P605, DOI 10.1113/jphysiol.1990.sp018310; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SHERIDAN RE, 1975, P NATL ACAD SCI USA, V72, P3496, DOI 10.1073/pnas.72.9.3496; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012	23	718	729	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	1991	252	5013					1715	1718		10.1126/science.1710829	http://dx.doi.org/10.1126/science.1710829			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1710829				2022-12-01	WOS:A1991FT11400049
J	CHOSSON, P; LANAU, C; CONNAN, J; DESSORT, D				CHOSSON, P; LANAU, C; CONNAN, J; DESSORT, D			BIODEGRADATION OF REFRACTORY HYDROCARBON BIOMARKERS FROM PETROLEUM UNDER LABORATORY CONDITIONS	NATURE			English	Article							CRUDE OILS; STERANES; SEDIMENTS; TERPANES	BIOMARKERS are of great value in petroleum exploration because they provide essential information about the geological history of oils and source rocks. Steranes 1 are of particular importance as they can be related to naturally occurring precursors 2, 3. These compounds generally experience intense biodegradation, however, which alters their original distribution 4-6 and obscures the information that they carry regarding oil maturity and source material. In an attempt to identify the microorganisms responsible for this degradation, we have investigated the capacity of 73 aerobic bacteria to degrade steranes present in Rozel Point (Utah) oil 7. Seven Gram-positive strains, belonging to a limited number of genera, were found to be active. Using Nocardia sp. SEBR 16, which caused the most extensive alteration, we have determined biodegradation rates for several isomers of steranes and methylsteranes. The preference for alteration of different isomers reflects that observed in natural environments, suggesting that the degradation intermediates could be used as indicators of the extent of the biodegradation in an oil. In addition, the microorganisms used here might be effective in biodegrading oil spills.	ELF AQUITAINE,CSTJF,F-64018 PAU,FRANCE	Total SA; Centre Scientifique et Technique Jean Feger (CSTJF)	CHOSSON, P (corresponding author), SANOFI ELF BIORECH,BP 137,F-31328 LABEGE,FRANCE.							BORTZ LC, 1987, AAPG STUDIES GEOLOGY, P555; DASTILLUNG M, 1977, NATURE, V269, P678, DOI 10.1038/269678b0; ENSMINGER A, 1978, TETRAHEDRON LETT, P1575; GOODWIN NS, 1988, ORG GEOCHEM, V12, P495, DOI 10.1016/0146-6380(88)90159-3; Goodwin NS, 1983, ADV ORG GEOCHEM, P650; Landais P., 1986, SCI GEOLOGIQUES B, V39, P293, DOI [10.3406/sgeol.1986.1732, DOI 10.3406/SGEOL.1986.1732]; Mackenzie AS, 1984, ADV PETROLEUM GEOCHE, P115, DOI DOI 10.1016/B978-0-12-032001-1.50008-0; McKirdy D.M., 1983, ADV ORG GEOCHEM, P99; OCONNOR JG, 1962, ANAL CHEM, V34, P82, DOI 10.1021/ac60181a022; RULKOTER J, 1982, GOECHIM COSMOCHIM AC, V46, P1545; SEIFERT WK, 1979, GEOCHIM COSMOCHIM AC, V43, P111, DOI 10.1016/0016-7037(79)90051-6; SEIFERT WK, 1978, GEOCHIM COSMOCHIM AC, V42, P77, DOI 10.1016/0016-7037(78)90219-3; SUMMONS RE, 1987, GEOCHIM COSMOCHIM AC, V51, P3075, DOI 10.1016/0016-7037(87)90381-4; VOLKMAN JK, 1983, GEOCHIM COSMOCHIM AC, V47, P785, DOI 10.1016/0016-7037(83)90112-6; [No title captured]	15	58	62	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1991	351	6328					640	642		10.1038/351640a0	http://dx.doi.org/10.1038/351640a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT112	2052089				2022-12-01	WOS:A1991FT11200061
J	CREEL, SR; MONFORT, SL; WILDT, DE; WASER, PM				CREEL, SR; MONFORT, SL; WILDT, DE; WASER, PM			SPONTANEOUS LACTATION IS AN ADAPTIVE RESULT OF PSEUDOPREGNANCY	NATURE			English	Article							DWARF MONGOOSE; ESTROUS-CYCLE; PROGESTERONE; PREGNANCY; REPRODUCTION; ESTRADIOL; INFANTS; DOG	LACTATION is almost exclusively associated with pregnancy and giving birth. Although lactation can be induced without a preceding pregnancy in some species, this requires exogenous hormones, artificially intense or extended suckling or both 1, 2. Spontaneous lactation, lactation by females that have neither been pregnant nor experimentally manipulated, is extremely unusual among eutherians 3-8. Among nondomesticated animals, spontaneous lactation has been observed repeatedly only in the dwarf mongoose Helogale parvula 9. We report here spontaneous lactation by free-living dwarf mongooses using data on urinary oestrogen conjugate concentrations (n = 560, 65 females) and body weight (n = 3,096, 25 females) from a population in Serengeti National Park, Tanzania. We use demographic data from this population to demonstrate that spontaneous lactation, and thus the endocrine phenomena that induce it, increase the evolutionary fitness of lactating females.	SMITHSONIAN INST,NATL ZOOL PK,CTR CONSERVAT & RES,ENDOCRINE RES LAB,FRONT ROYAL,VA 22630	Smithsonian Institution; Smithsonian National Zoological Park & Conservation Biology Institute	CREEL, SR (corresponding author), PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907, USA.							Brown J.L., 1981, P244; BROWN RE, 1977, PEDIATRICS, V60, P116; CONCANNON PW, 1977, BIOL REPROD, V16, P517; COWIE AT, 1984, HORMONAL CONTROL REP, P195; CREEL S, IN PRESS BEHAV ECOL; CREEL SR, IN PRESS ANIM BEHAV; CREEL SR, IN PRESS BEHAVL ECOL; DALY M, 1979, J THEOR BIOL, V78, P325, DOI 10.1016/0022-5193(79)90334-5; HADLEY JC, 1975, J REPROD FERTIL, V44, P453, DOI 10.1530/jrf.0.0440453; HOLMAN SD, 1980, HORM BEHAV, V14, P348, DOI 10.1016/0018-506X(80)90024-0; JAKUBOWSKI M, 1980, J REPROD FERTIL, V58, P55, DOI 10.1530/jrf.0.0580055; NALBANDOV AV, 1976, REPRODUCTIVE PHYSL B; PEREIRA ME, 1989, AM J PRIMATOL, V18, P101, DOI 10.1002/ajp.1350180204; RAPAPORT L, 1987, J MAMMAL, V68, P438, DOI 10.2307/1381494; RASA OAE, 1987, ADV STUD BEHAV, V17, P121, DOI 10.1016/S0065-3454(08)60178-3; RASA OAE, 1977, Z TIERPSYCHOL, V43, P337; ROOD JP, 1978, Z TIERPSYCHOL, V48, P277; ROOD JP, 1990, ANIM BEHAV, V39, P566, DOI 10.1016/S0003-3472(05)80423-3; ROOD JP, 1980, ANIM BEHAV, V28, P143, DOI 10.1016/S0003-3472(80)80019-4; ROOD JP, 1983, ADV STUDY MAMMALIAN, P454; SEAL US, 1979, BIOL REPROD, V21, P1057, DOI 10.1095/biolreprod21.5.1057; SMITH MS, 1974, ENDOCRINOLOGY, V94, P404, DOI 10.1210/endo-94-2-404; VERHAGE HG, 1976, BIOL REPROD, V14, P579, DOI 10.1095/biolreprod14.5.579; West Eberhard M.J., 1975, Quarterly Review of Biology, V50, P1	24	71	72	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1991	351	6328					660	662		10.1038/351660a0	http://dx.doi.org/10.1038/351660a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT112	2052092				2022-12-01	WOS:A1991FT11200069
J	HENRY, I; BONAITIPELLIE, C; CHEHENSSE, V; BELDJORD, C; SCHWARTZ, C; UTERMANN, G; JUNIEN, C				HENRY, I; BONAITIPELLIE, C; CHEHENSSE, V; BELDJORD, C; SCHWARTZ, C; UTERMANN, G; JUNIEN, C			UNIPARENTAL PATERNAL DISOMY IN A GENETIC CANCER-PREDISPOSING SYNDROME	NATURE			English	Article							WIEDEMANN-BECKWITH SYNDROME; WILMS TUMOR; ADRENOCORTICAL CARCINOMA; CHROMOSOME-11; 11P15.5; ALLELES; TRISOMY; MARKERS; LOCUS	THE 11p15.5 region of human chromosome 11 seems to contain a locus or loci involved in congenital overgrowth anomalies as well as in the genesis of many tumours associated with the Beckwith-Wiedemann syndrome (BWS) 1-6. Given the unusual differential parental allele involvement in the different aetiological forms of BWS 5, 7 and the loss of maternal alleles in associated tumours 8-10, we have now used 11p15.5 markers to determine the parental origin of chromosome 11 in eight sporadic cases of BWS. Probands in three informative families had uniparental paternal disomy for region 11p15.5. Further, an overall greatly increased frequency of homozygosity for several 11p15.5 markers in 21 sporadic BWS patients suggest that isodisomy probably accounts for an even higher proportion of BWS sporadic cases. This demonstrates that uniparental paternal disomy can be associated with a genetic cancer-predisposing syndrome.	INSERM,U155,F-75016 PARIS,FRANCE; INSERM,U129,F-75014 PARIS,FRANCE; GREENWOOD GENET CTR,GREENWOOD,SC 29646; UNIV INNSBRUCK,A-6020 INNSBRUCK,AUSTRIA	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Greenwood Genetic Center; University of Innsbruck	HENRY, I (corresponding author), INSERM,U73,CHATEAU LONGCHAMP,F-75016 PARIS,FRANCE.							ALECK K, 1985, ANN GENET-PARIS, V28, P102; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HENRY I, 1989, HUM GENET, V81, P273, DOI 10.1007/BF00279003; HENRY I, 1985, ANN HUM GENET, V49, P173, DOI 10.1111/j.1469-1809.1985.tb01691.x; JUNIEN C, 1989, CYTOGENET CELL GENET, V51, P226, DOI 10.1159/000132793; KNOLL JHM, 1990, AM J HUM GENET, V47, P149; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LUBINSKY M, 1974, LANCET, V1, P932; MANNENS M, 1988, AM J HUM GENET, V31, P41; MANNENS M, 1988, CYTOGENET CELL GENET, V46, P655; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; NIIKAWA N, 1986, AM J MED GENET, V24, P41, DOI 10.1002/ajmg.1320240107; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PING AJ, 1989, AM J HUM GENET, V44, P720; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; TAKAHIKO Y, 1989, J NATL CANCER I, V81, P518; TURLEAU C, 1985, ANN GENET-PARIS, V28, P93; VOSS R, 1989, AM J HUM GENET, V45, P373; WIEDEMANN HR, 1983, EUR J PEDIATR, V141, P129, DOI 10.1007/BF00496807	23	369	375	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1991	351	6328					665	667		10.1038/351665a0	http://dx.doi.org/10.1038/351665a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT112	1675767				2022-12-01	WOS:A1991FT11200071
J	HERRMANN, JE; TAYLOR, DN; ECHEVERRIA, P; BLACKLOW, NR				HERRMANN, JE; TAYLOR, DN; ECHEVERRIA, P; BLACKLOW, NR			ASTROVIRUSES AS A CAUSE OF GASTROENTERITIS IN CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONOCLONAL-ANTIBODIES; ANTIGEN-DETECTION; SEROTYPES; DIAGNOSIS; VIRUSES	Background. Infection with astroviruses has been associated with gastroenteritis in children, and serologic surveys indicate that this infection may be frequent. The importance of astroviruses as agents of gastroenteritis has not been shown in a controlled study, however. Methods. We used monoclonal antibody-based enzyme immunoassays to detect astroviruses, enteric adenoviruses, and rotaviruses in stool samples obtained from age-matched children with and children without gastroenteritis. The samples were obtained in two studies, three years apart, among patients attending an outpatient clinic in Bangkok, Thailand. Results. In the first study, astroviruses were detected in 8.6 percent (96 of 1111) of the children with gastroenteritis and in 2.0 percent (19 of 947) of the children without gastroenteritis. In the second study the rates were 8.6 percent (50 of 580) and 2.1 percent (11 of 512), respectively. For both studies combined, enteric adenoviruses were detected in 2.6 percent of those with gastroenteritis and in 0.5 percent of the controls, whereas rotaviruses were detected in 19 percent of those with gastroenteritis and in 1.0 percent of the controls. The clinical findings associated with astrovirus infection were similar to those associated with rotavirus infection, except for a trend toward greater dehydration in the children infected with rotaviruses. Conclusions. These two controlled studies involving a total of 3150 Thai children provide evidence that astroviruses are a common cause of viral gastroenteritis. Astroviruses were found in association with gastroenteritis more frequently than were enteric adenoviruses, and with nearly half the frequency of rotaviruses.	ARMED FORCES RES INST MED SCI,BANGKOK,THAILAND	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS)	HERRMANN, JE (corresponding author), UNIV MASSACHUSETTS,SCH MED,DIV INFECT DIS & IMMUNOL,WORCESTER,MA 01655, USA.							ASHLEY CR, 1978, J CLIN PATHOL, V31, P939, DOI 10.1136/jcp.31.10.939; CEPKO CL, 1983, J CLIN MICROBIOL, V17, P360, DOI 10.1128/JCM.17.2.360-364.1983; CUKOR G, 1984, J CLIN MICROBIOL, V19, P888, DOI 10.1128/JCM.19.6.888-892.1984; ECHEVERRIA P, 1989, J INFECT DIS, V159, P543, DOI 10.1093/infdis/159.3.543; ELLIS ME, 1984, ARCH DIS CHILD, V59, P848, DOI 10.1136/adc.59.9.848; GRAY JJ, 1987, J MED VIROL, V23, P377, DOI 10.1002/jmv.1890230410; HERRMANN JE, 1990, ARCH VIROL, V110, P213, DOI 10.1007/BF01311289; HERRMANN JE, 1987, LANCET, V2, P743; HERRMANN JE, 1987, J INFECT DIS, V155, P1167, DOI 10.1093/infdis/155.6.1167; HERRMANN JE, 1990, J INFECT DIS, V161, P226, DOI 10.1093/infdis/161.2.226; HERRMANN JE, 1988, J INFECT DIS, V158, P182, DOI 10.1093/infdis/158.1.182; KONNO T, 1982, J MED VIROL, V9, P11, DOI 10.1002/jmv.1890090103; KOTLOFF KL, 1975, LANCET, V2, P451; KURTZ J, 1978, MED MICROBIOL IMMUN, V166, P227, DOI 10.1007/BF02121154; KURTZ JB, 1987, CIBA F SYMP, V128, P92; KURTZ JB, 1984, LANCET, V2, P1405; KURTZ JB, 1977, J CLIN PATHOL, V30, P948, DOI 10.1136/jcp.30.10.948; KURTZ JB, 1979, J MED VIROL, V3, P221, DOI 10.1002/jmv.1890030308; LEE TW, 1981, J GEN VIROL, V57, P421, DOI 10.1099/0022-1317-57-2-421; MADELEY CR, 1977, J HYG-CAMBRIDGE, V78, P261, DOI 10.1017/S0022172400056151; MADELEY CR, 1975, LANCET, V2, P124; MADELEY CR, 1978, J HYG LOND, V82, P285; MIDDLETON PJ, 1982, VIRUS INFECTIONS GAS, P211; NAZER H, 1982, J PEDIATR GASTR NUTR, V1, P555, DOI 10.1097/00005176-198212000-00018; RIEPENHOFFTALTY M, 1983, J CLIN MICROBIOL, V17, P352, DOI 10.1128/JCM.17.2.352-356.1983; TAYLOR DN, 1986, J INFECT DIS, V153, P1132, DOI 10.1093/infdis/153.6.1132	26	159	164	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1991	324	25					1757	1760		10.1056/NEJM199106203242501	http://dx.doi.org/10.1056/NEJM199106203242501			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR681	1645459				2022-12-01	WOS:A1991FR68100001
J	LONERGAN, ET; KREVANS, JR				LONERGAN, ET; KREVANS, JR			A NATIONAL AGENDA FOR RESEARCH ON AGING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											LONERGAN, ET (corresponding author), UNIV CALIF SAN FRANCISCO,INST MED STUDY,SAN FRANCISCO,CA 94143, USA.								0	52	52	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1991	324	25					1825	1828		10.1056/NEJM199106203242527	http://dx.doi.org/10.1056/NEJM199106203242527			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FR681	2038376				2022-12-01	WOS:A1991FR68100029
J	MA, YH; HENDERSON, HE; VENMURTHY, MR; ROEDERER, G; MONSALVE, MV; CLARKE, LA; NORMAND, T; JULIEN, P; GAGNE, C; LAMBERT, M; DAVIGNON, J; LUPIEN, PJ; BRUNZELL, J; HAYDEN, MR				MA, YH; HENDERSON, HE; VENMURTHY, MR; ROEDERER, G; MONSALVE, MV; CLARKE, LA; NORMAND, T; JULIEN, P; GAGNE, C; LAMBERT, M; DAVIGNON, J; LUPIEN, PJ; BRUNZELL, J; HAYDEN, MR			A MUTATION IN THE HUMAN LIPOPROTEIN-LIPASE GENE AS THE MOST COMMON CAUSE OF FAMILIAL CHYLOMICRONEMIA IN FRENCH-CANADIANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MISSENSE MUTATION; DEFICIENCY; HETEROZYGOTE; BINDING; DNA; LPL	Background. Lipoprotein lipase hydrolyzes the triglyceride core of chylomicrons and very-low-density lipoproteins and has a crucial role in regulating plasma lipoprotein levels. Deficiencies of lipoprotein lipase activity lead to aberrations in lipoprotein levels. Worldwide, the frequency of lipoprotein lipase deficiency is highest among French Canadians. We sought to determine the molecular basis of the disorder in this population. Methods. The entire coding sequence of the lipoprotein lipase gene from one French Canadian patient was amplified by the polymerase chain reaction and sequenced. Exon 5 from 36 other French Canadian patients was amplified and analyzed by dot blot hybridization with allele-specific oligonucleotides. Results. Sequence analysis revealed a missense substitution of leucine (CTG) for proline (CCG) at residue 207 in exon 5. This mutation was found on 54 of the 74 mutant alleles (73 percent) in the patients. Studies of site-directed in vitro mutagenesis have confirmed that this mutation generates inactive lipoprotein lipase and is the cause of lipoprotein lipase deficiency. Conclusions. We have identified a missense mutation at residue 207 of the lipoprotein lipase gene that is the most common cause of lipoprotein lipase deficiency in French Canadians. This mutation can be easily detected by dot blot analysis, providing opportunity for definitive DNA diagnosis of the disorder and identification of heterozygous carriers.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V6T 1W5,BC,CANADA; UNIV LAVAL,DEPT BIOCHEM,QUEBEC CITY G1K 7P4,QUEBEC,CANADA; CLIN RES INST MONTREAL,MONTREAL H2W 1R7,QUEBEC,CANADA; UNIV MONTREAL,HOP ST JUSTINE,MONTREAL H3T 1C5,QUEBEC,CANADA; UNIV LAVAL,LIPID RES CTR,QUEBEC CITY G1K 7P4,QUEBEC,CANADA; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	University of British Columbia; Laval University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Laval University; University of Washington; University of Washington Seattle			Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419; Clarke, Lorne/0000-0003-0512-7281	NIDDK NIH HHS [DK-02456] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMEIS D, 1991, J CLIN INVEST, V87, P1165, DOI 10.1172/JCI115114; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; BRUNZELL JD, 1983, J LIPID RES, V24, P12; BRUNZELL JD, 1989, METABOLIC BASIS INHE, V1, P1165; CHARBONNEAU H, 1987, ATLAS HIST CANADA, V1, P118; CHENG CF, 1981, J BIOL CHEM, V256, P2893; CUPP M, 1987, J BIOL CHEM, V262, P6383; DEBRAEKELEER M, IN PRESS HUM HERED; DEEB SS, 1989, BIOCHEMISTRY-US, V28, P6786, DOI 10.1021/bi00442a036; DEVLIN RH, 1990, AM J HUM GENET, V46, P112; EMI M, 1990, J BIOL CHEM, V265, P5910; EMI M, 1990, AM J HUM GENET, V47, P107; FISHER KL, 1987, NUCLEIC ACIDS RES, V15, P7657, DOI 10.1093/nar/15.18.7657; FUNKE H, 1987, NUCLEIC ACIDS RES, V15, P9102, DOI 10.1093/nar/15.21.9102; GAGNE C, 1989, CAN MED ASSOC J, V140, P405; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HATA A, 1990, AM J HUM GENET, V47, P721; HENDERSON HE, 1990, MOL BIOL MED, V7, P511; HENDERSON HE, 1991, J CLIN INVEST, V87, P2005, DOI 10.1172/JCI115229; LANGLOIS S, 1989, P NATL ACAD SCI USA, V86, P948, DOI 10.1073/pnas.86.3.948; MONSALVE MV, 1990, J CLIN INVEST, V86, P728, DOI 10.1172/JCI114769; MULLENBACH R, 1989, TRENDS GENET, V5, P391; NIKKILA EA, 1983, METABOLIC BASIS INHE, P622; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; SPARKES R S, 1987, Genomics, V1, P138, DOI 10.1016/0888-7543(87)90005-X; WANG XB, 1989, DNA-J MOLEC CELL BIO, V8, P753, DOI 10.1089/dna.1989.8.753; WILSON DE, 1990, J CLIN INVEST, V86, P735, DOI 10.1172/JCI114770; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907	30	99	104	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1991	324	25					1761	1766		10.1056/NEJM199106203242502	http://dx.doi.org/10.1056/NEJM199106203242502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR681	2038366	Bronze			2022-12-01	WOS:A1991FR68100002
J	PLUMMER, MR; HESS, P				PLUMMER, MR; HESS, P			REVERSIBLE UNCOUPLING OF INACTIVATION IN N-TYPE CALCIUM CHANNELS	NATURE			English	Article							SINGLE SODIUM-CHANNELS; CHICK SENSORY NEURONS; SYMPATHETIC NEURONS; CA-2+ CHANNELS; CA-CHANNEL; CURRENTS; RELEASE; SENSITIVITY; MODULATION; MEMBRANE	N-TYPE calcium channels are thought to be expressed specifically in neuronal cells 1-3 and to have a dominant role in the control of neurotransmitter release from sympathetic neurons 4, 5. But their unitary properties are poorly understood and the separation of neuronal Ca2+ current into components carried by N-type or L-type Ca2+ channels is controversial 6. Here we show that individual N-type Ca2+ channels in sympathetic neurons can carry two kinetically distinct components of current, one that is rapidly transient and one that is long lasting. The mechanism that gives rise to these two components is unexpected for Ca2+ channels: a test depolarization elicits either a rapidly inactivating, single short burst with an average duration of 40 ms, or sustained, noninactivating channel activity lasting for over 1 s. The switching between inactivating and noninactivating activity is a slow process, the occurrence of each type of unitary kinetic behaviour remaining statistically correlated over several seconds. Variable coupling of inactivation in N-type Ca2+ channels could be an effective mechanism for the modulation of neuronal excitability and synaptic plasticity.	HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; BOLAND LM, 1990, J PHYSIOL-LONDON, V420, P223, DOI 10.1113/jphysiol.1990.sp017909; COOPER E, 1989, J GEN PHYSIOL, V94, P881, DOI 10.1085/jgp.94.5.881; FISHER RE, 1990, J NEUROPHYSIOL, V64, P91, DOI 10.1152/jn.1990.64.1.91; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; HORN R, 1984, BIOPHYS J, V45, P323, DOI 10.1016/S0006-3495(84)84158-2; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JONES SW, 1989, J GEN PHYSIOL, V94, P169, DOI 10.1085/jgp.94.1.169; KONGSAMUT S, 1989, ANN NY ACAD SCI, V560, P312, DOI 10.1111/j.1749-6632.1989.tb24112.x; KOSTYUK PG, 1988, PFLUG ARCH EUR J PHY, V411, P661, DOI 10.1007/BF00580863; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; MCMANUS OB, 1987, PFLUG ARCH EUR J PHY, V410, P530, DOI 10.1007/BF00586537; MOORMAN JR, 1990, NEURON, V4, P243, DOI 10.1016/0896-6273(90)90099-2; NILIUS B, 1988, BIOPHYS J, V53, P857, DOI 10.1016/S0006-3495(88)83166-7; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PATLAK JB, 1989, J GEN PHYSIOL, V94, P279, DOI 10.1085/jgp.94.2.279; PATLAK JB, 1985, J GEN PHYSIOL, V86, P89, DOI 10.1085/jgp.86.1.89; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; REGAN LJ, 1991, NEURON, V6, P1; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; SWANDULLA D, 1991, TRENDS NEUROSCI, V14, P46, DOI 10.1016/0166-2236(91)90018-P; USOWICZ MM, 1990, J PHYSIOL-LONDON, V426, P95, DOI 10.1113/jphysiol.1990.sp018128; Zar JH., 1999, BIOSTAT ANAL, V4	27	116	118	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1991	351	6328					657	659		10.1038/351657a0	http://dx.doi.org/10.1038/351657a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT112	1646965				2022-12-01	WOS:A1991FT11200068
J	RATTO, GM; ROBINSON, DW; YAN, B; MCNAUGHTON, PA				RATTO, GM; ROBINSON, DW; YAN, B; MCNAUGHTON, PA			DEVELOPMENT OF THE LIGHT RESPONSE IN NEONATAL MAMMALIAN RODS	NATURE			English	Article							DEVELOPING RAT RETINA; OUTER SEGMENTS; SPECTRAL SENSITIVITY; POSTNATAL-DEVELOPMENT; HUMAN INFANTS; RHODOPSIN; DESENSITIZATION; MECHANISMS; ACTIVATION; VISION	THE sensitivity to light is low in many neonatal mammals when compared with that in the adult. In human infants at one month of age, for example, the dark-adapted sensitivity for detection of large stimuli is 50 times lower than in the adult 1-4, and in rats the overall sensitivity of the neonatal retina is also low compared with the adult 5, 6. This low sensitivity in the neonate has been attributed to a number of factors 5-11, but the possibility that the photoreceptors themselves might be an important limitation on the overall visual sensitivity has not so far been clearly established. Here we record the light response of single neonatal rat rods and find that the sensitivity is considerably lower than in the adult. The response to a single photoisomerization is normal in the neonate, and the sensitivity deficit can therefore be attributed to a low level of functional rhodopsin. Opsin, the protein component of rhodopsin, must be present in normal amounts, as the sensitivity can be restored to adult levels by treating the retina with 9-cis retinal, an active homologue of the native chromophore 11-cis retinal. The low sensitivity of photoreceptors in the neonate can therefore be attributed mainly to a low concentration of 11-cis retinal in the developing retina.			RATTO, GM (corresponding author), PHYSIOL LAB,DOWNING ST,CAMBRIDGE CB2 3EG,ENGLAND.		Yan, Bing/B-7903-2009; Ratto, Gian Michele/AAX-8514-2020; Ratto, Gian Michele/AAB-8719-2021	Yan, Bing/0000-0002-7970-6764; Ratto, Gian Michele/0000-0001-9632-7769; McNaughton, Peter/0000-0003-1946-9610				ALPERN M, 1987, VISION RES, V27, P1459, DOI 10.1016/0042-6989(87)90155-6; BANKS MS, 1988, J OPT SOC AM A, V5, P2059, DOI 10.1364/JOSAA.5.002059; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; BROWN AM, 1986, VISION RES, V26, P707, DOI 10.1016/0042-6989(86)90084-2; CARTERDAWSON L, 1986, DEV BIOL, V116, P431, DOI 10.1016/0012-1606(86)90144-2; DOWLING JE, 1962, J CELL BIOL, V14, P73, DOI 10.1083/jcb.14.1.73; FULTON AB, 1980, VISION RES, V20, P819, DOI 10.1016/0042-6989(80)90062-0; FULTON AB, 1991, VISION RES, V31, P1259, DOI 10.1016/0042-6989(91)90050-F; FULTON AB, 1984, INVEST OPHTH VIS SCI, V25, P647; HAMER RD, 1984, VISION RES, V24, P77, DOI 10.1016/0042-6989(84)90146-9; HODGKIN AL, 1985, J PHYSIOL-LONDON, V358, P447, DOI 10.1113/jphysiol.1985.sp015561; JACOBS DS, 1988, VISION RES, V28, P947, DOI 10.1016/0042-6989(88)90104-6; LAMB TD, 1981, J PHYSIOL-LONDON, V319, P463, DOI 10.1113/jphysiol.1981.sp013921; Lewis JM, 1939, J PEDIATR-US, V15, P812, DOI 10.1016/S0022-3476(39)80081-6; MAKINO CL, 1990, J PHYSIOL-LONDON, V424, P545, DOI 10.1113/jphysiol.1990.sp018082; MCNAUGHTON PA, 1980, NATURE, V283, P85, DOI 10.1038/283085a0; NOELL WK, 1980, VISION RES, V20, P1163, DOI 10.1016/0042-6989(80)90055-3; POWERS MK, 1981, VISION RES, V21, P1005, DOI 10.1016/0042-6989(81)90004-3; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0; WILSON HR, 1988, VISION RES, V28, P611; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700	24	61	66	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1991	351	6328					654	657		10.1038/351654a0	http://dx.doi.org/10.1038/351654a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT112	2052091				2022-12-01	WOS:A1991FT11200067
J	VAN DE VELDE, H; VONHOEGEN, I; LUO, W; PARNES, JR; THIELEMANS, K				VAN DE VELDE, H; VONHOEGEN, I; LUO, W; PARNES, JR; THIELEMANS, K			THE B-CELL SURFACE PROTEIN CD72/LYB-2 IS THE LIGAND FOR CD5	NATURE			English	Article							T-CELLS; DIFFERENTIATION ANTIGEN; LYMPHOCYTES-T; RECEPTORS; ACTIVATION; ADHESION; ANTIBODY; SYSTEM; IDENTIFICATION; EXPRESSION	THE glycoprotein CD5 is expressed on the surface membrane of all mature T cells 1 and a small proportion of B lymphocytes 1, 2. Its exact role in immune interactions is still unknown. Studies 3-10 indicate that CD5 functions both in mice and humans as a receptor, delivering co-stimulatory signals to T cells in a manner similar to CD2 (ref. 11) and CD28 (ref. 12). Anti-CD5 antibodies stimulate both T-cell proliferation mediated by CD3 in association with the T-cell receptor and secretion of interleukin-2 and expression of its receptor, as well as inducing an increase in intracellular Ca2+ concentration (refs 5-10). To identify the ligand for CD5 we purified the human CD5 protein, labelled it with biotin and used it as a probe. Here we report that CD5 specifically interacts with the cell-surface protein CD72 exclusive to B cells. This interaction is blocked by anti-CD72 antibodies, but not by any other anti-B-cell antibodies. Moreover, non-B cells (mouse L-cell fibroblasts and human Jurkat T cells) expressing a transfected human CD72 complementary DNA could bind to the CD5-biotin conjugate. The results demonstrate that the B-cell surface protein CD72 (Lyb-2 in mice) is the ligand for CD5.	VRIJE UNIV BRUSSELS, SCH MED, DIV HAEMATOL IMMUNOL, B-1090 BRUSSELS, BELGIUM; STANFORD UNIV, MED CTR, DEPT IMMUNOL & RHEUMATOL, STANFORD, CA 94305 USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Stanford University								CEUPPENS JL, 1986, J IMMUNOL, V137, P1816; DORKEN B, 1989, LEUCOCYTE TYPING, V4, P15; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARDIN JA, 1990, CELL IMMUNOL, V126, P304, DOI 10.1016/0008-8749(90)90323-J; HAYAKAWA K, 1988, ANNU REV IMMUNOL, V6, P197, DOI 10.1146/annurev.iy.06.040188.001213; HUANG HJS, 1987, P NATL ACAD SCI USA, V84, P204, DOI 10.1073/pnas.84.1.204; JONES NH, 1986, NATURE, V323, P346, DOI 10.1038/323346a0; KAMAL M, IN PRESS EUR J IMMUN; KAWAMURA N, 1986, J CLIN INVEST, V78, P1331, DOI 10.1172/JCI112719; KURZINGER K, 1982, J BIOL CHEM, V257, P2412; LEDBETTER JA, 1987, P NATL ACAD SCI USA, V84, P1384, DOI 10.1073/pnas.84.5.1384; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MCMICHAEL AJ, 1987, LEUCOCYTE TYPING, V3, P31; NAKAYAMA E, 1989, P NATL ACAD SCI USA, V86, P1352, DOI 10.1073/pnas.86.4.1352; NISHIMURA Y, 1988, EUR J IMMUNOL, V18, P747, DOI 10.1002/eji.1830180514; PEZZUTTO A, 1989, LEUCOCYTE TYPING, V4, P178; SCHWARTING R, 1989, LEUCOCYTE TYPING, V4, P100; SNOW EC, 1986, J IMMUNOL, V137, P1793; SPERTINI F, 1991, J IMMUNOL, V146, P47; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUBBARAO B, 1984, CURR TOP MICROBIOL, V113, P72; SUBBARAO B, 1983, J IMMUNOL, V130, P2033; SUBBARAO B, 1988, CELL IMMUNOL, V112, P329, DOI 10.1016/0008-8749(88)90302-4; Subbarao B, 1982, Immunol Rev, V69, P81; TAKI S, 1989, J IMMUNOL METHODS, V122, P33, DOI 10.1016/0022-1759(89)90331-1; VANDENBERGHE P, 1991, EUR J IMMUNOL, V21, P251, DOI 10.1002/eji.1830210203; VERWILGHEN J, 1990, CELL IMMUNOL, V131, P109, DOI 10.1016/0008-8749(90)90238-M; VONHOEGEN I, 1990, J IMMUNOL, V144, P4870; VONHOEGEN I, IN PRESS EUR J IMMUN; WANG CY, 1980, J EXP MED, V151, P1539, DOI 10.1084/jem.151.6.1539; YAKURA H, 1981, J EXP MED, V153, P129, DOI 10.1084/jem.153.1.129	32	311	315	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 20	1991	351	6328					662	665						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT112	1711157				2022-12-01	WOS:A1991FT11200070
J	WIGLEY, DB; DAVIES, GJ; DODSON, EJ; MAXWELL, A; DODSON, G				WIGLEY, DB; DAVIES, GJ; DODSON, EJ; MAXWELL, A; DODSON, G			CRYSTAL-STRUCTURE OF AN N-TERMINAL FRAGMENT OF THE DNA GYRASE B-PROTEIN	NATURE			English	Article							ESCHERICHIA-COLI; A-PROTEIN; GYRB GENE; RESOLUTION; TOPOISOMERASES; REFINEMENT; COMPLEX; SITE	The crystal structure of an N-terminal fragment of the Escherichia coli DNA gyrase B protein, complexed with a nonhydrolysable ATP analogue, has been solved at 2.5 angstrom resolution. It consists of two domains, both containing novel protein folds. The protein fragment forms a dimer, whose N-terminal domains are responsible for ATP binding and hydrolysis. The C-terminal domains form the sides of a 20 angstrom hole through the protein dimer which may play a role in DNA strand passage during the supercoiling reaction.	UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,ENGLAND	University of Leicester	WIGLEY, DB (corresponding author), YORK UNIV,DEPT CHEM,YORK YO1 5DD,ENGLAND.		Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X; Maxwell, Anthony/0000-0002-5756-6430	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADACHI T, 1987, NUCLEIC ACIDS RES, V15, P771, DOI 10.1093/nar/15.2.771; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P6289, DOI 10.1073/pnas.76.12.6289; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; JACKSON AP, 1991, J MOL BIOL, V217, P15, DOI 10.1016/0022-2836(91)90606-7; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KRUEGER S, 1990, J MOL BIOL, V211, P211, DOI 10.1016/0022-2836(90)90021-D; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MORRISON A, 1980, J BIOL CHEM, V255, P2211; RAU DC, 1987, J MOL BIOL, V193, P555, DOI 10.1016/0022-2836(87)90266-X; REECE RJ, 1990, J MOL BIOL, V215, P493, DOI 10.1016/S0022-2836(05)80162-7; REECE RJ, 1989, J BIOL CHEM, V264, P19648; REECE RJ, 1991, NUCLEIC ACIDS RES, V19, P1399, DOI 10.1093/nar/19.7.1399; REECE RJ, 1991, J BIOL CHEM, V266, P3540; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; RICE DW, 1981, ACTA CRYSTALLOGR A, V37, P491, DOI 10.1107/S0567739481001186; SUBRAMANIAN E, 1977, P NATL ACAD SCI USA, V74, P556, DOI 10.1073/pnas.74.2.556; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; TAMURA JK, 1990, J BIOL CHEM, V265, P21342; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; YAMAGISHI J, 1986, MOL GEN GENET, V204, P367, DOI 10.1007/BF00331012	26	491	495	0	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1991	351	6328					624	629		10.1038/351624a0	http://dx.doi.org/10.1038/351624a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT112	1646964				2022-12-01	WOS:A1991FT11200055
J	COX, JD				COX, JD			RADIATION ONCOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRESIDENTIAL-ADDRESS; RADIOTHERAPY				COX, JD (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX 77025, USA.							CHAPMAN JD, 1989, PREDICTION TUMOR TRE, P323; COX JD, 1987, INT J RADIAT ONCOL, V13, P1271, DOI 10.1016/0360-3016(87)90215-X; FUKS Z, 1989, International Journal of Radiation Oncology, Biology, Physics, V17, P121; HONG WK, 1989, P AM SOC CLIN CONOL, V8, pA650; Horiot J C, 1988, Front Radiat Ther Oncol, V22, P149; LEIBEL S A, 1990, International Journal of Radiation Oncology, Biology, Physics, V19, P139, DOI 10.1016/0360-3016(90)90681-9; LIEBERMAN HB, 1990, 1990 COL U COLL PHYS, P162; ORDER SE, 1990, INT J RADIAT ONCOL, V18, P981, DOI 10.1016/0360-3016(90)90431-I; ROTMAN M, 1990, INT J RADIAT ONCOL, V19, P513, DOI 10.1016/0360-3016(90)90475-Y; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; TURRISI AT, 1988, INT J RADIAT ONCOL, V15, P183, DOI 10.1016/0360-3016(88)90364-1; WILSON JF, 1988, CURE PRESERVATION FU, P102; 1991, JAMA-J AM MED ASSOC, V265, P391	13	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3165	3167						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041139				2022-12-01	WOS:A1991FQ77000039
J	DELISA, JA; JAIN, SS				DELISA, JA; JAIN, SS			PHYSICAL MEDICINE AND REHABILITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									KESSLER INST REHABIL,W ORANGE,NJ	Kessler Institute for Rehabilitation	DELISA, JA (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,NEWARK,NJ 07103, USA.							AYERS JWT, 1988, FERTIL STERIL, V49, P1089; BACH JR, 1990, CHEST, V98, P613, DOI 10.1378/chest.98.3.613; BACH JR, IN PRESS B NY ACAD M; BEJJANI FJ, 1989, J BIOMECH, V22, P439, DOI 10.1016/0021-9290(89)90204-2; CAREY RG, 1988, ARCH PHYS MED REHAB, V69, P337; CHANG MS, 1987, ERGONOMICS, V30, P331; COHEN LG, 1991, BRAIN, V114, P615, DOI 10.1093/brain/114.1.615; Figoni S F, 1990, J Am Paraplegia Soc, V13, P33; GRESHAM GE, 1990, STROKE, V21, P1; JOHNSTON MV, IN PRESS BRAIN INJ; LINSENMEYER TA, 1991, NEUROREHABILITATION, V1, P22; PATTERSON RP, 1990, ARCH PHYS MED REHAB, V71, P340; ROBINSON LR, 1990, AM J PHYS MED REHAB, V69, P307, DOI 10.1097/00002060-199012000-00006; TRAVERS PH, 1988, OCCUP MED, V3, P271; VERVILLE RE, 1990, ARCH PHYS MED REHAB, V71, P1010	15	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3158	3160						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	1828273				2022-12-01	WOS:A1991FQ77000035
J	FISHER, LL; DOUGLAS, RG				FISHER, LL; DOUGLAS, RG			INFECTIOUS-DISEASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; CONTROLLED TRIAL; CORTICOSTEROIDS; EHRLICHIOSIS		MERCK SHARP & DOHME INT,RAHWAY,NJ		FISHER, LL (corresponding author), CORNELL UNIV,MED CTR,NEW YORK HOSP,NEW YORK,NY 10021, USA.							BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; ENG TR, 1990, JAMA-J AM MED ASSOC, V264, P2251, DOI 10.1001/jama.264.17.2251; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HIRSCH MS, 1990, J INFECT DIS, V161, P845, DOI 10.1093/infdis/161.5.845; MCDADE JE, 1990, J INFECT DIS, V161, P609, DOI 10.1093/infdis/161.4.609; MONTANER JSG, 1990, ANN INTERN MED, V113, P14, DOI 10.7326/0003-4819-113-1-14; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1990, MMWR, V39, P630; 1990, ANN INTERN MED, V113, P604; 1989, MMWR, V38, P1; 1990, MMWR, V39, P1	13	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3130	3132						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041125				2022-12-01	WOS:A1991FQ77000023
J	ALBERTI, A; CHEMELLO, L; CAVALLETTO, D; TAGGER, A; DALCANTON, A; BIZZARO, N; TAGARIELLO, G; RUOL, A				ALBERTI, A; CHEMELLO, L; CAVALLETTO, D; TAGGER, A; DALCANTON, A; BIZZARO, N; TAGARIELLO, G; RUOL, A			ANTIBODY TO HEPATITIS-C VIRUS AND LIVER-DISEASE IN VOLUNTEER BLOOD-DONORS	ANNALS OF INTERNAL MEDICINE			English	Article							RECOMBINANT IMMUNOBLOT ASSAY; NON-B-HEPATITIS; NON-A; TRANSFUSION	Objective: To evaluate the specificity of antibodies to hepatitis C virus (anti-HCV) and their relation to liver disease in blood donors. Design: Case series of consecutive blood donors found positive for anti-HCV by enzyme-linked immunosorbent assay (ELISA). Patients were evaluated for antibody specificity using a recombinant immunoblotting assay (RIBA) and were evaluated for biochemical evidence of liver disease. Patients showing increased alanine aminotransferase (ALT) levels had a liver biopsy. Setting: University hospital. Participants: Fifty consecutive blood donors found to be anti-HCV positive on both an initial and repeat ELISA. Inclusion criteria were as follows: an absence of hepatitis B surface antigens and non-organ-specific autoantibodies; a daily alcohol intake of < 50 g; no history of recent hepatotoxic drug use; and normal serum levels of alpha, antitrypsin, ceruloplasmin, and copper. Main Results: Anti-HCV positivity was confirmed by RIBA in only 13 of 50 donors (26%) who had positive ELISA results. These 13 donors had an elevated ALT level and histologic evidence of chronic hepatitis, which was active in 8 patients (62%) and had already produced cirrhosis in 2 patients (15%). In contrast, the 17 donors with an intermediate RIBA pattern had only mild and often nonspecific histologic liver abnormalities. The 20 patients with a negative RIBA result had normal ALT levels. Conclusion: In blood donors, the anti-HCV RIBA is not only more specific than the anti-HCV ELISA, but is also useful in identifying patients who have an underlying chronic liver disease.	IST VIROL, MILAN, ITALY; OSPED CASTELFRANCO VENETO, CTR TRASFUS, I-31033 CASTELFRANCO VENETO, ITALY; OSPED S DONA PIAVE, S DONA PIAVE, ITALY	ULSS 2 Marca TV; Ospedale Castelfranco Veneto	ALBERTI, A (corresponding author), CLIN MED 2, VIA GIUSTINIANI 2, I-35100 PADUA, ITALY.		chemello, liliana/AAU-9414-2020; dal canton, antonio/G-4388-2013	ALBERTI, ALFREDO/0000-0001-9926-2382				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BALDI M, 1990, HEPATOLOGY, V12, P960; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; EBELING F, 1990, LANCET, V335, P982, DOI 10.1016/0140-6736(90)91055-F; ESTEBAN JI, 1989, LANCET, V2, P294; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; SKIDMORE S, 1990, LANCET, V335, P1346, DOI 10.1016/0140-6736(90)91230-8; VANDERPOEL CL, 1990, LANCET, V336, P187, DOI 10.1016/0140-6736(90)91718-P; 1990, LANCET, V335, P1431	10	85	85	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1010	1012		10.7326/0003-4819-114-12-1010	http://dx.doi.org/10.7326/0003-4819-114-12-1010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	1851402				2022-12-01	WOS:A1991FQ55500003
J	ATKIN, SH; DASMAHAPATRA, A; JAKER, MA; CHOROST, MI; REDDY, S				ATKIN, SH; DASMAHAPATRA, A; JAKER, MA; CHOROST, MI; REDDY, S			FINGERSTICK GLUCOSE DETERMINATION IN SHOCK	ANNALS OF INTERNAL MEDICINE			English	Article						GLUCOSE; HYPOTENSION; REAGENT STRIPS, VENOUS; SHOCK; FINGERSTICK GLUCOSE TESTING	BLOOD-GLUCOSE; ACCURACY; SYSTEMS; INSULIN	Objective: To evaluate the accuracy of fingerstick glucose measurements in severely hypotensive patients. Design: Prospective, nonrandomized comparison study. Setting: Emergency department in a university hospital. Patients: Twenty-five severely hypotensive patients (systolic blood pressure less-than-or-equal-to 80 mm Hg) and 39 normotensive patients. Measurements: Simultaneous fingerstick reagent strip glucose, venous reagent strip glucose, and laboratory glucose values were compared. Data were analyzed using error-grid analysis. Results: In hypotensive patients, the mean fingerstick glucose values were significantly lower than the values obtained either by venous reagent strip or laboratory glucose measurements. Fingerstick glucose values in the hypotensive group were 67.5% of laboratory glucose values, and were significantly lower than the values obtained in the normotensive group (91.8%, P < 0.001). Only 36% of the hypotensive patients had fingerstick glucose values within the acceptable range of 20% of the laboratory glucose value. Thirty-two percent of hypotensive patients were incorrectly diagnosed as hypoglycemic (glucose < 3.89 mmol/L [70 mg/dL]); 2 of these patients were actually hyperglycemic (glucose > 11.10 mmol/L [200 mg/dL]). Venous reagent strip measurements accurately reflected laboratory glucose values in both hypotensive and normotensive patients. Conclusions: Fingerstick glucose testing does not accurately represent venous glucose levels in severely hypotensive patients. If fingerstick glucose testing is relied on for these patients, errors in clinical management may be made. Venous reagent strip glucose testing correlates well with laboratory glucose measurements and should be the preferred method for rapid assessment of glucose level in critically ill patients with severe hypotension.			ATKIN, SH (corresponding author), UNIV HOSP NEWARK, DEPT EMERGENCY, C384, 150 BERGEN ST, NEWARK, NJ 07103 USA.							[Anonymous], 1987, DIABETES CARE, V10, P95; BARR B, 1984, DIABETES CARE, V7, P261, DOI 10.2337/diacare.7.3.261; BORST GC, 1987, DIABETES CARE, V10, P256, DOI 10.2337/diacare.10.2.256; BROWNING RG, 1990, ANN EMERG MED, V19, P683, DOI 10.1016/S0196-0644(05)82479-5; CAREY LC, 1970, ANN SURG, V172, P342, DOI 10.1097/00000658-197009000-00004; CHERNOW B, 1982, CRIT CARE MED, V10, P463, DOI 10.1097/00003246-198207000-00012; CLARKE WL, 1987, DIABETES CARE, V10, P622, DOI 10.2337/diacare.10.5.622; CLOWES GHA, 1978, AM J SURG, V135, P577, DOI 10.1016/0002-9610(78)90040-5; COX DJ, 1985, DIABETES CARE, V8, P529, DOI 10.2337/diacare.8.6.529; COX DJ, 1989, DIABETES CARE, V12, P235, DOI 10.2337/diacare.12.3.235; GAZZANIGA AB, 1982, EMERGENCY CARE PRINC, P412; GODINE JE, 1986, AM J MED, V80, P803, DOI 10.1016/0002-9343(86)90619-4; HOLLOWAY R, 1983, ALA J MED SCI, V20, P383; KOSCHINSKY T, 1988, DIABETES CARE, V11, P619, DOI 10.2337/diacare.11.8.619; LIN HC, 1989, J PEDIATR-US, V115, P998, DOI 10.1016/S0022-3476(89)80757-7; MAISELS MJ, 1983, CRIT CARE MED, V11, P293, DOI 10.1097/00003246-198304000-00010; Moghni M R, 1970, J Egypt Med Assoc, V53, P803; PLUM F, 1980, DIAGNOSIS STUPOR COM, P345; POINTER JE, 1986, ANN EMERG MED, V15, P372, DOI 10.1016/S0196-0644(86)80588-1; RASAIAH B, 1985, CAN MED ASSOC J, V132, P1357; SHAPIRO B, 1981, DIABETES CARE, V4, P396, DOI 10.2337/diacare.4.3.396; SHERWOOD MJ, 1983, CLIN CHEM, V29, P438; VITEK V, 1979, CLIN CHIM ACTA, V95, P93, DOI 10.1016/0009-8981(79)90341-3; 1987, ACCU CHEK 2 BLOOD GL	24	116	119	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1020	1024		10.7326/0003-4819-114-12-1020	http://dx.doi.org/10.7326/0003-4819-114-12-1020			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	2029097				2022-12-01	WOS:A1991FQ55500005
J	BELL, D; LAYTON, AJ; GABBAY, J				BELL, D; LAYTON, AJ; GABBAY, J			USE OF A GUIDELINE BASED QUESTIONNAIRE TO AUDIT HOSPITAL-CARE OF ACUTE ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT	Objectives - To design an audit questionnaire and pilot its use by an audit assistant to monitor inpatient management of acute asthma and to compare the care given by chest physicians and general physicians. Design - Retrospective review by a chest physician and audit assistant of a random sample of 76 case records of patients by a criterion based questionnaire developed from hospital guidelines on management of acute asthma. Setting - One district general hospital. Patients - 76 adult patients with acute asthma: 38 admitted with a relevant primary diagnosis between April 1988 and March 1989 and a further 38 admitted through the accident and emergency department between April 1989 and March 1990. Main outcome measures - Conformity with recognised standards for assessment and management of acute asthma before and after the audit and by chest physicians and general physicians. Results - Age and sex did not differ significantly between the different groups of patients. Overall, deviations from the guidelines occurred in recording measures of severity of asthma, emergency treatment with beta-2 agonists (60/76, 79%) and steroids (43/76, 57%), and prescription of antibiotics in accordance with at least one criterion of the guidelines (29/45, 64%). Chest physicians were more rigorous than general physicians in recording severity measures, especially serum potassium concentration (chi-2 = 3.6, df = 1, p = 0.06), emergency steroid treatment within the correct period (chi-2 = 3.9, df = 1, p = 0.05), and referral for follow up at an outpatient chest clinic. Recording of arterial blood gas tensions improved significantly between the 1988-9 and 1989-90 samples (chi-2 = 7.0, df = 1, p = 0.08). Conclusions - The questionnaire proved easy to use for both doctor and audit assistant. The audit improved few standards of care and emphasises the need for further reinforcement and feedback.	CENT MIDDLESEX HOSP,ST MARYS HOSP,SCH MED,ACAD DEPT PUBL HLTH,HLTH CARE DEV UNIT,LONDON NW10 7NS,ENGLAND	Imperial College London				Bell, Derek/0000-0002-9944-1097				[Anonymous], 1990, BMJ, V301, P797; Averill B.A., 1980, CIENC BIOL COIMBRA, V5, P167; British Thoracic Association, 1982, BR MED J CLIN RES ED, V285, P1251; BUCKNALL CE, 1988, LANCET, V1, P748; GABBAY J, 1990, BRIT MED J, V301, P526, DOI 10.1136/bmj.301.6751.526; GRANT IWB, 1990, BRIT MED J, V301, P1045; HIGGINS RM, 1987, LANCET, V2, P863; Layton A, 1990, Health Serv J, V100, P1685; REBUCK AS, 1971, AM J MED, V51, P788, DOI 10.1016/0002-9343(71)90307-X; REED S, 1985, THORAX, V40, P897, DOI 10.1136/thx.40.12.897; 1989, STANDARD MORTALITY R	11	39	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 15	1991	302	6790					1440	1443		10.1136/bmj.302.6790.1440	http://dx.doi.org/10.1136/bmj.302.6790.1440			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR403	2070112	Green Published, Bronze			2022-12-01	WOS:A1991FR40300024
J	COLLINGE, J; PALMER, MS; DRYDEN, AJ				COLLINGE, J; PALMER, MS; DRYDEN, AJ			GENETIC PREDISPOSITION TO IATROGENIC CREUTZFELDT-JAKOB DISEASE	LANCET			English	Note							PRION	The spongiform encephalopathy Creutzfeldt-Jakob disease (CJD) has been transmitted to man via administration of growth hormone and gonadotropin extracted from large pooled batches of human cadaveric pituitary glands. In the UK, 1908 individuals were exposed to potentially contaminated growth hormone, of whom 6 have so far manifested CJD. Examination of the prion protein genes of all these cases and of a single case of gonadotropin-related CJD showed that 4 had the uncommon valine 129 homozygous genotype indicating genetic susceptibility to prion infection. Such genetic susceptibility may be important in the aetiology of sporadic CJD disease.			COLLINGE, J (corresponding author), ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,PRION DIS GRP,NORFOLK PL,LONDON W2 1PG,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BUCHANAN CR, 1991, BRIT MED J, V302, P824, DOI 10.1136/bmj.302.6780.824; COLLINGE J, 1989, LANCET, V2, P15, DOI 10.1016/S0140-6736(89)90256-0; GOLDFARB L G, 1989, American Journal of Human Genetics, V45, pA189; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WU Y, 1987, NUCLEIC ACIDS RES, V15, P3191, DOI 10.1093/nar/15.7.3191	6	474	491	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1441	1442		10.1016/0140-6736(91)93128-V	http://dx.doi.org/10.1016/0140-6736(91)93128-V			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675319				2022-12-01	WOS:A1991FR06000005
J	EMMERSON, BT				EMMERSON, BT			IDENTIFICATION OF THE CAUSES OF PERSISTENT HYPERURICEMIA	LANCET			English	Article								Accurate identification of the factors that contribute to hyperuricaemia in an individual may enable some of these factors to be modified, and lead to permanent correction of the hyperuricaemia. A protocol is described which can supplement clinical assessment. Measurement of the effects on serum urate and urinary urate excretion of a low-purine diet for 7 days facilitates the identification of the contributions made by urate production (either endogenous or from purine consumption) and renal underexcretion of urate (either as a low urate clearance in the absence of renal disease or due to renal glomerular insufficiency).			EMMERSON, BT (corresponding author), UNIV QUEENSLAND,PRINCESS ALEXANDRA HOSP,DEPT MED,BRISBANE,QLD 4102,AUSTRALIA.							BATCH JA, 1984, AUST NZ J MED, V14, P852, DOI 10.1111/j.1445-5994.1984.tb03788.x; BROCHNERMORTENS.K, 1937, ACTA MED SCAND, V84, P127; EMMERSON BT, 1983, HYPERURICAEMIA GOUT; FOX IH, 1981, METABOLISM, V30, P616, DOI 10.1016/0026-0495(81)90142-6; KELLEY WN, 1967, P NATL ACAD SCI USA, V57, P1735, DOI 10.1073/pnas.57.6.1735; NUGENT CA, 1959, J CLIN INVEST, V38, P1890, DOI 10.1172/JCI103966; SEEGMILLER J, 1961, J CLIN INVEST, V40, P1304, DOI 10.1172/JCI104360; STAFFORD W, 1983, ADV EXP MED BIOL, V165, P309	8	30	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1461	1463		10.1016/0140-6736(91)93141-U	http://dx.doi.org/10.1016/0140-6736(91)93141-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675330				2022-12-01	WOS:A1991FR06000017
J	GILBERT, GL; MACINNES, SJ; GUISE, IA				GILBERT, GL; MACINNES, SJ; GUISE, IA			RIFAMPICIN PROPHYLAXIS FOR THROAT CARRIAGE OF HAEMOPHILUS-INFLUENZAE TYPE-B IN PATIENTS WITH INVASIVE DISEASE AND THEIR CONTACTS	BRITISH MEDICAL JOURNAL			English	Article							HEMOPHILUS-INFLUENZAE; COLONIZATION; PREVENTION; INFECTIONS; SPREAD	Objective - To determine rates of colonisation with Haemophilus influenzae type b among household contacts of children with invasive H influenzae type b disease; compliance among medical staff with recommendations for use of rifampicin prophylaxis; and effects of rifampicin treatment in H influenzae type b colonisation of patients and contacts. Design - Prospective study of patients and their household contacts. Setting - Royal Children's Hospital (the major paediatric hospital) in Victoria, Australia, with catchment population of 4.2 million, including 300 000 children aged under 5 years. Subjects - 234 patients (age range 6 weeks to 8 years) with 235 episodes of all types of invasive H influenzae type b disease admitted during 1988-9 and their contacts. Main outcome measures - Positive cultures of H influenzae type b from throat swabs taken at admission and six weeks subsequently; recording of rifampicin prophylaxis. Results - The percentage of patients with positive throat cultures fell from 69% (33/48) on day 1 of admission to 9% (4/47) after three days' treatment; at six weeks' follow up 32% (32/99) of patients who had not received rifampicin and 8% (5/61) who had, had positive throat cultures. Among household contacts, 33% (62/190) of children and 7% (25/359) of adults were colonised, and the colonisation rates were similar in contacts of patients with all types of H influenzae type b disease. Rifampicin prophylaxis was indicated in 85 families; in 34% it was not prescribed at all for contacts and in 41% not as recommended. The colonisation rates at follow up were significantly less in siblings given rifampicin (12%, 9/78), particularly in families in which all members were treated (3%), than in those in which they were not (36%) (odds ratio 21.5; 95% confidence interval 3.0 to 103.4). Conclusions - The rate of throat colonisation with H influenzae type b was similar among siblings of children with all types of invasive H influenzae type b disease. Colonisation in contacts can be reduced by rifampicin prophylaxis, but some contacts remained colonised or were recolonised by the time of follow up. Medical staff complied poorly with current recommendations for rifampicin prophylaxis, which reduces its intrinsically limited value in preventing H influenzae type b disease.	ROYAL CHILDRENS HOSP,DEPT MICROBIOL & INFECT DIS,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne			Gilbert, Gwendolyn/B-7733-2013	Gilbert, Gwendolyn/0000-0001-7490-6727				APERT GA, 1985, J PEDIATR, V107, P555; BAND JD, 1984, JAMA-J AM MED ASSOC, V251, P2381, DOI 10.1001/jama.251.18.2381; BODIES EG, 1982, PEDIATRICS, V70, P141; CAMPBELL LR, 1980, PEDIATRICS, V66, P115; CLEMENTS DA, 1990, AUST NZ J MED, V20, P828, DOI 10.1111/j.1445-5994.1990.tb00435.x; FILICE GA, 1978, AM J DIS CHILD, V132, P578; GAUM RS, 1981, J PEDIATR, V98, P485; GILBERT GL, 1987, AUST PAEDIATR J, V23, P323; GILBERT GL, 1990, PEDIATR INFECT DIS J, V9, P252, DOI 10.1097/00006454-199004000-00006; GILBERT GL, 1987, ANTIOBIOTIC PROPHYLA; GILSDORF JR, 1986, PEDIATRICS, V77, P242; GLODE MP, 1985, PEDIATRICS, V76, P537; GLODE MP, 1990, BRIT MED J, V28, P899; LI KI, 1986, AM J DIS CHILD, V140, P381, DOI 10.1001/archpedi.1986.02140180115040; MICHAELS RH, 1976, J CLIN MICROBIOL, V4, P413; MICHAELS RH, 1975, PEDIATR RES, V9, P513, DOI 10.1203/00006450-197505000-00010; MICHAELS RH, 1977, J INFECT DIS, V136, P2228; MURPHY TV, 1981, J PEDIATR-US, V99, P406, DOI 10.1016/S0022-3476(81)80328-9; SCHWARTZ B, 1988, LANCET, V1, P1239; SHAPIRO ED, 1980, PEDIATRICS, V66, P5; WARD JI, 1979, NEW ENGL J MED, V301, P122, DOI 10.1056/NEJM197907193010302; 1982, MMWR-MORBID MORTAL W, V31, P679; 1982, MMWR-MORBID MORTAL W, V31, P672; 1984, PEDIATRICS, V74, P301	24	12	12	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 15	1991	302	6790					1432	1435		10.1136/bmj.302.6790.1432	http://dx.doi.org/10.1136/bmj.302.6790.1432			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR403	2070109	Bronze, Green Published			2022-12-01	WOS:A1991FR40300021
J	JONES, DA; BEYNON, D; LITTLEPAGE, BNC				JONES, DA; BEYNON, D; LITTLEPAGE, BNC			AUDIT OF AN OFFICIAL RECOMMENDATION ON SCREENING FOR CONGENITAL DISLOCATION OF THE HIP	BRITISH MEDICAL JOURNAL			English	Article									W GLAMORGAN HLTH AUTHOR,SWANSEA SA1 5AQ,WALES									[Anonymous], 1986, ARCH DIS CHILD, V61, P921; [Anonymous], 1969, SCREENING DETECTION; CATFORD JC, 1982, BMJ-BRIT MED J, V285, P1527, DOI 10.1136/bmj.285.6354.1527; MACFARLANE A, 1987, BRIT MED J, V294, P1047, DOI 10.1136/bmj.294.6579.1047; 1986, SCREENING DETECTION	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 15	1991	302	6790					1435	1436		10.1136/bmj.302.6790.1435	http://dx.doi.org/10.1136/bmj.302.6790.1435			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR403	2070110	Green Published, Bronze			2022-12-01	WOS:A1991FR40300022
J	ROMANOWSKI, B; SUTHERLAND, R; FICK, GH; MOONEY, D; LOVE, EJ				ROMANOWSKI, B; SUTHERLAND, R; FICK, GH; MOONEY, D; LOVE, EJ			SEROLOGIC RESPONSE TO TREATMENT OF INFECTIOUS SYPHILIS	ANNALS OF INTERNAL MEDICINE			English	Article							SECONDARY SYPHILIS; TESTS	Objective: To evaluate the serologic response to treatment of patients with infectious syphilis. Design: Historical cohort study of all cases of infectious syphilis in Alberta from 1981 to 1987. Patients: A total of 1090 patients were entered; 857 with primary syphilis, 183 with secondary syphilis, and 50 with early latent disease. Two hundred and eight patients were excluded who either were pregnant, had negative serologic results before treatment, had clinical relapse, were treatment failures, or were lost to follow-up. Interventions: All 882 evaluable patients were treated with a recommended antibiotic regimen for infectious syphilis and returned for re-assessment including repeat serologic testing. Measurements and Main Results: Seventy-two percent (95% CI, 66% to 77%) and 56% (CI, 43% to 70%) of patients with initial episodes of primary or secondary syphilis had seroreverted according to rapid plasma reagin (RPR) test results by 36 months. A 2- and 3-tube decline was seen by 6 and 12 months in primary and secondary syphilis. Early latent syphilis resulted in only a 2-tube decrease at 12 months. Serologic response was not affected by sex, age, race, or sexual orientation. Patients with their first infection were more likely to experience RPR seroreversal than those with repeat infections. The RPR reversal rates also depended on the pretreatment titer and stage of disease. At 36 months, 24% (CI, 20% to 28%) of patients had nonreactive fluorescent treponemal antibody absorption tests (FTA-Abs), and 13% (CI, 11% to 15%) had nonreactive microhemoglutination tests for Treponema pallidum (MHA-TP). Conclusions: Adequate therapeutic response for syphilis must be based on illness episode and the pretreatment RPR titer. Treponemal tests can demonstrate seroreversion after 36 months, and a negative treponemal test does not rule out a past history of syphilis.	UNIV CALGARY, FAC MED DEPT COMMUNITY HLTH SERV, CALGARY T2N 4N1, ALBERTA, CANADA	University of Calgary	ROMANOWSKI, B (corresponding author), ALBERTA HLTH, STD CONTROL, 4TH FLOOR, EXECUT BLDG, 10105 109TH ST, EDMONTON T5J 1M8, ALBERTA, CANADA.							ARMITAGE P, 1987, STATISTICAL METHODS, P424; BROWN ST, 1985, JAMA-J AM MED ASSOC, V253, P1296, DOI 10.1001/jama.253.9.1296; FIUMARA NJ, 1977, SEX TRANSM DIS, V4, P92, DOI 10.1097/00007435-197707000-00004; FIUMARA NJ, 1977, SEX TRANSM DIS, V4, P96, DOI 10.1097/00007435-197707000-00005; FIUMARA NJ, 1986, J AM ACAD DERMATOL, V15, P1059, DOI 10.1016/S0190-9622(86)80319-X; FIUMARA NJ, 1980, JAMA-J AM MED ASSOC, V243, P2500, DOI 10.1001/jama.243.24.2500; FIUMARA NJ, 1980, SEX TRANSM DIS, V7, P111, DOI 10.1097/00007435-198007000-00003; HAAS JS, 1990, J INFECT DIS, V162, P862, DOI 10.1093/infdis/162.4.862; PERRYMAN MW, 1982, J CLIN MICROBIOL, V16, P286, DOI 10.1128/JCM.16.2.286-290.1982; PETERSEN CS, 1984, DAN MED BULL, V31, P70; SCHROETER AL, 1972, J AMER MED ASSOC, V221, P471, DOI 10.1001/jama.221.5.471; WILLCOX RR, 1981, B WORLD HEALTH ORGAN, V59, P655; 1982, TECHNICAL REPORT SER, V674; 1951, J VENER DIS, V32, P355	14	177	186	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1005	1009		10.7326/0003-4819-114-12-1005	http://dx.doi.org/10.7326/0003-4819-114-12-1005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	2029095				2022-12-01	WOS:A1991FQ55500002
J	SRA, JS; ANDERSON, AJ; SHEIKH, SH; AVITALL, B; TCHOU, PJ; TROUP, PJ; GILBERT, CJ; AKHTAR, M; JAZAYERI, MR				SRA, JS; ANDERSON, AJ; SHEIKH, SH; AVITALL, B; TCHOU, PJ; TROUP, PJ; GILBERT, CJ; AKHTAR, M; JAZAYERI, MR			UNEXPLAINED SYNCOPE EVALUATED BY ELECTROPHYSIOLOGIC STUDIES AND HEAD-UP TILT TESTING	ANNALS OF INTERNAL MEDICINE			English	Article							NEURALLY-MEDIATED SYNCOPE; VAGAL C-FIBERS; RECURRENT SYNCOPE; DISOPYRAMIDE; ISOPROTERENOL; BRADYCARDIA; HYPOTENSION; REVERSAL	Objective: To determine the clinical characteristics of subgroups of patients with unexplained syncope having electrophysiologic studies and head-up tilt testing and to assess the efficacy of various therapies. Design: Retrospective study. Setting: Inpatient services of a tertiary referral center. Patients: Eighty-six consecutively referred patients with unexplained syncope. Measurements: All patients had electrophysiologic examinations. Patients with negative results subsequently had head-up tilt testing. Main Results: Twenty-nine (34%) patients (group 1) had abnormal electrophysiologic results, with sustained monomorphic ventricular tachycardia induced in 72%. Thirty-four (40%) patients (group 2) had syncope provoked by head-up tilt testing. The cause of syncope remained unexplained in 23 (26%) patients (group 3). Structural heart disease was present in 76%, 6%, and 30% of groups 1, 2, and 3, respectively. In group 1, pharmacologic or nonpharmacologic therapy was recommended based on electrophysiologic evaluation. All group 2 patients had negative results on head-up tilt testing while receiving oral beta blockers (27 patients) or disopyramide (7 patients). Group 3 patients did not receive any specific therapy. During a median follow-up period of 18.5 months, syncope recurred in 9 (10%) patients. Conclusions: The combination of electrophysiologic evaluation and head-up tilt testing can identify the underlying cause of syncope in as many as 74% of patients presenting with unexplained syncope. Therapeutic strategies formulated according to the results of these diagnostic tests appear to prevent syncope effectively in most patients.	MILWAUKEE CARDIOVASC DATA REGISTRY, MILWAUKEE, WI 53215 USA; SANDAHA HOME, LAHORE, PAKISTAN; PRESBYTERIAN UNIV HOSP, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian	SRA, JS (corresponding author), SINAI SAMARITAN MED CTR, 950 N 12TH ST, POB 342, MILWAUKEE, WI 53201 USA.							ABBOUD FM, 1976, PROG CARDIOVASC DIS, V18, P371, DOI 10.1016/0033-0620(76)90003-7; ABISAMRA F, 1988, PACE, V11, P1202, DOI 10.1111/j.1540-8159.1988.tb03973.x; AKHTAR M, 1983, PACE, V6, P192, DOI 10.1111/j.1540-8159.1983.tb04346.x; ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; DANILO P, 1976, AM HEART J, V92, P532; DERMKSIAN G, 1958, JAMA-J AM MED ASSOC, V168, P1200, DOI 10.1001/jama.1958.03000090030007; DIMARCO JP, 1981, ANN INTERN MED, V95, P542, DOI 10.7326/0003-4819-95-5-542; GOLDENBERG IF, 1987, CIRCULATION, V76, P133; JAZAYERI MR, 1989, J AM COLL CARDIOL, V14, P705, DOI 10.1016/0735-1097(89)90114-9; KAPOOR WN, 1983, NEW ENGL J MED, V309, P197, DOI 10.1056/NEJM198307283090401; KUSHNER JA, 1989, J AM COLL CARDIOL, V14, P391, DOI 10.1016/0735-1097(89)90191-5; Lewis T, 1932, BRIT MED J, V1932, P873, DOI 10.1136/bmj.1.3723.873; LUBROOK J, 1989, INT UNION PHYSL SCI, V4, P120; MILSTEIN S, 1987, CIRCULATION, V76, P175; OBERG B, 1972, ACTA PHYSIOL SCAND, V85, P164, DOI 10.1111/j.1748-1716.1972.tb05247.x; PODRID PJ, 1980, NEW ENGL J MED, V302, P614, DOI 10.1056/NEJM198003133021106; SHALEV Y, 1990, Journal of the American College of Cardiology, V15, p98A; SHARPEYSCHAFER EP, 1958, BMJ-BRIT MED J, V2, P878, DOI 10.1136/bmj.2.5101.878; SILVERSTEIN MD, 1982, JAMA-J AM MED ASSOC, V248, P1185, DOI 10.1001/jama.248.10.1185; SJOSTRAND T, 1952, ACTA PHYSIOL SCAND, V26, P312, DOI 10.1111/j.1748-1716.1952.tb00912.x; THAMES MD, 1980, AM J PHYSIOL, V238, pH465, DOI 10.1152/ajpheart.1980.238.4.H465; Thoren P, 1979, Rev Physiol Biochem Pharmacol, V86, P1, DOI 10.1007/BFb0031531; TONKIN AM, 1978, AUST NZ J MED, V8, P594, DOI 10.1111/j.1445-5994.1978.tb04846.x; WALTER PF, 1978, AM J CARDIOL, V42, P396, DOI 10.1016/0002-9149(78)90934-7	24	209	209	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1013	1019		10.7326/0003-4819-114-12-1013	http://dx.doi.org/10.7326/0003-4819-114-12-1013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	2029096				2022-12-01	WOS:A1991FQ55500004
J	WEBER, GF; MAERTENS, P; MENG, X; PIPPENGER, CE				WEBER, GF; MAERTENS, P; MENG, X; PIPPENGER, CE			GLUTATHIONE-PEROXIDASE DEFICIENCY AND CHILDHOOD SEIZURES	LANCET			English	Note								4 children with intractable seizures, repeated infections, and intolerance to anticonvulsants had evidence of glutathione peroxidase deficiency. 2 had low intracellular enzyme activity but normal blood selenium and high plasma glutathione peroxidase concentrations. The other 2 had low intracellular glutathione peroxidase activity with low circulating glutathione peroxidase and selenium concentrations. The clinical state of the children improved after discontinuation of anticonvulsant medication and selenium substitution.	UNIV SO ALABAMA,MED CTR,DEPT NEUROL,MOBILE,AL 36617; CLEVELAND CLIN FDN,DEPT BIOCHEM,CLEVELAND,OH 44195	University of South Alabama; Cleveland Clinic Foundation	WEBER, GF (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT BIOL CHEM & MOLEC PHARMACOL,44 BINNEY ST,BOSTON,MA 02115, USA.							BAKER SS, 1983, J IMMUNOL, V130, P2856; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; HOLMES B, 1970, NEW ENGL J MED, V283, P217, DOI 10.1056/NEJM197007302830501; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; PIPPENGER CE, 1989, ANTIEPILEPTIC DRUG I, P293; WILMORE LJ, 1981, NEUROLOGY, V31, P63	6	98	101	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1443	1444		10.1016/0140-6736(91)93130-2	http://dx.doi.org/10.1016/0140-6736(91)93130-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675321				2022-12-01	WOS:A1991FR06000007
J	AKIBA, T; YOSHIMURA, H; NAMBA, K				AKIBA, T; YOSHIMURA, H; NAMBA, K			MONOLAYER CRYSTALLIZATION OF FLAGELLAR L-P RINGS BY SEQUENTIAL ADDITION AND DEPLETION OF LIPID	SCIENCE			English	Article							BASAL-BODY COMPLEX; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; OUTER MEMBRANES; PROTEINS	The L-P ring complex is thought to be a molecular bushing that supports flagellar motor rotation at about 10,000 revolutions per minute with presumably very little friction. Structural studies of this complex have been limited because only very small amount of samples are available. Therefore devising an efficient method of crystallization was essential. The addition of a phospholipid and its subsequent slow depletion by phospholipase A2 have been used to successfully grow well-ordered monolayer crystals that extend up to about 10 micrometers. The interaction of the L-P ring complex with lipid membranes was also visualized during this process.	ERATO,MOLEC DYNAM ASSEMBLY PROJECT,5-9-5 TOKODAI,TSUKUBA 30026,JAPAN; JEOL LTD,BIOMETROL LAB,AKISHIMA 196,JAPAN	Jeol Ltd; JEOL Japan								AIZAWA S, 1985, J BACTERIOL, V161, P836, DOI 10.1128/JB.161.3.836-849.1985; DEPAMPHI.ML, 1971, J BACTERIOL, V105, P384, DOI 10.1128/JB.105.1.384-395.1971; JONES CJ, 1987, J BACTERIOL, V169, P1489, DOI 10.1128/jb.169.4.1489-1492.1987; JONES CJ, 1990, J MOL BIOL, V212, P377, DOI 10.1016/0022-2836(90)90132-6; JONES CJ, 1989, J BACTERIOL, V171, P3890, DOI 10.1128/jb.171.7.3890-3900.1989; KLEFFEL B, 1985, EMBO J, V4, P1589, DOI 10.1002/j.1460-2075.1985.tb03821.x; MANNELLA CA, 1984, SCIENCE, V224, P165, DOI 10.1126/science.6322311; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, P7; PATTERSO.J, 1973, ARCH MIKROBIOL, V90, P107, DOI 10.1007/BF00414513; STALLMEYER MJB, 1989, J MOL BIOL, V205, P519, DOI 10.1016/0022-2836(89)90223-4; YOSHIMURA H, 1990, ULTRAMICROSCOPY, V32, P265, DOI 10.1016/0304-3991(90)90004-6	11	50	52	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1991	252	5012					1544	1546		10.1126/science.2047860	http://dx.doi.org/10.1126/science.2047860			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR040	2047860				2022-12-01	WOS:A1991FR04000045
J	BAGCHI, S; WEINMANN, R; RAYCHAUDHURI, P				BAGCHI, S; WEINMANN, R; RAYCHAUDHURI, P			THE RETINOBLASTOMA PROTEIN COPURIFIES WITH E2F-I, AN E1A-REGULATED INHIBITOR OF THE TRANSCRIPTION FACTOR E2F	CELL			English	Article								Recently, we identified an inhibitory protein, E2F-I, that blocks the DNA-binding activity of the transcription factor E2F. We also showed that the adenovirus ElA protein reverses this inhibitory activity of E2F-I, thereby restoring the DNA-binding activity of E2F. We have now further purified this inhibitory activity and show that the most purified preparation of E2F-I contains a 105 kd E1A-binding protein. This 105 kd E1A-binding protein cross-reacts with two different antibodies against the retinoblastoma (RB) gene product. Moreover, the RB gene product copurifies with E2F-I activity. Taken together, we conclude that the product of the RB gene is a part of E2F-I and is involved in the regulation of E2F activity.	UNIV ILLINOIS, COLL DENT MC860, CTR RES PERIODONTAL DIS & ORAL MOLEC BIOL, CHICAGO, IL 60680 USA; WISTAR INST, PHILADELPHIA, PA 19104 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; The Wistar Institute	BAGCHI, S (corresponding author), UNIV ILLINOIS, DEPT BIOCHEM MC536, CHICAGO, IL 60680 USA.				NCI NIH HHS [CA 44466, CA 10815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815, R01CA044466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BABISS LE, 1989, J VIROL, V63, P2709, DOI 10.1128/JVI.63.6.2709-2717.1989; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; RAYCHAUDHURI P, 1991, IN PRESS GENES DEV; REICHEL R, 1987, CELL, V48, P501, DOI 10.1016/0092-8674(87)90200-5; REICHEL R, 1989, J VIROL, V63, P3643, DOI 10.1128/JVI.63.9.3643-3650.1989; REISSMANN PT, 1989, ONCOGENE, V4, P839; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	54	424	435	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1991	65	6					1063	1072		10.1016/0092-8674(91)90558-G	http://dx.doi.org/10.1016/0092-8674(91)90558-G			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1828393				2022-12-01	WOS:A1991FR04700017
J	BAKER, TA; MIZUUCHI, M; MIZUUCHI, K				BAKER, TA; MIZUUCHI, M; MIZUUCHI, K			MUB PROTEIN ALLOSTERICALLY ACTIVATES STRAND TRANSFER BY THE TRANSPOSASE OF PHAGE-MU	CELL			English	Article							BACTERIOPHAGE-MU; B-PROTEIN; TARGET IMMUNITY; DNA; MECHANISM; ENDS; PURIFICATION; INTEGRATION; INVITRO; TN10	The MuA and MuB proteins collaborate to mediate efficient transposition of the phage Mu genome into many DNA target sites. MuA (the transposase) carries out all the DNA cleavage and joining steps. MuB stimulates strand transfer by activating the MuA-donor DNA complex through direct protein-protein contact. The C-terminal domain of MuA is required for this MuA-MuB interaction. Activation of strand transfer occurs irrespective of whether MuB is bound to target DNA. When high levels of MuA generate a pool of free MuB (not bound to DNA) or when chemical modification of MuB impairs its ability to bind DNA, MuB still stimulates strand transfer. However, under these conditions, intramolecular target sites are used exclusively because of their close proximity to the MuA-MuB-donor DNA complex.			BAKER, TA (corresponding author), NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							ADZUMA K, 1989, CELL, V57, P41, DOI 10.1016/0092-8674(89)90170-0; ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ADZUMA K, 1991, J BIOL CHEM, V266, P6159; BAINTON R, 1991, IN PRESS CELL, V65; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CHACONAS G, 1985, CELL, V41, P857, DOI 10.1016/S0092-8674(85)80066-0; CRAIG NL, 1989, MOBILE DNA, P211; CRAIGIE R, 1985, J BIOL CHEM, V260, P1832; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DARZINS A, 1988, P NATL ACAD SCI USA, V85, P6826, DOI 10.1073/pnas.85.18.6826; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; GRINDLEY NDF, 1985, ANNU REV BIOCHEM, V54, P863, DOI 10.1146/annurev.biochem.54.1.863; GROENEN MAM, 1985, P NATL ACAD SCI USA, V82, P2087, DOI 10.1073/pnas.82.7.2087; HARSHEY RM, 1986, J GENET, V65, P159, DOI 10.1007/BF02931149; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MIZUUCHI K, 1986, ANNU REV GENET, V20, P385; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; SHERRATT D, 1989, MOBILE DNA, P163; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; Symonds N., 1987, PHAGE MU; WADDELL CS, 1988, GENE DEV, V2, P137, DOI 10.1101/gad.2.2.137; [No title captured]	30	99	101	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1003	1013		10.1016/0092-8674(91)90552-A	http://dx.doi.org/10.1016/0092-8674(91)90552-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1646076				2022-12-01	WOS:A1991FR04700011
J	BARGONETTI, J; FRIEDMAN, PN; KERN, SE; VOGELSTEIN, B; PRIVES, C				BARGONETTI, J; FRIEDMAN, PN; KERN, SE; VOGELSTEIN, B; PRIVES, C			WILD-TYPE BUT NOT MUTANT P53 IMMUNOPURIFIED PROTEINS BIND TO SEQUENCES ADJACENT TO THE SV40 ORIGIN OF REPLICATION	CELL			English	Article							LARGE-T-ANTIGEN; LARGE TUMOR-ANTIGEN; MONKEY CELLS; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; TRANSFORMED-CELLS; DNA-REPLICATION; MOUSE P53; GENE; TRANSCRIPTION	The DNA from a wide variety of human tumors has sustained mutations within the conserved p53 coding regions. We have purified wild-type and tumor-derived mutant p53 proteins expressed from baculovirus vectors and examined their interactions with SV40 DNA. Using DNAase I footprinting assays, we observed that both human and murine wild-type p53 proteins bind specifically to sequences adjacent to the late border of the viral replication origin. By contrast, mutant p53 proteins failed to bind specifically to these sequences. SV40 T antigen prevented wild-type p53 from interacting with this region. These data show that normal but not oncogenic forms of p53 are capable of sequence-specific interactions with viral DNA. Furthermore, they provide insights into the mechanisms by which viral proteins might regulate the control of viral growth and cell division.	JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	BARGONETTI, J (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Bargonetti, Jill/0000-0003-2692-0991	NCI NIH HHS [CA43460, CA33620] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043460, P01CA033620, R37CA043460] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DILLER L, 1990, MOL CELL BIOL, V10, P5775; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EHRHART JC, 1988, ONCOGENE, V3, P595; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FROMM M, 1982, Journal of Molecular and Applied Genetics, V1, P457; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN M, 1991, IN PRESS SCIENCE; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, IN PRESS SCIENCE; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Maxam A M, 1980, Methods Enzymol, V65, P499; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1988, ONCOGENE, V2, P621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; OROURKE RW, 1986, NATURE, V320, P182; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TACK LC, 1989, J VIROL, V63, P1310, DOI 10.1128/JVI.63.3.1310-1317.1989; Tooze J., 1981, MOL BIOL TUMOR VIRUS; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	65	395	407	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1083	1091		10.1016/0092-8674(91)90560-L	http://dx.doi.org/10.1016/0092-8674(91)90560-L			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1646078				2022-12-01	WOS:A1991FR04700019
J	CECCARELLI, A; MAHBUBANI, H; WILLIAMS, JG				CECCARELLI, A; MAHBUBANI, H; WILLIAMS, JG			POSITIVELY AND NEGATIVELY ACTING SIGNALS REGULATING STALK CELL AND ANTERIOR-LIKE CELL-DIFFERENTIATION IN DICTYOSTELIUM	CELL			English	Article							PRESTALK GENE-EXPRESSION; DISCOIDEUM; DIF; CAMP; TRANSFORMATION; MORPHOGEN; PROTEINS; FATE; SLUG	The Dictyostelium ecmB gene encodes an extracellular matrix protein and is inducible by the stalk cell morphogen DIF. It is expressed in a subset of prestalk (pstB) cells in the slug and surrounding pstA cells first express it at culmination. A region of the ecmB promoter can direct transcription in all anterior prestalk cells, but a separate, downstream region acts to prevent its expression in pstA cells prior to culmination. Th is may be the site of interaction of a repressor, regulated by an extracellular antagonist to DIF. At culmination, expression of the ecmB gene also becomes greatly elevated in anterior-like cells as they move to surround the spore mass. A distal region of the ecmB promoter directs increased expression in those anterior-like cells that surmount the spore head. This divergence in gene expression suggests that anterior-like cells and anterior prestalk cells experience different inductive conditions at culmination.			CECCARELLI, A (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,BLANCHE LANE,POTTERS BAR EN6 3LD,HERTS,ENGLAND.							AYRES K, 1987, MOL CELL BIOL, V7, P1823, DOI 10.1128/MCB.7.5.1823; BERKS M, 1988, DEV BIOL, V126, P108, DOI 10.1016/0012-1606(88)90244-8; BERKS M, 1990, DEVELOPMENT, V110, P977; BLASCHKE A, 1986, DIFFERENTIATION, V32, P1, DOI 10.1111/j.1432-0436.1986.tb00549.x; BONNER JT, 1952, AM NAT, V86, P79, DOI 10.1086/281707; BROOKMAN JJ, 1987, DEVELOPMENT, V100, P119; DEVINE KM, 1985, DEV BIOL, V107, P364, DOI 10.1016/0012-1606(85)90318-5; DINGERMANN T, 1989, GENE, V85, P353, DOI 10.1016/0378-1119(89)90428-9; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; EARLY AE, 1987, GENE, V59, P99, DOI 10.1016/0378-1119(87)90270-8; GREGG JH, 1982, DIFFERENTIATION, V21, P200, DOI 10.1111/j.1432-0436.1982.tb01214.x; GROSS JD, 1983, NATURE, V303, P244, DOI 10.1038/303244a0; INSALL R, 1990, EMBO J, V9, P3323, DOI 10.1002/j.1460-2075.1990.tb07532.x; JERMYN KA, 1991, DEVELOPMENT, V111, P779; JERMYN KA, 1989, NATURE, V340, P144, DOI 10.1038/340144a0; JERMYN KA, 1987, DEVELOPMENT, V100, P745; KAKUTANI T, 1986, DEV BIOL, V115, P439, DOI 10.1016/0012-1606(86)90264-2; MASENTO MS, 1988, BIOCHEM J, V256, P23, DOI 10.1042/bj2560023; MCROBBIE SJ, 1988, DEV BIOL, V125, P59, DOI 10.1016/0012-1606(88)90058-9; MCROBBIE SJ, 1988, DEVELOPMENT, V104, P275; MORRISSEY JH, 1984, DEV BIOL, V103, P414, DOI 10.1016/0012-1606(84)90329-4; NEAVE N, 1986, BIOCHEM CELL BIOL, V64, P85, DOI 10.1139/o86-015; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; PEARS CJ, 1988, NUCLEIC ACIDS RES, V16, P8467, DOI 10.1093/nar/16.17.8467; RILEY BB, 1990, DEVELOPMENT, V109, P715; SCHAAP P, 1985, DEV BIOL, V111, P51, DOI 10.1016/0012-1606(85)90434-8; SCHINDLER J, 1977, J MOL BIOL, V116, P161, DOI 10.1016/0022-2836(77)90124-3; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; STERNFELD J, 1981, DIFFERENTIATION, V20, P10, DOI 10.1111/j.1432-0436.1981.tb01150.x; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; THALLER C, 1987, NATURE, V327, P626; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; WANG M, 1990, DEV BIOL, V140, P182, DOI 10.1016/0012-1606(90)90065-Q; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9	34	112	113	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					983	989		10.1016/0092-8674(91)90550-I	http://dx.doi.org/10.1016/0092-8674(91)90550-I			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	2044155				2022-12-01	WOS:A1991FR04700009
J	CHELLAPPAN, SP; HIEBERT, S; MUDRYJ, M; HOROWITZ, JM; NEVINS, JR				CHELLAPPAN, SP; HIEBERT, S; MUDRYJ, M; HOROWITZ, JM; NEVINS, JR			THE E2F TRANSCRIPTION FACTOR IS A CELLULAR TARGET FOR THE RB PROTEIN	CELL			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; ADENOVIRUS E1A PROTEINS; DNA-BINDING ACTIVITY; TRANS-ACTIVATION; ENCODED PROTEIN; PRODUCT; EXPRESSION; CYCLE; PHOSPHORYLATION; ASSOCIATION	Although it is generally believed that the product of the retinoblastoma susceptibility gene (RB1) is an important regulator of cell proliferation, the biochemical mechanism for its action is unclear. We now show that the RB protein is found in a complex with the E2F transcription factor and that only the underphosphorylated form of RB is in the E2F complex. Moreover, the adenovirus E1A protein can dissociate the E2F-RB complex, dependent on E1A sequence also critical for E1A to bind to RB. These sequences are also critical for E1A to immortalize primary cell cultures and to transform in conjunction with other oncogenes. Taken together, these results suggest that the interaction of RB with E2F is an important event in the control of cellular proliferation and that the dissociation of the complex is part of the mechanism by which E1A inactivates RB function.	DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,CELL GROWTH REGULAT & ONCOGENESIS SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,GENET SECT,DURHAM,NC 27710	Duke University; Duke University	CHELLAPPAN, SP (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.		Hiebert, Scott W/C-9979-2010		NCI NIH HHS [CA53248] Funding Source: Medline; NIGMS NIH HHS [GM26765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EGAN C, 1989, ONCOGENE, V4, P383; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; MUDRYJ M, 1991, IN PRESS CELL; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; RAYCHAUDHURI P, 1991, IN PRESS GENES DEV; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; VARLEY JM, 1989, ONCOGENE, V4, P725; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YOKOTA J, 1988, ONCOGENE, V3, P471; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	52	1304	1328	2	53	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1053	1061		10.1016/0092-8674(91)90557-F	http://dx.doi.org/10.1016/0092-8674(91)90557-F			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1828392				2022-12-01	WOS:A1991FR04700016
J	CHITTENDEN, T; LIVINGSTON, DM; KAELIN, WG				CHITTENDEN, T; LIVINGSTON, DM; KAELIN, WG			THE T/E1A-BINDING DOMAIN OF THE RETINOBLASTOMA PRODUCT CAN INTERACT SELECTIVELY WITH A SEQUENCE-SPECIFIC DNA-BINDING PROTEIN	CELL			English	Article							E2F TRANSCRIPTION FACTOR; ADENOVIRUS E1A PROTEINS; LARGE T-ANTIGENS; SUSCEPTIBILITY GENE; REGULATORY PROTEINS; TRANS-ACTIVATION; CELL-CYCLE; RB GENE; SV40; PROMOTER	A DNA-binding site selection and enrichment procedure revealed a sequence-specific DNA-binding activity selectively associated with glutathione S-transferase-retinoblastoma protein chimeras (GST-RB) that had been incubated with a human cell extract. Appropriate mutant forms of GST-RB, incubated in equivalent extracts, did not associate with this specific DNA-binding activity, and a peptide replica of the HPV E7 RB-binding segment selectively inhibited the association of GST-RB with the sequence-specific DNA-binding protein(s). Sequence analysis of oligonucleotides with high affinity for GST-RB complexes, as well as the results of competition binding studies, strongly suggest that RB can associate specifically with the transcription factor E2F or with a protein having closely related DNA-binding properties.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	CHITTENDEN, T (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.							BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES RE, 1990, J BIOL CHEM, V265, P12782; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Maniatis T., 1982, MOL CLONING; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PIENTENPOL JA, 1990, CELL, V61, P777; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x	41	396	414	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1073	1082		10.1016/0092-8674(91)90559-H	http://dx.doi.org/10.1016/0092-8674(91)90559-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1828394				2022-12-01	WOS:A1991FR04700018
J	CRAWFORD, JD; CADERA, W; VILIS, T				CRAWFORD, JD; CADERA, W; VILIS, T			GENERATION OF TORSIONAL AND VERTICAL EYE POSITION SIGNALS BY THE INTERSTITIAL NUCLEUS OF CAJAL	SCIENCE			English	Article							VESTIBULO-OCULAR REFLEX; NEURAL INTEGRATOR; OCULOMOTOR SYSTEM; MOVEMENTS; MONKEY; VELOCITY; BEHAVIOR; LESIONS	The neural integrator, which converts eye velocity signals into position signals, is central to oculomotor theory. Similar integrators are probably necessary in any neural system that changes and maintains muscular tension. The integrator for horizontal eye position is in the pons, but the locations of the vertical and torsional integrators have not been clearly defined. Recording three-dimensional eye movements in alert monkeys during microstimulation and pharmacological inactivation of midbrain sites showed that the interstitial nucleus of Cajal generates both the torsional and vertical eye position signals. Up and down signals are linked with clockwise signals in the right brain and counterclockwise signals in the left brain. This three-dimensional coordinate system achieves orthogonality and bilateral symmetry without redundancy and optimizes energy efficiency for horizontal visual scanning.	UNIV WESTERN ONTARIO,DEPT OPHTHALMOL,LONDON N6A 5C1,ONTARIO,CANADA	Western University (University of Western Ontario)	CRAWFORD, JD (corresponding author), UNIV WESTERN ONTARIO,DEPT PHYSIOL,LONDON N6A 5C1,ONTARIO,CANADA.			Crawford, Doug/0000-0003-2288-1286				ANDERSON JH, 1979, NEUROSCI LETT, V14, P259, DOI 10.1016/0304-3940(79)96158-5; BUTTNERENNEVER JA, 1988, NEUROANATOMY OCULOMO, P137; CANNON SC, 1987, J NEUROPHYSIOL, V57, P1383, DOI 10.1152/jn.1987.57.5.1383; CHERON G, 1987, J PHYSIOL-LONDON, V394, P267, DOI 10.1113/jphysiol.1987.sp016870; CRAWFORD JD, 1991, J NEUROPHYSIOL, V65, P407, DOI 10.1152/jn.1991.65.3.407; EZURE K, 1984, NEUROSCIENCE, V12, P85, DOI 10.1016/0306-4522(84)90140-4; FUCHS AF, 1985, ANNU REV NEUROSCI, V8, P307, DOI 10.1146/annurev.ne.08.030185.001515; FUKUSHIMA K, 1990, EXP BRAIN RES, V79, P43; FUKUSHIMA K, 1987, PROG NEUROBIOL, V29, P107, DOI 10.1016/0301-0082(87)90016-5; KING WM, 1981, J NEUROPHYSIOL, V46, P549, DOI 10.1152/jn.1981.46.3.549; KING WM, 1982, PHYSL VERTICAL GAZE, P267; ROBINSON DA, 1970, J NEUROPHYSIOL, V33, P393, DOI 10.1152/jn.1970.33.3.393; ROBINSON DA, 1982, BIOL CYBERN, V46, P53, DOI 10.1007/BF00335351; ROBINSON DA, 1971, CONTROL EYE MOVEMENT, P519; TWEED D, 1987, J NEUROPHYSIOL, V58, P832, DOI 10.1152/jn.1987.58.4.832; TWEED D, 1990, VISION RES, V30, P111, DOI 10.1016/0042-6989(90)90131-4; TWEED D, 1990, VISION RES, V30, P97, DOI 10.1016/0042-6989(90)90130-D; VILIS T, 1989, EXP BRAIN RES, V77, P1	18	180	181	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1991	252	5012					1551	1553		10.1126/science.2047862	http://dx.doi.org/10.1126/science.2047862			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR040	2047862				2022-12-01	WOS:A1991FR04000048
J	DIAMOND, MS; STAUNTON, DE; MARLIN, SD; SPRINGER, TA				DIAMOND, MS; STAUNTON, DE; MARLIN, SD; SPRINGER, TA			BINDING OF THE INTEGRIN MAC-1 (CD11B/CD18) TO THE 3RD IMMUNOGLOBULIN-LIKE DOMAIN OF ICAM-1 (CD54) AND ITS REGULATION BY GLYCOSYLATION	CELL			English	Article								Both the integrins LFA-1 and Mac-1 bind to ICAM-1, an immunoglobulin superfamily member. Previously, we localized the binding sites of LFA-1 and the major group of human rhinoviruses to the first NH2-terminal immunoglobulin-like domain of ICAM-1. Here, we show that the binding site on ICAM-1 for Mac-1 is unexpectedly distinct from that for LFA-1 and maps to the third NH2-terminal immunoglobulin-like domain. These findings provide a function for the tandem duplication of immunoglobulin-like domains in ICAM-1 and have implications for other immunoglobulin superfamily members. Mutations at two sites in the third domain that destroy consensus sequences for N-linked glycosylation enhance binding to purified Mac-1. Agents that interfere with carbohydrate processing provide evidence that the size of the N-linked oligosaccharide side chains on ICAM-1 affects binding to Mac-1 but not to LFA- 1. Thus, we suggest that the extent of glycosylation on ICAM-1 may regulate adhesion to LFA-1 or Mac-1 in vivo.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, CTR BLOOD RES, BOSTON, MA 02115 USA; BOEHRINGER INGELHEIM PHARMACEUT, RIDGEFIELD, CT 06877 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Boehringer Ingelheim	DIAMOND, MS (corresponding author), HARVARD UNIV, SCH MED, COMM CELL & DEV BIOL, 800 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Diamond, Michael/AAH-1733-2019	Diamond, Michael/0000-0002-8791-3165	NCI NIH HHS [CA31799] Funding Source: Medline; NIGMS NIH HHS [T32GM07753-11, T32 GM007753] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031799, R37CA031799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.me.38.020187.001135; ANDERSON DC, 1986, J IMMUNOL, V137, P15; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; BARTON RW, 1989, J IMMUNOL, V143, P1278; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; BERNSTEIN ID, 1986, HUMAN MYELOID HEMATO, P1; BISCHOFF J, 1986, J BIOL CHEM, V261, P4766; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; COSIMI AB, 1990, J IMMUNOL, V144, P4604; DAVIGNON D, 1981, P NATL ACAD SCI-BIOL, V78, P4535, DOI 10.1073/pnas.78.7.4535; DEFOUGEROLLES AR, 1991, IN PRESS J EXP MED; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DUSTIN ML, 1989, COLD SPRING HARB SYM, V54, P753; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; DUSTIN ML, 1986, J IMMUNOL, V137, P245; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; EDELMAN GM, 1970, BIOCHEMISTRY-US, V9, P3197, DOI 10.1021/bi00818a012; FLAVIN T, 1991, TRANSPLANT P, V23, P533; FLEIT HB, 1989, LEUKOCYTE TYPING, V4, P579; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; HARLAN JM, 1985, BLOOD, V66, P167; HASKARD D, 1986, J IMMUNOL, V137, P2901; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HSIEH P, 1984, J BIOL CHEM, V259, P2375; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1, DOI 10.1016/S0065-2776(08)60639-2; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KRENSKY AM, 1983, J IMMUNOL, V131, P611; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1977, FEBS LETT, V82, P314, DOI 10.1016/0014-5793(77)80609-1; LO SK, 1989, J IMMUNOL, V143, P3325; MAIO M, 1989, J IMMUNOL, V143, P181; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MILLER LJ, 1986, J IMMUNOL, V137, P2891; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; PAUL JI, 1990, J BIOL CHEM, V265, P13074; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; SPRINGER TA, 1987, CURRENT PROTOCOLS MO; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; SUMMER MD, 1988, MANUAL METHODS BACUL; TAKEI F, 1985, J IMMUNOL, V134, P1403; TOMASSINI JE, 1989, J BIOL CHEM, V264, P1656; Uciechowski P., 1989, LEUCOCYTE TYPING, P543; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734	73	734	768	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1991	65	6					961	971		10.1016/0092-8674(91)90548-D	http://dx.doi.org/10.1016/0092-8674(91)90548-D			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1675157				2022-12-01	WOS:A1991FR04700007
J	DREWS, GN; BOWMAN, JL; MEYEROWITZ, EM				DREWS, GN; BOWMAN, JL; MEYEROWITZ, EM			NEGATIVE REGULATION OF THE ARABIDOPSIS HOMEOTIC GENE AGAMOUS BY THE APETALA2 PRODUCT	CELL			English	Article							FLOWER DEVELOPMENT; FLORAL DEVELOPMENT; ULTRABITHORAX TRANSCRIPTS; DROSOPHILA EMBRYOS; SPATIAL EXPRESSION; BITHORAX COMPLEX; ANTENNAPEDIA; THALIANA; PATTERN; PROTEIN	We characterized the distribution of AGAMOUS (AG) RNA during early flower development in Arabidopsis. Mutations in this homeotic gene cause the transformation of stamens to petals in floral whorl 3 and of carpels to another ag flower in floral whorl 4. We found that AG RNA is present in the stamen and carpel primordia but is undetectable in sepal and petal primordia throughout early wild-type flower development, consistent with the mutant phenotype. We also analyzed the distribution of AG RNA in apetela2 (ap2) mutant flowers. AP2 is a floral homeotic gene that is necessary for the normal development of sepals and petals in floral whorls 1 and 2. In ap2 mutant flowers, AG RNA is present in the organ primordia of all floral whorls. These observations show that the expression patterns of the Arabidopsis floral homeotic genes are in part established by regulatory interactions between these genes.			DREWS, GN (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Meyerowitz, Elliot M/A-7118-2009	Bowman, John/0000-0001-7347-3691	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013100, T32GM007616] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM13100-03, 5T32-GM07616] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAM M, 1987, DEVELOPMENT, V101, P1; AKAM ME, 1983, EMBO J, V2, P2075, DOI 10.1002/j.1460-2075.1983.tb01703.x; AKAM ME, 1985, EMBO J, V4, P1689, DOI 10.1002/j.1460-2075.1985.tb03838.x; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BLASER HW, 1950, AM J BOT, V37, P297, DOI 10.2307/2437850; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BOWMAN JL, 1991, IN PRESS S SOC EXPT, V44; BOWMAN JL, 1991, IN PRESS DEVELOPMENT; BOWMAN JL, 1988, OXFORD SURV PLANT MO, V5, P57; CARROLL SB, 1986, CELL, V47, P113, DOI 10.1016/0092-8674(86)90372-7; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; COX KH, 1988, PLANT MOL BIOL PRACT, P1; DERMEN H, 1947, AM J BOT, V34, P32, DOI 10.2307/2437192; DERMEN H, 1973, AM J BOT, V60, P283, DOI 10.2307/2441220; HAFEN E, 1984, NATURE, V307, P287, DOI 10.1038/307287a0; HARDING K, 1985, SCIENCE, V229, P1236, DOI 10.1126/science.3898362; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; INGHAM PW, 1986, NATURE, V324, P592, DOI 10.1038/324592a0; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; IRISH VF, 1989, EMBO J, V8, P1527, DOI 10.1002/j.1460-2075.1989.tb03537.x; JACK T, 1990, EMBO J, V9, P1187, DOI 10.1002/j.1460-2075.1990.tb08226.x; KOMAKI MK, 1988, DEVELOPMENT, V104, P195; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; LEVINE M, 1983, EMBO J, V2, P2037, DOI 10.1002/j.1460-2075.1983.tb01697.x; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MEYEROWITZ EM, 1989, DEVELOPMENT, V106, P209; MEYEROWITZ EM, 1991, IN PRESS DEVELOPME S; Pruitt RE, 1987, GENETIC REGULATION D, P327; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; Satina S, 1941, AM J BOT, V28, P862, DOI 10.2307/2436864; Satina S, 1944, AM J BOT, V31, P493, DOI 10.2307/2437412; Satina S, 1940, AM J BOT, V27, P895, DOI 10.2307/2436558; Satina S, 1943, AM J BOT, V30, P453, DOI 10.2307/2437281; SATINA S, 1945, AM J BOT, V32, P72, DOI 10.2307/2437113; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; WHITE RAH, 1986, CELL, V47, P311, DOI 10.1016/0092-8674(86)90453-8; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	38	522	576	6	84	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					991	1002		10.1016/0092-8674(91)90551-9	http://dx.doi.org/10.1016/0092-8674(91)90551-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1675158				2022-12-01	WOS:A1991FR04700010
J	DURRIN, LK; MANN, RK; KAYNE, PS; GRUNSTEIN, M				DURRIN, LK; MANN, RK; KAYNE, PS; GRUNSTEIN, M			YEAST HISTONE H4 N-TERMINAL SEQUENCE IS REQUIRED FOR PROMOTER ACTIVATION INVIVO	CELL			English	Article								To search for histone domains that may regulate transcription in vivo, we made deletions and amino acid substitutions in the histone N-termini of S. cerevisiae. Histone H4 N-terminal residues 4-23, which include the extremely conserved, reversibly acetylated lysines (at positions 5, 8, 12, and 16), were found to encompass a region required for the activation of the GAL1 promoter. Deletions in the H4 N-terminus reduce GAL1 activation 20-fold. This effect is specific to histone H4 in that large deletions in the N-termini of H2A, H2B, and H3 do not similarly decrease induction. Activation of the PH05 promoter is reduced approximately 4- to 5-fold by these H4 deletions. Mutations in histone H4 acetylation sites and surrounding residues can cause comparable and, in some cases, even greater effects on induction of these two promoters. We postulate that the H4 N-terminus may interact with a component of the transcription initiation complex, allowing nucleosome unfolding and subsequent initiation.	UNIV CALIF LOS ANGELES, DEPT BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	DURRIN, LK (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA.				NIGMS NIH HHS [GM23674] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023674, R37GM023674] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; Allfrey V. G, 1977, CHROMATIN CHROMOSOME, P167; ALLFREY VG, 1983, AFFINITY PROBES PROT; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ANNUNZIATO AT, 1988, CHROMOSOMA, V96, P132, DOI 10.1007/BF00331045; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FOGEL S, 1982, P NATL ACAD SCI-BIOL, V79, P5342, DOI 10.1073/pnas.79.17.5342; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HEREFORD L, 1979, CELL, V18, P1261, DOI 10.1016/0092-8674(79)90237-X; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P337, DOI 10.1073/pnas.81.2.337; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAUGHON A, 1982, P NATL ACAD SCI-BIOL, V79, P6827, DOI 10.1073/pnas.79.22.6827; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LOHR D, 1984, NUCLEIC ACIDS RES, V12, P8457, DOI 10.1093/nar/12.22.8457; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; Maniatis T., 1982, MOL CLONING; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; NELSON DA, 1982, J BIOL CHEM, V257, P1565; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; NORTON VG, 1990, J BIOL CHEM, V265, P19848; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RAINBOW M, 1989, BIOCHEMISTRY-US, V28, P7486, DOI 10.1021/bi00444a048; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHROTH GP, 1990, FEBS LETT, V268, P117, DOI 10.1016/0014-5793(90)80987-T; SCHUSTER T, 1986, CELL, V45, P445, DOI 10.1016/0092-8674(86)90330-2; Sherman F., 1986, METHODS YEAST GENETI; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; STJOHN TP, 1981, J MOL BIOL, V152, P285, DOI 10.1016/0022-2836(81)90244-8; STRAKA C, 1991, IN PRESS EMBO J, V10; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; van Holde K E, 1988, CHROMATIN; WALLIS JW, 1983, CELL, V35, P711, DOI 10.1016/0092-8674(83)90104-6; WATERBORG JH, 1984, EUR J BIOCHEM, V142, P329, DOI 10.1111/j.1432-1033.1984.tb08290.x; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; WHITLOCK JP, 1978, J BIOL CHEM, V253, P3857; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735; XU HX, 1990, MOL CELL BIOL, V10, P2687, DOI 10.1128/MCB.10.6.2687	58	282	284	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1991	65	6					1023	1031		10.1016/0092-8674(91)90554-C	http://dx.doi.org/10.1016/0092-8674(91)90554-C			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	2044150				2022-12-01	WOS:A1991FR04700013
J	ENGLER, P; HAASCH, D; PINKERT, CA; DOGLIO, L; GLYMOUR, M; BRINSTER, R; STORB, U				ENGLER, P; HAASCH, D; PINKERT, CA; DOGLIO, L; GLYMOUR, M; BRINSTER, R; STORB, U			A STRAIN-SPECIFIC MODIFIER ON MOUSE CHROMOSOME-4 CONTROLS THE METHYLATION OF INDEPENDENT TRANSGENE LOCI	CELL			English	Article								A transgene, pHRD, is highly methylated in 12 independent mouse lines when in a C57BL/6 strain background, but becomes progressively less methylated when bred into a DBA/2 background. Transgenes inherited from the mother are generally more methylated; however, this parental effect disappears following continued breeding into the nonmethylating strain. Mapping experiments using BXD recombinant inbred mice as well as other inbred strains indicate that a single strain-specific modifier (Ssm-1) linked to, but distinct from, Fv-1 is responsible for the strain effect. In addition to the methylated and unmethylated transgenic phenotypes, certain mice exhibit a partial methylation pattern that is a consequence of an unusual cellular mosaicism. The pHRD transgene, containing target sequences for the V(D)J recombinase, undergoes site-specific recombination only in lymphoid tissues. This V-J joining is restricted primarily to unmethylated transgene copies.	UNIV PENN, SCH VET MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	ENGLER, P (corresponding author), UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA.			Brinster, Ralph/0000-0003-1408-7656; Pinkert, Carl/0000-0001-7460-3881	NIAID NIH HHS [AI24780] Funding Source: Medline; NICHD NIH HHS [HD23089, HD07136] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024780, R01AI024780] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1985, P NATL ACAD SCI USA, V82, P2674, DOI 10.1073/pnas.82.9.2674; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BLACKWELL TK, 1989, ANNU REV GENET, V23, P605, DOI 10.1146/annurev.ge.23.120189.003133; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; DYNAN WS, 1989, TRENDS GENET, V5, P35, DOI 10.1016/0168-9525(89)90016-4; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; EISSENBERG JC, 1989, BIOESSAYS, V11, P14, DOI 10.1002/bies.950110105; ENGLER P, 1991, J IMMUNOL, V146, P2826; ENGLER P, 1987, P NATL ACAD SCI USA, V84, P4949, DOI 10.1073/pnas.84.14.4949; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; Hogan B., 1986, MANIPULATING MOUSE E; Jolicoeur P, 1979, Curr Top Microbiol Immunol, V86, P67; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LIN PF, 1985, MOL CELL BIOL, V5, P3149, DOI 10.1128/MCB.5.11.3149; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; Lyon ML, 1989, GENETIC VARIANTS STR, P773; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; REUTER G, 1990, NATURE, V344, P219, DOI 10.1038/344219a0; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SAPIENZA C, 1989, PROG NUCLEIC ACID RE, V36, P145; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SAPIENZA C, 1987, NATURE, V328, P251, DOI 10.1038/328251a0; SOLTER D, 1988, ANNU REV GENET, V22, P127; SPOFFORD JB, 1976, GENET BIOL DROSOPHIL, V1, P953; SPRADLING AC, 1990, GENETICS, V126, P779; STORB U, 1989, MOL CELL BIOL, V9, P711, DOI 10.1128/MCB.9.2.711; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; TABAK HF, 1978, NUCLEIC ACIDS RES, V5, P2321, DOI 10.1093/nar/5.7.2321; TARTOF KD, 1984, CELL, V37, P869, DOI 10.1016/0092-8674(84)90422-7; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; YANCOPOULOS GD, 1988, J EXP MED, V168, P417, DOI 10.1084/jem.168.1.417	37	193	196	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1991	65	6					939	947		10.1016/0092-8674(91)90546-B	http://dx.doi.org/10.1016/0092-8674(91)90546-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	2044153				2022-12-01	WOS:A1991FR04700005
J	GEISER, JR; VANTUINEN, D; BROCKERHOFF, SE; NEFF, MM; DAVIS, TN				GEISER, JR; VANTUINEN, D; BROCKERHOFF, SE; NEFF, MM; DAVIS, TN			CAN CALMODULIN FUNCTION WITHOUT BINDING CALCIUM	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; YEAST CALMODULIN; SCHIZOSACCHAROMYCES-POMBE; GENETIC-EVIDENCE; DNA-POLYMERASE; PROTEIN-KINASE; CA-2+; CELLS; VERTEBRATE	Calmodulin is a small Ca2+-binding protein proposed to act as the intracellular Ca2+ receptor that translates Ca2+ signals into cellular responses. We have constructed mutant yeast calmodulins in which the Ca2+-binding loops have been altered by site-directed mutagenesis. Each of the mutant proteins has a dramatically reduced affinity for Ca2+; one does not bind detectable levels of Ca-45(2+) either during gel filtration or when bound to a solid support. Furthermore, none of the mutant proteins change conformation even in the presence of high Ca2+ concentrations. Surprisingly, yeast strains relying on any of the mutant calmodulins not only survive but grow well. In contrast, yeast strains deleted for the calmodulin gene are not viable. Thus, calmodulin is required for growth, but it can perform its essential function without the apparent ability to bind Ca2+.			GEISER, JR (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195, USA.		Davis, Trisha/F-8584-2010	Davis, Trisha/0000-0003-4797-3152				ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BACHS O, 1990, J BIOL CHEM, V265, P18595; BLUMBERG H, 1987, NATURE, V328, P443, DOI 10.1038/328443a0; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRADLEY DE, 1980, J BACTERIOL, V143, P1466, DOI 10.1128/JB.143.3.1466-1470.1980; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; COHEN P, 1988, MOL ASPECTS CELL REG, V5, P123; CONZELMAN KA, 1987, J CELL BIOL, V105, P313, DOI 10.1083/jcb.105.1.313; COOPER JA, 1987, ONCOGENE RES, V1, P297; COX JA, 1981, BIOCHIM BIOPHYS ACTA, V670, P441, DOI 10.1016/0005-2795(81)90119-7; CRABTREE S, 1984, J BACTERIOL, V158, P354, DOI 10.1128/JB.158.1.354-356.1984; DAVIS TN, 1989, P NATL ACAD SCI USA, V86, P7909, DOI 10.1073/pnas.86.20.7909; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DINSMORE JH, 1988, CELL, V53, P769, DOI 10.1016/0092-8674(88)90094-3; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; GARRETT J, 1981, MOL GEN GENET, V182, P326, DOI 10.1007/BF00269678; GRATZNER WB, 1988, CALMODULIN, V5, P329; GREENLEE DV, 1982, BIOCHEMISTRY-US, V21, P2759, DOI 10.1021/bi00540a028; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; HARMON AC, 1985, BIOCHEM BIOPH RES CO, V127, P31, DOI 10.1016/S0006-291X(85)80121-2; HINRICHSEN RD, 1986, SCIENCE, V232, P503, DOI 10.1126/science.2421410; HOWE CL, 1983, J CELL BIOL, V97, P974, DOI 10.1083/jcb.97.4.974; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; IIDA H, 1990, J BIOL CHEM, V265, P13391; JOHNSTON M, 1987, NATURE, V328, P353, DOI 10.1038/328353a0; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KEITH CH, 1987, CELL MOTIL CYTOSKEL, V7, P1, DOI 10.1002/cm.970070102; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; KLEE CB, 1988, CALMODULIN MOL ASPEC, V5, P35; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LONDESBOROUGH J, 1987, FEBS LETT, V219, P249, DOI 10.1016/0014-5793(87)81226-7; LUAN Y, 1987, J BIOCHEM-TOKYO, V102, P1531, DOI 10.1093/oxfordjournals.jbchem.a122201; Marme D., 1983, CALCIUM CELL FUNCTIO, VIV, p263 ; Miller JH., 1972, EXPT MOL GENETICS; MINDICH L, 1976, J BACTERIOL, V126, P177, DOI 10.1128/JB.126.1.177-182.1976; MIYAKAWA T, 1989, J BACTERIOL, V171, P1417, DOI 10.1128/jb.171.3.1417-1422.1989; OHYA Y, 1987, EUR J BIOCHEM, V168, P13, DOI 10.1111/j.1432-1033.1987.tb13380.x; OHYA Y, 1989, BIOCHEM BIOPH RES CO, V158, P541, DOI 10.1016/S0006-291X(89)80083-X; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; PERSECHINI A, 1991, P NATL ACAD SCI USA, V88, P449, DOI 10.1073/pnas.88.2.449; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; RASMUSSEN CD, 1990, J BIOL CHEM, V265, P13767; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; RATAN RR, 1986, TRENDS BIOCHEM SCI, V11, P456, DOI 10.1016/0968-0004(86)90246-X; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAEFER WH, 1987, P NATL ACAD SCI USA, V84, P3931, DOI 10.1073/pnas.84.11.3931; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; Sherman F., 1986, METHODS YEAST GENETI; SLOTBOOM AJ, 1978, BIOCHEMISTRY-US, V17, P4593, DOI 10.1021/bi00615a003; STABEN C, 1986, J BIOL CHEM, V261, P4629; STULL JT, 1988, MOL ASPECTS CELLULAR, V5, P91; SWEET SC, 1988, J CELL BIOL, V107, P2243, DOI 10.1083/jcb.107.6.2243; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKEDA T, 1989, P NATL ACAD SCI USA, V86, P9737, DOI 10.1073/pnas.86.24.9737; TAKEDA T, 1987, P NATL ACAD SCI USA, V84, P3580, DOI 10.1073/pnas.84.11.3580; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501; Weber G, 1975, Adv Protein Chem, V29, P1, DOI 10.1016/S0065-3233(08)60410-6; YOUDERIAN P, 1980, VIROLOGY, V107, P258, DOI 10.1016/0042-6822(80)90291-3	65	277	280	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					949	959		10.1016/0092-8674(91)90547-C	http://dx.doi.org/10.1016/0092-8674(91)90547-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	2044154	Green Published			2022-12-01	WOS:A1991FR04700006
J	HATAKEYAMA, M; KONO, T; KOBAYASHI, N; KAWAHARA, A; LEVIN, SD; PERLMUTTER, RM; TANIGUCHI, T				HATAKEYAMA, M; KONO, T; KOBAYASHI, N; KAWAHARA, A; LEVIN, SD; PERLMUTTER, RM; TANIGUCHI, T			INTERACTION OF THE IL-2 RECEPTOR WITH THE SRC-FAMILY KINASE-P56LCK - IDENTIFICATION OF NOVEL INTERMOLECULAR ASSOCIATION	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; HUMAN INTERLEUKIN-2 RECEPTOR; HUMAN B-CELLS; BETA-CHAIN; CYTOPLASMIC DOMAINS; PROMOTER INSERTION; MOLECULAR-CLONING; LYMPHOCYTES-T; TAC ANTIGEN; EXPRESSION	In the interleukin-2 (IL-2) system, intracellular signal transduction is triggered by the beta-chain of the IL-2 receptor (IL-2R-beta); however, the responsible signaling mechanism remains unidentified. Evidence for the formation of a stable complex of IL-2R-beta and the lymphocyte-specific protein tyrosine kinase p56lck is presented. Specific association sites were identified in the tyrosine kinase catalytic domain of p56lck and in the cytoplasmic domain of IL-2R-beta. As a result of interaction, IL-2R-beta became phosphorylated in vitro by p56lck. Treatment of T lymphocytes with IL-2 promotes p56lck kinase activity. These data suggest the participation of p56lck as a critical signaling molecule downstream of IL-2R via a novel interaction.	UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	HATAKEYAMA, M (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN.							ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BENEDICT SH, 1987, J IMMUNOL, V139, P1694; BLACKMAN MA, 1986, CELL, V47, P609, DOI 10.1016/0092-8674(86)90625-2; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; FERRIS DK, 1989, J IMMUNOL, V143, P870; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1987, J EXP MED, V166, P362, DOI 10.1084/jem.166.2.362; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HATAKEYAMA M, UNPUB; HATAKEYAMA M, 1990, PEPTIDE GROWTH FACTO, V1, P523; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KONO T, 1990, P NATL ACAD SCI USA, V87, P1806, DOI 10.1073/pnas.87.5.1806; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LINK M, 1983, BLOOD, V62, P722; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MINAMOTO S, 1990, J IMMUNOL, V145, P2177; MORI H, 1991, INT IMMUNOL, V3, P149, DOI 10.1093/intimm/3.2.149; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAW AS, 1989, CELL, V59, P627; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; TAGA T, COMMUNICATION; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; TSUDO M, 1989, P NATL ACAD SCI USA, V86, P1982, DOI 10.1073/pnas.86.6.1982; TSUDO M, 1984, J EXP MED, V160, P612, DOI 10.1084/jem.160.2.612; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WALDMANN TA, 1984, J EXP MED, V160, P1450, DOI 10.1084/jem.160.5.1450; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YODOI J, 1985, J IMMUNOL, V134, P1623; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	57	636	646	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1991	252	5012					1523	1528		10.1126/science.2047859	http://dx.doi.org/10.1126/science.2047859			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR040	2047859				2022-12-01	WOS:A1991FR04000039
J	IGARASHI, K; ISHIHAMA, A				IGARASHI, K; ISHIHAMA, A			BIPARTITE FUNCTIONAL MAP OF THE ESCHERICHIA-COLI RNA POLYMERASE-ALPHA SUBUNIT - INVOLVEMENT OF THE C-TERMINAL REGION IN TRANSCRIPTION ACTIVATION BY CAMP-CRP	CELL			English	Article							AMP RECEPTOR PROTEIN; TEMPERATURE-SENSITIVE MUTATIONS; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; PROMOTER STRENGTH; SIGMA-FACTOR; GENE; EXPRESSION; OPERON; LACTOSE	The alpha-subunit of Escherichia coli RNA polymerase plays a major role in the subunit assembly. Carboxy-terminal deletion derivatives lacking 73 or 94 amino acid residues were assembled in vitro into enzyme molecules. Core enzymes consisting of these C-terminal-truncated alpha-subunits were as active in RNA synthesis as native core enzyme. By the addition of sigma-70 subunit, these mutant enzymes initiated transcription from certain promoters. The mutant RNA polymerases, however, did not show cAMP-CRP activated transcription. These results demonstrate that the N-terminal region of the alpha-subunit is involved in the formation of active enzyme molecule, while the C-terminal region plays an essential role in response to transcription activation by cAMP-CRP.			IGARASHI, K (corresponding author), NATL INST GENET,DEPT MOLEC GENET,MISHIMA,SHIZUOKA 411,JAPAN.			Igarashi, Kazuhiko/0000-0002-2470-2475				ADHYA S, 1990, J BIOL CHEM, V265, P10797; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BLANCO C, 1986, MOL GEN GENET, V202, P112, DOI 10.1007/BF00330526; DALE EC, 1986, J MOL BIOL, V192, P793, DOI 10.1016/0022-2836(86)90029-X; DONNELLY CE, 1987, J BACTERIOL, V169, P1812, DOI 10.1128/jb.169.5.1812-1817.1987; FUJIKI H, 1976, MOL GEN GENET, V145, P19, DOI 10.1007/BF00331552; FUKUDA R, 1974, J MOL BIOL, V83, P353, DOI 10.1016/0022-2836(74)90284-8; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GEIDUSCHEK EP, 1988, BACTERIOPHAGES, V2, P93; GIFFARD PM, 1988, MOL GEN GENET, V214, P148, DOI 10.1007/BF00340193; HALLING C, 1990, J BACTERIOL, V172, P3541, DOI 10.1128/jb.172.7.3541-3548.1990; HERBERT M, 1986, P NATL ACAD SCI USA, V83, P2807, DOI 10.1073/pnas.83.9.2807; HUGOUVIEUXCOTTEPATTAT N, 1983, J GEN MICROBIOL, V129, P3345; IGARASHI K, 1990, NUCLEIC ACIDS RES, V18, P5945, DOI 10.1093/nar/18.20.5945; IGARASHI K, 1991, J MOL BIOL, V218, P1, DOI 10.1016/0022-2836(91)90865-4; IRWIN N, 1987, P NATL ACAD SCI USA, V84, P8315, DOI 10.1073/pnas.84.23.8315; ISHIHAMA A, 1980, J MOL BIOL, V137, P137, DOI 10.1016/0022-2836(80)90321-6; Ishihama A, 1981, Adv Biophys, V14, P1; ISHIHAMA A, 1988, TRENDS GENET, V4, P282, DOI 10.1016/0168-9525(88)90170-9; KAJITANI M, 1983, NUCLEIC ACIDS RES, V11, P3873, DOI 10.1093/nar/11.12.3873; KAJITANI M, 1983, NUCLEIC ACIDS RES, V11, P671, DOI 10.1093/nar/11.3.671; KAJITANI M, 1980, MOL GEN GENET, V179, P489, DOI 10.1007/BF00271738; KAWAKAMI K, 1980, BIOCHEMISTRY-US, V19, P3491, DOI 10.1021/bi00556a013; KOBAYASHI M, 1990, NUCLEIC ACIDS RES, V18, P7367, DOI 10.1093/nar/18.24.7367; MALAN TP, 1984, CELL, V39, P173, DOI 10.1016/0092-8674(84)90203-4; MALAN TP, 1984, J MOL BIOL, V180, P881, DOI 10.1016/0022-2836(84)90262-6; MARTINDALE DW, 1990, NUCLEIC ACIDS RES, V18, P2953, DOI 10.1093/nar/18.10.2953; NAKAMURA Y, 1980, MOL GEN GENET, V178, P487, DOI 10.1007/BF00337853; PINKNEY M, 1988, BIOCHEM J, V250, P897, DOI 10.1042/bj2500897; REN YL, 1988, P NATL ACAD SCI USA, V85, P4138, DOI 10.1073/pnas.85.12.4138; RIFTINA F, 1990, BIOCHEMISTRY-US, V29, P4440, DOI 10.1021/bi00470a026; RIFTINA F, 1989, BIOCHEMISTRY-US, V28, P3299, DOI 10.1021/bi00434a027; ROWLAND GC, 1985, J BACTERIOL, V164, P972, DOI 10.1128/JB.164.2.972-975.1985; SAITOH T, 1976, J MOL BIOL, V206, P591; SPASSKY A, 1984, EMBO J, V3, P43, DOI 10.1002/j.1460-2075.1984.tb01759.x; STRANEY DC, 1989, J MOL BIOL, V206, P41, DOI 10.1016/0022-2836(89)90522-6; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUNSHINE MG, 1975, P NATL ACAD SCI USA, V72, P2770, DOI 10.1073/pnas.72.7.2770; VENEZIA ND, 1990, J BIOL CHEM, V265, P8122; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	40	304	314	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1015	1022		10.1016/0092-8674(91)90553-B	http://dx.doi.org/10.1016/0092-8674(91)90553-B			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1646077				2022-12-01	WOS:A1991FR04700012
J	PANINABORDIGNON, P; CORRADIN, G; ROOSNEK, E; SETTE, A; LANZAVECCHIA, A				PANINABORDIGNON, P; CORRADIN, G; ROOSNEK, E; SETTE, A; LANZAVECCHIA, A			RECOGNITION BY CLASS-II ALLOREACTIVE T-CELLS OF PROCESSED DETERMINANTS FROM HUMAN SERUM-PROTEINS	SCIENCE			English	Article							MHC CLASS-II; HLA PEPTIDE; ANTIGENS; BINDING; COMPLEXES; MOLECULE; EPITOPES	Alloreactive T cells recognize a complex composed of an allogeneic major histocompatibility complex (MHC) molecule and a peptide derived from the processing of nonpolymorphic proteins. A sizable fraction of MHC class II alloreactive T cells is shown to recognize peptides derived from constitutive processing of human serum proteins. One such epitope is a fragment of human serum albumin. This epitope bound selectively to the human class II molecule DRw11 and was constitutively present on antigen-presenting cells in vivo. These data indicate that, in the case of MHC class II, peptides involved in allorecognition may originate from exogenous proteins.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND; CYTEL,LA JOLLA,CA 92037; UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND	University of Lausanne			Panina, Paola/AAC-2424-2021; Panina, Paola/AAO-4563-2020; Sette, Alessandro/AFO-8916-2022	Panina, Paola/0000-0001-9913-8568; 				BUUS S, 1988, SCIENCE, V242, P1045, DOI 10.1126/science.3194755; CHEN BP, 1990, J EXP MED, V172, P779, DOI 10.1084/jem.172.3.779; DEKOSTER HS, 1989, J EXP MED, V169, P1191, DOI 10.1084/jem.169.3.1191; DEMOTZ S, 1989, J IMMUNOL METHODS, V122, P67, DOI 10.1016/0022-1759(89)90335-9; ECKELS DD, 1988, P NATL ACAD SCI USA, V85, P8191, DOI 10.1073/pnas.85.21.8191; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HEATH WR, 1989, NATURE, V341, P749, DOI 10.1038/341749a0; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LIN RH, 1989, EUR J IMMUNOL, V19, P105, DOI 10.1002/eji.1830190117; LOMBARDI G, 1989, J IMMUNOL, V142, P753; LORENZ RG, 1988, P NATL ACAD SCI USA, V85, P5220, DOI 10.1073/pnas.85.14.5220; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MARYANSKI JL, 1986, NATURE, V324, P578, DOI 10.1038/324578a0; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; OSULLIVAN D, 1990, J IMMUNOL, V145, P1850; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; PANINABORDIGNON P, UNPUB; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143	20	73	73	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1991	252	5012					1548	1550		10.1126/science.1710827	http://dx.doi.org/10.1126/science.1710827			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR040	1710827				2022-12-01	WOS:A1991FR04000047
J	POWER, RF; LYDON, JP; CONNEELY, OM; OMALLEY, BW				POWER, RF; LYDON, JP; CONNEELY, OM; OMALLEY, BW			DOPAMINE ACTIVATION OF AN ORPHAN OF THE STEROID-RECEPTOR SUPERFAMILY	SCIENCE			English	Article							COUP TRANSCRIPTION FACTOR; PROGESTERONE-RECEPTOR; MOLECULAR-CLONING; GENE; UPSTREAM; PHOSPHORYLATION; PURIFICATION; MEMBER; CELLS; DNA	The chicken ovalbumin upstream promoter transcription factor (COUP-TF) is a member of the steroid receptor superfamily and participates in the regulation of several genes. While a number of functions have been ascribed to COUP-TF, no ligand or activator molecule has been identified, and thus it is classified as one of a group of orphan receptors. Activation of COUP-TF by physiological concentrations of the neurotransmitter dopamine was observed in transient transfection assays. Treatment of transfected cells with the dopamine receptor agonist alpha-ergocryptine also activated COUP-dependent expression of a reporter gene. COUP-TF that contained a deletion in the COOH-terminal domain was not activated by these compounds. These observations suggest that dopamine may be a physiological activator of COUP-TF.	BAYLOR UNIV,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor University								CONNEELY OM, 1989, J BIOL CHEM, V264, P14062; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DENNER LA, 1989, ENDOCRINOLOGY, V125, P3051, DOI 10.1210/endo-125-6-3051; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DROUIN J, 1989, GENOME, V31, P510, DOI 10.1139/g89-099; EHINGER B, 1983, PROGR RETINAL RES, V2, P213, DOI DOI 10.1016/0278-4327(83)90009-3; FELDER CC, 1989, J BIOL CHEM, V264, P8739; FELDER RA, 1984, AM J PHYSIOL, V247, pF499, DOI 10.1152/ajprenal.1984.247.3.F499; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; HWUNG YP, 1988, MOL CELL BIOL, V8, P2070, DOI 10.1128/MCB.8.5.2070; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; Makman M H, 1975, Adv Cyclic Nucleotide Res, V5, P661; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; POWER R, UNPUB; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WATLING KJ, 1981, J NEUROCHEM, V36, P559, DOI 10.1111/j.1471-4159.1981.tb01628.x; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	23	208	210	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1991	252	5012					1546	1548		10.1126/science.2047861	http://dx.doi.org/10.1126/science.2047861			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR040	2047861				2022-12-01	WOS:A1991FR04000046
J	RUBINFELD, B; MUNEMITSU, S; CLARK, R; CONROY, L; WATT, K; CROSIER, WJ; MCCORMICK, F; POLAKIS, P				RUBINFELD, B; MUNEMITSU, S; CLARK, R; CONROY, L; WATT, K; CROSIER, WJ; MCCORMICK, F; POLAKIS, P			MOLECULAR-CLONING OF A GTPASE ACTIVATING PROTEIN-SPECIFIC FOR THE KREV-1 PROTEIN P21RAP1	CELL			English	Article							RAS-RELATED PROTEIN; BINDING-PROTEINS; HUMAN-PLATELETS; SUPPRESSOR ACTIVITY; KINASE SUBSTRATE; EFFECTOR DOMAIN; POINT MUTATIONS; RAS-P21 GTPASE; GENE-PRODUCT; BOVINE BRAIN	The rap1/Krev-1 gene encodes a ras-related protein that suppresses transformation by ras oncogenes. We have purified an 88 kd GTPase activating protein (GAP), specific for the rap1/Krev-1 gene product, from bovine brain. Based on partial amino acid sequences obtained from this protein, a 3.3 kb cDNA was isolated f rom a human brain library. Expression of the cDNA in insect Sf9 cells resulted in high level production of an 85-95 kd rap1GAP that specifically stimulated the GTPase activity of p2l(rap1). The complete deduced amino acid sequence is not homologous to any known protein sequences, including GAPs specific for p2l(ras). Northern and Western blotting analysis indicate that raplGAP is not ubiquitously expressed and appears most abundant in fetal tissues and certain tumor cell lines, particularly the Wilms' kidney tumor, SK-NEP-1, and the melanoma, SK-MEL-3, cell lines.			RUBINFELD, B (corresponding author), CETUS CORP,1400 53RD ST,EMERYVILLE,CA 94608, USA.			Rubinfeld, Bonnee/0000-0001-9861-6775	NCI NIH HHS [CA51992-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA051992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BIELINSKI DF, 1989, J BIOL CHEM, V264, P18363; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; CAMPA MJ, 1991, BIOCHEM BIOPH RES CO, V174, P1, DOI 10.1016/0006-291X(91)90475-M; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; FISCHER TH, 1987, BIOCHEM BIOPH RES CO, V149, P700, DOI 10.1016/0006-291X(87)90424-4; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HATA Y, 1990, J BIOL CHEM, V265, P7104; HAUBRUCK H, 1991, J CELL BIOCH B S, V15, P138; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; Maniatis T., 1982, MOL CLONING; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MIAORELLA B, 1988, BIOTECHNOLOGY, V6, P1506; MULCAHY LS, 1985, NATURE, V313, P2541; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NAGATA K, 1989, BIOCHEM BIOPH RES CO, V160, P235, DOI 10.1016/0006-291X(89)91646-X; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; SANDERS DA, 1990, CELL GROWTH DIFFER, V1, P251; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; Summers MD, 1987, TEXAS AGR EXPT STATI; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WALDO GL, 1987, BIOCHEM J, V246, P431, DOI 10.1042/bj2460431; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	55	240	250	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1033	1042		10.1016/0092-8674(91)90555-D	http://dx.doi.org/10.1016/0092-8674(91)90555-D			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1904317				2022-12-01	WOS:A1991FR04700014
J	RUPP, RAW; WEINTRAUB, H				RUPP, RAW; WEINTRAUB, H			UBIQUITOUS MYOD TRANSCRIPTION AT THE MIDBLASTULA TRANSITION PRECEDES INDUCTION-DEPENDENT MYOD EXPRESSION IN PRESUMPTIVE MESODERM OF X-LAEVIS	CELL			English	Article							EARLY XENOPUS-EMBRYOS; POLYMERASE CHAIN-REACTION; FIBROBLAST GROWTH-FACTOR; HOMEOBOX GENE XHOX3; MESSENGER-RNA; DNA-BINDING; DEVELOPMENTAL REGULATION; CELLS; FAMILY; EMBRYOGENESIS	We have used a quantitative reverse transcription-polymerase chain reaction assay to detect MyoD mRNA during early embryonic development of Xenopus laevis. We find that during a short period of time following the midblastula transition MyoD becomes transcriptionally activated at a low level ubiquitously throughout the embryo. Restriction of MyoD expression to muscle precursor cells appears as a subsequent event, in which the process of mesoderm induction stabilizes transcription only in the marginal zone of the embryo, the presumptive mesoderm.	FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98104	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	RUPP, RAW (corresponding author), FRED HUTCHINSON CANC RES CTR,DEPT GENET,SEATTLE,WA 98104, USA.			rupp, ralph/0000-0002-8068-9957				ALTABA ARI, 1990, DEVELOPMENT, V108, P595; ALTABA ARI, 1989, DEVELOPMENT, V106, P173; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; DWORKINRASTL E, 1986, J EMBRYOL EXP MORPH, V91, P153; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; GURDON JB, 1987, DEVELOPMENT, V99, P285; HARVEY RP, 1990, DEVELOPMENT, V108, P669; Holtzer H., 1978, STEM CELLS TISSUE HO, P1; HOPWOOD ND, 1990, NATURE, V347, P197, DOI 10.1038/347197a0; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; JONES EA, 1987, DEVELOPMENT, V101, P557; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRIEG PA, 1985, EMBO J, V4, P3463, DOI 10.1002/j.1460-2075.1985.tb04105.x; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LASSAR AB, 1991, TRANSCRIPTIONAL REGU; LEWIN B, 1980, GENE EXPRESSION, V2; MARTINEZSALAS E, 1989, GENE DEV, V3, P1493, DOI 10.1101/gad.3.10.1493; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; OCHMAN H, 1988, GENETICS, V120, P621; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCALES JB, 1990, MOL CELL BIOL, V10, P1516, DOI 10.1128/MCB.10.4.1516; SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P1255, DOI 10.1093/nar/18.5.1255; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; SMITH JC, 1989, DEVELOPMENT, V105, P665; SYMES K, 1987, DEVELOPMENT, V101, P339; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THAYER MJ, 1990, CELL, V63, P23, DOI 10.1016/0092-8674(90)90285-M; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; White T.J., 1990, PCR PROTOCOLS GUIDE, P272, DOI 10.1016/B978-0-12-372180-8.50037-8; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WORMINGTON WM, 1983, DEV BIOL, V99, P248, DOI 10.1016/0012-1606(83)90273-7; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	55	238	238	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					927	937		10.1016/0092-8674(91)90545-A	http://dx.doi.org/10.1016/0092-8674(91)90545-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1675156				2022-12-01	WOS:A1991FR04700004
J	SCHLAGGAR, BL; OLEARY, DDM				SCHLAGGAR, BL; OLEARY, DDM			POTENTIAL OF VISUAL-CORTEX TO DEVELOP AN ARRAY OF FUNCTIONAL UNITS UNIQUE TO SOMATOSENSORY CORTEX	SCIENCE			English	Article							EARLY POSTNATAL MOUSE; FETAL CORTICAL TRANSPLANTS; CEREBRAL-CORTEX; BARREL-FIELD; NEONATAL RAT; NEWBORN RATS; NEURONS; CONNECTIONS; PROJECTIONS; AXONS	The identification of specialized areas in the mammalian neocortex, such as the primary visual or somatosensory cortex, is based on distinctions in architectural and functional features. The extent to which certain features that distinguish neocortical areas in rats are prespecified or emerge as a result of epigenetic interactions was investigated. Late embryonic visual cortex transplanted to neonatal somatosensory cortex was later assayed for "barrels," anatomically identified functional units unique to somatosensory cortex, and for boundaries of glycoconjugated molecules associated with barrels. Barrels and boundaries form in transplanted visual cortex and are organized in an array that resembles the pattern in the normal barrelfield. These findings show that different regions of the developing neocortex have similar potentials to differentiate features that distinguish neocortical areas and contribute to their unique functional organizations.	SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,LA JOLLA,CA 92037	Salk Institute			Schlaggar, Bradley/AAZ-4153-2020		NATIONAL EYE INSTITUTE [R01EY007025] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS017763] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY07025] Funding Source: Medline; NINDS NIH HHS [P01 NS17763] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRES FL, 1985, DEV BRAIN RES, V20, P115, DOI 10.1016/0165-3806(85)90093-8; BRODMANN K, 1909, LOKCALISATIONSLEHRE; CASTRO AJ, 1987, EXP BRAIN RES, V66, P533, DOI 10.1007/BF00270686; CHANG FLF, 1984, DEV BRAIN RES, V13, P164, DOI 10.1016/0165-3806(84)90088-9; CHANG FLF, 1986, J COMP NEUROL, V244, P401, DOI 10.1002/cne.902440311; COOPER NGF, 1989, BRAIN RES, V489, P167, DOI 10.1016/0006-8993(89)90020-6; COOPER NGF, 1986, J COMP NEUROL, V249, P157, DOI 10.1002/cne.902490204; COOPER NGF, 1986, BRAIN RES, V380, P341, DOI 10.1016/0006-8993(86)90232-5; COWAN WM, 1972, BRAIN RES, V37, P21, DOI 10.1016/0006-8993(72)90344-7; CROSSIN KL, 1989, DEV BIOL, V136, P381, DOI 10.1016/0012-1606(89)90264-9; DAWSON DR, 1987, J COMP NEUROL, V256, P246, DOI 10.1002/cne.902560205; ERZURUMLU RS, 1990, DEV BRAIN RES, V56, P229; FLOETER MK, 1985, DEV BRAIN RES, V22, P19, DOI 10.1016/0165-3806(85)90065-3; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; HARRIS RM, 1981, J COMP NEUROL, V196, P357, DOI 10.1002/cne.901960302; HUTCHINS JB, 1990, J COMP NEUROL, V298, P113, DOI 10.1002/cne.902980109; HUTTON JC, 1984, PHILOS T R SOC LONDO, V304, P255; INNOCENTI GM, 1981, SCIENCE, V212, P824, DOI 10.1126/science.7221566; IVY GO, 1982, J NEUROSCI, V2, P735; JAEGER CB, 1981, EXP BRAIN RES, V40, P265; JEANMONOD D, 1981, NEUROSCIENCE, V6, P1503, DOI 10.1016/0306-4522(81)90222-0; Kaas J. H., 1986, HIGHER BRAIN FUNCTIO, P347; Killackey H P, 1990, J Cogn Neurosci, V2, P1, DOI 10.1162/jocn.1990.2.1.1; KILLACKEY HP, 1979, J COMP NEUROL, V183, P285, DOI 10.1002/cne.901830206; KOSTOVIC I, 1984, J NEUROSCI, V4, P25; KRIEG WJS, 1946, J COMP NEUROL, V84, P221, DOI 10.1002/cne.900840205; KRISTT DA, 1979, J COMP NEUROL, V186, P1, DOI 10.1002/cne.901860102; KRISTT DA, 1989, NEUROSCIENCE, V29, P27, DOI 10.1016/0306-4522(89)90330-8; KULJIS RO, 1990, P NATL ACAD SCI USA, V87, P5503; LIVINGSTONE MS, 1984, J NEUROSCI, V4, P309; LUND RD, 1977, J COMP NEUROL, V173, P289, DOI 10.1002/cne.901730206; MCCANDLISH C, 1989, EXP BRAIN RES, V77, P425, DOI 10.1007/BF00275001; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; MCCONNELL SK, 1989, TRENDS NEUROSCI, V12, P342, DOI 10.1016/0166-2236(89)90041-6; METIN C, 1989, P NATL ACAD SCI USA, V86, P357, DOI 10.1073/pnas.86.1.357; O'LEARY D D M, 1988, Society for Neuroscience Abstracts, V14, P1113; OLAND LA, 1990, J NEUROSCI, V10, P2096; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; OLEARY DDM, 1981, DEV BRAIN RES, V1, P607, DOI 10.1016/0165-3806(81)90012-2; OLEARY DDM, 1989, TRENDS NEUROSCI, V12, P400, DOI 10.1016/0166-2236(89)90080-5; PEINADO A, 1990, Society for Neuroscience Abstracts, V16, P1127; PEINADO A, 1989, Society for Neuroscience Abstracts, V15, P960; PURVES D, 1990, P NATL ACAD SCI USA, V87, P5764, DOI 10.1073/pnas.87.15.5764; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; REINOSO B S, 1990, Society for Neuroscience Abstracts, V16, P493; REINOSO B S, 1988, Society for Neuroscience Abstracts, V14, P1113; ROBERTSON RT, 1987, NEUROSCI LETT, V75, P259, DOI 10.1016/0304-3940(87)90531-3; ROBERTSON RT, 1991, DEV BRAIN RES, V58, P81, DOI 10.1016/0165-3806(91)90240-J; ROBERTSON RT, 1988, DEV BRAIN RES, V41, P1, DOI 10.1016/0165-3806(88)90165-4; SCHLAGGAR B L, 1988, Society for Neuroscience Abstracts, V14, P475; SCHLAGGAR B L, 1989, Society for Neuroscience Abstracts, V15, P1050; SCHLAGGAR BL, UNPUC; STANFIELD BB, 1985, NATURE, V313, P135, DOI 10.1038/313135a0; STANFIELD BB, 1982, NATURE, V298, P371, DOI 10.1038/298371a0; STEINDLER DA, 1989, DEV BIOL, V131, P243, DOI 10.1016/S0012-1606(89)80056-9; STEINDLER DA, 1990, EXP NEUROL, V109, P35, DOI 10.1016/S0014-4886(05)80007-X; STEINDLER DA, 1989, COMMENTS DEV NEUROBI, V1, P29; SUR M, 1988, SCIENCE, V242, P1437, DOI 10.1126/science.2462279; THONG IG, 1986, DEV BRAIN RES, V25, P227, DOI 10.1016/0165-3806(86)90212-9; VANDERLO.H, 1973, SCIENCE, V179, P395, DOI 10.1126/science.179.4071.395; VANESSEN DC, 1985, CEREBRAL CORTEX, V3, P289; WELKER E, 1986, J NEUROSCI, V6, P3355; WISE SP, 1978, J COMP NEUROL, V178, P187, DOI 10.1002/cne.901780202; Woolsey T.A., 1990, P461; WOOLSEY TA, 1976, J COMP NEUROL, V170, P53, DOI 10.1002/cne.901700105; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; ZHOU HF, 1990, J COMP NEUROL, V292, P320, DOI 10.1002/cne.902920213	67	240	245	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1991	252	5012					1556	1560		10.1126/science.2047863	http://dx.doi.org/10.1126/science.2047863			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR040	2047863				2022-12-01	WOS:A1991FR04000050
J	SEGEV, N				SEGEV, N			MEDIATION OF THE ATTACHMENT OR FUSION STEP IN VESICULAR TRANSPORT BY THE GTP-BINDING YPT1 PROTEIN	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; CHROMAFFIN GRANULES; SECRETORY VESICLES; GENE-PRODUCT; YEAST; MEMBRANE; RECONSTITUTION; COMPARTMENTS; INVITRO	The function of the guanosine triphosphate (GTP)-binding protein Ypt1 in regulating vesicular traffic was studied in a cell-free system that reconstitutes transport from the endoplasmic reticulum to the Golgi. Blocking the Ypt1 protein activity resulted in accumulation of vesicles that act as an intermediate passing between the two compartments. The Ypt1 protein was found on the outer side of these vesicles. The transport process is completed by fusion of these vesicles with the acceptor compartment, and Ypt1 protein activity was needed for this step. Thus, a specific GTP-binding protein is required for either attachment or fusion (or both) of secretory vesicles with the acceptor compartment during protein secretion.	UNIV CHICAGO,BEN MAY INST,CHICAGO,IL 60637	University of Chicago	SEGEV, N (corresponding author), UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637, USA.							BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BURGOYNE RD, 1989, TRENDS BIOCHEM SCI, V14, P394, DOI 10.1016/0968-0004(89)90281-8; BURGOYNE RD, 1989, FEBS LETT, V245, P122, DOI 10.1016/0014-5793(89)80204-2; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DOUCET JP, 1989, FEBS LETT, V247, P127, DOI 10.1016/0014-5793(89)81254-2; FISCHER, 1990, P NATL ACAD SCI USA, V87, P1988; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GALLWITZ D, 1983, NATURE, V306, P707; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; JEDD G, UNPUB; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PADFIELD PJ, 1989, J CELL BIOL, V109, P299; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RUBINS J, 1989, J CELL BIOL, V109, P298; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, UNPUB; THOMPSON RC, 1988, TRENDS BIOCHEM SCI, V13, P91, DOI 10.1016/0968-0004(88)90047-3; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; WIDEY GM, 1989, J CELL BIOL, V109, P293; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101	40	130	133	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1991	252	5012					1553	1556		10.1126/science.1904626	http://dx.doi.org/10.1126/science.1904626			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR040	1904626				2022-12-01	WOS:A1991FR04000049
J	ZHONG, Y; WU, CF				ZHONG, Y; WU, CF			ALTERATION OF 4 IDENTIFIED K+ CURRENTS IN DROSOPHILA MUSCLE BY MUTATIONS IN EAG	SCIENCE			English	Article							POTASSIUM-CHANNEL PROTEINS; VOLTAGE-CLAMP ANALYSIS; SHAKER LOCUS; XENOPUS-OOCYTES; COMPONENTS; DIVERSITY; MUTANTS; CALCIUM; MELANOGASTER; FIBERS	Voltage-clamp analysis of Drosophila larval muscle revealed that ether a go-go (eag) mutations affected all identified potassium currents, including those specifically eliminated by mutations in the Shaker or slowpoke gene. Together with DNA sequence analysis, the results suggest that the eag locus encodes a subunit common to different potassium channels. Thus, combinatorial assembly of polypeptides from different genes may contribute to potassium channel diversity.	UNIV IOWA, DEPT BIOL, IOWA CITY, IA 52242 USA	University of Iowa				Zhong, Yi/0000-0002-7927-5976; Zhong, Yi/0000-0001-7810-9899; Wu, Chun-Fang/0000-0002-4973-2021				AIDLEY DJ, 1989, PHYSL EXCITABLE CELL, P289; COVARRUBIAS AM, 1990, SOC NEUR ABSTR, V16, P3; DRYSDALE R, 1991, GENETICS, V127, P497; ELKINS T, 1986, P NATL ACAD SCI USA, V83, P8415, DOI 10.1073/pnas.83.21.8415; GANETZKY B, 1986, ANNU REV GENET, V20, P13; Ganetzky B, 1983, J NEUROGENET, V1, P17, DOI 10.3109/01677068309107069; GHO M, 1986, PFLUG ARCH EUR J PHY, V407, P526, DOI 10.1007/BF00657511; GORCZYCA MG, 1991, J MEMBRANE BIOL, V121, P237, DOI 10.1007/BF01951557; HAGIWARA S, 1981, ANNU REV NEUROSCI, V4, P69, DOI 10.1146/annurev.ne.04.030181.000441; HAUGLAND FN, 1990, J NEUROSCI, V10, P1357; HAUGLAND FN, 1987, SOC NEUR ABSTR, V13, P150; Hille B, 1984, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HUFFAKER TC, 1987, ANNU REV GENET, V21, P259; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; JOHN AK, 1990, CELL, V62, P165; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KAPLAN WD, 1969, GENETICS, V61, P399; MCCORMACK K, 1990, BIOPHYS J, V57, pA209; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SALKOFF L, 1981, NATURE, V293, P228, DOI 10.1038/293228a0; SALKOFF L, 1983, NATURE, V302, P249, DOI 10.1038/302249a0; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SINGH S, 1989, NEURON, V2, P1325, DOI 10.1016/0896-6273(89)90070-6; SOLC CK, 1987, SCIENCE, V236, P1094, DOI 10.1126/science.2437657; TANOUYE MA, 1986, ANNU REV NEUROSCI, V9, P255, DOI 10.1146/annurev.ne.09.030186.001351; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WEI A, 1986, SCIENCE, V233, P780, DOI 10.1126/science.2426780; WU CF, 1985, J NEUROSCI, V5, P2626; WU CF, 1983, SCIENCE, V220, P1076, DOI 10.1126/science.6302847; WU CF, 1989, J EXP BIOL, V147, P21; WU CF, 1986, ION CHANNELS NEURAL, P407; ZHONG Y, UNPUB	38	116	118	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	1991	252	5012					1562	1564		10.1126/science.2047864	http://dx.doi.org/10.1126/science.2047864			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR040	2047864				2022-12-01	WOS:A1991FR04000052
J	CHAKRABARTTY, A; SCHELLMAN, JA; BALDWIN, RL				CHAKRABARTTY, A; SCHELLMAN, JA; BALDWIN, RL			LARGE DIFFERENCES IN THE HELIX PROPENSITIES OF ALANINE AND GLYCINE	NATURE			English	Article							OCCURRING AMINO-ACIDS; COIL STABILITY-CONSTANTS; FORMING TENDENCIES; ALPHA-HELICES; PEPTIDES; WATER; PARAMETERS	THE standard view of alpha-helix formation in water, based on helix propensities determined by the host-guest method 1,2, is that differences in helix propensity among the amino acids are small, except for proline 3, and that the average value of the helix propagation parameter s is near 1. A contradictory view of alpha-helix formation in water is emerging from substitution experiments with short, unique-sequence peptides that contain only naturally occurring amino acids 4-9. Short peptides that contain only alanine and lysine, or alanine and glutamate, form surprisingly stable monomeric helices in water 9 and substitution of a single alanine residue by another amino acid in these or related peptides produces a wide range of changes in helix content, depending on which amino acid is substituted for alanine 4-6,8. We show here that the ratio of the helix propensities of alanine to glycine is large, about 100, in substitution experiments with a 17-residue reference peptide containing alanine and lysine. The helix propensity is identified with s, the helix propagation parameter of the statistical mechanics model for alpha-helix formation, and the results are interpreted by the Lifson-Roig theory 10. Single alanine --> glycine substitutions have been made at a series of positions in individual peptides. The helix-destabilizing effect of an Ala --> Gly substitution depends strongly on its position in the helix, as predicted by the Lifson-Roig theory if the ratio of s values for Ala:Gly is large.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403	University of Oregon	CHAKRABARTTY, A (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305, USA.			Chakrabartty, Avi/0000-0001-7002-8381				ALTMANN KH, 1990, BIOPOLYMERS, V30, P107, DOI 10.1002/bip.360300112; BRANT DA, 1967, J MOL BIOL, V23, P47, DOI 10.1016/S0022-2836(67)80066-4; CANTOR CR, 1980, BIOPHYSICAL CHEM, V3; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CREIGHTON TE, 1983, PROTEINS STRUCTURES, P162; GO M, 1971, J CHEM PHYS, V54, P4489, DOI 10.1063/1.1674701; HOUGHTEN RA, 1986, BIOTECHNIQUES, V4, P522; LIFSON S, 1961, J CHEM PHYS, V34, P1963, DOI 10.1063/1.1731802; LOTAN N, 1966, BIOPOLYMERS, V4, P365, DOI 10.1002/bip.1966.360040309; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MERUTKA G, 1990, BIOCHEMISTRY-US, V29, P7511, DOI 10.1021/bi00484a021; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; POLAND D, 1970, THEORY HELIX COIL TR; SCHERAGA HA, 1985, P NATL ACAD SCI USA, V82, P5585, DOI 10.1073/pnas.82.17.5585; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; STREHLOW KG, 1989, BIOCHEMISTRY-US, V28, P2130, DOI 10.1021/bi00431a025; SUEKI M, 1984, MACROMOLECULES, V17, P148, DOI 10.1021/ma00132a006; ZIMM BH, 1959, J CHEM PHYS, V31, P526, DOI 10.1063/1.1730390	20	317	324	1	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1991	351	6327					586	588		10.1038/351586a0	http://dx.doi.org/10.1038/351586a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	2046766				2022-12-01	WOS:A1991FR03400065
J	HAHM, JO; LANGDON, RB; SUR, M				HAHM, JO; LANGDON, RB; SUR, M			DISRUPTION OF RETINOGENICULATE AFFERENT SEGREGATION BY ANTAGONISTS TO NMDA RECEPTORS	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; VISUAL-CORTEX; CAT; INFUSION; FERRET; TETRODOTOXIN; PROJECTION; POTENTIALS; CELLS; FIELD	AFFERENT activity has an important role in the formation of connections in the developing mammalian visual system 1,2. But the extent to which the activity of target neurons shapes patterns of afferent termination and synaptic contact is not known. In the ferret's visual pathway, retinal ganglion cell axons from each eye segregate early in development into eye-specific laminae in the lateral geniculate nucleus (LGN)3. The dorsal laminae (termed laminae A and A1) then segregate further into inner and outer sublaminae that retain input from on-centre and off-centre retinal axons, respectively 4,5. Thus, individual retinogeniculate axons form terminal arbors within laminae A and A1 that are restricted to one inner or outer sublamina 6. We report here that blockade of N-methyl-D-aspartate (NMDA) receptors on LGN cells with specific antagonists during the period of sublamina formation prevents retinal afferents from segregating into 'On' and 'Off' sublaminae. Retinogeniculate axons have arbors that are not restricted appropriately, or are restricted in size but inappropriately positioned within the eye-specific laminae. NMDA receptor antagonists may specifically disrupt a mechanism by which LGN neurons detect correlated afferent and target activity 7, and have been shown to reduce retinogeniculate transmission more generally 8-10, causing LGN cells to have markedly reduced levels of activity. These results therefore indicate that the activity of postsynaptic cells can significantly influence the patterning of inputs and the structure of presynaptic afferents during development.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)								BEAR MF, 1990, J NEUROSCI, V10, P909; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1990, J NEUROSCI, V10, P1197; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; CONSTANTINEPATO.M, 1990, REV NEUROSCI, V13, P129; ESGUERRA M, 1990, NEUR ABST, V16, P159; ESGUERRA M, 1989, NEUR ABSTR, V15, P175; FOX K, 1989, J NEUROSCI, V9, P2443; HAHM J, 1988, NEUR ABSTR, V14, P460; HEGGELUND P, 1990, J NEUROPHYSIOL, V63, P1347, DOI 10.1152/jn.1990.63.6.1347; KWON YH, IN PRESS J NEUROPHYS; LANGDON RB, 1990, J NEUROPHYSIOL, V64, P1484, DOI 10.1152/jn.1990.64.5.1484; LINDEN DC, 1981, J COMP NEUROL, V203, P189, DOI 10.1002/cne.902030204; MILLER KD, 1989, P NATL ACAD SCI USA, V86, P5183, DOI 10.1073/pnas.86.13.5183; MOVSHON JA, 1981, ANNU REV PSYCHOL, V32, P477, DOI 10.1146/annurev.ps.32.020181.002401; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; ROE AW, 1989, J COMP NEUROL, V288, P208, DOI 10.1002/cne.902880203; SCHERER WJ, 1989, J NEUROSCI, V9, P3837; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHERMAN SM, 1982, PHYSIOL REV, V62, P740; SILLITO AM, 1990, J NEUROPHYSIOL, V63, P347, DOI 10.1152/jn.1990.63.2.347; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; STRYKER MP, 1983, J NEUROSCI, V3, P1943; ZAHS KR, 1985, J COMP NEUROL, V241, P210, DOI 10.1002/cne.902410208	24	225	229	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1991	351	6327					568	570		10.1038/351568a0	http://dx.doi.org/10.1038/351568a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1675433				2022-12-01	WOS:A1991FR03400059
J	HARTZELL, HC; MERY, PF; FISCHMEISTER, R; SZABO, G				HARTZELL, HC; MERY, PF; FISCHMEISTER, R; SZABO, G			SYMPATHETIC REGULATION OF CARDIAC CALCIUM CURRENT IS DUE EXCLUSIVELY TO CAMP-DEPENDENT PHOSPHORYLATION	NATURE			English	Article							G-PROTEIN; ION CHANNELS; SINGLE CELLS; ACETYLCHOLINE; HEART; STIMULATION; MYOCYTES; MODULATION; KINASE; ANALOG	THE positive inotropic effect of the sympathetic nervous system on the heart is partly mediated by an increase in the voltage-gated Ca2+ current (I(Ca)). This increase is generally attributed to beta-adrenergic receptor-stimulated cyclic AMP-dependent phosphorylation of the Ca2+ channel 1,2. It has been suggested that cAMP-dependent phosphorylation cannot explain all the effects of beta-adrenergic agonists on I(Ca) and that a parallel membrane-delimited pathway involving the 'direct' action of the G protein G(s) also stimulates I(Ca) (refs 3-7). A precedent exists for such a membrane-delimited pathway in the activation of a K+ channel by acetylcholine in heart 1,8. A membrane-delimited pathway for stimulation of I(Ca) might be important in rapid beat-to-beat regulation of contraction by the sympathetic nervous system 9, because isoproterenol may produce a biphasic increase in I(Ca) with the rapid phase (tau = 150 ms) putatively mediated by the direct pathway and the slow phase (tau = 35 s) by cAMP-dependent phosphorylation. Here we report that in frog, rat, and guinea pig ventricular myocytes I(Ca) increases slowly and monophasically in response to isoproterenol. The increase is completely blocked by inhibitors of cAMP-dependent phosphorylation. Furthermore, the time course of the increase in I(Ca) closely parallels the increase in contractile force produced by sympathetic nerve stimulation. These data refute earlier suggestions that regulation of Ca2+ channels by the sympathetic nervous system involves or requires a direct G-protein pathway.	UNIV PARIS 11, INSERM, U241, PHYSIOL CELLULAIRE CARDIAQUE LAB, F-91405 ORSAY, FRANCE; UNIV VIRGINIA, DEPT PHYSIOL, CHARLOTTESVILLE, VA 22908 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of Virginia	HARTZELL, HC (corresponding author), EMORY UNIV, SCH MED, DEPT ANAT & CELL BIOL, ATLANTA, GA 30322 USA.		Fischmeister, Rodolphe/L-6061-2018; MERY, Pierre-François/C-5903-2019	Fischmeister, Rodolphe/0000-0003-2086-9865; Mery, Pierre-Francois/0000-0001-6214-5422				BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; FISCHMEISTER R, 1986, J PHYSIOL-LONDON, V376, P183, DOI 10.1113/jphysiol.1986.sp016148; HARTZELL HC, 1986, NATURE, V323, P273, DOI 10.1038/323273a0; HARTZELL HC, 1988, PROG BIOPHYS MOL BIO, V52, P165, DOI 10.1016/0079-6107(88)90014-4; HARTZELL HC, 1987, MOL PHARMACOL, V32, P639; HARTZELL HC, 1991, BIOPHYS J, V59, P551; HUTTER OF, 1956, J GEN PHYSIOL, V39, P715, DOI 10.1085/jgp.39.5.715; IMOTO Y, 1988, AM J PHYSIOL, V255, pH722, DOI 10.1152/ajpheart.1988.255.4.H722; KAMEYAMA M, 1986, PFLUG ARCH EUR J PHY, V407, P123, DOI 10.1007/BF00580662; KEMP BE, 1988, METHOD ENZYMOL, V159, P173; MERY PF, 1991, BIOPHYS J, V59, P551; MITRA R, 1985, AM J PHYSIOL, V249, P1056, DOI 10.1152/ajpheart.1985.249.5.H1056; MORAD M, 1983, NATURE, V304, P635, DOI 10.1038/304635a0; PELZER S, 1990, AM J PHYSIOL, V259, pH264, DOI 10.1152/ajpheart.1990.259.1.H264; SHUBA YM, 1990, J PHYSIOL-LONDON, V424, P205, DOI 10.1113/jphysiol.1990.sp018063; SIMMONS MA, 1987, PFLUG ARCH EUR J PHY, V409, P454, DOI 10.1007/BF00583801; SPEAR JF, 1979, CIRC RES, V44, P75, DOI 10.1161/01.RES.44.1.75; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YATANI A, 1988, J BIOL CHEM, V263, P9887; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999	22	214	214	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1991	351	6327					573	576		10.1038/351573a0	http://dx.doi.org/10.1038/351573a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1710784				2022-12-01	WOS:A1991FR03400061
J	HORVITZ, HR; STERNBERG, PW				HORVITZ, HR; STERNBERG, PW			MULTIPLE INTERCELLULAR SIGNALING SYSTEMS CONTROL THE DEVELOPMENT OF THE CAENORHABDITIS-ELEGANS VULVA	NATURE			English	Article							SPECIFIES CELL FATES; EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; C-ELEGANS; EMBRYONIC-DEVELOPMENT; LATERAL INHIBITION; DROSOPHILA-NOTCH; GENETIC PATHWAY; TYROSINE KINASE; NERVOUS-SYSTEM	Developmental, genetic and molecular studies indicate that multiple intercellular signalling systems interact to specify the types and spatial patterns of cells generated during the formation of the vulva of the nematode Caenorhabditis elegans. Two classes of evolutionarily conserved transmembrane receptors and a Ras protein function in these signalling systems. The biology of vulval development provides a framework for understanding how cell interactions control the development of animals as diverse as nematodes, insects and mammals.	CALTECH,HOWARD HUGHES MED INST,DIV BIOL,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute	HORVITZ, HR (corresponding author), MIT,HOWARD HUGHES MED INST,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Sternberg, Paul/0000-0002-7699-0173				ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; Barbacid M., 1987, REV BIOCH, V56, P779; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FERGUSON EL, 1989, GENETICS, V123, P109; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GREENSPAN R J, 1990, New Biologist, V2, P595; GREENWALD I, 1989, TRENDS GENET, V5, P237, DOI 10.1016/0168-9525(89)90094-2; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GURDON JB, 1987, DEVELOPMENT, V99, P285; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HERMAN RK, 1984, GENETICS, V108, P165; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HORVITZ HR, 1980, GENETICS, V96, P435; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; LEWIS J, 1977, J THEOR BIOL, V65, P575; LI C, 1990, NEURON, V4, P681, DOI 10.1016/0896-6273(90)90195-L; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; NISHIDA H, 1989, DEV BIOL, V132, P355, DOI 10.1016/0012-1606(89)90232-7; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RABBITTS T, 1990, NATURE, V348, P418; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SHANKLAND M, 1987, TRENDS GENET, V3, P314, DOI 10.1016/0168-9525(87)90279-4; SIMPSON P, 1990, DEVELOPMENT, V109, P509; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1988, DEV BIOL, V130, P67, DOI 10.1016/0012-1606(88)90414-9; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEINBERG RA, 1991, J NIH RES, V3, P45; WHITE J, 1988, NEMATODE CAENORHABDI; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wood WB, 1988, NEMATODE CAENORHABDI; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	60	229	245	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1991	351	6327					535	541		10.1038/351535a0	http://dx.doi.org/10.1038/351535a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1646401				2022-12-01	WOS:A1991FR03400048
J	INGLES, CJ; SHALES, M; CRESS, WD; TRIEZENBERG, SJ; GREENBLATT, J				INGLES, CJ; SHALES, M; CRESS, WD; TRIEZENBERG, SJ; GREENBLATT, J			REDUCED BINDING OF TFIID TO TRANSCRIPTIONALLY COMPROMISED MUTANTS OF VP16	NATURE			English	Article							FUNCTIONAL DISSECTION; ACTIVATION DOMAIN; MAMMALIAN-CELLS; RNA-POLYMERASE; PROTEINS; EXPRESSION; YEAST; GENE	ACTIVATOR proteins that control transcription initiation by RNA polymerase II 1,2 usually have two domains: one binds to DNA, and the other activates transcription 3,4. A particularly potent acidic 5,6 activation domain at the C terminus of the herpes simplex virus protein VP16 7-9 binds directly and selectively to the human and yeast TATA box-binding factor TFIID 10. We have now investigated the biological significance of this in vitro interaction by using mutant forms of VP16 11. For changes at the critical phenylalanine residue at position 442 of VP16 there was a good correlation between transactivation activity in vivo and the binding of VP16 to TFIID in vitro. In contrast, mutants with reduced negative charge were more defective for binding than for activation.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University	INGLES, CJ (corresponding author), UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA.			Triezenberg, Steven/0000-0003-4184-5221				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718	17	292	297	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1991	351	6327					588	590		10.1038/351588a0	http://dx.doi.org/10.1038/351588a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1646402				2022-12-01	WOS:A1991FR03400066
J	LIANG, TJ; HASEGAWA, K; RIMON, N; WANDS, JR; BENPORATH, E				LIANG, TJ; HASEGAWA, K; RIMON, N; WANDS, JR; BENPORATH, E			A HEPATITIS-B VIRUS MUTANT ASSOCIATED WITH AN EPIDEMIC OF FULMINANT-HEPATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							E-ANTIGEN; PRECORE REGION; CORE ANTIGEN; NON-A; GENOME; LIVER; HBE; DNA; IDENTIFICATION; REPLICATION	Background. A nosocomial outbreak of fulminant hepatitis B occurred in five patients in Haifa, Israel. Previous investigations identified the suspected source as a carrier of hepatitis B surface antigen who was positive for antibodies to hepatitis B e antigen and had chronic liver disease. We examined the strain of hepatitis B virus (HBV) that caused this epidemic, in order to identify specific mutations in the precore or core region. Methods. The presence of HBV was identified by polymerase-chain-reaction amplification of viral DNA in serum from the source patient, the five patients with fulminant hepatitis B, and five controls with acute, self-limited hepatitis B. The amplified viral HBV DNA samples were then cloned and sequenced. Results. Sequence analysis of viral DNA established that the same HBV mutant with two mutations in the precore region was present in the source patient and the five patients with fulminant hepatic failure. This HBV mutant had significant sequence divergence from other known HBV subtypes in the X, precore, and core regions. Cloned HBV DNA derived from a hospitalized patient who had subclinical hepatitis B at the same time as the outbreak and from four other control subjects with acute, self-limited hepatitis B all contained the wild-type sequence in the precore region. Conclusions. In the outbreak we studied, a mutant hepatitis B viral strain was transmitted from a common source to five patients who subsequently died of fulminant hepatitis B infection. Naturally occurring viral mutations in the HBV genome may predispose the infected host to more severe liver injury.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02114; TECHNION ISRAEL INST TECHNOL,RAMBAM MED CTR,FAC MED,VIROL LAB,HAIFA,ISRAEL	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	LIANG, TJ (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC HEPATOL LAB,149 13TH ST,7TH FL,BOSTON,MA 02114, USA.				NATIONAL CANCER INSTITUTE [R37CA035711, R01CA035711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008169, R01AA002666, R37AA002666] Funding Source: NIH RePORTER; NCI NIH HHS [CA-35711] Funding Source: Medline; NIAAA NIH HHS [AA-08169, AA-02666] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BARKER LF, 1972, AM J MED SCI, V263, P27, DOI 10.1097/00000441-197201000-00005; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; BLUM HE, 1990, IN PRESS VIRAL HEPAT; BRECHOT C, 1984, BRIT MED J, V288, P270, DOI 10.1136/bmj.288.6413.270; BRUNETTO MR, 1990, J HEPATOL, V10, P258, DOI 10.1016/0168-8278(90)90062-V; BRUNETTO MR, 1989, ITAL J GASTROENTEROL, V21, P151; BRUNETTO MR, 1989, HEPATOLOGY, V10, P198, DOI 10.1002/hep.1840100213; CARMAN WF, 1989, LANCET, V2, P588; CARMAN WF, 1990, 1990 INT S VIR HEP L; CHANG C, 1987, J VIROL, V61, P3322, DOI 10.1128/JVI.61.10.3322-3325.1987; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DECOCK KM, 1986, ANN INTERN MED, V105, P546, DOI 10.7326/0003-4819-105-4-546; DELAPLANE D, 1983, PEDIATRICS, V72, P176; FAGAN EA, 1986, LANCET, V2, P538, DOI 10.1016/S0140-6736(86)90112-1; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GIRONES R, 1989, VIROLOGY, V170, P595, DOI 10.1016/0042-6822(89)90455-8; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; KWOK S, 1989, NATURE, V339, P490; LIANG TJ, 1989, J CLIN INVEST, V84, P1367, DOI 10.1172/JCI114308; LUGASSY C, 1987, J INFECT DIS, V155, P64, DOI 10.1093/infdis/155.1.64; MIYAZAKI K, 1990, 1990 M JAP ASS STUD; MONDELLI M, 1984, SEMIN LIVER DIS, V4, P47, DOI 10.1055/s-2008-1040645; OKAMOTO H, 1990, J VIROL, V64, P1298, DOI 10.1128/JVI.64.3.1298-1303.1990; OMATA M, 1991, NEW ENGL J MED, V324, P1699, DOI 10.1056/NEJM199106133242404; OREN I, 1989, ANN INTERN MED, V110, P691, DOI 10.7326/0003-4819-110-9-691; SALFELD J, 1989, J VIROL, V63, P798, DOI 10.1128/JVI.63.2.798-808.1989; SARACCO G, 1988, ANN INTERN MED, V108, P380, DOI 10.7326/0003-4819-108-3-380; SHAW FE, 1986, JAMA-J AM MED ASSOC, V255, P3260, DOI 10.1001/jama.255.23.3260; SUMMERS J, 1990, J VIROL, V64, P2819, DOI 10.1128/JVI.64.6.2819-2824.1990; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TOKITA M, 1990, 1990 M JAP ASS STUD; TONG SP, 1990, VIROLOGY, V176, P596, DOI 10.1016/0042-6822(90)90030-U; YOAKUM GH, 1983, SCIENCE, V222, P385, DOI 10.1126/science.6194563; 1984, MMWR, V33, P70; 1984, MMWR, V33, P76; 1979, MMWR, V28, P373	38	429	441	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1991	324	24					1705	1709		10.1056/NEJM199106133242405	http://dx.doi.org/10.1056/NEJM199106133242405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ155	2034247				2022-12-01	WOS:A1991FQ15500005
J	OMATA, M; EHATA, T; YOKOSUKA, O; HOSODA, K; OHTO, M				OMATA, M; EHATA, T; YOKOSUKA, O; HOSODA, K; OHTO, M			MUTATIONS IN THE PRECORE REGION OF HEPATITIS-B VIRUS-DNA IN PATIENTS WITH FULMINANT AND SEVERE HEPATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; POLYMERASE CHAIN-REACTION; CHRONIC LIVER-DISEASE; PRE-C REGION; E-ANTIGEN; SUBTYPE-ADR; ESCHERICHIA-COLI; CORE PROTEIN; SERUM; ANTIBODY	Background. The presence of the hepatitis B e antigen (HBeAg) in serum is known to be a marker of a high degree of viral infectivity. However, fulminant hepatitis may occur in persons who are negative for HBeAg. A single point mutation has been reported to produce a stop codon in the precore region of hepatitis B virus DNA and prevent the formation of the precore protein required to make HBeAg. To determine whether a precore-mutant virus is causally related to severe liver injury, we analyzed the entire precore region in viral strains isolated from patients with fatal cases and uncomplicated cases of hepatitis B. Methods. Serum was obtained from 9 patients with fatal hepatitis B(5 with fulminant and 4 with severe exacerbations of chronic hepatitis) and 10 patients with acute, self-limited hepatitis B. Serum samples from a sex partner implicated as the source of the virus in one case of fulminant hepatitis were also studied. The 87 nucleotides in the precore region of the hepatitis B virus were amplified by the polymerase chain reaction and then directly sequenced. Results. Of the nine patients with fatal hepatitis, seven had retrievable hepatitis B DNA. In all seven there was a point mutation from G to A at nucleotide 1896 of the precore region, converting tryptophan (TGG) to a stop codon (TAG). In contrast, this mutation was not found in the 10 patients with acute, self-limited hepatitis B. The hepatitis B DNA from the implicated source contained a sequence with the stop-codon mutation that was identical to the sequence in her partner, who had fulminant hepatitis. Conclusions. The presence of a mutant viral strain is associated with and may be involved in the pathogenesis of fulminant hepatitis B and severe exacerbations of chronic hepatitis.			OMATA, M (corresponding author), CHIBA UNIV,SCH MED,DEPT MED 1,1-8-1 INOHANA,CHIBA 280,JAPAN.							BICHKO V, 1985, FEBS LETT, V185, P208, DOI 10.1016/0014-5793(85)80771-7; BRUNETTO MR, 1989, ITAL J GASTROENTEROL, V21, P151; CARMAN WF, 1989, LANCET, V2, P588; CHANG MH, 1987, J PEDIATR-US, V111, P34, DOI 10.1016/S0022-3476(87)80338-4; DAVIS GL, 1984, GASTROENTEROLOGY, V86, P230; FAGAN EA, 1986, LANCET, V2, P538, DOI 10.1016/S0140-6736(86)90112-1; FUJIYAMA A, 1983, NUCLEIC ACIDS RES, V11, P4601, DOI 10.1093/nar/11.13.4601; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; HADZIYANNIS SJ, 1983, HEPATOLOGY, V3, P656; HOOFNAGLE JH, 1983, GASTROENTEROLOGY, V84, P422; IMAZEKI F, 1985, HEPATOLOGY, V5, P783, DOI 10.1002/hep.1840050513; KATO N, 1990, J CLIN INVEST, V86, P1764, DOI 10.1172/JCI114903; KOBAYASHI M, 1984, GENE, V30, P227; KROGSGAARD K, 1986, J INFECT DIS, V153, P298, DOI 10.1093/infdis/153.2.298; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; MATSUYAMA Y, 1985, GASTROENTEROLOGY, V89, P1104, DOI 10.1016/0016-5085(85)90216-1; OKAMOTO H, 1988, J GEN VIROL, V69, P2575, DOI 10.1099/0022-1317-69-10-2575; OKAMOTO H, 1990, J VIROL, V64, P1298, DOI 10.1128/JVI.64.3.1298-1303.1990; OKAMOTO H, 1986, J GEN VIROL, V67, P2305, DOI 10.1099/0022-1317-67-11-2305; OKUDA K, 1987, HEPATOLOGY, V7, P974; ONO Y, 1983, NUCLEIC ACIDS RES, V11, P1747, DOI 10.1093/nar/11.6.1747; OREN I, 1989, ANN INTERN MED, V110, P691, DOI 10.7326/0003-4819-110-9-691; OU JH, 1986, P NATL ACAD SCI USA, V83, P1578, DOI 10.1073/pnas.83.6.1578; PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0; RHO HM, 1989, NUCLEIC ACIDS RES, V17, P2124, DOI 10.1093/nar/17.5.2124; ROOSSINCK MJ, 1986, MOL CELL BIOL, V6, P1393, DOI 10.1128/MCB.6.5.1393; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLICHT HJ, 1989, J VIROL, V63, P5399, DOI 10.1128/JVI.63.12.5399-5404.1989; SCHLICHT HJ, 1987, J VIROL, V61, P3701, DOI 10.1128/JVI.61.12.3701-3709.1987; SHIRAKI K, 1980, J PEDIATR-US, V97, P768, DOI 10.1016/S0022-3476(80)80261-7; TADA M, 1990, CANCER RES, V50, P1121; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TONG SP, 1990, VIROLOGY, V176, P596, DOI 10.1016/0042-6822(90)90030-U; TREPO CG, 1976, GUT, V17, P10, DOI 10.1136/gut.17.1.10; UY A, 1986, VIROLOGY, V155, P89, DOI 10.1016/0042-6822(86)90170-4; VALENZUELA P, 1980, ICN UCLA S MOL CELLU, V18, P57; VAUDIN M, 1988, J GEN VIROL, V69, P1383, DOI 10.1099/0022-1317-69-6-1383; VENTO S, 1985, HEPATOLOGY, V5, P192, DOI 10.1002/hep.1840050206; YOKOSUKA O, 1986, NEW ENGL J MED, V315, P1187, DOI 10.1056/NEJM198611063151903	40	482	494	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1991	324	24					1699	1704		10.1056/NEJM199106133242404	http://dx.doi.org/10.1056/NEJM199106133242404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ155	2034246				2022-12-01	WOS:A1991FQ15500004
J	TODD, JA; AITMAN, TJ; CORNALL, RJ; GHOSH, S; HALL, JRS; HEARNE, CM; KNIGHT, AM; LOVE, JM; MCALEER, MA; PRINS, JB; RODRIGUES, N; LATHROP, M; PRESSEY, A; DELARATO, NH; PETERSON, LB; WICKER, LS				TODD, JA; AITMAN, TJ; CORNALL, RJ; GHOSH, S; HALL, JRS; HEARNE, CM; KNIGHT, AM; LOVE, JM; MCALEER, MA; PRINS, JB; RODRIGUES, N; LATHROP, M; PRESSEY, A; DELARATO, NH; PETERSON, LB; WICKER, LS			GENETIC-ANALYSIS OF AUTOIMMUNE TYPE-1 DIABETES-MELLITUS IN MICE	NATURE			English	Article							DNA POLYMORPHISMS; NOD MOUSE; NONOBESE; INSULITIS; EXPRESSION; PREVENTION; LINKAGE; HETEROGENEITY; RECOMBINATION; CONSTRUCTION	Two genes, Idd-3 and Idd-4, that influence the onset of autoimmune type 1 diabetes in the nonobese diabetic mouse have been located on chromosomes 3 and 11, outside the chromosome 17 major histocompatibility complex. A genetic map of the mouse genome, analysed using the polymerase chain reaction, has been assembled specifically for the study. On the basis of comparative maps of the mouse and human genomes, the homologue of Idd-3 may reside on human chromosomes 1 or 4 and Idd-4 on chromosome 17.	CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND; CTR ETUD POLYMORPHISME HUMAINE,F-75010 PARIS,FRANCE; MERCK SHARP & DOHME LTD,DEPT CELLULAR & MOLEC PHARMACOL,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,AUTOIMMUNE DIS RES,RAHWAY,NJ 07065	Merck & Company; Merck & Company	TODD, JA (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT SURG,OXFORD OX3 9DU,ENGLAND.		Todd, John A/A-3542-2010; Wicker, Linda S/F-7384-2010	Todd, John A/0000-0003-2740-8148; Prins, Jan-Bas/0000-0002-1831-8522; Aitman, Timothy/0000-0002-7875-4502	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; AITMAN TJ, IN PRESS MAMMALIAN G; BOTTAZZO GF, 1989, BRIT MED BULL, V45, P37, DOI 10.1093/oxfordjournals.bmb.a072319; CARTER TC, 1951, J GENET, V50, P307, DOI 10.1007/BF02996226; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CORNALL RJ, IN PRESS GENOMICS; FAUSTMAN D, 1989, DIABETES, V38, P1462, DOI 10.2337/diabetes.38.11.1462; HATAMORI N, 1990, DIABETES, V39, P1070, DOI 10.2337/diabetes.39.9.1070; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; HEARNE CM, IN PRESS MAMMALIAN G; HEROLD KC, 1990, DIABETES, V39, P815, DOI 10.2337/diabetes.39.7.815; HILLYARD AL, 1990, LOCUS MAP MOUSE COMP; JANSSEN LAJ, 1990, GENOMICS, V8, P237, DOI 10.1016/0888-7543(90)90277-2; KNIGHT AM, 1990, MOL CELL PROBE, V4, P497, DOI 10.1016/0890-8508(90)90008-N; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LATHROP GM, 1988, GENOMICS, V2, P157; LITT M, 1989, AM J HUM GENET, V44, P397; LIVINGSTONE A, 1991, J IMMUNOL, V146, P529; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; LUND T, 1990, NATURE, V345, P727, DOI 10.1038/345727a0; MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; MIYAZAKI T, 1990, NATURE, V345, P722, DOI 10.1038/345722a0; NADEAU JH, 1989, TRENDS GENET, V5, P82, DOI 10.1016/0168-9525(89)90031-0; NEUMANN PE, IN PRESS P NATN ACAD; OLDSTONE MBA, 1988, SCIENCE, V239, P500, DOI 10.1126/science.3277269; OLMOS P, 1988, DIABETOLOGIA, V31, P747, DOI 10.1007/BF00274777; OTT J, 1985, ANAL HUMAN GENETIC L; PARNES JR, 1982, CELL, V29, P661, DOI 10.1016/0092-8674(82)90182-9; PATERSON AH, 1991, GENETICS, V127, P181; PHILBRICK WM, 1990, EMBO J, V9, P2485, DOI 10.1002/j.1460-2075.1990.tb07427.x; PROCHAZKA M, 1987, SCIENCE, V237, P286, DOI 10.1126/science.2885918; RICE J, 1989, GENET EPIDEMIOL, V6, P161, DOI 10.1002/gepi.1370060130; RISCH N, 1987, AM J HUM GENET, V40, P1; SERREZE DV, 1988, J IMMUNOL, V140, P3801; SIBLEY RK, 1985, LAB INVEST, V53, P132; SLATTERY RM, 1990, NATURE, V345, P724, DOI 10.1038/345724a0; Suzuki T, 1987, IMMUNE DEFICIENT ANI, P112, DOI DOI 10.1159/000413303; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; THOMSON G, 1989, GENET EPIDEMIOL, V6, P155, DOI 10.1002/gepi.1370060129; THOMSON G, 1988, AM J HUM GENET, V43, P799; TODD JA, 1990, IMMUNOL TODAY, V11, P122, DOI 10.1016/0167-5699(90)90049-F; WEBER JL, 1989, AM J HUM GENET, V44, P388; WHITE R, 1985, NATURE, V313, P101, DOI 10.1038/313101a0; WICKER LS, 1987, J EXP MED, V165, P1639, DOI 10.1084/jem.165.6.1639; WICKER LS, 1989, J IMMUNOL, V142, P781; WICKER LS, IN PRESS P P S BIOME; WICKER LS, IN PRESS FRONTIERS D, V2; WILBERZ S, 1991, DIABETOLOGIA, V34, P2, DOI 10.1007/BF00404016	50	506	508	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1991	351	6327					542	547		10.1038/351542a0	http://dx.doi.org/10.1038/351542a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1675432				2022-12-01	WOS:A1991FR03400049
J	WHITE, RE; SCHONBRUNN, A; ARMSTRONG, DL				WHITE, RE; SCHONBRUNN, A; ARMSTRONG, DL			SOMATOSTATIN STIMULATES CA2+-ACTIVATED K+ CHANNELS THROUGH PROTEIN DEPHOSPHORYLATION	NATURE			English	Article							PITUITARY CELL-LINE; VASOACTIVE INTESTINAL PEPTIDE; AMP-INDEPENDENT ACTIONS; INTRACELLULAR FREE CALCIUM; PERTUSSIS TOXIN BLOCKS; CYCLIC-AMP; TUMOR-CELLS; GH3 CELLS; POTASSIUM CONDUCTANCE; PROLACTIN SECRETION	THE neuropeptide somatostatin inhibits secretion from electrically excitable cells in the pituitary, pancreas, gut and brain 1. In mammalian pituitary tumour cells somatostatin inhibits secretion through two distinct pertussis toxin-sensitive mechanisms 2-5. One involves inhibition of adenylyl cyclase 6, the other an unidentified cyclic AMP-independent mechanism that reduces Ca2+ influx 7,8 by increasing membrane conductance to potassium 9,10. Here we demonstrate that the predominant electrophysiological effect of somatostatin on metabolically intact pituitary tumour cells is a large, sustained increase in the activity of the large-conductance Ca2+- and voltage-activated K+ channels (BK). This action of somatostatin does not involve direct effects of Ca2+, cAMP or G proteins on the channels. Our results indicate instead that somatostatin stimulates BK channel activity through protein dephosphorylation.	NIEHS,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709; UNIV TEXAS,SCH MED,DEPT PHARMACOL,HOUSTON,TX 77225	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System								ARMSTRONG D, 1987, P NATL ACAD SCI USA, V84, P2518, DOI 10.1073/pnas.84.8.2518; ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DORFLINGER LJ, 1983, ENDOCRINOLOGY, V113, P1541, DOI 10.1210/endo-113-5-1541; DORFLINGER LJ, 1983, ENDOCRINOLOGY, V113, P1551, DOI 10.1210/endo-113-5-1551; DUBINSKY JM, 1984, J GEN PHYSIOL, V83, P309, DOI 10.1085/jgp.83.3.309; ENYEART JJ, 1985, AM J PHYSIOL, V248, pC510, DOI 10.1152/ajpcell.1985.248.5.C510; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KALMAN D, 1988, J GEN PHYSIOL, V92, P531, DOI 10.1085/jgp.92.4.531; KOCH BD, 1988, J BIOL CHEM, V263, P216; KOCH BD, 1985, J BIOL CHEM, V260, P3138; KOCH BD, 1988, J BIOL CHEM, V263, P226; KOCH BD, 1984, ENDOCRINOLOGY, V114, P1784, DOI 10.1210/endo-114-5-1784; KORN SJ, 1989, J GEN PHYSIOL, V94, P789, DOI 10.1085/jgp.94.5.789; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LECHLEITER JD, 1988, NEURON, V1, P27; LEWIS DL, 1986, P NATL ACAD SCI USA, V83, P9035, DOI 10.1073/pnas.83.23.9035; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; LUINI A, 1986, J NEUROSCI, V6, P3128; MARUYAMA Y, 1982, NATURE, V300, P61, DOI 10.1038/300061a0; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; MOLLARD P, 1988, ENDOCRINOLOGY, V123, P721, DOI 10.1210/endo-123-2-721; PATEL YC, 1990, METABOLISM, V39, P1, DOI 10.1016/0026-0495(90)90196-J; PFEUFFER T, 1988, CURR TOP CELL REGUL, V29, P129; REINHART PH, IN PRESS J NEUROSCI; RITCHIE AK, 1987, J PHYSIOL-LONDON, V385, P591, DOI 10.1113/jphysiol.1987.sp016509; ROSENTHAL W, 1988, EMBO J, V7, P1627, DOI 10.1002/j.1460-2075.1988.tb02989.x; SCHLEGEL W, 1984, CELL CALCIUM, V5, P223, DOI 10.1016/0143-4160(84)90038-1; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SIKDAR SK, 1989, BRAIN RES, V496, P113, DOI 10.1016/0006-8993(89)91057-3; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; TORO L, 1990, J GEN PHYSIOL, V96, P373, DOI 10.1085/jgp.96.2.373; YAJIMA Y, 1986, J BIOL CHEM, V261, P2684; YAMASHITA N, 1988, P NATL ACAD SCI USA, V85, P4924, DOI 10.1073/pnas.85.13.4924; YAMASHITA N, 1986, P NATL ACAD SCI USA, V83, P6198, DOI 10.1073/pnas.83.16.6198; YATANI A, 1987, MOL ENDOCRINOL, V1, P283, DOI 10.1210/mend-1-4-283	39	257	258	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1991	351	6327					570	573		10.1038/351570a0	http://dx.doi.org/10.1038/351570a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1710783				2022-12-01	WOS:A1991FR03400060
J	BLUMBERG, MS				BLUMBERG, MS			BIASED ESTIMATES OF EXPECTED ACUTE MYOCARDIAL-INFARCTION MORTALITY USING MEDISGROUPS ADMISSION SEVERITY GROUPS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURVIVAL; SYSTEM	This study examines whether the MedisGroups admission severity groups give unbiased estimates of 30-day mortality in 3037 Medicare-aged patients who were hospitalized in 1985 through 1986 with acute myocardial infarction. The average observed death rate for all acute myocardial infarction patients in the study who were in a given admission severity group was used to estimate the expected death probability for each case in a given group. (This is the same method used by the Pennsylvania Health Care Cost Containment Council for risk adjusting hospital mortality by diagnosis related groups in that state.) When compared with observed deaths, estimates of expected mortality were significantly biased for many patient attributes (eg, age, location of acute myocardial infarction, history of congestive heart failure, serum potassium level, serum urea nitrogen level, pulse rate, and blood pressure). These results are consistent with a conclusion that the MedisGroups scoring algorithm omits some important risk variables, inappropriately includes some other variables reflecting postadmission status, and gives the wrong weights to some appropriate risk variables. To the extent that these findings are also applicable to current MedisGroups scoring algorithms and to other conditions and procedures, MedisGroups admission severity groups cannot fairly adjust for interhospital case mix differences in outcome studies.			BLUMBERG, MS (corresponding author), KAISER FDN HLTH PLAN INC,ONE KAISER PLAZA,OAKLAND,CA 94612, USA.		Blumberg, Mark/K-3221-2019					ALEMI F, 1990, MED CARE, V28, P762, DOI 10.1097/00005650-199009000-00006; [Anonymous], 1986, MED THINKING PSYCHOL; [Anonymous], 1968, HDB SOC PSYCHOL; Blumberg M S, 1986, Med Care Rev, V43, P351, DOI 10.1177/107755878604300205; BLUMBERG MS, 1991, STAT MED, V10, P637, DOI 10.1002/sim.4780100414; BLUMBERG MS, 1989, RISK ADJUSTED 30 DAY; GOMEZMARIN O, 1987, NEW ENGL J MED, V316, P1353, DOI 10.1056/NEJM198705283162201; IEZZONI LI, 1988, JAMA-J AM MED ASSOC, V260, P3159, DOI 10.1001/jama.260.21.3159; IEZZONI LI, 1991, AM J PUBLIC HEALTH, V81, P74, DOI 10.2105/AJPH.81.1.74; Iezzoni LI, 1988, ABILITY MEDISGROUPS; IEZZONI LI, 1987, MEDISGROUP CLIN ANAL; IEZZONI LI, 1989, ADMISSION MIDSTAY ME; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEGALL JR, 1987, ICU COST BENEFIT ANA; SACCO RL, 1990, ARCH NEUROL-CHICAGO, V147, P1181; SACHS L, 1984, APPLIED STATISTICS H, P66; 1990, HE189 PENNS HLTH CAR, pB4; 1990, HE5488 PENNS HLTH CA, P3	19	42	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2965	2970						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	2033767				2022-12-01	WOS:A1991FP63500033
J	JORDAN, TJ; LEWIT, EM; MONTGOMERY, RL; REICHMAN, LB				JORDAN, TJ; LEWIT, EM; MONTGOMERY, RL; REICHMAN, LB			ISONIAZID AS PREVENTIVE THERAPY IN HIV-INFECTED INTRAVENOUS DRUG-ABUSERS - A DECISION-ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; AGE THRESHOLD; TUBERCULOSIS; RISK; CHEMOTHERAPY; FLORIDA; LEAVE; AIDS	Tuberculin skin testing is a notoriously poor marker of tuberculosis infection in patients who are serologically positive for the human immunodeficiency virus. A decision analysis was performed to determine if and when isoniazid should be prescribed to prevent tuberculosis in these patients. The decision was analyzed for an intravenous drug abuser who may have been anergic, while tuberculin test status, race, and gender were varied. The assumptions and parameter estimates selected for this investigation represent a highly conservative vantage point opposing the use of isoniazid as a preventive therapy. Nevertheless, results showed a benefit from the use of isoniazid as a preventive therapy for all groups, even without tuberculin testing, except tuberculin-negative black women. This benefit of isoniazid therapy increased patient life expectancy as much as 285 days. Further, the decisions continue to favor prescribing isoniazid even when the suspected incidence of tuberculosis infection falls as low as 3% to 8%. Tuberculin testing appears important primarily for black women, since those who have negative tuberculin skin tests may not be candidates for isoniazid therapy.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DIV PULM MED,150 BERGEN ST,I-354,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DIV INFORMAT,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MED,NEWARK,NJ 07103	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center					NHLBI NIH HHS [1-K07-HL-02095-04, 1-HR-76032A] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR076032] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL002095] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		American Thoracic Society, 1981, AM REV RESPIR DIS, V124, P356; BROWN LS, 1989, JAMA-J AM MED ASSOC, V262, P615; BRUDNEY D, 1989, 5TH INT C AIDS MONTR; CANESSA PA, 1989, CHEST, V96, P1215, DOI 10.1378/chest.96.5.1215; CHIASSON RE, 1987, AM REV RESPIR DIS, V136, P570; DIPERRI G, 1989, LANCET, V2, P1502; FREBEE SH, 1970, ADV TUBERC RES, V17, P28; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; LUI KJ, 1988, SCIENCE, V240, P1333, DOI 10.1126/science.3163848; MARKOWITZ N, 1990, AM REV RESPIR DIS, V141, P617; MEDLEY GF, 1988, PROC R SOC SER B-BIO, V233, P367, DOI 10.1098/rspb.1988.0026; MEHTA JB, 1988, CHEST, V94, P138, DOI 10.1378/chest.94.1.138; MOULDING TS, 1989, AM REV RESPIR DIS, V140, P700, DOI 10.1164/ajrccm/140.3.700; MURRAY JF, 1990, AM REV RESPIR DIS, V141, P1356, DOI 10.1164/ajrccm/141.5_Pt_1.1356; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; PITCHENIK AE, 1986, NEW ENGL J MED, V314, P447; REICHMAN LB, 1979, ARCH INTERN MED, V139, P337, DOI 10.1001/archinte.139.3.337; REICHMAN LB, 1987, JAMA-J AM MED ASSOC, V257, P1728, DOI 10.1001/jama.1987.03390130046012; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; ROBERT CF, 1989, NEW ENGL J MED, V321, P1268; ROSE DN, 1986, JAMA-J AM MED ASSOC, V256, P2709, DOI 10.1001/jama.256.19.2709; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, ANN INTERN MED, V111, P761, DOI 10.7326/0003-4819-111-9-761; SNIDER DE, 1987, AM REV RESPIR DIS, V136, P492; SNIDER DE, 1988, AM REV RESPIR DIS, V137, P2, DOI 10.1164/ajrccm/137.1.2; STEAD WW, 1987, ANN INTERN MED, V107, P843, DOI 10.7326/0003-4819-107-6-843; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; SUNDERAM G, 1987, AM REV RESPIR DIS, V136, P1475, DOI 10.1164/ajrccm/136.6.1475; TAYLOR WC, 1981, ANN INTERN MED, V94, P808, DOI 10.7326/0003-4819-94-6-808; THEUER CP, 1989, WESTERN J MED, V150, P700; TSEVAT J, 1988, AM REV RESPIR DIS, V137, P215, DOI 10.1164/ajrccm/137.1.215; 1989, MMWR S3, V38, P1; 1909, MMWR, V38, P236; 1989, MMWR, V38, P243; 1990, MMWR, V39, P645; [No title captured]; 1990, MMWR, V39, P638	38	66	66	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2987	2991		10.1001/jama.265.22.2987	http://dx.doi.org/10.1001/jama.265.22.2987			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP635	2033771				2022-12-01	WOS:A1991FP63500037
J	LEVIN, BW; DRISCOLL, JM; FLEISCHMAN, AR				LEVIN, BW; DRISCOLL, JM; FLEISCHMAN, AR			TREATMENT CHOICE FOR INFANTS IN THE NEONATAL-INTENSIVE-CARE-UNIT AT RISK FOR AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; INFECTION; TYPE-1; WOMEN; BORN	Many infants admitted to neonatal intensive care units are the children of women infected with the human immunodeficiency virus (HIV); they have approximately a 30% risk of infection. To investigate attitudes surrounding treatment for such newborns, we conducted a survey of professionals at six neonatal intensive care units in New York City. A significant proportion of the 247 respondents recommended less aggressive treatment for non-HIV-related conditions for infants at risk for HIV compared with those not at risk. For example, 97% of respondents recommended open heart surgery for an infant with no known HIV risk but only 77% recommended surgery for an infant whose mother had acquired immunodeficiency syndrome; if certain the infant was infected, 42% of respondents recommended surgery. We conclude that perceived HIV status may influence decision making about treatment for non-HIV-related conditions for critically ill patients, including infants not actually infected. Ethical issues concerning the relevance of HIV status need to be examined.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PEDIAT,DIV NEONATOL,BRONX,NY 10461; COLUMBIA UNIV COLL PHYS & SURG,DEPT PEDIAT,DIV PERINATAL MED,NEW YORK,NY 10032; MONTEFIORE MED CTR,BRONX,NY 10467	Yeshiva University; Albert Einstein College of Medicine; Columbia University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	LEVIN, BW (corresponding author), CUNY BROOKLYN COLL,DEPT HLTH & NUTR,BROOKLYN,NY 11210, USA.		Levin, Betty Wolder/L-3479-2019	Levin, Betty Wolder/0000-0002-4288-6052				BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; CONDIT D, 1989, ANN THORAC SURG, V47, P182, DOI 10.1016/0003-4975(89)90266-X; CRANE D, 1975, SANCTITY SOCIAL LIFE; Guillemin J, 1986, MIXED BLESSINGS INTE; KATZ BZ, 1989, SEMIN PERINATOL, V13, P27; LEVIN BW, 1988, CHILDBIRTH AM ANTHR; LEVIN BW, 1985, WHICH BABIES LIVE ME; NICHOLAS SW, 1989, PEDIATRICS, V83, P293; OLESKE JM, 1988, PEDIATR ANN, V17, P332, DOI 10.3928/0090-4481-19880501-07; PIZZO PA, 1989, JAMA-J AM MED ASSOC, V262, P1989, DOI 10.1001/jama.262.14.1989; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SEPTIMUS A, 1989, SEMIN PERINATOL, V13, P49; SHEARER W, 1990, SEMIN PEDIATR INFECT, V1, P1; STEVENS A, 1990, BRIT MED J, V300, P447, DOI 10.1136/bmj.300.6722.447; Weir Robert F., 1984, SELECTIVE NONTREATME; 1987, HASTINGS CTR REP, V17, P5	17	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2976	2981		10.1001/jama.265.22.2976	http://dx.doi.org/10.1001/jama.265.22.2976			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	2033769				2022-12-01	WOS:A1991FP63500035
J	MASON, JO				MASON, JO			A MESSAGE TO HEALTH-PROFESSIONALS ABOUT FLUOROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MASON, JO (corresponding author), US PHS,DIV NEWS,ROOM 719H,200 INDEPENDENCE AVE SW,WASHINGTON,DC 20201, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2939	2939						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	2033755				2022-12-01	WOS:A1991FP63500009
J	MCGEE, S				MCGEE, S			RESTLESS LEGS SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							DOUBLE-BLIND; PERIODIC MOVEMENTS; SLEEP				MCGEE, S (corresponding author), UNIV WASHINGTON,SCH MED,SEATTLE,WA 98195, USA.							AKPINAR S, 1987, CLIN NEUROPHARMACOL, V10, P69; BRODEUR C, 1988, NEUROLOGY, V38, P1845, DOI 10.1212/WNL.38.12.1845; CLOUGH C, 1987, BRIT MED J, V294, P262, DOI 10.1136/bmj.294.6567.262; EKBOM KA, 1970, HDB CLIN NEUROLOGY, V8, P311; GIBB WRG, 1986, POSTGRAD MED J, V62, P329, DOI 10.1136/pgmj.62.727.329; KRUEGER BR, 1990, MAYO CLIN PROC, V65, P999, DOI 10.1016/S0025-6196(12)65163-5; MONTAGNA P, 1984, ACTA NEUROL SCAND, V69, P428, DOI 10.1111/j.1600-0404.1984.tb07826.x; TELSTAD W, 1984, BRIT MED J, V288, P444, DOI 10.1136/bmj.288.6415.444; VONSCHEELE C, 1986, LANCET, V2, P426; WALTERS AS, 1988, ANN NEUROL, V24, P455, DOI 10.1002/ana.410240318	10	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					3014	3014		10.1001/jama.265.22.3014	http://dx.doi.org/10.1001/jama.265.22.3014			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	2033777				2022-12-01	WOS:A1991FP63500044
J	NIGHTINGALE, SL				NIGHTINGALE, SL			INTERFERON ALFA APPROVED FOR NON-A, NON-B HEPATITIS TYPE-C	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2934	2934						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	1903461				2022-12-01	WOS:A1991FP63500008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			SAFETY OF DENTAL AMALGAMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2934	2934						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	1903461				2022-12-01	WOS:A1991FP63500006
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ALGLUCERASE APPROVED FOR GAUCHERS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1990, JAMA-J AM MED ASSOC, V264, P1239	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2934	2934						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	1903461				2022-12-01	WOS:A1991FP63500007
J	NIGHTINGALE, SL				NIGHTINGALE, SL			INTERNATIONAL-CONFERENCE ON HARMONIZING TECHNICAL REQUIREMENTS FOR DRUG APPROVALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2934	2934						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	1903461				2022-12-01	WOS:A1991FP63500005
J	TAYLOR, WC				TAYLOR, WC			INDIRECT LARYNGOSCOPY AS A SCREENING-TEST FOR LARYNGEAL-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ADULT HEALTH MAINTENANCE; PREVENTION; DISEASES				TAYLOR, WC (corresponding author), HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, BOSTON, MA 02215 USA.							[Anonymous], 1989, GUIDE CLIN PREVENTIV; Canadian Task Force on the Periodic Health Examination, 1979, CAN MED ASSOC J, V121, P1193; DEWEESE DD, 1982, TXB OTOLARYNGOLOGY, P111; DRIPPS RD, 1988, INTRO ANESTHESIA PRI, P403; Frame P S, 1975, J Fam Pract, V2, P189; Frame P S, 1975, J Fam Pract, V2, P283; Frame P S, 1975, J Fam Pract, V2, P29; FRAME PS, 1986, J FAM PRACTICE, V22, P341; FRAME PS, 1986, J FAM PRACTICE, V22, P511; FRAME PS, 1986, J FAM PRACTICE, V22, P417; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; LEMORE T, 1987, PHS871250 DEP HLTH H; OBOLER SK, 1989, ANN INTERN MED, V110, P214, DOI 10.7326/0003-4819-110-3-214; SACKETT DL, 1987, J FAM PRACTICE, V24, P233; TAYLOR WC, 1980, ANN INTERN MED, V93, P773, DOI 10.7326/0003-4819-93-5-773; Wilson JMG, 1968, PRINCIPLES PRACTICE; 1991, JAMA-J AM MED ASSOC, V265, P412; 1988, 8820M AM CANC SOC PR; 1989, 89450M AM CAN SOC PU, P8	19	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					3011	+		10.1001/jama.265.22.3011	http://dx.doi.org/10.1001/jama.265.22.3011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	2033776				2022-12-01	WOS:A1991FP63500043
J	DEGRAEFFMEEDER, ER; VANDERZEE, R; RIJKERS, GT; SCHUURMAN, HJ; KUIS, W; BIJLSMA, JWJ; ZEGERS, BJM; VANEDEN, W				DEGRAEFFMEEDER, ER; VANDERZEE, R; RIJKERS, GT; SCHUURMAN, HJ; KUIS, W; BIJLSMA, JWJ; ZEGERS, BJM; VANEDEN, W			RECOGNITION OF HUMAN 60 KD HEAT-SHOCK PROTEIN BY MONONUCLEAR-CELLS FROM PATIENTS WITH JUVENILE CHRONIC ARTHRITIS	LANCET			English	Article							65-KILODALTON MYCOBACTERIAL ANTIGEN; RHEUMATOID-ARTHRITIS; TUBERCULOSIS; REACTIVITY; PATHOGENESIS; LYMPHOCYTES; THERAPY; CLONES	A postulated mechanism for autoimmune disorders is that the immunoreactivity develops against bacterial antigens which show a high degree of sequence homology with mammalian proteins. The mycobacterial 65 kD heat shock protein (hsp) has been implicated in several forms of arthritis. Substantial amounts of the human 60 kD homologue (hsp60) were produced by insertion of the gene into Escherichia coli. To investigate the hypothesis that T-cell reactivity is directed against the endogenous hsp, T-cell proliferation of synovial-fluid and peripheral-blood mononuclear cells in response to hsp60 was studied in samples from six patients with juvenile chronic arthritis (JCA) and nine adult patients with rheumatoid arthritis (RA). There was no T-lymphocyte proliferative response to purified fractions of hsp60 in mononuclear cells from RA patients or healthy children and young adults. However, both synovial-fluid and peripheral-blood mononuclear cells from JCA patients showed significant correlation between the stimulation indices for human hsp60 and for mycobacterial hsp65 (r = 0.948, p < 0.02). A similar correlation for hsp60 and mycobacterial hsp70 did not achieve significance. Immunohistochemistry showed that hsp65 and hsp70 homologues were expressed in the synovial membrane in these patients but not in controls. These findings suggest a sequence of events in which hsps become expressed during synovial inflammation and function as autoantigens. In JCA this may be manifested by specific T-cell reactivity which apparently is lost in the more bone-eroding and non-remitting adult disease.	NATL INST PUBL HLTH & ENVIRONM PROTECT,BILTHOVEN,NETHERLANDS; STATE UNIV UTRECHT HOSP,DEPT PATHOL,3511 GV UTRECHT,NETHERLANDS; STATE UNIV UTRECHT HOSP,DEPT INTERNAL MED,3511 GV UTRECHT,NETHERLANDS; STATE UNIV UTRECHT HOSP,DEPT RHEUMATOL,3511 GV UTRECHT,NETHERLANDS; STATE UNIV UTRECHT,FAC VET MED,INST INFECT DIS & IMMUNOL,UTRECHT,NETHERLANDS	Netherlands National Institute for Public Health & the Environment; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University	DEGRAEFFMEEDER, ER (corresponding author), STATE UNIV UTRECHT,HET WILHELMINA KINDERZIEKENHUIS,DEPT IMMUNOL,POB 18009,3501 CA UTRECHT,NETHERLANDS.		van der Zee, Ruurd/O-5256-2015; Rijkers, Ger/AAW-6143-2020; Rijkers, Ger/R-7236-2019	van der Zee, Ruurd/0000-0002-4331-2755; Rijkers, Ger/0000-0001-6948-6123				ABRAHAMSEN TG, 1978, SCAND J IMMUNOL, V7, P81, DOI 10.1111/j.1365-3083.1978.tb00429.x; BAHR GM, 1988, CLIN EXP IMMUNOL, V74, P211; BILLINGHAM MEJ, 1990, J EXP MED, V171, P339, DOI 10.1084/jem.171.1.339; COHEN IR, 1986, IMMUNOL REV, V94, P5, DOI 10.1111/j.1600-065X.1986.tb01161.x; COHEN IR, 1985, ARTHRITIS RHEUM, V28, P841, DOI 10.1002/art.1780280802; DEGRAEFFMEEDER ER, 1990, AM J PATHOL, V137, P1013; DUDANI AK, 1989, INFECT IMMUN, V57, P2786, DOI 10.1128/IAI.57.9.2786-2793.1989; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; GASTON JSH, 1990, J EXP MED, V171, P831, DOI 10.1084/jem.171.3.831; GASTON JSH, 1989, J IMMUNOL, V143, P2492; HOLOSHITZ J, 1986, LANCET, V2, P305; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; JONES DB, 1990, LANCET, P583; KAUFMANN SHE, 1990, IMMUNOL TODAY, V11, P129, DOI 10.1016/0167-5699(90)90050-J; LYDYARD P, 1990, IMMUNOL TODAY, V2, P228; MEHLERT A, 1989, MOL MICROBIOL, V3, P125, DOI 10.1111/j.1365-2958.1989.tb01801.x; Munthe E, 1978, CARE RHEUMATIC CHILD, P47; OTTENHOFF THM, 1986, LANCET, V2, P310; PALACIOSBOIX AA, 1988, J IMMUNOL, V140, P1844; POPE RM, 1991, CELL IMMUNOL, V133, P95, DOI 10.1016/0008-8749(91)90182-B; RES PCM, 1988, LANCET, V2, P478, DOI 10.1016/S0140-6736(88)90123-7; RES PCM, 1990, LANCET, V336, P1406, DOI 10.1016/0140-6736(90)93104-W; STOKER NG, 1989, GENE, V78, P93, DOI 10.1016/0378-1119(89)90317-X; THOLE JER, 1987, INFECT IMMUN, V55, P1466, DOI 10.1128/IAI.55.6.1466-1475.1987; THOMPSON SJ, 1990, EUR J IMMUNOL, V20, P2479, DOI 10.1002/eji.1830201118; VANDENBROEK MF, 1989, J EXP MED, V170, P449, DOI 10.1084/jem.170.2.449; VANDENBROEK MF, 1989, APMIS, V97, P861; VANEDEN W, 1990, IMMUNOL RES, V9, P157, DOI 10.1007/BF02918175; VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0; VANEDENW, 1900, APMIS, V98, P383	30	173	180	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1991	337	8754					1368	1372		10.1016/0140-6736(91)93057-G	http://dx.doi.org/10.1016/0140-6736(91)93057-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP870	1674762				2022-12-01	WOS:A1991FP87000002
J	HICKMAN, M; ALDOUS, J; PORTER, J; DURMAN, L				HICKMAN, M; ALDOUS, J; PORTER, J; DURMAN, L			HIV SURVEILLANCE - THE VALUE OF AUDIT	BRITISH MEDICAL JOURNAL			English	Article									PUBL HLTH LAB SERV,COMMUNICABLE DIS SURVEILLANCE CTR,LONDON NW9 5EQ,ENGLAND	Public Health England	HICKMAN, M (corresponding author), RIVERSIDE HLTH AUTHOR,DEPT PUBL HLTH,LONDON SW6 4UL,ENGLAND.		Hickman, Matthew/Y-2400-2019	Hickman, Matthew/0000-0001-9864-459X				BOBBY JJ, 1988, PUBLIC HEALTH, V102, P519, DOI 10.1016/S0033-3506(88)80020-9; DUFF C, 1988, BRIT MED J, V297, P965, DOI 10.1136/bmj.297.6654.965; GILL ON, 1989, BRIT MED J, V299, P1295, DOI 10.1136/bmj.299.6711.1295; MCCORMICK A, 1989, PHILOS T ROY SOC B, V325, P163, DOI 10.1098/rstb.1989.0081	4	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1991	302	6789					1376	1377		10.1136/bmj.302.6789.1376	http://dx.doi.org/10.1136/bmj.302.6789.1376			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR057	2059717	Green Published, Bronze			2022-12-01	WOS:A1991FR05700021
J	MCCORMICK, A				MCCORMICK, A			UNRECOGNIZED HIV RELATED DEATHS	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To establish whether follow up of deaths from selected HIV related causes could increase the number of cases of HIV infection reported to the Public Health Laboratory Service Communicable Disease Surveillance Centre (CDSC), and to estimate the proportion of deaths among HIV positive men that occurred in men who were not known to be HIV positive at the time of death by the person who signed the death certificate. Design - Follow up of draft death entries received by the Office of Population Censuses and Surveys on which one of 11 medical or external causes likely to be related to HIV was stated; letters were sent to the people who signed the certificates. The respondents were invited to report men known to have been HIV positive who were not already on the CDSC register. Setting - England and Wales. Subjects - Men aged 15-54 who died in February 1989 to July 1989 with one of the 11 selected HIV related diseases as cause of death on their death certificates. Main outcome measures - Number of men reported to the CDSC as a result of this follow up; estimate of excess deaths due to an HIV related cause; estimate of the proportion of excess deaths that occurred in those who were not known to be HIV positive at the time of death. Results - Replies were received for 473 deaths (86%). Forty were for men known to have been HIV positive, 31 of whom had been reported to CDSC by the time they died; six were subsequently reported. The respondent did not know that the deceased was HIV positive for 20 (35%) of the 57 excess deaths in men for whom one of the medical causes was stated and 41 (93%) of the 44 excess deaths in men for whom one of the external causes was stated. Conclusion - Follow up of death registrations is not an efficient way of increasing the number of cases of HIV infection reported to CDSC. Between 35% and 60% of HIV positive people for whom certain causes are stated may be dying without HIV positivity having been diagnosed. There may be implications for those caring for people with these conditions and those who carry out postmortem examinations.			MCCORMICK, A (corresponding author), OFF POPULAT CENSUSES & SURVEYS,LONDON WC2B 6JP,ENGLAND.							MARZUK PM, 1988, JAMA-J AM MED ASSOC, V259, P1333, DOI 10.1001/jama.259.9.1333; MCCORMICK A, 1991, BRIT MED J, V302, P1375, DOI 10.1136/bmj.302.6789.1375	2	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1991	302	6789					1365	1367		10.1136/bmj.302.6789.1365	http://dx.doi.org/10.1136/bmj.302.6789.1365			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR057	2059714	Bronze, Green Published			2022-12-01	WOS:A1991FR05700017
J	MCCORMICK, A				MCCORMICK, A			EXCESS MORTALITY ASSOCIATED WITH THE HIV EPIDEMIC IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article							TRENDS; AIDS				MCCORMICK, A (corresponding author), OFF POPULAT CENSUSES & SURVEYS,LONDON WC2B 6JP,ENGLAND.							BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; DARBY SC, 1989, BMJ, V298, P1046; MARZUK PM, 1988, JAMA-J AM MED ASSOC, V259, P1333, DOI 10.1001/jama.259.9.1333; MCCORMICK A, 1988, BRIT MED J, V296, P1289, DOI 10.1136/bmj.296.6632.1289; 1988, MMWR, V37, P593	5	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1991	302	6789					1375	1376		10.1136/bmj.302.6789.1375	http://dx.doi.org/10.1136/bmj.302.6789.1375			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FR057	2059716	Bronze, Green Published			2022-12-01	WOS:A1991FR05700020
J	SIGFUSSON, N; SIGVALDASON, H; STEINGRIMSDOTTIR, L; GUDMUNDSDOTTIR, II; STEFANSDOTTIR, I; THORSTEINSSON, T; SIGURDSSON, G				SIGFUSSON, N; SIGVALDASON, H; STEINGRIMSDOTTIR, L; GUDMUNDSDOTTIR, II; STEFANSDOTTIR, I; THORSTEINSSON, T; SIGURDSSON, G			DECLINE IN ISCHEMIC-HEART-DISEASE IN ICELAND AND CHANGE IN RISK FACTOR LEVELS	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; TRENDS	Objective - To monitor trends in mortality and morbidity due to ischaemic heart disease and compare these with observed levels of risk factors from population surveys. Design - Analysis of trends in death rates from ischaemic heart disease in Iceland compared with expected rates computed from population surveys. Risk factor levels together with beta-factors obtained from Cox's regression analysis were used to compute expected death rates. Trends in morbidity due to acute myocardial infarction were assessed and secular trends in dietary consumption compared with trends in cholesterol concentrations. Setting - Reykjavik, Iceland (total population 250 000; over half the population live in Reykjavik). Subjects - 12 814 randomly selected residents in the Reykjavik area aged 45-64 (6623 men, 6191 women; 72% and 80% of those invited). Main outcome measures - Age adjusted rates of myocardial infarction and deaths from ischaemic heart disease. Expected risk from risk factor levels (smoking, total serum cholesterol concentration, systolic blood pressure) at each unique survey visit. Results - Mortality from ischaemic heart disease has decreased by 17-18% since 1970. During 1981-6 the myocardial infarction attack rate in men under 75 decreased by 23%. A decrease occurred in the level of all three major risk factors after 1968. The fall in the serum cholesterol concentration coincided with a reduction in consumption of dairy fat and margarine . The calculated reduction in risk for the age group 45-64 was about 35%, which was closely similar to the observed decrease in mortality due to ischaemic heart disease in that age group. Conclusion - The reduction in mortality from ischaemic heart disease was substantially due to a decreased incidence of myocardial infarction and could be attributed largely to the reduction in risk factors.	REYKJAVIK CITY HOSP,DEPT MED,IS-108 REYKJAVIK,ICELAND; ICELAND HEART ASSOC,REYKJAVIK,ICELAND; ICELAND NUTR COUNCIL,REYKJAVIK,ICELAND	Landspitali National University Hospital; Icelandic Heart Association			Steingrimsdottir, Laufey/L-3150-2015					BEAGLEHOLE R, 1981, NEW ZEAL MED J, V93, P371; BLOCK WD, 1966, CLIN CHEM, V10, P681; Breslow NE., 1980, IARC SCI PUBLICATION, V32; COX DR, 1972, J R STAT SOC B, V34, P187; DOBSON AJ, 1987, COMMUNITY HEALTH ST, V11, P2; DWYER T, 1980, INT J EPIDEMIOL, V9, P65, DOI 10.1093/ije/9.1.65; HILMARSDOTTIR E, 1989, MANNELDI NEYSLA, P155; KEYS A, 1957, LANCET, V1, P787; RAGNARSSON JO, 1981, ICELANDIC NUTRITIONA, P74; RIFKIND BM, 1988, ATHEROSCLER REV, V18, P59; ROSE GA, 1968, CARDIOVASCULAR SURVE, P160; SEGI M, 1960, CANCER MORTALITY SEL; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; THORGEIRSSON G, 1990, European Heart Journal, V11, P326; TUNSTALLPEDOE H, 1989, INT J EPIDEMIOL, V18, P169; TUOMILEHTO J, 1989, INT J EPIDEMIOL, V18, pS38; UEMURA K, 1988, World Health Statistics Quarterly, V41, P155; WAXVEILER RJ, 1983, J OCCUP MED, V25, P115; 1971, HAGTIDINDI IDNADARVO, V56; 1980, ARBOK LANDBUNADARINS; 1987, ARBOK LANDBUNADARINS; 1983, WHOMNC821; 1982, JAMA-J AM MED ASSOC, V248, P1465; 1975, ARBOK LANDBUNADARINS; 1970, ARBOK LANDBUNADARINS; 1981, HAGTIDINDI IDNADARVO, V66; 1985, ARBOK LANDBUNADARINS	27	86	86	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1991	302	6789					1371	1375		10.1136/bmj.302.6789.1371	http://dx.doi.org/10.1136/bmj.302.6789.1371			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR057	2059715	Green Published, Bronze			2022-12-01	WOS:A1991FR05700019
J	SQUIRE, SB; ELFORD, J; BOR, R; TILSED, G; SALT, H; BAGDADES, EK; JANOSSY, G; GRIFFITHS, PD; JOHNSON, MA				SQUIRE, SB; ELFORD, J; BOR, R; TILSED, G; SALT, H; BAGDADES, EK; JANOSSY, G; GRIFFITHS, PD; JOHNSON, MA			OPEN ACCESS CLINIC PROVIDING HIV-I ANTIBODY RESULTS ON DAY OF TESTING - THE 1ST 12 MONTHS	BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED TRIAL; EARLY DIAGNOSIS; ZIDOVUDINE AZT; INFECTION; EFFICACY; SAFETY	Objectives - To determine the sociodemographic profile, risk category, and prevalence of HIV-1 infection among people attending a clinic providing counselling, medical advice, and results of HIV-1 antibody testing on the day of consultation; to determine the stage of infection and peripheral blood CD4 cell count among attenders with detectable HIV-1 antibodies. Design - Analysis of prospectively collected data for the 12 months from March 1989. Setting - Same day testing clinic run by the HIV/AIDS team at an urban teaching hospital. Patients - 561 consecutive people choosing to attend and proceeding to HIV-1 testing. Results - The demand for the service caused it to run to capacity within six months. The median age of those attending was 28 years and 65% (364 patients) were male. The overall prevalence of HIV-1 infection was 3.9% (22 patients). The greatest prevalence was in men reporting their primary risk as homosexual contact (11.9%, 13/109. The median CD4 cell count in the 22 patients who had detectable HIV-1 antibodies was 0.31 X 10(9) cells/l (normal range 0.5 X l0(9)/l to 1.2 X l0(9)/l). Twenty of these patients were asymptomatic (Centers for Disease Control stages 11 or 111), 14 had CD4 cell counts below 0.5 X l0(9)/l. Conclusions - There is a recognisable demand for a service providing rapid results of HIV-1 antibody testing in this setting. The overall seroprevalence of 3.9% is comparable with the 5.8% reported from freestanding clinics in the United States. Most patients with HIV-I antibodies detected in this way are asymptomatic but could benefit from early medical intervention because of low CD4 cell counts.			SQUIRE, SB (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON NW3 2QG,ENGLAND.			Squire, Stephen/0000-0001-7173-9038				BECK EJ, 1987, BRIT MED J, V295, P191, DOI 10.1136/bmj.295.6591.191; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; GREEN J, 1987, CURRENT TOPICS AIDS, V1, P287; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LO B, 1989, ANN INTERN MED, V110, P727; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MOSS AR, 1989, AIDS, V3, P55, DOI 10.1097/00002030-198902000-00001; MURPHY FA, 1989, MMWR S5, V38, pS1; PHILLIPS AN, 1991, LANCET, V337, P389; SCHWARTZ JS, 1988, JAMA-J AM MED ASSOC, V259, P2574, DOI 10.1001/jama.259.17.2574; SONNEX C, 1987, BRIT MED J, V295, P193, DOI 10.1136/bmj.295.6591.193; SQUIRE SB, 1990, BRIT J HOSP MED, V44, P9; VOLBERDING P, 1989, J ACQ IMMUN DEF SYND, V2, P421; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1990, MMWR, V39, P137; 1987, MMWR S1, V36, pS3	17	27	27	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1991	302	6789					1383	1386		10.1136/bmj.302.6789.1383	http://dx.doi.org/10.1136/bmj.302.6789.1383			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR057	1676319	Green Published, Bronze			2022-12-01	WOS:A1991FR05700026
J	VANNOORDZAADSTRA, BM; LOOMAN, CWN; ALSBACH, H; HABBEMA, JDF; VELDE, ERT; KARBAAT, J				VANNOORDZAADSTRA, BM; LOOMAN, CWN; ALSBACH, H; HABBEMA, JDF; VELDE, ERT; KARBAAT, J			DELAYING CHILDBEARING - EFFECT OF AGE ON FECUNDITY AND OUTCOME OF PREGNANCY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FERTILITY; INSEMINATION	Objectives - To study the age of the start of the fall (critical age) in fecundity; the probability of a pregnancy leading to a healthy baby taking into account the age of the woman; and, combining these results, to determine the age dependent probability of getting a healthy baby. Design - Cohort study of all women who had entered a donor insemination programme. Setting - Two fertility clinics serving a large part of The Netherlands. Subjects - Of 1637 women attending for artificial insemination 751 fulfilled the selection criteria, being married to an azoospermic husband and nulliparous and never having received donor insemination before. Main outcome measures - The number of cycles before pregnancy (a positive pregnancy test result) or stopping treatment; and result of the pregnancy (successful outcome). Results - Of the 751 women, 555 became pregnant and 461 had healthy babies. The fall in fecundity was estimated to start at around 31 years (critical age); after 12 cycles the probability of pregnancy in a woman aged > 31 was 0.54 compared with 0.74 in a woman aged 20-31. After 24 cycles this difference had decreased (probability of conception 0.75 in women > 31 and 0.85 in women 20-31). The probability of having a healthy baby also decreased-by 3.5% a year after the age of 30. Combining both these age effects, the chance of a woman aged 35 having a healthy baby was about half that of a woman aged 25. Conclusion - After the age of 31 the probability of conception fall rapidly, but this can be partly compensated for by continuing insemination for more cycles. In addition, the probability of an adverse pregnancy outcome starts to increase at about the same age.	ERASMUS UNIV, SCH MED, DEPT PUBL HLTH & SOCIAL MED, 3000 DR ROTTERDAM, NETHERLANDS; STATE UNIV UTRECHT HOSP, DEPT OBSTET & GYNAECOL, 3511 GV UTRECHT, NETHERLANDS; CRYO BIOL LABS, BARENDRECHT, NETHERLANDS	Erasmus University Rotterdam; Utrecht University; Utrecht University Medical Center	VANNOORDZAADSTRA, BM (corresponding author), DIV CHILD HLTH, POB 124, 2300 AC LEIDEN, NETHERLANDS.							AITKIN M, 1989, STATISTICAL MODELLIN; BERKOWITZ GS, 1990, NEW ENGL J MED, V322, P659, DOI 10.1056/NEJM199003083221004; BONGAARTS J, 1982, FAM PLANN PERSPECT, V14, P75, DOI 10.2307/2134817; COX DR, 1972, J R STAT SOC B, V34, P187; EMPERAIRE JC, 1982, FERTIL STERIL, V37, P90; HARRISON KL, 1989, AUST NZ J OBSTET GYN, V29, P326, DOI 10.1111/j.1479-828X.1989.tb01755.x; HARTZ SC, 1991, FERTIL STERIL, V55, P14; HOWE G, 1985, BRIT MED J, V290, P1697, DOI 10.1136/bmj.290.6483.1697; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAMB EJ, 1989, AM J OBSTET GYNECOL, V160, P1470, DOI 10.1016/0002-9378(89)90872-7; MENKEN J, 1986, SCIENCE, V233, P1389, DOI 10.1126/science.3755843; SAUER MV, 1990, NEW ENGL J MED, V323, P1157, DOI 10.1056/NEJM199010253231702; SCHWARTZ D, 1982, NEW ENGL J MED, V306, P404, DOI 10.1056/NEJM198202183060706; SPIRA A, 1988, MATURITAS, P15; STEIN ZA, 1985, AM J EPIDEMIOL, V121, P327, DOI 10.1093/oxfordjournals.aje.a114004; van Noord-Zaadstra B M, 1989, Paediatr Perinat Epidemiol, V3, P11; YOSHIMURA Y, 1986, FERTIL STERIL, V45, P800	17	284	289	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 8	1991	302	6789					1361	1365		10.1136/bmj.302.6789.1361	http://dx.doi.org/10.1136/bmj.302.6789.1361			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR057	2059713	Bronze, Green Published			2022-12-01	WOS:A1991FR05700016
J	CLORE, GM; GRONENBORN, AM				CLORE, GM; GRONENBORN, AM			STRUCTURES OF LARGER PROTEINS IN SOLUTION - 3-DIMENSIONAL AND 4-DIMENSIONAL HETERONUCLEAR NMR-SPECTROSCOPY	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; INTERPROTON DISTANCE RESTRAINTS; TWO-DIMENSIONAL NMR; MOLECULAR-DYNAMICS; STEREOSPECIFIC ASSIGNMENTS; SOLUTION CONFORMATION; COUPLING-CONSTANTS; AQUEOUS-SOLUTION; ANTENNAPEDIA HOMEODOMAIN; N-15-LABELED PROTEINS	Three- and four-dimensional heteronuclear nuclear magnetic resonance (NMR) spectroscopy offers dramatic improvements in spectral resolution by spreading through-bond and through-space correlations in three and four orthogonal frequency axes. Simultaneously, large heteronuclear couplings are exploited to circumvent problems due to the larger linewidths that are associated with increasing molecular weight. These novel experiments have been designed to extend the application of NMR as a method for determining three-dimensional structures of proteins in solution beyond the limits of conventional two-dimensional NMR (approximately 100 residues) to molecules in the 150- to 300-residue range. This potential has recently been confirmed with the determination of the high-resolution NMR structure of a protein greater than 150 residues, namely, interleukin-1-beta.			CLORE, GM (corresponding author), NIDDKD, CHEM PHYS LAB, BLDG 2, BETHESDA, MD 20892 USA.		Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525				ARSENIEV A, 1988, J MOL BIOL, V201, P637, DOI 10.1016/0022-2836(88)90644-4; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BAX A, 1988, J MAGN RESON, V79, P429, DOI 10.1016/0022-2364(88)90080-7; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BAX A, 1990, J MAGN RESON, V87, P620, DOI 10.1016/0022-2364(90)90320-9; BAX A, 1986, SCIENCE, V232, P960, DOI 10.1126/science.3518060; BAX A, 1989, ANNU REV BIOCHEM, V58, P223; BILLETER M, 1990, J MOL BIOL, V214, P183, DOI 10.1016/0022-2836(90)90155-F; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; BRAUN W, 1987, Q REV BIOPHYS, V19, P115, DOI 10.1017/S0033583500004108; BRAUN W, 1985, J MOL BIOL, V186, P611, DOI 10.1016/0022-2836(85)90134-2; BRUNGER AT, 1991, ANNU REV PHYS CHEM, V42, P197, DOI 10.1146/annurev.pc.42.100191.001213; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNGER AT, 1991, MOL DYNAMICS APPLICA, P137; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CLORE GM, 1990, J MOL BIOL, V214, P811, DOI 10.1016/0022-2836(90)90336-K; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P5671, DOI 10.1021/bi00476a004; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; CLORE GM, 1986, J MOL BIOL, V191, P523, DOI 10.1016/0022-2836(86)90146-4; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; CLORE GM, 1987, PROTEIN ENG, V1, P275, DOI 10.1093/protein/1.4.275; CLORE GM, 1985, J MOL BIOL, V186, P435, DOI 10.1016/0022-2836(85)90116-0; CLORE GM, 1991, ANNU REV BIOPHYS BIO, V20, P29, DOI 10.1146/annurev.biophys.20.1.29; CLORE GM, 1991, THEOR BIOCH MOL BIOP, V2, P1; CLORE GM, IN PRESS J BIOMOL NM; CLORE GM, 1989, COMPUTER AIDED MOL D, P203; CLORE GM, IN PRESS J MOL BIOL; CRIPPEN GM, 1978, ACTA CRYSTALLOGR A, V34, P282, DOI 10.1107/S0567739478000522; CRIPPEN GM, 1988, DISTANCE GEOMETRY CO; DEMARCO A, 1978, BIOPOLYMERS, V17, P617, DOI 10.1002/bip.1978.360170307; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P4668, DOI 10.1021/bi00471a023; DRISCOLL PC, 1989, BIOCHEMISTRY-US, V28, P2188, DOI 10.1021/bi00431a033; DRISCOLL PC, 1989, FEBS LETT, V243, P223, DOI 10.1016/0014-5793(89)80134-6; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P3542, DOI 10.1021/bi00466a018; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; FESIK SW, 1990, J AM CHEM SOC, V112, P886, DOI 10.1021/ja00158a069; FOLKERS PJM, 1989, BIOCHEMISTRY-US, V28, P2601, DOI 10.1021/bi00432a038; FORMANKAY JD, 1991, BIOCHEMISTRY-US, V30, P2685, DOI 10.1021/bi00224a017; FORMANKAY JD, 1990, BIOCHEMISTRY-US, V29, P1566, DOI 10.1021/bi00458a030; FRENKIEL T, 1990, J MAGN RESON, V90, P420, DOI 10.1016/0022-2364(90)90152-Y; GRIESINGER C, 1987, J MAGN RESON, V73, P574, DOI 10.1016/0022-2364(87)90027-8; GRONENBORN AM, 1989, FEBS LETT, V243, P93, DOI 10.1016/0014-5793(89)81224-4; GRONENBORN AM, 1989, BIOCHEMISTRY-US, V28, P5978, DOI 10.1021/bi00440a039; GRONENBORN AM, 1990, ANAL CHEM, V62, P2, DOI 10.1021/ac00200a003; GUNTERT P, 1989, J AM CHEM SOC, V111, P3997; HARUYAMA H, 1989, BIOCHEMISTRY-US, V28, P4301, DOI 10.1021/bi00436a027; HAVEL TF, 1985, J MOL BIOL, V182, P281, DOI 10.1016/0022-2836(85)90346-8; HAVEL TF, 1983, B MATH BIOL, V45, P665; HYBERTS SG, 1987, EUR J BIOCHEM, V164, P625, DOI 10.1111/j.1432-1033.1987.tb11173.x; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; IKURA M, IN PRESS J BIOMOL NM; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JEENER J, 1971, AMPERE INT SUMMER SC; KAPTEIN R, 1985, J MOL BIOL, V182, P179, DOI 10.1016/0022-2836(85)90036-1; KAPTEIN R, 1988, BIOCHEMISTRY-US, V27, P5389, DOI 10.1021/bi00415a001; KARPLUS M, 1963, J AM CHEM SOC, V85, P2870, DOI 10.1021/ja00901a059; KAY LE, 1991, J MAGN RESON, V91, P84, DOI 10.1016/0022-2364(91)90410-U; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1990, J AM CHEM SOC, V112, P888, DOI 10.1021/ja00158a070; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; KLINE AD, 1988, J MOL BIOL, V204, P675, DOI 10.1016/0022-2836(88)90364-6; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; KUNTZ ID, 1989, METHOD ENZYMOL, V177, P159; KURIYAN J, 1986, J MOL BIOL, V190, P227, DOI 10.1016/0022-2836(86)90295-0; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MARION D, 1988, J MAGN RESON, V80, P528, DOI 10.1016/0022-2364(88)90250-8; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARKLEY JL, 1989, METHOD ENZYMOL, V176, P12; MESSERLE BA, 1989, J MAGN RESON, V85, P608, DOI 10.1016/0022-2364(89)90252-7; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILSSON L, 1986, J MOL BIOL, V188, P455, DOI 10.1016/0022-2836(86)90168-3; NOGGLE JH, 1971, NUCLEAR OVERHAUSER E; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; OSCHKINAT H, 1988, NATURE, V332, P374, DOI 10.1038/332374a0; OVERHAUSER AW, 1953, PHYS REV, V89, P689, DOI 10.1103/PhysRev.89.689; OVERHAUSER AW, 1953, PHYS REV, V92, P411, DOI 10.1103/PhysRev.92.411; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; POWERS R, IN PRESS J MAGN RESO; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; SCHEEK RM, 1989, METHOD ENZYMOL, V177, P204; SOLOMON I, 1955, PHYS REV, V99, P559, DOI 10.1103/PhysRev.99.559; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WILLIAMSON MP, 1985, J MOL BIOL, V182, P295, DOI 10.1016/0022-2836(85)90347-X; WUTHRICH K, 1989, SCIENCE, V243, P45, DOI 10.1126/science.2911719; WUTHRICH K, 1990, J BIOL CHEM, V265, P22059; WUTHRICH K, 1986, NMR PROTEINS; ZUIDERWEG ERP, 1991, J AM CHEM SOC, V113, P370, DOI 10.1021/ja00001a060; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008; ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P210, DOI 10.1016/0022-2364(90)90228-2	106	407	414	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	1991	252	5011					1390	1399		10.1126/science.2047852	http://dx.doi.org/10.1126/science.2047852			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP868	2047852	Green Submitted			2022-12-01	WOS:A1991FP86800025
J	HAVRAN, WL; CHIEN, YH; ALLISON, JP				HAVRAN, WL; CHIEN, YH; ALLISON, JP			RECOGNITION OF SELF ANTIGENS BY SKIN-DERIVED T-CELLS WITH INVARIANT GAMMA-DELTA-ANTIGEN RECEPTORS	SCIENCE			English	Article							DENDRITIC EPIDERMAL-CELLS; MYCOBACTERIUM-TUBERCULOSIS; MURINE EPIDERMIS; PRECURSORS; PROTEINS; PRODUCT; SUBSET; MICE	Thy-1+ dendritic epidermal T cells (dECs) express invariant gamma-delta-antigen receptors and are found in intimate contact with keratinocytes in murine epidermis - thus raising the possibility that keratinocytes express a ligand for the antigen receptor of these T cells. Thy-1+ dECs were stimulated to produce lymphokines by interaction with keratinocytes in vitro. This stimulation was mediated through the dEC antigen receptor and did not appear to be restricted by the major histocompatibility complex. Thus, dECs can recognize self antigens and may participate in immune surveillance for cellular damage rather than for foreign antigens.	UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720; STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	University of California System; University of California Berkeley; Stanford University	HAVRAN, WL (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.			Allison, James/0000-0001-8980-5697	NATIONAL CANCER INSTITUTE [R01CA040041, R37CA040041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026942] Funding Source: NIH RePORTER; NCI NIH HHS [CA40041] Funding Source: Medline; NIAID NIH HHS [AI26942] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allison J P, 1990, Semin Immunol, V2, P59; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; ASARNOW DM, 1989, NATURE, V341, P60, DOI 10.1038/341060a0; BERGSTRESSER PR, 1984, J INVEST DERMATOL, V83, P83, DOI 10.1111/1523-1747.ep12262587; BERGSTRESSER PR, 1983, J INVEST DERMATOL, V81, P286, DOI 10.1111/1523-1747.ep12518332; BONNEVILLE M, 1989, P NATL ACAD SCI USA, V86, P5928, DOI 10.1073/pnas.86.15.5928; BORN W, 1990, IMMUNOL TODAY, V11, P40; GILLIS S, 1978, J IMMUNOL, V120, P2027; HAVRAN WL, 1989, J IMMUNOL, V142, P1422; HAVRAN WL, 1990, NATURE, V344, P68, DOI 10.1038/344068a0; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HAVRAN WL, UNPUB; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; JANIS EM, 1989, SCIENCE, V244, P713, DOI 10.1126/science.2524098; KORMAN AJ, 1988, J EXP MED, V168, P1021, DOI 10.1084/jem.168.3.1021; KUPPER TS, 1987, J INVEST DERMATOL, V88, P501; KUZIEL WA, 1987, NATURE, V328, P263, DOI 10.1038/328263a0; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; OBRIEN RL, 1989, CELL, V57, P667, DOI 10.1016/0092-8674(89)90135-9; STINGL G, 1987, P NATL ACAD SCI USA, V84, P2430, DOI 10.1073/pnas.84.8.2430; SULLIVAN S, 1985, J INVEST DERMATOL, V84, P491, DOI 10.1111/1523-1747.ep12273454; VIDOVIC D, 1989, NATURE, V340, P646, DOI 10.1038/340646a0; YOUNG RA, 1989, CELL, V59, P5, DOI 10.1016/0092-8674(89)90861-1	24	338	340	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1991	252	5011					1430	1432		10.1126/science.1828619	http://dx.doi.org/10.1126/science.1828619			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP868	1828619				2022-12-01	WOS:A1991FP86800036
J	SAMBHARA, SR; MILLER, RG				SAMBHARA, SR; MILLER, RG			PROGRAMMED CELL-DEATH OF T-CELLS SIGNALED BY THE T-CELL RECEPTOR AND THE ALPHA-3 DOMAIN OF CLASS-I MHC	SCIENCE			English	Article							CYTO-TOXIC RESPONSES; LYMPHOCYTES-T; BONE-MARROW; CYTOTOXIC LYMPHOCYTES; MONOCLONAL-ANTIBODIES; SELF ANTIGENS; EXPRESSION; VETO; CD8; RECOGNITION	As well as being activated or rendered unresponsive, mature T lymphocytes can be deleted, depending on the signals received by the cell. Deletion by programmed cell death (apoptosis) is triggered if a T cell that has received a signal through its T cell receptor complex also receives a signal through the alpha-3 domain of its class I major histocompatibility complex (MHC) molecule. Such a signal can be delivered by a CD8 molecule, which recognizes the alpha-3 domain, or by an antibody to this domain. Precursors of both cytotoxic T lymphocytes (CTL's) and T helper cells are sensitive to this signal but become resistant at some point before completing differentiation into functioning CTL's or T helper cells. Because CTL's carry CD8, they can induce cell death in T cells that recognize them. This pathway may be important in both removal of autoreactive T cells and immunoregulation.	UNIV TORONTO,DEPT IMMUNOL,500 SHERBOURNE ST,TORONTO M4X 1K9,ONTARIO,CANADA	University of Toronto			Sambhara, Suryaprakash/AAC-4428-2021					ALLEN H, 1984, NATURE, V309, P279, DOI 10.1038/309279a0; ALTEVOGT P, 1980, EUR J IMMUNOL, V10, P908, DOI 10.1002/eji.1830101204; AZUMA E, 1988, J IMMUNOL, V141, P2601; BEVAN MJ, 1975, J IMMUNOL, V114, P559; BLUESTONE JA, 1987, NATURE, V326, P82, DOI 10.1038/326082a0; CASSELL DJ, 1990, J IMMUNOL, V144, P4075; CHARRON D, 1980, J EXP MED, V152, P1275; CLAESSON MH, 1984, J EXP MED, V160, P1702, DOI 10.1084/jem.160.6.1702; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; EVANS GA, 1982, NATURE, V300, P755, DOI 10.1038/300755a0; FINK PJ, 1984, J IMMUNOL, V133, P1775; FINK PJ, 1988, ANNU REV IMMUNOL, V6, P115; FINK PJ, 1984, J IMMUNOL, V133, P1769; GRAF L, 1985, MOL IMMUNOL, V22, P1371, DOI 10.1016/0161-5890(85)90059-8; HAMBOR JE, 1990, J IMMUNOL, V145, P1646; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HEUER J, 1985, J IMMUNOL, V134, P4031; KANAGAWA O, 1989, J EXP MED, V170, P901, DOI 10.1084/jem.170.3.901; KAPLAN DR, 1989, P NATL ACAD SCI USA, V86, P8512, DOI 10.1073/pnas.86.21.8512; KIZIROGLU F, 1991, J IMMUNOL, V146, P1104; KO HS, 1979, J EXP MED, V150, P246, DOI 10.1084/jem.150.2.246; KOCH N, 1983, IMMUNOGENETICS, V17, P497, DOI 10.1007/BF00696873; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P119; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; MILLER RG, 1986, IMMUNOL TODAY, V7, P112, DOI 10.1016/0167-5699(86)90151-9; MILLER RG, 1979, J IMMUNOL, V122, P1502; MILLER RG, 1980, NATURE, V287, P544, DOI 10.1038/287544a0; MILLER RG, 1974, CELL IMMUNOL, V14, P284, DOI 10.1016/0008-8749(74)90212-3; MILLER RG, 1980, STRATEGIES IMMUNE RE, P507; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; MURAOKA S, 1980, J EXP MED, V152, P54, DOI 10.1084/jem.152.1.54; NAKAMURA H, 1990, TRANSPLANTATION, V49, P931, DOI 10.1097/00007890-199005000-00020; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; RAMMENSEE HG, 1989, INT REV IMMUNOL, V4, P177; RESKEKUNZ AB, 1986, J IMMUNOL, V136, P2033; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAMBHARA SR, UNPUB; Sambrooke J., 1989, MOL CLONING LAB MANU, pE3; SHAPIRO HM, 1988, PRACTICAL FLOW CYTOM, P168; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TAKAHASHI T, 1990, J EXP MED, V172, P901, DOI 10.1084/jem.172.3.901; WALLACE VA, 1991, EUR J IMMUNOL, V20, P2471	46	200	211	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1991	252	5011					1424	1427						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP868	1828618				2022-12-01	WOS:A1991FP86800034
J	SHENG, M; THOMPSON, MA; GREENBERG, ME				SHENG, M; THOMPSON, MA; GREENBERG, ME			CREB - A CA2+-REGULATED TRANSCRIPTION FACTOR PHOSPHORYLATED BY CALMODULIN-DEPENDENT KINASES	SCIENCE			English	Article							AMP RESPONSE ELEMENT; NUCLEAR FACTOR CREB; PROTEIN-KINASE; CYCLIC-AMP; LEUCINE ZIPPER; C-FOS; SOMATOSTATIN GENE; BINDING-PROTEIN; PYRUVATE-KINASE; NERVOUS-SYSTEM	The mechanism by which Ca2+ mediates gene induction in response to membrane depolarization was investigated. The adenosine 3',5'-monophosphate (cAMP) response element-binding protein (CREB) was shown to function as a Ca2+-regulated transcription factor and as a substrate for depolarization-activated Ca2+-calmodulin-dependent protein kinases (CaM kinases) I and II. CREB residue Ser133 was the major site of phosphorylation by the CaM kinases in vitro and of phosphorylation after membrane depolarization in vivo. Mutation of Ser133 impaired the ability of CREB to respond to Ca2+. These results suggest that CaM kinases may transduce electrical signals to the nucleus and that CREB functions to integrate Ca2+ and cAMP signals.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School				Sheng, Morgan/0000-0002-8703-5366	NCI NIH HHS [R01 CA 43855] Funding Source: Medline; NINDS NIH HHS [R01 NS 28829] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028829] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DASH PK, IN PRESS P NATL ACAD; DOSKELAND AP, 1984, EUR J BIOCHEM, V145, P31, DOI 10.1111/j.1432-1033.1984.tb08518.x; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; GRIFFITH LC, 1988, J BIOL CHEM, V263, P9542; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NGUYEN TV, 1990, J NEUROSCI, V10, P2825; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1988, NATURE, V335, P559; SCHWORER CM, 1985, J BIOL CHEM, V260, P3018; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SODERLING TR, 1986, BIOCHEM BIOPH RES CO, V139, P1017, DOI 10.1016/S0006-291X(86)80279-0; THOMPSON M, UNPUB; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZHU Z, 1989, J BIOL CHEM, V264, P6550	30	1363	1386	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1991	252	5011					1427	1430		10.1126/science.1646483	http://dx.doi.org/10.1126/science.1646483			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP868	1646483				2022-12-01	WOS:A1991FP86800035
J	ALDOVINI, A; YOUNG, RA				ALDOVINI, A; YOUNG, RA			HUMORAL AND CELL-MEDIATED IMMUNE-RESPONSES TO LIVE RECOMBINANT BCG-HIV VACCINES	NATURE			English	Article							HELPER T-CELLS; STRESS PROTEINS; FOREIGN DNA; HTLV-III; MYCOBACTERIA; VIRUS; EXPRESSION; PROTECTION; INFECTION	SEVERAL viral and bacterial live recombinant vaccine vehicles are being developed to produce a new generation of vaccines against a broad spectrum of infectious diseases 1. The human tuberculosis vaccine Mycobacterium bovis bacillus Calmette-Guerin (BCG) 2 has features that make it a particularly attractive live recombinant vaccine vehicle. BCG and other mycobacteria are highly effective adjuvants, and the immune response to mycobacteria has been studied extensively. With nearly two billion immunizations, BCG has a long record of safe use in man 3,4. It is one of the few vaccines that can be given at birth, it engenders long-lived immune responses with only a single dose, and there is a worldwide distribution network with experience in BCG vaccination. Recently developed molecular genetic tools and methods for mycobacteria have provided the means to introduce foreign genes into BCG 5-8. Here we report that a variety of human immunodeficiency virus type 1 polypeptides can be expressed in BCG recombinants under the control of the mycobacterial hsp70 promoter and that the foreign polypeptides produced in BCG can induce antibody and T-cell responses. These results demonstrate that BCG can be used as a live recombinant vaccine vehicle to induce immune responses to pathogen proteins produced by the bacillus.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	ALDOVINI, A (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BLOOM BR, 1986, J IMMUNOL, V137, pR1; BLOOM BR, 1989, NATURE, V342, P115, DOI 10.1038/342115a0; BUCHMEIER NA, 1990, SCIENCE, V248, P730, DOI 10.1126/science.1970672; Calmette A., 1924, B ACAD MED, V91, P787; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; FISHER AG, 1985, NATURE, V316, P262, DOI 10.1038/316262a0; HUSSON RN, 1990, J BACTERIOL, V172, P519, DOI 10.1128/jb.172.2.519-524.1990; JACOBS WR, 1987, NATURE, V327, P532, DOI 10.1038/327532a0; KAUFMANN SHE, 1990, IMMUNOL TODAY, V11, P129, DOI 10.1016/0167-5699(90)90050-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB JR, 1990, MOL BIOL MED, V7, P311; Lotte A, 1984, Adv Tuberc Res, V21, P107; LUELMO F, 1982, AM REV RESPIR DIS, V125, P70; Maniatis T., 1982, MOL CLONING; MARTIN C, 1990, NATURE, V345, P739, DOI 10.1038/345739a0; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; NAGLERANDERSON C, 1988, J IMMUNOL, V141, P3299; NEIDHARDT FC, 1987, CELLULAR MOL BIOL, P1654; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; SNAPPER SB, 1988, P NATL ACAD SCI USA, V85, P6987, DOI 10.1073/pnas.85.18.6987; SWAIN SL, 1988, J IMMUNOL, V141, P3445; WALKER BD, 1990, TECHNIQUES HIV RES, P201; WALL KA, 1988, P NATL ACAD SCI USA, V85, P5644, DOI 10.1073/pnas.85.15.5644; WYLER DJ, 1987, J IMMUNOL, V138, P1246; YOUNG RA, 1990, ANNU REV IMMUNOL, V8, P401, DOI 10.1146/annurev.immunol.8.1.401	28	283	325	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 6	1991	351	6326					479	482		10.1038/351479a0	http://dx.doi.org/10.1038/351479a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	2046750				2022-12-01	WOS:A1991FP75800055
J	BANDARA, LR; LATHANGUE, NB				BANDARA, LR; LATHANGUE, NB			ADENOVIRUS-E1A PREVENTS THE RETINOBLASTOMA GENE-PRODUCT FROM COMPLEXING WITH A CELLULAR TRANSCRIPTION FACTOR	NATURE			English	Article							E1A PROTEINS; DIFFERENTIATION; DOMAINS	THE transforming proteins of several DNA tumour viruses, including adenovirus E1a and simian virus 40 large T antigen, complex with the retinoblastoma (Rb) tumour-suppressor gene product 1,2. This requires regions in these viral proteins necessary for transformation and is thought to inactivate the growth-suppressing properties of the Rb protein by disrupting its interaction with cellular targets 3. Indeed, regions of Rb required to form a complex with E1a and large T antigen are often mutated in transformed cells 4. The level at which the Rb protein regulates proliferation is unknown, although one possibility is transcription. We have previously characterized a sequence-specific transcription factor, DRTF1, the activity of which is downregulated as embryonal carcinoma stem cells differentiate. DRTF1 is found in several discrete protein complexes (a, b and c) which are of different sizes but have the same DNA specificity 5,6. We now show that one of these also contains the Rb protein and, further, that the adenovirus E1a protein causes the dissociation of the Rb protein from this complex. This requires conserved regions 1 and 2 of E1a that are known to be required for efficient transformation 7. These results demonstrate that the Rb protein forms a complex with a DNA-bound transcription factor, and suggests that the Rb protein might act by regulating transcription.			BANDARA, LR (corresponding author), NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.							DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LATHANGUE NB, 1984, EMBO J, V3, P267, DOI 10.1002/j.1460-2075.1984.tb01796.x; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; SHIVJI MKK, 1991, MOL CELL BIOL, V11, P1686, DOI 10.1128/MCB.11.3.1686; TASSIOS P T, 1990, New Biologist, V2, P1123; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	13	426	438	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1991	351	6326					494	497		10.1038/351494a0	http://dx.doi.org/10.1038/351494a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	1710781				2022-12-01	WOS:A1991FP75800060
J	BRZOZOWSKI, AM; DEREWENDA, U; DEREWENDA, ZS; DODSON, GG; LAWSON, DM; TURKENBURG, JP; BJORKLING, F; HUGEJENSEN, B; PATKAR, SA; THIM, L				BRZOZOWSKI, AM; DEREWENDA, U; DEREWENDA, ZS; DODSON, GG; LAWSON, DM; TURKENBURG, JP; BJORKLING, F; HUGEJENSEN, B; PATKAR, SA; THIM, L			A MODEL FOR INTERFACIAL ACTIVATION IN LIPASES FROM THE STRUCTURE OF A FUNGAL LIPASE-INHIBITOR COMPLEX	NATURE			English	Article							MIEHEI TRIGLYCERIDE LIPASE; TRANSITION-STATE ANALOG; MACROMOLECULAR STRUCTURES; VENOM PHOSPHOLIPASE-A2; PANCREATIC LIPASE; CRYSTAL-STRUCTURE; REFINEMENT; CRYSTALLOGRAPHY	LIPASES are hydrolytic enzymes which break down triacylglycerides into free fatty acids and glycerols. They have been classified as serine hydrolases owing to their inhibition by diethyl p-nitrophenyl phosphate 1. Lipase activity is greatly increased at the lipid-water interface 2,3, a phenomenon known as interfacial activation. X-ray analysis has revealed the atomic structures of two triacylglycerol lipases, unrelated in sequence: the human pancreatic lipase (hPL) 4, and an enzyme isolated from the fungus Rhizomucor (formerly Mucor) miehei 5 (RmL). In both enzymes the active centres contain structurally analogous Asp-His-Ser triads (characteristic of serine proteinases), which are buried completely beneath a short helical segment, or 'lid'. Here we present the crystal structure (at 3 angstrom resolution) of a complex of R. miehei lipase with n-hexylphosphonate ethyl ester in which the enzyme's active site is exposed by the movement of the helical lid. This movement also increases the nonpolarity of the surface surrounding the catalytic site. We propose that the structure of the enzyme in this complex is equivalent to the activated state generated by the oil-water interface.	UNIV ALBERTA,DEPT BIOCHEM,MRC,PROT STRUCT & FUNCT GRP,474 MED SCI BLDG,EDMONTON T6G 2H7,ALBERTA,CANADA; UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND; UNIV LODZ,INST CHEM,DEPT CRYSTALLOG,PL-91416 LODZ,POLAND	University of Alberta; University of York - UK; University of Lodz			Lawson, David M/D-1810-2009	Turkenburg, Johan/0000-0001-6992-6838				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOEL E, 1988, LIPIDS, V23, P701, DOI 10.1007/BF02535672; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BROCKERHOFF H, 1968, BIOCHIM BIOPHYS ACTA, V159, P296, DOI 10.1016/0005-2744(68)90078-8; BROCKMAN HL, 1973, J BIOL CHEM, V248, P965; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CHAPUSAND C, 1976, BIOCHEMISTRY-US, V15, P4987; DEREWENDA Z, 1989, J APPL CRYSTALLOGR, V22, P123, DOI 10.1107/S0021889888012348; DEREWENDA ZS, 1989, ACTA CRYSTALLOGR A, V45, P227, DOI 10.1107/S0108767388010700; ENTRESSANGLES B, 1974, BIOCHIM BIOPHYS ACTA, V341, P437, DOI 10.1016/0005-2744(74)90236-8; FUKUTO TR, 1959, J AM CHEM SOC, V81, P372, DOI 10.1021/ja01511a025; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HUGEJENSEN B, 1987, LIPIDS, V22, P559, DOI 10.1007/BF02537281; HUGEJENSEN B, 1989, LIPIDS, V24, P781, DOI 10.1007/BF02544584; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; MARCH J, 1985, ADV ORG CHEM, P335; PEITERSON WA, 1974, BIOCHEMISTRY-US, V13, P1455; SARDA L, 1958, BIOCHIM BIOPHYS ACTA, V30, P513, DOI 10.1016/0006-3002(58)90097-0; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; WELLS MA, 1974, BIOCHEMISTRY-US, V13, P2248, DOI 10.1021/bi00708a002; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; 1986, CCP4 PROGRAM SUITE	26	1002	1034	2	188	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1991	351	6326					491	494		10.1038/351491a0	http://dx.doi.org/10.1038/351491a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	2046751				2022-12-01	WOS:A1991FP75800059
J	CO, MS; QUEEN, C				CO, MS; QUEEN, C			HUMANIZED ANTIBODIES FOR THERAPY	NATURE			English	Article							INTERLEUKIN-2 RECEPTOR; MOUSE				CO, MS (corresponding author), PROT DESIGN LABS INC,2375 GARCIA AVE,MT VIEW,CA 94043, USA.							BROWN PS, 1991, P NATL ACAD SCI USA, V88, P2663, DOI 10.1073/pnas.88.7.2663; CO MS, 1991, P NATL ACAD SCI USA, V88, P2869, DOI 10.1073/pnas.88.7.2869; DiMaggio J J, 1990, Cancer Chemother Biol Response Modif, V11, P177; HALE G, 1988, LANCET, V2, P1394; JAFFERS GJ, 1986, TRANSPLANTATION, V41, P572, DOI 10.1097/00007890-198605000-00004; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; JUNGHANS RP, 1990, CANCER RES, V50, P1495; MATHIESON PW, 1990, NEW ENGL J MED, V323, P250, DOI 10.1056/NEJM199007263230407; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; REICHMANN L, 1988, NATURE, V332, P323; TEMPEST PR, 1991, BIO-TECHNOL, V9, P266, DOI 10.1038/nbt0391-266; 1991, 6TH INT C MON ANT IM	13	78	124	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1991	351	6326					501	502		10.1038/351501a0	http://dx.doi.org/10.1038/351501a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	2046753				2022-12-01	WOS:A1991FP75800062
J	DESAI, KM; SESSA, WC; VANE, JR				DESAI, KM; SESSA, WC; VANE, JR			INVOLVEMENT OF NITRIC-OXIDE IN THE REFLEX RELAXATION OF THE STOMACH TO ACCOMMODATE FOOD OR FLUID	NATURE			English	Article							L-ARGININE; GLYCERYL TRINITRATE; GUANYLATE-CYCLASE; METHYLENE-BLUE; STIMULATION; NITROPRUSSIDE; INHIBITOR; MUSCLE	THE fundus of the guinea-pig stomach actively dilates in response to low increases in intragastric pressure 1. This physiological response, now called adaptive relaxation 2,3, accommodates the intake of liquid or food. It is independent of external innervation, resistant to ganglion blockade, but reflex in origin. The nerves involved are neither adrenergic nor cholinergic in nature. Non-adrenergic, non-cholinergic (NANC) nerves have now been recognized in many parts of the gastrointestinal tract 4 and have recently been linked with release of nitric oxide (NO) on electrical stimulation 5-7. Here we show that adaptive relaxation in isolated stomach of the guinea pig is mediated by a NANC neurotransmitter substance indistinguishable from NO derived from L-arginine 8. This is substantiated by inhibition of adaptive relaxation by N(G)-monomethyl-L-arginine or N-omega-nitro-L-arginine methyl ester, both inhibitors of NO synthesis 9,10, and by methylene blue, an inhibitor of soluble guanylate cyclase 11. There are two distinct neuronal pathways signalling NO-dependent adaptive relaxation, as evidenced by tetrodotoxin sensitivity. The first is a local reflex arc, the afferent fibres of which sense changes in intragastric pressure. The second is stimulated by an agonist for ganglionic nicotinic receptors. Thus, the functional significance of NO release from NANC nerves in the stomach is to bring about adaptive relaxation through a reflex response to increases in intragastric pressure.	ST BARTHOLOMEWS HOSP,COLL MED,WILLIAM HARVEY RES INST,LONDON EC1M 6BQ,ENGLAND	University of London; Queen Mary University London			Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938; Desai, Kaushik/0000-0001-9355-4528				ABRAHAMSSON H, 1973, ACTA PHYSL SCAND S, V390, P5; BOECKXSTAENS GE, 1991, BRIT J PHARMACOL, V102, P434, DOI 10.1111/j.1476-5381.1991.tb12191.x; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P1080, DOI 10.1111/j.1476-5381.1989.tb12650.x; GILLESPIE JS, 1982, MOTILIYT DIGESTIVE T; GRUETTER CA, 1981, J PHARMACOL EXP THER, V219, P181; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LI CG, 1990, EUR J PHARMACOL, V191, P303; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; MEYER JH, 1987, PHYSL GASTROINTESTIN; MOORE PK, 1990, BRIT J PHARMACOL, V99, P408, DOI 10.1111/j.1476-5381.1990.tb14717.x; MURPHY S, 1990, J NEUROCHEM, V55, P349, DOI 10.1111/j.1471-4159.1990.tb08860.x; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PATON WDM, 1963, J PHYSIOL-LONDON, V165, P10, DOI 10.1113/jphysiol.1963.sp007040; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x	18	507	519	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1991	351	6326					477	479		10.1038/351477a0	http://dx.doi.org/10.1038/351477a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	1675430				2022-12-01	WOS:A1991FP75800054
